

# **APPROVED DRUG PRODUCTS**

**WITH**

**THERAPEUTIC  
EQUIVALENCE  
EVALUATIONS**

**30<sup>th</sup> EDITION**

**THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER  
SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH  
OFFICE OF PHARMACEUTICAL SCIENCE  
OFFICE OF GENERIC DRUGS**

**2010**

# **APPROVED DRUG PRODUCTS** with **THERAPEUTIC EQUIVALENCE EVALUATIONS**

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2009.

## **30<sup>th</sup> EDITION**



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH  
OFFICE OF PHARMACEUTICAL SCIENCE  
OFFICE OF GENERIC DRUGS

**2010**

**FOOD AND DRUG ADMINISTRATION  
 CENTER FOR DRUG EVALUATION AND RESEARCH  
 APPROVED DRUG PRODUCTS  
 with  
 Therapeutic Equivalence Evaluations**

**CONTENTS**

	<i>PAGE</i>
PREFACE TO THIRTIETH EDITION.....	iv
1 INTRODUCTION.....	vi
1.1 Content and Exclusion.....	vi
1.2 Therapeutic Equivalence-Related Terms .....	vi
1.3 Statistical Criteria for Bioequivalence .....	viii
1.4 Reference Listed Drug.....	x
1.5 General Policies and Legal Status .....	x
1.6 Practitioner/User Responsibilities.....	xi
1.7 Therapeutic Equivalence Evaluations Codes .....	xiii
1.8 Description of Special Situations .....	xx
1.9 Therapeutic Equivalence Code Change for a Drug Entity.....	xxii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product .....	xxii
1.11 Discontinued Section.....	xxiii
1.12 Changes to the Orange Book .....	xxiii
1.13 Availability of the Edition.....	xxiii
2 HOW TO USE THE DRUG PRODUCTS LISTS .....	2-1
2.1 Key Sections for Using the Drug Product Lists .....	2-1
2.2 Drug Product Illustration .....	2-3
2.3 Therapeutic Equivalence Evaluations Illustration .....	2-4
<b>DRUG PRODUCT LISTS</b>	
Prescription Drug Product List .....	3-1
OTC Drug Product List .....	4-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	5-1
Discontinued Drug Product List .....	6-1
Orphan Products Designations and Approvals List .....	7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	8-1
<b>APPENDICES</b>	
A. Product Name Index .....	A-1
B. Product Name Index Listed by Applicant .....	B-1
C. Uniform Terms .....	C-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM .....	AD1
A. Patent and Exclusivity Lists .....	ADA1
B. Patent and Exclusivity Terms .....	ADB1

**FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH  
APPROVED DRUG PRODUCTS**

**with  
Therapeutic Equivalence Evaluations**

**PREFACE TO THIRTIETH EDITION**

The publication, *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act). Drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal® Tablets and Librax® Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]) are not included in this publication. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the List contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the Act.

**Background of the Publication.** To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The List was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the Act.

The therapeutic equivalence evaluations in the List reflect FDA's application of specific criteria to the multisource prescription drug products on the List approved under Section 505 of the Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the code appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication, October 1980, of

the final version of the List incorporated appropriate corrections and additions. Each subsequent edition has included the new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act (1984 Amendments). The 1984 Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The *Approved Drug Products with Therapeutic Equivalence Evaluations* publication and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the 1984 Amendments for periods of exclusivity (during which ANDAs or applications described in Section 505(b)(2) of the Act for those drugs may not be submitted for a specified period of time and, if allowed to be submitted, would be tentatively approved) and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or Section 505(b)(2) applications. The *Addendum* also provides additional information that may be helpful to those submitting a new drug application to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Labeling and Program Support, HFD-610, Office of Generic Drugs, Center for Drug and Evaluation and Research, 7500 Standish Place, Rockville, MD 20855. Comments received are publicly available to the extent allowable under the Freedom of Information regulations.

# 1. INTRODUCTION

## 1.1 Content and Exclusion

The List is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.<sup>1</sup> This publication also includes indices of prescription and OTC drug products by trade or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as prescribed in (21 CFR 299.4(e)). The latter list includes applicants' names as abbreviated in this publication; in addition, a list of uniform terms is provided.

An *Addendum* contains drug patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research because the main purpose of the publication was to provide information to states regarding FDA's recommendation as to which generic prescription drug products were acceptable candidates for drug product selection. The 1984 Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the 1984 Amendments, some drug products were given tentative approvals. Prior to the effective date, the Agency will not include drug products with tentative approval in the List; however, they are available at <http://www.fda.gov/cder/ogd/approvals/default.htm>. When the tentative approval becomes a full approval through a subsequent action letter to the application holder, the Agency will list the drug product and the final, effective approval date in the appropriate approved drug product list.

Distributors or repackagers of products on the List are not identified. Because distributors or repackagers are not required to notify FDA when they shift their sources of supply from one approved manufacturer to another, it is not possible to maintain complete information linking product approval with the distributor or repackager handling the products.

## 1.2 Therapeutic Equivalence-Related Terms

**Pharmaceutical Equivalents.** Drug products are considered pharmaceutical equivalents if they contain the same active ingredient(s), are of the same dosage form, route of administration and are identical in strength or concentration (e.g., chlordiazepoxide hydrochloride, 5mg capsules).

---

<sup>1</sup> Newly approved products are added to parts 1, 2, or 3, of the List, depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication.

Pharmaceutically equivalent drug products are formulated to contain the same amount of active ingredient in the same dosage form and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity), but they may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration time, and, within certain limits, labeling.

**Pharmaceutical Alternatives.** Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different salts, esters, or complexes of that moiety, or are different dosage forms or strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules). Data are generally not available for FDA to make the determination of tablet to capsule bioequivalence. Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

**Therapeutic Equivalents.** Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents and if they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the List, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., propoxyphene hydrochloride vs. pentazocine hydrochloride for the treatment of pain).* Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. Therapeutic equivalence determinations are not made for unapproved, off-label indications.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and minor aspects of labeling (e.g., the presence of specific pharmacokinetic information) and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a particular brand be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

**Bioavailability.** This term means the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by

measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.

**Bioequivalent Drug Products.** This term describes pharmaceutical equivalent or pharmaceutical alternative products that display comparable bioavailability when studied under similar experimental conditions. Section 505 (j)(7)(B) of the Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

the rate and extent of absorption of the test drug do not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or

the extent of absorption of the test drug does not show a significant difference from the extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the reference drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

Bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.

### 1.3 Statistical Criteria for Bioequivalence

Under the Drug Price Competition and Patent Term Restoration Act of 1984, manufacturers seeking approval to market a generic drug product must submit data demonstrating that the drug product is bioequivalent to the pioneer (innovator) drug product. A major premise underlying the 1984 law is that bioequivalent drug products are therapeutically equivalent, and therefore, interchangeable.

Bioavailability refers to the rate and extent to which the active ingredient or therapeutic ingredient is absorbed from a drug product and becomes available at the site of drug action (Federal Food, Drug and Cosmetic Act, section 505(j)(8)). Bioequivalence refers to equivalent release of the same drug substance from two or more drug products or formulations. This leads to an equivalent rate and extent of absorption from these formulations. Underlying the concept of bioequivalence is the thesis that, if a drug product contains a drug substance that is chemically identical and is delivered to the site of action at the same rate and extent as another drug product, then it is equivalent and can be substituted for that drug product. Methods used to define bioequivalence can be found in 21 CFR 320.24, and include (1) pharmacokinetic (PK) studies, (2) pharmacodynamic (PD) studies, (3) comparative clinical trials, and (4) in-vitro studies. The choice of study used is based on the site of action of the drug and the ability of the study design to compare drug delivered to that site by the two products.

The standard bioequivalence (PK) study is conducted using a two-treatment crossover study design in a limited number of volunteers, usually 24 to 36 adults. Alternately, a four-period, replicate design crossover study may also be used. Single doses of the test and reference drug products are administered and blood or plasma levels of the drug are measured over time.



Pharmacokinetic parameters characterizing rate and extent of drug absorption are evaluated statistically. The PK parameters of interest are the resulting area under the plasma concentration-time curve (AUC), calculated to the last measured concentration ( $AUC_{(0-t)}$ ) and extrapolated to infinity ( $AUC_{(0-inf)}$ ), for extent of absorption; and the maximum or peak drug concentrations ( $C_{max}$ ), for rate of absorption. Crossover studies may not be practical in drugs with a long half-life in the body, and a parallel study design may be used instead. Alternate study methods, such as in-vitro studies or equivalence studies with clinical or pharmacodynamic endpoints, are used for drug products where plasma concentrations are not useful to determine delivery of the drug substance to the site of activity (such as inhalers, nasal sprays and topical products applied to the skin).

The statistical methodology for analyzing these bioequivalence studies is called the two one-sided test procedure. Two situations are tested with this statistical methodology. The first of the two one-sided tests determines whether a generic product (test), when substituted for a brand-name product (reference) is significantly less bioavailable. The second of the two one-sided tests determines whether a brand-name product when substituted for a generic product is significantly less bioavailable. Based on the opinions of FDA medical experts, a difference of greater than 20% for each of the above tests was determined to be significant, and therefore, undesirable for all drug products. Numerically, this is expressed as a limit of test-product average/reference-product average of 80% for the first statistical test and a limit of reference-product average/test-product average of 80% for the second statistical test. By convention, all data is expressed as a ratio of the average response (AUC and  $C_{max}$ ) for test/reference, so the limit expressed in the second statistical test is 125% (reciprocal of 80%).

For statistical reasons, all data is log-transformed prior to conducting statistical testing. In practice, these statistical tests are carried out using an analysis of variance procedure (ANOVA) and calculating a 90% confidence interval for each pharmacokinetic parameter ( $C_{max}$  and AUC). The confidence interval for both pharmacokinetic parameters, AUC and  $C_{max}$ , must be entirely within the 80% to 125% boundaries cited above. Because the mean of the study data lies in the center of the 90% confidence interval, the mean of the data is usually close to 100% (a test/reference ratio of 1). Different statistical criteria are sometimes used when bioequivalence is demonstrated through comparative clinical trials pharmacodynamic studies, or comparative in-vitro methodology.

The bioequivalence methodology and criteria described above simultaneously control for both, differences in the average response between test and reference, as well as the precision with which the average response in the population is estimated. This precision depends on the within-subject (normal volunteer or patient) variability in the pharmacokinetic parameters (AUC and  $C_{max}$ ) of the two products and on the number of subjects in the study. The width of the 90% confidence interval is a reflection in part of the within-subject variability of the test and reference products in the bioequivalence study. A test product with no differences in the average response when compared to the reference might still fail to pass the bioequivalence criteria if the variability of one or both products is high and the bioequivalence study has insufficient statistical power (i.e., insufficient number of subjects). Likewise, a test product with low variability may pass the bioequivalence criteria, when there are somewhat larger differences in the average response.

This system of assessing bioequivalence of generic products assures that these substitutable products do not deviate substantially in in-vivo performance from the reference product. The Office of Generic Drugs has conducted two surveys to quantify the differences between generic and brand name products. The first survey included 224 bioequivalence studies submitted in approved applications during 1985 and 1986. The observed average differences between reference and generic products for AUC was 3.5% (JAMA, Sept. 4, 1987, Vol. 258, No. 9). The second survey included 127 bioequivalence studies submitted to the agency in 273 ANDAs approved in 1997.

The three measures reviewed include  $AUC_{(0-t)}$ ,  $AUC_{(0-inf)}$ , and  $C_{max}$ . The observed average differences between the reference and generic products were  $\pm 3.47\%$  (SD 2.84) for  $AUC_{(0-t)}$ ,  $\pm 3.25\%$  (SD 2.97) for  $AUC_{(0-inf)}$ , and  $\pm 4.29\%$  (SD 3.72) for  $C_{max}$  (JAMA, Dec. 1, 1999, Vol. 282, No. 21).

The primary concern from the regulatory point of view is the protection of the patient against approval of products that are not bioequivalent. The current practice of carrying out two one-sided tests at the 0.05 level of significance ensures that there is no more than a 5% chance that a generic product that is not truly equivalent to the reference will be approved.

#### 1.4 Reference Listed Drug

A reference listed drug (21 CFR 314.94(a)(3)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence (reference standard) and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to different reference listed drugs. However, in some instances when listed drugs are approved for a single drug product, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. A firm wishing to market a generic version of a listed drug that is not designated as the reference listed drug may petition the Agency through the Citizen Petition procedure (see 21 CFR 10.25(a) and CFR 10.30). When the Citizen Petition is approved, the second listed drug will be designated as an additional reference listed drug and the petitioner may submit an Abbreviated New Drug Application citing the designated reference listed drug. Section 1.7, *Therapeutic Equivalence Evaluations Codes products meeting necessary bioequivalence requirements* explains the (AB, AB1, AB2, AB3... coding system for multisource drug products listed under the same heading with two reference listed drugs.

In addition, there are two situations in which two listed drugs that have been shown to be bioequivalent to each other may both be designated as reference listed drugs. The first situation occurs when the *in vivo* determination of bioequivalence is self-evident and a waiver of the *in vivo* bioequivalence may be granted. The second situation occurs when the bioequivalence of two listed products may be determined through *in vitro* methodology. The reference listed drug is identified by the symbol "+" in the Prescription and Over-the-Counter (OTC) Drug Product Lists. These identified reference listed drugs represent the best judgment of the Division of Bioequivalence at this time. The Prescription and OTC Drug Product Lists identify reference drugs for oral dosage forms, Injectables, ophthalmics, otics, and topical products. It is recommended that a firm planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, contact the Division of Bioequivalence, Office of Generic Drugs, to confirm the appropriate reference listed drug.

#### 1.5 General Policies and Legal Status

The List contains public information and advice. It does not mandate the drug products which may be purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the List sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners and to the states regarding drug

product selection. These evaluations do not constitute determinations that any product is in violation of the Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the List identifies drug products approved under Section 505 of the Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the List does not necessarily mean that the drug product is either in violation of Section 505 of the Act, or that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion is based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

## 1.6 Practitioner/User Responsibilities

### ***Professional care and judgment should be exercised in using the List.***

Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be better stability of one product over another under adverse storage conditions, or allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's specification of that product is appropriate. Pharmacists must also be familiar with the expiration dates/times and labeling directions for storage of the different products, particularly for reconstituted products, to assure that patients are properly advised when one product is substituted for another.

***Multisource and single-source drug products.*** FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and, in addition, product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included on the List, but no therapeutic equivalence code is included with such products. Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, although not identified in the List, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

**Products on the List are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product.** The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In most instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is permitted by regulation to appear on the label, even when the manufacturer is not the marketer.

Although the products on the List are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms, that the applicant designations on the List are, in most cases, correct.

To relate firm name information on a product label to that on the List, the following should be noted: the applicant's name always appears on the List. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears on the List and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears on the List and both firm names may appear on the label. Firms with known corporate relationships are displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears on the List; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the List, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that on the List, the following should be noted: if the applicant is the marketer, its name appears on the List and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established drug name if no trade name exists) appears on the List. If a corporate relationship exists between an application holder and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the application holder to appear on the List. If there is no known corporate relationship between the applicant and the marketer, the established drug name appears on the List.

**Every product on the List is subject at all times to regulatory action.** From time to time, approved products may be found in violation of one or more provisions of the Act. In such circumstances, the Agency will commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product on the List. The main criterion for inclusion of a product is that it has an application with an effective approval that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product on the List will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the data upon which the Agency's assessment of whether a product meets the criteria for therapeutic equivalence was made.

## 1.7 Therapeutic Equivalence Evaluations Codes

The coding system for therapeutic equivalence evaluations is constructed to allow users to determine quickly whether the Agency has evaluated a particular approved product as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With few exceptions, the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter as follows:

**A Drug products that FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, i.e., drug products for which:**

- (1) there are no known or suspected bioequivalence problems. These are designated **AA, AN, AO, AP, or AT**, depending on the dosage form; or
- (2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

**B Drug products that FDA at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products, i.e.,**

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC, BD, BE, BN, BP, BR, BS, BT, BX, or B\***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

### "A" CODES

**Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.**

"A" products are those for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bio-equivalence. Drug products designated with an "A" code fall under one of two main policies:

- (1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is presumed and considered self-evident based on other data in the application for some dosage forms (e.g., solutions) or satisfied for solid oral dosage forms by a showing that an acceptable *in vitro* dissolution standard is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA, AN, AO, AP, or AT**, depending on the dosage form, as described below); or

(2) for those DESI drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional. For example, pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution. An FDA evaluation that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in the labeling of that product.

The Agency will use notes in this publication to point out special situations such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Special Situations*.

For example, in rare instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note will be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts and esters of the same therapeutic moiety are regarded as pharmaceutical alternatives. For the purpose of this publication, such products are not considered to be therapeutically equivalent. There are no instances in this List where pharmaceutical alternatives are evaluated or coded with regard to therapeutic equivalence. Anhydrous and hydrated entities, as well as different polymorphs, are considered pharmaceutical equivalents and must meet the same standards and, where necessary, as in the case of

ampicillin/ampicillin trihydrate, their equivalence is supported by appropriate bioavailability/bioequivalence studies.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives may differ among some therapeutically equivalent drug products. Differences in preservatives and other inactive ingredients do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

## **AA Products in conventional dosage forms not presenting bioequivalence problems**

Products coded as **AA** contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

## **AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements**

Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents*) generally will be coded **AB** if a study is submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

For example, Adalat® CC (Miles) and Procardia XL® (Pfizer), extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved, Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. The generic drug products bioequivalent to Adalat® CC would be assigned a rating of **AB1** and those bioequivalent to Procardia XL® would be assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the List, they are considered therapeutically equivalent to the application holder's drug product if the application holder's drug product is rated either with an **AB** or three-character code or is single source in the List. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code

under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

### **AN Solutions and powders for aerosolization**

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

### **AO Injectable oil solutions**

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

### **AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions**

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included on the List (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.



The strength of parenteral drugs products is defined as the total drug content of the container. Until recently the strength of liquid parenteral drug products in the Orange Book have not been displayed. The concentration of the liquid parenteral drug product in the Orange Book has been shown as xmg/ml. The amount of dry powder or freeze dried powder in a container has always been identified as the strength.

With the finalization of the Waxman-Hatch amendments that characterized each strength of a drug product as a listed drug, it became evident that the format of the Orange Book should be changed to reflect each strength of a parenteral solution. To this end the OGD has started to display the strength of all new approvals of parenteral solutions. Previously we would have displayed only the concentration of an approved parenteral solution, e.g. 50mg/ml. If this drug product had a 20 ml and 60 ml container approved the two products would be shown as 1Gm / 20ml (50mg/ml) and 3Gm / 60ml (50mg/ml).

### **AT Topical products**

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

### **"B" CODES**

#### **Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.**

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "B" code fall under one of three main policies:

- (1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bio-equivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or
- (2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or
- (3) the drug products are under regulatory review.

The specific coding definitions and policies for the "B" sub-codes are as follows:

## **B\* Drug products requiring further FDA investigation and review to determine therapeutic equivalence**

The code **B\*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B\*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

## **BC Extended-release dosage forms (capsules, injectables and tablets)**

Extended-release tablets are formulated in such a manner as to make the contained medicament available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because firms developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

## **BD Active ingredients and dosage forms with documented bioequivalence problems**

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

## **BE Delayed-release oral dosage forms**

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

## **BN Products in aerosol-nebulizer drug delivery systems**

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard, such products are coded **AB**.

## **BP Active ingredients and dosage forms with potential bioequivalence problems**

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate *in vivo* bioequivalence data are submitted, such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence, such products would be coded **AB**.

## **BR Suppositories or enemas that deliver drugs for systemic absorption**

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bio-equivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the product is coded **AB**. If such evidence is not available, the products are coded **BR**.

## **BS Products having drug standard deficiencies**

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

## **BT Topical products with bioequivalence issues**

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

## **BX Drug products for which the data are insufficient to determine therapeutic equivalence**

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically

inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

## 1.8 Description of Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. Following is a description of those special situations:

**Amino Acid and Protein Hydrolysate Injections.** These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

**Follitropin Alfa and Beta.** Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

**Gaviscon®.** Gaviscon® is an OTC product which has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test which is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs which cite Gaviscon® tablets as the listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

**Levothyroxine Sodium.** Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products with other products being similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KING PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

**Patent Certification(s) Reference Listed Drug based upon a suitability petition.** An abbreviated new drug application that refers to a Reference Listed Drug (RLD) approved pursuant to a suitability petition must demonstrate that the proposed product is bioequivalent to the RLD, and it must include appropriate patent certification(s) and an exclusivity statement with respect to the listed drug which served as the basis for the approved suitability petition. This concept also applies to an ANDA applicant that cites a RLD that was based upon an NDA that is still covered by patent (s) and/or exclusivity, e.g. a second RLD that was selected when the in vivo determination of bioequivalence of the original RLD is self evident and the waiver of the in vivo determination of bioequivalence may be granted.

**Waived exclusivity.** If a new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the latest expiring patent or exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waives its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. An NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The applicant referencing

this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity.

### 1.9 Therapeutic Equivalence Code Change for a Drug Entity

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multi-source drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of drug products in the List (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying a bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of drugs, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comment. Comments, along with scientific data, may be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, HFD-650, 7500 Standish Place, Rockville, MD 20855.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submission is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. These submissions should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and such submissions are discouraged. Copies of supporting reports published in the scientific literature or unpublished material, however, are welcome.

### 1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The aforementioned procedure does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

## 1.11 Discontinued Section

Those drug products in the Discontinued Section of the Orange Book in which a determination has already been made that the products were not withdrawn for safety or efficacy reasons have "\*\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*" following the product strength. Those drug products are only reflective of citizen petitions determinations made since 1995. The identification of these drug products in the Discontinued Section of the Orange Book should avoid the submission of multiple citizen petitions for the same drug product. FR notices no longer applicable are removed from the Annual Edition (i.e., there is a currently marketed Reference Listed Drug and no applicable patent or exclusivity). [FR Safety or Effectiveness Determinations List](#) lists products that have current and removed notices. The list is updated quarterly. Notices issued during the year are added to the [Electronic Orange Book Query](#) in the month they become effective.

Generally, approved products are added to the Discontinued Section of the Orange Book when the applicant holder notifies the Orange Book staff of the products' not marketed status. Products may also be added if annual reports indicate the product is no longer marketed or other Agency administrative action (e.g., Withdrawal of an Application). Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the Act.

## 1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. Please inform the OBS when products are no longer marketed. Notification of the Orange Book staff to include the newly approved product in the Discontinued Drug Product List rather than parts 1, 2 or 3 of the List (as discussed in Section 1.1) must occur by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update

We can be contacted by email at [drugproducts@fda.hhs.gov](mailto:drugproducts@fda.hhs.gov). Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff  
Office of Generic Drugs, HFD-610  
7500 Standish Place  
Rockville, MD 20855

## 1.13 Availability of the Edition

Commencing with the 25<sup>th</sup> edition, the Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the EOB home page, <http://www.fda.gov/cder/ob/default.htm>, by clicking on Publications. The PDF annual format duplicates previous paper versions except for the Orphan Products Designations and Approvals List. An annual subscription of the PDF format may be obtained from the U.S. Government Printing Office, 866-512-1800.

## 2. HOW TO USE THE DRUG PRODUCT LISTS

### 2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

**Illustrations.** The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

**Drug Product Lists.** The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, application holders, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by "N" is a New Drug Application (NDA or commonly the innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "A" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and



Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the 12th Cumulative Supplement of the 29th Edition List have been added to the Discontinued Drug Product List appearing in the 30th Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Section of the Orange Book.


**Product Name Index** (*Prescription and OTC Drug Product Lists*). This is an index of drug products by established or trade name. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

**Product Name Index Listed by Applicant** (*Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (\*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.


**Uniform Terms.** To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

## 2.2 DRUG PRODUCT ILLUSTRATION

### SINGLE INGREDIENT



### MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION



THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

## 2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **"A"**) UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **A**) AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH **"B"**) AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A **"B"**) ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE INTRODUCTION.

		<u>SULFASALAZINE</u>			
		TABLET; ORAL			
		<u>FAZINE</u>			
PRODUCTS CONSIDERED THERAPEUTICALLY EQUIVALENT TO EACH OTHER	→	<u>AB</u>	PARKLAND	<u>500MG</u>	A42999 001
		<u>SULAZINE</u>			
		<u>AB</u>	URSA	<u>500MG</u>	A40222 001
		SULFASALAZINE			
PRODUCTS CONSIDERED <b>NOT</b> THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCTS LISTED	→	BP	BROWN	500MG	A41297 001
		<u>SULFASALAZINE</u>			
		TABLET; ORAL			
		<u>FAZINE</u>			
PRODUCTS CONSIDERED <b>NOT</b> THERAPEUTICALLY EQUIVALENT TO EACH OTHER	→	<u>AB</u>	PARKLAND	<u>500MG</u>	A42999 001
			SULFASALAZINE		
		BP	BROWN	500MG	A41297 001
			SOUTH	500MG	A40627 001

NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

## PRESCRIPTION DRUG PRODUCT LIST

3 - 1 (of 393)

ABACAVIR SULFATE

SOLUTION; ORAL  
 ZIAGEN  
 + VIIV HLTHCARE EQ 20MG BASE/ML N020978 001 Dec 17, 1998

TABLET; ORAL  
 ZIAGEN  
 + VIIV HLTHCARE EQ 300MG BASE N020977 001 Dec 17, 1998

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL  
 EPZICOM  
 + VIIV HLTHCARE EQ 600MG BASE;300MG N021652 001 Aug 02, 2004

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL  
 TRIZIVIR  
 + VIIV HLTHCARE EQ 300MG BASE;150MG;300MG N021205 001 Nov 14, 2000

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL  
 CAMPRAL  
 + FOREST LABS 333MG N021431 001 Jul 29, 2004

ACARBOSE

TABLET; ORAL  
ACARBOSE

<u>AB</u>	COBALT LABS INC	<u>25MG</u>	<u>A077532</u>	<u>001</u>	May 07, 2008
<u>AB</u>		<u>50MG</u>	<u>A077532</u>	<u>002</u>	May 07, 2008
<u>AB</u>		<u>100MG</u>	<u>A077532</u>	<u>003</u>	May 07, 2008
<u>AB</u>	IMPAX LABS	<u>25MG</u>	<u>A078441</u>	<u>001</u>	May 14, 2009
<u>AB</u>		<u>50MG</u>	<u>A078441</u>	<u>002</u>	May 14, 2009
<u>AB</u>		<u>100MG</u>	<u>A078441</u>	<u>003</u>	May 14, 2009
<u>AB</u>	ROXANE	<u>25MG</u>	<u>A078470</u>	<u>001</u>	May 07, 2008
<u>AB</u>		<u>50MG</u>	<u>A078470</u>	<u>002</u>	May 07, 2008
<u>AB</u>		<u>100MG</u>	<u>A078470</u>	<u>003</u>	May 07, 2008

PRECOSE

<u>AB</u>	+ BAYER HLTHCARE	<u>25MG</u>	<u>N020482</u>	<u>004</u>	May 29, 1997
<u>AB</u>		<u>50MG</u>	<u>N020482</u>	<u>001</u>	Sep 06, 1995
<u>AB</u>		<u>100MG</u>	<u>N020482</u>	<u>002</u>	Sep 06, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL  
ACEBUTOLOL HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARM	<u>EQ 200MG BASE</u>	<u>A075047</u>	<u>001</u>	Dec 30, 1999
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A075047</u>	<u>002</u>	Dec 30, 1999
<u>AB</u>	MYLAN	<u>EQ 200MG BASE</u>	<u>A074288</u>	<u>001</u>	Apr 24, 1995
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A074288</u>	<u>002</u>	Apr 24, 1995
<u>AB</u>	WATSON LABS	<u>EQ 200MG BASE</u>	<u>A074007</u>	<u>001</u>	Oct 18, 1995
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A074007</u>	<u>002</u>	Oct 18, 1995

SECTRAL

<u>AB</u>	PROMIUS PHARMA	<u>EQ 200MG BASE</u>	<u>N018917</u>	<u>001</u>	Dec 28, 1984
<u>AB</u>	+	<u>EQ 400MG BASE</u>	<u>N018917</u>	<u>003</u>	Dec 28, 1984

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL  
 ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE  
 + MIKART 150MG;180MG;30MG A081096 001 Oct 26, 1990

## PRESCRIPTION DRUG PRODUCT LIST

3 - 2 (of 393)

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

PHRENILIN FORTE

+ VALEANT	650MG;50MG	A088831	001	Jun 19, 1985
-----------	------------	---------	-----	--------------

TABLET; ORAL

BUTAPAP

<u>AB</u> MIKART	<u>325MG;50MG</u>	<u>A089987</u>	<u>001</u>	Oct 26, 1992
------------------	-------------------	----------------	------------	--------------

PHRENILIN

<u>AB</u> + VALEANT	<u>325MG;50MG</u>	<u>A087811</u>	<u>001</u>	Jun 19, 1985
---------------------	-------------------	----------------	------------	--------------

BUTAPAP

+ MIKART	650MG;50MG	A089988	001	Oct 26, 1992
----------	------------	---------	-----	--------------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

<u>AB</u> WEST WARD	<u>500MG;50MG;40MG</u>	<u>A040261</u>	<u>001</u>	Oct 28, 1998
---------------------	------------------------	----------------	------------	--------------

ESGIC-PLUS

<u>AB</u> + MIKART	<u>500MG;50MG;40MG</u>	<u>A040085</u>	<u>001</u>	Mar 28, 1996
--------------------	------------------------	----------------	------------	--------------

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+ MIKART	325MG;50MG;40MG	A089007	001	Mar 17, 1986
----------	-----------------	---------	-----	--------------

NEXGEN PHARMA	300MG;50MG;40MG	A040885	001	Nov 16, 2009
---------------	-----------------	---------	-----	--------------

SOLUTION; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+ MIKART	325MG/15ML;50MG/15ML;40MG/15ML	A040387	001	Jan 31, 2003
----------	--------------------------------	---------	-----	--------------

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

<u>AB</u> CONCORD LABS NJ	<u>325MG;50MG;40MG</u>	<u>A040864</u>	<u>001</u>	Dec 01, 2008
---------------------------	------------------------	----------------	------------	--------------

<u>AB</u>	<u>500MG;50MG;40MG</u>	<u>A040883</u>	<u>001</u>	Dec 23, 2008
-----------	------------------------	----------------	------------	--------------

<u>AB</u> MALLINCKRODT	<u>325MG;50MG;40MG</u>	<u>A087804</u>	<u>001</u>	Jan 24, 1985
------------------------	------------------------	----------------	------------	--------------

<u>AB</u> MIKART	<u>325MG;50MG;40MG</u>	<u>A089175</u>	<u>001</u>	Jan 21, 1987
------------------	------------------------	----------------	------------	--------------

<u>AB</u> VINTAGE PHARMS	<u>325MG;50MG;40MG</u>	<u>A040511</u>	<u>001</u>	Aug 27, 2003
--------------------------	------------------------	----------------	------------	--------------

<u>AB</u>	<u>500MG;50MG;40MG</u>	<u>A040513</u>	<u>001</u>	Aug 25, 2003
-----------	------------------------	----------------	------------	--------------

<u>AB</u> WATSON LABS	<u>500MG;50MG;40MG</u>	<u>A040267</u>	<u>001</u>	Jul 30, 1998
-----------------------	------------------------	----------------	------------	--------------

<u>AB</u> WEST WARD	<u>325MG;50MG;40MG</u>	<u>A089718</u>	<u>001</u>	Jun 12, 1995
---------------------	------------------------	----------------	------------	--------------

<u>AB</u>	<u>500MG;50MG;40MG</u>	<u>A040336</u>	<u>001</u>	Aug 18, 1999
-----------	------------------------	----------------	------------	--------------

ESGIC-PLUS

<u>AB</u> + MIKART	<u>500MG;50MG;40MG</u>	<u>A089451</u>	<u>001</u>	May 23, 1988
--------------------	------------------------	----------------	------------	--------------

FIORICET

<u>AB</u> + WATSON PHARMS	<u>325MG;50MG;40MG</u>	<u>A088616</u>	<u>001</u>	Nov 09, 1984
---------------------------	------------------------	----------------	------------	--------------

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+ MIKART	750MG;50MG;40MG	A040496	001	Dec 23, 2003
----------	-----------------	---------	-----	--------------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

<u>AB</u> NEXGEN PHARMA INC	<u>325MG;50MG;40MG;30MG</u>	<u>A076560</u>	<u>001</u>	Jun 10, 2004
-----------------------------	-----------------------------	----------------	------------	--------------

<u>AB</u> VINTAGE PHARMS	<u>325MG;50MG;40MG;30MG</u>	<u>A075929</u>	<u>001</u>	Apr 22, 2002
--------------------------	-----------------------------	----------------	------------	--------------

<u>AB</u> WEST WARD	<u>325MG;50MG;40MG;30MG</u>	<u>A075618</u>	<u>001</u>	Mar 23, 2001
---------------------	-----------------------------	----------------	------------	--------------

FIORICET W/ CODEINE

<u>AB</u> + WATSON PHARMS	<u>325MG;50MG;40MG;30MG</u>	<u>N020232</u>	<u>001</u>	Jul 30, 1992
---------------------------	-----------------------------	----------------	------------	--------------

PHRENILIN WITH CAFFEINE AND CODEINE

<u>AB</u> VALEANT	<u>325MG;50MG;40MG;30MG</u>	<u>A074911</u>	<u>001</u>	Aug 22, 2001
-------------------	-----------------------------	----------------	------------	--------------

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

<u>AA</u> E5 PHARMA INC	<u>356.4MG;30MG;16MG</u>	<u>A040688</u>	<u>001</u>	Apr 03, 2007
-------------------------	--------------------------	----------------	------------	--------------

<u>AA</u> + MIKART	<u>356.4MG;30MG;16MG</u>	<u>A040109</u>	<u>001</u>	Aug 26, 1997
--------------------	--------------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 3 (of 393)

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

<u>AA</u>	BOCA PHARMA	<u>712.8MG;60MG;32MG</u>	<u>A040701</u>	<u>001</u>	Apr 03, 2007
<u>AA</u>	+ MIKART	<u>712.8MG;60MG;32MG</u>	<u>A040316</u>	<u>001</u>	Apr 28, 1999
<u>AA</u>	WEST WARD	<u>712.8MG;60MG;32MG</u>	<u>A040637</u>	<u>001</u>	Sep 22, 2006

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>120MG/5ML;12MG/5ML</u>	<u>A085861</u>	<u>001</u>	
<u>AA</u>	HI TECH PHARMA	<u>120MG/5ML;12MG/5ML</u>	<u>A040119</u>	<u>001</u>	Apr 26, 1996
<u>AA</u>	MIKART	<u>120MG/5ML;12MG/5ML</u>	<u>A089450</u>	<u>001</u>	Oct 27, 1992
<u>AA</u>	MORTON GROVE	<u>120MG/5ML;12MG/5ML</u>	<u>A087006</u>	<u>001</u>	
<u>AA</u>	PHARM ASSOC	<u>120MG/5ML;12MG/5ML</u>	<u>A087508</u>	<u>001</u>	

SUSPENSION; ORAL

CAPITAL AND CODEINE

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>120MG/5ML;12MG/5ML</u>	<u>A085883</u>	<u>001</u>	
<u>AA</u>	+ VALEANT	<u>120MG/5ML;12MG/5ML</u>	<u>A086024</u>	<u>001</u>	

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	AMNEAL PHARMS NY	<u>300MG;30MG</u>	<u>A040779</u>	<u>001</u>	May 29, 2008
<u>AA</u>	+ DURAMED PHARMS BARR	<u>300MG;15MG</u>	<u>A040223</u>	<u>001</u>	Nov 18, 1997
<u>AA</u>		<u>300MG;30MG</u>	<u>A040223</u>	<u>002</u>	Nov 18, 1997
<u>AA</u>		<u>300MG;60MG</u>	<u>A040223</u>	<u>003</u>	Nov 18, 1997
<u>AA</u>	MALLINCKRODT	<u>300MG;15MG</u>	<u>A040419</u>	<u>001</u>	May 31, 2001
<u>AA</u>		<u>300MG;30MG</u>	<u>A040419</u>	<u>002</u>	May 31, 2001
<u>AA</u>		<u>300MG;60MG</u>	<u>A040419</u>	<u>003</u>	May 31, 2001
<u>AA</u>	MIKART	<u>300MG;30MG</u>	<u>A089238</u>	<u>001</u>	Feb 25, 1986
<u>AA</u>	RANBAXY	<u>300MG;30MG</u>	<u>A085868</u>	<u>001</u>	
<u>AA</u>		<u>300MG;60MG</u>	<u>A087083</u>	<u>001</u>	
<u>AA</u>	TEVA	<u>300MG;15MG</u>	<u>A088627</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG;30MG</u>	<u>A088628</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>	+	<u>300MG;60MG</u>	<u>A088629</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>	VINTAGE	<u>300MG;15MG</u>	<u>A089990</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>		<u>300MG;30MG</u>	<u>A089805</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>	VINTAGE PHARMS	<u>300MG;60MG</u>	<u>A089828</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>	WATSON LABS	<u>300MG;15MG</u>	<u>A089997</u>	<u>001</u>	Dec 28, 1994
<u>AA</u>		<u>300MG;30MG</u>	<u>A089998</u>	<u>001</u>	Dec 28, 1994
<u>AA</u>		<u>300MG;60MG</u>	<u>A089999</u>	<u>001</u>	Dec 28, 1994
<u>AA</u>	WATSON LABS FLORIDA	<u>300MG;15MG</u>	<u>A040443</u>	<u>001</u>	Jan 22, 2003
<u>AA</u>		<u>300MG;30MG</u>	<u>A040443</u>	<u>002</u>	Jan 22, 2003
<u>AA</u>		<u>300MG;60MG</u>	<u>A040443</u>	<u>003</u>	Jan 22, 2003
	<u>TYLENOL W/ CODEINE NO. 3</u>				
<u>AA</u>	+ ORTHO MCNEIL JANSSEN	<u>300MG;30MG</u>	<u>A085055</u>	<u>003</u>	
	<u>TYLENOL W/ CODEINE NO. 4</u>				
<u>AA</u>	ORTHO MCNEIL JANSSEN	<u>300MG;60MG</u>	<u>A085055</u>	<u>004</u>	
	ACETAMINOPHEN AND CODEINE PHOSPHATE				
	+ MIKART	650MG;30MG	A089231	001	Mar 03, 1986
	+	650MG;60MG	A089363	001	Sep 09, 1991

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	MIKART	<u>500MG;5MG</u>	<u>A081067</u>	<u>001</u>	Nov 30, 1989
<u>AA</u>		<u>500MG;5MG</u>	<u>A089008</u>	<u>001</u>	Feb 21, 1986

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	KV PHARM	<u>500MG/15ML;7.5MG/15ML</u>	<u>A040366</u>	<u>001</u>	Jan 23, 2002
-----------	----------	------------------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 4 (of 393)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	MALLINCKRODT	<u>500MG/15ML; 7.5MG/15ML</u>	<u>A040418</u>	<u>001</u>	Jun 27, 2001
<u>AA</u>	+ MIKART	<u>500MG/15ML; 7.5MG/15ML</u>	<u>A081051</u>	<u>001</u>	Aug 28, 1992
<u>AA</u>	PHARM ASSOC	<u>500MG/15ML; 7.5MG/15ML</u>	<u>A040182</u>	<u>001</u>	Mar 13, 1998
<u>AA</u>	VINTAGE PHARMS	<u>500MG/15ML; 7.5MG/15ML</u>	<u>A040520</u>	<u>001</u>	Oct 30, 2003
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
	+ MALLINCKRODT	500MG/15ML; 10MG/15ML	A040508	001	Aug 29, 2003
	+ MIKART	325MG/15ML; 7.5MG/15ML	A040482	001	Sep 25, 2003
	+ PHARM ASSOC	325MG/15ML; 10MG/15ML	A040834	001	Apr 18, 2008

TABLET; ORAL

ANEXSIA

<u>AA</u>	MALLINCKRODT	<u>500MG; 5MG</u>	<u>A089160</u>	<u>001</u>	Apr 23, 1987
<u>AA</u>		<u>750MG; 10MG</u>	<u>A040468</u>	<u>001</u>	Oct 31, 2002
	<u>ANEXSIA 5/325</u>				
<u>AA</u>	MALLINCKRODT	<u>325MG; 5MG</u>	<u>A040409</u>	<u>001</u>	Oct 20, 2000
	<u>ANEXSIA 7.5/325</u>				
<u>AA</u>	MALLINCKRODT	<u>325MG; 7.5MG</u>	<u>A040405</u>	<u>001</u>	Sep 08, 2000
	<u>ANEXSIA 7.5/650</u>				
<u>AA</u>	MALLINCKRODT	<u>650MG; 7.5MG</u>	<u>A089725</u>	<u>001</u>	Sep 30, 1987
	<u>CO-GESIC</u>				
<u>AA</u>	SCHWARZ PHARMA	<u>500MG; 5MG</u>	<u>A087757</u>	<u>001</u>	May 03, 1982

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	AMNEAL PHARMS NY	<u>325MG; 5MG</u>	<u>A040736</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040746</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>500MG; 5MG</u>	<u>A040729</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040748</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>500MG; 10MG</u>	<u>A040813</u>	<u>001</u>	Feb 23, 2007
<u>AA</u>		<u>650MG; 7.5MG</u>	<u>A040754</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040757</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>750MG; 7.5MG</u>	<u>A040769</u>	<u>001</u>	Aug 28, 2006
<u>AA</u>	MALLINCKRODT	<u>325MG; 10MG</u>	<u>A040400</u>	<u>001</u>	Jul 26, 2000
<u>AA</u>		<u>500MG; 5MG</u>	<u>A040084</u>	<u>002</u>	Jun 01, 1995
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040201</u>	<u>001</u>	Feb 27, 1998
<u>AA</u>		<u>500MG; 10MG</u>	<u>A040201</u>	<u>002</u>	Feb 27, 1998
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040084</u>	<u>004</u>	Oct 16, 1996
<u>AA</u>		<u>660MG; 10MG</u>	<u>A040084</u>	<u>003</u>	Jul 29, 1996
<u>AA</u>		<u>750MG; 7.5MG</u>	<u>A040084</u>	<u>001</u>	Jun 01, 1995
<u>AA</u>	MIKART	<u>325MG; 7.5MG</u>	<u>A040432</u>	<u>001</u>	Jan 22, 2003
<u>AA</u>		<u>500MG; 2.5MG</u>	<u>A089698</u>	<u>001</u>	Aug 25, 1989
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A089699</u>	<u>001</u>	Aug 25, 1989
<u>AA</u>		<u>650MG; 7.5MG</u>	<u>A089689</u>	<u>001</u>	Jun 29, 1988
<u>AA</u>		<u>650MG; 10MG</u>	<u>A081223</u>	<u>001</u>	May 29, 1992
<u>AA</u>	RANBAXY	<u>325MG; 10MG</u>	<u>A040826</u>	<u>001</u>	Aug 16, 2007
<u>AA</u>		<u>500MG; 5MG</u>	<u>A040825</u>	<u>001</u>	Aug 16, 2007
<u>AA</u>		<u>500MG; 10MG</u>	<u>A040824</u>	<u>001</u>	Aug 16, 2007
<u>AA</u>		<u>750MG; 7.5MG</u>	<u>A040822</u>	<u>001</u>	Aug 16, 2007
<u>AA</u>	SANDOZ	<u>500MG; 5MG</u>	<u>A040149</u>	<u>001</u>	Jan 27, 1997
<u>AA</u>		<u>750MG; 7.5MG</u>	<u>A040149</u>	<u>002</u>	Jan 27, 1997
<u>AA</u>	SUN PHARM INDS INC	<u>325MG; 5MG</u>	<u>A090118</u>	<u>001</u>	Dec 23, 2008
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090118</u>	<u>002</u>	Dec 23, 2008
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090118</u>	<u>003</u>	Dec 23, 2008
<u>AA</u>		<u>500MG; 5MG</u>	<u>A090265</u>	<u>001</u>	Dec 23, 2008
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A090265</u>	<u>002</u>	Dec 23, 2008
<u>AA</u>		<u>500MG; 10MG</u>	<u>A090265</u>	<u>003</u>	Dec 23, 2008
<u>AA</u>		<u>650MG; 7.5MG</u>	<u>A090380</u>	<u>001</u>	Dec 23, 2008
<u>AA</u>		<u>650MG; 10MG</u>	<u>A090380</u>	<u>002</u>	Dec 23, 2008
<u>AA</u>		<u>660MG; 10MG</u>	<u>A090380</u>	<u>003</u>	Dec 23, 2008
<u>AA</u>		<u>750MG; 7.5MG</u>	<u>A090380</u>	<u>004</u>	Dec 23, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 5 (of 393)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	VINTAGE PHARMS	<u>325MG; 5MG</u>	<u>A040655</u>	<u>001</u>	Jan 19, 2006
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040656</u>	<u>001</u>	Jan 19, 2006
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040355</u>	<u>001</u>	May 31, 2000
<u>AA</u>		<u>500MG; 2.5MG</u>	<u>A040144</u>	<u>002</u>	Apr 25, 1997
<u>AA</u>		<u>500MG; 5MG</u>	<u>A089971</u>	<u>001</u>	Dec 02, 1988
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040144</u>	<u>001</u>	Feb 22, 1996
<u>AA</u>		<u>500MG; 10MG</u>	<u>A040356</u>	<u>001</u>	May 31, 2000
<u>AA</u>		<u>650MG; 7.5MG</u>	<u>A040155</u>	<u>001</u>	Apr 14, 1997
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040143</u>	<u>001</u>	Feb 22, 1996
<u>AA</u>		<u>660MG; 10MG</u>	<u>A040358</u>	<u>001</u>	May 31, 2000
<u>AA</u>		<u>750MG; 7.5MG</u>	<u>A040157</u>	<u>001</u>	Apr 12, 1996
<u>AA</u>	WATSON LABS	<u>325MG; 10MG</u>	<u>A040248</u>	<u>002</u>	Apr 28, 2000
<u>AA</u>		<u>500MG; 2.5MG</u>	<u>A040123</u>	<u>003</u>	Mar 04, 1996
<u>AA</u>		<u>500MG; 2.5MG</u>	<u>A081079</u>	<u>001</u>	Aug 30, 1991
<u>AA</u>		<u>500MG; 5MG</u>	<u>A089883</u>	<u>001</u>	Dec 01, 1988
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040123</u>	<u>004</u>	Mar 04, 1996
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A081080</u>	<u>001</u>	Aug 30, 1991
<u>AA</u>		<u>500MG; 10MG</u>	<u>A040148</u>	<u>002</u>	Feb 14, 1997
<u>AA</u>		<u>650MG; 7.5MG</u>	<u>A040094</u>	<u>001</u>	Sep 29, 1995
<u>AA</u>		<u>650MG; 7.5MG</u>	<u>A040123</u>	<u>001</u>	Mar 04, 1996
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040094</u>	<u>002</u>	Sep 29, 1995
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040123</u>	<u>002</u>	Mar 04, 1996
<u>AA</u>		<u>660MG; 10MG</u>	<u>A040094</u>	<u>003</u>	Aug 08, 2000
<u>AA</u>		<u>750MG; 7.5MG</u>	<u>A081083</u>	<u>001</u>	Aug 30, 1991
<u>AA</u>	+	<u>750MG; 10MG</u>	<u>A040094</u>	<u>004</u>	Mar 22, 1999
<u>AA</u>	WATSON LABS FLORIDA	<u>500MG; 5MG</u>	<u>A040493</u>	<u>001</u>	May 28, 2003
<u>AA</u>		<u>660MG; 10MG</u>	<u>A040495</u>	<u>001</u>	May 28, 2003
<u>AA</u>		<u>750MG; 7.5MG</u>	<u>A040494</u>	<u>001</u>	May 28, 2003
	<u>LORTAB</u>				
<u>AA</u>	MALLINCKRODT	<u>500MG; 5MG</u>	<u>A087722</u>	<u>001</u>	Jul 09, 1982
<u>AA</u>	+	<u>500MG; 10MG</u>	<u>A040100</u>	<u>001</u>	Jan 26, 1996
	<u>NORCO</u>				
<u>AA</u>	+	<u>325MG; 5MG</u>	<u>A040099</u>	<u>001</u>	Jun 25, 1997
<u>AA</u>	+	<u>325MG; 7.5MG</u>	<u>A040148</u>	<u>003</u>	Sep 12, 2000
<u>AA</u>	+	<u>325MG; 10MG</u>	<u>A040148</u>	<u>001</u>	Feb 14, 1997
	<u>VICODIN</u>				
<u>AA</u>	+	<u>500MG; 5MG</u>	<u>A088058</u>	<u>001</u>	Jan 07, 1983
	<u>VICODIN ES</u>				
<u>AA</u>	+	<u>750MG; 7.5MG</u>	<u>A089736</u>	<u>001</u>	Dec 09, 1988
	<u>VICODIN HP</u>				
<u>AA</u>	ABBOTT	<u>660MG; 10MG</u>	<u>A040117</u>	<u>001</u>	Sep 23, 1996
	<u>HYDROCODONE BITARTRATE AND ACETAMINOPHEN</u>				
	MIKART	300MG; 5MG	A040658	001	Jan 19, 2006
	+	300MG; 7.5MG	A040556	002	Mar 24, 2006
	+	300MG; 10MG	A040556	001	Jun 23, 2004
	ZYDONE				
	+	400MG; 5MG	A040288	001	Nov 27, 1998
	+	400MG; 7.5MG	A040288	002	Nov 27, 1998
	+	400MG; 10MG	A040288	003	Nov 27, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	ACTAVIS TOTOWA	<u>500MG; 5MG</u>	<u>A040199</u>	<u>001</u>	Dec 30, 1998
<u>AA</u>	DURAMED PHARMS BARR	<u>500MG; 5MG</u>	<u>A040289</u>	<u>001</u>	Mar 16, 1999
<u>AA</u>	ENDO PHARMS	<u>500MG; 5MG</u>	<u>A040303</u>	<u>001</u>	Dec 30, 1999
<u>AA</u>	MALLINCKRODT	<u>500MG; 5MG</u>	<u>A040257</u>	<u>001</u>	Aug 04, 1998



## PRESCRIPTION DRUG PRODUCT LIST

3 - 6 (of 393)

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	VINTAGE PHARMS	<u>500MG; 5MG</u>	<u>A040106</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>	WATSON LABS	<u>500MG; 5MG</u>	<u>A040234</u>	<u>001</u>	Oct 30, 1997
<u>ROXILOX</u>					
<u>AA</u>	ROXANE	<u>500MG; 5MG</u>	<u>A040061</u>	<u>001</u>	Jul 03, 1995
<u>TYLOX</u>					
<u>AA</u>	+ ORTHO MCNEIL JANSSEN	<u>500MG; 5MG</u>	<u>A088790</u>	<u>001</u>	Dec 12, 1984

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	MALLINCKRODT	<u>325MG/ 5ML; 5MG/ 5ML</u>	<u>A040680</u>	<u>001</u>	Sep 29, 2006
<u>ROXICET</u>					
<u>AA</u>	+ ROXANE	<u>325MG/ 5ML; 5MG/ 5ML</u>	<u>A089351</u>	<u>001</u>	Dec 03, 1986

TABLET; ORAL

OXYCET

<u>AA</u>	MALLINCKRODT	<u>325MG; 5MG</u>	<u>A087463</u>	<u>001</u>	Dec 07, 1983
-----------	--------------	-------------------	----------------	------------	--------------

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	ACTAVIS TOTOWA	<u>325MG; 5MG</u>	<u>A040203</u>	<u>001</u>	Mar 15, 1999
<u>AA</u>	AMNEAL PHARMS NY	<u>325MG; 5MG</u>	<u>A040777</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040778</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040789</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040789</u>	<u>002</u>	Nov 27, 2007
<u>AA</u>	COASTAL PHARMS	<u>325MG; 2.5MG</u>	<u>A090177</u>	<u>001</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090177</u>	<u>002</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090177</u>	<u>003</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090177</u>	<u>004</u>	Oct 20, 2008
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A090177</u>	<u>005</u>	Oct 20, 2008
<u>AA</u>		<u>650MG; 10MG</u>	<u>A090177</u>	<u>006</u>	Oct 20, 2008
<u>AA</u>	MALLINCKRODT	<u>325MG; 7.5MG</u>	<u>A040545</u>	<u>001</u>	Jun 30, 2004
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040545</u>	<u>002</u>	Jun 30, 2004
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040550</u>	<u>001</u>	Jun 30, 2004
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040550</u>	<u>002</u>	Jun 30, 2004
<u>AA</u>	VINTAGE PHARMS	<u>325MG; 5MG</u>	<u>A040105</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>	WATSON LABS	<u>325MG; 5MG</u>	<u>A040171</u>	<u>001</u>	Oct 30, 1997
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040535</u>	<u>001</u>	Sep 05, 2003
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040535</u>	<u>002</u>	Sep 05, 2003
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040371</u>	<u>001</u>	Dec 29, 2000
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040371</u>	<u>002</u>	Dec 29, 2000

PERCOCET

<u>AA</u>	+ ENDO PHARMS	<u>325MG; 2.5MG</u>	<u>A040330</u>	<u>001</u>	Jun 25, 1999
<u>AA</u>	+	<u>325MG; 5MG</u>	<u>A040330</u>	<u>002</u>	Jun 25, 1999
<u>AA</u>	+	<u>325MG; 7.5MG</u>	<u>A040434</u>	<u>001</u>	Nov 23, 2001
<u>AA</u>	+	<u>325MG; 10MG</u>	<u>A040434</u>	<u>002</u>	Nov 23, 2001
<u>AA</u>	+	<u>500MG; 7.5MG</u>	<u>A040341</u>	<u>001</u>	Jul 26, 1999
<u>AA</u>	+	<u>650MG; 10MG</u>	<u>A040341</u>	<u>002</u>	Jul 26, 1999

ROXICET

<u>AA</u>	ROXANE	<u>325MG; 5MG</u>	<u>A087003</u>	<u>001</u>	
<u>OXYCODONE AND ACETAMINOPHEN</u>					
+	MIKART	300MG; 2.5MG	A040608	001	Dec 30, 2005
+		300MG; 5MG	A040608	002	Dec 30, 2005
+		300MG; 7.5MG	A040608	003	Dec 30, 2005
+		300MG; 10MG	A040608	004	Dec 30, 2005
+		400MG; 2.5MG	A040679	001	May 16, 2006
+		400MG; 5MG	A040687	001	Apr 27, 2006
+		400MG; 7.5MG	A040698	001	Apr 27, 2006
+		400MG; 10MG	A040692	001	Apr 27, 2006
+		500MG; 10MG	A040676	001	Apr 19, 2006

ROXICET 5/500

+	ROXANE	500MG; 5MG	A089775	001	Jan 12, 1989
---	--------	------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 7 (of 393)

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>650MG;EQ 25MG BASE</u>	<u>A076202</u>	<u>001</u>	Aug 02, 2002
<u>AB</u>	WATSON LABS	<u>650MG;EQ 25MG BASE</u>	<u>A074699</u>	<u>001</u>	Mar 24, 2000
<u>TALACEN</u>					
<u>AB</u>	+ SANOFI AVENTIS US	<u>650MG;EQ 25MG BASE</u>	<u>N018458</u>	<u>001</u>	Sep 23, 1982

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

<u>AA</u>	+ MYLAN	<u>650MG;65MG</u>	<u>A083978</u>	<u>001</u>	
<u>AA</u>	VINTAGE PHARMS	<u>650MG;65MG</u>	<u>A040507</u>	<u>001</u>	Jul 30, 2003

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500

<u>AB</u>	XANODYNE PHARM	<u>500MG;100MG</u>	<u>A076429</u>	<u>001</u>	Sep 10, 2003
<u>DARVOCET-N 100</u>					
<u>AB</u>	+ XANODYNE PHARM	<u>650MG;100MG</u>	<u>N017122</u>	<u>002</u>	
<u>DARVOCET-N 50</u>					
<u>AB</u>	XANODYNE PHARM	<u>325MG;50MG</u>	<u>N017122</u>	<u>001</u>	
<u>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN</u>					
<u>AB</u>	CONCORD LABS NJ	<u>650MG;100MG</u>	<u>A077821</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>	CORNERSTONE	<u>500MG;100MG</u>	<u>A076750</u>	<u>001</u>	Jun 28, 2004
<u>AB</u>	MYLAN	<u>650MG;100MG</u>	<u>A070145</u>	<u>001</u>	Jun 12, 1985
<u>AB</u>	TEVA	<u>650MG;100MG</u>	<u>A074119</u>	<u>001</u>	Dec 19, 1994
<u>AB</u>	VINTAGE PHARMS	<u>325MG;50MG</u>	<u>A074843</u>	<u>002</u>	Feb 15, 2001
<u>AB</u>		<u>650MG;100MG</u>	<u>A074843</u>	<u>001</u>	Feb 12, 1997
<u>AB</u>	WOCKHARDT	<u>325MG;50MG</u>	<u>A077677</u>	<u>001</u>	Mar 16, 2007
<u>AB</u>		<u>650MG;100MG</u>	<u>A077677</u>	<u>002</u>	Mar 16, 2007
	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN				
	CORNERSTONE	<u>325MG;100MG</u>	<u>A076743</u>	<u>001</u>	May 07, 2004

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

<u>AB</u>	AMNEAL PHARMS	<u>325MG;37.5MG</u>	<u>A090485</u>	<u>001</u>	Dec 09, 2009
<u>AB</u>	CARACO	<u>325MG;37.5MG</u>	<u>A077184</u>	<u>001</u>	Dec 16, 2005
<u>AB</u>	KALI LABS	<u>325MG;37.5MG</u>	<u>A076475</u>	<u>001</u>	Apr 21, 2005
<u>AB</u>	MYLAN	<u>325MG;37.5MG</u>	<u>A077858</u>	<u>001</u>	Sep 26, 2008
<u>AB</u>	WATSON LABS	<u>325MG;37.5MG</u>	<u>A076914</u>	<u>001</u>	Jul 26, 2006
<u>ULTRACET</u>					
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>325MG;37.5MG</u>	<u>N021123</u>	<u>001</u>	Aug 15, 2001

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

<u>AB</u>	ZYDUS PHARMS USA INC	<u>500MG</u>	<u>A040904</u>	<u>001</u>	Dec 10, 2008
<u>DIAMOX</u>					
<u>AB</u>	+ DURAMED PHARMS BARR	<u>500MG</u>	<u>N012945</u>	<u>001</u>	

TABLET; ORAL

ACETAZOLAMIDE

<u>AB</u>	LANNETT	<u>250MG</u>	<u>A084840</u>	<u>001</u>	
<u>AB</u>	MUTUAL PHARM	<u>125MG</u>	<u>A089752</u>	<u>001</u>	Jun 22, 1988
<u>AB</u>	TARO	<u>125MG</u>	<u>A040195</u>	<u>001</u>	May 28, 1997
<u>AB</u>	+	<u>250MG</u>	<u>A040195</u>	<u>002</u>	May 28, 1997
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A088882</u>	<u>001</u>	Oct 22, 1985

## PRESCRIPTION DRUG PRODUCT LIST

3 - 8 (of 393)

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

<u>AP</u>	BEDFORD	<u>EQ 500MG BASE/VIAL</u>	<u>A040089</u>	<u>001</u>	Feb 28, 1995
<u>AP</u>	X GEN PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A040784</u>	<u>001</u>	Dec 10, 2008
<u>DIAMOX</u>					
<u>AP</u>	+ DURAMED PHARMS BARR	<u>EQ 500MG BASE/VIAL</u>	<u>N009388</u>	<u>001</u>	Dec 05, 1990

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>250MG/100ML</u>	<u>N018161</u>	<u>001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>250MG/100ML</u>	<u>N018523</u>	<u>001</u>	Feb 19, 1982
<u>AT</u>	HOSPIRA	<u>250MG/100ML</u>	<u>N017656</u>	<u>001</u>	

SOLUTION/DROPS; OTIC

ACETASOL

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>2%</u>	<u>A087146</u>	<u>001</u>	
<u>ACETIC ACID</u>					
<u>AT</u>	+ MORTON GROVE	<u>2%</u>	<u>A040166</u>	<u>001</u>	Jul 26, 1996
<u>AT</u>	TARO	<u>2%</u>	<u>A088638</u>	<u>001</u>	Sep 06, 1984
<u>AT</u>	VINTAGE	<u>2%</u>	<u>A040607</u>	<u>001</u>	Feb 24, 2005
<u>VOSOL</u>					
<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>N012179</u>	<u>001</u>	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

	+ BAUSCH AND LOMB	<u>2%;0.79%</u>	A040063	001	Feb 25, 1994
--	-------------------	-----------------	---------	-----	--------------

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETASOL HC

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>2%;1%</u>	<u>A087143</u>	<u>001</u>	Jan 13, 1982
<u>HYDROCORTISONE AND ACETIC ACID</u>					
<u>AT</u>	TARO	<u>2%;1%</u>	<u>A088759</u>	<u>001</u>	Mar 04, 1985
<u>AT</u>	VINTAGE	<u>2%;1%</u>	<u>A040609</u>	<u>001</u>	Feb 06, 2006
<u>VOSOL HC</u>					
<u>AT</u>	+ HI TECH PHARMA	<u>2%;1%</u>	<u>N012770</u>	<u>001</u>	

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

	WATSON LABS	250MG	A071893	001	Nov 25, 1987
	+	500MG	A071894	001	Nov 25, 1987

ACETOHYDROXAMIC ACID

TABLET; ORAL

LITHOSTAT

	+ MISSION PHARMA	250MG	N018749	001	May 31, 1983
--	------------------	-------	---------	-----	--------------

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL-E

	+ NOVARTIS	20MG/VIAL	N020213	001	Sep 22, 1993
--	------------	-----------	---------	-----	--------------

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTE

	+ CUMBERLAND PHARMS	6GM/30ML (200MG/ML)	N021539	001	Jan 23, 2004
--	---------------------	---------------------	---------	-----	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 35 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 9 (of 393)

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

<u>AN</u>	BEDFORD	<u>10%</u>	<u>A072323</u>	<u>001</u>	Apr 30, 1992
<u>AN</u>		<u>20%</u>	<u>A072324</u>	<u>001</u>	Apr 30, 1992
<u>AN</u>	HOSPIRA	<u>10%</u>	<u>A073664</u>	<u>001</u>	Aug 30, 1994
<u>AN</u>		<u>20%</u>	<u>A074037</u>	<u>001</u>	Aug 30, 1994
<u>AN</u>	+ LUITPOLD	<u>10%</u>	<u>A072489</u>	<u>001</u>	Jul 28, 1995
<u>AN</u>	+	<u>20%</u>	<u>A072547</u>	<u>001</u>	Jul 28, 1995

ACITRETIN

CAPSULE; ORAL

SORIATANE

	STIEFEL LABS INC	10MG	N019821	001	Oct 28, 1996
+		25MG	N019821	002	Oct 28, 1996

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+	UCB INC	8MG;60MG	N019806	001	Mar 25, 1994
---	---------	----------	---------	-----	--------------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

<u>AB</u>	ACTAVIS ELIZABETH	<u>200MG</u>	<u>A074906</u>	<u>001</u>	Aug 26, 1997
<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A075677</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>	DAVA PHARMS INC	<u>200MG</u>	<u>A074833</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>	GENPHARM	<u>200MG</u>	<u>A074977</u>	<u>001</u>	Apr 13, 1998
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>200MG</u>	<u>A074674</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>	RANBAXY	<u>200MG</u>	<u>A074975</u>	<u>001</u>	Sep 30, 1998
<u>AB</u>	STASON	<u>200MG</u>	<u>A075090</u>	<u>001</u>	Jan 26, 1999
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074578</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>	WATSON LABS	<u>200MG</u>	<u>A075101</u>	<u>001</u>	Apr 15, 1998

<u>AB</u>	+ GLAXOSMITHKLINE	<u>200MG</u>	<u>N018828</u>	<u>001</u>	Jan 25, 1985
-----------	-------------------	--------------	----------------	------------	--------------

CREAM; TOPICAL

ZOVIRAX

+	GLAXOSMITHKLINE	5%	N021478	001	Dec 30, 2002
---	-----------------	----	---------	-----	--------------

OINTMENT; TOPICAL

ZOVIRAX

+	GLAXOSMITHKLINE	5%	N018604	001	Mar 29, 1982
---	-----------------	----	---------	-----	--------------

SUSPENSION; ORAL

ACYCLOVIR

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>200MG/5ML</u>	<u>A074738</u>	<u>001</u>	Apr 28, 1997
<u>AB</u>	HI TECH PHARMA	<u>200MG/5ML</u>	<u>A077026</u>	<u>001</u>	Jun 07, 2005

ZOVIRAX

<u>AB</u>	+ GLAXOSMITHKLINE	<u>200MG/5ML</u>	<u>N019909</u>	<u>001</u>	Dec 22, 1989
-----------	-------------------	------------------	----------------	------------	--------------

TABLET; ORAL

ACYCLOVIR

<u>AB</u>	ACTAVIS ELIZABETH	<u>400MG</u>	<u>A074870</u>	<u>001</u>	Jun 05, 1997
<u>AB</u>		<u>800MG</u>	<u>A074870</u>	<u>002</u>	Jun 05, 1997
<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A077309</u>	<u>001</u>	Sep 29, 2005
<u>AB</u>		<u>800MG</u>	<u>A077309</u>	<u>002</u>	Sep 29, 2005
<u>AB</u>	CARLSBAD	<u>400MG</u>	<u>A075382</u>	<u>001</u>	Apr 30, 1999
<u>AB</u>		<u>800MG</u>	<u>A075382</u>	<u>002</u>	Apr 30, 1999
<u>AB</u>	DAVA PHARMS INC	<u>400MG</u>	<u>A074946</u>	<u>001</u>	Nov 19, 1997
<u>AB</u>		<u>800MG</u>	<u>A074946</u>	<u>002</u>	Nov 19, 1997
<u>AB</u>	GENPHARM	<u>400MG</u>	<u>A074976</u>	<u>001</u>	Apr 13, 1998
<u>AB</u>		<u>800MG</u>	<u>A074976</u>	<u>002</u>	Apr 13, 1998

## PRESCRIPTION DRUG PRODUCT LIST

3 - 10 (of 393)

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>400MG</u>	<u>A074836</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>		<u>800MG</u>	<u>A074836</u>	<u>002</u>	Apr 22, 1997
<u>AB</u>	RANBAXY	<u>400MG</u>	<u>A074980</u>	<u>001</u>	Sep 30, 1998
<u>AB</u>		<u>800MG</u>	<u>A074980</u>	<u>002</u>	Sep 30, 1998
<u>AB</u>	TEVA	<u>400MG</u>	<u>A074556</u>	<u>002</u>	Apr 22, 1997
<u>AB</u>		<u>800MG</u>	<u>A074556</u>	<u>003</u>	Apr 22, 1997
<u>ZOVIRAX</u>					
<u>AB</u>	GLAXOSMITHKLINE	<u>400MG</u>	<u>N020089</u>	<u>001</u>	Apr 30, 1991
<u>AB</u>	+	<u>800MG</u>	<u>N020089</u>	<u>002</u>	Apr 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

<u>AP</u>	+	APP PHARMS	<u>EQ 50MG BASE/ML</u>	<u>A074930</u>	<u>001</u>	May 13, 1998
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A075015</u>	<u>001</u>	Apr 30, 1998
<u>AP</u>		BAXTER HLTHCARE	<u>EQ 500MG BASE/VIAL</u>	<u>A074913</u>	<u>001</u>	Oct 15, 1997
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A074913</u>	<u>002</u>	Oct 15, 1997
<u>AP</u>		BEDFORD	<u>EQ 500MG BASE/VIAL</u>	<u>A074596</u>	<u>002</u>	Apr 22, 1997
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A074596</u>	<u>001</u>	Apr 22, 1997
<u>AP</u>		HOSPIRA	<u>EQ 50MG BASE/ML</u>	<u>A075065</u>	<u>001</u>	Feb 25, 1999
<u>AP</u>		TEVA PARENTERAL	<u>EQ 50MG BASE/ML</u>	<u>A075627</u>	<u>001</u>	Mar 28, 2001
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A074969</u>	<u>001</u>	Aug 26, 1997
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A074969</u>	<u>002</u>	Aug 26, 1997
<u>ZOVIRAX</u>						
<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 500MG BASE/VIAL</u>	<u>N018603</u>	<u>001</u>	Oct 22, 1982
<u>AP</u>	+		<u>EQ 1GM BASE/VIAL</u>	<u>N018603</u>	<u>002</u>	Jun 29, 1989
		ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE				
	+	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997
			EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997
		ACYCLOVIR SODIUM				
	+	HOSPIRA	EQ 25MG BASE/ML	A074720	001	Apr 22, 1997

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

ACYCLOVIR AND HYDROCORTISONE

	+	MEDIVIR	5%;1%	N022436	001	Jul 31, 2009
--	---	---------	-------	---------	-----	--------------

ADAPALENE

CREAM; TOPICAL

DIFFERIN

	+	GALDERMA LABS LP	0.1%	N020748	001	May 26, 2000
--	---	------------------	------	---------	-----	--------------

GEL; TOPICAL

DIFFERIN

	+	GALDERMA LABS LP	0.1%	N020380	001	May 31, 1996
	+		0.3%	N021753	001	Jun 19, 2007

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

EPIDUO

	+	GALDERMA LABS	0.1%;2.5%	N022320	001	Dec 08, 2008
--	---	---------------	-----------	---------	-----	--------------

ADEFOVIR DIPIVOXIL

TABLET; ORAL

HEPSERA

	+	GILEAD	10MG	N021449	001	Sep 20, 2002
--	---	--------	------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 11 (of 393)

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

<u>AP</u>	+	ASTELLAS	<u>3MG/ML</u>	<u>N019937</u>	<u>002</u>	Oct 30, 1989
<u>ADENOSINE</u>						
<u>AP</u>		AKORN	<u>3MG/ML</u>	<u>A078076</u>	<u>001</u>	Oct 31, 2008
<u>AP</u>		APP PHARMS	<u>3MG/ML</u>	<u>A077133</u>	<u>001</u>	Apr 27, 2005
<u>AP</u>		BAXTER HLTHCARE	<u>3MG/ML</u>	<u>A076500</u>	<u>001</u>	Jun 16, 2004
<u>AP</u>			<u>3MG/ML</u>	<u>A076501</u>	<u>001</u>	Jun 16, 2004
<u>AP</u>		BEDFORD	<u>3MG/ML</u>	<u>A076404</u>	<u>001</u>	Jun 16, 2004
<u>AP</u>		GLAND PHARMA LTD	<u>3MG/ML</u>	<u>A077283</u>	<u>001</u>	Jun 14, 2007
<u>AP</u>		LUITPOLD	<u>3MG/ML</u>	<u>A090010</u>	<u>001</u>	Apr 28, 2009
<u>AP</u>		STRIDES ARCOLAB LTD	<u>3MG/ML</u>	<u>A078686</u>	<u>001</u>	May 13, 2009
<u>AP</u>		TEVA PARENTERAL	<u>3MG/ML</u>	<u>A076564</u>	<u>001</u>	Jun 16, 2004
<u>AP</u>			<u>3MG/ML</u>	<u>A078676</u>	<u>001</u>	Jul 31, 2008
<u>AP</u>		WOCKHARDT	<u>3MG/ML</u>	<u>A090220</u>	<u>001</u>	Jul 20, 2009
		ADENOSCAN				
	+	ASTELLAS	3MG/ML	N020059	001	May 18, 1995

ALBENDAZOLE

TABLET; ORAL

ALBENZA

	+	GLAXOSMITHKLINE	200MG	N020666	001	Jun 11, 1996
--	---	-----------------	-------	---------	-----	--------------

ALBUMIN HUMAN

INJECTABLE; INJECTION

OPTISON

	+	GE HEALTHCARE	10MG/ML	N020899	001	Dec 31, 1997
--	---	---------------	---------	---------	-----	--------------

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

JEANATOPE

		ISO TEX	100UCI/10ML (10UCI/ML)	N017836	003	Jun 08, 2004
			500uCi/0.5ML	N017836	001	
	+		1,000uCi/ML	N017836	002	

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

	+	ISO TEX	0.5mCi/VIAL	N017837	001	
	+		1mCi/VIAL	N017837	002	

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROAIR HFA

BX	+	TEVA GLOBAL	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004
		PROVENTIL-HFA				
BX	+	3M	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996
		VENTOLIN HFA				
BX	+	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001

SOLUTION; INHALATION

ACCUNEB

<u>AN</u>	+	DEY	<u>EQ 0.021% BASE</u>	<u>N020949</u>	<u>002</u>	Apr 30, 2001
<u>AN</u>	+		<u>EQ 0.042% BASE</u>	<u>N020949</u>	<u>001</u>	Apr 30, 2001

ALBUTEROL SULFATE

<u>AN</u>		ACTAVIS MID ATLANTIC	<u>EQ 0.083% BASE</u>	<u>A073533</u>	<u>001</u>	Sep 26, 1995
<u>AN</u>		APOTEX INC	<u>EQ 0.083% BASE</u>	<u>A075717</u>	<u>001</u>	Feb 02, 2007
<u>AN</u>	+	BAUSCH AND LOMB	<u>EQ 0.5% BASE</u>	<u>A075050</u>	<u>001</u>	Jun 18, 1998
<u>AN</u>		COBALT LABS INC	<u>EQ 0.083% BASE</u>	<u>A076370</u>	<u>001</u>	Nov 24, 2003

## PRESCRIPTION DRUG PRODUCT LIST

3 - 12 (of 393)

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

<u>AN</u>	+	DEY	<u>EQ 0.083% BASE</u>	<u>A072652</u>	<u>001</u>	Feb 21, 1992
<u>AN</u>		HI TECH PHARMA	<u>EQ 0.083% BASE</u>	<u>A075063</u>	<u>001</u>	Feb 09, 1999
<u>AN</u>			<u>EQ 0.5% BASE</u>	<u>A074543</u>	<u>001</u>	Jan 15, 1998
<u>AN</u>		HOLOPACK INTL	<u>EQ 0.083% BASE</u>	<u>A077839</u>	<u>001</u>	Dec 16, 2008
<u>AN</u>		LANDELA PHARM	<u>EQ 0.083% BASE</u>	<u>A077569</u>	<u>001</u>	Apr 04, 2006
<u>AN</u>		MORTON GROVE	<u>EQ 0.083% BASE</u>	<u>A075394</u>	<u>001</u>	Nov 22, 1999
<u>AN</u>		NEPHRON	<u>EQ 0.042% BASE</u>	<u>A076355</u>	<u>001</u>	Jun 28, 2004
<u>AN</u>			<u>EQ 0.083% BASE</u>	<u>A074880</u>	<u>001</u>	Sep 17, 1997
<u>AN</u>			<u>EQ 0.5% BASE</u>	<u>A075664</u>	<u>001</u>	Jun 26, 2001
<u>AN</u>		NOVEX	<u>EQ 0.5% BASE</u>	<u>A076391</u>	<u>001</u>	Apr 01, 2003
<u>AN</u>		TEVA PARENTERAL	<u>EQ 0.083% BASE</u>	<u>A075343</u>	<u>001</u>	Nov 09, 1999
<u>AN</u>		WATSON LABS	<u>EQ 0.021% BASE</u>	<u>A077772</u>	<u>001</u>	Sep 25, 2007
<u>AN</u>			<u>EQ 0.042% BASE</u>	<u>A077772</u>	<u>002</u>	Sep 25, 2007

SYRUP; ORAL

ALBUTEROL SULFATE

<u>AA</u>		ACTAVIS MID ATLANTIC	<u>EQ 2MG BASE/5ML</u>	<u>A074454</u>	<u>001</u>	Sep 25, 1995
<u>AA</u>		HI TECH PHARMA	<u>EQ 2MG BASE/5ML</u>	<u>A074749</u>	<u>001</u>	Jan 30, 1998
<u>AA</u>	+	TEVA	<u>EQ 2MG BASE/5ML</u>	<u>A073419</u>	<u>001</u>	Mar 30, 1992
<u>AA</u>		VINTAGE	<u>EQ 2MG BASE/5ML</u>	<u>A078105</u>	<u>001</u>	Dec 27, 2006
<u>AA</u>		VISTAPHARM	<u>EQ 2MG BASE/5ML</u>	<u>A077788</u>	<u>001</u>	Jun 26, 2007

TABLET; ORAL

ALBUTEROL SULFATE

<u>AB</u>		MUTUAL PHARM	<u>EQ 2MG BASE</u>	<u>A072637</u>	<u>002</u>	Dec 05, 1989
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A072637</u>	<u>001</u>	Dec 05, 1989
<u>AB</u>		MYLAN	<u>EQ 2MG BASE</u>	<u>A072894</u>	<u>002</u>	Jan 17, 1991
<u>AB</u>	+		<u>EQ 4MG BASE</u>	<u>A072894</u>	<u>001</u>	Jan 17, 1991
<u>AB</u>		WATSON LABS	<u>EQ 2MG BASE</u>	<u>A072764</u>	<u>001</u>	Aug 28, 1991

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

<u>AB</u>		MYLAN	<u>EQ 4MG BASE</u>	<u>A078092</u>	<u>002</u>	Jan 29, 2007
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A078092</u>	<u>001</u>	Jan 29, 2007
		<u>VOSPIRE ER</u>				
<u>AB</u>		DAVA PHARMS INC	<u>EQ 4MG BASE</u>	<u>A076130</u>	<u>002</u>	Sep 26, 2002
<u>AB</u>	+		<u>EQ 8MG BASE</u>	<u>A076130</u>	<u>003</u>	Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

COMBIVENT

	+	BOEHRINGER INGELHEIM	<u>EQ 0.09MG BASE/INH;0.018MG/INH</u>	<u>N020291</u>	<u>001</u>	Oct 24, 1996
--	---	----------------------	---------------------------------------	----------------	------------	--------------

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

<u>AN</u>		APOTEX CORP	<u>EQ 0.083% BASE;0.017%</u>	<u>A077117</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>		COBALT LABS INC	<u>EQ 0.083% BASE;0.017%</u>	<u>A077063</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>		NEPHRON	<u>EQ 0.083% BASE;0.017%</u>	<u>A076749</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>		SANDOZ	<u>EQ 0.083% BASE;0.017%</u>	<u>A076867</u>	<u>001</u>	Dec 21, 2006
<u>AN</u>		TEVA PARENTERAL	<u>EQ 0.083% BASE;0.017%</u>	<u>A076724</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>		WATSON LABS	<u>EQ 0.083% BASE;0.017%</u>	<u>A077559</u>	<u>001</u>	Dec 31, 2007
		<u>DUONEE</u>				
<u>AN</u>	+	DEY	<u>EQ 0.083% BASE;0.017%</u>	<u>N020950</u>	<u>001</u>	Mar 21, 2001

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE

<u>AB</u>	+	GLAXOSMITHKLINE	<u>0.05%</u>	<u>N018707</u>	<u>001</u>	Dec 14, 1982
		<u>ALCLOMETASONE DIPROPIONATE</u>				
<u>AB</u>		ALTANA	<u>0.05%</u>	<u>A076973</u>	<u>001</u>	Jul 12, 2005

## PRESCRIPTION DRUG PRODUCT LIST

3 - 13 (of 393)

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

<u>AB</u>	GLENMARK GENERICS	<u>0.05%</u>	<u>A079061</u>	<u>001</u>	Jun 23, 2009
<u>AB</u>	TARO	<u>0.05%</u>	<u>A076587</u>	<u>001</u>	Sep 15, 2005

OINTMENT; TOPICAL

ACLOVATE

<u>AB</u>	+ GLAXOSMITHKLINE	<u>0.05%</u>	<u>N018702</u>	<u>001</u>	Dec 14, 1982
-----------	-------------------	--------------	----------------	------------	--------------

ALCLOMETASONE DIPROPIONATE

<u>AB</u>	ALTANA	<u>0.05%</u>	<u>A076884</u>	<u>001</u>	Jul 18, 2005
<u>AB</u>	GLENMARK GENERICS	<u>0.05%</u>	<u>A079227</u>	<u>001</u>	Jul 30, 2009
<u>AB</u>	TARO	<u>0.05%</u>	<u>A076730</u>	<u>001</u>	Jul 29, 2004

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% AND DEXTROSE 5%

<u>AP</u>	+ B BRAUN	<u>5ML/100ML;5GM/100ML</u>	<u>N004589</u>	<u>004</u>	
-----------	-----------	----------------------------	----------------	------------	--

ALCOHOL 5% IN D5-W

<u>AP</u>	HOSPIRA	<u>5ML/100ML;5GM/100ML</u>	<u>A083263</u>	<u>001</u>	
-----------	---------	----------------------------	----------------	------------	--

ALCOHOL 10% AND DEXTROSE 5%

	+ B BRAUN	<u>10ML/100ML;5GM/100ML</u>	<u>N004589</u>	<u>006</u>	
--	-----------	-----------------------------	----------------	------------	--

ALENDRONATE SODIUM

SOLUTION; ORAL

FOSAMAX

	+ MERCK	<u>EQ 70MG BASE/75ML</u>	<u>N021575</u>	<u>001</u>	Sep 17, 2003
--	---------	--------------------------	----------------	------------	--------------

TABLET; ORAL

ALENDRONATE SODIUM

<u>AB</u>	APOTEX	<u>EQ 5MG BASE</u>	<u>A077982</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077982</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A077982</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A077982</u>	<u>004</u>	Aug 04, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A090124</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090124</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090124</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>	AUSTARPHARMA LLC	<u>EQ 5MG BASE</u>	<u>A090258</u>	<u>001</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090258</u>	<u>002</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090258</u>	<u>003</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090258</u>	<u>004</u>	Sep 24, 2009
<u>AB</u>	BARR	<u>EQ 35MG BASE</u>	<u>A076184</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076184</u>	<u>001</u>	Feb 06, 2008
<u>AB</u>	COBALT LABS INC	<u>EQ 35MG BASE</u>	<u>A076984</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076984</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076984</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 5MG BASE</u>	<u>A079109</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079109</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A079049</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A079049</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>	GENPHARM ULC	<u>EQ 35MG BASE</u>	<u>A078638</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A078638</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076584</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076584</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076584</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076584</u>	<u>004</u>	Aug 04, 2008
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A075871</u>	<u>001</u>	Apr 22, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075871</u>	<u>002</u>	Apr 22, 2009
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A075871</u>	<u>004</u>	Apr 22, 2009
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075871</u>	<u>003</u>	Apr 22, 2009
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A075871</u>	<u>005</u>	Apr 22, 2009
<u>AB</u>	SUN PHARM INDS	<u>EQ 5MG BASE</u>	<u>A090022</u>	<u>001</u>	Sep 10, 2008



## PRESCRIPTION DRUG PRODUCT LIST

3 - 14 (of 393)

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

<u>AB</u>	SUN PHARM INDS	<u>EQ 10MG BASE</u>	<u>A090022</u>	<u>002</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090022</u>	<u>003</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090022</u>	<u>004</u>	Sep 10, 2008
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A075710</u>	<u>001</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075710</u>	<u>002</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A075710</u>	<u>003</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075710</u>	<u>004</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A075710</u>	<u>005</u>	Feb 06, 2008
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A076768</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076768</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076768</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076768</u>	<u>004</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076768</u>	<u>005</u>	Aug 04, 2008
	<u>FOSAMAX</u>				
<u>AB</u>	MERCK AND CO INC	<u>EQ 5MG BASE</u>	<u>N020560</u>	<u>003</u>	Apr 25, 1997
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>N020560</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>N020560</u>	<u>004</u>	Oct 20, 2000
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>N020560</u>	<u>002</u>	Sep 29, 1995
<u>AB</u>	+	<u>EQ 70MG BASE</u>	<u>N020560</u>	<u>005</u>	Oct 20, 2000

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

MERCK

EQ 70MG BASE;2,800 IU

N021762 001

Apr 07, 2005

+

EQ 70MG BASE;5,600 IU

N021762 002

Apr 26, 2007

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

<u>AP</u>	+	AKORN	<u>EQ 0.5MG BASE/ML</u>	<u>N019353</u>	<u>001</u>	Dec 29, 1986
<u>AP</u>		HOSPIRA	<u>EQ 0.5MG BASE/ML</u>	<u>A075221</u>	<u>001</u>	Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

UROXATRAL

+ SANOFI AVENTIS US

10MG

N021287 001

Jun 12, 2003

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

+ GENZYME

80 UNITS/ML

N020057 003

Apr 05, 1991

ALISKIREN HEMIFUMARATE

TABLET; ORAL

TEKTURNA

NOVARTIS

EQ 150MG BASE

N021985 001

Mar 05, 2007

+

EQ 300MG BASE

N021985 002

Mar 05, 2007

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTURNA HCT

NOVARTIS

EQ 150MG BASE;12.5MG

N022107 001

Jan 18, 2008

EQ 150MG BASE;25MG

N022107 002

Jan 18, 2008

+

EQ 300MG BASE;12.5MG

N022107 003

Jan 18, 2008

+

EQ 300MG BASE;25MG

N022107 004

Jan 18, 2008

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 41 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 15 (of 393)

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET; ORAL

VALTURNA

NOVARTIS	EQ 150MG BASE;160MG	N022217	001	Sep 16, 2009
+	EQ 300MG BASE;320MG	N022217	002	Sep 16, 2009

ALITRETINOIN

GEL; TOPICAL

PANRETIN

+ EISAI INC	EQ 0.1% BASE	N020886	001	Feb 02, 1999
-------------	--------------	---------	-----	--------------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077353</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>		<u>300MG</u>	<u>A077353</u>	<u>002</u>	Sep 08, 2005
<u>AB</u>	CARACO	<u>100MG</u>	<u>A078390</u>	<u>001</u>	Aug 30, 2007
<u>AB</u>		<u>300MG</u>	<u>A078390</u>	<u>002</u>	Aug 30, 2007
<u>AB</u>	MUTUAL PHARM	<u>100MG</u>	<u>A071449</u>	<u>001</u>	Jan 09, 1987
<u>AB</u>		<u>300MG</u>	<u>A071450</u>	<u>001</u>	Jan 09, 1987
<u>AB</u>	MYLAN	<u>100MG</u>	<u>N018659</u>	<u>001</u>	Oct 24, 1986
<u>AB</u>		<u>300MG</u>	<u>N018659</u>	<u>002</u>	Oct 24, 1986
<u>AB</u>	NORTHSTAR HLTHCARE	<u>100MG</u>	<u>A078253</u>	<u>001</u>	Sep 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A078253</u>	<u>002</u>	Sep 11, 2007
<u>AB</u>	VINTAGE PHARMS	<u>100MG</u>	<u>A075798</u>	<u>001</u>	Jun 27, 2003
<u>AB</u>		<u>300MG</u>	<u>A075798</u>	<u>002</u>	Jun 27, 2003
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>N018832</u>	<u>002</u>	Sep 28, 1984
<u>AB</u>		<u>300MG</u>	<u>N018877</u>	<u>001</u>	Sep 28, 1984
	<u>LOPURIN</u>				
<u>AB</u>	DR REDDYS LA	<u>100MG</u>	<u>A071586</u>	<u>001</u>	Apr 02, 1987
<u>AB</u>		<u>300MG</u>	<u>A071587</u>	<u>001</u>	Apr 02, 1987
	<u>ZYLOPRIM</u>				
<u>AB</u>	PROMETHEUS LABS	<u>100MG</u>	<u>N016084</u>	<u>001</u>	
<u>AB</u>	+	<u>300MG</u>	<u>N016084</u>	<u>002</u>	

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

<u>AP</u>	BEDFORD LABS	<u>EQ 500MG BASE/VIAL</u>	<u>A076870</u>	<u>001</u>	Aug 26, 2004
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N020298</u>	<u>001</u>	May 17, 1996

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

ORTHO MCNEIL JANSSEN	EQ 6.25MG BASE	N021001	001	May 07, 2001
+	EQ 12.5MG BASE	N021001	002	May 07, 2001

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTRONEX

PROMETHEUS LABS	EQ 0.5MG BASE	N021107	002	Dec 23, 2003
+	EQ 1MG BASE	N021107	001	Feb 09, 2000

## PRESCRIPTION DRUG PRODUCT LIST

3 - 16 (of 393)

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN;  
DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-  
PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION  
INFUVITE ADULT

+ SANDOZ	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1 .2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000
----------	---	---------	-----	--------------

INJECTABLE; IV (INFUSION)

+ SANDOZ	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1 .2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003
----------	--	---------	-----	--------------

ALPRAZOLAM

CONCENTRATE; ORAL  
ALPRAZOLAM

+ ROXANE	1MG/ML	A074312	001	Oct 31, 1993
----------	--------	---------	-----	--------------

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A074342</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074342</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>		<u>1MG</u>	<u>A074342</u>	<u>003</u>	Oct 31, 1993
<u>AB</u>		<u>2MG</u>	<u>A074342</u>	<u>004</u>	Oct 31, 1993
<u>AB</u>	ALPHAPHARM	<u>0.25MG</u>	<u>A074046</u>	<u>001</u>	Oct 19, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074046</u>	<u>002</u>	Oct 19, 1993
<u>AB</u>		<u>1MG</u>	<u>A074046</u>	<u>003</u>	Oct 19, 1993
<u>AB</u>		<u>2MG</u>	<u>A074046</u>	<u>004</u>	May 07, 1997
<u>AB</u>	APOTEX INC	<u>0.25MG</u>	<u>A077741</u>	<u>001</u>	Jan 19, 2007
<u>AB</u>		<u>0.5MG</u>	<u>A077741</u>	<u>002</u>	Jan 19, 2007
<u>AB</u>		<u>1MG</u>	<u>A077741</u>	<u>003</u>	Jan 19, 2007
<u>AB</u>		<u>2MG</u>	<u>A077741</u>	<u>004</u>	Jan 19, 2007
<u>AB</u>	DAVA INTL INC	<u>0.25MG</u>	<u>A074174</u>	<u>001</u>	Oct 19, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074174</u>	<u>002</u>	Oct 19, 1993
<u>AB</u>		<u>1MG</u>	<u>A074174</u>	<u>003</u>	Oct 19, 1993
<u>AB</u>		<u>2MG</u>	<u>A074174</u>	<u>004</u>	Oct 19, 1993
<u>AB</u>	MYLAN	<u>0.25MG</u>	<u>A074215</u>	<u>001</u>	Jan 27, 1994
<u>AB</u>		<u>0.5MG</u>	<u>A074215</u>	<u>002</u>	Jan 27, 1994
<u>AB</u>		<u>1MG</u>	<u>A074215</u>	<u>003</u>	Jan 27, 1994
<u>AB</u>		<u>2MG</u>	<u>A074215</u>	<u>004</u>	Jan 27, 1994
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A074112</u>	<u>001</u>	Dec 29, 1995
<u>AB</u>		<u>0.5MG</u>	<u>A074112</u>	<u>002</u>	Dec 29, 1995
<u>AB</u>		<u>1MG</u>	<u>A074112</u>	<u>003</u>	Dec 29, 1995
<u>AB</u>		<u>2MG</u>	<u>A074909</u>	<u>001</u>	Mar 25, 1998
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078491</u>	<u>001</u>	Sep 25, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078491</u>	<u>002</u>	Sep 25, 2008
<u>AB</u>		<u>1MG</u>	<u>A078491</u>	<u>003</u>	Sep 25, 2008
<u>AB</u>		<u>2MG</u>	<u>A078491</u>	<u>004</u>	Dec 12, 2008

XANAX

<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.25MG</u>	<u>N018276</u>	<u>001</u>	
<u>AB</u>		<u>0.5MG</u>	<u>N018276</u>	<u>002</u>	
<u>AB</u>		<u>1MG</u>	<u>N018276</u>	<u>003</u>	
<u>AB</u>		<u>2MG</u>	<u>N018276</u>	<u>004</u>	Nov 27, 1985

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A078056</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>		<u>1MG</u>	<u>A078056</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>		<u>2MG</u>	<u>A078056</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>		<u>3MG</u>	<u>A078056</u>	<u>004</u>	Feb 13, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 17 (of 393)

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>	AMNEAL PHARMS NY	<u>0.5MG</u>	<u>A078387</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A078387</u>	<u>002</u>	May 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A078387</u>	<u>003</u>	May 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A078387</u>	<u>004</u>	May 30, 2008
<u>AB</u>	APOTEX INC	<u>0.5MG</u>	<u>A078449</u>	<u>001</u>	Nov 12, 2008
<u>AB</u>		<u>2MG</u>	<u>A078449</u>	<u>002</u>	Nov 12, 2008
<u>AB</u>		<u>3MG</u>	<u>A078449</u>	<u>003</u>	Nov 12, 2008
<u>AB</u>	BARR	<u>0.5MG</u>	<u>A077725</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>1MG</u>	<u>A077725</u>	<u>002</u>	Jul 31, 2006
<u>AB</u>		<u>2MG</u>	<u>A077725</u>	<u>004</u>	Jul 31, 2006
<u>AB</u>		<u>3MG</u>	<u>A077725</u>	<u>003</u>	Jul 31, 2006
<u>AB</u>	COREPHARMA	<u>0.5MG</u>	<u>A077996</u>	<u>001</u>	Jan 31, 2007
<u>AB</u>		<u>1MG</u>	<u>A077996</u>	<u>002</u>	Jan 31, 2007
<u>AB</u>		<u>2MG</u>	<u>A077996</u>	<u>003</u>	Jan 31, 2007
<u>AB</u>		<u>3MG</u>	<u>A077996</u>	<u>004</u>	Jan 31, 2007
<u>AB</u>	IMPAX LABS	<u>0.5MG</u>	<u>A077968</u>	<u>004</u>	May 24, 2007
<u>AB</u>		<u>1MG</u>	<u>A077968</u>	<u>003</u>	May 24, 2007
<u>AB</u>		<u>2MG</u>	<u>A077968</u>	<u>002</u>	May 24, 2007
<u>AB</u>		<u>3MG</u>	<u>A077968</u>	<u>001</u>	May 24, 2007
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A077391</u>	<u>002</u>	Jan 26, 2006
<u>AB</u>		<u>1MG</u>	<u>A077391</u>	<u>003</u>	Jan 26, 2006
<u>AB</u>		<u>2MG</u>	<u>A077391</u>	<u>004</u>	Jan 26, 2006
<u>AB</u>		<u>3MG</u>	<u>A077391</u>	<u>001</u>	Jan 26, 2006
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A077777</u>	<u>001</u>	Jun 30, 2006
<u>AB</u>		<u>1MG</u>	<u>A077777</u>	<u>002</u>	Jun 30, 2006
<u>AB</u>		<u>2MG</u>	<u>A077777</u>	<u>003</u>	Jun 30, 2006
<u>AB</u>		<u>3MG</u>	<u>A077777</u>	<u>004</u>	Jun 30, 2006
<u>AB</u>	TEVA PHARMS	<u>0.5MG</u>	<u>A077979</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>		<u>1MG</u>	<u>A077979</u>	<u>002</u>	Feb 28, 2007
<u>AB</u>		<u>2MG</u>	<u>A077979</u>	<u>003</u>	Feb 28, 2007
<u>AB</u>		<u>3MG</u>	<u>A077979</u>	<u>004</u>	Feb 28, 2007
<u>AB</u>	VINTAGE	<u>0.5MG</u>	<u>A078442</u>	<u>001</u>	Oct 15, 2007
<u>AB</u>		<u>1MG</u>	<u>A078442</u>	<u>002</u>	Oct 15, 2007
<u>AB</u>		<u>2MG</u>	<u>A078442</u>	<u>003</u>	Oct 15, 2007
<u>AB</u>		<u>3MG</u>	<u>A078442</u>	<u>004</u>	Oct 15, 2007
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.5MG</u>	<u>A078489</u>	<u>001</u>	Oct 17, 2008
<u>AB</u>		<u>1MG</u>	<u>A078489</u>	<u>002</u>	Oct 17, 2008
<u>AB</u>		<u>2MG</u>	<u>A078489</u>	<u>003</u>	Oct 17, 2008
<u>AB</u>		<u>3MG</u>	<u>A078489</u>	<u>004</u>	Oct 17, 2008

XANAX XR

<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.5MG</u>	<u>N021434</u>	<u>001</u>	Jan 17, 2003
<u>AB</u>		<u>1MG</u>	<u>N021434</u>	<u>002</u>	Jan 17, 2003
<u>AB</u>		<u>2MG</u>	<u>N021434</u>	<u>003</u>	Jan 17, 2003
<u>AB</u>	+	<u>3MG</u>	<u>N021434</u>	<u>004</u>	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

<u>AB</u>	KALI LABS	<u>0.25MG</u>	<u>A078088</u>	<u>001</u>	Jan 09, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078088</u>	<u>002</u>	Jan 09, 2009
<u>AB</u>		<u>1MG</u>	<u>A078088</u>	<u>003</u>	Jan 09, 2009
<u>AB</u>		<u>2MG</u>	<u>A078088</u>	<u>004</u>	Jan 09, 2009
<u>AB</u>	<u>NIRAVAM</u>				
<u>AB</u>	SCHWARZ PHARMA	<u>0.25MG</u>	<u>N021726</u>	<u>001</u>	Jan 19, 2005
<u>AB</u>		<u>0.5MG</u>	<u>N021726</u>	<u>002</u>	Jan 19, 2005
<u>AB</u>	+	<u>1MG</u>	<u>N021726</u>	<u>003</u>	Jan 19, 2005
<u>AB</u>		<u>2MG</u>	<u>N021726</u>	<u>004</u>	Jan 19, 2005

## PRESCRIPTION DRUG PRODUCT LIST

3 - 18 (of 393)

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

<u>AP</u>	BEDFORD	<u>0.5MG/ML</u>	<u>A074815</u>	<u>001</u>	Jan 20, 1998	
<u>AP</u>	TEVA PARENTERAL	<u>0.5MG/ML</u>	<u>A075196</u>	<u>001</u>	Apr 30, 1999	
<u>CAVERJECT</u>						
<u>AP</u>	PHARMACIA AND UPJOHN	<u>0.01MG/VIAL</u>	<u>N020379</u>	<u>001</u>	Jul 06, 1995	
<u>AP</u>	+	<u>0.02MG/VIAL</u>	<u>N020379</u>	<u>002</u>	Jul 06, 1995	
<u>AP</u>	+	<u>0.04MG/VIAL</u>	<u>N020379</u>	<u>004</u>	May 19, 1997	
<u>EDEX</u>						
<u>AP</u>	SCHWARZ PHARMA	<u>0.01MG/VIAL</u>	<u>N020649</u>	<u>002</u>	Jun 12, 1997	
<u>AP</u>		<u>0.02MG/VIAL</u>	<u>N020649</u>	<u>003</u>	Jun 12, 1997	
<u>AP</u>	+	<u>0.04MG/VIAL</u>	<u>N020649</u>	<u>004</u>	Jun 12, 1997	
<u>PROSTIN VR PEDIATRIC</u>						
<u>AP</u>	+	<u>PHARMACIA AND UPJOHN</u>	<u>0.5MG/ML</u>	<u>N018484</u>	<u>001</u>	
	CAVERJECT					
	PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379	003	Jun 27, 1996	
	CAVERJECT IMPULSE					
	PHARMACIA AND UPJOHN	0.01MG/VIAL	N021212	001	Jun 11, 2002	
		0.02MG/VIAL	N021212	002	Jun 11, 2002	
	EDEX					
	+	SCHWARZ PHARMA	0.01MG/VIAL	N020649	005	Jul 30, 1998
	+		0.02MG/VIAL	N020649	006	Jul 30, 1998
	+		0.04MG/VIAL	N020649	007	Jul 30, 1998

SUPPOSITORY; URETHRAL

MUSE

	VIVUS	0.125MG	N020700	001	Nov 19, 1996
		0.25MG	N020700	002	Nov 19, 1996
		0.5MG	N020700	003	Nov 19, 1996
	+	1MG	N020700	004	Nov 19, 1996

ALTRETAMINE

CAPSULE; ORAL

HEXALEN

	+	EISAI INC	50MG	N019926	001	Dec 26, 1990
--	---	-----------	------	---------	-----	--------------

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

	+	ADOLOR	12MG	N021775	001	May 20, 2008
--	---	--------	------	---------	-----	--------------

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>100MG</u>	<u>A077659</u>	<u>001</u>	Feb 23, 2006	
<u>AB</u>	BANNER PHARMACAPS	<u>100MG</u>	<u>A078720</u>	<u>001</u>	May 29, 2008	
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A071293</u>	<u>001</u>	Feb 18, 1987	
<u>AB</u>	+	USL PHARMA	<u>100MG</u>	<u>A070589</u>	<u>001</u>	Aug 05, 1986

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

<u>AA</u>	+	CAROLINA MEDCL	<u>50MG/5ML</u>	<u>A075819</u>	<u>001</u>	Sep 11, 2002
<u>AA</u>	+	HI TECH PHARMA	<u>50MG/5ML</u>	<u>A074170</u>	<u>001</u>	Oct 28, 1994
<u>AA</u>	+	MIKART	<u>50MG/5ML</u>	<u>A074028</u>	<u>001</u>	Jun 28, 1993
<u>AA</u>	+	MORTON GROVE	<u>50MG/5ML</u>	<u>A075060</u>	<u>001</u>	Dec 24, 1998
<u>AA</u>	+	PHARM ASSOC	<u>50MG/5ML</u>	<u>A074509</u>	<u>001</u>	Jul 17, 1995
<u>AA</u>	+	SILARX	<u>50MG/5ML</u>	<u>A076352</u>	<u>001</u>	Sep 10, 2004
<u>AA</u>	+	VINTAGE	<u>50MG/5ML</u>	<u>A077992</u>	<u>001</u>	Dec 12, 2006

## PRESCRIPTION DRUG PRODUCT LIST

3 - 19 (of 393)

AMANTADINE HYDROCHLORIDE

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

<u>AB</u>	USL PHARMA	<u>100MG</u>	<u>A076186</u>	<u>001</u>	Dec 16, 2002
<u>AB</u>	+ ENDO PHARMS	<u>100MG</u>	<u>N018101</u>	<u>001</u>	

AMBENONIUM CHLORIDE

TABLET; ORAL

MYTELASE

	+ SANOFI AVENTIS US	10MG	N010155	002	
--	---------------------	------	---------	-----	--

AMBRISENTAN

TABLET; ORAL

LETAIRIS

	GILEAD	5MG	N022081	001	Jun 15, 2007
	+	10MG	N022081	002	Jun 15, 2007

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

<u>AB</u>	+ ALTANA	<u>0.1%</u>	<u>A076065</u>	<u>001</u>	May 15, 2003
<u>AB</u>	TARO PHARM INDS	<u>0.1%</u>	<u>A076229</u>	<u>001</u>	May 31, 2002

LOTION; TOPICAL

AMCINONIDE

	+ ALTANA	0.1%	A076329	001	Nov 06, 2002
--	----------	------	---------	-----	--------------

OINTMENT; TOPICAL

AMCINONIDE

<u>AB</u>	+ ALTANA	<u>0.1%</u>	<u>A076096</u>	<u>001</u>	Nov 19, 2002
<u>AB</u>	TARO PHARM INDS	<u>0.1%</u>	<u>A076367</u>	<u>001</u>	Mar 19, 2003

AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE

<u>AP</u>	SUN PHARM INDS	<u>500MG/VIAL</u>	<u>A077126</u>	<u>001</u>	Mar 14, 2008
<u>AP</u>	+ MEDIMMUNE	<u>500MG/VIAL</u>	<u>N020221</u>	<u>001</u>	Dec 08, 1995

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

<u>AP</u>	+ BEDFORD	<u>EQ 50MG BASE/ML</u>	<u>A063313</u>	<u>001</u>	Apr 11, 1994
<u>AP</u>	+	<u>EQ 250MG BASE/ML</u>	<u>A063315</u>	<u>001</u>	Apr 11, 1994
<u>AP</u>	HOSPIRA	<u>EQ 50MG BASE/ML</u>	<u>A063263</u>	<u>001</u>	Nov 30, 1994
<u>AP</u>		<u>EQ 250MG BASE/ML</u>	<u>A063264</u>	<u>001</u>	Nov 30, 1994
<u>AP</u>	TEVA PARENTERAL	<u>EQ 250MG BASE/ML</u>	<u>A064045</u>	<u>002</u>	Sep 28, 1993
	AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	HOSPIRA	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

<u>AB</u>	+ PAR PHARM	<u>5MG</u>	<u>A070346</u>	<u>001</u>	Jan 22, 1986
<u>AB</u>	SIGMAPHARM LABS LLC	<u>5MG</u>	<u>A079133</u>	<u>001</u>	Jan 30, 2009
<u>AB</u>	PADDOCK LABS	<u>5MG</u>	<u>N018200</u>	<u>001</u>	

## PRESCRIPTION DRUG PRODUCT LIST

3 - 20 (of 393)

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	BARR	<u>EQ 5MG ANHYDROUS;50MG</u>	<u>A071111</u>	<u>001</u>	May 10, 1988
<u>AB</u>	+ MYLAN	<u>EQ 5MG ANHYDROUS;50MG</u>	<u>A073209</u>	<u>001</u>	Oct 31, 1991

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 10%

HOSPIRA

10% (10GM/100ML)

N017673 003

AMINOSYN 10% (PH6)

HOSPIRA

10% (10GM/100ML)

N017673 008

Nov 18, 1985

AMINOSYN 3.5%

HOSPIRA

3.5% (3.5GM/100ML)

N017789 004

AMINOSYN 5%

HOSPIRA

5% (5GM/100ML)

N017673 001

AMINOSYN 7%

HOSPIRA

7% (7GM/100ML)

N017673 002

AMINOSYN 7% (PH6)

HOSPIRA

7% (7GM/100ML)

N017673 006

Nov 18, 1985

AMINOSYN 8.5%

HOSPIRA

8.5% (8.5GM/100ML)

N017673 004

AMINOSYN 8.5% (PH6)

HOSPIRA

8.5% (8.5GM/100ML)

N017673 007

Nov 18, 1985

AMINOSYN II 10%

HOSPIRA

10% (10GM/100ML)

N019438 005

Apr 03, 1986

AMINOSYN II 10% IN PLASTIC CONTAINER

HOSPIRA

10% (10GM/100ML)

N020015 001

Dec 19, 1991

AMINOSYN II 15% IN PLASTIC CONTAINER

HOSPIRA

15% (15GM/100ML)

N020041 001

Dec 19, 1991

AMINOSYN II 7%

HOSPIRA

7% (7GM/100ML)

N019438 003

Apr 03, 1986

AMINOSYN II 8.5%

HOSPIRA

8.5% (8.5GM/100ML)

N019438 004

Apr 03, 1986

AMINOSYN-HBC 7%

HOSPIRA

7% (7GM/100ML)

N019374 001

Jul 12, 1985

AMINOSYN-HF 8%

HOSPIRA

8% (8GM/100ML)

N020345 001

Apr 04, 1996

AMINOSYN-PF 10%

HOSPIRA

10% (10GM/100ML)

N019492 002

Oct 17, 1986

AMINOSYN-PF 7%

HOSPIRA

7% (7GM/100ML)

N019398 001

Sep 06, 1985

AMINOSYN-RF 5.2%

HOSPIRA

5.2% (5.2GM/100ML)

N018429 001

BRANCHAMIN 4% IN PLASTIC CONTAINER

BAXTER HLTHCARE

4% (4GM/100ML)

N018684 001

Sep 28, 1984

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

CLINTEC NUTR

15% (15GM/100ML)

A020512 001

Aug 30, 1996

FREAMINE HBC 6.9%

B BRAUN

6.9% (6.9GM/100ML)

N016822 006

May 17, 1983

FREAMINE III 10%

B BRAUN

10% (10GM/100ML)

N016822 005

FREAMINE III 8.5%

B BRAUN

8.5% (8.5GM/100ML)

N016822 004

HEPATAMINE 8%

B BRAUN

8% (8GM/100ML)

N018676 001

Aug 03, 1982

HEPATASOL 8%

BAXTER HLTHCARE

8% (8GM/100ML)

N020360 001

Apr 04, 1996

NEPHRAMINE 5.4%

B BRAUN

5.4% (5.4GM/100ML)

N017766 001

## PRESCRIPTION DRUG PRODUCT LIST

3 - 21 (of 393)

AMINO ACIDS

## INJECTABLE; INJECTION

NOVAMINE 11.4%				
+ HOSPIRA	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982
NOVAMINE 15%				
+ HOSPIRA	15% (15GM/100ML)	N017957	004	Nov 28, 1986
PREMASOL 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	10% (10GM/100ML)	A075880	002	Jun 19, 2003
PREMASOL 6% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	6% (6GM/100ML)	A075880	001	Jun 19, 2003
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	20% (20GM/100ML)	N020849	001	Aug 26, 1998
RENAMIN W/O ELECTROLYTES				
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982
TRAVASOL 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	10% (10MG/100ML)	N018931	003	Aug 23, 1984
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006	
TRAVASOL 5.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931	001	Aug 23, 1984
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004	
TRAVASOL 8.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931	002	Aug 23, 1984
TRAVASOL 8.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005	
TROPHAMINE				
+ B BRAUN	6% (6GM/100ML)	N019018	001	Jul 20, 1984
TROPHAMINE 10%				
+ B BRAUN	10% (10GM/100ML)	N019018	003	Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

## PROCALAMINE

B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG /100ML;150MG/100ML;200MG/100ML;120MG/10 OML	N018582	001	May 08, 1982
---------	---	---------	-----	--------------

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

## AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

HOSPIRA	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML ;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	001	Nov 07, 1988
---------	--	---------	-----	--------------

## AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

HOSPIRA	4.25%;36.8MG/100ML;20GM/100ML;51MG/100M L;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	002	Nov 07, 1988
---------	---	---------	-----	--------------

## AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

HOSPIRA	4.25%;36.8MG/100ML;25GM/100ML;51MG/100M L;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	003	Nov 07, 1988
---------	---	---------	-----	--------------

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

## CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;217MG/100ML;112MG/100ML	N020678	002	Mar 26, 1997
-------------------	--	---------	-----	--------------

## CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;217MG/100ML;112MG/100ML	N020678	005	Mar 26, 1997
-------------------	--	---------	-----	--------------



## PRESCRIPTION DRUG PRODUCT LIST

3 - 22 (of 393)

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE,  
DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;2	N020678 001	Mar 26,	1997
	61MG/100ML;217MG/100ML;112MG/100ML			
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;	N020678 009	Mar 26,	1997
	261MG/100ML;297MG/100ML;77MG/100ML			
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;	N020678 011	Mar 26,	1997
	261MG/100ML;297MG/100ML;77MG/100ML			
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;	N020678 012	Mar 26,	1997
	261MG/100ML;297MG/100ML;77MG/100ML			
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;2	N020678 008	Mar 26,	1997
	61MG/100ML;297MG/100ML;77MG/100ML			
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261	N020678 016	Mar 26,	1997
	MG/100ML;340MG/100ML;59MG/100ML			
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261	N020678 017	Mar 26,	1997
	MG/100ML;340MG/100ML;59MG/100ML			
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261	N020678 018	Mar 26,	1997
	MG/100ML;340MG/100ML;59MG/100ML			
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261	N020678 019	Mar 26,	1997
	MG/100ML;340MG/100ML;59MG/100ML			
CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261	N020678 021	Mar 26,	1997
	MG/100ML;340MG/100ML;59MG/100ML			

AMINO ACIDS; DEXTROSE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
HOSPIRA	3.5%;25GM/100ML	N019681 001	Nov 01,	1988
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER				
HOSPIRA	3.5%;5GM/100ML	N019681 002	Nov 01,	1988
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
HOSPIRA	4.25%;10GM/100ML	N019681 004	Nov 01,	1988
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER				
HOSPIRA	4.25%;20GM/100ML	N019681 005	Nov 01,	1988
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER				
HOSPIRA	4.25%;25GM/100ML	N019681 003	Nov 01,	1988
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
HOSPIRA	5%;25GM/100ML	N019681 006	Nov 01,	1988
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;10GM/100ML	N020734 002	Sep 29,	1997
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;25GM/100ML	N020734 005	Sep 29,	1997
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;5GM/100ML	N020734 001	Sep 29,	1997
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;10GM/100ML	N020734 008	Sep 29,	1997
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;20GM/100ML	N020734 010	Sep 29,	1997
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;25GM/100ML	N020734 011	Sep 29,	1997
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;5GM/100ML	N020734 007	Sep 29,	1997

## PRESCRIPTION DRUG PRODUCT LIST

3 - 23 (of 393)

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%;10GM/100ML	N020734 014	Sep 29, 1997
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%;15GM/100ML	N020734 015	Sep 29, 1997
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%;20GM/100ML	N020734 016	Sep 29, 1997
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%;25GM/100ML	N020734 017	Sep 29, 1997
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%;35GM/100ML	N020734 018	Sep 29, 1997

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682 001	Nov 01, 1988
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER			
HOSPIRA	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682 002	Nov 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES			
B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/100ML;440MG/100ML;690MG/100ML	N016822 007	Jul 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M			
HOSPIRA	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N017789 003	

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

FREAMINE III 3% W/ ELECTROLYTES			
B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N016822 003	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES			
HOSPIRA	10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437 004	Apr 03, 1986
AMINOSYN II 8.5% W/ ELECTROLYTES			
HOSPIRA	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437 005	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER			
BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177 001	Oct 23, 1995
TRAVASOL 3.5% W/ ELECTROLYTES			
BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N017493 003	

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 50 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 24 (of 393)

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE;  
SODIUM CHLORIDE

## INJECTABLE; INJECTION

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N020173	001	Oct 27, 1995
TRAVASOL 5.5% W/ ELECTROLYTES				
BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N017493	001	
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER				
BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N020173	002	Oct 27, 1995
TRAVASOL 8.5% W/ ELECTROLYTES				
BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N017493	002	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES				
HOSPIRA	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789	002	
AMINOSYN 8.5% W/ ELECTROLYTES				
HOSPIRA	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673	005	

AMINOCAPROIC ACID

## INJECTABLE; INJECTION

<u>AMINOCAPROIC ACID</u>				
<u>AP</u>	LUITPOLD	<u>250MG/ML</u>	<u>A071192</u>	<u>001</u> Dec 01, 1987
<u>AMINOCAPROIC ACID IN PLASTIC CONTAINER</u>				
<u>AP</u>	+ HOSPIRA	<u>250MG/ML</u>	<u>A070010</u>	<u>001</u> Mar 09, 1987
SYRUP; ORAL				
<u>AMICAR</u>				
<u>AA</u>	+ XANODYNE PHARM	<u>1.25GM/5ML</u>	<u>N015230</u>	<u>002</u>
<u>AMINOCAPROIC ACID</u>				
<u>AA</u>	MIKART	<u>1.25GM/5ML</u>	<u>A074759</u>	<u>001</u> Sep 02, 1998
TABLET; ORAL				
<u>AMICAR</u>				
<u>AB</u>	XANODYNE PHARM	<u>500MG</u>	<u>N015197</u>	<u>001</u>
<u>AMINOCAPROIC</u>				
<u>AB</u>	MIKART	<u>500MG</u>	<u>A075602</u>	<u>001</u> May 24, 2001
AMICAR				
	+ XANODYNE PHARM	1GM	N015197	002 Jun 24, 2004

AMINOHIPPURATE SODIUM

## INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM				
+ MERCK	20%	N005619	001	

AMINOLEVULINIC ACID HYDROCHLORIDE

## SOLUTION; TOPICAL

LEVULAN				
+ DUSA	20%	N020965	001	Dec 03, 1999

AMINOPHYLLINE

## INJECTABLE; INJECTION

<u>AMINOPHYLLINE</u>				
<u>AP</u>	+ HOSPIRA	<u>25MG/ML</u>	<u>A087242</u>	<u>001</u> Oct 26, 1983
<u>AP</u>	INTL MEDICATION	<u>25MG/ML</u>	<u>A087209</u>	<u>001</u> Feb 01, 1982
<u>AP</u>	LUITPOLD	<u>25MG/ML</u>	<u>A087240</u>	<u>001</u>
<u>AP</u>		<u>25MG/ML</u>	<u>A087600</u>	<u>001</u>

## PRESCRIPTION DRUG PRODUCT LIST

3 - 25 (of 393)

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

<u>AP</u>	PHARMA SERVE NY	<u>25MG/ML</u>	<u>A087392</u>	<u>001</u>	Dec 15, 1983
<u>AP</u>	TEVA PARENTERAL	<u>25MG/ML</u>	<u>A081142</u>	<u>001</u>	Sep 25, 1991

TABLET; ORAL

AMINOPHYLLINE

+	WEST WARD	100MG	A084540	001	
+		200MG	A085003	001	

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL

PASER

+	JACOBUS	4GM/PACKET	A074346	001	Jun 30, 1994
---	---------	------------	---------	-----	--------------

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

<u>AP</u>	+	AKORN	<u>50MG/ML</u>	<u>A076232</u>	<u>001</u>	Jul 05, 2006
<u>AP</u>	+	APOTEX INC	<u>50MG/ML</u>	<u>A076394</u>	<u>001</u>	Apr 25, 2003
<u>AP</u>	+	APP PHARMS	<u>50MG/ML</u>	<u>A075761</u>	<u>001</u>	Oct 15, 2002
<u>AP</u>	+	BEDFORD	<u>50MG/ML</u>	<u>A076018</u>	<u>001</u>	Oct 15, 2002
<u>AP</u>	+	BEDFORD LABS	<u>50MG/ML</u>	<u>A076299</u>	<u>001</u>	Oct 24, 2002
<u>AP</u>	+	BIONICHE PHARMA	<u>50MG/ML</u>	<u>A076217</u>	<u>001</u>	Oct 15, 2002
<u>AP</u>	+	GLAND PHARMA LTD	<u>50MG/ML</u>	<u>A077161</u>	<u>001</u>	Apr 20, 2005
<u>AP</u>		HIKMA FARMACEUTICA	<u>50MG/ML</u>	<u>A077234</u>	<u>001</u>	Feb 25, 2008
<u>AP</u>	+	HOSPIRA	<u>50MG/ML</u>	<u>A075955</u>	<u>001</u>	Oct 18, 2002
<u>AP</u>	+	TEVA PARENTERAL	<u>50MG/ML</u>	<u>A076163</u>	<u>001</u>	Sep 05, 2003
<u>AP</u>		WOCKHARDT	<u>50MG/ML</u>	<u>A077610</u>	<u>001</u>	Oct 30, 2008
<u>AP</u>			<u>50MG/ML</u>	<u>A077834</u>	<u>001</u>	Oct 30, 2008
<u>NEXTERONE</u>						
<u>AP</u>		PRISM PHARMS	<u>50MG/ML</u>	<u>N022325</u>	<u>001</u>	Dec 24, 2008

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

<u>AB</u>		APOTEX CORP	<u>200MG</u>	<u>A078578</u>	<u>001</u>	Nov 06, 2008
<u>AB</u>		AUROSAL PHARMS	<u>200MG</u>	<u>A077069</u>	<u>001</u>	Apr 08, 2005
<u>AB</u>			<u>400MG</u>	<u>A077069</u>	<u>002</u>	Apr 08, 2005
<u>AB</u>		BARR	<u>200MG</u>	<u>A075389</u>	<u>001</u>	Jan 25, 2001
<u>AB</u>		MYLAN	<u>200MG</u>	<u>A075188</u>	<u>001</u>	Feb 24, 1999
<u>AB</u>		SANDOZ	<u>200MG</u>	<u>A075315</u>	<u>001</u>	Dec 23, 1998
<u>AB</u>			<u>400MG</u>	<u>A075315</u>	<u>002</u>	Jun 30, 2000
<u>AB</u>		TARO	<u>100MG</u>	<u>A075424</u>	<u>002</u>	Dec 18, 2002
<u>AB</u>			<u>200MG</u>	<u>A075424</u>	<u>001</u>	Mar 30, 2001
<u>AB</u>			<u>400MG</u>	<u>A076362</u>	<u>001</u>	Nov 29, 2002
<u>AB</u>		TEVA PHARMS	<u>200MG</u>	<u>A074739</u>	<u>001</u>	Nov 30, 1998
<u>AB</u>		ZYDUS PHARMS USA INC	<u>200MG</u>	<u>A079029</u>	<u>001</u>	Sep 16, 2008
<u>CORDARONE</u>						
<u>AB</u>	+	WYETH PHARMS INC	<u>200MG</u>	<u>N018972</u>	<u>001</u>	Dec 24, 1985
<u>PACERONE</u>						
<u>AB</u>		UPSHER SMITH	<u>100MG</u>	<u>A075135</u>	<u>002</u>	Apr 12, 2005
<u>AB</u>			<u>200MG</u>	<u>A075135</u>	<u>001</u>	Apr 30, 1998
		AMIODARONE HYDROCHLORIDE				
		TARO	300MG	A076362	002	Dec 02, 2003

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>		CARACO	<u>10MG</u>	<u>A040815</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>			<u>25MG</u>	<u>A040816</u>	<u>001</u>	Jun 27, 2008

PRESCRIPTION DRUG PRODUCT LIST

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>	CARACO	<u>50MG</u>	<u>A040817</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>		<u>75MG</u>	<u>A040818</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>		<u>100MG</u>	<u>A040819</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>		<u>150MG</u>	<u>A040820</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A089398</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>25MG</u>	<u>A089399</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>50MG</u>	<u>A089400</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>75MG</u>	<u>A089401</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>100MG</u>	<u>A089402</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>150MG</u>	<u>A089403</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A086009</u>	<u>002</u>	
<u>AB</u>		<u>25MG</u>	<u>A086009</u>	<u>003</u>	
<u>AB</u>		<u>50MG</u>	<u>A086009</u>	<u>001</u>	
<u>AB</u>		<u>75MG</u>	<u>A086009</u>	<u>004</u>	
<u>AB</u>		<u>100MG</u>	<u>A086009</u>	<u>005</u>	
<u>AB</u>		<u>150MG</u>	<u>A086009</u>	<u>006</u>	
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A085969</u>	<u>001</u>	
<u>AB</u>	+	<u>25MG</u>	<u>A085966</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A085968</u>	<u>001</u>	
<u>AB</u>		<u>75MG</u>	<u>A085971</u>	<u>001</u>	
<u>AB</u>		<u>100MG</u>	<u>A085967</u>	<u>001</u>	
<u>AB</u>		<u>150MG</u>	<u>A085970</u>	<u>001</u>	
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A040218</u>	<u>001</u>	Sep 11, 1997
<u>AB</u>		<u>25MG</u>	<u>A040218</u>	<u>002</u>	Sep 11, 1997
<u>AB</u>		<u>50MG</u>	<u>A040218</u>	<u>003</u>	Sep 11, 1997
<u>AB</u>		<u>75MG</u>	<u>A040218</u>	<u>004</u>	Sep 11, 1997
<u>AB</u>		<u>100MG</u>	<u>A040218</u>	<u>005</u>	Sep 11, 1997
<u>AB</u>		<u>150MG</u>	<u>A040218</u>	<u>006</u>	Sep 11, 1997

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 12.5MG BASE;5MG</u>	<u>A071297</u>	<u>002</u>	Dec 10, 1986
<u>AB</u>		<u>EQ 25MG BASE;10MG</u>	<u>A071297</u>	<u>001</u>	Dec 10, 1986
		<u>LIMBITROL</u>			
<u>AB</u>	VALEANT PHARM INTL	<u>EQ 12.5MG BASE;5MG</u>	<u>N016949</u>	<u>001</u>	
		<u>LIMBITROL DS</u>			
<u>AB</u>	+	<u>EQ 25MG BASE;10MG</u>	<u>N016949</u>	<u>002</u>	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN	10MG; 2MG	A071443	002	Nov 10, 1988
		10MG; 4MG	A071443	003	Nov 10, 1988
	+	25MG; 2MG	A071443	004	Nov 10, 1988
	+	25MG; 4MG	A071443	005	Nov 10, 1988
	+	50MG; 4MG	A071443	001	Nov 10, 1988

AMLEXANOX

PASTE; DENTAL

APHTHASOL

	+	ULURU	5%	N020511	001	Dec 17, 1996
--	---	-------	----	---------	-----	--------------

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>	ACTAVIS TOTOVA	<u>EQ 2.5MG BASE</u>	<u>A078131</u>	<u>001</u>	Sep 04, 2007
-----------	----------------	----------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 27 (of 393)

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>	ACTAVIS TOTOWA	<u>EQ 5MG BASE</u>	<u>A078131</u>	<u>002</u>	Sep 04, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078131</u>	<u>003</u>	Sep 04, 2007
<u>AB</u>	ALKEM	<u>EQ 2.5MG BASE</u>	<u>A078925</u>	<u>001</u>	May 04, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078925</u>	<u>002</u>	May 04, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078925</u>	<u>003</u>	May 04, 2009
<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 2.5MG BASE</u>	<u>A078477</u>	<u>001</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078477</u>	<u>002</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078477</u>	<u>003</u>	Jan 16, 2008
<u>AB</u>	APOTEX	<u>EQ 2.5MG BASE</u>	<u>A076719</u>	<u>001</u>	May 23, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076719</u>	<u>002</u>	May 23, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076719</u>	<u>003</u>	May 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 2.5MG BASE</u>	<u>A078021</u>	<u>001</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078021</u>	<u>002</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078021</u>	<u>003</u>	Jul 17, 2007
<u>AB</u>	CARACO	<u>EQ 2.5MG BASE</u>	<u>A078231</u>	<u>001</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078231</u>	<u>002</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078231</u>	<u>003</u>	Nov 30, 2007
<u>AB</u>	COBALT	<u>EQ 2.5MG BASE</u>	<u>A077671</u>	<u>001</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077671</u>	<u>002</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077671</u>	<u>003</u>	Jul 19, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A076692</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076692</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076692</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>	GEDEON RICHTER USA	<u>EQ 2.5MG BASE</u>	<u>A077333</u>	<u>001</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077333</u>	<u>002</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077333</u>	<u>003</u>	Jul 17, 2007
<u>AB</u>	GLENMARK GENERICS	<u>EQ 2.5MG BASE</u>	<u>A078552</u>	<u>001</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078552</u>	<u>002</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078552</u>	<u>003</u>	Apr 08, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077955</u>	<u>001</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077955</u>	<u>002</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077955</u>	<u>003</u>	Aug 28, 2007
<u>AB</u>	KALI LABS INC	<u>EQ 2.5MG BASE</u>	<u>A077516</u>	<u>001</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077516</u>	<u>002</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077516</u>	<u>003</u>	Jul 11, 2007
<u>AB</u>	LEK PHARMS DD	<u>EQ 2.5MG BASE</u>	<u>A076859</u>	<u>001</u>	Sep 10, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076859</u>	<u>002</u>	Sep 10, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076859</u>	<u>003</u>	Sep 10, 2007
<u>AB</u>	LUPIN	<u>EQ 2.5MG BASE</u>	<u>A078043</u>	<u>001</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078043</u>	<u>002</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078043</u>	<u>003</u>	Jul 12, 2007
<u>AB</u>	MATRIX LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A078224</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078224</u>	<u>002</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078224</u>	<u>003</u>	Feb 27, 2008
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE</u>	<u>A076418</u>	<u>001</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076418</u>	<u>002</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076418</u>	<u>003</u>	Oct 03, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A078453</u>	<u>001</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078453</u>	<u>002</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078453</u>	<u>003</u>	Jul 02, 2009
<u>AB</u>	RANBAXY	<u>EQ 2.5MG BASE</u>	<u>A077974</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077974</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077974</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	ROXANE	<u>EQ 2.5MG BASE</u>	<u>A077262</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077262</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077262</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	SYNTHON PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077080</u>	<u>001</u>	Jun 27, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 28 (of 393)

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>	SYNTHON PHARMS	<u>EQ 5MG BASE</u>	<u>A077080</u>	<u>002</u>	Jun 27, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077080</u>	<u>003</u>	Jun 27, 2007
<u>AB</u>	TEVA	<u>EQ 2.5MG BASE</u>	<u>A076846</u>	<u>001</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076846</u>	<u>002</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076846</u>	<u>003</u>	Jun 28, 2007
<u>AB</u>	TORRENT PHARMS	<u>EQ 2.5MG BASE</u>	<u>A078573</u>	<u>001</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078573</u>	<u>002</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078573</u>	<u>003</u>	Sep 22, 2008
<u>AB</u>	UPSHER SMITH	<u>EQ 2.5MG BASE</u>	<u>A077759</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077759</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077759</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE</u>	<u>A077073</u>	<u>001</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077073</u>	<u>002</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077073</u>	<u>003</u>	Sep 26, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 2.5MG BASE</u>	<u>A078500</u>	<u>001</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078500</u>	<u>002</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078500</u>	<u>003</u>	Sep 06, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 2.5MG BASE</u>	<u>A078226</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078226</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078226</u>	<u>003</u>	Jul 09, 2007
	<u>NORVASC</u>				
<u>AB</u>	PFIZER	<u>EQ 2.5MG BASE</u>	<u>N019787</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N019787</u>	<u>002</u>	Jul 31, 1992
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N019787</u>	<u>003</u>	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

CADUET

	PFIZER	EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004
		EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004
		EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004
		EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004
		EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004
		EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004
		EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004
		EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004
		EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004
		EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004
	+	EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	TEVA PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077179</u>	<u>001</u>	May 18, 2007
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077179</u>	<u>002</u>	May 18, 2007
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077179</u>	<u>003</u>	May 18, 2007
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077179</u>	<u>004</u>	May 18, 2007
	<u>LOTREL</u>				
<u>AB</u>	NOVARTIS	<u>EQ 2.5MG BASE;10MG</u>	<u>N020364</u>	<u>002</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>N020364</u>	<u>003</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>N020364</u>	<u>004</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>N020364</u>	<u>005</u>	Jun 20, 2002
	LOTREL				
	NOVARTIS	EQ 5MG BASE;40MG	N020364	007	Apr 11, 2006
	+	EQ 10MG BASE;40MG	N020364	006	Apr 11, 2006

## PRESCRIPTION DRUG PRODUCT LIST

3 - 29 (of 393)

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AZOR

DAIICHI SANKYO	EQ 5MG BASE;20MG	N022100	001	Sep 26, 2007
	EQ 5MG BASE;40MG	N022100	002	Sep 26, 2007
	EQ 10MG BASE;20MG	N022100	003	Sep 26, 2007
+	EQ 10MG BASE;40MG	N022100	004	Sep 26, 2007

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TWINSTA

BOEHRINGER INGELHEIM	EQ 5MG BASE;40MG	N022401	001	Oct 16, 2009
	EQ 5MG BASE;80MG	N022401	003	Oct 16, 2009
	EQ 10MG BASE;40MG	N022401	002	Oct 16, 2009
+	EQ 10MG BASE;80MG	N022401	004	Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

EXFORGE

NOVARTIS	EQ 5MG BASE;160MG	N021990	002	Jun 20, 2007
	EQ 5MG BASE;320MG	N021990	004	Jun 20, 2007
+	EQ 10MG BASE;160MG	N021990	003	Jun 20, 2007
+	EQ 10MG BASE;320MG	N021990	005	Jun 20, 2007

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

EXFORGE HCT

NOVARTIS	5MG;12.5MG;160MG	N022314	001	Apr 30, 2009
	5MG;25MG;160MG	N022314	002	Apr 30, 2009
	10MG;12.5MG;160MG	N022314	003	Apr 30, 2009
	10MG;25MG;160MG	N022314	004	Apr 30, 2009
+	10MG;25MG;320MG	N022314	005	Apr 30, 2009

AMMONIA, N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

+	FEINSTEIN	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	N022119	001	Aug 23, 2007
---	-----------	------------------------------------	---------	-----	--------------

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	5MEQ/ML	A088366	001	Jun 13, 1984
---	---------	---------	---------	-----	--------------

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	PADDOCK	<u>EQ 12% BASE</u>	<u>A076829</u>	<u>001</u>	Feb 07, 2006	
<u>AB</u>	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075774</u>	<u>001</u>	May 01, 2002	
<u>AB</u>	TARO	<u>EQ 12% BASE</u>	<u>A075883</u>	<u>001</u>	Apr 10, 2003	
	<u>LAC-HYDRIN</u>					
<u>AB</u>	+	<u>RANBAXY</u>	<u>EQ 12% BASE</u>	<u>N020508</u>	<u>001</u>	Aug 29, 1996

LOTION; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	PADDOCK	<u>EQ 12% BASE</u>	<u>A075575</u>	<u>001</u>	Jun 11, 2002	
<u>AB</u>	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075570</u>	<u>001</u>	Jun 23, 2004	
<u>AB</u>	TARO	<u>EQ 12% BASE</u>	<u>A076216</u>	<u>001</u>	May 28, 2004	
	<u>LAC-HYDRIN</u>					
<u>AB</u>	+	<u>RANBAXY</u>	<u>EQ 12% BASE</u>	<u>N019155</u>	<u>001</u>	Apr 24, 1985



## PRESCRIPTION DRUG PRODUCT LIST

3 - 30 (of 393)

AMOXAPINE

TABLET; ORAL

AMOXAPINE

WATSON LABS	25MG	A072688	001	Aug 28, 1992
	50MG	A072689	001	Aug 28, 1992
	100MG	A072690	001	Aug 28, 1992
+	150MG	A072691	001	Aug 28, 1992

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>250MG</u>	<u>A065271</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>500MG</u>	<u>A065271</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	DAVA PHARMS INC	<u>250MG</u>	<u>A062884</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>		<u>500MG</u>	<u>A062881</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>	HIKMA PHARMS	<u>250MG</u>	<u>A065291</u>	<u>001</u>	Feb 05, 2007
<u>AB</u>		<u>500MG</u>	<u>A065291</u>	<u>002</u>	Feb 05, 2007
<u>AB</u>	RANBAXY	<u>250MG</u>	<u>A065016</u>	<u>001</u>	Apr 08, 1999
<u>AB</u>		<u>500MG</u>	<u>A065016</u>	<u>002</u>	Apr 08, 1999
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A064076</u>	<u>001</u>	Sep 30, 1994
<u>AB</u>		<u>500MG</u>	<u>A064076</u>	<u>002</u>	Sep 30, 1994
<u>AB</u>	TEVA	<u>250MG</u>	<u>A061926</u>	<u>001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>A061926</u>	<u>003</u>	

FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>200MG/5ML</u>	<u>A065334</u>	<u>001</u>	Dec 28, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065334</u>	<u>002</u>	Dec 28, 2006
<u>AB</u>	DAVA PHARMS INC	<u>125MG/5ML</u>	<u>A062927</u>	<u>001</u>	Nov 25, 1988
<u>AB</u>		<u>250MG/5ML</u>	<u>A062927</u>	<u>002</u>	Nov 25, 1988
<u>AB</u>	HIKMA	<u>125MG/5ML</u>	<u>A065322</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>200MG/5ML</u>	<u>A065325</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065322</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065325</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>	MORTON GROVE	<u>400MG/5ML</u>	<u>A065319</u>	<u>002</u>	Jun 18, 2007
<u>AB</u>	RANBAXY	<u>200MG/5ML</u>	<u>A065113</u>	<u>001</u>	Nov 29, 2002
<u>AB</u>		<u>400MG/5ML</u>	<u>A065113</u>	<u>002</u>	Nov 29, 2002
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065387</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>200MG/5ML</u>	<u>A065378</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065387</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>		<u>400MG/5ML</u>	<u>A065378</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>	TEVA	<u>125MG/5ML</u>	<u>A061931</u>	<u>001</u>	
<u>AB</u>		<u>200MG/5ML</u>	<u>A065119</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A061931</u>	<u>002</u>	
<u>AB</u>	+	<u>400MG/5ML</u>	<u>A065119</u>	<u>002</u>	Dec 04, 2002

AMOXICILLIN PEDIATRIC

<u>AB</u>	TEVA	<u>50MG/ML</u>	<u>A061931</u>	<u>003</u>	Dec 01, 1982
-----------	------	----------------	----------------	------------	--------------

LAROTID

<u>AB</u>	GLAXOSMITHKLINE	<u>125MG/5ML</u>	<u>A062226</u>	<u>003</u>	
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>004</u>	

TRIMOX

<u>AB</u>	APOTHECON	<u>50MG/ML</u>	<u>A061886</u>	<u>001</u>	
<u>AB</u>		<u>125MG/5ML</u>	<u>A061886</u>	<u>002</u>	
<u>AB</u>		<u>125MG/5ML</u>	<u>A062885</u>	<u>001</u>	Mar 08, 1988
<u>AB</u>		<u>250MG/5ML</u>	<u>A061886</u>	<u>003</u>	
<u>AB</u>		<u>250MG/5ML</u>	<u>A062885</u>	<u>002</u>	Mar 08, 1988

TABLET; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A065256</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>875MG</u>	<u>A065256</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	DAVA PHARMS INC	<u>875MG</u>	<u>A065344</u>	<u>001</u>	Jan 15, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 31 (of 393)

AMOXICILLIN

TABLET; ORAL

AMOXICILLIN

<u>AB</u>	HIKMA	<u>875MG</u>	<u>A065255</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>	RANBAXY	<u>500MG</u>	<u>A065059</u>	<u>001</u>	Nov 24, 2000
<u>AB</u>		<u>875MG</u>	<u>A065059</u>	<u>002</u>	Nov 24, 2000
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065228</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>		<u>875MG</u>	<u>A065228</u>	<u>002</u>	Jul 13, 2005
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065056</u>	<u>001</u>	Sep 18, 2000
<u>AB</u>	+	<u>875MG</u>	<u>A065056</u>	<u>002</u>	Sep 18, 2000

TABLET, CHEWABLE; ORAL

AMOXICILLIN

<u>AB</u>	DAVA PHARMS INC	<u>125MG</u>	<u>A064139</u>	<u>001</u>	Jan 29, 1996
<u>AB</u>		<u>250MG</u>	<u>A064139</u>	<u>002</u>	Jan 29, 1996
<u>AB</u>	RANBAXY	<u>125MG</u>	<u>A065021</u>	<u>001</u>	Dec 23, 1999
<u>AB</u>		<u>250MG</u>	<u>A065021</u>	<u>002</u>	Dec 23, 1999
<u>AB</u>	TEVA	<u>125MG</u>	<u>A064013</u>	<u>002</u>	Sep 11, 1995
<u>AB</u>		<u>250MG</u>	<u>A064013</u>	<u>001</u>	Dec 22, 1992
	AMOXICILLIN				
	RANBAXY	200MG	A065060	001	Nov 29, 2000
		400MG	A065060	002	Nov 29, 2000

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

	+	MIDDLEBROOK PHARMS	775MG	N050813	001	Jan 23, 2008
--	---	--------------------	-------	---------	-----	--------------

TABLET, FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO PHARMA	<u>200MG</u>	<u>A065324</u>	<u>001</u>	Jan 17, 2007	
<u>AB</u>		<u>400MG</u>	<u>A065324</u>	<u>002</u>	Jan 17, 2007	
	<u>DISPERMOX</u>					
<u>AB</u>	RANBAXY	<u>200MG</u>	<u>A065080</u>	<u>002</u>	Aug 11, 2003	
<u>AB</u>	+	<u>400MG</u>	<u>A065080</u>	<u>001</u>	Aug 11, 2003	
	DISPERMOX					
	+	RANBAXY	600MG	A065159	001	Dec 04, 2003

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS; ORAL

PREVPAC

	+	TAKEDA PHARMS NA	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	N050757	001	Dec 02, 1997
--	---	------------------	--	---------	-----	--------------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	HIKMA PHARMS	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065191</u>	<u>002</u>	Jan 25, 2005
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065191</u>	<u>001</u>	Jan 25, 2005
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065373</u>	<u>001</u>	Nov 09, 2007
<u>AB</u>	LEK PHARMS	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065098</u>	<u>001</u>	Dec 16, 2002
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065098</u>	<u>002</u>	Dec 16, 2002
<u>AB</u>	LEK PHARMS DD	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065358</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>	RANBAXY	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065132</u>	<u>001</u>	Mar 19, 2003
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065132</u>	<u>002</u>	Mar 19, 2003
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065207</u>	<u>002</u>	Jan 30, 2007
<u>AB</u>	SANDOZ	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065066</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065066</u>	<u>002</u>	Jun 05, 2002
<u>AB</u>	TEVA	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065089</u>	<u>001</u>	May 25, 2004
<u>AB</u>	+	<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065089</u>	<u>002</u>	May 25, 2004
<u>AB</u>	+	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065162</u>	<u>001</u>	Mar 12, 2004
	AMOXICILLIN AND CLAVULANATE POTASSIUM				
	MORTON GROVE PHARMS	250MG/5ML;EQ 62.5MG BASE/5ML	A065431	001	Nov 25, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 32 (of 393)

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	APOTEX	<u>250MG;EQ 125MG BASE</u>	<u>A065333</u>	<u>001</u>	Feb 24, 2009
<u>AB</u>		<u>500MG;EQ 125MG BASE</u>	<u>A065333</u>	<u>002</u>	Feb 24, 2009
<u>AB</u>	APOTEX INC	<u>875MG;EQ 125MG BASE</u>	<u>A065317</u>	<u>003</u>	Oct 20, 2008
<u>AB</u>	LEK PHARMS	<u>500MG;EQ 125MG BASE</u>	<u>A065117</u>	<u>001</u>	Nov 27, 2002
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A065093</u>	<u>001</u>	Nov 21, 2002
<u>AB</u>	RANBAXY	<u>500MG;EQ 125MG BASE</u>	<u>A065109</u>	<u>001</u>	Nov 04, 2002
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A065102</u>	<u>001</u>	Sep 17, 2002
<u>AB</u>	SANDOZ	<u>250MG;EQ 125MG BASE</u>	<u>A065189</u>	<u>001</u>	Aug 23, 2005
<u>AB</u>		<u>500MG;EQ 125MG BASE</u>	<u>A065064</u>	<u>001</u>	Mar 15, 2002
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A065063</u>	<u>001</u>	Mar 14, 2002
<u>AB</u>	TEVA	<u>500MG;EQ 125MG BASE</u>	<u>A065101</u>	<u>001</u>	Oct 30, 2002
<u>AB</u>	+	<u>875MG;EQ 125MG BASE</u>	<u>A065096</u>	<u>001</u>	Oct 29, 2002

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	RANBAXY	<u>200MG;EQ 28.5MG BASE</u>	<u>A065161</u>	<u>001</u>	Dec 03, 2003
<u>AB</u>		<u>400MG;EQ 57MG BASE</u>	<u>A065161</u>	<u>002</u>	Dec 03, 2003
<u>AB</u>	SANDOZ	<u>200MG;EQ 28.5MG BASE</u>	<u>A065065</u>	<u>001</u>	Apr 18, 2002
<u>AB</u>		<u>400MG;EQ 57MG BASE</u>	<u>A065065</u>	<u>002</u>	Apr 18, 2002
<u>AB</u>	TEVA	<u>200MG;EQ 28.5MG BASE</u>	<u>A065205</u>	<u>001</u>	Feb 09, 2005
<u>AB</u>	+	<u>400MG;EQ 57MG BASE</u>	<u>A065205</u>	<u>002</u>	Feb 09, 2005

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

SHIRE 2.5MG;2.5MG;2.5MG;2.5MG N021303 001 Oct 11, 2001

ADDERALL XR 15

SHIRE 3.75MG;3.75MG;3.75MG;3.75MG N021303 006 May 22, 2002

ADDERALL XR 20

SHIRE 5MG;5MG;5MG;5MG N021303 002 Oct 11, 2001

ADDERALL XR 25

SHIRE 6.25MG;6.25MG;6.25MG;6.25MG N021303 004 May 22, 2002

ADDERALL XR 30

+ SHIRE 7.5MG;7.5MG;7.5MG;7.5MG N021303 003 Oct 11, 2001

ADDERALL XR 5

SHIRE 1.25MG;1.25MG;1.25MG;1.25MG N021303 005 May 22, 2002

TABLET; ORAL

ADDERALL 10AB DURAMED RES 2.5MG;2.5MG;2.5MG;2.5MG N011522 007 Feb 13, 1996ADDERALL 12.5AB DURAMED RES 3.125MG;3.125MG;3.125MG;3.125MG N011522 012 Aug 31, 2000ADDERALL 15AB DURAMED RES 3.75MG;3.75MG;3.75MG;3.75MG N011522 013 Aug 31, 2000ADDERALL 20AB DURAMED RES 5MG;5MG;5MG;5MG N011522 008 Feb 13, 1996ADDERALL 30AB + DURAMED RES 7.5MG;7.5MG;7.5MG;7.5MG N011522 010 May 12, 1997ADDERALL 5AB DURAMED RES 1.25MG;1.25MG;1.25MG;1.25MG N011522 009 May 12, 1997ADDERALL 7.5AB DURAMED RES 1.875MG;1.875MG;1.875MG;1.875MG N011522 011 Aug 31, 2000DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATEAB BARR 1.25MG;1.25MG;1.25MG;1.25MG A040422 001 Feb 11, 2002AB 1.875MG;1.875MG;1.875MG;1.875MG A040422 005 Mar 19, 2003AB 2.5MG;2.5MG;2.5MG;2.5MG A040422 002 Feb 11, 2002AB 3.125MG;3.125MG;3.125MG;3.125MG A040422 006 Mar 19, 2003AB 3.75MG;3.75MG;3.75MG;3.75MG A040422 007 Mar 19, 2003

## PRESCRIPTION DRUG PRODUCT LIST

3 - 33 (of 393)

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;  
DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

<u>DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE</u>					
<u>AB</u>	BARR	<u>5MG; 5MG; 5MG; 5MG</u>	<u>A040422</u>	<u>003</u>	Feb 11, 2002
<u>AB</u>		<u>7.5MG; 7.5MG; 7.5MG; 7.5MG</u>	<u>A040422</u>	<u>004</u>	Feb 11, 2002
<u>AB</u>	COREPHARMA	<u>1.25MG; 1.25MG; 1.25MG; 1.25MG</u>	<u>A040444</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>		<u>2.5MG; 2.5MG; 2.5MG; 2.5MG</u>	<u>A040444</u>	<u>002</u>	Jun 19, 2002
<u>AB</u>		<u>5MG; 5MG; 5MG; 5MG</u>	<u>A040444</u>	<u>003</u>	Jun 19, 2002
<u>AB</u>		<u>7.5MG; 7.5MG; 7.5MG; 7.5MG</u>	<u>A040444</u>	<u>004</u>	Jun 19, 2002
<u>AB</u>	MALLINCKRODT	<u>1.25MG; 1.25MG; 1.25MG; 1.25MG</u>	<u>A040440</u>	<u>001</u>	Oct 07, 2003
<u>AB</u>		<u>1.875MG; 1.875MG; 1.875MG; 1.875MG</u>	<u>A040440</u>	<u>002</u>	Oct 07, 2003
<u>AB</u>		<u>2.5MG; 2.5MG; 2.5MG; 2.5MG</u>	<u>A040440</u>	<u>003</u>	Oct 07, 2003
<u>AB</u>		<u>3.125MG; 3.125MG; 3.125MG; 3.125MG</u>	<u>A040440</u>	<u>004</u>	Oct 07, 2003
<u>AB</u>		<u>3.75MG; 3.75MG; 3.75MG; 3.75MG</u>	<u>A040440</u>	<u>005</u>	Oct 07, 2003
<u>AB</u>		<u>5MG; 5MG; 5MG; 5MG</u>	<u>A040440</u>	<u>006</u>	Oct 07, 2003
<u>AB</u>		<u>7.5MG; 7.5MG; 7.5MG; 7.5MG</u>	<u>A040440</u>	<u>007</u>	Oct 07, 2003
<u>AB</u>	SANDOZ	<u>1.25MG; 1.25MG; 1.25MG; 1.25MG</u>	<u>A040439</u>	<u>004</u>	Sep 27, 2002
<u>AB</u>		<u>2.5MG; 2.5MG; 2.5MG; 2.5MG</u>	<u>A040439</u>	<u>001</u>	Jun 14, 2002
<u>AB</u>		<u>5MG; 5MG; 5MG; 5MG</u>	<u>A040439</u>	<u>002</u>	Jun 14, 2002
<u>AB</u>		<u>7.5MG; 7.5MG; 7.5MG; 7.5MG</u>	<u>A040439</u>	<u>003</u>	Jun 14, 2002
<u>AB</u>	TEVA PHARMS	<u>1.25MG; 1.25MG; 1.25MG; 1.25MG</u>	<u>A040472</u>	<u>001</u>	Sep 30, 2003
<u>AB</u>		<u>2.5MG; 2.5MG; 2.5MG; 2.5MG</u>	<u>A040472</u>	<u>002</u>	Sep 30, 2003
<u>AB</u>		<u>5MG; 5MG; 5MG; 5MG</u>	<u>A040472</u>	<u>003</u>	Sep 30, 2003
<u>AB</u>		<u>7.5MG; 7.5MG; 7.5MG; 7.5MG</u>	<u>A040472</u>	<u>004</u>	Sep 30, 2003

AMPHOTERICIN B

INJECTABLE; INJECTION

<u>AMPHOTERICIN B</u>					
<u>AP</u>	TEVA PARENTERAL	<u>50MG/VIAL</u>	<u>A064062</u>	<u>001</u>	Mar 31, 1995
<u>AP</u>	X GEN PHARMS	<u>50MG/VIAL</u>	<u>A063206</u>	<u>001</u>	Apr 29, 1992
<u>FUNGIZONE</u>					
<u>AP</u>	+ APOTHECON	<u>50MG/VIAL</u>	<u>A060517</u>	<u>001</u>	
INJECTABLE, LIPID COMPLEX; INJECTION					
	ABELCET				
	+ ENZON	5MG/ML	N050724	001	Nov 20, 1995
	AMPHOTEC				
	+ THREE RIVERS PHARMS	50MG/VIAL	N050729	001	Nov 22, 1996
	+	100MG/VIAL	N050729	002	Nov 22, 1996
INJECTABLE, LIPOSOMAL; INJECTION					
	AMBISOME				
	+ ASTELLAS	50MG/VIAL	N050740	001	Aug 11, 1997

AMPICILLIN SODIUM

INJECTABLE; INJECTION

<u>AMPICILLIN SODIUM</u>					
<u>AP</u>	ACIC FINE CHEMS	<u>EQ 250MG BASE/VIAL</u>	<u>A090354</u>	<u>001</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090354</u>	<u>002</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090354</u>	<u>003</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090354</u>	<u>004</u>	Dec 28, 2009
<u>AP</u>	HANFORD GC	<u>EQ 500MG BASE/VIAL</u>	<u>A063146</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062772</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A063140</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063142</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>	IBI	<u>EQ 250MG BASE/VIAL</u>	<u>A062719</u>	<u>001</u>	May 12, 1987
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A062719</u>	<u>003</u>	May 12, 1987
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062719</u>	<u>002</u>	May 12, 1987
<u>AP</u>	INSTITUTO BIOCHEMICO	<u>EQ 125MG BASE/VIAL</u>	<u>A062797</u>	<u>001</u>	Jul 12, 1993
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062797</u>	<u>002</u>	Jul 12, 1993
<u>AP</u>	+ SANDOZ	<u>EQ 125MG BASE/VIAL</u>	<u>A061395</u>	<u>001</u>	

## PRESCRIPTION DRUG PRODUCT LIST

3 - 34 (of 393)

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

<u>AP</u>	+	SANDOZ	<u>EQ 250MG BASE/VIAL</u>	<u>A061395</u>	<u>002</u>	
<u>AP</u>	+		<u>EQ 500MG BASE/VIAL</u>	<u>A061395</u>	<u>003</u>	
<u>AP</u>	+		<u>EQ 1GM BASE/VIAL</u>	<u>A061395</u>	<u>004</u>	
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A062738</u>	<u>001</u>	Feb 19, 1987
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A061395</u>	<u>005</u>	
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A062738</u>	<u>002</u>	Feb 19, 1987
<u>AP</u>	+		<u>EQ 10GM BASE/VIAL</u>	<u>A061395</u>	<u>006</u>	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

<u>AP</u>		ACS DOBFAR	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065406</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065406</u>	<u>002</u>	Dec 22, 2009
<u>AP</u>			<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065403</u>	<u>001</u>	Dec 23, 2009
<u>AP</u>		BAXTER HLTHCARE	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065074</u>	<u>001</u>	Mar 19, 2002
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065074</u>	<u>002</u>	Mar 19, 2002
<u>AP</u>			<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065076</u>	<u>001</u>	Mar 19, 2002
<u>AP</u>		GENERAMEDIX	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065316</u>	<u>001</u>	Jun 29, 2007
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065316</u>	<u>002</u>	Jun 29, 2007
<u>AP</u>		HANFORD GC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065176</u>	<u>001</u>	Nov 30, 2005
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065176</u>	<u>002</u>	Nov 30, 2005
<u>AP</u>			<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065188</u>	<u>001</u>	Nov 25, 2005
<u>AP</u>		INSTITUTO BIOCHIMICO	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065222</u>	<u>001</u>	Nov 29, 2005
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065222</u>	<u>002</u>	Nov 29, 2005
<u>AP</u>			<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065314</u>	<u>001</u>	Nov 27, 2006
<u>AP</u>		SANDOZ	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065241</u>	<u>001</u>	Jul 25, 2006
<u>AP</u>			<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065310</u>	<u>001</u>	Jul 25, 2006
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065241</u>	<u>002</u>	Jul 25, 2006
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065310</u>	<u>002</u>	Jul 25, 2006
<u>AP</u>			<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065240</u>	<u>001</u>	Jul 25, 2006
		<u>UNASYN</u>				
<u>AP</u>		PFIZER	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A062901</u>	<u>001</u>	Nov 23, 1988
<u>AP</u>	+		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050608</u>	<u>002</u>	Dec 31, 1986
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>N050608</u>	<u>001</u>	Dec 31, 1986
<u>AP</u>	+		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>N050608</u>	<u>005</u>	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

<u>AB</u>		DAVA PHARMS INC	<u>EQ 250MG BASE</u>	<u>A062883</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>	+		<u>EQ 500MG BASE</u>	<u>A062882</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>		SANDOZ	<u>EQ 250MG BASE</u>	<u>A064082</u>	<u>001</u>	Aug 29, 1995
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A064082</u>	<u>002</u>	Aug 29, 1995

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

<u>AB</u>		DAVA PHARMS INC	<u>EQ 125MG BASE/5ML</u>	<u>A062982</u>	<u>001</u>	Feb 10, 1989
		<u>PRINCIPEN</u>				
<u>AB</u>		APOTHECON	<u>EQ 125MG BASE/5ML</u>	<u>A061394</u>	<u>002</u>	
		AMPICILLIN TRIHYDRATE				
	+	DAVA PHARMS INC	EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

	+	GLAXOSMITHKLINE	50MG	N021007	001	Apr 15, 1999
--	---	-----------------	------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 35 (of 393)

AMPRENAVIR

SOLUTION; ORAL

AGENERASE

+ GLAXOSMITHKLINE 15MG/ML N021039 001 Apr 15, 1999

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLINAB SHIRE EQ 0.5MG BASE N020333 001 Mar 14, 1997ANAGRELIDE HYDROCHLORIDEAB ALPHAPHARM EQ 0.5MG BASE A077613 001 Jun 27, 2006AB EQ 1MG BASE A077613 002 Jun 27, 2006AB BARR EQ 0.5MG BASE A076530 001 Apr 18, 2005AB EQ 1MG BASE A076530 002 Apr 18, 2005AB IMPAX LABS EQ 0.5MG BASE A076910 001 Apr 18, 2005AB EQ 1MG BASE A076910 002 Apr 18, 2005AB IVAX SUB TEVA PHARMS EQ 0.5MG BASE A076468 001 Apr 18, 2005AB + EQ 1MG BASE A076468 002 Apr 18, 2005AB MYLAN EQ 0.5MG BASE A076811 001 Apr 18, 2005AB EQ 1MG BASE A076811 002 Apr 18, 2005AB SANDOZ EQ 0.5MG BASE A076683 001 Apr 18, 2005AB EQ 1MG BASE A076683 002 Apr 18, 2005AB WATSON LABS EQ 0.5MG BASE A076417 001 Apr 18, 2005AB EQ 1MG BASE A076417 002 Apr 18, 2005ANASTROZOLE

TABLET; ORAL

ARIMIDEX

+ ASTRAZENECA 1MG N020541 001 Dec 27, 1995

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

+ VICURON 50MG/VIAL N021632 001 Feb 17, 2006

+ 100MG/VIAL N021632 002 Nov 14, 2006

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

+ IPSEN LTD 30MG/3ML (10MG/ML) N021264 002 Apr 20, 2004

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLONIDINE HYDROCHLORIDEAT AKORN INC EQ 0.5% BASE A077764 001 Mar 12, 2009IOPIDINEAT + ALCON EQ 0.5% BASE N020258 001 Jul 30, 1993

IOPIDINE

+ ALCON EQ 1% BASE N019779 001 Dec 31, 1987

APREPITANT

CAPSULE; ORAL

EMEND

MERCK 40MG N021549 003 Jun 30, 2006

80MG N021549 001 Mar 26, 2003

+ 125MG N021549 002 Mar 26, 2003

## PRESCRIPTION DRUG PRODUCT LIST

3 - 36 (of 393)

APROTININ

INJECTABLE; INJECTION				
TRASYLOL				
+ BAYER HLTHCARE	10,000KIU/ML	N020304	001	Dec 29, 1993

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION				
BROVANA				
+ SEPRACOR	EQ 0.015MG BASE/2ML	N021912	001	Oct 06, 2006

ARGATROBAN

INJECTABLE; INJECTION				
ARGATROBAN				
+ PFIZER	100MG/ML	N020883	001	Jun 30, 2000

ARGININE HYDROCHLORIDE

INJECTABLE; INJECTION				
R-GENE 10				
+ PHARMACIA AND UPJOHN	10GM/100ML	N016931	001	

ARIPIPIRAZOLE

INJECTABLE; INTRAMUSCULAR				
ABILIFY				
+ OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006

SOLUTION; ORAL				
ABILIFY				
+ OTSUKA	1MG/ML	N021713	001	Dec 10, 2004

TABLET; ORAL				
ABILIFY				
OTSUKA	2MG	N021436	006	Nov 15, 2002
+	5MG	N021436	005	Nov 15, 2002
+	10MG	N021436	001	Nov 15, 2002
	15MG	N021436	002	Nov 15, 2002
	20MG	N021436	003	Nov 15, 2002
	30MG	N021436	004	Nov 15, 2002

TABLET, ORALLY DISINTEGRATING; ORAL				
ABILIFY				
+ OTSUKA	10MG	N021729	002	Jun 07, 2006
	15MG	N021729	003	Jun 07, 2006

ARMODAFINIL

TABLET; ORAL				
NUVIGIL				
CEPHALON	50MG	N021875	001	Jun 15, 2007
	100MG	N021875	002	Mar 26, 2009
	150MG	N021875	003	Jun 15, 2007
	200MG	N021875	005	Mar 26, 2009
+	250MG	N021875	004	Jun 15, 2007

ARSENIC TRIOXIDE

INJECTABLE; INJECTION				
TRISENOX				
+ CEPHALON	1MG/ML	N021248	001	Sep 25, 2000

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL				
COARTEM				
NOVARTIS	20MG;120MG	N022268	001	Apr 07, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 37 (of 393)

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SEPTOCAINE

+ DEPROCO	4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)	N022010 001	Mar 30, 2006
+	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971 001	Apr 03, 2000

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID;  
NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A;  
VITAMIN K

INJECTABLE; IV (INFUSION)

+ SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VI AL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/ VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265 001	Feb 21, 2001
+	INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)		
+ SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VI AL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/ VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021646 001	Jan 29, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;  
NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM;  
THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ HOSPIRA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/ VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL; 0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N018920 001	Sep 21, 2000
-----------	--	-------------	--------------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;  
NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE  
HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 (WITHOUT VITAMIN K)

+ HOSPIRA	20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML; 0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0 .36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML	N008809 006	Sep 09, 2004
-----------	---	-------------	--------------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;  
NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE  
HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+ HOSPIRA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15M G/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIA L;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL ;10MG/VIAL;0.15MG/VIAL	N021625 001	Jan 30, 2004
+	M.V.I. ADULT (PHARMACY BULK PACKAGE)		
+ HOSPIRA	200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5 ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5 ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0 .15MG/5ML	N021643 001	Feb 18, 2004

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE;  
SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

+ SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	N021881 001	Aug 02, 2006
----------------	---	-------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

3 - 38 (of 393)

ASENAPINE MALEATETABLET; SUBLINGUAL  
SAPHRIS

ORGANON USA INC	EQ 5MG BASE	N022117	001	Aug 13, 2009
+	EQ 10MG BASE	N022117	002	Aug 13, 2009

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

<u>AB</u> + WATSON PHARMS	<u>325MG; 50MG; 40MG</u>	<u>N017534</u>	<u>005</u>	Apr 16, 1986
---------------------------	--------------------------	----------------	------------	--------------

LANORINAL

<u>AB</u> LANNETT	<u>325MG; 50MG; 40MG</u>	<u>A086996</u>	<u>002</u>	Oct 11, 1985
-------------------	--------------------------	----------------	------------	--------------

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

<u>AB</u> ACTAVIS ELIZABETH	<u>325MG; 50MG; 40MG</u>	<u>A086710</u>	<u>002</u>	Aug 23, 1983
-----------------------------	--------------------------	----------------	------------	--------------

<u>AB</u> + WEST WARD	<u>325MG; 50MG; 40MG</u>	<u>A086162</u>	<u>002</u>	Feb 16, 1984
-----------------------	--------------------------	----------------	------------	--------------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

<u>AB</u> NEXGEN PHARMA INC	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A075231</u>	<u>001</u>	Nov 30, 2001
-----------------------------	--------------------------------	----------------	------------	--------------

<u>AB</u> STEVENS J	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A074951</u>	<u>001</u>	Aug 31, 1998
---------------------	--------------------------------	----------------	------------	--------------

<u>AB</u> WATSON LABS	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A074359</u>	<u>001</u>	Aug 31, 1995
-----------------------	--------------------------------	----------------	------------	--------------

FIORINAL W/CODEINE

<u>AB</u> + WATSON PHARMS	<u>325MG; 50MG; 40MG; 30MG</u>	<u>N019429</u>	<u>003</u>	Oct 26, 1990
---------------------------	--------------------------------	----------------	------------	--------------

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

+	CARACO	356.4MG; 30MG; 16MG	N011483	004	Sep 06, 1983
---	--------	---------------------	---------	-----	--------------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

<u>AB</u> SANDOZ	<u>385MG; 30MG; 25MG</u>	<u>A074817</u>	<u>001</u>	Nov 27, 1996
------------------	--------------------------	----------------	------------	--------------

INVAGESIC FORTE

<u>AB</u> SANDOZ	<u>770MG; 60MG; 50MG</u>	<u>A074817</u>	<u>002</u>	Nov 27, 1996
------------------	--------------------------	----------------	------------	--------------

NORGESIC

<u>AB</u> GRACEWAY	<u>385MG; 30MG; 25MG</u>	<u>N013416</u>	<u>003</u>	Oct 27, 1982
--------------------	--------------------------	----------------	------------	--------------

NORGESIC FORTE

<u>AB</u> + GRACEWAY	<u>770MG; 60MG; 50MG</u>	<u>N013416</u>	<u>004</u>	Oct 27, 1982
----------------------	--------------------------	----------------	------------	--------------

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

<u>AB</u> SANDOZ	<u>385MG; 30MG; 25MG</u>	<u>A074654</u>	<u>001</u>	Dec 31, 1996
------------------	--------------------------	----------------	------------	--------------

<u>AB</u>	<u>770MG; 60MG; 50MG</u>	<u>A074654</u>	<u>002</u>	Dec 31, 1996
-----------	--------------------------	----------------	------------	--------------

<u>AB</u> STEVENS J	<u>385MG; 30MG; 25MG</u>	<u>A074988</u>	<u>001</u>	Apr 30, 1999
---------------------	--------------------------	----------------	------------	--------------

<u>AB</u>	<u>770MG; 60MG; 50MG</u>	<u>A074988</u>	<u>002</u>	Apr 30, 1999
-----------	--------------------------	----------------	------------	--------------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

<u>AB</u> ACTAVIS TOTOWA	<u>325MG; 200MG</u>	<u>A040252</u>	<u>001</u>	Dec 10, 1997
--------------------------	---------------------	----------------	------------	--------------

<u>AB</u> CONCORD LABS NJ	<u>325MG; 200MG</u>	<u>A040832</u>	<u>001</u>	Jan 07, 2010
---------------------------	---------------------	----------------	------------	--------------

<u>AB</u> PAR PHARM	<u>325MG; 200MG</u>	<u>A089594</u>	<u>001</u>	Mar 31, 1989
---------------------	---------------------	----------------	------------	--------------

<u>AB</u> SANDOZ	<u>325MG; 200MG</u>	<u>A040116</u>	<u>001</u>	Apr 25, 1996
------------------	---------------------	----------------	------------	--------------

SOMA COMPOUND

<u>AB</u> + MEDA PHARMS	<u>325MG; 200MG</u>	<u>N012365</u>	<u>005</u>	Jul 11, 1983
-------------------------	---------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 39 (of 393)

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

<u>AB</u>	ACTAVIS TOTOWA	<u>325MG;200MG;16MG</u>	<u>A040283</u>	<u>001</u>	Dec 29, 1998
<u>AB</u>	CONCORD LABS NJ	<u>325MG;200MG;16MG</u>	<u>A040860</u>	<u>001</u>	Jan 07, 2010
<u>AB</u>	SANDOZ	<u>325MG;200MG;16MG</u>	<u>A040118</u>	<u>001</u>	Apr 16, 1996
<u>SOMA COMPOUND W/ CODEINE</u>					
<u>AB</u>	+ MEDA PHARMS	<u>325MG;200MG;16MG</u>	<u>N012366</u>	<u>002</u>	Jul 11, 1983

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

AGGRENOX

<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>25MG;200MG</u>	<u>N020884</u>	<u>001</u>	Nov 22, 1999
<u>ASPIRIN AND DIPYRIDAMOLE</u>					
<u>AB</u>	BARR	<u>25MG;200MG</u>	<u>A078804</u>	<u>001</u>	Aug 14, 2009

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

<u>AB</u>	+ IVAX PHARMS	<u>325MG;400MG</u>	<u>A087211</u>	<u>001</u>	Dec 22, 1982
<u>AB</u>	STEVENS J	<u>325MG;400MG</u>	<u>A081145</u>	<u>001</u>	Jan 31, 1995

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

PERCODAN

	+ ENDO PHARMS	325MG;4.8355MG	N007337	007	Aug 05, 2005
--	---------------	----------------	---------	-----	--------------

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

<u>AA</u>	WATSON LABS	<u>325MG;4.5MG;0.38MG</u>	<u>A040255</u>	<u>001</u>	Feb 27, 1998
<u>PERCODAN</u>					
<u>AA</u>	+ ENDO PHARMS	<u>325MG;4.5MG;0.38MG</u>	<u>N007337</u>	<u>006</u>	

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

	BRISTOL MYERS SQUIBB	EQ 100MG BASE	N021567	001	Jun 20, 2003
		EQ 150MG BASE	N021567	002	Jun 20, 2003
		EQ 200MG BASE	N021567	003	Jun 20, 2003
	+ ENDO PHARMS	EQ 300MG BASE	N021567	004	Oct 16, 2006

ATENOLOL

TABLET; ORAL

ATENOLOL

<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078512</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>		<u>50MG</u>	<u>A078512</u>	<u>002</u>	Oct 31, 2007
<u>AB</u>		<u>100MG</u>	<u>A078512</u>	<u>003</u>	Oct 31, 2007
<u>AB</u>	CARACO	<u>25MG</u>	<u>A078210</u>	<u>001</u>	Jul 10, 2007
<u>AB</u>		<u>50MG</u>	<u>A078210</u>	<u>002</u>	Jul 10, 2007
<u>AB</u>		<u>100MG</u>	<u>A078210</u>	<u>003</u>	Jul 10, 2007
<u>AB</u>	DAVA PHARMS INC	<u>25MG</u>	<u>A074099</u>	<u>001</u>	Apr 28, 1992
<u>AB</u>		<u>50MG</u>	<u>A073542</u>	<u>001</u>	Dec 19, 1991
<u>AB</u>		<u>100MG</u>	<u>A073543</u>	<u>001</u>	Dec 19, 1991
<u>AB</u>	GENPHARM	<u>25MG</u>	<u>A074126</u>	<u>003</u>	Aug 26, 1998
<u>AB</u>		<u>50MG</u>	<u>A074126</u>	<u>001</u>	Mar 23, 1994
<u>AB</u>		<u>100MG</u>	<u>A074126</u>	<u>002</u>	Mar 23, 1994
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A077877</u>	<u>001</u>	Dec 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077877</u>	<u>002</u>	Dec 27, 2006

## PRESCRIPTION DRUG PRODUCT LIST

3 - 40 (of 393)

ATENOLOL

TABLET; ORAL

ATENOLOL

<u>AB</u>	IPCA LABS LTD	<u>100MG</u>	<u>A077877</u>	<u>003</u>	Dec 27, 2006
<u>AB</u>	IPR	<u>25MG</u>	<u>A073646</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		<u>50MG</u>	<u>A072303</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>		<u>100MG</u>	<u>A072304</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>	MUTUAL PHARM	<u>25MG</u>	<u>A074499</u>	<u>001</u>	Jul 30, 1997
<u>AB</u>		<u>50MG</u>	<u>A073475</u>	<u>001</u>	Mar 30, 1993
<u>AB</u>		<u>100MG</u>	<u>A073476</u>	<u>001</u>	Mar 30, 1993
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A073457</u>	<u>002</u>	Apr 26, 1999
<u>AB</u>		<u>50MG</u>	<u>A073456</u>	<u>001</u>	Jan 24, 1992
<u>AB</u>		<u>100MG</u>	<u>A073457</u>	<u>001</u>	Jan 24, 1992
<u>AB</u>	NORTHSTAR HLTHCARE	<u>25MG</u>	<u>A078254</u>	<u>001</u>	Sep 25, 2009
<u>AB</u>		<u>50MG</u>	<u>A078254</u>	<u>002</u>	Sep 25, 2009
<u>AB</u>		<u>100MG</u>	<u>A078254</u>	<u>003</u>	Sep 25, 2009
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A074052</u>	<u>001</u>	May 01, 1992
<u>AB</u>		<u>50MG</u>	<u>A073025</u>	<u>001</u>	Sep 17, 1991
<u>AB</u>		<u>100MG</u>	<u>A073026</u>	<u>001</u>	Sep 17, 1991
<u>AB</u>	TEVA	<u>25MG</u>	<u>A074056</u>	<u>003</u>	Jul 19, 2004
<u>AB</u>		<u>50MG</u>	<u>A074056</u>	<u>001</u>	Jan 18, 1995
<u>AB</u>		<u>100MG</u>	<u>A074056</u>	<u>002</u>	Jan 18, 1995
<u>AB</u>	UNIQUE PHARM LABS	<u>25MG</u>	<u>A077443</u>	<u>001</u>	Sep 13, 2006
<u>AB</u>		<u>50MG</u>	<u>A077443</u>	<u>002</u>	Sep 13, 2006
<u>AB</u>		<u>100MG</u>	<u>A077443</u>	<u>003</u>	Sep 13, 2006
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A073352</u>	<u>001</u>	Dec 27, 1991
<u>AB</u>		<u>100MG</u>	<u>A073353</u>	<u>001</u>	Dec 27, 1991
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A076900</u>	<u>001</u>	Jan 28, 2005
<u>AB</u>		<u>50MG</u>	<u>A076900</u>	<u>002</u>	Jan 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076900</u>	<u>003</u>	Jan 28, 2005
	<u>TENORMIN</u>				
<u>AB</u>	ASTRAZENECA	<u>25MG</u>	<u>N018240</u>	<u>004</u>	Apr 09, 1990
<u>AB</u>		<u>50MG</u>	<u>N018240</u>	<u>001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N018240</u>	<u>002</u>	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

<u>AB</u>	IPR	<u>50MG; 25MG</u>	<u>A072301</u>	<u>001</u>	May 31, 1990	
<u>AB</u>		<u>100MG; 25MG</u>	<u>A072302</u>	<u>001</u>	May 31, 1990	
<u>AB</u>	MUTUAL PHARM	<u>50MG; 25MG</u>	<u>A073581</u>	<u>001</u>	Apr 29, 1993	
<u>AB</u>		<u>100MG; 25MG</u>	<u>A073582</u>	<u>001</u>	Apr 29, 1993	
<u>AB</u>	MYLAN	<u>50MG; 25MG</u>	<u>A074203</u>	<u>001</u>	Oct 31, 1993	
<u>AB</u>		<u>100MG; 25MG</u>	<u>A074203</u>	<u>002</u>	Oct 31, 1993	
<u>AB</u>	WATSON LABS	<u>50MG; 25MG</u>	<u>A073665</u>	<u>001</u>	Jul 02, 1992	
<u>AB</u>		<u>100MG; 25MG</u>	<u>A073665</u>	<u>002</u>	Jul 02, 1992	
	<u>TENORETIC 100</u>					
<u>AB</u>	+	<u>ASTRAZENECA</u>	<u>100MG; 25MG</u>	<u>N018760</u>	<u>001</u>	Jun 08, 1984
	<u>TENORETIC 50</u>					
<u>AB</u>	ASTRAZENECA	<u>50MG; 25MG</u>	<u>N018760</u>	<u>002</u>	Jun 08, 1984	

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

LILLY

	10MG	N021411	002	Nov 26, 2002
	18MG	N021411	003	Nov 26, 2002
	25MG	N021411	004	Nov 26, 2002
	40MG	N021411	005	Nov 26, 2002
+	60MG	N021411	006	Nov 26, 2002
	80MG	N021411	007	Feb 14, 2005

## PRESCRIPTION DRUG PRODUCT LIST

3 - 41 (of 393)

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL				
STRATTERA				
LILLY	100MG	N021411	008	Feb 14, 2005

ATORVASTATIN CALCIUM

TABLET; ORAL				
LIPITOR				
PFIZER	EQ 10MG BASE	N020702	001	Dec 17, 1996
	EQ 20MG BASE	N020702	002	Dec 17, 1996
	EQ 40MG BASE	N020702	003	Dec 17, 1996
+	EQ 80MG BASE	N020702	004	Apr 07, 2000

ATOVAQUONE

SUSPENSION; ORAL					
MEPRON					
+	GLAXOSMITHKLINE	750MG/5ML	N020500	001	Feb 08, 1995

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL					
MALARONE					
+	GLAXOSMITHKLINE	250MG;100MG	N021078	001	Jul 14, 2000
	MALARONE PEDIATRIC				
+	GLAXOSMITHKLINE	62.5MG;25MG	N021078	002	Jul 14, 2000

ATRACURIUM BESYLATE

INJECTABLE; INJECTION					
ATRACURIUM BESYLATE					
+	BEDFORD	10MG/ML	A074901	001	Jul 18, 1997
	ATRACURIUM BESYLATE PRESERVATIVE FREE				
+	BEDFORD	10MG/ML	A074900	001	Jul 18, 1997

ATROPINE

INJECTABLE; INJECTION					
ATROPEN					
+	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004
+		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003
+		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003
+		EQ 2MG SULFATE/0.7ML	N017106	001	

ATROPINE SULFATE

INJECTABLE; IM-IV-SC				
ATROPINE SULFATE ANSYR PLASTIC SYRINGE				
HOSPIRA	0.05MG/ML	N021146	002	Jul 09, 2001
+	0.1MG/ML	N021146	001	Jul 09, 2001

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL				
MOTOFEN				
+	VALEANT	0.025MG;1MG	N017744	002

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL					
<u>DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE</u>					
<u>AA</u>	ROXANE	<u>0.025MG/5ML; 2.5MG/5ML</u>	<u>A087708</u>	<u>001</u>	May 03, 1982
	<u>LOMOTIL</u>				
<u>AA</u>	+	GD SEARLE LLC	<u>0.025MG/5ML; 2.5MG/5ML</u>	<u>N012699</u>	<u>001</u>

## PRESCRIPTION DRUG PRODUCT LIST

3 - 42 (of 393)

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

<u>AA</u>	LANNETT	<u>0.025MG;2.5MG</u>	<u>A085372</u>	<u>001</u>	
<u>AA</u>	MYLAN	<u>0.025MG;2.5MG</u>	<u>A085762</u>	<u>001</u>	
<u>AA</u>	PAR PHARM	<u>0.025MG;2.5MG</u>	<u>A040357</u>	<u>001</u>	May 02, 2000
<u>LOMOTIL</u>					
<u>AA</u>	+ GD SEARLE LLC	<u>0.025MG;2.5MG</u>	<u>N012462</u>	<u>001</u>	
<u>LONOX</u>					
<u>AA</u>	SANDOZ	<u>0.025MG;2.5MG</u>	<u>A085311</u>	<u>002</u>	

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

+	BIONICHE PHARMA	0.14MG/ML;10MG/ML	N019677	001	Nov 06, 1991
+		0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+	MERIDIAN MEDCL	2.1MG/0.7ML;600MG/2ML	N021983	001	Sep 28, 2006
---	----------------	-----------------------	---------	-----	--------------

AURANOFIN

CAPSULE; ORAL

RIDAURA

+	PROMETHEUS LABS	3MG	N018689	001	May 24, 1985
---	-----------------	-----	---------	-----	--------------

AZACITIDINE

INJECTABLE; IV-SC

VIDAZA

+	CELGENE	100MG/VIAL	N050794	001	May 19, 2004
---	---------	------------	---------	-----	--------------

AZATHIOPRINE

TABLET; ORAL

AZASAN

<u>AB</u>	AAIPHARMA LLC	<u>25MG</u>	<u>A075252</u>	<u>002</u>	Feb 03, 2003
<u>AB</u>		<u>50MG</u>	<u>A075252</u>	<u>001</u>	Jun 07, 1999
<u>AB</u>		<u>75MG</u>	<u>A075252</u>	<u>003</u>	Feb 03, 2003
<u>AB</u>		<u>100MG</u>	<u>A075252</u>	<u>004</u>	Feb 03, 2003

AZATHIOPRINE

<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075568</u>	<u>001</u>	Dec 13, 1999
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A074069</u>	<u>001</u>	Feb 16, 1996
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077621</u>	<u>002</u>	Sep 05, 2008
<u>AB</u>		<u>50MG</u>	<u>A077621</u>	<u>001</u>	Mar 15, 2007
<u>AB</u>		<u>75MG</u>	<u>A077621</u>	<u>003</u>	Sep 05, 2008
<u>AB</u>		<u>100MG</u>	<u>A077621</u>	<u>004</u>	Sep 05, 2008

IMURAN

<u>AB</u>	+ PROMETHEUS LABS	<u>50MG</u>	<u>N016324</u>	<u>001</u>	
-----------	-------------------	-------------	----------------	------------	--

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

+	BEDFORD	EQ 100MG BASE/VIAL	A074419	001	Mar 31, 1995
---	---------	--------------------	---------	-----	--------------

AZELAIC ACID

CREAM; TOPICAL

AZELEX

+	ALLERGAN	20%	N020428	001	Sep 13, 1995
---	----------	-----	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 43 (of 393)

AZELAIC ACID

GEL; TOPICAL

FINACEA

+ INTENDIS 15% N021470 001 Dec 24, 2002

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDEAT APOTEX INC 0.05% A078621 001 Aug 03, 2009OPTIVARAT + MEDA PHARMS 0.05% N021127 001 May 22, 2000

SPRAY, METERED; NASAL

ASTELIN

+ MEDA PHARMS EQ 0.125MG BASE/SPRAY N020114 001 Nov 01, 1996

ASTEPRO

+ MEDA PHARMS EQ 0.125MG BASE/SPRAY N022203 001 Oct 15, 2008

+ EQ 0.1876MG BASE/SPRAY N022371 001 Aug 31, 2009

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCINAB PLIVA EQ 100MG BASE/5ML A065246 002 Jul 05, 2006AB EQ 200MG BASE/5ML A065246 001 Jul 05, 2006AB SANDOZ EQ 100MG BASE/5ML A065297 001 Sep 18, 2006AB EQ 200MG BASE/5ML A065297 002 Sep 18, 2006AB TEVA PHARMS EQ 100MG BASE/5ML A065419 001 Jun 24, 2008AB EQ 200MG BASE/5ML A065419 002 Jun 24, 2008ZITHROMAXAB PFIZER EQ 100MG BASE/5ML N050710 001 Oct 19, 1995AB + EQ 200MG BASE/5ML N050710 002 Oct 19, 1995

ZITHROMAX

+ PFIZER EQ 1GM BASE/PACKET N050693 001 Sep 28, 1994

FOR SUSPENSION, EXTENDED RELEASE; ORAL

ZMAX

+ PFIZER GLOBAL EQ 2GM BASE/BOT N050797 001 Jun 10, 2005

INJECTABLE; INJECTION

AZITHROMYCINAP APP PHARMS EQ 500MG BASE/VIAL A065179 001 Dec 13, 2005AP GENERAMEDIX EQ 500MG BASE/VIAL A065501 001 Nov 09, 2009AP HOSPIRA EQ 500MG BASE/VIAL A065500 001 Jun 26, 2009AP EQ 500MG BASE/VIAL A065511 001 Jun 26, 2009AP PLIVA HRVATSKA DOO EQ 500MG BASE/VIAL A065265 001 Jan 18, 2007AP SAGENT STRIDES EQ 500MG BASE/VIAL A065506 001 Mar 24, 2009AP + TEVA PARENTERAL EQ 500MG BASE/VIAL N050809 001 Dec 19, 2006ZITHROMAXAP + PFIZER EQ 500MG BASE/VIAL N050733 001 Jan 30, 1997

AZITHROMYCIN

+ TEVA PARENTERAL EQ 2.5GM BASE/VIAL N050809 002 Dec 19, 2006

SOLUTION/DROPS; OPHTHALMIC

+ INSPIRE 1% N050810 001 Apr 27, 2007

TABLET; ORAL

AZITHROMYCINAB MYLAN EQ 250MG BASE A065365 001 May 30, 2007AB EQ 500MG BASE A065366 001 May 30, 2007AB EQ 600MG BASE A065360 001 Jan 08, 2007AB PLIVA EQ 250MG BASE A065225 001 Nov 14, 2005AB EQ 500MG BASE A065223 001 Nov 14, 2005AB EQ 600MG BASE A065218 001 Nov 14, 2005

## PRESCRIPTION DRUG PRODUCT LIST

3 - 44 (of 393)

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A065211</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065212</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065209</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A065153</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065193</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065150</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	WOCKHARDT	<u>EQ 250MG BASE</u>	<u>A065404</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065405</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065302</u>	<u>003</u>	Feb 11, 2008
	<u>ZITHROMAX</u>				
<u>AB</u>	PFIIZER	<u>EQ 250MG BASE</u>	<u>N050711</u>	<u>001</u>	Jul 18, 1996
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N050784</u>	<u>001</u>	May 24, 2002
<u>AB</u>	+	<u>EQ 600MG BASE</u>	<u>N050730</u>	<u>001</u>	Jun 12, 1996

AZTREONAM

INJECTABLE; INJECTION

## AZACTAM

+	BRISTOL MYERS SQUIBB	1GM/VIAL	N050580	002	Dec 31, 1986
+		2GM/VIAL	N050580	003	Dec 31, 1986
	AZACTAM IN PLASTIC CONTAINER				
+	BRISTOL MYERS SQUIBB	20MG/ML	N050632	002	May 24, 1989
+		40MG/ML	N050632	001	May 24, 1989

BACITRACIN

INJECTABLE; INJECTION

BACIIM

<u>AP</u>	X GEN PHARMS	<u>50,000 UNITS/VIAL</u>	<u>A064153</u>	<u>001</u>	May 09, 1997
	<u>BACITRACIN</u>				
<u>AP</u>	APP PHARMS	<u>50,000 UNITS/VIAL</u>	<u>A065116</u>	<u>001</u>	Dec 03, 2002
<u>AP</u>	+	<u>PHARMACIA AND UPJOHN</u>	<u>50,000 UNITS/VIAL</u>	<u>A060733</u>	<u>002</u>
	BACITRACIN				
	PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733	001	
	OINTMENT; OPHTHALMIC				
	BACITRACIN				
+	ALTANA	500 UNITS/GM	A061212	001	
	POWDER; FOR RX COMPOUNDING				
	BACI-RX				
	X GEN PHARMS	5,000,000 UNITS/BOT	A061580	001	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

+	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995
---	-----------------	---	---------	-----	--------------

OINTMENT; TOPICAL

CORTISPORIN

+	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168	002	May 04, 1984
---	----------------	--	---------	-----	--------------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

<u>AT</u>	AKORN	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A065088</u>	<u>001</u>	Feb 06, 2004
<u>AT</u>	ALTANA	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A060764</u>	<u>002</u>	

## PRESCRIPTION DRUG PRODUCT LIST

3 - 45 (of 393)

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

<u>AT</u>	+	BAUSCH AND LOMB	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064064</u>	<u>001</u>	Oct 30, 1995
-----------	---	-----------------	--	----------------	------------	--------------

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

<u>AT</u>		AKORN	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064028</u>	<u>001</u>	Jan 30, 1995
<u>AT</u>		ALTANA	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A065022</u>	<u>001</u>	Feb 27, 2002
<u>AT</u>	+	BAUSCH AND LOMB	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064046</u>	<u>001</u>	Jan 26, 1995

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	+	PHARMADERM	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002	
--	---	------------	---	---------	-----	--

BACLOFEN

INJECTABLE; INTRATHECAL

LIORESAL

	+	MEDTRONIC	0.05MG/ML	N020075	003	Nov 07, 1996
	+		0.5MG/ML	N020075	001	Jun 17, 1992
	+		2MG/ML	N020075	002	Jun 17, 1992

TABLET; ORAL

BACLOFEN

<u>AB</u>		ACTAVIS TOTOWA	<u>10MG</u>	<u>A077089</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>			<u>20MG</u>	<u>A077088</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>		CARACO	<u>10MG</u>	<u>A077984</u>	<u>001</u>	Aug 14, 2006
<u>AB</u>			<u>20MG</u>	<u>A077862</u>	<u>002</u>	Aug 14, 2006
<u>AB</u>		IMPAX LABS	<u>10MG</u>	<u>A078146</u>	<u>001</u>	Oct 26, 2007
<u>AB</u>			<u>20MG</u>	<u>A077971</u>	<u>002</u>	Oct 26, 2007
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>10MG</u>	<u>A072234</u>	<u>001</u>	Jul 21, 1988
<u>AB</u>	+		<u>20MG</u>	<u>A072235</u>	<u>001</u>	Jul 21, 1988
<u>AB</u>		LANNETT	<u>10MG</u>	<u>A078220</u>	<u>001</u>	Jul 06, 2007
<u>AB</u>			<u>20MG</u>	<u>A077241</u>	<u>001</u>	Dec 20, 2005
<u>AB</u>		MYLAN	<u>10MG</u>	<u>A077181</u>	<u>001</u>	Jul 29, 2005
<u>AB</u>			<u>20MG</u>	<u>A077121</u>	<u>002</u>	Jul 29, 2005
<u>AB</u>		NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078504</u>	<u>001</u>	Sep 18, 2009
<u>AB</u>			<u>20MG</u>	<u>A078401</u>	<u>001</u>	Sep 18, 2009
<u>AB</u>		USL PHARMA	<u>10MG</u>	<u>A074584</u>	<u>001</u>	Aug 19, 1996
<u>AB</u>			<u>20MG</u>	<u>A074584</u>	<u>002</u>	Aug 19, 1996
<u>AB</u>		VINTAGE PHARMS	<u>10MG</u>	<u>A077156</u>	<u>001</u>	Aug 30, 2005
<u>AB</u>			<u>20MG</u>	<u>A077068</u>	<u>001</u>	Aug 30, 2005
<u>AB</u>		WATSON LABS	<u>10MG</u>	<u>A072824</u>	<u>001</u>	Sep 18, 1991
<u>AB</u>			<u>20MG</u>	<u>A072825</u>	<u>001</u>	Sep 18, 1991

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

		SCHWARZ PHARMA	10MG	N021589	001	Oct 30, 2003
	+		20MG	N021589	002	Oct 30, 2003

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

<u>AB</u>		APOTEX INC	<u>750MG</u>	<u>A077883</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>		MYLAN	<u>750MG</u>	<u>A077807</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>		ROXANE	<u>750MG</u>	<u>A077806</u>	<u>001</u>	Dec 28, 2007



## PRESCRIPTION DRUG PRODUCT LIST

3 - 46 (of 393)

BALSALAZIDE DISODIUM

CAPSULE; ORAL

COLAZAL

<u>AB</u>	+	SALIX PHARMS	<u>750MG</u>	<u>N020610</u>	<u>001</u>	Jul 18, 2000
-----------	---	--------------	--------------	----------------	------------	--------------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

+	TEVA GLOBAL	0.04MG/INH	N020911	002	Sep 15, 2000
---	-------------	------------	---------	-----	--------------

QVAR 80

+	TEVA GLOBAL	0.08MG/INH	N020911	001	Sep 15, 2000
---	-------------	------------	---------	-----	--------------

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

BECONASE AQ

+	GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N019389	001	Jul 27, 1987
---	-----------------	-------------------------	---------	-----	--------------

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077128</u>	<u>001</u>	Mar 08, 2006
<u>AB</u>		<u>10MG</u>	<u>A077128</u>	<u>002</u>	Mar 08, 2006
<u>AB</u>		<u>20MG</u>	<u>A077128</u>	<u>003</u>	Mar 08, 2006
<u>AB</u>		<u>40MG</u>	<u>A077128</u>	<u>004</u>	Mar 08, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>10MG</u>	<u>A078212</u>	<u>001</u>	May 22, 2008
<u>AB</u>		<u>20MG</u>	<u>A078212</u>	<u>002</u>	May 22, 2008
<u>AB</u>		<u>40MG</u>	<u>A078212</u>	<u>003</u>	May 22, 2008
<u>AB</u>	BIOKEY	<u>5MG</u>	<u>A076820</u>	<u>001</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A076820</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>20MG</u>	<u>A076820</u>	<u>003</u>	Feb 03, 2006
<u>AB</u>		<u>40MG</u>	<u>A076820</u>	<u>004</u>	Feb 03, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076333</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076333</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076333</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076333</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	KV PHARM	<u>5MG</u>	<u>A076118</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076118</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076118</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076118</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076430</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076430</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076430</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076430</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076344</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076344</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076344</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076344</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A076402</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076402</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076402</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076402</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076211</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076211</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076211</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076211</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	WATSON LABS FLORIDA	<u>5MG</u>	<u>A076267</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076267</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076267</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076267</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A078848</u>	<u>001</u>	May 23, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 47 (of 393)

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	ZYDUS PHARMS USA	<u>10MG</u>	<u>A078848</u>	<u>002</u>	May 23, 2008
<u>AB</u>		<u>20MG</u>	<u>A078848</u>	<u>003</u>	May 23, 2008
<u>AB</u>		<u>40MG</u>	<u>A078848</u>	<u>004</u>	May 23, 2008
<u>LOTENSIN</u>					
<u>AB</u>	NOVARTIS	<u>5MG</u>	<u>N019851</u>	<u>001</u>	Jun 25, 1991
<u>AB</u>		<u>10MG</u>	<u>N019851</u>	<u>002</u>	Jun 25, 1991
<u>AB</u>		<u>20MG</u>	<u>N019851</u>	<u>003</u>	Jun 25, 1991
<u>AB</u>	+	<u>40MG</u>	<u>N019851</u>	<u>004</u>	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	GENPHARM	<u>5MG; 6.25MG</u>	<u>A076612</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076612</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076612</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076612</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG; 6.25MG</u>	<u>A076348</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076348</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076348</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076348</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG; 6.25MG</u>	<u>A076688</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076688</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076688</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076688</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	RANBAXY	<u>5MG; 6.25MG</u>	<u>A077483</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A077483</u>	<u>002</u>	Sep 08, 2005
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A077483</u>	<u>003</u>	Sep 08, 2005
<u>AB</u>		<u>20MG; 25MG</u>	<u>A077483</u>	<u>004</u>	Sep 08, 2005
<u>AB</u>	SANDOZ	<u>5MG; 6.25MG</u>	<u>A076631</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076631</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076631</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076631</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	WATSON LABS FLORIDA	<u>5MG; 6.25MG</u>	<u>A076342</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076342</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076342</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076342</u>	<u>004</u>	Feb 11, 2004
<u>LOTENSIN HCT</u>					
<u>AB</u>	NOVARTIS	<u>5MG; 6.25MG</u>	<u>N020033</u>	<u>001</u>	May 19, 1992
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>N020033</u>	<u>002</u>	May 19, 1992
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>N020033</u>	<u>004</u>	May 19, 1992
<u>AB</u>	+	<u>20MG; 25MG</u>	<u>N020033</u>	<u>003</u>	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

+	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009
+		100MG/VIAL	N022249	001	Mar 20, 2008

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

<u>AB</u>	KING PHARMS	<u>5MG; 40MG</u>	<u>N018647</u>	<u>001</u>	May 25, 1983
<u>AB</u>	+	<u>5MG; 80MG</u>	<u>N018647</u>	<u>002</u>	May 25, 1983
<u>NADOLOL AND BENDROFLUMETHIAZIDE</u>					
<u>AB</u>	MYLAN	<u>5MG; 40MG</u>	<u>A078688</u>	<u>001</u>	Feb 15, 2008
<u>AB</u>		<u>5MG; 80MG</u>	<u>A078688</u>	<u>002</u>	Feb 15, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 48 (of 393)

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

NADOLOL AND BENDROFLUMETHIAZIDE

<u>AB</u>	IMPAX LABS	<u>5MG;40MG</u>	<u>A077833</u>	<u>001</u>	Mar 30, 2007
<u>AB</u>		<u>5MG;80MG</u>	<u>A077833</u>	<u>002</u>	Mar 30, 2007

BENZONATATE

CAPSULE; ORAL

BENZONATATE

<u>AA</u>	BANNER PHARMACAPS	<u>100MG</u>	<u>A081297</u>	<u>001</u>	Jan 29, 1993
<u>AA</u>		<u>200MG</u>	<u>A081297</u>	<u>002</u>	Oct 30, 2007
<u>AA</u>	KV PHARM	<u>100MG</u>	<u>A040795</u>	<u>001</u>	Oct 31, 2007
<u>AA</u>		<u>200MG</u>	<u>A040795</u>	<u>002</u>	Oct 31, 2007
<u>AA</u>	MIKART	<u>100MG</u>	<u>A040851</u>	<u>001</u>	Nov 09, 2009
<u>AA</u>		<u>200MG</u>	<u>A040851</u>	<u>003</u>	Nov 09, 2009
<u>AA</u>	ORIT LABS LLC	<u>100MG</u>	<u>A040682</u>	<u>001</u>	Jul 30, 2007
<u>AA</u>		<u>200MG</u>	<u>A040682</u>	<u>002</u>	Jul 30, 2007
<u>AA</u>	SUN PHARM INDS INC	<u>100MG</u>	<u>A040587</u>	<u>001</u>	Mar 19, 2008
<u>AA</u>		<u>200MG</u>	<u>A040587</u>	<u>002</u>	Mar 19, 2008
<u>AA</u>	THE PHARMA NETWORK	<u>100MG</u>	<u>A040627</u>	<u>001</u>	Mar 30, 2007
<u>AA</u>		<u>200MG</u>	<u>A040749</u>	<u>001</u>	Jul 25, 2007
<u>AA</u>	ZYDUS PHARMS USA	<u>100MG</u>	<u>A040597</u>	<u>001</u>	Jun 08, 2007
<u>AA</u>		<u>200MG</u>	<u>A040597</u>	<u>002</u>	Jun 08, 2007

TESSALON

<u>AA</u>	+ FOREST LABS	<u>100MG</u>	<u>N011210</u>	<u>001</u>	
<u>AA</u>	+ BENZONATATE	<u>200MG</u>	<u>N011210</u>	<u>003</u>	Jun 25, 1999
	MIKART	150MG	A040851	002	Nov 09, 2009

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

<u>AB</u>	+ SANOFI AVENTIS US	<u>5%;EQ 1% BASE</u>	<u>N050756</u>	<u>001</u>	Dec 21, 2000
	<u>CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>				
<u>AB</u>	DOW PHARM SCIENCES	<u>5%;EQ 1% BASE</u>	<u>A065443</u>	<u>001</u>	Aug 11, 2009
	BENZACLIN				
BT	+ SANOFI AVENTIS US	5%;EQ 1% BASE	N050756	002	Apr 20, 2007
	DUAC				
BT	+ STIEFEL	5%;EQ 1% BASE	N050741	001	Aug 26, 2002
	ACANYA				
	+ DOW PHARM SCI	2.5%;1.2%	N050819	001	Oct 23, 2008

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

<u>AB</u>	+ SANOFI AVENTIS US	<u>5%;3%</u>	<u>N050557</u>	<u>001</u>	Oct 26, 1984
	<u>ERYTHROMYCIN AND BENZOYL PEROXIDE</u>				
<u>AB</u>	TOLMAR	<u>5%;3%</u>	<u>A065112</u>	<u>001</u>	Mar 29, 2004
	BENZAMYCIN PAK				
	+ SANOFI AVENTIS US	5%;3%	N050769	001	Nov 27, 2000

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

<u>AA</u>	COREPHARMA	<u>50MG</u>	<u>A040714</u>	<u>001</u>	Oct 29, 2007
<u>AA</u>	IMPAX LABS	<u>50MG</u>	<u>A040845</u>	<u>001</u>	Nov 18, 2008
<u>AA</u>	PADDOCK	<u>50MG</u>	<u>A040578</u>	<u>001</u>	Apr 17, 2006
<u>AA</u>	TEDOR PHARM	<u>50MG</u>	<u>A040747</u>	<u>001</u>	Mar 30, 2007
<u>AA</u>	TYCO HLTHCARE	<u>50MG</u>	<u>A040773</u>	<u>001</u>	Apr 25, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 49 (of 393)

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DIDREX

<u>AA</u>	+	PHARMACIA AND UPJOHN	<u>50MG</u>	<u>N012427</u>	<u>002</u>	
-----------	---	----------------------	-------------	----------------	------------	--

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A090287</u>	<u>001</u>	Aug 31, 2009
-----------	--	--------------------	---------------	----------------	------------	--------------

<u>AP</u>		NEXUS PHARMS	<u>1MG/ML</u>	<u>A090233</u>	<u>001</u>	Jul 28, 2009
-----------	--	--------------	---------------	----------------	------------	--------------

COGENTIN

<u>AP</u>	+	LUNDBECK INC	<u>1MG/ML</u>	<u>N012015</u>	<u>001</u>	
-----------	---	--------------	---------------	----------------	------------	--

TABLET; ORAL

BENZTROPINE MESYLATE

<u>AA</u>		ACTAVIS TOTOWA	<u>0.5MG</u>	<u>A040699</u>	<u>001</u>	Feb 14, 2008
-----------	--	----------------	--------------	----------------	------------	--------------

<u>AA</u>			<u>1MG</u>	<u>A040705</u>	<u>001</u>	Feb 14, 2008
-----------	--	--	------------	----------------	------------	--------------

<u>AA</u>			<u>2MG</u>	<u>A040706</u>	<u>001</u>	Feb 14, 2008
-----------	--	--	------------	----------------	------------	--------------

<u>AA</u>		COREPHARMA	<u>0.5MG</u>	<u>A072264</u>	<u>001</u>	Feb 27, 1989
-----------	--	------------	--------------	----------------	------------	--------------

<u>AA</u>			<u>1MG</u>	<u>A072265</u>	<u>001</u>	Feb 27, 1989
-----------	--	--	------------	----------------	------------	--------------

<u>AA</u>			<u>2MG</u>	<u>A072266</u>	<u>001</u>	Feb 27, 1989
-----------	--	--	------------	----------------	------------	--------------

<u>AA</u>	+	PAR PHARM	<u>0.5MG</u>	<u>A088877</u>	<u>001</u>	Apr 11, 1985
-----------	---	-----------	--------------	----------------	------------	--------------

<u>AA</u>	+		<u>1MG</u>	<u>A088894</u>	<u>001</u>	Apr 11, 1985
-----------	---	--	------------	----------------	------------	--------------

<u>AA</u>	+		<u>2MG</u>	<u>A088895</u>	<u>001</u>	Apr 11, 1985
-----------	---	--	------------	----------------	------------	--------------

<u>AA</u>		PLIVA	<u>0.5MG</u>	<u>A089058</u>	<u>001</u>	Aug 10, 1988
-----------	--	-------	--------------	----------------	------------	--------------

<u>AA</u>			<u>1MG</u>	<u>A089059</u>	<u>001</u>	Aug 10, 1988
-----------	--	--	------------	----------------	------------	--------------

<u>AA</u>			<u>2MG</u>	<u>A089060</u>	<u>001</u>	Aug 10, 1988
-----------	--	--	------------	----------------	------------	--------------

<u>AA</u>		USL PHARMA	<u>0.5MG</u>	<u>A040103</u>	<u>001</u>	Dec 12, 1996
-----------	--	------------	--------------	----------------	------------	--------------

<u>AA</u>			<u>1MG</u>	<u>A040103</u>	<u>002</u>	Dec 12, 1996
-----------	--	--	------------	----------------	------------	--------------

<u>AA</u>			<u>2MG</u>	<u>A040103</u>	<u>003</u>	Dec 12, 1996
-----------	--	--	------------	----------------	------------	--------------

<u>AA</u>		VINTAGE	<u>0.5MG</u>	<u>A040738</u>	<u>001</u>	Aug 27, 2007
-----------	--	---------	--------------	----------------	------------	--------------

<u>AA</u>			<u>1MG</u>	<u>A040742</u>	<u>001</u>	Aug 27, 2007
-----------	--	--	------------	----------------	------------	--------------

<u>AA</u>			<u>2MG</u>	<u>A040715</u>	<u>003</u>	Aug 27, 2007
-----------	--	--	------------	----------------	------------	--------------

BENZYL ALCOHOL

LOTION; TOPICAL

ULESFIA

	+	SCIELE PHARMA INC	5%	N022129	001	Apr 09, 2009
--	---	-------------------	----	---------	-----	--------------

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPREVE

	+	ISTA PHARMS	1.5%	N022288	001	Sep 08, 2009
--	---	-------------	------	---------	-----	--------------

BERACTANT

SUSPENSION; INTRATRACHEAL

SURVANTA

	+	ROSS LABS	25MG/ML	N020032	001	Jul 01, 1991
--	---	-----------	---------	---------	-----	--------------

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BESIVANCE

	+	BAUSCH AND LOMB	EQ 0.6% BASE	N022308	001	May 28, 2009
--	---	-----------------	--------------	---------	-----	--------------

BETAINE HYDROCHLORIDE

FOR SOLUTION; ORAL

CYSTADANE

	+	RARE DIS THERAP	1GM/SCOOPFUL	N020576	001	Oct 25, 1996
--	---	-----------------	--------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 50 (of 393)

BETAMETHASONE

SYRUP; ORAL  
CELESTONE  
+ SCHERING

0.6MG/5ML

N014215 002

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

<u>AB</u>	PHARMAFORCE	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>A090747</u>	<u>001</u>	Jul 31, 2009
	<u>CELESTONE SOLUSPAN</u>				
<u>AB</u>	+ SCHERING	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>N014602</u>	<u>001</u>	

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A070885</u>	<u>001</u>	Feb 03, 1987
<u>AB</u>	+ FOUGERA	<u>EQ 0.05% BASE</u>	<u>N019137</u>	<u>001</u>	Jun 26, 1984
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A073552</u>	<u>001</u>	Apr 30, 1992

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	ALTANA	<u>EQ 0.05% BASE</u>	<u>A076215</u>	<u>001</u>	Dec 09, 2003
<u>AB</u>	GLENMARK GENERICS	<u>EQ 0.05% BASE</u>	<u>A078930</u>	<u>001</u>	Sep 23, 2008
<u>AB</u>	PERRIGO NEW YORK	<u>EQ 0.05% BASE</u>	<u>A076592</u>	<u>001</u>	Dec 09, 2003
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A076543</u>	<u>001</u>	Dec 09, 2003
<u>AB</u>	TOLMAR	<u>EQ 0.05% BASE</u>	<u>A076603</u>	<u>001</u>	Jan 23, 2004
	<u>DIPROLENE AF</u>				
<u>AB</u>	+ SCHERING	<u>EQ 0.05% BASE</u>	<u>N019555</u>	<u>001</u>	Apr 27, 1987

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	+ ALTANA	<u>EQ 0.05% BASE</u>	<u>A075276</u>	<u>001</u>	May 13, 2003
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A076508</u>	<u>001</u>	Dec 02, 2003

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A070281</u>	<u>001</u>	Jul 31, 1985
<u>AB</u>	+ FOUGERA	<u>EQ 0.05% BASE</u>	<u>A070275</u>	<u>001</u>	Aug 12, 1985
<u>AB</u>	PERRIGO NEW YORK	<u>EQ 0.05% BASE</u>	<u>A072538</u>	<u>001</u>	Jan 31, 1990
<u>AB</u>	TEVA	<u>EQ 0.05% BASE</u>	<u>A071467</u>	<u>001</u>	Aug 10, 1987

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	ALTANA	<u>EQ 0.05% BASE</u>	<u>A077111</u>	<u>001</u>	May 21, 2007
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A077477</u>	<u>001</u>	May 21, 2007
	<u>DIPROLENE</u>				
<u>AB</u>	+ SCHERING	<u>EQ 0.05% BASE</u>	<u>N019716</u>	<u>001</u>	Aug 01, 1988

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A071012</u>	<u>001</u>	Feb 03, 1987
<u>AB</u>	+ FOUGERA	<u>EQ 0.05% BASE</u>	<u>N019141</u>	<u>001</u>	Sep 04, 1984
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A074271</u>	<u>001</u>	Sep 15, 1994

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A074304</u>	<u>001</u>	Aug 31, 1995
<u>AB</u>	ALTANA	<u>EQ 0.05% BASE</u>	<u>A075373</u>	<u>001</u>	Jun 22, 1999
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A076753</u>	<u>001</u>	Oct 12, 2004
	<u>DIPROLENE</u>				
<u>AB</u>	+ SCHERING	<u>EQ 0.05% BASE</u>	<u>N018741</u>	<u>001</u>	Jul 27, 1983

## PRESCRIPTION DRUG PRODUCT LIST

3 - 51 (of 393)

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

TACLONEX

+ LEO PHARM	0.064%;0.005%	N021852	001	Jan 09, 2006
-------------	---------------	---------	-----	--------------

SUSPENSION; TOPICAL

TACLONEX SCALP

+ LEO PHARM PRODS	0.064%;0.005%	N022185	001	May 09, 2008
-------------------	---------------	---------	-----	--------------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE;1%</u>	<u>A076002</u>	<u>001</u>	Aug 02, 2002
-----------	----------------------	-------------------------	----------------	------------	--------------

<u>AB</u>	ALTANA	<u>EQ 0.05% BASE;1%</u>	<u>A075502</u>	<u>001</u>	Jun 05, 2001
-----------	--------	-------------------------	----------------	------------	--------------

<u>AB</u>	TARO	<u>EQ 0.05% BASE;1%</u>	<u>A075673</u>	<u>001</u>	May 29, 2001
-----------	------	-------------------------	----------------	------------	--------------

LOTRISONE

<u>AB</u>	+ SCHERING	<u>EQ 0.05% BASE;1%</u>	<u>N018827</u>	<u>001</u>	Jul 10, 1984
-----------	------------	-------------------------	----------------	------------	--------------

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

<u>AB</u>	ALTANA PHARMA	<u>EQ 0.05% BASE;1%</u>	<u>A076516</u>	<u>001</u>	Jun 16, 2005
-----------	---------------	-------------------------	----------------	------------	--------------

<u>AB</u>	TARO	<u>EQ 0.05% BASE;1%</u>	<u>A076493</u>	<u>001</u>	Jul 28, 2004
-----------	------	-------------------------	----------------	------------	--------------

LOTRISONE

<u>AB</u>	+ SCHERING PLOUGH RES	<u>EQ 0.05% BASE;1%</u>	<u>N020010</u>	<u>001</u>	Dec 08, 2000
-----------	-----------------------	-------------------------	----------------	------------	--------------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

LUXIQ

+ CONNECTICS	EQ 0.12% BASE	N020934	001	Feb 28, 1999
--------------	---------------	---------	-----	--------------

CREAM; TOPICAL

BETAMETHASONE VALERATE

<u>AB</u>	+ FOUGERA	<u>EQ 0.1% BASE</u>	<u>N018861</u>	<u>001</u>	Aug 31, 1983
-----------	-----------	---------------------	----------------	------------	--------------

BETA-VAL

<u>AB</u>	TEVA	<u>EQ 0.1% BASE</u>	<u>N018642</u>	<u>001</u>	Mar 24, 1983
-----------	------	---------------------	----------------	------------	--------------

DERMABET

<u>AB</u>	TARO	<u>EQ 0.1% BASE</u>	<u>A072041</u>	<u>001</u>	Jan 06, 1988
-----------	------	---------------------	----------------	------------	--------------

VALNAC

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.1% BASE</u>	<u>A070050</u>	<u>001</u>	Oct 10, 1984
-----------	----------------------	---------------------	----------------	------------	--------------

LOTION; TOPICAL

BETAMETHASONE VALERATE

<u>AB</u>	+ FOUGERA	<u>EQ 0.1% BASE</u>	<u>N018866</u>	<u>001</u>	Aug 31, 1983
-----------	-----------	---------------------	----------------	------------	--------------

<u>AB</u>	STAT TRADE	<u>EQ 0.1% BASE</u>	<u>A070052</u>	<u>001</u>	Jul 31, 1985
-----------	------------	---------------------	----------------	------------	--------------

BETA-VAL

<u>AB</u>	TEVA	<u>EQ 0.1% BASE</u>	<u>A070072</u>	<u>001</u>	Jun 27, 1985
-----------	------	---------------------	----------------	------------	--------------

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.1% BASE</u>	<u>A070051</u>	<u>001</u>	Oct 10, 1984
-----------	----------------------	---------------------	----------------	------------	--------------

<u>AB</u>	+ FOUGERA	<u>EQ 0.1% BASE</u>	<u>N018865</u>	<u>001</u>	Aug 31, 1983
-----------	-----------	---------------------	----------------	------------	--------------

BETAXOLOL

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL

<u>AT</u>	WOCKHARDT	<u>EQ 0.5% BASE</u>	<u>A078694</u>	<u>001</u>	Nov 16, 2009
-----------	-----------	---------------------	----------------	------------	--------------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL

<u>AT</u>	AKORN	<u>EQ 0.5% BASE</u>	<u>A075386</u>	<u>001</u>	Jun 30, 2000
-----------	-------	---------------------	----------------	------------	--------------

<u>AT</u>	NOVEX	<u>EQ 0.5% BASE</u>	<u>A075446</u>	<u>001</u>	Sep 28, 2000
-----------	-------	---------------------	----------------	------------	--------------

BETAXOLOL HYDROCHLORIDE

<u>AT</u>	BAUSCH AND LOMB	<u>EQ 0.5% BASE</u>	<u>A075630</u>	<u>001</u>	Apr 12, 2001
-----------	-----------------	---------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 52 (of 393)

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETOPTIC

<u>AT</u>	+	ALCON	<u>EQ 0.5% BASE</u>	<u>N019270</u>	<u>001</u>	Aug 30, 1985
-----------	---	-------	---------------------	----------------	------------	--------------

SUSPENSION/DROPS; OPHTHALMIC

	+	ALCON	EQ 0.25% BASE	N019845	001	Dec 29, 1989
--	---	-------	---------------	---------	-----	--------------

TABLET; ORAL

BETAXOLOL HYDROCHLORIDE

<u>AB</u>		ACTAVIS TOTOWA	<u>10MG</u>	<u>A075541</u>	<u>001</u>	Oct 22, 1999
<u>AB</u>	+		<u>20MG</u>	<u>A075541</u>	<u>002</u>	Oct 22, 1999
<u>AB</u>		KVK TECH	<u>10MG</u>	<u>A078962</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>			<u>20MG</u>	<u>A078962</u>	<u>002</u>	Jun 27, 2008

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

<u>AA</u>		ACTAVIS TOTOWA	<u>5MG</u>	<u>A040552</u>	<u>001</u>	Oct 28, 2004
<u>AA</u>			<u>10MG</u>	<u>A040553</u>	<u>001</u>	Oct 28, 2004
<u>AA</u>			<u>25MG</u>	<u>A040554</u>	<u>001</u>	Oct 28, 2004
<u>AA</u>		AMNEAL PHARM	<u>5MG</u>	<u>A040855</u>	<u>001</u>	Nov 21, 2007
<u>AA</u>			<u>10MG</u>	<u>A040855</u>	<u>002</u>	Nov 21, 2007
<u>AA</u>			<u>25MG</u>	<u>A040855</u>	<u>003</u>	Nov 21, 2007
<u>AA</u>			<u>50MG</u>	<u>A040855</u>	<u>004</u>	Nov 21, 2007
<u>AA</u>		IMPAX LABS	<u>5MG</u>	<u>A040739</u>	<u>001</u>	Nov 01, 2006
<u>AA</u>			<u>10MG</u>	<u>A040741</u>	<u>001</u>	Nov 01, 2006
<u>AA</u>			<u>25MG</u>	<u>A040740</u>	<u>001</u>	Nov 01, 2006
<u>AA</u>			<u>50MG</u>	<u>A040721</u>	<u>004</u>	Nov 01, 2006
<u>AA</u>		LANNETT	<u>5MG</u>	<u>A040703</u>	<u>001</u>	Mar 27, 2008
<u>AA</u>			<u>10MG</u>	<u>A040704</u>	<u>001</u>	Mar 27, 2008
<u>AA</u>			<u>25MG</u>	<u>A040678</u>	<u>003</u>	Mar 27, 2008
<u>AA</u>			<u>50MG</u>	<u>A040677</u>	<u>001</u>	Mar 27, 2008
<u>AA</u>		PHARMAX	<u>5MG</u>	<u>A040725</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>			<u>10MG</u>	<u>A040726</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>			<u>25MG</u>	<u>A040727</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>			<u>50MG</u>	<u>A040728</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>		SUN PHARM INDS INC	<u>5MG</u>	<u>A040897</u>	<u>001</u>	Apr 22, 2009
<u>AA</u>			<u>10MG</u>	<u>A040897</u>	<u>002</u>	Apr 22, 2009
<u>AA</u>			<u>25MG</u>	<u>A040897</u>	<u>003</u>	Apr 22, 2009
<u>AA</u>			<u>50MG</u>	<u>A040897</u>	<u>004</u>	Apr 22, 2009
<u>AA</u>		UPSHER SMITH	<u>5MG</u>	<u>A040633</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>			<u>10MG</u>	<u>A040634</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>			<u>25MG</u>	<u>A040635</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>			<u>50MG</u>	<u>A040636</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>		WOCKHARDT	<u>5MG</u>	<u>A040532</u>	<u>001</u>	Sep 29, 2003
<u>AA</u>			<u>10MG</u>	<u>A040533</u>	<u>001</u>	Sep 29, 2003
<u>AA</u>			<u>25MG</u>	<u>A040534</u>	<u>001</u>	Sep 29, 2003
<u>AA</u>			<u>50MG</u>	<u>A040518</u>	<u>001</u>	Sep 29, 2003
		<u>DUVOID</u>				
<u>AA</u>		WELLSPRING PHARM	<u>10MG</u>	<u>A086262</u>	<u>001</u>	
<u>AA</u>			<u>25MG</u>	<u>A086263</u>	<u>001</u>	
<u>AA</u>			<u>50MG</u>	<u>A085882</u>	<u>003</u>	
		<u>URECHOLINE</u>				
<u>AA</u>	+	ODYSSEY PHARMS	<u>5MG</u>	<u>A089095</u>	<u>001</u>	Dec 19, 1985
<u>AA</u>	+		<u>10MG</u>	<u>A088440</u>	<u>001</u>	May 29, 1984
<u>AA</u>	+		<u>25MG</u>	<u>A088441</u>	<u>001</u>	May 29, 1984
<u>AA</u>	+		<u>50MG</u>	<u>A089096</u>	<u>001</u>	Dec 19, 1985

## PRESCRIPTION DRUG PRODUCT LIST

3 - 53 (of 393)

BEXAROTENE

CAPSULE; ORAL					
TARGRETIN					
+ EISAI INC	75MG		N021055	001	Dec 29, 1999
GEL; TOPICAL					
TARGRETIN					
+ EISAI INC	1%		N021056	001	Jun 28, 2000

BICALUTAMIDE

TABLET; ORAL					
<u>BICALUTAMIDE</u>					
<u>AB</u>	ACCORD HLTHCARE INC	<u>50MG</u>	<u>A078917</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	ACTAVIS TOTOWA	<u>50MG</u>	<u>A078634</u>	<u>001</u>	Aug 28, 2009
<u>AB</u>	KUDCO IRELAND	<u>50MG</u>	<u>A077995</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A079185</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A078575</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	SUN PHARMA GLOBAL	<u>50MG</u>	<u>A079110</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	SYNTHON PHARMS	<u>50MG</u>	<u>A077973</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076932</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A079089</u>	<u>001</u>	Jul 06, 2009
	<u>CASODEX</u>				
<u>AB</u>	+ ASTRAZENECA	<u>50MG</u>	<u>N020498</u>	<u>001</u>	Oct 04, 1995

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC					
LUMIGAN					
+ ALLERGAN	0.03%		N021275	001	Mar 16, 2001
SOLUTION/DROPS; TOPICAL					
+ ALLERGAN	0.03%		N022369	001	Dec 24, 2008

BIPERIDEN HYDROCHLORIDE

TABLET; ORAL					
AKINETON					
+ ABBOTT	2MG		N012003	001	

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

TABLET, DELAYED RELEASE, FOR SOLUTION; ORAL					
HALFLYTELY					
+ BRAINTREE	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM		N021551	002	Sep 24, 2007
	;N/A,5.6GM				

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL					
PYLERA					
+ AXCAN SCANDIPHARM	140MG;125MG;125MG		N050786	001	Sep 28, 2006

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL					
HELIDAC					
+ PROMETHEUS LABS	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,5		N050719	001	Aug 15, 1996
	00MG				

BISOPROLOL FUMARATE

TABLET; ORAL					
<u>BISOPROLOL FUMARATE</u>					
<u>AB</u>	UNICHEM PHARMS (USA)	<u>5MG</u>	<u>A078635</u>	<u>001</u>	Aug 18, 2009
<u>AB</u>		<u>10MG</u>	<u>A078635</u>	<u>002</u>	Aug 18, 2009

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 80 of 1114**



## PRESCRIPTION DRUG PRODUCT LIST

3 - 54 (of 393)

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A077910</u>	<u>001</u>	Dec 27, 2006
<u>AB</u>		<u>10MG</u>	<u>A077910</u>	<u>002</u>	Dec 27, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A075831</u>	<u>001</u>	Dec 14, 2005
<u>AB</u>		<u>10MG</u>	<u>A075831</u>	<u>002</u>	Dec 14, 2005
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A075643</u>	<u>001</u>	Nov 16, 2000
<u>AB</u>		<u>10MG</u>	<u>A075643</u>	<u>002</u>	Nov 16, 2000
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A075644</u>	<u>001</u>	Jun 26, 2001
<u>AB</u>		<u>10MG</u>	<u>A075644</u>	<u>002</u>	Jun 26, 2001
<u>ZEBETA</u>					
<u>AB</u>	DURAMED PHARMS BARR	<u>5MG</u>	<u>N019982</u>	<u>002</u>	Jul 31, 1992
<u>AB</u>	+	<u>10MG</u>	<u>N019982</u>	<u>001</u>	Jul 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>2.5MG;6.25MG</u>	<u>A075672</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG;6.25MG</u>	<u>A075672</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG;6.25MG</u>	<u>A075672</u>	<u>003</u>	Sep 25, 2000
<u>AB</u>	MYLAN	<u>2.5MG;6.25MG</u>	<u>A075768</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG;6.25MG</u>	<u>A075768</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG;6.25MG</u>	<u>A075768</u>	<u>003</u>	Sep 25, 2000
<u>AB</u>	SANDOZ	<u>2.5MG;6.25MG</u>	<u>A075579</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG;6.25MG</u>	<u>A075579</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG;6.25MG</u>	<u>A075579</u>	<u>003</u>	Sep 25, 2000
<u>AB</u>	WATSON LABS	<u>2.5MG;6.25MG</u>	<u>A075469</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG;6.25MG</u>	<u>A075469</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG;6.25MG</u>	<u>A075469</u>	<u>003</u>	Sep 25, 2000
<u>ZIAC</u>					
<u>AB</u>	DURAMED PHARMS BARR	<u>2.5MG;6.25MG</u>	<u>N020186</u>	<u>003</u>	Mar 26, 1993
<u>AB</u>		<u>5MG;6.25MG</u>	<u>N020186</u>	<u>001</u>	Mar 26, 1993
<u>AB</u>	+	<u>10MG;6.25MG</u>	<u>N020186</u>	<u>002</u>	Mar 26, 1993

BIVALIRUDININJECTABLE; INTRAVENOUS  
ANGIOMAX

+	MEDICINES CO	250MG/VIAL	N020873	001	Dec 15, 2000
---	--------------	------------	---------	-----	--------------

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLENOXANE

<u>AP</u>	+	BRISTOL MYERS SQUIBB	<u>EQ 15 UNITS BASE/VIAL</u>	<u>N050443</u>	<u>001</u>	
<u>AP</u>	+		<u>EQ 30 UNITS BASE/VIAL</u>	<u>N050443</u>	<u>002</u>	Sep 07, 1995

BLEOMYCIN SULFATE

<u>AP</u>		APP PHARMS	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065185</u>	<u>001</u>	Jan 28, 2008
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065185</u>	<u>002</u>	Jan 28, 2008
<u>AP</u>		BEDFORD	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065042</u>	<u>002</u>	Oct 17, 2001
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065042</u>	<u>001</u>	Oct 17, 2001
<u>AP</u>		HOSPIRA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065031</u>	<u>001</u>	Mar 10, 2000
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065031</u>	<u>002</u>	Mar 10, 2000
<u>AP</u>		PHARMACHEMIE BV	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065201</u>	<u>001</u>	Dec 13, 2007
<u>AP</u>		TEVA PARENTERAL	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065033</u>	<u>001</u>	Jun 27, 2000
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065033</u>	<u>002</u>	Jun 27, 2000

BORTEZOMIBINJECTABLE; INTRAVENOUS  
VELCADE

+	MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003
---	-------------------	------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 55 (of 393)

BOSENTAN

TABLET; ORAL

TRACLEER

ACTELION	62.5MG	N021290	001	Nov 20, 2001
+	125MG	N021290	002	Nov 20, 2001

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

<u>AP</u>	+	HOSPIRA	<u>50MG/ML</u>	<u>N019030</u>	<u>001</u>	Apr 29, 1986
<u>AP</u>		LUITPOLD	<u>50MG/ML</u>	<u>A070891</u>	<u>001</u>	Jul 26, 1988

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>200MG/100ML</u>	<u>N019121</u>	<u>002</u>	Apr 29, 1986
<u>AP</u>	+		<u>400MG/100ML</u>	<u>N019121</u>	<u>003</u>	Apr 29, 1986
<u>AP</u>	+	HOSPIRA	<u>200MG/100ML</u>	<u>N019008</u>	<u>002</u>	Apr 29, 1986
<u>AP</u>	+		<u>400MG/100ML</u>	<u>N019008</u>	<u>003</u>	Apr 29, 1986
		BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
	+	B BRAUN	100MG/100ML	N019121	001	Apr 29, 1986

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P

<u>AT</u>	+	ALLERGAN	<u>0.15%</u>	<u>N021262</u>	<u>001</u>	Mar 16, 2001
		<u>BRIMONIDINE TARTRATE</u>				
<u>AT</u>		AKORN	<u>0.2%</u>	<u>A076439</u>	<u>001</u>	Mar 14, 2006
<u>AT</u>		ALCON	<u>0.2%</u>	<u>A076254</u>	<u>001</u>	Sep 16, 2003
<u>AT</u>		ALCON RES	<u>0.15%</u>	<u>N021764</u>	<u>001</u>	May 22, 2006
<u>AT</u>	+	BAUSCH AND LOMB	<u>0.2%</u>	<u>A076260</u>	<u>001</u>	May 28, 2003
<u>AT</u>		SANDOZ	<u>0.2%</u>	<u>A078075</u>	<u>001</u>	Jan 30, 2008
<u>AT</u>		TEVA PARENTERAL	<u>0.2%</u>	<u>A076372</u>	<u>001</u>	Sep 10, 2004
		ALPHAGAN P				
	+	ALLERGAN	0.1%	N021770	001	Aug 19, 2005

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COMBIGAN

+	ALLERGAN	0.2%;0.5%	N021398	001	Oct 30, 2007
---	----------	-----------	---------	-----	--------------

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

AZOPT

+	ALCON	1%	N020816	001	Apr 01, 1998
---	-------	----	---------	-----	--------------

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

XIBROM

+	ISTA PHARMS	0.09%	N021664	001	Mar 24, 2005
---	-------------	-------	---------	-----	--------------

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

<u>AB</u>		MYLAN	<u>EQ 5MG BASE</u>	<u>A077226</u>	<u>001</u>	Apr 04, 2005
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 5MG BASE</u>	<u>A078899</u>	<u>001</u>	Jul 30, 2008
		<u>PARLODEL</u>				
<u>AB</u>	+	NOVARTIS	<u>EQ 5MG BASE</u>	<u>N017962</u>	<u>002</u>	Mar 01, 1982

TABLET; ORAL

BROMOCRIPTINE MESYLATE

<u>AB</u>		LEK PHARMS	<u>EQ 2.5MG BASE</u>	<u>A074631</u>	<u>001</u>	Jan 13, 1998
<u>AB</u>		MYLAN	<u>EQ 2.5MG BASE</u>	<u>A076962</u>	<u>001</u>	Sep 24, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 56 (of 393)

BROMOCRIPTINE MESYLATE

TABLET; ORAL

BROMOCRIPTINE MESYLATE

<u>AB</u>	PADDOCK	<u>EQ 2.5MG BASE</u>	<u>A077646</u>	<u>001</u>	Oct 01, 2008
<u>AB</u>	<u>PARLODEL</u>				
<u>AB</u>	+ NOVARTIS	<u>EQ 2.5MG BASE</u>	<u>N017962</u>	<u>001</u>	
	CYCLOSET				
	+ VEROSCIENCE	EQ 0.8MG BASE	N020866	001	May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

	+ MORTON GROVE	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985
--	----------------	---------------------------	---------	-----	--------------

BUDESONIDE

CAPSULE; ORAL

ENTOCORT EC

	+ ASTRAZENECA	3MG	N021324	001	Oct 02, 2001
--	---------------	-----	---------	-----	--------------

POWDER, METERED; INHALATION

PULMICORT

	+ ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997
--	---------------	------------	---------	-----	--------------

PULMICORT FLEXHALER

	ASTRAZENECA	0.08MG/INH	N021949	001	Jul 12, 2006
--	-------------	------------	---------	-----	--------------

	+	0.16MG/INH	N021949	002	Jul 12, 2006
--	---	------------	---------	-----	--------------

SPRAY, METERED; NASAL

RHINOCORT

	+ ASTRAZENECA	0.032MG/INH	N020746	001	Oct 01, 1999
--	---------------	-------------	---------	-----	--------------

SUSPENSION; INHALATION

BUDESONIDE

<u>AN</u>	APOTEX	<u>0.25MG/2ML</u>	<u>A078202</u>	<u>001</u>	Mar 30, 2009
<u>AN</u>		<u>0.5MG/2ML</u>	<u>A078202</u>	<u>002</u>	Mar 30, 2009
<u>AN</u>	TEVA PARENTERAL	<u>0.25MG/2ML</u>	<u>A077519</u>	<u>001</u>	Nov 18, 2008
<u>AN</u>		<u>0.5MG/2ML</u>	<u>A077519</u>	<u>002</u>	Nov 18, 2008
	<u>PULMICORT RESPULES</u>				
<u>AN</u>	ASTRAZENECA	<u>0.25MG/2ML</u>	<u>N020929</u>	<u>001</u>	Aug 08, 2000
<u>AN</u>		<u>0.5MG/2ML</u>	<u>N020929</u>	<u>002</u>	Aug 08, 2000
	PULMICORT RESPULES				
	+ ASTRAZENECA	1MG/2ML	N020929	003	Aug 08, 2000

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

SPRAY, METERED; INHALATION

SYMBICORT

	+ ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006
--	---------------	-------------------------	---------	-----	--------------

	+	0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006
--	---	-------------------------	---------	-----	--------------

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

<u>AP</u>	BAXTER HLTHCARE	<u>0.25MG/ML</u>	<u>A079196</u>	<u>001</u>	Apr 30, 2008
<u>AP</u>	+ BEDFORD	<u>0.25MG/ML</u>	<u>A074441</u>	<u>001</u>	Jan 27, 1995
<u>AP</u>	HOSPIRA	<u>0.25MG/ML</u>	<u>A074332</u>	<u>001</u>	Oct 31, 1994
<u>AP</u>	TEVA PARENTERAL	<u>0.25MG/ML</u>	<u>A074613</u>	<u>001</u>	Nov 18, 1997

TABLET; ORAL

BUMETANIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.5MG</u>	<u>A074225</u>	<u>001</u>	Apr 24, 1995
<u>AB</u>		<u>1MG</u>	<u>A074225</u>	<u>002</u>	Apr 24, 1995
<u>AB</u>		<u>2MG</u>	<u>A074225</u>	<u>003</u>	Apr 24, 1995
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074700</u>	<u>001</u>	Nov 21, 1996
<u>AB</u>		<u>1MG</u>	<u>A074700</u>	<u>002</u>	Nov 21, 1996

## PRESCRIPTION DRUG PRODUCT LIST

3 - 57 (of 393)

BUMETANIDE

TABLET; ORAL

BUMETANIDE

<u>AB</u>	+ SANDOZ	<u>2MG</u>	<u>A074700</u>	<u>003</u>	Nov 21, 1996
-----------	----------	------------	----------------	------------	--------------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>0.25%</u>	<u>A070583</u>	<u>001</u>	Feb 17, 1987
<u>AP</u>		<u>0.25%</u>	<u>A070586</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.25%</u>	<u>A070590</u>	<u>001</u>	Feb 17, 1987
<u>AP</u>		<u>0.25%</u>	<u>N018053</u>	<u>002</u>	
<u>AP</u>		<u>0.5%</u>	<u>A070584</u>	<u>001</u>	Feb 17, 1986
<u>AP</u>		<u>0.5%</u>	<u>A070597</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.5%</u>	<u>A070609</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.5%</u>	<u>N018053</u>	<u>001</u>	
<u>AP</u>		<u>0.75%</u>	<u>A070585</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.75%</u>	<u>A070587</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.75%</u>	<u>N018053</u>	<u>003</u>	

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	INTL MEDICATED	<u>0.25%</u>	<u>A076012</u>	<u>001</u>	Jan 09, 2002
<u>AP</u>		<u>0.5%</u>	<u>A076012</u>	<u>002</u>	Jan 09, 2002
<u>AP</u>		<u>0.75%</u>	<u>A076012</u>	<u>003</u>	Jan 09, 2002

MARCAINE HYDROCHLORIDE

<u>AP</u>	+ HOSPIRA	<u>0.25%</u>	<u>N016964</u>	<u>001</u>	
<u>AP</u>	+	<u>0.5%</u>	<u>N016964</u>	<u>006</u>	

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	+ HOSPIRA	<u>0.25%</u>	<u>N016964</u>	<u>012</u>	
<u>AP</u>	+	<u>0.5%</u>	<u>N016964</u>	<u>005</u>	
<u>AP</u>	+	<u>0.75%</u>	<u>N016964</u>	<u>009</u>	

SENSORCAINE

<u>AP</u>	APP PHARMS	<u>0.25%</u>	<u>A070552</u>	<u>001</u>	May 21, 1986
<u>AP</u>		<u>0.25%</u>	<u>N018304</u>	<u>001</u>	
<u>AP</u>		<u>0.5%</u>	<u>A070553</u>	<u>001</u>	May 21, 1986
<u>AP</u>		<u>0.5%</u>	<u>N018304</u>	<u>002</u>	
<u>AP</u>		<u>0.75%</u>	<u>A070554</u>	<u>001</u>	May 21, 1986
<u>AP</u>		<u>0.75%</u>	<u>N018304</u>	<u>003</u>	

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>0.75%</u>	<u>A071810</u>	<u>001</u>	Dec 11, 1987
	<u>MARCAINE</u>				
<u>AP</u>	+ HOSPIRA	<u>0.75%</u>	<u>N018692</u>	<u>001</u>	May 04, 1984
	<u>SENSORCAINE</u>				
<u>AP</u>	APP PHARMS	<u>0.75%</u>	<u>A071202</u>	<u>001</u>	Apr 15, 1987

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

+	HOSPIRA	<u>0.25%;0.005MG/ML</u>	<u>A071165</u>	<u>001</u>	Jun 16, 1988
		<u>0.25%;0.005MG/ML</u>	<u>A071167</u>	<u>001</u>	Jun 16, 1988
+		<u>0.5%;0.005MG/ML</u>	<u>A071168</u>	<u>001</u>	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>	SEPTODONT	<u>0.5%;0.0091MG/ML</u>	<u>A077250</u>	<u>001</u>	Sep 27, 2006
	<u>BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE</u>				
<u>AP</u>	+ HOSPIRA	<u>0.5%;0.0091MG/ML</u>	<u>N022046</u>	<u>001</u>	Jul 13, 1983
	<u>MARCAINE HYDROCHLORIDE W/ EPINEPHRINE</u>				
<u>AP</u>	+ HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964</u>	<u>004</u>	

## PRESCRIPTION DRUG PRODUCT LIST

3 - 58 (of 393)

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

<u>AP</u>	+	HOSPIRA	<u>0.5%;0.0091MG/ML</u>	<u>N016964</u>	<u>008</u>	
-----------	---	---------	-------------------------	----------------	------------	--

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE

<u>AP</u>	+	HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964</u>	<u>013</u>	
-----------	---	---------	--------------------------	----------------	------------	--

<u>AP</u>	+		<u>0.5%;0.0091MG/ML</u>	<u>N016964</u>	<u>007</u>	
-----------	---	--	-------------------------	----------------	------------	--

<u>AP</u>	+		<u>0.75%;0.0091MG/ML</u>	<u>N016964</u>	<u>010</u>	
-----------	---	--	--------------------------	----------------	------------	--

SENSORCAINE

<u>AP</u>		APP PHARMS	<u>0.25%;0.0091MG/ML</u>	<u>A070966</u>	<u>001</u>	Oct 13, 1987
-----------	--	------------	--------------------------	----------------	------------	--------------

<u>AP</u>			<u>0.25%;0.0091MG/ML</u>	<u>A070967</u>	<u>001</u>	Oct 13, 1987
-----------	--	--	--------------------------	----------------	------------	--------------

<u>AP</u>			<u>0.5%;0.0091MG/ML</u>	<u>A070968</u>	<u>001</u>	Oct 13, 1987
-----------	--	--	-------------------------	----------------	------------	--------------

<u>AP</u>			<u>0.5%;0.0091MG/ML</u>	<u>N018304</u>	<u>004</u>	Sep 02, 1983
-----------	--	--	-------------------------	----------------	------------	--------------

<u>AP</u>			<u>0.75%;0.0091MG/ML</u>	<u>N018304</u>	<u>005</u>	Sep 02, 1983
-----------	--	--	--------------------------	----------------	------------	--------------

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENEX

<u>AP</u>	+	RECKITT BENCKISER	<u>EQ 0.3MG BASE/ML</u>	<u>N018401</u>	<u>001</u>	
-----------	---	-------------------	-------------------------	----------------	------------	--

BUPRENORPHINE HYDROCHLORIDE

<u>AP</u>		BEDFORD	<u>EQ 0.3MG BASE/ML</u>	<u>A076931</u>	<u>001</u>	Mar 02, 2005
-----------	--	---------	-------------------------	----------------	------------	--------------

<u>AP</u>		HOSPIRA	<u>EQ 0.3MG BASE/ML</u>	<u>A074137</u>	<u>001</u>	Jun 03, 1996
-----------	--	---------	-------------------------	----------------	------------	--------------

<u>AP</u>		PHARMAFORCE	<u>EQ 0.3MG BASE/ML</u>	<u>A078331</u>	<u>001</u>	Mar 27, 2007
-----------	--	-------------	-------------------------	----------------	------------	--------------

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

<u>AB</u>		ROXANE	<u>EQ 2MG BASE</u>	<u>A078633</u>	<u>001</u>	Oct 08, 2009
-----------	--	--------	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A078633</u>	<u>002</u>	Oct 08, 2009
-----------	--	--	--------------------	----------------	------------	--------------

SUBUTEX

<u>AB</u>		RECKITT BENCKISER	<u>EQ 2MG BASE</u>	<u>N020732</u>	<u>002</u>	Oct 08, 2002
-----------	--	-------------------	--------------------	----------------	------------	--------------

<u>AB</u>	+		<u>EQ 8MG BASE</u>	<u>N020732</u>	<u>003</u>	Oct 08, 2002
-----------	---	--	--------------------	----------------	------------	--------------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

## SUBOXONE

		RECKITT BENCKISER	2MG;0.5MG	N020733	001	Oct 08, 2002
--	--	-------------------	-----------	---------	-----	--------------

	+		8MG;2MG	N020733	002	Oct 08, 2002
--	---	--	---------	---------	-----	--------------

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

## APLENZIN

	+	BIOVAIL LABS INTL	174MG	N022108	001	Apr 23, 2008
--	---	-------------------	-------	---------	-----	--------------

			348MG	N022108	002	Apr 23, 2008
--	--	--	-------	---------	-----	--------------

			522MG	N022108	003	Apr 23, 2008
--	--	--	-------	---------	-----	--------------

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

<u>AB</u>		APOTEX INC	<u>75MG</u>	<u>A076143</u>	<u>001</u>	Jan 17, 2006
-----------	--	------------	-------------	----------------	------------	--------------

<u>AB</u>			<u>100MG</u>	<u>A076143</u>	<u>002</u>	Jan 17, 2006
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		MYLAN	<u>75MG</u>	<u>A075491</u>	<u>001</u>	Apr 17, 2000
-----------	--	-------	-------------	----------------	------------	--------------

<u>AB</u>			<u>100MG</u>	<u>A075491</u>	<u>002</u>	Apr 17, 2000
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		SANDOZ	<u>75MG</u>	<u>A075584</u>	<u>001</u>	Feb 07, 2000
-----------	--	--------	-------------	----------------	------------	--------------

<u>AB</u>			<u>100MG</u>	<u>A075584</u>	<u>002</u>	Feb 07, 2000
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		TEVA	<u>75MG</u>	<u>A075310</u>	<u>001</u>	Nov 29, 1999
-----------	--	------	-------------	----------------	------------	--------------

<u>AB</u>			<u>100MG</u>	<u>A075310</u>	<u>002</u>	Nov 29, 1999
-----------	--	--	--------------	----------------	------------	--------------

WELLBUTRIN

<u>AB</u>		GLAXOSMITHKLINE	<u>75MG</u>	<u>N018644</u>	<u>002</u>	Dec 30, 1985
-----------	--	-----------------	-------------	----------------	------------	--------------

<u>AB</u>	+		<u>100MG</u>	<u>N018644</u>	<u>003</u>	Dec 30, 1985
-----------	---	--	--------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 59 (of 393)

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

<u>AB1</u>	ACTAVIS	<u>150MG</u>	<u>A077455</u>	<u>002</u>	Mar 12, 2008
<u>AB1</u>	IMPAX LABS	<u>100MG</u>	<u>A075913</u>	<u>001</u>	Jan 28, 2004
<u>AB1</u>		<u>150MG</u>	<u>A075913</u>	<u>002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A076711</u>	<u>001</u>	Dec 03, 2004
<u>AB1</u>	SANDOZ	<u>100MG</u>	<u>A075932</u>	<u>001</u>	Nov 25, 2003
<u>AB1</u>		<u>150MG</u>	<u>A075932</u>	<u>002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A075932</u>	<u>003</u>	Jun 22, 2005
<u>AB1</u>	WATSON LABS	<u>100MG</u>	<u>A079095</u>	<u>001</u>	Mar 24, 2009
<u>AB1</u>		<u>150MG</u>	<u>A079095</u>	<u>002</u>	Mar 24, 2009
<u>AB1</u>		<u>200MG</u>	<u>A079095</u>	<u>003</u>	Mar 24, 2009

WELLBUTRIN SR

<u>AB1</u>	GLAXOSMITHKLINE	<u>100MG</u>	<u>N020358</u>	<u>002</u>	Oct 04, 1996
<u>AB1</u> +		<u>150MG</u>	<u>N020358</u>	<u>003</u>	Oct 04, 1996
<u>AB1</u>		<u>200MG</u>	<u>N020358</u>	<u>004</u>	Jun 14, 2002

BUPROPION HYDROCHLORIDE

<u>AB2</u>	ACTAVIS	<u>150MG</u>	<u>A077475</u>	<u>001</u>	Mar 12, 2008
<u>AB2</u>	IMPAX LABS	<u>150MG</u>	<u>A075914</u>	<u>001</u>	May 27, 2004
<u>AB2</u>	WATSON LABS	<u>150MG</u>	<u>A079094</u>	<u>001</u>	Mar 24, 2009

ZYBAN

<u>AB2</u> +	GLAXOSMITHKLINE	<u>150MG</u>	<u>N020711</u>	<u>003</u>	May 14, 1997
--------------	-----------------	--------------	----------------	------------	--------------

BUPROPION HYDROCHLORIDE

<u>AB3</u>	ACTAVIS	<u>150MG</u>	<u>A077285</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077285</u>	<u>002</u>	Aug 15, 2008
<u>AB3</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A077284</u>	<u>001</u>	Dec 14, 2006
<u>AB3</u>		<u>300MG</u>	<u>A077284</u>	<u>002</u>	Dec 14, 2006
<u>AB3</u>	IMPAX LABS	<u>150MG</u>	<u>A077415</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077415</u>	<u>002</u>	Dec 15, 2006
<u>AB3</u>	WATSON LABS	<u>150MG</u>	<u>A077715</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077715</u>	<u>002</u>	Jun 13, 2007

WELLBUTRIN XL

<u>AB3</u> +	BIOVAIL LABS INTL	<u>150MG</u>	<u>N021515</u>	<u>001</u>	Aug 28, 2003
<u>AB3</u>		<u>300MG</u>	<u>N021515</u>	<u>002</u>	Aug 28, 2003
	WELLBUTRIN SR GLAXOSMITHKLINE	50MG	N020358	001	Oct 04, 1996

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>5MG</u>	<u>N018731</u>	<u>001</u>	Sep 29, 1986
<u>AB</u>		<u>10MG</u>	<u>N018731</u>	<u>002</u>	Sep 29, 1986
<u>AB</u> +		<u>15MG</u>	<u>N018731</u>	<u>003</u>	Apr 22, 1996

BUSPIRONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>5MG</u>	<u>A075388</u>	<u>001</u>	May 09, 2002
<u>AB</u>		<u>10MG</u>	<u>A075388</u>	<u>002</u>	May 09, 2002
<u>AB</u>		<u>15MG</u>	<u>A075388</u>	<u>003</u>	May 09, 2002
<u>AB</u>		<u>30MG</u>	<u>A078302</u>	<u>001</u>	Dec 17, 2007
<u>AB</u>	APOTEX	<u>5MG</u>	<u>A075521</u>	<u>001</u>	Apr 05, 2002
<u>AB</u>		<u>10MG</u>	<u>A075521</u>	<u>002</u>	Apr 05, 2002
<u>AB</u>		<u>15MG</u>	<u>A075521</u>	<u>003</u>	Apr 05, 2002
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A078246</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A078246</u>	<u>002</u>	Feb 27, 2009
<u>AB</u>		<u>15MG</u>	<u>A078246</u>	<u>003</u>	Feb 27, 2009
<u>AB</u>		<u>30MG</u>	<u>A078246</u>	<u>004</u>	Feb 27, 2009
<u>AB</u>	EGIS	<u>5MG</u>	<u>A075119</u>	<u>001</u>	Mar 14, 2002
<u>AB</u>		<u>10MG</u>	<u>A075119</u>	<u>002</u>	Mar 14, 2002
<u>AB</u>		<u>15MG</u>	<u>A075119</u>	<u>003</u>	Jan 23, 2003
<u>AB</u>	KV PHARM	<u>5MG</u>	<u>A075572</u>	<u>001</u>	Feb 27, 2002

## PRESCRIPTION DRUG PRODUCT LIST

3 - 60 (of 393)

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>	KV PHARM	<u>10MG</u>	<u>A075572</u>	<u>002</u>	Feb 27, 2002
<u>AB</u>		<u>15MG</u>	<u>A075572</u>	<u>003</u>	Feb 27, 2002
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A075272</u>	<u>001</u>	Mar 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075467</u>	<u>001</u>	Feb 28, 2002
<u>AB</u>		<u>7.5MG</u>	<u>A075467</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A075272</u>	<u>002</u>	Mar 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075467</u>	<u>003</u>	Feb 28, 2002
<u>AB</u>		<u>15MG</u>	<u>A075272</u>	<u>003</u>	Mar 28, 2001
<u>AB</u>		<u>15MG</u>	<u>A075467</u>	<u>004</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A076008</u>	<u>001</u>	Jun 28, 2001
<u>AB</u>	TEVA	<u>5MG</u>	<u>A075022</u>	<u>001</u>	Feb 28, 2002
<u>AB</u>		<u>10MG</u>	<u>A075022</u>	<u>002</u>	Feb 28, 2002
<u>AB</u>		<u>15MG</u>	<u>A075022</u>	<u>003</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A075022</u>	<u>004</u>	Mar 25, 2004
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A074253</u>	<u>001</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A074253</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>15MG</u>	<u>A074253</u>	<u>003</u>	Mar 13, 2002
<u>AB</u>	ZENITH GOLDLINE	<u>5MG</u>	<u>A075385</u>	<u>001</u>	Mar 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075385</u>	<u>002</u>	Mar 01, 2002
<u>AB</u>		<u>15MG</u>	<u>A075385</u>	<u>003</u>	Mar 01, 2002

BUSULFAN

INJECTABLE; INJECTION

BUSULFEX

+ OTSUKA PHARM 6MG/ML N020954 001 Feb 04, 1999

TABLET; ORAL

MYLERAN

+ GLAXOSMITHKLINE 2MG N009386 001

BUTABARBITAL SODIUM

ELIXIR; ORAL

BUTISOL SODIUM

+ MEDA PHARMS 30MG/5ML A085380 001

TABLET; ORAL

BUTISOL SODIUM

+ MEDA PHARMS 30MG N000793 004

+ 50MG N000793 003

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX

+ MYLAN BERTEK 1% N020524 001 Oct 18, 1996

MENTAX-TC

+ MYLAN BERTEK 1% N021408 001 Oct 17, 2002

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

GYNAZOLE-1

+ KV PHARM 2% N019881 001 Feb 07, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

<u>AP</u>	APOTEX INC	<u>2MG/ML</u>	<u>A075697</u>	<u>001</u>	Oct 23, 2001
<u>AP</u>	BEDFORD	<u>2MG/ML</u>	<u>A075046</u>	<u>001</u>	Aug 12, 1998
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078400</u>	<u>001</u>	May 01, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 61 (of 393)

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

<u>AP</u>	HIKMA FARMACEUTICA	<u>2MG/ML</u>	<u>A078247</u>	<u>001</u>	Apr 29, 2009
<u>AP</u>		<u>2MG/ML</u>	<u>A078400</u>	<u>002</u>	May 01, 2009
<u>BUTORPHANOL TARTRATE PRESERVATIVE FREE</u>					
<u>AP</u>	APOTEX INC	<u>1MG/ML</u>	<u>A075695</u>	<u>001</u>	Oct 23, 2001
<u>AP</u>		<u>2MG/ML</u>	<u>A075695</u>	<u>002</u>	Oct 23, 2001
<u>AP</u>	BEDFORD	<u>1MG/ML</u>	<u>A075045</u>	<u>001</u>	Aug 12, 1998
<u>AP</u>		<u>2MG/ML</u>	<u>A075045</u>	<u>002</u>	Aug 12, 1998
<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A074626</u>	<u>001</u>	Jan 23, 1997
<u>AP</u>		<u>2MG/ML</u>	<u>A074626</u>	<u>002</u>	Jan 23, 1997
<u>STADOL</u>					
<u>AP</u>	+ APOTHECON	<u>2MG/ML</u>	<u>N017857</u>	<u>004</u>	
<u>STADOL PRESERVATIVE FREE</u>					
<u>AP</u>	+ APOTHECON	<u>1MG/ML</u>	<u>N017857</u>	<u>001</u>	
<u>AP</u>	+	<u>2MG/ML</u>	<u>N017857</u>	<u>002</u>	

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

<u>AB</u>	+ MYLAN	<u>1MG/SPRAY</u>	<u>A075759</u>	<u>001</u>	Aug 08, 2001
<u>AB</u>	NOVEX	<u>1MG/SPRAY</u>	<u>A075499</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>	ROXANE	<u>1MG/SPRAY</u>	<u>A075824</u>	<u>001</u>	Mar 12, 2002

CABERGOLINE

TABLET; ORAL

CABERGOLINE

<u>AB</u>	COBALT LABS INC	<u>0.5MG</u>	<u>A078035</u>	<u>001</u>	Apr 21, 2008
<u>AB</u>	IVAX PHARMS INC	<u>0.5MG</u>	<u>A077750</u>	<u>001</u>	Mar 07, 2007
<u>AB</u>	+ PAR PHARM	<u>0.5MG</u>	<u>A076310</u>	<u>001</u>	Dec 29, 2005
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A077843</u>	<u>001</u>	Jul 03, 2007

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAF CIT

<u>AP</u>	+ MEAD JOHNSON	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N020793</u>	<u>001</u>	Sep 21, 1999
<u>CAFFEINE CITRATE</u>					
<u>AP</u>	APP PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077997</u>	<u>001</u>	Jul 20, 2007
<u>AP</u>	LUITPOLD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077906</u>	<u>001</u>	May 15, 2007
<u>AP</u>	PADDOCK LABS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077233</u>	<u>001</u>	Sep 21, 2006
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090077</u>	<u>001</u>	Sep 30, 2009

SOLUTION; ORAL

CAF CIT

<u>AA</u>	+ MEAD JOHNSON	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N020793</u>	<u>002</u>	Apr 12, 2000
<u>CAFFEINE CITRATE</u>					
<u>AA</u>	APP PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A078002</u>	<u>001</u>	Jan 31, 2008
<u>AA</u>	LUITPOLD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090064</u>	<u>001</u>	Nov 20, 2009
<u>AA</u>	PHARMAFORCE	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077304</u>	<u>001</u>	Sep 21, 2006
<u>AA</u>	SUN PHARM INDS LTD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090357</u>	<u>001</u>	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

+	G AND W LABS	100MG;2MG	A086557	001	Oct 04, 1983
---	--------------	-----------	---------	-----	--------------

TABLET; ORAL

CAF ERGOT

<u>AA</u>	+ SANDOZ	<u>100MG;1MG</u>	<u>A084294</u>	<u>001</u>	
<u>ERGOTAMINE TARTRATE AND CAFFEINE</u>					
<u>AA</u>	MIKART	<u>100MG;1MG</u>	<u>A040590</u>	<u>001</u>	Sep 16, 2005
<u>AA</u>	WEST WARD	<u>100MG;1MG</u>	<u>A040510</u>	<u>001</u>	Sep 17, 2004



## PRESCRIPTION DRUG PRODUCT LIST

3 - 62 (of 393)

CALCIPOTRIENE

CREAM; TOPICAL

DOVONEX

+ LEO PHARM 0.005% N020554 001 Jul 22, 1996

SOLUTION; TOPICAL

CALCIPOTRIENEAT HI TECH PHARMA 0.005% A077579 001 Nov 19, 2009AT NYCOMED US 0.005% A078305 001 May 06, 2008AT TOLMAR 0.005% A077029 001 Nov 20, 2009DOVONEXAT + LEO PHARM 0.005% N020611 001 Mar 03, 1997CALCITONIN SALMON RECOMBINANT

SPRAY, METERED; NASAL

FORTICAL

+ UPSHER SMITH 200 IU/SPRAY N021406 001 Aug 12, 2005

CALCITONIN, SALMON

INJECTABLE; INJECTION

MIACALCIN

+ NOVARTIS 200 IU/ML N017808 002 Mar 29, 1991

SPRAY, METERED; NASAL

CALCITONIN-SALMONAB APOTEX INC 200 IU/SPRAY A076396 001 Nov 17, 2008AB PAR PHARM 200 IU/SPRAY A076979 001 Jun 08, 2009MIACALCINAB + NOVARTIS 200 IU/SPRAY N020313 002 Aug 17, 1995CALCITRIOL

CAPSULE; ORAL

CALCITRIOLAB ROXANE 0.25MCG A076917 001 Mar 27, 2006AB TEVA 0.25MCG A075765 001 Oct 12, 2001AB 0.5MCG A075765 002 Oct 12, 2001ROCALTROLAB VALIDUS PHARMS 0.25MCG N018044 001AB + 0.5MCG N018044 002

INJECTABLE; INJECTION

CALCIJEXAP + ABBOTT 0.001MG/ML N018874 001 Sep 25, 1986AP + 0.002MG/ML N018874 002 Sep 25, 1986CALCITRIOLAP AKORN 0.001MG/ML A078066 001 Jan 29, 2008AP 0.002MG/ML A078066 002 Jan 29, 2008AP APP PHARMS 0.001MG/ML A075836 001 Dec 31, 2002AP 0.002MG/ML A075836 002 Dec 31, 2002AP FRESENIUS MEDCL 0.001MG/ML A075766 001 Feb 20, 2003AP 0.002MG/ML A075766 002 Feb 20, 2003AP GENIX THERAP 0.001MG/ML A077102 001 Feb 08, 2006AP LUITPOLD 0.001MG/ML A075746 001 Sep 26, 2003AP 0.002MG/ML A075746 002 Sep 26, 2003AP LYNE 0.001MG/ML A076206 001 Sep 17, 2003AP TEVA PARENTERAL 0.001MG/ML A075823 001 Mar 31, 2003AP 0.002MG/ML A075823 002 Mar 31, 2003

OINTMENT; TOPICAL

VECTICAL

+ GALDERMA LABS LP 3MCG/GM N022087 001 Jan 23, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 63 (of 393)

CALCITRIOL

SOLUTION; ORAL

CALCITRIOL

<u>AA</u>	ROXANE	<u>1MCG/ML</u>	<u>A076242</u>	<u>001</u>	Jul 18, 2003
-----------	--------	----------------	----------------	------------	--------------

ROCALTRON

<u>AA</u>	+ VALIDUS PHARMS	<u>1MCG/ML</u>	<u>N021068</u>	<u>001</u>	Nov 20, 1998
-----------	------------------	----------------	----------------	------------	--------------

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

<u>AB</u>	ROXANE	<u>EQ 169MG CALCIUM</u>	<u>A077728</u>	<u>001</u>	Feb 26, 2008
-----------	--------	-------------------------	----------------	------------	--------------

PHOSLO GELCAPS

<u>AB</u>	+ FRESENIUS MEDCL	<u>EQ 169MG CALCIUM</u>	<u>N021160</u>	<u>003</u>	Apr 02, 2001
-----------	-------------------	-------------------------	----------------	------------	--------------

TABLET; ORAL

ELIPHOS

	+ CYPRESS PHARM	EQ 169MG CALCIUM	A078502	001	Nov 25, 2008
--	-----------------	------------------	---------	-----	--------------

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

	+ HOSPIRA	100MG/ML	N021117	001	Jan 28, 2000
--	-----------	----------	---------	-----	--------------

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

BSS PLUS

<u>AT</u>	+ ALCON	<u>0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML</u>	<u>N018469</u>	<u>001</u>	
-----------	---------	--	----------------	------------	--

ENDOSOL EXTRA

<u>AT</u>	+ AKORN	<u>0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML</u>	<u>N020079</u>	<u>001</u>	Nov 27, 1991
-----------	---------	--	----------------	------------	--------------

NAVSTEL

	+ ALCON	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N022193	001	Jul 24, 2008
--	---------	---	---------	-----	--------------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

	+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML	N021703	010	Oct 10, 2008
--	----------------------	--	---------	-----	--------------

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

	+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML	N021703	011	Oct 10, 2008
--	----------------------	--	---------	-----	--------------

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

	+ GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML	N021703	013	Oct 10, 2008
--	----------------------	---	---------	-----	--------------

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

	+ GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML	N021703	006	Oct 25, 2006
--	----------------------	---	---------	-----	--------------

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

	+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML	N021703	002	Oct 25, 2006
--	----------------------	--	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 64 (of 393)

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE;  
SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML; 2.03GM/1000ML;0.157GM/1000ML;3.09GM/100 0ML;6.46GM/1000ML	N021703 003	Oct 25, 2006
----------------------	---	-------------	--------------

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.4 4GM/1000ML;0.314GM/1000ML;3.09GM/1000ML ;6.46GM/1000ML	N021703 015	Oct 10, 2008
----------------------	--	-------------	--------------

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML; 3.05GM/1000ML;0.314GM/1000ML;3.09GM/100 0ML;6.46GM/1000ML	N021703 004	Oct 25, 2006
----------------------	---	-------------	--------------

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44 GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46 GM/1000ML	N021703 014	Oct 10, 2008
----------------------	---	-------------	--------------

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2 .03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6 .46GM/1000ML	N021703 001	Oct 25, 2006
----------------------	--	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE;  
SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/1 00ML;330MG/100ML;88MG/100ML	N019864 001	Jun 10, 1993
-----------	--	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE;  
SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/10 0ML;640MG/100ML;500MG/100ML;74MG/100ML	N019867 001	Dec 20, 1993
-----------	---	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE;  
SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;119MG/1 00ML;161MG/100ML;94MG/100ML;138MG/100ML	N017390 001	
-------------------	--	-------------	--

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

+ B BRAUN	510MG/100ML;30GM/100ML;200MG/100ML;9.4G M/100ML;11GM/100ML	N018807 003	Aug 26, 1983
-----------	---	-------------	--------------

+	510MG/100ML;30GM/100ML;200MG/100ML;9.2G M/100ML;9.6GM/100ML	N018807 001	Aug 26, 1983
---	--	-------------	--------------

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

+ B BRAUN	510MG/100ML;50GM/100ML;200MG/100ML;9.4G M/100ML;11GM/100ML	N018807 004	Aug 26, 1983
-----------	---	-------------	--------------

+	510MG/100ML;50GM/100ML;200MG/100ML;9.2G M/100ML;9.6GM/100ML	N018807 002	Aug 26, 1983
---	--	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	<u>N018379 002</u>
-----------	-----------------	---	--------------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 65 (of 393)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

<u>DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>		
<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u> <u>N018883</u> <u>001</u> Nov 30, 1984
<u>DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER</u>		
<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u> <u>N018883</u> <u>004</u> Nov 30, 1984
<u>DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER</u>		
<u>AT</u>	FRESENIUS MEDCL	<u>18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u> <u>N020171</u> <u>001</u> Aug 19, 1992
<u>DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>		
<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u> <u>N018379</u> <u>003</u>
<u>AT</u>		<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u> <u>N018883</u> <u>002</u> Nov 30, 1984
<u>DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER</u>		
<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u> <u>N018883</u> <u>005</u> Nov 30, 1984
<u>DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER</u>		
<u>AT</u>	FRESENIUS MEDCL	<u>18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u> <u>N020171</u> <u>002</u> Aug 19, 1992
<u>DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>		
<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u> <u>N018379</u> <u>007</u> Jun 24, 1988
<u>DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>		
<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML; 567MG/100ML;392MG/100ML</u> <u>N018379</u> <u>001</u>
<u>AT</u>		<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML; 567MG/100ML;392MG/100ML</u> <u>N018883</u> <u>003</u> Nov 30, 1984
<u>DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER</u>		
<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML</u> <u>N018883</u> <u>006</u> Nov 30, 1984
<u>DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER</u>		
<u>AT</u>	FRESENIUS MEDCL	<u>18.4MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML</u> <u>N020171</u> <u>003</u> Aug 19, 1992
<u>DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>		
<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u> <u>N018379</u> <u>004</u> Jul 07, 1982
<u>DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>		
<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u> <u>N018379</u> <u>005</u> Jul 07, 1982
<u>DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>		
<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u> <u>N018379</u> <u>008</u> Jun 24, 1988
<u>DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>		
<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML</u> <u>N018379</u> <u>006</u> Jul 07, 1982
<u>DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>		
<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u> <u>N017512</u> <u>001</u>
<u>DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>		
<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u> <u>N017512</u> <u>003</u>
<u>DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>		
<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML; 567MG/100ML;392MG/100ML</u> <u>N017512</u> <u>002</u>
<u>DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>		
<u>AT</u>	BAXTER HLTHCARE	<u>18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u> <u>N020183</u> <u>001</u> Dec 04, 1992
<u>DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>		
<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u> <u>N017512</u> <u>007</u> Jul 09, 1984

## PRESCRIPTION DRUG PRODUCT LIST

3 - 66 (of 393)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

<u>DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>							
<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5</u> <u>67MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>008</u>		Jul 09, 1984	
<u>DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>							
<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;5</u> <u>67MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>010</u>		Nov 18, 1985	
<u>DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>							
<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;</u> <u>567MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>009</u>		Jul 09, 1984	
<u>DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>							
<u>AT</u>	BAXTER HLTHCARE	<u>18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N017512</u>	<u>004</u>			
<u>AT</u>		<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N020163</u>	<u>001</u>		Dec 04, 1992	
<u>DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>							
<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N017512</u>	<u>005</u>			
<u>AT</u>		<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N020163</u>	<u>002</u>		Dec 04, 1992	
<u>DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>							
<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N017512</u>	<u>011</u>		Nov 18, 1985	
<u>DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>							
<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;</u> <u>538MG/100ML;448MG/100ML</u>	<u>N017512</u>	<u>006</u>			
<u>AT</u>		<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;</u> <u>538MG/100ML;448MG/100ML</u>	<u>N020163</u>	<u>003</u>		Dec 04, 1992	
<u>INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>							
<u>AT</u>	FRESENIUS	<u>18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N020374</u>	<u>001</u>		Jun 13, 1994	
<u>INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>							
<u>AT</u>	FRESENIUS	<u>18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N020374</u>	<u>002</u>		Jun 13, 1994	
<u>INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>							
<u>AT</u>	FRESENIUS	<u>18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;</u> <u>538MG/100ML;448MG/100ML</u>	<u>N020374</u>	<u>004</u>		Jun 13, 1994	
<u>DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>							
	B BRAUN	26MG/100ML;1.5GM/100ML;5MG/100ML;530MG/ 100ML;450MG/100ML	N018460	007		Jan 29, 1986	
<u>DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>							
	B BRAUN	26MG/100ML;2.5GM/100ML;5MG/100ML;530MG/ 100ML;450MG/100ML	N018460	005		Nov 02, 1983	
<u>DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>							
	B BRAUN	26MG/100ML;4.25GM/100ML;5MG/100ML;530MG /100ML;450MG/100ML	N018460	009		Jan 29, 1986	
<u>DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>							
	BAXTER HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML	N020183	002		Dec 04, 1992	
<u>DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>							
	BAXTER HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML	N020183	003		Dec 04, 1992	
<u>DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>							
	BAXTER HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML	N020183	004		Dec 04, 1992	
<u>INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>							
	FRESENIUS	18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML	N020374	003		Jun 13, 1994	

## PRESCRIPTION DRUG PRODUCT LIST

3 - 67 (of 393)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATEINJECTABLE; INTRATHECAL  
ELLIOTTS B SOLUTION+ QOL MEDCL 0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9 N020577 001 Sep 27, 1996  
MG/ML;7.3MG/ML;0.2MG/MLCALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

+ B BRAUN 20MG/100ML;5GM/100ML;30MG/100ML;380MG/1 N018258 001  
00ML;600MG/100MLCALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINERAP HOSPIRA 33MG/100ML;5GM/100ML;30MG/100ML;860MG/1 N018254 001  
00MLDEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINERAP B BRAUN 33MG/100ML;5GM/100ML;30MG/100ML;860MG/1 N020000 001 Apr 17, 1992  
00MLAP BAXTER HLTHCARE 33MG/100ML;5GM/100ML;30MG/100ML;860MG/1 N016695 001  
00MLCALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINERAP HOSPIRA 20MG/100ML;5GM/100ML;30MG/100ML;600MG/1 N017608 001  
00ML;310MG/100MLDEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINERAP B BRAUN 20MG/100ML;5GM/100ML;30MG/100ML;600MG/1 N019634 003 Feb 24, 1988  
00ML;310MG/100MLLACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINERAP BAXTER HLTHCARE 20MG/100ML;5GM/100ML;30MG/100ML;600MG/1 N016679 001  
00ML;310MG/100MLPOTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINERAP BAXTER HLTHCARE 20MG/100ML;5GM/100ML;254MG/100ML;600MG/1 N019367 006 Apr 05, 1985  
100ML;310MG/100MLPOTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINERAP BAXTER HLTHCARE 20MG/100ML;5GM/100ML;179MG/100ML;600MG/1 N019367 004 Apr 05, 1985  
100ML;310MG/100MLAP 20MG/100ML;5GM/100ML;328MG/100ML;600MG/1 N019367 005 Apr 05, 1985  
100ML;310MG/100MLAP HOSPIRA 20MG/100ML;5GM/100ML;179MG/100ML;600MG/1 N019685 002 Oct 17, 1988  
100ML;310MG/100MLAP 20MG/100ML;5GM/100ML;328MG/100ML;600MG/1 N019685 008 Oct 17, 1988  
100ML;310MG/100MLPOTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINERAP BAXTER HLTHCARE 20MG/100ML;5GM/100ML;254MG/100ML;600MG/1 N019367 007 Apr 05, 1985  
100ML;310MG/100MLPOTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINERAP BAXTER HLTHCARE 20MG/100ML;5GM/100ML;328MG/100ML;600MG/1 N019367 008 Apr 05, 1985  
100ML;310MG/100MLAP HOSPIRA 20MG/100ML;5GM/100ML;328MG/100ML;600MG/1 N019685 004 Oct 17, 1988  
100ML;310MG/100ML

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN 10MG/100ML;2.5GM/100ML;15MG/100ML;300MG N019634 001 Feb 24, 1988  
/100ML;160MG/100ML

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

BAXTER HLTHCARE 20MG/100ML;5GM/100ML;105MG/100ML;600MG/ N019367 002 Apr 05, 1985  
100ML;310MG/100ML20MG/100ML;5GM/100ML;179MG/100ML;600MG/ N019367 003 Apr 05, 1985  
100ML;310MG/100ML

## PRESCRIPTION DRUG PRODUCT LIST

3 - 68 (of 393)

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER  
 BAXTER HLTHCARE 20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML N019367 001 Apr 05, 1985

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER  
 + HOSPIRA 16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML N018895 001 Jul 20, 1984

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER  
 + B BRAUN 35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML N019718 001 Sep 29, 1989

SOLUTION; IRRIGATION

BALANCED SALT

AT AKORN 0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML A075503 001 Sep 27, 2006

BSS

AT + ALCON 0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML N020742 001 Dec 10, 1997

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER  
 + BAXTER HLTHCARE 36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML N017438 001

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML A075323 001 Apr 21, 2000

PLEGISOL IN PLASTIC CONTAINER

AT + HOSPIRA 17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML N018608 001 Feb 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP B BRAUN 33MG/100ML;30MG/100ML;860MG/100ML N020002 001 Apr 17, 1992  
AP BAXTER HLTHCARE 33MG/100ML;30MG/100ML;860MG/100ML N016693 001  
AP HOSPIRA 33MG/100ML;30MG/100ML;860MG/100ML N018251 001

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT B BRAUN 33MG/100ML;30MG/100ML;860MG/100ML N018156 001  
AT BAXTER HLTHCARE 33MG/100ML;30MG/100ML;860MG/100ML N018495 001 Feb 19, 1982  
AT HOSPIRA 33MG/100ML;30MG/100ML;860MG/100ML N017635 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP B BRAUN 20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML N019632 001 Feb 29, 1988

## PRESCRIPTION DRUG PRODUCT LIST

3 - 69 (of 393)

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG</u> <u>/100ML</u>	<u>N016682</u>	<u>001</u>	
<u>AP</u>	HOSPIRA	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG</u> <u>/100ML</u>	<u>N017641</u>	<u>001</u>	

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG</u> <u>/100ML</u>	<u>N018681</u>	<u>001</u>	Dec 27, 1982
<u>AT</u>	BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG</u> <u>/100ML</u>	<u>N018494</u>	<u>001</u>	Feb 19, 1982
<u>AT</u>		<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG</u> <u>/100ML</u>	<u>N018921</u>	<u>001</u>	Apr 03, 1984
<u>AT</u>		<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG</u> <u>/100ML</u>	<u>N019933</u>	<u>001</u>	Aug 29, 1989
<u>AT</u>	HOSPIRA	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG</u> <u>/100ML</u>	<u>N019416</u>	<u>001</u>	Jan 17, 1986

CALFACTANT

SUSPENSION; INTRATRACHEAL

INFASURF PRESERVATIVE FREE

+	ONY	35MG/ML	N020521	001	Jul 01, 1998
---	-----	---------	---------	-----	--------------

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

	ASTRAZENECA	4MG	N020838	001	Jun 04, 1998
		8MG	N020838	002	Jun 04, 1998
		16MG	N020838	003	Jun 04, 1998
+		32MG	N020838	004	Jun 04, 1998

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

	ASTRAZENECA	16MG; 12.5MG	N021093	001	Sep 05, 2000
		32MG; 12.5MG	N021093	002	Sep 05, 2000
+		32MG; 25MG	N021093	003	May 16, 2008

CAPECITABINE

TABLET; ORAL

XELODA

	HOFFMANN LA ROCHE	150MG	N020896	001	Apr 30, 1998
+		500MG	N020896	002	Apr 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION

CAPASTAT SULFATE

+	AKORN	EQ 1GM BASE/VIAL	N050095	001	
---	-------	------------------	---------	-----	--

CAPSAICIN

PATCH; TOPICAL

QUTENZA

+	NEUROGESX	8%	N022395	001	Nov 16, 2009
---	-----------	----	---------	-----	--------------

CAPTOPRIL

TABLET; ORAL

CAPOTEN

<u>AB</u>	PAR PHARM	12.5MG	<u>N018343</u>	<u>005</u>	Jan 17, 1985
-----------	-----------	--------	----------------	------------	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 96 of 1114**



## PRESCRIPTION DRUG PRODUCT LIST

3 - 70 (of 393)

CAPTOPRIL

TABLET; ORAL

<u>CAPOTEN</u>					
<u>AB</u>	PAR PHARM	<u>25MG</u>	<u>N018343</u>	<u>002</u>	
<u>AB</u>		<u>50MG</u>	<u>N018343</u>	<u>001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N018343</u>	<u>003</u>	
<u>CAPTOPRIL</u>					
<u>AB</u>	APOTEX	<u>12.5MG</u>	<u>A074737</u>	<u>001</u>	Oct 28, 1998
<u>AB</u>		<u>25MG</u>	<u>A074737</u>	<u>002</u>	Oct 28, 1998
<u>AB</u>		<u>50MG</u>	<u>A074737</u>	<u>003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A074737</u>	<u>004</u>	Oct 28, 1998
<u>AB</u>	KALI LABS	<u>12.5MG</u>	<u>A074477</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074477</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074477</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074477</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A074434</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074434</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074434</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074434</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	SANDOZ	<u>12.5MG</u>	<u>A074363</u>	<u>001</u>	Nov 09, 1995
<u>AB</u>		<u>25MG</u>	<u>A074363</u>	<u>002</u>	Nov 09, 1995
<u>AB</u>		<u>50MG</u>	<u>A074363</u>	<u>003</u>	Nov 09, 1995
<u>AB</u>		<u>100MG</u>	<u>A074363</u>	<u>004</u>	Nov 09, 1995
<u>AB</u>	STASON	<u>12.5MG</u>	<u>A074677</u>	<u>004</u>	May 30, 1997
<u>AB</u>		<u>25MG</u>	<u>A074677</u>	<u>002</u>	May 30, 1997
<u>AB</u>		<u>50MG</u>	<u>A074677</u>	<u>001</u>	May 30, 1997
<u>AB</u>		<u>100MG</u>	<u>A074677</u>	<u>003</u>	May 30, 1997
<u>AB</u>	TEVA	<u>12.5MG</u>	<u>A074322</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>		<u>12.5MG</u>	<u>A074483</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074322</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074483</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074322</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074483</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074322</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074483</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	WATSON LABS	<u>12.5MG</u>	<u>A074386</u>	<u>001</u>	May 23, 1996
<u>AB</u>		<u>12.5MG</u>	<u>A074451</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074386</u>	<u>002</u>	May 23, 1996
<u>AB</u>		<u>25MG</u>	<u>A074451</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074386</u>	<u>003</u>	May 23, 1996
<u>AB</u>		<u>50MG</u>	<u>A074451</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074386</u>	<u>004</u>	May 23, 1996
<u>AB</u>		<u>100MG</u>	<u>A074451</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	WEST WARD	<u>12.5MG</u>	<u>A074505</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074505</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074505</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074505</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	WOCKHARDT	<u>12.5MG</u>	<u>A074532</u>	<u>001</u>	Mar 28, 1997
<u>AB</u>		<u>25MG</u>	<u>A074532</u>	<u>002</u>	Mar 28, 1997
<u>AB</u>		<u>50MG</u>	<u>A074532</u>	<u>003</u>	Mar 28, 1997
<u>AB</u>		<u>100MG</u>	<u>A074532</u>	<u>004</u>	Mar 28, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

<u>CAPOZIDE 25/15</u>					
<u>AB</u>	APOTHECON	<u>25MG;15MG</u>	<u>N018709</u>	<u>001</u>	Oct 12, 1984
<u>AB</u>		<u>CAPOZIDE 25/25</u>			
<u>AB</u>	+	<u>25MG;25MG</u>	<u>N018709</u>	<u>002</u>	Oct 12, 1984
<u>AB</u>		<u>CAPOZIDE 50/15</u>			
<u>AB</u>	+	<u>50MG;15MG</u>	<u>N018709</u>	<u>004</u>	Oct 12, 1984

## PRESCRIPTION DRUG PRODUCT LIST

3 - 71 (of 393)

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

<u>CAPOZIDE 50/25</u>					
<u>AB</u>	APOTHECON	<u>50MG;25MG</u>	<u>N018709</u>	<u>003</u>	Oct 12, 1984
<u>CAPTOPRIL AND HYDROCHLOROTHIAZIDE</u>					
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG;15MG</u>	<u>A075055</u>	<u>001</u>	Jun 18, 1998
<u>AB</u>		<u>25MG;25MG</u>	<u>A075055</u>	<u>002</u>	Jun 18, 1998
<u>AB</u>		<u>50MG;15MG</u>	<u>A075055</u>	<u>004</u>	Jun 18, 1998
<u>AB</u>		<u>50MG;25MG</u>	<u>A075055</u>	<u>003</u>	Jun 18, 1998
<u>AB</u>	MYLAN	<u>25MG;15MG</u>	<u>A074896</u>	<u>001</u>	Dec 29, 1997
<u>AB</u>		<u>25MG;25MG</u>	<u>A074896</u>	<u>002</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;15MG</u>	<u>A074896</u>	<u>004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;25MG</u>	<u>A074896</u>	<u>003</u>	Dec 29, 1997
<u>AB</u>	TEVA	<u>25MG;15MG</u>	<u>A074827</u>	<u>001</u>	Dec 29, 1997
<u>AB</u>		<u>25MG;25MG</u>	<u>A074827</u>	<u>002</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;15MG</u>	<u>A074827</u>	<u>004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;25MG</u>	<u>A074827</u>	<u>003</u>	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

MIOSTAT

+ ALCON

0.01%

N016968 001

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

SHIRE

100MG

N020712 003

Sep 30, 1997

200MG

N020712 001

Sep 30, 1997

+

300MG

N020712 002

Sep 30, 1997

EQUETRO

VALIDUS PHARMS INC

100MG

N021710 001

Dec 10, 2004

200MG

N021710 002

Dec 10, 2004

+

300MG

N021710 003

Dec 10, 2004

SUSPENSION; ORAL

CARBAMAZEPINE

<u>AB</u>	MORTON GROVE	<u>100MG/5ML</u>	<u>A075714</u>	<u>001</u>	Jun 05, 2002
<u>TEGRETOL</u>					
<u>AB</u>	+ NOVARTIS	<u>100MG/5ML</u>	<u>N018927</u>	<u>001</u>	Dec 18, 1987
<u>TERIL</u>					
<u>AB</u>	TARO	<u>100MG/5ML</u>	<u>A076729</u>	<u>001</u>	Sep 20, 2004

TABLET; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A075948</u>	<u>001</u>	Feb 27, 2002
<u>AB</u>	INWOOD LABS	<u>200MG</u>	<u>A070231</u>	<u>001</u>	Aug 14, 1986
<u>AB</u>	TARO	<u>200MG</u>	<u>A074649</u>	<u>001</u>	Oct 03, 1996
<u>AB</u>	TORRENT PHARMS	<u>200MG</u>	<u>A077272</u>	<u>002</u>	Dec 07, 2005
<u>EPITOL</u>					
<u>AB</u>	TEVA	<u>200MG</u>	<u>A070541</u>	<u>001</u>	Sep 17, 1986
<u>TEGRETOL</u>					
<u>AB</u>	+ NOVARTIS	<u>200MG</u>	<u>N016608</u>	<u>001</u>	
<u>CARBAMAZEPINE</u>					
	TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005
		300MG	A077272	003	Dec 07, 2005
		400MG	A077272	004	Dec 07, 2005

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

<u>AB</u>	TARO PHARM INDS	<u>100MG</u>	<u>A075687</u>	<u>001</u>	Oct 24, 2000
<u>AB</u>	TORRENT PHARMS	<u>100MG</u>	<u>A075712</u>	<u>001</u>	Jul 05, 2001
<u>EPITOL</u>					
<u>AB</u>	TEVA	100MG	A073524	001	Jul 29, 1992

## PRESCRIPTION DRUG PRODUCT LIST

3 - 72 (of 393)

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL

TEGRETOL

<u>AB</u>	+ NOVARTIS	<u>100MG</u>	<u>N018281</u>	<u>001</u>	
	CARBAMAZEPINE				
	+ TARO PHARM INDS	200MG	A075687	002	Jul 29, 2002

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

<u>AB</u>	TARO	<u>100MG</u>	<u>A078115</u>	<u>001</u>	Mar 31, 2009
<u>AB</u>		<u>200MG</u>	<u>A078115</u>	<u>002</u>	Mar 31, 2009
<u>AB</u>		<u>400MG</u>	<u>A078115</u>	<u>003</u>	Mar 31, 2009
	<u>TEGRETOL-XR</u>				
<u>AB</u>	NOVARTIS	<u>100MG</u>	<u>N020234</u>	<u>001</u>	Mar 25, 1996
<u>AB</u>		<u>200MG</u>	<u>N020234</u>	<u>002</u>	Mar 25, 1996
<u>AB</u>	+	<u>400MG</u>	<u>N020234</u>	<u>003</u>	Mar 25, 1996

CARBIDOPA

TABLET; ORAL

## LODOSYN

	+ BRISTOL MYERS SQUIBB	25MG	N017830	001	
--	------------------------	------	---------	-----	--

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

## STALEVO 100

	ORION	25MG;200MG;100MG	N021485	002	Jun 11, 2003
	STALEVO 125				
	ORION	31.25MG;200MG;125MG	N021485	006	Aug 29, 2008
	STALEVO 150				
	ORION	37.5MG;200MG;150MG	N021485	003	Jun 11, 2003
	STALEVO 200				
	+ ORION	50MG;200MG;200MG	N021485	004	Aug 02, 2007
	STALEVO 50				
	+ ORION	12.5MG;200MG;50MG	N021485	001	Jun 11, 2003
	STALEVO 75				
	ORION	18.75MG;200MG;75MG	N021485	005	Aug 29, 2008

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG;100MG</u>	<u>A074260</u>	<u>001</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;100MG</u>	<u>A074260</u>	<u>002</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;250MG</u>	<u>A074260</u>	<u>003</u>	Sep 03, 1993
<u>AB</u>	APOTEX INC	<u>10MG;100MG</u>	<u>A077120</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A077120</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A077120</u>	<u>003</u>	Jun 02, 2008
<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A090324</u>	<u>001</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;100MG</u>	<u>A090324</u>	<u>002</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;250MG</u>	<u>A090324</u>	<u>003</u>	Sep 28, 2009
<u>AB</u>	SUN PHARM INDS	<u>10MG;100MG</u>	<u>A078536</u>	<u>001</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A078536</u>	<u>002</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A078536</u>	<u>003</u>	Oct 28, 2008
<u>AB</u>	TEVA	<u>10MG;100MG</u>	<u>A073618</u>	<u>001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;100MG</u>	<u>A073589</u>	<u>001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;250MG</u>	<u>A073607</u>	<u>001</u>	Aug 28, 1992
	<u>SINEMET</u>				
<u>AB</u>	BRISTOL MYERS SQUIBB	<u>10MG;100MG</u>	<u>N017555</u>	<u>001</u>	
<u>AB</u>		<u>25MG;100MG</u>	<u>N017555</u>	<u>003</u>	
<u>AB</u>	+	<u>25MG;250MG</u>	<u>N017555</u>	<u>002</u>	

## PRESCRIPTION DRUG PRODUCT LIST

3 - 73 (of 393)

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	APOTEX	<u>25MG;100MG</u>	<u>A076212</u>	<u>001</u>	Jun 16, 2004
<u>AB</u>		<u>50MG;200MG</u>	<u>A076212</u>	<u>002</u>	Jun 16, 2004
<u>AB</u>	IMPAX LABS	<u>25MG;100MG</u>	<u>A076521</u>	<u>001</u>	May 14, 2004
<u>AB</u>		<u>50MG;200MG</u>	<u>A076521</u>	<u>002</u>	May 14, 2004
<u>AB</u>	MYLAN	<u>25MG;100MG</u>	<u>A075091</u>	<u>002</u>	Apr 21, 2000
<u>AB</u>		<u>50MG;200MG</u>	<u>A075091</u>	<u>001</u>	Sep 30, 1999
<u>AB</u>	SUN PHARM INDS	<u>25MG;100MG</u>	<u>A077828</u>	<u>001</u>	Aug 23, 2007
<u>AB</u>		<u>50MG;200MG</u>	<u>A077828</u>	<u>002</u>	Aug 23, 2007

SINEMET CR

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>25MG;100MG</u>	<u>N019856</u>	<u>002</u>	Dec 24, 1992
<u>AB</u>	+	<u>50MG;200MG</u>	<u>N019856</u>	<u>001</u>	May 30, 1991

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A078893</u>	<u>001</u>	Sep 18, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A078893</u>	<u>002</u>	Sep 18, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A078893</u>	<u>003</u>	Sep 18, 2008
<u>AB</u>	SUN PHARM INDS	<u>10MG;100MG</u>	<u>A078690</u>	<u>001</u>	Jul 31, 2009
<u>AB</u>		<u>25MG;100MG</u>	<u>A078690</u>	<u>002</u>	Jul 31, 2009
<u>AB</u>		<u>25MG;250MG</u>	<u>A078690</u>	<u>003</u>	Jul 31, 2009
<u>PARCOPA</u>					
<u>AB</u>	SCHWARZ PHARMA	<u>10MG;100MG</u>	<u>A076699</u>	<u>001</u>	Aug 27, 2004
<u>AB</u>		<u>25MG;100MG</u>	<u>A076699</u>	<u>002</u>	Aug 27, 2004
<u>AB</u>	+	<u>25MG;250MG</u>	<u>A076699</u>	<u>003</u>	Aug 27, 2004

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	BOCA PHARMA	<u>4MG/5ML</u>	<u>A040814</u>	<u>001</u>	Feb 26, 2008
<u>AA</u>	+	<u>4MG/5ML</u>	<u>A040458</u>	<u>001</u>	Apr 25, 2003

TABLET; ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	BOCA PHARMA	<u>4MG</u>	<u>A040639</u>	<u>002</u>	May 30, 2008
<u>AA</u>	+	<u>4MG</u>	<u>A040442</u>	<u>001</u>	Mar 19, 2003

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

<u>AP</u>	APP PHARMS	<u>50MG/VIAL</u>	<u>A076235</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>		<u>150MG/VIAL</u>	<u>A076235</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>		<u>450MG/VIAL</u>	<u>A076235</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>	BEDFORD	<u>50MG/VIAL</u>	<u>A076099</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>		<u>150MG/VIAL</u>	<u>A076099</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>		<u>450MG/VIAL</u>	<u>A076099</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>	PLIVA	<u>50MG/VIAL</u>	<u>A076602</u>	<u>001</u>	Nov 16, 2004
<u>AP</u>		<u>150MG/VIAL</u>	<u>A076602</u>	<u>002</u>	Nov 16, 2004
<u>AP</u>		<u>450MG/VIAL</u>	<u>A076602</u>	<u>003</u>	Nov 16, 2004
<u>AP</u>	SANDOZ	<u>50MG/VIAL</u>	<u>A076959</u>	<u>001</u>	Mar 18, 2005
<u>AP</u>		<u>150MG/VIAL</u>	<u>A076959</u>	<u>002</u>	Mar 18, 2005
<u>AP</u>		<u>450MG/VIAL</u>	<u>A076959</u>	<u>003</u>	Mar 18, 2005
<u>AP</u>	+	<u>50MG/VIAL</u>	<u>A076162</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>		<u>50MG/VIAL</u>	<u>A077383</u>	<u>001</u>	Jan 27, 2006
<u>AP</u>	+	<u>150MG/VIAL</u>	<u>A076162</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>		<u>150MG/VIAL</u>	<u>A077383</u>	<u>002</u>	Jan 27, 2006
<u>AP</u>	+	<u>450MG/VIAL</u>	<u>A076162</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>		<u>450MG/VIAL</u>	<u>A077383</u>	<u>003</u>	Jan 27, 2006

## PRESCRIPTION DRUG PRODUCT LIST

3 - 74 (of 393)

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

<u>AP</u>	AKORN	<u>50MG/5ML (10MG/ML)</u>	<u>A090475</u>	<u>001</u>	Jul 29, 2009
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A090475</u>	<u>002</u>	Jul 29, 2009
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A090475</u>	<u>003</u>	Jul 29, 2009
<u>AP</u>	APP PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A077266</u>	<u>001</u>	Feb 15, 2006
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077266</u>	<u>002</u>	Feb 15, 2006
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077247</u>	<u>003</u>	Oct 21, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077266</u>	<u>003</u>	Feb 15, 2006
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077266</u>	<u>004</u>	Feb 15, 2006
<u>AP</u>	BEDFORD LABS	<u>50MG/5ML (10MG/ML)</u>	<u>A077244</u>	<u>001</u>	Oct 15, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077244</u>	<u>002</u>	Oct 15, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077244</u>	<u>003</u>	Oct 15, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077244</u>	<u>004</u>	Jan 20, 2006
<u>AP</u>	EBEWE PHARMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078280</u>	<u>001</u>	May 08, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078280</u>	<u>002</u>	May 08, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078280</u>	<u>003</u>	May 08, 2008
<u>AP</u>	FRESENIUS KABI ONCOL	<u>50MG/5ML (10MG/ML)</u>	<u>A077432</u>	<u>001</u>	Sep 29, 2006
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077432</u>	<u>002</u>	Sep 29, 2006
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077432</u>	<u>003</u>	Sep 29, 2006
<u>AP</u>	GENERAMEDIX	<u>50MG/5ML (10MG/ML)</u>	<u>A077998</u>	<u>001</u>	Apr 24, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077998</u>	<u>002</u>	Apr 24, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077998</u>	<u>003</u>	Apr 24, 2007
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A076517</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A076517</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A076517</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077059</u>	<u>001</u>	Nov 23, 2004
<u>AP</u>	+ PHARMACHEMIE	<u>50MG/5ML (10MG/ML)</u>	<u>A077269</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>	+	<u>150MG/15ML (10MG/ML)</u>	<u>A077269</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>	+	<u>450MG/45ML (10MG/ML)</u>	<u>A077269</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>	+	<u>600MG/60ML (10MG/ML)</u>	<u>A077269</u>	<u>004</u>	Dec 28, 2007
<u>AP</u>	PHARMACHEMIE BV	<u>50MG/5ML (10MG/ML)</u>	<u>A077679</u>	<u>001</u>	Feb 25, 2009
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077679</u>	<u>002</u>	Feb 25, 2009
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077679</u>	<u>003</u>	Feb 25, 2009
<u>AP</u>	PLIVA LACHEMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078631</u>	<u>001</u>	Dec 02, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078631</u>	<u>002</u>	Dec 02, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078631</u>	<u>003</u>	Dec 02, 2008
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A078631</u>	<u>004</u>	Dec 02, 2008
<u>AP</u>	SUN PHARM INDS	<u>50MG/5ML (10MG/ML)</u>	<u>A077926</u>	<u>001</u>	Sep 19, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077926</u>	<u>002</u>	Sep 19, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077926</u>	<u>003</u>	Sep 19, 2008
<u>AP</u>	+ TEVA PARENTERAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077139</u>	<u>001</u>	Sep 21, 2005
<u>AP</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A077389</u>	<u>001</u>	Mar 30, 2007
<u>AP</u>	+	<u>150MG/15ML (10MG/ML)</u>	<u>A077139</u>	<u>002</u>	Sep 21, 2005
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077389</u>	<u>002</u>	Mar 30, 2007
<u>AP</u>	+	<u>450MG/45ML (10MG/ML)</u>	<u>A077139</u>	<u>003</u>	Sep 21, 2005
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077389</u>	<u>003</u>	Mar 30, 2007
<u>AP</u>	+	<u>600MG/60ML (10MG/ML)</u>	<u>A077139</u>	<u>004</u>	Sep 21, 2005
<u>AP</u>	WATSON LABS	<u>50MG/5ML (10MG/ML)</u>	<u>A077861</u>	<u>001</u>	Jan 18, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077861</u>	<u>002</u>	Jan 18, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077861</u>	<u>003</u>	Jan 18, 2007
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077861</u>	<u>004</u>	Jan 18, 2007
	<u>PARAPLATIN</u>				
<u>AP</u>	+ BRISTOL MYERS SQUIBB	<u>50MG/5ML (10MG/ML)</u>	<u>N020452</u>	<u>001</u>	Jul 14, 2003
<u>AP</u>	+	<u>150MG/15ML (10MG/ML)</u>	<u>N020452</u>	<u>002</u>	Jul 14, 2003
<u>AP</u>	+	<u>450MG/45ML (10MG/ML)</u>	<u>N020452</u>	<u>003</u>	Jul 14, 2003
<u>AP</u>	+	<u>600MG/60ML (10MG/ML)</u>	<u>N020452</u>	<u>004</u>	Jan 15, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 75 (of 393)

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

HEMABATE

+ PHARMACIA AND UPJOHN EQ 0.25MG BASE/ML N017989 001

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

<u>AA</u>	ACTAVIS TOTOWA	<u>350MG</u>	<u>A040188</u>	<u>001</u>	Mar 07, 1997
<u>AA</u>	ADVENT PHARMS	<u>350MG</u>	<u>A040576</u>	<u>001</u>	Jun 07, 2005
<u>AA</u>	AUROBINDO PHARMA	<u>350MG</u>	<u>A040792</u>	<u>001</u>	Aug 06, 2009
<u>AA</u>	CONCORD LABS NJ	<u>350MG</u>	<u>A040823</u>	<u>001</u>	Oct 22, 2008
<u>AA</u>	COREPHARMA	<u>350MG</u>	<u>A040397</u>	<u>001</u>	Sep 21, 2000
<u>AA</u>	MUTUAL PHARM	<u>350MG</u>	<u>A089346</u>	<u>001</u>	Oct 17, 1991
<u>AA</u>	SUN PHARM INDS LTD	<u>350MG</u>	<u>A040755</u>	<u>001</u>	Feb 27, 2007
<u>AA</u>	VINTAGE PHARMS	<u>350MG</u>	<u>A040245</u>	<u>001</u>	Sep 08, 1997
<u>AA</u>	WATSON LABS	<u>350MG</u>	<u>A087499</u>	<u>001</u>	Apr 20, 1982
<u>AA</u>	WEST WARD	<u>350MG</u>	<u>A040124</u>	<u>001</u>	Jan 24, 1996

SOMA

<u>AA</u>	MEDA PHARMS	<u>350MG</u>	<u>N011792</u>	<u>001</u>	
	SOMA				
	+ MEDA PHARMS	250MG	N011792	004	Sep 13, 2007

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+ EISAI INC 7.7MG N020637 001 Sep 23, 1996

INJECTABLE; INJECTION

BICNU

+ BRISTOL 100MG/VIAL N017422 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

<u>AT</u>	ALCON	<u>1%</u>	<u>A075476</u>	<u>001</u>	Jan 03, 2000
<u>AT</u>	BAUSCH AND LOMB	<u>1%</u>	<u>A075546</u>	<u>001</u>	Jan 20, 2000
<u>AT</u>	NOVEX	<u>1%</u>	<u>A076097</u>	<u>001</u>	Feb 06, 2002
	<u>OCUPRESS</u>				
<u>AT</u>	+ NOVARTIS	<u>1%</u>	<u>N019972</u>	<u>001</u>	May 23, 1990

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>	ACTAVIS ELIZABETH	<u>3.125MG</u>	<u>A078384</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078384</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078384</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078384</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	APOTEX INC	<u>3.125MG</u>	<u>A078165</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078165</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078165</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078165</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>3.125MG</u>	<u>A078332</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078332</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078332</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078332</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	CARACO	<u>3.125MG</u>	<u>A077346</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077346</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077346</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077346</u>	<u>003</u>	Sep 05, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 76 (of 393)

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>	DR REDDYS LABS LTD	<u>3.125MG</u>	<u>A076649</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076649</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076649</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076649</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	GLENMARK GENERICS	<u>3.125MG</u>	<u>A078251</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078251</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078251</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078251</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	HIKMA	<u>3.125MG</u>	<u>A077887</u>	<u>001</u>	Sep 07, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077887</u>	<u>002</u>	Sep 07, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077887</u>	<u>003</u>	Sep 07, 2007
<u>AB</u>		<u>25MG</u>	<u>A077887</u>	<u>004</u>	Sep 07, 2007
<u>AB</u>	LUPIN	<u>3.125MG</u>	<u>A078217</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078217</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078217</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078217</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	MYLAN	<u>3.125MG</u>	<u>A077316</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077316</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077316</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077316</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>3.125MG</u>	<u>A078240</u>	<u>001</u>	Oct 30, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078240</u>	<u>002</u>	Oct 30, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078240</u>	<u>003</u>	Oct 30, 2007
<u>AB</u>		<u>25MG</u>	<u>A078240</u>	<u>004</u>	Oct 30, 2007
<u>AB</u>	RANBAXY	<u>3.125MG</u>	<u>A076989</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076989</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076989</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076989</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	SANDOZ	<u>3.125MG</u>	<u>A078227</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078227</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078227</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078227</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	TARO	<u>3.125MG</u>	<u>A077780</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077780</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077780</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077780</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	TEVA	<u>3.125MG</u>	<u>A076373</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076373</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076373</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076373</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	WATSON LABS	<u>3.125MG</u>	<u>A077474</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077474</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077474</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077474</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	WOCKHARDT	<u>3.125MG</u>	<u>A078786</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>		<u>6.25MG</u>	<u>A078786</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>		<u>12.5MG</u>	<u>A078786</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078786</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>3.125MG</u>	<u>A077614</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077614</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077614</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077614</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>	<u>COREG</u>				
<u>AB</u>	SMITHKLINE BEECHAM	<u>3.125MG</u>	<u>N020297</u>	<u>004</u>	May 29, 1997
<u>AB</u>		<u>6.25MG</u>	<u>N020297</u>	<u>003</u>	Sep 14, 1995
<u>AB</u>	+	<u>12.5MG</u>	<u>N020297</u>	<u>002</u>	Sep 14, 1995
<u>AB</u>		<u>25MG</u>	<u>N020297</u>	<u>001</u>	Sep 14, 1995

## PRESCRIPTION DRUG PRODUCT LIST

3 - 77 (of 393)

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

COREG CR

SB PHARMCO	10MG	N022012	001	Oct 20, 2006
	20MG	N022012	002	Oct 20, 2006
	40MG	N022012	003	Oct 20, 2006
+	80MG	N022012	004	Oct 20, 2006

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)

+	MERCK	50MG/VIAL	N021227	001	Jan 26, 2001
+		70MG/VIAL	N021227	002	Jan 26, 2001

CEFACLOR

CAPSULE; ORAL

CEFACLOR

<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065350</u>	<u>001</u>	Apr 03, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065350</u>	<u>002</u>	Apr 03, 2007
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE</u>	<u>A064156</u>	<u>001</u>	Aug 28, 1997
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A064156</u>	<u>002</u>	Aug 28, 1997
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065146</u>	<u>001</u>	Jan 22, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065146</u>	<u>002</u>	Jan 22, 2004

FOR SUSPENSION; ORAL

CEFACLOR

+	RANBAXY	EQ 125MG BASE/5ML	A064166	001	Oct 02, 1997
+		EQ 187MG BASE/5ML	A064165	001	Oct 02, 1997
+		EQ 250MG BASE/5ML	A064164	001	Oct 02, 1997
+		EQ 375MG BASE/5ML	A064155	001	Oct 02, 1997

TABLET, CHEWABLE; ORAL

RANICLOR

	RANBAXY	EQ 125MG BASE	A065092	001	Dec 22, 2003
		EQ 187MG BASE	A065092	002	Dec 22, 2003
		EQ 250MG BASE	A065092	003	Dec 22, 2003
+		EQ 375MG BASE	A065092	004	Dec 22, 2003

TABLET, EXTENDED RELEASE; ORAL

CEFACLOR

<u>AB</u>	+	PAR PHARM	<u>EQ 500MG BASE</u>	<u>A065057</u>	<u>001</u>	Jan 05, 2001
<u>AB</u>		TEVA	<u>EQ 500MG BASE</u>	<u>A065058</u>	<u>002</u>	Sep 04, 2002
		CEFACLOR				
		TEVA	EQ 375MG BASE	A065058	001	Sep 04, 2002

CEFADROXIL ANHYDROUS

FOR SUSPENSION; ORAL

CEFADROXIL

	RANBAXY	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003
--	---------	-------------------	---------	-----	--------------

TABLET; ORAL

CEFADROXIL

+	IVAX SUB TEVA PHARMS	EQ 1GM BASE	A062774	001	Apr 08, 1987
---	----------------------	-------------	---------	-----	--------------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 500MG BASE</u>	<u>A065352</u>	<u>001</u>	Jan 25, 2007
<u>AB</u>	HIKMA	<u>EQ 500MG BASE</u>	<u>A065311</u>	<u>001</u>	Feb 07, 2006
<u>AB</u>	LUPIN	<u>EQ 500MG BASE</u>	<u>A065392</u>	<u>001</u>	May 29, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 500MG BASE</u>	<u>A065309</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>	RANBAXY	<u>EQ 500MG BASE</u>	<u>A065015</u>	<u>001</u>	Jun 22, 1999
<u>AB</u>	SANDOZ	EQ 500MG BASE	A062291	001	



## PRESCRIPTION DRUG PRODUCT LIST

3 - 78 (of 393)

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

<u>AB</u>	TEVA PHARMS	<u>EQ 500MG BASE</u>	<u>A065282</u>	<u>001</u>	Jan 20, 2006
-----------	-------------	----------------------	----------------	------------	--------------

FOR SUSPENSION; ORAL

CEFADROXIL

<u>AB</u>	LUPIN	<u>EQ 250MG BASE/5ML</u>	<u>A065396</u>	<u>001</u>	Feb 21, 2008
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065396</u>	<u>002</u>	Feb 21, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE/5ML</u>	<u>A065307</u>	<u>002</u>	Oct 16, 2006
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065307</u>	<u>003</u>	Oct 16, 2006
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE/5ML</u>	<u>A065115</u>	<u>002</u>	Mar 26, 2003
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065115</u>	<u>003</u>	Mar 26, 2003
<u>AB</u>	TEVA PHARMS	<u>EQ 250MG BASE/5ML</u>	<u>A065278</u>	<u>001</u>	Jan 20, 2006
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065278</u>	<u>002</u>	Jan 20, 2006

DURICEF

<u>AB</u>	WARNER CHILCOTT	<u>EQ 250MG BASE/5ML</u>	<u>N050527</u>	<u>003</u>	
<u>AB</u>	+	<u>EQ 500MG BASE/5ML</u>	<u>N050527</u>	<u>001</u>	

TABLET; ORAL

CEFADROXIL

<u>AB</u>	HIKMA	<u>EQ 1GM BASE</u>	<u>A065260</u>	<u>001</u>	Mar 30, 2006
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1GM BASE</u>	<u>A065301</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>	RANBAXY	<u>EQ 1GM BASE</u>	<u>A065018</u>	<u>001</u>	Apr 23, 1999

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A065303</u>	<u>001</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065303</u>	<u>002</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065306</u>	<u>001</u>	Oct 22, 2008
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A064169</u>	<u>001</u>	Aug 14, 1998
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A064169</u>	<u>002</u>	Aug 14, 1998
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A064170</u>	<u>001</u>	Mar 18, 1998
<u>AP</u>	+	<u>EQ 20GM BASE/VIAL</u>	<u>A064170</u>	<u>002</u>	Mar 18, 1998
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 500MG BASE/VIAL</u>	<u>A065395</u>	<u>001</u>	Aug 08, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065395</u>	<u>002</u>	Aug 08, 2008
<u>AP</u>	CEPHAZONE PHARMA	<u>EQ 500MG BASE/VIAL</u>	<u>A065280</u>	<u>001</u>	Mar 18, 2009
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065280</u>	<u>002</u>	Mar 18, 2009
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065295</u>	<u>001</u>	Mar 18, 2009
<u>AP</u>		<u>EQ 20GM BASE/VIAL</u>	<u>A065296</u>	<u>001</u>	Mar 18, 2009
<u>AP</u>	HANFORD GC	<u>EQ 1GM BASE/VIAL</u>	<u>A063207</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A063208</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063209</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 500MG BASE/VIAL</u>	<u>A065047</u>	<u>001</u>	Sep 18, 2001
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065047</u>	<u>002</u>	Sep 18, 2001
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065143</u>	<u>001</u>	Oct 18, 2004
<u>AP</u>	ORCHID HLTHCARE	<u>EQ 500MG BASE/VIAL</u>	<u>A065226</u>	<u>001</u>	Apr 21, 2005
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065226</u>	<u>002</u>	Apr 21, 2005
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065244</u>	<u>001</u>	Aug 12, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065247</u>	<u>001</u>	Aug 12, 2005
<u>AP</u>	SANDOZ	<u>EQ 500MG BASE/VIAL</u>	<u>A062831</u>	<u>001</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062831</u>	<u>002</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065345</u>	<u>001</u>	May 09, 2007
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A062831</u>	<u>003</u>	Sep 25, 1992

KEFZOL

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A061773</u>	<u>002</u>	
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A061773</u>	<u>003</u>	
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A061773</u>	<u>004</u>	

ANCEF IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002	001	Mar 28, 1991
+		EQ 20MG BASE/ML	A063002	002	Mar 28, 1991

## PRESCRIPTION DRUG PRODUCT LIST

3 - 79 (of 393)

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

+ B BRAUN	EQ 1GM BASE/VIAL	N050779	002	Jul 27, 2000
CEFAZOLIN SODIUM				
+ SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141	001	Nov 29, 2006
+	EQ 300GM BASE/VIAL	A065141	002	Nov 29, 2006

CEFDINIR

CAPSULE; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>300MG</u>	<u>A065434</u>	<u>001</u>	Jan 07, 2008
<u>AB</u>	LUPIN	<u>300MG</u>	<u>A065264</u>	<u>001</u>	May 19, 2006
<u>AB</u>	ORCHID HLTHCARE	<u>300MG</u>	<u>A065418</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>	SANDOZ	<u>300MG</u>	<u>A065330</u>	<u>001</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>300MG</u>	<u>A065368</u>	<u>001</u>	May 09, 2007
<u>OMNICEF</u>					
<u>AB</u>	+ ABBOTT	<u>300MG</u>	<u>N050739</u>	<u>001</u>	Dec 04, 1997

FOR SUSPENSION; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065473</u>	<u>001</u>	Dec 14, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065473</u>	<u>002</u>	Dec 14, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065259</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065259</u>	<u>002</u>	May 07, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065429</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065429</u>	<u>002</u>	Jul 18, 2007
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065337</u>	<u>001</u>	Apr 06, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065337</u>	<u>002</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065332</u>	<u>001</u>	May 04, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065332</u>	<u>002</u>	May 04, 2007
<u>OMNICEF</u>					
<u>AB</u>	ABBOTT	<u>125MG/5ML</u>	<u>N050749</u>	<u>001</u>	Dec 04, 1997
<u>AB</u>	+	<u>250MG/5ML</u>	<u>N050749</u>	<u>002</u>	Jul 29, 2004

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

CORNERSTONE	200MG	N021222	001	Aug 29, 2001
+	400MG	N021222	002	Jul 21, 2008

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065441</u>	<u>001</u>	Mar 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065441</u>	<u>002</u>	Mar 20, 2008
<u>AP</u>	ORCHID HLTHCARE	<u>EQ 500MG BASE/VIAL</u>	<u>A065369</u>	<u>001</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065369</u>	<u>002</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065369</u>	<u>003</u>	Jun 18, 2007
<u>MAXIPIME</u>					
<u>AP</u>	+ BRISTOL MYERS SQUIBB	<u>EQ 500MG BASE/VIAL</u>	<u>N050679</u>	<u>001</u>	Jan 18, 1996
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N050679</u>	<u>002</u>	Jan 18, 1996
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>N050679</u>	<u>003</u>	Jan 18, 1996
CEFEPIME IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N050817	001	Aug 05, 2008
+		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N050817	002	Aug 05, 2008

CEFIXIME

SUSPENSION; ORAL

SUPRAX

LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004
--------------	-----------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 80 (of 393)

CEFIXIME

SUSPENSION; ORAL

SUPRAX

+ LUPIN PHARMS 200MG/5ML A065355 001 Apr 10, 2007

TABLET; ORAL

SUPRAX

+ LUPIN 400MG A065130 001 Feb 12, 2004

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIMEAP APP PHARMS EQ 500MG BASE/VIAL A064200 001 Mar 24, 2000AP EQ 1GM BASE/VIAL A064200 002 Mar 24, 2000AP EQ 2GM BASE/VIAL A064200 003 Mar 24, 2000AP EQ 10GM BASE/VIAL A064201 001 Mar 24, 2000AP HIKMA EQ 500MG BASE/VIAL A065072 001 Nov 20, 2002AP EQ 1GM BASE/VIAL A065072 002 Nov 20, 2002AP EQ 2GM BASE/VIAL A065072 003 Nov 20, 2002AP EQ 10GM BASE/VIAL A065071 001 Nov 20, 2002AP WOCKHARDT EQ 1GM BASE/VIAL A065197 001 Aug 29, 2006CEFOTAXIME SODIUMAP AUROBINDO PHARMA EQ 500MG BASE/VIAL A065517 001 Nov 06, 2009AP EQ 1GM BASE/VIAL A065517 002 Nov 06, 2009AP EQ 2GM BASE/VIAL A065517 003 Nov 06, 2009AP EQ 10GM BASE/VIAL A065516 001 Nov 06, 2009AP LUPIN EQ 500MG BASE/VIAL A065124 001 Sep 24, 2003AP EQ 1GM BASE/VIAL A065124 002 Sep 24, 2003AP EQ 2GM BASE/VIAL A065124 003 Sep 24, 2003AP ORCHID HLTHCARE EQ 500MG BASE/VIAL A065290 001 Aug 11, 2006AP EQ 1GM BASE/VIAL A065290 002 Aug 11, 2006AP EQ 1GM BASE/VIAL A065293 001 Aug 10, 2006AP EQ 2GM BASE/VIAL A065290 003 Aug 11, 2006AP EQ 2GM BASE/VIAL A065293 002 Aug 10, 2006AP EQ 10GM BASE/VIAL A065292 001 Aug 10, 2006AP WOCKHARDT EQ 500MG BASE/VIAL A065197 002 Jun 20, 2008AP EQ 2GM BASE/VIAL A065197 003 Jun 20, 2008CLAFORANAP + SANOFI AVENTIS US EQ 500MG BASE/VIAL N050547 001AP EQ 1GM BASE/VIAL A062659 001 Jan 13, 1987AP + EQ 1GM BASE/VIAL N050547 002AP EQ 2GM BASE/VIAL A062659 002 Jan 13, 1987AP + EQ 2GM BASE/VIAL N050547 003AP + EQ 10GM BASE/VIAL N050547 004 Dec 29, 1983

CEFOTAXIME

+ APP PHARMS EQ 20GM BASE/VIAL A064201 002 Mar 24, 2000

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ SANOFI AVENTIS US EQ 20MG BASE/ML N050596 002 May 20, 1985

+ EQ 40MG BASE/ML N050596 004 May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTETAN

+ APP PHARMS EQ 1GM BASE/VIAL A065374 001 Aug 09, 2007

+ EQ 2GM BASE/VIAL A065374 002 Aug 09, 2007

+ EQ 10GM BASE/VIAL A065375 001 Aug 09, 2007

CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER

+ B BRAUN EQ 1GM BASE/VIAL A065430 001 Aug 09, 2007

+ EQ 2GM BASE/VIAL A065430 002 Aug 09, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 81 (of 393)

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065414</u>	<u>001</u>	Jun 12, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065414</u>	<u>002</u>	Jun 12, 2009
<u>AP</u>	+ APP PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A065012</u>	<u>001</u>	Jul 03, 2000
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A065012</u>	<u>002</u>	Jul 03, 2000
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A065011</u>	<u>001</u>	Jul 03, 2000
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 1GM BASE/VIAL</u>	<u>A065051</u>	<u>001</u>	Sep 11, 2000
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065051</u>	<u>002</u>	Sep 11, 2000
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065050</u>	<u>001</u>	Sep 11, 2000
<u>AP</u>	ORCHID HLTHCARE	<u>EQ 1GM BASE/VIAL</u>	<u>A065313</u>	<u>001</u>	Jan 23, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065313</u>	<u>002</u>	Jan 23, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065312</u>	<u>001</u>	Feb 13, 2006
<u>CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>A065214</u>	<u>001</u>	Mar 10, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065214</u>	<u>002</u>	Mar 10, 2006
MEFOXIN IN PLASTIC CONTAINER					
+	BIONICHE PHARMA	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993
+		EQ 40MG BASE/ML	A063182	002	Jan 25, 1993

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 50MG BASE/5ML</u>	<u>A065409</u>	<u>001</u>	Jun 08, 2007
<u>AB</u>	+	<u>EQ 100MG BASE/5ML</u>	<u>A065409</u>	<u>002</u>	Jun 08, 2007
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE/5ML</u>	<u>A065082</u>	<u>001</u>	May 31, 2002
<u>AB</u>		<u>EQ 100MG BASE/5ML</u>	<u>A065082</u>	<u>002</u>	May 31, 2002
<u>AB</u>	SANDOZ	<u>EQ 50MG BASE/5ML</u>	<u>A090031</u>	<u>001</u>	Jan 14, 2009
<u>AB</u>		<u>EQ 100MG BASE/5ML</u>	<u>A090031</u>	<u>002</u>	Jan 14, 2009

TABLET; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 100MG BASE</u>	<u>A065370</u>	<u>001</u>	Jun 11, 2007
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065370</u>	<u>002</u>	Jun 11, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 100MG BASE</u>	<u>A065388</u>	<u>001</u>	Nov 14, 2007
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065388</u>	<u>002</u>	Nov 14, 2007
<u>AB</u>	RANBAXY	<u>EQ 100MG BASE</u>	<u>A065083</u>	<u>001</u>	Aug 20, 2003
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065083</u>	<u>002</u>	Aug 20, 2003
<u>AB</u>	SANDOZ	<u>EQ 100MG BASE</u>	<u>A065462</u>	<u>001</u>	May 28, 2008
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065462</u>	<u>002</u>	May 28, 2008
<u>VANTIN</u>					
<u>AB</u>	PHARMACIA AND UPJOHN	<u>EQ 100MG BASE</u>	<u>N050674</u>	<u>001</u>	Aug 07, 1992
<u>AB</u>	+	<u>EQ 200MG BASE</u>	<u>N050674</u>	<u>002</u>	Aug 07, 1992

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065381</u>	<u>001</u>	Jan 30, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065381</u>	<u>002</u>	Jan 30, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065261</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065261</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065284</u>	<u>002</u>	Dec 30, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065284</u>	<u>001</u>	Dec 30, 2005
<u>AB</u>	RANBAXY	<u>125MG/5ML</u>	<u>A065202</u>	<u>001</u>	Jun 30, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065202</u>	<u>002</u>	Jun 30, 2006
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065257</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065257</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065236</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065236</u>	<u>002</u>	Dec 08, 2005

## PRESCRIPTION DRUG PRODUCT LIST

3 - 82 (of 393)

CEFPROZIL

FOR SUSPENSION; ORAL

CEFZIL

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>125MG/5ML</u>	<u>N050665</u>	<u>001</u>	Dec 23, 1991
<u>AB</u>	+	<u>250MG/5ML</u>	<u>N050665</u>	<u>002</u>	Dec 23, 1991

TABLET; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A065327</u>	<u>001</u>	Mar 26, 2008
<u>AB</u>		<u>500MG</u>	<u>A065327</u>	<u>002</u>	Mar 26, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A065340</u>	<u>001</u>	May 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A065340</u>	<u>002</u>	May 24, 2007
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A065276</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>500MG</u>	<u>A065276</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A065267</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>		<u>500MG</u>	<u>A065267</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	RANBAXY	<u>250MG</u>	<u>A065198</u>	<u>001</u>	Dec 13, 2006
<u>AB</u>		<u>500MG</u>	<u>A065198</u>	<u>002</u>	Dec 13, 2006
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065235</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>500MG</u>	<u>A065235</u>	<u>002</u>	Nov 14, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065208</u>	<u>001</u>	Dec 06, 2005
<u>AB</u>		<u>500MG</u>	<u>A065208</u>	<u>002</u>	Dec 06, 2005
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065428</u>	<u>001</u>	Jun 14, 2007
<u>AB</u>		<u>500MG</u>	<u>A065428</u>	<u>002</u>	Jun 14, 2007

CEFZIL

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>250MG</u>	<u>N050664</u>	<u>001</u>	Dec 23, 1991
<u>AB</u>	+	<u>500MG</u>	<u>N050664</u>	<u>002</u>	Dec 23, 1991

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

<u>AP</u>	ACS DOBFAR	<u>500MG/VIAL</u>	<u>A062640</u>	<u>001</u>	Nov 20, 1985
<u>AP</u>		<u>1GM/VIAL</u>	<u>A062640</u>	<u>002</u>	Nov 20, 1985
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062640</u>	<u>003</u>	Nov 20, 1985
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062640</u>	<u>004</u>	Feb 03, 1992
<u>AP</u>	WOCKHARDT	<u>1GM/VIAL</u>	<u>A065196</u>	<u>001</u>	Oct 15, 2008

FORTAZ

<u>AP</u>	+	GLAXOSMITHKLINE	<u>500MG/VIAL</u>	<u>N050578</u>	<u>001</u>	Jul 19, 1985
<u>AP</u>	+		<u>1GM/VIAL</u>	<u>N050578</u>	<u>002</u>	Jul 19, 1985
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N050578</u>	<u>003</u>	Jul 19, 1985
<u>AP</u>	+		<u>6GM/VIAL</u>	<u>N050578</u>	<u>004</u>	Jul 19, 1985

TAZICEF

<u>AP</u>	HOSPIRA	<u>500MG/VIAL</u>	<u>A062662</u>	<u>001</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A062662</u>	<u>002</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A064032</u>	<u>001</u>	Oct 31, 1993
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062662</u>	<u>003</u>	Mar 06, 1986
<u>AP</u>		<u>2GM/VIAL</u>	<u>A064032</u>	<u>002</u>	Oct 31, 1993
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062662</u>	<u>004</u>	Mar 06, 1986

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

+	GLAXOSMITHKLINE	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989
+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

+	SCIELE PHARMA INC	EQ 400MG BASE	N050685	002	Dec 20, 1995
---	-------------------	---------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 83 (of 393)

CEFTIBUTEN DIHYDRATEFOR SUSPENSION; ORAL  
CEDAX

+ SCIELE PHARMA INC EQ 90MG BASE/5ML N050686 001 Dec 20, 1995

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

<u>AP</u>	APP PHARMS	<u>EQ 250MG BASE/VIAL</u>	<u>A065245</u>	<u>001</u>	Feb 15, 2006
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065245</u>	<u>002</u>	Feb 15, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065245</u>	<u>003</u>	Feb 15, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065245</u>	<u>004</u>	Feb 15, 2006
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE/VIAL</u>	<u>A065505</u>	<u>001</u>	Jul 31, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065505</u>	<u>002</u>	Jul 31, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065505</u>	<u>003</u>	Jul 31, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065505</u>	<u>004</u>	Jul 31, 2008
<u>AP</u>	BEDFORD	<u>EQ 250MG BASE/VIAL</u>	<u>A065465</u>	<u>001</u>	Aug 18, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065465</u>	<u>002</u>	Aug 18, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065465</u>	<u>003</u>	Aug 18, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065465</u>	<u>004</u>	Aug 18, 2008
<u>AP</u>	CEPHAZONE PHARMA	<u>EQ 250MG BASE/VIAL</u>	<u>A065294</u>	<u>001</u>	Mar 26, 2007
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065294</u>	<u>002</u>	Mar 26, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065294</u>	<u>003</u>	Mar 26, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065294</u>	<u>004</u>	Mar 26, 2007
<u>AP</u>	HANFORD GC	<u>EQ 1GM BASE/VIAL</u>	<u>A065268</u>	<u>001</u>	Feb 28, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065268</u>	<u>002</u>	Feb 28, 2007
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 250MG BASE/VIAL</u>	<u>A065342</u>	<u>001</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065342</u>	<u>002</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065342</u>	<u>003</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065342</u>	<u>004</u>	Jan 10, 2008
<u>AP</u>	LUITPOLD	<u>EQ 250MG BASE/VIAL</u>	<u>A065305</u>	<u>001</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065305</u>	<u>002</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065305</u>	<u>003</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065305</u>	<u>004</u>	Jan 11, 2008
<u>AP</u>	LUPIN	<u>EQ 250MG BASE/VIAL</u>	<u>A065125</u>	<u>001</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065125</u>	<u>002</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065125</u>	<u>003</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065125</u>	<u>004</u>	Sep 30, 2003
<u>AP</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE/VIAL</u>	<u>A065230</u>	<u>001</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065230</u>	<u>002</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065230</u>	<u>003</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065230</u>	<u>004</u>	Aug 02, 2005
<u>AP</u>	+ SANDOZ	<u>EQ 250MG BASE/VIAL</u>	<u>A065169</u>	<u>001</u>	May 09, 2005
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065169</u>	<u>002</u>	May 09, 2005
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065169</u>	<u>003</u>	May 09, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065169</u>	<u>004</u>	May 09, 2005
<u>AP</u>	TEVA	<u>EQ 1GM BASE/VIAL</u>	<u>A065262</u>	<u>001</u>	Jun 29, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065262</u>	<u>002</u>	Jun 29, 2006
<u>AP</u>	TEVA PARENTERAL	<u>EQ 250MG BASE/VIAL</u>	<u>A065227</u>	<u>001</u>	Mar 15, 2007
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065227</u>	<u>002</u>	Mar 15, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065227</u>	<u>003</u>	Mar 15, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065227</u>	<u>004</u>	Mar 15, 2007
<u>AP</u>	WOCKHARDT	<u>EQ 250MG BASE/VIAL</u>	<u>A065391</u>	<u>001</u>	Apr 12, 2007
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065391</u>	<u>002</u>	Apr 12, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065391</u>	<u>003</u>	Apr 12, 2007

INJECTABLE; INJECTION

CEFTRIAZONE

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A065329</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065329</u>	<u>002</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065329</u>	<u>003</u>	Jul 24, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 84 (of 393)

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

<u>AP</u>	ACS DOBFAR	<u>EQ 10GM BASE/VIAL</u>	<u>A065328</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>	APP PHARMS	<u>EQ 10GM BASE/VIAL</u>	<u>A065252</u>	<u>001</u>	Feb 15, 2006
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 10GM BASE/VIAL</u>	<u>A065504</u>	<u>001</u>	Jul 31, 2008
<u>AP</u>	BEDFORD	<u>EQ 10GM BASE/VIAL</u>	<u>A065475</u>	<u>001</u>	Aug 18, 2008
<u>AP</u>	HANFORD GC	<u>EQ 10GM BASE/VIAL</u>	<u>A065269</u>	<u>001</u>	Feb 28, 2007
<u>AP</u>	LUPIN	<u>EQ 10GM BASE/VIAL</u>	<u>A065263</u>	<u>001</u>	Sep 12, 2006
<u>AP</u>	ORCHID HLTHCARE	<u>EQ 1GM BASE/VIAL</u>	<u>A065231</u>	<u>001</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065231</u>	<u>002</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065232</u>	<u>001</u>	Aug 02, 2005
<u>AP</u>	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A065204</u>	<u>001</u>	May 03, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065204</u>	<u>002</u>	May 03, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065168</u>	<u>001</u>	May 17, 2005
<u>AP</u>	TEVA	<u>EQ 10GM BASE/VIAL</u>	<u>A065274</u>	<u>001</u>	May 01, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 1GM BASE/VIAL</u>	<u>A065180</u>	<u>001</u>	May 12, 2006

CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+ B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>N050796</u>	<u>001</u>	Apr 20, 2005
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>N050796</u>	<u>002</u>	Apr 20, 2005

ROCEPHIN

<u>AP</u>	+ HLR	<u>EQ 500MG BASE/VIAL</u>	<u>A063239</u>	<u>002</u>	Aug 13, 1993
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A063239</u>	<u>003</u>	Aug 13, 1993

CEFTRIAXONE IN PLASTIC CONTAINER

	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005
		EQ 40MG BASE/ML	A065224	002	Aug 23, 2005

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 125MG BASE/5ML</u>	<u>N050672</u>	<u>001</u>	Jun 30, 1994
<u>AB</u>	+	<u>EQ 250MG BASE/5ML</u>	<u>N050672</u>	<u>002</u>	Apr 29, 1997

CEFUROXIME AXETIL

<u>AB</u>	RANBAXY	<u>EQ 125MG BASE/5ML</u>	<u>A065323</u>	<u>001</u>	Feb 05, 2008
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065323</u>	<u>002</u>	Feb 05, 2008

TABLET; ORAL

CEFTIN

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 125MG BASE</u>	<u>N050605</u>	<u>001</u>	Dec 28, 1987
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>N050605</u>	<u>002</u>	Dec 28, 1987
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N050605</u>	<u>003</u>	Dec 28, 1987

CEFUROXIME AXETIL

<u>AB</u>	APOTEX INC	<u>EQ 250MG BASE</u>	<u>A065069</u>	<u>001</u>	Oct 02, 2002
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065069</u>	<u>002</u>	Oct 02, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 125MG BASE</u>	<u>A065308</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065308</u>	<u>002</u>	Mar 29, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065308</u>	<u>003</u>	Mar 29, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065135</u>	<u>001</u>	Jul 25, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065135</u>	<u>002</u>	Jul 25, 2003
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG BASE</u>	<u>A065359</u>	<u>001</u>	Feb 15, 2008
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065359</u>	<u>002</u>	Feb 15, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065359</u>	<u>003</u>	Feb 15, 2008
<u>AB</u>	RANBAXY	<u>EQ 125MG BASE</u>	<u>A065043</u>	<u>003</u>	Feb 15, 2002
<u>AB</u>		<u>EQ 125MG BASE</u>	<u>A065118</u>	<u>001</u>	Apr 25, 2003
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065043</u>	<u>002</u>	Feb 15, 2002
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065118</u>	<u>002</u>	Apr 25, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065043</u>	<u>001</u>	Feb 15, 2002
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065118</u>	<u>003</u>	Apr 25, 2003
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A065126</u>	<u>001</u>	Oct 28, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065126</u>	<u>002</u>	Oct 28, 2003
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A065190</u>	<u>001</u>	Oct 18, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 85 (of 393)

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

<u>AB</u>	TEVA	<u>EQ 500MG BASE</u>	<u>A065190</u>	<u>002</u>	Oct 18, 2004
<u>AB</u>	WOCKHARDT	<u>EQ 125MG BASE</u>	<u>A065166</u>	<u>001</u>	Jul 29, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065166</u>	<u>002</u>	Jul 29, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065166</u>	<u>003</u>	Jul 29, 2005

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

<u>AB</u>	APP PHARMS	<u>EQ 750MG BASE/VIAL</u>	<u>A065001</u>	<u>001</u>	May 30, 2001
<u>AB</u>	HANFORD GC	<u>EQ 750MG BASE/VIAL</u>	<u>A064125</u>	<u>001</u>	May 30, 1997
<u>AB</u>	TEVA	<u>EQ 750MG BASE/VIAL</u>	<u>A064192</u>	<u>002</u>	Apr 16, 1998
<u>ZINACEF</u>					
<u>AB</u>	+ GLAXOSMITHKLINE	<u>EQ 750MG BASE/VIAL</u>	<u>N050558</u>	<u>002</u>	Oct 19, 1983
<u>CEFUROXIME SODIUM</u>					
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 750MG BASE/VIAL</u>	<u>A065048</u>	<u>001</u>	Jan 09, 2004
<u>AP</u>	ORCHID HLTHCARE	<u>EQ 750MG BASE/VIAL</u>	<u>A065483</u>	<u>001</u>	Oct 15, 2008

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+ B BRAUN	<u>EQ 750MG BASE/VIAL</u>	<u>N050780</u>	<u>001</u>	Feb 21, 2001
<u>AP</u>	+	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050780</u>	<u>002</u>	Feb 21, 2001

CEFUROXIME SODIUM

<u>AP</u>	APP PHARMS	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065001</u>	<u>002</u>	May 30, 2001
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065002</u>	<u>001</u>	Sep 28, 1998
<u>AP</u>	HANFORD GC	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064125</u>	<u>002</u>	May 30, 1997
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A064124</u>	<u>001</u>	May 30, 1997
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065048</u>	<u>002</u>	Jan 09, 2004
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065046</u>	<u>001</u>	Jan 09, 2004
<u>AP</u>	ORCHID HLTHCARE	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065483</u>	<u>002</u>	Oct 15, 2008
<u>AP</u>		<u>EQ 1.5GM BASE/VIAL</u>	<u>A065503</u>	<u>001</u>	Oct 15, 2008
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065484</u>	<u>001</u>	Oct 15, 2008
<u>AP</u>	TEVA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064192</u>	<u>001</u>	Apr 16, 1998
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A064191</u>	<u>001</u>	Apr 16, 1998

ZINACEF

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050558</u>	<u>003</u>	Oct 19, 1983
<u>AP</u>	+	<u>EQ 7.5GM BASE/VIAL</u>	<u>N050558</u>	<u>004</u>	Oct 23, 1986

CEFUROXIME SODIUM IN PLASTIC CONTAINER

+	SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251	001	Dec 30, 2009
+		EQ 225GM BASE/VIAL	A065251	002	Dec 30, 2009

ZINACEF IN PLASTIC CONTAINER

+	GLAXOSMITHKLINE	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989
+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989

CELECOXIB

CAPSULE; ORAL

CELEBREX

	GD SEARLE	50MG	N020998	004	Dec 15, 2006
		100MG	N020998	001	Dec 31, 1998
		200MG	N020998	002	Dec 31, 1998
+		400MG	N020998	003	Aug 29, 2002

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A065253</u>	<u>001</u>	Nov 16, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065253</u>	<u>002</u>	Nov 16, 2005
<u>AB</u>	BELCHER	<u>EQ 250MG BASE</u>	<u>A062713</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062713</u>	<u>002</u>	Jul 15, 1988



## PRESCRIPTION DRUG PRODUCT LIST

3 - 86 (of 393)

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

<u>AB</u>	CEPH INTL	<u>EQ 250MG BASE</u>	<u>A062118</u>	<u>001</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062118</u>	<u>002</u>	
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065215</u>	<u>001</u>	Jan 24, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065215</u>	<u>002</u>	Jan 24, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 250MG BASE</u>	<u>A061969</u>	<u>001</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A061969</u>	<u>002</u>	
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065229</u>	<u>001</u>	Nov 25, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065229</u>	<u>002</u>	Nov 25, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A065248</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065248</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE</u>	<u>A065007</u>	<u>001</u>	Sep 16, 1999
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065007</u>	<u>002</u>	Sep 16, 1999
<u>AB</u>	STEVENS J	<u>EQ 250MG BASE</u>	<u>A062870</u>	<u>001</u>	Mar 17, 1988
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 250MG BASE</u>	<u>A062791</u>	<u>001</u>	Jun 11, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062791</u>	<u>002</u>	Jun 11, 1987
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062702</u>	<u>001</u>	Feb 13, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062702</u>	<u>002</u>	Feb 13, 1987
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065152</u>	<u>001</u>	Feb 24, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065152</u>	<u>002</u>	Feb 24, 2005

KEFLEX

<u>AB</u>	MIDDLEBROOK PHARMS	<u>EQ 250MG BASE</u>	<u>N050405</u>	<u>002</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N050405</u>	<u>003</u>	
	KEFLEX				
	+ MIDDLEBROOK PHARMS	EQ 750MG BASE	N050405	005	May 12, 2006

FOR SUSPENSION; ORAL

CEPHALEXIN

<u>AB</u>	CEPH INTL	<u>EQ 125MG BASE/5ML</u>	<u>A062117</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 250MG BASE/5ML</u>	<u>A062117</u>	<u>003</u>	
<u>AB</u>	HIKMA PHARMS	<u>EQ 125MG BASE/5ML</u>	<u>A065444</u>	<u>001</u>	Aug 28, 2009
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065444</u>	<u>002</u>	Aug 28, 2009
<u>AB</u>	LUPIN	<u>EQ 125MG BASE/5ML</u>	<u>A065234</u>	<u>001</u>	Aug 17, 2005
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065234</u>	<u>002</u>	Aug 17, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG BASE/5ML</u>	<u>A065326</u>	<u>001</u>	Jul 10, 2006
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065326</u>	<u>002</u>	Jul 10, 2006
<u>AB</u>	RANBAXY	<u>EQ 125MG BASE/5ML</u>	<u>A065081</u>	<u>001</u>	Jul 27, 2001
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065081</u>	<u>002</u>	Jul 27, 2001
<u>AB</u>	TEVA	<u>EQ 125MG BASE/5ML</u>	<u>A062703</u>	<u>001</u>	Feb 13, 1987
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A062703</u>	<u>002</u>	Feb 13, 1987
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 125MG BASE/5ML</u>	<u>A065336</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065336</u>	<u>002</u>	Jul 25, 2007

TABLET; ORAL

CEPHALEXIN

	TEVA	EQ 250MG BASE	A063023	001	Jan 12, 1989
	+	EQ 500MG BASE	A063024	001	Jan 12, 1989

TABLET, FOR SUSPENSION; ORAL

PANIXINE DISPERDOSE

	RANBAXY	EQ 125MG BASE	A065100	002	Sep 11, 2003
	+	EQ 250MG BASE	A065100	001	Sep 11, 2003

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>5MG/5ML</u>	<u>A090766</u>	<u>001</u>	Oct 07, 2009
<u>AA</u>	APOTEX INC	<u>5MG/5ML</u>	<u>A078412</u>	<u>001</u>	Jun 18, 2008
<u>AA</u>	AUROBINDO PHARMA	<u>5MG/5ML</u>	<u>A090751</u>	<u>001</u>	Dec 16, 2009
<u>AA</u>	CYPRESS PHARM	<u>5MG/5ML</u>	<u>A078488</u>	<u>001</u>	Oct 06, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 87 (of 393)

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

<u>AA</u>	DR REDDYS LABS LTD	<u>5MG/5ML</u>	<u>A078870</u>	<u>001</u>	Apr 27, 2009
<u>AA</u>	PERRIGO ISRAEL	<u>5MG/5ML</u>	<u>A078398</u>	<u>001</u>	Jun 17, 2008
<u>AA</u>	RANBAXY	<u>5MG/5ML</u>	<u>A077472</u>	<u>001</u>	Jun 18, 2008
<u>AA</u>	SUN PHARM INDS INC	<u>5MG/5ML</u>	<u>A090191</u>	<u>001</u>	Nov 12, 2009
<u>AA</u>	TARO	<u>5MG/5ML</u>	<u>A076601</u>	<u>001</u>	Jun 20, 2008
<u>AA</u>	TEVA PHARMS	<u>5MG/5ML</u>	<u>A077279</u>	<u>001</u>	May 27, 2008
<u>AA</u>	VINTAGE	<u>5MG/5ML</u>	<u>A078496</u>	<u>001</u>	Sep 25, 2009
<u>AA</u>	WOCKHARDT	<u>5MG/5ML</u>	<u>A078757</u>	<u>001</u>	Aug 28, 2009
	<u>ZYRTEC</u>				
<u>AA</u>	+ MCNEIL CONSUMER	<u>5MG/5ML</u>	<u>N020346</u>	<u>001</u>	Sep 27, 1996

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

	+ EMD SERONO	EQ 0.25MG BASE/ML	N021197	001	Aug 11, 2000
	+	EQ 3MG BASE/ML	N021197	002	Aug 11, 2000

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

EVOXAC

	+ DAIICHI SANKYO CO	EQ 30MG BASE	N020989	002	Jan 11, 2000
--	---------------------	--------------	---------	-----	--------------

CHENODIOL

TABLET; ORAL

CHENODIOL

	+ NEXGEN PHARMA	250MG	A091019	001	Oct 22, 2009
--	-----------------	-------	---------	-----	--------------

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

	+ SMITHKLINE BEECHAM	2MG	N010669	002	
--	----------------------	-----	---------	-----	--

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

	+ APP PHARMS	EQ 1GM BASE/VIAL	A062365	001	Aug 25, 1982
--	--------------	------------------	---------	-----	--------------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

<u>AB</u>	BARR	<u>5MG</u>	<u>A084768</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A083116</u>	<u>001</u>	
<u>AB</u>		<u>25MG</u>	<u>A084769</u>	<u>001</u>	
<u>AB</u>	USL PHARMA	<u>10MG</u>	<u>A084623</u>	<u>001</u>	
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A086383</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A086294</u>	<u>001</u>	
<u>AB</u>		<u>25MG</u>	<u>A086382</u>	<u>001</u>	
	<u>LIBRIUM</u>				
<u>AB</u>	VALEANT PHARM INTL	<u>5MG</u>	<u>A085461</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A085472</u>	<u>001</u>	
<u>AB</u>	+	<u>25MG</u>	<u>A085475</u>	<u>001</u>	

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>0.12%</u>	<u>A074291</u>	<u>001</u>	Dec 28, 1995
-----------	----------------------	--------------	----------------	------------	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 114 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 88 (of 393)

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

<u>AT</u>	HI TECH PHARMA	<u>0.12%</u>	<u>A074356</u>	<u>001</u>	May 07, 1996
<u>AT</u>	JOHN O BUTLER CO	<u>0.12%</u>	<u>A076434</u>	<u>001</u>	Nov 29, 2005
<u>AT</u>	MORTON GROVE	<u>0.12%</u>	<u>A075006</u>	<u>001</u>	Mar 03, 2004
<u>AT</u>	NOVEX	<u>0.12%</u>	<u>A075561</u>	<u>001</u>	Nov 14, 2000
<u>AT</u>	TEVA	<u>0.12%</u>	<u>A074522</u>	<u>001</u>	Dec 15, 1995
<u>AT</u>	XTTRIUM	<u>0.12%</u>	<u>A077789</u>	<u>001</u>	Jun 18, 2009

PERIDEX

<u>AT</u>	+ 3M	<u>0.12%</u>	<u>N019028</u>	<u>001</u>	Aug 13, 1986
-----------	------	--------------	----------------	------------	--------------

PERIOGARD

<u>AT</u>	COLGATE	<u>0.12%</u>	<u>A073695</u>	<u>001</u>	Jan 14, 1994
-----------	---------	--------------	----------------	------------	--------------

TABLET; DENTAL

PERIOCHIP

	+ DEXCEL PHARMA	2.5MG	N020774	001	May 15, 1998
--	-----------------	-------	---------	-----	--------------

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLOROPROCAINE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>2%</u>	<u>A040273</u>	<u>001</u>	Sep 09, 1998
<u>AP</u>		<u>3%</u>	<u>A040273</u>	<u>002</u>	Sep 09, 1998
<u>AP</u>	HOSPIRA	<u>2%</u>	<u>A087447</u>	<u>001</u>	Apr 16, 1982
<u>AP</u>		<u>3%</u>	<u>A087446</u>	<u>001</u>	Apr 16, 1982

NESACAINE

<u>AP</u>	APP PHARMS	<u>2%</u>	<u>N009435</u>	<u>002</u>	
-----------	------------	-----------	----------------	------------	--

NESACAINE-MPF

<u>AP</u>	+ APP PHARMS	<u>2%</u>	<u>N009435</u>	<u>006</u>	May 02, 1996
-----------	--------------	-----------	----------------	------------	--------------

<u>AP</u>	+ NESACAINE	<u>3%</u>	<u>N009435</u>	<u>007</u>	May 02, 1996
-----------	-------------	-----------	----------------	------------	--------------

NESACAINE

	+ APP PHARMS	1%	N009435	001	
--	--------------	----	---------	-----	--

CHLOROQUINE PHOSPHATE

TABLET; ORAL

ARALEN

<u>AA</u>	+ SANOFI AVENTIS US	<u>EQ 300MG BASE</u>	<u>N006002</u>	<u>001</u>	
-----------	---------------------	----------------------	----------------	------------	--

CHLOROQUINE PHOSPHATE

<u>AA</u>	IMPAX LABS	<u>EQ 150MG BASE</u>	<u>A080880</u>	<u>001</u>	
<u>AA</u>		<u>EQ 300MG BASE</u>	<u>A040516</u>	<u>001</u>	Aug 29, 2003
<u>AA</u>	OHM LABS	<u>EQ 150MG BASE</u>	<u>A090610</u>	<u>001</u>	Dec 03, 2009
<u>AA</u>		<u>EQ 300MG BASE</u>	<u>A090249</u>	<u>001</u>	Dec 03, 2009
<u>AA</u>	+ WEST WARD	<u>EQ 150MG BASE</u>	<u>A083082</u>	<u>001</u>	
<u>AA</u>		<u>EQ 300MG BASE</u>	<u>A083082</u>	<u>002</u>	Sep 17, 1999

CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

	+ SALIX PHARMS	250MG/5ML	N011870	001	
--	----------------	-----------	---------	-----	--

TABLET; ORAL

CHLOROTHIAZIDE

<u>AB</u>	+ MYLAN	<u>250MG</u>	<u>A084388</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A084217</u>	<u>001</u>	
<u>AB</u>	WEST WARD	<u>250MG</u>	<u>A086028</u>	<u>001</u>	Jul 14, 1982
<u>AB</u>		<u>500MG</u>	<u>A087736</u>	<u>001</u>	Jul 14, 1982

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

<u>AP</u>	APP PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A090896</u>	<u>001</u>	Oct 16, 2009
-----------	------------	---------------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 89 (of 393)

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

DIURIL

<u>AP</u>	+	LUNDBECK INC	<u>EQ 500MG BASE/VIAL</u>	<u>N011145</u>	<u>005</u>	
-----------	---	--------------	---------------------------	----------------	------------	--

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE; ORAL

TUSSICAPS

		TYCO HLTHCARE	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273	002	Sep 24, 2007
	+		EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273	001	Sep 24, 2007

SUSPENSION, EXTENDED RELEASE; ORAL

TUSSIONEX PENNKINETIC

	+	UCB INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	N019111	001	Dec 31, 1987
--	---	---------	---	---------	-----	--------------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

	+	BAXTER HLTHCARE	25MG/ML	A083329	001	
--	---	-----------------	---------	---------	-----	--

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

BP		SANDOZ	10MG	A080439	001	
BP			25MG	A080439	002	
BP			50MG	A080439	003	
BP	+		100MG	A080439	004	
BP			200MG	A080439	005	
BP		USL PHARMA	10MG	A083386	001	
BP			25MG	A084112	001	
BP			50MG	A084113	001	
BP			100MG	A084114	001	
BP			200MG	A084115	001	

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

<u>AB</u>		MYLAN	<u>100MG</u>	<u>A088549</u>	<u>002</u>	Jun 01, 1984
<u>AB</u>			<u>250MG</u>	<u>A088549</u>	<u>001</u>	Jun 01, 1984
<u>AB</u>		PLIVA	<u>100MG</u>	<u>A088921</u>	<u>001</u>	Apr 12, 1985
<u>AB</u>			<u>250MG</u>	<u>A088922</u>	<u>001</u>	Apr 12, 1985
<u>AB</u>		WATSON LABS	<u>100MG</u>	<u>A088852</u>	<u>001</u>	Sep 26, 1984
<u>AB</u>			<u>250MG</u>	<u>A088826</u>	<u>001</u>	Sep 26, 1984

DIABINESE

<u>AB</u>		PFIZER	<u>100MG</u>	<u>N011641</u>	<u>003</u>	
<u>AB</u>	+		<u>250MG</u>	<u>N011641</u>	<u>006</u>	

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

<u>AB</u>		MYLAN	<u>25MG</u>	<u>A086831</u>	<u>002</u>	
<u>AB</u>	+		<u>50MG</u>	<u>A086831</u>	<u>001</u>	
<u>AB</u>		PLIVA	<u>25MG</u>	<u>A088902</u>	<u>001</u>	Sep 19, 1985
<u>AB</u>			<u>50MG</u>	<u>A088903</u>	<u>001</u>	Sep 19, 1985
		THALITONE				
	+	MONARCH PHARMS	15MG	N019574	001	Dec 20, 1988

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLORPRES

		MYLAN	15MG;0.1MG	A071325	003	Feb 09, 1987
--	--	-------	------------	---------	-----	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 116 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 90 (of 393)

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLORPRES

MYLAN	15MG;0.2MG	A071325	002	Feb 09, 1987
+	15MG;0.3MG	A071325	001	Feb 09, 1987

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

<u>AA</u>	ACTAVIS TOTOWA	<u>250MG</u>	<u>A088928</u>	<u>001</u>	May 08, 1987
<u>AA</u>		<u>500MG</u>	<u>A040113</u>	<u>001</u>	Sep 29, 1995
<u>AA</u>	BARR	<u>500MG</u>	<u>A089895</u>	<u>001</u>	May 04, 1988
<u>AA</u>	OHM LABS	<u>250MG</u>	<u>A081298</u>	<u>001</u>	Dec 29, 1993
<u>AA</u>		<u>500MG</u>	<u>A081299</u>	<u>001</u>	Dec 29, 1993
<u>AA</u>	WATSON LABS	<u>500MG</u>	<u>A040137</u>	<u>001</u>	Aug 09, 1996
<u>AA</u>		<u>500MG</u>	<u>A081040</u>	<u>001</u>	Aug 22, 1989
<u>AA</u>		<u>500MG</u>	<u>A089859</u>	<u>001</u>	May 04, 1988
	<u>PARAFON FORTE DSC</u>				
<u>AA</u>	+ ORTHO MCNEIL JANSSEN	<u>500MG</u>	<u>N011529</u>	<u>002</u>	Jun 15, 1987

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

<u>AB</u>	PAR PHARM	<u>EQ 4GM RESIN/PACKET</u>	<u>A077204</u>	<u>001</u>	Aug 26, 2005
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A077204</u>	<u>002</u>	Aug 26, 2005
<u>AB</u>	SANDOZ	<u>EQ 4GM RESIN/PACKET</u>	<u>A074557</u>	<u>001</u>	Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074557</u>	<u>002</u>	Aug 15, 1996
	<u>CHOLESTYRAMINE LIGHT</u>				
<u>AB</u>	PAR PHARM	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A077203</u>	<u>002</u>	Aug 26, 2005
<u>AB</u>		<u>EQ 4GM RESIN/PACKET</u>	<u>A077203</u>	<u>001</u>	Aug 26, 2005
<u>AB</u>	SANDOZ	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074558</u>	<u>002</u>	Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/PACKET</u>	<u>A074558</u>	<u>001</u>	Aug 15, 1996
	<u>LOCHOLEST</u>				
<u>AB</u>	SANDOZ	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074561</u>	<u>002</u>	Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/PACKET</u>	<u>A074561</u>	<u>001</u>	Aug 15, 1996
	<u>LOCHOLEST LIGHT</u>				
<u>AB</u>	SANDOZ	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074562</u>	<u>002</u>	Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/PACKET</u>	<u>A074562</u>	<u>001</u>	Aug 15, 1996
	<u>PREVALITE</u>				
<u>AB</u>	UPSHER SMITH	<u>EQ 4GM RESIN/PACKET</u>	<u>A073263</u>	<u>001</u>	Feb 22, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A073263</u>	<u>002</u>	Oct 30, 1997
	<u>QUESTRAN</u>				
<u>AB</u>	BRISTOL MYERS	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>N016640</u>	<u>003</u>	
<u>AB</u>	+	<u>EQ 4GM RESIN/PACKET</u>	<u>N016640</u>	<u>001</u>	
	<u>QUESTRAN LIGHT</u>				
<u>AB</u>	BRISTOL MYERS	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>N019669</u>	<u>003</u>	Dec 05, 1988
<u>AB</u>		<u>EQ 4GM RESIN/PACKET</u>	<u>N019669</u>	<u>001</u>	Dec 05, 1988

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

TRILIPIX

ABBOTT LABS	EQ 45MG FENOFIBRIC ACID	N022224	001	Dec 15, 2008
+	EQ 135MG FENOFIBRIC ACID	N022224	002	Dec 15, 2008

CHORIOGONADOTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

OVIDREL

+	EMD SERONO	EQ 0.25MG /0.5ML	N021149	002	Oct 06, 2003
---	------------	------------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 91 (of 393)

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N018961	001	Jun 26, 1986
---	---------	------------------------	---------	-----	--------------

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

	NYCOMED US	0.08MG/INH	N021658	002	Jan 10, 2008
+		0.16MG/INH	N021658	003	Jan 10, 2008

SPRAY, METERED; NASAL

OMNARIS

+	NYCOMED US	0.05MG/INH	N022004	001	Oct 20, 2006
---	------------	------------	---------	-----	--------------

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

<u>AB</u>	ALTANA	<u>0.77%</u>	<u>A076435</u>	<u>001</u>	Dec 29, 2004
<u>AB</u>	GLENMARK PHARMS	<u>0.77%</u>	<u>A090273</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>	PERRIGO	<u>0.77%</u>	<u>A077364</u>	<u>001</u>	Mar 03, 2006
<u>AB</u>	TARO	<u>0.77%</u>	<u>A076790</u>	<u>001</u>	Apr 12, 2005

LOPROX

<u>AB</u>	+ MEDICIS	<u>0.77%</u>	<u>N018748</u>	<u>001</u>	Dec 30, 1982
-----------	-----------	--------------	----------------	------------	--------------

GEL; TOPICAL

CICLOPIROX

<u>AB</u>	NYCOMED US	<u>0.77%</u>	<u>A077896</u>	<u>001</u>	Jun 10, 2008
<u>AB</u>	PADDOCK	<u>0.77%</u>	<u>A078266</u>	<u>001</u>	Jan 07, 2009

LOPROX

<u>AB</u>	+ MEDICIS	<u>0.77%</u>	<u>N020519</u>	<u>001</u>	Jul 21, 1997
-----------	-----------	--------------	----------------	------------	--------------

SHAMPOO; TOPICAL

CICLOPIROX

<u>AT</u>	PADDOCK LABS	<u>1%</u>	<u>A090490</u>	<u>001</u>	Nov 24, 2009
-----------	--------------	-----------	----------------	------------	--------------

LOPROX

<u>AT</u>	+ MEDICIS	<u>1%</u>	<u>N021159</u>	<u>001</u>	Feb 28, 2003
-----------	-----------	-----------	----------------	------------	--------------

SOLUTION; TOPICAL

CICLOPIROX

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>8%</u>	<u>A078046</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	APOTEX CORP	<u>8%</u>	<u>A078172</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	G AND W LABS	<u>8%</u>	<u>A078233</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	HI TECH PHARMA	<u>8%</u>	<u>A078270</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	PERRIGO NEW YORK	<u>8%</u>	<u>A077623</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	SYNERX PHARMA	<u>8%</u>	<u>A078567</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	TARO PHARM INDS	<u>8%</u>	<u>A078144</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	TEVA PHARMS	<u>8%</u>	<u>A078079</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	TOLMAR	<u>8%</u>	<u>A077687</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	WATSON LABS	<u>8%</u>	<u>A078124</u>	<u>001</u>	Sep 18, 2007

PENLAC

<u>AT</u>	+ SANOFI AVENTIS US	<u>8%</u>	<u>N021022</u>	<u>001</u>	Dec 17, 1999
-----------	---------------------	-----------	----------------	------------	--------------

SUSPENSION; TOPICAL

CICLOPIROX

<u>AB</u>	ALTANA	<u>0.77%</u>	<u>A076422</u>	<u>001</u>	Aug 06, 2004
<u>AB</u>	PERRIGO NEW YORK	<u>0.77%</u>	<u>A077676</u>	<u>001</u>	Dec 15, 2006
<u>AB</u>	TARO	<u>0.77%</u>	<u>A077092</u>	<u>001</u>	Aug 10, 2005

LOPROX

<u>AB</u>	+ MEDICIS	<u>0.77%</u>	<u>N019824</u>	<u>001</u>	Dec 30, 1988
-----------	-----------	--------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 92 (of 393)

CIDOFOVIR

INJECTABLE; INJECTION

VISTIDE

+	GILEAD	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996
---	--------	-----------------	---------	-----	--------------

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION

PRIMAXIN

MERCK

		EQ 250MG BASE/VIAL;250MG/VIAL	A062756	001	Jan 08, 1987
--	--	-------------------------------	---------	-----	--------------

+		EQ 250MG BASE/VIAL;250MG/VIAL	N050587	001	Nov 26, 1985
---	--	-------------------------------	---------	-----	--------------

		EQ 500MG BASE/VIAL;500MG/VIAL	A062756	002	Jan 08, 1987
--	--	-------------------------------	---------	-----	--------------

+		EQ 500MG BASE/VIAL;500MG/VIAL	N050587	002	Nov 26, 1985
---	--	-------------------------------	---------	-----	--------------

		EQ 500MG BASE/VIAL;500MG/VIAL	N050630	001	Dec 14, 1990
--	--	-------------------------------	---------	-----	--------------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

<u>AB</u>	ACTAVIS TOTOWA	<u>100MG</u>	<u>A077028</u>	<u>002</u>	Nov 26, 2004
<u>AB</u>	ALPHAPHARM	<u>50MG</u>	<u>A077019</u>	<u>001</u>	Nov 23, 2004
<u>AB</u>		<u>100MG</u>	<u>A077019</u>	<u>002</u>	Nov 23, 2004
<u>AB</u>	APOTEX INC	<u>50MG</u>	<u>A077030</u>	<u>001</u>	Dec 10, 2004
<u>AB</u>		<u>100MG</u>	<u>A077030</u>	<u>002</u>	Dec 10, 2004
<u>AB</u>	BRECKENRIDGE PHARM	<u>50MG</u>	<u>A077708</u>	<u>001</u>	Sep 28, 2009
<u>AB</u>		<u>100MG</u>	<u>A077708</u>	<u>002</u>	Sep 28, 2009
<u>AB</u>	COREPHARMA	<u>50MG</u>	<u>A077150</u>	<u>001</u>	Mar 11, 2005
<u>AB</u>		<u>100MG</u>	<u>A077022</u>	<u>001</u>	Nov 23, 2004
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A077020</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A077323</u>	<u>002</u>	Apr 20, 2006
<u>AB</u>		<u>100MG</u>	<u>A077323</u>	<u>001</u>	Apr 20, 2006
<u>AB</u>	PLIVA HRVATSKA DOO	<u>50MG</u>	<u>A077898</u>	<u>001</u>	Oct 29, 2007
<u>AB</u>		<u>100MG</u>	<u>A077898</u>	<u>002</u>	Oct 29, 2007
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A077024</u>	<u>001</u>	May 17, 2005
<u>AB</u>		<u>100MG</u>	<u>A077024</u>	<u>002</u>	May 17, 2005
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A077310</u>	<u>001</u>	Nov 08, 2005
<u>AB</u>		<u>100MG</u>	<u>A077021</u>	<u>001</u>	Nov 23, 2004
<u>AB</u>	TEVA	<u>50MG</u>	<u>A077027</u>	<u>001</u>	Nov 24, 2004
<u>AB</u>		<u>100MG</u>	<u>A077027</u>	<u>002</u>	Nov 24, 2004
	<u>PLETAL</u>				
<u>AB</u>	+ OTSUKA	<u>50MG</u>	<u>N020863</u>	<u>001</u>	Jan 15, 1999
<u>AB</u>	+	<u>100MG</u>	<u>N020863</u>	<u>002</u>	Jan 15, 1999

CIMETIDINE

TABLET; ORAL

CIMETIDINE

<u>AB</u>	APOTEX	<u>200MG</u>	<u>A074890</u>	<u>001</u>	Dec 18, 1998
<u>AB</u>		<u>300MG</u>	<u>A074890</u>	<u>002</u>	Dec 18, 1998
<u>AB</u>		<u>400MG</u>	<u>A074890</u>	<u>003</u>	Dec 18, 1998
<u>AB</u>		<u>800MG</u>	<u>A074890</u>	<u>004</u>	Dec 18, 1998
<u>AB</u>	DAVA PHARMS INC	<u>300MG</u>	<u>A074340</u>	<u>001</u>	Jun 23, 1995
<u>AB</u>		<u>400MG</u>	<u>A074340</u>	<u>002</u>	Jun 23, 1995
<u>AB</u>		<u>800MG</u>	<u>A074339</u>	<u>001</u>	Jun 23, 1995
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>200MG</u>	<u>A074424</u>	<u>001</u>	Jul 28, 1995
<u>AB</u>		<u>300MG</u>	<u>A074424</u>	<u>002</u>	Jul 28, 1995
<u>AB</u>		<u>400MG</u>	<u>A074424</u>	<u>003</u>	Jul 28, 1995
<u>AB</u>		<u>800MG</u>	<u>A074424</u>	<u>004</u>	Jul 28, 1995
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A074246</u>	<u>001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074246</u>	<u>002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074246</u>	<u>003</u>	May 17, 1994
<u>AB</u>		<u>800MG</u>	<u>A074246</u>	<u>004</u>	May 17, 1994
<u>AB</u>	PLIVA	<u>200MG</u>	<u>A074568</u>	<u>001</u>	Feb 27, 1997

## PRESCRIPTION DRUG PRODUCT LIST

3 - 93 (of 393)

CIMETIDINE

TABLET; ORAL

CIMETIDINE

<u>AB</u>	PLIVA	<u>300MG</u>	<u>A074568</u>	<u>002</u>	Feb 27, 1997
<u>AB</u>		<u>400MG</u>	<u>A074568</u>	<u>003</u>	Feb 27, 1997
<u>AB</u>		<u>800MG</u>	<u>A074566</u>	<u>001</u>	Feb 27, 1997
<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A074506</u>	<u>001</u>	Jan 24, 1996
<u>AB</u>		<u>300MG</u>	<u>A074506</u>	<u>002</u>	Jan 24, 1996
<u>AB</u>		<u>400MG</u>	<u>A074506</u>	<u>003</u>	Jan 24, 1996
<u>AB</u>		<u>800MG</u>	<u>A074506</u>	<u>004</u>	Jan 24, 1996
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074151</u>	<u>001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074151</u>	<u>002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074151</u>	<u>003</u>	May 17, 1994
<u>AB</u>		<u>800MG</u>	<u>A074463</u>	<u>001</u>	May 17, 1994
<u>AB</u>	WATSON LABS	<u>200MG</u>	<u>A074349</u>	<u>001</u>	Aug 30, 1996
<u>AB</u>		<u>300MG</u>	<u>A074349</u>	<u>002</u>	Aug 30, 1996
<u>AB</u>		<u>400MG</u>	<u>A074349</u>	<u>003</u>	Aug 30, 1996
<u>AB</u>		<u>800MG</u>	<u>A074316</u>	<u>001</u>	Feb 28, 1996
	<u>TAGAMET</u>				
<u>AB</u>	GLAXOSMITHKLINE	<u>200MG</u>	<u>N017920</u>	<u>002</u>	
<u>AB</u>		<u>300MG</u>	<u>N017920</u>	<u>003</u>	
<u>AB</u>		<u>400MG</u>	<u>N017920</u>	<u>004</u>	Dec 14, 1983
<u>AB</u>	+	<u>800MG</u>	<u>N017920</u>	<u>005</u>	Apr 30, 1986

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

<u>AP</u>	DAVA PHARMS INC	<u>EQ 300MG BASE/2ML</u>	<u>A074428</u>	<u>001</u>	Apr 25, 1996
<u>AP</u>	HOSPIRA	<u>EQ 300MG BASE/2ML</u>	<u>A074344</u>	<u>001</u>	Jan 31, 1995
<u>AP</u>		<u>EQ 300MG BASE/2ML</u>	<u>A074345</u>	<u>001</u>	Jan 31, 1995
<u>AP</u>	TEVA PARENTERAL	<u>EQ 300MG BASE/2ML</u>	<u>A074252</u>	<u>001</u>	Nov 26, 1997
	CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	+	HOSPIRA	EQ 6MG BASE/ML	A074269	001 Dec 27, 1994

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

<u>AA</u>	+	HI TECH PHARMA	<u>EQ 300MG BASE/5ML</u>	<u>A074664</u>	<u>001</u>	Oct 28, 1997
<u>AA</u>		MORTON GROVE	<u>EQ 300MG BASE/5ML</u>	<u>A074757</u>	<u>001</u>	Oct 17, 1997
<u>AA</u>		NOVEX	<u>EQ 300MG BASE/5ML</u>	<u>A075560</u>	<u>001</u>	Mar 15, 2000
<u>AA</u>		PHARM ASSOC	<u>EQ 300MG BASE/5ML</u>	<u>A074553</u>	<u>001</u>	Jan 27, 1997
<u>AA</u>		TEVA	<u>EQ 300MG BASE/5ML</u>	<u>A074610</u>	<u>001</u>	Sep 26, 1996

CINACALCET HYDROCHLORIDE

TABLET; ORAL

SENSIPAR

	AMGEN	EQ 30MG BASE	N021688	001	Mar 08, 2004
		EQ 60MG BASE	N021688	002	Mar 08, 2004
	+	EQ 90MG BASE	N021688	003	Mar 08, 2004

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

	BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997
	+	500MG/5ML	N020780	002	Sep 26, 1997

INJECTABLE; INJECTION

CIPRO

<u>AP</u>	+	BAYER HLTHCARE	<u>400MG/40ML (10MG/ML)</u>	<u>N019847</u>	<u>001</u>	Dec 26, 1990
<u>AP</u>	+		<u>200MG/20ML (10MG/ML)</u>	<u>N019847</u>	<u>002</u>	Dec 26, 1990
		<u>CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER</u>				
<u>AP</u>	+	BAYER HLTHCARE	<u>200MG/100ML</u>	<u>N019857</u>	<u>001</u>	Dec 26, 1990



## PRESCRIPTION DRUG PRODUCT LIST

3 - 94 (of 393)

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+ BAYER HLTHCARE	<u>400MG/200ML</u>	<u>N019857</u>	<u>002</u>	Dec 26, 1990
-----------	------------------	--------------------	----------------	------------	--------------

CIPROFLOXACIN

<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/20ML (10MG/ML)</u>	<u>A078062</u>	<u>001</u>	Apr 29, 2008
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A078062</u>	<u>002</u>	Apr 29, 2008
<u>AP</u>	HOSPIRA	<u>200MG/20ML (10MG/ML)</u>	<u>A077245</u>	<u>001</u>	Aug 28, 2006
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A077245</u>	<u>002</u>	Aug 28, 2006
<u>AP</u>	TEVA PARENTERAL	<u>200MG/20ML (10MG/ML)</u>	<u>A077782</u>	<u>001</u>	Aug 28, 2006
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A077782</u>	<u>002</u>	Aug 28, 2006
<u>AP</u>	WEST WARD	<u>200MG/20ML (10MG/ML)</u>	<u>A076717</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A076717</u>	<u>002</u>	Dec 22, 2009

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	ACS DOBFAR INFO SA	<u>200MG/100ML</u>	<u>A078252</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078252</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML</u>	<u>A077888</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A077888</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/100ML</u>	<u>A078024</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078024</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>400MG/200ML</u>	<u>A078431</u>	<u>001</u>	Nov 18, 2009
<u>AP</u>	HOSPIRA	<u>200MG/100ML</u>	<u>A077753</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A077753</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	TEVA PARENTERAL	<u>200MG/100ML</u>	<u>A077138</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A077138</u>	<u>002</u>	Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN

	+ ALCON	EQ 0.3% BASE	N020369	001	Mar 30, 1998
--	---------	--------------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

<u>AT</u>	+ ALCON	<u>EQ 0.3% BASE</u>	<u>N019992</u>	<u>001</u>	Dec 31, 1990
-----------	---------	---------------------	----------------	------------	--------------

CIPROFLOXACIN HYDROCHLORIDE

<u>AT</u>	AKORN INC	<u>EQ 0.3% BASE</u>	<u>A076555</u>	<u>001</u>	Dec 11, 2008
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 0.3% BASE</u>	<u>A076754</u>	<u>001</u>	Jun 09, 2004
<u>AT</u>	FDC LTD	<u>EQ 0.3% BASE</u>	<u>A077568</u>	<u>001</u>	Jun 30, 2008
<u>AT</u>	HITECH PHARMA	<u>EQ 0.3% BASE</u>	<u>A076673</u>	<u>001</u>	Jan 21, 2005
<u>AT</u>	NEXUS PHARMS	<u>EQ 0.3% BASE</u>	<u>A077689</u>	<u>001</u>	Dec 13, 2006
<u>AT</u>	NOVEX	<u>EQ 0.3% BASE</u>	<u>A075928</u>	<u>001</u>	Jun 09, 2004
<u>AT</u>	PHARMAFORCE	<u>EQ 0.3% BASE</u>	<u>A078598</u>	<u>001</u>	Jan 16, 2008

SOLUTION/DROPS; OTIC

	+ WRASER PHARMS	EQ 0.2% BASE	N021918	001	May 01, 2009
--	-----------------	--------------	---------	-----	--------------

TABLET; ORAL

CIPRO

<u>AB</u>	BAYER HLTHCARE	<u>EQ 100MG BASE</u>	<u>N019537</u>	<u>001</u>	Apr 08, 1996
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>N019537</u>	<u>002</u>	Oct 22, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N019537</u>	<u>003</u>	Oct 22, 1987
<u>AB</u>	+	<u>EQ 750MG BASE</u>	<u>N019537</u>	<u>004</u>	Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 250MG BASE</u>	<u>A076896</u>	<u>001</u>	Nov 04, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076896</u>	<u>002</u>	Nov 04, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076896</u>	<u>003</u>	Nov 04, 2004
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A077859</u>	<u>001</u>	Apr 26, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A077859</u>	<u>002</u>	Apr 26, 2007
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A077859</u>	<u>003</u>	Apr 26, 2007
<u>AB</u>	CARLSBAD	<u>EQ 250MG BASE</u>	<u>A076126</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076126</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076126</u>	<u>004</u>	Jun 09, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 95 (of 393)

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

<u>AB</u>	COBALT	<u>EQ 100MG BASE</u>	<u>A076794</u>	<u>001</u>	Feb 10, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A076794</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076794</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076794</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 100MG BASE</u>	<u>A075593</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075593</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075593</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075593</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A076558</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076558</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076558</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 250MG BASE</u>	<u>A076089</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076089</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076089</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	MYLAN	<u>EQ 100MG BASE</u>	<u>A075817</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075685</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075817</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075685</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075817</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075685</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075817</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE</u>	<u>A075747</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075747</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075747</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>	TARO	<u>EQ 100MG BASE</u>	<u>A076912</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A076912</u>	<u>002</u>	Oct 06, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076912</u>	<u>003</u>	Oct 06, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076912</u>	<u>004</u>	Oct 06, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>EQ 250MG BASE</u>	<u>A076639</u>	<u>001</u>	Sep 10, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076639</u>	<u>002</u>	Sep 10, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076639</u>	<u>003</u>	Sep 10, 2004
	<u>CIPROFLOXACIN HYDROCHLORIDE</u>				
BX	PLIVA	EQ 100MG BASE	A076426	001	Jun 15, 2005
BX		EQ 250MG BASE	A076426	002	Jun 15, 2005
BX		EQ 500MG BASE	A076426	003	Jun 15, 2005
BX		EQ 750MG BASE	A076426	004	Jun 15, 2005

TABLET, EXTENDED RELEASE; ORAL

PROQUIN XR

+ DEPOMED INC EQ 500MG BASE N021744 001 May 19, 2005

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

+ ALCON EQ 0.2% BASE;1% N020805 001 Feb 10, 1998

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

<u>AB</u>	+ BAYER HLTHCARE	<u>212.6MG;EQ 287.5MG BASE</u>	<u>N021473</u>	<u>001</u>	Dec 13, 2002
<u>AB</u>	+	<u>425.2MG;EQ 574.9MG BASE</u>	<u>N021473</u>	<u>002</u>	Aug 28, 2003
	<u>CIPROFLOXACIN EXTENDED RELEASE</u>				
<u>AB</u>	DR REDDYS LABS LTD	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A077902</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>		<u>425.2MG;EQ 574.9MG BASE</u>	<u>A077701</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>	MYLAN	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A078183</u>	<u>001</u>	Mar 22, 2007
<u>AB</u>		<u>425.2MG;EQ 574.9MG BASE</u>	<u>A078183</u>	<u>002</u>	Mar 22, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 96 (of 393)

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC

+	ALCON	0.3%;0.1%	N021537	001	Jul 18, 2003
---	-------	-----------	---------	-----	--------------

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

NIMBEX

+	ABBOTT	EQ 2MG BASE/ML	N020551	001	Dec 15, 1995
---	--------	----------------	---------	-----	--------------

NIMBEX PRESERVATIVE FREE

+	ABBOTT	EQ 2MG BASE/ML	N020551	003	Dec 15, 1995
---	--------	----------------	---------	-----	--------------

+		EQ 10MG BASE/ML	N020551	002	Dec 15, 1995
---	--	-----------------	---------	-----	--------------

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

<u>AP</u>	APP PHARMS	<u>1MG/ML</u>	<u>A074735</u>	<u>001</u>	Jul 16, 1999
-----------	------------	---------------	----------------	------------	--------------

<u>AP</u>	BEDFORD	<u>1MG/ML</u>	<u>A075036</u>	<u>001</u>	Nov 07, 2000
-----------	---------	---------------	----------------	------------	--------------

<u>AP</u>	PHARMACHEMIE	<u>1MG/ML</u>	<u>A074656</u>	<u>001</u>	May 16, 2000
-----------	--------------	---------------	----------------	------------	--------------

<u>AP</u>	TEVA PARENTERAL	<u>1MG/ML</u>	<u>A074814</u>	<u>001</u>	May 16, 2000
-----------	-----------------	---------------	----------------	------------	--------------

PLATINOL-AQ

<u>AP</u>	+	BRISTOL MYERS	<u>1MG/ML</u>	<u>N018057</u>	<u>004</u>	Nov 08, 1988
-----------	---	---------------	---------------	----------------	------------	--------------

PLATINOL

+	BRISTOL MYERS	10MG/VIAL	N018057	001	
---	---------------	-----------	---------	-----	--

+		50MG/VIAL	N018057	002	
---	--	-----------	---------	-----	--

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

	ALPHAPHARM	EQ 10MG BASE	A077668	001	Feb 28, 2007
--	------------	--------------	---------	-----	--------------

		EQ 20MG BASE	A077668	002	Feb 28, 2007
--	--	--------------	---------	-----	--------------

+		EQ 40MG BASE	A077668	003	Feb 28, 2007
---	--	--------------	---------	-----	--------------

SOLUTION; ORAL

CELEXA

<u>AA</u>	+	FOREST LABS	<u>EQ 10MG BASE/5ML</u>	<u>N021046</u>	<u>001</u>	Dec 22, 1999
-----------	---	-------------	-------------------------	----------------	------------	--------------

CITALOPRAM HYDROBROMIDE

<u>AA</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE/5ML</u>	<u>A077812</u>	<u>001</u>	Aug 28, 2006
-----------	----------------------	-------------------------	----------------	------------	--------------

<u>AA</u>	ROXANE	<u>EQ 10MG BASE/5ML</u>	<u>A077043</u>	<u>001</u>	Dec 13, 2004
-----------	--------	-------------------------	----------------	------------	--------------

<u>AA</u>	SILARX	<u>EQ 10MG BASE/5ML</u>	<u>A077629</u>	<u>001</u>	Jun 15, 2006
-----------	--------	-------------------------	----------------	------------	--------------

TABLET; ORAL

CELEXA

<u>AB</u>	FOREST LABS	<u>EQ 10MG BASE</u>	<u>N020822</u>	<u>001</u>	Apr 27, 2000
-----------	-------------	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N020822</u>	<u>002</u>	Jul 17, 1998
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	+		<u>EQ 40MG BASE</u>	<u>N020822</u>	<u>003</u>	Jul 17, 1998
-----------	---	--	---------------------	----------------	------------	--------------

CITALOPRAM HYDROBROMIDE

<u>AB</u>	ALPHAPHARM	<u>EQ 10MG BASE</u>	<u>A077037</u>	<u>001</u>	Nov 05, 2004
-----------	------------	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077037</u>	<u>002</u>	Nov 05, 2004
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077037</u>	<u>003</u>	Nov 05, 2004
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 10MG BASE</u>	<u>A077289</u>	<u>001</u>	Nov 30, 2006
-----------	------------------	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077289</u>	<u>002</u>	Nov 30, 2006
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077289</u>	<u>003</u>	Nov 30, 2006
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE</u>	<u>A077046</u>	<u>001</u>	Nov 24, 2004
-----------	------------	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077046</u>	<u>002</u>	Nov 24, 2004
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077046</u>	<u>003</u>	Nov 24, 2004
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	AUROBINDO	<u>EQ 10MG BASE</u>	<u>A077031</u>	<u>001</u>	Oct 28, 2004
-----------	-----------	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077031</u>	<u>002</u>	Oct 28, 2004
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077031</u>	<u>003</u>	Oct 28, 2004
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	CARACO	<u>EQ 10MG BASE</u>	<u>A077032</u>	<u>001</u>	Nov 12, 2004
-----------	--------	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077032</u>	<u>002</u>	Nov 12, 2004
-----------	--	---------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 97 (of 393)

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

<u>AB</u>	CARACO	<u>EQ 40MG BASE</u>	<u>A077032</u>	<u>003</u>	Nov 12, 2004
<u>AB</u>	COBALT	<u>EQ 10MG BASE</u>	<u>A077034</u>	<u>001</u>	Jun 30, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077034</u>	<u>002</u>	Jun 30, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077034</u>	<u>003</u>	Jun 30, 2005
<u>AB</u>	COREPHARMA	<u>EQ 10MG BASE</u>	<u>A077036</u>	<u>001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077036</u>	<u>002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077036</u>	<u>003</u>	Oct 28, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A077038</u>	<u>001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077038</u>	<u>002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077038</u>	<u>003</u>	Oct 28, 2004
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A077654</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077654</u>	<u>002</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077654</u>	<u>003</u>	Feb 27, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 10MG BASE</u>	<u>A077534</u>	<u>001</u>	Oct 03, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077534</u>	<u>002</u>	Oct 03, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077534</u>	<u>003</u>	Oct 03, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A077048</u>	<u>001</u>	Nov 16, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077048</u>	<u>002</u>	Nov 16, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077048</u>	<u>003</u>	Nov 16, 2004
<u>AB</u>	MATRIX LABS INC	<u>EQ 10MG BASE</u>	<u>A077042</u>	<u>001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077042</u>	<u>002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077042</u>	<u>003</u>	Nov 05, 2004
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A077039</u>	<u>001</u>	Feb 03, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077039</u>	<u>002</u>	Feb 03, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077039</u>	<u>003</u>	Feb 03, 2005
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A077141</u>	<u>002</u>	Apr 10, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077141</u>	<u>001</u>	Apr 10, 2008
<u>AB</u>	PLIVA	<u>EQ 10MG BASE</u>	<u>A077232</u>	<u>001</u>	Oct 31, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077232</u>	<u>002</u>	Oct 31, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077232</u>	<u>003</u>	Oct 31, 2005
<u>AB</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A077035</u>	<u>001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077035</u>	<u>002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077035</u>	<u>003</u>	Oct 28, 2004
<u>AB</u>	TORRENT PHARMS	<u>EQ 10MG BASE</u>	<u>A078216</u>	<u>001</u>	Mar 27, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078216</u>	<u>002</u>	Mar 27, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078216</u>	<u>003</u>	Mar 27, 2007
<u>AB</u>	WATSON LABS	<u>EQ 10MG BASE</u>	<u>A077044</u>	<u>001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077044</u>	<u>002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077044</u>	<u>003</u>	Nov 05, 2004

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION

RENACIDIN

+ UNITED GUARDIAN 6.602GM/100ML;198MG/100ML;3.177GM/100ML N019481 001 Oct 02, 1990

CITRIC ACID; UREA C-13

FOR SOLUTION; TABLET, FOR SOLUTION; ORAL

IDKIT:HP

+ EXALENZ BIOSCIENCE N/A,4GM;75MG,N/A N021314 001 Dec 17, 2002

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINEAP APP PHARMS 1MG/ML A076571 001 Apr 22, 2004AP BEDFORD 1MG/ML A075405 001 Feb 28, 2000LEUSTATINAP + ORTHO BIOTECH 1MG/ML N020229 001 Feb 26, 1993

## PRESCRIPTION DRUG PRODUCT LIST

3 - 98 (of 393)

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

<u>AB</u>	ABBOTT	<u>125MG/5ML</u>	<u>N050698</u>	<u>001</u>	Dec 23, 1993
<u>AB</u>	+	<u>250MG/5ML</u>	<u>N050698</u>	<u>002</u>	Dec 23, 1993

CLARITHROMYCIN

<u>AB</u>	RANBAXY	<u>125MG/5ML</u>	<u>A065382</u>	<u>001</u>	Aug 30, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065382</u>	<u>002</u>	Aug 30, 2007
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065283</u>	<u>002</u>	Sep 04, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065283</u>	<u>003</u>	Sep 04, 2007

TABLET; ORAL

BIAXIN

<u>AB</u>	+	ABBOTT	<u>250MG</u>	<u>N050662</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>	+		<u>500MG</u>	<u>N050662</u>	<u>002</u>	Oct 31, 1991

CLARITHROMYCIN

<u>AB</u>	APOTEX CORP	<u>250MG</u>	<u>A065384</u>	<u>001</u>	Aug 20, 2007
<u>AB</u>		<u>500MG</u>	<u>A065384</u>	<u>002</u>	Aug 20, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>250MG</u>	<u>A065137</u>	<u>001</u>	May 31, 2005
<u>AB</u>		<u>500MG</u>	<u>A065137</u>	<u>002</u>	May 31, 2005
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A065195</u>	<u>001</u>	Mar 11, 2005
<u>AB</u>		<u>500MG</u>	<u>A065195</u>	<u>002</u>	Mar 11, 2005
<u>AB</u>	RANBAXY	<u>250MG</u>	<u>A065174</u>	<u>001</u>	Sep 24, 2004
<u>AB</u>		<u>500MG</u>	<u>A065174</u>	<u>002</u>	Sep 24, 2004
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A065178</u>	<u>002</u>	May 25, 2004
<u>AB</u>		<u>500MG</u>	<u>A065178</u>	<u>001</u>	May 25, 2004
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065144</u>	<u>001</u>	Oct 18, 2005
<u>AB</u>		<u>500MG</u>	<u>A065136</u>	<u>001</u>	Aug 25, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065155</u>	<u>001</u>	May 31, 2005
<u>AB</u>		<u>500MG</u>	<u>A065155</u>	<u>002</u>	May 31, 2005
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065266</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>500MG</u>	<u>A065266</u>	<u>002</u>	May 31, 2006

TABLET, EXTENDED RELEASE; ORAL

BIAXIN XL

<u>AB</u>	+	ABBOTT	<u>500MG</u>	<u>N050775</u>	<u>001</u>	Mar 03, 2000
-----------	---	--------	--------------	----------------	------------	--------------

CLARITHROMYCIN

<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065250</u>	<u>001</u>	Aug 25, 2005
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065154</u>	<u>001</u>	May 18, 2005
<u>AB</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A065145</u>	<u>001</u>	Jun 24, 2004

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

## TIMENTIN

+	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987
		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986
+		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985
+		EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985
	TIMENTIN IN PLASTIC CONTAINER				
+	GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.5MG BASE/5ML</u>	<u>A074075</u>	<u>001</u>	Oct 31, 1993	
<u>AA</u>	MORTON GROVE	<u>EQ 0.5MG BASE/5ML</u>	<u>A074863</u>	<u>001</u>	Mar 13, 1998	
<u>AA</u>	NOVEX	<u>EQ 0.5MG BASE/5ML</u>	<u>A075703</u>	<u>001</u>	Nov 27, 2000	
<u>AA</u>	SILARX	<u>EQ 0.5MG BASE/5ML</u>	<u>A074884</u>	<u>001</u>	Dec 17, 1997	
<u>AA</u>	+	TEVA	<u>EQ 0.5MG BASE/5ML</u>	<u>A073399</u>	<u>001</u>	Jun 30, 1994

## PRESCRIPTION DRUG PRODUCT LIST

3 - 99 (of 393)

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

<u>AB</u>	SANDOZ	<u>2.68MG</u>	<u>A073459</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>	+ TEVA	<u>2.68MG</u>	<u>A073283</u>	<u>001</u>	Jan 31, 1992

CLEVIDIPINE BUTYRATE

EMULSION; INTRAVENOUS

CLEVIPREX

	+ MEDICINES CO	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008
	+	50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HYDROCHLORIDE

<u>AB</u>	PHARMACIA AND UPJOHN	<u>EQ 75MG BASE</u>	<u>N050162</u>	<u>001</u>	
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>N050162</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N050162</u>	<u>003</u>	Apr 14, 1988

CLINDAMYCIN HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 150MG BASE</u>	<u>A065442</u>	<u>001</u>	Aug 26, 2009
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065442</u>	<u>002</u>	Aug 26, 2009
<u>AB</u>	COREPHARMA	<u>EQ 150MG BASE</u>	<u>A065194</u>	<u>001</u>	Mar 22, 2004
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065194</u>	<u>002</u>	Mar 22, 2004
<u>AB</u>	LANNETT	<u>EQ 75MG BASE</u>	<u>A065242</u>	<u>001</u>	Aug 12, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065242</u>	<u>002</u>	Aug 12, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065243</u>	<u>001</u>	Aug 12, 2005
<u>AB</u>	RANBAXY	<u>EQ 150MG BASE</u>	<u>A065061</u>	<u>001</u>	Feb 02, 2001
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065061</u>	<u>002</u>	Feb 02, 2001
<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A063029</u>	<u>001</u>	Sep 20, 1989
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A063029</u>	<u>002</u>	Aug 05, 2005
<u>AB</u>	WATSON LABS	<u>EQ 150MG BASE</u>	<u>A063083</u>	<u>001</u>	Jul 31, 1991
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A063083</u>	<u>002</u>	Mar 18, 2003
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 75MG BASE</u>	<u>A065217</u>	<u>001</u>	Jan 31, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065217</u>	<u>002</u>	Jan 31, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065217</u>	<u>003</u>	Jan 31, 2005

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

	+ PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML	A062644	001	Apr 07, 1986
--	------------------------	------------------	---------	-----	--------------

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL

EVOCLIN

	+ STIEFEL LABS INC	1%	N050801	001	Oct 22, 2004
--	--------------------	----	---------	-----	--------------

CREAM; VAGINAL

CLEOCIN

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>EQ 2% BASE</u>	<u>N050680</u>	<u>002</u>	Mar 02, 1998
-----------	------------------------	-------------------	----------------	------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AB</u>	ALTANA PHARMA	<u>EQ 2% BASE</u>	<u>A065139</u>	<u>001</u>	Dec 27, 2004
-----------	---------------	-------------------	----------------	------------	--------------

CLINDESSE

	+ KV PHARM	EQ 2% BASE	N050793	001	Nov 30, 2004
--	------------	------------	---------	-----	--------------

GEL; TOPICAL

CLEOCIN T

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050615</u>	<u>001</u>	Jan 07, 1987
-----------	------------------------	-------------------	----------------	------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AB</u>	ALTANA	<u>EQ 1% BASE</u>	<u>A064160</u>	<u>001</u>	Jan 28, 2000
-----------	--------	-------------------	----------------	------------	--------------

CLINDAGEL

BT	GALDERMA LABS LP	EQ 1% BASE	N050782	001	Nov 27, 2000
----	------------------	------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 100 (of 393)

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

<u>AP</u>	PHARMACIA AND UPJOHN	<u>EQ 150MG BASE/ML</u>	<u>A062803</u>	<u>001</u>	Oct 16, 1987
<u>AP</u>	+	<u>EQ 150MG BASE/ML</u>	<u>N050441</u>	<u>001</u>	
	<u>CLINDAMYCIN PHOSPHATE</u>				
<u>AP</u>	APP PHARMS	<u>EQ 150MG BASE/ML</u>	<u>A065346</u>	<u>001</u>	Mar 29, 2007
<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A065347</u>	<u>001</u>	May 09, 2007
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 150MG BASE/ML</u>	<u>A062889</u>	<u>001</u>	Apr 25, 1988
<u>AP</u>	BEDFORD	<u>EQ 150MG BASE/ML</u>	<u>A065206</u>	<u>001</u>	Sep 24, 2004
<u>AP</u>	HOSPIRA	<u>EQ 150MG BASE/ML</u>	<u>A062800</u>	<u>001</u>	Jul 24, 1987
<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A062801</u>	<u>001</u>	Jul 24, 1987
<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A062943</u>	<u>001</u>	Sep 29, 1988
	CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639	001	Aug 30, 1989
+		EQ 12MG BASE/ML	N050639	002	Aug 30, 1989
+		EQ 18MG BASE/ML	N050639	003	Apr 10, 1991
	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%				
+	ABRAXIS PHARM	EQ 900MG BASE/100ML	N050635	001	Dec 22, 1989

LOTION; TOPICAL

CLEOCIN T

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050600</u>	<u>001</u>	May 31, 1989
-----------	---	----------------------	-------------------	----------------	------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AB</u>		ALTANA	<u>EQ 1% BASE</u>	<u>A065067</u>	<u>001</u>	Jan 31, 2002
-----------	--	--------	-------------------	----------------	------------	--------------

SOLUTION; TOPICAL

CLEOCIN T

<u>AT</u>	+	PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537</u>	<u>001</u>	
-----------	---	----------------------	-------------------	----------------	------------	--

CLINDA-DERM

<u>AT</u>		PADDOCK	<u>EQ 1% BASE</u>	<u>A063329</u>	<u>001</u>	Sep 30, 1992
-----------	--	---------	-------------------	----------------	------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AT</u>		ACTAVIS MID ATLANTIC	<u>EQ 1% BASE</u>	<u>A062811</u>	<u>001</u>	Sep 01, 1988
<u>AT</u>		ALTANA	<u>EQ 1% BASE</u>	<u>A065254</u>	<u>001</u>	Feb 14, 2006
<u>AT</u>		FOUGERA	<u>EQ 1% BASE</u>	<u>A064159</u>	<u>001</u>	Jun 05, 1997
<u>AT</u>		MORTON GROVE	<u>EQ 1% BASE</u>	<u>A063304</u>	<u>001</u>	Jul 15, 1997
<u>AT</u>		PERRIGO NEW YORK	<u>EQ 1% BASE</u>	<u>A064050</u>	<u>001</u>	Nov 30, 1995
<u>AT</u>		TARO PHARM INDS	<u>EQ 1% BASE</u>	<u>A065184</u>	<u>001</u>	Mar 31, 2004

SUPPOSITORY; VAGINAL

CLEOCIN

+	PHARMACIA AND UPJOHN	100MG	N050767	001	Aug 13, 1999
---	----------------------	-------	---------	-----	--------------

SWAB; TOPICAL

CLEOCIN

<u>AT</u>		PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537</u>	<u>002</u>	Feb 22, 1994
-----------	--	----------------------	-------------------	----------------	------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AT</u>		PERRIGO NEW YORK	<u>EQ 1% BASE</u>	<u>A065049</u>	<u>001</u>	May 25, 2000
-----------	--	------------------	-------------------	----------------	------------	--------------

CLINDETS

<u>AT</u>		PERRIGO	<u>EQ 1% BASE</u>	<u>A064136</u>	<u>001</u>	Sep 30, 1996
-----------	--	---------	-------------------	----------------	------------	--------------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

ZIANA

+	MEDICIS	1.2%; 0.025%	N050802	001	Nov 07, 2006
---	---------	--------------	---------	-----	--------------

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

<u>AB</u>		PERRIGO ISRAEL	<u>0.05%</u>	<u>A077763</u>	<u>001</u>	Mar 10, 2008
-----------	--	----------------	--------------	----------------	------------	--------------

OLUX

<u>AB</u>	+	CONNETICS	<u>0.05%</u>	<u>N021142</u>	<u>001</u>	May 26, 2000
-----------	---	-----------	--------------	----------------	------------	--------------

OLUX E

+	STIEFFEL LABS INC	0.05%	N022013	001	Jan 12, 2007
---	-------------------	-------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 101 (of 393)

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

<u>AB1</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A074139</u>	<u>001</u>	Aug 03, 1994
<u>AB1</u>	FOUGERA	<u>0.05%</u>	<u>A074392</u>	<u>001</u>	Sep 30, 1996
<u>AB1</u>	TARO	<u>0.05%</u>	<u>A074249</u>	<u>001</u>	Jul 08, 1996
<u>AB1</u>	TEVA PHARMS	<u>0.05%</u>	<u>A074087</u>	<u>001</u>	Feb 16, 1994

CORMAX

<u>AB1</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A074220</u>	<u>001</u>	May 16, 1997
------------	----------------	--------------	----------------	------------	--------------

TEMOVATE

<u>AB1</u> +	ALTANA	<u>0.05%</u>	<u>N019322</u>	<u>001</u>	Dec 27, 1985
--------------	--------	--------------	----------------	------------	--------------

CLOBETASOL PROPIONATE (EMOLLIENT)

<u>AB2</u>	ALTANA	<u>0.05%</u>	<u>A075430</u>	<u>001</u>	May 26, 1999
<u>AB2</u>	TARO	<u>0.05%</u>	<u>A075633</u>	<u>001</u>	May 17, 2000

EMBELINE E

<u>AB2</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A075325</u>	<u>001</u>	Dec 24, 1998
------------	----------------	--------------	----------------	------------	--------------

TEMOVATE E

<u>AB2</u> +	ALTANA	<u>0.05%</u>	<u>N020340</u>	<u>001</u>	Jun 17, 1994
--------------	--------	--------------	----------------	------------	--------------

GEL; TOPICAL

CLOBETASOL PROPIONATE

<u>AB</u>	ALTANA	<u>0.05%</u>	<u>A075368</u>	<u>001</u>	Feb 15, 2000
<u>AB</u>	PERRIGO	<u>0.05%</u>	<u>A075027</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>	TARO	<u>0.05%</u>	<u>A075279</u>	<u>001</u>	May 28, 1999

EMBELINE

<u>AB</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A076141</u>	<u>001</u>	Apr 12, 2002
-----------	----------------	--------------	----------------	------------	--------------

TEMOVATE

<u>AB</u> +	ALTANA	<u>0.05%</u>	<u>N020337</u>	<u>001</u>	Apr 29, 1994
-------------	--------	--------------	----------------	------------	--------------

LOTION; TOPICAL

CLOBETASOL PROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A078223</u>	<u>001</u>	Dec 04, 2008
-----------	----------------------	--------------	----------------	------------	--------------

CLOBEX

<u>AB</u> +	GALDERMA LABS LP	<u>0.05%</u>	<u>N021535</u>	<u>001</u>	Jul 24, 2003
-------------	------------------	--------------	----------------	------------	--------------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A074128</u>	<u>001</u>	Aug 03, 1994
<u>AB</u>	FOUGERA	<u>0.05%</u>	<u>A074407</u>	<u>001</u>	Feb 23, 1996
<u>AB</u>	TARO	<u>0.05%</u>	<u>A074248</u>	<u>001</u>	Jul 12, 1996
<u>AB</u>	TEVA PHARMS	<u>0.05%</u>	<u>A074089</u>	<u>001</u>	Feb 16, 1994

EMBELINE

<u>AB</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A074221</u>	<u>001</u>	Mar 31, 1995
-----------	----------------	--------------	----------------	------------	--------------

TEMOVATE

<u>AB</u> +	ALTANA	<u>0.05%</u>	<u>N019323</u>	<u>001</u>	Dec 27, 1985
-------------	--------	--------------	----------------	------------	--------------

SHAMPOO; TOPICAL

CLOBEX

+	GALDERMA LABS	0.05%	N021644	001	Feb 05, 2004
---	---------------	-------	---------	-----	--------------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A074331</u>	<u>001</u>	Dec 15, 1995
<u>AT</u>	ALTANA	<u>0.05%</u>	<u>A075391</u>	<u>001</u>	Feb 08, 1999
<u>AT</u>	MORTON GROVE	<u>0.05%</u>	<u>A075205</u>	<u>001</u>	Nov 13, 1998
<u>AT</u>	TARO	<u>0.05%</u>	<u>A075224</u>	<u>001</u>	Nov 16, 1998
<u>AT</u>		<u>0.05%</u>	<u>A075363</u>	<u>001</u>	Dec 29, 2000
<u>AT</u>	TOLMAR	<u>0.05%</u>	<u>A076977</u>	<u>001</u>	Aug 05, 2005

EMBELINE

<u>AT</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A074222</u>	<u>001</u>	Dec 06, 1995
-----------	----------------	--------------	----------------	------------	--------------

TEMOVATE

<u>AT</u> +	ALTANA	<u>0.05%</u>	<u>N019966</u>	<u>001</u>	Feb 22, 1990
-------------	--------	--------------	----------------	------------	--------------

SPRAY; TOPICAL

CLOBEX

+	GALDERMA LABS LP	0.05%	N021835	001	Oct 27, 2005
---	------------------	-------	---------	-----	--------------



## PRESCRIPTION DRUG PRODUCT LIST

3 - 102 (of 393)

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

+ DOW PHARM SCIENCES 0.1% N017765 001

CLOFARABINE

INJECTABLE; IV (INFUSION)

CLOLAR

+ GENZYME 20MG/20ML (1MG/ML) N021673 001 Dec 28, 2004

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

+ NOVARTIS 50MG N019500 002 Dec 15, 1986

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMIDAB + SANOFI AVENTIS US 50MG N016131 002CLOMIPHENE CITRATEAB PAR PHARM 50MG A075528 001 Aug 30, 1999SEROPHENEAB EMD SERONO 50MG N018361 001 Mar 22, 1982CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANILAB TYCO HLTHCARE 25MG N019906 001 Dec 29, 1989AB + 50MG N019906 002 Dec 29, 1989AB 75MG N019906 003 Dec 29, 1989CLOMIPRAMINE HYDROCHLORIDEAB MYLAN 25MG A074947 001 Apr 30, 1998AB 50MG A074947 002 Apr 30, 1998AB 75MG A074947 003 Apr 30, 1998AB SANDOZ 25MG A074364 001 Mar 29, 1996AB 50MG A074364 002 Mar 29, 1996AB 75MG A074364 003 Mar 29, 1996AB TARO 25MG A074694 001 Dec 31, 1996AB 50MG A074694 002 Dec 31, 1996AB 75MG A074694 003 Dec 31, 1996AB TEVA 25MG A074958 001 Aug 26, 1997AB 50MG A074958 002 Aug 26, 1997AB 75MG A074958 003 Aug 26, 1997CLONAZEPAM

TABLET; ORAL

CLONAZEPAMAB ACTAVIS ELIZABETH 0.5MG A074869 001 Oct 31, 1996AB 1MG A074869 002 Oct 31, 1996AB 2MG A074869 003 Oct 31, 1996AB ALPHAPHARM 0.5MG A074940 001 Oct 30, 1997AB 1MG A074940 002 Oct 30, 1997AB 2MG A074940 003 Oct 30, 1997AB APOTEX 0.5MG A075468 001 Oct 06, 2000AB 1MG A075468 002 Oct 06, 2000AB 2MG A075468 003 Oct 06, 2000AB CARACO 0.5MG A075423 001 Apr 27, 2001AB 1MG A075423 002 Apr 27, 2001AB 2MG A075423 003 Apr 27, 2001

## PRESCRIPTION DRUG PRODUCT LIST

3 - 103 (of 393)

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A075150</u>	<u>001</u>	Oct 05, 1998
<u>AB</u>		<u>1MG</u>	<u>A075150</u>	<u>002</u>	Oct 05, 1998
<u>AB</u>		<u>2MG</u>	<u>A075150</u>	<u>003</u>	Oct 05, 1998
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074979</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>1MG</u>	<u>A074979</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>		<u>2MG</u>	<u>A074979</u>	<u>003</u>	Aug 29, 1997
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A074569</u>	<u>001</u>	Sep 10, 1996
<u>AB</u>		<u>1MG</u>	<u>A074569</u>	<u>002</u>	Sep 10, 1996
<u>AB</u>		<u>2MG</u>	<u>A074569</u>	<u>003</u>	Sep 10, 1996
<u>AB</u>	VINTAGE PHARMS	<u>0.5MG</u>	<u>A077856</u>	<u>001</u>	Jun 28, 2006
<u>AB</u>		<u>1MG</u>	<u>A077856</u>	<u>002</u>	Jun 28, 2006
<u>AB</u>		<u>2MG</u>	<u>A077856</u>	<u>003</u>	Jun 28, 2006
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A074964</u>	<u>001</u>	Dec 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074964</u>	<u>002</u>	Dec 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074964</u>	<u>003</u>	Dec 30, 1997
	<u>KLONOPIN</u>				
<u>AB</u>	ROCHE	<u>0.5MG</u>	<u>N017533</u>	<u>001</u>	
<u>AB</u>	+	<u>1MG</u>	<u>N017533</u>	<u>002</u>	
<u>AB</u>		<u>2MG</u>	<u>N017533</u>	<u>003</u>	

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAM

<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077194</u>	<u>001</u>	Aug 10, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077194</u>	<u>002</u>	Aug 10, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077194</u>	<u>003</u>	Aug 10, 2005
<u>AB</u>		<u>1MG</u>	<u>A077194</u>	<u>004</u>	Aug 10, 2005
<u>AB</u>		<u>2MG</u>	<u>A077194</u>	<u>005</u>	Aug 10, 2005
<u>AB</u>	KALI LABS	<u>0.125MG</u>	<u>A077171</u>	<u>001</u>	Aug 03, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077171</u>	<u>002</u>	Aug 03, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077171</u>	<u>003</u>	Aug 03, 2005
<u>AB</u>	+	<u>1MG</u>	<u>A077171</u>	<u>004</u>	Aug 03, 2005
<u>AB</u>		<u>2MG</u>	<u>A077171</u>	<u>005</u>	Aug 03, 2005

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CATAPRES-TTS-1

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG/24HR</u>	<u>N018891</u>	<u>001</u>	Oct 10, 1984
	<u>CATAPRES-TTS-2</u>				
<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.2MG/24HR</u>	<u>N018891</u>	<u>002</u>	Oct 10, 1984
	<u>CATAPRES-TTS-3</u>				
<u>AB</u>	+	<u>0.3MG/24HR</u>	<u>N018891</u>	<u>003</u>	Oct 10, 1984

CLONIDINE

<u>AB</u>	AVEVA	<u>0.1MG/24HR</u>	<u>A076157</u>	<u>001</u>	Aug 18, 2009
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076157</u>	<u>002</u>	Aug 18, 2009
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076157</u>	<u>003</u>	Aug 18, 2009

SUSPENSION, EXTENDED RELEASE; ORAL

CLONIDINE

+	TRIS PHARMA	EQ 0.09MG BASE/ML	N022499	001	Dec 03, 2009
---	-------------	-------------------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE

	TRIS PHARMA	EQ 0.17MG BASE	N022500	001	Dec 03, 2009
+		EQ 0.26MG BASE	N022500	002	Dec 03, 2009

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>	PHARMAFORCE	<u>1 MG/10 ML (0.1 MG/ML)</u>	<u>A091104</u>	<u>001</u>	Oct 08, 2009
-----------	-------------	-------------------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 104 (of 393)

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>	PHARMAFORCE	<u>5 MG/10 ML (0.5 MG/ML)</u>	<u>A091104</u>	<u>002</u>	Oct 08, 2009
	<u>DURACLON</u>				
<u>AP</u>	XANODYNE PHARM	<u>1 MG/10 ML (0.1 MG/ML)</u>	<u>N020615</u>	<u>001</u>	Oct 02, 1996
<u>AP</u>	+	<u>5 MG/10 ML (0.5 MG/ML)</u>	<u>N020615</u>	<u>002</u>	Apr 27, 1999

TABLET; ORAL

CATAPRES

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG</u>	<u>N017407</u>	<u>001</u>	
<u>AB</u>		<u>0.2MG</u>	<u>N017407</u>	<u>002</u>	
<u>AB</u>	+	<u>0.3MG</u>	<u>N017407</u>	<u>003</u>	

CLONIDINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A070974</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>		<u>0.2MG</u>	<u>A070975</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>		<u>0.3MG</u>	<u>A070976</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>	DAVA PHARMS INC	<u>0.1MG</u>	<u>A071783</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>		<u>0.2MG</u>	<u>A071784</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>		<u>0.3MG</u>	<u>A071785</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>	IMPAX LABS	<u>0.1MG</u>	<u>A078099</u>	<u>001</u>	Aug 27, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078099</u>	<u>002</u>	Aug 27, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078099</u>	<u>003</u>	Aug 27, 2009
<u>AB</u>	MUTUAL PHARM	<u>0.1MG</u>	<u>A070925</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070924</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070923</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>	MYLAN	<u>0.1MG</u>	<u>A070317</u>	<u>002</u>	Jul 09, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070317</u>	<u>003</u>	Jun 09, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070317</u>	<u>001</u>	Jun 09, 1987
<u>AB</u>	UNICHEM	<u>0.1MG</u>	<u>A078895</u>	<u>001</u>	Aug 26, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078895</u>	<u>002</u>	Aug 26, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078895</u>	<u>003</u>	Aug 26, 2009
<u>AB</u>	VINTAGE	<u>0.1MG</u>	<u>A077901</u>	<u>001</u>	Mar 09, 2007
<u>AB</u>		<u>0.2MG</u>	<u>A077901</u>	<u>002</u>	Mar 09, 2007
<u>AB</u>		<u>0.3MG</u>	<u>A077901</u>	<u>003</u>	Mar 09, 2007
<u>AB</u>	WATSON LABS	<u>0.3MG</u>	<u>A070963</u>	<u>001</u>	Jul 08, 1986
	JENLOGA				
BX	SCIELE PHARMA INC	0.1MG	N022331	001	Sep 30, 2009

CLOPIDOGREL BISULFATE

TABLET; ORAL

## PLAVIX

	SANOFI AVENTIS US	EQ 75MG BASE	N020839	001	Nov 17, 1997
	+	EQ 300MG BASE	N020839	002	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

<u>AB</u>	MYLAN	<u>3.75MG</u>	<u>A071858</u>	<u>002</u>	Jul 17, 1987
<u>AB</u>		<u>7.5MG</u>	<u>A071858</u>	<u>003</u>	Jul 17, 1987
<u>AB</u>		<u>15MG</u>	<u>A071858</u>	<u>001</u>	Jul 17, 1987
<u>AB</u>	RANBAXY	<u>3.75MG</u>	<u>A076911</u>	<u>001</u>	Sep 29, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A076911</u>	<u>002</u>	Sep 29, 2004
<u>AB</u>		<u>15MG</u>	<u>A076911</u>	<u>003</u>	Sep 29, 2004
<u>AB</u>	TARO	<u>3.75MG</u>	<u>A075731</u>	<u>003</u>	Apr 27, 2000
<u>AB</u>		<u>7.5MG</u>	<u>A075731</u>	<u>002</u>	Apr 27, 2000
<u>AB</u>		<u>15MG</u>	<u>A075731</u>	<u>001</u>	Apr 27, 2000
<u>AB</u>	WATSON LABS	<u>3.75MG</u>	<u>A071852</u>	<u>001</u>	Feb 09, 1988
<u>AB</u>		<u>7.5MG</u>	<u>A071853</u>	<u>001</u>	Feb 09, 1988
<u>AB</u>		<u>15MG</u>	<u>A071854</u>	<u>001</u>	Feb 09, 1988

## PRESCRIPTION DRUG PRODUCT LIST

3 - 105 (of 393)

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

GEN-XENE

<u>AB</u>	ALRA	<u>3.75MG</u>	<u>A071787</u>	<u>001</u>	Apr 26, 1988
<u>AB</u>		<u>7.5MG</u>	<u>A071788</u>	<u>001</u>	Apr 26, 1988
<u>AB</u>		<u>15MG</u>	<u>A071789</u>	<u>001</u>	Apr 26, 1988

TRANXENE

<u>AB</u>	LUNDBECK INC	<u>3.75MG</u>	<u>N017105</u>	<u>006</u>	
<u>AB</u>		<u>7.5MG</u>	<u>N017105</u>	<u>007</u>	
<u>AB</u>	+	<u>15MG</u>	<u>N017105</u>	<u>008</u>	

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

<u>AB</u>	NYCOMED US	<u>1%</u>	<u>A078338</u>	<u>001</u>	Sep 02, 2008
<u>AB</u>	+	<u>1%</u>	<u>A072640</u>	<u>001</u>	Aug 31, 1993

SOLUTION; TOPICAL

CLOTRIMAZOLE

<u>AT</u>	TARO	<u>1%</u>	<u>A074580</u>	<u>001</u>	Jul 29, 1996
<u>AT</u>	TEVA	<u>1%</u>	<u>A073306</u>	<u>001</u>	Feb 28, 1995
<u>AT</u>	+	<u>1%</u>	<u>N018181</u>	<u>001</u>	

MYCELEX

TROCHE/LOZENGE; ORAL

CLOTRIMAZOLE

<u>AB</u>	PADDOCK	<u>10MG</u>	<u>A076763</u>	<u>001</u>	Oct 28, 2005
<u>AB</u>	ROXANE	<u>10MG</u>	<u>A076387</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>	+	<u>10MG</u>	<u>N018713</u>	<u>001</u>	Jun 17, 1983

MYCELEXCLOZAPINE

TABLET; ORAL

CLOZAPINE

<u>AB</u>	CARACO	<u>25MG</u>	<u>A075713</u>	<u>001</u>	Nov 15, 2002
<u>AB</u>		<u>50MG</u>	<u>A075713</u>	<u>003</u>	Aug 19, 2005
<u>AB</u>		<u>100MG</u>	<u>A075713</u>	<u>002</u>	Nov 15, 2002
<u>AB</u>	GOLDLINE	<u>50MG</u>	<u>A076809</u>	<u>003</u>	Dec 16, 2005
<u>AB</u>		<u>100MG</u>	<u>A076809</u>	<u>002</u>	Dec 16, 2005
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A074949</u>	<u>001</u>	Nov 26, 1997
<u>AB</u>		<u>50MG</u>	<u>A074949</u>	<u>004</u>	Apr 25, 2005
<u>AB</u>		<u>100MG</u>	<u>A074949</u>	<u>002</u>	Nov 26, 1997
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A075417</u>	<u>001</u>	May 27, 1999
<u>AB</u>		<u>100MG</u>	<u>A075417</u>	<u>002</u>	May 27, 1999

CLOZARIL

<u>AB</u>	NOVARTIS	<u>25MG</u>	<u>N019758</u>	<u>001</u>	Sep 26, 1989
<u>AB</u>	+	<u>100MG</u>	<u>N019758</u>	<u>002</u>	Sep 26, 1989

CLOZAPINE

	GOLDLINE	200MG	A076809	001	Dec 16, 2005
	IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

	AZUR PHARMA INTL	12.5MG	N021590	004	May 30, 2007
		25MG	N021590	001	Feb 10, 2004
	+	100MG	N021590	002	Feb 10, 2004

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

<u>AA</u>	VINTAGE	<u>10MG/5ML; 5MG/5ML; 6.25MG/5ML</u>	<u>A040660</u>	<u>001</u>	Dec 07, 2006
-----------	---------	--------------------------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 106 (of 393)

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH VC W/ CODEINE

<u>AA</u>	+	ACTAVIS MID ATLANTIC	<u>10MG/5ML;5MG/5ML;6.25MG/5ML</u>	<u>A088764</u>	<u>001</u>	Oct 31, 1984
-----------	---	----------------------	------------------------------------	----------------	------------	--------------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

<u>AA</u>	+	ACTAVIS MID ATLANTIC	<u>10MG/5ML;6.25MG/5ML</u>	<u>A088763</u>	<u>001</u>	Oct 31, 1984
-----------	---	----------------------	----------------------------	----------------	------------	--------------

<u>AA</u>		HI TECH PHARMA	<u>10MG/5ML;6.25MG/5ML</u>	<u>A040151</u>	<u>001</u>	Aug 26, 1997
-----------	--	----------------	----------------------------	----------------	------------	--------------

<u>AA</u>		MORTON GROVE	<u>10MG/5ML;6.25MG/5ML</u>	<u>A088875</u>	<u>001</u>	Dec 17, 1984
-----------	--	--------------	----------------------------	----------------	------------	--------------

<u>AA</u>		PHARM ASSOC	<u>10MG/5ML;6.25MG/5ML</u>	<u>A089647</u>	<u>001</u>	Dec 22, 1988
-----------	--	-------------	----------------------------	----------------	------------	--------------

PROMETHAZINE WITH CODEINE

<u>AA</u>		VINTAGE	<u>10MG/5ML;6.25MG/5ML</u>	<u>A040650</u>	<u>001</u>	Jan 31, 2006
-----------	--	---------	----------------------------	----------------	------------	--------------

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIACIN-C

	+	STI PHARMA LLC	10MG/5ML;30MG/5ML;1.25MG/5ML	A088704	001	Mar 22, 1985
--	---	----------------	------------------------------	---------	-----	--------------

CODEINE SULFATE

TABLET; ORAL

CODEINE SULFATE

ROXANE

		15MG	N022402	001	Jul 16, 2009
--	--	------	---------	-----	--------------

		30MG	N022402	002	Jul 16, 2009
--	--	------	---------	-----	--------------

+		60MG	N022402	003	Jul 16, 2009
---	--	------	---------	-----	--------------

COLCHICINE

TABLET; ORAL

COLCRYS

	+	AR HOLDING CO INC	0.6MG	N022352	001	Jul 29, 2009
--	---	-------------------	-------	---------	-----	--------------

COLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID

<u>AB</u>	+	WATSON LABS	<u>0.5MG;500MG</u>	<u>A084279</u>	<u>001</u>	
-----------	---	-------------	--------------------	----------------	------------	--

PROBENECID AND COLCHICINE

<u>AB</u>		CONCORD LABS NJ	<u>0.5MG;500MG</u>	<u>A040618</u>	<u>001</u>	May 13, 2008
-----------	--	-----------------	--------------------	----------------	------------	--------------

PROBENECID AND COLCHICINE

BP		IVAX SUB TEVA PHARMS	0.5MG;500MG	A083734	001	
----	--	----------------------	-------------	---------	-----	--

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

WELCHOL

		DAIICHI SANKYO	1.875GM/PACKET	N022362	001	Oct 02, 2009
--	--	----------------	----------------	---------	-----	--------------

+			3.75GM/PACKET	N022362	002	Oct 02, 2009
---	--	--	---------------	---------	-----	--------------

TABLET; ORAL

WELCHOL

	+	DAIICHI SANKYO	625MG	N021176	001	May 26, 2000
--	---	----------------	-------	---------	-----	--------------

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

<u>AB</u>		PHARMACIA AND UPJOHN	<u>5GM/SCOOPFUL</u>	<u>N017563</u>	<u>003</u>	Sep 22, 1995
-----------	--	----------------------	---------------------	----------------	------------	--------------

<u>AB</u>	+		<u>5GM/PACKET</u>	<u>N017563</u>	<u>004</u>	Sep 22, 1995
-----------	---	--	-------------------	----------------	------------	--------------

COLESTIPOL HYDROCHLORIDE

<u>AB</u>		IMPAX LABS	<u>5GM/SCOOPFUL</u>	<u>A077277</u>	<u>001</u>	May 02, 2006
-----------	--	------------	---------------------	----------------	------------	--------------

<u>AB</u>			<u>5GM/PACKET</u>	<u>A077277</u>	<u>002</u>	May 02, 2006
-----------	--	--	-------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 107 (of 393)

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

FLAVORED COLESTID

PHARMACIA AND UPJOHN	5GM/SCOOPFUL	N017563	002	
	5GM/PACKET	N017563	001	

TABLET; ORAL

COLESTID

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>1GM</u>	<u>N020222</u>	<u>001</u>	Jul 19, 1994
		<u>COLESTIPOL HYDROCHLORIDE</u>				
<u>AB</u>		IMPAX LABS	<u>1GM</u>	<u>A077510</u>	<u>001</u>	Oct 24, 2006

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

<u>AP</u>		APP PHARMS	<u>EQ 150MG BASE/VIAL</u>	<u>A065364</u>	<u>001</u>	Apr 17, 2008
<u>AP</u>		PADDOCK	<u>EQ 150MG BASE/VIAL</u>	<u>A065177</u>	<u>001</u>	Mar 19, 2004
<u>AP</u>		X GEN PHARMS	<u>EQ 150MG BASE/VIAL</u>	<u>A064216</u>	<u>001</u>	Feb 26, 1999
		<u>COLY-MYCIN M</u>				
<u>AP</u>	+	JHP PHARMS	<u>EQ 150MG BASE/VIAL</u>	<u>N050108</u>	<u>002</u>	

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+	JHP PHARMS	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001	
---	------------	---	---------	-----	--

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

+	ASTELLAS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008
---	----------	-----------------------	---------	-----	--------------

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+	DURAMED RES	309MG/COPPER	N018680	001	Nov 15, 1984
---	-------------	--------------	---------	-----	--------------

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE; INJECTION

ACTHREL

+	FERRING	EQ 0.1MG BASE/VIAL	N020162	001	May 23, 1996
---	---------	--------------------	---------	-----	--------------

CORTICOTROPIN

INJECTABLE; INJECTION

H.P. ACTHAR GEL

+	QUESTCOR PHARMS	80 UNITS/ML	N008372	008	
---	-----------------	-------------	---------	-----	--

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

+	WEST WARD	25MG	A080776	002	
---	-----------	------	---------	-----	--

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

<u>AP</u>	+	AMPHASTAR	<u>0.25MG/VIAL</u>	<u>N016750</u>	<u>001</u>	
		<u>COSYNTROPIN</u>				

<u>AP</u>		GENERAMEDIX	<u>0.25MG/VIAL</u>	<u>A090574</u>	<u>001</u>	Dec 17, 2009
-----------	--	-------------	--------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 108 (of 393)

COSYNTROPINSOLUTION; INTRAVENOUS  
COSYNTROPIN

SANDOZ 0.25MG/ML (0.25MG/ML) N022028 001 Feb 21, 2008

CROMOLYN SODIUMAEROSOL, METERED; INHALATION  
INTAL

+ KING PHARMS 0.8MG/INH N018887 001 Dec 05, 1985

CONCENTRATE; ORAL

CROMOLYN SODIUMAA + GENERA PHARMS 100MG/5ML A090954 001 Dec 18, 2009GASTROCROMAA + AZUR PHARMA 100MG/5ML N020479 001 Feb 29, 1996

SOLUTION; INHALATION

CROMOLYN SODIUMAN ACTAVIS MID ATLANTIC 10MG/ML A075067 001 Jul 19, 1999AN BAUSCH AND LOMB 10MG/ML A075585 001 Dec 21, 2000AN DEY 10MG/ML A074209 001 Apr 26, 1994AN MORTON GROVE 10MG/ML A075346 001 Oct 25, 1999AN NOVEX 10MG/ML A075333 001 Apr 30, 2002AN RESPIRARE 10MG/ML A076469 001 Jun 17, 2005AN + TEVA PARENTERAL 10MG/ML A075271 001 Jan 18, 2000

SOLUTION/DROPS; OPHTHALMIC

CROLOMAT BAUSCH AND LOMB 4% A074443 001 Jan 30, 1995CROMOLYN SODIUMAT AKORN 4% A074706 001 Apr 29, 1998AT ALCON 4% A075282 001 Jun 16, 1999AT NOVEX 4% A075615 001 Jan 26, 2001OPTICROMAT + ALLERGAN 4% N018155 001 Oct 03, 1984CROTAMITONCREAM; TOPICAL  
EURAX

+ RANBAXY 10% N006927 001

LOTION; TOPICAL

CROTANAT SUMMERS 10% A087204 001EURAXAT + RANBAXY 10% N009112 003CUPRIC CHLORIDEINJECTABLE; INJECTION  
CUPRIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA EQ 0.4MG COPPER/ML N018960 001 Jun 26, 1986

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMINAP + LUITPOLD 1MG/ML A080737 001VIBISONEAP + APP PHARMS 1MG/ML A080557 003

SPRAY, METERED; NASAL

## CALOMIST

+ FLEMING 25MCG/SPRAY N022102 001 Jul 27, 2007

## NASCOBAL

+ PAR PHARM 0.5MG/SPRAY N021642 001 Jan 31, 2005

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 135 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 109 (of 393)

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

ANESTA AG	15MG	N021777	001	Feb 01, 2007
+	30MG	N021777	002	Feb 01, 2007

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>5MG</u>	<u>A077291</u>	<u>001</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A077209</u>	<u>001</u>	Oct 04, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078643</u>	<u>001</u>	Sep 26, 2008
<u>AB</u>		<u>10MG</u>	<u>A078643</u>	<u>002</u>	Sep 26, 2008
<u>AB</u>	CADISTA PHARMS	<u>5MG</u>	<u>A077563</u>	<u>001</u>	Apr 19, 2006
<u>AB</u>		<u>10MG</u>	<u>A077563</u>	<u>002</u>	Apr 19, 2006
<u>AB</u>	MUTUAL PHARM	<u>5MG</u>	<u>A073541</u>	<u>002</u>	Apr 06, 2006
<u>AB</u>		<u>10MG</u>	<u>A073541</u>	<u>001</u>	May 23, 1995
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A073144</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A073144</u>	<u>001</u>	May 30, 1991
<u>AB</u>	ORIT LABS LLC	<u>10MG</u>	<u>A078218</u>	<u>001</u>	Apr 18, 2008
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A074421</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A078722</u>	<u>001</u>	May 12, 2008
<u>AB</u>		<u>7.5MG</u>	<u>A078722</u>	<u>002</u>	May 12, 2008
<u>AB</u>		<u>10MG</u>	<u>A078722</u>	<u>003</u>	May 12, 2008
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A072854</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A072854</u>	<u>001</u>	Nov 19, 1991
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A077797</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>		<u>10MG</u>	<u>A077797</u>	<u>002</u>	Feb 28, 2007
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A071611</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A071611</u>	<u>003</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A071611</u>	<u>001</u>	May 03, 1989
	<u>FLEXERIL</u>				
<u>AB</u>	MCNEIL PED	<u>5MG</u>	<u>N017821</u>	<u>001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N017821</u>	<u>002</u>	

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

<u>AT</u>	AKORN	<u>1%</u>	<u>A040164</u>	<u>001</u>	Jan 13, 1997
<u>AT</u>		<u>2%</u>	<u>A040165</u>	<u>001</u>	Jan 13, 1997

CYCLOGYL

<u>AT</u>	+	ALCON	<u>1%</u>	<u>A084110</u>	<u>001</u>
<u>AT</u>	+		<u>2%</u>	<u>A084108</u>	<u>001</u>

PENTOLAIR

<u>AT</u>	BAUSCH AND LOMB	<u>1%</u>	<u>A040075</u>	<u>001</u>	Apr 29, 1994
	CYCLOGYL				
	+	ALCON	0.5%	A084109	001

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

+	ALCON	0.2%;1%	A084300	001
---	-------	---------	---------	-----

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

<u>AP</u>	BAXTER HLTHCARE	<u>500MG/VIAL</u>	<u>A040745</u>	<u>001</u>	May 21, 2008
<u>AP</u>		<u>1GM/VIAL</u>	<u>A040745</u>	<u>002</u>	May 21, 2008
<u>AP</u>		<u>2GM/VIAL</u>	<u>A040745</u>	<u>003</u>	May 21, 2008

LYOPHILIZED CYTOXAN

<u>AP</u>	+	BAXTER HLTHCARE	<u>500MG/VIAL</u>	<u>N012142</u>	<u>008</u>	Jan 04, 1984
<u>AP</u>	+		<u>1GM/VIAL</u>	<u>N012142</u>	<u>010</u>	Sep 24, 1985



## PRESCRIPTION DRUG PRODUCT LIST

3 - 110 (of 393)

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

LYOPHILIZED CYTOXAN

<u>AP</u> +	BAXTER HLTHCARE	<u>2GM/VIAL</u>	<u>N012142</u>	<u>009</u>	Dec 10, 1984
	LYOPHILIZED CYTOXAN				
+	BAXTER HLTHCARE	100MG/VIAL	N012142	006	Dec 05, 1985
+		200MG/VIAL	N012142	007	Dec 10, 1985

TABLET; ORAL

CYCLOPHOSPHAMIDE

	ROXANE	25MG	A040032	001	Aug 17, 1999
+		50MG	A040032	002	Aug 17, 1999

CYCLOSERINE

CAPSULE; ORAL

SEROMYCIN

+	PURDUE GMP	250MG	A060593	001	
---	------------	-------	---------	-----	--

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A065110</u>	<u>003</u>	Mar 29, 2005
<u>AB1</u>		<u>50MG</u>	<u>A065110</u>	<u>001</u>	Mar 29, 2005
<u>AB1</u>		<u>100MG</u>	<u>A065110</u>	<u>002</u>	Mar 29, 2005
<u>AB1</u>	PLIVA	<u>25MG</u>	<u>A065044</u>	<u>002</u>	Dec 20, 2000
<u>AB1</u>		<u>100MG</u>	<u>A065044</u>	<u>001</u>	Dec 20, 2000
<u>AB1</u>	SANDOZ	<u>25MG</u>	<u>A065017</u>	<u>002</u>	Jan 13, 2000
<u>AB1</u>		<u>100MG</u>	<u>A065017</u>	<u>001</u>	Jan 13, 2000
	<u>GENGRAF</u>				
<u>AB1</u>	ABBOTT	<u>25MG</u>	<u>A065003</u>	<u>001</u>	May 12, 2000
<u>AB1</u>		<u>50MG</u>	<u>A065003</u>	<u>002</u>	May 12, 2000
<u>AB1</u>		<u>100MG</u>	<u>A065003</u>	<u>003</u>	May 12, 2000
	<u>NEORAL</u>				
<u>AB1</u>	NOVARTIS	<u>25MG</u>	<u>N050715</u>	<u>001</u>	Jul 14, 1995
<u>AB1</u> +		<u>100MG</u>	<u>N050715</u>	<u>002</u>	Jul 14, 1995
	<u>CYCLOSPORINE</u>				
<u>AB2</u>	APOTEX	<u>25MG</u>	<u>A065040</u>	<u>001</u>	May 09, 2002
<u>AB2</u>		<u>100MG</u>	<u>A065040</u>	<u>002</u>	May 09, 2002
	<u>SANDIMMUNE</u>				
<u>AB2</u>	NOVARTIS	<u>25MG</u>	<u>N050625</u>	<u>001</u>	Mar 02, 1990
<u>AB2</u> +		<u>100MG</u>	<u>N050625</u>	<u>002</u>	Mar 02, 1990
	SANDIMMUNE				
BX	NOVARTIS	50MG	N050625	003	Nov 23, 1992

EMULSION; OPHTHALMIC

RESTASIS

+	ALLERGAN	0.05%	N050790	001	Dec 23, 2002
---	----------	-------	---------	-----	--------------

INJECTABLE; INJECTION

CYCLOSPORINE

<u>AP</u>	BEDFORD	<u>50MG/ML</u>	<u>A065004</u>	<u>001</u>	Oct 29, 1999
<u>AP</u>	PHARMAFORCE	<u>50MG/ML</u>	<u>A065151</u>	<u>001</u>	Oct 07, 2003
	<u>SANDIMMUNE</u>				
<u>AP</u> +	NOVARTIS	<u>50MG/ML</u>	<u>N050573</u>	<u>001</u>	Nov 14, 1983

SOLUTION; ORAL

CYCLOSPORINE

<u>AB1</u>	ABBOTT	<u>100MG/ML</u>	<u>A065025</u>	<u>001</u>	Mar 03, 2000
<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>100MG/ML</u>	<u>A065078</u>	<u>001</u>	Mar 25, 2005
<u>AB1</u>	NOVEX	<u>100MG/ML</u>	<u>A065167</u>	<u>001</u>	Jan 05, 2005
<u>AB1</u>	WATSON LABS	<u>100MG/ML</u>	<u>A065054</u>	<u>001</u>	Dec 18, 2001
	<u>NEORAL</u>				
<u>AB1</u> +	NOVARTIS	<u>100MG/ML</u>	<u>N050716</u>	<u>001</u>	Jul 14, 1995

## PRESCRIPTION DRUG PRODUCT LIST

3 - 111 (of 393)

CYCLOSPORINE

SOLUTION; ORAL

CYCLOSPORINE

<u>AB2</u>	MORTON GROVE	<u>100MG/ML</u>	<u>A065133</u>	<u>001</u>	Sep 17, 2004
<u>AB2</u>	+ NOVARTIS	<u>100MG/ML</u>	<u>N050574</u>	<u>001</u>	Nov 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>2MG/5ML</u>	<u>A086833</u>	<u>001</u>	
<u>AA</u>	LYNE	<u>2MG/5ML</u>	<u>A040668</u>	<u>001</u>	Jun 28, 2006

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

<u>AA</u>	COREPHARMA	<u>4MG</u>	<u>A040537</u>	<u>001</u>	Sep 30, 2003
<u>AA</u>	+ IVAX PHARMS	<u>4MG</u>	<u>A087056</u>	<u>001</u>	
<u>AA</u>	PAR PHARM	<u>4MG</u>	<u>A087129</u>	<u>001</u>	
<u>AA</u>	PLIVA	<u>4MG</u>	<u>A088205</u>	<u>001</u>	Jul 26, 1983
<u>AA</u>	STASON PHARMS	<u>4MG</u>	<u>A040644</u>	<u>001</u>	May 30, 2006

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

CYSTAGON

	MYLAN	EQ 50MG BASE	N020392	001	Aug 15, 1994
+		EQ 150MG BASE	N020392	002	Aug 15, 1994

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

<u>AP</u>	+ APP PHARMS	<u>100MG/ML</u>	<u>A076512</u>	<u>001</u>	Jan 15, 2004
<u>AP</u>	BEDFORD	<u>100MG/VIAL</u>	<u>A071471</u>	<u>001</u>	Aug 02, 1989
<u>AP</u>		<u>500MG/VIAL</u>	<u>A071472</u>	<u>001</u>	Aug 02, 1989
<u>AP</u>		<u>1GM/VIAL</u>	<u>A074245</u>	<u>001</u>	Aug 31, 1994
<u>AP</u>		<u>2GM/VIAL</u>	<u>A074245</u>	<u>002</u>	Aug 31, 1994
<u>AP</u>	HOSPIRA	<u>20MG/ML</u>	<u>A071868</u>	<u>001</u>	Jun 04, 1990
<u>AP</u>	+	<u>20MG/ML</u>	<u>A072945</u>	<u>001</u>	Feb 28, 1994
<u>AP</u>		<u>100MG/ML</u>	<u>A075383</u>	<u>001</u>	Nov 22, 1999

CYTOSAR-U

<u>AP</u>	TEVA PARENTERAL	<u>100MG/VIAL</u>	<u>A075206</u>	<u>001</u>	Dec 30, 1998
<u>AP</u>	+	<u>500MG/VIAL</u>	<u>A075206</u>	<u>002</u>	Dec 30, 1998
<u>AP</u>	+	<u>1GM/VIAL</u>	<u>A075206</u>	<u>004</u>	Dec 30, 1998
<u>AP</u>	+	<u>2GM/VIAL</u>	<u>A075206</u>	<u>003</u>	Dec 30, 1998
	CYTARABINE				
	HOSPIRA	20MG/ML	A072168	001	Aug 31, 1990

INJECTABLE, LIPOSOMAL; INJECTION

DEPOCYT

+	PACIRA PHARMS INC	10MG/ML	N021041	001	Apr 01, 1999
---	-------------------	---------	---------	-----	--------------

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

<u>AP</u>	APP PHARMS	<u>100MG/VIAL</u>	<u>A075371</u>	<u>001</u>	Aug 27, 1999
<u>AP</u>		<u>200MG/VIAL</u>	<u>A075371</u>	<u>002</u>	Aug 27, 1999
<u>AP</u>	BEDFORD	<u>200MG/VIAL</u>	<u>A075812</u>	<u>001</u>	Jun 15, 2001
<u>AP</u>		<u>500MG/VIAL</u>	<u>A075812</u>	<u>002</u>	Oct 31, 2002
<u>AP</u>	HOSPIRA	<u>200MG/VIAL</u>	<u>A075940</u>	<u>001</u>	Oct 18, 2001
<u>AP</u>	TEVA PARENTERAL	<u>200MG/VIAL</u>	<u>A075259</u>	<u>002</u>	Aug 27, 1998
<u>AP</u>	+	<u>500MG/VIAL</u>	<u>A075259</u>	<u>001</u>	Sep 22, 2000

## PRESCRIPTION DRUG PRODUCT LIST

3 - 112 (of 393)

DACARBAZINE

INJECTABLE; INJECTION

DTIC-DOME

<u>AP</u>	+	BAYER HLTHCARE	<u>100MG/VIAL</u>	<u>N017575</u>	<u>001</u>	
<u>AP</u>	+		<u>200MG/VIAL</u>	<u>N017575</u>	<u>002</u>	

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

+	LUNDBECK INC	0.5MG/VIAL		N050682	001	
---	--------------	------------	--	---------	-----	--

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

+	KING PHARMS	350MG/VIAL;150MG/VIAL		N050748	001	Sep 21, 1999
---	-------------	-----------------------	--	---------	-----	--------------

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

FRAGMIN

	EISAI INC	2,500IU/0.2ML (12,500IU/ML)		N020287	001	Dec 22, 1994
		5,000IU/0.2ML (25,000IU/ML)		N020287	003	Mar 18, 1996
		7,500IU/0.3ML (25,000IU/ML)		N020287	005	Apr 04, 2002
		10,000IU/ML (10,000IU/ML)		N020287	004	Jan 30, 1998
		10,000IU/0.4ML (25,000IU/ML)		N020287	002	May 01, 2007
		12,500IU/0.5ML (25,000IU/ML)		N020287	009	May 01, 2007
		15,000IU/0.6ML (25,000IU/ML)		N020287	010	May 01, 2007
		18,000IU/0.72ML (25,000IU/ML)		N020287	011	May 01, 2007
		95,000IU/9.5ML (10,000IU/ML)		N020287	007	Apr 04, 2002
+		95,000IU/3.8ML (25,000IU/ML)		N020287	006	Apr 04, 2002

DANAZOL

CAPSULE; ORAL

DANAZOL

<u>AB</u>		BARR	<u>50MG</u>	<u>A074582</u>	<u>003</u>	May 29, 1998
<u>AB</u>			<u>100MG</u>	<u>A074582</u>	<u>002</u>	May 29, 1998
<u>AB</u>	+		<u>200MG</u>	<u>A074582</u>	<u>001</u>	Aug 09, 1996
<u>AB</u>		LANNETT	<u>50MG</u>	<u>A078214</u>	<u>001</u>	Apr 19, 2007
<u>AB</u>			<u>100MG</u>	<u>A078214</u>	<u>002</u>	Apr 19, 2007
<u>AB</u>			<u>200MG</u>	<u>A077246</u>	<u>001</u>	Sep 28, 2005

DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIUM

<u>AB</u>		JHP PHARMS	<u>25MG</u>	<u>N017443</u>	<u>001</u>	
<u>AB</u>			<u>50MG</u>	<u>N017443</u>	<u>003</u>	
<u>AB</u>	+		<u>100MG</u>	<u>N017443</u>	<u>002</u>	

DANTROLENE SODIUM

<u>AB</u>		ACTAVIS TOTOWA	<u>25MG</u>	<u>A076686</u>	<u>001</u>	Oct 24, 2005
<u>AB</u>			<u>50MG</u>	<u>A076686</u>	<u>002</u>	Oct 24, 2005
<u>AB</u>			<u>100MG</u>	<u>A076686</u>	<u>003</u>	Oct 24, 2005
<u>AB</u>		IMPAX LABS	<u>25MG</u>	<u>A076856</u>	<u>001</u>	Mar 01, 2005
<u>AB</u>			<u>50MG</u>	<u>A076856</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>			<u>100MG</u>	<u>A076856</u>	<u>003</u>	Mar 01, 2005

INJECTABLE; INJECTION

DANTRIUM

<u>AP</u>	+	JHP PHARMS	<u>20MG/VIAL</u>	<u>N018264</u>	<u>001</u>	
-----------	---	------------	------------------	----------------	------------	--

DANTROLENE SODIUM

<u>AP</u>		US WORLDMEDS	<u>20MG/VIAL</u>	<u>A078378</u>	<u>001</u>	Jul 24, 2007
-----------	--	--------------	------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 113 (of 393)

DAPSONE

GEL; TOPICAL				
ACZONE				
+	ALLERGAN	5%	N021794	001 Jul 07, 2005
TABLET; ORAL				
DAPSONE				
	JACOBUS	25MG	A086841	001
+		100MG	A086842	001

DAPTOMYCIN

INJECTABLE; IV (INFUSION)				
+	CUBIST	500MG/VIAL	N021572	002 Sep 12, 2003

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL				
ENABLEX				
	NOVARTIS	EQ 7.5MG BASE	N021513	001 Dec 22, 2004
+		EQ 15MG BASE	N021513	002 Dec 22, 2004

DARUNAVIR ETHANOLATE

TABLET; ORAL				
PREZISTA				
	CENTOCOR ORTHO	EQ 75MG BASE	N021976	004 Dec 18, 2008
		EQ 150MG BASE	N021976	005 Dec 18, 2008
		EQ 300MG BASE	N021976	001 Jun 23, 2006
		EQ 400MG BASE	N021976	003 Oct 21, 2008
+		EQ 600MG BASE	N021976	002 Feb 25, 2008

DASATINIB

TABLET; ORAL				
SPRYCEL				
	BRISTOL MYERS SQUIBB	20MG	N021986	001 Jun 28, 2006
		50MG	N021986	002 Jun 28, 2006
		70MG	N021986	003 Jun 28, 2006
+		100MG	N021986	004 May 30, 2008

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION				
<u>CERUBIDINE</u>				
<u>AP</u>	+	BEDFORD	<u>EQ 20MG BASE/VIAL</u>	<u>A064103</u> <u>001</u> Feb 03, 1995
<u>DAUNORUBICIN HYDROCHLORIDE</u>				
<u>AP</u>		APP PHARMS	<u>EQ 20MG BASE/VIAL</u>	<u>A065000</u> <u>001</u> May 25, 1999
<u>AP</u>	+	BEDFORD	<u>EQ 5MG BASE/ML</u>	<u>N050731</u> <u>001</u> Jan 30, 1998
<u>AP</u>		TEVA PARENTERAL	<u>EQ 5MG BASE/ML</u>	<u>A065035</u> <u>001</u> Jan 24, 2000
DAUNORUBICIN HYDROCHLORIDE				
		APP PHARMS	EQ 5MG BASE/VIAL	A065034 001 Nov 20, 2001

DECITABINE

INJECTABLE; INTRAVENOUS				
DACOGEN				
+	EISAI INC	50MG/VIAL	N021790	001 May 02, 2006

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL				
EXJADE				
	NOVARTIS	125MG	N021882	001 Nov 02, 2005
		250MG	N021882	002 Nov 02, 2005
+		500MG	N021882	003 Nov 02, 2005

## PRESCRIPTION DRUG PRODUCT LIST

3 - 114 (of 393)

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

<u>AP</u>	APP PHARMS	<u>500MG/VIAL</u>	<u>A078718</u>	<u>001</u>	Sep 15, 2009
<u>AP</u>		<u>2GM/VIAL</u>	<u>A078718</u>	<u>002</u>	Sep 15, 2009
<u>AP</u>	BEDFORD	<u>500MG/VIAL</u>	<u>A078086</u>	<u>001</u>	May 30, 2007
<u>AP</u>		<u>2GM/VIAL</u>	<u>A078086</u>	<u>002</u>	May 30, 2007
<u>AP</u>	HOSPIRA	<u>500MG/VIAL</u>	<u>A076019</u>	<u>001</u>	Mar 17, 2004
<u>AP</u>		<u>2GM/VIAL</u>	<u>A076019</u>	<u>002</u>	Mar 17, 2004
<u>AP</u>	WATSON LABS	<u>500MG/VIAL</u>	<u>A076806</u>	<u>001</u>	Mar 31, 2006
<u>AP</u>		<u>2GM/VIAL</u>	<u>A076806</u>	<u>002</u>	Mar 31, 2006
	<u>DESFERAL</u>				
<u>AP</u>	+ NOVARTIS	<u>500MG/VIAL</u>	<u>N016267</u>	<u>001</u>	
<u>AP</u>	+	<u>2GM/VIAL</u>	<u>N016267</u>	<u>002</u>	May 25, 2000

DEGARELIX ACETATE

POWDER; SUBCUTANEOUS

FIRMAGON

	FERRING	EQ 80MG BASE/VIAL	N022201	001	Dec 24, 2008
+		EQ 120MG BASE/VIAL	N022201	002	Dec 24, 2008

DELAVIRDINE MESYLATE

TABLET; ORAL

RESCRIPTOR

	VIIV HLTHCARE	100MG	N020705	001	Apr 04, 1997
+		200MG	N020705	002	Jul 14, 1999

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

<u>AB</u>	STIEFEL	<u>150MG</u>	<u>N050261</u>	<u>002</u>	
<u>AB</u>	+	<u>300MG</u>	<u>N050261</u>	<u>003</u>	

DEMECLOCYCLINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARM	<u>150MG</u>	<u>A065425</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>		<u>300MG</u>	<u>A065425</u>	<u>002</u>	Feb 27, 2008
<u>AB</u>	BARR	<u>150MG</u>	<u>A065171</u>	<u>001</u>	Dec 13, 2004
<u>AB</u>		<u>300MG</u>	<u>A065171</u>	<u>002</u>	Dec 13, 2004
<u>AB</u>	COVENANT PHARMA INC	<u>150MG</u>	<u>A065389</u>	<u>001</u>	Dec 01, 2008
<u>AB</u>		<u>300MG</u>	<u>A065389</u>	<u>002</u>	Dec 01, 2008
<u>AB</u>	IMPAX LABS	<u>150MG</u>	<u>A065094</u>	<u>001</u>	Mar 22, 2004
<u>AB</u>		<u>300MG</u>	<u>A065094</u>	<u>002</u>	Mar 22, 2004

DESFLURANE

LIQUID; INHALATION

SUPRANE

+	BAXTER HLTHCARE CORP	99.9%	N020118	001	Sep 18, 1992
---	----------------------	-------	---------	-----	--------------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>10MG</u>	<u>A074430</u>	<u>001</u>	Feb 09, 1996
<u>AB</u>		<u>25MG</u>	<u>A071601</u>	<u>001</u>	Jun 05, 1987
<u>AB</u>		<u>75MG</u>	<u>A071602</u>	<u>001</u>	Oct 05, 1987
<u>AB</u>		<u>100MG</u>	<u>A071766</u>	<u>001</u>	Oct 05, 1987
<u>AB</u>		<u>150MG</u>	<u>A074430</u>	<u>002</u>	Feb 09, 1996
<u>AB</u>	AMIDE PHARM	<u>50MG</u>	<u>A071588</u>	<u>001</u>	Jun 05, 1987
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A072099</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>25MG</u>	<u>A072100</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>50MG</u>	<u>A072101</u>	<u>001</u>	May 24, 1988

## PRESCRIPTION DRUG PRODUCT LIST

3 - 115 (of 393)

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A072102</u>	<u>001</u>	Jun 20, 1988
<u>AB</u>		<u>100MG</u>	<u>A072103</u>	<u>001</u>	Jun 20, 1988
<u>AB</u>		<u>150MG</u>	<u>A072104</u>	<u>001</u>	Jun 20, 1988
<u>NORPRAMIN</u>					
<u>AB</u>	SANOFI AVENTIS US	<u>10MG</u>	<u>N014399</u>	<u>007</u>	Feb 11, 1982
<u>AB</u>		<u>25MG</u>	<u>N014399</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>N014399</u>	<u>003</u>	
<u>AB</u>		<u>75MG</u>	<u>N014399</u>	<u>004</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N014399</u>	<u>005</u>	
<u>AB</u>		<u>150MG</u>	<u>N014399</u>	<u>006</u>	

DESIRUDIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPRIVASK

+	CANYON	15MG/VIAL	N021271	001	Apr 04, 2003
---	--------	-----------	---------	-----	--------------

DESLOMATADINE

SYRUP; ORAL

CLARINEX

+	SCHERING	0.5MG/ML	N021300	001	Sep 01, 2004
---	----------	----------	---------	-----	--------------

TABLET; ORAL

CLARINEX

+	SCHERING PLOUGH	5MG	N021165	001	Dec 21, 2001
---	-----------------	-----	---------	-----	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

	SCHERING	2.5MG	N021312	002	Jul 14, 2005
+		5MG	N021312	001	Jun 26, 2002

DESLOMATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

+	SCHERING	5MG;240MG	N021605	001	Mar 03, 2005
---	----------	-----------	---------	-----	--------------

CLARINEX-D 12 HOUR

+	SCHERING	2.5MG;120MG	N021313	001	Feb 01, 2006
---	----------	-------------	---------	-----	--------------

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

<u>AP</u>	+	SANOFI AVENTIS US	<u>0.004MG/ML</u>	<u>N018938</u>	<u>001</u>	Mar 30, 1984
-----------	---	-------------------	-------------------	----------------	------------	--------------

DESMOPRESSIN ACETATE

<u>AP</u>		HOSPIRA	<u>0.004MG/ML</u>	<u>A075220</u>	<u>001</u>	Aug 28, 2000
-----------	--	---------	-------------------	----------------	------------	--------------

<u>AP</u>		TEVA PARENTERAL	<u>0.004MG/ML</u>	<u>A074888</u>	<u>001</u>	Oct 15, 1997
-----------	--	-----------------	-------------------	----------------	------------	--------------

SOLUTION; NASAL

DDAVP

+	SANOFI AVENTIS US	0.01%	N017922	001	
---	-------------------	-------	---------	-----	--

SPRAY, METERED; NASAL

DDAVP (NEEDS NO REFRIGERATION)

<u>AB</u>	+	SANOFI AVENTIS US	<u>0.01MG/SPRAY</u>	<u>N017922</u>	<u>003</u>	Aug 07, 1996
-----------	---	-------------------	---------------------	----------------	------------	--------------

DESMOPRESSIN ACETATE

<u>AB</u>	+	BAUSCH AND LOMB	<u>0.01MG/SPRAY</u>	<u>A074830</u>	<u>001</u>	Jan 25, 1999
-----------	---	-----------------	---------------------	----------------	------------	--------------

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

<u>AB</u>		APOTEX INC	<u>0.01MG/SPRAY</u>	<u>A076703</u>	<u>001</u>	Jan 27, 2005
-----------	--	------------	---------------------	----------------	------------	--------------

MINIRIN

<u>AB</u>	+	FERRING	<u>0.01MG/SPRAY</u>	<u>N021333</u>	<u>001</u>	Sep 16, 2002
-----------	---	---------	---------------------	----------------	------------	--------------

STIMATE

+	CSL BEHRING	0.15MG/SPRAY	N020355	001	Mar 07, 1994
---	-------------	--------------	---------	-----	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 142 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 116 (of 393)

DESMOPRESSIN ACETATE

TABLET; ORAL

DDAVP

<u>AB</u>	SANOFI AVENTIS US	<u>0.1MG</u>	<u>N019955</u>	<u>001</u>	Sep 06, 1995
<u>AB</u>	+	<u>0.2MG</u>	<u>N019955</u>	<u>002</u>	Sep 06, 1995
	<u>DESMOPRESSIN ACETATE</u>				
<u>AB</u>	APOTEX INC	<u>0.1MG</u>	<u>A077414</u>	<u>001</u>	Mar 07, 2006
<u>AB</u>		<u>0.2MG</u>	<u>A077414</u>	<u>002</u>	Mar 07, 2006
<u>AB</u>	TEVA PHARMS	<u>0.1MG</u>	<u>A077122</u>	<u>001</u>	Jan 25, 2006
<u>AB</u>		<u>0.2MG</u>	<u>A077122</u>	<u>002</u>	Jan 25, 2006
<u>AB</u>	WATSON LABS	<u>0.1MG</u>	<u>A076470</u>	<u>001</u>	Jul 01, 2005
<u>AB</u>		<u>0.2MG</u>	<u>A076470</u>	<u>002</u>	Jul 01, 2005
	<u>DESMOPRESSIN ACETATE</u>				
	FERRING	0.1MG	N021795	001	May 08, 2008
	+	0.2MG	N021795	002	May 08, 2008

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

CYCLESSA

<u>AB</u>	+	ORGANON USA INC	<u>0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG</u>	<u>N021090</u>	<u>001</u>	Dec 20, 2000
		<u>DESOGEN</u>				
<u>AB</u>		ORGANON USA INC	<u>0.15MG;0.03MG</u>	<u>N020071</u>	<u>002</u>	Dec 10, 1992
		<u>DESOGESTREL AND ETHINYL ESTRADIOL</u>				
<u>AB</u>		DURAMED PHARMS BARR	<u>0.15MG;0.03MG</u>	<u>A075256</u>	<u>002</u>	Aug 12, 1999
<u>AB</u>		WATSON LABS	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A076916</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>			<u>0.15MG;0.03MG</u>	<u>A076915</u>	<u>001</u>	Jul 29, 2005
		<u>KARIVA</u>				
<u>AB</u>		BARR	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A075863</u>	<u>001</u>	Apr 05, 2002
		<u>MIRCETTE</u>				
<u>AB</u>	+	DURAMED	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>N020713</u>	<u>001</u>	Apr 22, 1998
		<u>ORTHO-CEPT</u>				
<u>AB</u>	+	ORTHO MCNEIL JANSSEN	<u>0.15MG;0.03MG</u>	<u>N020301</u>	<u>002</u>	Dec 14, 1992
		<u>VELIVET</u>				
<u>AB</u>		DURAMED PHARMS BARR	<u>0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG</u>	<u>A076455</u>	<u>001</u>	Feb 24, 2004

DESONIDEAEROSOL, FOAM; TOPICAL  
VERDESO

+ STIEFEL LABS INC 0.05% N021978 001 Sep 19, 2006

CREAM; TOPICAL

DESONIDE

<u>AB</u>	+	PERRIGO NEW YORK	<u>0.05%</u>	<u>N017010</u>	<u>001</u>	
<u>AB</u>		TARO	<u>0.05%</u>	<u>A073548</u>	<u>001</u>	Jun 30, 1992
		<u>DESOWEN</u>				
<u>AB</u>		GALDERMA LABS LP	<u>0.05%</u>	<u>N019048</u>	<u>001</u>	Dec 14, 1984

GEL; TOPICAL

DESONATE

+ INTENDIS 0.05% N021844 001 Oct 20, 2006

LOTION; TOPICAL

DESONIDE

<u>AB</u>		ALTANA	<u>0.05%</u>	<u>A075860</u>	<u>001</u>	Mar 19, 2002
		<u>DESOWEN</u>				
<u>AB</u>	+	GALDERMA LABS LP	<u>0.05%</u>	<u>A072354</u>	<u>001</u>	Jan 24, 1992

OINTMENT; TOPICAL

DESONIDE

<u>AB</u>		ALTANA	<u>0.05%</u>	<u>A075751</u>	<u>001</u>	Mar 12, 2001
<u>AB</u>	+	PERRIGO NEW YORK	<u>0.05%</u>	<u>N017426</u>	<u>001</u>	
<u>AB</u>		TARO	<u>0.05%</u>	<u>A074254</u>	<u>001</u>	Aug 03, 1994

## PRESCRIPTION DRUG PRODUCT LIST

3 - 117 (of 393)

DESONIDE

OINTMENT; TOPICAL

DESOWEN

<u>AB</u>	GALDERMA LABS LP	<u>0.05%</u>	<u>A071425</u>	<u>001</u>	Jun 15, 1988
-----------	------------------	--------------	----------------	------------	--------------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

<u>AB</u>	PERRIGO NEW YORK	<u>0.25%</u>	<u>A076510</u>	<u>001</u>	Jul 01, 2003
-----------	------------------	--------------	----------------	------------	--------------

<u>AB</u>	TARO	<u>0.05%</u>	<u>A073210</u>	<u>001</u>	Nov 30, 1990
-----------	------	--------------	----------------	------------	--------------

<u>AB</u>		<u>0.25%</u>	<u>A073193</u>	<u>001</u>	Nov 30, 1990
-----------	--	--------------	----------------	------------	--------------

TOPICORT

<u>AB</u>	+ TARO PHARMS NORTH	<u>0.25%</u>	<u>N017856</u>	<u>001</u>	
-----------	---------------------	--------------	----------------	------------	--

TOPICORT LP

<u>AB</u>	+ TARO PHARMS NORTH	<u>0.05%</u>	<u>N018309</u>	<u>001</u>	
-----------	---------------------	--------------	----------------	------------	--

GEL; TOPICAL

DESOXIMETASONE

<u>AB</u>	PERRIGO NEW YORK	<u>0.05%</u>	<u>A077552</u>	<u>001</u>	Jan 09, 2006
-----------	------------------	--------------	----------------	------------	--------------

<u>AB</u>	TARO	<u>0.05%</u>	<u>A074904</u>	<u>001</u>	Jul 14, 1998
-----------	------	--------------	----------------	------------	--------------

TOPICORT

<u>AB</u>	+ TARO PHARMS NORTH	<u>0.05%</u>	<u>N018586</u>	<u>001</u>	Mar 29, 1982
-----------	---------------------	--------------	----------------	------------	--------------

OINTMENT; TOPICAL

DESOXIMETASONE

<u>AB</u>	TARO	<u>0.25%</u>	<u>A074286</u>	<u>001</u>	Jun 07, 1996
-----------	------	--------------	----------------	------------	--------------

TOPICORT

<u>AB</u>	+ TARO PHARMS NORTH	<u>0.25%</u>	<u>N018763</u>	<u>001</u>	Sep 30, 1983
-----------	---------------------	--------------	----------------	------------	--------------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

## PRISTIQ

	+ WYETH PHARMS INC	EQ 50MG BASE	N021992	001	Feb 29, 2008
--	--------------------	--------------	---------	-----	--------------

		EQ 100MG BASE	N021992	002	Feb 29, 2008
--	--	---------------	---------	-----	--------------

DEXAMETHASONE

CONCENTRATE; ORAL

## DEXAMETHASONE INTENSOL

	+ ROXANE	1MG/ML	A088252	001	Sep 01, 1983
--	----------	--------	---------	-----	--------------

ELIXIR; ORAL

DEXAMETHASONE

<u>AA</u>	+ MORTON GROVE	<u>0.5MG/5ML</u>	<u>A088254</u>	<u>001</u>	Jul 27, 1983
-----------	----------------	------------------	----------------	------------	--------------

<u>AA</u>	+ STI PHARMA LLC	<u>0.5MG/5ML</u>	<u>A084754</u>	<u>001</u>	
-----------	------------------	------------------	----------------	------------	--

IMPLANT; INTRAVITREAL

## OZURDEX

	+ ALLERGAN	0.7MG	N022315	001	Jun 17, 2009
--	------------	-------	---------	-----	--------------

SOLUTION; ORAL

## DEXAMETHASONE

	+ ROXANE	0.5MG/5ML	A088248	001	Sep 01, 1983
--	----------	-----------	---------	-----	--------------

SUSPENSION/DROPS; OPHTHALMIC

	+ ALCON	0.1%	N013422	001	
--	---------	------	---------	-----	--

TABLET; ORAL

DEXAMETHASONE

<u>AB</u>	ECR	<u>1.5MG</u>	<u>A040700</u>	<u>001</u>	Aug 15, 2008
-----------	-----	--------------	----------------	------------	--------------

<u>AB</u>	ROXANE	<u>1.5MG</u>	<u>A084610</u>	<u>001</u>	
-----------	--------	--------------	----------------	------------	--

DEXAMETHASONE

	ROXANE	0.5MG	A084611	001	
--	--------	-------	---------	-----	--

		0.75MG	A084613	001	
--	--	--------	---------	-----	--

		1MG	A088306	001	Sep 15, 1983
--	--	-----	---------	-----	--------------



## PRESCRIPTION DRUG PRODUCT LIST

3 - 118 (of 393)

DEXAMETHASONETABLET; ORAL  
DEXAMETHASONE

ROXANE	2MG	A087916	001	Aug 26, 1982
	4MG	A084612	001	
+	6MG	A088316	001	Sep 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

<u>AP</u>	AKORN STRIDES	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A040803</u>	<u>001</u>	Aug 29, 2008
<u>AP</u>		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040802</u>	<u>001</u>	Aug 29, 2008
<u>AP</u>	APP PHARMS	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A084916</u>	<u>001</u>	
<u>AP</u>		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040491</u>	<u>001</u>	Apr 11, 2003
<u>AP</u>		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040572</u>	<u>001</u>	Apr 22, 2005
<u>AP</u>	+ BAXTER HLTHCARE	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A087702</u>	<u>001</u>	Sep 07, 1982
<u>AP</u>	+ LUITPOLD	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A087440</u>	<u>001</u>	Jul 21, 1982
<u>AP</u>	+ TEVA PARENTERAL	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A081126</u>	<u>001</u>	Aug 31, 1990

SOLUTION/DROPS; OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

<u>AT</u>	+ ALCON UNIVERSAL	<u>EQ 0.1% PHOSPHATE</u>	<u>A088771</u>	<u>001</u>	Jan 16, 1985
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 0.1% PHOSPHATE</u>	<u>A040069</u>	<u>001</u>	Jul 26, 1996

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

MAXITROL

<u>AT</u>	+ FALCON PHARMS	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>N050065</u>	<u>002</u>	
		<u>NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE</u>			
<u>AT</u>	BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064063</u>	<u>001</u>	Jul 25, 1994
<u>AT</u>	FOUGERA	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A062938</u>	<u>001</u>	Jul 31, 1989

SUSPENSION/DROPS; OPHTHALMIC

DEXASPORIN

<u>AT</u>	BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064135</u>	<u>001</u>	Sep 13, 1995
-----------	-----------------	--	----------------	------------	--------------

MAXITROL

<u>AT</u>	ALCON	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062341</u>	<u>001</u>	May 22, 1984
<u>AT</u>	+ FALCON PHARMS	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>N050023</u>	<u>002</u>	
		<u>NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE</u>			
<u>AT</u>	ALCON UNIVERSAL	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062721</u>	<u>001</u>	Nov 17, 1986

DEXAMETHASONE; TOBRAMYCIN

OINTMENT; OPHTHALMIC

## TOBRADEX

+	ALCON	0.1%;0.3%	N050616	001	Sep 28, 1988
---	-------	-----------	---------	-----	--------------

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX

<u>AB</u>	+ ALCON	<u>0.1%;0.3%</u>	<u>N050592</u>	<u>001</u>	Aug 18, 1988
		<u>TOBRAMYCIN AND DEXAMETHASONE</u>			
<u>AB</u>	BAUSCH AND LOMB	<u>0.1%;0.3%</u>	<u>A064134</u>	<u>001</u>	Oct 27, 1999
	TOBRADEX ST				
+	ALCON	0.05%;0.3%	N050818	001	Feb 13, 2009

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

DEXCHLORPHENIRAMINE MALEATE

+	MORTON GROVE	2MG/5ML	A088251	001	Mar 23, 1984
---	--------------	---------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 119 (of 393)

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

KAPIDEX

TAKEDA PHARMS

30MG

N022287 001

Jan 30, 2009

+

60MG

N022287 002

Jan 30, 2009

DEXMEDETOMIDINE

INJECTABLE; INJECTION

PRECEDEX

+ HOSPIRA

EQ 100MCG BASE/ML

N021038 001

Dec 17, 1999

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FOCALIN XR

NOVARTIS

5MG

N021802 001

May 26, 2005

10MG

N021802 002

May 26, 2005

15MG

N021802 004

Aug 01, 2006

20MG

N021802 003

May 26, 2005

+

30MG

N021802 005

Oct 23, 2009

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDEAB TEVA PHARMS2.5MGA077107 003

Jan 29, 2007

AB5MGA077107 001

Jan 29, 2007

AB10MGA077107 002

Jan 29, 2007

FOCALINAB NOVARTIS2.5MGN021278 001

Nov 13, 2001

AB5MGN021278 002

Nov 13, 2001

AB +10MGN021278 003

Nov 13, 2001

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDEAP BEDFORDEQ 250MG BASE/VIALA076068 001

Sep 28, 2004

APEQ 500MG BASE/VIALA076068 002

Sep 28, 2004

ZINECARDAP + PHARMACIA AND UPJOHNEQ 250MG BASE/VIALN020212 001

May 26, 1995

AP +EQ 500MG BASE/VIALN020212 002

May 26, 1995

TOTECT

+ TOPOTARGET

EQ 500MG BASE/VIAL

N022025 001

Sep 06, 2007

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINEAB SMITHKLINE BEECHAM5MGN017078 001AB10MGN017078 002AB +15MGN017078 003DEXTROAMPHETAMINE SULFATEAB BARR5MGA076137 001

Jan 18, 2002

AB10MGA076137 002

Jan 18, 2002

AB15MGA076137 003

Jan 18, 2002

AB MALLINCKRODT5MGA076353 001

May 06, 2003

AB10MGA076353 002

May 06, 2003

AB15MGA076353 003

May 06, 2003

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

+ OUTLOOK PHARMS

5MG/5ML

A040776 001

Jan 29, 2008

TABLET; ORAL

DEXTROAMPHETAMINE SULFATEAA BARR5MGA040361 001

Jan 31, 2001

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 146 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 120 (of 393)

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	+	BARR	<u>10MG</u>	<u>A040361</u>	<u>002</u>	Jan 31, 2001
<u>AA</u>		KV PHARM	<u>5MG</u>	<u>A040365</u>	<u>001</u>	Oct 31, 2002
<u>AA</u>			<u>10MG</u>	<u>A040367</u>	<u>001</u>	Oct 31, 2002
<u>AA</u>		MALLINCKRODT	<u>5MG</u>	<u>A040436</u>	<u>001</u>	Jan 29, 2002
<u>AA</u>			<u>10MG</u>	<u>A040436</u>	<u>002</u>	Jan 29, 2002

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN

<u>AA</u>	+	ACTAVIS MID ATLANTIC	<u>15MG/5ML;6.25MG/5ML</u>	<u>A088762</u>	<u>001</u>	Oct 31, 1984
<u>AA</u>		VINTAGE	<u>15MG/5ML;6.25MG/5ML</u>	<u>A040649</u>	<u>001</u>	Feb 14, 2006
<u>AA</u>		HI TECH PHARMA	<u>15MG/5ML;6.25MG/5ML</u>	<u>A040027</u>	<u>001</u>	Jul 31, 1996
<u>AA</u>		MORTON GROVE	<u>15MG/5ML;6.25MG/5ML</u>	<u>A088864</u>	<u>001</u>	Jan 04, 1985

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>10GM/100ML</u>	<u>N019626</u>	<u>004</u>	Feb 02, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N016694</u>	<u>001</u>	
<u>AP</u>	+	HOSPIRA	<u>10GM/100ML</u>	<u>N018080</u>	<u>001</u>	

DEXTROSE 20% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N017521</u>	<u>004</u>	
<u>AP</u>	+	HOSPIRA	<u>20GM/100ML</u>	<u>N018564</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 30% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>30GM/100ML</u>	<u>N017521</u>	<u>003</u>	
<u>AP</u>	+	HOSPIRA	<u>30GM/100ML</u>	<u>N019345</u>	<u>001</u>	Jan 26, 1985

DEXTROSE 40% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>40GM/100ML</u>	<u>N017521</u>	<u>002</u>	
<u>AP</u>	+	HOSPIRA	<u>40GM/100ML</u>	<u>N018562</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>50MG/ML</u>	<u>N016730</u>	<u>002</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N016730</u>	<u>001</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019626</u>	<u>002</u>	Feb 02, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>50MG/ML</u>	<u>N016673</u>	<u>003</u>	Oct 30, 1985
<u>AP</u>	+		<u>50MG/ML</u>	<u>N020179</u>	<u>002</u>	Dec 07, 1992
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N016673</u>	<u>001</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N020179</u>	<u>001</u>	Dec 07, 1992
<u>AP</u>	+	HOSPIRA	<u>50MG/ML</u>	<u>N016367</u>	<u>002</u>	
<u>AP</u>	+		<u>50MG/ML</u>	<u>N019222</u>	<u>001</u>	Jul 13, 1984
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019466</u>	<u>001</u>	Jul 15, 1985
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019479</u>	<u>001</u>	Sep 17, 1985

DEXTROSE 50% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>50GM/100ML</u>	<u>N017521</u>	<u>001</u>	
<u>AP</u>	+		<u>50GM/100ML</u>	<u>N020047</u>	<u>001</u>	Jul 02, 1991
<u>AP</u>		HOSPIRA	<u>500MG/ML</u>	<u>N019445</u>	<u>001</u>	Jun 03, 1986
<u>AP</u>	+		<u>50GM/100ML</u>	<u>N018563</u>	<u>001</u>	Mar 23, 1982
<u>AP</u>	+		<u>50GM/100ML</u>	<u>N019894</u>	<u>001</u>	Dec 26, 1989

DEXTROSE 60% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>60GM/100ML</u>	<u>N017521</u>	<u>005</u>	Mar 26, 1982
-----------	---	-----------------	-------------------	----------------	------------	--------------

DEXTROSE 70% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>70GM/100ML</u>	<u>N017521</u>	<u>006</u>	Mar 26, 1982
<u>AP</u>	+		<u>70GM/100ML</u>	<u>N020047</u>	<u>003</u>	Jul 02, 1991
<u>AP</u>	+	HOSPIRA	<u>70GM/100ML</u>	<u>N018561</u>	<u>001</u>	Mar 23, 1982
<u>AP</u>	+		<u>70GM/100ML</u>	<u>N019893</u>	<u>001</u>	Dec 26, 1989

## PRESCRIPTION DRUG PRODUCT LIST

3 - 121 (of 393)

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 25%

+ HOSPIRA 250MG/ML N019445 002 Nov 23, 1998

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML;32MG/100ML;128MG/100ML;234MG/  
100ML N017385 001DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;21MG/100ML;128MG/100ML;234MG/  
100ML N017610 001DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC;  
SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;31MG/100ML;130MG/100ML;26MG/1  
00ML;320MG/100ML N019873 001 Jun 10, 1993DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC;  
SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;53MG/100ML;100MG/100ML;100MG/  
100ML;180MG/100ML;280MG/100ML;16MG/100M  
L N019515 001 May 08, 1986DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC;  
SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML;31MG/100ML;141MG/100ML;20MG/1  
00ML;12MG/100ML;260MG/100ML N017484 001DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC;  
SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;30MG/100ML;141MG/100ML;15MG/1  
00ML;260MG/100ML;25MG/100ML N019513 001 May 08, 1986DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;30MG/100ML;97MG/100ML;220MG/1  
00ML;140MG/100ML N019844 001 Jun 10, 1993DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE;  
SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;30MG/100ML;37MG/100ML;370MG/1  
00ML;530MG/100ML;500MG/100ML N019843 001 Aug 09, 1993

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;30MG/100ML;37MG/100ML;222MG/1  
00ML;526MG/100ML;502MG/100ML N017609 001

## PRESCRIPTION DRUG PRODUCT LIST

3 - 122 (of 393)

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE;  
SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER  
 BAXTER HLTHCARE 5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML N017451 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER  
AP BRISTOL MYERS SQUIBB 5GM/100ML;75MG/100ML N017634 004

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER  
AP BRISTOL MYERS SQUIBB 5GM/100ML;150MG/100ML N017634 001

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER  
AP BRISTOL MYERS SQUIBB 5GM/100ML;224MG/100ML N017634 003

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER  
AP BRISTOL MYERS SQUIBB 5GM/100ML;300MG/100ML N017634 002

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER  
AP B BRAUN 5GM/100ML;75MG/100ML N018744 001 Nov 09, 1982

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER  
AP B BRAUN 5GM/100ML;150MG/100ML N018744 002 Nov 09, 1982

AP 5GM/100ML;150MG/100ML N019699 004 Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER  
AP B BRAUN 5GM/100ML;300MG/100ML N018744 004 Nov 09, 1982

AP 5GM/100ML;300MG/100ML N019699 006 Sep 29, 1989

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER  
AP HOSPIRA 5GM/100ML;224MG/100ML N018371 003

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER  
 B BRAUN 5GM/100ML;220MG/100ML N018744 003 Nov 09, 1982

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;149MG/100ML N018371 001

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;298MG/100ML N018371 002

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE,  
MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;111MG/100ML;256MG/100ML;146MG/100ML;207MG/100ML N019514 001 May 08, 1986

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM  
CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER  
 B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML N019870 001 Jun 10, 1993

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE;  
SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER  
 BAXTER HLTHCARE 5GM/100ML;205MG/100ML;100MG/100ML;120MG/100ML;220MG/100ML N018840 001 Jun 29, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ  
AP BAXTER HLTHCARE 5GM/100ML;75MG/100ML;200MG/100ML N018037 006 Apr 13, 1982

AP 5GM/100ML;150MG/100ML;200MG/100ML N018037 007 Apr 13, 1982

## PRESCRIPTION DRUG PRODUCT LIST

3 - 123 (of 393)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION

	<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;224MG/100ML;200MG/100ML</u>	<u>N018037 004</u>
	<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;150MG/100ML;200MG/100ML</u>	<u>N018037 008</u> Apr 13, 1982
	<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;300MG/100ML;200MG/100ML</u>	<u>N018037 001</u>
	<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;224MG/100ML;200MG/100ML</u>	<u>N018037 005</u> Apr 13, 1982
	<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;300MG/100ML;200MG/100ML</u>	<u>N018037 009</u> Apr 13, 1982
	<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;75MG/100ML;200MG/100ML</u>	<u>N018037 002</u>
	<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;150MG/100ML;200MG/100ML</u>	<u>N018037 003</u>
	<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;75MG/100ML;330MG/100ML</u>	<u>N018629 005</u> Mar 23, 1982
<u>AP</u>		<u>5GM/100ML;150MG/100ML;330MG/100ML</u>	<u>N018629 002</u> Mar 23, 1982
	<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;224MG/100ML;330MG/100ML</u>	<u>N018629 003</u> Mar 23, 1982
	<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;150MG/100ML;330MG/100ML</u>	<u>N018629 004</u> Mar 23, 1982
<u>AP</u>		<u>5GM/100ML;300MG/100ML;330MG/100ML</u>	<u>N018629 006</u> Mar 23, 1982
	<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;224MG/100ML;330MG/100ML</u>	<u>N018629 007</u> Mar 23, 1982
	<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;300MG/100ML;330MG/100ML</u>	<u>N018629 008</u> Mar 23, 1982
	<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;75MG/100ML;330MG/100ML</u>	<u>N018629 001</u> Mar 23, 1982
	<u>DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;300MG/100ML;450MG/100ML</u>	<u>N018008 010</u>
	<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;75MG/100ML;200MG/100ML</u>	<u>N019630 008</u> Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;75MG/100ML;330MG/100ML</u>	<u>N019630 014</u> Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;75MG/100ML;450MG/100ML</u>	<u>N019630 020</u> Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;75MG/100ML;900MG/100ML</u>	<u>N019630 026</u> Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;200MG/100ML</u>	<u>N019630 010</u> Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;330MG/100ML</u>	<u>N019630 016</u> Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N019630 022</u> Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019630 028</u> Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;200MG/100ML</u>	<u>N019630 012</u> Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;330MG/100ML</u>	<u>N019630 018</u> Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;450MG/100ML</u>	<u>N019630 024</u> Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019630 030</u> Feb 17, 1988
	<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;75MG/100ML;450MG/100ML</u>	<u>N018008 005</u> Apr 28, 1982
<u>AP</u>		<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008 006</u> Apr 28, 1982
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362 005</u> Mar 28, 1988
<u>AP</u>		<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362 009</u> Jul 05, 1983

## PRESCRIPTION DRUG PRODUCT LIST

3 - 124 (of 393)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION

<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;75MG/100ML;900MG/100ML</u>	<u>N019308</u>	<u>004</u>	Apr 05,	1985
<u>AP</u>		<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308</u>	<u>002</u>	Apr 05,	1985
<u>AP</u>	HOSPIRA	<u>5GM/100ML;74.5MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>002</u>	Mar 24,	1988
<u>AP</u>		<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>004</u>	Mar 24,	1988
<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
<u>AP</u>	HOSPIRA	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>006</u>	Mar 28,	1988
<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	HOSPIRA	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>006</u>	Mar 24,	1988
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008</u>	<u>007</u>	Apr 28,	1982
<u>AP</u>	HOSPIRA	<u>5GM/100ML;149MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>010</u>	Jul 05,	1983
<u>AP</u>		<u>5GM/100ML;298MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>007</u>	Mar 28,	1988
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308</u>	<u>005</u>	Apr 05,	1985
<u>AP</u>		<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019308</u>	<u>003</u>	Apr 05,	1985
<u>AP</u>	HOSPIRA	<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>005</u>	Mar 24,	1988
<u>AP</u>		<u>5GM/100ML;298MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>008</u>	Mar 24,	1988
<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018008</u>	<u>008</u>	Apr 28,	1982
<u>AP</u>	HOSPIRA	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>002</u>		
<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019308</u>	<u>006</u>	Apr 05,	1985
<u>AP</u>	HOSPIRA	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>007</u>	Mar 24,	1988
<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;300MG/100ML;450MG/100ML</u>	<u>N018008</u>	<u>009</u>	Apr 28,	1982
<u>AP</u>	HOSPIRA	<u>5GM/100ML;298MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>003</u>		
<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019308</u>	<u>007</u>	Apr 05,	1985
<u>AP</u>	HOSPIRA	<u>5GM/100ML;298MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>009</u>	Mar 24,	1988
<u>POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008</u>	<u>004</u>		
<u>AP</u>	HOSPIRA	<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>008</u>	Mar 28,	1988
<u>AP</u>		<u>5GM/100ML;149MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>004</u>	Mar 28,	1988
<u>POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308</u>	<u>001</u>	Apr 05,	1985
<u>AP</u>	HOSPIRA	<u>5GM/100ML;74.5MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>001</u>	Mar 24,	1988
<u>AP</u>		<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>003</u>	Mar 24,	1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	B BRAUN	10GM/100ML;37MG/100ML;200MG/100ML	N019630	031	Feb 17,	1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	B BRAUN	10GM/100ML;37MG/100ML;450MG/100ML	N019630	037	Feb 17,	1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	B BRAUN	10GM/100ML;37MG/100ML;900MG/100ML	N019630	043	Feb 17,	1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	B BRAUN	5GM/100ML;37MG/100ML;110MG/100ML	N019630	001	Feb 17,	1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	B BRAUN	5GM/100ML;37MG/100ML;200MG/100ML	N019630	007	Feb 17,	1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER	B BRAUN	5GM/100ML;37MG/100ML;330MG/100ML	N019630	013	Feb 17,	1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	B BRAUN	5GM/100ML;37MG/100ML;450MG/100ML	N019630	019	Feb 17,	1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	B BRAUN	5GM/100ML;37MG/100ML;900MG/100ML	N019630	025	Feb 17,	1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	B BRAUN	10GM/100ML;75MG/100ML;200MG/100ML	N019630	032	Feb 17,	1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	B BRAUN	10GM/100ML;75MG/100ML;450MG/100ML	N019630	038	Feb 17,	1988

## PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;75MG/100ML;900MG/100ML	N019630 044	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;75MG/100ML;300MG/100ML	N019630 049	May 07, 1992
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;75MG/100ML;110MG/100ML	N019630 002	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;110MG/100ML;200MG/100ML	N019630 033	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;110MG/100ML;450MG/100ML	N019630 039	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;110MG/100ML;900MG/100ML	N019630 045	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;110MG/100ML;300MG/100ML	N019630 050	May 07, 1992
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;110MG/100ML	N019630 003	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;200MG/100ML	N019630 009	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;330MG/100ML	N019630 015	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;450MG/100ML	N019630 021	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;900MG/100ML	N019630 027	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;150MG/100ML;200MG/100ML	N019630 034	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;150MG/100ML;450MG/100ML	N019630 040	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;150MG/100ML;900MG/100ML	N019630 046	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;150MG/100ML;300MG/100ML	N019630 051	May 07, 1992
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;150MG/100ML;110MG/100ML	N019630 004	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;220MG/100ML;200MG/100ML	N019630 035	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;220MG/100ML;450MG/100ML	N019630 041	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;220MG/100ML;900MG/100ML	N019630 047	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;220MG/100ML;300MG/100ML	N019630 052	May 07, 1992
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;110MG/100ML	N019630 005	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N019630 011	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N019630 017	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N019630 023	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;900MG/100ML	N019630 029	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;200MG/100ML	N019630 036	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;450MG/100ML	N019630 042	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;900MG/100ML	N019630 048	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;300MG/100ML;300MG/100ML	N019630 053	May 07, 1992



## PRESCRIPTION DRUG PRODUCT LIST

3 - 126 (of 393)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;300MG/100ML;110MG/100ML	N019630	006	Feb 17, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	002	Jul 05, 1983
	5GM/100ML;149MG/100ML;225MG/100ML	N018365	006	Mar 28, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	001	Jan 17, 1986
	5GM/100ML;149MG/100ML;300MG/100ML	N018876	006	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N018365	008	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N018876	007	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001	
	5GM/100ML;298MG/100ML;225MG/100ML	N018365	009	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N018876	008	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;149MG/100ML;300MG/100ML	N018876	002	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N018365	003	Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N018876	003	Jan 17, 1986
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;298MG/100ML;225MG/100ML	N018365	004	Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N018876	004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	005	Mar 28, 1988
	5GM/100ML;149MG/100ML;225MG/100ML	N018365	007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	005	Mar 28, 1988
	5GM/100ML;149MG/100ML;300MG/100ML	N018876	009	Mar 28, 1988

DEXTROSE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

	<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>10GM/100ML;900MG/100ML</u>	<u>N019631</u>	<u>015</u> Feb 24, 1988
<u>AP</u>	BAXTER HLTHCARE	<u>10GM/100ML;900MG/100ML</u>	<u>N016696</u>	<u>001</u>
	<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>2.5GM/100ML;450MG/100ML</u>	<u>N019631</u>	<u>004</u> Feb 24, 1988
<u>AP</u>	BAXTER HLTHCARE	<u>2.5GM/100ML;450MG/100ML</u>	<u>N016697</u>	<u>001</u>
	<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>5GM/100ML;200MG/100ML</u>	<u>N019631</u>	<u>007</u> Feb 24, 1988
	<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>5GM/100ML;330MG/100ML</u>	<u>N019631</u>	<u>008</u> Feb 24, 1988
	<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>5GM/100ML;450MG/100ML</u>	<u>N019631</u>	<u>009</u> Feb 24, 1988
<u>AP</u>	HOSPIRA	<u>5GM/100ML;450MG/100ML</u>	<u>N017607</u>	<u>001</u>
	<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	B BRAUN	<u>5GM/100ML;900MG/100ML</u>	<u>N019631</u>	<u>010</u> Feb 24, 1988
<u>AP</u>	HOSPIRA	<u>5GM/100ML;900MG/100ML</u>	<u>N017585</u>	<u>001</u>
	<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;200MG/100ML</u>	<u>N016689</u>	<u>001</u>
	<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;330MG/100ML</u>	<u>N016687</u>	<u>001</u>
	<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;450MG/100ML</u>	<u>N016683</u>	<u>001</u>

## PRESCRIPTION DRUG PRODUCT LIST

3 - 127 (of 393)

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>			<u>N016678</u>	<u>001</u>	
	BAXTER HLTHCARE	<u>5GM/100ML;900MG/100ML</u>			
	DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;110MG/100ML	N019631	011	Feb 24, 1988
	DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;200MG/100ML	N019631	012	Feb 24, 1988
	DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;330MG/100ML	N019631	013	Feb 24, 1988
	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;450MG/100ML	N019631	014	Feb 24, 1988
	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;110MG/100ML	N019631	001	Feb 24, 1988
	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;200MG/100ML	N019631	002	Feb 24, 1988
	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;330MG/100ML	N019631	003	Feb 24, 1988
	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;900MG/100ML	N019631	005	Feb 24, 1988
	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;300MG/100ML	N019631	016	Jan 19, 1990
	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML	N019631	006	Feb 24, 1988
	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;225MG/100ML	N017606	001	
	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;300MG/100ML	N017799	001	

DIATRIZOATE MEGLUMINE

SOLUTION; URETHRAL

CYSTOGRAFIN

BRACCO

30%

N010040 018

CYSTOGRAFIN DILUTE

BRACCO

18%

N010040 022 Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-76RAP + MALLINCKRODT 66%;10% N019292 001 Sep 29, 1989RENOGRAFIN-76AP + BRACCO 66%;10% N010040 001

SOLUTION; ORAL, RECTAL

GASTROGRAFINAA + BRACCO 66%;10% N011245 003MD-GASTROVIEWAA MALLINCKRODT 66%;10% A087388 001DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

SINOGRAFIN

+ BRACCO

52.7%;26.8%

N011324 002

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE

100%

N011386 001

## PRESCRIPTION DRUG PRODUCT LIST

3 - 128 (of 393)

DIAZEPAM

CONCENTRATE; ORAL					
DIAZEPAM INTENSOL					
+	ROXANE	5MG/ML	A071415	001	Apr 03, 1987
GEL; RECTAL					
DIASTAT					
	VALEANT	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997
DIASTAT ACUDIAL					
	VALEANT	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005
+		20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005
INJECTABLE; INJECTION					
<u>DIAZEPAM</u>					
<u>AP</u>	+	<u>HOSPIRA</u>	<u>5MG/ML</u>	<u>A071583</u>	<u>001</u> Oct 13, 1987
<u>AP</u>			<u>5MG/ML</u>	<u>A071584</u>	<u>001</u> Oct 13, 1987
<u>AP</u>			<u>5MG/ML</u>	<u>A072079</u>	<u>001</u> Dec 20, 1988
<u>AP</u>		WATSON LABS	<u>5MG/ML</u>	<u>A070296</u>	<u>001</u> Feb 12, 1986
SOLUTION; ORAL					
DIAZEPAM					
+	ROXANE	5MG/5ML	A070928	001	Apr 03, 1987
TABLET; ORAL					
<u>DIAZEPAM</u>					
<u>AB</u>		<u>ACTAVIS ELIZABETH</u>	<u>2MG</u>	<u>A070781</u>	<u>001</u> Mar 19, 1986
<u>AB</u>			<u>5MG</u>	<u>A070706</u>	<u>001</u> Mar 19, 1986
<u>AB</u>			<u>10MG</u>	<u>A070707</u>	<u>001</u> Mar 19, 1986
<u>AB</u>		<u>BARR</u>	<u>2MG</u>	<u>A070152</u>	<u>001</u> Nov 01, 1985
<u>AB</u>			<u>5MG</u>	<u>A070153</u>	<u>001</u> Nov 01, 1985
<u>AB</u>			<u>10MG</u>	<u>A070154</u>	<u>001</u> Nov 01, 1985
<u>AB</u>		<u>DAVA PHARMS INC</u>	<u>2MG</u>	<u>A070226</u>	<u>001</u> Sep 26, 1985
<u>AB</u>		<u>IVAX SUB TEVA PHARMS</u>	<u>2MG</u>	<u>A071307</u>	<u>001</u> Dec 10, 1986
<u>AB</u>			<u>5MG</u>	<u>A071321</u>	<u>001</u> Dec 10, 1986
<u>AB</u>			<u>10MG</u>	<u>A071322</u>	<u>001</u> Dec 10, 1986
<u>AB</u>		<u>MYLAN</u>	<u>2MG</u>	<u>A070325</u>	<u>002</u> Sep 04, 1985
<u>AB</u>			<u>5MG</u>	<u>A070325</u>	<u>003</u> Sep 04, 1985
<u>AB</u>			<u>10MG</u>	<u>A070325</u>	<u>001</u> Sep 04, 1985
<u>AB</u>		<u>VINTAGE PHARMS</u>	<u>2MG</u>	<u>A077749</u>	<u>001</u> Mar 31, 2006
<u>AB</u>			<u>5MG</u>	<u>A077749</u>	<u>002</u> Mar 31, 2006
<u>AB</u>			<u>10MG</u>	<u>A077749</u>	<u>003</u> Mar 31, 2006
<u>AB</u>		<u>WATSON LABS</u>	<u>2MG</u>	<u>A071134</u>	<u>001</u> Feb 03, 1987
<u>AB</u>			<u>5MG</u>	<u>A071135</u>	<u>001</u> Feb 03, 1987
<u>AB</u>			<u>10MG</u>	<u>A071136</u>	<u>001</u> Feb 03, 1987
<u>VALIUM</u>					
<u>AB</u>		<u>ROCHE</u>	<u>2MG</u>	<u>N013263</u>	<u>002</u>
<u>AB</u>			<u>5MG</u>	<u>N013263</u>	<u>004</u>
<u>AB</u>	+		<u>10MG</u>	<u>N013263</u>	<u>006</u>
<u>DIAZOXIDE</u>					
SUSPENSION; ORAL					
PROGLYCEM					
+	TEVA GLOBAL	50MG/ML	N017453	001	
<u>DICLOFENAC EPOLAMINE</u>					
PATCH; TOPICAL					
FLECTOR					
+	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007
<u>DICLOFENAC POTASSIUM</u>					
CAPSULE; ORAL					
ZIPSOR					
+	XANODYNE PHARM	25MG	N022202	001	Jun 18, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 129 (of 393)

DICLOFENAC POTASSIUM

FOR SOLUTION; ORAL

CAMBIA

+ KOWA PHARMS 50MG N022165 001 Jun 17, 2009

TABLET; ORAL

CATAFLAMAB + NOVARTIS 50MG N020142 002 Nov 24, 1993DICLOFENAC POTASSIUMAB APOTEX 50MG A076561 001 Mar 18, 2004AB MYLAN 50MG A075463 001 Jul 26, 1999AB SANDOZ 50MG A075229 001 Nov 20, 1998AB 50MG A075582 001 Feb 23, 2001AB TEVA 50MG A075219 001 Aug 06, 1998AB WATSON LABS 50MG A075152 001 Nov 27, 1998DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

+ NYCOMED US 3% N021005 001 Oct 16, 2000

VOLTAREN

+ NOVARTIS 1% N022122 001 Oct 17, 2007

SOLUTION; TOPICAL

PENNSAID

+ NUVO RES 1.5% N020947 001 Nov 04, 2009

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUMAT AKORN 0.1% A077845 001 Apr 17, 2008AT ALCON 0.1% A078031 001 Feb 06, 2008AT APOTEX INC 0.1% A077600 001 Nov 13, 2008AT BAUSCH AND LOMB 0.1% A078792 001 Dec 28, 2007AT NEXUS PHARMS 0.1% A078553 001 Dec 28, 2007VOLTARENAT + NOVARTIS 0.1% N020037 001 Mar 28, 1991

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUMAB ACTAVIS ELIZABETH 50MG A074514 001 Mar 26, 1996AB 75MG A074514 002 Mar 26, 1996AB ALPHAPHARM 50MG A075281 002 Feb 12, 2002AB 75MG A075281 003 Feb 12, 2002AB CARLSBAD 25MG A075185 002 Nov 13, 1998AB 50MG A075185 003 Nov 13, 1998AB 75MG A075185 001 Nov 13, 1998AB NOSTRUM LABS 50MG A074986 001 Feb 26, 1999AB 75MG A074986 002 Feb 26, 1999AB + SANDOZ 25MG A074376 001 Sep 28, 1995AB + 50MG A074376 002 Sep 28, 1995AB 75MG A074394 001 Nov 30, 1995AB UNIQUE PHARM LABS 75MG A077863 003 Jun 08, 2007VOLTARENAB + NOVARTIS 75MG N019201 003 Jul 28, 1988

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUMAB ACTAVIS ELIZABETH 100MG A075910 001 Jan 07, 2002AB BIOVAIL 100MG A075492 001 Feb 11, 2000AB DEXCEL LTD 100MG A076201 001 Nov 06, 2002AB MYLAN 100MG A076152 001 Dec 13, 2001VOLTAREN-XRAB + NOVARTIS 100MG N020254 001 Mar 08, 1996

## PRESCRIPTION DRUG PRODUCT LIST

3 - 130 (of 393)

DICLOFENAC SODIUM; MISOPROSTOLTABLET, DELAYED RELEASE; ORAL  
ARTHROTEC

GD SEARLE LLC	50MG;0.2MG	N020607	001	Dec 24, 1997
+	75MG;0.2MG	N020607	002	Dec 24, 1997

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A061454</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A061454</u>	<u>003</u>	
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062286</u>	<u>001</u>	Jun 03, 1982
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062286</u>	<u>002</u>	Jun 03, 1982
	DICLOXACILLIN SODIUM				
	SANDOZ	EQ 125MG BASE	A061454	002	

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

BENTYL

<u>AB</u>	+	<u>AXCAN</u>	<u>10MG</u>	<u>N007409</u>	<u>003</u>	Oct 15, 1984
		<u>DICYCLOMINE HYDROCHLORIDE</u>				
<u>AB</u>		LANNETT	<u>10MG</u>	<u>A084285</u>	<u>001</u>	
<u>AB</u>		MYLAN	<u>10MG</u>	<u>A040319</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>		WATSON LABS	<u>10MG</u>	<u>A085082</u>	<u>001</u>	Jun 19, 1986
<u>AB</u>		WEST WARD	<u>10MG</u>	<u>A040204</u>	<u>001</u>	Feb 28, 1997

INJECTABLE; INJECTION

BENTYL

<u>AP</u>	+	<u>AXCAN</u>	<u>10MG/ML</u>	<u>N008370</u>	<u>001</u>	Oct 15, 1984
		<u>BENTYL PRESERVATIVE FREE</u>				
<u>AP</u>	+	<u>AXCAN</u>	<u>10MG/ML</u>	<u>N008370</u>	<u>002</u>	Oct 15, 1984
		<u>DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE)</u>				
<u>AP</u>		BEDFORD	<u>10MG/ML</u>	<u>A040465</u>	<u>001</u>	Jun 30, 2003

SYRUP; ORAL

BENTYL

<u>AA</u>	+	<u>AXCAN</u>	<u>10MG/5ML</u>	<u>N007961</u>	<u>002</u>	Oct 15, 1984
		<u>DICYCLOMINE HYDROCHLORIDE</u>				
<u>AA</u>		MIKART	<u>10MG/5ML</u>	<u>A040169</u>	<u>001</u>	Mar 24, 2005

TABLET; ORAL

BENTYL

<u>AB</u>	+	<u>AXCAN</u>	<u>20MG</u>	<u>N007409</u>	<u>001</u>	Oct 15, 1984
		<u>DICYCLOMINE HYDROCHLORIDE</u>				
<u>AB</u>		LANNETT	<u>20MG</u>	<u>A040230</u>	<u>001</u>	Feb 26, 1999
<u>AB</u>		MYLAN	<u>20MG</u>	<u>A040317</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>		WATSON LABS	<u>20MG</u>	<u>A085223</u>	<u>001</u>	Jul 30, 1986
<u>AB</u>		WEST WARD	<u>20MG</u>	<u>A040161</u>	<u>001</u>	Oct 01, 1996

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

<u>AB</u>	AUROBINDO PHARMA	<u>125MG</u>	<u>A090094</u>	<u>001</u>	Sep 24, 2008
<u>AB</u>		<u>200MG</u>	<u>A090094</u>	<u>002</u>	Sep 24, 2008
<u>AB</u>		<u>250MG</u>	<u>A090094</u>	<u>003</u>	Sep 24, 2008
<u>AB</u>		<u>400MG</u>	<u>A090094</u>	<u>004</u>	Sep 24, 2008
<u>AB</u>	BARR	<u>200MG</u>	<u>A077167</u>	<u>001</u>	Dec 03, 2004
<u>AB</u>		<u>250MG</u>	<u>A077167</u>	<u>002</u>	Dec 03, 2004
<u>AB</u>		<u>400MG</u>	<u>A077167</u>	<u>003</u>	Dec 03, 2004
	<u>VIDEX EC</u>				
<u>AB</u>	BRISTOL MYERS SQUIBB	<u>125MG</u>	<u>N021183</u>	<u>001</u>	Oct 31, 2000
<u>AB</u>		<u>200MG</u>	<u>N021183</u>	<u>002</u>	Oct 31, 2000

## PRESCRIPTION DRUG PRODUCT LIST

3 - 131 (of 393)

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

VIDEX EC

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>250MG</u>	<u>N021183</u>	<u>003</u>	Oct 31, 2000
<u>AB</u>	+	<u>400MG</u>	<u>N021183</u>	<u>004</u>	Oct 31, 2000

FOR SOLUTION; ORAL

DIDANOSINE

<u>AA</u>	AUROBINDO PHARMA	<u>10MG/ML</u>	<u>A078112</u>	<u>001</u>	Mar 08, 2007
<u>AA</u>	+	<u>10MG/ML</u>	<u>N020156</u>	<u>001</u>	Oct 09, 1991

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

<u>AA</u>	COREPHARMA	<u>25MG</u>	<u>A040828</u>	<u>001</u>	Nov 05, 2008
<u>AA</u>	+	<u>25MG</u>	<u>N011722</u>	<u>002</u>	

TABLET, EXTENDED RELEASE; ORAL

TENUATE DOSPAN

+	WATSON PHARMS	75MG	N012546	001	
---	---------------	------	---------	-----	--

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

<u>AB1</u>	ALTANA	<u>0.05%</u>	<u>A075187</u>	<u>001</u>	Mar 30, 1998
<u>AB1</u>	TARO	<u>0.05%</u>	<u>A075508</u>	<u>001</u>	Apr 24, 2000
<u>AB1</u>	+	<u>0.05%</u>	<u>N020205</u>	<u>001</u>	Nov 20, 1992
	DIFLORASONE DIACETATE				
BX	+	0.05%	A076263	001	Dec 20, 2002

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

<u>AB</u>	ALTANA	<u>0.05%</u>	<u>A075374</u>	<u>001</u>	Apr 27, 1999
<u>AB</u>	+	<u>0.05%</u>	<u>A075331</u>	<u>001</u>	May 14, 1999

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

+	TEVA	500MG	A073673	001	Jul 31, 1992
---	------	-------	---------	-----	--------------

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DUREZOL

+	SIRION THERAP	0.05%	N022212	001	Jun 23, 2008
---	---------------	-------	---------	-----	--------------

DIGOXIN

CAPSULE; ORAL

LANOXICAPS

	SMITHKLINE BEECHAM	0.05MG	N018118	002	Jul 26, 1982
		0.1MG	N018118	003	Jul 26, 1982
+		0.2MG	N018118	001	Jul 26, 1982

ELIXIR; ORAL

DIGOXIN

+	ROXANE	0.05MG/ML	N021648	001	Aug 26, 2004
---	--------	-----------	---------	-----	--------------

INJECTABLE; INJECTION

DIGOXIN

<u>AP</u>	BAXTER HLTHCARE	<u>0.25MG/ML</u>	<u>A083391</u>	<u>001</u>	
<u>AP</u>	HOSPIRA	<u>0.25MG/ML</u>	<u>A040093</u>	<u>001</u>	May 16, 1996

## PRESCRIPTION DRUG PRODUCT LIST

3 - 132 (of 393)

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

<u>AP</u>	SANDOZ	<u>0.25MG/ML</u>	<u>A040481</u>	<u>001</u>	Aug 21, 2003
-----------	--------	------------------	----------------	------------	--------------

LANOXIN

<u>AP</u>	+ GLAXOSMITHKLINE	<u>0.25MG/ML</u>	<u>N009330</u>	<u>002</u>	
	LANOXIN PEDIATRIC				
	+ GLAXOSMITHKLINE	0.1MG/ML	N009330	004	

TABLET; ORAL

DIGOXIN

<u>AB</u>	ACTAVIS TOTOWA	<u>0.125MG</u>	<u>A040282</u>	<u>001</u>	Dec 23, 1999
<u>AB</u>		<u>0.25MG</u>	<u>A040282</u>	<u>002</u>	Dec 23, 1999
<u>AB</u>	CARACO	<u>0.125MG</u>	<u>A076363</u>	<u>001</u>	Jan 31, 2003
<u>AB</u>		<u>0.25MG</u>	<u>A076363</u>	<u>002</u>	Jan 31, 2003
<u>AB</u>	IMPAX LABS	<u>0.125MG</u>	<u>A078556</u>	<u>001</u>	Jul 20, 2009
<u>AB</u>		<u>0.25MG</u>	<u>A078556</u>	<u>002</u>	Jul 20, 2009
<u>AB</u>	STEVENS J	<u>0.125MG</u>	<u>A076268</u>	<u>001</u>	Jul 26, 2002
<u>AB</u>		<u>0.25MG</u>	<u>A076268</u>	<u>002</u>	Jul 26, 2002
<u>AB</u>	WEST WARD	<u>0.125MG</u>	<u>A077002</u>	<u>002</u>	Oct 30, 2007
<u>AB</u>		<u>0.25MG</u>	<u>A077002</u>	<u>001</u>	Oct 30, 2007

LANOXIN

<u>AB</u>	SMITHKLINE BEECHAM	<u>0.125MG</u>	<u>N020405</u>	<u>002</u>	Sep 30, 1997
<u>AB</u>	+	<u>0.25MG</u>	<u>N020405</u>	<u>004</u>	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

<u>AP</u>	+ VALEANT	<u>1MG/ML</u>	<u>N005929</u>	<u>001</u>	
-----------	-----------	---------------	----------------	------------	--

DIHYDROERGOTAMINE MESYLATE

<u>AP</u>	BEDFORD LABS	<u>1MG/ML</u>	<u>A040453</u>	<u>001</u>	Jun 09, 2003
<u>AP</u>	PADDOCK	<u>1MG/ML</u>	<u>A040475</u>	<u>001</u>	Apr 28, 2003

SPRAY, METERED; NASAL

MIGRANAL

	+ VALEANT	0.5MG/INH	N020148	001	Dec 08, 1997
--	-----------	-----------	---------	-----	--------------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILACOR XR

<u>AB2</u>	WATSON LABS	<u>120MG</u>	<u>N020092</u>	<u>001</u>	May 29, 1992
<u>AB2</u>		<u>180MG</u>	<u>N020092</u>	<u>002</u>	May 29, 1992
<u>AB2</u>	+	<u>240MG</u>	<u>N020092</u>	<u>003</u>	May 29, 1992

DILTIAZEM HYDROCHLORIDE

<u>AB2</u>	APOTEX	<u>120MG</u>	<u>A074943</u>	<u>003</u>	Dec 19, 2000
<u>AB2</u>		<u>180MG</u>	<u>A074943</u>	<u>002</u>	Dec 19, 2000
<u>AB2</u>		<u>240MG</u>	<u>A074943</u>	<u>001</u>	Aug 06, 1998
<u>AB2</u>	MYLAN	<u>120MG</u>	<u>A075124</u>	<u>002</u>	Mar 18, 1998
<u>AB2</u>		<u>180MG</u>	<u>A075124</u>	<u>003</u>	Mar 18, 1998
<u>AB2</u>		<u>240MG</u>	<u>A075124</u>	<u>001</u>	Mar 18, 1998
<u>AB2</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A074852</u>	<u>001</u>	Oct 10, 1997
<u>AB2</u>		<u>180MG</u>	<u>A074852</u>	<u>002</u>	Oct 10, 1997
<u>AB2</u>		<u>240MG</u>	<u>A074852</u>	<u>003</u>	Oct 10, 1997

CARDIZEM CD

<u>AB3</u>	BIOVAIL	<u>120MG</u>	<u>N020062</u>	<u>001</u>	Aug 10, 1992
<u>AB3</u>		<u>180MG</u>	<u>N020062</u>	<u>002</u>	Dec 27, 1991
<u>AB3</u>		<u>240MG</u>	<u>N020062</u>	<u>003</u>	Dec 27, 1991
<u>AB3</u>		<u>300MG</u>	<u>N020062</u>	<u>004</u>	Dec 27, 1991

CARTIA XT

<u>AB3</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A074752</u>	<u>002</u>	Jul 09, 1998
<u>AB3</u>		<u>180MG</u>	<u>A074752</u>	<u>001</u>	Jul 09, 1998
<u>AB3</u>		<u>240MG</u>	<u>A074752</u>	<u>003</u>	Jul 09, 1998

## PRESCRIPTION DRUG PRODUCT LIST

3 - 133 (of 393)

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARTIA XT

<u>AB3</u>	WATSON LABS FLORIDA	<u>300MG</u>	<u>A074752</u>	<u>004</u>	Jul 09, 1998
------------	---------------------	--------------	----------------	------------	--------------

DILT-CD

<u>AB3</u>	APOTEX	<u>120MG</u>	<u>A076151</u>	<u>001</u>	May 20, 2004
<u>AB3</u>		<u>180MG</u>	<u>A076151</u>	<u>002</u>	May 20, 2004
<u>AB3</u>		<u>240MG</u>	<u>A076151</u>	<u>003</u>	May 20, 2004
<u>AB3</u>		<u>300MG</u>	<u>A076151</u>	<u>004</u>	May 20, 2004

DILTIAZEM HYDROCHLORIDE

<u>AB3</u>	ACTAVIS ELIZABETH	<u>120MG</u>	<u>A074984</u>	<u>001</u>	Dec 20, 1999
<u>AB3</u>		<u>180MG</u>	<u>A074984</u>	<u>002</u>	Dec 20, 1999
<u>AB3</u>		<u>240MG</u>	<u>A074984</u>	<u>003</u>	Dec 20, 1999
<u>AB3</u>		<u>300MG</u>	<u>A074984</u>	<u>004</u>	Dec 20, 1999
<u>AB3</u>	BIOVAIL	<u>120MG</u>	<u>A075116</u>	<u>001</u>	Dec 23, 1999
<u>AB3</u>		<u>180MG</u>	<u>A075116</u>	<u>002</u>	Dec 23, 1999
<u>AB3</u>		<u>240MG</u>	<u>A075116</u>	<u>003</u>	Dec 23, 1999
<u>AB3</u>		<u>300MG</u>	<u>A075116</u>	<u>004</u>	Dec 23, 1999

DILTIAZEM HYDROCHLORIDE

<u>AB4</u>	KV PHARM	<u>120MG</u>	<u>A076563</u>	<u>002</u>	Sep 12, 2006
<u>AB4</u>		<u>180MG</u>	<u>A076563</u>	<u>003</u>	Sep 12, 2006
<u>AB4</u>		<u>240MG</u>	<u>A076563</u>	<u>004</u>	Sep 12, 2006
<u>AB4</u>		<u>300MG</u>	<u>A076563</u>	<u>005</u>	Sep 12, 2006
<u>AB4</u>		<u>360MG</u>	<u>A076563</u>	<u>006</u>	Sep 12, 2006
<u>AB4</u>		<u>420MG</u>	<u>A076563</u>	<u>001</u>	Sep 12, 2006

DILTZAC

<u>AB4</u>	APOTEX INC	<u>120MG</u>	<u>A076395</u>	<u>001</u>	Feb 01, 2006
<u>AB4</u>		<u>180MG</u>	<u>A076395</u>	<u>002</u>	Feb 01, 2006
<u>AB4</u>		<u>240MG</u>	<u>A076395</u>	<u>003</u>	Feb 01, 2006
<u>AB4</u>		<u>300MG</u>	<u>A076395</u>	<u>004</u>	Feb 01, 2006
<u>AB4</u>		<u>360MG</u>	<u>A076395</u>	<u>005</u>	Feb 01, 2006

TAZTIA XT

<u>AB4</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A075401</u>	<u>001</u>	Apr 10, 2003
<u>AB4</u>		<u>180MG</u>	<u>A075401</u>	<u>002</u>	Apr 10, 2003
<u>AB4</u>		<u>240MG</u>	<u>A075401</u>	<u>003</u>	Apr 10, 2003
<u>AB4</u>		<u>300MG</u>	<u>A075401</u>	<u>004</u>	Apr 10, 2003
<u>AB4</u>		<u>360MG</u>	<u>A075401</u>	<u>005</u>	Apr 10, 2003

TIAZAC

<u>AB4</u>	BIOVAIL	<u>120MG</u>	<u>N020401</u>	<u>001</u>	Sep 11, 1995
<u>AB4</u>		<u>180MG</u>	<u>N020401</u>	<u>002</u>	Sep 11, 1995
<u>AB4</u>		<u>240MG</u>	<u>N020401</u>	<u>003</u>	Sep 11, 1995
<u>AB4</u>		<u>300MG</u>	<u>N020401</u>	<u>004</u>	Sep 11, 1995
<u>AB4</u>		<u>360MG</u>	<u>N020401</u>	<u>005</u>	Sep 11, 1995
<u>AB4</u> +		<u>420MG</u>	<u>N020401</u>	<u>006</u>	Oct 16, 1998

BC +	CARDIZEM CD BIOVAIL	360MG	N020062	005	Aug 24, 1999
------	------------------------	-------	---------	-----	--------------

BC +	DILTIAZEM HYDROCHLORIDE MYLAN	120MG	A074910	003	May 02, 1997
------	----------------------------------	-------	---------	-----	--------------

	DILTIAZEM HYDROCHLORIDE MYLAN	60MG	A074910	001	May 02, 1997
		90MG	A074910	002	May 02, 1997

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

<u>AP</u>	APOTEX INC	<u>5MG/ML</u>	<u>A075375</u>	<u>001</u>	Sep 30, 1999
<u>AP</u>	BAXTER HLTHCARE	<u>5MG/ML</u>	<u>A078538</u>	<u>001</u>	Dec 17, 2008
<u>AP</u> +	BEDFORD	<u>5MG/ML</u>	<u>A074617</u>	<u>001</u>	Feb 28, 1996
<u>AP</u>	HOSPIRA	<u>5MG/ML</u>	<u>A074941</u>	<u>001</u>	Apr 15, 1998
<u>AP</u>	INTL MEDICATION	<u>5MG/ML</u>	<u>A075749</u>	<u>001</u>	Nov 21, 2001
<u>AP</u>	TAYLOR PHARMA	<u>5MG/ML</u>	<u>A075086</u>	<u>001</u>	Apr 09, 1998
<u>AP</u>	TEVA PARENTERAL	<u>5MG/ML</u>	<u>A074894</u>	<u>001</u>	Aug 26, 1997



## PRESCRIPTION DRUG PRODUCT LIST

3 - 134 (of 393)

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

+ HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002
+ TEVA PARENTERAL	10MG/ML	A074894	002	Apr 19, 2002

TABLET; ORAL

CARDIZEM

<u>AB</u>	BIOVAIL LABS INTL	<u>30MG</u>	<u>N018602</u>	<u>001</u>	Nov 05, 1982
<u>AB</u>		<u>60MG</u>	<u>N018602</u>	<u>002</u>	Nov 05, 1982
<u>AB</u>		<u>90MG</u>	<u>N018602</u>	<u>003</u>	Dec 08, 1986
<u>AB</u>	+	<u>120MG</u>	<u>N018602</u>	<u>004</u>	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	DAVA PHARMS INC	<u>30MG</u>	<u>A074093</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>		<u>60MG</u>	<u>A074093</u>	<u>002</u>	Nov 05, 1992
<u>AB</u>		<u>90MG</u>	<u>A074093</u>	<u>003</u>	Nov 05, 1992
<u>AB</u>		<u>120MG</u>	<u>A074093</u>	<u>004</u>	Nov 05, 1992
<u>AB</u>	MYLAN	<u>30MG</u>	<u>A073185</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>		<u>60MG</u>	<u>A073186</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>		<u>90MG</u>	<u>A072837</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>		<u>120MG</u>	<u>A072838</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>	TEVA	<u>30MG</u>	<u>A074185</u>	<u>001</u>	May 31, 1995
<u>AB</u>		<u>60MG</u>	<u>A074185</u>	<u>002</u>	May 31, 1995
<u>AB</u>		<u>90MG</u>	<u>A074185</u>	<u>003</u>	May 31, 1995
<u>AB</u>		<u>120MG</u>	<u>A074185</u>	<u>004</u>	May 31, 1995

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

BIOVAIL LABS INTL	120MG	N021392	001	Feb 06, 2003
	180MG	N021392	002	Feb 06, 2003
	240MG	N021392	003	Feb 06, 2003
	300MG	N021392	004	Feb 06, 2003
	360MG	N021392	005	Feb 06, 2003
+	420MG	N021392	006	Feb 06, 2003

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

<u>AP</u>	APP PHARMS	<u>50MG/ML</u>	<u>A040519</u>	<u>001</u>	Jun 23, 2004
<u>AP</u>	+	<u>50MG/ML</u>	<u>A080615</u>	<u>001</u>	

DIMERCAPROL

INJECTABLE; INJECTION

BAL

+ AKORN	10%	N005939	001	
---------	-----	---------	-----	--

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE

<u>AT</u>	BIONICHE PHARMA	<u>50%</u>	<u>A076185</u>	<u>001</u>	Nov 29, 2002
<u>AT</u>	+	<u>50%</u>	<u>N017788</u>	<u>001</u>	

DINOPROSTONE

GEL; ENDOCERVICAL

PREPIDIL

+ PHARMACIA AND UPJOHN	0.5MG/3GM	N019617	001	Dec 09, 1992
------------------------	-----------	---------	-----	--------------

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

+ CONTROLLED THERAP	10MG	N020411	001	Mar 30, 1995
---------------------	------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 135 (of 393)

DINOPROSTONE

SUPPOSITORY; VAGINAL

PROSTIN E2

+ PHARMACIA AND UPJOHN 20MG N017810 001

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+ BARR 50MG A080738 001

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+ PHARM ASSOC 12.5MG/5ML A087513 001 Feb 10, 1982

INJECTABLE; INJECTION

BENADRYLAP + MCNEIL CONS 50MG/ML N006146 002BENADRYL PRESERVATIVE FREEAP + MCNEIL CONS 50MG/ML N009486 001DIPHENHYDRAMINE HYDROCHLORIDEAP APP PHARMS 50MG/ML A040466 001 May 28, 2002AP BAXTER HLTHCARE 50MG/ML A080817 002AP BIONICHE PHARMA 50MG/ML A040498 001 Jul 12, 2005AP HOSPIRA 50MG/ML A040140 001 Nov 20, 1998AP WATSON LABS 50MG/ML A080873 002DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREEAP INTL MEDICATION 50MG/ML A084094 001AP WATSON LABS 50MG/ML A080873 003

DIPHENHYDRAMINE HYDROCHLORIDE

+ WATSON LABS 10MG/ML A080873 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPROAT AKORN 0.1% A074382 001 Sep 29, 1995DIPIVEFRIN HYDROCHLORIDEAT BAUSCH AND LOMB 0.1% A074188 001 May 19, 1995AT FALCON PHARMS 0.1% A073636 001 Jun 30, 1994PROPINEAT + ALLERGAN 0.1% N018239 001DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLEAP APOTEX INC 5MG/ML A075769 001 Nov 27, 2002AP APP PHARMS 5MG/ML A074956 001 Sep 30, 1998AP BAXTER HLTHCARE 5MG/ML A074521 001 Oct 18, 1996AP + BEDFORD 5MG/ML A074939 001 Apr 13, 1998AP HOSPIRA 5MG/ML A074601 001 Dec 19, 1997AP TEVA PARENTERAL 5MG/ML A074952 001 Nov 26, 1997

TABLET; ORAL

DIPYRIDAMOLEAB ACTAVIS TOTOWA 25MG A040542 001 Apr 21, 2006AB 50MG A040542 002 Apr 21, 2006AB 75MG A040542 003 Apr 21, 2006AB BARR 25MG A087184 001 Oct 03, 1990AB 50MG A087716 001 Oct 03, 1990AB 75MG A087717 001 Oct 03, 1990AB GLENMARK GENERICS 25MG A088999 001 Feb 05, 1991AB 50MG A089000 001 Feb 05, 1991AB 75MG A089001 001 Feb 05, 1991

## PRESCRIPTION DRUG PRODUCT LIST

3 - 136 (of 393)

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

<u>AB</u>	IMPAX LABS	<u>25MG</u>	<u>A040782</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>		<u>50MG</u>	<u>A040782</u>	<u>002</u>	Jul 18, 2007
<u>AB</u>		<u>75MG</u>	<u>A040782</u>	<u>003</u>	Jul 18, 2007
<u>AB</u>	LANNETT	<u>25MG</u>	<u>A040898</u>	<u>001</u>	Apr 23, 2008
<u>AB</u>		<u>50MG</u>	<u>A040898</u>	<u>002</u>	Apr 23, 2008
<u>AB</u>		<u>75MG</u>	<u>A040898</u>	<u>003</u>	Apr 23, 2008
<u>AB</u>	MURTY PHARMS	<u>25MG</u>	<u>A040733</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>		<u>50MG</u>	<u>A040733</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>		<u>75MG</u>	<u>A040733</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>	PUREPAC PHARM	<u>25MG</u>	<u>A089425</u>	<u>001</u>	Jul 12, 1990
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A087160</u>	<u>001</u>	Jun 07, 1996
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A040874</u>	<u>001</u>	Jan 28, 2008
<u>AB</u>		<u>50MG</u>	<u>A040874</u>	<u>002</u>	Jan 28, 2008
<u>AB</u>		<u>75MG</u>	<u>A040874</u>	<u>003</u>	Jan 28, 2008
	<u>PERSANTINE</u>				
<u>AB</u>	BOEHRINGER INGELHEIM	<u>25MG</u>	<u>N012836</u>	<u>003</u>	Dec 22, 1986
<u>AB</u>		<u>50MG</u>	<u>N012836</u>	<u>004</u>	Feb 06, 1987
<u>AB</u>	+	<u>75MG</u>	<u>N012836</u>	<u>005</u>	Feb 06, 1987

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

<u>AB</u>	TEVA	<u>EQ 100MG BASE</u>	<u>A070101</u>	<u>001</u>	Feb 22, 1985
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A070102</u>	<u>001</u>	Feb 22, 1985
<u>AB</u>	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A070173</u>	<u>001</u>	May 31, 1985
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A070174</u>	<u>001</u>	May 31, 1985
	<u>NORPACE</u>				
<u>AB</u>	GD SEARLE LLC	<u>EQ 100MG BASE</u>	<u>N017447</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N017447</u>	<u>002</u>	

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

<u>AB</u>	KV PHARM	<u>EQ 150MG BASE</u>	<u>A071200</u>	<u>001</u>	Dec 15, 1987
	<u>NORPACE CR</u>				
<u>AB</u>	+ GD SEARLE LLC	<u>EQ 150MG BASE</u>	<u>N018655</u>	<u>002</u>	Jul 20, 1982
	NORPACE CR				
	GD SEARLE LLC	EQ 100MG BASE	N018655	001	Jul 20, 1982

DISULFIRAM

TABLET; ORAL

ANTABUSE

	ODYSSEY PHARMS	250MG	A088482	001	Dec 08, 1983
	+	500MG	A088483	001	Dec 08, 1983

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

<u>AB</u>	+ ABBOTT	<u>EQ 125MG VALPROIC ACID</u>	<u>N019680</u>	<u>001</u>	Sep 12, 1989
	<u>DIVALPROEX SODIUM</u>				
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078979</u>	<u>001</u>	Jan 23, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A078919</u>	<u>001</u>	Jan 27, 2009

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

<u>AB</u>	ABBOTT	<u>EQ 125MG VALPROIC ACID</u>	<u>N018723</u>	<u>003</u>	Oct 26, 1984
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>N018723</u>	<u>001</u>	Mar 10, 1983
<u>AB</u>	+	<u>EQ 500MG VALPROIC ACID</u>	<u>N018723</u>	<u>002</u>	Mar 10, 1983

DIVALPROEX SODIUM

<u>AB</u>	ANCHEN PHARMS	EQ 500MG VALPROIC ACID	A078411	001	Nov 03, 2008
-----------	---------------	------------------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 137 (of 393)

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078755</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078755</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078755</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	LUPIN	<u>EQ 125MG VALPROIC ACID</u>	<u>A078790</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078790</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078790</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A077254</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 125MG VALPROIC ACID</u>	<u>A090062</u>	<u>001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077254</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090062</u>	<u>002</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077254</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090062</u>	<u>003</u>	Mar 17, 2009
<u>AB</u>	NU PHARM	<u>EQ 125MG VALPROIC ACID</u>	<u>A077615</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077615</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077615</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG VALPROIC ACID</u>	<u>A078853</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078853</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078853</u>	<u>003</u>	Nov 25, 2008
<u>AB</u>	SANDOZ	<u>EQ 125MG VALPROIC ACID</u>	<u>A078290</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078290</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078290</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	SUN PHARM INDS	<u>EQ 125MG VALPROIC ACID</u>	<u>A078597</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078597</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078597</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	TEVA	<u>EQ 125MG VALPROIC ACID</u>	<u>A076941</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A076941</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A076941</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	UPSHER SMITH	<u>EQ 125MG VALPROIC ACID</u>	<u>A078182</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078182</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078182</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	VINTAGE	<u>EQ 125MG VALPROIC ACID</u>	<u>A090210</u>	<u>001</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090210</u>	<u>002</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090210</u>	<u>003</u>	Nov 30, 2009
<u>AB</u>	WOCKHARDT	<u>EQ 125MG VALPROIC ACID</u>	<u>A077296</u>	<u>001</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077296</u>	<u>002</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077296</u>	<u>003</u>	Jul 31, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A077100</u>	<u>001</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077100</u>	<u>002</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077100</u>	<u>003</u>	Mar 05, 2009

TABLET, EXTENDED RELEASE; ORAL

DEPAKOTE ER

<u>AB</u>	ABBOTT	<u>EQ 250MG VALPROIC ACID</u>	<u>N021168</u>	<u>002</u>	May 31, 2002
<u>AB</u>	+	<u>EQ 500MG VALPROIC ACID</u>	<u>N021168</u>	<u>001</u>	Aug 04, 2000

DIVALPROEX SODIUM

<u>AB</u>	ANCHEN PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078445</u>	<u>001</u>	Feb 26, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078445</u>	<u>002</u>	Aug 04, 2009
<u>AB</u>	IMPAX LABS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078791</u>	<u>001</u>	May 06, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078791</u>	<u>002</u>	Aug 04, 2009
<u>AB</u>	MYLAN	<u>EQ 250MG VALPROIC ACID</u>	<u>A077567</u>	<u>001</u>	Jan 29, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077567</u>	<u>002</u>	Jan 29, 2009
<u>AB</u>	TEVA PHARMS	<u>EQ 500MG VALPROIC ACID</u>	<u>A078700</u>	<u>001</u>	Aug 03, 2009
<u>AB</u>	WOCKHARDT	<u>EQ 250MG VALPROIC ACID</u>	<u>A078705</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078705</u>	<u>001</u>	Aug 04, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 250MG VALPROIC ACID</u>	<u>A078239</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078239</u>	<u>002</u>	Aug 04, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 138 (of 393)

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 12.5MG BASE/ML</u>	<u>A074277</u>	<u>001</u>	Oct 31, 1994
<u>AP</u>	HOSPIRA	<u>EQ 12.5MG BASE/ML</u>	<u>A074086</u>	<u>001</u>	Nov 29, 1993
<u>AP</u>		<u>EQ 12.5MG BASE/ML</u>	<u>A074292</u>	<u>001</u>	Feb 16, 1995
<u>AP</u>	TEVA PARENTERAL	<u>EQ 12.5MG BASE/ML</u>	<u>A074206</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	WATSON LABS	<u>EQ 12.5MG BASE/ML</u>	<u>A074114</u>	<u>001</u>	Nov 30, 1993
<u>DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%</u>					
<u>AP</u>	+ HOSPIRA	<u>EQ 50MG BASE/100ML</u>	<u>N020269</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 100MG BASE/100ML</u>	<u>N020269</u>	<u>002</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 200MG BASE/100ML</u>	<u>N020269</u>	<u>003</u>	Oct 19, 1993
<u>DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	+ BAXTER HLHCARE	<u>EQ 50MG BASE/100ML</u>	<u>N020255</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 100MG BASE/100ML</u>	<u>N020255</u>	<u>003</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 200MG BASE/100ML</u>	<u>N020255</u>	<u>004</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 400MG BASE/100ML</u>	<u>N020255</u>	<u>005</u>	Oct 19, 1993
<u>AP</u>	+ HOSPIRA	<u>EQ 50MG BASE/100ML</u>	<u>N020201</u>	<u>003</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 100MG BASE/100ML</u>	<u>N020201</u>	<u>002</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 200MG BASE/100ML</u>	<u>N020201</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 400MG BASE/100ML</u>	<u>N020201</u>	<u>006</u>	Jul 07, 1994

DOCETAXEL

INJECTABLE; INJECTION

TAXOTERE

+	SANOFI AVENTIS US	EQ 40MG BASE/ML	N020449	001	May 14, 1996
---	-------------------	-----------------	---------	-----	--------------

DOFETILIDE

CAPSULE; ORAL

TIKOSYN

	PFIZER	0.125MG	N020931	001	Oct 01, 1999
		0.25MG	N020931	002	Oct 01, 1999
+		0.5MG	N020931	003	Oct 01, 1999

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

+	SANOFI AVENTIS US	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997
+		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001

TABLET; ORAL

ANZEMET

	SANOFI AVENTIS US	50MG	N020623	001	Sep 11, 1997
+		100MG	N020623	002	Sep 11, 1997

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N020690</u>	<u>002</u>	Nov 25, 1996
<u>AB</u>	+	<u>10MG</u>	<u>N020690</u>	<u>001</u>	Nov 25, 1996
<u>DONEPEZIL HYDROCHLORIDE</u>					
<u>AB</u>	TEVA	<u>5MG</u>	<u>A077344</u>	<u>001</u>	Apr 28, 2008
<u>AB</u>		<u>10MG</u>	<u>A077344</u>	<u>002</u>	Apr 28, 2008

TABLET, ORALLY DISINTEGRATING; ORAL

ARICEPT ODT

<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N021720</u>	<u>001</u>	Oct 18, 2004
<u>AB</u>	+	<u>10MG</u>	<u>N021720</u>	<u>002</u>	Oct 18, 2004

DONEPEZIL HYDROCHLORIDE

<u>AB</u>	MUTUAL PHARM	<u>5MG</u>	<u>A077975</u>	<u>002</u>	Dec 11, 2009
-----------	--------------	------------	----------------	------------	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 165 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 139 (of 393)

DONEPEZIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A077975</u>	<u>001</u>	Dec 11, 2009
-----------	--------------	-------------	----------------	------------	--------------

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

<u>AP</u>	+ HOSPIRA	<u>40MG/ML</u>	<u>N018132</u>	<u>001</u>	
<u>AP</u>	+	<u>80MG/100ML</u>	<u>N018132</u>	<u>002</u>	Feb 04, 1982
<u>AP</u>	+	<u>80MG/ML</u>	<u>N018132</u>	<u>004</u>	Jul 09, 1982
<u>AP</u>	+	<u>160MG/100ML</u>	<u>N018132</u>	<u>003</u>	Feb 04, 1982
<u>AP</u>	+ LUITPOLD	<u>40MG/ML</u>	<u>A070799</u>	<u>001</u>	Feb 11, 1987
<u>AP</u>	+	<u>80MG/ML</u>	<u>A070820</u>	<u>001</u>	Feb 11, 1987
<u>AP</u>	+	<u>160MG/ML</u>	<u>A070826</u>	<u>001</u>	Feb 11, 1987

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

<u>AP</u>	+ B BRAUN	<u>80MG/100ML</u>	<u>N019099</u>	<u>002</u>	Oct 15, 1986
<u>AP</u>	+	<u>320MG/100ML</u>	<u>N019099</u>	<u>004</u>	Oct 15, 1986

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+ B BRAUN	<u>160MG/100ML</u>	<u>N019099</u>	<u>003</u>	Oct 15, 1986
-----------	-----------	--------------------	----------------	------------	--------------

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>80MG/100ML</u>	<u>N019615</u>	<u>001</u>	Mar 27, 1987
<u>AP</u>	+	<u>160MG/100ML</u>	<u>N019615</u>	<u>002</u>	Mar 27, 1987
<u>AP</u>	+	<u>320MG/100ML</u>	<u>N019615</u>	<u>003</u>	Mar 27, 1987
<u>AP</u>	+ HOSPIRA	<u>80MG/100ML</u>	<u>N018826</u>	<u>001</u>	Sep 30, 1983
<u>AP</u>	+	<u>160MG/100ML</u>	<u>N018826</u>	<u>002</u>	Sep 30, 1983
<u>AP</u>	+	<u>320MG/100ML</u>	<u>N018826</u>	<u>003</u>	Sep 30, 1983

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

	+ B BRAUN	40MG/100ML	N019099	001	Oct 15, 1986
--	-----------	------------	---------	-----	--------------

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

	+ BAXTER HLTHCARE	640MG/100ML	N019615	004	Mar 27, 1987
--	-------------------	-------------	---------	-----	--------------

DORIPENEM

INJECTABLE; IV (INFUSION)

	+ ORTHO MCNEIL JANSSEN	500MG/VIAL	N022106	001	Oct 12, 2007
--	------------------------	------------	---------	-----	--------------

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

<u>AT</u>	ALCON	<u>EQ 2% BASE</u>	<u>A078981</u>	<u>001</u>	Apr 13, 2009
<u>AT</u>	APOTEX INC	<u>EQ 2% BASE</u>	<u>A078395</u>	<u>001</u>	Oct 28, 2008
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 2% BASE</u>	<u>A090143</u>	<u>001</u>	Jun 25, 2009
<u>AT</u>	HI TECH PHARMA	<u>EQ 2% BASE</u>	<u>A077846</u>	<u>001</u>	Oct 28, 2008
<u>AT</u>	PHARMAFORCE	<u>EQ 2% BASE</u>	<u>A079186</u>	<u>001</u>	Nov 18, 2009
<u>AT</u>	SANDOZ	<u>EQ 2% BASE</u>	<u>A078748</u>	<u>001</u>	Nov 06, 2008
<u>AT</u>	TEVA PHARMS	<u>EQ 2% BASE</u>	<u>A078756</u>	<u>001</u>	Dec 04, 2008

TRUSOPT

<u>AT</u>	+ MERCK	<u>EQ 2% BASE</u>	<u>N020408</u>	<u>001</u>	Dec 09, 1994
-----------	---------	-------------------	----------------	------------	--------------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT

<u>AT</u>	+ MERCK	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>N020869</u>	<u>001</u>	Apr 07, 1998
-----------	---------	--------------------------------	----------------	------------	--------------

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

<u>AT</u>	ALCON RES	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A090604</u>	<u>001</u>	Nov 18, 2009
<u>AT</u>	APOTEX INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A078201</u>	<u>001</u>	Oct 28, 2008
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A090037</u>	<u>001</u>	Jul 14, 2009
<u>AT</u>	HI TECH PHARMA	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A077847</u>	<u>001</u>	Oct 28, 2008
<u>AT</u>	SANDOZ	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A078749</u>	<u>001</u>	Nov 06, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 140 (of 393)

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

<u>AT</u>	TEVA PARNTL	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A078704</u>	<u>001</u>	Sep 28, 2009
-----------	-------------	--------------------------------	----------------	------------	--------------

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

<u>AP</u>	+ BAXTER HLTHCARE	<u>20MG/ML</u>	<u>N014879</u>	<u>001</u>	
<u>DOXAPRAM HYDROCHLORIDE</u>					
<u>AP</u>	BEDFORD	<u>20MG/ML</u>	<u>A076266</u>	<u>001</u>	Jan 10, 2003
<u>AP</u>	WATSON LABS	<u>20MG/ML</u>	<u>A073529</u>	<u>001</u>	Jan 30, 1992

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

<u>AB</u>	+ PFIZER	<u>EQ 1MG BASE</u>	<u>N019668</u>	<u>001</u>	Nov 02, 1990
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>N019668</u>	<u>002</u>	Nov 02, 1990
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N019668</u>	<u>003</u>	Nov 02, 1990
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N019668</u>	<u>004</u>	Nov 02, 1990

DOXAZOSIN MESYLATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 1MG BASE</u>	<u>A075574</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075574</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075574</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075574</u>	<u>004</u>	Oct 18, 2000
<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A075580</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075580</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075580</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075580</u>	<u>004</u>	Oct 18, 2000
<u>AB</u>	DAVA PHARMS INC	<u>EQ 1MG BASE</u>	<u>A076161</u>	<u>001</u>	Jun 10, 2004
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A076161</u>	<u>002</u>	Jun 10, 2004
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076161</u>	<u>003</u>	Jun 10, 2004
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076161</u>	<u>004</u>	Jun 10, 2004
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A075453</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075453</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075453</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075453</u>	<u>004</u>	Oct 18, 2000
<u>AB</u>	KV PHARM	<u>EQ 1MG BASE</u>	<u>A075609</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075609</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075609</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075609</u>	<u>004</u>	Oct 18, 2000
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A075509</u>	<u>001</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075509</u>	<u>002</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075509</u>	<u>003</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075509</u>	<u>004</u>	Oct 19, 2000
<u>AB</u>	PLIVA	<u>EQ 1MG BASE</u>	<u>A075750</u>	<u>001</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075750</u>	<u>002</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075750</u>	<u>003</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075750</u>	<u>004</u>	Jun 08, 2001
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A075432</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075432</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075432</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075432</u>	<u>004</u>	Oct 18, 2000
<u>AB</u>	TEVA	<u>EQ 1MG BASE</u>	<u>A075536</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075536</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075536</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075536</u>	<u>004</u>	Oct 18, 2000
<u>AB</u>	WATSON LABS	<u>EQ 1MG BASE</u>	<u>A075426</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075426</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075426</u>	<u>003</u>	Oct 18, 2000

## PRESCRIPTION DRUG PRODUCT LIST

3 - 141 (of 393)

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

<u>AB</u>	WATSON LABS	<u>EQ 8MG BASE</u>	<u>A075426</u>	<u>004</u>	Oct 18, 2000
TABLET, EXTENDED RELEASE; ORAL					
CARDURA XL					
	PFIZER	EQ 4MG BASE	N021269	001	Feb 22, 2005
	+	EQ 8MG BASE	N021269	002	Feb 22, 2005

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A070791</u>	<u>002</u>	May 13, 1986
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A070791</u>	<u>003</u>	May 13, 1986
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A070791</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A070791</u>	<u>004</u>	May 13, 1986
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A070791</u>	<u>005</u>	May 13, 1986
<u>AB</u>	PAR PHARM	<u>EQ 10MG BASE</u>	<u>A071697</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>A071437</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A071595</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A071608</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A071422</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>	WATSON LABS	<u>EQ 10MG BASE</u>	<u>A071485</u>	<u>001</u>	Apr 30, 1987
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A071486</u>	<u>001</u>	Apr 30, 1987
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A071238</u>	<u>001</u>	Apr 30, 1987
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A071326</u>	<u>001</u>	Apr 30, 1987
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A071239</u>	<u>001</u>	Apr 30, 1987
	DOXEPIN HYDROCHLORIDE				
	PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987
CONCENTRATE; ORAL					
<u>DOXEPIN HYDROCHLORIDE</u>					
<u>AA</u>	MORTON GROVE	<u>EQ 10MG BASE/ML</u>	<u>A071918</u>	<u>001</u>	Jul 20, 1988
<u>AA</u>	PHARM ASSOC	<u>EQ 10MG BASE/ML</u>	<u>A075924</u>	<u>001</u>	Jan 15, 2004
<u>AA</u>	SILARX	<u>EQ 10MG BASE/ML</u>	<u>A074721</u>	<u>001</u>	Dec 29, 1998
<u>AA</u>	+	<u>EQ 10MG BASE/ML</u>	<u>A071609</u>	<u>001</u>	Nov 09, 1987
CREAM; TOPICAL					
ZONALON					
	+	5%	N020126	001	Apr 01, 1994

DOXERCALCIFEROL

CAPSULE; ORAL

HECTOROL

	GENZYME	0.5MCG	N020862	002	Apr 23, 2004
		1MCG	N020862	003	Jul 13, 2009
	+	2.5MCG	N020862	001	Jun 09, 1999

INJECTABLE; INJECTION

HECTOROL

	+	GENZYME	2MCG/ML	N021027	001	Apr 06, 2000
--	---	---------	---------	---------	-----	--------------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	APP PHARMS	<u>2MG/ML</u>	<u>A063277</u>	<u>001</u>	Oct 26, 1995
<u>AP</u>	+	<u>2MG/ML</u>	<u>A062975</u>	<u>001</u>	Mar 17, 1989
<u>AP</u>	+	<u>10MG/VIAL</u>	<u>A062921</u>	<u>001</u>	Mar 17, 1989
<u>AP</u>	+	<u>20MG/VIAL</u>	<u>A062921</u>	<u>002</u>	Mar 17, 1989
<u>AP</u>	+	<u>50MG/VIAL</u>	<u>A062921</u>	<u>003</u>	Mar 17, 1989
<u>AP</u>	+	<u>200MG/100ML</u>	<u>A064097</u>	<u>001</u>	Sep 13, 1994
<u>AP</u>	PHARMACHEMIE	<u>2MG/ML</u>	<u>A063336</u>	<u>001</u>	Feb 28, 1995



## PRESCRIPTION DRUG PRODUCT LIST

3 - 142 (of 393)

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	PHARMACHEMIE	<u>10MG/VIAL</u>	<u>A063097</u>	<u>001</u>	May 21, 1990
<u>AP</u>		<u>20MG/VIAL</u>	<u>A063097</u>	<u>002</u>	May 21, 1990
<u>AP</u>		<u>50MG/VIAL</u>	<u>A063097</u>	<u>003</u>	May 21, 1990
<u>AP</u>		<u>200MG/100ML</u>	<u>A063336</u>	<u>004</u>	Feb 28, 1995
<u>AP</u>	TEVA PARENTERAL	<u>2MG/ML</u>	<u>A064140</u>	<u>001</u>	Jul 28, 1995
<u>AP</u>		<u>200MG/100ML</u>	<u>A064140</u>	<u>002</u>	Jul 28, 1995

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

+	ORTHO BIOTECH	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995
+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065055</u>	<u>001</u>	Dec 01, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065055</u>	<u>002</u>	Dec 01, 2000
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065053</u>	<u>001</u>	Nov 22, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065053</u>	<u>003</u>	Sep 10, 2003
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065053</u>	<u>002</u>	Nov 22, 2000
<u>AB</u>	SANDOZ	<u>EQ 50MG BASE</u>	<u>A065032</u>	<u>001</u>	Jun 30, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065032</u>	<u>002</u>	Jun 30, 2000
<u>AB</u>	WATSON LABS	<u>EQ 50MG BASE</u>	<u>A065041</u>	<u>001</u>	Apr 28, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065041</u>	<u>002</u>	Apr 28, 2000

MONODOX

<u>AB</u>	WATSON PHARMS	<u>EQ 50MG BASE</u>	<u>N050641</u>	<u>002</u>	Feb 10, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N050641</u>	<u>003</u>	Oct 18, 2006
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N050641</u>	<u>001</u>	Dec 29, 1989
	DOXYCYCLINE				
+	PAR PHARM	EQ 150MG BASE	A065055	003	Jul 15, 2005
	ORACEA				
+	GALDERMA LABS LP	40MG	N050805	001	May 26, 2006

FOR SUSPENSION; ORAL

DOXYCYCLINE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 25MG BASE/5ML</u>	<u>A065454</u>	<u>001</u>	Jul 16, 2008
-----------	----------------------	-------------------------	----------------	------------	--------------

VIBRAMYCIN

<u>AB</u>	+	<u>EQ 25MG BASE/5ML</u>	<u>N050006</u>	<u>001</u>	
-----------	---	-------------------------	----------------	------------	--

TABLET; ORAL

DOXYCYCLINE

<u>AB</u>	LANNETT	<u>EQ 50MG BASE</u>	<u>A065285</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065285</u>	<u>003</u>	Jul 30, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065285</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065285</u>	<u>004</u>	Jul 30, 2008
<u>AB</u>	MUTUAL PHARM	<u>EQ 50MG BASE</u>	<u>A065471</u>	<u>001</u>	Apr 17, 2009
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065471</u>	<u>002</u>	Apr 17, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065471</u>	<u>003</u>	Apr 17, 2009
<u>AB</u>	MYLAN	<u>EQ 50MG BASE</u>	<u>A065377</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065377</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065377</u>	<u>003</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065427</u>	<u>001</u>	Jun 07, 2007
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065070</u>	<u>001</u>	Dec 15, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065070</u>	<u>003</u>	Dec 30, 2002
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065070</u>	<u>002</u>	Dec 15, 2000
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>A065070</u>	<u>004</u>	Jul 14, 2005
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065356</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065356</u>	<u>002</u>	May 31, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065356</u>	<u>003</u>	May 31, 2006
<u>AB</u>	SANDOZ	<u>EQ 50MG BASE</u>	<u>A065353</u>	<u>001</u>	Nov 27, 2006

## PRESCRIPTION DRUG PRODUCT LIST

3 - 143 (of 393)

DOXYCYCLINE

TABLET; ORAL

DOXYCYCLINE

<u>AB</u>	SANDOZ	<u>EQ 75MG BASE</u>	<u>A065353</u>	<u>002</u>	Nov 27, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065353</u>	<u>003</u>	Nov 27, 2006

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

VIBRAMYCIN

+	PFIZER	EQ 50MG BASE/5ML	N050480	001	
---	--------	------------------	---------	-----	--

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 50MG BASE</u>	<u>A062500</u>	<u>001</u>	Sep 11, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062500</u>	<u>002</u>	Sep 11, 1984
<u>AB</u>	MUTUAL PHARM	<u>EQ 50MG BASE</u>	<u>A062675</u>	<u>001</u>	Jul 10, 1986
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062676</u>	<u>001</u>	Jul 10, 1986
<u>AB</u>	WATSON LABS	<u>EQ 50MG BASE</u>	<u>A062031</u>	<u>002</u>	Oct 13, 1982
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062031</u>	<u>001</u>	
<u>AB</u>	WEST WARD	<u>EQ 50MG BASE</u>	<u>A062396</u>	<u>002</u>	Nov 07, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062396</u>	<u>001</u>	May 07, 1984

VIBRAMYCIN

<u>AB</u>	PFIZER	<u>EQ 50MG BASE</u>	<u>N050007</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N050007</u>	<u>002</u>	
	DOXYCYCLINE HYCLATE				
+	WEST WARD	EQ 20MG BASE	A065103	001	May 13, 2005

CAPSULE, DELAYED RELEASE; ORAL

DOXYCYCLINE HYCLATE

	SANDOZ	EQ 75MG BASE	A065281	001	Dec 21, 2005
+		EQ 100MG BASE	A065281	002	Dec 21, 2005

INJECTABLE; INJECTION

DOXY 100

<u>AP</u>	+	APP PHARMS	<u>EQ 100MG BASE/VIAL</u>	<u>A062475</u>	<u>001</u>	Dec 09, 1983
<u>AP</u>	+	DOXYCYCLINE	<u>EQ 100MG BASE/VIAL</u>	<u>A062569</u>	<u>001</u>	Mar 09, 1988
		DOXY 200				
+		APP PHARMS	EQ 200MG BASE/VIAL	A062475	002	Dec 09, 1983

SYSTEM, EXTENDED RELEASE; PERIODONTAL

ATRIDOX

+	TOLMAR	50MG	N050751	001	Sep 03, 1998
---	--------	------	---------	-----	--------------

TABLET; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	COREPHARMA	<u>EQ 20MG BASE</u>	<u>A065182</u>	<u>001</u>	May 13, 2005
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A065163</u>	<u>001</u>	May 13, 2005
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062505</u>	<u>001</u>	Sep 11, 1984
<u>AB</u>	LANNETT	<u>EQ 20MG BASE</u>	<u>A065277</u>	<u>001</u>	Nov 10, 2005
<u>AB</u>	MUTUAL PHARM	<u>EQ 100MG BASE</u>	<u>A062677</u>	<u>001</u>	Jul 10, 1986
<u>AB</u>	MUTUAL PHARMA	<u>EQ 20MG BASE</u>	<u>A065134</u>	<u>001</u>	May 13, 2005
<u>AB</u>	VINTAGE PHARMS	<u>EQ 100MG BASE</u>	<u>A062538</u>	<u>001</u>	Apr 07, 1986
<u>AB</u>	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A062421</u>	<u>001</u>	Feb 02, 1983
<u>AB</u>	WEST WARD	<u>EQ 100MG BASE</u>	<u>A065095</u>	<u>001</u>	Jul 02, 2003

PERIOSTAT

<u>AB</u>	+	GALDERMA LABS LP	<u>EQ 20MG BASE</u>	<u>N050783</u>	<u>001</u>	Feb 02, 2001
-----------	---	------------------	---------------------	----------------	------------	--------------

VIBRA-TABS

<u>AB</u>	+	PFIZER	<u>EQ 100MG BASE</u>	<u>N050533</u>	<u>001</u>	
-----------	---	--------	----------------------	----------------	------------	--

TABLET, DELAYED RELEASE; ORAL

DORYX

	MAYNE PHARMA INTL	EQ 75MG BASE	N050795	001	May 06, 2005
--	-------------------	--------------	---------	-----	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 170 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 144 (of 393)

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE; ORAL

DORYX

MAYNE PHARMA INTL	EQ 100MG BASE	N050795	002	May 06, 2005
+	EQ 150MG BASE	N050795	003	Jun 20, 2008

DRONABINOL

CAPSULE; ORAL

DRONABINOL

<u>AB</u>	SVC PHARMA	<u>2.5MG</u>	<u>A078292</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>		<u>5MG</u>	<u>A078292</u>	<u>002</u>	Jun 27, 2008
<u>AB</u>		<u>10MG</u>	<u>A078292</u>	<u>003</u>	Jun 27, 2008

MARINOL

<u>AB</u>	UNIMED	<u>2.5MG</u>	<u>N018651</u>	<u>001</u>	May 31, 1985
<u>AB</u>	+	<u>5MG</u>	<u>N018651</u>	<u>002</u>	May 31, 1985
<u>AB</u>		<u>10MG</u>	<u>N018651</u>	<u>003</u>	May 31, 1985

DRONEDARONE HYDROCHLORIDE

TABLET; ORAL

MULTAQ

+	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009
---	-------------------	---------------	---------	-----	--------------

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

<u>AP</u>	HOSPIRA	<u>2.5MG/ML</u>	<u>A071981</u>	<u>001</u>	Feb 29, 1988
<u>AP</u>	LUITPOLD	<u>2.5MG/ML</u>	<u>A072123</u>	<u>001</u>	Oct 24, 1988
<u>AP</u>		<u>2.5MG/ML</u>	<u>A072335</u>	<u>001</u>	Oct 24, 1988

INAPSINE

<u>AP</u>	+	AKORN INC	<u>2.5MG/ML</u>	<u>N016796</u>	<u>001</u>
-----------	---	-----------	-----------------	----------------	------------

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

+	BAYER HLTHCARE	0.5MG;1MG	N021355	002	Sep 28, 2005
---	----------------	-----------	---------	-----	--------------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

<u>AB</u>	BARR	<u>3MG;0.02MG</u>	<u>A078515</u>	<u>001</u>	Mar 30, 2009
-----------	------	-------------------	----------------	------------	--------------

YAZ

<u>AB</u>	+	BAYER HLTHCARE	<u>3MG;0.02MG</u>	<u>N021676</u>	<u>001</u>	Mar 16, 2006
-----------	---	----------------	-------------------	----------------	------------	--------------

TABLET; ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

<u>AB</u>	BARR	<u>3MG;0.03MG</u>	<u>A077527</u>	<u>001</u>	May 09, 2008
-----------	------	-------------------	----------------	------------	--------------

YASMIN

<u>AB</u>	+	BAYER HLTHCARE	<u>3MG;0.03MG</u>	<u>N021098</u>	<u>001</u>	May 11, 2001
-----------	---	----------------	-------------------	----------------	------------	--------------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

CYMBALTA

LILLY	EQ 20MG BASE	N021427	001	Aug 03, 2004
	EQ 30MG BASE	N021427	002	Aug 03, 2004
	EQ 40MG BASE	N021427	003	Nov 19, 2009
+	EQ 60MG BASE	N021427	004	Aug 03, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 145 (of 393)

DUTASTERIDE

CAPSULE; ORAL

AVODART

+ GLAXOSMITHKLINE	0.5MG	N021319	001	Nov 20, 2001
-------------------	-------	---------	-----	--------------

DYPHYLLINE

TABLET; ORAL

LUFYLLIN

MEDA PHARMS	200MG	A084566	001	
+	400MG	A084566	002	

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

PHOSPHOLINE IODIDE

+ WYETH PHARMS INC	0.125%	N011963	001	
--------------------	--------	---------	-----	--

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

<u>AB</u> + ALTANA	<u>1%</u>	<u>A076075</u>	<u>001</u>	Nov 26, 2002
<u>AB</u> PERRIGO NEW YORK	<u>1%</u>	<u>A076479</u>	<u>001</u>	Jun 23, 2004
<u>AB</u> PRASCO	<u>1%</u>	<u>A076574</u>	<u>001</u>	Dec 17, 2004
<u>AB</u> TARO	<u>1%</u>	<u>A076005</u>	<u>001</u>	Nov 26, 2002

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION

CALCIUM DISODIUM VERSENATE

+ GRACEWAY	200MG/ML	N008922	001	
------------	----------	---------	-----	--

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

<u>AP</u> HOSPIRA	<u>10MG/ML</u>	<u>A040131</u>	<u>001</u>	Feb 24, 1998
<u>AP</u> BIONICHE PHARMA	<u>10MG/ML</u>	<u>A088873</u>	<u>001</u>	Aug 06, 1985
<u>AP</u> + VALEANT PHARM INTL	<u>10MG/ML</u>	<u>N007959</u>	<u>001</u>	
<u>AP</u> + VALEANT PHARM INTL	<u>10MG/ML</u>	<u>N007959</u>	<u>002</u>	

EFAVIRENZ

CAPSULE; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB	50MG	N020972	001	Sep 17, 1998
+	200MG	N020972	003	Sep 17, 1998

TABLET; ORAL

SUSTIVA

+ BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002
------------------------	-------	---------	-----	--------------

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

ATRIPLA

+ GILEAD	600MG; 200MG; 300MG	N021937	001	Jul 12, 2006
----------	---------------------	---------	-----	--------------

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

+ SKINMEDICA	13.9%	N021145	001	Jul 27, 2000
--------------	-------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 146 (of 393)

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

RELPAK

PFIZER IRELAND	EQ 20MG BASE	N021016	001	Dec 26, 2002
+	EQ 40MG BASE	N021016	002	Dec 26, 2002

ELTROMBOPAG OLAMINE

TABLET; ORAL

PROMACTA

GLAXOSMITHKLINE	EQ 25MG ACID	N022291	001	Nov 20, 2008
+	EQ 50MG ACID	N022291	002	Nov 20, 2008

EMEDASTINE DIFUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALCON	0.05%	N020706	001	Dec 29, 1997
-------	-------	---------	-----	--------------

EMTRICITABINE

CAPSULE; ORAL

EMTRIVA

GILEAD	200MG	N021500	001	Jul 02, 2003
--------	-------	---------	-----	--------------

SOLUTION; ORAL

EMTRIVA

GILEAD	10MG/ML	N021896	001	Sep 28, 2005
--------	---------	---------	-----	--------------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TRUVADA

GILEAD	200MG; 300MG	N021752	001	Aug 02, 2004
--------	--------------	---------	-----	--------------

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

<u>AB</u>	APOTEX	<u>2.5MG</u>	<u>A075178</u>	<u>002</u>	Mar 23, 2001
<u>AB</u>		<u>5MG</u>	<u>A075178</u>	<u>001</u>	Mar 23, 2001
<u>AB</u>		<u>10MG</u>	<u>A075178</u>	<u>003</u>	Mar 23, 2001
<u>AB</u>		<u>20MG</u>	<u>A075178</u>	<u>004</u>	Mar 23, 2001
<u>AB</u>	GENPHARM	<u>2.5MG</u>	<u>A075472</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075472</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075472</u>	<u>003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075472</u>	<u>004</u>	Aug 22, 2000
<u>AB</u>	KRKA DD NOVO MESTO	<u>2.5MG</u>	<u>A075370</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075370</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075369</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075369</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>	LEK PHARMS	<u>2.5MG</u>	<u>A075496</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075496</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075459</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075459</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A075480</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075480</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075480</u>	<u>003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075480</u>	<u>004</u>	Aug 22, 2000
<u>AB</u>	RANBAXY	<u>2.5MG</u>	<u>A075556</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075556</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075556</u>	<u>003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075556</u>	<u>004</u>	Aug 22, 2000
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A075621</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075621</u>	<u>002</u>	Aug 22, 2000

## PRESCRIPTION DRUG PRODUCT LIST

3 - 147 (of 393)

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A075621</u>	<u>003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075621</u>	<u>004</u>	Aug 22, 2000
<u>AB</u>	TARO	<u>2.5MG</u>	<u>A075657</u>	<u>001</u>	Jan 23, 2001
<u>AB</u>		<u>5MG</u>	<u>A075657</u>	<u>002</u>	Jan 23, 2001
<u>AB</u>		<u>10MG</u>	<u>A075657</u>	<u>003</u>	Jan 23, 2001
<u>AB</u>		<u>20MG</u>	<u>A075657</u>	<u>004</u>	Jan 23, 2001
<u>AB</u>	TEVA	<u>2.5MG</u>	<u>A075479</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075479</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075479</u>	<u>003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075479</u>	<u>004</u>	Aug 22, 2000
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A075501</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075501</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075501</u>	<u>003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075501</u>	<u>004</u>	Aug 22, 2000
<u>AB</u>	WOCKHARDT	<u>2.5MG</u>	<u>A075483</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075483</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075483</u>	<u>003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075483</u>	<u>004</u>	Aug 22, 2000
	<u>VASOTEC</u>				
<u>AB</u>	BIOVAIL LABS INTL	<u>2.5MG</u>	<u>N018998</u>	<u>005</u>	Jul 26, 1988
<u>AB</u>		<u>5MG</u>	<u>N018998</u>	<u>001</u>	Dec 24, 1985
<u>AB</u>		<u>10MG</u>	<u>N018998</u>	<u>002</u>	Dec 24, 1985
<u>AB</u>	+	<u>20MG</u>	<u>N018998</u>	<u>003</u>	Dec 24, 1985

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXXEL

+ ASTRAZENECA 5MG;5MG N020668 001 Dec 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>5MG;12.5MG</u>	<u>A076486</u>	<u>001</u>	Oct 27, 2004
<u>AB</u>		<u>10MG;25MG</u>	<u>A076486</u>	<u>002</u>	Oct 27, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG;12.5MG</u>	<u>A075909</u>	<u>001</u>	Oct 15, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075909</u>	<u>002</u>	Oct 15, 2001
<u>AB</u>	MYLAN	<u>5MG;12.5MG</u>	<u>A075624</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075624</u>	<u>002</u>	Sep 18, 2001
<u>AB</u>	SANDOZ	<u>5MG;12.5MG</u>	<u>A076116</u>	<u>001</u>	Sep 19, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A076116</u>	<u>002</u>	Sep 19, 2001
<u>AB</u>	TARO PHARM INDS	<u>5MG;12.5MG</u>	<u>A075788</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075788</u>	<u>002</u>	Sep 18, 2001
<u>AB</u>	TEVA	<u>5MG;12.5MG</u>	<u>A075727</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075727</u>	<u>002</u>	Sep 18, 2001
	<u>VASERETIC</u>				
<u>AB</u>	BIOVAIL LABS INTL	<u>5MG;12.5MG</u>	<u>N019221</u>	<u>003</u>	Jul 12, 1995
<u>AB</u>	+	<u>10MG;25MG</u>	<u>N019221</u>	<u>001</u>	Oct 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

<u>AP</u>	+	BEDFORD	<u>1.25MG/ML</u>	<u>A075634</u>	<u>001</u>	Aug 22, 2000
<u>AP</u>		HIKMA FARMACEUTICA	<u>1.25MG/ML</u>	<u>A078687</u>	<u>001</u>	Dec 23, 2008
<u>AP</u>	+	HOSPIRA	<u>1.25MG/ML</u>	<u>A075458</u>	<u>001</u>	Aug 22, 2000
<u>AP</u>		TEVA PARENTERAL	<u>1.25MG/ML</u>	<u>A075578</u>	<u>001</u>	Aug 22, 2000

## PRESCRIPTION DRUG PRODUCT LIST

3 - 148 (of 393)

ENFLURANE

LIQUID; INHALATION

ENFLURANE

<u>AN</u>	MINRAD	<u>99.9%</u>	<u>A074396</u>	<u>001</u>	Jul 29, 1994
-----------	--------	--------------	----------------	------------	--------------

ETHRANE

<u>AN</u>	+ BAXTER HLTHCARE CORP	<u>99.9%</u>	<u>N017087</u>	<u>001</u>	
-----------	------------------------	--------------	----------------	------------	--

ENFUVRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

	+ ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003
--	---------	-----------	---------	-----	--------------

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX

	SANOFI AVENTIS US	300MG/3ML (100MG/ML)	N020164	009	Jan 23, 2003
--	-------------------	----------------------	---------	-----	--------------

LOVENOX (PRESERVATIVE FREE)

	SANOFI AVENTIS US	30MG/0.3ML (100MG/ML)	N020164	001	Mar 29, 1993
--	-------------------	-----------------------	---------	-----	--------------

		40MG/0.4ML (100MG/ML)	N020164	002	Jan 30, 1998
--	--	-----------------------	---------	-----	--------------

		60MG/0.6ML (100MG/ML)	N020164	003	Mar 27, 1998
--	--	-----------------------	---------	-----	--------------

		80MG/0.8ML (100MG/ML)	N020164	004	Mar 27, 1998
--	--	-----------------------	---------	-----	--------------

+		100MG/ML (100MG/ML)	N020164	005	Mar 27, 1998
---	--	---------------------	---------	-----	--------------

		120MG/0.8ML (150MG/ML)	N020164	007	Jun 02, 2000
--	--	------------------------	---------	-----	--------------

		150MG/ML (150MG/ML)	N020164	008	Jun 02, 2000
--	--	---------------------	---------	-----	--------------

ENTACAPONE

TABLET; ORAL

COMTAN

	+ ORION	200MG	N020796	001	Oct 19, 1999
--	---------	-------	---------	-----	--------------

ENTECAVIR

SOLUTION; ORAL

BARACLUDE

	+ BRISTOL MYERS SQUIBB	0.05MG/ML	N021798	001	Mar 29, 2005
--	------------------------	-----------	---------	-----	--------------

TABLET; ORAL

BARACLUDE

	BRISTOL MYERS SQUIBB	0.5MG	N021797	001	Mar 29, 2005
--	----------------------	-------	---------	-----	--------------

+		1MG	N021797	002	Mar 29, 2005
---	--	-----	---------	-----	--------------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	+ ALLERGAN	0.05%	N021565	001	Oct 16, 2003
--	------------	-------	---------	-----	--------------

EPINEPHRINE

INJECTABLE; IM-SC

TWINJECT 0.15

	+ SCIELE PHARMA INC	EQ 0.15MG /DELIVERY	N020800	002	May 28, 2004
--	---------------------	---------------------	---------	-----	--------------

TWINJECT 0.3

	+ SCIELE PHARMA INC	EQ 0.3MG /DELIVERY	N020800	001	May 30, 2003
--	---------------------	--------------------	---------	-----	--------------

INJECTABLE; INTRAMUSCULAR

EPIPEN

	+ MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N019430	001	Dec 22, 1987
--	------------------------	----------------	---------	-----	--------------

EPIPEN JR.

	+ MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N019430	002	Dec 22, 1987
--	------------------------	-----------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 149 (of 393)

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIGNOSPAN FORTE

+ DEPROCO EQ 0.02MG BASE/ML;2% A088389 001 Jan 22, 1985

LIGNOSPAN STANDARD

+ DEPROCO EQ 0.01MG BASE/ML;2% A088390 001 Jan 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL

+ DENTSPLY PHARM 0.005MG/ML;4% N021383 001

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINEAP EASTMAN KODAK 0.01MG/ML;2% A040057 002 Feb 26, 1993AP 0.02MG/ML;2% A040057 001 Feb 26, 1993AP HOSPIRA 0.005MG/ML;0.5% A089635 001 Jun 21, 1988AP 0.005MG/ML;1% A089649 001 Jun 21, 1988AP 0.005MG/ML;1.5% A088571 001 Sep 13, 1985AP 0.005MG/ML;1.5% A089645 001 Jun 21, 1988AP 0.005MG/ML;2% A089651 001 Jun 21, 1988AP 0.01MG/ML;1% A089644 001 Jun 21, 1988AP 0.01MG/ML;2% A078772 001 May 12, 2008AP 0.01MG/ML;2% A089646 001 Jun 21, 1988AP 0.02MG/ML;2% A078772 002 May 12, 2008OCTOCAINEAP SEPTODONT 0.01MG/ML;2% A084048 001AP + 0.02MG/ML;2% A084048 002XYLOCAINE DENTAL WITH EPINEPHRINEAP + DENTSPLY PHARM 0.01MG/ML;2% N021381 001AP + 0.02MG/ML;2% N021381 002XYLOCAINE W/ EPINEPHRINEAP + APP PHARMS 0.005MG/ML;0.5% N006488 012AP + 0.005MG/ML;1% N006488 018 Nov 13, 1986AP + 0.005MG/ML;1.5% N006488 017AP + 0.005MG/ML;2% N006488 019 Nov 13, 1986AP + 0.01MG/ML;1% N006488 004AP + 0.02MG/ML;2% N006488 005EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLENCAP + PFIZER INC 200MG/100ML (2MG/ML) N050778 001 Sep 15, 1999AP 50MG/25ML (2MG/ML) N050778 002 Sep 15, 1999EPIRUBICIN HYDROCHLORIDEAP ACTAVIS TOTOWA 10MG/5ML (2MG/ML) A065445 001 Sep 18, 2008AP 50MG/25ML (2MG/ML) A065445 002 Sep 18, 2008AP 200MG/100ML (2MG/ML) A065445 003 Sep 18, 2008AP AKORN INC 50MG/25ML (2MG/ML) A090163 001 Jun 24, 2009AP APP PHARMS 150MG/75ML (2MG/ML) A065408 003 Oct 15, 2007AP 50MG/25ML (2MG/ML) A065408 002 Oct 15, 2007AP 200MG/100ML (2MG/ML) A065408 004 Oct 15, 2007AP 10MG/5ML (2MG/ML) A065408 001 Oct 15, 2007AP BEDFORD 50MG/25ML (2MG/ML) A065289 001 Jun 27, 2007AP 200MG/100ML (2MG/ML) A065289 002 Jun 27, 2007AP EBEWE PHARMA 50MG/25ML (2MG/ML) A065339 001 Dec 22, 2009AP 200MG/100ML (2MG/ML) A065339 002 Dec 22, 2009AP FRESENIUS KABI ONCOL 50MG/25ML (2MG/ML) A065411 002 Aug 20, 2007AP 200MG/100ML (2MG/ML) A065411 001 Aug 20, 2007**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 176 of 1114**



## PRESCRIPTION DRUG PRODUCT LIST

3 - 150 (of 393)

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

<u>AP</u>	GENERAMEDIX	<u>50MG/25ML (2MG/ML)</u>	<u>A065371</u>	<u>001</u>	Nov 28, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065371</u>	<u>002</u>	Nov 28, 2007
<u>AP</u>	HOSPIRA	<u>10MG/5ML (2MG/ML)</u>	<u>A065343</u>	<u>001</u>	Apr 19, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065343</u>	<u>004</u>	Apr 19, 2007
<u>AP</u>		<u>150MG/75ML (2MG/ML)</u>	<u>A065343</u>	<u>003</u>	Apr 19, 2007
<u>AP</u>		<u>50MG/25ML (2MG/ML)</u>	<u>A065343</u>	<u>002</u>	Apr 19, 2007
<u>AP</u>	TEVA PARENTERAL	<u>50MG/25ML (2MG/ML)</u>	<u>A065331</u>	<u>001</u>	Aug 09, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065331</u>	<u>002</u>	Aug 09, 2007
<u>AP</u>	WATSON LABS	<u>200MG/100ML (2MG/ML)</u>	<u>A065361</u>	<u>002</u>	Oct 22, 2007
<u>AP</u>		<u>50MG/25ML (2MG/ML)</u>	<u>A065361</u>	<u>001</u>	Oct 22, 2007

INJECTABLE; IV (INFUSION)

+	HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006
---	---------	-----------	---------	-----	--------------

EPLERENONE

TABLET; ORAL

EPLERENONE

<u>AB</u>	APOTEX	<u>25MG</u>	<u>A078482</u>	<u>001</u>	Jul 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A078482</u>	<u>002</u>	Jul 30, 2008
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A078510</u>	<u>001</u>	Aug 01, 2008
<u>AB</u>		<u>50MG</u>	<u>A078510</u>	<u>002</u>	Aug 01, 2008
	<u>INSPIRA</u>				
<u>AB</u>	GD SEARLE LLC	<u>25MG</u>	<u>N021437</u>	<u>001</u>	Sep 27, 2002
<u>AB</u>	+	<u>50MG</u>	<u>N021437</u>	<u>002</u>	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

<u>AP</u>	TEVA PARENTERAL	<u>EQ 0.5MG BASE/VIAL</u>	<u>A078396</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>		<u>EQ 1.5MG BASE/VIAL</u>	<u>A078396</u>	<u>002</u>	Apr 23, 2008
	<u>FLOLAN</u>				
<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 0.5MG BASE/VIAL</u>	<u>N020444</u>	<u>001</u>	Sep 20, 1995
<u>AP</u>	+	<u>EQ 1.5MG BASE/VIAL</u>	<u>N020444</u>	<u>002</u>	Sep 20, 1995
	EPOPROSTENOL SODIUM				
	+ ACTELION	EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

	ABBOTT	EQ 400MG BASE	N020738	005	Dec 22, 1997
+		EQ 600MG BASE	N020738	006	May 27, 1999

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

	ABBOTT	600MG;12.5MG	N021268	001	Nov 01, 2001
+		600MG;25MG	N021268	002	Nov 01, 2001

EPTIFIBATIDE

INJECTABLE; INJECTION

INTEGRILIN

+	SCHERING	2MG/ML	N020718	001	May 18, 1998
+		75MG/100ML	N020718	002	May 18, 1998

## PRESCRIPTION DRUG PRODUCT LIST

3 - 151 (of 393)

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOLAA + SANOFI AVENTIS US 50,000 IU N003444 001ERGOCALCIFEROLAA ORIT LABS LLC 50,000 IU A040833 001 May 20, 2009AA SUN PHARM INDS INC 50,000 IU A040865 001 Dec 29, 2009VITAMIN DAA BANNER PHARMACAPS 50,000 IU A080704 001ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATESAB MUTUAL PHARM 1MG A081113 001 Oct 31, 1991HYDERGINEAB + NOVARTIS 1MG N017993 001

TABLET; SUBLINGUAL

ERGOLOID MESYLATES

WATSON LABS 0.5MG A087233 001

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

+ ROSEDALE THERAPEUTIC 2MG A087693 001 Feb 24, 1983

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

TARCEVA

OSI PHARMS EQ 25MG BASE N021743 001 Nov 18, 2004

EQ 100MG BASE N021743 002 Nov 18, 2004

+ EQ 150MG BASE N021743 003 Nov 18, 2004

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)

+ MERCK EQ 1GM BASE/VIAL N021337 001 Nov 21, 2001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYCAB + HOSPIRA 250MG N050536 001AB WARNER CHILCOTT 250MG A062338 001ERYTHROMYCINAB ABBOTT 250MG A062746 001 Dec 22, 1986

GEL; TOPICAL

E-GLADESAT STIEFEL LABS INC 2% A065009 001 Mar 18, 2002ERYGELAT + MERZ PHARMS 2% N050617 001 Oct 21, 1987ERYTHROMYCINAT ALTANA 2% A064184 001 Sep 30, 1997AT PERRIGO 2% A063211 001 Jan 29, 1993

OINTMENT; OPHTHALMIC

ERYTHROMYCINAT BAUSCH AND LOMB 0.5% A064067 001 Jul 29, 1994AT + FOUGERA 0.5% A062447 001 Sep 26, 1983

OINTMENT; TOPICAL

AKNE-MYCIN

+ DOW PHARM SCIENCES 2% N050584 001 Jan 10, 1985

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 178 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 152 (of 393)

ERYTHROMYCIN

SOLUTION; TOPICAL

ERYTHRA-DERM

<u>AT</u>	PADDOCK	<u>2%</u>	<u>A062687</u>	<u>001</u>	Feb 05, 1988
-----------	---------	-----------	----------------	------------	--------------

ERYTHROMYCIN

<u>AT</u>	+ ALTANA	<u>2%</u>	<u>A064187</u>	<u>001</u>	Sep 30, 1997
-----------	----------	-----------	----------------	------------	--------------

<u>AT</u>	MORTON GROVE	<u>2%</u>	<u>A062825</u>	<u>001</u>	Oct 23, 1987
-----------	--------------	-----------	----------------	------------	--------------

<u>AT</u>	PERRIGO NEW YORK	<u>2%</u>	<u>A063038</u>	<u>001</u>	Jan 11, 1991
-----------	------------------	-----------	----------------	------------	--------------

ERYTHRO-STATIN

<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>A064101</u>	<u>001</u>	Oct 22, 1996
-----------	----------------	-----------	----------------	------------	--------------

SWAB; TOPICAL

ERYTHROMYCIN

<u>AT</u>	+ ALTANA	<u>2%</u>	<u>A065320</u>	<u>001</u>	Jul 25, 2006
-----------	----------	-----------	----------------	------------	--------------

<u>AT</u>	+ PERRIGO	<u>2%</u>	<u>A064126</u>	<u>001</u>	Jul 03, 1996
-----------	-----------	-----------	----------------	------------	--------------

TABLET; ORAL

ERYTHROMYCIN

	ABBOTT	250MG	A061621	001	
--	--------	-------	---------	-----	--

	+	500MG	A061621	002	
--	---	-------	---------	-----	--

TABLET, COATED PARTICLES; ORAL

PCE

	ABBOTT	333MG	N050611	001	Sep 09, 1986
--	--------	-------	---------	-----	--------------

	+	500MG	N050611	002	Aug 22, 1990
--	---	-------	---------	-----	--------------

TABLET, DELAYED RELEASE; ORAL

ERY-TAB

	+ ABBOTT	250MG	A062298	001	
--	----------	-------	---------	-----	--

	+	333MG	A062298	003	Mar 29, 1982
--	---	-------	---------	-----	--------------

	+	500MG	A062298	002	
--	---	-------	---------	-----	--

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

<u>AB</u>	ABBOTT	<u>EQ 200MG BASE/5ML</u>	<u>N050207</u>	<u>001</u>	
-----------	--------	--------------------------	----------------	------------	--

ERYPED

<u>AB</u>	ABBOTT	<u>EQ 200MG BASE/5ML</u>	<u>N050207</u>	<u>003</u>	Mar 30, 1987
-----------	--------	--------------------------	----------------	------------	--------------

ERYPED

	+ ABBOTT	EQ 400MG BASE/5ML	N050207	002	
--	----------	-------------------	---------	-----	--

SUSPENSION; ORAL

E.E.S. 200

<u>AB</u>	ABBOTT	<u>EQ 200MG BASE/5ML</u>	<u>A061639</u>	<u>001</u>	
-----------	--------	--------------------------	----------------	------------	--

E.E.S. 400

<u>AB</u>	+ ABBOTT	<u>EQ 400MG BASE/5ML</u>	<u>A061639</u>	<u>002</u>	
-----------	----------	--------------------------	----------------	------------	--

PEDIAMYCIN

<u>AB</u>	ROSS LABS	<u>EQ 200MG BASE/5ML</u>	<u>A062304</u>	<u>001</u>	
-----------	-----------	--------------------------	----------------	------------	--

PEDIAMYCIN 400

<u>AB</u>	ROSS LABS	<u>EQ 400MG BASE/5ML</u>	<u>A062304</u>	<u>002</u>	
-----------	-----------	--------------------------	----------------	------------	--

TABLET; ORAL

E.E.S. 400

	+ ABBOTT	EQ 400MG BASE	A061905	002	Aug 12, 1982
--	----------	---------------	---------	-----	--------------

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

	+ BARR	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	A062759	001	May 20, 1988
--	--------	-------------------------------------	---------	-----	--------------

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

<u>AP</u>	HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A062638</u>	<u>001</u>	Oct 31, 1986
-----------	---------	---------------------------	----------------	------------	--------------

<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N050609</u>	<u>001</u>	Sep 24, 1986
-----------	---	---------------------------	----------------	------------	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 179 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 153 (of 393)

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

<u>AP</u>	+	HOSPIRA	<u>EQ 1GM BASE/VIAL</u>	<u>A062638</u>	<u>002</u>	Oct 31, 1986
-----------	---	---------	-------------------------	----------------	------------	--------------

ERYTHROMYCIN LACTOBIONATE

<u>AP</u>		TEVA PARENTERAL	<u>EQ 500MG BASE/VIAL</u>	<u>A063253</u>	<u>001</u>	Jul 30, 1993
-----------	--	-----------------	---------------------------	----------------	------------	--------------

<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A063253</u>	<u>002</u>	Jul 30, 1993
-----------	--	--	-------------------------	----------------	------------	--------------

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

ABBOTT

EQ 250MG BASE

A060359 001

+

EQ 500MG BASE

A060359 003

ESCITALOPRAM OXALATE

CAPSULE; ORAL

ESCITALOPRAM OXALATE

ALPHAPHARM

EQ 5MG BASE

A077660 001

Jul 31, 2007

EQ 10MG BASE

A077660 002

Jul 31, 2007

+

EQ 20MG BASE

A077660 003

Jul 31, 2007

SOLUTION; ORAL

LEXAPRO

+ FOREST LABS

EQ 5MG BASE/5ML

N021365 001

Nov 27, 2002

TABLET; ORAL

LEXAPRO

FOREST LABS

EQ 5MG BASE

N021323 001

Aug 14, 2002

EQ 10MG BASE

N021323 002

Aug 14, 2002

+

EQ 20MG BASE

N021323 003

Aug 14, 2002

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

<u>AP</u>	+	BAXTER HLTHCARE CORP	<u>10MG/ML</u>	<u>N019386</u>	<u>006</u>	Feb 25, 2003
-----------	---	----------------------	----------------	----------------	------------	--------------

ESMOLOL HYDROCHLORIDE

<u>AP</u>		APP PHARMS	<u>10MG/ML</u>	<u>A076573</u>	<u>001</u>	May 02, 2005
-----------	--	------------	----------------	----------------	------------	--------------

<u>AP</u>		BEDFORD LABS	<u>10MG/ML</u>	<u>A076323</u>	<u>001</u>	Aug 10, 2004
-----------	--	--------------	----------------	----------------	------------	--------------

<u>AP</u>		BIONICHE PHARMA	<u>10MG/ML</u>	<u>A076474</u>	<u>001</u>	May 02, 2005
-----------	--	-----------------	----------------	----------------	------------	--------------

BREVIBLOC

+ BAXTER HLTHCARE CORP 20MG/ML

N019386 007

May 28, 2003

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP 2GM/100ML

N019386 005

Jan 27, 2003

BREVIBLOC IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP 1GM/100ML

N019386 004

Feb 16, 2001

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

NEXIUM

ASTRAZENECA

EQ 20MG BASE

N021153 001

Feb 20, 2001

+

EQ 40MG BASE

N021153 002

Feb 20, 2001

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

ASTRAZENECA

EQ 10MG BASE/PACKET

N022101 001

Feb 27, 2008

EQ 20MG BASE/PACKET

N021957 001

Oct 20, 2006

+

EQ 40MG BASE/PACKET

N021957 002

Oct 20, 2006

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

NEXIUM IV

+ ASTRAZENECA

EQ 20MG BASE/VIAL

N021689 001

Mar 31, 2005

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 180 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 154 (of 393)

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

NEXIUM IV

+ ASTRAZENECA EQ 40MG BASE/VIAL N021689 002 Mar 31, 2005

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

<u>AB</u>	PAR PHARM	<u>1MG</u>	<u>A074826</u>	<u>001</u>	Jul 03, 1997
<u>AB</u>		<u>2MG</u>	<u>A074826</u>	<u>002</u>	Jul 03, 1997
<u>AB</u>	TEVA	<u>1MG</u>	<u>A074921</u>	<u>001</u>	Jul 10, 1997
<u>AB</u>	+	<u>2MG</u>	<u>A074921</u>	<u>002</u>	Jul 10, 1997
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A074818</u>	<u>001</u>	Aug 19, 1997
<u>AB</u>		<u>2MG</u>	<u>A074818</u>	<u>002</u>	Aug 19, 1997

ESTRADIOL

CREAM; VAGINAL

ESTRACE

+ WARNER CHILCOTT 0.01% A086069 001 Jan 31, 1984

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

<u>AB</u>	BAYER HLTHCARE	<u>0.0375MG/24HR</u>	<u>N020375</u>	<u>005</u>	May 27, 2003
<u>AB</u>		<u>0.06MG/24HR</u>	<u>N020375</u>	<u>006</u>	May 27, 2003

ESTRADIOL

<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.0375MG/24HR</u>	<u>A075182</u>	<u>004</u>	Jul 20, 2006
<u>AB</u>		<u>0.06MG/24HR</u>	<u>A075182</u>	<u>005</u>	Jul 20, 2006

VIVELLE

<u>AB1</u>	NOVARTIS	<u>0.05MG/24HR</u>	<u>N020323</u>	<u>002</u>	Oct 28, 1994
<u>AB1</u>		<u>0.1MG/24HR</u>	<u>N020323</u>	<u>004</u>	Oct 28, 1994

VIVELLE-DOT

<u>AB1</u>	NOVARTIS	<u>0.05MG/24HR</u>	<u>N020538</u>	<u>006</u>	Jan 08, 1999
<u>AB1</u>	+	<u>0.1MG/24HR</u>	<u>N020538</u>	<u>008</u>	Jan 08, 1999

CLIMARA

<u>AB2</u>	BAYER HLTHCARE	<u>0.025MG/24HR</u>	<u>N020375</u>	<u>004</u>	Mar 05, 1999
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>N020375</u>	<u>001</u>	Dec 22, 1994
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>N020375</u>	<u>003</u>	Mar 23, 1998
<u>AB2</u>	+	<u>0.1MG/24HR</u>	<u>N020375</u>	<u>002</u>	Dec 22, 1994

ESTRADIOL

<u>AB2</u>	MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A075182</u>	<u>003</u>	Jan 26, 2005
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>A075182</u>	<u>006</u>	Feb 24, 2000
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>A075182</u>	<u>002</u>	Jan 26, 2005
<u>AB2</u>		<u>0.1MG/24HR</u>	<u>A075182</u>	<u>001</u>	Feb 24, 2000

ALORA

BX	WATSON LABS	0.025MG/24HR	N020655	004	Apr 05, 2002
BX		0.05MG/24HR	N020655	001	Dec 20, 1996
BX		0.075MG/24HR	N020655	002	Dec 20, 1996
BX		0.1MG/24HR	N020655	003	Dec 20, 1996

ESTRADERM

BX	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986
BX	+	0.1MG/24HR	N019081	003	Sep 10, 1986

VIVELLE-DOT

BX	NOVARTIS	0.025MG/24HR	N020538	009	May 03, 2002
BX		0.0375MG/24HR	N020538	005	Jan 08, 1999
BX		0.075MG/24HR	N020538	007	Jan 08, 1999

MENOSTAR

+ BAYER HLTHCARE 0.014MG/24HR N021674 001 Jun 08, 2004

GEL; TRANSDERMAL

DIVIGEL

UPSHER SMITH	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007
	0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 155 (of 393)

ESTRADIOL

GEL; TRANSDERMAL					
DIVIGEL					
+	UPSHER SMITH	0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007
GEL, METERED; TRANSDERMAL					
ELESTRIN					
+	AZUR PHARMA II	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006
ESTROGEL					
+	ASCEND	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004
INSERT, EXTENDED RELEASE; VAGINAL					
ESTRING					
+	PHARMACIA AND UPJOHN	0.0075MG/24HR	N020472	001	Apr 26, 1996
SPRAY; TRANSDERMAL					
EVAMIST					
+	KV PHARM	1.53MG/SPRAY	N022014	001	Jul 27, 2007
TABLET; ORAL					
<u>ESTRACE</u>					
<u>AB</u>	BRISTOL MYERS SQUIBB	<u>0.5MG</u>	<u>A081295</u>	<u>001</u>	Jun 30, 1993
<u>AB</u>		<u>1MG</u>	<u>A084499</u>	<u>001</u>	
<u>AB</u>	+	<u>2MG</u>	<u>A084500</u>	<u>001</u>	
<u>ESTRADIOL</u>					
<u>AB</u>	BARR	<u>0.5MG</u>	<u>A040197</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>		<u>1MG</u>	<u>A040197</u>	<u>002</u>	Oct 22, 1997
<u>AB</u>		<u>2MG</u>	<u>A040197</u>	<u>003</u>	Oct 22, 1997
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A040326</u>	<u>001</u>	Apr 21, 1999
<u>AB</u>		<u>1MG</u>	<u>A040326</u>	<u>002</u>	Apr 21, 1999
<u>AB</u>		<u>2MG</u>	<u>A040326</u>	<u>003</u>	Apr 21, 1999
<u>AB</u>	USL PHARMA	<u>0.5MG</u>	<u>A040297</u>	<u>001</u>	Apr 17, 2002
<u>AB</u>		<u>1MG</u>	<u>A040297</u>	<u>002</u>	Apr 17, 2002
<u>AB</u>		<u>2MG</u>	<u>A040297</u>	<u>003</u>	Apr 17, 2002
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A040114</u>	<u>003</u>	Mar 14, 1996
<u>AB</u>		<u>1MG</u>	<u>A040114</u>	<u>001</u>	Mar 14, 1996
<u>AB</u>		<u>2MG</u>	<u>A040114</u>	<u>002</u>	Mar 14, 1996
TABLET; VAGINAL					
VAGIFEM					
	NOVO NORDISK INC	10MCG	N020908	002	Nov 25, 2009
+		25MCG	N020908	001	Mar 26, 1999
<u>ESTRADIOL ACETATE</u>					
INSERT, EXTENDED RELEASE; VAGINAL					
FEMRING					
	GALEN LTD	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003
+		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003
TABLET; ORAL					
FEMTRACE					
	WARNER CHILCOTT	0.45MG	N021633	001	Aug 20, 2004
		0.9MG	N021633	002	Aug 20, 2004
+		1.8MG	N021633	003	Aug 20, 2004
<u>ESTRADIOL CYPIONATE</u>					
INJECTABLE; INJECTION					
<u>DEPO-ESTRADIOL</u>					
<u>AO</u>	PHARMACIA AND UPJOHN	<u>5MG/ML</u>	<u>A085470</u>	<u>003</u>	
<u>ESTRADIOL CYPIONATE</u>					
<u>AO</u>	WATSON LABS	<u>5MG/ML</u>	<u>A085620</u>	<u>001</u>	

## PRESCRIPTION DRUG PRODUCT LIST

3 - 156 (of 393)

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL

ESTRASORB

+ GRACEWAY 0.25% N021371 001 Oct 09, 2003

ESTRADIOL VALERATE

INJECTABLE; INJECTION

DELESTROGENAO + JHP PHARMS 10MG/ML N009402 002AO + 20MG/ML N009402 004AO + 40MG/ML N009402 003ESTRADIOL VALERATEAO SANDOZ 10MG/ML A040628 001 Oct 04, 2007AO 20MG/ML A040628 002 Oct 04, 2007AO 40MG/ML A040628 003 Oct 04, 2007AO WATSON LABS 20MG/ML A083547 001AO 40MG/ML A083714 001ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA PRO

+ BAYER HLTHCARE 0.045MG/24HR;0.015MG/24HR N021258 001 Nov 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL

COMBIPATCH

NOVARTIS 0.05MG/24HR;0.14MG/24HR N020870 001 Aug 07, 1998

+ 0.05MG/24HR;0.25MG/24HR N020870 002 Aug 07, 1998

TABLET; ORAL

ACTIVELLAAB + NOVO NORDISK INC 1MG;0.5MG N020907 001 Nov 18, 1998ESTRADIOL AND NORETHINDRONE ACETATEAB BRECKENRIDGE PHARM 1MG;0.5MG A078324 001 Apr 17, 2008

ACTIVELLA

NOVO NORDISK INC 0.5MG;0.1MG N020907 002 Dec 28, 2006

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ESTRADIOL AND NORGESTIMATEAB BARR 1MG,1MG;N/A,0.09MG A076812 001 Apr 29, 2005PREFESTAB + DURAMED RES 1MG,1MG;N/A,0.09MG N021040 001 Oct 22, 1999ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE; ORAL

EMCYT

+ PHARMACIA AND UPJOHN EQ 140MG PHOSPHATE N018045 001

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL

PREMARIN

+ WYETH PHARMS INC 0.625MG/GM N020216 001

INJECTABLE; INJECTION

PREMARIN

+ WYETH PHARMS INC 25MG/VIAL N010402 001

TABLET; ORAL

PREMARIN

WYETH PHARMS INC 0.3MG N004782 003

0.45MG N004782 006 Jul 16, 2003

## PRESCRIPTION DRUG PRODUCT LIST

3 - 157 (of 393)

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

+ WYETH PHARMS INC	0.625MG	N004782	004	
+	0.9MG	N004782	005	Jan 26, 1984
+	1.25MG	N004782	001	

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM; VAGINAL

SYNTHETIC CONJUGATED ESTROGENS A

+ DURAMED RES	0.625MG/GM	N021788	001	Nov 28, 2008
---------------	------------	---------	-----	--------------

TABLET; ORAL

CENESTIN

DURAMED	0.3MG	N020992	001	Jun 21, 2002
	0.45MG	N020992	005	Feb 05, 2004
	0.625MG	N020992	002	Mar 24, 1999
	0.9MG	N020992	003	Mar 24, 1999
+	1.25MG	N020992	004	Mar 13, 2000

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

DURAMED	0.3MG	N021443	001	Dec 20, 2004
	0.45MG	N021443	002	Dec 20, 2004
	0.625MG	N021443	003	May 10, 2004
	0.9MG	N021443	005	Apr 27, 2007
+	1.25MG	N021443	004	May 10, 2004

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE 14/14

+ WYETH PHARMS INC	0.625MG, 0.625MG;N/A, 5MG	N020527	002	Nov 17, 1995
PREMPRO				
+ WYETH PHARMS INC	0.3MG;1.5MG	N020527	005	Jun 04, 2003
+	0.45MG;1.5MG	N020527	004	Mar 12, 2003
+	0.625MG;2.5MG	N020527	001	Nov 17, 1995
+	0.625MG;5MG	N020527	003	Jan 09, 1998

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

MONARCH PHARMS	0.3MG	A084951	001	
	0.625MG	A084948	001	
	1.25MG	A084950	001	
+	2.5MG	A084949	001	

ESTRONE

INJECTABLE; INJECTION

ESTRONE

+ WATSON LABS	5MG/ML	A085239	001	
---------------	--------	---------	-----	--

ESTROPIPATE

CREAM; VAGINAL

OGEN

+ PHARMACIA AND UPJOHN	1.5MG/GM	A084710	001	
------------------------	----------	---------	-----	--

TABLET; ORAL

ESTROPIPATE

<u>AB</u>	BARR	<u>0.75MG</u>	<u>A040135</u>	<u>001</u>	Nov 27, 1996
<u>AB</u>		<u>1.5MG</u>	<u>A040135</u>	<u>002</u>	Nov 27, 1996



## PRESCRIPTION DRUG PRODUCT LIST

3 - 158 (of 393)

ESTROPIPATE

TABLET; ORAL

ESTROPIPATE

<u>AB</u>	BARR	<u>3MG</u>	<u>A040135</u>	<u>003</u>	Nov 27, 1996
<u>AB</u>	MYLAN	<u>0.75MG</u>	<u>A040359</u>	<u>001</u>	Aug 26, 1999
<u>AB</u>		<u>1.5MG</u>	<u>A040359</u>	<u>002</u>	Aug 26, 1999
<u>AB</u>	WATSON LABS	<u>0.75MG</u>	<u>A081213</u>	<u>001</u>	Sep 23, 1993
<u>AB</u>		<u>1.5MG</u>	<u>A081214</u>	<u>001</u>	Sep 23, 1993
<u>AB</u>		<u>3MG</u>	<u>A081215</u>	<u>001</u>	Sep 23, 1993
<u>AB</u>		<u>6MG</u>	<u>A081216</u>	<u>001</u>	Sep 23, 1993
	<u>OGEN .625</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.75MG</u>	<u>A083220</u>	<u>001</u>	
	<u>OGEN 1.25</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>1.5MG</u>	<u>A083220</u>	<u>002</u>	
	<u>OGEN 2.5</u>				
<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>3MG</u>	<u>A083220</u>	<u>003</u>	
	<u>OGEN 5</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>6MG</u>	<u>A083220</u>	<u>004</u>	
	<u>ORTHO-EST</u>				
<u>AB</u>	SUN PHARM INDS (IN)	<u>0.75MG</u>	<u>A089567</u>	<u>001</u>	Feb 27, 1991
<u>AB</u>		<u>1.5MG</u>	<u>A089582</u>	<u>001</u>	Jul 17, 1991

ESZOPICLONE

TABLET; ORAL

LUNESTA

	SEPRACOR	1MG	N021476	001	Dec 15, 2004
		2MG	N021476	002	Dec 15, 2004
	+	3MG	N021476	003	Dec 15, 2004

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECIN

	+ ATON	EQ 50MG BASE/VIAL	N016093	001	
--	--------	-------------------	---------	-----	--

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

	+ ATON	25MG	N016092	001	
--	--------	------	---------	-----	--

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

<u>AB</u>	BARR	<u>400MG</u>	<u>A076057</u>	<u>001</u>	Nov 26, 2001
<u>AB</u>	LUPIN	<u>100MG</u>	<u>A078939</u>	<u>001</u>	Jun 17, 2009
<u>AB</u>		<u>400MG</u>	<u>A078939</u>	<u>002</u>	Jun 17, 2009
<u>AB</u>	WEST WARD	<u>100MG</u>	<u>A075095</u>	<u>001</u>	Nov 30, 1999
<u>AB</u>	+	<u>400MG</u>	<u>A075095</u>	<u>002</u>	Nov 30, 1999
	<u>MYAMBUTOL</u>				
<u>AB</u>	STI PHARMA LLC	<u>100MG</u>	<u>N016320</u>	<u>001</u>	
<u>AB</u>		<u>400MG</u>	<u>N016320</u>	<u>003</u>	

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

ETHAMOLIN

	+ QOL MEDCL	50MG/ML	N019357	001	Dec 22, 1988
--	-------------	---------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 159 (of 393)

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

KELNOR

<u>AB</u>	BARR	<u>0.035MG;1MG</u>	<u>A076785</u>	<u>001</u>	May 23, 2005
	<u>ZOVIA 1/35E-28</u>				
<u>AB</u>	WATSON LABS	<u>0.035MG;1MG</u>	<u>A072721</u>	<u>001</u>	Dec 30, 1991
	ZOVIA 1/50E-28				
	+ WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991

ETHINYL ESTRADIOL; ETNOGESTREL

RING; VAGINAL

NUVARING

	+ ORGANON USA INC	0.015MG;0.12MG	N021187	001	Oct 03, 2001
--	-------------------	----------------	---------	-----	--------------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

QUASENSE

<u>AB</u>	WATSON LABS	<u>0.03MG;0.15MG</u>	<u>A077101</u>	<u>001</u>	Sep 06, 2006
	<u>SEASONALE</u>				
<u>AB</u>	+ DURAMED RES	<u>0.03MG;0.15MG</u>	<u>N021544</u>	<u>001</u>	Sep 05, 2003
	LOSEASONIQUE				
	DURAMED	0.02MG,0.01MG;0.1MG,N/A	N022262	001	Oct 24, 2008
	LYBREL				
	+ WYETH PHARMS INC	0.02MG;0.09MG	N021864	001	May 22, 2007
	SEASONIQUE				
	+ DURAMED RES	0.03MG,0.01MG;0.15MG,N/A	N021840	001	May 25, 2006

TABLET; ORAL-28

ENPRESSE-28

<u>AB</u>	DURAMED PHARMS BARR	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A075809</u>	<u>002</u>	Jul 16, 2001
	<u>LEVORA 0.15/30-28</u>				
<u>AB</u>	WATSON LABS	<u>0.03MG;0.15MG</u>	<u>A073594</u>	<u>001</u>	Dec 13, 1993
	<u>NORDETTE-28</u>				
<u>AB</u>	+ DURAMED	<u>0.03MG;0.15MG</u>	<u>N018782</u>	<u>001</u>	Jul 21, 1982
	<u>PORTIA-28</u>				
<u>AB</u>	BARR	<u>0.03MG;0.15MG</u>	<u>A075866</u>	<u>002</u>	May 23, 2002
	<u>TRIVORA-28</u>				
<u>AB</u>	+ WATSON LABS	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A074538</u>	<u>002</u>	Dec 18, 1997
	<u>AVIANE-28</u>				
<u>AB1</u>	DURAMED PHARMS BARR	<u>0.02MG;0.1MG</u>	<u>A075796</u>	<u>001</u>	Apr 30, 2001
	<u>LEVONORGESTREL AND ETHINYL ESTRADIOL</u>				
<u>AB1</u>	+ WATSON LABS	<u>0.02MG;0.1MG</u>	<u>A076625</u>	<u>001</u>	Nov 18, 2004
	<u>LESSINA-28</u>				
<u>AB2</u>	BARR	<u>0.02MG;0.1MG</u>	<u>A075803</u>	<u>002</u>	Mar 20, 2002
	<u>LEVONORGESTREL AND ETHINYL ESTRADIOL</u>				
<u>AB2</u>	+ WATSON LABS	<u>0.02MG;0.1MG</u>	<u>A077681</u>	<u>001</u>	May 31, 2006

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

	+ ORTHO MCNEIL JANSSEN	0.02MG/24HR;0.15MG/24HR	N021180	001	Nov 20, 2001
--	------------------------	-------------------------	---------	-----	--------------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21

<u>AB</u>	WATSON LABS	<u>0.035MG;1MG</u>	<u>A071480</u>	<u>001</u>	Apr 12, 1988
	<u>NORETHINDRONE AND ETHINYL ESTRADIOL</u>				
<u>AB</u>	WATSON LABS	<u>0.035MG;1MG</u>	<u>A070685</u>	<u>001</u>	Jan 29, 1987
	<u>NORINYL 1+35 21-DAY</u>				
<u>AB</u>	WATSON LABS	<u>0.035MG;1MG</u>	<u>N017565</u>	<u>001</u>	

## PRESCRIPTION DRUG PRODUCT LIST

3 - 160 (of 393)

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORTREL 1/35-21

<u>AB</u>	BARR	<u>0.035MG;1MG</u>	<u>A072693</u>	<u>001</u>	Feb 28, 1992
	NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)				
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071043	001	Apr 01, 1988
	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)				
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071041	001	Sep 24, 1991
	NORTREL 7/7/7				
	BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A075478	001	Aug 30, 2002

TABLET; ORAL-28

ARANELLE

<u>AB</u>	BARR	<u>0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG</u>	<u>A076783</u>	<u>001</u>	Sep 29, 2004
-----------	------	--	----------------	------------	--------------

BALZIVA-28

<u>AB</u>	BARR	<u>0.035MG;0.4MG</u>	<u>A076238</u>	<u>001</u>	Apr 22, 2004
-----------	------	----------------------	----------------	------------	--------------

BREVICON 28-DAY

<u>AB</u>	WATSON LABS	<u>0.035MG;0.5MG</u>	<u>N017743</u>	<u>001</u>	
-----------	-------------	----------------------	----------------	------------	--

MODICON 28

<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>0.035MG;0.5MG</u>	<u>N017735</u>	<u>001</u>	
-----------	------------------------	----------------------	----------------	------------	--

NORETHIN 1/35E-28

<u>AB</u>	WATSON LABS	<u>0.035MG;1MG</u>	<u>A071481</u>	<u>001</u>	Apr 12, 1988
-----------	-------------	--------------------	----------------	------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL

<u>AB</u>	WATSON LABS	<u>0.035MG;0.5MG</u>	<u>A070686</u>	<u>001</u>	Jan 29, 1987
-----------	-------------	----------------------	----------------	------------	--------------

<u>AB</u>		<u>0.035MG;1MG</u>	<u>A070687</u>	<u>001</u>	Jan 29, 1987
-----------	--	--------------------	----------------	------------	--------------

NORINYL 1+35 28-DAY

<u>AB</u>	WATSON LABS	<u>0.035MG;1MG</u>	<u>N017565</u>	<u>002</u>	
-----------	-------------	--------------------	----------------	------------	--

NORTREL 0.5/35-28

<u>AB</u>	BARR	<u>0.035MG;0.5MG</u>	<u>A072695</u>	<u>001</u>	Feb 28, 1992
-----------	------	----------------------	----------------	------------	--------------

NORTREL 1/35-28

<u>AB</u>	BARR	<u>0.035MG;1MG</u>	<u>A072696</u>	<u>001</u>	Feb 28, 1992
-----------	------	--------------------	----------------	------------	--------------

NORTREL 7/7/7

<u>AB</u>	BARR	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A075478</u>	<u>002</u>	Aug 30, 2002
-----------	------	---	----------------	------------	--------------

ORTHO-NOVUM 1/35-28

<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>0.035MG;1MG</u>	<u>N017919</u>	<u>002</u>	
-----------	------------------------	--------------------	----------------	------------	--

ORTHO-NOVUM 7/7/7-28

<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>N018985</u>	<u>002</u>	Apr 04, 1984
-----------	------------------------	---	----------------	------------	--------------

OVCON-35

<u>AB</u>	+ WARNER CHILCOTT	<u>0.035MG;0.4MG</u>	<u>N017716</u>	<u>001</u>	
-----------	-------------------	----------------------	----------------	------------	--

TRI-NORINYL 28-DAY

<u>AB</u>	+ WATSON LABS	<u>0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG</u>	<u>N018977</u>	<u>002</u>	Apr 13, 1984
-----------	---------------	--	----------------	------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071044	001	Apr 01, 1988
--	-------------	---------------------------	---------	-----	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071042	001	Sep 24, 1991
--	-------------	---------------------------	---------	-----	--------------

OVCON-50

	+ WARNER CHILCOTT	0.05MG;1MG	N017576	001	
--	-------------------	------------	---------	-----	--

TABLET, CHEWABLE; ORAL-28

FEMCON FE

	+ WARNER CHILCOTT	0.035MG;0.4MG	N021490	001	Nov 14, 2003
--	-------------------	---------------	---------	-----	--------------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

<u>AB</u>	+ WARNER CHILCOTT	<u>0.005MG;1MG</u>	<u>N021065</u>	<u>002</u>	Oct 15, 1999
-----------	-------------------	--------------------	----------------	------------	--------------

LOESTRIN 24 FE

<u>AB</u>	+ WARNER CHILCOTT	<u>0.02MG;1MG</u>	<u>N021871</u>	<u>001</u>	Feb 17, 2006
-----------	-------------------	-------------------	----------------	------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

<u>AB</u>	BARR	<u>0.005MG;1MG</u>	<u>A076221</u>	<u>001</u>	Nov 06, 2009
-----------	------	--------------------	----------------	------------	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 187 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 161 (of 393)

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL					
FEMHRT					
	WARNER CHILCOTT	0.0025MG;0.5MG	N021065	001	Jan 14, 2005
TABLET; ORAL-21					
	<u>JUNEL 1.5/30</u>				
<u>AB</u>	BARR	<u>0.03MG;1.5MG</u>	<u>A076381</u>	<u>001</u>	May 30, 2003
	<u>JUNEL 1/20</u>				
<u>AB</u>	BARR	<u>0.02MG;1MG</u>	<u>A076380</u>	<u>001</u>	May 30, 2003
	<u>LOESTRIN 21 1.5/30</u>				
<u>AB</u>	WARNER CHILCOTT	<u>0.03MG;1.5MG</u>	<u>N017875</u>	<u>001</u>	
	<u>LOESTRIN 21 1/20</u>				
<u>AB</u>	WARNER CHILCOTT	<u>0.02MG;1MG</u>	<u>N017876</u>	<u>001</u>	
	<u>MICROGESTIN 1.5/30</u>				
<u>AB</u>	WATSON LABS	<u>0.03MG;1.5MG</u>	<u>A075548</u>	<u>002</u>	Jul 30, 2003
	<u>MICROGESTIN 1/20</u>				
<u>AB</u>	WATSON LABS	<u>0.02MG;1MG</u>	<u>A075647</u>	<u>002</u>	Jul 30, 2003
	TRI-LEGEST 21				
	BARR	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076405	001	Oct 26, 2007
TABLET; ORAL-28					
	<u>ESTROSTEP FE</u>				
<u>AB</u>	+ WARNER CHILCOTT	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>N020130</u>	<u>002</u>	Oct 09, 1996
	<u>JUNEL FE 1.5/30</u>				
<u>AB</u>	BARR	<u>0.03MG;1.5MG</u>	<u>A076064</u>	<u>001</u>	Sep 18, 2003
	<u>JUNEL FE 1/20</u>				
<u>AB</u>	BARR	<u>0.02MG;1MG</u>	<u>A076081</u>	<u>001</u>	Sep 18, 2003
	<u>LOESTRIN FE 1.5/30</u>				
<u>AB</u>	+ WARNER CHILCOTT	<u>0.03MG;1.5MG</u>	<u>N017355</u>	<u>001</u>	
	<u>LOESTRIN FE 1/20</u>				
<u>AB</u>	WARNER CHILCOTT	<u>0.02MG;1MG</u>	<u>N017354</u>	<u>001</u>	
	<u>MICROGESTIN FE 1.5/30</u>				
<u>AB</u>	WATSON LABS	<u>0.03MG;1.5MG</u>	<u>A075548</u>	<u>001</u>	Feb 05, 2001
	<u>MICROGESTIN FE 1/20</u>				
<u>AB</u>	WATSON LABS	<u>0.02MG;1MG</u>	<u>A075647</u>	<u>001</u>	Feb 05, 2001
	<u>NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>				
<u>AB</u>	TEVA PHARMS	<u>0.02MG;1MG</u>	<u>A077077</u>	<u>001</u>	May 20, 2005
<u>AB</u>		<u>0.03MG;1.5MG</u>	<u>A077075</u>	<u>001</u>	Apr 28, 2005
<u>AB</u>	WATSON LABS	<u>0.02MG;1MG</u>	<u>A078267</u>	<u>001</u>	Sep 01, 2009
	<u>TRI-LEGEST FE</u>				
<u>AB</u>	BARR	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>A076105</u>	<u>001</u>	Oct 26, 2007
<u>ETHINYL ESTRADIOL; NORGESTIMATE</u>					
TABLET; ORAL-28					
	<u>NORGESTIMATE AND ETHINYL ESTRADIOL</u>				
<u>AB</u>	WATSON LABS	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	<u>A076626</u>	<u>001</u>	Aug 17, 2006
<u>AB</u>		<u>0.035MG;0.25MG</u>	<u>A076627</u>	<u>001</u>	Aug 17, 2006
	<u>ORTHO CYCLEN-28</u>				
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>0.035MG;0.25MG</u>	<u>N019653</u>	<u>002</u>	Dec 29, 1989
	<u>ORTHO TRI-CYCLEN</u>				
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	<u>N019697</u>	<u>001</u>	Jul 03, 1992
	<u>ORTHO TRI-CYCLEN LO</u>				
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG</u>	<u>N021241</u>	<u>001</u>	Aug 22, 2002
	<u>PREVIFEM</u>				
<u>AB</u>	TEVA PHARMS	<u>0.035MG;0.25MG</u>	<u>A076334</u>	<u>001</u>	Jan 09, 2004
	<u>SPRINTEC</u>				
<u>AB</u>	BARR	<u>0.035MG;0.25MG</u>	<u>A075804</u>	<u>001</u>	Sep 25, 2002

## PRESCRIPTION DRUG PRODUCT LIST

3 - 162 (of 393)

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

<u>AB</u>	<u>TRI LO SPRINTec</u> BARR	<u>0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG</u>	<u>A076784</u>	<u>001</u>	Jun 29, 2009
<u>AB</u>	<u>TRI-PREVIFEM</u> TEVA PHARMS	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG</u>	<u>A076335</u>	<u>001</u>	Mar 26, 2004
<u>AB</u>	<u>TRI-SPRINTec</u> BARR	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG</u>	<u>A075808</u>	<u>001</u>	Dec 29, 2003

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

<u>AB</u>	<u>CRYSELLE</u> DURAMED PHARMS BARR	<u>0.03MG;0.3MG</u>	<u>A075840</u>	<u>001</u>	Nov 30, 2001
<u>AB</u>	<u>LOW-OGESTREL-21</u> + WATSON LABS	<u>0.03MG;0.3MG</u>	<u>A075288</u>	<u>001</u>	Jul 28, 1999

TABLET; ORAL-28

<u>AB</u>	<u>CRYSELLE</u> DURAMED PHARMS BARR	<u>0.03MG;0.3MG</u>	<u>A075840</u>	<u>002</u>	Nov 30, 2001
<u>AB</u>	<u>LO/OVRAL-28</u> AKRIMAX PHARMS	<u>0.03MG;0.3MG</u>	<u>N017802</u>	<u>001</u>	
<u>AB</u>	<u>LOW-OGESTREL-28</u> WATSON LABS	<u>0.03MG;0.3MG</u>	<u>A075288</u>	<u>002</u>	Jul 28, 1999
	OGESTREL 0.5/50-28 + WATSON LABS	0.05MG;0.5MG	A075406	002	Dec 15, 1999

ETHIODIZED OIL

OIL; INTRALYMPHATIC

ETHIODOL

SAVAGE LABS

99%

N009190 001

ETHIONAMIDE

TABLET; ORAL

TRECATOR

+ WYETH PHARMS INC

250MG

N013026 002

ETHOSUXIMIDE

CAPSULE; ORAL

<u>AB</u>	<u>ETHOSUXIMIDE</u> BANNER PHARMACAPS	<u>250MG</u>	<u>A040430</u>	<u>001</u>	Oct 28, 2002
<u>AB</u>	COVENANT PHARMA INC	<u>250MG</u>	<u>A040686</u>	<u>001</u>	May 28, 2008
<u>AB</u>	<u>ZARONTIN</u> + PARKE DAVIS	<u>250MG</u>	<u>N012380</u>	<u>001</u>	
	SYRUP; ORAL				
<u>AA</u>	<u>ETHOSUXIMIDE</u> MIKART	<u>250MG/5ML</u>	<u>A040506</u>	<u>001</u>	Dec 22, 2003
<u>AA</u>	PHARM ASSOC	<u>250MG/5ML</u>	<u>A040253</u>	<u>001</u>	Nov 22, 2000
<u>AA</u>	TEVA PHARMS	<u>250MG/5ML</u>	<u>A081306</u>	<u>001</u>	Jul 30, 1993
<u>AA</u>	<u>ZARONTIN</u> + PARKE DAVIS	<u>250MG/5ML</u>	<u>A080258</u>	<u>001</u>	

ETHOTOIN

TABLET; ORAL

PEGANONE

+ LUNDBECK INC

250MG

N010841 001

## PRESCRIPTION DRUG PRODUCT LIST

3 - 163 (of 393)

ETIDRONATE DISODIUM

TABLET; ORAL

DIDRONEL

<u>AB</u>	PROCTER AND GAMBLE	<u>200MG</u>	<u>N017831</u>	<u>001</u>	
<u>AB</u>	+	<u>400MG</u>	<u>N017831</u>	<u>002</u>	

ETIDRONATE DISODIUM

<u>AB</u>	MYLAN	<u>200MG</u>	<u>A075800</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>400MG</u>	<u>A075800</u>	<u>002</u>	Jan 24, 2003

ETODOLAC

CAPSULE; ORAL

ETODOLAC

<u>AB</u>	APOTEX	<u>200MG</u>	<u>A075419</u>	<u>001</u>	Jul 28, 2000
<u>AB</u>		<u>300MG</u>	<u>A075419</u>	<u>002</u>	Jul 28, 2000
<u>AB</u>	TARO	<u>200MG</u>	<u>A075078</u>	<u>001</u>	Apr 30, 1998
<u>AB</u>	+	<u>300MG</u>	<u>A075078</u>	<u>002</u>	Apr 30, 1998
<u>AB</u>	TEVA	<u>300MG</u>	<u>A075126</u>	<u>002</u>	Sep 16, 1999

TABLET; ORAL

ETODOLAC

<u>AB</u>	ACTAVIS ELIZABETH	<u>400MG</u>	<u>A074819</u>	<u>001</u>	Feb 28, 1997
<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A076004</u>	<u>001</u>	Dec 03, 2002
<u>AB</u>		<u>500MG</u>	<u>A076004</u>	<u>002</u>	Dec 03, 2002
<u>AB</u>	MYLAN	<u>400MG</u>	<u>A075104</u>	<u>001</u>	Feb 06, 1998
<u>AB</u>		<u>500MG</u>	<u>A075104</u>	<u>002</u>	Nov 20, 1998
<u>AB</u>	SANDOZ	<u>400MG</u>	<u>A074903</u>	<u>001</u>	Apr 11, 1997
<u>AB</u>		<u>500MG</u>	<u>A074903</u>	<u>002</u>	Apr 19, 1999
<u>AB</u>	TARO PHARM INDS	<u>400MG</u>	<u>A075074</u>	<u>001</u>	Mar 11, 1998
<u>AB</u>	+	<u>500MG</u>	<u>A075074</u>	<u>002</u>	Apr 25, 2000
<u>AB</u>	TEVA	<u>400MG</u>	<u>A075009</u>	<u>001</u>	Nov 26, 1997
<u>AB</u>		<u>500MG</u>	<u>A075009</u>	<u>002</u>	Dec 28, 1999

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

<u>AB</u>	TARO	<u>400MG</u>	<u>A076174</u>	<u>001</u>	Mar 13, 2003
<u>AB</u>		<u>500MG</u>	<u>A076174</u>	<u>002</u>	Mar 13, 2003
<u>AB</u>		<u>600MG</u>	<u>A076174</u>	<u>003</u>	Mar 13, 2003
<u>AB</u>	TEVA	<u>400MG</u>	<u>A075665</u>	<u>003</u>	Feb 05, 2001
<u>AB</u>		<u>500MG</u>	<u>A075665</u>	<u>002</u>	Jul 31, 2000
<u>AB</u>	+	<u>600MG</u>	<u>A075665</u>	<u>001</u>	Jul 31, 2000

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

<u>AP</u>	+	HOSPIRA	<u>2MG/ML</u>	<u>N018227</u>	<u>001</u>	Sep 07, 1982
-----------	---	---------	---------------	----------------	------------	--------------

ETOMIDATE

<u>AP</u>	BEDFORD	<u>2MG/ML</u>	<u>A074593</u>	<u>001</u>	Nov 04, 1996
<u>AP</u>	PARENTA PHARMS	<u>2MG/ML</u>	<u>A078289</u>	<u>001</u>	Jan 02, 2009
<u>AP</u>	PHARMAFORCE	<u>2MG/ML</u>	<u>A078867</u>	<u>001</u>	Dec 22, 2009

ETONOGESTREL

IMPLANT; IMPLANTATION

## IMPLANON

+	ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006
---	-----------------	--------------	---------	-----	--------------

ETOPOSIDE

CAPSULE; ORAL

## ETOPOSIDE

+	MYLAN	50MG	A075635	001	Sep 19, 2001
---	-------	------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 164 (of 393)

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

<u>AP</u>	ACCORD HLTHCARE INC	<u>20MG/ML</u>	<u>A074513</u>	<u>001</u>	Mar 14, 1996
<u>AP</u>	APP PHARMS	<u>20MG/ML</u>	<u>A074983</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>	BEDFORD	<u>20MG/ML</u>	<u>A074290</u>	<u>001</u>	Jul 17, 1995
<u>AP</u>	PHARMACHEMIE	<u>20MG/ML</u>	<u>A074227</u>	<u>001</u>	Feb 22, 1996
<u>AP</u>	TEVA PARENTERAL	<u>20MG/ML</u>	<u>A074284</u>	<u>001</u>	Feb 10, 1994
<u>AP</u>		<u>20MG/ML</u>	<u>A074529</u>	<u>001</u>	Jul 24, 1996

VEPESID

<u>AP</u>	+ BRISTOL MYERS SQUIBB	<u>20MG/ML</u>	<u>N018768</u>	<u>001</u>	Nov 10, 1983
-----------	------------------------	----------------	----------------	------------	--------------

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPHOS PRESERVATIVE FREE

	+ BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996
--	------------------------	--------------------	---------	-----	--------------

ETRAVIRINE

TABLET; ORAL

INTELENCE

	+ TIBOTEC	100MG	N022187	001	Jan 18, 2008
--	-----------	-------	---------	-----	--------------

EVEROLIMUS

TABLET; ORAL

AFINITOR

	NOVARTIS	5MG	N022334	001	Mar 30, 2009
--	----------	-----	---------	-----	--------------

	+	10MG	N022334	002	Mar 30, 2009
--	---	------	---------	-----	--------------

EXEMESTANE

TABLET; ORAL

AROMASIN

	+ PHARMACIA AND UPJOHN	25MG	N020753	001	Oct 21, 1999
--	------------------------	------	---------	-----	--------------

EXENATIDE SYNTHETIC

INJECTABLE; SUBCUTANEOUS

BYETTA

	+ AMYLIN	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005
--	----------	--------------------------	---------	-----	--------------

	+	600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005
--	---	--------------------------	---------	-----	--------------

EZETIMIBE

TABLET; ORAL

ZETIA

	+ MSP SINGAPORE	10MG	N021445	001	Oct 25, 2002
--	-----------------	------	---------	-----	--------------

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

	MSP SINGAPORE	10MG;10MG	N021687	001	Jul 23, 2004
--	---------------	-----------	---------	-----	--------------

		10MG;20MG	N021687	002	Jul 23, 2004
--	--	-----------	---------	-----	--------------

		10MG;40MG	N021687	003	Jul 23, 2004
--	--	-----------	---------	-----	--------------

	+	10MG;80MG	N021687	004	Jul 23, 2004
--	---	-----------	---------	-----	--------------

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

<u>AB</u>	TEVA PHARMS	<u>125MG</u>	<u>A077487</u>	<u>001</u>	Aug 24, 2007
-----------	-------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>250MG</u>	<u>A077487</u>	<u>002</u>	Aug 24, 2007
-----------	--	--------------	----------------	------------	--------------

<u>AB</u>		<u>500MG</u>	<u>A077487</u>	<u>003</u>	Aug 24, 2007
-----------	--	--------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 165 (of 393)

FAMCICLOVIR

TABLET; ORAL

FAMVIR

<u>AB</u>	NOVARTIS	<u>125MG</u>	<u>N020363</u>	<u>003</u>	Dec 11, 1995
<u>AB</u>		<u>250MG</u>	<u>N020363</u>	<u>001</u>	Apr 26, 1996
<u>AB</u>	+	<u>500MG</u>	<u>N020363</u>	<u>002</u>	Jun 29, 1994

FAMOTIDINE

FOR SUSPENSION; ORAL

PEPCID

+	SALIX PHARMS	40MG/5ML	N019527	001	Feb 02, 1987
---	--------------	----------	---------	-----	--------------

INJECTABLE; INJECTION

FAMOTIDINE

<u>AP</u>	AKORN STRIDES	<u>10MG/ML</u>	<u>A078641</u>	<u>001</u>	Jun 25, 2008
<u>AP</u>	APP PHARMS	<u>10MG/ML</u>	<u>A075709</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	BAXTER HLTHCARE	<u>10MG/ML</u>	<u>A075488</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>		<u>10MG/ML</u>	<u>A075799</u>	<u>001</u>	Apr 30, 2002
<u>AP</u>	BEDFORD	<u>10MG/ML</u>	<u>A075651</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>		<u>10MG/ML</u>	<u>A075684</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	HOSPIRA	<u>10MG/ML</u>	<u>A075870</u>	<u>001</u>	Nov 23, 2001
	<u>FAMOTIDINE PRESERVATIVE FREE</u>				
<u>AP</u>	AKORN STRIDES	<u>10MG/ML</u>	<u>A078642</u>	<u>001</u>	Jun 25, 2008
<u>AP</u>	APOTEX INC	<u>10MG/ML</u>	<u>A076324</u>	<u>001</u>	Nov 27, 2002
<u>AP</u>	APP PHARMS	<u>10MG/ML</u>	<u>A075813</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	BAXTER HLTHCARE	<u>10MG/ML</u>	<u>A075486</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>		<u>10MG/ML</u>	<u>A075789</u>	<u>001</u>	Apr 30, 2002
<u>AP</u>	BEDFORD	<u>10MG/ML</u>	<u>A075622</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	BEN VENUE	<u>10MG/ML</u>	<u>A075825</u>	<u>001</u>	Apr 17, 2001
	<u>FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)</u>				
<u>AP</u>	APOTEX INC	<u>10MG/ML</u>	<u>A076322</u>	<u>001</u>	Nov 27, 2002
	<u>FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>0.4MG/ML</u>	<u>A075591</u>	<u>001</u>	May 10, 2001
	<u>PEPCID</u>				
<u>AP</u>	+	<u>10MG/ML</u>	<u>N019510</u>	<u>001</u>	Nov 04, 1986
	<u>PEPCID PRESERVATIVE FREE</u>				
<u>AP</u>	+	<u>10MG/ML</u>	<u>N019510</u>	<u>004</u>	Nov 04, 1986
	<u>PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER</u>				
<u>AP</u>	+	<u>0.4MG/ML</u>	<u>N020249</u>	<u>001</u>	Feb 18, 1994

TABLET; ORAL

FAMOTIDINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>20MG</u>	<u>A075650</u>	<u>001</u>	Sep 14, 2001
<u>AB</u>		<u>40MG</u>	<u>A075650</u>	<u>002</u>	Sep 14, 2001
<u>AB</u>	ALEMBIC LTD	<u>20MG</u>	<u>A078916</u>	<u>001</u>	May 22, 2009
<u>AB</u>		<u>40MG</u>	<u>A078916</u>	<u>002</u>	May 22, 2009
<u>AB</u>	APOTEX	<u>20MG</u>	<u>A075611</u>	<u>001</u>	Jul 23, 2001
<u>AB</u>		<u>40MG</u>	<u>A075611</u>	<u>002</u>	Jul 23, 2001
<u>AB</u>	CARLSBAD	<u>20MG</u>	<u>A075805</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075805</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A075718</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075718</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	GENPHARM	<u>20MG</u>	<u>A075457</u>	<u>001</u>	Apr 18, 2001
<u>AB</u>		<u>40MG</u>	<u>A075457</u>	<u>002</u>	Apr 18, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A075511</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075511</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A075704</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075704</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	PERRIGO	<u>20MG</u>	<u>A077352</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>		<u>40MG</u>	<u>A077352</u>	<u>001</u>	Jul 27, 2005
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>A075607</u>	<u>001</u>	May 10, 2001
<u>AB</u>		<u>40MG</u>	<u>A075607</u>	<u>002</u>	May 10, 2001



## PRESCRIPTION DRUG PRODUCT LIST

3 - 166 (of 393)

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

<u>AB</u>	TEVA	<u>20MG</u>	<u>A075311</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075311</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A075062</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075062</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>	WOCKHARDT	<u>20MG</u>	<u>A075786</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075786</u>	<u>002</u>	Apr 16, 2001
	<u>PEPCID</u>				
<u>AB</u>	MERCK	<u>20MG</u>	<u>N019462</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>	+	<u>40MG</u>	<u>N019462</u>	<u>002</u>	Oct 15, 1986

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

	SCHWARZ PHARMA	20MG	N021712	001	Sep 24, 2004
+		40MG	N021712	002	Sep 24, 2004

FEBUXOSTAT

TABLET; ORAL

ULORIC

	TAKEDA PHARMS	40MG	N021856	001	Feb 13, 2009
+		80MG	N021856	002	Feb 13, 2009

FELBAMATE

SUSPENSION; ORAL

FELBATOL

+	MEDA PHARMS	600MG/5ML	N020189	003	Jul 29, 1993
---	-------------	-----------	---------	-----	--------------

TABLET; ORAL

FELBATOL

	MEDA PHARMS	400MG	N020189	001	Jul 29, 1993
+		600MG	N020189	002	Jul 29, 1993

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

<u>AB</u>	MUTUAL PHARM	<u>2.5MG</u>	<u>A075896</u>	<u>001</u>	Nov 02, 2004
<u>AB</u>		<u>5MG</u>	<u>A075896</u>	<u>002</u>	Nov 02, 2004
<u>AB</u>		<u>10MG</u>	<u>A075896</u>	<u>003</u>	Nov 02, 2004
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A078855</u>	<u>001</u>	Apr 17, 2008
<u>AB</u>		<u>5MG</u>	<u>A078855</u>	<u>002</u>	Apr 17, 2008
<u>AB</u>	+	<u>10MG</u>	<u>A078855</u>	<u>003</u>	Apr 17, 2008

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

<u>AB</u>	IMPAX LABS	<u>67MG</u>	<u>A075868</u>	<u>001</u>	Oct 27, 2003
<u>AB</u>		<u>134MG</u>	<u>A075868</u>	<u>002</u>	Oct 27, 2003
<u>AB</u>		<u>200MG</u>	<u>A075868</u>	<u>003</u>	Oct 27, 2003
<u>AB</u>	TEVA	<u>67MG</u>	<u>A075753</u>	<u>001</u>	Sep 03, 2002
<u>AB</u>		<u>134MG</u>	<u>A075753</u>	<u>002</u>	Apr 09, 2002
<u>AB</u>	+	<u>200MG</u>	<u>A075753</u>	<u>003</u>	Apr 09, 2002
	ANTARA (MICRONIZED)				
	OSCIENT	43MG	N021695	001	Nov 30, 2004
+		130MG	N021695	003	Nov 30, 2004
	LIPOFEN				
	CIPHER PHARMS INC	50MG	N021612	001	Jan 11, 2006
		100MG	N021612	002	Jan 11, 2006
+		150MG	N021612	003	Jan 11, 2006

## PRESCRIPTION DRUG PRODUCT LIST

3 - 167 (of 393)

FENOFIBRATE

TABLET; ORAL

FENOFIBRATE

<u>AB</u>	IMPAX LABS	<u>54MG</u>	<u>A076509</u>	<u>001</u>	Mar 26, 2008	
<u>AB</u>		<u>160MG</u>	<u>A076509</u>	<u>002</u>	Mar 26, 2008	
<u>AB</u>	MYLAN	<u>54MG</u>	<u>A076520</u>	<u>001</u>	Oct 25, 2007	
<u>AB</u>		<u>160MG</u>	<u>A076520</u>	<u>003</u>	Oct 25, 2007	
<u>AB</u>	RANBAXY	<u>54MG</u>	<u>A076635</u>	<u>001</u>	Oct 31, 2005	
<u>AB</u>		<u>160MG</u>	<u>A076635</u>	<u>003</u>	Oct 31, 2005	
<u>AB</u>	TEVA	<u>54MG</u>	<u>A076433</u>	<u>001</u>	May 13, 2005	
<u>AB</u>	+	<u>160MG</u>	<u>A076433</u>	<u>002</u>	May 13, 2005	
	TRIGLIDE					
BX	+	SKYEPHARMA AG	160MG	N021350	002	May 07, 2005
	FENOFIBRATE					
		RANBAXY	107MG	A076635	002	Oct 31, 2005
	FENOGLIDE					
		SCIELE PHARMA INC	40MG	N022118	001	Aug 10, 2007
	+		120MG	N022118	002	Aug 10, 2007
	TRICOR					
		ABBOTT	48MG	N021656	001	Nov 05, 2004
	+		145MG	N021656	002	Nov 05, 2004
	TRIGLIDE					
		SKYEPHARMA AG	50MG	N021350	001	May 07, 2005

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

	AR HOLDING CO INC	35MG	N022418	001	Aug 14, 2009
	+	105MG	N022418	002	Aug 14, 2009

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

<u>AP</u>	+	HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>N019922</u>	<u>001</u>	Sep 23, 1997
		<u>FENOLDOPAM MESYLATE</u>				
<u>AP</u>		BEDFORD LABS	<u>EQ 10MG BASE/ML</u>	<u>A076582</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>		PHARMAFORCE	<u>EQ 10MG BASE/ML</u>	<u>A076656</u>	<u>001</u>	Dec 01, 2003
<u>AP</u>		SANDOZ	<u>EQ 10MG BASE/ML</u>	<u>A077155</u>	<u>001</u>	Feb 15, 2005
<u>AP</u>		TEVA PARENTERAL	<u>EQ 10MG BASE/ML</u>	<u>A077826</u>	<u>001</u>	Mar 07, 2007

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

	+	PEDINOL	EQ 200MG BASE	N017604	003	
			EQ 400MG BASE	N017604	004	Jul 21, 2009

TABLET; ORAL

FENOPROFEN CALCIUM

<u>AB</u>		IVAX SUB TEVA PHARMS	<u>EQ 600MG BASE</u>	<u>A072557</u>	<u>001</u>	Aug 29, 1988
<u>AB</u>	+	MYLAN	<u>EQ 600MG BASE</u>	<u>A072267</u>	<u>001</u>	Aug 17, 1988

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-100

<u>AB</u>		ORTHO MCNEIL JANSSEN	<u>100MCG/HR</u>	<u>N019813</u>	<u>001</u>	Aug 07, 1990
		<u>DURAGESIC-12</u>				
<u>AB</u>		ORTHO MCNEIL JANSSEN	<u>12.5MCG/HR</u>	<u>N019813</u>	<u>005</u>	Feb 04, 2005
		<u>DURAGESIC-25</u>				
<u>AB</u>	+	ORTHO MCNEIL JANSSEN	<u>25MCG/HR</u>	<u>N019813</u>	<u>004</u>	Aug 07, 1990
		<u>DURAGESIC-50</u>				
<u>AB</u>		ORTHO MCNEIL JANSSEN	<u>50MCG/HR</u>	<u>N019813</u>	<u>003</u>	Aug 07, 1990

## PRESCRIPTION DRUG PRODUCT LIST

3 - 168 (of 393)

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

<u>DURAGESIC-75</u>					
<u>AB</u>	ORTHO MCNEIL JANSSEN	<u>75MCG/HR</u>	<u>N019813</u>	<u>002</u>	Aug 07, 1990
<u>FENTANYL-100</u>					
<u>AB</u>	ACTAVIS	<u>100MCG/HR</u>	<u>A077062</u>	<u>004</u>	Aug 20, 2007
<u>AB</u>	LAVIPHARM LABS	<u>100MCG/HR</u>	<u>A077051</u>	<u>004</u>	Aug 04, 2006
<u>AB</u>	MYLAN TECHNOLOGIES	<u>100MCG/HR</u>	<u>A076258</u>	<u>004</u>	Jan 28, 2005
<u>AB</u>	NOVEN	<u>100MCG/HR</u>	<u>A077775</u>	<u>004</u>	Oct 16, 2009
<u>AB</u>	TEVA PHARMS	<u>100MCG/HR</u>	<u>A077449</u>	<u>004</u>	Oct 20, 2008
<u>AB</u>	WATSON LABS	<u>100MCG/HR</u>	<u>A076709</u>	<u>004</u>	Aug 20, 2007
<u>FENTANYL-12</u>					
<u>AB</u>	MYLAN TECHNOLOGIES	<u>12.5MCG/HR</u>	<u>A076258</u>	<u>005</u>	Jan 23, 2007
<u>FENTANYL-25</u>					
<u>AB</u>	ACTAVIS	<u>25MCG/HR</u>	<u>A077062</u>	<u>001</u>	Aug 20, 2007
<u>AB</u>	LAVIPHARM LABS	<u>25MCG/HR</u>	<u>A077051</u>	<u>001</u>	Aug 04, 2006
<u>AB</u>	MYLAN TECHNOLOGIES	<u>25MCG/HR</u>	<u>A076258</u>	<u>001</u>	Jan 28, 2005
<u>AB</u>	NOVEN	<u>25MCG/HR</u>	<u>A077775</u>	<u>001</u>	Oct 16, 2009
<u>AB</u>	TEVA PHARMS	<u>25MCG/HR</u>	<u>A077449</u>	<u>001</u>	Oct 20, 2008
<u>AB</u>	WATSON LABS	<u>25MCG/HR</u>	<u>A076709</u>	<u>001</u>	Aug 20, 2007
<u>FENTANYL-50</u>					
<u>AB</u>	ACTAVIS	<u>50MCG/HR</u>	<u>A077062</u>	<u>002</u>	Aug 20, 2007
<u>AB</u>	LAVIPHARM LABS	<u>50MCG/HR</u>	<u>A077051</u>	<u>002</u>	Aug 04, 2006
<u>AB</u>	MYLAN TECHNOLOGIES	<u>50MCG/HR</u>	<u>A076258</u>	<u>002</u>	Jan 28, 2005
<u>AB</u>	NOVEN	<u>50MCG/HR</u>	<u>A077775</u>	<u>002</u>	Oct 16, 2009
<u>AB</u>	TEVA PHARMS	<u>50MCG/HR</u>	<u>A077449</u>	<u>002</u>	Oct 20, 2008
<u>AB</u>	WATSON LABS	<u>50MCG/HR</u>	<u>A076709</u>	<u>002</u>	Aug 20, 2007
<u>FENTANYL-75</u>					
<u>AB</u>	ACTAVIS	<u>75MCG/HR</u>	<u>A077062</u>	<u>003</u>	Aug 20, 2007
<u>AB</u>	LAVIPHARM LABS	<u>75MCG/HR</u>	<u>A077051</u>	<u>003</u>	Aug 04, 2006
<u>AB</u>	MYLAN TECHNOLOGIES	<u>75MCG/HR</u>	<u>A076258</u>	<u>003</u>	Jan 28, 2005
<u>AB</u>	NOVEN	<u>75MCG/HR</u>	<u>A077775</u>	<u>003</u>	Oct 16, 2009
<u>AB</u>	TEVA PHARMS	<u>75MCG/HR</u>	<u>A077449</u>	<u>003</u>	Oct 20, 2008
<u>AB</u>	WATSON LABS	<u>75MCG/HR</u>	<u>A076709</u>	<u>003</u>	Aug 20, 2007

FENTANYL CITRATEFILM; BUCCAL  
ONSOLIS

	MEDA PHARMS	EQ 0.2MG BASE	N022266	001	Jul 16, 2009
+		EQ 0.4MG BASE	N022266	002	Jul 16, 2009
		EQ 0.6MG BASE	N022266	003	Jul 16, 2009
		EQ 0.8MG BASE	N022266	004	Jul 16, 2009
		EQ 1.2MG BASE	N022266	005	Jul 16, 2009

INJECTABLE; INJECTION

<u>FENTANYL CITRATE</u>					
<u>AP</u>	HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>N019115</u>	<u>001</u>	Jan 12, 1985
<u>FENTANYL CITRATE PRESERVATIVE FREE</u>					
<u>AP</u>	+ BAXTER HLTHCARE	<u>EQ 0.05MG BASE/ML</u>	<u>N019101</u>	<u>001</u>	Jul 11, 1984
<u>AP</u>	HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>A072786</u>	<u>001</u>	Sep 24, 1991
<u>SUBLIMAZE PRESERVATIVE FREE</u>					
<u>AP</u>	+ AKORN	<u>EQ 0.05MG BASE/ML</u>	<u>N016619</u>	<u>001</u>	

TABLET; BUCCAL

FENTORA					
	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006
		EQ 0.2MG BASE	N021947	002	Sep 25, 2006
+		EQ 0.3MG BASE	N021947	006	Mar 02, 2007
		EQ 0.4MG BASE	N021947	003	Sep 25, 2006
		EQ 0.6MG BASE	N021947	004	Sep 25, 2006
		EQ 0.8MG BASE	N021947	005	Sep 25, 2006

## PRESCRIPTION DRUG PRODUCT LIST

3 - 169 (of 393)

FENTANYL CITRATE

TROCHE/LOZENGE; TRANSMUCOSAL

ACTIQ

<u>AB</u>	CEPHALON	<u>EQ 0.2MG BASE</u>	<u>N020747</u>	<u>001</u>	Nov 04, 1998
<u>AB</u>	+	<u>EQ 0.4MG BASE</u>	<u>N020747</u>	<u>002</u>	Nov 04, 1998
<u>AB</u>		<u>EQ 0.6MG BASE</u>	<u>N020747</u>	<u>003</u>	Nov 04, 1998
<u>AB</u>		<u>EQ 0.8MG BASE</u>	<u>N020747</u>	<u>004</u>	Nov 04, 1998
<u>AB</u>		<u>EQ 1.2MG BASE</u>	<u>N020747</u>	<u>005</u>	Nov 04, 1998
<u>AB</u>		<u>EQ 1.6MG BASE</u>	<u>N020747</u>	<u>006</u>	Nov 04, 1998

FENTANYL CITRATE

<u>AB</u>	BARR	<u>EQ 0.2MG BASE</u>	<u>A077312</u>	<u>001</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.4MG BASE</u>	<u>A077312</u>	<u>002</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.6MG BASE</u>	<u>A077312</u>	<u>003</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.8MG BASE</u>	<u>A077312</u>	<u>004</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 1.2MG BASE</u>	<u>A077312</u>	<u>005</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 1.6MG BASE</u>	<u>A077312</u>	<u>006</u>	Oct 30, 2009
<u>AB</u>	MALLINCKRODT	<u>EQ 0.2MG BASE</u>	<u>A078907</u>	<u>001</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.4MG BASE</u>	<u>A078907</u>	<u>002</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.6MG BASE</u>	<u>A078907</u>	<u>003</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.8MG BASE</u>	<u>A078907</u>	<u>004</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 1.2MG BASE</u>	<u>A078907</u>	<u>005</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 1.6MG BASE</u>	<u>A078907</u>	<u>006</u>	Oct 30, 2009

FERRIC HEXACYANOFERRATE(II)

CAPSULE; ORAL

RADIOGARDASE (PRUSSIAN BLUE)

+	HEYL CHEMISCH	500MG	N021626	001	Oct 02, 2003
---	---------------	-------	---------	-----	--------------

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

+	AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416	001	Aug 30, 1996
---	-----------------	-------------------	---------	-----	--------------

FERUMOXSYL

SUSPENSION; ORAL

GASTROMARK

+	AMAG PHARMS INC	EQ 0.175MG IRON/ML	N020410	001	Dec 06, 1996
---	-----------------	--------------------	---------	-----	--------------

FERUMOXYTOL

SOLUTION; INTRAVENOUS

FERAHEME

+	AMAG PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009
---	-----------------	--------------------------------------	---------	-----	--------------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

TOVIAZ

	PFIZER	4MG	N022030	001	Oct 31, 2008
--	--------	-----	---------	-----	--------------

+		8MG	N022030	002	Oct 31, 2008
---	--	-----	---------	-----	--------------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

+	SANOFI AVENTIS US	30MG/5ML	N021963	001	Oct 16, 2006
---	-------------------	----------	---------	-----	--------------

TABLET; ORAL

ALLEGRA

<u>AB</u>	SANOFI AVENTIS US	<u>30MG</u>	<u>N020872</u>	<u>001</u>	Feb 25, 2000
<u>AB</u>		<u>60MG</u>	<u>N020872</u>	<u>002</u>	Feb 25, 2000
<u>AB</u>	+	<u>180MG</u>	<u>N020872</u>	<u>004</u>	Feb 25, 2000

## PRESCRIPTION DRUG PRODUCT LIST

3 - 170 (of 393)

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>30MG</u>	<u>A076191</u>	<u>001</u>	Aug 31, 2005
<u>AB</u>		<u>60MG</u>	<u>A076191</u>	<u>002</u>	Aug 31, 2005
<u>AB</u>		<u>180MG</u>	<u>A076191</u>	<u>003</u>	Aug 31, 2005
<u>AB</u>	DR REDDYS LABS LTD	<u>30MG</u>	<u>A076502</u>	<u>001</u>	Apr 11, 2006
<u>AB</u>		<u>60MG</u>	<u>A076502</u>	<u>002</u>	Apr 11, 2006
<u>AB</u>		<u>180MG</u>	<u>A076502</u>	<u>003</u>	Apr 11, 2006
<u>AB</u>	MYLAN	<u>30MG</u>	<u>A077081</u>	<u>002</u>	Apr 11, 2008
<u>AB</u>		<u>60MG</u>	<u>A077081</u>	<u>003</u>	Apr 11, 2008
<u>AB</u>		<u>180MG</u>	<u>A077081</u>	<u>001</u>	Apr 16, 2007
<u>AB</u>	TEVA	<u>30MG</u>	<u>A076447</u>	<u>001</u>	Sep 01, 2005
<u>AB</u>		<u>60MG</u>	<u>A076447</u>	<u>002</u>	Sep 01, 2005
<u>AB</u>		<u>180MG</u>	<u>A076447</u>	<u>003</u>	Sep 01, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

ALLEGRA

+ SANOFI AVENTIS US 30MG N021909 001 Jul 26, 2007

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR

<u>AB</u>	+ SANOFI AVENTIS US	<u>60MG;120MG</u>	<u>N020786</u>	<u>001</u>	Dec 24, 1997
<u>AB</u>	BARR	<u>60MG;120MG</u>	<u>A076236</u>	<u>001</u>	Apr 14, 2005
	ALLEGRA D 24 HOUR				
	+ SANOFI AVENTIS US	180MG;240MG	N021704	001	Oct 19, 2004

FINASTERIDE

TABLET; ORAL

FINASTERIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>5MG</u>	<u>A077914</u>	<u>001</u>	Mar 28, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078341</u>	<u>001</u>	Oct 30, 2007
<u>AB</u>	DR REDDYS LABS INC	<u>1MG</u>	<u>A076436</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076437</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>	GEDEON RICHTER USA	<u>5MG</u>	<u>A077251</u>	<u>001</u>	Dec 22, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A077578</u>	<u>001</u>	Dec 18, 2006
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076511</u>	<u>001</u>	Dec 15, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078900</u>	<u>001</u>	Dec 28, 2009
<u>AB</u>	+ MERCK	<u>1MG</u>	<u>N020788</u>	<u>001</u>	Dec 19, 1997
<u>AB</u>	+ MERCK	<u>5MG</u>	<u>N020180</u>	<u>001</u>	Jun 19, 1992

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

<u>AB</u>	HAMPTON LAINE LLC	<u>100MG</u>	<u>A076835</u>	<u>001</u>	Nov 30, 2005
<u>AB</u>	IMPAX PHARMS	<u>100MG</u>	<u>A076234</u>	<u>001</u>	Aug 28, 2003
<u>AB</u>	PADDOCK	<u>100MG</u>	<u>A076831</u>	<u>001</u>	Dec 16, 2004
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>100MG</u>	<u>N016769</u>	<u>001</u>	

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

<u>AB</u>	AMNEAL PHARM	<u>50MG</u>	<u>A075442</u>	<u>001</u>	Jul 31, 2001
<u>AB</u>		<u>100MG</u>	<u>A075442</u>	<u>002</u>	Jul 31, 2001
<u>AB</u>		<u>150MG</u>	<u>A075442</u>	<u>003</u>	Jul 31, 2001
<u>AB</u>	APOTEX INC	<u>50MG</u>	<u>A079164</u>	<u>001</u>	Jul 09, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 171 (of 393)

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A079164</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>		<u>150MG</u>	<u>A079164</u>	<u>003</u>	Jul 09, 2009
<u>AB</u>	BARR	<u>50MG</u>	<u>A075882</u>	<u>001</u>	Oct 28, 2002
<u>AB</u>		<u>100MG</u>	<u>A075882</u>	<u>002</u>	Oct 28, 2002
<u>AB</u>		<u>150MG</u>	<u>A075882</u>	<u>003</u>	Oct 28, 2002
<u>AB</u>	RANBAXY	<u>50MG</u>	<u>A076421</u>	<u>001</u>	Mar 28, 2003
<u>AB</u>		<u>100MG</u>	<u>A076421</u>	<u>002</u>	Mar 28, 2003
<u>AB</u>		<u>150MG</u>	<u>A076421</u>	<u>003</u>	Mar 28, 2003
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A076278</u>	<u>001</u>	Jan 14, 2003
<u>AB</u>		<u>100MG</u>	<u>A076278</u>	<u>002</u>	Jan 14, 2003
<u>AB</u>		<u>150MG</u>	<u>A076278</u>	<u>003</u>	Jan 14, 2003
	<u>TAMBOCOR</u>				
<u>AB</u>	GRACEWAY	<u>50MG</u>	<u>N018830</u>	<u>004</u>	Aug 23, 1988
<u>AB</u>		<u>100MG</u>	<u>N018830</u>	<u>001</u>	Oct 31, 1985
<u>AB</u>	+	<u>150MG</u>	<u>N018830</u>	<u>003</u>	Jun 03, 1988

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE

<u>AP</u>	APP PHARMS	<u>500MG/VIAL</u>	<u>A075837</u>	<u>001</u>	Feb 22, 2001
<u>AP</u>	+	<u>500MG/VIAL</u>	<u>A075387</u>	<u>001</u>	Apr 16, 2000

FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCAN

<u>AB</u>	PFIZER	<u>50MG/5ML</u>	<u>N020090</u>	<u>001</u>	Dec 23, 1993
<u>AB</u>	+	<u>200MG/5ML</u>	<u>N020090</u>	<u>002</u>	Dec 23, 1993

FLUCONAZOLE

<u>AB</u>	AUROBINDO PHARM	<u>50MG/5ML</u>	<u>A079150</u>	<u>001</u>	Sep 18, 2009
<u>AB</u>		<u>200MG/5ML</u>	<u>A079150</u>	<u>002</u>	Sep 18, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>50MG/5ML</u>	<u>A077523</u>	<u>001</u>	Sep 12, 2007
<u>AB</u>		<u>200MG/5ML</u>	<u>A077523</u>	<u>002</u>	Sep 12, 2007
<u>AB</u>	RANBAXY	<u>50MG/5ML</u>	<u>A076332</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>200MG/5ML</u>	<u>A076332</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>	ROXANE	<u>50MG/5ML</u>	<u>A076246</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>200MG/5ML</u>	<u>A076246</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>	TARO PHARM INDS	<u>50MG/5ML</u>	<u>A076918</u>	<u>001</u>	Dec 18, 2006
<u>AB</u>		<u>200MG/5ML</u>	<u>A076918</u>	<u>002</u>	Dec 18, 2006

INJECTABLE; INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	<u>PFIZER</u>	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>003</u>	Sep 29, 1992
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>005</u>	Jul 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%

<u>AP</u>	+	<u>PFIZER</u>	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>001</u>	Jan 29, 1990
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>006</u>	Jan 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+	<u>PFIZER</u>	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>002</u>	Jan 29, 1990
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>004</u>	Jan 29, 1990

FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	ACS DOBFAR INFO SA	<u>200MG/100ML (2MG/ML)</u>	<u>A079104</u>	<u>001</u>	Jul 30, 2009
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A079104</u>	<u>002</u>	Jul 30, 2009

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	APOTEX INC	<u>200MG/100ML (2MG/ML)</u>	<u>A076888</u>	<u>001</u>	Mar 25, 2005
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076888</u>	<u>002</u>	Mar 25, 2005
<u>AP</u>	HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A076304</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076304</u>	<u>002</u>	Jul 29, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 172 (of 393)

FLUCONAZOLE

## INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

<u>AP</u>	APP PHARMS	<u>200MG/100ML (2MG/ML)</u>	<u>A076145</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076145</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>	BEDFORD	<u>200MG/100ML (2MG/ML)</u>	<u>A076087</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076087</u>	<u>003</u>	Jul 29, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A076736</u>	<u>001</u>	Aug 23, 2005
<u>AP</u>	TEVA PARENTERAL	<u>200MG/100ML (2MG/ML)</u>	<u>A076653</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076653</u>	<u>002</u>	Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML (2MG/ML)</u>	<u>A076766</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076766</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>	BEDFORD LABS	<u>200MG/100ML (2MG/ML)</u>	<u>A078107</u>	<u>001</u>	Jul 30, 2008
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078107</u>	<u>002</u>	Jul 30, 2008
<u>AP</u>	HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A076303</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A076617</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076303</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076617</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>	TEVA PARENTERAL	<u>200MG/100ML (2MG/ML)</u>	<u>A076837</u>	<u>001</u>	Jan 13, 2005
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076837</u>	<u>002</u>	Jan 13, 2005
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	BEDFORD	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008

## TABLET; ORAL

DIFLUCAN

<u>AB</u>	PFIZER	<u>50MG</u>	<u>N019949</u>	<u>001</u>	Jan 29, 1990
<u>AB</u>		<u>100MG</u>	<u>N019949</u>	<u>002</u>	Jan 29, 1990
<u>AB</u>		<u>150MG</u>	<u>N019949</u>	<u>004</u>	Jun 30, 1994
<u>AB</u>	+	<u>200MG</u>	<u>N019949</u>	<u>003</u>	Jan 29, 1990

FLUCONAZOLE

<u>AB</u>	APOTEX	<u>50MG</u>	<u>A076665</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076665</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076665</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076665</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	AUROBINDO PHARMA	<u>50MG</u>	<u>A077731</u>	<u>001</u>	Oct 07, 2008
<u>AB</u>		<u>100MG</u>	<u>A077731</u>	<u>002</u>	Oct 07, 2008
<u>AB</u>		<u>150MG</u>	<u>A077731</u>	<u>003</u>	Oct 07, 2008
<u>AB</u>		<u>200MG</u>	<u>A077731</u>	<u>004</u>	Oct 07, 2008
<u>AB</u>	GENPHARM	<u>50MG</u>	<u>A076042</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076042</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076042</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076042</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	GLENMARK GENERICS	<u>50MG</u>	<u>A077253</u>	<u>001</u>	Jan 25, 2006
<u>AB</u>		<u>100MG</u>	<u>A077253</u>	<u>002</u>	Jan 25, 2006
<u>AB</u>		<u>150MG</u>	<u>A077253</u>	<u>003</u>	Jan 25, 2006
<u>AB</u>		<u>200MG</u>	<u>A077253</u>	<u>004</u>	Jan 25, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>50MG</u>	<u>A076077</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076077</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076077</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076077</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A076351</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076351</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076351</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076351</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	RANBAXY	<u>50MG</u>	<u>A076386</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076386</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076386</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076386</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	TARO	<u>50MG</u>	<u>A076507</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076507</u>	<u>002</u>	Jul 29, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 173 (of 393)

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

<u>AB</u>	TARO	<u>150MG</u>	<u>A076507</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076507</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	TEVA	<u>50MG</u>	<u>A074681</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A074681</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A074681</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A074681</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>50MG</u>	<u>A076957</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076957</u>	<u>002</u>	Sep 28, 2005
<u>AB</u>		<u>200MG</u>	<u>A076957</u>	<u>003</u>	Sep 28, 2005
FLUCONAZOLE					
BX	DR REDDYS LABS INC	50MG	A076658	001	Jul 29, 2004
BX		100MG	A076658	002	Jul 29, 2004
BX		150MG	A076658	003	Jul 29, 2004
BX		200MG	A076658	004	Jul 29, 2004
BX	PLIVA	50MG	A076424	001	Jul 29, 2004
BX		100MG	A076424	002	Jul 29, 2004
BX		150MG	A076424	003	Jul 29, 2004
BX		200MG	A076424	004	Jul 29, 2004

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

	VALEANT	250MG	N017001	001	
+		500MG	N017001	002	

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

<u>AP</u>	+ GENZYME	<u>50MG/VIAL</u>	<u>N020038</u>	<u>001</u>	Apr 18, 1991
<u>FLUDARABINE PHOSPHATE</u>					
<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078610</u>	<u>001</u>	Feb 11, 2009
<u>AP</u>	APP PHARMS	<u>50MG/2ML (25MG/ML)</u>	<u>A078393</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>		<u>50MG/VIAL</u>	<u>A078544</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>	+ EBWE PHARMA	<u>50MG/2ML (25MG/ML)</u>	<u>N022137</u>	<u>001</u>	Sep 21, 2007
<u>AP</u>	HOSPIRA	<u>50MG/VIAL</u>	<u>A077790</u>	<u>001</u>	Apr 06, 2007
<u>AP</u>	TEVA PARENTERAL	<u>50MG/VIAL</u>	<u>A076349</u>	<u>001</u>	Aug 28, 2003
<u>AP</u>	+	<u>50MG/2ML (25MG/ML)</u>	<u>A076661</u>	<u>001</u>	Apr 28, 2004

TABLET; ORAL

OFORTA

+	SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008
---	-------------------	------	---------	-----	--------------

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F 18

+	WEILL MEDCL COLL	10-100mCi/ML	N021768	001	Aug 05, 2004
FLUDEOXYGLUCOSE F18					
+	FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

<u>AB</u>	BARR	<u>0.1MG</u>	<u>A040425</u>	<u>001</u>	Jan 21, 2003
<u>AB</u>	+ IMPAX LABS	<u>0.1MG</u>	<u>A040431</u>	<u>001</u>	Mar 18, 2002



## PRESCRIPTION DRUG PRODUCT LIST

3 - 174 (of 393)

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

<u>AP</u>	AKORN STRIDES	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078595</u>	<u>001</u>	May 13, 2008
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A078595</u>	<u>002</u>	May 13, 2008
<u>AP</u>	APOTEX INC	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076755</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076755</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	APP PHARMS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076955</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076955</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	BAXTER HLTHCARE	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076787</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076787</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	BEDFORD LABS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076256</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076256</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078527</u>	<u>001</u>	Mar 23, 2009
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A078527</u>	<u>002</u>	Mar 23, 2009
<u>AP</u>	SANDOZ	<u>1MG/10ML (0.1MG/ML)</u>	<u>A077071</u>	<u>002</u>	May 03, 2005
<u>AP</u>		<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A077071</u>	<u>001</u>	May 03, 2005
<u>AP</u>	TEVA PARENTERAL	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076589</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076589</u>	<u>001</u>	Oct 12, 2004
	<u>ROMAZICON</u>				
<u>AP</u>	+ HLR	<u>1MG/10ML (0.1MG/ML)</u>	<u>N020073</u>	<u>001</u>	Dec 20, 1991
<u>AP</u>		<u>0.5MG/5ML (0.1MG/ML)</u>	<u>N020073</u>	<u>002</u>	Dec 20, 1991

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROBID

	+ ROCHE PALO	0.25MG/INH	N018340	001	Aug 17, 1984
	AEROSPAN HFA				
	+ FOREST LABS	EQ 78MCG BASE/INH	N021247	001	Jan 27, 2006

SPRAY, METERED; NASAL

FLUNISOLIDE

<u>AB</u>	APOTEX INC	<u>0.029MG/SPRAY</u>	<u>A077436</u>	<u>001</u>	Aug 09, 2007
<u>AB</u>	+ BAUSCH AND LOMB	<u>0.025MG/SPRAY</u>	<u>A074805</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>	QPHARMA	<u>0.025MG/SPRAY</u>	<u>A077704</u>	<u>001</u>	Aug 03, 2006

NASAREL

<u>AB</u>	+ TEVA GLOBAL	<u>0.029MG/SPRAY</u>	<u>N020409</u>	<u>001</u>	Mar 08, 1995
-----------	---------------	----------------------	----------------	------------	--------------

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>0.01%</u>	<u>A088170</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		<u>0.025%</u>	<u>A088169</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	TARO	<u>0.025%</u>	<u>A087104</u>	<u>001</u>	Apr 27, 1982
	<u>SYNALAR</u>				
<u>AT</u>	+ MEDICIS	<u>0.01%</u>	<u>N012787</u>	<u>004</u>	
<u>AT</u>		<u>0.025%</u>	<u>N012787</u>	<u>005</u>	
<u>AT</u>		<u>0.025%</u>	<u>N012787</u>	<u>002</u>	

IMPLANT; INTRAVITREAL

RETISERT

	+ BAUSCH AND LOMB	0.59MG	N021737	001	Apr 08, 2005
--	-------------------	--------	---------	-----	--------------

OIL; TOPICAL

DERMA-SMOOTHIE/FS

	+ HILL DERMAC	0.01%	N019452	002	Nov 09, 2005
		0.01%	N019452	001	Feb 03, 1988

OIL/DROPS; OTIC

	+ HILL DERMAC	0.01%	N019452	003	Nov 09, 2005
--	---------------	-------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 175 (of 393)

FLUOCINOLONE ACETONIDE

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>0.025%</u>	<u>A088168</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	TARO	<u>0.025%</u>	<u>A040041</u>	<u>001</u>	Sep 15, 1994
<u>SYNALAR</u>					
<u>AT</u>	+ MEDICIS	<u>0.025%</u>	<u>N013960</u>	<u>001</u>	

SHAMPOO; TOPICAL

CAPEX

	+ GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990
--	--------------------	-------	---------	-----	--------------

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>0.01%</u>	<u>A088167</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	TARO	<u>0.01%</u>	<u>A089124</u>	<u>001</u>	Sep 11, 1985
<u>SYNALAR</u>					
<u>AT</u>	+ MEDICIS	<u>0.01%</u>	<u>N015296</u>	<u>001</u>	

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL

TRI-LUMA

	+ GALDERMA LABS LP	0.01%;4%;0.05%	N021112	001	Jan 18, 2002
--	--------------------	----------------	---------	-----	--------------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

<u>AB1</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A073085</u>	<u>001</u>	Feb 14, 1992
<u>AB1</u>	FOUGERA	<u>0.05%</u>	<u>A073030</u>	<u>001</u>	Oct 17, 1994
<u>AB1</u>	TARO	<u>0.05%</u>	<u>N019117</u>	<u>001</u>	Jun 26, 1984
<u>AB1</u>	TEVA	<u>0.05%</u>	<u>A072488</u>	<u>001</u>	Feb 06, 1989

LIDEX

<u>AB1</u>	+ MEDICIS	<u>0.05%</u>	<u>N016908</u>	<u>002</u>	
------------	-----------	--------------	----------------	------------	--

FLUOCINONIDE EMULSIFIED BASE

<u>AB2</u>	ALTANA	<u>0.05%</u>	<u>A076586</u>	<u>001</u>	Jun 23, 2004
<u>AB2</u>	TARO	<u>0.05%</u>	<u>A072494</u>	<u>001</u>	Jan 19, 1989
<u>AB2</u>	TEVA	<u>0.05%</u>	<u>A072490</u>	<u>001</u>	Feb 07, 1989

LIDEX-E

<u>AB2</u>	+ MEDICIS	<u>0.05%</u>	<u>N016908</u>	<u>003</u>	
VANOS					
	+ MEDICIS	0.1%	N021758	001	Feb 11, 2005

GEL; TOPICAL

FLUOCINONIDE

<u>AB</u>	FOUGERA	<u>0.05%</u>	<u>A072933</u>	<u>001</u>	Dec 30, 1994
<u>AB</u>	TARO	<u>0.05%</u>	<u>A074935</u>	<u>001</u>	Jul 29, 1997
<u>AB</u>	TEVA	<u>0.05%</u>	<u>A072537</u>	<u>001</u>	Feb 07, 1989

LIDEX

<u>AB</u>	+ MEDICIS	<u>0.05%</u>	<u>N017373</u>	<u>001</u>	
-----------	-----------	--------------	----------------	------------	--

OINTMENT; TOPICAL

FLUOCINONIDE

<u>AB</u>	ALTANA	<u>0.05%</u>	<u>A074905</u>	<u>001</u>	Aug 26, 1997
<u>AB</u>	TARO	<u>0.05%</u>	<u>A075008</u>	<u>001</u>	Jun 30, 1999
<u>AB</u>	TEVA	<u>0.05%</u>	<u>A073481</u>	<u>001</u>	Dec 27, 1991

LIDEX

<u>AB</u>	+ MEDICIS	<u>0.05%</u>	<u>N016909</u>	<u>002</u>	
-----------	-----------	--------------	----------------	------------	--

SOLUTION; TOPICAL

FLUOCINONIDE

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A071535</u>	<u>001</u>	Dec 02, 1988
<u>AT</u>	FOUGERA	<u>0.05%</u>	<u>A072934</u>	<u>001</u>	Feb 27, 1995
<u>AT</u>	TARO	<u>0.05%</u>	<u>A074799</u>	<u>001</u>	Dec 31, 1996
<u>AT</u>	TEVA	<u>0.05%</u>	<u>A072511</u>	<u>001</u>	Feb 07, 1989

## PRESCRIPTION DRUG PRODUCT LIST

3 - 176 (of 393)

FLUOCINONIDE

SOLUTION; TOPICAL

LIDEX

<u>AT</u> +	MEDICIS	<u>0.05%</u>	<u>N018849</u>	<u>001</u>	Apr 06, 1984
-------------	---------	--------------	----------------	------------	--------------

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 10%

<u>AP</u>	AKORN	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N022186</u>	<u>001</u>	Aug 08, 2008
-----------	-------	---	----------------	------------	--------------

FLUORESCITE

<u>AP</u> +	ALCON	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N021980</u>	<u>001</u>	Mar 28, 2006
-------------	-------	---	----------------	------------	--------------

AK-FLUOR 25%

	AKORN	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008
--	-------	--------------------------------------	---------	-----	--------------

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC

FML

+	ALLERGAN	0.1%	N017760	001	Sep 04, 1985
---	----------	------	---------	-----	--------------

SUSPENSION/DROPS; OPHTHALMIC

FML

+	ALLERGAN	0.1%	N016851	002	Jul 28, 1982
---	----------	------	---------	-----	--------------

FML FORTE

	ALLERGAN	0.25%	N019216	001	Apr 23, 1986
--	----------	-------	---------	-----	--------------

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

+	ALCON	0.1%	N019079	001	Feb 11, 1986
---	-------	------	---------	-----	--------------

FLUOROURACIL

CREAM; TOPICAL

EFUDEX

<u>AB</u> +	VALEANT PHARM INTL	<u>5%</u>	<u>N016831</u>	<u>003</u>	
-------------	--------------------	-----------	----------------	------------	--

FLUOROURACIL

<u>AB</u>	SPEAR PHARMS	<u>5%</u>	<u>A077524</u>	<u>001</u>	Apr 11, 2008
-----------	--------------	-----------	----------------	------------	--------------

CARAC

+	SANOVI AVENTIS US	0.5%	N020985	001	Oct 27, 2000
---	-------------------	------	---------	-----	--------------

FLUOROPLEX

+	ALLERGAN HERBERT	1%	N016988	001	
---	------------------	----	---------	-----	--

INJECTABLE; INJECTION

FLUOROURACIL

<u>AP</u> +	APP PHARMS	<u>500MG/10ML (50MG/ML)</u>	<u>A040279</u>	<u>002</u>	Sep 30, 1998
-------------	------------	-----------------------------	----------------	------------	--------------

<u>AP</u> +		<u>1GM/20ML (50MG/ML)</u>	<u>A040279</u>	<u>001</u>	Sep 30, 1998
-------------	--	---------------------------	----------------	------------	--------------

<u>AP</u> +		<u>2.5GM/50ML (50MG/ML)</u>	<u>A040278</u>	<u>001</u>	Sep 30, 1998
-------------	--	-----------------------------	----------------	------------	--------------

<u>AP</u> +		<u>5GM/100ML (50MG/ML)</u>	<u>A040278</u>	<u>002</u>	Sep 30, 1998
-------------	--	----------------------------	----------------	------------	--------------

<u>AP</u>	EBEWE PHARMA	<u>500MG/10ML (50MG/ML)</u>	<u>A040772</u>	<u>001</u>	Aug 11, 2008
-----------	--------------	-----------------------------	----------------	------------	--------------

<u>AP</u> +	GENERAMEDIX	<u>500MG/10ML (50MG/ML)</u>	<u>A040743</u>	<u>002</u>	Apr 26, 2007
-------------	-------------	-----------------------------	----------------	------------	--------------

<u>AP</u> +		<u>1GM/20ML (50MG/ML)</u>	<u>A040743</u>	<u>001</u>	Apr 26, 2007
-------------	--	---------------------------	----------------	------------	--------------

<u>AP</u> +		<u>2.5GM/50ML (50MG/ML)</u>	<u>A040798</u>	<u>002</u>	Apr 26, 2007
-------------	--	-----------------------------	----------------	------------	--------------

<u>AP</u> +		<u>5GM/100ML (50MG/ML)</u>	<u>A040798</u>	<u>001</u>	Apr 26, 2007
-------------	--	----------------------------	----------------	------------	--------------

<u>AP</u> +	TEVA PARENTERAL	<u>500MG/10ML (50MG/ML)</u>	<u>A040333</u>	<u>001</u>	Jan 27, 2000
-------------	-----------------	-----------------------------	----------------	------------	--------------

<u>AP</u> +		<u>2.5GM/50ML (50MG/ML)</u>	<u>A040334</u>	<u>001</u>	Feb 25, 2000
-------------	--	-----------------------------	----------------	------------	--------------

<u>AP</u> +		<u>5GM/100ML (50MG/ML)</u>	<u>A040334</u>	<u>002</u>	Feb 25, 2000
-------------	--	----------------------------	----------------	------------	--------------

<u>AP</u> +	VALEANT	<u>500MG/10ML (50MG/ML)</u>	<u>N012209</u>	<u>001</u>	
-------------	---------	-----------------------------	----------------	------------	--

SOLUTION; TOPICAL

EFUDEX

<u>AT</u> +	VALEANT PHARM INTL	<u>2%</u>	<u>N016831</u>	<u>001</u>	
-------------	--------------------	-----------	----------------	------------	--

<u>AT</u> +		<u>5%</u>	<u>N016831</u>	<u>002</u>	
-------------	--	-----------	----------------	------------	--

## PRESCRIPTION DRUG PRODUCT LIST

3 - 177 (of 393)

FLUOROURACIL

SOLUTION; TOPICAL

FLUOROURACIL

<u>AT</u>	TARO	<u>2%</u>	<u>A076526</u>	<u>001</u>	Nov 05, 2003
<u>AT</u>		<u>5%</u>	<u>A076526</u>	<u>002</u>	Nov 05, 2003

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC LTD	<u>EQ 40MG BASE</u>	<u>A090223</u>	<u>003</u>	Mar 19, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 40MG BASE</u>	<u>A078619</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 40MG BASE</u>	<u>A075465</u>	<u>003</u>	Aug 02, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 40MG BASE</u>	<u>A075245</u>	<u>003</u>	Sep 28, 2004
<u>AB</u>	MYLAN	<u>EQ 40MG BASE</u>	<u>A075207</u>	<u>003</u>	May 25, 2007
<u>AB</u>	RANBAXY	<u>EQ 40MG BASE</u>	<u>A076990</u>	<u>001</u>	Dec 13, 2004
<u>AB</u>	SANDOZ	<u>EQ 40MG BASE</u>	<u>A075049</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	TEVA	<u>EQ 40MG BASE</u>	<u>A075452</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	WOCKHARDT	<u>EQ 40MG BASE</u>	<u>A078143</u>	<u>003</u>	Jan 16, 2008

PROZAC

<u>AB</u>	+ LILLY	<u>EQ 40MG BASE</u>	<u>N018936</u>	<u>003</u>	Jun 15, 1999
-----------	---------	---------------------	----------------	------------	--------------

FLUOXETINE HYDROCHLORIDE

<u>AB1</u>	ALEMBIC LTD	<u>EQ 10MG BASE</u>	<u>A090223</u>	<u>001</u>	Mar 19, 2009
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A090223</u>	<u>002</u>	Mar 19, 2009
<u>AB1</u>	ALPHAPHARM	<u>EQ 10MG BASE</u>	<u>A075577</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075577</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078619</u>	<u>001</u>	Jan 31, 2008
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A078619</u>	<u>002</u>	Jan 31, 2008
<u>AB1</u>	BARR	<u>EQ 10MG BASE</u>	<u>A074803</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A074803</u>	<u>001</u>	Aug 02, 2001
<u>AB1</u>	BEIJING DOUBLE CRANE	<u>EQ 10MG BASE</u>	<u>A076165</u>	<u>001</u>	Feb 01, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A076165</u>	<u>002</u>	Feb 01, 2002
<u>AB1</u>	DR REDDYS LABS INC	<u>EQ 10MG BASE</u>	<u>A075465</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075465</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A075245</u>	<u>002</u>	Jan 31, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075245</u>	<u>001</u>	Jan 31, 2002
<u>AB1</u>	LANDELA PHARM	<u>EQ 10MG BASE</u>	<u>A075464</u>	<u>001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075464</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>	MALLINCKRODT	<u>EQ 10MG BASE</u>	<u>A075658</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075658</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075207</u>	<u>001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075207</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>	PLIVA	<u>EQ 10MG BASE</u>	<u>A076001</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A076001</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A075049</u>	<u>001</u>	Aug 02, 2001
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075049</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075452</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075452</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	WOCKHARDT	<u>EQ 10MG BASE</u>	<u>A078143</u>	<u>001</u>	Jan 16, 2008
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A078143</u>	<u>002</u>	Jan 16, 2008

PROZAC

<u>AB1</u>	LILLY	<u>EQ 10MG BASE</u>	<u>N018936</u>	<u>006</u>	Dec 23, 1992
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>N018936</u>	<u>001</u>	Dec 29, 1987

FLUOXETINE HYDROCHLORIDE

<u>AB2</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078045</u>	<u>001</u>	Nov 17, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A078045</u>	<u>002</u>	Nov 17, 2008
<u>AB2</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A077469</u>	<u>001</u>	Nov 17, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A077469</u>	<u>002</u>	Nov 17, 2008
<u>AB2</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A076287</u>	<u>001</u>	May 20, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A076287</u>	<u>002</u>	May 20, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 178 (of 393)

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

SARAFEM

<u>AB2</u>	LILLY	<u>EQ 10MG BASE</u>	<u>N018936</u>	<u>007</u>	Jul 06, 2000
<u>AB2</u>	+	<u>EQ 20MG BASE</u>	<u>N018936</u>	<u>008</u>	Jul 06, 2000

CAPSULE, DELAYED REL PELLETS; ORAL

PROZAC WEEKLY

	+	LILLY	EQ 90MG BASE	N021235	001	Feb 26, 2001
--	---	-------	--------------	---------	-----	--------------

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AA</u>	AUROBINDO PHARM	<u>EQ 20MG BASE/5ML</u>	<u>A079209</u>	<u>001</u>	Mar 20, 2009	
<u>AA</u>	MALLINCKRODT	<u>EQ 20MG BASE/5ML</u>	<u>A075920</u>	<u>001</u>	Jan 29, 2002	
<u>AA</u>	MORTON GROVE	<u>EQ 20MG BASE/5ML</u>	<u>A075514</u>	<u>001</u>	Aug 29, 2002	
<u>AA</u>	NOVEX	<u>EQ 20MG BASE/5ML</u>	<u>A075292</u>	<u>001</u>	Feb 07, 2002	
<u>AA</u>	PAR PHARM	<u>EQ 20MG BASE/5ML</u>	<u>A076458</u>	<u>001</u>	May 14, 2004	
<u>AA</u>	+	PHARM ASSOC	<u>EQ 20MG BASE/5ML</u>	<u>A076015</u>	<u>001</u>	Jan 30, 2002
<u>AA</u>	SILARX	<u>EQ 20MG BASE/5ML</u>	<u>A077849</u>	<u>001</u>	Feb 09, 2007	
<u>AA</u>	TEVA	<u>EQ 20MG BASE/5ML</u>	<u>A075506</u>	<u>001</u>	Aug 02, 2001	

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS INC	<u>EQ 10MG BASE</u>	<u>A076006</u>	<u>001</u>	Jan 30, 2002	
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075755</u>	<u>001</u>	Aug 02, 2001	
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075872</u>	<u>001</u>	Jan 29, 2002	
	FLUOXETINE HYDROCHLORIDE					
	+	MYLAN	EQ 20MG BASE	A075755	002	Aug 02, 2001
	SARAFEM					
	WARNER CHILCOTT	EQ 10MG BASE	N021860	001	May 19, 2006	
		EQ 15MG BASE	N021860	002	May 19, 2006	
	+	EQ 20MG BASE	N021860	003	May 19, 2006	

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

SYMBYAX

	LILLY	EQ 25MG BASE;EQ 3MG BASE	N021520	001	Apr 09, 2007
		EQ 25MG BASE;EQ 6MG BASE	N021520	002	Dec 24, 2003
		EQ 25MG BASE;EQ 12MG BASE	N021520	004	Dec 24, 2003
	+	EQ 50MG BASE;EQ 6MG BASE	N021520	003	Dec 24, 2003
		EQ 50MG BASE;EQ 12MG BASE	N021520	005	Dec 24, 2003

FLUOXYMESTERONE

TABLET; ORAL

FLUOXYMESTERONE

	+	USL PHARMA	10MG	A088342	001	Oct 21, 1983
--	---	------------	------	---------	-----	--------------

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

<u>AO</u>	APOTEX INC	<u>25MG/ML</u>	<u>A075918</u>	<u>001</u>	Aug 17, 2001	
<u>AO</u>	APP PHARMS	<u>25MG/ML</u>	<u>A071413</u>	<u>001</u>	Jul 14, 1987	
<u>AO</u>	+	BEDFORD	<u>25MG/ML</u>	<u>A074531</u>	<u>001</u>	Aug 30, 1996
<u>AO</u>	TEVA PARENTERAL	<u>25MG/ML</u>	<u>A074795</u>	<u>001</u>	Sep 10, 1996	

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

	+	PHARM ASSOC	5MG/ML	A074725	001	Sep 16, 1996
--	---	-------------	--------	---------	-----	--------------

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

	+	PHARM ASSOC	2.5MG/5ML	A040146	001	Aug 21, 1996
--	---	-------------	-----------	---------	-----	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 205 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 179 (of 393)

FLUPHENAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

FLUPHENAZINE HYDROCHLORIDE

+ APP PHARMS	2.5MG/ML	A089556	001	Apr 16, 1987
--------------	----------	---------	-----	--------------

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

<u>AB</u>	LANNETT	<u>1MG</u>	<u>A089740</u>	<u>001</u>	Aug 25, 1988
<u>AB</u>		<u>2.5MG</u>	<u>A089741</u>	<u>001</u>	Aug 25, 1988
<u>AB</u>		<u>5MG</u>	<u>A089742</u>	<u>001</u>	Aug 25, 1988
<u>AB</u>		<u>10MG</u>	<u>A089743</u>	<u>001</u>	Aug 25, 1988
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A089804</u>	<u>002</u>	Aug 12, 1988
<u>AB</u>		<u>2.5MG</u>	<u>A089804</u>	<u>003</u>	Aug 12, 1988
<u>AB</u>		<u>5MG</u>	<u>A089804</u>	<u>004</u>	Aug 12, 1988
<u>AB</u>	+	<u>10MG</u>	<u>A089804</u>	<u>001</u>	Aug 12, 1988
<u>AB</u>	SANDOZ	<u>1MG</u>	<u>A089583</u>	<u>001</u>	Oct 16, 1987
<u>AB</u>		<u>2.5MG</u>	<u>A089584</u>	<u>001</u>	Oct 16, 1987
<u>AB</u>		<u>5MG</u>	<u>A089585</u>	<u>001</u>	Oct 16, 1987
<u>AB</u>		<u>10MG</u>	<u>A089586</u>	<u>001</u>	Oct 16, 1987

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

+ WATSON PHARMS	0.025%	N012806	003	
-----------------	--------	---------	-----	--

+	0.05%	N012806	002	
---	-------	---------	-----	--

LOTION; TOPICAL

CORDRAN

+ WATSON LABS	0.05%	N013790	001	
---------------	-------	---------	-----	--

OINTMENT; TOPICAL

CORDRAN

+ WATSON PHARMS	0.025%	N012806	004	
-----------------	--------	---------	-----	--

+	0.05%	N012806	001	
---	-------	---------	-----	--

TAPE; TOPICAL

CORDRAN

+ WATSON PHARMS	0.004MG/SQ CM	N016455	001	
-----------------	---------------	---------	-----	--

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

DALMANE

<u>AB</u>	VALEANT PHARM INTL	<u>15MG</u>	<u>N016721</u>	<u>001</u>	
-----------	--------------------	-------------	----------------	------------	--

<u>AB</u>	+	<u>30MG</u>	<u>N016721</u>	<u>002</u>	
-----------	---	-------------	----------------	------------	--

FLURAZEPAM HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>15MG</u>	<u>A070345</u>	<u>002</u>	Nov 27, 1985
-----------	-------	-------------	----------------	------------	--------------

<u>AB</u>		<u>30MG</u>	<u>A070345</u>	<u>001</u>	Nov 27, 1985
-----------	--	-------------	----------------	------------	--------------

<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A071205</u>	<u>001</u>	Nov 25, 1986
-----------	-------------	-------------	----------------	------------	--------------

<u>AB</u>		<u>30MG</u>	<u>A071068</u>	<u>001</u>	Nov 25, 1986
-----------	--	-------------	----------------	------------	--------------

<u>AB</u>		<u>30MG</u>	<u>A072369</u>	<u>001</u>	Mar 30, 1989
-----------	--	-------------	----------------	------------	--------------

<u>AB</u>	WEST WARD	<u>15MG</u>	<u>A071107</u>	<u>001</u>	Dec 08, 1986
-----------	-----------	-------------	----------------	------------	--------------

<u>AB</u>		<u>30MG</u>	<u>A071108</u>	<u>001</u>	Dec 08, 1986
-----------	--	-------------	----------------	------------	--------------

FLURBIPROFEN

TABLET; ORAL

ANSAID

<u>AB</u>	PHARMACIA AND UPJOHN	<u>50MG</u>	<u>N018766</u>	<u>002</u>	Oct 31, 1988
-----------	----------------------	-------------	----------------	------------	--------------

<u>AB</u>	+	<u>100MG</u>	<u>N018766</u>	<u>003</u>	Oct 31, 1988
-----------	---	--------------	----------------	------------	--------------

FLURBIPROFEN

<u>AB</u>	CARACO	<u>50MG</u>	<u>A075058</u>	<u>001</u>	Apr 27, 2001
-----------	--------	-------------	----------------	------------	--------------

<u>AB</u>		<u>100MG</u>	<u>A075058</u>	<u>002</u>	Apr 27, 2001
-----------	--	--------------	----------------	------------	--------------

<u>AB</u>	MYLAN	<u>50MG</u>	<u>A074358</u>	<u>001</u>	Jun 20, 1994
-----------	-------	-------------	----------------	------------	--------------

<u>AB</u>		<u>100MG</u>	<u>A074358</u>	<u>002</u>	Jun 20, 1994
-----------	--	--------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 180 (of 393)

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

<u>AB</u>	TEVA	<u>100MG</u>	<u>A074431</u>	<u>001</u>	May 31, 1995
-----------	------	--------------	----------------	------------	--------------

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUM

<u>AT</u>	BAUSCH AND LOMB	<u>0.03%</u>	<u>A074447</u>	<u>001</u>	Jan 04, 1995
-----------	-----------------	--------------	----------------	------------	--------------

OCUFEN

<u>AT</u>	+ ALLERGAN	<u>0.03%</u>	<u>N019404</u>	<u>001</u>	Dec 31, 1986
-----------	------------	--------------	----------------	------------	--------------

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

<u>AB</u>	GENPHARM	<u>125MG</u>	<u>A076224</u>	<u>001</u>	May 09, 2003
-----------	----------	--------------	----------------	------------	--------------

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>125MG</u>	<u>A075780</u>	<u>001</u>	Sep 19, 2001
-----------	----------------------	--------------	----------------	------------	--------------

<u>AB</u>	PAR PHARM	<u>125MG</u>	<u>A075298</u>	<u>001</u>	Sep 18, 2001
-----------	-----------	--------------	----------------	------------	--------------

<u>AB</u>	+ SANDOZ	<u>125MG</u>	<u>A075818</u>	<u>001</u>	Sep 18, 2001
-----------	----------	--------------	----------------	------------	--------------

<u>AB</u>	WATSON LABS	<u>125MG</u>	<u>A075820</u>	<u>001</u>	Sep 18, 2001
-----------	-------------	--------------	----------------	------------	--------------

FLUTICASONE FUROATE

SPRAY, METERED; NASAL

VERAMYST

	+ GLAXOSMITHKLINE	0.0275MG/INH	N022051	001	Apr 27, 2007
--	-------------------	--------------	---------	-----	--------------

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

	+ GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004
--	-----------------	-------------	---------	-----	--------------

		0.11MG/INH	N021433	002	May 14, 2004
--	--	------------	---------	-----	--------------

		0.22MG/INH	N021433	001	May 14, 2004
--	--	------------	---------	-----	--------------

CREAM; TOPICAL

CUTIVATE

<u>AB</u>	+ ALTANA	<u>0.05%</u>	<u>N019958</u>	<u>001</u>	Dec 18, 1990
-----------	----------	--------------	----------------	------------	--------------

FLUTICASONE PROPIONATE

<u>AB</u>	ALTANA	<u>0.05%</u>	<u>A076451</u>	<u>001</u>	May 14, 2004
-----------	--------	--------------	----------------	------------	--------------

<u>AB</u>	G AND W LABS	<u>0.05%</u>	<u>A077055</u>	<u>001</u>	Jun 30, 2006
-----------	--------------	--------------	----------------	------------	--------------

<u>AB</u>	KV PHARM	<u>0.05%</u>	<u>A076865</u>	<u>001</u>	Sep 10, 2004
-----------	----------	--------------	----------------	------------	--------------

<u>AB</u>	PERRIGO NEW YORK	<u>0.05%</u>	<u>A076793</u>	<u>001</u>	May 14, 2004
-----------	------------------	--------------	----------------	------------	--------------

<u>AB</u>	TOLMAR	<u>0.05%</u>	<u>A076633</u>	<u>001</u>	May 14, 2004
-----------	--------	--------------	----------------	------------	--------------

LOTION; TOPICAL

CUTIVATE

	+ NYCOMED US	0.05%	N021152	001	Mar 31, 2005
--	--------------	-------	---------	-----	--------------

OINTMENT; TOPICAL

CUTIVATE

<u>AB</u>	+ ALTANA	<u>0.005%</u>	<u>N019957</u>	<u>001</u>	Dec 14, 1990
-----------	----------	---------------	----------------	------------	--------------

FLUTICASONE PROPIONATE

<u>AB</u>	ALTANA	<u>0.005%</u>	<u>A076300</u>	<u>001</u>	May 14, 2004
-----------	--------	---------------	----------------	------------	--------------

<u>AB</u>	G AND W LABS	<u>0.005%</u>	<u>A077168</u>	<u>001</u>	Mar 03, 2006
-----------	--------------	---------------	----------------	------------	--------------

<u>AB</u>	PERRIGO NEW YORK	<u>0.005%</u>	<u>A076668</u>	<u>001</u>	May 14, 2004
-----------	------------------	---------------	----------------	------------	--------------

POWDER; INHALATION

FLOVENT DISKUS 100

	+ GLAXOSMITHKLINE	0.1MG/INH	N020833	002	Sep 29, 2000
--	-------------------	-----------	---------	-----	--------------

FLOVENT DISKUS 250

	+ GLAXOSMITHKLINE	0.25MG/INH	N020833	003	Sep 29, 2000
--	-------------------	------------	---------	-----	--------------

FLOVENT DISKUS 50

	+ GLAXOSMITHKLINE	0.05MG/INH	N020833	001	Sep 29, 2000
--	-------------------	------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 181 (of 393)

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

FLONASE

<u>AB</u>	+	GLAXOSMITHKLINE	<u>0.05MG/SPRAY</u>	<u>N020121</u>	<u>001</u>	Oct 19, 1994
<u>AB</u>		<u>FLUTICASONE PROPIONATE</u>				
<u>AB</u>		APOTEX INC	<u>0.05MG/SPRAY</u>	<u>A077538</u>	<u>001</u>	Sep 12, 2007
<u>AB</u>		HI TECH PHARMA	<u>0.05MG/SPRAY</u>	<u>A077570</u>	<u>001</u>	Jan 16, 2008
<u>AB</u>		ROXANE	<u>0.05MG/SPRAY</u>	<u>A076504</u>	<u>001</u>	Feb 22, 2006

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

ADVAIR HFA

+	GLAXOSMITHKLINE	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006
+		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006
+		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006

POWDER; INHALATION

ADVAIR DISKUS 100/50

+	GLAXOSMITHKLINE	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000
+	GLAXOSMITHKLINE	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000
+	GLAXOSMITHKLINE	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000

FLUVASTATIN SODIUM

CAPSULE; ORAL

LESCOL

	NOVARTIS	EQ 20MG BASE	N020261	001	Dec 31, 1993
+		EQ 40MG BASE	N020261	002	Dec 31, 1993

TABLET, EXTENDED RELEASE; ORAL

LESCOL XL

+	NOVARTIS	80MG	N021192	001	Oct 06, 2000
---	----------	------	---------	-----	--------------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

LUVOX CR

	JAZZ	100MG	N022033	001	Feb 28, 2008
+		150MG	N022033	002	Feb 28, 2008

TABLET; ORAL

FLUVOXAMINE MALEATE

<u>AB</u>		<u>APOTEX</u>	<u>25MG</u>	<u>A075902</u>	<u>001</u>	May 07, 2001
<u>AB</u>			<u>50MG</u>	<u>A075902</u>	<u>002</u>	May 07, 2001
<u>AB</u>			<u>100MG</u>	<u>A075902</u>	<u>003</u>	May 07, 2001
<u>AB</u>		<u>BARR</u>	<u>25MG</u>	<u>A075897</u>	<u>001</u>	Jan 25, 2001
<u>AB</u>			<u>50MG</u>	<u>A075897</u>	<u>002</u>	Jan 25, 2001
<u>AB</u>			<u>100MG</u>	<u>A075897</u>	<u>003</u>	Jan 25, 2001
<u>AB</u>		<u>CARACO</u>	<u>25MG</u>	<u>A075900</u>	<u>001</u>	Feb 23, 2006
<u>AB</u>			<u>50MG</u>	<u>A075900</u>	<u>002</u>	Feb 23, 2006
<u>AB</u>			<u>100MG</u>	<u>A075900</u>	<u>003</u>	Feb 23, 2006
<u>AB</u>		<u>MYLAN</u>	<u>25MG</u>	<u>A075889</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>			<u>50MG</u>	<u>A075889</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>			<u>100MG</u>	<u>A075889</u>	<u>003</u>	Nov 29, 2000
<u>AB</u>		<u>SANDOZ</u>	<u>25MG</u>	<u>A075888</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>			<u>50MG</u>	<u>A075888</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>			<u>100MG</u>	<u>A075888</u>	<u>003</u>	Nov 29, 2000
<u>AB</u>	+		<u>100MG</u>	<u>A075888</u>	<u>003</u>	Nov 29, 2000
<u>AB</u>		<u>TEVA</u>	<u>25MG</u>	<u>A075893</u>	<u>001</u>	Sep 10, 2002
<u>AB</u>			<u>50MG</u>	<u>A075893</u>	<u>002</u>	Sep 10, 2002
<u>AB</u>			<u>100MG</u>	<u>A075893</u>	<u>003</u>	Sep 10, 2002
<u>AB</u>		<u>LUVOX</u>				
<u>AB</u>		JAZZ	<u>25MG</u>	<u>N021519</u>	<u>001</u>	Dec 20, 2007



## PRESCRIPTION DRUG PRODUCT LIST

3 - 182 (of 393)

FLUVOXAMINE MALEATE

TABLET; ORAL

LUVOX

<u>AB</u>	JAZZ	<u>50MG</u>	<u>N021519</u>	<u>002</u>	Dec 20, 2007
<u>AB</u>		<u>100MG</u>	<u>N021519</u>	<u>003</u>	Dec 20, 2007

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

+	APP PHARMS	5MG/ML	A089202	001	Feb 18, 1986
---	------------	--------	---------	-----	--------------

TABLET; ORAL

FOLIC ACID

<u>AA</u>	CADISTA PHARMS	<u>1MG</u>	<u>A040514</u>	<u>001</u>	Jun 14, 2005
<u>AA</u>	CONTRACT PHARMACAL	<u>1MG</u>	<u>A085061</u>	<u>001</u>	
<u>AA</u>	EXCELLIUM	<u>1MG</u>	<u>A040796</u>	<u>001</u>	Jan 12, 2009
<u>AA</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A090035</u>	<u>001</u>	Jun 09, 2009
<u>AA</u>	MUTUAL PHARM	<u>1MG</u>	<u>A040582</u>	<u>001</u>	Jul 18, 2005
<u>AA</u>	PHARMAX	<u>1MG</u>	<u>A040625</u>	<u>001</u>	Jul 21, 2005
<u>AA</u>	WEST WARD	<u>1MG</u>	<u>A080600</u>	<u>001</u>	

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

+	ORGANON USA INC	75 IU/0.5ML	N021273	001	Aug 26, 2005
+		150 IU/0.5ML	N021273	002	Aug 26, 2005
+		300 IU/0.36ML	N021211	001	Mar 23, 2004
+		600 IU/0.72ML	N021211	002	Mar 23, 2004
+		900 IU/1.08ML	N021211	004	Feb 11, 2005

GONAL-F

+	EMD SERONO	450 IU/VIAL	N020378	005	Mar 26, 2004
		1,050 IU/VIAL	N020378	004	Feb 28, 2001

GONAL-F RFF

+	EMD SERONO	75 IU/VIAL	N021765	002	Mar 25, 2004
---	------------	------------	---------	-----	--------------

GONAL-F RFF PEN

+	EMD SERONO	300 IU/0.5ML	N021684	001	May 25, 2004
+		450 IU/0.75ML	N021684	002	May 25, 2004
+		900 IU/1.5ML	N021684	003	May 25, 2004

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL

<u>AP</u>	+ PALADIN LABS	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>N020696</u>	<u>001</u>	Dec 04, 1997
-----------	----------------	-----------------------------	----------------	------------	--------------

FOMEPIZOLE

<u>AP</u>	GENERAMEDIX	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A079033</u>	<u>001</u>	Apr 07, 2009
<u>AP</u>	NAVINTA LLC	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078537</u>	<u>001</u>	Mar 06, 2008
<u>AP</u>	PHARMAFORCE	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078368</u>	<u>001</u>	Dec 14, 2007
<u>AP</u>	SYNERX PHARMA	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078639</u>	<u>001</u>	Mar 03, 2008

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

+	GLAXOSMITHKLINE	2.5MG/0.5ML	N021345	001	Dec 07, 2001
+		5MG/0.4ML	N021345	002	May 28, 2004
+		7.5MG/0.6ML	N021345	003	May 28, 2004
+		10MG/0.8ML	N021345	004	May 28, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 183 (of 393)

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

+ NOVARTIS 0.012MG/INH N020831 001 Feb 16, 2001

FORADIL CERTIHALER

+ NOVARTIS 0.0085MG/INH N021592 001 Dec 15, 2006

SOLUTION; INHALATION

PERFOROMIST

+ DEY LP 0.02MG/2ML N022007 001 May 11, 2007

FOSAMPRENAVIR CALCIUM

SUSPENSION; ORAL

LEXIVA

+ VIIIV HLTHCARE EQ 50MG BASE/ML N022116 001 Jun 14, 2007

TABLET; ORAL

LEXIVA

+ VIIIV HLTHCARE EQ 700MG BASE N021548 001 Oct 20, 2003

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

+ MERCK AND CO INC EQ 115MG BASE/VIAL N022023 001 Jan 25, 2008

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUMAP HOSPIRA 2.4GM/100ML A077174 001 May 31, 2005FOSCAVIRAP + ASTRAZENECA 2.4GM/100ML N020068 001 Sep 27, 1991FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL

MONUROL

+ ZAMBON SPA EQ 3GM BASE/PACKET N050717 001 Dec 19, 1996

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUMAB APOTEX INC 10MG A076906 001 May 17, 2005AB 20MG A076906 002 May 17, 2005AB 40MG A076906 003 May 17, 2005AB COBALT 10MG A077531 001 Aug 31, 2006AB 20MG A077531 002 Aug 31, 2006AB 40MG A077531 003 Aug 31, 2006AB INVAGEN PHARMS 10MG A077222 001 Apr 20, 2005AB 20MG A077222 002 Apr 20, 2005AB 40MG A077222 003 Apr 20, 2005AB RANBAXY 10MG A076580 001 Apr 23, 2004AB 20MG A076580 002 Apr 23, 2004AB 40MG A076580 003 Apr 23, 2004AB SANDOZ 10MG A076483 001 Apr 23, 2004AB 20MG A076483 002 Apr 23, 2004AB 40MG A076483 003 Apr 23, 2004AB TEVA 10MG A076139 001 Nov 25, 2003AB 20MG A076139 002 Nov 25, 2003AB + 40MG A076139 003 Nov 25, 2003AB WATSON LABS 10MG A076987 001 Dec 23, 2004AB 20MG A076987 002 Dec 23, 2004AB 40MG A076987 003 Dec 23, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 184 (of 393)

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

<u>AB</u>	WATSON LABS FLORIDA	<u>10MG</u>	<u>A076620</u>	<u>001</u>	Oct 15, 2004
<u>AB</u>		<u>20MG</u>	<u>A076620</u>	<u>002</u>	Oct 15, 2004
<u>AB</u>		<u>40MG</u>	<u>A076620</u>	<u>003</u>	Oct 15, 2004
<u>MONOPRIL</u>					
<u>AB</u>	BRISTOL MYERS SQUIBB	<u>10MG</u>	<u>N019915</u>	<u>002</u>	May 16, 1991
<u>AB</u>		<u>20MG</u>	<u>N019915</u>	<u>003</u>	May 16, 1991
<u>AB</u>	+	<u>40MG</u>	<u>N019915</u>	<u>004</u>	Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	AUROBINDO PHARMA	<u>10MG;12.5MG</u>	<u>A079245</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A079245</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>	INVAGEN PHARMS	<u>10MG;12.5MG</u>	<u>A090228</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A090228</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>	MYLAN	<u>10MG;12.5MG</u>	<u>A077705</u>	<u>001</u>	Aug 14, 2006
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A077705</u>	<u>002</u>	Aug 14, 2006
<u>AB</u>	RANBAXY	<u>10MG;12.5MG</u>	<u>A076739</u>	<u>001</u>	Dec 17, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076739</u>	<u>002</u>	Dec 17, 2004
<u>AB</u>	SANDOZ	<u>10MG;12.5MG</u>	<u>A076961</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076961</u>	<u>002</u>	Sep 28, 2005
<u>AB</u>	WATSON LABS FLORIDA	<u>10MG;12.5MG</u>	<u>A076608</u>	<u>001</u>	Dec 03, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076608</u>	<u>002</u>	Dec 03, 2004

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

<u>AP</u>	+	PARKE DAVIS	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>N020450</u>	<u>001</u>	Aug 05, 1996
<u>FOSPHENYTOIN SODIUM</u>						
<u>AP</u>		AKORN STRIDES	<u>EQ 50MG PNEYTOIN NA/ML</u>	<u>A078476</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		APOTEX INC	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078126</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>		APP PHARMS	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078052</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>		BAXTER HLTHCARE	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077989</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>		BEDFORD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077481</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078765</u>	<u>001</u>	Dec 02, 2009
<u>AP</u>		HOSPIRA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078158</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>		IV THERAP	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078277</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>		SUN PHARM INDS	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078417</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		TEVA PARENTERAL	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A076886</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>		WOCKHARDT	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078137</u>	<u>001</u>	Aug 06, 2007

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

+	EISAI INC	1050MG/30ML (35MG/ML)	N022244	001	Dec 12, 2008
---	-----------	-----------------------	---------	-----	--------------

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

+	ENDO PHARMS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001
---	-------------	---------------	---------	-----	--------------

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

+	ASTRAZENECA	50MG/ML	N021344	001	Apr 25, 2002
---	-------------	---------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 185 (of 393)

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

<u>AP</u>	APP PHARMS	<u>10MG/ML</u>	<u>N018902</u>	<u>001</u>	May 22, 1984
<u>AP</u>	HOSPIRA	<u>10MG/ML</u>	<u>A070578</u>	<u>001</u>	Jul 08, 1987
<u>AP</u>		<u>10MG/ML</u>	<u>A075241</u>	<u>001</u>	May 28, 1999
<u>AP</u>		<u>10MG/ML</u>	<u>N018667</u>	<u>001</u>	May 28, 1982
<u>AP</u>	INTL MEDICATION	<u>10MG/ML</u>	<u>N018025</u>	<u>001</u>	
<u>AP</u>	+ LUITPOLD	<u>10MG/ML</u>	<u>N018579</u>	<u>001</u>	Nov 30, 1983
<u>AP</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A077941</u>	<u>001</u>	Mar 22, 2007

SOLUTION; ORAL

FUROSEMIDE

<u>AA</u>	MORTON GROVE	<u>10MG/ML</u>	<u>A070655</u>	<u>001</u>	Oct 02, 1987
<u>AA</u>	+ ROXANE	<u>10MG/ML</u>	<u>A070434</u>	<u>001</u>	Apr 22, 1987
	FUROSEMIDE				
	ROXANE	40MG/5ML	A070433	001	Apr 22, 1987

TABLET; ORAL

FUROSEMIDE

<u>AB</u>	DAVA PHARMS INC	<u>20MG</u>	<u>N018415</u>	<u>001</u>	Jul 27, 1982
<u>AB</u>		<u>40MG</u>	<u>N018415</u>	<u>002</u>	Jul 27, 1982
<u>AB</u>		<u>80MG</u>	<u>N018415</u>	<u>003</u>	Nov 26, 1984
<u>AB</u>	EXCELLIUM	<u>20MG</u>	<u>A077293</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077293</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>		<u>80MG</u>	<u>A077293</u>	<u>003</u>	Nov 09, 2005
<u>AB</u>	IPCA LABS LTD	<u>20MG</u>	<u>A078010</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>		<u>40MG</u>	<u>A078010</u>	<u>002</u>	Sep 18, 2006
<u>AB</u>		<u>80MG</u>	<u>A078010</u>	<u>003</u>	Sep 18, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>N018413</u>	<u>001</u>	Nov 30, 1983
<u>AB</u>		<u>40MG</u>	<u>N018413</u>	<u>002</u>	Nov 30, 1983
<u>AB</u>	MYLAN	<u>20MG</u>	<u>N018487</u>	<u>001</u>	
<u>AB</u>		<u>40MG</u>	<u>N018487</u>	<u>002</u>	
<u>AB</u>		<u>80MG</u>	<u>A070082</u>	<u>001</u>	Oct 29, 1986
<u>AB</u>	ROXANE	<u>20MG</u>	<u>N018823</u>	<u>001</u>	Nov 10, 1983
<u>AB</u>		<u>40MG</u>	<u>N018823</u>	<u>002</u>	Nov 10, 1983
<u>AB</u>		<u>80MG</u>	<u>A070086</u>	<u>001</u>	Jan 24, 1986
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>N018569</u>	<u>002</u>	
<u>AB</u>		<u>40MG</u>	<u>N018569</u>	<u>001</u>	
<u>AB</u>		<u>80MG</u>	<u>N018569</u>	<u>005</u>	Aug 14, 1984
<u>AB</u>	VINTAGE PHARMS	<u>20MG</u>	<u>A076796</u>	<u>001</u>	Mar 26, 2004
<u>AB</u>		<u>40MG</u>	<u>A076796</u>	<u>002</u>	Mar 26, 2004
<u>AB</u>		<u>80MG</u>	<u>A076796</u>	<u>003</u>	Mar 26, 2004
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A070412</u>	<u>001</u>	Feb 26, 1986
<u>AB</u>		<u>20MG</u>	<u>A070449</u>	<u>001</u>	Nov 22, 1985
<u>AB</u>		<u>20MG</u>	<u>A071379</u>	<u>001</u>	Jan 02, 1987
<u>AB</u>		<u>40MG</u>	<u>A070450</u>	<u>001</u>	Nov 22, 1985
<u>AB</u>		<u>80MG</u>	<u>A070528</u>	<u>001</u>	Jan 07, 1986
<u>AB</u>		<u>80MG</u>	<u>A071594</u>	<u>001</u>	Feb 09, 1988
	<u>LASIX</u>				
<u>AB</u>	SANOFI AVENTIS US	<u>20MG</u>	<u>N016273</u>	<u>002</u>	
<u>AB</u>		<u>40MG</u>	<u>N016273</u>	<u>001</u>	
<u>AB</u>	+	<u>80MG</u>	<u>N016273</u>	<u>003</u>	

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A075350</u>	<u>001</u>	Sep 12, 2003
<u>AB</u>		<u>300MG</u>	<u>A075350</u>	<u>002</u>	Sep 12, 2003
<u>AB</u>		<u>400MG</u>	<u>A075350</u>	<u>003</u>	Sep 12, 2003
<u>AB</u>	AMNEAL PHARMS NY	<u>100MG</u>	<u>A078428</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078428</u>	<u>002</u>	Jul 25, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 186 (of 393)

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>	AMNEAL PHARMS NY	<u>400MG</u>	<u>A078428</u>	<u>003</u>	Jul 25, 2007
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A075360</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>		<u>300MG</u>	<u>A075360</u>	<u>002</u>	Apr 06, 2005
<u>AB</u>		<u>400MG</u>	<u>A075360</u>	<u>003</u>	Apr 06, 2005
<u>AB</u>	AUROBINDO PHARM	<u>100MG</u>	<u>A078787</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>		<u>300MG</u>	<u>A078787</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>		<u>400MG</u>	<u>A078787</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	HIKMA	<u>100MG</u>	<u>A078150</u>	<u>001</u>	Sep 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078150</u>	<u>002</u>	Sep 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078150</u>	<u>003</u>	Sep 25, 2007
<u>AB</u>	INVAGEN PHARMS	<u>100MG</u>	<u>A090705</u>	<u>001</u>	Dec 30, 2009
<u>AB</u>		<u>300MG</u>	<u>A090705</u>	<u>002</u>	Dec 30, 2009
<u>AB</u>		<u>400MG</u>	<u>A090705</u>	<u>003</u>	Dec 30, 2009
<u>AB</u>	RANBAXY	<u>100MG</u>	<u>A076606</u>	<u>001</u>	Oct 07, 2005
<u>AB</u>		<u>300MG</u>	<u>A076606</u>	<u>002</u>	Oct 07, 2005
<u>AB</u>		<u>400MG</u>	<u>A076606</u>	<u>003</u>	Oct 07, 2005
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A075539</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>		<u>300MG</u>	<u>A075539</u>	<u>002</u>	Apr 06, 2005
<u>AB</u>		<u>400MG</u>	<u>A075539</u>	<u>003</u>	Apr 06, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>100MG</u>	<u>A077242</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>300MG</u>	<u>A077242</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>		<u>400MG</u>	<u>A077242</u>	<u>003</u>	Aug 24, 2006
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A075435</u>	<u>001</u>	Oct 08, 2004
<u>AB</u>		<u>300MG</u>	<u>A075435</u>	<u>002</u>	Oct 08, 2004
<u>AB</u>		<u>400MG</u>	<u>A075435</u>	<u>003</u>	Oct 08, 2004
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075485</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A075485</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>400MG</u>	<u>A075485</u>	<u>001</u>	May 11, 2007

NEURONTIN

<u>AB</u>	PFIZER PHARMS	<u>100MG</u>	<u>N020235</u>	<u>001</u>	Dec 30, 1993
<u>AB</u>		<u>300MG</u>	<u>N020235</u>	<u>002</u>	Dec 30, 1993
<u>AB</u>	+	<u>400MG</u>	<u>N020235</u>	<u>003</u>	Dec 30, 1993

SOLUTION; ORAL

NEURONTIN

	+ PARKE DAVIS	250MG/5ML	N021129	001	Mar 02, 2000
--	---------------	-----------	---------	-----	--------------

TABLET; ORAL

GABAPENTIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>600MG</u>	<u>A075694</u>	<u>001</u>	Oct 21, 2004
<u>AB</u>		<u>800MG</u>	<u>A075694</u>	<u>002</u>	Oct 21, 2004
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077894</u>	<u>001</u>	Oct 10, 2006
<u>AB</u>		<u>300MG</u>	<u>A077894</u>	<u>002</u>	Oct 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077894</u>	<u>003</u>	Oct 10, 2006
<u>AB</u>		<u>600MG</u>	<u>A077661</u>	<u>004</u>	Sep 13, 2006
<u>AB</u>		<u>800MG</u>	<u>A077661</u>	<u>005</u>	Sep 13, 2006
<u>AB</u>	GLENMARK GENERICS	<u>600MG</u>	<u>A077662</u>	<u>001</u>	Aug 18, 2006
<u>AB</u>		<u>800MG</u>	<u>A077662</u>	<u>002</u>	Aug 18, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A076017</u>	<u>001</u>	Apr 28, 2004
<u>AB</u>		<u>300MG</u>	<u>A076017</u>	<u>002</u>	Apr 28, 2004
<u>AB</u>		<u>400MG</u>	<u>A076017</u>	<u>003</u>	Apr 28, 2004
<u>AB</u>		<u>600MG</u>	<u>A076017</u>	<u>004</u>	Apr 29, 2005
<u>AB</u>		<u>800MG</u>	<u>A076017</u>	<u>005</u>	Apr 29, 2005
<u>AB</u>	SANDOZ	<u>600MG</u>	<u>A076877</u>	<u>001</u>	Jul 06, 2006
<u>AB</u>		<u>800MG</u>	<u>A076877</u>	<u>002</u>	Jul 06, 2006
<u>AB</u>	SUN PHARM INDS LTD	<u>600MG</u>	<u>A077525</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>800MG</u>	<u>A077525</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>	TEVA	<u>600MG</u>	<u>A075827</u>	<u>001</u>	Dec 15, 2004
<u>AB</u>		<u>800MG</u>	<u>A075827</u>	<u>002</u>	Dec 15, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 187 (of 393)

GABAPENTIN

TABLET; ORAL

NEURONTIN

<u>AB</u>	PFIZER PHARMS	<u>600MG</u>	<u>N020882</u>	<u>001</u>	Oct 09, 1998
<u>AB</u>	+	<u>800MG</u>	<u>N020882</u>	<u>002</u>	Oct 09, 1998

GADOBENATE DIMEGLUMINEINJECTABLE; INTRAVENOUS  
MULTIHANCE

+	BRACCO	2.645GM/5ML (529MG/ML)	N021357	001	Nov 23, 2004
+		5.29GM/10ML (529MG/ML)	N021357	002	Nov 23, 2004
+		7.935GM/15ML (529MG/ML)	N021357	003	Nov 23, 2004
+		10.58GM/20ML (529MG/ML)	N021357	004	Nov 23, 2004
	MULTIHANCE MULTIPACK				
+	BRACCO	26.45GM/50ML (529MG/ML)	N021358	001	Nov 23, 2004
+		52.9GM/100ML (529MG/ML)	N021358	002	Nov 23, 2004

GADODIAMIDEINJECTABLE; INJECTION  
OMNISCAN

+	GE HEALTHCARE	287MG/ML	N020123	001	Jan 08, 1993
+		28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007

GADOFOSVESET TRISODIUMSOLUTION; INTRAVENOUS  
ABLAVAR

	LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711	001	Dec 22, 2008
+		3660MG/15ML (244MG/ML)	N021711	002	Dec 22, 2008

GADOPENTETATE DIMEGLUMINEINJECTABLE; INJECTION  
MAGNEVIST

+	BAYER HLTHCARE	469.01MG/ML	N019596	001	Jun 02, 1988
+		469.01MG/ML	N021037	001	Mar 10, 2000

GADOTERIDOLINJECTABLE; INJECTION  
PROHANCE

+	BRACCO	279.3MG/ML	N020131	001	Nov 16, 1992
	PROHANCE MULTIPACK				
+	BRACCO	279.3MG/ML	N021489	001	Oct 09, 2003

GADOVERSETAMIDEINJECTABLE; INJECTION  
OPTIMARK

+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999
+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999
+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999
+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999
+		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999
	OPTIMARK IN PLASTIC CONTAINER				
+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N020976	001	Dec 08, 1999
+		3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999

## PRESCRIPTION DRUG PRODUCT LIST

3 - 188 (of 393)

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

+ BAYER HLTHCARE 1.8143GM/10ML (181.43MG/ML) N022090 001 Jul 03, 2008

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>	BARR	<u>EQ 8MG BASE</u>	<u>A078189</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A078189</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078189</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>	IMPAX LABS	<u>EQ 8MG BASE</u>	<u>A078484</u>	<u>001</u>	May 27, 2009
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A078484</u>	<u>002</u>	May 27, 2009
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078484</u>	<u>003</u>	May 27, 2009
<u>AB</u>	WATSON LABS	<u>EQ 8MG BASE</u>	<u>A079028</u>	<u>001</u>	Dec 15, 2008
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A079028</u>	<u>002</u>	Dec 15, 2008
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A079028</u>	<u>003</u>	Dec 15, 2008
	<u>RAZADYNE ER</u>				
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>EQ 8MG BASE</u>	<u>N021615</u>	<u>001</u>	Apr 01, 2005
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>N021615</u>	<u>002</u>	Apr 01, 2005
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>N021615</u>	<u>003</u>	Apr 01, 2005

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

<u>AA</u>	ROXANE	<u>4MG/ML</u>	<u>A078185</u>	<u>001</u>	Jan 30, 2009
-----------	--------	---------------	----------------	------------	--------------

RAZADYNE

<u>AA</u>	+ ORTHO MCNEIL JANSSEN	<u>4MG/ML</u>	<u>N021224</u>	<u>001</u>	Jun 22, 2001
-----------	------------------------	---------------	----------------	------------	--------------

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 4MG BASE</u>	<u>A077585</u>	<u>001</u>	Sep 15, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077585</u>	<u>002</u>	Sep 15, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077585</u>	<u>003</u>	Sep 15, 2009
<u>AB</u>	BARR	<u>EQ 4MG BASE</u>	<u>A077605</u>	<u>001</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077605</u>	<u>002</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077605</u>	<u>003</u>	Aug 28, 2008
<u>AB</u>	BEJING YABAO	<u>EQ 4MG BASE</u>	<u>A077604</u>	<u>001</u>	Feb 06, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077604</u>	<u>002</u>	Feb 06, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077604</u>	<u>003</u>	Feb 06, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A077593</u>	<u>001</u>	Sep 11, 2008
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077593</u>	<u>002</u>	Sep 11, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077593</u>	<u>003</u>	Sep 11, 2008
<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A077590</u>	<u>001</u>	May 29, 2009
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077603</u>	<u>001</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077590</u>	<u>002</u>	May 29, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077603</u>	<u>002</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077590</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077603</u>	<u>003</u>	Aug 28, 2008
<u>AB</u>	ROXANE	<u>EQ 4MG BASE</u>	<u>A077608</u>	<u>001</u>	Feb 11, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077608</u>	<u>002</u>	Feb 11, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077608</u>	<u>003</u>	Feb 11, 2009
<u>AB</u>	SANDOZ	<u>EQ 4MG BASE</u>	<u>A077589</u>	<u>001</u>	Jun 22, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077589</u>	<u>002</u>	Jun 22, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077589</u>	<u>003</u>	Jun 22, 2009
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A077587</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077587</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077587</u>	<u>003</u>	Jul 09, 2009
	<u>RAZADYNE</u>				
<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>EQ 4MG BASE</u>	<u>N021169</u>	<u>001</u>	Feb 28, 2001
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N021169</u>	<u>002</u>	Feb 28, 2001
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>N021169</u>	<u>003</u>	Feb 28, 2001

## PRESCRIPTION DRUG PRODUCT LIST

3 - 189 (of 393)

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION  
GALLIUM CITRATE GA 67

BS	LANTHEUS MEDCL	2mCi/ML	N017478	001	
BS	MALLINCKRODT	2mCi/ML	N018058	001	

GALLIUM NITRATE

INJECTABLE; INJECTION  
GANITE

+	GENTA	25MG/ML	N019961	002	Jan 17, 1991
---	-------	---------	---------	-----	--------------

GANCICLOVIR

CAPSULE; ORAL  
GANCICLOVIR

	RANBAXY	250MG	A076457	001	Jun 27, 2003
+		500MG	A076457	002	Jun 27, 2003

GEL; OPHTHALMIC  
ZIRGAN

+	SIRION THERAP	0.15%	N022211	001	Sep 15, 2009
---	---------------	-------	---------	-----	--------------

IMPLANT; IMPLANTATION  
VITRASERT

+	BAUSCH AND LOMB	4.5MG	N020569	001	Mar 04, 1996
---	-----------------	-------	---------	-----	--------------

GANCICLOVIR SODIUM

INJECTABLE; INJECTION  
GANCICLOVIR SODIUM

	BEDFORD	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003
--	---------	--------------------	---------	-----	--------------

GANIRELIX ACETATE

INJECTABLE; INJECTION  
GANIRELIX ACETATE INJECTION

+	ORGANON USA INC	EQ 250MCG BASE/0.5ML	N021057	001	Jul 29, 1999
---	-----------------	----------------------	---------	-----	--------------

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

+	ALLERGAN	0.3%	N021493	001	Mar 28, 2003
---	----------	------	---------	-----	--------------

GEFITINIB

TABLET; ORAL  
IRESSA

+	ASTRAZENECA	250MG	N021399	001	May 05, 2003
---	-------------	-------	---------	-----	--------------

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION  
GEMCITABINE HYDROCHLORIDE

<u>AP</u>	TEVA PARENTERAL	<u>EQ 200MG BASE/VIAL</u>	<u>A077983</u>	<u>002</u>	May 04, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A077983</u>	<u>001</u>	Dec 18, 2008

GEMZAR

<u>AP</u>	+ LILLY	<u>EQ 200MG BASE/VIAL</u>	<u>N020509</u>	<u>001</u>	May 15, 1996
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N020509</u>	<u>002</u>	May 15, 1996

GEMFIBROZIL

TABLET; ORAL  
GEMFIBROZIL

<u>AB</u>	APOTEX	<u>600MG</u>	<u>A075034</u>	<u>001</u>	Jul 20, 1998
<u>AB</u>	IMPAX PHARMS	<u>600MG</u>	<u>A078207</u>	<u>001</u>	Jun 01, 2007
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A077836</u>	<u>001</u>	Jul 27, 2006



## PRESCRIPTION DRUG PRODUCT LIST

3 - 190 (of 393)

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

<u>AB</u>	PERRIGO R AND D	<u>600MG</u>	<u>A078012</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>	SUN PHARM INDS INC	<u>600MG</u>	<u>A079239</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>	TEVA	<u>600MG</u>	<u>A074256</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>	WATSON LABS	<u>600MG</u>	<u>A074442</u>	<u>001</u>	Apr 28, 1995

LOPID

<u>AB</u>	+ PFIZER PHARMS	<u>600MG</u>	<u>N018422</u>	<u>003</u>	Nov 20, 1986
-----------	-----------------	--------------	----------------	------------	--------------

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

	+ OSCIENT	EQ 320MG BASE	N021158	001	Apr 04, 2003
--	-----------	---------------	---------	-----	--------------

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION

MYLOTARG

	+ WYETH PHARMS INC	5MG/VIAL	N021174	001	May 17, 2000
--	--------------------	----------	---------	-----	--------------

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

<u>AT</u>	+ FOUGERA	<u>EQ 0.1% BASE</u>	<u>A062531</u>	<u>001</u>	Jul 05, 1984
<u>AT</u>	PERRIGO NEW YORK	<u>EQ 0.1% BASE</u>	<u>A062307</u>	<u>001</u>	
<u>AT</u>	TARO	<u>EQ 0.1% BASE</u>	<u>A062427</u>	<u>001</u>	May 26, 1983

INJECTABLE; INJECTION

GENTAMICIN SULFATE

<u>AP</u>	+ APP PHARMS	<u>EQ 10MG BASE/ML</u>	<u>A062356</u>	<u>001</u>	Mar 04, 1982
<u>AP</u>		<u>EQ 40MG BASE/ML</u>	<u>A062356</u>	<u>002</u>	Mar 04, 1982
<u>AP</u>		<u>EQ 40MG BASE/ML</u>	<u>A062366</u>	<u>001</u>	Aug 04, 1983
<u>AP</u>	HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A062420</u>	<u>001</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A062612</u>	<u>004</u>	Feb 20, 1986
<u>AP</u>		<u>EQ 40MG BASE/ML</u>	<u>A062420</u>	<u>002</u>	Aug 15, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+ B BRAUN	<u>EQ 0.8MG BASE/ML</u>	<u>A062814</u>	<u>001</u>	Aug 28, 1987
<u>AP</u>		<u>EQ 1.2MG BASE/ML</u>	<u>A062814</u>	<u>002</u>	Aug 28, 1987
<u>AP</u>		<u>EQ 1.4MG BASE/ML</u>	<u>A062814</u>	<u>003</u>	Aug 28, 1987
<u>AP</u>		<u>EQ 1.6MG BASE/ML</u>	<u>A062814</u>	<u>004</u>	Aug 28, 1987
<u>AP</u>		<u>EQ 1.8MG BASE/ML</u>	<u>A062814</u>	<u>005</u>	Aug 28, 1987
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A062814</u>	<u>006</u>	Aug 28, 1987
<u>AP</u>		<u>EQ 2.4MG BASE/ML</u>	<u>A062814</u>	<u>007</u>	Aug 28, 1987
<u>AP</u>		<u>EQ 40MG BASE/100ML</u>	<u>A062814</u>	<u>008</u>	Aug 28, 1987
<u>AP</u>		<u>EQ 60MG BASE/100ML</u>	<u>A062814</u>	<u>009</u>	Aug 28, 1987
<u>AP</u>		<u>EQ 70MG BASE/100ML</u>	<u>A062814</u>	<u>010</u>	Aug 28, 1987
<u>AP</u>		<u>EQ 80MG BASE/100ML</u>	<u>A062814</u>	<u>011</u>	Aug 28, 1987
<u>AP</u>		<u>EQ 90MG BASE/100ML</u>	<u>A062814</u>	<u>012</u>	Aug 28, 1987
<u>AP</u>		<u>EQ 100MG BASE/100ML</u>	<u>A062814</u>	<u>013</u>	Aug 28, 1987
<u>AP</u>		<u>EQ 120MG BASE/100ML</u>	<u>A062814</u>	<u>014</u>	Aug 28, 1987
<u>AP</u>	HOSPIRA	<u>EQ 1.2MG BASE/ML</u>	<u>A062414</u>	<u>001</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 1.4MG BASE/ML</u>	<u>A062414</u>	<u>002</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 1.6MG BASE/ML</u>	<u>A062414</u>	<u>003</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 1.8MG BASE/ML</u>	<u>A062414</u>	<u>004</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A062414</u>	<u>005</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 60MG BASE/100ML</u>	<u>A062414</u>	<u>006</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 70MG BASE/100ML</u>	<u>A062414</u>	<u>007</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 80MG BASE/100ML</u>	<u>A062414</u>	<u>008</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 90MG BASE/100ML</u>	<u>A062414</u>	<u>009</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 100MG BASE/100ML</u>	<u>A062414</u>	<u>010</u>	Aug 15, 1983

## PRESCRIPTION DRUG PRODUCT LIST

3 - 191 (of 393)

GENTAMICIN SULFATE

INJECTABLE; INJECTION

ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>EQ 0.8MG BASE/ML</u>	<u>A062373</u>	<u>001</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 1.2MG BASE/ML</u>	<u>A062373</u>	<u>007</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 1.6MG BASE/ML</u>	<u>A062373</u>	<u>008</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A062373</u>	<u>009</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 2.4MG BASE/ML</u>	<u>A062373</u>	<u>010</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 40MG BASE/100ML</u>	<u>A062373</u>	<u>003</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 60MG BASE/100ML</u>	<u>A062373</u>	<u>004</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 80MG BASE/100ML</u>	<u>A062373</u>	<u>002</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 100MG BASE/100ML</u>	<u>A062373</u>	<u>005</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 120MG BASE/100ML</u>	<u>A062373</u>	<u>006</u>	Sep 07, 1982

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

<u>AT</u>	+ AKORN	<u>EQ 0.3% BASE</u>	<u>A064093</u>	<u>001</u>	Aug 31, 1995
<u>AT</u>	ALTANA	<u>EQ 0.3% BASE</u>	<u>A065024</u>	<u>001</u>	Jul 30, 2004

OINTMENT; TOPICAL

GENTAMICIN SULFATE

<u>AT</u>	FOUGERA	<u>EQ 0.1% BASE</u>	<u>A062533</u>	<u>001</u>	Oct 05, 1984
<u>AT</u>	+ PERRIGO NEW YORK	<u>EQ 0.1% BASE</u>	<u>A062351</u>	<u>001</u>	Feb 18, 1982
<u>AT</u>	TARO	<u>EQ 0.1% BASE</u>	<u>A062477</u>	<u>001</u>	Dec 23, 1983

SOLUTION/DROPS; OPHTHALMIC

GENOPTIC

<u>AT</u>	ALLERGAN	<u>EQ 0.3% BASE</u>	<u>A062452</u>	<u>001</u>	Oct 10, 1984
-----------	----------	---------------------	----------------	------------	--------------

GENTAK

<u>AT</u>	AKORN	<u>EQ 0.3% BASE</u>	<u>A064163</u>	<u>001</u>	Oct 12, 2001
-----------	-------	---------------------	----------------	------------	--------------

GENTAMICIN SULFATE

<u>AT</u>	AKORN	<u>EQ 0.3% BASE</u>	<u>A062635</u>	<u>001</u>	Jan 08, 1987
<u>AT</u>	ALTANA	<u>EQ 0.3% BASE</u>	<u>A065121</u>	<u>001</u>	Jan 30, 2004
<u>AT</u>	+ BAUSCH AND LOMB	<u>EQ 0.3% BASE</u>	<u>A064048</u>	<u>001</u>	May 11, 1994
<u>AT</u>	FALCON PHARMS	<u>EQ 0.3% BASE</u>	<u>A062196</u>	<u>001</u>	

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

PRED-G

	+ ALLERGAN	EQ 0.3% BASE;0.6%	N050612	001	Dec 01, 1989
--	------------	-------------------	---------	-----	--------------

SUSPENSION/DROPS; OPHTHALMIC

	+ ALLERGAN	EQ 0.3% BASE;1%	N050586	001	Jun 10, 1988
--	------------	-----------------	---------	-----	--------------

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS

COPAXONE

	+ TEVA	20MG/ML	N020622	002	Feb 12, 2002
--	--------	---------	---------	-----	--------------

GLIMEPIRIDE

TABLET; ORAL

AMARYL

<u>AB</u>	+ SANOFI AVENTIS US	<u>1MG</u>	<u>N020496</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>		<u>2MG</u>	<u>N020496</u>	<u>002</u>	Nov 30, 1995
<u>AB</u>		<u>4MG</u>	<u>N020496</u>	<u>003</u>	Nov 30, 1995

GLIMEPIRIDE

<u>AB</u>	ACCORD HLTHCARE	<u>1MG</u>	<u>A078181</u>	<u>001</u>	Aug 23, 2007
<u>AB</u>		<u>2MG</u>	<u>A078181</u>	<u>002</u>	Aug 23, 2007
<u>AB</u>		<u>4MG</u>	<u>A078181</u>	<u>003</u>	Aug 23, 2007
<u>AB</u>	CARLSBAD	<u>1MG</u>	<u>A077911</u>	<u>001</u>	Sep 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A077911</u>	<u>002</u>	Sep 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A077911</u>	<u>003</u>	Sep 22, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 192 (of 393)

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

<u>AB</u>	COBALT	<u>1MG</u>	<u>A077280</u>	<u>001</u>	Feb 03, 2006
<u>AB</u>		<u>2MG</u>	<u>A077280</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>4MG</u>	<u>A077280</u>	<u>003</u>	Feb 03, 2006
<u>AB</u>	COREPHARMA	<u>1MG</u>	<u>A077274</u>	<u>001</u>	Oct 06, 2005
<u>AB</u>		<u>2MG</u>	<u>A077274</u>	<u>002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A077274</u>	<u>003</u>	Oct 06, 2005
<u>AB</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A077091</u>	<u>001</u>	Oct 06, 2005
<u>AB</u>		<u>2MG</u>	<u>A077091</u>	<u>002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A077091</u>	<u>003</u>	Oct 06, 2005
<u>AB</u>	GENPHARM	<u>1MG</u>	<u>A077486</u>	<u>001</u>	Feb 10, 2006
<u>AB</u>		<u>2MG</u>	<u>A077486</u>	<u>002</u>	Feb 10, 2006
<u>AB</u>		<u>4MG</u>	<u>A077486</u>	<u>003</u>	Feb 10, 2006
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A077295</u>	<u>001</u>	Oct 06, 2005
<u>AB</u>		<u>2MG</u>	<u>A077295</u>	<u>002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A077295</u>	<u>003</u>	Oct 06, 2005
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A077624</u>	<u>001</u>	Nov 28, 2005
<u>AB</u>		<u>2MG</u>	<u>A077624</u>	<u>002</u>	Nov 28, 2005
<u>AB</u>		<u>4MG</u>	<u>A077624</u>	<u>003</u>	Nov 28, 2005
<u>AB</u>	RANBAXY	<u>1MG</u>	<u>A076875</u>	<u>001</u>	Oct 06, 2005
<u>AB</u>		<u>2MG</u>	<u>A076875</u>	<u>002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A076875</u>	<u>003</u>	Oct 06, 2005
<u>AB</u>	TEVA	<u>1MG</u>	<u>A076802</u>	<u>001</u>	Oct 06, 2005
<u>AB</u>		<u>2MG</u>	<u>A076802</u>	<u>002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A076802</u>	<u>003</u>	Oct 06, 2005
	GLIMEPIRIDE				
	RANBAXY	8MG	A076875	004	Oct 06, 2005

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

+	TAKEDA GLOBAL	2MG; 30MG	N021925	001	Jul 28, 2006
		4MG; 30MG	N021925	002	Jul 28, 2006

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDARYL

+	SB PHARMCO	1MG; 4MG	N021700	001	Nov 23, 2005
		2MG; 4MG	N021700	002	Nov 23, 2005
		2MG; 8MG	N021700	004	Mar 30, 2007
		4MG; 4MG	N021700	003	Nov 23, 2005
		4MG; 8MG	N021700	005	Mar 30, 2007

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

<u>AB</u>	ALPHAPHARM	<u>5MG</u>	<u>A074438</u>	<u>001</u>	Jun 20, 1995
<u>AB</u>		<u>10MG</u>	<u>A074438</u>	<u>002</u>	Jun 20, 1995
<u>AB</u>	APOTEX	<u>5MG</u>	<u>A075795</u>	<u>001</u>	Jun 13, 2001
<u>AB</u>		<u>10MG</u>	<u>A075795</u>	<u>002</u>	Jun 13, 2001
<u>AB</u>	CARACO	<u>5MG</u>	<u>A077820</u>	<u>001</u>	Jul 11, 2006
<u>AB</u>		<u>10MG</u>	<u>A077820</u>	<u>002</u>	Jul 11, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A074497</u>	<u>001</u>	Aug 31, 1995
<u>AB</u>		<u>10MG</u>	<u>A074497</u>	<u>002</u>	Aug 31, 1995
<u>AB</u>	KALI LABS	<u>5MG</u>	<u>A074550</u>	<u>001</u>	Sep 11, 1997
<u>AB</u>		<u>10MG</u>	<u>A074550</u>	<u>002</u>	Sep 11, 1997
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A074226</u>	<u>001</u>	May 10, 1994
<u>AB</u>		<u>10MG</u>	<u>A074226</u>	<u>002</u>	May 10, 1994

## PRESCRIPTION DRUG PRODUCT LIST

3 - 193 (of 393)

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A074305</u>	<u>001</u>	Apr 07, 1995
<u>AB</u>		<u>10MG</u>	<u>A074305</u>	<u>002</u>	Apr 07, 1995
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A074223</u>	<u>001</u>	Feb 27, 1995
<u>AB</u>		<u>5MG</u>	<u>A074370</u>	<u>001</u>	Nov 22, 1994
<u>AB</u>		<u>10MG</u>	<u>A074223</u>	<u>002</u>	Feb 27, 1995
<u>AB</u>		<u>10MG</u>	<u>A074370</u>	<u>002</u>	Nov 22, 1994
<u>GLUCOTROL</u>					
<u>AB</u>	PFIZER	<u>5MG</u>	<u>N017783</u>	<u>001</u>	May 08, 1984
<u>AB</u>	+	<u>10MG</u>	<u>N017783</u>	<u>002</u>	May 08, 1984

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A076467</u>	<u>003</u>	Mar 27, 2006
<u>AB</u>		<u>5MG</u>	<u>A076467</u>	<u>001</u>	Sep 08, 2003
<u>AB</u>		<u>10MG</u>	<u>A076467</u>	<u>002</u>	Nov 07, 2003
<u>GLUCOTROL XL</u>					
<u>AB</u>	PFIZER	<u>2.5MG</u>	<u>N020329</u>	<u>003</u>	Aug 10, 1999
<u>AB</u>		<u>5MG</u>	<u>N020329</u>	<u>001</u>	Apr 26, 1994
<u>AB</u>	+	<u>10MG</u>	<u>N020329</u>	<u>002</u>	Apr 26, 1994

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	CARACO	<u>2.5MG; 250MG</u>	<u>A077620</u>	<u>001</u>	Jan 11, 2008
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A077620</u>	<u>002</u>	Jan 11, 2008
<u>AB</u>		<u>5MG; 500MG</u>	<u>A077620</u>	<u>003</u>	Jan 11, 2008
<u>AB</u>	COREPHARMA	<u>2.5MG; 250MG</u>	<u>A077507</u>	<u>001</u>	Oct 27, 2005
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A077507</u>	<u>002</u>	Oct 27, 2005
<u>AB</u>		<u>5MG; 500MG</u>	<u>A077507</u>	<u>003</u>	Oct 27, 2005
<u>AB</u>	MYLAN	<u>2.5MG; 250MG</u>	<u>A078083</u>	<u>001</u>	Apr 12, 2007
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A078083</u>	<u>002</u>	Apr 12, 2007
<u>AB</u>		<u>5MG; 500MG</u>	<u>A078083</u>	<u>003</u>	Apr 12, 2007
<u>AB</u>	TEVA PHARMS	<u>2.5MG; 250MG</u>	<u>A077270</u>	<u>001</u>	Oct 28, 2005
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A077270</u>	<u>002</u>	Oct 28, 2005
<u>AB</u>		<u>5MG; 500MG</u>	<u>A077270</u>	<u>003</u>	Oct 28, 2005
<u>METAGLIP</u>					
<u>AB</u>	BRISTOL MYERS SQUIBB	<u>2.5MG; 250MG</u>	<u>N021460</u>	<u>001</u>	Oct 21, 2002
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>N021460</u>	<u>002</u>	Oct 21, 2002
<u>AB</u>	+	<u>5MG; 500MG</u>	<u>N021460</u>	<u>003</u>	Oct 21, 2002

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION

GLUCAGEN

+ NOVO NORDISK EQ 1MG BASE/VIAL N020918 001 Jun 22, 1998

GLUCAGON RECOMBINANT

INJECTABLE; INJECTION

GLUCAGON

+ LILLY 1MG/VIAL N020928 001 Sep 11, 1998

GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

+ NUTRITIONAL RESTART 5GM/PACKET N021667 001 Jun 10, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 194 (of 393)

GLYBURIDE

TABLET; ORAL

GLYBURIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>1.5MG</u>	<u>A075947</u>	<u>001</u>	Nov 14, 2002
<u>AB</u>		<u>3MG</u>	<u>A075947</u>	<u>002</u>	Nov 14, 2002
<u>AB</u>		<u>6MG</u>	<u>A075947</u>	<u>003</u>	Nov 14, 2002
<u>AB</u>	AUROBINDO PHARMA	<u>1.25MG</u>	<u>A077537</u>	<u>001</u>	Oct 18, 2007
<u>AB</u>		<u>2.5MG</u>	<u>A077537</u>	<u>002</u>	Oct 18, 2007
<u>AB</u>		<u>5MG</u>	<u>A077537</u>	<u>003</u>	Oct 18, 2007
<u>AB</u>	COREPHARMA	<u>1.25MG</u>	<u>A076257</u>	<u>001</u>	Jun 27, 2002
<u>AB</u>		<u>2.5MG</u>	<u>A076257</u>	<u>002</u>	Jun 27, 2002
<u>AB</u>		<u>5MG</u>	<u>A076257</u>	<u>003</u>	Jun 27, 2002
<u>AB</u>	TEVA	<u>1.25MG</u>	<u>A074388</u>	<u>001</u>	Aug 29, 1995
<u>AB</u>		<u>2.5MG</u>	<u>A074388</u>	<u>002</u>	Aug 29, 1995
<u>AB</u>	+	<u>5MG</u>	<u>A074388</u>	<u>003</u>	Aug 29, 1995
	<u>GLYBURIDE (MICRONIZED)</u>				
<u>AB</u>	DAVA PHARMS INC	<u>1.5MG</u>	<u>A074591</u>	<u>001</u>	Dec 22, 1997
<u>AB</u>		<u>3MG</u>	<u>A074591</u>	<u>002</u>	Dec 22, 1997
<u>AB</u>		<u>4.5MG</u>	<u>A074591</u>	<u>003</u>	Dec 22, 1997
<u>AB</u>		<u>6MG</u>	<u>A074591</u>	<u>004</u>	Dec 22, 1997
<u>AB</u>	HIKMA	<u>1.5MG</u>	<u>A075890</u>	<u>001</u>	Jul 31, 2003
<u>AB</u>		<u>3MG</u>	<u>A075890</u>	<u>002</u>	Jul 31, 2003
<u>AB</u>		<u>6MG</u>	<u>A075890</u>	<u>003</u>	Jul 31, 2003
<u>AB</u>	MYLAN	<u>1.5MG</u>	<u>A074792</u>	<u>001</u>	Jun 26, 1998
<u>AB</u>		<u>3MG</u>	<u>A074792</u>	<u>002</u>	Jun 26, 1998
<u>AB</u>		<u>6MG</u>	<u>A074792</u>	<u>003</u>	Aug 17, 1999
<u>AB</u>	TEVA	<u>1.5MG</u>	<u>A074686</u>	<u>001</u>	Apr 20, 1999
<u>AB</u>		<u>3MG</u>	<u>A074686</u>	<u>002</u>	Apr 20, 1999
<u>AB</u>		<u>4.5MG</u>	<u>A074686</u>	<u>003</u>	Apr 20, 1999
<u>AB</u>		<u>6MG</u>	<u>A074686</u>	<u>004</u>	Apr 20, 1999
	<u>GLYNASE</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>1.5MG</u>	<u>N020051</u>	<u>001</u>	Mar 04, 1992
<u>AB</u>		<u>3MG</u>	<u>N020051</u>	<u>002</u>	Mar 04, 1992
<u>AB</u>	+	<u>6MG</u>	<u>N020051</u>	<u>004</u>	Sep 24, 1993
	DIABETA				
BX	SANOFI AVENTIS US	1.25MG	N017532	001	May 01, 1984
BX		2.5MG	N017532	002	May 01, 1984
BX	+	5MG	N017532	003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>1.25MG; 250MG</u>	<u>N021178</u>	<u>001</u>	Jul 31, 2000
<u>AB</u>	+	<u>2.5MG; 500MG</u>	<u>N021178</u>	<u>002</u>	Jul 31, 2000
<u>AB</u>		<u>5MG; 500MG</u>	<u>N021178</u>	<u>003</u>	Jul 31, 2000
	<u>GLYBURIDE AND METFORMIN HYDROCHLORIDE</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG; 250MG</u>	<u>A076716</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A076716</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>		<u>5MG; 500MG</u>	<u>A076716</u>	<u>003</u>	Jun 28, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>1.25MG; 250MG</u>	<u>A077870</u>	<u>001</u>	Nov 14, 2007
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A077870</u>	<u>002</u>	Nov 14, 2007
<u>AB</u>		<u>5MG; 500MG</u>	<u>A077870</u>	<u>003</u>	Nov 14, 2007
<u>AB</u>	COREPHARMA	<u>1.25MG; 250MG</u>	<u>A076731</u>	<u>001</u>	Nov 19, 2004
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A076731</u>	<u>002</u>	Nov 19, 2004
<u>AB</u>		<u>5MG; 500MG</u>	<u>A076731</u>	<u>003</u>	Nov 19, 2004
<u>AB</u>	DR REDDYS LABS INC	<u>1.25MG; 250MG</u>	<u>A079009</u>	<u>001</u>	Jun 03, 2009
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A079009</u>	<u>002</u>	Jun 03, 2009
<u>AB</u>		<u>5MG; 500MG</u>	<u>A079009</u>	<u>003</u>	Jun 03, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>1.25MG; 250MG</u>	<u>A076345</u>	<u>001</u>	Feb 18, 2004
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A076345</u>	<u>002</u>	Feb 18, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 195 (of 393)

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

<u>GLYBURIDE AND METFORMIN HYDROCHLORIDE</u>				
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG;500MG</u>	<u>A076345</u>	<u>003</u> Feb 18, 2004
<u>AB</u>	TEVA	<u>1.25MG;250MG</u>	<u>A076821</u>	<u>001</u> Jan 27, 2005
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A076821</u>	<u>002</u> Jan 27, 2005
<u>AB</u>		<u>5MG;500MG</u>	<u>A076821</u>	<u>003</u> Jan 27, 2005

GLYCINE

SOLUTION; IRRIGATION

<u>AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER</u>				
<u>AT</u>	BAXTER HLTHCARE	<u>1.5GM/100ML</u>	<u>N017865</u>	<u>001</u>
<u>GLYCINE 1.5% IN PLASTIC CONTAINER</u>				
<u>AT</u>	B BRAUN	<u>1.5GM/100ML</u>	<u>N016784</u>	<u>001</u>
<u>AT</u>	HOSPIRA	<u>1.5GM/100ML</u>	<u>N018315</u>	<u>001</u>

GLYCOPYRROLATE

INJECTABLE; INJECTION

<u>GLYCOPYRROLATE</u>				
<u>AP</u>	LUITPOLD	<u>0.2MG/ML</u>	<u>A089335</u>	<u>001</u> Jul 23, 1986
<u>ROBINUL</u>				
<u>AP</u>	+ BAXTER HLTHCARE	<u>0.2MG/ML</u>	<u>N017558</u>	<u>001</u>

TABLET; ORAL

<u>GLYCOPYRROLATE</u>				
<u>AA</u>	COREPHARMA	<u>1MG</u>	<u>A040568</u>	<u>001</u> Dec 22, 2004
<u>AA</u>		<u>2MG</u>	<u>A040568</u>	<u>002</u> Dec 22, 2004
<u>AA</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A040847</u>	<u>001</u> Mar 21, 2008
<u>AA</u>		<u>2MG</u>	<u>A040847</u>	<u>002</u> Mar 21, 2008
<u>AA</u>	KALI LABS	<u>1MG</u>	<u>A040653</u>	<u>001</u> Aug 31, 2006
<u>AA</u>		<u>2MG</u>	<u>A040653</u>	<u>002</u> Aug 31, 2006
<u>AA</u>	RANBAXY	<u>1MG</u>	<u>A040844</u>	<u>001</u> Aug 18, 2009
<u>AA</u>		<u>2MG</u>	<u>A040844</u>	<u>002</u> Aug 18, 2009
<u>AA</u>	VINTAGE	<u>1MG</u>	<u>A040821</u>	<u>001</u> Dec 29, 2008
<u>AA</u>		<u>2MG</u>	<u>A040821</u>	<u>002</u> Dec 29, 2008
<u>AA</u>	WEST WARD	<u>1MG</u>	<u>A040836</u>	<u>001</u> Mar 05, 2009
<u>AA</u>		<u>2MG</u>	<u>A040836</u>	<u>002</u> Mar 05, 2009
<u>ROBINUL</u>				
<u>AA</u>	+ SCIELE PHARMA INC	<u>1MG</u>	<u>N012827</u>	<u>001</u>
<u>ROBINUL FORTE</u>				
<u>AA</u>	+ SCIELE PHARMA INC	<u>2MG</u>	<u>N012827</u>	<u>002</u>

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

<u>CHORIONIC GONADOTROPIN</u>				
<u>AP</u>	+ APP PHARMS	<u>10,000 UNITS/VIAL</u>	<u>N017067</u>	<u>002</u>
<u>AP</u>	+ FERRING	<u>10,000 UNITS/VIAL</u>	<u>N017016</u>	<u>007</u>
<u>PREGNYL</u>				
<u>AP</u>	+ ORGANON USA INC	<u>10,000 UNITS/VIAL</u>	<u>N017692</u>	<u>001</u>

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

<u>ZOLADEX</u>				
	+ ASTRAZENECA	EQ 3.6MG BASE	N019726	001 Dec 29, 1989
		EQ 10.8MG BASE	N020578	001 Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

<u>NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN</u>				
<u>AT</u>	+ BAUSCH AND LOMB	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A064047</u>	<u>001</u> Jan 31, 1996

## PRESCRIPTION DRUG PRODUCT LIST

3 - 196 (of 393)

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

<u>AT</u>	PHARMAFORCE	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A065187</u>	<u>001</u>	Oct 28, 2005
-----------	-------------	---	----------------	------------	--------------

NEOSPORIN

<u>AT</u>	+ MONARCH PHARMS	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A060582</u>	<u>001</u>	
-----------	------------------	---	----------------	------------	--

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL

SANCUSO

	+ STRAKAN	3.1MG/24HR	N022198	001	Sep 12, 2008
--	-----------	------------	---------	-----	--------------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A079119</u>	<u>001</u>	Sep 10, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A079078</u>	<u>002</u>	Sep 14, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A079078</u>	<u>001</u>	Sep 14, 2009
<u>AP</u>	APOTEX CORP	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078197</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078198</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078198</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	APP PHARMS	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078522</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078090</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077177</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>	BEDFORD LABS	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A077913</u>	<u>001</u>	Jun 26, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077186</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077187</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	DR REDDYS LABS INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078863</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078880</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	EBEWE PHARMA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078808</u>	<u>001</u>	Apr 29, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078835</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078835</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	SANDOZ	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078534</u>	<u>001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078531</u>	<u>001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078531</u>	<u>002</u>	Apr 30, 2009
<u>AP</u>	TEVA PARENTERAL	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078392</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077963</u>	<u>001</u>	Jan 03, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077297</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	WATSON LABS	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078262</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078258</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078258</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	WOCKHARDT USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078566</u>	<u>001</u>	Feb 29, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078564</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078565</u>	<u>001</u>	Jun 30, 2008
		<u>GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE</u>			
<u>AP</u>	APP PHARMS	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078096</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	DR REDDYS LABS INC	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078863</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	TEVA PARENTERAL	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077165</u>	<u>001</u>	Dec 31, 2007
		<u>GRANISTERON HYDROCHLORIDE</u>			
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078629</u>	<u>001</u>	Dec 23, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078629</u>	<u>002</u>	Dec 23, 2009
		<u>KYTRIL</u>			
<u>AP</u>	+ ROCHE	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>N020239</u>	<u>003</u>	Sep 17, 2004
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>N020239</u>	<u>004</u>	Mar 11, 1994
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N020239</u>	<u>002</u>	Mar 11, 1994

SOLUTION; ORAL

GRANISETRON HYDROCHLORIDE

	+ CYPRESS PHARM	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008
--	-----------------	------------------	---------	-----	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 223 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 197 (of 393)

GRANISETRON HYDROCHLORIDE

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 1MG BASE</u>	<u>A078843</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>	BARR	<u>EQ 1MG BASE</u>	<u>A078221</u>	<u>001</u>	Dec 31, 2007
<u>AB</u>	CIPLA LTD	<u>EQ 1MG BASE</u>	<u>A078037</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>	COREPHARMA	<u>EQ 1MG BASE</u>	<u>A078260</u>	<u>001</u>	Dec 31, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 1MG BASE</u>	<u>A078846</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A078725</u>	<u>001</u>	Jan 30, 2008
<u>AB</u>	NATCO PHARMA	<u>EQ 1MG BASE</u>	<u>A078969</u>	<u>001</u>	Jun 22, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A078678</u>	<u>001</u>	Feb 13, 2008
<u>AB</u>	ROXANE	<u>EQ 1MG BASE</u>	<u>A077842</u>	<u>001</u>	Dec 31, 2007
<u>AB</u>	TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078080</u>	<u>001</u>	Dec 31, 2007
<u>KYTRIL</u>					
<u>AB</u>	+ ROCHE	<u>EQ 1MG BASE</u>	<u>N020305</u>	<u>001</u>	Mar 16, 1995

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

<u>AB</u>	+ ORTHONEUTROGENA	<u>125MG/5ML</u>	<u>A062483</u>	<u>001</u>	Jan 26, 1984
<u>GRISEOFULVIN</u>					
<u>AB</u>	ACTAVIS MID ATLANTIC	<u>125MG/5ML</u>	<u>A065394</u>	<u>001</u>	Jul 06, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>125MG/5ML</u>	<u>A065354</u>	<u>001</u>	Sep 10, 2007
<u>AB</u>	PERRIGO CO TENNESSEE	<u>125MG/5ML</u>	<u>A065200</u>	<u>001</u>	Mar 02, 2005

TABLET; ORAL

## GRIFULVIN V

	+ ORTHONEUTROGENA	500MG	A062279	003	
--	-------------------	-------	---------	-----	--

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

## GRIS-PEG

	PEDINOL	125MG	N050475	001	
	+	250MG	N050475	002	

GUANABENZ ACETATE

TABLET; ORAL

## GUANABENZ ACETATE

	IVAX SUB TEVA PHARMS	EQ 4MG BASE	A074149	001	Apr 07, 1995
	+	EQ 8MG BASE	A074149	002	Apr 07, 1995

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>EQ 1MG BASE</u>	<u>A074673</u>	<u>001</u>	Feb 28, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074673</u>	<u>002</u>	Feb 28, 1997
<u>AB</u>	AMNEAL PHARM	<u>EQ 1MG BASE</u>	<u>A075109</u>	<u>001</u>	Nov 25, 1998
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075109</u>	<u>002</u>	Nov 25, 1998
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A074796</u>	<u>001</u>	Jan 27, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074796</u>	<u>002</u>	Jan 27, 1997
<u>AB</u>	WATSON LABS	<u>EQ 1MG BASE</u>	<u>A074145</u>	<u>001</u>	Oct 17, 1995
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074145</u>	<u>002</u>	Oct 17, 1995
<u>TENEX</u>					
<u>AB</u>	PROMIUS PHARMA	<u>EQ 1MG BASE</u>	<u>N019032</u>	<u>001</u>	Oct 27, 1986
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N019032</u>	<u>002</u>	Nov 07, 1988

TABLET, EXTENDED RELEASE; ORAL

## INTUNIV

	SHIRE	EQ 1MG BASE	N022037	001	Sep 02, 2009
		EQ 2MG BASE	N022037	002	Sep 02, 2009
		EQ 3MG BASE	N022037	003	Sep 02, 2009



## PRESCRIPTION DRUG PRODUCT LIST

3 - 198 (of 393)

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

INTUNIV

+ SHIRE EQ 4MG BASE N022037 004 Sep 02, 2009

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

GUANIDINE HYDROCHLORIDE

SCHERING 125MG N001546 001

HALCINONIDE

CREAM; TOPICAL

HALOG

+ RANBAXY 0.1% N017556 001

OINTMENT; TOPICAL

HALOG

+ RANBAXY 0.1% N017824 001

SOLUTION; TOPICAL

HALOG

RANBAXY 0.1% N017823 001

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATEAB ALTANA 0.05% A077001 001 Dec 16, 2004AB G AND W LABS 0.05% A078162 001 Apr 24, 2007AB PERRIGO ISRAEL 0.05% A077123 001 Dec 16, 2004AB TARO 0.05% A077227 001 Aug 04, 2005ULTRAVATEAB + RANBAXY 0.05% N019967 001 Dec 27, 1990

OINTMENT; TOPICAL

HALOBETASOL PROPIONATEAB ACTAVIS MID ATLANTIC 0.05% A077109 001 Jun 14, 2005AB ALTANA 0.05% A076903 001 Dec 16, 2004AB G AND W LABS 0.05% A077721 001 Sep 07, 2006AB PERRIGO 0.05% A076872 001 Dec 16, 2004AB TARO 0.05% A076994 001 Dec 16, 2004ULTRAVATEAB + RANBAXY 0.05% N019968 001 Dec 17, 1990HALOPERIDOL

TABLET; ORAL

HALOPERIDOLAB MYLAN 0.5MG A070278 006 Jun 10, 1986AB 1MG A070278 004 Jun 10, 1986AB 2MG A070278 001 Jun 10, 1986AB 5MG A070278 005 Jun 10, 1986AB 10MG A070278 002 Jul 16, 2009AB 20MG A070278 003 Jul 16, 2009AB SANDOZ 0.5MG A071206 001 Nov 17, 1986AB 1MG A071207 001 Nov 17, 1986AB + 2MG A071208 001 Nov 17, 1986AB 5MG A071209 001 Nov 17, 1986AB 10MG A071210 001 Mar 11, 1988AB 20MG A071211 001 Mar 11, 1988AB ZYDUS PHARMS USA 5MG A077580 003 Nov 29, 2007AB 10MG A077580 004 Nov 29, 2007AB 20MG A077580 005 Nov 29, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 199 (of 393)

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL

<u>AO</u>	+ ORTHO MCNEIL JANSSEN	<u>EQ 50MG BASE/ML</u>	<u>N018701</u>	<u>001</u>	Jan 14, 1986
<u>AO</u>	+	<u>EQ 100MG BASE/ML</u>	<u>N018701</u>	<u>002</u>	Jan 31, 1997
<u>HALOPERIDOL DECANOATE</u>					
<u>AO</u>	APOTEX INC	<u>EQ 50MG BASE/ML</u>	<u>A075440</u>	<u>001</u>	Feb 28, 2000
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075440</u>	<u>002</u>	Feb 28, 2000
<u>AO</u>	APP PHARMS	<u>EQ 50MG BASE/ML</u>	<u>A074893</u>	<u>001</u>	Dec 19, 1997
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A074893</u>	<u>002</u>	Dec 19, 1997
<u>AO</u>	BEDFORD	<u>EQ 50MG BASE/ML</u>	<u>A074811</u>	<u>001</u>	Jan 30, 1998
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075305</u>	<u>001</u>	Sep 28, 1998
<u>AO</u>	TEVA PARENTERAL	<u>EQ 50MG BASE/ML</u>	<u>A075393</u>	<u>001</u>	May 11, 1999
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075393</u>	<u>002</u>	May 11, 1999

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

<u>AA</u>	PHARM ASSOC	<u>EQ 2MG BASE/ML</u>	<u>A073037</u>	<u>001</u>	Feb 26, 1993
<u>AA</u>	SILARX	<u>EQ 2MG BASE/ML</u>	<u>A073364</u>	<u>001</u>	Sep 28, 1993
<u>AA</u>	+ TEVA PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A071617</u>	<u>001</u>	Dec 01, 1988

INJECTABLE; INJECTION

HALDOL

<u>AP</u>	+ ORTHO MCNEIL JANSSEN	<u>EQ 5MG BASE/ML</u>	<u>N015923</u>	<u>001</u>	
<u>HALOPERIDOL</u>					
<u>AP</u>	AKORN STRIDES	<u>EQ 5MG BASE/ML</u>	<u>A078347</u>	<u>001</u>	Sep 14, 2009
<u>AP</u>	APOTEX INC	<u>EQ 5MG BASE/ML</u>	<u>A076791</u>	<u>001</u>	Aug 25, 2004
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A076828</u>	<u>001</u>	Aug 25, 2004
<u>AP</u>	APP PHARMS	<u>EQ 5MG BASE/ML</u>	<u>A075689</u>	<u>001</u>	Mar 09, 2001
<u>AP</u>	BEDFORD	<u>EQ 5MG BASE/ML</u>	<u>A075858</u>	<u>001</u>	Jun 18, 2001
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 5MG BASE/ML</u>	<u>A076774</u>	<u>001</u>	Aug 25, 2004
<u>AP</u>	TEVA PARENTERAL	<u>EQ 5MG BASE/ML</u>	<u>A076035</u>	<u>001</u>	Aug 29, 2001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>	+ APP PHARMS	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>001</u>	
<u>AP</u>	+	<u>5,000 UNITS/ML</u>	<u>N017651</u>	<u>006</u>	
<u>AP</u>	+	<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>003</u>	
<u>AP</u>	+	<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>004</u>	
<u>AP</u>	+ BAXTER HLTHCARE	<u>1,000 UNITS/ML</u>	<u>N017037</u>	<u>001</u>	
<u>AP</u>	+	<u>5,000 UNITS/ML</u>	<u>N017037</u>	<u>002</u>	
<u>AP</u>	+	<u>10,000 UNITS/ML</u>	<u>N017037</u>	<u>003</u>	
<u>AP</u>	HOSPIRA	<u>5,000 UNITS/ML</u>	<u>A088100</u>	<u>001</u>	Apr 28, 1983
<u>AP</u>	HOSPIRA INC	<u>1,000 UNITS/ML</u>	<u>A090571</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A090571</u>	<u>002</u>	Aug 31, 2009
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A090571</u>	<u>003</u>	Aug 31, 2009
<u>HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609</u>	<u>001</u>	Apr 28, 1982
<u>HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>200 UNITS/100ML</u>	<u>N019953</u>	<u>001</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916</u>	<u>010</u>	Jun 23, 1989
<u>HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	HOSPIRA	<u>10,000 UNITS/100ML</u>	<u>N019339</u>	<u>003</u>	Mar 27, 1985
<u>HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609</u>	<u>002</u>	Apr 28, 1982
<u>HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916</u>	<u>011</u>	Jun 23, 1989
<u>HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>4,000 UNITS/100ML</u>	<u>N018814</u>	<u>001</u>	Oct 31, 1983

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 226 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 200 (of 393)

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>4,000 UNITS/100ML</u>	<u>N019952</u>	<u>001</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>4,000 UNITS/100ML</u>	<u>N019805</u>	<u>001</u>	Jan 25, 1989

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5,000 UNITS/100ML</u>	<u>N018814</u>	<u>003</u>	Jul 09, 1985
<u>AP</u>		<u>10,000 UNITS/100ML</u>	<u>N018814</u>	<u>004</u>	Jul 02, 1987

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>5,000 UNITS/100ML</u>	<u>N019952</u>	<u>004</u>	Jul 20, 1992
<u>AP</u>		<u>10,000 UNITS/100ML</u>	<u>N019952</u>	<u>005</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>5,000 UNITS/100ML</u>	<u>N019339</u>	<u>004</u>	Mar 27, 1985
<u>AP</u>		<u>5,000 UNITS/100ML</u>	<u>N019805</u>	<u>002</u>	Jan 25, 1989
<u>AP</u>		<u>10,000 UNITS/100ML</u>	<u>N019339</u>	<u>002</u>	Mar 27, 1985

HEPARIN SODIUM IN PLASTIC CONTAINER

<u>AP</u>	+ APP PHARMS	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>013</u>	Dec 05, 1985
<u>AP</u>	+	<u>5,000 UNITS/ML</u>	<u>N017029</u>	<u>014</u>	Dec 05, 1985
<u>AP</u>	+	<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>015</u>	Dec 05, 1985
<u>AP</u>	+	<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>016</u>	Dec 05, 1985

HEPARIN SODIUM PRESERVATIVE FREE

<u>AP</u>	+ APP PHARMS	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>010</u>	Apr 28, 1986
<u>AP</u>	+ HOSPIRA	<u>10,000 UNITS/ML</u>	<u>A089522</u>	<u>001</u>	May 04, 1987

## HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	5,000 UNITS/100ML	N019339	001	Mar 27, 1985
--	---------	-------------------	---------	-----	--------------

## HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	HOSPIRA	5,000 UNITS/100ML	N018916	006	Jan 31, 1984
--	---------	-------------------	---------	-----	--------------

## HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	HOSPIRA	5,000 UNITS/100ML	N018916	007	Jan 31, 1984
		10,000 UNITS/100ML	N018916	008	Jan 31, 1984

## HEPARIN SODIUM PRESERVATIVE FREE

	+ HOSPIRA	2,000 UNITS/ML	N005264	013	Apr 07, 1986
	+	2,500 UNITS/ML	N005264	014	Apr 07, 1986

HEXACHLOROPHENE

EMULSION; TOPICAL

PHISOHEX

	+ SANOFI AVENTIS US	3%	N006882	001	
--	---------------------	----	---------	-----	--

SPONGE; TOPICAL

PRE-OP

<u>AT</u>	+ DAVIS AND GECK	<u>480MG</u>	<u>N017433</u>	<u>001</u>	
-----------	------------------	--------------	----------------	------------	--

PRE-OP II

<u>AT</u>	DAVIS AND GECK	<u>480MG</u>	<u>N017433</u>	<u>002</u>	
-----------	----------------	--------------	----------------	------------	--

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

	+ ENDO PHARM	50MG	N022058	001	May 03, 2007
--	--------------	------	---------	-----	--------------

VANTAS

	+ ENDO PHARM	50MG	N021732	001	Oct 12, 2004
--	--------------	------	---------	-----	--------------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>1.5MG/5ML;5MG/5ML</u>	<u>A088017</u>	<u>001</u>	Jul 05, 1983
<u>AA</u>	+ HI TECH PHARMA	<u>1.5MG/5ML;5MG/5ML</u>	<u>A040613</u>	<u>001</u>	Feb 08, 2008
<u>AA</u>	MORTON GROVE	<u>1.5MG/5ML;5MG/5ML</u>	<u>A088008</u>	<u>001</u>	Mar 03, 1983

TABLET; ORAL

TUSSIGON

	+ KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985
--	---------------	-----------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 201 (of 393)

HYALURONIDASE

INJECTABLE; INJECTION

AMPHADASE

+ AMPHASTAR PHARM	150 UNITS/ML	N021665	001	Oct 26, 2004
HYDASE				
+ PRIMAPHARM	150 UNITS/ML	N021716	001	Oct 25, 2005
VITRASE				
+ ISTA PHARMS	200 UNITS/VIAL	N021640	002	Dec 02, 2004

HYALURONIDASE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HYLENEX RECOMBINANT

+ HALOZYME THERAP	150 UNITS/ML	N021859	001	Dec 02, 2005
-------------------	--------------	---------	-----	--------------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

<u>AP</u>	AKORN	<u>20MG/ML</u>	<u>A040730</u>	<u>001</u>	Apr 21, 2009
<u>AP</u>	APP PHARMS	<u>20MG/ML</u>	<u>A040388</u>	<u>001</u>	Mar 13, 2001
<u>AP</u>	+ LUITPOLD	<u>20MG/ML</u>	<u>A040136</u>	<u>001</u>	Jun 30, 1997

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

<u>AA</u>	GLENMARK PHARMS LTD	<u>10MG</u>	<u>A090527</u>	<u>001</u>	May 27, 2009
<u>AA</u>		<u>25MG</u>	<u>A090527</u>	<u>002</u>	May 27, 2009
<u>AA</u>		<u>50MG</u>	<u>A090527</u>	<u>003</u>	May 27, 2009
<u>AA</u>		<u>100MG</u>	<u>A090527</u>	<u>004</u>	May 27, 2009
<u>AA</u>	HERITAGE PHARMS INC	<u>25MG</u>	<u>A086242</u>	<u>003</u>	
<u>AA</u>		<u>50MG</u>	<u>A086242</u>	<u>002</u>	
<u>AA</u>	HETERO DRUGS LTD	<u>10MG</u>	<u>A040901</u>	<u>001</u>	Sep 12, 2008
<u>AA</u>		<u>25MG</u>	<u>A040901</u>	<u>002</u>	Sep 12, 2008
<u>AA</u>		<u>50MG</u>	<u>A040901</u>	<u>003</u>	Sep 12, 2008
<u>AA</u>		<u>100MG</u>	<u>A040901</u>	<u>004</u>	Sep 12, 2008
<u>AA</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090255</u>	<u>001</u>	Dec 15, 2008
<u>AA</u>		<u>25MG</u>	<u>A090255</u>	<u>002</u>	Dec 15, 2008
<u>AA</u>		<u>50MG</u>	<u>A090255</u>	<u>003</u>	Dec 15, 2008
<u>AA</u>		<u>100MG</u>	<u>A090255</u>	<u>004</u>	Dec 15, 2008
<u>AA</u>	PAR PHARM	<u>10MG</u>	<u>A087836</u>	<u>001</u>	Oct 05, 1982
<u>AA</u>		<u>25MG</u>	<u>A086961</u>	<u>002</u>	
<u>AA</u>		<u>50MG</u>	<u>A086962</u>	<u>001</u>	
<u>AA</u>		<u>100MG</u>	<u>A088391</u>	<u>001</u>	Sep 27, 1983
<u>AA</u>	+ PLIVA	<u>10MG</u>	<u>A089097</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	+	<u>25MG</u>	<u>A088467</u>	<u>001</u>	May 01, 1984
<u>AA</u>	+	<u>50MG</u>	<u>A088468</u>	<u>001</u>	May 01, 1984
<u>AA</u>	+	<u>100MG</u>	<u>A089098</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	WATSON LABS	<u>25MG</u>	<u>A084504</u>	<u>001</u>	
<u>AA</u>		<u>50MG</u>	<u>A084503</u>	<u>001</u>	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRA-ZIDE

PAR PHARM	25MG; 25MG	A088957	001	Oct 21, 1985
+	50MG; 50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

+ NITROMED	37.5MG; 20MG	N020727	001	Jun 23, 2005
------------	--------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 202 (of 393)

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX	<u>12.5MG</u>	<u>A078389</u>	<u>001</u>	May 16, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG</u>	<u>A078164</u>	<u>001</u>	Sep 18, 2007
<u>AB</u>	CADISTA PHARMS	<u>12.5MG</u>	<u>A078391</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A079237</u>	<u>001</u>	Apr 02, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG</u>	<u>A077005</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A075640</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>	VINTAGE PHARMS	<u>12.5MG</u>	<u>A075907</u>	<u>001</u>	Sep 17, 2002
<u>AB</u>	WEST WARD	<u>12.5MG</u>	<u>A077885</u>	<u>001</u>	Nov 26, 2007

MICROZIDE

<u>AB</u>	+ WATSON LABS	<u>12.5MG</u>	<u>N020504</u>	<u>001</u>	Dec 27, 1996
-----------	---------------	---------------	----------------	------------	--------------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>12.5MG</u>	<u>A040707</u>	<u>001</u>	Feb 27, 2007
<u>AB</u>		<u>25MG</u>	<u>A085054</u>	<u>002</u>	
<u>AB</u>		<u>50MG</u>	<u>A085208</u>	<u>001</u>	
<u>AB</u>	APOTEX	<u>25MG</u>	<u>A040774</u>	<u>001</u>	Oct 03, 2007
<u>AB</u>		<u>50MG</u>	<u>A040774</u>	<u>002</u>	Oct 03, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A040780</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040780</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A040809</u>	<u>001</u>	Sep 04, 2007
<u>AB</u>		<u>50MG</u>	<u>A040809</u>	<u>002</u>	Sep 04, 2007
<u>AB</u>	CARACO	<u>12.5MG</u>	<u>A040857</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>25MG</u>	<u>A040810</u>	<u>001</u>	Mar 27, 2007
<u>AB</u>		<u>50MG</u>	<u>A040810</u>	<u>002</u>	Mar 27, 2007
<u>AB</u>	DAVA PHARMS INC	<u>25MG</u>	<u>A087059</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A087068</u>	<u>001</u>	
<u>AB</u>	EXCELLIUM	<u>25MG</u>	<u>A040702</u>	<u>001</u>	Mar 16, 2007
<u>AB</u>		<u>50MG</u>	<u>A040702</u>	<u>002</u>	Mar 16, 2007
<u>AB</u>	HERITAGE PHARMS INC	<u>25MG</u>	<u>A085182</u>	<u>002</u>	
<u>AB</u>		<u>50MG</u>	<u>A085182</u>	<u>001</u>	
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A040807</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>25MG</u>	<u>A040807</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040807</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A083177</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A083177</u>	<u>002</u>	
<u>AB</u>	LANNETT	<u>25MG</u>	<u>A084325</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084324</u>	<u>001</u>	
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A040770</u>	<u>001</u>	Jan 23, 2007
<u>AB</u>		<u>25MG</u>	<u>A040735</u>	<u>002</u>	Jan 23, 2007
<u>AB</u>	+ SANDOZ	<u>50MG</u>	<u>A040735</u>	<u>003</u>	Jan 23, 2007
<u>AB</u>		<u>50MG</u>	<u>A085219</u>	<u>001</u>	
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A040907</u>	<u>001</u>	Aug 15, 2008
<u>AB</u>		<u>50MG</u>	<u>A040907</u>	<u>002</u>	Aug 15, 2008
<u>AB</u>	VINTAGE PHARMS	<u>25MG</u>	<u>A040412</u>	<u>001</u>	Mar 29, 2002
<u>AB</u>		<u>50MG</u>	<u>A040412</u>	<u>002</u>	Mar 29, 2002
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A081189</u>	<u>001</u>	Jan 24, 1992
<u>AB</u>	WEST WARD	<u>25MG</u>	<u>A084878</u>	<u>002</u>	Jul 12, 2006
<u>AB</u>		<u>50MG</u>	<u>A084878</u>	<u>001</u>	
	<u>ORETIC</u>				
<u>AB</u>	ABBOTT	<u>50MG</u>	<u>N011971</u>	<u>002</u>	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

	SANOFI AVENTIS US	12.5MG;150MG	N020758	002	Sep 30, 1997
		12.5MG;300MG	N020758	003	Aug 31, 1998
+		25MG;300MG	N020758	004	Mar 15, 2005

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 229 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 203 (of 393)

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>12.5MG;10MG</u>	<u>A076230</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076230</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076230</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	APOTEX INC	<u>12.5MG;10MG</u>	<u>A076674</u>	<u>001</u>	Oct 05, 2004
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076674</u>	<u>002</u>	Oct 05, 2004
<u>AB</u>		<u>25MG;20MG</u>	<u>A076674</u>	<u>003</u>	Oct 05, 2004
<u>AB</u>	AUROBINDO	<u>12.5MG;10MG</u>	<u>A077606</u>	<u>001</u>	Mar 14, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077606</u>	<u>002</u>	Mar 14, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077606</u>	<u>003</u>	Mar 14, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG;10MG</u>	<u>A075776</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A075776</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A075776</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	LUPIN	<u>12.5MG;10MG</u>	<u>A077912</u>	<u>001</u>	Sep 27, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077912</u>	<u>002</u>	Sep 27, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077912</u>	<u>003</u>	Sep 27, 2006
<u>AB</u>	MYLAN	<u>12.5MG;10MG</u>	<u>A076113</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076113</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076113</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	RANBAXY	<u>12.5MG;10MG</u>	<u>A076007</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076007</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076007</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>12.5MG;10MG</u>	<u>A076262</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076262</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076262</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	TEVA	<u>12.5MG;10MG</u>	<u>A075869</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A075869</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A075869</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>12.5MG;10MG</u>	<u>A076194</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076194</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076194</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>	WEST WARD	<u>12.5MG;10MG</u>	<u>A076265</u>	<u>001</u>	Jul 08, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076265</u>	<u>002</u>	Jul 08, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076265</u>	<u>003</u>	Jul 08, 2002
	<u>PRINZIDE</u>				
<u>AB</u>	MERCK	<u>12.5MG;10MG</u>	<u>N019778</u>	<u>003</u>	Nov 18, 1993
<u>AB</u>		<u>12.5MG;20MG</u>	<u>N019778</u>	<u>001</u>	Feb 16, 1989
	<u>ZESTORETIC</u>				
<u>AB</u>	ASTRAZENECA	<u>12.5MG;10MG</u>	<u>N019888</u>	<u>003</u>	Nov 18, 1993
<u>AB</u>	+	<u>12.5MG;20MG</u>	<u>N019888</u>	<u>001</u>	Sep 20, 1990
<u>AB</u>	+	<u>25MG;20MG</u>	<u>N019888</u>	<u>002</u>	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

	MERCK	12.5MG;50MG	N020387	001	Apr 28, 1995
		12.5MG;100MG	N020387	003	Oct 20, 2005
	+	25MG;100MG	N020387	002	Nov 10, 1998

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	MYLAN	15MG;250MG	A070264	001	Jan 23, 1986
	+	25MG;250MG	A070265	001	Jan 23, 1986

## PRESCRIPTION DRUG PRODUCT LIST

3 - 204 (of 393)

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

<u>AB</u>	NOVARTIS	<u>25MG;50MG</u>	<u>N018303</u>	<u>001</u>	Dec 31, 1984
<u>AB</u>	+	<u>25MG;100MG</u>	<u>N018303</u>	<u>002</u>	Dec 31, 1984
		<u>METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE</u>			
<u>AB</u>	MYLAN	<u>25MG;50MG</u>	<u>A076792</u>	<u>001</u>	Aug 20, 2004
<u>AB</u>		<u>25MG;100MG</u>	<u>A076792</u>	<u>002</u>	Aug 20, 2004
<u>AB</u>		<u>50MG;100MG</u>	<u>A076792</u>	<u>003</u>	Aug 20, 2004

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	PADDOCK	<u>12.5MG;7.5MG</u>	<u>A090096</u>	<u>001</u>	Sep 25, 2008
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A090096</u>	<u>002</u>	Sep 25, 2008
<u>AB</u>		<u>25MG;15MG</u>	<u>A090096</u>	<u>003</u>	Sep 25, 2008
<u>AB</u>	TEVA	<u>12.5MG;7.5MG</u>	<u>A076980</u>	<u>001</u>	Mar 07, 2007
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A076980</u>	<u>003</u>	Mar 07, 2007
<u>AB</u>		<u>25MG;15MG</u>	<u>A076980</u>	<u>002</u>	Mar 07, 2007
		<u>UNIRETIC</u>			
<u>AB</u>	SCHWARZ PHARMA	<u>12.5MG;7.5MG</u>	<u>N020729</u>	<u>001</u>	Jun 27, 1997
<u>AB</u>		<u>12.5MG;15MG</u>	<u>N020729</u>	<u>003</u>	Feb 14, 2002
<u>AB</u>	+	<u>25MG;15MG</u>	<u>N020729</u>	<u>002</u>	Jun 27, 1997

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

	DAIICHI SANKYO	12.5MG;20MG	N021532	002	Jun 05, 2003
		12.5MG;40MG	N021532	003	Jun 05, 2003
	+	25MG;40MG	N021532	005	Jun 05, 2003

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

<u>AB</u>	AKRIMAX PHARMS	<u>25MG;40MG</u>	<u>N018031</u>	<u>001</u>	
		<u>PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE</u>			
<u>AB</u>	MYLAN	<u>25MG;40MG</u>	<u>A070946</u>	<u>001</u>	Mar 04, 1987
<u>AB</u>	+	<u>25MG;80MG</u>	<u>A070947</u>	<u>001</u>	Apr 01, 1987
<u>AB</u>	PLIVA	<u>25MG;40MG</u>	<u>A072042</u>	<u>001</u>	Mar 14, 1988
<u>AB</u>		<u>25MG;80MG</u>	<u>A072043</u>	<u>001</u>	Mar 14, 1988
<u>AB</u>	WATSON LABS	<u>25MG;40MG</u>	<u>A070301</u>	<u>001</u>	Apr 18, 1986
<u>AB</u>		<u>25MG;80MG</u>	<u>A070305</u>	<u>001</u>	Apr 18, 1986

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

<u>AB</u>	PFIZER PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>N020125</u>	<u>001</u>	Dec 28, 1999
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>N020125</u>	<u>002</u>	Dec 28, 1999
<u>AB</u>	+	<u>25MG;EQ 20MG BASE</u>	<u>N020125</u>	<u>003</u>	Dec 28, 1999
		<u>QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE</u>			
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG;EQ 10MG BASE</u>	<u>A078450</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A078450</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A078450</u>	<u>003</u>	Aug 24, 2007
<u>AB</u>	MYLAN	<u>12.5MG;EQ 10MG BASE</u>	<u>A077093</u>	<u>001</u>	Mar 28, 2005
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A077093</u>	<u>002</u>	Mar 28, 2005
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A077093</u>	<u>003</u>	Mar 28, 2005
<u>AB</u>	RANBAXY	<u>12.5MG;EQ 10MG BASE</u>	<u>A078211</u>	<u>001</u>	Mar 04, 2009
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A078211</u>	<u>002</u>	Mar 04, 2009
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A078211</u>	<u>003</u>	Mar 04, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 205 (of 393)

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINARETIC

<u>AB</u>	ACTAVIS TOTOWA	<u>12.5MG;EQ 10MG BASE</u>	<u>A076374</u>	<u>001</u>	Mar 31, 2004
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A076374</u>	<u>002</u>	Mar 31, 2004
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A076374</u>	<u>003</u>	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

<u>AB</u>	GD SEARLE LLC	<u>25MG;25MG</u>	<u>N012616</u>	<u>004</u>	Dec 30, 1982
		<u>SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE</u>			
<u>AB</u>	MUTUAL PHARM	<u>25MG;25MG</u>	<u>A089534</u>	<u>001</u>	Jul 02, 1987
<u>AB</u>	MYLAN	<u>25MG;25MG</u>	<u>A086513</u>	<u>001</u>	
<u>AB</u>	WATSON LABS	<u>25MG;25MG</u>	<u>A087398</u>	<u>001</u>	
	ALDACTAZIDE				
	+ GD SEARLE LLC	50MG;50MG	N012616	005	Dec 30, 1982

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

## MICARDIS HCT

	BOEHRINGER INGELHEIM	12.5MG;40MG	N021162	001	Nov 17, 2000
		12.5MG;80MG	N021162	002	Nov 17, 2000
	+	25MG;80MG	N021162	003	Apr 19, 2004

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

<u>AB</u>	+ GLAXOSMITHKLINE	<u>25MG;37.5MG</u>	<u>N016042</u>	<u>003</u>	Mar 03, 1994
		<u>TRIAMTERENE AND HYDROCHLOROTHIAZIDE</u>			
<u>AB</u>	DURAMED PHARMS BARR	<u>25MG;37.5MG</u>	<u>A075052</u>	<u>001</u>	Jun 18, 1999
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG;50MG</u>	<u>A074259</u>	<u>001</u>	Mar 30, 1995
<u>AB</u>	MYLAN	<u>25MG;37.5MG</u>	<u>A074701</u>	<u>001</u>	Jun 07, 1996
<u>AB</u>	SANDOZ	<u>25MG;37.5MG</u>	<u>A074821</u>	<u>001</u>	Jun 05, 1997
<u>AB</u>	+	<u>25MG;50MG</u>	<u>A073191</u>	<u>001</u>	Jul 31, 1991

TABLET; ORAL

MAXZIDE

<u>AB</u>	+ MYLAN BERTEK	<u>50MG;75MG</u>	<u>N019129</u>	<u>001</u>	Oct 22, 1984
		<u>MAXZIDE-25</u>			
<u>AB</u>	MYLAN BERTEK	<u>25MG;37.5MG</u>	<u>N019129</u>	<u>003</u>	May 13, 1988
		<u>TRIAMTERENE AND HYDROCHLOROTHIAZIDE</u>			
<u>AB</u>	APOTEX INC	<u>25MG;37.5MG</u>	<u>A071251</u>	<u>002</u>	May 05, 1998
<u>AB</u>		<u>50MG;75MG</u>	<u>A071251</u>	<u>001</u>	Apr 17, 1988
<u>AB</u>	PLIVA	<u>25MG;37.5MG</u>	<u>A074026</u>	<u>001</u>	Apr 26, 1996
<u>AB</u>		<u>50MG;75MG</u>	<u>A073467</u>	<u>001</u>	Jan 31, 1996
<u>AB</u>	SANDOZ	<u>25MG;37.5MG</u>	<u>A073281</u>	<u>001</u>	Apr 30, 1992
<u>AB</u>		<u>50MG;75MG</u>	<u>A072011</u>	<u>001</u>	Jun 17, 1988
<u>AB</u>	WATSON LABS	<u>25MG;37.5MG</u>	<u>A073449</u>	<u>001</u>	Sep 23, 1993
<u>AB</u>		<u>50MG;75MG</u>	<u>A071851</u>	<u>001</u>	Nov 30, 1988
<u>AB</u>		<u>50MG;75MG</u>	<u>A071969</u>	<u>001</u>	Apr 17, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

## DIOVAN HCT

	NOVARTIS	12.5MG;80MG	N020818	001	Mar 06, 1998
		12.5MG;160MG	N020818	002	Mar 06, 1998
		12.5MG;320MG	N020818	004	Apr 28, 2006
		25MG;160MG	N020818	003	Jan 17, 2002
	+	25MG;320MG	N020818	005	Apr 28, 2006



## PRESCRIPTION DRUG PRODUCT LIST

3 - 206 (of 393)

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

<u>AB</u>	AMNEAL PHARMS NY	<u>5MG;200MG</u>	<u>A076642</u>	<u>002</u>	Mar 18, 2004
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A076642</u>	<u>001</u>	Oct 12, 2004
<u>AB</u>	TEVA	<u>7.5MG;200MG</u>	<u>A076023</u>	<u>001</u>	Apr 11, 2003
<u>AB</u>	VINTAGE PHARMS	<u>5MG;200MG</u>	<u>A077727</u>	<u>001</u>	Nov 06, 2006
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A077723</u>	<u>001</u>	Nov 06, 2006
<u>AB</u>		<u>10MG;200MG</u>	<u>A077723</u>	<u>002</u>	Nov 06, 2006
<u>AB</u>	WATSON LABS FLORIDA	<u>7.5MG;200MG</u>	<u>A076604</u>	<u>001</u>	Dec 31, 2003
<u>VICOPROFEN</u>					
<u>AB</u>	+ ABBOTT	<u>7.5MG;200MG</u>	<u>N020716</u>	<u>001</u>	Sep 23, 1997
	REPRESXAIN				
	AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007
		10MG;200MG	A076642	004	Oct 19, 2007

HYDROCORTISONE

CREAM; TOPICAL

ALA-CORT

<u>AT</u>	DEL RAY LABS	<u>1%</u>	<u>A080706</u>	<u>006</u>	
<u>ANUSOL HC</u>					
<u>AT</u>	SALIX PHARMS	<u>2.5%</u>	<u>A088250</u>	<u>001</u>	Jun 06, 1984
<u>HYDROCORTISONE</u>					
<u>AT</u>	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087795</u>	<u>001</u>	May 03, 1983
<u>AT</u>		<u>2.5%</u>	<u>A089682</u>	<u>001</u>	Mar 10, 1988
<u>AT</u>	FOUGERA	<u>1%</u>	<u>A080693</u>	<u>003</u>	
<u>AT</u>		<u>2.5%</u>	<u>A089414</u>	<u>001</u>	Dec 16, 1986
<u>AT</u>	PERRIGO NEW YORK	<u>2.5%</u>	<u>A085025</u>	<u>001</u>	
<u>AT</u>	TARO	<u>1%</u>	<u>A086155</u>	<u>001</u>	
<u>AT</u>		<u>2.5%</u>	<u>A088799</u>	<u>001</u>	Nov 09, 1984
<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040503</u>	<u>001</u>	Mar 12, 2004
<u>HYTONE</u>					
<u>AT</u>	+ SANOFI AVENTIS US	<u>1%</u>	<u>A080472</u>	<u>003</u>	
<u>AT</u>		<u>2.5%</u>	<u>A080472</u>	<u>004</u>	
<u>SYNACORT</u>					
<u>AT</u>	MEDICIS	<u>1%</u>	<u>A087458</u>	<u>001</u>	
<u>AT</u>		<u>2.5%</u>	<u>A087457</u>	<u>001</u>	

ENEMA; RECTAL

COLOCORT

<u>AB</u>	PADDOCK	<u>100MG/60ML</u>	<u>A075172</u>	<u>001</u>	Dec 03, 1999
<u>CORTENEMA</u>					
<u>AB</u>	+ ANI PHARMS	<u>100MG/60ML</u>	<u>N016199</u>	<u>001</u>	
<u>HYDROCORTISONE</u>					
<u>AB</u>	TEVA PHARMS	<u>100MG/60ML</u>	<u>A074171</u>	<u>001</u>	May 27, 1994

LOTION; TOPICAL

ALA-CORT

<u>AT</u>	DEL RAY LABS	<u>1%</u>	<u>A083201</u>	<u>001</u>	
<u>HYDROCORTISONE</u>					
<u>AT</u>	ALTANA	<u>2.5%</u>	<u>A040351</u>	<u>001</u>	Jul 25, 2000
<u>AT</u>	TARO	<u>2.5%</u>	<u>A040247</u>	<u>001</u>	Jul 23, 1999
<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040417</u>	<u>001</u>	Jul 30, 2003
<u>HYTONE</u>					
<u>AT</u>	+ SANOFI AVENTIS US	<u>1%</u>	<u>A080473</u>	<u>003</u>	
<u>AT</u>		<u>2.5%</u>	<u>A080473</u>	<u>004</u>	Nov 30, 1982
<u>NUTRACORT</u>					
<u>AT</u>	CORIA	<u>1%</u>	<u>A080443</u>	<u>003</u>	
<u>AT</u>		<u>2.5%</u>	<u>A087644</u>	<u>001</u>	Aug 24, 1982
<u>STIE-CORT</u>					
<u>AT</u>	PERRIGO	<u>1%</u>	<u>A089066</u>	<u>001</u>	Nov 25, 1985
<u>AT</u>		<u>2.5%</u>	<u>A089074</u>	<u>001</u>	Nov 26, 1985

## PRESCRIPTION DRUG PRODUCT LIST

3 - 207 (of 393)

HYDROCORTISONE

LOTION; TOPICAL				
ALA-SCALP				
	DEL RAY LABS	2%	A083231	001
OINTMENT; TOPICAL				
<u>HYDROCORTISONE</u>				
<u>AT</u>	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087796</u>	<u>001</u> Oct 13, 1982
<u>AT</u>	ALTANA	<u>1%</u>	<u>A080692</u>	<u>001</u>
<u>AT</u>	FOUGERA	<u>2.5%</u>	<u>A081203</u>	<u>001</u> May 28, 1993
<u>AT</u>	PERRIGO NEW YORK	<u>2.5%</u>	<u>A085027</u>	<u>001</u>
<u>AT</u>	TARO	<u>1%</u>	<u>A086257</u>	<u>001</u>
<u>AT</u>		<u>2.5%</u>	<u>A040310</u>	<u>001</u> Dec 29, 2000
<u>HYDROCORTISONE IN ABSORBASE</u>				
<u>AT</u>	CAROLINA MEDCL	<u>1%</u>	<u>A088138</u>	<u>001</u> Sep 06, 1985
POWDER; FOR RX COMPOUNDING				
HYDRO-RX				
	+ X GEN PHARMS	100%	A085982	001
TABLET; ORAL				
<u>CORTEF</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>5MG</u>	<u>N008697</u>	<u>003</u>
<u>AB</u>		<u>10MG</u>	<u>N008697</u>	<u>001</u>
<u>AB</u>	+	<u>20MG</u>	<u>N008697</u>	<u>002</u>
<u>HYDROCORTISONE</u>				
<u>AB</u>	STIEFEL GSK	<u>5MG</u>	<u>A040646</u>	<u>001</u> Mar 30, 2007
<u>AB</u>		<u>10MG</u>	<u>A040646</u>	<u>002</u> Mar 30, 2007
<u>AB</u>		<u>20MG</u>	<u>A040646</u>	<u>003</u> Mar 30, 2007
<u>AB</u>	VINTAGE	<u>5MG</u>	<u>A040761</u>	<u>001</u> Jul 16, 2007
<u>AB</u>		<u>10MG</u>	<u>A040761</u>	<u>002</u> Jul 16, 2007
<u>AB</u>		<u>20MG</u>	<u>A040761</u>	<u>003</u> Jul 16, 2007
HYDROCORTISONE				
BP	WEST WARD	20MG	A083365	001

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL				
CORTIFOAM				
	+ SCHWARZ PHARMA	10%	N017351	001 Feb 10, 1982
CREAM; TOPICAL				
HYDROCORTISONE ACETATE				
	+ FERNDAL LABS	2.5%	A040259	001 Jul 29, 1999
MICORT-HC				
	+ FERNDAL LABS	2%	A040398	001 Mar 29, 2002
		2.5%	A040396	001 Feb 27, 2001
PASTE; TOPICAL				
ORABASE HCA				
	COLGATE	0.5%	A083205	001
POWDER; FOR RX COMPOUNDING				
HYDROCORTISONE ACETATE				
	X GEN PHARMS	100%	A085981	001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL				
CORTISPORIN				
	+ MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218	001 Aug 09, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL				
EPIFOAM				
BX	SCHWARZ PHARMA	1%;1%	A086457	001

## PRESCRIPTION DRUG PRODUCT LIST

3 - 208 (of 393)

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL				
PROCTOFOAM HC				
BX	UCB INC	1%;1%	A086195	001
CREAM; TOPICAL				
PRAMOSONE				
	FERNDAL E LABS	0.5%;1%	A083778	001
		1%;1%	A085368	001
LOTION; TOPICAL				
PRAMOSONE				
	FERNDAL E LABS	1%;1%	A085980	001
		2.5%;1%	A085979	001

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL				
<u>CARMOL HC</u>				
<u>AT</u>	+ NYCOMED US	<u>1%;10%</u>	<u>A080505</u>	<u>001</u>
<u>U-CORT</u>				
<u>AT</u>	TARO	<u>1%;10%</u>	<u>A089472</u>	<u>001</u> Jun 13, 1988

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL				
<u>HYDROCORTISONE BUTYRATE</u>				
<u>AB</u>	TARO PHARM INDS	<u>0.1%</u>	<u>A076654</u>	<u>001</u> Aug 03, 2005
<u>LOCOID</u>				
<u>AB</u>	+ TRIAX PHARMS LLC	<u>0.1%</u>	<u>N018514</u>	<u>001</u> Mar 31, 1982
	LOCOID LIPOCREAM			
	+ TRIAX PHARMS LLC	0.1%	N020769	001 Sep 08, 1997
LOTION; TOPICAL				
LOCOID				
	+ TRIAX PHARMS LLC	0.1%	N022076	001 May 18, 2007
OINTMENT; TOPICAL				
<u>HYDROCORTISONE BUTYRATE</u>				
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076842</u>	<u>001</u> Dec 27, 2004
<u>LOCOID</u>				
<u>AB</u>	+ TRIAX PHARMS LLC	<u>0.1%</u>	<u>N018652</u>	<u>001</u> Oct 29, 1982
SOLUTION; TOPICAL				
<u>HYDROCORTISONE BUTYRATE</u>				
<u>AT</u>	TARO PHARM INDS	<u>0.1%</u>	<u>A076364</u>	<u>001</u> Jan 14, 2004
<u>LOCOID</u>				
<u>AT</u>	+ TRIAX PHARMS LLC	<u>0.1%</u>	<u>N019116</u>	<u>001</u> Feb 25, 1987

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL				
PANDEL				
	+ SAVAGE LABS	0.1%	N020453	001 Feb 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION				
<u>A-HYDROCORT</u>				
<u>AP</u>	HOSPIRA	<u>EQ 100MG BASE/VIAL</u>	<u>A040666</u>	<u>001</u> Apr 06, 2006
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A085930</u>	<u>001</u>
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A085931</u>	<u>001</u>
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A085932</u>	<u>001</u>
<u>SOLU-CORTEF</u>				
<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>EQ 100MG BASE/VIAL</u>	<u>N009866</u>	<u>001</u>
<u>AP</u>	+	<u>EQ 250MG BASE/VIAL</u>	<u>N009866</u>	<u>002</u>
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N009866</u>	<u>003</u>
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N009866</u>	<u>004</u>

## PRESCRIPTION DRUG PRODUCT LIST

3 - 209 (of 393)

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

<u>AB</u>	PERRIGO NEW YORK	<u>0.2%</u>	<u>A075666</u>	<u>001</u>	May 24, 2000
<u>AB</u>	TARO	<u>0.2%</u>	<u>A075042</u>	<u>001</u>	Aug 25, 1998

WESTCORT

<u>AB</u>	+ RANBAXY	<u>0.2%</u>	<u>N017950</u>	<u>001</u>	
-----------	-----------	-------------	----------------	------------	--

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

<u>AB</u>	ALTANA	<u>0.2%</u>	<u>A075085</u>	<u>001</u>	Jul 31, 2001
<u>AB</u>	TARO	<u>0.2%</u>	<u>A075043</u>	<u>001</u>	Aug 25, 1998

WESTCORT

<u>AB</u>	+ RANBAXY	<u>0.2%</u>	<u>N018726</u>	<u>001</u>	Aug 08, 1983
-----------	-----------	-------------	----------------	------------	--------------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

CORTISPORIN

<u>AT</u>	+ MONARCH PHARMS	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>N050479</u>	<u>001</u>	
-----------	------------------	--	----------------	------------	--

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

<u>AT</u>	ALCON	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062423</u>	<u>001</u>	Aug 25, 1983
<u>AT</u>	BAUSCH AND LOMB	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064053</u>	<u>001</u>	Dec 29, 1995
<u>AT</u>	PHARMAFORCE	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A065216</u>	<u>001</u>	Oct 31, 2005

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

	+ ALCON UNIVERSAL	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	A062874	001	May 11, 1988
--	-------------------	--	---------	-----	--------------

SUSPENSION/DROPS; OTIC

CORTISPORIN

<u>AT</u>	+ MONARCH PHARMS	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A060613</u>	<u>001</u>	
-----------	------------------	--	----------------	------------	--

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

<u>AT</u>	ALCON UNIVERSAL	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062488</u>	<u>001</u>	Nov 06, 1985
<u>AT</u>	PHARMAFORCE	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A065219</u>	<u>001</u>	May 01, 2006

OTICAIR

<u>AT</u>	BAUSCH AND LOMB	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064065</u>	<u>001</u>	Aug 28, 1996
-----------	-----------------	--	----------------	------------	--------------

PEDIOTIC

<u>AT</u>	MONARCH PHARMS	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062822</u>	<u>001</u>	Sep 29, 1987
-----------	----------------	--	----------------	------------	--------------

HYDROFLUMETHIAZIDE

TABLET; ORAL

HYDROFLUMETHIAZIDE

<u>AB</u>	PAR PHARM	<u>50MG</u>	<u>A088850</u>	<u>001</u>	May 31, 1985
-----------	-----------	-------------	----------------	------------	--------------

SALURON

<u>AB</u>	+ SHIRE	<u>50MG</u>	<u>N011949</u>	<u>001</u>	
-----------	---------	-------------	----------------	------------	--

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID-HP

<u>AP</u>	+ PURDUE PHARM PRODS	<u>10MG/ML</u>	<u>N019034</u>	<u>001</u>	Jan 11, 1984
-----------	----------------------	----------------	----------------	------------	--------------

HYDROMORPHONE HYDROCHLORIDE

<u>AP</u>	BARR	<u>10MG/ML</u>	<u>A076444</u>	<u>001</u>	Apr 25, 2003
<u>AP</u>	HOSPIRA	<u>10MG/ML</u>	<u>A074598</u>	<u>001</u>	Jun 19, 1997
<u>AP</u>	HOSPIRA INC	<u>10MG/ML</u>	<u>A078591</u>	<u>001</u>	Jun 17, 2008

DILAUDID

	+ PURDUE PHARM PRODS	1MG/ML	N019034	003	Apr 30, 2009
--	----------------------	--------	---------	-----	--------------

		2MG/ML	N019034	004	Apr 30, 2009
--	--	--------	---------	-----	--------------

		4MG/ML	N019034	005	Apr 30, 2009
--	--	--------	---------	-----	--------------

DILAUDID-HP

	+ PURDUE PHARM PRODS	250MG/VIAL	N019034	002	Aug 04, 1994
--	----------------------	------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 210 (of 393)

HYDROMORPHONE HYDROCHLORIDE

SOLUTION; ORAL

DILAUDID

<u>AA</u>	+	PURDUE PHARM PRODS	<u>5MG/5ML</u>	<u>N019891</u>	<u>001</u>	Dec 07, 1992
-----------	---	--------------------	----------------	----------------	------------	--------------

HYDROMORPHONE HYDROCHLORIDE

<u>AA</u>		ROXANE	<u>5MG/5ML</u>	<u>A074653</u>	<u>001</u>	Jul 29, 1998
-----------	--	--------	----------------	----------------	------------	--------------

TABLET; ORAL

DILAUDID

<u>AB</u>		PURDUE PHARM PRODS	<u>2MG</u>	<u>N019892</u>	<u>003</u>	Nov 09, 2007
-----------	--	--------------------	------------	----------------	------------	--------------

<u>AB</u>			<u>4MG</u>	<u>N019892</u>	<u>002</u>	Nov 09, 2007
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>	+		<u>8MG</u>	<u>N019892</u>	<u>001</u>	Dec 07, 1992
-----------	---	--	------------	----------------	------------	--------------

HYDROMORPHONE HYDROCHLORIDE

<u>AB</u>		ACTAVIS TOTOWA	<u>8MG</u>	<u>A076723</u>	<u>001</u>	Oct 18, 2005
-----------	--	----------------	------------	----------------	------------	--------------

<u>AB</u>		KV PHARM	<u>2MG</u>	<u>A077311</u>	<u>001</u>	Nov 09, 2005
-----------	--	----------	------------	----------------	------------	--------------

<u>AB</u>			<u>4MG</u>	<u>A077311</u>	<u>002</u>	Nov 09, 2005
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>			<u>8MG</u>	<u>A077311</u>	<u>003</u>	Nov 09, 2005
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>		LANNETT	<u>2MG</u>	<u>A078439</u>	<u>001</u>	Dec 09, 2009
-----------	--	---------	------------	----------------	------------	--------------

<u>AB</u>			<u>4MG</u>	<u>A078439</u>	<u>002</u>	Dec 09, 2009
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>			<u>8MG</u>	<u>A077471</u>	<u>001</u>	Dec 09, 2009
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>		MALLINCKRODT	<u>8MG</u>	<u>A076855</u>	<u>001</u>	Dec 23, 2004
-----------	--	--------------	------------	----------------	------------	--------------

<u>AB</u>		ROXANE	<u>4MG</u>	<u>A074597</u>	<u>003</u>	May 29, 2009
-----------	--	--------	------------	----------------	------------	--------------

<u>AB</u>			<u>8MG</u>	<u>A074597</u>	<u>001</u>	Jul 29, 1998
-----------	--	--	------------	----------------	------------	--------------

<u>AB</u>		TYCO HLTHCARE	<u>2MG</u>	<u>A078273</u>	<u>001</u>	Sep 19, 2007
-----------	--	---------------	------------	----------------	------------	--------------

<u>AB</u>			<u>4MG</u>	<u>A078273</u>	<u>002</u>	Sep 19, 2007
-----------	--	--	------------	----------------	------------	--------------

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

	+	MERCK SANTE SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006
--	---	-----------------	----------------------	---------	-----	--------------

HYDROXOCOBALAMIN

	+	WATSON LABS	1MG/ML	A085998	001	
--	---	-------------	--------	---------	-----	--

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

	+	AKORN	1%;0.25%	N019261	001	Jan 30, 1992
--	---	-------	----------	---------	-----	--------------

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

<u>AB</u>		IPCA LABS LTD	<u>200MG</u>	<u>A040766</u>	<u>001</u>	Jun 14, 2007
-----------	--	---------------	--------------	----------------	------------	--------------

<u>AB</u>		MYLAN	<u>200MG</u>	<u>A040274</u>	<u>001</u>	May 29, 1998
-----------	--	-------	--------------	----------------	------------	--------------

<u>AB</u>		SANDOZ	<u>200MG</u>	<u>A040104</u>	<u>001</u>	Nov 30, 1995
-----------	--	--------	--------------	----------------	------------	--------------

<u>AB</u>			<u>200MG</u>	<u>A040150</u>	<u>001</u>	Jan 27, 1996
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		TEVA PHARMS	<u>200MG</u>	<u>A040081</u>	<u>001</u>	Sep 30, 1994
-----------	--	-------------	--------------	----------------	------------	--------------

<u>AB</u>		WATSON LABS	<u>200MG</u>	<u>A040133</u>	<u>001</u>	Nov 30, 1995
-----------	--	-------------	--------------	----------------	------------	--------------

<u>AB</u>		WEST WARD	<u>200MG</u>	<u>A040760</u>	<u>001</u>	Aug 15, 2007
-----------	--	-----------	--------------	----------------	------------	--------------

<u>AB</u>		ZYDUS PHARMS USA INC	<u>200MG</u>	<u>A040657</u>	<u>001</u>	Sep 21, 2007
-----------	--	----------------------	--------------	----------------	------------	--------------

PLAQUENIL

<u>AB</u>	+	SANOFI AVENTIS US	<u>200MG</u>	<u>N009768</u>	<u>001</u>	
-----------	---	-------------------	--------------	----------------	------------	--

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

	+	ATON	5MG	N018771	001	
--	---	------	-----	---------	-----	--

## PRESCRIPTION DRUG PRODUCT LIST

3 - 211 (of 393)

HYDROXYUREA

CAPSULE; ORAL

HYDREA

<u>AB</u>	+	BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N016295</u>	<u>001</u>	
<u>HYDROXYUREA</u>						
<u>AB</u>		BARR	<u>500MG</u>	<u>A075143</u>	<u>001</u>	Oct 16, 1998
<u>AB</u>		PAR PHARM	<u>500MG</u>	<u>A075340</u>	<u>001</u>	Feb 24, 1999
<u>DROXIA</u>						
		BRISTOL MYERS SQUIBB	200MG	N016295	002	Feb 25, 1998
			300MG	N016295	003	Feb 25, 1998
			400MG	N016295	004	Feb 25, 1998

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

<u>AP</u>	+	APP PHARMS	<u>25MG/ML</u>	<u>A087329</u>	<u>001</u>	
<u>AP</u>	+		<u>50MG/ML</u>	<u>A087329</u>	<u>002</u>	
<u>AP</u>		LUITPOLD	<u>25MG/ML</u>	<u>A087408</u>	<u>001</u>	
<u>AP</u>			<u>50MG/ML</u>	<u>A087408</u>	<u>002</u>	

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

<u>AA</u>	+	HI TECH PHARMA	<u>10MG/5ML</u>	<u>A040010</u>	<u>001</u>	Oct 28, 1994
<u>AA</u>	+	MORTON GROVE	<u>10MG/5ML</u>	<u>A087294</u>	<u>001</u>	Apr 12, 1982
<u>AA</u>	+	VINTAGE PHARMS	<u>10MG/5ML</u>	<u>A040391</u>	<u>001</u>	Apr 10, 2002

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS TOTOWA	<u>10MG</u>	<u>A040600</u>	<u>001</u>	Dec 28, 2004
<u>AB</u>			<u>25MG</u>	<u>A040602</u>	<u>001</u>	Dec 28, 2004
<u>AB</u>			<u>50MG</u>	<u>A040604</u>	<u>001</u>	Dec 28, 2004
<u>AB</u>		AMNEAL PHARM	<u>10MG</u>	<u>A040808</u>	<u>001</u>	Sep 24, 2008
<u>AB</u>			<u>25MG</u>	<u>A040808</u>	<u>002</u>	Sep 24, 2008
<u>AB</u>			<u>50MG</u>	<u>A040808</u>	<u>003</u>	Sep 24, 2008
<u>AB</u>		ANDAPHARM	<u>10MG</u>	<u>A040804</u>	<u>001</u>	Jun 30, 2008
<u>AB</u>			<u>25MG</u>	<u>A040804</u>	<u>002</u>	Jun 30, 2008
<u>AB</u>			<u>50MG</u>	<u>A040804</u>	<u>003</u>	Jun 30, 2008
<u>AB</u>		HETERO DRUGS LTD	<u>10MG</u>	<u>A040805</u>	<u>001</u>	May 29, 2008
<u>AB</u>			<u>25MG</u>	<u>A040805</u>	<u>002</u>	May 29, 2008
<u>AB</u>			<u>50MG</u>	<u>A040805</u>	<u>003</u>	May 29, 2008
<u>AB</u>		INVAGEN PHARMS	<u>10MG</u>	<u>A040812</u>	<u>001</u>	Mar 12, 2008
<u>AB</u>			<u>25MG</u>	<u>A040812</u>	<u>002</u>	Mar 12, 2008
<u>AB</u>			<u>50MG</u>	<u>A040812</u>	<u>003</u>	Mar 12, 2008
<u>AB</u>		KVK TECH	<u>10MG</u>	<u>A040786</u>	<u>001</u>	Mar 20, 2007
<u>AB</u>			<u>25MG</u>	<u>A040787</u>	<u>001</u>	Mar 20, 2007
<u>AB</u>			<u>50MG</u>	<u>A040788</u>	<u>001</u>	Mar 20, 2007
<u>AB</u>		MUTUAL PHARM	<u>10MG</u>	<u>A089381</u>	<u>001</u>	May 19, 1986
<u>AB</u>			<u>25MG</u>	<u>A089382</u>	<u>001</u>	May 19, 1986
<u>AB</u>			<u>50MG</u>	<u>A089383</u>	<u>001</u>	May 19, 1986
<u>AB</u>		NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A040841</u>	<u>001</u>	Mar 31, 2008
<u>AB</u>			<u>25MG</u>	<u>A040842</u>	<u>001</u>	Mar 31, 2008
<u>AB</u>			<u>50MG</u>	<u>A040840</u>	<u>001</u>	Mar 31, 2008
<u>AB</u>	+	PLIVA	<u>10MG</u>	<u>A088617</u>	<u>001</u>	Jan 10, 1986
<u>AB</u>	+		<u>25MG</u>	<u>A088618</u>	<u>001</u>	Jan 10, 1986
<u>AB</u>	+		<u>50MG</u>	<u>A088619</u>	<u>001</u>	Jan 10, 1986
<u>AB</u>		SUN PHARM INDS INC	<u>10MG</u>	<u>A040899</u>	<u>001</u>	Jun 10, 2008
<u>AB</u>			<u>25MG</u>	<u>A040899</u>	<u>002</u>	Jun 10, 2008
<u>AB</u>			<u>50MG</u>	<u>A040899</u>	<u>003</u>	Jun 10, 2008
<u>AB</u>		VINTAGE PHARMS	<u>10MG</u>	<u>A040579</u>	<u>001</u>	May 27, 2005
<u>AB</u>			<u>25MG</u>	<u>A040574</u>	<u>001</u>	May 27, 2005
<u>AB</u>			<u>50MG</u>	<u>A040580</u>	<u>001</u>	May 27, 2005
<u>AB</u>		WATSON LABS	<u>10MG</u>	<u>A081149</u>	<u>001</u>	Mar 18, 1994

## PRESCRIPTION DRUG PRODUCT LIST

3 - 212 (of 393)

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A088348</u>	<u>001</u>	Sep 15, 1983
<u>AB</u>		<u>25MG</u>	<u>A081150</u>	<u>001</u>	Mar 18, 1994
<u>AB</u>		<u>25MG</u>	<u>A088349</u>	<u>001</u>	Sep 15, 1983
<u>AB</u>		<u>50MG</u>	<u>A081151</u>	<u>001</u>	Mar 18, 1994
<u>AB</u>		<u>50MG</u>	<u>A088350</u>	<u>001</u>	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

<u>AB</u>	BARR	<u>EQ 25MG HCL</u>	<u>A088496</u>	<u>001</u>	Jun 15, 1984
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A088487</u>	<u>001</u>	Jun 15, 1984
<u>AB</u>	IVAX PHARMS	<u>EQ 25MG HCL</u>	<u>A087761</u>	<u>001</u>	Mar 05, 1982
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A087760</u>	<u>001</u>	Mar 05, 1982
<u>AB</u>	SANDOZ	<u>EQ 25MG HCL</u>	<u>A087479</u>	<u>001</u>	
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A086183</u>	<u>001</u>	
<u>AB</u>	WATSON LABS	<u>EQ 25MG HCL</u>	<u>A040156</u>	<u>001</u>	Jul 15, 1996
<u>AB</u>		<u>EQ 25MG HCL</u>	<u>A081165</u>	<u>001</u>	Jul 31, 1991
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A040156</u>	<u>002</u>	Jul 15, 1996

VISTARIL

<u>AB</u>	PFIZER	<u>EQ 25MG HCL</u>	<u>N011459</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 50MG HCL</u>	<u>N011459</u>	<u>004</u>	
	HYDROXYZINE PAMOATE				
	BARR	EQ 100MG HCL	A088488	001	Jun 15, 1984

SUSPENSION; ORAL

## VISTARIL

+	PFIZER	EQ 25MG HCL/5ML	N011795	001	
---	--------	-----------------	---------	-----	--

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

## BONIVA

+	ROCHE	EQ 3MG BASE/3ML	N021858	001	Jan 06, 2006
---	-------	-----------------	---------	-----	--------------

TABLET; ORAL

## BONIVA

+	ROCHE	EQ 150MG BASE	N021455	002	Mar 24, 2005
---	-------	---------------	---------	-----	--------------

IBUPROFEN

SOLUTION; INTRAVENOUS

## CALDOLOR

	CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348	001	Jun 11, 2009
+		800MG/8ML (100MG/ML)	N022348	002	Jun 11, 2009

SUSPENSION; ORAL

IBUPROFEN

<u>AB</u>	+	ACTAVIS MID ATLANTIC	<u>100MG/5ML</u>	<u>A074978</u>	<u>001</u>	Mar 25, 1998
<u>AB</u>		PERRIGO R AND D	<u>100MG/5ML</u>	<u>A076925</u>	<u>001</u>	Sep 23, 2004

TABLET; ORAL

IBUPROFEN

<u>AB</u>	AMNEAL PHARMS NY	<u>400MG</u>	<u>A071334</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>		<u>400MG</u>	<u>A078558</u>	<u>001</u>	Jun 18, 2007
<u>AB</u>		<u>600MG</u>	<u>A071335</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>		<u>600MG</u>	<u>A078558</u>	<u>002</u>	Jun 18, 2007
<u>AB</u>		<u>800MG</u>	<u>A071935</u>	<u>001</u>	Oct 13, 1987
<u>AB</u>		<u>800MG</u>	<u>A078558</u>	<u>003</u>	Jun 18, 2007
<u>AB</u>	DR REDDYS LA	<u>400MG</u>	<u>A075682</u>	<u>001</u>	Nov 14, 2001
<u>AB</u>		<u>600MG</u>	<u>A075682</u>	<u>002</u>	Nov 14, 2001
<u>AB</u>	+	<u>800MG</u>	<u>A075682</u>	<u>003</u>	Nov 14, 2001
<u>AB</u>	DR REDDYS LABS INC	<u>400MG</u>	<u>A076112</u>	<u>001</u>	Oct 31, 2001

## PRESCRIPTION DRUG PRODUCT LIST

3 - 213 (of 393)

IBUPROFEN

TABLET; ORAL

IBUPROFEN

<u>AB</u>	DR REDDYS LABS INC	<u>600MG</u>	<u>A076112</u>	<u>002</u>	Oct 31, 2001
<u>AB</u>		<u>800MG</u>	<u>A076112</u>	<u>003</u>	Oct 31, 2001
<u>AB</u>	LEINER	<u>400MG</u>	<u>A071267</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>		<u>600MG</u>	<u>A071268</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>		<u>800MG</u>	<u>A072300</u>	<u>001</u>	Jul 01, 1988
<u>AB</u>	NORTHSTAR HLTHCARE	<u>400MG</u>	<u>A078132</u>	<u>001</u>	Sep 10, 2007
<u>AB</u>		<u>600MG</u>	<u>A078132</u>	<u>002</u>	Sep 10, 2007
<u>AB</u>		<u>800MG</u>	<u>A078132</u>	<u>003</u>	Sep 10, 2007
<u>AB</u>	OHM LABS	<u>400MG</u>	<u>A070818</u>	<u>001</u>	Dec 26, 1985
<u>AB</u>	PERRIGO R AND D	<u>400MG</u>	<u>A077114</u>	<u>001</u>	Jul 18, 2005
<u>AB</u>		<u>600MG</u>	<u>A077114</u>	<u>002</u>	Jul 18, 2005
<u>AB</u>		<u>800MG</u>	<u>A077114</u>	<u>003</u>	Jul 18, 2005
<u>AB</u>	SHASUN USA	<u>400MG</u>	<u>A078329</u>	<u>001</u>	Feb 05, 2009
<u>AB</u>		<u>600MG</u>	<u>A078329</u>	<u>002</u>	Feb 05, 2009
<u>AB</u>		<u>800MG</u>	<u>A078329</u>	<u>003</u>	Feb 05, 2009
<u>AB</u>	VINTAGE PHARMS	<u>300MG</u>	<u>A071230</u>	<u>001</u>	Oct 22, 1986
<u>AB</u>		<u>400MG</u>	<u>A071231</u>	<u>001</u>	Oct 22, 1986
<u>AB</u>		<u>400MG</u>	<u>A071644</u>	<u>001</u>	Feb 01, 1988
<u>AB</u>		<u>600MG</u>	<u>A071232</u>	<u>001</u>	Oct 22, 1986
<u>AB</u>		<u>800MG</u>	<u>A072004</u>	<u>001</u>	Nov 18, 1987
<u>AB</u>	WATSON LABS	<u>400MG</u>	<u>A070436</u>	<u>001</u>	Aug 21, 1985
<u>AB</u>		<u>600MG</u>	<u>A070437</u>	<u>001</u>	Aug 21, 1985
	<u>IBUPROHM</u>				
<u>AB</u>	OHM LABS	<u>400MG</u>	<u>A070469</u>	<u>001</u>	Aug 29, 1985
	<u>IBU-TAB</u>				
<u>AB</u>	ALRA	<u>400MG</u>	<u>A071058</u>	<u>001</u>	Aug 11, 1988
<u>AB</u>		<u>600MG</u>	<u>A071059</u>	<u>001</u>	Aug 11, 1988

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ LUNDBECK INC EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N021903 001 Apr 13, 2006

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

<u>AB</u>	+ FOREST LABS	<u>400MG;5MG</u>	<u>N021378</u>	<u>001</u>	Nov 26, 2004
	<u>OXYCODONE HYDROCHLORIDE AND IBUPROFEN</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>400MG;5MG</u>	<u>A078769</u>	<u>001</u>	Jan 04, 2008
<u>AB</u>	BARR	<u>400MG;5MG</u>	<u>A078316</u>	<u>001</u>	Nov 29, 2007
<u>AB</u>	WATSON LABS	<u>400MG;5MG</u>	<u>A078394</u>	<u>001</u>	Nov 26, 2007

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT

<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>0.1MG/ML</u>	<u>N020491</u>	<u>001</u>	Dec 28, 1995
	<u>IBUTILIDE FUMARATE</u>				
<u>AP</u>	BIONICHE PHARMA USA	<u>0.1MG/ML</u>	<u>A090643</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>	GENERAMEDIX	<u>0.1MG/ML</u>	<u>A090924</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>	PHARMAFORCE	<u>0.1MG/ML</u>	<u>A090240</u>	<u>001</u>	Jan 11, 2010

ICODEXTRIN

SOLUTION; INTRAPERITONEAL

EXTRANEAAL

+ BAXTER HLTHCARE 7.5GM/100ML N021321 001 Dec 20, 2002



## PRESCRIPTION DRUG PRODUCT LIST

3 - 214 (of 393)

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN PFS

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>1MG/ML</u>	<u>N050734</u>	<u>001</u>	Feb 17, 1997
-----------	---	----------------------	---------------	----------------	------------	--------------

IDARUBICIN HYDROCHLORIDE

<u>AP</u>		APP PHARMS	<u>1MG/ML</u>	<u>A065440</u>	<u>001</u>	Aug 04, 2009
-----------	--	------------	---------------	----------------	------------	--------------

<u>AP</u>		BEDFORD LABS	<u>1MG/ML</u>	<u>A065275</u>	<u>001</u>	Dec 14, 2006
-----------	--	--------------	---------------	----------------	------------	--------------

<u>AP</u>			<u>1MG/ML</u>	<u>A065288</u>	<u>001</u>	May 15, 2007
-----------	--	--	---------------	----------------	------------	--------------

IDARUBICIN HYDROCHLORIDE PFS

<u>AP</u>		TEVA PARENTERAL	<u>1MG/ML</u>	<u>A065036</u>	<u>001</u>	May 01, 2002
-----------	--	-----------------	---------------	----------------	------------	--------------

IDARUBICIN HYDROCHLORIDE

+		TEVA PARENTERAL	5MG/VIAL	A065037	003	May 01, 2002
---	--	-----------------	----------	---------	-----	--------------

+			10MG/VIAL	A065037	002	May 01, 2002
---	--	--	-----------	---------	-----	--------------

+			20MG/VIAL	A065037	001	May 01, 2002
---	--	--	-----------	---------	-----	--------------

IDOXURIDINE

SOLUTION/DROPS; OPHTHALMIC

DENDRID

<u>AT</u>	+	ALCON	<u>0.1%</u>	<u>N014169</u>	<u>001</u>	
-----------	---	-------	-------------	----------------	------------	--

HERPLEX

<u>AT</u>	+	ALLERGAN	<u>0.1%</u>	<u>N013935</u>	<u>002</u>	
-----------	---	----------	-------------	----------------	------------	--

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

<u>AP</u>	+	APP PHARMS	<u>1GM/VIAL</u>	<u>A076078</u>	<u>001</u>	May 28, 2002
-----------	---	------------	-----------------	----------------	------------	--------------

<u>AP</u>			<u>1GM/VIAL</u>	<u>A090181</u>	<u>001</u>	Sep 22, 2009
-----------	--	--	-----------------	----------------	------------	--------------

<u>AP</u>	+		<u>3GM/VIAL</u>	<u>A076078</u>	<u>002</u>	May 28, 2002
-----------	---	--	-----------------	----------------	------------	--------------

<u>AP</u>			<u>3GM/VIAL</u>	<u>A090181</u>	<u>002</u>	Sep 22, 2009
-----------	--	--	-----------------	----------------	------------	--------------

IFOSFAMIDE

+		TEVA PARENTERAL	1GM/20ML (50MG/ML)	A076657	001	Apr 04, 2007
---	--	-----------------	--------------------	---------	-----	--------------

+			3GM/60ML (50MG/ML)	A076657	002	Apr 04, 2007
---	--	--	--------------------	---------	-----	--------------

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

+		BAXTER HLTHCARE	1GM/VIAL;100MG/ML	N019763	003	Oct 10, 1992
---	--	-----------------	-------------------	---------	-----	--------------

+			3GM/VIAL;100MG/ML	N019763	004	Oct 10, 1992
---	--	--	-------------------	---------	-----	--------------

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

+		TEVA PARENTERAL	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	001	Feb 26, 2002
---	--	-----------------	--------------------------------------	---------	-----	--------------

+			3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	002	Feb 26, 2002
---	--	--	--------------------------------------	---------	-----	--------------

ILOPERIDONE

TABLET; ORAL

FANAPT

		VANDA PHARMS INC	1MG	N022192	001	May 06, 2009
--	--	------------------	-----	---------	-----	--------------

			2MG	N022192	002	May 06, 2009
--	--	--	-----	---------	-----	--------------

			4MG	N022192	003	May 06, 2009
--	--	--	-----	---------	-----	--------------

			6MG	N022192	004	May 06, 2009
--	--	--	-----	---------	-----	--------------

			8MG	N022192	005	May 06, 2009
--	--	--	-----	---------	-----	--------------

			10MG	N022192	006	May 06, 2009
--	--	--	------	---------	-----	--------------

+			12MG	N022192	007	May 06, 2009
---	--	--	------	---------	-----	--------------

ILOPROST

SOLUTION; INHALATION

VENTAVIS

+		ACTELION PHARMS LTD	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005
---	--	---------------------	---------------------	---------	-----	--------------

+			20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004
---	--	--	----------------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 215 (of 393)

IMATINIB MESYLATE

TABLET; ORAL

GLEEVEC

NOVARTIS	EQ 100MG BASE	N021588	001	Apr 18, 2003
+	EQ 400MG BASE	N021588	002	Apr 18, 2003

IMIGLUCERASE

INJECTABLE; INJECTION

CEREZYME

GENZYME	200 UNITS/VIAL	N020367	001	May 23, 1994
+	400 UNITS/VIAL	N020367	002	Sep 22, 1999

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>10MG</u>	<u>A040753</u>	<u>001</u>	Feb 28, 2008
<u>AB</u>		<u>25MG</u>	<u>A040752</u>	<u>001</u>	Feb 28, 2008
<u>AB</u>		<u>50MG</u>	<u>A040751</u>	<u>001</u>	Feb 28, 2008
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A081048</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>		<u>25MG</u>	<u>A081049</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>		<u>50MG</u>	<u>A081050</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>	PAR PHARM	<u>10MG</u>	<u>A088292</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>		<u>10MG</u>	<u>A089422</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>25MG</u>	<u>A088262</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A084936</u>	<u>002</u>	
<u>AB</u>		<u>25MG</u>	<u>A083745</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084937</u>	<u>001</u>	
	<u>TOFRANIL</u>				
<u>AB</u>	TYCO HLTHCARE	<u>10MG</u>	<u>A087844</u>	<u>001</u>	May 22, 1984
<u>AB</u>		<u>25MG</u>	<u>A087845</u>	<u>001</u>	May 22, 1984
<u>AB</u>	+	<u>50MG</u>	<u>A087846</u>	<u>001</u>	May 22, 1984

IMIPRAMINE PAMOATE

CAPSULE; ORAL

TOFRANIL-PM

+	TYCO HLTHCARE	EQ 75MG HCL	N017090	001	
		EQ 100MG HCL	N017090	004	
		EQ 125MG HCL	N017090	003	
		EQ 150MG HCL	N017090	002	

IMIQUIMOD

CREAM; TOPICAL

ALDARA

+	GRACEWAY	5%	N020723	001	Feb 27, 1997
---	----------	----	---------	-----	--------------

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

<u>AP</u>	BAXTER HLTHCARE CORP	<u>EQ 5MG BASE/ML</u>	<u>A075542</u>	<u>001</u>	May 10, 2000
<u>AP</u>	+	<u>EQ 5MG BASE/ML</u>	<u>A075513</u>	<u>001</u>	May 09, 2000

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG</u>	<u>A074722</u>	<u>001</u>	Jun 17, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074722</u>	<u>002</u>	Jun 17, 1996
<u>AB</u>	ALPHAPHARM	<u>1.25MG</u>	<u>A075105</u>	<u>001</u>	Jul 23, 1998
<u>AB</u>		<u>2.5MG</u>	<u>A075105</u>	<u>002</u>	Jul 23, 1998
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>1.25MG</u>	<u>A074299</u>	<u>002</u>	Apr 29, 1996

## PRESCRIPTION DRUG PRODUCT LIST

3 - 216 (of 393)

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>2.5MG</u>	<u>A074299</u>	<u>001</u>	Jul 27, 1995
<u>AB</u>	MYLAN	<u>1.25MG</u>	<u>A074461</u>	<u>002</u>	Mar 26, 1997
<u>AB</u>	+	<u>2.5MG</u>	<u>A074461</u>	<u>001</u>	Mar 27, 1996
<u>AB</u>	SANDOZ	<u>1.25MG</u>	<u>A074594</u>	<u>001</u>	May 23, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074594</u>	<u>002</u>	May 23, 1996
<u>AB</u>	WATSON LABS	<u>1.25MG</u>	<u>A074585</u>	<u>001</u>	Sep 26, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074585</u>	<u>002</u>	Sep 26, 1996

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

	MERCK SHARP DOHME	EQ 100MG BASE	N020685	006	Apr 19, 2000
		EQ 200MG BASE	N020685	003	Mar 13, 1996
+		EQ 400MG BASE	N020685	001	Mar 13, 1996

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDICLOR

+	GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992
	INDIUM IN 111 CHLORIDE				
+	MALLINCKRODT	5mCi/0.5ML	N019841	001	Sep 27, 1994

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN-111 OXYQUINOLINE

+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985
---	---------------	---------	---------	-----	--------------

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL

MPI INDIUM DTPA IN 111

+	GE HEALTHCARE	1mCi/ML	N017707	001	Feb 18, 1982
---	---------------	---------	---------	-----	--------------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+	MALLINCKRODT	3mCi/ML	N020314	001	Jun 02, 1994
---	--------------	---------	---------	-----	--------------

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

<u>AP</u>	+	AKORN	<u>25MG/VIAL</u>	<u>N011525</u>	<u>001</u>
		<u>INDOCYANINE GREEN</u>			
<u>AP</u>		PULSION MEDCL	<u>25MG/VIAL</u>	<u>A040811</u>	<u>001</u>

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A070719</u>	<u>001</u>	Feb 12, 1986
<u>AB</u>		<u>50MG</u>	<u>A070756</u>	<u>001</u>	Feb 12, 1986
<u>AB</u>	MYLAN	<u>25MG</u>	<u>N018858</u>	<u>001</u>	Apr 20, 1984
<u>AB</u>	+	<u>50MG</u>	<u>A070624</u>	<u>001</u>	Sep 04, 1985
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A070673</u>	<u>001</u>	Apr 29, 1987
<u>AB</u>		<u>50MG</u>	<u>A070674</u>	<u>001</u>	Apr 29, 1987

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR

<u>AB</u>	+	SANDOZ	75MG	<u>A074464</u>	<u>001</u>	May 28, 1998
-----------	---	--------	------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 217 (of 393)

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

<u>AB</u>	AVANTHI INC	<u>75MG</u>	<u>A079175</u>	<u>001</u>	Mar 06, 2009
-----------	-------------	-------------	----------------	------------	--------------

SUPPOSITORY; RECTAL

INDOMETHACIN

+	G AND W LABS	50MG	A073314	001	Aug 31, 1992
---	--------------	------	---------	-----	--------------

SUSPENSION; ORAL

INDOCIN

+	IROKO PHARMS	25MG/5ML	N018332	001	Oct 10, 1985
---	--------------	----------	---------	-----	--------------

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

<u>AP</u>	+ LUNDBECK INC	<u>EQ 1MG BASE/VIAL</u>	<u>N018878</u>	<u>001</u>	Jan 30, 1985
-----------	----------------	-------------------------	----------------	------------	--------------

INDOMETHACIN SODIUM

<u>AP</u>	BEDFORD	<u>EQ 1MG BASE/VIAL</u>	<u>A078713</u>	<u>001</u>	Jul 16, 2008
-----------	---------	-------------------------	----------------	------------	--------------

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG MIX 70/30

+	NOVO NORDISK INC	70 UNITS/ML;30 UNITS/ML	N021172	001	Nov 01, 2001
---	------------------	-------------------------	---------	-----	--------------

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG

+	NOVO NORDISK INC	100 UNITS/ML	N020986	001	Jun 07, 2000
---	------------------	--------------	---------	-----	--------------

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR

+	NOVO NORDISK INC	100 UNITS/ML	N021536	001	Jun 16, 2005
---	------------------	--------------	---------	-----	--------------

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION

LANTUS

+	SANOFI AVENTIS US	100 UNITS/ML	N021081	001	Apr 20, 2000
---	-------------------	--------------	---------	-----	--------------

INSULIN GLULISINE RECOMBINANT

INJECTABLE; IV (INFUSION)-SC

+	SANOFI AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N021629	001	Apr 16, 2004
---	-------------------	--------------------------------	---------	-----	--------------

+		300 UNITS/3ML (100 UNITS/ML)	N021629	002	Dec 20, 2005
---	--	------------------------------	---------	-----	--------------

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

	SANOFI AVENTIS US	300 UNITS/3ML	N021629	003	Feb 24, 2009
--	-------------------	---------------	---------	-----	--------------

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50

+	LILLY	50 UNITS/ML;50 UNITS/ML	N021018	001	Dec 22, 1999
---	-------	-------------------------	---------	-----	--------------

HUMALOG MIX 50/50 KWIKPEN

+	LILLY	50 UNITS/ML;50 UNITS/ML	N021018	002	Sep 06, 2007
---	-------	-------------------------	---------	-----	--------------

HUMALOG MIX 75/25

+	LILLY	75 UNITS/ML;25 UNITS/ML	N021017	001	Dec 22, 1999
---	-------	-------------------------	---------	-----	--------------

HUMALOG MIX 75/25 KWIKPEN

+	LILLY	75 UNITS/ML;25 UNITS/ML	N021017	002	Sep 06, 2007
---	-------	-------------------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 218 (of 393)

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION				
HUMALOG				
+ LILLY	100 UNITS/ML	N020563	001	Jun 14, 1996
HUMALOG KWIKPEN				
+ LILLY	100 UNITS/ML	N020563	003	Sep 06, 2007
HUMALOG PEN				
+ LILLY	100 UNITS/ML	N020563	002	Aug 06, 1998

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION				
HUMULIN R				
+ LILLY	500 UNITS/ML	N018780	004	Mar 31, 1994

IOBENGUANE SULFATE I 123

SOLUTION; INTRAVENOUS				
ADREVIEW				
+ GE HEALTHCARE	10MCI/5ML (2MCI/ML)	N022290	001	Sep 19, 2008

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION				
CHOLOGRAFIN MEGLUMINE				
+ BRACCO	52%	N009321	003	

IODIXANOL

INJECTABLE; INJECTION				
VISIPAQUE 270				
+ GE HEALTHCARE	55%	N020351	001	Mar 22, 1996
	55%	N020808	001	Aug 29, 1997
VISIPAQUE 320				
+ GE HEALTHCARE	65.2%	N020351	002	Mar 22, 1996
	65.2%	N020808	002	Aug 29, 1997

IOHEXOL

INJECTABLE; INJECTION				
OMNIPAQUE 140				
+ GE HEALTHCARE	30.2%	N018956	005	Nov 30, 1988
SOLUTION; INJECTION, ORAL				
OMNIPAQUE 350				
+ GE HEALTHCARE	75.5%	N018956	004	Dec 26, 1985
	75.5%	N020608	003	Oct 24, 1995
SOLUTION; INJECTION, ORAL, RECTAL				
OMNIPAQUE 180				
+ GE HEALTHCARE	38.8%	N018956	001	Dec 26, 1985
OMNIPAQUE 240				
+ GE HEALTHCARE	51.8%	N018956	002	Dec 26, 1985
	51.8%	N020608	001	Oct 24, 1995
OMNIPAQUE 300				
+ GE HEALTHCARE	64.7%	N018956	003	Dec 26, 1985
	64.7%	N020608	002	Oct 24, 1995

IOPAMIDOL

INJECTABLE; INJECTION				
<u>IOPAMIDOL-200</u>				
<u>AP</u> HOSPIRA	<u>41%</u>	<u>A074898</u>	<u>001</u>	Dec 30, 1997
<u>IOPAMIDOL-200 IN PLASTIC CONTAINER</u>				
<u>AP</u> HOSPIRA	<u>41%</u>	<u>A074636</u>	<u>001</u>	Dec 30, 1997
<u>IOPAMIDOL-250</u>				
<u>AP</u> APP PHARMS	<u>51%</u>	<u>A074679</u>	<u>001</u>	Apr 02, 1997

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 245 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 219 (of 393)

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-250

<u>AP</u>	HOSPIRA	51%	<u>A074898</u>	<u>002</u>	Dec 30, 1997
<u>AP</u>		51%	<u>A075005</u>	<u>001</u>	Feb 24, 1998

IOPAMIDOL-250 IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	51%	<u>A074636</u>	<u>002</u>	Dec 30, 1997
-----------	---------	-----	----------------	------------	--------------

IOPAMIDOL-300

<u>AP</u>	APP PHARMS	61%	<u>A074679</u>	<u>002</u>	Apr 02, 1997
<u>AP</u>	HOSPIRA	61%	<u>A074898</u>	<u>003</u>	Dec 30, 1997
<u>AP</u>		61%	<u>A075005</u>	<u>002</u>	Feb 24, 1998

IOPAMIDOL-300 IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	61%	<u>A074636</u>	<u>003</u>	Dec 30, 1997
<u>AP</u>		61%	<u>A074637</u>	<u>001</u>	Apr 03, 1997

IOPAMIDOL-370

<u>AP</u>	APP PHARMS	76%	<u>A074679</u>	<u>003</u>	Apr 02, 1997
<u>AP</u>	HOSPIRA	76%	<u>A074898</u>	<u>004</u>	Dec 30, 1997
<u>AP</u>		76%	<u>A075005</u>	<u>003</u>	Feb 24, 1998

IOPAMIDOL-370 IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	76%	<u>A074636</u>	<u>004</u>	Dec 30, 1997
-----------	---------	-----	----------------	------------	--------------

ISOVUE-200

<u>AP</u>	+ BRACCO	41%	<u>N018735</u>	<u>006</u>	Jul 07, 1987
-----------	----------	-----	----------------	------------	--------------

ISOVUE-250

<u>AP</u>	+ BRACCO	51%	<u>N018735</u>	<u>007</u>	Jul 06, 1992
<u>AP</u>		51%	<u>N020327</u>	<u>002</u>	Oct 12, 1994

ISOVUE-300

<u>AP</u>	+ BRACCO	61%	<u>N018735</u>	<u>002</u>	Dec 31, 1985
<u>AP</u>		61%	<u>N020327</u>	<u>003</u>	Oct 12, 1994

ISOVUE-370

<u>AP</u>	+ BRACCO	76%	<u>N018735</u>	<u>003</u>	Dec 31, 1985
<u>AP</u>		76%	<u>N020327</u>	<u>004</u>	Oct 12, 1994

	ISOVUE-M 200				
	+ BRACCO	41%	N018735	001	Dec 31, 1985
	ISOVUE-M 300				
	+ BRACCO	61%	N018735	004	Dec 31, 1985

IOPROMIDE

INJECTABLE; INJECTION

## ULTRAVIST (PHARMACY BULK)

	+ BAYER HLTHCARE	49.9%	N021425	003	Mar 12, 2004
		62.3%	N021425	001	Sep 20, 2002
		76.9%	N021425	002	Sep 20, 2002

## ULTRAVIST 150

	+ BAYER HLTHCARE	31.2%	N020220	004	May 10, 1995
--	------------------	-------	---------	-----	--------------

## ULTRAVIST 240

	+ BAYER HLTHCARE	49.9%	N020220	003	May 10, 1995
--	------------------	-------	---------	-----	--------------

## ULTRAVIST 300

	+ BAYER HLTHCARE	62.3%	N020220	002	May 10, 1995
--	------------------	-------	---------	-----	--------------

## ULTRAVIST 300 IN PLASTIC CONTAINER

	+ BAYER HLTHCARE	62.3%	N020220	005	Nov 18, 2008
--	------------------	-------	---------	-----	--------------

## ULTRAVIST 370

	+ BAYER HLTHCARE	76.9%	N020220	001	May 10, 1995
--	------------------	-------	---------	-----	--------------

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION

## CONRAY

	+ MALLINCKRODT	60%	N013295	001	
--	----------------	-----	---------	-----	--

## CONRAY 30

	+ MALLINCKRODT	30%	N016983	001	
--	----------------	-----	---------	-----	--

## CONRAY 43

	+ MALLINCKRODT	43%	N013295	002	
--	----------------	-----	---------	-----	--

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 246 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 220 (of 393)

IOTHALAMATE MEGLUMINESOLUTION; INTRAVESICAL  
CYSTO-CONRAY II

MALLINCKRODT 17.2% N017057 002

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 160

+ MALLINCKRODT 34% N019710 003 Dec 30, 1988

OPTIRAY 240

+ MALLINCKRODT 51% N019710 002 Dec 30, 1988

OPTIRAY 300

+ MALLINCKRODT 64% N019710 004 Jan 22, 1992

+ 64% N020923 004 May 13, 1999

OPTIRAY 320

+ MALLINCKRODT 68% N019710 001 Dec 30, 1988

OPTIRAY 350

+ MALLINCKRODT 74% N019710 005 Jan 22, 1992

+ 74% N020923 003 May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION

HEXABRIX

+ GUERBET 39.3%;19.6% N018905 002 Jul 26, 1985

IOXILAN

INJECTABLE; INJECTION

OXILAN-300

GUERBET 62% N020316 001 Dec 21, 1995

OXILAN-350

GUERBET 73% N020316 002 Dec 21, 1995

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT HFA

+ BOEHRINGER INGELHEIM 0.021MG/INH N021527 001 Nov 27, 2004

SOLUTION; INHALATION

IPRATROPIUM BROMIDEAN ACTAVIS MID ATLANTIC 0.02% A075111 001 Apr 22, 1999AN BAUSCH AND LOMB 0.02% A075835 001 Oct 15, 2001AN COBALT LABS INC 0.02% A076291 001 May 09, 2005AN + DEY 0.02% A074755 001 Jan 10, 1997AN HOLOPACK INTL 0.02% A075693 001 Jan 26, 2001AN LANDELA PHARM 0.02% A077072 001 Jul 19, 2005AN NEPHRON 0.02% A075562 001 Sep 27, 2001AN NOVEX 0.02% A075441 001 Mar 28, 2001AN TEVA PARENTERAL 0.02% A075313 001 Feb 07, 2000

SPRAY, METERED; NASAL

ATROVENTAB + BOEHRINGER INGELHEIM 0.021MG/SPRAY N020393 001 Oct 20, 1995AB + 0.042MG/SPRAY N020394 001 Oct 20, 1995IPRATROPIUM BROMIDEAB BAUSCH AND LOMB 0.021MG/SPRAY A076025 001 Mar 31, 2003AB 0.042MG/SPRAY A076103 001 Mar 31, 2003AB DEY 0.021MG/SPRAY A075552 001 Mar 31, 2003AB 0.042MG/SPRAY A075553 001 Mar 31, 2003AB NOVEX 0.021MG/SPRAY A076156 001 Apr 18, 2003AB 0.042MG/SPRAY A076155 001 Apr 18, 2003AB ROXANE 0.021MG/SPRAY A076664 001 Nov 05, 2003

## PRESCRIPTION DRUG PRODUCT LIST

3 - 221 (of 393)

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

<u>AB</u>	ROXANE	<u>0.042MG/SPRAY</u>	<u>A076598</u>	<u>001</u>	Nov 05, 2003
-----------	--------	----------------------	----------------	------------	--------------

IRBESARTAN

TABLET; ORAL

AVAPRO

	SANOFI AVENTIS US	75MG	N020757	001	Sep 30, 1997
		150MG	N020757	002	Sep 30, 1997
+		300MG	N020757	003	Sep 30, 1997

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

CAMPTOSAR

<u>AP</u>	+	PFIZER INC	<u>40MG/2ML (20MG/ML)</u>	<u>N020571</u>	<u>001</u>	Jun 14, 1996
<u>AP</u>	+		<u>100MG/5ML (20MG/ML)</u>	<u>N020571</u>	<u>002</u>	Jun 14, 1996

IRINOTECAN HYDROCHLORIDE

<u>AP</u>		ACCORD HLTHCARE	<u>40MG/2ML (20MG/ML)</u>	<u>A079068</u>	<u>001</u>	Nov 21, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A079068</u>	<u>002</u>	Nov 21, 2008
<u>AP</u>		ACTAVIS TOTOWA	<u>40MG/2ML (20MG/ML)</u>	<u>A078589</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078589</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>		AKORN	<u>40MG/2ML (20MG/ML)</u>	<u>A090726</u>	<u>001</u>	Sep 16, 2009
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A090726</u>	<u>002</u>	Sep 16, 2009
<u>AP</u>		APP PHARMS	<u>40MG/2ML (20MG/ML)</u>	<u>A077776</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A077776</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>		BEDFORD LABS	<u>40MG/2ML (20MG/ML)</u>	<u>A078753</u>	<u>001</u>	Dec 24, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078753</u>	<u>002</u>	Dec 24, 2008
<u>AP</u>		EBEWE PHARMA	<u>40MG/2ML (20MG/ML)</u>	<u>A090137</u>	<u>001</u>	Nov 12, 2009
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A090137</u>	<u>002</u>	Nov 12, 2009
<u>AP</u>		FRESENIUS KABI ONCOL	<u>40MG/2ML (20MG/ML)</u>	<u>A078188</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078188</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>		HOSPIRA	<u>40MG/2ML (20MG/ML)</u>	<u>A077915</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A077915</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	+		<u>500MG/25ML (20MG/ML)</u>	<u>A078796</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		PHARMAFORCE	<u>40MG/2ML (20MG/ML)</u>	<u>A090016</u>	<u>001</u>	Jan 28, 2009
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A090016</u>	<u>002</u>	Jan 28, 2009
<u>AP</u>		PLIVA LACHEMA	<u>40MG/2ML (20MG/ML)</u>	<u>A078122</u>	<u>001</u>	Oct 31, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078122</u>	<u>002</u>	Oct 31, 2008
<u>AP</u>		SANDOZ	<u>40MG/2ML (20MG/ML)</u>	<u>A077994</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A077994</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>		SUN PHARMA GLOBAL	<u>40MG/2ML (20MG/ML)</u>	<u>A078805</u>	<u>001</u>	Apr 21, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078805</u>	<u>002</u>	Apr 21, 2008
<u>AP</u>		TEVA PARENTERAL	<u>40MG/2ML (20MG/ML)</u>	<u>A077260</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A077260</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>			<u>500MG/25ML (20MG/ML)</u>	<u>A090101</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>		WATSON LABS	<u>40MG/2ML (20MG/ML)</u>	<u>A077219</u>	<u>001</u>	Feb 20, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A077219</u>	<u>002</u>	Feb 20, 2008

IRON DEXTRAN

INJECTABLE; INJECTION

DEXFERRUM

BP		LUITPOLD	EQ 50MG IRON/ML	A040024	001	Feb 23, 1996
		INFED				
BP	+	WATSON LABS (UTAH)	EQ 50MG IRON/ML	N017441	001	
		PROFERDEX				
BP		NEW RIVER	EQ 50MG IRON/ML	N017807	001	



## PRESCRIPTION DRUG PRODUCT LIST

3 - 222 (of 393)

IRON SUCROSEINJECTABLE; INTRAVENOUS  
VENOFER

+	LUITPOLD	EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135	001	Nov 06, 2000
		EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135	004	Feb 09, 2007

ISOCARBOXAZIDTABLET; ORAL  
MARPLAN

+	VALIDUS PHARMS INC	10MG	N011961	001	
---	--------------------	------	---------	-----	--

ISOFLURANE

LIQUID; INHALATION

FORANE

<u>AN</u>	+	BAXTER HLTHCARE CORP	<u>99.9%</u>	<u>N017624</u>	<u>001</u>	
-----------	---	----------------------	--------------	----------------	------------	--

ISOFLURANE

<u>AN</u>		HALOCARBON PRODS	<u>99.9%</u>	<u>A075225</u>	<u>001</u>	Oct 20, 1999
<u>AN</u>		HOSPIRA	<u>99.9%</u>	<u>A074097</u>	<u>001</u>	Jan 25, 1993
<u>AN</u>		MINRAD	<u>99.9%</u>	<u>A074416</u>	<u>001</u>	Sep 30, 1994
<u>AN</u>		RHODIA	<u>99.9%</u>	<u>A074502</u>	<u>001</u>	Jun 27, 1995

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

+	SANDOZ	100MG/ML	A040648	001	Jul 05, 2005
---	--------	----------	---------	-----	--------------

SYRUP; ORAL

ISONIAZID

+	CAROLINA MEDCL	50MG/5ML	A088235	001	Nov 10, 1983
---	----------------	----------	---------	-----	--------------

TABLET; ORAL

ISONIAZID

<u>AA</u>		BARR	<u>100MG</u>	<u>A080936</u>	<u>001</u>	
<u>AA</u>			<u>300MG</u>	<u>A080937</u>	<u>002</u>	
<u>AA</u>		MIKART	<u>100MG</u>	<u>A040090</u>	<u>001</u>	Jun 26, 1997
<u>AA</u>			<u>300MG</u>	<u>A040090</u>	<u>002</u>	Jun 26, 1997
<u>AA</u>	+	SANDOZ	<u>100MG</u>	<u>N008678</u>	<u>002</u>	
<u>AA</u>	+		<u>300MG</u>	<u>N008678</u>	<u>003</u>	
<u>AA</u>		WATSON LABS	<u>300MG</u>	<u>A080521</u>	<u>001</u>	
<u>AA</u>		WEST WARD	<u>100MG</u>	<u>A080212</u>	<u>001</u>	
<u>AA</u>			<u>300MG</u>	<u>A087425</u>	<u>001</u>	

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

RIFATER

+	SANOFI AVENTIS US	50MG; 300MG; 120MG	N050705	001	May 31, 1994
---	-------------------	--------------------	---------	-----	--------------

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE

<u>AB</u>	+	SANOFI AVENTIS US	<u>150MG; 300MG</u>	<u>A061884</u>	<u>001</u>	
-----------	---	-------------------	---------------------	----------------	------------	--

RIFAMPIN AND ISONIAZID

<u>AB</u>		WESTWARD	<u>150MG; 300MG</u>	<u>A065221</u>	<u>001</u>	Jul 29, 2005
-----------	--	----------	---------------------	----------------	------------	--------------

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

<u>AP</u>		INTL MEDICATION	<u>0.2MG/ML</u>	<u>A083724</u>	<u>001</u>	
-----------	--	-----------------	-----------------	----------------	------------	--

ISUPREL

<u>AP</u>	+	HOSPIRA	<u>0.2MG/ML</u>	<u>N010515</u>	<u>001</u>	
-----------	---	---------	-----------------	----------------	------------	--

## PRESCRIPTION DRUG PRODUCT LIST

3 - 223 (of 393)

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL			
DILATRATE-SR			
+	SCHWARZ PHARMA	40MG	N019790 001 Sep 02, 1988
TABLET; ORAL			
<u>ISORDIL</u>			
<u>AB</u>	BIOVAIL	<u>5MG</u>	<u>N012093 007</u> Jul 29, 1988
<u>AB</u>		<u>10MG</u>	<u>N012093 002</u> Jul 29, 1988
<u>AB</u>		<u>20MG</u>	<u>N012093 006</u> Jul 29, 1988
<u>AB</u>	+	<u>30MG</u>	<u>N012093 005</u> Jul 29, 1988
<u>ISOSORBIDE DINITRATE</u>			
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A086923 001</u> Mar 12, 1987
<u>AB</u>		<u>10MG</u>	<u>A086925 001</u> Mar 12, 1987
<u>AB</u>		<u>20MG</u>	<u>A087537 001</u> Oct 02, 1987
<u>AB</u>		<u>30MG</u>	<u>A087946 001</u> Jan 12, 1988
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A086221 001</u> Jan 07, 1988
<u>AB</u>		<u>10MG</u>	<u>A086223 001</u> Jan 07, 1988
<u>AB</u>		<u>20MG</u>	<u>A089367 001</u> Apr 07, 1988
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A086034 001</u> Jan 06, 1988
<u>AB</u>		<u>10MG</u>	<u>A086032 001</u> Jan 07, 1988
<u>AB</u>	WEST WARD	<u>5MG</u>	<u>A086067 001</u> Oct 29, 1987
<u>AB</u>		<u>10MG</u>	<u>A086066 001</u> Oct 29, 1987
<u>AB</u>		<u>20MG</u>	<u>A088088 001</u> Nov 02, 1987
<u>AB</u>		<u>30MG</u>	<u>A040591 001</u> Jan 10, 2007
ISORDIL			
+	BIOVAIL	40MG	N012093 001 Jul 29, 1988
TABLET; SUBLINGUAL			
<u>ISOSORBIDE DINITRATE</u>			
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A086033 001</u> Feb 26, 1988
<u>AB</u>	+	<u>5MG</u>	<u>A086031 001</u> Sep 29, 1987
<u>AB</u>	WEST WARD	<u>2.5MG</u>	<u>A086054 001</u> Oct 29, 1987
<u>AB</u>		<u>5MG</u>	<u>A086055 001</u> Nov 02, 1987
TABLET, EXTENDED RELEASE; ORAL			
<u>ISOSORBIDE DINITRATE</u>			
<u>AB</u>	COREPHARMA	<u>40MG</u>	<u>A040723 001</u> Mar 17, 2008
<u>AB</u>	+	<u>40MG</u>	<u>A040009 001</u> Dec 30, 1998
<u>ISOSORBIDE MONONITRATE</u>			
TABLET; ORAL			
<u>ISMO</u>			
<u>AB</u>	PROMIUS PHARMA	<u>20MG</u>	<u>N019091 001</u> Dec 30, 1991
<u>ISOSORBIDE MONONITRATE</u>			
<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A075037 002</u> Oct 30, 1998
<u>AB</u>		<u>20MG</u>	<u>A075037 001</u> Oct 30, 1998
<u>AB</u>	TEVA	<u>20MG</u>	<u>A075147 001</u> Nov 27, 1998
<u>AB</u>	WEST WARD	<u>20MG</u>	<u>A075361 001</u> Oct 05, 2000
<u>MONOKET</u>			
<u>AB</u>	SCHWARZ	<u>10MG</u>	<u>N020215 002</u> Jun 30, 1993
<u>AB</u>	+	<u>20MG</u>	<u>N020215 001</u> Jun 30, 1993
TABLET, EXTENDED RELEASE; ORAL			
<u>ISOSORBIDE MONONITRATE</u>			
<u>AB</u>	ACTAVIS ELIZABETH	<u>30MG</u>	<u>A075306 001</u> Dec 31, 1998
<u>AB</u>		<u>60MG</u>	<u>A075306 002</u> Dec 31, 1998
<u>AB</u>	BRIGHTSTONE	<u>60MG</u>	<u>A075166 001</u> Oct 07, 1999
<u>AB</u>	DEXCEL LTD	<u>60MG</u>	<u>A075522 001</u> Apr 17, 2000
<u>AB</u>	ELAN PHARM	<u>60MG</u>	<u>A075041 001</u> Sep 22, 1998
<u>AB</u>	KREMERS URBAN	<u>30MG</u>	<u>A075155 002</u> Jan 13, 2000
<u>AB</u>		<u>60MG</u>	<u>A075155 001</u> Oct 30, 1998
<u>AB</u>	+	<u>120MG</u>	<u>A075155 003</u> Aug 04, 2000

## PRESCRIPTION DRUG PRODUCT LIST

3 - 224 (of 393)

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

<u>AB</u>	KV PHARM	<u>30MG</u>	<u>A075395</u>	<u>001</u>	Mar 16, 2000
<u>AB</u>		<u>60MG</u>	<u>A075395</u>	<u>002</u>	Mar 16, 2000
<u>AB</u>		<u>120MG</u>	<u>A075395</u>	<u>003</u>	Mar 16, 2000
<u>AB</u>	WEST WARD	<u>30MG</u>	<u>A076813</u>	<u>002</u>	Mar 30, 2006
<u>AB</u>		<u>60MG</u>	<u>A076813</u>	<u>001</u>	Jan 07, 2005

ISOSULFAN BLUE

INJECTABLE; INJECTION

LYMPHAZURIN

+ US SURGCL 1% N018310 001

ISOTRETINOIN

CAPSULE; ORAL

AMNESTEEM

<u>AB</u>	GENPHARM	<u>10MG</u>	<u>A075945</u>	<u>001</u>	Nov 08, 2002
<u>AB</u>	+	<u>20MG</u>	<u>A075945</u>	<u>002</u>	Nov 08, 2002
<u>AB</u>	+	<u>40MG</u>	<u>A075945</u>	<u>003</u>	Nov 08, 2002

CLARAVIS

<u>AB</u>	BARR	<u>10MG</u>	<u>A076356</u>	<u>001</u>	Apr 11, 2003
<u>AB</u>		<u>20MG</u>	<u>A076135</u>	<u>002</u>	Apr 11, 2003
<u>AB</u>		<u>30MG</u>	<u>A076135</u>	<u>003</u>	May 11, 2006
<u>AB</u>		<u>40MG</u>	<u>A076135</u>	<u>001</u>	Apr 11, 2003

SOTRET

<u>AB</u>	RANBAXY	<u>10MG</u>	<u>A076041</u>	<u>001</u>	Dec 24, 2002
<u>AB</u>		<u>20MG</u>	<u>A076041</u>	<u>002</u>	Dec 24, 2002
<u>AB</u>		<u>30MG</u>	<u>A076503</u>	<u>001</u>	Jun 20, 2003
<u>AB</u>		<u>40MG</u>	<u>A076041</u>	<u>003</u>	Dec 24, 2002

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

<u>AB</u>	ACTAVIS TOTOWA	<u>2.5MG</u>	<u>A077169</u>	<u>001</u>	Apr 24, 2006
<u>AB</u>		<u>5MG</u>	<u>A077169</u>	<u>002</u>	Apr 24, 2006
<u>AB</u>	COBALT LABS INC	<u>2.5MG</u>	<u>A077317</u>	<u>001</u>	Jan 05, 2006
<u>AB</u>	+	<u>5MG</u>	<u>A077317</u>	<u>002</u>	Jan 05, 2006

TABLET, EXTENDED RELEASE; ORAL

DYNACIRC CR

SMITHKLINE BEECHAM 5MG N020336 001 Jun 01, 1994

+ 10MG N020336 002 Jun 01, 1994

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A076104</u>	<u>001</u>	May 28, 2004
<u>AB</u>	+	<u>SPORANOX</u>	<u>N020083</u>	<u>001</u>	Sep 11, 1992

INJECTABLE; INJECTION

SPORANOX

+ ORTHO MCNEIL JANSSEN 10MG/ML N020966 001 Mar 30, 1999

SOLUTION; ORAL

SPORANOX

+ ORTHO MCNEIL JANSSEN 10MG/ML N020657 001 Feb 21, 1997

## PRESCRIPTION DRUG PRODUCT LIST

3 - 225 (of 393)

IVERMECTINTABLET; ORAL  
STROMEKTOL

+ MERCK 3MG N050742 002 Oct 08, 1998

IXABEPILONE

INJECTABLE; IV (INFUSION)

+ BRISTOL MYERS SQUIBB 15MG/VIAL N022065 001 Oct 16, 2007  
+ 45MG/VIAL N022065 002 Oct 16, 2007KANAMYCIN SULFATEINJECTABLE; INJECTION  
KANAMYCIN SULFATEAPP PHARMS EQ 500MG BASE/2ML A065111 001 Dec 17, 2002  
+ EQ 1GM BASE/3ML A065111 002 Dec 17, 2002KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALARAP + JHP PHARMS EQ 10MG BASE/ML N016812 001  
AP + EQ 50MG BASE/ML N016812 002  
AP + EQ 100MG BASE/ML N016812 003KETAMINE HYDROCHLORIDEAP BEDFORD EQ 50MG BASE/ML A074524 001 Mar 22, 1996  
AP EQ 100MG BASE/ML A074524 002 Mar 22, 1996  
AP BIONICHE PHARMA EQ 10MG BASE/ML A076092 001 Sep 30, 2008  
AP EQ 50MG BASE/ML A076092 002 Dec 28, 2001  
AP EQ 100MG BASE/ML A076092 003 Oct 25, 2002  
AP HOSPIRA EQ 50MG BASE/ML A074549 001 Jun 27, 1996  
AP EQ 100MG BASE/ML A074549 002 Jun 27, 1996KETOCONAZOLEAEROSOL, FOAM; TOPICAL  
EXTINA

+ STIEFEL LABS INC 2% N021738 001 Jun 12, 2007

CREAM; TOPICAL

KETOCONAZOLEAB ALTANA 2% A076294 001 Apr 28, 2004  
AB + TEVA 2% A075581 001 Apr 25, 2000KETOZOLEAB TARO 2% A075638 001 Dec 18, 2002GEL; TOPICAL  
XOLEGEL

+ STIEFEL LABS INC 2% N021946 001 Jul 28, 2006

SHAMPOO; TOPICAL

KETOCONAZOLEAB PERRIGO NEW YORK 2% A076419 001 Jan 07, 2004  
AB TOLMAR 2% A076942 001 Apr 11, 2005NIZORALAB + ORTHO MCNEIL JANSSEN 2% N019927 001 Aug 31, 1990

TABLET; ORAL

KETOCONAZOLEAB APOTEX 200MG A075912 001 Jan 10, 2002  
AB MUTUAL PHARMA 200MG A075314 001 Jun 15, 1999  
AB MYLAN 200MG A075597 001 Dec 23, 1999  
AB PLIVA 200MG A075362 001 Jun 15, 1999  
AB TARO 200MG A075319 001 Jun 15, 1999  
AB TEVA 200MG A075273 001 Jun 15, 1999

## PRESCRIPTION DRUG PRODUCT LIST

3 - 226 (of 393)

KETOCONAZOLE

TABLET; ORAL

NIZORAL

<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>200MG</u>	<u>N018533</u>	<u>001</u>	
-----------	------------------------	--------------	----------------	------------	--

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

<u>AB</u>	HERITAGE PHARMS INC	<u>50MG</u>	<u>A074014</u>	<u>002</u>	Jan 29, 1993
<u>AB</u>		<u>75MG</u>	<u>A074014</u>	<u>003</u>	Jan 29, 1993
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A074035</u>	<u>002</u>	Dec 31, 1996
<u>AB</u>		<u>75MG</u>	<u>A074035</u>	<u>003</u>	Dec 31, 1996
<u>AB</u>	TEVA	<u>50MG</u>	<u>A073516</u>	<u>001</u>	Dec 22, 1992
<u>AB</u>	+	<u>75MG</u>	<u>A073517</u>	<u>001</u>	Dec 22, 1992

KETOPROFEN

HERITAGE PHARMS INC 25MG

A074014 001 Jan 29, 1993

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

<u>AB</u>	ELAN PHARM	<u>200MG</u>	<u>A074879</u>	<u>001</u>	Dec 10, 1997
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A075679</u>	<u>003</u>	Feb 20, 2002
<u>AB</u>		<u>150MG</u>	<u>A075679</u>	<u>002</u>	Feb 20, 2002
<u>AB</u>	+	<u>200MG</u>	<u>A075679</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>	WATSON LABS FLORIDA	<u>100MG</u>	<u>A075270</u>	<u>002</u>	Mar 24, 1999
<u>AB</u>		<u>150MG</u>	<u>A075270</u>	<u>003</u>	Mar 24, 1999
<u>AB</u>		<u>200MG</u>	<u>A075270</u>	<u>001</u>	Mar 24, 1999

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

<u>AP</u>	AKORN STRIDES	<u>15MG/ML</u>	<u>A078299</u>	<u>001</u>	Jul 16, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A078299</u>	<u>002</u>	Jul 16, 2007
<u>AP</u>	APOTEX INC	<u>15MG/ML</u>	<u>A075631</u>	<u>002</u>	Jun 29, 2001
<u>AP</u>		<u>30MG/ML</u>	<u>A075631</u>	<u>001</u>	Jun 29, 2001
<u>AP</u>	APP PHARMS	<u>15MG/ML</u>	<u>A075784</u>	<u>001</u>	Jan 11, 2002
<u>AP</u>		<u>30MG/ML</u>	<u>A075784</u>	<u>002</u>	Jan 11, 2002
<u>AP</u>	BAXTER HLTHCARE	<u>15MG/ML</u>	<u>A075772</u>	<u>001</u>	Jul 21, 2004
<u>AP</u>		<u>30MG/ML</u>	<u>A075772</u>	<u>002</u>	Jul 21, 2004
<u>AP</u>	BAXTER HLTHCARE CORP	<u>15MG/ML</u>	<u>A075299</u>	<u>001</u>	Nov 03, 1999
<u>AP</u>		<u>30MG/ML</u>	<u>A075299</u>	<u>002</u>	Nov 03, 1999
<u>AP</u>	+	<u>15MG/ML</u>	<u>A075222</u>	<u>001</u>	Apr 26, 1999
<u>AP</u>	+	<u>30MG/ML</u>	<u>A075222</u>	<u>002</u>	Apr 26, 1999
<u>AP</u>	+	<u>30MG/ML</u>	<u>A075228</u>	<u>001</u>	Apr 26, 1999
<u>AP</u>	HOSPIRA	<u>15MG/ML</u>	<u>A074802</u>	<u>001</u>	Jun 05, 1997
<u>AP</u>		<u>15MG/ML</u>	<u>A074993</u>	<u>001</u>	Jan 27, 1999
<u>AP</u>		<u>30MG/ML</u>	<u>A074802</u>	<u>002</u>	Jun 05, 1997
<u>AP</u>		<u>30MG/ML</u>	<u>A074993</u>	<u>002</u>	Jan 27, 1999
<u>AP</u>	LUITPOLD	<u>15MG/ML</u>	<u>A078145</u>	<u>001</u>	Jan 14, 2008
<u>AP</u>		<u>30MG/ML</u>	<u>A078145</u>	<u>002</u>	Jan 14, 2008
<u>AP</u>	SANDOZ	<u>15MG/ML</u>	<u>A076271</u>	<u>001</u>	Oct 06, 2004
<u>AP</u>		<u>30MG/ML</u>	<u>A076271</u>	<u>002</u>	Oct 06, 2004
<u>AP</u>	SUN PHARMA GLOBAL	<u>15MG/ML</u>	<u>A078737</u>	<u>001</u>	Oct 06, 2008
<u>AP</u>		<u>30MG/ML</u>	<u>A078737</u>	<u>002</u>	Oct 06, 2008
<u>AP</u>	WOCKHARDT	<u>15MG/ML</u>	<u>A077942</u>	<u>001</u>	Mar 27, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A077942</u>	<u>002</u>	Mar 27, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A077943</u>	<u>001</u>	Mar 27, 2007

SOLUTION/DROPS; OPHTHALMIC

ACULAR

<u>AT</u>	+	ALLERGAN	<u>0.5%</u>	<u>N019700</u>	<u>001</u>	Nov 09, 1992
-----------	---	----------	-------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 227 (of 393)

KETOROLAC TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

ACULAR LS

<u>AT</u>	+ ALLERGAN	<u>0.4%</u>	<u>N021528</u>	<u>001</u>	May 30, 2003
	<u>KETOROLAC TROMETHAMINE</u>				
<u>AT</u>	AKORN	<u>0.4%</u>	<u>A078399</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A078434</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	ALCON	<u>0.4%</u>	<u>A078721</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076583</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	APOTEX INC	<u>0.4%</u>	<u>A077308</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076109</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	SUN PHARMA GLOBAL	<u>0.5%</u>	<u>A090017</u>	<u>001</u>	Nov 05, 2009
	ACULAR PRESERVATIVE FREE				
	+ ALLERGAN	0.5%	N020811	001	Nov 03, 1997
	ACUVAIL				
	+ ALLERGAN	0.45%	N022427	001	Jul 22, 2009

TABLET; ORAL

KETOROLAC TROMETHAMINE

<u>AB</u>	+ MYLAN	<u>10MG</u>	<u>A074761</u>	<u>001</u>	May 16, 1997
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A075284</u>	<u>001</u>	Jun 23, 1999
<u>AB</u>	TEVA	<u>10MG</u>	<u>A074754</u>	<u>001</u>	May 16, 1997

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

<u>AP</u>	APOTEX INC	<u>5MG/ML</u>	<u>A076051</u>	<u>001</u>	Jul 05, 2002
<u>AP</u>	BEDFORD	<u>5MG/ML</u>	<u>A075303</u>	<u>001</u>	May 28, 1999
<u>AP</u>	+ HOSPIRA	<u>5MG/ML</u>	<u>A075239</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>		<u>5MG/ML</u>	<u>A075240</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>	TAYLOR	<u>5MG/ML</u>	<u>A075431</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>		<u>5MG/ML</u>	<u>A075524</u>	<u>001</u>	Nov 29, 1999

TABLET; ORAL

LABETALOL HYDROCHLORIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A074787</u>	<u>001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A074787</u>	<u>002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A074787</u>	<u>003</u>	Aug 03, 1998
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A075113</u>	<u>001</u>	Aug 04, 1998
<u>AB</u>		<u>200MG</u>	<u>A075113</u>	<u>002</u>	Aug 04, 1998
<u>AB</u>		<u>300MG</u>	<u>A075113</u>	<u>003</u>	Aug 04, 1998
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075133</u>	<u>001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A075133</u>	<u>002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A075133</u>	<u>003</u>	Aug 03, 1998
	<u>TRANDATE</u>				
<u>AB</u>	PROMETHEUS LABS	<u>100MG</u>	<u>N018716</u>	<u>001</u>	May 24, 1985
<u>AB</u>		<u>200MG</u>	<u>N018716</u>	<u>002</u>	Aug 01, 1984
<u>AB</u>		<u>300MG</u>	<u>N018716</u>	<u>003</u>	Aug 01, 1984

LACOSAMIDE

SOLUTION; INTRAVENOUS

VIMPAT

	+ SCHWARZ BIOSCIENCES	200MG/20ML (10MG/ML)	N022254	001	Oct 28, 2008
--	-----------------------	----------------------	---------	-----	--------------

TABLET; ORAL

VIMPAT

	SCHWARZ BIOSCIENCES	50MG	N022253	001	Oct 28, 2008
		100MG	N022253	002	Oct 28, 2008
		150MG	N022253	003	Oct 28, 2008
		200MG	N022253	004	Oct 28, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 228 (of 393)

LACTULOSE

FOR SOLUTION; ORAL					
LACTULOSE					
	+ INALCO	10GM/PACKET	A074712	001	Dec 10, 1997
	+	20GM/PACKET	A074712	002	Dec 10, 1997
SOLUTION; ORAL					
<u>CONSTILAC</u>					
<u>AA</u>	ALRA	<u>10GM/15ML</u>	<u>A071054</u>	<u>001</u>	Jul 26, 1988
<u>CONSTULOSE</u>					
<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>10GM/15ML</u>	<u>A070288</u>	<u>001</u>	Aug 15, 1988
<u>LACTULOSE</u>					
<u>AA</u>	ANI PHARMS	<u>10GM/15ML</u>	<u>A078430</u>	<u>001</u>	Nov 28, 2007
<u>AA</u>	HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074076</u>	<u>001</u>	Jul 03, 1995
<u>AA</u>	MORTON GROVE	<u>10GM/15ML</u>	<u>A074602</u>	<u>001</u>	Nov 14, 1996
<u>AA</u>	NOVEX	<u>10GM/15ML</u>	<u>A075911</u>	<u>001</u>	Feb 21, 2002
<u>AA</u>	PHARM ASSOC	<u>10GM/15ML</u>	<u>A074623</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>	ROXANE	<u>10GM/15ML</u>	<u>A073591</u>	<u>001</u>	May 29, 1992
<u>AA</u>	VINTAGE PHARMS	<u>10GM/15ML</u>	<u>A075993</u>	<u>001</u>	Jul 26, 2001
<u>AA</u>	VISTAPHARM	<u>10GM/15ML</u>	<u>A074138</u>	<u>001</u>	Sep 30, 1992
SOLUTION; ORAL, RECTAL					
<u>CHOLAC</u>					
<u>AA</u>	ALRA	<u>10GM/15ML</u>	<u>A071331</u>	<u>001</u>	Jul 26, 1988
<u>ENULOSE</u>					
<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>10GM/15ML</u>	<u>A071548</u>	<u>001</u>	Aug 15, 1988
<u>GENERLAC</u>					
<u>AA</u>	MORTON GROVE PHARMS	<u>10GM/15ML</u>	<u>A074603</u>	<u>001</u>	Oct 31, 1996
<u>LACTULOSE</u>					
<u>AA</u>	ANI PHARMS	<u>10GM/15ML</u>	<u>A090426</u>	<u>001</u>	Nov 21, 2008
<u>AA</u>	HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074077</u>	<u>001</u>	Jul 03, 1995
<u>AA</u>	NOVEX	<u>10GM/15ML</u>	<u>A076645</u>	<u>001</u>	Jul 28, 2003

LAMIVUDINE

SOLUTION; ORAL					
EPIVIR					
	+ VIIV HLTHCARE	10MG/ML	N020596	001	Nov 17, 1995
EPIVIR-HBV					
	+ GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998
TABLET; ORAL					
EPIVIR					
	VIIV HLTHCARE	150MG	N020564	001	Nov 17, 1995
	+	300MG	N020564	003	Jun 24, 2002
EPIVIR-HBV					
	+ GLAXOSMITHKLINE	100MG	N021003	001	Dec 08, 1998

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL					
COMBIVIR					
	+ VIIV HLTHCARE	150MG;300MG	N020857	001	Sep 26, 1997

LAMOTRIGINE

TABLET; ORAL					
<u>LAMICTAL</u>					
<u>AB</u>	+ GLAXOSMITHKLINE	<u>25MG</u>	<u>N020241</u>	<u>005</u>	Dec 27, 1994
<u>AB</u>		<u>100MG</u>	<u>N020241</u>	<u>001</u>	Dec 27, 1994
<u>AB</u>		<u>150MG</u>	<u>N020241</u>	<u>002</u>	Dec 27, 1994
<u>AB</u>		<u>200MG</u>	<u>N020241</u>	<u>003</u>	Dec 27, 1994
<u>LAMOTRIGINE</u>					
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A078625</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078625</u>	<u>002</u>	Jan 27, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 229 (of 393)

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

<u>AB</u>	APOTEX INC	<u>150MG</u>	<u>A078625</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078625</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078956</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078956</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078956</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078956</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A079132</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079132</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A079132</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079132</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A076708</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076708</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A076708</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076708</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	MATRIX LABS LTD	<u>25MG</u>	<u>A078443</u>	<u>001</u>	Feb 11, 2009
<u>AB</u>		<u>100MG</u>	<u>A078443</u>	<u>002</u>	Feb 11, 2009
<u>AB</u>		<u>150MG</u>	<u>A078443</u>	<u>003</u>	Feb 11, 2009
<u>AB</u>		<u>200MG</u>	<u>A078443</u>	<u>004</u>	Feb 11, 2009
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077420</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077420</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077420</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077420</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	ROXANE	<u>25MG</u>	<u>A077392</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077392</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077392</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077392</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A078645</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078645</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078645</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078645</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TARO PHARM INDS	<u>25MG</u>	<u>A078525</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078525</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078525</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078525</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076388</u>	<u>001</u>	Aug 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A076388</u>	<u>002</u>	Aug 30, 2006
<u>AB</u>		<u>150MG</u>	<u>A076388</u>	<u>003</u>	Aug 30, 2006
<u>AB</u>		<u>200MG</u>	<u>A076388</u>	<u>004</u>	Aug 30, 2006
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A078947</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078947</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078947</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078947</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A078310</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>100MG</u>	<u>A078310</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>		<u>150MG</u>	<u>A078310</u>	<u>003</u>	Feb 04, 2009
<u>AB</u>		<u>200MG</u>	<u>A078310</u>	<u>004</u>	Feb 04, 2009
<u>AB</u>	WOCKHARDT	<u>25MG</u>	<u>A078982</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078982</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078982</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078982</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077633</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077633</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077633</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077633</u>	<u>005</u>	Jan 27, 2009
LAMOTRIGINE	ZYDUS PHARMS USA	50MG	A077633	002	Jan 27, 2009
		250MG	A077633	006	Jan 27, 2009



## PRESCRIPTION DRUG PRODUCT LIST

3 - 230 (of 393)

LAMOTRIGINE

TABLET, CHEWABLE; ORAL

LAMICTAL CD

<u>AB</u>	GLAXOSMITHKLINE	<u>2MG</u>	<u>N020764</u>	<u>004</u>	Sep 08, 2000
<u>AB</u>		<u>5MG</u>	<u>N020764</u>	<u>001</u>	Aug 24, 1998
<u>AB</u>	+	<u>25MG</u>	<u>N020764</u>	<u>002</u>	Aug 24, 1998

LAMOTRIGINE

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A090401</u>	<u>002</u>	Nov 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A090401</u>	<u>003</u>	Nov 04, 2009
<u>AB</u>	COBALT LABS INC	<u>2MG</u>	<u>A076928</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>5MG</u>	<u>A076928</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076928</u>	<u>003</u>	Jan 22, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076701</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076701</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A079099</u>	<u>001</u>	Feb 19, 2009
<u>AB</u>		<u>25MG</u>	<u>A079099</u>	<u>002</u>	Feb 19, 2009
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076630</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076630</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>	TARO	<u>5MG</u>	<u>A079204</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A079204</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076420</u>	<u>001</u>	Jun 21, 2006
<u>AB</u>		<u>25MG</u>	<u>A076420</u>	<u>002</u>	Jun 21, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078009</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078009</u>	<u>003</u>	Jan 22, 2009

TABLET, EXTENDED RELEASE; ORAL

## LAMICTAL XR

	SMITHKLINE BEECHAM	25MG	N022115	001	May 29, 2009
+		50MG	N022115	002	May 29, 2009
		100MG	N022115	003	May 29, 2009
		200MG	N022115	004	May 29, 2009

TABLET, ORALLY DISINTEGRATING; ORAL

## LAMICTAL ODT

	SMITHKLINE BEECHAM	25MG	N022251	001	May 08, 2009
+		50MG	N022251	002	May 08, 2009
		100MG	N022251	003	May 08, 2009
		200MG	N022251	004	May 08, 2009

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

## SOMATULINE DEPOT

+	BEAUFOR IPSEN	EQ 60MG BASE	N022074	001	Aug 30, 2007
+		EQ 90MG BASE	N022074	002	Aug 30, 2007
+		EQ 120MG BASE	N022074	003	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

<u>AB</u>	MATRIX LABS LTD	<u>15MG</u>	<u>A090763</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A090763</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>	TEVA PHARMS	<u>15MG</u>	<u>A077255</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A077255</u>	<u>002</u>	Nov 10, 2009

PREVACID

<u>AB</u>	TAKEDA PHARMS NA	<u>15MG</u>	<u>N020406</u>	<u>001</u>	May 10, 1995
<u>AB</u>	+	<u>30MG</u>	<u>N020406</u>	<u>002</u>	May 10, 1995

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

## PREVACID

	TAKEDA PHARMS NA	15MG	N021428	001	Aug 30, 2002
+		30MG	N021428	002	Aug 30, 2002

## PRESCRIPTION DRUG PRODUCT LIST

3 - 231 (of 393)

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

SHIRE

EQ 500MG BASE

N021468 002

Oct 26, 2004

EQ 750MG BASE

N021468 003

Nov 23, 2005

+

EQ 1GM BASE

N021468 004

Nov 23, 2005

LAPATINIB DITOSYLATE

TABLET; ORAL

TYKERB

+ SMITHKLINE BEECHAM

EQ 250MG BASE

N022059 001

Mar 13, 2007

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

+ PHARMACIA AND UPJOHN 0.005%

N020597 001

Jun 05, 1996

LEFLUNOMIDE

TABLET; ORAL

ARAVAAB SANOFI AVENTIS US10MGN020905 001

Sep 10, 1998

AB +20MGN020905 002

Sep 10, 1998

LEFLUNOMIDEAB APOTEX INC10MGA077090 001

Sep 13, 2005

AB20MGA077090 002

Sep 13, 2005

AB

BARR

10MGA077083 001

Sep 13, 2005

AB20MGA077083 002

Sep 13, 2005

AB

HERITAGE PHARMS INC

10MGA077086 001

Sep 13, 2005

AB20MGA077086 002

Sep 13, 2005

AB

SANDOZ

10MGA077087 001

Sep 13, 2005

AB20MGA077087 002

Sep 13, 2005

AB

TEVA PHARMS

10MGA077084 001

Sep 13, 2005

AB20MGA077084 002

Sep 13, 2005

ARAVA

+ SANOFI AVENTIS US

100MG

N020905 003

Sep 10, 1998

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

CELGENE

5MG

N021880 001

Dec 27, 2005

10MG

N021880 002

Dec 27, 2005

15MG

N021880 003

Jun 29, 2006

+

25MG

N021880 004

Jun 29, 2006

LEPIRUDIN RECOMBINANT

INJECTABLE; INJECTION

REFLUDAN

+ BAYER HLTHCARE

50MG/VIAL

N020807 001

Mar 06, 1998

LETROZOLE

TABLET; ORAL

FEMARAAB + NOVARTIS PHARMS2.5MGN020726 001

Jul 25, 1997

LETROZOLEAB MYLAN2.5MGA078190 001

Dec 24, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 232 (of 393)

LEUCOVORIN CALCIUM

## INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

<u>AP</u>	+	BEDFORD	<u>EQ 50MG BASE/VIAL</u>	<u>A089384</u>	<u>001</u>	Sep 14, 1987
<u>AP</u>	+		<u>EQ 100MG BASE/VIAL</u>	<u>A089717</u>	<u>001</u>	Mar 28, 1988
<u>AP</u>	+	HOSPIRA	<u>EQ 350MG BASE/VIAL</u>	<u>N008107</u>	<u>005</u>	Apr 05, 1989
<u>AP</u>		TEVA PARENTERAL	<u>EQ 50MG BASE/VIAL</u>	<u>A081278</u>	<u>001</u>	Sep 28, 1993
<u>AP</u>			<u>EQ 100MG BASE/VIAL</u>	<u>A081277</u>	<u>001</u>	Sep 28, 1993
<u>AP</u>			<u>EQ 350MG BASE/VIAL</u>	<u>A040174</u>	<u>001</u>	Jun 12, 1997

LEUCOVORIN CALCIUM PRESERVATIVE FREE

<u>AP</u>		APP PHARMS	<u>EQ 200MG BASE/VIAL</u>	<u>A040258</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>	+	BEDFORD	<u>EQ 200MG BASE/VIAL</u>	<u>A040056</u>	<u>001</u>	May 23, 1995
<u>AP</u>			<u>EQ 350MG BASE/VIAL</u>	<u>A040335</u>	<u>001</u>	Apr 20, 2000
<u>AP</u>		LUITPOLD	<u>EQ 50MG BASE/VIAL</u>	<u>A040338</u>	<u>001</u>	Jan 31, 2001
		LEUCOVORIN CALCIUM PRESERVATIVE FREE				
	+	APP PHARMS	EQ 500MG BASE/VIAL	A040286	001	Feb 26, 1999
	+	BEDFORD	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000

## TABLET; ORAL

LEUCOVORIN CALCIUM

<u>AB</u>		BARR	<u>EQ 5MG BASE</u>	<u>A071198</u>	<u>001</u>	Sep 24, 1987
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A071199</u>	<u>001</u>	Sep 24, 1987
<u>AB</u>		ROXANE	<u>EQ 5MG BASE</u>	<u>A072733</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A072735</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>	+		<u>EQ 25MG BASE</u>	<u>A072736</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>		SANDOZ	<u>EQ 15MG BASE</u>	<u>A075327</u>	<u>001</u>	Mar 24, 1999
		LEUCOVORIN CALCIUM				
		ROXANE	EQ 10MG BASE	A072734	001	Feb 22, 1993

LEUPROLIDE ACETATE

## INJECTABLE; INJECTION

LEUPROLIDE ACETATE

<u>AP</u>		BEDFORD LABS	<u>1MG/0.2ML</u>	<u>A074728</u>	<u>001</u>	Aug 04, 1998
<u>AP</u>		GENZYME	<u>1MG/0.2ML</u>	<u>A075721</u>	<u>001</u>	Nov 29, 2001
<u>AP</u>		SUN PHARMA GLOBAL	<u>1MG/0.2ML</u>	<u>A078885</u>	<u>001</u>	Mar 09, 2009
<u>AP</u>		TEVA PARENTERAL	<u>1MG/0.2ML</u>	<u>A075471</u>	<u>001</u>	Oct 25, 2000

LUPRON

<u>AP</u>	+	ABBOTT LABS	<u>1MG/0.2ML</u>	<u>N019010</u>	<u>001</u>	Apr 09, 1985
		LUPRON DEPOT				
	+	ABBOTT LABS	3.75MG/VIAL	N020011	001	Oct 22, 1990
	+		7.5MG/VIAL	N019732	001	Jan 26, 1989
	+		22.5MG/VIAL	N020517	001	Dec 22, 1995
		LUPRON DEPOT-3				
	+	ABBOTT LABS	11.25MG/VIAL	N020708	001	Mar 07, 1997
		LUPRON DEPOT-4				
	+	ABBOTT LABS	30MG/VIAL	N020517	002	May 30, 1997
		LUPRON DEPOT-PED				
	+	ABBOTT LABS	7.5MG/VIAL	N020263	002	Apr 16, 1993
	+		11.25MG/VIAL	N020263	005	Jan 21, 1994
	+		15MG/VIAL	N020263	006	Jan 21, 1994

## INJECTABLE; SUBCUTANEOUS

## ELIGARD

	+	TOLMAR THERAP	7.5MG/VIAL	N021343	001	Jan 23, 2002
	+		22.5MG/VIAL	N021379	001	Jul 24, 2002
	+		30MG/VIAL	N021488	001	Feb 13, 2003
	+		45MG/VIAL	N021731	001	Dec 14, 2004

LEVALBUTEROL HYDROCHLORIDE

## SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

<u>AN</u>		BREATH LTD	EQ 0.0103% BASE	A077756	003	Apr 09, 2008
-----------	--	------------	-----------------	---------	-----	--------------

**WATSON LABORATORIES, INC., IPR2017-01621, Ex. 1085, p. 259 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 233 (of 393)

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

<u>AN</u>	BREATH LTD	<u>EQ 0.021% BASE</u>	<u>A077756</u>	<u>001</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077756</u>	<u>002</u>	Apr 09, 2008
<u>AN</u>	DEY	<u>EQ 0.25% BASE</u>	<u>A078309</u>	<u>001</u>	Mar 20, 2009
	<u>XOPENEX</u>				
<u>AN</u>	+ SEPRACOR	<u>EQ 0.0103% BASE</u>	<u>N020837</u>	<u>003</u>	Jan 30, 2002
<u>AN</u>	+	<u>EQ 0.021% BASE</u>	<u>N020837</u>	<u>001</u>	Mar 25, 1999
<u>AN</u>	+	<u>EQ 0.042% BASE</u>	<u>N020837</u>	<u>002</u>	Mar 25, 1999
<u>AN</u>	+	<u>EQ 0.25% BASE</u>	<u>N020837</u>	<u>004</u>	Jul 18, 2003

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION

XOPENEX HFA

+	SEPRACOR	EQ 0.045MG BASE/INH	N021730	001	Mar 11, 2005
---	----------	---------------------	---------	-----	--------------

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

+	UCB INC	500MG/5ML (100MG/ML)	N021872	001	Jul 31, 2006
---	---------	----------------------	---------	-----	--------------

SOLUTION; ORAL

KEPPRA

<u>AA</u>	+ UCB INC	<u>100MG/ML</u>	<u>N021505</u>	<u>001</u>	Jul 15, 2003
-----------	-----------	-----------------	----------------	------------	--------------

LEVETIRACETAM

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>100MG/ML</u>	<u>A078976</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>	AMNEAL PHARMS	<u>100MG/ML</u>	<u>A090992</u>	<u>001</u>	Oct 27, 2009
<u>AA</u>	AUROBINDO PHARM	<u>100MG/ML</u>	<u>A079063</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>	CYPRESS PHARM	<u>100MG/ML</u>	<u>A079120</u>	<u>001</u>	Jan 16, 2009
<u>AA</u>	ROXANE	<u>100MG/ML</u>	<u>A078582</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>	SILARX	<u>100MG/ML</u>	<u>A090263</u>	<u>001</u>	Apr 03, 2009
<u>AA</u>	TARO	<u>100MG/ML</u>	<u>A078774</u>	<u>001</u>	Feb 10, 2009
<u>AA</u>	TOLMAR	<u>100MG/ML</u>	<u>A079107</u>	<u>001</u>	Jan 15, 2009

TABLET; ORAL

KEPPRA

<u>AB</u>	UCB INC	<u>250MG</u>	<u>N021035</u>	<u>001</u>	Nov 30, 1999
<u>AB</u>		<u>500MG</u>	<u>N021035</u>	<u>002</u>	Nov 30, 1999
<u>AB</u>		<u>750MG</u>	<u>N021035</u>	<u>003</u>	Nov 30, 1999
<u>AB</u>	+	<u>1GM</u>	<u>N021035</u>	<u>004</u>	Jan 06, 2006

LEVETIRACETAM

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A078869</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>		<u>500MG</u>	<u>A078869</u>	<u>002</u>	Mar 13, 2009
<u>AB</u>		<u>750MG</u>	<u>A078869</u>	<u>003</u>	Mar 13, 2009
<u>AB</u>		<u>1GM</u>	<u>A078869</u>	<u>004</u>	Mar 13, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>250MG</u>	<u>A078993</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078993</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078993</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078993</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	BOCA PHARMA	<u>250MG</u>	<u>A077319</u>	<u>001</u>	Mar 20, 2009
<u>AB</u>		<u>500MG</u>	<u>A077319</u>	<u>002</u>	Mar 20, 2009
<u>AB</u>		<u>750MG</u>	<u>A077319</u>	<u>003</u>	Mar 20, 2009
<u>AB</u>	COBALT LABS INC	<u>250MG</u>	<u>A077384</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A077384</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A077384</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078797</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>250MG</u>	<u>A076920</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A076920</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A076920</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078904</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A078234</u>	<u>001</u>	Jan 15, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 234 (of 393)

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>	INVAGEN PHARMS	<u>500MG</u>	<u>A078234</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078234</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A078154</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078154</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078154</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090025</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A076919</u>	<u>001</u>	Nov 04, 2008
<u>AB</u>		<u>500MG</u>	<u>A076919</u>	<u>002</u>	Nov 04, 2008
<u>AB</u>		<u>750MG</u>	<u>A076919</u>	<u>003</u>	Nov 04, 2008
<u>AB</u>		<u>1GM</u>	<u>A090261</u>	<u>001</u>	Dec 08, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A078526</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078526</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078526</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A078042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A077324</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A077324</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A077324</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A077324</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	SOLCO HLTHCARE	<u>250MG</u>	<u>A078106</u>	<u>001</u>	Feb 10, 2009
<u>AB</u>		<u>500MG</u>	<u>A078106</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>		<u>750MG</u>	<u>A078106</u>	<u>003</u>	Feb 10, 2009
<u>AB</u>		<u>1GM</u>	<u>A078106</u>	<u>004</u>	Feb 10, 2009
<u>AB</u>	TEVA PHARMS	<u>250MG</u>	<u>A078101</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078101</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078101</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078101</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A078858</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078858</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078858</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078858</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A079042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A079042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A079042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A079042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A078918</u>	<u>001</u>	Apr 29, 2009
<u>AB</u>		<u>1GM</u>	<u>A078918</u>	<u>002</u>	Apr 29, 2009
TABLET, EXTENDED RELEASE; ORAL					
	KEPPRA XR				
	UCB INC	500MG	N022285	001	Sep 12, 2008
	+	750MG	N022285	002	Feb 12, 2009

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKBETA

<u>AT</u>	AKORN	<u>0.25%</u>	<u>A074779</u>	<u>001</u>	Oct 29, 1996
<u>AT</u>		<u>0.5%</u>	<u>A074780</u>	<u>001</u>	Oct 29, 1996
<u>BETAGAN</u>					
<u>AT</u>	+ ALLERGAN	<u>0.25%</u>	<u>N019814</u>	<u>001</u>	Jun 28, 1989
<u>AT</u>	+	<u>0.5%</u>	<u>N019219</u>	<u>002</u>	Dec 19, 1985

LEVOBUNOLOL HYDROCHLORIDE

<u>AT</u>	BAUSCH AND LOMB	<u>0.25%</u>	<u>A074307</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>		<u>0.5%</u>	<u>A074326</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>	FALCON PHARMS	<u>0.25%</u>	<u>A074851</u>	<u>001</u>	Oct 28, 1996
<u>AT</u>		<u>0.5%</u>	<u>A074850</u>	<u>001</u>	Oct 28, 1996

## PRESCRIPTION DRUG PRODUCT LIST

3 - 235 (of 393)

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

<u>AT</u>	NOVEX	<u>0.25%</u>	<u>A075473</u>	<u>001</u>	Aug 03, 2000
<u>AT</u>		<u>0.5%</u>	<u>A075475</u>	<u>001</u>	Aug 03, 2000

LEVOCARNITINE

INJECTABLE; INJECTION

CARNITOR

<u>AP</u>	+ SIGMA TAU	<u>200MG/ML</u>	<u>N020182</u>	<u>001</u>	Dec 16, 1992
-----------	-------------	-----------------	----------------	------------	--------------

LEVOCARNITINE

<u>AP</u>	BEDFORD	<u>200MG/ML</u>	<u>A075567</u>	<u>001</u>	Mar 29, 2001
<u>AP</u>	LUITPOLD	<u>200MG/ML</u>	<u>A075861</u>	<u>001</u>	Jun 22, 2001
<u>AP</u>	TEVA PARENTERAL	<u>200MG/ML</u>	<u>A075881</u>	<u>001</u>	Mar 29, 2001

SOLUTION; ORAL

CARNITOR

<u>AA</u>	+ SIGMA TAU	<u>1GM/10ML</u>	<u>N019257</u>	<u>001</u>	Apr 10, 1986
-----------	-------------	-----------------	----------------	------------	--------------

CARNITOR SF

<u>AA</u>	SIGMA TAU	<u>1GM/10ML</u>	<u>N019257</u>	<u>002</u>	Mar 28, 2007
-----------	-----------	-----------------	----------------	------------	--------------

LEVOCARNITINE

<u>AA</u>	HI TECH PHARMA	<u>1GM/10ML</u>	<u>A077399</u>	<u>001</u>	Oct 25, 2007
<u>AA</u>	LYNE	<u>1GM/10ML</u>	<u>A076851</u>	<u>001</u>	Aug 10, 2004

TABLET; ORAL

CARNITOR

<u>AB</u>	+ SIGMA TAU	<u>330MG</u>	<u>N018948</u>	<u>001</u>	Dec 27, 1985
-----------	-------------	--------------	----------------	------------	--------------

LEVOCARNITINE

<u>AB</u>	COREPHARMA	<u>330MG</u>	<u>A076858</u>	<u>001</u>	Sep 20, 2004
-----------	------------	--------------	----------------	------------	--------------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

XYZAL

	+ UCB INC	2.5MG/5ML	N022157	001	Jan 28, 2008
--	-----------	-----------	---------	-----	--------------

TABLET; ORAL

XYZAL

	+ UCB INC	5MG	N022064	001	May 25, 2007
--	-----------	-----	---------	-----	--------------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

	+ ORTHO MCNEIL PHARM	EQ 500MG/20ML (EQ 25MG/ML)	N020635	001	Dec 20, 1996
--	----------------------	----------------------------	---------	-----	--------------

	+	EQ 750MG/30ML (EQ 25MG/ML)	N020635	004	Dec 20, 1996
--	---	----------------------------	---------	-----	--------------

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

	+ ORTHO MCNEIL PHARM	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996
--	----------------------	---------------------------	---------	-----	--------------

	+	EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996
--	---	----------------------------	---------	-----	--------------

	+	EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996
--	---	----------------------------	---------	-----	--------------

SOLUTION; ORAL

LEVAQUIN

	+ ORTHO MCNEIL JANSSEN	250MG/10ML	N021721	001	Oct 21, 2004
--	------------------------	------------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

	+ SANTEN	1.5%	N021571	001	Mar 01, 2004
--	----------	------	---------	-----	--------------

QUIXIN

	+ SANTEN	0.5%	N021199	001	Aug 18, 2000
--	----------	------	---------	-----	--------------

TABLET; ORAL

LEVAQUIN

	ORTHO MCNEIL JANSSEN	250MG	N020634	001	Dec 20, 1996
--	----------------------	-------	---------	-----	--------------

		500MG	N020634	002	Dec 20, 1996
--	--	-------	---------	-----	--------------

	+	750MG	N020634	003	Sep 08, 2000
--	---	-------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 236 (of 393)

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

+ SPECTRUM PHARMS EQ 50MG BASE/VIAL N020140 001 Mar 07, 2008

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRINAP NOVOCOL 0.05MG/ML;2% A084697 001SCANDONEST LAP DEPROCO 0.05MG/ML;2% A088388 001 Oct 10, 1984LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

MIRENA

+ BAYER HLTHCARE 52MG N021225 001 Dec 06, 2000

TABLET; ORAL

LEVONORGESTRELAB WATSON LABS 0.75MG A078665 001 Aug 28, 2009AB 0.75MG A078666 001 Jun 24, 2009PLAN BAB + DURAMED 0.75MG N021045 002 Aug 24, 2006

PLAN B ONE-STEP

+ DURAMED 1.5MG N021998 001 Jul 10, 2009

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORANAB + VALEANT PHARM INTL 2MG N008720 001 Dec 19, 1991LEVORPHANOL TARTRATEAB ROXANE 2MG A074278 001 Mar 31, 2000LEVOTHYROXINE SODIUM\*\*

\*\*Refer to Preface Section 1.8 Levothyroxine Sodium for amplifying information\*\*

TABLET; ORAL

LEVO-T

--&gt; ALARA PHARM --&gt; AB2,AB3 0.025MG N021342 001 Mar 01, 2002

--&gt; --&gt; AB2,AB3 0.05MG N021342 002 Mar 01, 2002

--&gt; --&gt; AB2,AB3 0.075MG N021342 003 Mar 01, 2002

--&gt; --&gt; AB2,AB3 0.088MG N021342 004 Mar 01, 2002

--&gt; --&gt; AB2,AB3 0.1MG N021342 005 Mar 01, 2002

--&gt; --&gt; AB2,AB3 0.112MG N021342 006 Mar 01, 2002

--&gt; --&gt; AB2,AB3 0.125MG N021342 007 Mar 01, 2002

--&gt; --&gt; AB2,AB3 0.137MG N021342 012 Dec 08, 2003

--&gt; --&gt; AB2,AB3 0.15MG N021342 008 Mar 01, 2002

--&gt; --&gt; AB2,AB3 0.175MG N021342 009 Mar 01, 2002

--&gt; --&gt; AB2,AB3 0.2MG N021342 010 Mar 01, 2002

--&gt; + --&gt; AB2,AB3 0.3MG N021342 011 Mar 01, 2002

LEVOTHYROXINE SODIUM

--&gt; MERCK KGAA --&gt; AB2,AB3 0.025MG A076752 001 Jun 16, 2005

--&gt; --&gt; AB2,AB3 0.05MG A076752 002 Jun 16, 2005

--&gt; --&gt; AB2,AB3 0.075MG A076752 003 Jun 16, 2005

--&gt; --&gt; AB2,AB3 0.088MG A076752 004 Jun 16, 2005

--&gt; --&gt; AB2,AB3 0.1MG A076752 005 Jun 16, 2005

--&gt; --&gt; AB2,AB3 0.112MG A076752 006 Jun 16, 2005

--&gt; --&gt; AB2,AB3 0.125MG A076752 007 Jun 16, 2005

--&gt; --&gt; AB2,AB3 0.15MG A076752 008 Jun 16, 2005

--&gt; --&gt; AB2,AB3 0.175MG A076752 009 Jun 16, 2005

--&gt; --&gt; AB2,AB3 0.2MG A076752 010 Jun 16, 2005

## PRESCRIPTION DRUG PRODUCT LIST

3 - 237 (of 393)

LEVOTHYROXINE SODIUM\*\*

\*\*Refer to Preface Section 1.8 Levothyroxine Sodium for amplifying information\*\*

TABLET; ORAL						
LEVOTHYROXINE SODIUM						
-->	MERCK KGAA	-->	AB2,AB3	0.3MG	A076752	011 Jun 16, 2005
-->	MYLAN	-->	AB1,AB2,AB3,AB4	0.025MG	A076187	001 Jun 05, 2002
-->		-->	AB1,AB2,AB3,AB4	0.05MG	A076187	002 Jun 05, 2002
-->		-->	AB1,AB2,AB3,AB4	0.075MG	A076187	003 Jun 05, 2002
-->		-->	AB1,AB2,AB3,AB4	0.088MG	A076187	004 Jun 05, 2002
-->		-->	AB1,AB2,AB3,AB4	0.1MG	A076187	005 Jun 05, 2002
-->		-->	AB1,AB2,AB3,AB4	0.112MG	A076187	006 Jun 05, 2002
-->		-->	AB1,AB2,AB3,AB4	0.125MG	A076187	007 Jun 05, 2002
-->		-->	AB1,AB2,AB3,AB4	0.137MG	A076187	012 Dec 13, 2006
-->		-->	AB1,AB2,AB3,AB4	0.15MG	A076187	008 Jun 05, 2002
-->		-->	AB1,AB2,AB3,AB4	0.175MG	A076187	009 Jun 05, 2002
-->		-->	AB1,AB2,AB3,AB4	0.2MG	A076187	010 Jun 05, 2002
-->		-->	AB1,AB2,AB3,AB4	0.3MG	A076187	011 Jun 05, 2002
LEVOXYL						
-->	KING PHARMS	-->	AB1,AB3	0.025MG	N021301	001 May 25, 2001
-->		-->	AB1,AB3	0.05MG	N021301	002 May 25, 2001
-->		-->	AB1,AB3	0.075MG	N021301	003 May 25, 2001
-->		-->	AB1,AB3	0.088MG	N021301	004 May 25, 2001
-->		-->	AB1,AB3	0.1MG	N021301	005 May 25, 2001
-->		-->	AB1,AB3	0.112MG	N021301	006 May 25, 2001
-->		-->	AB1,AB3	0.125MG	N021301	007 May 25, 2001
-->		-->	AB1,AB3	0.137MG	N021301	008 May 25, 2001
-->		-->	AB1,AB3	0.15MG	N021301	009 May 25, 2001
-->		-->	AB1,AB3	0.175MG	N021301	010 May 25, 2001
--> +		-->	AB1,AB3	0.2MG	N021301	011 May 25, 2001
SYNTHROID						
-->	ABBOTT	-->	AB1,AB2	0.025MG	N021402	001 Jul 24, 2002
-->		-->	AB1,AB2	0.05MG	N021402	002 Jul 24, 2002
-->		-->	AB1,AB2	0.075MG	N021402	003 Jul 24, 2002
-->		-->	AB1,AB2	0.088MG	N021402	004 Jul 24, 2002
-->		-->	AB1,AB2	0.1MG	N021402	005 Jul 24, 2002
-->		-->	AB1,AB2	0.112MG	N021402	006 Jul 24, 2002
-->		-->	AB1,AB2	0.125MG	N021402	007 Jul 24, 2002
-->		-->	AB1,AB2	0.137MG	N021402	008 Jul 24, 2002
-->		-->	AB1,AB2	0.15MG	N021402	009 Jul 24, 2002
-->		-->	AB1,AB2	0.175MG	N021402	010 Jul 24, 2002
-->		-->	AB1,AB2	0.2MG	N021402	012 Jul 24, 2002
--> +		-->	AB1,AB2	0.3MG	N021402	011 Jul 24, 2002
UNITHROID						
-->	STEVENS J	-->	AB1,AB2,AB3	0.025MG	N021210	001 Aug 21, 2000
-->		-->	AB1,AB2,AB3	0.05MG	N021210	002 Aug 21, 2000
-->		-->	AB1,AB2,AB3	0.075MG	N021210	003 Aug 21, 2000
-->		-->	AB1,AB2,AB3	0.088MG	N021210	004 Aug 21, 2000
-->		-->	AB1,AB2,AB3	0.1MG	N021210	005 Aug 21, 2000
-->		-->	AB1,AB2,AB3	0.112MG	N021210	006 Aug 21, 2000
-->		-->	AB1,AB2,AB3	0.125MG	N021210	007 Aug 21, 2000
-->		-->	AB1,AB2,AB3	0.137MG	N021210	012 Feb 08, 2008
-->		-->	AB1,AB2,AB3	0.15MG	N021210	008 Aug 21, 2000
-->		-->	AB1,AB2,AB3	0.175MG	N021210	009 Aug 21, 2000
-->		-->	AB1,AB2,AB3	0.2MG	N021210	010 Aug 21, 2000
--> +		-->	AB1,AB2,AB3	0.3MG	N021210	011 Aug 21, 2000
<u>LEVOTHROID</u>						
<u>AB4</u>	LLOYD		<u>0.025MG</u>		<u>N021116</u>	<u>001</u> Oct 24, 2002
<u>AB4</u>			<u>0.05MG</u>		<u>N021116</u>	<u>002</u> Oct 24, 2002
<u>AB4</u>			<u>0.075MG</u>		<u>N021116</u>	<u>003</u> Oct 24, 2002
<u>AB4</u>			<u>0.088MG</u>		<u>N021116</u>	<u>010</u> Oct 24, 2002



## PRESCRIPTION DRUG PRODUCT LIST

3 - 238 (of 393)

LEVOTHYROXINE SODIUM\*\*

\*\*Refer to Preface Section 1.8 Levothyroxine Sodium for amplifying information\*\*

TABLET; ORAL

LEVOTHROID

<u>AB4</u>	LLOYD	<u>0.1MG</u>	<u>N021116</u>	<u>004</u>	Oct 24, 2002
<u>AB4</u>		<u>0.112MG</u>	<u>N021116</u>	<u>011</u>	Oct 24, 2002
<u>AB4</u>		<u>0.125MG</u>	<u>N021116</u>	<u>005</u>	Oct 24, 2002
<u>AB4</u>		<u>0.137MG</u>	<u>N021116</u>	<u>012</u>	Dec 07, 2004
<u>AB4</u>		<u>0.15MG</u>	<u>N021116</u>	<u>006</u>	Oct 24, 2002
<u>AB4</u>		<u>0.175MG</u>	<u>N021116</u>	<u>007</u>	Oct 24, 2002
<u>AB4</u>		<u>0.2MG</u>	<u>N021116</u>	<u>008</u>	Oct 24, 2002
<u>AB4</u> +		<u>0.3MG</u>	<u>N021116</u>	<u>009</u>	Oct 24, 2002

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

<u>AT</u>	+ FOUGERA	<u>5%</u>	<u>A080198</u>	<u>001</u>	
<u>AT</u>	TARO	<u>5%</u>	<u>A086724</u>	<u>001</u>	

PATCH; TOPICAL

LIDODERM

	+ TEIKOKU PHARMA USA	5%	N020612	001	Mar 19, 1999
--	----------------------	----	---------	-----	--------------

LIDOCAINE HYDROCHLORIDE

GEL; OPHTHALMIC

AKTEN

	+ AKORN	3.5%	N022221	001	Oct 07, 2008
--	---------	------	---------	-----	--------------

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088328</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>1%</u>	<u>A040013</u>	<u>001</u>	Jun 23, 1995
<u>AP</u>		<u>1%</u>	<u>A083158</u>	<u>001</u>	
<u>AP</u>		<u>1%</u>	<u>A088329</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>2%</u>	<u>A040078</u>	<u>001</u>	Jun 23, 1995
<u>AP</u>		<u>2%</u>	<u>A083158</u>	<u>002</u>	
<u>AP</u>		<u>2%</u>	<u>A088294</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>20%</u>	<u>A083158</u>	<u>003</u>	
<u>AP</u>	INTL MEDICATION	<u>1%</u>	<u>A083173</u>	<u>001</u>	
<u>AP</u>		<u>2%</u>	<u>A083173</u>	<u>002</u>	
<u>AP</u>	LUITPOLD	<u>1%</u>	<u>A080850</u>	<u>001</u>	
<u>AP</u>		<u>2%</u>	<u>A083198</u>	<u>001</u>	

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>200MG/100ML</u>	<u>N019830</u>	<u>002</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML</u>	<u>N018461</u>	<u>002</u>	

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>400MG/100ML</u>	<u>N019830</u>	<u>003</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>400MG/100ML</u>	<u>N018461</u>	<u>003</u>	

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>400MG/100ML</u>	<u>N018388</u>	<u>002</u>	
-----------	---------	--------------------	----------------	------------	--

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>800MG/100ML</u>	<u>N019830</u>	<u>004</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>800MG/100ML</u>	<u>N018461</u>	<u>004</u>	Feb 22, 1982

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>800MG/100ML</u>	<u>N018388</u>	<u>003</u>	Nov 05, 1982
-----------	---------	--------------------	----------------	------------	--------------

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

<u>AP</u>	APP PHARMS	<u>1%</u>	<u>A088586</u>	<u>001</u>	Jul 24, 1985
<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088325</u>	<u>001</u>	Jul 31, 1984
<u>AP</u>		<u>1%</u>	<u>A088299</u>	<u>001</u>	Jul 31, 1984
<u>AP</u>		<u>2%</u>	<u>A088327</u>	<u>001</u>	Jul 31, 1984

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	ABRAXIS PHARM	2%	N017584	001	
-----------	---------------	----	---------	-----	--

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 265 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 239 (of 393)

LIDOCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	ABRAXIS PHARM	<u>4%</u>	<u>N017584</u>	<u>002</u>	
<u>AP</u>	APP PHARMS	<u>1%</u>	<u>A080404</u>	<u>002</u>	
<u>AP</u>		<u>2%</u>	<u>A080404</u>	<u>003</u>	
<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A080408</u>	<u>001</u>	
<u>AP</u>		<u>1.5%</u>	<u>A080408</u>	<u>002</u>	
<u>AP</u>		<u>4%</u>	<u>A088295</u>	<u>001</u>	May 17, 1984
<u>AP</u>	INTL MEDICATION	<u>20%</u>	<u>N017702</u>	<u>001</u>	

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A040302</u>	<u>001</u>	Sep 28, 1998
<u>AP</u>		<u>2%</u>	<u>A040302</u>	<u>002</u>	Sep 28, 1998

LIDOPEN

<u>AP</u>	MERIDIAN MEDCL TECHN	<u>10%</u>	<u>N017549</u>	<u>001</u>	
-----------	----------------------	------------	----------------	------------	--

XYLOCAINE

<u>AP</u>	+ APP PHARMS	<u>0.5%</u>	<u>N006488</u>	<u>008</u>	
<u>AP</u>	+	<u>1%</u>	<u>N006488</u>	<u>007</u>	
<u>AP</u>	+	<u>1.5%</u>	<u>N006488</u>	<u>010</u>	
<u>AP</u>	+	<u>2%</u>	<u>N006488</u>	<u>002</u>	

XYLOCAINE 4% PRESERVATIVE FREE

<u>AP</u>	+ APP PHARMS	<u>4%</u>	<u>N010417</u>	<u>001</u>	
-----------	--------------	-----------	----------------	------------	--

XYLOCAINE DENTAL

<u>AP</u>	+ DENTSPLY PHARM	<u>2%</u>	<u>N021380</u>	<u>001</u>	
-----------	------------------	-----------	----------------	------------	--

XYLOCAINE PRESERVATIVE FREE

<u>AP</u>	APP PHARMS	<u>1%</u>	<u>N016801</u>	<u>005</u>	Jan 19, 1988
<u>AP</u>	+	<u>2%</u>	<u>N016801</u>	<u>001</u>	
<u>AP</u>		<u>4%</u>	<u>N016801</u>	<u>002</u>	
<u>AP</u>	+	<u>10%</u>	<u>N016801</u>	<u>003</u>	
<u>AP</u>	+	<u>20%</u>	<u>N016801</u>	<u>004</u>	

## INJECTABLE; SPINAL

	LIDOCAINE HYDROCHLORIDE	5% AND DEXTROSE 7.5%			
	+ HOSPIRA	5%	A083914	001	

## JELLY; TOPICAL

ANESTACON

<u>AT</u>	POLYMEDICA	<u>2%</u>	<u>A080429</u>	<u>001</u>	
-----------	------------	-----------	----------------	------------	--

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	AKORN	<u>2%</u>	<u>A040433</u>	<u>001</u>	Feb 12, 2003
<u>AT</u>	INTL MEDICATION	<u>2%</u>	<u>A086283</u>	<u>001</u>	
<u>AT</u>	TEVA PHARMS	<u>2%</u>	<u>A081318</u>	<u>001</u>	Apr 29, 1993

XYLOCAINE

<u>AT</u>	+ APP PHARMS	<u>2%</u>	<u>N008816</u>	<u>001</u>	
-----------	--------------	-----------	----------------	------------	--

## SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>A040014</u>	<u>001</u>	Jul 10, 1995
<u>AT</u>	MORTON GROVE	<u>2%</u>	<u>A087872</u>	<u>001</u>	Nov 18, 1982

LIDOCAINE HYDROCHLORIDE VISCOUS

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>2%</u>	<u>A086578</u>	<u>001</u>	
<u>AT</u>	VINTAGE	<u>2%</u>	<u>A040708</u>	<u>001</u>	Feb 27, 2007

LIDOCAINE VISCOUS

<u>AT</u>	ROXANE	<u>2%</u>	<u>A088802</u>	<u>001</u>	Apr 26, 1985
-----------	--------	-----------	----------------	------------	--------------

XYLOCAINE VISCOUS

<u>AT</u>	+ APP PHARMS	<u>2%</u>	<u>N009470</u>	<u>001</u>	
-----------	--------------	-----------	----------------	------------	--

## SOLUTION; TOPICAL

LARYNG-O-JET KIT

<u>AT</u>	INTL MEDICATION	<u>4%</u>	<u>A086364</u>	<u>001</u>	
-----------	-----------------	-----------	----------------	------------	--

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	MORTON GROVE	<u>4%</u>	<u>A087881</u>	<u>001</u>	Nov 18, 1982
<u>AT</u>	ROXANE	<u>4%</u>	<u>A088803</u>	<u>001</u>	Apr 03, 1985
<u>AT</u>	VINTAGE	<u>4%</u>	<u>A040710</u>	<u>001</u>	Feb 27, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 240 (of 393)

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

LTA II KIT

<u>AT</u>	HOSPIRA	4%	<u>A080409</u>	<u>001</u>	
	<u>XYLOCAINE 4% PRESERVATIVE FREE</u>				
<u>AT</u>	+ APP PHARMS	4%	<u>N010417</u>	<u>002</u>	
	PEDIATRIC LTA KIT				
	HOSPIRA	2%	A085995	001	

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

<u>AB</u>	+ APP PHARMS	2.5%;2.5%	<u>N019941</u>	<u>001</u>	Dec 30, 1992
	<u>LIDOCAINE AND PRILOCAINE</u>				
<u>AB</u>	ALTANA	2.5%;2.5%	<u>A076453</u>	<u>001</u>	Aug 18, 2003
<u>AB</u>	HI TECH PHARMA	2.5%;2.5%	<u>A076290</u>	<u>001</u>	Sep 25, 2003
<u>AB</u>	TOLMAR	2.5%;2.5%	<u>A076320</u>	<u>001</u>	Aug 27, 2003

GEL; PERIODONTAL

## ORAQIX

	+ DENTSPLY PHARM	2.5%;2.5%	N021451	001	Dec 19, 2003
--	------------------	-----------	---------	-----	--------------

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

## LIDOCAINE AND TETRACAINE

	+ GALDERMA LABS LP	7%;7%	N021717	001	Jun 29, 2006
--	--------------------	-------	---------	-----	--------------

PATCH; TOPICAL

## SYNERA

	+ ZARS PHARM	70MG;70MG	N021623	001	Jun 23, 2005
--	--------------	-----------	---------	-----	--------------

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

## LINCOCIN

	+ PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N050317	001	
--	------------------------	------------------	---------	-----	--

LINDANE

LOTION; TOPICAL

## LINDANE

	+ MORTON GROVE	1%	A088190	001	Aug 16, 1984
--	----------------	----	---------	-----	--------------

SHAMPOO; TOPICAL

LINDANE

<u>AT</u>	MORTON GROVE	1%	<u>A088191</u>	<u>001</u>	Sep 18, 1984
<u>AT</u>	+ OLTA PHARMS	1%	<u>A087266</u>	<u>001</u>	

LINEZOLID

FOR SUSPENSION; ORAL

## ZYVOX

	+ PHARMACIA AND UPJOHN	100MG/5ML	N021132	001	Apr 18, 2000
--	------------------------	-----------	---------	-----	--------------

INJECTABLE; INJECTION

## ZYVOX

	+ PHARMACIA AND UPJOHN	200MG/100ML	N021131	001	Apr 18, 2000
--	------------------------	-------------	---------	-----	--------------

TABLET; ORAL

## ZYVOX

	+ PHARMACIA AND UPJOHN	600MG	N021130	002	Apr 18, 2000
--	------------------------	-------	---------	-----	--------------

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

LIOTHYRONINE SODIUM

<u>AP</u>	X GEN PHARMS	EQ 0.01MG BASE/ML	<u>A076923</u>	<u>001</u>	Aug 17, 2005
-----------	--------------	-------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 241 (of 393)

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

TRIOSTAT

<u>AP</u> +	JHP PHARMS	<u>EQ 0.01MG BASE/ML</u>	<u>N020105</u>	<u>001</u>	Dec 31, 1991
-------------	------------	--------------------------	----------------	------------	--------------

TABLET; ORAL

CYTOMEL

<u>AB</u>	KING PHARMS	<u>EQ 0.005MG BASE</u>	<u>N010379</u>	<u>001</u>	
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>N010379</u>	<u>002</u>	
<u>AB</u> +		<u>EQ 0.05MG BASE</u>	<u>N010379</u>	<u>003</u>	

LIOTHYRONINE SODIUM

<u>AB</u>	COASTAL PHARMS	<u>EQ 0.005MG BASE</u>	<u>A090097</u>	<u>001</u>	Mar 20, 2009
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A090097</u>	<u>002</u>	Mar 20, 2009
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A090097</u>	<u>003</u>	Mar 20, 2009
<u>AB</u>	MYLAN	<u>EQ 0.005MG BASE</u>	<u>A090326</u>	<u>001</u>	Jul 14, 2009
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A090326</u>	<u>002</u>	Jul 14, 2009
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A090326</u>	<u>003</u>	Jul 14, 2009

LIOTRIX (T4;T3)

TABLET; ORAL

THYROLAR-0.25

FOREST LABS	0.0125MG;0.0031MG	N016807	001	
-------------	-------------------	---------	-----	--

THYROLAR-0.5

FOREST LABS	0.025MG;0.0063MG	N016807	005	
-------------	------------------	---------	-----	--

THYROLAR-1

FOREST LABS	0.05MG;0.0125MG	N016807	004	
-------------	-----------------	---------	-----	--

THYROLAR-2

FOREST LABS	0.1MG;0.025MG	N016807	002	
-------------	---------------	---------	-----	--

THYROLAR-3

+ FOREST LABS	0.15MG;0.0375MG	N016807	003	
---------------	-----------------	---------	-----	--

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

VYVANSE

SHIRE DEVELOPMENT	20MG	N021977	004	Dec 10, 2007
-------------------	------	---------	-----	--------------

	30MG	N021977	001	Feb 23, 2007
--	------	---------	-----	--------------

	40MG	N021977	005	Dec 10, 2007
--	------	---------	-----	--------------

	50MG	N021977	002	Feb 23, 2007
--	------	---------	-----	--------------

	60MG	N021977	006	Dec 10, 2007
--	------	---------	-----	--------------

+	70MG	N021977	003	Feb 23, 2007
---	------	---------	-----	--------------

LISINOPRIL

TABLET; ORAL

LISINOPRIL

<u>AB</u>	ACTAVIS ELIZABETH	<u>2.5MG</u>	<u>A076180</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076180</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076180</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076164</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076164</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076164</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A076102</u>	<u>001</u>	Sep 30, 2002
<u>AB</u>		<u>5MG</u>	<u>A076102</u>	<u>002</u>	Sep 30, 2002
<u>AB</u>		<u>10MG</u>	<u>A076102</u>	<u>003</u>	Sep 30, 2002
<u>AB</u>		<u>20MG</u>	<u>A076102</u>	<u>004</u>	Sep 30, 2002
<u>AB</u>		<u>30MG</u>	<u>A076102</u>	<u>005</u>	Sep 30, 2002
<u>AB</u>		<u>40MG</u>	<u>A076102</u>	<u>006</u>	Sep 30, 2002
<u>AB</u>	AUROBINDO	<u>2.5MG</u>	<u>A077622</u>	<u>001</u>	Feb 22, 2006
<u>AB</u>		<u>5MG</u>	<u>A077622</u>	<u>002</u>	Feb 22, 2006
<u>AB</u>		<u>10MG</u>	<u>A077622</u>	<u>003</u>	Feb 22, 2006
<u>AB</u>		<u>20MG</u>	<u>A077622</u>	<u>004</u>	Feb 22, 2006
<u>AB</u>		<u>30MG</u>	<u>A077622</u>	<u>005</u>	Feb 22, 2006

## PRESCRIPTION DRUG PRODUCT LIST

3 - 242 (of 393)

LISINOPRIL

TABLET; ORAL

LISINOPRIL

<u>AB</u>	AUROBINDO	<u>40MG</u>	<u>A077622</u>	<u>006</u>	Feb 22, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>2.5MG</u>	<u>A075752</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075752</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075752</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075752</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075752</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075752</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	LEK PHARMS	<u>2.5MG</u>	<u>A075999</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075999</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075999</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075999</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075999</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075999</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	LUPIN	<u>2.5MG</u>	<u>A077321</u>	<u>001</u>	Sep 09, 2005
<u>AB</u>		<u>5MG</u>	<u>A077321</u>	<u>002</u>	Sep 09, 2005
<u>AB</u>		<u>10MG</u>	<u>A077321</u>	<u>003</u>	Sep 09, 2005
<u>AB</u>		<u>20MG</u>	<u>A077321</u>	<u>004</u>	Sep 09, 2005
<u>AB</u>		<u>30MG</u>	<u>A077321</u>	<u>005</u>	Sep 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077321</u>	<u>006</u>	Sep 09, 2005
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076071</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076071</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076071</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076071</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076071</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076071</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	RANBAXY	<u>2.5MG</u>	<u>A075944</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075944</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075944</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075944</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075944</u>	<u>006</u>	Feb 11, 2003
<u>AB</u>		<u>40MG</u>	<u>A075944</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A075903</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>2.5MG</u>	<u>A075994</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075903</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075994</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075903</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075994</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075903</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075994</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075903</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075994</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075903</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075994</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	TEVA	<u>2.5MG</u>	<u>A075783</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075783</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075783</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075783</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075783</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075783</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	VINTAGE	<u>2.5MG</u>	<u>A075743</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075743</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075743</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075743</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075743</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075743</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A076059</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076059</u>	<u>002</u>	Jul 01, 2002

## PRESCRIPTION DRUG PRODUCT LIST

3 - 243 (of 393)

LISINOPRIL

TABLET; ORAL

LISINOPRIL

<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A076059</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076059</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076059</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076059</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	WEST WARD	<u>2.5MG</u>	<u>A076063</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076063</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076063</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076063</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076063</u>	<u>006</u>	Jun 27, 2003
<u>AB</u>		<u>40MG</u>	<u>A076063</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>	WOCKHARDT	<u>2.5MG</u>	<u>A078402</u>	<u>001</u>	Apr 19, 2007
<u>AB</u>		<u>5MG</u>	<u>A078402</u>	<u>002</u>	Apr 19, 2007
<u>AB</u>		<u>10MG</u>	<u>A078402</u>	<u>003</u>	Apr 19, 2007
<u>AB</u>		<u>20MG</u>	<u>A078402</u>	<u>004</u>	Apr 19, 2007
<u>AB</u>		<u>30MG</u>	<u>A078402</u>	<u>005</u>	Apr 19, 2007
<u>AB</u>		<u>40MG</u>	<u>A078402</u>	<u>006</u>	Apr 19, 2007
	<u>PRINIVIL</u>				
<u>AB</u>	MERCK	<u>5MG</u>	<u>N019558</u>	<u>001</u>	Dec 29, 1987
<u>AB</u>		<u>10MG</u>	<u>N019558</u>	<u>002</u>	Dec 29, 1987
<u>AB</u>		<u>20MG</u>	<u>N019558</u>	<u>003</u>	Dec 29, 1987
<u>AB</u>		<u>40MG</u>	<u>N019558</u>	<u>004</u>	Oct 25, 1988
	<u>ZESTRIL</u>				
<u>AB</u>	ASTRAZENECA	<u>2.5MG</u>	<u>N019777</u>	<u>005</u>	Apr 29, 1993
<u>AB</u>		<u>5MG</u>	<u>N019777</u>	<u>001</u>	May 19, 1988
<u>AB</u>		<u>10MG</u>	<u>N019777</u>	<u>002</u>	May 19, 1988
<u>AB</u>		<u>20MG</u>	<u>N019777</u>	<u>003</u>	May 19, 1988
<u>AB</u>		<u>30MG</u>	<u>N019777</u>	<u>006</u>	Jan 20, 1999
<u>AB</u>	+	<u>40MG</u>	<u>N019777</u>	<u>004</u>	May 19, 1988

LITHIUM CARBONATE

CAPSULE; ORAL

ESKALITH

<u>AB</u>	NOVEN THERAP	<u>300MG</u>	<u>N016860</u>	<u>001</u>	
	<u>LITHIUM CARBONATE</u>				
<u>AB</u>	ALEMBIC LTD	<u>150MG</u>	<u>A079159</u>	<u>001</u>	Jan 12, 2009
<u>AB</u>		<u>300MG</u>	<u>A079159</u>	<u>002</u>	Jan 12, 2009
<u>AB</u>		<u>600MG</u>	<u>A079159</u>	<u>003</u>	Jan 12, 2009
<u>AB</u>	APOTEX INC	<u>300MG</u>	<u>A076795</u>	<u>001</u>	Nov 22, 2004
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A079139</u>	<u>001</u>	Feb 03, 2009
<u>AB</u>		<u>300MG</u>	<u>A079139</u>	<u>002</u>	Feb 03, 2009
<u>AB</u>		<u>600MG</u>	<u>A079139</u>	<u>003</u>	Feb 03, 2009
<u>AB</u>	HETERO DRUGS LTD	<u>150MG</u>	<u>A090702</u>	<u>001</u>	Sep 25, 2009
<u>AB</u>		<u>300MG</u>	<u>A090702</u>	<u>002</u>	Sep 25, 2009
<u>AB</u>		<u>600MG</u>	<u>A090702</u>	<u>003</u>	Sep 25, 2009
<u>AB</u>	ROXANE	<u>150MG</u>	<u>N017812</u>	<u>002</u>	Jan 28, 1987
<u>AB</u>		<u>300MG</u>	<u>N017812</u>	<u>001</u>	
<u>AB</u>	+	<u>600MG</u>	<u>N017812</u>	<u>003</u>	Jan 28, 1987
<u>AB</u>	WEST WARD	<u>150MG</u>	<u>A076243</u>	<u>002</u>	Feb 24, 2003
<u>AB</u>		<u>300MG</u>	<u>A076243</u>	<u>001</u>	Jun 27, 2002
<u>AB</u>		<u>600MG</u>	<u>A078763</u>	<u>001</u>	Apr 15, 2008

TABLET; ORAL

LITHIUM CARBONATE

+	ROXANE	300MG	N018558	001	Jan 29, 1982
---	--------	-------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

<u>AB</u>	ROXANE	<u>300MG</u>	<u>A076832</u>	<u>001</u>	Oct 28, 2004
<u>AB</u>	+	<u>450MG</u>	<u>A076691</u>	<u>001</u>	Jan 05, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 244 (of 393)

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

<u>AB</u>	WEST WARD	<u>450MG</u>	<u>A076490</u>	<u>001</u>	Jun 17, 2003
<u>AB</u>	+ NOVEN THERAP	<u>300MG</u>	<u>N018027</u>	<u>001</u>	

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE

<u>AA</u>	MORTON GROVE	<u>EQ 300MG CARBONATE/5ML</u>	<u>A070755</u>	<u>001</u>	May 21, 1986
<u>AA</u>	+ ROXANE	<u>EQ 300MG CARBONATE/5ML</u>	<u>N018421</u>	<u>001</u>	

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

	+ ALCON	EQ 0.1% BASE	N020191	001	Sep 23, 1993
--	---------	--------------	---------	-----	--------------

LOMUSTINE

CAPSULE; ORAL

CEENU

	BRISTOL MYERS SQUIBB	10MG	N017588	001	
		40MG	N017588	002	
	+	100MG	N017588	003	

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

IMODIUM

<u>AB</u>	+ MCNEIL CONS	<u>2MG</u>	<u>N017694</u>	<u>001</u>	
-----------	---------------	------------	----------------	------------	--

LOPERAMIDE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>2MG</u>	<u>A072741</u>	<u>001</u>	Sep 18, 1991
<u>AB</u>	TEVA	<u>2MG</u>	<u>A073192</u>	<u>001</u>	Apr 30, 1992

LOPINAVIR; RITONAVIR

CAPSULE; ORAL

KALETRA

	+ ABBOTT	133.3MG; 33.3MG	N021226	001	Sep 15, 2000
--	----------	-----------------	---------	-----	--------------

SOLUTION; ORAL

KALETRA

	+ ABBOTT	80MG/ML; 20MG/ML	N021251	001	Sep 15, 2000
--	----------	------------------	---------	-----	--------------

TABLET; ORAL

KALETRA

	ABBOTT	100MG; 25MG	N021906	002	Nov 09, 2007
	+	200MG; 50MG	N021906	001	Oct 28, 2005

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

<u>AA</u>	AMNEAL PHARMS	<u>2MG/ML</u>	<u>A091383</u>	<u>001</u>	Dec 23, 2009
<u>AA</u>	PADDOCK LABS	<u>2MG/ML</u>	<u>A079244</u>	<u>001</u>	Apr 28, 2009
<u>AA</u>	+ ROXANE	<u>2MG/ML</u>	<u>A072755</u>	<u>001</u>	Jun 28, 1991

INJECTABLE; INJECTION

ATIVAN

<u>AP</u>	+ BAXTER HLTHCARE CORP	<u>2MG/ML</u>	<u>N018140</u>	<u>001</u>	
<u>AP</u>	+	<u>4MG/ML</u>	<u>N018140</u>	<u>002</u>	

LORAZEPAM

<u>AP</u>	BEDFORD	<u>2MG/ML</u>	<u>A077076</u>	<u>001</u>	Jul 13, 2005
<u>AP</u>		<u>4MG/ML</u>	<u>A077076</u>	<u>002</u>	Jul 13, 2005

## PRESCRIPTION DRUG PRODUCT LIST

3 - 245 (of 393)

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

<u>AP</u>	HOSPIRA	<u>2MG/ML</u>	<u>A074243</u>	<u>001</u>	Apr 12, 1994
<u>AP</u>		<u>2MG/ML</u>	<u>A074282</u>	<u>001</u>	May 27, 1994
<u>AP</u>		<u>2MG/ML</u>	<u>A074300</u>	<u>001</u>	Apr 12, 1994
<u>AP</u>		<u>4MG/ML</u>	<u>A074243</u>	<u>002</u>	Apr 12, 1994
<u>AP</u>		<u>4MG/ML</u>	<u>A074282</u>	<u>002</u>	May 27, 1994
<u>AP</u>	INTL MEDICATION SYS	<u>2MG/ML</u>	<u>A076150</u>	<u>001</u>	Nov 15, 2004
<u>AP</u>	WATSON LABS	<u>2MG/ML</u>	<u>A074276</u>	<u>001</u>	Apr 15, 1994
<u>AP</u>		<u>4MG/ML</u>	<u>A074276</u>	<u>002</u>	Apr 15, 1994
<u>LORAZEPAM PRESERVATIVE FREE</u>					
<u>AP</u>	BEDFORD LABS	<u>2MG/ML</u>	<u>A077074</u>	<u>001</u>	Jul 13, 2005
<u>AP</u>		<u>4MG/ML</u>	<u>A077074</u>	<u>002</u>	Jul 13, 2005

TABLET; ORAL

ATIVAN

<u>AB</u>	BIOVAIL	<u>0.5MG</u>	<u>N017794</u>	<u>001</u>	
<u>AB</u>		<u>1MG</u>	<u>N017794</u>	<u>002</u>	
<u>AB</u>	+	<u>2MG</u>	<u>N017794</u>	<u>003</u>	

LORAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A071403</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>		<u>1MG</u>	<u>A071404</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>		<u>2MG</u>	<u>A071141</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>	EXCELLIUM	<u>0.5MG</u>	<u>A078203</u>	<u>001</u>	Jul 30, 2007
<u>AB</u>		<u>1MG</u>	<u>A078203</u>	<u>002</u>	Jul 30, 2007
<u>AB</u>		<u>2MG</u>	<u>A078203</u>	<u>003</u>	Jul 30, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.5MG</u>	<u>A077396</u>	<u>001</u>	Dec 13, 2006
<u>AB</u>		<u>1MG</u>	<u>A077396</u>	<u>002</u>	Dec 13, 2006
<u>AB</u>		<u>2MG</u>	<u>A077396</u>	<u>003</u>	Dec 13, 2006
<u>AB</u>	MUTUAL PHARM	<u>0.5MG</u>	<u>A072553</u>	<u>001</u>	Mar 29, 1991
<u>AB</u>		<u>1MG</u>	<u>A072554</u>	<u>001</u>	Mar 29, 1991
<u>AB</u>		<u>2MG</u>	<u>A072555</u>	<u>001</u>	Mar 29, 1991
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A071589</u>	<u>001</u>	Oct 13, 1987
<u>AB</u>		<u>0.5MG</u>	<u>A077657</u>	<u>001</u>	Mar 16, 2006
<u>AB</u>		<u>1MG</u>	<u>A071590</u>	<u>001</u>	Oct 13, 1987
<u>AB</u>		<u>1MG</u>	<u>A077657</u>	<u>002</u>	Mar 16, 2006
<u>AB</u>		<u>2MG</u>	<u>A071591</u>	<u>001</u>	Oct 13, 1987
<u>AB</u>		<u>2MG</u>	<u>A077657</u>	<u>003</u>	Mar 16, 2006
<u>AB</u>	RANBAXY	<u>0.5MG</u>	<u>A076045</u>	<u>001</u>	Aug 29, 2001
<u>AB</u>		<u>1MG</u>	<u>A076045</u>	<u>002</u>	Aug 29, 2001
<u>AB</u>		<u>2MG</u>	<u>A076045</u>	<u>003</u>	Aug 29, 2001
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A071193</u>	<u>001</u>	Apr 15, 1988
<u>AB</u>		<u>1MG</u>	<u>A071194</u>	<u>001</u>	Apr 15, 1988
<u>AB</u>		<u>2MG</u>	<u>A071195</u>	<u>001</u>	Apr 15, 1988
<u>AB</u>	VINTAGE PHARMS	<u>0.5MG</u>	<u>A077754</u>	<u>001</u>	May 10, 2006
<u>AB</u>		<u>1MG</u>	<u>A077754</u>	<u>002</u>	May 10, 2006
<u>AB</u>		<u>2MG</u>	<u>A077754</u>	<u>003</u>	May 10, 2006
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A072926</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>		<u>1MG</u>	<u>A071118</u>	<u>001</u>	Jul 24, 1986
<u>AB</u>		<u>1MG</u>	<u>A072927</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>		<u>2MG</u>	<u>A072928</u>	<u>001</u>	Oct 31, 1991

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

	MERCK	25MG	N020386	001	Apr 14, 1995
		50MG	N020386	002	Apr 14, 1995
+		100MG	N020386	003	Oct 13, 1998



## PRESCRIPTION DRUG PRODUCT LIST

3 - 246 (of 393)

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

ALREX

+ BAUSCH AND LOMB 0.2% N020803 001 Mar 09, 1998

LOTEMAX

+ BAUSCH AND LOMB 0.5% N020583 001 Mar 09, 1998

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

+ BAUSCH AND LOMB 0.5%;0.3% N050804 001 Dec 14, 2004

LOVASTATIN

TABLET; ORAL

LOVASTATIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A075828</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075828</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075828</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A077748</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>		<u>20MG</u>	<u>A077748</u>	<u>002</u>	Feb 28, 2007
<u>AB</u>		<u>40MG</u>	<u>A077748</u>	<u>003</u>	Feb 28, 2007
<u>AB</u>	CARLSBAD	<u>10MG</u>	<u>A075991</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>		<u>20MG</u>	<u>A075991</u>	<u>002</u>	Jun 05, 2002
<u>AB</u>		<u>40MG</u>	<u>A075991</u>	<u>003</u>	Jun 05, 2002
<u>AB</u>	LUPIN	<u>10MG</u>	<u>A078296</u>	<u>001</u>	Mar 14, 2008
<u>AB</u>		<u>20MG</u>	<u>A078296</u>	<u>002</u>	Nov 01, 2007
<u>AB</u>		<u>40MG</u>	<u>A078296</u>	<u>003</u>	Nov 01, 2007
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A077520</u>	<u>001</u>	Apr 14, 2006
<u>AB</u>		<u>20MG</u>	<u>A077520</u>	<u>002</u>	Apr 14, 2006
<u>AB</u>		<u>40MG</u>	<u>A077520</u>	<u>003</u>	Apr 14, 2006
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075451</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>10MG</u>	<u>A075935</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075451</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075935</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075451</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075935</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A075300</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>10MG</u>	<u>A075636</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075300</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075636</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075300</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075636</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	TEVA	<u>10MG</u>	<u>A075551</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075551</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075551</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>	<u>MEVACOR</u>				
<u>AB</u>	MERCK	<u>20MG</u>	<u>N019643</u>	<u>003</u>	Aug 31, 1987
<u>AB</u>	+	<u>40MG</u>	<u>N019643</u>	<u>004</u>	Dec 14, 1988

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

ANDRX LABS LLC 20MG N021316 002 Jun 26, 2002

40MG N021316 003 Jun 26, 2002

+ 60MG N021316 004 Jun 26, 2002

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

ADVICOR

+ ABBOTT 20MG;500MG N021249 001 Dec 17, 2001

+ 20MG;750MG N021249 002 Dec 17, 2001

## PRESCRIPTION DRUG PRODUCT LIST

3 - 247 (of 393)

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

ADVICOR

+	ABBOTT	20MG;1GM	N021249	003	Dec 17, 2001
+		40MG;1GM	N021249	004	Apr 27, 2006

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076762</u>	<u>001</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076762</u>	<u>002</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A076762</u>	<u>003</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076762</u>	<u>004</u>	Nov 01, 2004
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A072204</u>	<u>001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A072205</u>	<u>001</u>	Jun 15, 1988
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>A072206</u>	<u>001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A072062</u>	<u>001</u>	Jun 15, 1988

LUBIPROSTONE

CAPSULE; ORAL

AMITIZA

	SUCAMPO PHARMS	8MCG	N021908	002	Apr 29, 2008
+		24MCG	N021908	001	Jan 31, 2006

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

+	EMD SERONO	75 IU/VIAL	N021322	001	Oct 08, 2004
---	------------	------------	---------	-----	--------------

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLON

+	UDL LABS	EQ 85MG BASE/GM	N016763	001	
---	----------	-----------------	---------	-----	--

FOR SOLUTION; TOPICAL

SULFAMYLON

+	UDL LABS	5%	N019832	003	Jun 05, 1998
---	----------	----	---------	-----	--------------

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

	BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984
--	-----------------	------------------------------------	---------	-----	--------------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019696	001	Sep 29, 1989
---	---------	---	---------	-----	--------------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML</u>	<u>N017378</u>	<u>001</u>	
-----------	-----------------	--	----------------	------------	--

PLASMA-LYTE A IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML</u>	<u>N017378</u>	<u>002</u>	Nov 22, 1982
-----------	-----------------	--	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 248 (of 393)

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

## INJECTABLE; INJECTION

## ISOLYTE S IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG /100ML; 500MG/100ML	N019711	001	Sep 29, 1989
---------	---	---------	-----	--------------

## NORMOSOL-R IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG /100ML; 502MG/100ML	N017586	001	
---------	---	---------	-----	--

## SOLUTION; IRRIGATION

## PHYSIOLYTE IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG /100ML; 500MG/100ML	N019024	001	Jun 08, 1984
---------	---	---------	-----	--------------

## PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG /100ML; 502MG/100ML	N017637	002	Jul 08, 1982
---------	---	---------	-----	--------------

## PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG /100ML; 502MG/100ML	N018406	002	Jul 08, 1982
---------	---	---------	-----	--------------

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

## SOLUTION; INJECTION

## NORMOCARB HF 25

+ DIALYSIS SUPS	0.21GM/100ML; 2.8GM/100ML; 9.07GM/100ML	N021910	001	Jul 26, 2006
-----------------	---	---------	-----	--------------

## NORMOCARB HF 35

+ DIALYSIS SUPS	0.21GM/100ML; 3.97GM/100ML; 8.3GM/100ML	N021910	002	Jul 26, 2006
-----------------	---	---------	-----	--------------

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

## TABLET; ORAL

## MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

SANTARUS	343MG; 20MG; 750MG	N022456	001	Dec 04, 2009
----------	--------------------	---------	-----	--------------

+	343MG; 40MG; 750MG	N022456	002	Dec 04, 2009
---	--------------------	---------	-----	--------------

## TABLET, CHEWABLE; ORAL

## ZEGERID

SANTARUS	700MG; 20MG; 600MG	N021850	001	Mar 24, 2006
----------	--------------------	---------	-----	--------------

+	700MG; 40MG; 600MG	N021850	002	Mar 24, 2006
---	--------------------	---------	-----	--------------

MAGNESIUM SULFATE

## INJECTABLE; INJECTION

MAGNESIUM SULFATE

<u>AP</u> + ABRAXIS PHARM	<u>500MG/ML</u>	<u>N019316</u>	<u>001</u>	Sep 08, 1986
---------------------------	-----------------	----------------	------------	--------------

<u>AP</u> HOSPIRA	<u>500MG/ML</u>	<u>A075151</u>	<u>001</u>	Apr 25, 2000
-------------------	-----------------	----------------	------------	--------------

## MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995
-----------	-----------	---------	-----	--------------

+	2GM/100ML	N020488	002	Jul 11, 1995
---	-----------	---------	-----	--------------

## MAGNESIUM SULFATE IN PLASTIC CONTAINER

HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007
---------	--------------------	---------	-----	--------------

+	4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994
---	---------------------	---------	-----	--------------

+	4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994
---	--------------------	---------	-----	--------------

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

## SOLUTION; IRRIGATION

TIS-U-SOL

<u>AT</u> BAXTER HLTHCARE	<u>20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML</u>	<u>N018508</u>	<u>001</u>	Feb 19, 1982
---------------------------	--	----------------	------------	--------------

TIS-U-SOL IN PLASTIC CONTAINER

<u>AT</u> BAXTER HLTHCARE	<u>20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML</u>	<u>N018336</u>	<u>001</u>	
---------------------------	--	----------------	------------	--

## PRESCRIPTION DRUG PRODUCT LIST

3 - 249 (of 393)

MALATHION

LOTION; TOPICAL

MALATHION

<u>AT</u>	SYNERX PHARMA	<u>0.5%</u>	<u>A078743</u>	<u>001</u>	Mar 06, 2009
	<u>OVIDE</u>				
<u>AT</u>	+ TARO PHARMS NORTH	<u>0.5%</u>	<u>N018613</u>	<u>001</u>	Aug 02, 1982

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986
---------	-----------------------	---------	-----	--------------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

<u>AP</u>	B BRAUN	<u>10GM/100ML</u>	<u>N016080</u>	<u>002</u>	
	<u>MANNITOL 10% IN PLASTIC CONTAINER</u>				
<u>AP</u>	B BRAUN	<u>10GM/100ML</u>	<u>N020006</u>	<u>002</u>	Jul 26, 1993
<u>AP</u>	HOSPIRA	<u>10GM/100ML</u>	<u>N019603</u>	<u>002</u>	Jan 08, 1987
	<u>MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER</u>				
<u>AP</u>	B BRAUN	<u>10GM/100ML</u>	<u>N016080</u>	<u>006</u>	
	<u>MANNITOL 15%</u>				
<u>AP</u>	B BRAUN	<u>15GM/100ML</u>	<u>N016080</u>	<u>003</u>	
	<u>MANNITOL 15% IN PLASTIC CONTAINER</u>				
<u>AP</u>	B BRAUN	<u>15GM/100ML</u>	<u>N020006</u>	<u>003</u>	Jul 26, 1993
<u>AP</u>	HOSPIRA	<u>15GM/100ML</u>	<u>N019603</u>	<u>003</u>	Jan 08, 1990
	<u>MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%</u>				
<u>AP</u>	B BRAUN	<u>15GM/100ML</u>	<u>N016080</u>	<u>005</u>	
	<u>MANNITOL 20%</u>				
<u>AP</u>	B BRAUN	<u>20GM/100ML</u>	<u>N014738</u>	<u>001</u>	
<u>AP</u>		<u>20GM/100ML</u>	<u>N016080</u>	<u>004</u>	
	<u>MANNITOL 20% IN PLASTIC CONTAINER</u>				
<u>AP</u>	B BRAUN	<u>20GM/100ML</u>	<u>N020006</u>	<u>004</u>	Jul 26, 1993
<u>AP</u>	HOSPIRA	<u>20GM/100ML</u>	<u>N019603</u>	<u>004</u>	Jan 08, 1990
	<u>MANNITOL 25%</u>				
<u>AP</u>	APP PHARMS	<u>12.5GM/50ML</u>	<u>A080677</u>	<u>001</u>	
<u>AP</u>	HOSPIRA	<u>12.5GM/50ML</u>	<u>N016269</u>	<u>006</u>	Aug 25, 1994
<u>AP</u>	INTL MEDICATION	<u>12.5GM/50ML</u>	<u>A083051</u>	<u>001</u>	
<u>AP</u>	LUITPOLD	<u>12.5GM/50ML</u>	<u>A087409</u>	<u>001</u>	Jan 21, 1982
	<u>MANNITOL 5%</u>				
<u>AP</u>	B BRAUN	<u>5GM/100ML</u>	<u>N016080</u>	<u>001</u>	
	<u>MANNITOL 5% IN PLASTIC CONTAINER</u>				
<u>AP</u>	B BRAUN	<u>5GM/100ML</u>	<u>N020006</u>	<u>001</u>	Jul 26, 1993
<u>AP</u>	HOSPIRA	<u>5GM/100ML</u>	<u>N019603</u>	<u>001</u>	Jan 08, 1987
	<u>MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%</u>				
<u>AP</u>	B BRAUN	<u>5GM/100ML</u>	<u>N016080</u>	<u>007</u>	
	<u>OSMITROL 10% IN WATER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N013684</u>	<u>002</u>	
	<u>OSMITROL 10% IN WATER IN PLASTIC CONTAINER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N013684</u>	<u>006</u>	
	<u>OSMITROL 15% IN WATER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>15GM/100ML</u>	<u>N013684</u>	<u>004</u>	
	<u>OSMITROL 15% IN WATER IN PLASTIC CONTAINER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>15GM/100ML</u>	<u>N013684</u>	<u>008</u>	
	<u>OSMITROL 20% IN WATER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N013684</u>	<u>003</u>	
	<u>OSMITROL 20% IN WATER IN PLASTIC CONTAINER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N013684</u>	<u>007</u>	
	<u>OSMITROL 5% IN WATER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N013684</u>	<u>001</u>	

## PRESCRIPTION DRUG PRODUCT LIST

3 - 250 (of 393)

MANNITOL

INJECTABLE; INJECTION

OSMITROL 5% IN WATER IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N013684</u>	<u>005</u>	
-----------	-----------------	------------------	----------------	------------	--

SOLUTION; IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML	N016772	002	
--	---------	-----------	---------	-----	--

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

	HOSPIRA	540MG/100ML; 2.7GM/100ML	N018316	001	
--	---------	--------------------------	---------	-----	--

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HYDROCHLORIDE

	MYLAN	25MG	A072285	002	Oct 03, 1988
+		50MG	A072285	001	Oct 03, 1988
		75MG	A072285	003	Oct 03, 1988

MARAVIROC

TABLET; ORAL

SELZENTRY

	VIIIV HLTHCARE	150MG	N022128	001	Aug 06, 2007
+		300MG	N022128	002	Aug 06, 2007

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

MEBENDAZOLE

+	TEVA PHARMS	100MG	A073580	001	Jan 04, 1995
---	-------------	-------	---------	-----	--------------

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+	TERCICA	40MG/4ML (10MG/ML)	N021839	001	Aug 30, 2005
---	---------	--------------------	---------	-----	--------------

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

MUSTARGEN

+	LUNDBECK INC	10MG/VIAL	N006695	001	
---	--------------	-----------	---------	-----	--

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

<u>AA</u>	+	PFIZER	<u>12.5MG</u>	<u>N010721</u>	<u>006</u>
-----------	---	--------	---------------	----------------	------------

<u>AA</u>	+		<u>25MG</u>	<u>N010721</u>	<u>004</u>
-----------	---	--	-------------	----------------	------------

MECLIZINE HYDROCHLORIDE

<u>AA</u>		PAR PHARM	<u>12.5MG</u>	<u>A087127</u>	<u>001</u>
-----------	--	-----------	---------------	----------------	------------

<u>AA</u>			<u>25MG</u>	<u>A087128</u>	<u>001</u>
-----------	--	--	-------------	----------------	------------

<u>AA</u>			<u>50MG</u>	<u>A089674</u>	<u>001</u> Mar 31, 1988
-----------	--	--	-------------	----------------	-------------------------

<u>AA</u>		SANDOZ	<u>12.5MG</u>	<u>A084843</u>	<u>002</u> May 22, 1989
-----------	--	--------	---------------	----------------	-------------------------

<u>AA</u>			<u>25MG</u>	<u>A084092</u>	<u>003</u> May 22, 1989
-----------	--	--	-------------	----------------	-------------------------

<u>AA</u>		VINTAGE PHARMS	<u>12.5MG</u>	<u>A040179</u>	<u>001</u> Jan 30, 1997
-----------	--	----------------	---------------	----------------	-------------------------

<u>AA</u>			<u>25MG</u>	<u>A040179</u>	<u>002</u> Jan 30, 1997
-----------	--	--	-------------	----------------	-------------------------

<u>AA</u>		WATSON LABS	<u>25MG</u>	<u>A085740</u>	<u>001</u>
-----------	--	-------------	-------------	----------------	------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 251 (of 393)

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

<u>AB</u>	MYLAN	<u>EQ 50MG BASE</u>	<u>A071081</u>	<u>002</u>	Sep 03, 1986
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A071081</u>	<u>001</u>	Sep 03, 1986
<u>AB</u>	WATSON LABS	<u>EQ 50MG BASE</u>	<u>A071468</u>	<u>001</u>	Apr 15, 1987
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A071469</u>	<u>001</u>	Apr 15, 1987

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>150MG/ML</u>	<u>N020246</u>	<u>001</u>	Oct 29, 1992
-----------	---	----------------------	-----------------	----------------	------------	--------------

MEDROXYPROGESTERONE ACETATE

<u>AB</u>		SANDOZ	<u>150MG/ML</u>	<u>A078711</u>	<u>001</u>	May 20, 2009
<u>AB</u>		TEVA PARENTERAL	<u>150MG/ML</u>	<u>A076552</u>	<u>001</u>	Oct 27, 2004
<u>AB</u>			<u>150MG/ML</u>	<u>A076553</u>	<u>001</u>	Jul 28, 2004
		DEPO-PROVERA				
	+	PHARMACIA AND UPJOHN	400MG/ML	N012541	003	

INJECTABLE; SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

	+	PHARMACIA AND UPJOHN	104MG/0.65ML	N021583	001	Dec 17, 2004
--	---	----------------------	--------------	---------	-----	--------------

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

<u>AB</u>		BARR	<u>2.5MG</u>	<u>A040159</u>	<u>001</u>	Aug 09, 1996
<u>AB</u>			<u>5MG</u>	<u>A040159</u>	<u>002</u>	Aug 09, 1996
<u>AB</u>			<u>10MG</u>	<u>A040159</u>	<u>003</u>	Aug 09, 1996
		<u>PROVERA</u>				
<u>AB</u>		PHARMACIA AND UPJOHN	<u>2.5MG</u>	<u>N011839</u>	<u>001</u>	
<u>AB</u>			<u>5MG</u>	<u>N011839</u>	<u>003</u>	
<u>AB</u>	+		<u>10MG</u>	<u>N011839</u>	<u>004</u>	
		MEDROXYPROGESTERONE ACETATE				
BP		USL PHARMA	10MG	A088484	001	Jul 26, 1984

MEFENAMIC ACID

CAPSULE; ORAL

PONSTEL

	+	SCIELE PHARMA INC	250MG	N015034	003	
--	---	-------------------	-------	---------	-----	--

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

<u>AB</u>		BARR	<u>250MG</u>	<u>A076392</u>	<u>001</u>	Dec 29, 2003
<u>AB</u>		ROXANE	<u>250MG</u>	<u>A076523</u>	<u>001</u>	Oct 01, 2004
<u>AB</u>	+	SANDOZ	<u>250MG</u>	<u>A076175</u>	<u>001</u>	Feb 20, 2002

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

<u>AB</u>	+	BRISTOL MYERS SQUIBB	<u>40MG/ML</u>	<u>N020264</u>	<u>001</u>	Sep 10, 1993
-----------	---	----------------------	----------------	----------------	------------	--------------

MEGESTROL ACETATE

<u>AB</u>		APOTEX INC	<u>40MG/ML</u>	<u>A077404</u>	<u>001</u>	Feb 16, 2006
<u>AB</u>		MORTON GROVE	<u>40MG/ML</u>	<u>A076721</u>	<u>001</u>	Nov 01, 2004
<u>AB</u>		PAR PHARM	<u>40MG/ML</u>	<u>A075671</u>	<u>001</u>	Jul 25, 2001
<u>AB</u>		ROXANE	<u>40MG/ML</u>	<u>A075997</u>	<u>001</u>	Feb 15, 2002
<u>AB</u>		TEVA PHARMS	<u>40MG/ML</u>	<u>A075681</u>	<u>001</u>	May 05, 2003
		MEGACE ES				
	+	PAR PHARM	125MG/ML	N021778	001	Jul 05, 2005

## PRESCRIPTION DRUG PRODUCT LIST

3 - 252 (of 393)

MEGESTROL ACETATE

TABLET; ORAL

MEGACE

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>20MG</u>	<u>N016979</u>	<u>001</u>	
<u>AB</u>	+	<u>40MG</u>	<u>N016979</u>	<u>002</u>	

MEGESTROL ACETATE

<u>AB</u>	BARR	<u>20MG</u>	<u>A074621</u>	<u>002</u>	Aug 16, 1996
<u>AB</u>		<u>40MG</u>	<u>A074621</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	PAR PHARM	<u>20MG</u>	<u>A072422</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>		<u>40MG</u>	<u>A072423</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	ROXANE	<u>20MG</u>	<u>A074458</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>		<u>40MG</u>	<u>A074458</u>	<u>002</u>	Sep 29, 1995

MELOXICAM

SUSPENSION; ORAL

MOBIC

	+	BOEHRINGER INGELHEIM	7.5MG/5ML	N021530	001	Jun 01, 2004
--	---	----------------------	-----------	---------	-----	--------------

TABLET; ORAL

MELOXICAM

<u>AB</u>	ACTAVIS TOTOWA	<u>7.5MG</u>	<u>A077938</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077938</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A077882</u>	<u>001</u>	Jul 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077882</u>	<u>002</u>	Jul 20, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>7.5MG</u>	<u>A078008</u>	<u>001</u>	Oct 02, 2006
<u>AB</u>		<u>15MG</u>	<u>A078008</u>	<u>002</u>	Oct 02, 2006
<u>AB</u>	BEIJING DOUBLE CRANE	<u>7.5MG</u>	<u>A078039</u>	<u>001</u>	Dec 14, 2006
<u>AB</u>		<u>15MG</u>	<u>A078039</u>	<u>002</u>	Dec 14, 2006
<u>AB</u>	BEJING YABAO	<u>7.5MG</u>	<u>A077933</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077933</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	BRECKENRIDGE PHARM	<u>7.5MG</u>	<u>A077920</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077920</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	CARACO	<u>7.5MG</u>	<u>A077937</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077937</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	CARLSBAD	<u>7.5MG</u>	<u>A077918</u>	<u>001</u>	Dec 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A077918</u>	<u>002</u>	Dec 07, 2006
<u>AB</u>	COREPHARMA	<u>7.5MG</u>	<u>A077930</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077930</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>7.5MG</u>	<u>A077931</u>	<u>001</u>	Jul 25, 2006
<u>AB</u>		<u>15MG</u>	<u>A077931</u>	<u>002</u>	Jul 25, 2006
<u>AB</u>	GENPHARM	<u>7.5MG</u>	<u>A077934</u>	<u>001</u>	Jul 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077934</u>	<u>002</u>	Jul 20, 2006
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A077932</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077932</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	LUPIN PHARMS	<u>7.5MG</u>	<u>A077944</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077944</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	MYLAN	<u>7.5MG</u>	<u>A077923</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077923</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	STRIDES ARCOLAB LTD	<u>7.5MG</u>	<u>A077928</u>	<u>001</u>	May 13, 2009
<u>AB</u>		<u>15MG</u>	<u>A077928</u>	<u>002</u>	May 13, 2009
<u>AB</u>	TARO	<u>7.5MG</u>	<u>A078102</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A078102</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>	TEVA PHARMS	<u>7.5MG</u>	<u>A077936</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077936</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	UNICHEM	<u>7.5MG</u>	<u>A077927</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077927</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>	WATSON LABS	<u>7.5MG</u>	<u>A077929</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077929</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>7.5MG</u>	<u>A077921</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077921</u>	<u>002</u>	Jul 19, 2006

## PRESCRIPTION DRUG PRODUCT LIST

3 - 253 (of 393)

MELOXICAM

TABLET; ORAL

MOBIC

<u>AB</u>	BOEHRINGER INGELHEIM	<u>7.5MG</u>	<u>N020938</u>	<u>001</u>	Apr 13, 2000
<u>AB</u>	+	<u>15MG</u>	<u>N020938</u>	<u>002</u>	Aug 23, 2000

MELPHALAN

TABLET; ORAL

ALKERAN

+	GLAXOSMITHKLINE	2MG	N014691	002	
---	-----------------	-----	---------	-----	--

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 50MG BASE/VIAL</u>	<u>N020207</u>	<u>001</u>	Nov 18, 1992
-----------	---	-----------------	--------------------------	----------------	------------	--------------

MELPHALAN HYDROCHLORIDE

<u>AP</u>		GENERAMEDIX	<u>EQ 50MG BASE/VIAL</u>	<u>A090299</u>	<u>001</u>	Oct 27, 2009
-----------	--	-------------	--------------------------	----------------	------------	--------------

<u>AP</u>		SYNERX	<u>EQ 50MG BASE/VIAL</u>	<u>A090270</u>	<u>001</u>	Jun 09, 2009
-----------	--	--------	--------------------------	----------------	------------	--------------

MEMANTINE HYDROCHLORIDE

SOLUTION; ORAL

NAMENDA

+	FOREST LABS	2MG/ML	N021627	001	Apr 18, 2005
---	-------------	--------	---------	-----	--------------

TABLET; ORAL

NAMENDA

	FOREST LABS	5MG	N021487	001	Oct 16, 2003
--	-------------	-----	---------	-----	--------------

+		10MG	N021487	002	Oct 16, 2003
---	--	------	---------	-----	--------------

MENOTROPINS (FSH;LH)

INJECTABLE; IM-SC

REPRONEX

+	FERRING	75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999
---	---------	-----------------------	---------	-----	--------------

INJECTABLE; SUBCUTANEOUS

MENOPUR

+	FERRING	75 IU/VIAL;75 IU/VIAL	N021663	001	Oct 29, 2004
---	---------	-----------------------	---------	-----	--------------

MEPENZOLATE BROMIDE

TABLET; ORAL

CANTIL

+	SANOFI AVENTIS US	25MG	N010679	003	
---	-------------------	------	---------	-----	--

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

<u>AP</u>	+	HOSPIRA	<u>25MG/ML</u>	<u>N021171</u>	<u>001</u>
-----------	---	---------	----------------	----------------	------------

<u>AP</u>	+		<u>50MG/ML</u>	<u>N021171</u>	<u>002</u>
-----------	---	--	----------------	----------------	------------

<u>AP</u>	+		<u>75MG/ML</u>	<u>N021171</u>	<u>003</u>
-----------	---	--	----------------	----------------	------------

<u>AP</u>	+		<u>100MG/ML</u>	<u>N021171</u>	<u>004</u>
-----------	---	--	-----------------	----------------	------------

MEPERIDINE HYDROCHLORIDE

<u>AP</u>		BAXTER HLTHCARE CORP	<u>25MG/ML</u>	<u>A080455</u>	<u>007</u>
-----------	--	----------------------	----------------	----------------	------------

<u>AP</u>			<u>50MG/ML</u>	<u>A080455</u>	<u>008</u>
-----------	--	--	----------------	----------------	------------

<u>AP</u>			<u>75MG/ML</u>	<u>A080455</u>	<u>009</u>
-----------	--	--	----------------	----------------	------------

<u>AP</u>			<u>100MG/ML</u>	<u>A080455</u>	<u>010</u>
-----------	--	--	-----------------	----------------	------------

<u>AP</u>		ELKINS SINN	<u>25MG/ML</u>	<u>A080445</u>	<u>001</u>
-----------	--	-------------	----------------	----------------	------------

<u>AP</u>			<u>50MG/ML</u>	<u>A080445</u>	<u>002</u>
-----------	--	--	----------------	----------------	------------

<u>AP</u>			<u>75MG/ML</u>	<u>A080445</u>	<u>003</u>
-----------	--	--	----------------	----------------	------------

<u>AP</u>			<u>100MG/ML</u>	<u>A080445</u>	<u>004</u>
-----------	--	--	-----------------	----------------	------------

<u>AP</u>		WATSON LABS	<u>50MG/ML</u>	<u>A073444</u>	<u>001</u>	Mar 17, 1992
-----------	--	-------------	----------------	----------------	------------	--------------

<u>AP</u>			<u>100MG/ML</u>	<u>A073445</u>	<u>001</u>	Mar 17, 1992
-----------	--	--	-----------------	----------------	------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

3 - 254 (of 393)

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	ASTRAZENECA	<u>10MG/ML</u>	<u>A081002</u>	<u>001</u>	Jul 30, 1993
<u>AP</u>	+ HOSPIRA	<u>10MG/ML</u>	<u>A088432</u>	<u>001</u>	Aug 16, 1984
<u>AP</u>	INTL MEDICATION	<u>10MG/ML</u>	<u>A081309</u>	<u>001</u>	Aug 30, 1993
<u>AP</u>	WATSON LABS	<u>10MG/ML</u>	<u>A073443</u>	<u>001</u>	Mar 17, 1992

SYRUP; ORAL

DEMEROL

<u>AA</u>	+ SANOFI AVENTIS US	<u>50MG/5ML</u>	<u>N005010</u>	<u>005</u>	
<u>MEPERIDINE HYDROCHLORIDE</u>					
<u>AA</u>	ROXANE	<u>50MG/5ML</u>	<u>A088744</u>	<u>001</u>	Jan 30, 1985

TABLET; ORAL

DEMEROL

<u>AA</u>	+ SANOFI AVENTIS US	<u>50MG</u>	<u>N005010</u>	<u>001</u>	
<u>AA</u>	+	<u>100MG</u>	<u>N005010</u>	<u>004</u>	
<u>MEPERIDINE HYDROCHLORIDE</u>					
<u>AA</u>	ACTAVIS TOTOWA	<u>50MG</u>	<u>A040331</u>	<u>001</u>	May 28, 1999
<u>AA</u>		<u>100MG</u>	<u>A040331</u>	<u>002</u>	May 28, 1999
<u>AA</u>	BARR	<u>50MG</u>	<u>A088639</u>	<u>001</u>	Jul 02, 1984
<u>AA</u>		<u>100MG</u>	<u>A088640</u>	<u>001</u>	Sep 19, 1984
<u>AA</u>	CARACO	<u>50MG</u>	<u>A040446</u>	<u>001</u>	Aug 08, 2002
<u>AA</u>		<u>100MG</u>	<u>A040446</u>	<u>002</u>	Aug 08, 2002
<u>AA</u>	MALLINCKRODT	<u>50MG</u>	<u>A040352</u>	<u>001</u>	Jun 13, 2000
<u>AA</u>		<u>100MG</u>	<u>A040352</u>	<u>002</u>	Jun 13, 2000
<u>AA</u>	MIKART	<u>50MG</u>	<u>A040893</u>	<u>001</u>	Jun 24, 2009
<u>AA</u>		<u>100MG</u>	<u>A040893</u>	<u>003</u>	Jun 24, 2009
<u>AA</u>	ROXANE	<u>50MG</u>	<u>A040110</u>	<u>001</u>	Mar 12, 1997
<u>AA</u>		<u>100MG</u>	<u>A040110</u>	<u>002</u>	Mar 12, 1997
<u>AA</u>	VINTAGE PHARMS	<u>50MG</u>	<u>A040191</u>	<u>001</u>	Dec 17, 1998
<u>AA</u>		<u>100MG</u>	<u>A040191</u>	<u>002</u>	Dec 17, 1998
<u>AA</u>	WATSON LABS	<u>50MG</u>	<u>A040186</u>	<u>001</u>	Jun 30, 1997
<u>AA</u>		<u>100MG</u>	<u>A040186</u>	<u>002</u>	Jun 30, 1997

MEPERIDINE HYDROCHLORIDE

	MIKART	75MG	A040893	002	Jun 24, 2009
		150MG	A040893	004	Jun 24, 2009

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

<u>AP</u>	+ HOSPIRA	<u>1%</u>	<u>N012250</u>	<u>001</u>	
<u>AP</u>	+	<u>1.5%</u>	<u>N012250</u>	<u>005</u>	
<u>AP</u>	+	<u>2%</u>	<u>N012250</u>	<u>002</u>	

ISOCAINE HYDROCHLORIDE

<u>AP</u>	+ NOVOCOL	<u>3%</u>	<u>A080925</u>	<u>001</u>	
-----------	-----------	-----------	----------------	------------	--

MEPIVACAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA INC	<u>3%</u>	<u>A040806</u>	<u>001</u>	Apr 28, 2008
<u>AP</u>	WATSON LABS	<u>1%</u>	<u>A088769</u>	<u>001</u>	Nov 20, 1984
<u>AP</u>		<u>2%</u>	<u>A088770</u>	<u>001</u>	Nov 20, 1984

POLOCAINE

<u>AP</u>	APP PHARMS	<u>1%</u>	<u>A089407</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>		<u>2%</u>	<u>A089410</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>	DENTSPLY PHARM	<u>3%</u>	<u>A088653</u>	<u>001</u>	Aug 21, 1984

POLOCAINE-MPF

<u>AP</u>	APP PHARMS	<u>1%</u>	<u>A089406</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>		<u>1.5%</u>	<u>A089408</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>		<u>2%</u>	<u>A089409</u>	<u>001</u>	Dec 01, 1986

SCANDONEST PLAIN

<u>AP</u>	+ DEPROCO	<u>3%</u>	<u>A088387</u>	<u>001</u>	Oct 10, 1984
-----------	-----------	-----------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 255 (of 393)

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

<u>AA</u>	ALEMBIC LTD	<u>200MG</u>	<u>A090122</u>	<u>001</u>	Feb 18, 2009
<u>AA</u>		<u>400MG</u>	<u>A090122</u>	<u>002</u>	Feb 18, 2009
<u>AA</u>	INVAGEN PHARMS	<u>200MG</u>	<u>A040797</u>	<u>001</u>	Feb 27, 2008
<u>AA</u>		<u>400MG</u>	<u>A040797</u>	<u>002</u>	Feb 27, 2008
<u>AA</u>	+ WATSON LABS	<u>200MG</u>	<u>A083304</u>	<u>001</u>	
<u>AA</u>	+	<u>400MG</u>	<u>A083308</u>	<u>001</u>	

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

	+ STIEFEL LABS INC	2%;0.01%	N020922	001	Dec 10, 1999
--	--------------------	----------	---------	-----	--------------

MERCAPTOPYRINE

TABLET; ORAL

MERCAPTOPYRINE

<u>AB</u>	MYLAN	<u>50MG</u>	<u>A040594</u>	<u>001</u>	Jul 01, 2005
<u>AB</u>	PROMETHEUS LABS	<u>50MG</u>	<u>A040461</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A040528</u>	<u>001</u>	Feb 13, 2004

PURINETHOL

<u>AB</u>	+ TEVA	<u>50MG</u>	<u>N009053</u>	<u>002</u>	
-----------	--------	-------------	----------------	------------	--

MEROPENEM

INJECTABLE; INJECTION

MERREM I.V.

	+ ASTRAZENECA	500MG/VIAL	N050706	003	Jun 21, 1996
	+	1GM/VIAL	N050706	001	Jun 21, 1996

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

APRISO

	+ SALIX PHARMS	375MG	N022301	001	Oct 31, 2008
	PENTASA				
	SHIRE	250MG	N020049	001	May 10, 1993
	+	500MG	N020049	002	Jul 08, 2004

ENEMA; RECTAL

MESALAMINE

<u>AB</u>	PERRIGO ISRAEL	<u>4GM/60ML</u>	<u>A076751</u>	<u>001</u>	Sep 17, 2004
<u>AB</u>	TEVA	<u>4GM/60ML</u>	<u>A076841</u>	<u>001</u>	Sep 30, 2004
	<u>ROWASA</u>				
<u>AB</u>	+ ALAVEN PHARM	<u>4GM/60ML</u>	<u>N019618</u>	<u>001</u>	Dec 24, 1987
	<u>SFROWASA</u>				
<u>AB</u>	ALAVEN PHARM	<u>4GM/60ML</u>	<u>N019618</u>	<u>002</u>	Jun 20, 2008

SUPPOSITORY; RECTAL

CANASA

	+ AXCAN SCANDIPHARM	1GM	N021252	002	Nov 05, 2004
--	---------------------	-----	---------	-----	--------------

TABLET, DELAYED RELEASE; ORAL

ASACOL

	+ PROCTER AND GAMBLE	400MG	N019651	001	Jan 31, 1992
	ASACOL HD				
	+ PROCTER AND GAMBLE	800MG	N021830	001	May 29, 2008
	LIALDA				
	+ SHIRE	1.2GM	N022000	001	Jan 16, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 256 (of 393)

MESNA

INJECTABLE; INTRAVENOUS

MESNA

<u>AP</u>	APP PHARMS	<u>100MG/ML</u>	<u>A075811</u>	<u>001</u>	Apr 26, 2001
<u>AP</u>	BEDFORD	<u>100MG/ML</u>	<u>A075739</u>	<u>001</u>	Jan 09, 2004
<u>AP</u>	TEVA PARENTERAL	<u>100MG/ML</u>	<u>A075764</u>	<u>001</u>	Apr 27, 2001

MESNEX

<u>AP</u>	+ BAXTER HLTHCARE	<u>100MG/ML</u>	<u>N019884</u>	<u>001</u>	Dec 30, 1988
-----------	-------------------	-----------------	----------------	------------	--------------

TABLET; ORAL

## MESNEX

	+ BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002
--	-------------------	-------	---------	-----	--------------

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

NORINYL 1+50 28-DAY

	+ WATSON LABS	0.05MG;1MG	N016659	001	
--	---------------	------------	---------	-----	--

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

<u>AN</u>	+ DEY	<u>0.4%</u>	<u>A071786</u>	<u>001</u>	Aug 05, 1988
<u>AN</u>	+	<u>0.6%</u>	<u>A070804</u>	<u>001</u>	Aug 17, 1987
<u>AN</u>	MORTON GROVE	<u>0.4%</u>	<u>A075586</u>	<u>001</u>	May 30, 2002
<u>AN</u>		<u>0.6%</u>	<u>A075586</u>	<u>002</u>	May 30, 2002
<u>AN</u>	NEPHRON	<u>0.4%</u>	<u>A071855</u>	<u>001</u>	Jul 14, 1988
<u>AN</u>		<u>0.6%</u>	<u>A071726</u>	<u>001</u>	Jul 14, 1988
<u>AN</u>	NOVEX	<u>0.4%</u>	<u>A075402</u>	<u>001</u>	Feb 28, 2001
<u>AN</u>		<u>0.6%</u>	<u>A075403</u>	<u>001</u>	Feb 28, 2001

SYRUP; ORAL

METAPROTERENOL SULFATE

<u>AA</u>	NOVEX	<u>10MG/5ML</u>	<u>A075235</u>	<u>001</u>	Jan 27, 2000
<u>AA</u>	+ SILARX	<u>10MG/5ML</u>	<u>A073632</u>	<u>001</u>	Jul 22, 1992

TABLET; ORAL

METAPROTERENOL SULFATE

<u>AB</u>	PAR PHARM	<u>10MG</u>	<u>A072024</u>	<u>001</u>	Jun 28, 1988
<u>AB</u>	+	<u>20MG</u>	<u>A072025</u>	<u>001</u>	Jun 28, 1988
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A073013</u>	<u>001</u>	Jan 31, 1991
<u>AB</u>		<u>20MG</u>	<u>A072795</u>	<u>001</u>	Jan 31, 1991

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

	+ APP PHARMS	EQ 10MG BASE/ML	A080722	001	
--	--------------	-----------------	---------	-----	--

METAXALONE

TABLET; ORAL

SKELAXIN

	+ KING PHARMS	800MG	N013217	003	Aug 30, 2002
--	---------------	-------	---------	-----	--------------

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

	+ RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003
--	-----------	-----------	---------	-----	--------------

TABLET; ORAL

GLUCOPHAGE

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N020357</u>	<u>001</u>	Mar 03, 1995
<u>AB</u>		<u>850MG</u>	<u>N020357</u>	<u>002</u>	Mar 03, 1995
<u>AB</u>	+	<u>1GM</u>	<u>N020357</u>	<u>005</u>	Nov 05, 1998

## PRESCRIPTION DRUG PRODUCT LIST

3 - 257 (of 393)

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>	ALPHAPHARM	<u>500MG</u>	<u>A075969</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>		<u>850MG</u>	<u>A075969</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>		<u>1GM</u>	<u>A075969</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	ALVOGEN	<u>500MG</u>	<u>A076033</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A076033</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A076033</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	AMNEAL PHARMS NY	<u>500MG</u>	<u>A077880</u>	<u>001</u>	Jun 05, 2006
<u>AB</u>		<u>850MG</u>	<u>A077880</u>	<u>002</u>	Jun 05, 2006
<u>AB</u>		<u>1GM</u>	<u>A077880</u>	<u>003</u>	Jun 05, 2006
<u>AB</u>	APOTEX	<u>500MG</u>	<u>A075984</u>	<u>001</u>	Apr 23, 2002
<u>AB</u>		<u>850MG</u>	<u>A075984</u>	<u>002</u>	Apr 23, 2002
<u>AB</u>		<u>1GM</u>	<u>A075984</u>	<u>003</u>	Apr 23, 2002
<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A077095</u>	<u>001</u>	Jan 14, 2005
<u>AB</u>		<u>850MG</u>	<u>A077095</u>	<u>002</u>	Jan 14, 2005
<u>AB</u>		<u>1GM</u>	<u>A077095</u>	<u>003</u>	Jan 14, 2005
<u>AB</u>	CARACO	<u>500MG</u>	<u>A075967</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>		<u>850MG</u>	<u>A075967</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>		<u>1GM</u>	<u>A075967</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	DR REDDYS LABS INC	<u>500MG</u>	<u>A077787</u>	<u>001</u>	Aug 23, 2006
<u>AB</u>		<u>850MG</u>	<u>A077787</u>	<u>002</u>	Aug 23, 2006
<u>AB</u>		<u>1GM</u>	<u>A077787</u>	<u>003</u>	Aug 23, 2006
<u>AB</u>	GENPHARM	<u>500MG</u>	<u>A075973</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075973</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075973</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	GLENMARK GENERICS	<u>500MG</u>	<u>A078170</u>	<u>001</u>	May 23, 2008
<u>AB</u>		<u>850MG</u>	<u>A078170</u>	<u>002</u>	May 23, 2008
<u>AB</u>		<u>1GM</u>	<u>A078170</u>	<u>003</u>	May 23, 2008
<u>AB</u>	GOLDLINE	<u>500MG</u>	<u>A075972</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>625MG</u>	<u>A075972</u>	<u>005</u>	Jan 24, 2002
<u>AB</u>		<u>750MG</u>	<u>A075972</u>	<u>004</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075972</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075972</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	INDICUS PHARMA	<u>500MG</u>	<u>A079148</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>850MG</u>	<u>A079148</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>		<u>1GM</u>	<u>A079148</u>	<u>003</u>	Nov 25, 2008
<u>AB</u>	IPCA LABS LTD	<u>500MG</u>	<u>A078422</u>	<u>001</u>	Aug 06, 2007
<u>AB</u>		<u>850MG</u>	<u>A078422</u>	<u>002</u>	Aug 06, 2007
<u>AB</u>		<u>1GM</u>	<u>A078422</u>	<u>003</u>	Aug 06, 2007
<u>AB</u>	MUTUAL PHARMA	<u>500MG</u>	<u>A076038</u>	<u>001</u>	Feb 21, 2002
<u>AB</u>		<u>850MG</u>	<u>A076038</u>	<u>002</u>	Feb 21, 2002
<u>AB</u>		<u>1GM</u>	<u>A076038</u>	<u>003</u>	Feb 21, 2002
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A075976</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075976</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075976</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	PROVIDENT PHARM	<u>500MG</u>	<u>A077853</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>		<u>850MG</u>	<u>A077853</u>	<u>002</u>	Jul 28, 2006
<u>AB</u>		<u>1GM</u>	<u>A077853</u>	<u>003</u>	Jul 28, 2006
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A075965</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075985</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075965</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075985</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075965</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075985</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	TEVA	<u>500MG</u>	<u>A075978</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075978</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075978</u>	<u>003</u>	Nov 05, 2002
<u>AB</u>	TORRENT PHARMS	<u>500MG</u>	<u>A077711</u>	<u>001</u>	Jan 24, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 258 (of 393)

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>	TORRENT PHARMS	<u>850MG</u>	<u>A077711</u>	<u>002</u>	Jan 24, 2007
<u>AB</u>		<u>1GM</u>	<u>A077711</u>	<u>003</u>	Jan 24, 2007
<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A075979</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075979</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075979</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A075961</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075961</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075961</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	ZENITH GOLDLINE	<u>500MG</u>	<u>A075975</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>625MG</u>	<u>A075975</u>	<u>004</u>	Jan 24, 2002
<u>AB</u>		<u>750MG</u>	<u>A075975</u>	<u>005</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075975</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075975</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077064</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>850MG</u>	<u>A077064</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>		<u>1GM</u>	<u>A077064</u>	<u>003</u>	Apr 18, 2005

TABLET, EXTENDED RELEASE; ORAL

GLUCOPHAGE XR

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N021202</u>	<u>001</u>	Oct 13, 2000
<u>AB</u>	+	<u>750MG</u>	<u>N021202</u>	<u>004</u>	Apr 11, 2003

METFORMIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>500MG</u>	<u>A076450</u>	<u>001</u>	Oct 01, 2004
<u>AB</u>		<u>750MG</u>	<u>A076878</u>	<u>001</u>	Apr 13, 2005
<u>AB</u>	AMNEAL PHARMS NY	<u>500MG</u>	<u>A078596</u>	<u>001</u>	Jan 03, 2008
<u>AB</u>		<u>750MG</u>	<u>A078596</u>	<u>002</u>	Jan 03, 2008
<u>AB</u>	APOTEX INC	<u>500MG</u>	<u>A076706</u>	<u>001</u>	Dec 14, 2004
<u>AB</u>		<u>750MG</u>	<u>A076706</u>	<u>002</u>	Dec 29, 2005
<u>AB</u>	BARR	<u>750MG</u>	<u>A076863</u>	<u>001</u>	Oct 14, 2004
<u>AB</u>	COBALT	<u>500MG</u>	<u>A076818</u>	<u>001</u>	Dec 14, 2004
<u>AB</u>	IMPAX LABS	<u>500MG</u>	<u>A076249</u>	<u>001</u>	Jul 30, 2004
<u>AB</u>		<u>750MG</u>	<u>A076985</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>500MG</u>	<u>A076545</u>	<u>001</u>	Dec 01, 2003
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A076650</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>750MG</u>	<u>A077113</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>	NEUROSCI INC	<u>500MG</u>	<u>A078321</u>	<u>001</u>	Apr 17, 2008
<u>AB</u>		<u>750MG</u>	<u>A078321</u>	<u>002</u>	Apr 17, 2008
<u>AB</u>	NOSTRUM	<u>500MG</u>	<u>A076756</u>	<u>001</u>	Jul 26, 2006
<u>AB</u>	RANBAXY	<u>500MG</u>	<u>A076413</u>	<u>001</u>	Jun 18, 2004
<u>AB</u>		<u>750MG</u>	<u>A077211</u>	<u>001</u>	Jun 29, 2005
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A076873</u>	<u>001</u>	Dec 14, 2004
<u>AB</u>	SUN PHARM INDS (IN)	<u>500MG</u>	<u>A077336</u>	<u>001</u>	Feb 09, 2006
<u>AB</u>		<u>750MG</u>	<u>A077336</u>	<u>002</u>	Feb 09, 2006
<u>AB</u>	TEVA	<u>500MG</u>	<u>A076269</u>	<u>001</u>	Jun 18, 2004
<u>AB</u>		<u>750MG</u>	<u>A076864</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	TORRENT PHARM	<u>500MG</u>	<u>A090014</u>	<u>001</u>	Dec 30, 2009
<u>AB</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A076172</u>	<u>001</u>	Jun 16, 2004
<u>AB</u>		<u>750MG</u>	<u>A076869</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077060</u>	<u>001</u>	Apr 20, 2005
<u>AB</u>		<u>750MG</u>	<u>A077078</u>	<u>001</u>	Apr 21, 2005
	FORTAMET				
BX	ANDRX LABS LLC	500MG	N021574	001	Apr 27, 2004
BX	+	1GM	N021574	002	Apr 27, 2004
	GLUMETZA				
BX	DEPOMED INC	500MG	N021748	001	Jun 03, 2005
BX	+	1GM	N021748	002	Jun 03, 2005

## PRESCRIPTION DRUG PRODUCT LIST

3 - 259 (of 393)

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842	001	Aug 29, 2005
+	850MG;EQ 15MG BASE	N021842	002	Aug 29, 2005

TABLET, EXTENDED RELEASE; ORAL

ACTOPLUS MET XR

TAKEDA GLOBAL	1GM;EQ 15MG BASE	N022024	001	May 12, 2009
+	1GM;EQ 30MG BASE	N022024	002	May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET; ORAL

PRANDIMET

NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008
+	500MG;2MG	N022386	002	Jun 23, 2008

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

SB PHARMCO	500MG;EQ 1MG BASE	N021410	001	Oct 10, 2002
	500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002
	500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002
	1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003
+	1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

MERCK	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007
+	1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

+ METHAPHARM	100MG/VIAL	N019193	001	Oct 31, 1986
--------------	------------	---------	-----	--------------

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	ROXANE	<u>10MG/ML</u>	<u>A040180</u>	<u>001</u>	Apr 30, 1998
<u>AA</u>	VISTAPHARM	<u>10MG/ML</u>	<u>A040088</u>	<u>001</u>	Nov 30, 1994
	<u>METHADONE HYDROCHLORIDE</u>	<u>INTENSOL</u>			
<u>AA</u>	ROXANE	<u>10MG/ML</u>	<u>A089897</u>	<u>001</u>	Sep 06, 1988
	<u>METHADOSE</u>				
<u>AA</u>	+ MALLINCKRODT	<u>10MG/ML</u>	<u>N017116</u>	<u>002</u>	

INJECTABLE; INJECTION

DOLOPHINE HYDROCHLORIDE

+ XANODYNE PHARM	10MG/ML	N021624	001	
------------------	---------	---------	-----	--

POWDER; FOR RX COMPOUNDING

METHADONE HYDROCHLORIDE

MALLINCKRODT	50GM/BOT	N006383	002	
	100GM/BOT	N006383	003	
	500GM/BOT	N006383	004	

SOLUTION; ORAL

METHADONE HYDROCHLORIDE

+ ROXANE	5MG/5ML	A087393	001	
+	10MG/5ML	A087997	001	Aug 30, 1982

## PRESCRIPTION DRUG PRODUCT LIST

3 - 260 (of 393)

METHADONE HYDROCHLORIDE

TABLET; ORAL

DOLOPHINE HYDROCHLORIDE

<u>AA</u>	+	ROXANE	<u>5MG</u>	<u>N006134</u>	<u>002</u>	
<u>AA</u>	+		<u>10MG</u>	<u>N006134</u>	<u>010</u>	

METHADONE HYDROCHLORIDE

<u>AA</u>		MALLINCKRODT	<u>5MG</u>	<u>A040517</u>	<u>001</u>	Apr 27, 2004
<u>AA</u>			<u>10MG</u>	<u>A040517</u>	<u>002</u>	Apr 27, 2004
<u>AA</u>			<u>40MG</u>	<u>A077142</u>	<u>001</u>	Jul 12, 2005
<u>AA</u>	+	ROXANE	<u>40MG</u>	<u>N017058</u>	<u>001</u>	
<u>AA</u>		SANDOZ	<u>10MG</u>	<u>A040241</u>	<u>002</u>	May 29, 1998
<u>AA</u>			<u>40MG</u>	<u>A075082</u>	<u>001</u>	Mar 25, 1998
<u>AA</u>		THE PHARMANETWORK	<u>10MG</u>	<u>A090635</u>	<u>001</u>	Nov 25, 2009

METHADOSE

<u>AA</u>		MALLINCKRODT	<u>5MG</u>	<u>A040050</u>	<u>001</u>	Apr 15, 1993
<u>AA</u>			<u>10MG</u>	<u>A040050</u>	<u>002</u>	Apr 15, 1993
<u>AA</u>			<u>40MG</u>	<u>A074184</u>	<u>001</u>	Apr 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

	+	LUNDBECK INC	5MG	N005378	002	
--	---	--------------	-----	---------	-----	--

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

<u>AB</u>		MIKART	<u>25MG</u>	<u>A040062</u>	<u>001</u>	Jan 27, 1994
<u>AB</u>	+		<u>50MG</u>	<u>A040062</u>	<u>002</u>	Jan 27, 1994
<u>AB</u>		SANDOZ	<u>25MG</u>	<u>A040036</u>	<u>001</u>	Jun 30, 1993
<u>AB</u>			<u>50MG</u>	<u>A040036</u>	<u>002</u>	Jun 30, 1993
<u>AB</u>		TEVA PHARMS	<u>25MG</u>	<u>A040001</u>	<u>001</u>	Jun 30, 1993
<u>AB</u>			<u>50MG</u>	<u>A040001</u>	<u>002</u>	Jun 30, 1993

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

<u>AB</u>	+	SANOFI AVENTIS US	<u>1GM</u>	<u>N017681</u>	<u>001</u>	
-----------	---	-------------------	------------	----------------	------------	--

METHENAMINE HIPPURATE

<u>AB</u>		COREPHARMA	<u>1GM</u>	<u>A076411</u>	<u>001</u>	Jun 20, 2003
-----------	--	------------	------------	----------------	------------	--------------

UREX

<u>AB</u>		VATRING PHARMS	<u>1GM</u>	<u>N016151</u>	<u>001</u>	
-----------	--	----------------	------------	----------------	------------	--

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

<u>AB</u>		ACTAVIS TOTOWA	<u>5MG</u>	<u>A040734</u>	<u>001</u>	Dec 14, 2007
<u>AB</u>			<u>10MG</u>	<u>A040734</u>	<u>002</u>	Dec 14, 2007
<u>AB</u>		CARACO	<u>5MG</u>	<u>A040870</u>	<u>001</u>	Sep 25, 2007
<u>AB</u>			<u>10MG</u>	<u>A040870</u>	<u>002</u>	Sep 25, 2007
<u>AB</u>		CEDAR PHARMS	<u>5MG</u>	<u>A040547</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>			<u>10MG</u>	<u>A040547</u>	<u>002</u>	Feb 18, 2005
<u>AB</u>		MYLAN	<u>5MG</u>	<u>A040350</u>	<u>001</u>	Mar 29, 2000
<u>AB</u>	+		<u>10MG</u>	<u>A040350</u>	<u>002</u>	Mar 29, 2000
<u>AB</u>		SANDOZ	<u>5MG</u>	<u>A040411</u>	<u>001</u>	Mar 27, 2001
<u>AB</u>			<u>10MG</u>	<u>A040411</u>	<u>002</u>	Mar 27, 2001

TAPAZOLE

<u>AB</u>		KING PHARMS	<u>5MG</u>	<u>A040320</u>	<u>001</u>	Mar 31, 2000
<u>AB</u>			<u>10MG</u>	<u>A040320</u>	<u>002</u>	Mar 31, 2000

## PRESCRIPTION DRUG PRODUCT LIST

3 - 261 (of 393)

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

<u>AP</u>	WATSON LABS	<u>100MG/ML</u>	<u>A086459</u>	<u>001</u>	
-----------	-------------	-----------------	----------------	------------	--

ROBAXIN

<u>AP</u>	+ BAXTER HLTHCARE CORP	<u>100MG/ML</u>	<u>N011790</u>	<u>001</u>	
-----------	------------------------	-----------------	----------------	------------	--

TABLET; ORAL

METHOCARBAMOL

<u>AA</u>	HETERO DRUGS	<u>500MG</u>	<u>A090200</u>	<u>001</u>	Nov 06, 2009
<u>AA</u>		<u>750MG</u>	<u>A090200</u>	<u>002</u>	Nov 06, 2009
<u>AA</u>	LANNETT	<u>500MG</u>	<u>A084756</u>	<u>002</u>	Mar 31, 2003
<u>AA</u>		<u>750MG</u>	<u>A084756</u>	<u>001</u>	
<u>AA</u>	SANDOZ	<u>500MG</u>	<u>A084616</u>	<u>001</u>	
<u>AA</u>		<u>750MG</u>	<u>A084615</u>	<u>001</u>	
<u>AA</u>	VINTAGE PHARMS	<u>500MG</u>	<u>A040489</u>	<u>001</u>	Jan 29, 2003
<u>AA</u>		<u>750MG</u>	<u>A040489</u>	<u>002</u>	Jan 29, 2003
<u>AA</u>	WATSON LABS	<u>500MG</u>	<u>A084277</u>	<u>001</u>	
<u>AA</u>		<u>500MG</u>	<u>A085180</u>	<u>001</u>	
<u>AA</u>		<u>750MG</u>	<u>A084276</u>	<u>002</u>	
<u>AA</u>		<u>750MG</u>	<u>A085192</u>	<u>001</u>	
<u>AA</u>	WEST WARD	<u>500MG</u>	<u>A085159</u>	<u>001</u>	
<u>AA</u>		<u>750MG</u>	<u>A085123</u>	<u>001</u>	

ROBAXIN

<u>AA</u>	+ SCHWARZ PHARMA	<u>500MG</u>	<u>N011011</u>	<u>004</u>	
-----------	------------------	--------------	----------------	------------	--

ROBAXIN-750

<u>AA</u>	+ SCHWARZ PHARMA	<u>750MG</u>	<u>N011011</u>	<u>006</u>	
-----------	------------------	--------------	----------------	------------	--

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

	+ JHP PHARMS	500MG/VIAL	N011559	001	
	+	2.5GM/VIAL	N011559	002	

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM

<u>AP</u>	+ APP PHARMS	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>	+	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>002</u>	Feb 26, 1999
<u>AP</u>	+ HOSPIRA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>010</u>	Dec 15, 2004

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u>	+ BEDFORD	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A089340</u>	<u>001</u>	Sep 16, 1986
<u>AP</u>	+	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A089343</u>	<u>001</u>	Sep 16, 1986
<u>AP</u>	EBEWE PHARMA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>001</u>	Mar 31, 2009
<u>AP</u>		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>002</u>	Mar 31, 2009
<u>AP</u>		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A090029</u>	<u>001</u>	Mar 31, 2009
<u>AP</u>	+ GENERAMEDIX	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040767</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	+	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040768</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	+	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040716</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	+ HOSPIRA	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>012</u>	Apr 13, 2005
<u>AP</u>	PHARMACHEMIE BV	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040850</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>		<u>EQ 250MG/10ML (EQ 25MG BASE/ML)</u>	<u>A040853</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>001</u>	Jan 11, 2010
	METHOTREXATE SODIUM				
	+ BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986
	+	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986
	METHOTREXATE SODIUM PRESERVATIVE FREE				
	+ BEDFORD	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005

TABLET; ORAL

METHOTREXATE SODIUM

<u>AB</u>	BARR	EQ 2.5MG BASE	A081099	001	Oct 15, 1990
-----------	------	---------------	---------	-----	--------------



## PRESCRIPTION DRUG PRODUCT LIST

3 - 262 (of 393)

METHOTREXATE SODIUM

TABLET; ORAL

METHOTREXATE SODIUM

<u>AB</u>	+	DAVA PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>N008085</u>	<u>002</u>	
<u>AB</u>		MYLAN	<u>EQ 2.5MG BASE</u>	<u>A081235</u>	<u>001</u>	May 15, 1992
<u>AB</u>		ROXANE	<u>EQ 2.5MG BASE</u>	<u>A040054</u>	<u>001</u>	Aug 01, 1994
		TREXALL				
		BARR	EQ 5MG BASE	A040385	001	Mar 21, 2001
			EQ 7.5MG BASE	A040385	002	Mar 21, 2001
			EQ 10MG BASE	A040385	003	Mar 21, 2001
	+		EQ 15MG BASE	A040385	004	Mar 21, 2001

METHOXSALEN

CAPSULE; ORAL

8-MOP

	+	VALEANT PHARM INTL	10MG	N009048	001	
		OXSORALEN-ULTRA				
	+	VALEANT PHARM INTL	10MG	N019600	001	Oct 30, 1986

INJECTABLE; INJECTION

UVADEX

	+	THERAKOS	0.02MG/ML	N020969	001	Feb 25, 1999
--	---	----------	-----------	---------	-----	--------------

LOTION; TOPICAL

OXSORALEN

	+	VALEANT PHARM INTL	1%	N009048	002	
--	---	--------------------	----	---------	-----	--

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

<u>AA</u>		BOCA PHARMA	<u>2.5MG</u>	<u>A040624</u>	<u>001</u>	Dec 28, 2006
<u>AA</u>			<u>5MG</u>	<u>A040624</u>	<u>002</u>	Dec 28, 2006
		<u>PAMINE</u>				
<u>AA</u>	+	NYCOMED US	<u>2.5MG</u>	<u>N008848</u>	<u>001</u>	
		<u>PAMINE FORTE</u>				
<u>AA</u>	+	NYCOMED US	<u>5MG</u>	<u>N008848</u>	<u>002</u>	Mar 25, 2003

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

		PARKE DAVIS	150MG	N010596	007	
	+		300MG	N010596	008	

METHYCLOTHIAZIDE

TABLET; ORAL

ENDURON

<u>AB</u>	+	ABBOTT	<u>5MG</u>	<u>N012524</u>	<u>004</u>	
-----------	---	--------	------------	----------------	------------	--

METHYCLOTHIAZIDE

<u>AB</u>		MYLAN	<u>5MG</u>	<u>A087672</u>	<u>001</u>	Aug 17, 1982
<u>AB</u>		WATSON LABS	<u>5MG</u>	<u>A088724</u>	<u>001</u>	Sep 06, 1984
		ENDURON				
		ABBOTT	2.5MG	N012524	001	

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METVIXIA

	+	GALDERMA LABS LP	EQ 16.8% BASE	N021415	001	Jul 27, 2004
--	---	------------------	---------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 263 (of 393)

METHYLDOPA

TABLET; ORAL

METHYLDOPA

<u>AB</u>	ACCORD HLTH	<u>250MG</u>	<u>A070084</u>	<u>001</u>	Oct 15, 1985
<u>AB</u>		<u>500MG</u>	<u>A070085</u>	<u>001</u>	Oct 15, 1985
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>250MG</u>	<u>A070098</u>	<u>001</u>	Feb 20, 1986
<u>AB</u>		<u>500MG</u>	<u>A070343</u>	<u>001</u>	Feb 20, 1986
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A070075</u>	<u>001</u>	Apr 18, 1985
<u>AB</u>	+	<u>500MG</u>	<u>A070076</u>	<u>001</u>	Apr 18, 1985
<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A070625</u>	<u>001</u>	Jun 06, 1986

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

<u>AP</u>	+	LUITPOLD	<u>50MG/ML</u>	<u>A071279</u>	<u>001</u>	Oct 02, 1987
<u>AP</u>		TEVA PARENTERAL	<u>50MG/ML</u>	<u>A072974</u>	<u>001</u>	Nov 22, 1991

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

<u>AP</u>	+	NOVARTIS	<u>0.2MG/ML</u>	<u>N006035</u>	<u>004</u>	
<u>AP</u>		PHARMAFORCE	<u>0.2MG/ML</u>	<u>A090193</u>	<u>001</u>	Nov 24, 2008

TABLET; ORAL

## METHERGINE

+ NOVARTIS 0.2MG N006035 003

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS

## RELISTOR

+ PROGENICS 12MG/0.6ML (12MG/0.6ML) N021964 001 Apr 24, 2008

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL

## DAYTRANA

	SHIRE	10MG/9HR (1.1MG/HR)	N021514	001	Apr 06, 2006
		15MG/9HR (1.6MG/HR)	N021514	002	Apr 06, 2006
		20MG/9HR (2.2MG/HR)	N021514	003	Apr 06, 2006
+		30MG/9HR (3.3MG/HR)	N021514	004	Apr 06, 2006

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

## METADATE CD

BX	UCB INC	10MG	N021259	003	May 27, 2003
BX		20MG	N021259	001	Apr 03, 2001
BX		30MG	N021259	002	Jun 19, 2003
BX		40MG	N021259	004	Feb 19, 2006
	RITALIN LA				
BX	NOVARTIS	10MG	N021284	004	Apr 10, 2004
BX		20MG	N021284	001	Jun 05, 2002
BX		30MG	N021284	002	Jun 05, 2002
BX	+	40MG	N021284	003	Jun 05, 2002
	METADATE CD				
	UCB INC	50MG	N021259	005	Feb 19, 2006
+		60MG	N021259	006	Feb 19, 2006

SOLUTION; ORAL

## METHYLIN

+	MALLINCKRODT	5MG/5ML	N021419	001	Dec 19, 2002
+		10MG/5ML	N021419	002	Dec 19, 2002

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 290 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 264 (of 393)

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A040321</u>	<u>001</u>	Feb 05, 2002
<u>AB</u>		<u>10MG</u>	<u>A040321</u>	<u>002</u>	Feb 05, 2002
<u>AB</u>		<u>20MG</u>	<u>A040321</u>	<u>003</u>	Feb 05, 2002
<u>AB</u>	MALLINCKRODT	<u>5MG</u>	<u>A040300</u>	<u>001</u>	Nov 27, 1998
<u>AB</u>		<u>10MG</u>	<u>A040300</u>	<u>002</u>	Nov 27, 1998
<u>AB</u>		<u>20MG</u>	<u>A040300</u>	<u>003</u>	Nov 27, 1998
<u>AB</u>	UCB INC	<u>5MG</u>	<u>A086429</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A085799</u>	<u>001</u>	
<u>AB</u>		<u>20MG</u>	<u>A086428</u>	<u>001</u>	
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A040220</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>10MG</u>	<u>A040220</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>		<u>20MG</u>	<u>A040220</u>	<u>003</u>	Aug 29, 1997
	<u>RITALIN</u>				
<u>AB</u>	NOVARTIS	<u>5MG</u>	<u>N010187</u>	<u>003</u>	
<u>AB</u>		<u>10MG</u>	<u>N010187</u>	<u>006</u>	
<u>AB</u>	+	<u>20MG</u>	<u>N010187</u>	<u>010</u>	

TABLET, CHEWABLE; ORAL

## METHYLIN

	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003
		5MG	N021475	002	Apr 15, 2003
	+	10MG	N021475	003	Apr 15, 2003

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

<u>AB</u>	UCB INC	<u>10MG</u>	<u>A040306</u>	<u>001</u>	Oct 20, 1999
<u>AB</u>	+	<u>20MG</u>	<u>A089601</u>	<u>001</u>	Jun 01, 1988

METHYLIN ER

<u>AB</u>	MALLINCKRODT	<u>10MG</u>	<u>A075629</u>	<u>001</u>	May 09, 2000
<u>AB</u>		<u>20MG</u>	<u>A075629</u>	<u>002</u>	May 09, 2000

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>20MG</u>	<u>A075450</u>	<u>001</u>	Dec 21, 2001
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A040410</u>	<u>001</u>	Feb 09, 2001

RITALIN-SR

<u>AB</u>	NOVARTIS	<u>20MG</u>	<u>N018029</u>	<u>001</u>	Mar 30, 1982
	CONCERTA				
	ORTHO MCNEIL JANSSEN	18MG	N021121	001	Aug 01, 2000
		27MG	N021121	004	Apr 01, 2002
		36MG	N021121	002	Aug 01, 2000
	+	54MG	N021121	003	Dec 08, 2000

METHYLPREDNISOLONE

TABLET; ORAL

MEDROL

<u>AB</u>	PHARMACIA AND UPJOHN	<u>4MG</u>	<u>N011153</u>	<u>001</u>	
<u>AB</u>		<u>8MG</u>	<u>N011153</u>	<u>004</u>	
<u>AB</u>		<u>16MG</u>	<u>N011153</u>	<u>003</u>	
<u>AB</u>	+	<u>32MG</u>	<u>N011153</u>	<u>006</u>	

METHYLPREDNISOLONE

<u>AB</u>	CADISTA PHARMS	<u>4MG</u>	<u>A040189</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>		<u>8MG</u>	<u>A040189</u>	<u>002</u>	Oct 31, 1997
<u>AB</u>		<u>16MG</u>	<u>A040189</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>		<u>32MG</u>	<u>A040189</u>	<u>004</u>	Jul 20, 2007
<u>AB</u>	DURAMED PHARMS BARR	<u>4MG</u>	<u>A088497</u>	<u>001</u>	Feb 21, 1984
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A040194</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>	VINTAGE PHARMS	<u>4MG</u>	<u>A040183</u>	<u>001</u>	Dec 22, 1998
<u>AB</u>	WATSON LABS	<u>4MG</u>	<u>A040232</u>	<u>001</u>	Oct 16, 1997

## PRESCRIPTION DRUG PRODUCT LIST

3 - 265 (of 393)

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>40MG/ML</u>	<u>N011757</u>	<u>001</u>	
<u>AB</u>	+		<u>80MG/ML</u>	<u>N011757</u>	<u>004</u>	

METHYLPREDNISOLONE ACETATE

<u>AB</u>		SANDOZ	<u>40MG/ML</u>	<u>A040719</u>	<u>001</u>	Jan 29, 2009
<u>AB</u>			<u>40MG/ML</u>	<u>A040794</u>	<u>001</u>	Mar 05, 2009
<u>AB</u>			<u>80MG/ML</u>	<u>A040719</u>	<u>002</u>	Jan 29, 2009
<u>AB</u>			<u>80MG/ML</u>	<u>A040794</u>	<u>002</u>	Mar 05, 2009
<u>AB</u>		TEVA PARENTERAL	<u>40MG/ML</u>	<u>A040557</u>	<u>001</u>	Feb 23, 2005
<u>AB</u>			<u>40MG/ML</u>	<u>A040620</u>	<u>001</u>	Oct 27, 2006
<u>AB</u>			<u>80MG/ML</u>	<u>A040557</u>	<u>002</u>	Feb 23, 2005
<u>AB</u>			<u>80MG/ML</u>	<u>A040620</u>	<u>002</u>	Oct 27, 2006
		DEPO-MEDROL				
	+	PHARMACIA AND UPJOHN	20MG/ML	N011757	002	

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

<u>AP</u>		HEMOPHARM USA	<u>EQ 40MG BASE/VIAL</u>	<u>A040793</u>	<u>001</u>	Nov 25, 2008
<u>AP</u>			<u>EQ 125MG BASE/VIAL</u>	<u>A040827</u>	<u>001</u>	Nov 25, 2008
<u>AP</u>		HOSPIRA	<u>EQ 40MG BASE/VIAL</u>	<u>A040664</u>	<u>001</u>	Dec 20, 2005
<u>AP</u>			<u>EQ 125MG BASE/VIAL</u>	<u>A040665</u>	<u>001</u>	Dec 20, 2005
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A089173</u>	<u>001</u>	Aug 18, 1987
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A089174</u>	<u>001</u>	Aug 18, 1987

METHYLPREDNISOLONE SODIUM SUCCINATE

<u>AP</u>		APP PHARMS	<u>EQ 40MG BASE/VIAL</u>	<u>A040583</u>	<u>001</u>	Jul 30, 2004
<u>AP</u>			<u>EQ 125MG BASE/VIAL</u>	<u>A040583</u>	<u>002</u>	Jul 30, 2004
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A040612</u>	<u>001</u>	Aug 12, 2004
<u>AP</u>		BEDFORD LABS	<u>EQ 40MG BASE/VIAL</u>	<u>A040662</u>	<u>001</u>	Feb 21, 2007
<u>AP</u>			<u>EQ 125MG BASE/VIAL</u>	<u>A040641</u>	<u>002</u>	Feb 21, 2007
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A040641</u>	<u>003</u>	Feb 21, 2007
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A040709</u>	<u>001</u>	Feb 21, 2007
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A040641</u>	<u>004</u>	Feb 21, 2007
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A040709</u>	<u>002</u>	Feb 21, 2007
<u>AP</u>		TEVA PARENTERAL	<u>EQ 125MG BASE/VIAL</u>	<u>A081266</u>	<u>001</u>	Nov 30, 1992

SOLU-MEDROL

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>EQ 40MG BASE/VIAL</u>	<u>N011856</u>	<u>003</u>	
<u>AP</u>	+		<u>EQ 125MG BASE/VIAL</u>	<u>N011856</u>	<u>004</u>	
<u>AP</u>	+		<u>EQ 500MG BASE/VIAL</u>	<u>N011856</u>	<u>005</u>	
<u>AP</u>	+		<u>EQ 1GM BASE/VIAL</u>	<u>N011856</u>	<u>006</u>	
		SOLU-MEDROL				
	+	PHARMACIA AND UPJOHN	EQ 2GM BASE/VIAL	N011856	007	Feb 27, 1985

METHYLTESTOSTERONE

CAPSULE; ORAL

TESTRED

	+	VALEANT PHARM INTL	10MG	A083976	001	
--	---	--------------------	------	---------	-----	--

TABLET; ORAL

ANDROID 10

BP		VALEANT PHARM INTL	10MG	A086450	001	
----	--	--------------------	------	---------	-----	--

ANDROID 25

BP	+	VALEANT PHARM INTL	25MG	A087147	001	
----	---	--------------------	------	---------	-----	--

METHYLTESTOSTERONE

BP		IMPAX LABS	10MG	A080767	002	
----	--	------------	------	---------	-----	--

BP			25MG	A084310	001	
----	--	--	------	---------	-----	--

## PRESCRIPTION DRUG PRODUCT LIST

3 - 266 (of 393)

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

<u>AT</u>	FALCON PHARMS	<u>0.3%</u>	<u>A075720</u>	<u>001</u>	Aug 06, 2001
<u>AT</u>	+ BAUSCH AND LOMB	<u>0.3%</u>	<u>N019907</u>	<u>001</u>	Dec 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>EQ 5MG BASE/ML</u>	<u>A073117</u>	<u>001</u>	Jan 17, 1991
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A073118</u>	<u>001</u>	Jan 17, 1991
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A074147</u>	<u>001</u>	Aug 02, 1996
<u>AP</u>	TEVA PARENTERAL	<u>EQ 5MG BASE/ML</u>	<u>A073135</u>	<u>001</u>	Nov 27, 1991
<u>REGLAN</u>					
<u>AP</u>	+ BAXTER HLTHCARE CORP	<u>EQ 5MG BASE/ML</u>	<u>N017862</u>	<u>001</u>	

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AA</u>	ANI PHARMS	<u>EQ 5MG BASE/5ML</u>	<u>A071402</u>	<u>001</u>	Jun 25, 1993
<u>AA</u>	+ MORTON GROVE	<u>EQ 5MG BASE/5ML</u>	<u>A074703</u>	<u>001</u>	Oct 31, 1997
<u>AA</u>	PHARM ASSOC	<u>EQ 5MG BASE/5ML</u>	<u>A072744</u>	<u>001</u>	May 28, 1991
<u>AA</u>	SILARX	<u>EQ 5MG BASE/5ML</u>	<u>A073680</u>	<u>001</u>	Oct 27, 1992
<u>AA</u>	VISTAPHARM	<u>EQ 5MG BASE/5ML</u>	<u>A075051</u>	<u>001</u>	Jan 26, 2001

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 10MG BASE</u>	<u>A070581</u>	<u>001</u>	Oct 17, 1985
<u>AB</u>	IPCA LABS LTD	<u>EQ 5MG BASE</u>	<u>A078807</u>	<u>001</u>	Jun 12, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078807</u>	<u>002</u>	Jun 12, 2008
<u>AB</u>	MUTUAL PHARM	<u>EQ 5MG BASE</u>	<u>A071536</u>	<u>002</u>	Jan 16, 1997
<u>AB</u>	NORTHSTAR HLTHCARE	<u>EQ 5MG BASE</u>	<u>A078374</u>	<u>001</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078374</u>	<u>002</u>	Nov 30, 2007
<u>AB</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A074478</u>	<u>002</u>	Oct 05, 1995
<u>AB</u>	TEVA	<u>EQ 5MG BASE</u>	<u>A072801</u>	<u>001</u>	Jun 15, 1993
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A070184</u>	<u>001</u>	Jul 29, 1985
<u>AB</u>	VINTAGE PHARMS	<u>EQ 5MG BASE</u>	<u>A077878</u>	<u>001</u>	Aug 28, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077878</u>	<u>002</u>	Aug 28, 2006
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A072750</u>	<u>001</u>	Dec 28, 1995
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A070511</u>	<u>001</u>	Jan 22, 1986
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A071250</u>	<u>001</u>	Feb 03, 1988
<u>REGLAN</u>					
<u>AB</u>	ALAVEN PHARM	<u>EQ 5MG BASE</u>	<u>N017854</u>	<u>002</u>	May 05, 1987
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N017854</u>	<u>001</u>	

TABLET, ORALLY DISINTEGRATING; ORAL

METOZOLV ODT

	SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009
		EQ 10MG BASE	N022246	002	Sep 04, 2009

METOLAZONE

TABLET; ORAL

METOLAZONE

<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076698</u>	<u>001</u>	Dec 23, 2003
<u>AB</u>		<u>5MG</u>	<u>A076698</u>	<u>002</u>	Oct 19, 2004
<u>AB</u>		<u>10MG</u>	<u>A076698</u>	<u>003</u>	Oct 19, 2004
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076732</u>	<u>001</u>	Dec 19, 2003
<u>AB</u>		<u>5MG</u>	<u>A076466</u>	<u>001</u>	Dec 19, 2003
<u>AB</u>		<u>10MG</u>	<u>A076466</u>	<u>002</u>	Dec 19, 2003
<u>AB</u>	TEVA	<u>2.5MG</u>	<u>A076600</u>	<u>001</u>	Jan 06, 2004
<u>AB</u>		<u>5MG</u>	<u>A076833</u>	<u>001</u>	Mar 01, 2004
<u>AB</u>		<u>10MG</u>	<u>A075543</u>	<u>003</u>	Dec 24, 2003

## PRESCRIPTION DRUG PRODUCT LIST

3 - 267 (of 393)

METOLAZONE

TABLET; ORAL

ZAROXOLYN

<u>AB</u>	UCB INC	<u>2.5MG</u>	<u>N017386</u>	<u>001</u>	
<u>AB</u>	+	<u>5MG</u>	<u>N017386</u>	<u>002</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N017386</u>	<u>003</u>	

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

<u>AB</u>	KV PHARM	<u>EQ 25MG TARTRATE</u>	<u>A077779</u>	<u>001</u>	Mar 20, 2008
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A077176</u>	<u>001</u>	May 14, 2008
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A076640</u>	<u>002</u>	May 18, 2007
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A076640</u>	<u>001</u>	May 18, 2007
<u>AB</u>	SANDOZ	<u>EQ 25MG TARTRATE</u>	<u>A076969</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A076969</u>	<u>002</u>	May 18, 2007
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A076969</u>	<u>003</u>	Mar 20, 2008
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A076969</u>	<u>004</u>	Mar 20, 2008
<u>AB</u>	WATSON LABS FLORIDA	<u>EQ 25MG TARTRATE</u>	<u>A077118</u>	<u>001</u>	Aug 03, 2009
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A076862</u>	<u>001</u>	Aug 03, 2009
	<u>TOPROL-XL</u>				
<u>AB</u>	ASTRAZENECA	<u>EQ 25MG TARTRATE</u>	<u>N019962</u>	<u>004</u>	Feb 05, 2001
<u>AB</u>	+	<u>EQ 50MG TARTRATE</u>	<u>N019962</u>	<u>001</u>	Jan 10, 1992
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>N019962</u>	<u>002</u>	Jan 10, 1992
<u>AB</u>	+	<u>EQ 200MG TARTRATE</u>	<u>N019962</u>	<u>003</u>	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE; INJECTION

LOPRESSOR

<u>AP</u>	NOVARTIS	<u>1MG/ML</u>	<u>N018704</u>	<u>001</u>	Mar 30, 1984
	<u>METOPROLOL TARTRATE</u>				
<u>AP</u>	BEDFORD LABS	<u>1MG/ML</u>	<u>A076495</u>	<u>001</u>	Jul 07, 2003
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077761</u>	<u>001</u>	May 30, 2007
<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A074133</u>	<u>001</u>	Dec 21, 1993
<u>AP</u>		<u>1MG/ML</u>	<u>A075160</u>	<u>001</u>	Jul 06, 1998
<u>AP</u>		<u>1MG/ML</u>	<u>A078085</u>	<u>001</u>	Apr 29, 2008
<u>AP</u>	LUITPOLD	<u>1MG/ML</u>	<u>A090386</u>	<u>001</u>	Sep 30, 2009
<u>AP</u>	SANDOZ	<u>1MG/ML</u>	<u>A077360</u>	<u>001</u>	Oct 02, 2007
<u>AP</u>	WATSON LABS	<u>1MG/ML</u>	<u>A074032</u>	<u>001</u>	Dec 21, 1993

TABLET; ORAL

LOPRESSOR

<u>AB</u>	NOVARTIS	<u>50MG</u>	<u>N017963</u>	<u>001</u>	
<u>AB</u>		<u>100MG</u>	<u>N017963</u>	<u>002</u>	
	<u>METOPROLOL TARTRATE</u>				
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A077739</u>	<u>001</u>	Sep 11, 2007
<u>AB</u>		<u>50MG</u>	<u>A077739</u>	<u>002</u>	Sep 11, 2007
<u>AB</u>		<u>100MG</u>	<u>A077739</u>	<u>003</u>	Sep 11, 2007
<u>AB</u>	CARACO	<u>25MG</u>	<u>A076670</u>	<u>001</u>	Jan 15, 2004
<u>AB</u>		<u>50MG</u>	<u>A074644</u>	<u>001</u>	Dec 10, 1996
<u>AB</u>		<u>100MG</u>	<u>A074644</u>	<u>002</u>	Dec 10, 1996
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A078459</u>	<u>001</u>	Jun 17, 2008
<u>AB</u>		<u>50MG</u>	<u>A078459</u>	<u>002</u>	Jun 17, 2008
<u>AB</u>		<u>100MG</u>	<u>A078459</u>	<u>003</u>	Jun 17, 2008
<u>AB</u>	MUTUAL PHARM	<u>25MG</u>	<u>A073654</u>	<u>002</u>	Jul 15, 2009
<u>AB</u>		<u>50MG</u>	<u>A073653</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		<u>100MG</u>	<u>A073654</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A076704</u>	<u>001</u>	Jan 16, 2004
<u>AB</u>		<u>50MG</u>	<u>A076704</u>	<u>002</u>	Jan 16, 2004
<u>AB</u>	+	<u>100MG</u>	<u>A076704</u>	<u>003</u>	Jan 16, 2004
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A073288</u>	<u>001</u>	Mar 25, 1994

## PRESCRIPTION DRUG PRODUCT LIST

3 - 268 (of 393)

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A073289</u>	<u>001</u>	Mar 25, 1994
<u>AB</u>	TEVA	<u>50MG</u>	<u>A074141</u>	<u>001</u>	Jan 31, 1995
<u>AB</u>		<u>100MG</u>	<u>A074141</u>	<u>002</u>	Jan 31, 1995
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A074217</u>	<u>001</u>	May 27, 1994
<u>AB</u>		<u>100MG</u>	<u>A074217</u>	<u>002</u>	May 27, 1994

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

<u>AB</u>	+ GD SEARLE LLC	<u>375MG</u>	<u>N020334</u>	<u>001</u>	May 03, 1995
-----------	-----------------	--------------	----------------	------------	--------------

METRONIDAZOLE

<u>AB</u>	ALEMBIC LTD	<u>375MG</u>	<u>A079065</u>	<u>001</u>	Jun 23, 2009
<u>AB</u>	KALI LABS	<u>375MG</u>	<u>A076522</u>	<u>001</u>	Jan 29, 2004

CREAM; TOPICAL

METROCREAM

<u>AB</u>	+ GALDERMA LABS LP	<u>0.75%</u>	<u>N020531</u>	<u>001</u>	Sep 20, 1995
-----------	--------------------	--------------	----------------	------------	--------------

METRONIDAZOLE

<u>AB</u>	ALTANA	<u>0.75%</u>	<u>A076408</u>	<u>001</u>	May 28, 2004
<u>AB</u>	G AND W LABS	<u>0.75%</u>	<u>A077549</u>	<u>001</u>	Dec 19, 2007
	NORITATE				
	+ SANOFI AVENTIS US	1%	N020743	001	Sep 26, 1997

GEL; TOPICAL

METROGEL

<u>AB</u>	+ GALDERMA LABS LP	<u>0.75%</u>	<u>N019737</u>	<u>001</u>	Nov 22, 1988
-----------	--------------------	--------------	----------------	------------	--------------

METRONIDAZOLE

<u>AB</u>	ALTANA	<u>0.75%</u>	<u>A077018</u>	<u>001</u>	Jun 06, 2006
<u>AB</u>	TARO	<u>0.75%</u>	<u>A077819</u>	<u>001</u>	Jul 18, 2006
<u>AB</u>	TOLMAR	<u>0.75%</u>	<u>A077547</u>	<u>001</u>	Jul 13, 2006
	METROGEL				
	+ GALDERMA LABS LP	1%	N021789	001	Jun 30, 2005

GEL; VAGINAL

METROGEL-VAGINAL

<u>AB</u>	+ GRACEWAY	<u>0.75%</u>	<u>N020208</u>	<u>001</u>	Aug 17, 1992
-----------	------------	--------------	----------------	------------	--------------

METRONIDAZOLE

<u>AB</u>	TOLMAR	<u>0.75%</u>	<u>A077264</u>	<u>001</u>	Oct 31, 2006
	VANDAZOLE				
BX	TEVA PHARMS	0.75%	N021806	001	May 20, 2005

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>500MG/100ML</u>	<u>N018657</u>	<u>001</u>	
<u>AP</u>	+ GD SEARLE LLC	<u>500MG/100ML</u>	<u>N018353</u>	<u>002</u>	

METRO I.V. IN PLASTIC CONTAINER

<u>AP</u>	+ B BRAUN	<u>500MG/100ML</u>	<u>N018900</u>	<u>001</u>	Sep 29, 1983
-----------	-----------	--------------------	----------------	------------	--------------

METRONIDAZOLE IN PLASTIC CONTAINER

<u>AP</u>	CLARIS LIFESCIENCES	<u>500MG/100ML</u>	<u>A078084</u>	<u>001</u>	Mar 31, 2008
<u>AP</u>	+ HOSPIRA	<u>500MG/100ML</u>	<u>N018890</u>	<u>002</u>	Nov 18, 1983

LOTION; TOPICAL

METROLOTION

<u>AB</u>	+ GALDERMA LABS LP	<u>0.75%</u>	<u>N020901</u>	<u>001</u>	Nov 24, 1998
-----------	--------------------	--------------	----------------	------------	--------------

METRONIDAZOLE

<u>AB</u>	ALTANA	<u>0.75%</u>	<u>A077197</u>	<u>001</u>	May 24, 2006
-----------	--------	--------------	----------------	------------	--------------

TABLET; ORAL

FLAGYL

<u>AB</u>	GD SEARLE LLC	<u>250MG</u>	<u>N012623</u>	<u>001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>N012623</u>	<u>003</u>	

## PRESCRIPTION DRUG PRODUCT LIST

3 - 269 (of 393)

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

<u>AB</u>	ALEMBIC LTD	<u>250MG</u>	<u>A079067</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>		<u>500MG</u>	<u>A079067</u>	<u>002</u>	Mar 13, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>250MG</u>	<u>N018517</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>N018517</u>	<u>002</u>	May 05, 1982
<u>AB</u>	MUTUAL PHARM	<u>250MG</u>	<u>A070772</u>	<u>001</u>	Jul 16, 1986
<u>AB</u>		<u>500MG</u>	<u>A070773</u>	<u>001</u>	Jul 16, 1986
<u>AB</u>	PLIVA	<u>250MG</u>	<u>A070027</u>	<u>001</u>	Nov 06, 1984
<u>AB</u>		<u>500MG</u>	<u>A070033</u>	<u>001</u>	Dec 06, 1984
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>N018620</u>	<u>001</u>	Mar 04, 1982
<u>AB</u>		<u>500MG</u>	<u>N018620</u>	<u>002</u>	Jun 02, 1983
<u>AB</u>	TEVA	<u>500MG</u>	<u>A070044</u>	<u>001</u>	Feb 08, 1985
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A070035</u>	<u>001</u>	Dec 20, 1984
<u>AB</u>		<u>250MG</u>	<u>N018764</u>	<u>001</u>	Sep 17, 1982
<u>AB</u>		<u>500MG</u>	<u>N018764</u>	<u>002</u>	Dec 20, 1982

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

+	GD SEARLE LLC	750MG	N020868	001	Nov 26, 1997
---	---------------	-------	---------	-----	--------------

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

+	GD SEARLE LLC	EQ 500MG BASE/VIAL	N018353	001	
---	---------------	--------------------	---------	-----	--

METYRAPONE

CAPSULE; ORAL

METOPIRONE

+	NOVARTIS	250MG	N012911	002	Aug 09, 1996
---	----------	-------	---------	-----	--------------

METYROSINE

CAPSULE; ORAL

DEMSEER

+	ATON	250MG	N017871	001	
---	------	-------	---------	-----	--

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

<u>AB</u>	TEVA	<u>150MG</u>	<u>A074377</u>	<u>001</u>	May 16, 1995
<u>AB</u>		<u>200MG</u>	<u>A074377</u>	<u>002</u>	May 16, 1995
<u>AB</u>	+	<u>250MG</u>	<u>A074377</u>	<u>003</u>	May 16, 1995
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A074711</u>	<u>001</u>	Feb 26, 1997
<u>AB</u>		<u>150MG</u>	<u>A074865</u>	<u>001</u>	Apr 13, 1998
<u>AB</u>		<u>200MG</u>	<u>A074711</u>	<u>002</u>	Feb 26, 1997
<u>AB</u>		<u>200MG</u>	<u>A074865</u>	<u>002</u>	Apr 13, 1998
<u>AB</u>		<u>250MG</u>	<u>A074711</u>	<u>003</u>	Feb 26, 1997
<u>AB</u>		<u>250MG</u>	<u>A074865</u>	<u>003</u>	Apr 13, 1998

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

+	ASTELLAS	50MG/VIAL	N021506	002	Mar 16, 2005
		100MG/VIAL	N021506	003	Jun 27, 2006

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>200MG</u>	<u>A073508</u>	<u>001</u>	Nov 19, 1993
-----------	----------------------	--------------	----------------	------------	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 296 of 1114**



## PRESCRIPTION DRUG PRODUCT LIST

3 - 270 (of 393)

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MONISTAT 3

<u>AB</u>	+	PERSONAL PRODS	<u>200MG</u>	<u>N018888</u>	<u>001</u>	Aug 15, 1984
-----------	---	----------------	--------------	----------------	------------	--------------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

	+	STIEFEL LABS INC	0.25%;81.35%;15%	N021026	001	Feb 16, 2006
--	---	------------------	------------------	---------	-----	--------------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

<u>AP</u>		APOTEX INC	<u>EQ 1MG BASE/ML</u>	<u>A075637</u>	<u>001</u>	Oct 31, 2000
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A075637</u>	<u>002</u>	Oct 31, 2000
<u>AP</u>		APP PHARMS	<u>EQ 1MG BASE/ML</u>	<u>A075154</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A075154</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>		BAXTER HLTHCARE	<u>EQ 1MG BASE/ML</u>	<u>A075243</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A075243</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>		BAXTER HLTHCARE CORP	<u>EQ 1MG BASE/ML</u>	<u>A075324</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A075324</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>		BEDFORD	<u>EQ 1MG BASE/ML</u>	<u>A075247</u>	<u>002</u>	Jun 23, 2000
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A075247</u>	<u>001</u>	Jun 23, 2000
<u>AP</u>		BEN VENUE	<u>EQ 1MG BASE/ML</u>	<u>A075421</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A075421</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>	+	HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075293</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>			<u>EQ 1MG BASE/ML</u>	<u>A075409</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>			<u>EQ 1MG BASE/ML</u>	<u>A075856</u>	<u>001</u>	Jun 13, 2002
<u>AP</u>	+		<u>EQ 5MG BASE/ML</u>	<u>A075293</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A075856</u>	<u>002</u>	Jun 13, 2002
<u>AP</u>		INTL MEDICATED	<u>EQ 1MG BASE/ML</u>	<u>A076144</u>	<u>001</u>	Jan 26, 2005
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A076144</u>	<u>002</u>	Jan 26, 2005
<u>AP</u>		INTL MEDICATION	<u>EQ 1MG BASE/ML</u>	<u>A076020</u>	<u>001</u>	Jul 16, 2004
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A076020</u>	<u>002</u>	Jul 16, 2004
<u>AP</u>		TAYLOR	<u>EQ 1MG BASE/ML</u>	<u>A075494</u>	<u>001</u>	Jun 30, 2000
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A075481</u>	<u>001</u>	Jun 30, 2000
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A075494</u>	<u>002</u>	Jun 30, 2000
<u>AP</u>		WOCKHARDT	<u>EQ 1MG BASE/ML</u>	<u>A078141</u>	<u>001</u>	May 30, 2008
<u>AP</u>			<u>EQ 1MG BASE/ML</u>	<u>A078511</u>	<u>001</u>	Nov 10, 2008
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A078141</u>	<u>002</u>	May 30, 2008
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A078511</u>	<u>002</u>	Nov 10, 2008
		<u>MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE</u>				
<u>AP</u>	+	HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075857</u>	<u>001</u>	Jul 22, 2002
<u>AP</u>	+		<u>EQ 5MG BASE/ML</u>	<u>A075857</u>	<u>002</u>	Jul 22, 2002

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

<u>AA</u>		APOTEX INC	<u>EQ 2MG BASE/ML</u>	<u>A077115</u>	<u>001</u>	Sep 09, 2005
<u>AA</u>		HI TECH PHARMA	<u>EQ 2MG BASE/ML</u>	<u>A075958</u>	<u>001</u>	Sep 04, 2003
<u>AA</u>		PADDOCK	<u>EQ 2MG BASE/ML</u>	<u>A076379</u>	<u>001</u>	May 02, 2005
<u>AA</u>		RANBAXY	<u>EQ 2MG BASE/ML</u>	<u>A076058</u>	<u>001</u>	Mar 15, 2002
<u>AA</u>	+	ROXANE	<u>EQ 2MG BASE/ML</u>	<u>A075873</u>	<u>001</u>	Apr 30, 2002

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

<u>AB</u>		APOTEX INC	<u>2.5MG</u>	<u>A077746</u>	<u>001</u>	Sep 12, 2006
<u>AB</u>			<u>5MG</u>	<u>A077746</u>	<u>002</u>	Sep 12, 2006
<u>AB</u>			<u>10MG</u>	<u>A077746</u>	<u>003</u>	Sep 12, 2006
<u>AB</u>		IMPAX PHARMS	<u>2.5MG</u>	<u>A076449</u>	<u>001</u>	May 27, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 271 (of 393)

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

<u>AB</u>	IMPAX PHARMS	<u>5MG</u>	<u>A076449</u>	<u>002</u>	May 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A076449</u>	<u>003</u>	Dec 16, 2005
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076577</u>	<u>001</u>	Sep 10, 2003
<u>AB</u>		<u>5MG</u>	<u>A076577</u>	<u>002</u>	Sep 10, 2003
<u>AB</u>		<u>10MG</u>	<u>A076577</u>	<u>003</u>	Sep 10, 2003
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076514</u>	<u>001</u>	Sep 11, 2003
<u>AB</u>		<u>5MG</u>	<u>A076514</u>	<u>002</u>	Sep 11, 2003
<u>AB</u>		<u>10MG</u>	<u>A076514</u>	<u>003</u>	Jul 02, 2004
	<u>ORVATEN</u>				
<u>AB</u>	UPSHER SMITH	<u>2.5MG</u>	<u>A076725</u>	<u>001</u>	Nov 03, 2004
<u>AB</u>		<u>5MG</u>	<u>A076725</u>	<u>002</u>	Nov 03, 2004
<u>AB</u>		<u>10MG</u>	<u>A076725</u>	<u>003</u>	Nov 03, 2004
	<u>PROAMATINE</u>				
<u>AB</u>	SHIRE	<u>2.5MG</u>	<u>N019815</u>	<u>001</u>	Sep 06, 1996
<u>AB</u>	+	<u>5MG</u>	<u>N019815</u>	<u>002</u>	Sep 06, 1996
<u>AB</u>		<u>10MG</u>	<u>N019815</u>	<u>003</u>	Mar 20, 2002

MIFEPRISTONE

TABLET; ORAL

MIFEPREX

+	DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000
---	----------------	-------	---------	-----	--------------

MIGLITOL

TABLET; ORAL

GLYSET

	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996
		50MG	N020682	002	Dec 18, 1996
+		100MG	N020682	003	Dec 18, 1996

MIGLUSTAT

CAPSULE; ORAL

ZAVESCA

+	ACTELION PHARMS LTD	100MG	N021348	001	Jul 31, 2003
---	---------------------	-------	---------	-----	--------------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

	CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009
		25MG	N022256	002	Jan 14, 2009
		50MG	N022256	003	Jan 14, 2009
+		100MG	N022256	004	Jan 14, 2009

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

<u>AP</u>	APOTEX INC	<u>EQ 1MG BASE/ML</u>	<u>A076427</u>	<u>001</u>	Sep 21, 2004
<u>AP</u>	APP PHARMS	<u>EQ 1MG BASE/ML</u>	<u>A075936</u>	<u>001</u>	May 28, 2002
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 1MG BASE/ML</u>	<u>A075530</u>	<u>001</u>	May 28, 2002
<u>AP</u>	+	<u>EQ 1MG BASE/ML</u>	<u>A075660</u>	<u>001</u>	May 28, 2002
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 1MG BASE/ML</u>	<u>A077190</u>	<u>001</u>	Oct 31, 2006
<u>AP</u>	HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075884</u>	<u>001</u>	May 28, 2002
<u>AP</u>	INTL MEDICATED	<u>EQ 1MG BASE/ML</u>	<u>A076013</u>	<u>001</u>	Aug 02, 2002
	<u>MILRINONE LACTATE IN DEXTROSE 5%</u>				
<u>AP</u>	APOTEX INC	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A077151</u>	<u>002</u>	Jul 20, 2005
	<u>MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER</u>				
<u>AP</u>	APOTEX INC	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A077151</u>	<u>001</u>	Jul 20, 2005

## PRESCRIPTION DRUG PRODUCT LIST

3 - 272 (of 393)

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A076414</u>	<u>001</u>	Aug 18, 2004
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075834</u>	<u>001</u>	May 28, 2002
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075834</u>	<u>002</u>	May 28, 2002
<u>AP</u>	BEDFORD LABS	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A078113</u>	<u>001</u>	May 21, 2008
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A078113</u>	<u>002</u>	May 21, 2008
<u>AP</u>	HOSPIRA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075885</u>	<u>001</u>	May 28, 2002
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075885</u>	<u>002</u>	May 28, 2002
<u>PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	+ SANOFI AVENTIS US	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>N020343</u>	<u>003</u>	Aug 09, 1994
<u>AP</u>	+	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>N020343</u>	<u>004</u>	Aug 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

<u>AB</u>	MEDICIS	<u>EQ 75MG BASE</u>	<u>A063067</u>	<u>002</u>	Sep 15, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063067</u>	<u>001</u>	Jul 31, 1990

MINOCIN

<u>AB</u>	TRIAx PHARMS LLC	<u>EQ 50MG BASE</u>	<u>N050649</u>	<u>001</u>	May 31, 1990
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N050649</u>	<u>002</u>	May 31, 1990

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 50MG BASE</u>	<u>A065470</u>	<u>001</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065470</u>	<u>002</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065470</u>	<u>003</u>	Mar 11, 2008
<u>AB</u>	IMPAX LABS	<u>EQ 50MG BASE</u>	<u>A065005</u>	<u>001</u>	Mar 23, 1999
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065005</u>	<u>003</u>	Apr 18, 2001
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065005</u>	<u>002</u>	Mar 23, 1999
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065062</u>	<u>001</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065062</u>	<u>002</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065062</u>	<u>003</u>	Nov 30, 2000
<u>AB</u>	TEVA	<u>EQ 50MG BASE</u>	<u>A063011</u>	<u>001</u>	Mar 02, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063009</u>	<u>002</u>	Aug 12, 2003
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A063009</u>	<u>001</u>	Mar 02, 1992
<u>AB</u>	WATSON LABS	<u>EQ 50MG BASE</u>	<u>A063181</u>	<u>001</u>	Dec 30, 1991
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063065</u>	<u>002</u>	Jun 10, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063065</u>	<u>001</u>	Dec 30, 1991

INJECTABLE; INJECTION

MINOCIN

+	TRIAx PHARMS LLC	EQ 100MG BASE/VIAL	N050444	001	
---	------------------	--------------------	---------	-----	--

POWDER, EXTENDED RELEASE; DENTAL

ARESTIN

+	ORAPHARMA	EQ 1MG BASE	N050781	001	Feb 16, 2001
---	-----------	-------------	---------	-----	--------------

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 50MG BASE</u>	<u>A065436</u>	<u>001</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065436</u>	<u>002</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065436</u>	<u>003</u>	Dec 26, 2007
<u>AB</u>	MEDICIS	<u>EQ 50MG BASE</u>	<u>A065131</u>	<u>001</u>	Apr 16, 2003
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065131</u>	<u>002</u>	Apr 16, 2003
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A065131</u>	<u>003</u>	Apr 16, 2003
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065156</u>	<u>001</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065156</u>	<u>002</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065156</u>	<u>003</u>	Jan 06, 2004

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>EQ 45MG BASE</u>	<u>A065485</u>	<u>001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A065485</u>	<u>002</u>	Mar 17, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 273 (of 393)

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>EQ 135MG BASE</u>	<u>A065485</u>	<u>003</u>	Mar 17, 2009
<u>AB</u>	IMPAX LABS INC	<u>EQ 45MG BASE</u>	<u>A090024</u>	<u>001</u>	Feb 03, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090024</u>	<u>002</u>	Feb 03, 2009
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090024</u>	<u>003</u>	Feb 03, 2009
<u>AB</u>	SANDOZ	<u>EQ 45MG BASE</u>	<u>A090422</u>	<u>001</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090422</u>	<u>002</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090422</u>	<u>003</u>	Aug 13, 2009
	<u>SOLODYN</u>				
<u>AB</u>	MEDICIS	<u>EQ 45MG BASE</u>	<u>N050808</u>	<u>001</u>	May 08, 2006
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>N050808</u>	<u>002</u>	May 08, 2006
<u>AB</u>	+	<u>EQ 135MG BASE</u>	<u>N050808</u>	<u>003</u>	May 08, 2006
	SOLODYN				
	MEDICIS	EQ 65MG BASE	N050808	004	Jul 23, 2009
		EQ 115MG BASE	N050808	005	Jul 23, 2009

MINOXIDIL

TABLET; ORAL

MINOXIDIL

<u>AB</u>	MUTUAL PHARM	<u>2.5MG</u>	<u>A072708</u>	<u>001</u>	Dec 14, 1995
<u>AB</u>		<u>10MG</u>	<u>A072709</u>	<u>001</u>	Dec 14, 1995
<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A071826</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>		<u>10MG</u>	<u>A071839</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A071344</u>	<u>001</u>	Mar 03, 1987
<u>AB</u>	+	<u>10MG</u>	<u>A071345</u>	<u>001</u>	Mar 03, 1987

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>15MG</u>	<u>A076308</u>	<u>001</u>	Jun 20, 2003
<u>AB</u>		<u>30MG</u>	<u>A076308</u>	<u>002</u>	Jun 20, 2003
<u>AB</u>		<u>45MG</u>	<u>A076308</u>	<u>003</u>	Jun 20, 2003
<u>AB</u>	ACTAVIS TOTOWA	<u>15MG</u>	<u>A076241</u>	<u>001</u>	Jun 25, 2003
<u>AB</u>		<u>30MG</u>	<u>A076241</u>	<u>002</u>	Jun 25, 2003
<u>AB</u>		<u>45MG</u>	<u>A076241</u>	<u>003</u>	Jun 25, 2003
<u>AB</u>	ALPHAPHARM	<u>15MG</u>	<u>A076176</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076176</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076176</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	APOTEX INC	<u>15MG</u>	<u>A077666</u>	<u>001</u>	Aug 22, 2007
<u>AB</u>		<u>30MG</u>	<u>A077666</u>	<u>002</u>	Aug 22, 2007
<u>AB</u>		<u>45MG</u>	<u>A077666</u>	<u>003</u>	Aug 22, 2007
<u>AB</u>	AUROBINDO	<u>7.5MG</u>	<u>A076921</u>	<u>001</u>	Oct 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076921</u>	<u>002</u>	Oct 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076921</u>	<u>003</u>	Oct 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076921</u>	<u>004</u>	Oct 22, 2004
<u>AB</u>	CARACO	<u>7.5MG</u>	<u>A076541</u>	<u>004</u>	Apr 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076541</u>	<u>001</u>	Apr 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076541</u>	<u>002</u>	Apr 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076541</u>	<u>003</u>	Apr 22, 2004
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A076122</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076122</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076122</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A076219</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076219</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076219</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076119</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>30MG</u>	<u>A076119</u>	<u>002</u>	Jan 24, 2003
<u>AB</u>		<u>45MG</u>	<u>A076119</u>	<u>003</u>	Jun 19, 2003

## PRESCRIPTION DRUG PRODUCT LIST

3 - 274 (of 393)

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A076312</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076312</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076312</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	WATSON LABS FLORIDA	<u>15MG</u>	<u>A076336</u>	<u>001</u>	Jun 20, 2003
<u>AB</u>		<u>30MG</u>	<u>A076336</u>	<u>002</u>	Jun 20, 2003
<u>AB</u>		<u>45MG</u>	<u>A076336</u>	<u>003</u>	Jun 20, 2003
<u>REMERON</u>					
<u>AB</u>	+ ORGANON USA INC	<u>15MG</u>	<u>N020415</u>	<u>001</u>	Jun 14, 1996
<u>AB</u>		<u>30MG</u>	<u>N020415</u>	<u>002</u>	Jun 14, 1996
<u>AB</u>		<u>45MG</u>	<u>N020415</u>	<u>003</u>	Mar 17, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

<u>AB</u>	ACTAVIS TOTOWA	<u>15MG</u>	<u>A076689</u>	<u>001</u>	Aug 31, 2005
<u>AB</u>		<u>30MG</u>	<u>A076689</u>	<u>002</u>	Aug 31, 2005
<u>AB</u>		<u>45MG</u>	<u>A076689</u>	<u>003</u>	Aug 31, 2005
<u>AB</u>	AUROBINDO PHARMA LTD	<u>15MG</u>	<u>A077376</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077376</u>	<u>003</u>	Dec 08, 2005
<u>AB</u>		<u>45MG</u>	<u>A077376</u>	<u>004</u>	Feb 28, 2006
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076901</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>		<u>30MG</u>	<u>A076901</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>		<u>45MG</u>	<u>A076901</u>	<u>003</u>	Jun 28, 2005
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A076307</u>	<u>001</u>	Dec 17, 2003
<u>AB</u>		<u>30MG</u>	<u>A076307</u>	<u>002</u>	Dec 17, 2003
<u>AB</u>		<u>45MG</u>	<u>A076307</u>	<u>003</u>	Feb 28, 2006
<u>REMERON SOLTAB</u>					
<u>AB</u>	+ ORGANON USA INC	<u>15MG</u>	<u>N021208</u>	<u>001</u>	Jan 12, 2001
<u>AB</u>		<u>30MG</u>	<u>N021208</u>	<u>002</u>	Jan 12, 2001
<u>AB</u>		<u>45MG</u>	<u>N021208</u>	<u>003</u>	Jan 12, 2001

MISOPROSTOL

TABLET; ORAL

CYTOTEC

<u>AB</u>	GD SEARLE LLC	<u>0.1MG</u>	<u>N019268</u>	<u>003</u>	Sep 21, 1990
<u>AB</u>	+	<u>0.2MG</u>	<u>N019268</u>	<u>001</u>	Dec 27, 1988

MISOPROSTOL

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.1MG</u>	<u>A076095</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>		<u>0.2MG</u>	<u>A076095</u>	<u>002</u>	Jul 10, 2002

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

<u>AP</u>	ACCORD HLTHCARE	<u>5MG/VIAL</u>	<u>A064144</u>	<u>001</u>	Apr 30, 1998
<u>AP</u>		<u>20MG/VIAL</u>	<u>A064144</u>	<u>002</u>	Apr 30, 1998
<u>AP</u>		<u>40MG/VIAL</u>	<u>A064144</u>	<u>003</u>	Aug 11, 2009
<u>AP</u>	BAXTER HLTHCARE	<u>5MG/VIAL</u>	<u>A064180</u>	<u>001</u>	Dec 23, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A064180</u>	<u>002</u>	Dec 23, 1999
<u>AP</u>	BEDFORD	<u>5MG/VIAL</u>	<u>A064117</u>	<u>001</u>	Apr 19, 1995
<u>AP</u>		<u>20MG/VIAL</u>	<u>A064117</u>	<u>002</u>	Apr 19, 1995
<u>MUTAMYCIN</u>					
<u>AP</u>	+ BRISTOL MYERS	<u>5MG/VIAL</u>	<u>A062336</u>	<u>001</u>	
<u>AP</u>	+	<u>20MG/VIAL</u>	<u>A062336</u>	<u>002</u>	
<u>AP</u>	+	<u>40MG/VIAL</u>	<u>A062336</u>	<u>003</u>	Mar 10, 1988

MITOTANE

TABLET; ORAL

LYSODREN

+ BRISTOL MYERS SQUIBB 500MG

N016885 001

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 301 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 275 (of 393)

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<u>AP</u>	APP PHARMS	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	BEDFORD	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	FRESENIUS KABI ONCOL	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A078606</u>	<u>001</u>	May 14, 2008
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A078606</u>	<u>002</u>	May 14, 2008
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A078606</u>	<u>003</u>	May 14, 2008
<u>AP</u>	GENERAMEDIX	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A078980</u>	<u>001</u>	Apr 13, 2009
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A078980</u>	<u>002</u>	Apr 13, 2009
<u>AP</u>	HOSPIRA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	TEVA PARENTERAL	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>003</u>	Apr 11, 2006
	<u>NOVANTRONE</u>				
<u>AP</u>	+ EMD SERONO	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>N019297</u>	<u>001</u>	Dec 23, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

+ EBEWE PARENTA EQ 2MG BASE/ML A078562 001 Apr 30, 2009

MODAFINIL

TABLET; ORAL

PROVIGIL

	CEPHALON	100MG	N020717	001	Dec 24, 1998
+		200MG	N020717	002	Dec 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A078454</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>		<u>15MG</u>	<u>A078454</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>	PADDOCK	<u>7.5MG</u>	<u>A077536</u>	<u>001</u>	Nov 30, 2006
<u>AB</u>		<u>15MG</u>	<u>A077536</u>	<u>002</u>	Nov 30, 2006
<u>AB</u>	TEVA	<u>7.5MG</u>	<u>A076204</u>	<u>001</u>	May 08, 2003
<u>AB</u>		<u>15MG</u>	<u>A076204</u>	<u>002</u>	May 08, 2003
	<u>UNIVASC</u>				
<u>AB</u>	SCHWARZ PHARMA	<u>7.5MG</u>	<u>N020312</u>	<u>001</u>	Apr 19, 1995
<u>AB</u>	+	<u>15MG</u>	<u>N020312</u>	<u>002</u>	Apr 19, 1995

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOBAN

	ENDO PHARMS	5MG	N017111	004	
		10MG	N017111	005	
+		25MG	N017111	006	
+		50MG	N017111	007	

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

<u>AB</u>	+ SCHERING	<u>0.1%</u>	<u>N019625</u>	<u>001</u>	May 06, 1987
-----------	------------	-------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 276 (of 393)

MOMETASONE FUROATE

CREAM; TOPICAL

MOMETASONE FUROATE

<u>AB</u>	ALTANA	<u>0.1%</u>	<u>A076171</u>	<u>001</u>	Apr 08, 2005
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077447</u>	<u>001</u>	May 22, 2006
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A078541</u>	<u>001</u>	May 28, 2008
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076679</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076591</u>	<u>001</u>	Apr 18, 2007

LOTION; TOPICAL

ELOCON

<u>AB</u>	+ SCHERING	<u>0.1%</u>	<u>N019796</u>	<u>001</u>	Mar 30, 1989
-----------	------------	-------------	----------------	------------	--------------

MOMETASONE FUROATE

<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077678</u>	<u>001</u>	Nov 21, 2007
<u>AB</u>	NYCOMED US	<u>0.1%</u>	<u>A075919</u>	<u>001</u>	Nov 29, 2007
<u>AB</u>	PERRIGO	<u>0.1%</u>	<u>A077180</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076788</u>	<u>001</u>	Mar 15, 2006
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076499</u>	<u>001</u>	Nov 21, 2007

OINTMENT; TOPICAL

ELOCON

<u>AB</u>	+ SCHERING	<u>0.1%</u>	<u>N019543</u>	<u>001</u>	Apr 30, 1987
-----------	------------	-------------	----------------	------------	--------------

MOMETASONE FUROATE

<u>AB</u>	ALTANA	<u>0.1%</u>	<u>A077061</u>	<u>001</u>	Mar 28, 2005
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077401</u>	<u>001</u>	Jun 20, 2006
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A078571</u>	<u>001</u>	May 28, 2008
<u>AB</u>	PERRIGO NEW YORK	<u>0.1%</u>	<u>A076067</u>	<u>001</u>	Mar 18, 2002
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076624</u>	<u>001</u>	Dec 03, 2004
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076481</u>	<u>001</u>	Nov 14, 2003

POWDER; INHALATION

ASMANEX TWISTHALER

	SCHERING	0.11MG/INH	N021067	002	Feb 01, 2008
	+	0.22MG/INH	N021067	001	Mar 30, 2005

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL

NASONEX

	+ SCHERING PLOUGH	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997
--	-------------------	----------------------	---------	-----	--------------

MONTELUKAST SODIUM

GRANULE; ORAL

SINGULAIR

	+ MERCK	EQ 4MG BASE/PACKET	N021409	001	Jul 26, 2002
--	---------	--------------------	---------	-----	--------------

TABLET; ORAL

SINGULAIR

	+ MERCK	EQ 10MG BASE	N020829	002	Feb 20, 1998
--	---------	--------------	---------	-----	--------------

TABLET, CHEWABLE; ORAL

SINGULAIR

	MERCK	EQ 4MG BASE	N020830	002	Mar 03, 2000
	+	EQ 5MG BASE	N020830	001	Feb 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

BX	KING PHARMS	30MG	N021260	001	Mar 20, 2002
BX		60MG	N021260	002	Mar 20, 2002
	KADIAN				
BX	ACTAVIS ELIZABETH	30MG	N020616	004	Mar 09, 2001
BX		60MG	N020616	005	Mar 09, 2001
	AVINZA				
	KING PHARMS	45MG	N021260	005	Dec 18, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 277 (of 393)

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL					
AVINZA					
	KING PHARMS	75MG	N021260	006	Dec 18, 2008
		90MG	N021260	003	Mar 20, 2002
+		120MG	N021260	004	Mar 20, 2002
KADIAN					
+	ACTAVIS ELIZABETH	10MG	N020616	008	Apr 20, 2007
		20MG	N020616	001	Jul 03, 1996
		50MG	N020616	002	Jul 03, 1996
+		80MG	N020616	006	Oct 27, 2006
+		100MG	N020616	003	Jul 03, 1996
		200MG	N020616	007	Feb 27, 2007
INJECTABLE; INJECTION					
<u>ASTRAMORPH PF</u>					
<u>AP</u>	APP PHARMS	<u>0.5MG/ML</u>	<u>A071050</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>0.5MG/ML</u>	<u>A071051</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>1MG/ML</u>	<u>A071052</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>1MG/ML</u>	<u>A071053</u>	<u>001</u>	Oct 07, 1986
<u>DURAMORPH PF</u>					
<u>AP</u>	+ BAXTER HLTHCARE	<u>0.5MG/ML</u>	<u>N018565</u>	<u>001</u>	Sep 18, 1984
<u>AP</u>	+	<u>1MG/ML</u>	<u>N018565</u>	<u>002</u>	Sep 18, 1984
<u>MORPHINE SULFATE</u>					
<u>AP</u>	HOSPIRA	<u>0.5MG/ML</u>	<u>A071849</u>	<u>001</u>	May 11, 1988
<u>AP</u>		<u>0.5MG/ML</u>	<u>A073509</u>	<u>001</u>	Sep 30, 1992
<u>AP</u>		<u>1MG/ML</u>	<u>A071850</u>	<u>001</u>	May 11, 1988
<u>AP</u>		<u>1MG/ML</u>	<u>A073510</u>	<u>001</u>	Sep 30, 1992
<u>AP</u>	+	<u>1MG/ML</u>	<u>N019916</u>	<u>001</u>	Oct 30, 1992
<u>AP</u>	WATSON LABS	<u>0.5MG/ML</u>	<u>A073373</u>	<u>001</u>	Sep 30, 1991
<u>AP</u>		<u>0.5MG/ML</u>	<u>A073375</u>	<u>001</u>	Sep 30, 1991
<u>AP</u>		<u>1MG/ML</u>	<u>A073374</u>	<u>001</u>	Sep 30, 1991
<u>AP</u>		<u>1MG/ML</u>	<u>A073376</u>	<u>001</u>	Sep 30, 1991
INFUMORPH					
+	BAXTER HLTHCARE	10MG/ML	N018565	003	Jul 19, 1991
+		25MG/ML	N018565	004	Jul 19, 1991
MORPHINE SULFATE					
+	HOSPIRA	5MG/ML	N019916	002	Oct 27, 2006
+	MERIDIAN MEDCL TECHN	15MG/ML	N019999	001	Jul 12, 1990
INJECTABLE, LIPOSOMAL; EPIDURAL					
DEPODUR					
	PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671	001	May 18, 2004
+		15MG/1.5ML (10MG/ML)	N021671	002	May 18, 2004
SOLUTION; ORAL					
MORPHINE SULFATE					
	ROXANE	10MG/5ML	N022195	001	Mar 17, 2008
+		20MG/5ML	N022195	002	Mar 17, 2008
TABLET; ORAL					
MORPHINE SULFATE					
	ROXANE	15MG	N022207	001	Mar 17, 2008
+		30MG	N022207	002	Mar 17, 2008
TABLET, EXTENDED RELEASE; ORAL					
<u>MORPHINE SULFATE</u>					
<u>AB</u>	ENDO PHARMS	<u>15MG</u>	<u>A075295</u>	<u>001</u>	Oct 28, 1998
<u>AB</u>		<u>30MG</u>	<u>A075295</u>	<u>002</u>	Oct 28, 1998
<u>AB</u>		<u>60MG</u>	<u>A075295</u>	<u>003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A075295</u>	<u>004</u>	Sep 15, 2000
<u>AB</u>		<u>200MG</u>	<u>A075295</u>	<u>005</u>	Sep 15, 2000
<u>AB</u>	KV PHARM	<u>15MG</u>	<u>A076733</u>	<u>001</u>	May 19, 2004
<u>AB</u>		<u>30MG</u>	<u>A076720</u>	<u>002</u>	Dec 23, 2005



## PRESCRIPTION DRUG PRODUCT LIST

3 - 278 (of 393)

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

<u>AB</u>	KV PHARM	<u>60MG</u>	<u>A076720</u>	<u>001</u>	May 19, 2004
<u>AB</u>		<u>100MG</u>	<u>A077855</u>	<u>001</u>	Sep 27, 2007
<u>AB</u>		<u>200MG</u>	<u>A077855</u>	<u>002</u>	Sep 27, 2007
<u>AB</u>	MALLINCKRODT	<u>15MG</u>	<u>A076412</u>	<u>001</u>	Jul 31, 2003
<u>AB</u>		<u>30MG</u>	<u>A076412</u>	<u>002</u>	Jul 31, 2003
<u>AB</u>		<u>60MG</u>	<u>A076412</u>	<u>003</u>	Jul 31, 2003
<u>AB</u>		<u>100MG</u>	<u>A076438</u>	<u>001</u>	Jul 03, 2003
<u>AB</u>		<u>200MG</u>	<u>A076438</u>	<u>002</u>	Jul 03, 2003
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075656</u>	<u>001</u>	Jan 30, 2001
<u>MS CONTIN</u>					
<u>AB</u>	PURDUE PHARMA LP	<u>15MG</u>	<u>N019516</u>	<u>003</u>	Sep 12, 1989
<u>AB</u>		<u>30MG</u>	<u>N019516</u>	<u>001</u>	May 29, 1987
<u>AB</u>	+	<u>60MG</u>	<u>N019516</u>	<u>002</u>	Apr 08, 1988
<u>AB</u>		<u>100MG</u>	<u>N019516</u>	<u>004</u>	Jan 16, 1990
<u>AB</u>		<u>200MG</u>	<u>N019516</u>	<u>005</u>	Nov 08, 1993
ORAMORPH SR					
BC	XANODYNE PHARM	15MG	N019977	004	Nov 23, 1994
BC		30MG	N019977	001	Aug 15, 1991
BC	+	60MG	N019977	002	Aug 15, 1991
BC		100MG	N019977	003	Aug 15, 1991

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

## EMBEDA

	ALPHARMA KING	20MG; 0.8MG	N022321	001	Aug 13, 2009
		30MG; 1.2MG	N022321	002	Aug 13, 2009
		50MG; 2MG	N022321	003	Aug 13, 2009
		60MG; 2.4MG	N022321	004	Aug 13, 2009
		80MG; 3.2MG	N022321	005	Aug 13, 2009
	+	100MG; 4MG	N022321	006	Aug 13, 2009

MOXIFLOXACIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

+	BAYER HLTHCARE	160MG/100ML	N021277	001	Nov 30, 2001
---	----------------	-------------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

+	ALCON	0.5%	N021598	001	Apr 15, 2003
---	-------	------	---------	-----	--------------

TABLET; ORAL

AVELOX

+	BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999
---	----------------	---------------	---------	-----	--------------

MUPIROCIN

OINTMENT; TOPICAL

BACTROBAN

<u>AB</u>	+	GLAXOSMITHKLINE	<u>2%</u>	<u>N050591</u>	<u>001</u>	Dec 31, 1987
-----------	---	-----------------	-----------	----------------	------------	--------------

MUPIROCIN

<u>AB</u>		ALTANA	<u>2%</u>	<u>A065192</u>	<u>001</u>	Nov 30, 2005
<u>AB</u>		PERRIGO NEW YORK	<u>2%</u>	<u>A065123</u>	<u>001</u>	Nov 07, 2003
<u>AB</u>		TARO	<u>2%</u>	<u>A065170</u>	<u>001</u>	Sep 23, 2005
<u>AB</u>		TEVA	<u>2%</u>	<u>A065085</u>	<u>001</u>	Nov 07, 2003
CENTANY						
BX		PERRIGO NEW YORK	2%	N050788	001	Dec 04, 2002

## PRESCRIPTION DRUG PRODUCT LIST

3 - 279 (of 393)

MUPIROICIN CALCIUM

CREAM, AUGMENTED; TOPICAL

BACTROBAN

+ GLAXOSMITHKLINE EQ 2% BASE N050746 001 Dec 11, 1997

OINTMENT; NASAL

BACTROBAN

+ GLAXOSMITHKLINE EQ 2% BASE N050703 001 Sep 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

CELLCEPTAB + ROCHE PALO 250MG N050722 001 May 03, 1995MYCOPHENOLATE MOFETILAB ACCORD HLTHCARE INC 250MG A090253 001 May 04, 2009AB APOTEX CORP 250MG A090419 001 Apr 22, 2009AB ENDO PHARMS 250MG A090111 001 Dec 22, 2009AB MYLAN 250MG A065520 001 May 04, 2009AB ROXANE 250MG A065410 001 Jul 29, 2008AB SANDOZ 250MG A065379 001 Oct 15, 2008AB TEVA PHARMS 250MG A065491 001 May 06, 2009AB ZYDUS PHARMS USA INC 250MG A065433 001 May 04, 2009

SUSPENSION; ORAL

CELLCEPT

+ ROCHE PALO 200MG/ML N050759 001 Oct 01, 1998

TABLET; ORAL

CELLCEPTAB + ROCHE PALO 500MG N050723 001 Jun 19, 1997MYCOPHENOLATE MOFETILAB ACCORD HLTHCARE 500MG A065416 001 May 04, 2009AB APOTEX 500MG A090499 001 Apr 22, 2009AB MYLAN 500MG A065521 001 May 04, 2009AB ROXANE 500MG A065413 001 Jul 29, 2008AB SANDOZ 500MG A065451 001 Oct 15, 2008AB TEVA PHARMS 500MG A065457 001 May 04, 2009AB ZYDUS PHARMS USA INC 500MG A065477 001 May 04, 2009MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

CELLCEPT

+ ROCHE PALO 500MG/VIAL N050758 001 Aug 12, 1998

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYFORTIC

NOVARTIS 180MG N050791 001 Feb 27, 2004

+ 360MG N050791 002 Feb 27, 2004

NABILONE

CAPSULE; ORAL

CESAMET

+ MEDA PHARMS 1MG N018677 001 Dec 26, 1985

NABUMETONE

TABLET; ORAL

NABUMETONEAB ACTAVIS ELIZABETH 500MG A079093 001 Feb 27, 2009AB 750MG A079093 002 Feb 27, 2009AB DR REDDYS LABS LTD 500MG A078420 001 Sep 24, 2008AB 750MG A078420 002 Sep 24, 2008**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 306 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 280 (of 393)

NABUMETONE

TABLET; ORAL

NABUMETONE

<u>AB</u>	INVAGEN PHARMS	<u>500MG</u>	<u>A078671</u>	<u>001</u>	Mar 07, 2008
<u>AB</u>		<u>750MG</u>	<u>A078671</u>	<u>002</u>	Mar 07, 2008
<u>AB</u>	PAR PHARM	<u>500MG</u>	<u>A076009</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>750MG</u>	<u>A076009</u>	<u>002</u>	Jan 24, 2003
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A075280</u>	<u>001</u>	Feb 25, 2002
<u>AB</u>		<u>750MG</u>	<u>A075280</u>	<u>002</u>	Feb 25, 2002
<u>AB</u>	TEVA	<u>500MG</u>	<u>A075189</u>	<u>001</u>	May 26, 2000
<u>AB</u>	+	<u>750MG</u>	<u>A075189</u>	<u>002</u>	Sep 24, 2001

NADOLOL

TABLET; ORAL

CORGARD

<u>AB</u>	KING PHARMS	<u>20MG</u>	<u>N018063</u>	<u>005</u>	Oct 28, 1986
<u>AB</u>		<u>40MG</u>	<u>N018063</u>	<u>001</u>	
<u>AB</u>	+	<u>80MG</u>	<u>N018063</u>	<u>002</u>	

NADOLOL

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A074229</u>	<u>001</u>	Aug 30, 1996
<u>AB</u>		<u>40MG</u>	<u>A074229</u>	<u>002</u>	Aug 30, 1996
<u>AB</u>		<u>80MG</u>	<u>A074255</u>	<u>001</u>	Jan 24, 1996
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A074172</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>		<u>40MG</u>	<u>A074172</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>		<u>80MG</u>	<u>A074172</u>	<u>003</u>	Oct 31, 1993
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>A074501</u>	<u>001</u>	Nov 09, 1995
<u>AB</u>		<u>40MG</u>	<u>A074501</u>	<u>002</u>	Nov 09, 1995
<u>AB</u>		<u>80MG</u>	<u>A074501</u>	<u>003</u>	Nov 09, 1995

NAFARELIN ACETATE

SPRAY, METERED; NASAL

SYNAREL

+	GD SEARLE LLC	EQ 0.2MG BASE/SPRAY	N019886	001	Feb 13, 1990
---	---------------	---------------------	---------	-----	--------------

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

<u>AP</u>	+	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062527</u>	<u>002</u>	Aug 02, 1984
<u>AP</u>	+		<u>EQ 1GM BASE/VIAL</u>	<u>A062732</u>	<u>001</u>	Dec 23, 1986
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A062527</u>	<u>003</u>	Aug 02, 1984
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A062732</u>	<u>002</u>	Dec 23, 1986
		NAFCILLIN SODIUM				
	+	SANDOZ	EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984
		NALLPEN IN PLASTIC CONTAINER				
	+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655	001	Oct 31, 1989
	+		EQ 2GM BASE/100ML	N050655	002	Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+	MERZ PHARMS	1%	N019599	001	Feb 29, 1988
---	-------------	----	---------	-----	--------------

GEL; TOPICAL

NAFTIN

+	MERZ PHARMS	1%	N019356	001	Jun 18, 1990
---	-------------	----	---------	-----	--------------

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>10MG/ML</u>	<u>A070914</u>	<u>001</u>	Feb 03, 1989
-----------	---	---------	----------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 281 (of 393)

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>10MG/ML</u>	<u>A070915</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>	+		<u>20MG/ML</u>	<u>A070916</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>	+		<u>20MG/ML</u>	<u>A070918</u>	<u>001</u>	Feb 03, 1989

NALIDIXIC ACID

TABLET; ORAL

NEGGRAM

		SANOFI AVENTIS US	250MG	N014214	002	
			500MG	N014214	004	
	+		1GM	N014214	005	

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>0.4MG/ML</u>	<u>A070172</u>	<u>001</u>	Sep 24, 1986
<u>AP</u>	+		<u>0.4MG/ML</u>	<u>A070254</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>	+		<u>0.4MG/ML</u>	<u>A070256</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>	+		<u>0.4MG/ML</u>	<u>A070257</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>		INTL MEDICATION	<u>0.4MG/ML</u>	<u>A070639</u>	<u>001</u>	Sep 24, 1986
<u>AP</u>	+		<u>1MG/ML</u>	<u>A072076</u>	<u>001</u>	Mar 24, 1988

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

PENTAZOCINE AND NALOXONE HYDROCHLORIDE

<u>AB</u>		ACTAVIS TOTOWA	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A075735</u>	<u>001</u>	Jul 11, 2001
<u>AB</u>		RANBAXY	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A075523</u>	<u>001</u>	Mar 17, 2000
<u>AB</u>		WATSON LABS	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A074736</u>	<u>001</u>	Jan 21, 1997
<u>AB</u>		<u>TALWIN NX</u>				
<u>AB</u>	+	SANOFI AVENTIS US	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>N018733</u>	<u>001</u>	Dec 16, 1982

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

VIVITROL

	+	ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006
--	---	----------	------------	---------	-----	--------------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

<u>AB</u>		ACTAVIS TOTOWA	<u>50MG</u>	<u>A075274</u>	<u>001</u>	May 26, 1999
<u>AB</u>		BARR	<u>50MG</u>	<u>A074918</u>	<u>001</u>	May 08, 1998
<u>AB</u>		MALLINCKRODT	<u>50MG</u>	<u>A076264</u>	<u>002</u>	Mar 22, 2002
<u>AB</u>		SANDOZ	<u>50MG</u>	<u>A075434</u>	<u>001</u>	Mar 08, 2000
<u>AB</u>		<u>REVIA</u>				
<u>AB</u>	+	DURAMED	<u>50MG</u>	<u>N018932</u>	<u>001</u>	Nov 20, 1984
		NALTREXONE HYDROCHLORIDE				
		MALLINCKRODT	25MG	A076264	001	Mar 22, 2002
			100MG	A076264	003	Mar 22, 2002

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALBALON

<u>AT</u>	+	ALLERGAN	<u>0.1%</u>	<u>A080248</u>	<u>001</u>	
-----------	---	----------	-------------	----------------	------------	--

NAFAZAIR

<u>AT</u>		BAUSCH AND LOMB	<u>0.1%</u>	<u>A040073</u>	<u>001</u>	May 25, 1994
-----------	--	-----------------	-------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 282 (of 393)

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE

<u>AT</u>	TAYLOR	<u>0.1%</u>	<u>A083590</u>	<u>001</u>	
-----------	--------	-------------	----------------	------------	--

NAPROXEN

SUSPENSION; ORAL

NAPROSYN

<u>AB</u>	+	ROCHE PALO	<u>25MG/ML</u>	<u>N018965</u>	<u>001</u>	Mar 23, 1987
-----------	---	------------	----------------	----------------	------------	--------------

NAPROXEN

<u>AB</u>		ROXANE	<u>25MG/ML</u>	<u>A074190</u>	<u>001</u>	Mar 30, 1994
-----------	--	--------	----------------	----------------	------------	--------------

TABLET; ORAL

NAPROSYN

<u>AB</u>		ROCHE PALO	<u>250MG</u>	<u>N017581</u>	<u>002</u>	
-----------	--	------------	--------------	----------------	------------	--

<u>AB</u>			<u>375MG</u>	<u>N017581</u>	<u>003</u>	
-----------	--	--	--------------	----------------	------------	--

<u>AB</u>	+		<u>500MG</u>	<u>N017581</u>	<u>004</u>	Apr 15, 1982
-----------	---	--	--------------	----------------	------------	--------------

NAPROXEN

<u>AB</u>		AMNEAL PHARMS NY	<u>250MG</u>	<u>A075927</u>	<u>001</u>	Dec 18, 2001
-----------	--	------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>375MG</u>	<u>A075927</u>	<u>002</u>	Dec 18, 2001
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A075927</u>	<u>003</u>	Dec 18, 2001
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		DAVA PHARMS INC	<u>250MG</u>	<u>A074410</u>	<u>001</u>	Apr 28, 1995
-----------	--	-----------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>375MG</u>	<u>A074410</u>	<u>002</u>	Apr 28, 1995
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A074410</u>	<u>003</u>	Apr 28, 1995
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		GLENMARK GENERICS	<u>250MG</u>	<u>A078250</u>	<u>001</u>	Mar 28, 2007
-----------	--	-------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>375MG</u>	<u>A078250</u>	<u>002</u>	Mar 28, 2007
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A078250</u>	<u>003</u>	Mar 28, 2007
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		MYLAN	<u>250MG</u>	<u>A074121</u>	<u>001</u>	Dec 21, 1993
-----------	--	-------	--------------	----------------	------------	--------------

<u>AB</u>			<u>375MG</u>	<u>A074121</u>	<u>002</u>	Dec 21, 1993
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A074121</u>	<u>003</u>	Dec 21, 1993
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		PERRIGO R AND D	<u>250MG</u>	<u>A077339</u>	<u>001</u>	Apr 27, 2005
-----------	--	-----------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>375MG</u>	<u>A077339</u>	<u>002</u>	Apr 27, 2005
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A077339</u>	<u>003</u>	Apr 27, 2005
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		SANDOZ	<u>250MG</u>	<u>A074140</u>	<u>001</u>	Dec 21, 1993
-----------	--	--------	--------------	----------------	------------	--------------

<u>AB</u>			<u>375MG</u>	<u>A074140</u>	<u>002</u>	Dec 21, 1993
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A074140</u>	<u>003</u>	Dec 21, 1993
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		TEVA	<u>250MG</u>	<u>A074201</u>	<u>001</u>	Dec 21, 1993
-----------	--	------	--------------	----------------	------------	--------------

<u>AB</u>			<u>375MG</u>	<u>A074201</u>	<u>002</u>	Dec 21, 1993
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A074201</u>	<u>003</u>	Dec 21, 1993
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		WATSON LABS	<u>250MG</u>	<u>A074457</u>	<u>001</u>	May 31, 1995
-----------	--	-------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>375MG</u>	<u>A074457</u>	<u>002</u>	May 31, 1995
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A074457</u>	<u>003</u>	May 31, 1995
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		WESTWARD	<u>250MG</u>	<u>A076494</u>	<u>001</u>	Jan 14, 2004
-----------	--	----------	--------------	----------------	------------	--------------

<u>AB</u>			<u>375MG</u>	<u>A076494</u>	<u>002</u>	Jan 14, 2004
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A076494</u>	<u>003</u>	Jan 14, 2004
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		ZYDUS PHARMS USA	<u>250MG</u>	<u>A078620</u>	<u>001</u>	Jun 07, 2007
-----------	--	------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>375MG</u>	<u>A078620</u>	<u>002</u>	Jun 07, 2007
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A078620</u>	<u>003</u>	Jun 07, 2007
-----------	--	--	--------------	----------------	------------	--------------

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYN

<u>AB</u>	+	ROCHE PALO	<u>375MG</u>	<u>N020067</u>	<u>002</u>	Oct 14, 1994
-----------	---	------------	--------------	----------------	------------	--------------

<u>AB</u>	+		<u>500MG</u>	<u>N020067</u>	<u>003</u>	Oct 14, 1994
-----------	---	--	--------------	----------------	------------	--------------

NAPROXEN

<u>AB</u>		ACTAVIS ELIZABETH	<u>375MG</u>	<u>A074936</u>	<u>001</u>	Feb 24, 1998
-----------	--	-------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A074936</u>	<u>002</u>	Feb 24, 1998
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		ALPHAPHARM	<u>375MG</u>	<u>A075390</u>	<u>001</u>	Apr 19, 2001
-----------	--	------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A075390</u>	<u>002</u>	Apr 19, 2001
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		PLIVA	<u>375MG</u>	<u>A075337</u>	<u>001</u>	May 26, 1999
-----------	--	-------	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A075337</u>	<u>002</u>	May 26, 1999
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		SANDOZ	<u>375MG</u>	<u>A075061</u>	<u>001</u>	Feb 18, 1998
-----------	--	--------	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A075061</u>	<u>002</u>	Feb 18, 1998
-----------	--	--	--------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 283 (of 393)

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

<u>AB</u>	TEVA	<u>375MG</u>	<u>A075227</u>	<u>001</u>	Jun 30, 1998
<u>AB</u>		<u>500MG</u>	<u>A075227</u>	<u>002</u>	Jun 30, 1998

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

<u>AB</u>	ROCHE PALO	<u>EQ 250MG BASE</u>	<u>N018164</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N018164</u>	<u>003</u>	Sep 30, 1987

NAPROXEN SODIUM

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 250MG BASE</u>	<u>A078432</u>	<u>001</u>	Apr 25, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078432</u>	<u>002</u>	Apr 25, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG BASE</u>	<u>A078486</u>	<u>001</u>	Jul 26, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078486</u>	<u>002</u>	Jul 26, 2007
<u>AB</u>	GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078314</u>	<u>001</u>	Apr 27, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078314</u>	<u>002</u>	Apr 27, 2007
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A074480</u>	<u>002</u>	Feb 18, 1998
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074480</u>	<u>001</u>	May 14, 1996
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A074162</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A074495</u>	<u>001</u>	Dec 05, 1994
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074162</u>	<u>002</u>	Dec 21, 1993
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074495</u>	<u>002</u>	Dec 05, 1994
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A074198</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074198</u>	<u>002</u>	Dec 21, 1993
<u>AB</u>	WATSON LABS	<u>EQ 250MG BASE</u>	<u>A074455</u>	<u>001</u>	May 31, 1995
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074455</u>	<u>002</u>	May 31, 1995

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

	STAT TRADE	EQ 375MG BASE	N020353	001	Jan 05, 1996
		EQ 500MG BASE	N020353	002	Jan 05, 1996
	+	EQ 750MG BASE	N020353	003	Jan 05, 1996

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

	+	GLAXOSMITHKLINE	500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008
--	---	-----------------	--------------------	---------	-----	--------------

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

AMERGE

		GLAXOSMITHKLINE	EQ 1MG BASE	N020763	002	Feb 10, 1998
	+		EQ 2.5MG BASE	N020763	001	Feb 10, 1998

NATAMYCIN

SUSPENSION; OPHTHALMIC

NATACYN

	+	ALCON	5%	N050514	001	
--	---	-------	----	---------	-----	--

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>60MG</u>	<u>A077461</u>	<u>001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077461</u>	<u>002</u>	Sep 09, 2009
<u>AB</u>	PAR PHARM	<u>60MG</u>	<u>A077463</u>	<u>001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077463</u>	<u>002</u>	Sep 09, 2009
<u>AB</u>	TEVA PHARMS	<u>60MG</u>	<u>A077467</u>	<u>001</u>	Sep 09, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 284 (of 393)

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

<u>AB</u>	TEVA PHARMS	<u>120MG</u>	<u>A077467</u>	<u>002</u>	Sep 09, 2009
	<u>STARLIX</u>				
<u>AB</u>	NOVARTIS	<u>60MG</u>	<u>N021204</u>	<u>001</u>	Dec 22, 2000
<u>AB</u>	+	<u>120MG</u>	<u>N021204</u>	<u>002</u>	Dec 22, 2000

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

	FOREST LABS	EQ 2.5MG BASE	N021742	002	Dec 17, 2007
		EQ 5MG BASE	N021742	003	Dec 17, 2007
		EQ 10MG BASE	N021742	004	Dec 17, 2007
	+	EQ 20MG BASE	N021742	005	Oct 08, 2008

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALOCRIL

	+	ALLERGAN	2%	N021009	001	Dec 08, 1999
--	---	----------	----	---------	-----	--------------

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>50MG</u>	<u>A075763</u>	<u>001</u>	Sep 16, 2003
<u>AB</u>		<u>100MG</u>	<u>A075763</u>	<u>002</u>	Sep 16, 2003
<u>AB</u>		<u>150MG</u>	<u>A075763</u>	<u>003</u>	Sep 16, 2003
<u>AB</u>		<u>200MG</u>	<u>A075763</u>	<u>004</u>	Sep 16, 2003
<u>AB</u>		<u>250MG</u>	<u>A075763</u>	<u>005</u>	Sep 16, 2003
<u>AB</u>	RANBAXY	<u>50MG</u>	<u>A076409</u>	<u>001</u>	Sep 16, 2003
<u>AB</u>		<u>100MG</u>	<u>A076409</u>	<u>002</u>	Sep 16, 2003
<u>AB</u>		<u>150MG</u>	<u>A076409</u>	<u>003</u>	Sep 16, 2003
<u>AB</u>		<u>200MG</u>	<u>A076409</u>	<u>004</u>	Sep 16, 2003
<u>AB</u>		<u>250MG</u>	<u>A076409</u>	<u>005</u>	Sep 16, 2003
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A076302</u>	<u>001</u>	Sep 16, 2003
<u>AB</u>		<u>100MG</u>	<u>A076302</u>	<u>002</u>	Sep 16, 2003
<u>AB</u>		<u>150MG</u>	<u>A076302</u>	<u>003</u>	Sep 16, 2003
<u>AB</u>		<u>200MG</u>	<u>A076302</u>	<u>004</u>	Sep 16, 2003
<u>AB</u>		<u>250MG</u>	<u>A076302</u>	<u>005</u>	Sep 16, 2003
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076037</u>	<u>001</u>	Sep 16, 2003
<u>AB</u>		<u>100MG</u>	<u>A076037</u>	<u>002</u>	Sep 16, 2003
<u>AB</u>		<u>150MG</u>	<u>A076037</u>	<u>003</u>	Sep 16, 2003
<u>AB</u>		<u>200MG</u>	<u>A076037</u>	<u>004</u>	Sep 16, 2003
<u>AB</u>	+	<u>250MG</u>	<u>A076037</u>	<u>005</u>	Sep 16, 2003
	<u>NEFAZODONE HYDROCHLORIDE</u>				
BX	DR REDDYS LABS INC	50MG	A076309	001	Sep 16, 2003
BX		100MG	A076309	002	Sep 16, 2003
BX		150MG	A076309	003	Sep 16, 2003
BX		200MG	A076309	004	Sep 16, 2003
BX		250MG	A076309	005	Sep 16, 2003

NELARABINE

INJECTABLE; IV (INFUSION)

	+	SMITHKLINE BEECHAM	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005
--	---	--------------------	---------------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 285 (of 393)

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

+ AGOURON EQ 50MG BASE/SCOOPFUL N020778 001 Mar 14, 1997

TABLET; ORAL

VIRACEPT

+ AGOURON EQ 250MG BASE N020779 001 Mar 14, 1997

+ EQ 625MG BASE N021503 001 Apr 30, 2003

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

X GEN PHARMS 100% A061579 001

SOLUTION; ORAL

NEO-FRADIN

+ X GEN PHARMS EQ 87.5MG BASE/5ML A065010 001 May 23, 2002

TABLET; ORAL

NEOMYCIN SULFATEAA + TEVA 500MG A060304 001AA X GEN PHARMS 500MG A065220 001 Jul 28, 2006NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATEAT WATSON LABS EQ 40MG BASE/ML;200,000 UNITS/ML A062664 001 Apr 08, 1986AT X GEN PHARMS EQ 40MG BASE/ML;200,000 UNITS/ML A065106 001 Jan 31, 2006AT EQ 40MG BASE/ML;200,000 UNITS/ML A065108 001 Jan 31, 2006NEOSPORIN G.U. IRRIGANTAT + MONARCH PHARMS EQ 40MG BASE/ML;200,000 UNITS/ML A060707 001NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

POLY-PRED

+ ALLERGAN EQ 0.35% BASE;10,000 UNITS/ML;0.5% N050081 002

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

+ ALCON 0.1% N021862 001 Aug 19, 2005

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS

NATRECOR

+ SCIOS 1.5MG/VIAL N020920 001 Aug 10, 2001

NEVIRAPINE

SUSPENSION; ORAL

VIRAMUNE

+ BOEHRINGER INGELHEIM 50MG/5ML N020933 001 Sep 11, 1998

TABLET; ORAL

VIRAMUNE

+ BOEHRINGER INGELHEIM 200MG N020636 001 Jun 21, 1996

NIACIN

TABLET; ORAL

NIACINAA WOCKHARDT 500MG A081134 001 Apr 28, 1992



## PRESCRIPTION DRUG PRODUCT LIST

3 - 286 (of 393)

NIACIN

TABLET; ORAL

NIACOR

<u>AA</u>	+	UPSHER SMITH	<u>500MG</u>	<u>A040378</u>	<u>001</u>	May 03, 2000
-----------	---	--------------	--------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

NIASPAN

		ABBOTT	500MG	N020381	002	Jul 28, 1997
	+		750MG	N020381	003	Jul 28, 1997
	+		1GM	N020381	004	Jul 28, 1997

NIACIN; SIMVASTATIN

TABLET, EXTENDED RELEASE; ORAL

SIMCOR

	+	ABBOTT	500MG; 20MG	N022078	001	Feb 15, 2008
	+		750MG; 20MG	N022078	002	Feb 15, 2008
	+		1GM; 20MG	N022078	003	Feb 15, 2008

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

<u>AB</u>		EKR THERAP	<u>20MG</u>	<u>N019488</u>	<u>001</u>	Dec 21, 1988
<u>AB</u>	+		<u>30MG</u>	<u>N019488</u>	<u>002</u>	Dec 21, 1988

NICARDIPINE HYDROCHLORIDE

<u>AB</u>		AMNEAL PHARM	<u>20MG</u>	<u>A074928</u>	<u>001</u>	Mar 19, 1998
<u>AB</u>			<u>30MG</u>	<u>A074928</u>	<u>002</u>	Mar 19, 1998
<u>AB</u>		BARR	<u>20MG</u>	<u>A074439</u>	<u>001</u>	Dec 10, 1996
<u>AB</u>			<u>30MG</u>	<u>A074439</u>	<u>002</u>	Dec 10, 1996
<u>AB</u>		MYLAN	<u>20MG</u>	<u>A074642</u>	<u>001</u>	Jul 18, 1996
<u>AB</u>			<u>30MG</u>	<u>A074642</u>	<u>002</u>	Jul 18, 1996
<u>AB</u>		TEVA	<u>20MG</u>	<u>A074540</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>			<u>30MG</u>	<u>A074540</u>	<u>002</u>	Oct 28, 1996
<u>AB</u>		WATSON LABS	<u>20MG</u>	<u>A074670</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>			<u>30MG</u>	<u>A074670</u>	<u>002</u>	Oct 28, 1996

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

	+	EKR THERAP	30MG	N020005	001	Feb 21, 1992
	+		45MG	N020005	002	Feb 21, 1992
	+		60MG	N020005	003	Feb 21, 1992

INJECTABLE; INJECTION

CARDENE

<u>AP</u>	+	EKR THERAP	<u>25MG/10ML (2.5MG/ML)</u>	<u>N019734</u>	<u>001</u>	Jan 30, 1992
-----------	---	------------	-----------------------------	----------------	------------	--------------

NICARDIPINE HYDROCHLORIDE

<u>AP</u>		BEDFORD	<u>25MG/10ML (2.5MG/ML)</u>	<u>A078714</u>	<u>001</u>	Dec 28, 2009
<u>AP</u>		GENERAMEDIX	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090664</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>		NAVINTA LLC	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090125</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>		PHARMAFORCE	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090534</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>		SUN PHARM INDS INC	<u>25MG/10ML (2.5MG/ML)</u>	<u>A078405</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>		TEVA PARENTERAL	<u>25MG/10ML (2.5MG/ML)</u>	<u>N022276</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>		WOCKHARDT	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090671</u>	<u>001</u>	Nov 17, 2009

INJECTABLE; INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

	+	EKR THERAP	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008
--	---	------------	-----------------------	---------	-----	--------------

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

	+	EKR THERAP	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008
--	---	------------	-----------------------	---------	-----	--------------

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

	+	EKR THERAP	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008
--	---	------------	-----------------------	---------	-----	--------------

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

	+	EKR THERAP	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008
--	---	------------	-----------------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 287 (of 393)

NICOTINE

INHALANT; ORAL

NICOTROL

+ PHARMACIA AND UPJOHN 4MG/CARTRIDGE N020714 001 May 02, 1997

SPRAY, METERED; NASAL

NICOTROL

+ PFIZER INC 0.5MG/SPRAY N020385 001 Mar 22, 1996

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINEAB ACTAVIS ELIZABETH 10MG A072579 001 Jan 08, 1991AB CATALENT 10MG A073250 001 Oct 08, 1991AB INVERNESS MEDCL 10MG A072781 001 Jul 30, 1993PROCARDIAAB + PFIZER 10MG N018482 001

NIFEDIPINE

ACTAVIS ELIZABETH 20MG A072556 001 Sep 20, 1990

TABLET, EXTENDED RELEASE; ORAL

ADALAT CCAB1 BAYER HLTHCARE 30MG N020198 001 Apr 21, 1993AB1 + 60MG N020198 002 Apr 21, 1993AB1 + 90MG N020198 003 Apr 21, 1993AFEDITAB CRAB1 WATSON LABS 30MG A075128 001 Mar 10, 2000AB1 60MG A075659 001 Oct 26, 2001NIFEDIPINEAB1 ACTAVIS 30MG A077899 001 Dec 13, 2006AB1 60MG A077899 002 Dec 13, 2006AB1 BIOVAIL 30MG A075269 001 Dec 04, 2000AB1 60MG A075269 002 Dec 04, 2000AB1 90MG A076070 001 Aug 16, 2002NIFEDIPINEAB2 BIOVAIL 30MG A075289 002 Feb 06, 2001AB2 60MG A075289 001 Sep 27, 2000AB2 OSMOTICA PHARM 30MG A077127 001 Nov 21, 2005AB2 60MG A077127 002 Nov 21, 2005AB2 90MG A077410 001 Oct 03, 2007PROCARDIA XLAB2 PFIZER 30MG N019684 001 Sep 06, 1989AB2 60MG N019684 002 Sep 06, 1989AB2 + 90MG N019684 003 Sep 06, 1989NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE; ORAL

TASIGNA

+ NOVARTIS EQ 200MG BASE N022068 001 Oct 29, 2007

NILUTAMIDE

TABLET; ORAL

NILANDRON

+ SANOFI AVENTIS US 150MG N020169 002 Apr 30, 1999

NIMODIPINE

CAPSULE; ORAL

NIMODIPINEAB BANNER PHARMACAPS 30MG A076740 001 Jan 17, 2008AB + BARR 30MG A077811 001 May 02, 2007AB SUN PHARM INDS INC 30MG A077067 001 Apr 17, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 288 (of 393)

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

+ MYLAN	20MG	A079051	001	Jul 25, 2008
+	30MG	A079051	002	Jul 25, 2008
+	40MG	A079051	003	Jul 25, 2008
SULAR				
+ SCIELE PHARMA INC	8.5MG	N020356	008	Jan 02, 2008
+	17MG	N020356	007	Jan 02, 2008
	25.5MG	N020356	006	Jan 02, 2008
+	34MG	N020356	005	Jan 02, 2008

NITAZOXANIDE

FOR SUSPENSION; ORAL

ALINIA

+ ROMARK	100MG/5ML	N021498	001	Nov 22, 2002
----------	-----------	---------	-----	--------------

TABLET; ORAL

ALINIA

+ ROMARK	500MG	N021497	001	Jul 21, 2004
----------	-------	---------	-----	--------------

NITISINONE

CAPSULE; ORAL

ORFADIN

RARE DIS

	2MG	N021232	001	Jan 18, 2002
	5MG	N021232	002	Jan 18, 2002
+	10MG	N021232	003	Jan 18, 2002

NITRIC OXIDE

GAS; INHALATION

INOMAX

INO

	100PPM	N020845	002	Dec 23, 1999
+	800PPM	N020845	003	Dec 23, 1999

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

+ SCIELE PHARMA INC	25MG/5ML	N009175	001	
---------------------	----------	---------	-----	--

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

<u>AB</u>	PROCTER AND GAMBLE	<u>25MG</u>	<u>N016620</u>	<u>003</u>	
<u>AB</u>		<u>50MG</u>	<u>N016620</u>	<u>001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N016620</u>	<u>002</u>	

NITROFURANTOIN

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>50MG</u>	<u>A073671</u>	<u>001</u>	Jan 28, 1993
<u>AB</u>		<u>100MG</u>	<u>A073652</u>	<u>001</u>	Jan 28, 1993
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A074967</u>	<u>001</u>	Jul 09, 1997
<u>AB</u>		<u>100MG</u>	<u>A077025</u>	<u>001</u>	Aug 18, 2004
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A073696</u>	<u>001</u>	Dec 31, 1992
<u>AB</u>		<u>50MG</u>	<u>A073696</u>	<u>002</u>	Dec 31, 1992
<u>AB</u>		<u>100MG</u>	<u>A073696</u>	<u>003</u>	Dec 31, 1992

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

<u>AB</u>	+	PROCTER AND GAMBLE	<u>75MG;25MG</u>	<u>N020064</u>	<u>001</u>	Dec 24, 1991
-----------	---	--------------------	------------------	----------------	------------	--------------

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

<u>AB</u>	MYLAN	<u>75MG;25MG</u>	<u>A076648</u>	<u>001</u>	Mar 22, 2004
-----------	-------	------------------	----------------	------------	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 315 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 289 (of 393)

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

<u>AB</u>	RANBAXY	<u>75MG;25MG</u>	<u>A076951</u>	<u>001</u>	Mar 30, 2005
<u>AB</u>	SANDOZ	<u>75MG;25MG</u>	<u>A077066</u>	<u>001</u>	Apr 05, 2005

NITROGLYCERIN

AEROSOL, METERED; SUBLINGUAL

NITROMIST

+	AKRIMAX PHARMS	0.4MG/SPRAY	N021780	001	Nov 02, 2006
---	----------------	-------------	---------	-----	--------------

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

<u>AB1</u>	GRACEWAY	<u>0.1MG/HR</u>	<u>A089771</u>	<u>001</u>	Aug 30, 1996
<u>AB1</u>		<u>0.2MG/HR</u>	<u>A089772</u>	<u>001</u>	Aug 30, 1996
<u>AB1</u>		<u>0.4MG/HR</u>	<u>A089773</u>	<u>001</u>	Aug 30, 1996
<u>AB1</u>		<u>0.6MG/HR</u>	<u>A089774</u>	<u>001</u>	Aug 30, 1996

NITRO-DUR

<u>AB1</u>	+	KEY PHARMS	<u>0.1MG/HR</u>	<u>N020145</u>	<u>001</u>	Apr 04, 1995
<u>AB1</u>	+		<u>0.2MG/HR</u>	<u>N020145</u>	<u>002</u>	Apr 04, 1995
<u>AB1</u>	+		<u>0.4MG/HR</u>	<u>N020145</u>	<u>004</u>	Apr 04, 1995
<u>AB1</u>	+		<u>0.6MG/HR</u>	<u>N020145</u>	<u>005</u>	Apr 04, 1995

NITROGLYCERIN

<u>AB1</u>	KREMERS URBAN	<u>0.2MG/HR</u>	<u>A075115</u>	<u>001</u>	Aug 10, 2004
<u>AB1</u>		<u>0.4MG/HR</u>	<u>A075115</u>	<u>002</u>	Aug 10, 2004

NITROGLYCERIN

<u>AB2</u>	HERCON LABS	<u>0.2MG/HR</u>	<u>A089884</u>	<u>001</u>	Oct 30, 1998	
<u>AB2</u>		<u>0.4MG/HR</u>	<u>A089885</u>	<u>001</u>	Oct 30, 1998	
<u>AB2</u>		<u>0.6MG/HR</u>	<u>A089886</u>	<u>001</u>	Oct 30, 1998	
<u>AB2</u>	+	MYLAN TECHNOLOGIES	<u>0.2MG/HR</u>	<u>A074559</u>	<u>003</u>	Aug 30, 1996
<u>AB2</u>	+		<u>0.4MG/HR</u>	<u>A074559</u>	<u>002</u>	Aug 30, 1996
<u>AB2</u>	+		<u>0.6MG/HR</u>	<u>A074559</u>	<u>001</u>	Aug 30, 1996

NITRO-DUR

+	KEY PHARMS	0.3MG/HR	N020145	003	Apr 04, 1995
+		0.8MG/HR	N020145	006	Apr 04, 1995

NITROGLYCERIN

+	MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998
---	--------------------	----------	---------	-----	--------------

INJECTABLE; INJECTION

NITROGLYCERIN

<u>AP</u>	+	HOSPIRA	<u>5MG/ML</u>	<u>N018531</u>	<u>001</u>	
<u>AP</u>	+	LUITPOLD	<u>5MG/ML</u>	<u>A072034</u>	<u>001</u>	May 24, 1988

NITROGLYCERIN IN DEXTROSE 5%

<u>AP</u>	+	BAXTER HLTHCARE	<u>10MG/100ML</u>	<u>N019970</u>	<u>001</u>	Dec 29, 1989
<u>AP</u>	+		<u>20MG/100ML</u>	<u>N019970</u>	<u>002</u>	Dec 29, 1989
<u>AP</u>	+		<u>40MG/100ML</u>	<u>N019970</u>	<u>003</u>	Dec 29, 1989
<u>AP</u>		HOSPIRA	<u>10MG/100ML</u>	<u>A071846</u>	<u>001</u>	Aug 31, 1990
<u>AP</u>			<u>20MG/100ML</u>	<u>A071847</u>	<u>001</u>	Aug 31, 1990
<u>AP</u>			<u>40MG/100ML</u>	<u>A071848</u>	<u>001</u>	Aug 31, 1990

OINTMENT; TRANSDERMAL

NITROGLYCERIN

+	FOUGERA	2%	A087355	001	Jul 08, 1988
---	---------	----	---------	-----	--------------

SPRAY, METERED; SUBLINGUAL

NITROLINGUAL PUMPSPRAY

+	POHL BOSKAMP	0.4MG/SPRAY	N018705	002	Jan 10, 1997
---	--------------	-------------	---------	-----	--------------

TABLET; SUBLINGUAL

NITROSTAT

	PFIZER PHARMS	0.3MG	N021134	001	May 01, 2000
		0.4MG	N021134	002	May 01, 2000
+		0.6MG	N021134	003	May 01, 2000

## PRESCRIPTION DRUG PRODUCT LIST

3 - 290 (of 393)

NIZATIDINE

CAPSULE; ORAL

AXID

<u>AB</u>	SMITHKLINE BEECHAM	<u>150MG</u>	<u>N019508</u>	<u>001</u>	Apr 12, 1988
<u>AB</u>	+	<u>300MG</u>	<u>N019508</u>	<u>002</u>	Apr 12, 1988

NIZATIDINE

<u>AB</u>	APOTEX	<u>150MG</u>	<u>A076383</u>	<u>001</u>	Jan 23, 2003
<u>AB</u>		<u>300MG</u>	<u>A076383</u>	<u>002</u>	Jan 23, 2003
<u>AB</u>	DR REDDYS LABS LTD	<u>150MG</u>	<u>A077314</u>	<u>001</u>	Sep 15, 2005
<u>AB</u>		<u>300MG</u>	<u>A077314</u>	<u>002</u>	Sep 15, 2005
<u>AB</u>	GENPHARM	<u>150MG</u>	<u>A075934</u>	<u>001</u>	Jul 09, 2002
<u>AB</u>		<u>300MG</u>	<u>A075934</u>	<u>002</u>	Jul 09, 2002
<u>AB</u>	MYLAN	<u>150MG</u>	<u>A075806</u>	<u>001</u>	Jul 05, 2002
<u>AB</u>		<u>300MG</u>	<u>A075806</u>	<u>002</u>	Jul 05, 2002
<u>AB</u>	SANDOZ	<u>150MG</u>	<u>A076178</u>	<u>001</u>	Jul 05, 2002
<u>AB</u>		<u>300MG</u>	<u>A076178</u>	<u>002</u>	Jul 05, 2002
<u>AB</u>	TEVA	<u>150MG</u>	<u>A075668</u>	<u>001</u>	Sep 12, 2002
<u>AB</u>		<u>300MG</u>	<u>A075668</u>	<u>002</u>	Sep 12, 2002
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A075616</u>	<u>001</u>	Jul 09, 2002
<u>AB</u>		<u>300MG</u>	<u>A075616</u>	<u>002</u>	Jul 09, 2002

SOLUTION; ORAL

AXID

<u>AA</u>	+	BRAINTREE	<u>15MG/ML</u>	<u>N021494</u>	<u>001</u>	May 25, 2004
-----------	---	-----------	----------------	----------------	------------	--------------

NIZATIDINE

<u>AA</u>		AMNEAL PHARMS	<u>15MG/ML</u>	<u>A090576</u>	<u>001</u>	Nov 18, 2009
-----------	--	---------------	----------------	----------------	------------	--------------

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

<u>AP</u>	+	HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>N007513</u>	<u>001</u>	
<u>AP</u>		BEDFORD	<u>EQ 1MG BASE/ML</u>	<u>A040462</u>	<u>001</u>	Oct 31, 2003
<u>AP</u>		METRICS PHARM	<u>EQ 1MG BASE/ML</u>	<u>A040522</u>	<u>001</u>	Sep 30, 2004
<u>AP</u>		TEVA PARENTERAL	<u>EQ 1MG BASE/ML</u>	<u>A040455</u>	<u>001</u>	Mar 03, 2003

NORETHINDRONE

TABLET; ORAL-28

CAMILA

<u>AB1</u>		BARR	<u>0.35MG</u>	<u>A076177</u>	<u>001</u>	Oct 21, 2002
------------	--	------	---------------	----------------	------------	--------------

NOR-QD

<u>AB1</u>	+	WATSON LABS (UTAH)	<u>0.35MG</u>	<u>N017060</u>	<u>001</u>	
------------	---	--------------------	---------------	----------------	------------	--

ERRIN

<u>AB2</u>		BARR	<u>0.35MG</u>	<u>A076225</u>	<u>001</u>	Oct 21, 2002
------------	--	------	---------------	----------------	------------	--------------

MICRONOR

<u>AB2</u>	+	ORTHO MCNEIL JANSSEN	<u>0.35MG</u>	<u>N016954</u>	<u>001</u>	
------------	---	----------------------	---------------	----------------	------------	--

NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTIN

<u>AB</u>	+	DURAMED RES	<u>5MG</u>	<u>N018405</u>	<u>001</u>	Apr 21, 1982
-----------	---	-------------	------------	----------------	------------	--------------

NORETHINDRONE ACETATE

<u>AB</u>		BARR	<u>5MG</u>	<u>A075951</u>	<u>001</u>	May 25, 2001
-----------	--	------	------------	----------------	------------	--------------

NORFLOXACIN

TABLET; ORAL

NOROXIN

	+	MERCK	400MG	N019384	002	Oct 31, 1986
--	---	-------	-------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 291 (of 393)

## NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A074234</u>	<u>001</u>	Jul 26, 1993
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A074234</u>	<u>002</u>	Jul 26, 1993
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A074234</u>	<u>003</u>	Jul 26, 1993
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A074234</u>	<u>004</u>	Jul 26, 1993
<u>AB</u>	TARO	<u>EQ 10MG BASE</u>	<u>A075520</u>	<u>004</u>	May 08, 2000
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A075520</u>	<u>003</u>	May 08, 2000
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A075520</u>	<u>001</u>	May 08, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A075520</u>	<u>002</u>	May 08, 2000
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A074132</u>	<u>001</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A074132</u>	<u>002</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A074132</u>	<u>003</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A074132</u>	<u>004</u>	Mar 27, 1995
<u>AB</u>	WATSON LABS	<u>EQ 10MG BASE</u>	<u>A073553</u>	<u>001</u>	Mar 30, 1992
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A073554</u>	<u>001</u>	Mar 30, 1992
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A073555</u>	<u>001</u>	Mar 30, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A073556</u>	<u>001</u>	Mar 30, 1992
<u>PAMELOR</u>					
<u>AB</u>	TYCO HLTHCARE	<u>EQ 10MG BASE</u>	<u>N018013</u>	<u>001</u>	
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>N018013</u>	<u>002</u>	
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N018013</u>	<u>004</u>	
<u>AB</u>	+	<u>EQ 75MG BASE</u>	<u>N018013</u>	<u>003</u>	

SOLUTION; ORAL

AVENTYL HYDROCHLORIDE

<u>AA</u>	+	RANBAXY	<u>EQ 10MG BASE/5ML</u>	<u>N014685</u>	<u>001</u>
-----------	---	---------	-------------------------	----------------	------------

NORTRIPTYLINE HYDROCHLORIDE

<u>AA</u>		PHARM ASSOC	<u>EQ 10MG BASE/5ML</u>	<u>A075606</u>	<u>001</u>	Aug 28, 2000
<u>AA</u>		TARO	<u>EQ 10MG BASE/5ML</u>	<u>A077965</u>	<u>001</u>	Jun 20, 2006
<u>PAMELOR</u>						
<u>AA</u>		TYCO HLTHCARE	<u>EQ 10MG BASE/5ML</u>	<u>N018012</u>	<u>001</u>	

## NYSTATIN

CREAM; TOPICAL

MYCOSTATIN

<u>AT</u>	+	BRISTOL MYERS SQUIBB	<u>100,000 UNITS/GM</u>	<u>A060575</u>	<u>001</u>
-----------	---	----------------------	-------------------------	----------------	------------

NYSTATIN

<u>AT</u>		ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062949</u>	<u>001</u>	Jun 13, 1988
<u>AT</u>		ALTANA	<u>100,000 UNITS/GM</u>	<u>A062129</u>	<u>001</u>	
<u>AT</u>		PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062225</u>	<u>001</u>	
<u>AT</u>		TARO	<u>100,000 UNITS/GM</u>	<u>A064022</u>	<u>001</u>	Jan 29, 1993
<u>AT</u>		VINTAGE	<u>100,000 UNITS/GM</u>	<u>A065315</u>	<u>001</u>	May 31, 2006

OINTMENT; TOPICAL

NYSTATIN

<u>AT</u>		ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062840</u>	<u>001</u>	Nov 13, 1987
<u>AT</u>	+	ALTANA	<u>100,000 UNITS/GM</u>	<u>A062124</u>	<u>002</u>	Sep 23, 1982
<u>AT</u>		PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062472</u>	<u>001</u>	Feb 13, 1984

POWDER; TOPICAL

MYCOSTATIN

<u>AT</u>	+	BRISTOL MYERS SQUIBB	<u>100,000 UNITS/GM</u>	<u>A060578</u>	<u>001</u>
-----------	---	----------------------	-------------------------	----------------	------------

NYSTATIN

<u>AT</u>		COASTAL PHARMS	<u>100,000 UNITS/GM</u>	<u>A065203</u>	<u>001</u>	Jul 15, 2004
<u>AT</u>		GAVIS PHARMS	<u>100,000 UNITS/GM</u>	<u>A065138</u>	<u>001</u>	Jul 23, 2004
<u>AT</u>		KV PHARM	<u>100,000 UNITS/GM</u>	<u>A065321</u>	<u>001</u>	Aug 18, 2006
<u>AT</u>		UPSHER SMITH	<u>100,000 UNITS/GM</u>	<u>A065183</u>	<u>001</u>	May 03, 2005
<u>AT</u>		X GEN PHARMS	<u>100,000 UNITS/GM</u>	<u>A065175</u>	<u>001</u>	Dec 17, 2004

NYSTOP

<u>AT</u>		PADDOCK	<u>100,000 UNITS/GM</u>	<u>A064118</u>	<u>001</u>	Aug 16, 1996
-----------	--	---------	-------------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 292 (of 393)

NYSTATIN

SUSPENSION; ORAL

NILSTAT

<u>AA</u>	+ GLENMARK GENERICS	<u>100,000 UNITS/ML</u>	<u>N050299</u>	<u>001</u>	
-----------	---------------------	-------------------------	----------------	------------	--

NYSTATIN

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/ML</u>	<u>A062349</u>	<u>001</u>	Jul 14, 1982
<u>AA</u>	BAUSCH AND LOMB	<u>100,000 UNITS/ML</u>	<u>A064042</u>	<u>001</u>	Feb 28, 1994
<u>AA</u>	FOUGERA	<u>100,000 UNITS/ML</u>	<u>A062517</u>	<u>001</u>	Jun 07, 1984
<u>AA</u>	+ MORTON GROVE	<u>100,000 UNITS/ML</u>	<u>A062512</u>	<u>001</u>	Oct 29, 1984
<u>AA</u>	TARO	<u>100,000 UNITS/ML</u>	<u>A062876</u>	<u>001</u>	Feb 29, 1988
<u>AA</u>	VINTAGE PHARMS	<u>100,000 UNITS/ML</u>	<u>A065148</u>	<u>001</u>	Jun 28, 2005
<u>AA</u>	VISTAPHARM	<u>100,000 UNITS/ML</u>	<u>A064142</u>	<u>001</u>	Jun 25, 1998

TABLET; ORAL

NYSTATIN

<u>AA</u>	MUTUAL PHARM	<u>500,000 UNITS</u>	<u>A062838</u>	<u>001</u>	Dec 22, 1988
<u>AA</u>	+ TEVA	<u>500,000 UNITS</u>	<u>A062506</u>	<u>001</u>	Jan 16, 1984

TABLET; VAGINAL

NYSTATIN

	+ ODYSSEY PHARMS	100,000 UNITS	A062615	001	Oct 17, 1985
--	------------------	---------------	---------	-----	--------------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM;0.1%</u>	<u>A062367</u>	<u>001</u>	May 28, 1985
-----------	----------------------	------------------------------	----------------	------------	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>100,000 UNITS/GM;0.1%</u>	<u>A062599</u>	<u>001</u>	Oct 08, 1985
<u>AT</u>	+ TARO	<u>100,000 UNITS/GM;0.1%</u>	<u>A062364</u>	<u>001</u>	Dec 22, 1987

OINTMENT; TOPICAL

MYKACET

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM;0.1%</u>	<u>A062733</u>	<u>001</u>	Mar 09, 1987
-----------	----------------------	------------------------------	----------------	------------	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>100,000 UNITS/GM;0.1%</u>	<u>A062602</u>	<u>001</u>	Oct 09, 1985
<u>AT</u>	+ TARO	<u>100,000 UNITS/GM;0.1%</u>	<u>A063305</u>	<u>001</u>	Mar 29, 1993

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

<u>AP</u>	APP PHARMS	<u>EQ 0.2MG BASE/ML</u>	<u>A077450</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077450</u>	<u>002</u>	Feb 10, 2006
<u>AP</u>	+ BEDFORD	<u>EQ 0.2MG BASE/ML</u>	<u>A076330</u>	<u>001</u>	Apr 08, 2005
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A076330</u>	<u>002</u>	Apr 08, 2005
<u>AP</u>	SUN PHARM INDS	<u>EQ 0.05MG BASE/ML</u>	<u>A077329</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.05MG BASE/ML</u>	<u>A077372</u>	<u>001</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077329</u>	<u>002</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077372</u>	<u>002</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A077330</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A077373</u>	<u>001</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077329</u>	<u>003</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077372</u>	<u>003</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077331</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077373</u>	<u>002</u>	Aug 14, 2007
<u>AP</u>	TEVA PARENTERAL	<u>EQ 0.05MG BASE/ML</u>	<u>A075957</u>	<u>001</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A075957</u>	<u>002</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A075959</u>	<u>001</u>	Nov 21, 2005
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A075957</u>	<u>003</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075959</u>	<u>002</u>	Nov 21, 2005

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	APP PHARMS	<u>EQ 0.05MG BASE/ML</u>	<u>A077457</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077457</u>	<u>002</u>	Feb 10, 2006

## PRESCRIPTION DRUG PRODUCT LIST

3 - 293 (of 393)

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	APP PHARMS	<u>EQ 0.5MG BASE/ML</u>	<u>A077457</u>	<u>003</u>	Feb 10, 2006
<u>AP</u>	+ BEDFORD	<u>EQ 0.05MG BASE/ML</u>	<u>A076313</u>	<u>001</u>	Mar 28, 2005
<u>AP</u>	+	<u>EQ 0.1MG BASE/ML</u>	<u>A076313</u>	<u>003</u>	Mar 28, 2005
<u>AP</u>	+	<u>EQ 0.5MG BASE/ML</u>	<u>A076313</u>	<u>002</u>	Mar 28, 2005
<u>SANDOSTATIN</u>					
<u>AP</u>	+ NOVARTIS	<u>EQ 0.05MG BASE/ML</u>	<u>N019667</u>	<u>001</u>	Oct 21, 1988
<u>AP</u>	+	<u>EQ 0.1MG BASE/ML</u>	<u>N019667</u>	<u>002</u>	Oct 21, 1988
<u>AP</u>	+	<u>EQ 0.2MG BASE/ML</u>	<u>N019667</u>	<u>004</u>	Jun 12, 1991
<u>AP</u>	+	<u>EQ 0.5MG BASE/ML</u>	<u>N019667</u>	<u>003</u>	Oct 21, 1988
<u>AP</u>	+	<u>EQ 1MG BASE/ML</u>	<u>N019667</u>	<u>005</u>	Jun 12, 1991
SANDOSTATIN LAR					
	NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998
		EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998
	+	EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

<u>AT</u>	+ ALLERGAN	<u>0.3%</u>	<u>N019921</u>	<u>001</u>	Jul 30, 1993
<u>OFLOXACIN</u>					
<u>AT</u>	AKORN	<u>0.3%</u>	<u>A076407</u>	<u>001</u>	Apr 15, 2008
<u>AT</u>	ALCON	<u>0.3%</u>	<u>A076231</u>	<u>001</u>	May 14, 2004
<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A076622</u>	<u>001</u>	May 14, 2004
<u>AT</u>	FDC LTD	<u>0.3%</u>	<u>A078559</u>	<u>001</u>	Feb 25, 2009
<u>AT</u>	HI TECH PHARMA	<u>0.3%</u>	<u>A076615</u>	<u>001</u>	May 14, 2004
<u>AT</u>	NOVEX	<u>0.3%</u>	<u>A076513</u>	<u>001</u>	May 14, 2004
<u>AT</u>	PHARMAFORCE	<u>0.3%</u>	<u>A076830</u>	<u>001</u>	Aug 31, 2004
<u>AT</u>	SANDOZ	<u>0.3%</u>	<u>A076848</u>	<u>001</u>	Nov 25, 2008

SOLUTION/DROPS; OTIC

FLOXIN OTIC

<u>AT</u>	+ DAIICHI	<u>0.3%</u>	<u>N020799</u>	<u>001</u>	Dec 16, 1997
<u>OFLOXACIN</u>					
<u>AT</u>	ALCON	<u>0.3%</u>	<u>A078222</u>	<u>001</u>	Mar 17, 2008
<u>AT</u>	APOTEX INC	<u>0.3%</u>	<u>A076527</u>	<u>001</u>	Sep 28, 2007
<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A076128</u>	<u>001</u>	Mar 17, 2008
<u>AT</u>	HI TECH PHARMA	<u>0.3%</u>	<u>A076616</u>	<u>001</u>	Mar 17, 2008
<u>AT</u>	PHARMAFORCE	<u>0.3%</u>	<u>A090395</u>	<u>001</u>	Aug 11, 2009

TABLET; ORAL

OFLOXACIN

<u>AB</u>	DR REDDYS LABS LTD	<u>200MG</u>	<u>A077098</u>	<u>001</u>	Feb 10, 2006
<u>AB</u>		<u>300MG</u>	<u>A077098</u>	<u>002</u>	Feb 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077098</u>	<u>003</u>	Feb 10, 2006
<u>AB</u>	RANBAXY	<u>200MG</u>	<u>A076220</u>	<u>001</u>	Sep 02, 2003
<u>AB</u>		<u>300MG</u>	<u>A076220</u>	<u>002</u>	Sep 02, 2003
<u>AB</u>		<u>400MG</u>	<u>A076220</u>	<u>003</u>	Sep 02, 2003
<u>AB</u>	TEVA	<u>200MG</u>	<u>A076182</u>	<u>001</u>	Sep 02, 2003
<u>AB</u>		<u>300MG</u>	<u>A076182</u>	<u>002</u>	Sep 02, 2003
<u>AB</u>	+	<u>400MG</u>	<u>A076182</u>	<u>003</u>	Sep 02, 2003

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

## ZYPREXA

	+ LILLY	10MG/VIAL	N021253	001	Mar 29, 2004
--	---------	-----------	---------	-----	--------------

TABLET; ORAL

## ZYPREXA

	LILLY	2.5MG	N020592	001	Sep 30, 1996
--	-------	-------	---------	-----	--------------



## PRESCRIPTION DRUG PRODUCT LIST

3 - 294 (of 393)

OLANZAPINE

TABLET; ORAL

ZYPREXA

+ LILLY	5MG	N020592	002	Sep 30, 1996
	7.5MG	N020592	003	Sep 30, 1996
	10MG	N020592	004	Sep 30, 1996
	15MG	N020592	005	Sep 09, 1997
	20MG	N020592	006	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

ZYPREXA ZYDIS

+ LILLY	5MG	N021086	001	Apr 06, 2000
	10MG	N021086	002	Apr 06, 2000
	15MG	N021086	003	Apr 06, 2000
	20MG	N021086	004	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ZYPREXA RELPREVV

ELI LILLY CO	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009
	EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009
+	EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009

OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR

DAIICHI SANKYO	5MG	N021286	001	Apr 25, 2002
	20MG	N021286	003	Apr 25, 2002
+	40MG	N021286	004	Apr 25, 2002

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

+ ALCON	EQ 0.2% BASE	N021545	001	Dec 22, 2004
PATANOL				
+ ALCON	EQ 0.1% BASE	N020688	001	Dec 18, 1996
SPRAY, METERED; NASAL				
PATANASE				
+ ALCON	0.665MG/SPRAY	N021861	001	Apr 15, 2008

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+ UCB INC	250MG	N019715	001	Jul 31, 1990
-----------	-------	---------	-----	--------------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

LOVAZA

+ SMITHKLINE BEECHAM	1GM	N021654	001	Nov 10, 2004
----------------------	-----	---------	-----	--------------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

<u>AB</u>	APOTEX	<u>10MG</u>	<u>A076048</u>	<u>001</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A076048</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>		<u>40MG</u>	<u>A076048</u>	<u>003</u>	Jan 21, 2009
<u>AB</u>	DR REDDYS LABS	<u>40MG</u>	<u>A078490</u>	<u>001</u>	Apr 17, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A075576</u>	<u>003</u>	Oct 22, 2007
<u>AB</u>		<u>10MG</u>	<u>A078693</u>	<u>001</u>	Mar 16, 2009
<u>AB</u>		<u>20MG</u>	<u>A075576</u>	<u>002</u>	Oct 22, 2007

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 321 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 295 (of 393)

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

<u>AB</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A078693</u>	<u>002</u>	Mar 16, 2009
<u>AB</u>		<u>40MG</u>	<u>A075576</u>	<u>001</u>	Jan 21, 2009
<u>AB</u>	IMPAX LABS	<u>10MG</u>	<u>A075785</u>	<u>001</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A075785</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>		<u>40MG</u>	<u>A075785</u>	<u>003</u>	Jan 21, 2009
<u>AB</u>	KREMERS URBAN DEV	<u>10MG</u>	<u>A075410</u>	<u>001</u>	Nov 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075410</u>	<u>002</u>	Nov 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075410</u>	<u>003</u>	Jan 23, 2009
<u>AB</u>	LEK PHARMS	<u>10MG</u>	<u>A075757</u>	<u>001</u>	Jan 28, 2003
<u>AB</u>		<u>20MG</u>	<u>A075757</u>	<u>002</u>	Jan 28, 2003
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075876</u>	<u>001</u>	May 29, 2003
<u>AB</u>		<u>20MG</u>	<u>A075876</u>	<u>002</u>	May 29, 2003
<u>AB</u>		<u>40MG</u>	<u>A075876</u>	<u>003</u>	Jan 21, 2009
<u>AB</u>	SANDOZ	<u>40MG</u>	<u>A076515</u>	<u>001</u>	Jan 21, 2009
<u>AB</u>	WATSON LABS FLORIDA	<u>10MG</u>	<u>A075347</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A075347</u>	<u>002</u>	May 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A075347</u>	<u>003</u>	May 30, 2008
	<u>PRILOSEC</u>				
<u>AB</u>	ASTRAZENECA	<u>10MG</u>	<u>N019810</u>	<u>003</u>	Oct 05, 1995
<u>AB</u>	+	<u>20MG</u>	<u>N019810</u>	<u>001</u>	Sep 14, 1989
<u>AB</u>	+	<u>40MG</u>	<u>N019810</u>	<u>002</u>	Jan 15, 1998

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PRILOSEC

	ASTRAZENECA	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008
+		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

ZEGERID

	SANTARUS	20MG;1.1GM	N021849	001	Feb 27, 2006
+		40MG;1.1GM	N021849	002	Feb 27, 2006

FOR SUSPENSION; ORAL

ZEGERID

	SANTARUS	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004
+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

<u>AB</u>	BARR	<u>4MG</u>	<u>A076693</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A076693</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	GLENMARK GENERICS	<u>4MG</u>	<u>A078152</u>	<u>001</u>	Jun 27, 2007
<u>AB</u>		<u>8MG</u>	<u>A078152</u>	<u>002</u>	Jun 27, 2007
<u>AB</u>	KALI LABS	<u>4MG</u>	<u>A076506</u>	<u>001</u>	Dec 26, 2006
<u>AB</u>		<u>8MG</u>	<u>A076506</u>	<u>002</u>	Dec 26, 2006
<u>AB</u>	KV PHARM	<u>4MG</u>	<u>A077717</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A077717</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	MYLAN	<u>4MG</u>	<u>A078139</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A078139</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A078050</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>		<u>8MG</u>	<u>A078050</u>	<u>002</u>	Aug 13, 2007
<u>AB</u>	SUN PHARM INDS	<u>4MG</u>	<u>A077557</u>	<u>001</u>	Aug 02, 2007
<u>AB</u>		<u>8MG</u>	<u>A077557</u>	<u>002</u>	Aug 02, 2007
<u>AB</u>	TEVA	<u>4MG</u>	<u>A076810</u>	<u>001</u>	Jun 25, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 296 (of 393)

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

<u>ONDANSETRON</u>					
<u>AB</u>	TEVA	<u>8MG</u>	<u>A076810</u>	<u>002</u>	Jun 25, 2007
<u>ZOFRAN ODT</u>					
<u>AB</u>	GLAXOSMITHKLINE	<u>4MG</u>	<u>N020781</u>	<u>001</u>	Jan 27, 1999
<u>AB</u>	+	<u>8MG</u>	<u>N020781</u>	<u>002</u>	Jan 27, 1999
	ONDANSETRON				
	KALI LABS	16MG	A077406	001	Dec 26, 2006
		24MG	A077406	002	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

<u>ONDANSETRON HYDROCHLORIDE</u>					
<u>AP</u>	AKORN STRIDES	<u>EQ 2MG BASE/ML</u>	<u>A078257</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>	APOTEX	<u>EQ 2MG BASE/ML</u>	<u>A077368</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	APP PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A076974</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A077365</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	BEDFORD	<u>EQ 2MG BASE/ML</u>	<u>A076967</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A079224</u>	<u>001</u>	Sep 25, 2009
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076781</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077473</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077840</u>	<u>001</u>	Jan 19, 2007
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A079039</u>	<u>001</u>	Nov 18, 2008
<u>AP</u>	PHARMAFORCE	<u>EQ 2MG BASE/ML</u>	<u>A077582</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	PLIVA HRVATSKA DOO	<u>EQ 2MG BASE/ML</u>	<u>A077544</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	SANDOZ	<u>EQ 2MG BASE/ML</u>	<u>A077430</u>	<u>001</u>	Jun 27, 2007
<u>AP</u>	SPECTRUM PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A078180</u>	<u>001</u>	Mar 26, 2007
<u>AP</u>	SUN PHARM INDS (IN)	<u>EQ 2MG BASE/ML</u>	<u>A077172</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077577</u>	<u>001</u>	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

<u>AP</u>	BEDFORD LABS	<u>EQ 0.64MG BASE/ML</u>	<u>A078291</u>	<u>001</u>	Apr 13, 2009
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 0.64MG BASE/ML</u>	<u>A078308</u>	<u>001</u>	Mar 17, 2008
<u>AP</u>	HOSPIRA	<u>EQ 0.64MG BASE/ML</u>	<u>A077348</u>	<u>001</u>	Feb 01, 2007
<u>AP</u>	TEVA PARENTERAL	<u>EQ 0.64MG BASE/ML</u>	<u>A077480</u>	<u>001</u>	Nov 22, 2006

ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>EQ 0.64MG BASE/ML</u>	<u>N021915</u>	<u>002</u>	Dec 27, 2006
-----------	---	-----------------	--------------------------	----------------	------------	--------------

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	AKORN STRIDES	<u>EQ 2MG BASE/ML</u>	<u>A078244</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>	APOTEX INC	<u>EQ 2MG BASE/ML</u>	<u>A077343</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	APP PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A076972</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A077541</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	BEDFORD LABS	<u>EQ 2MG BASE/ML</u>	<u>A077011</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076780</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077548</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A079032</u>	<u>001</u>	Nov 18, 2008
<u>AP</u>	PHARMAFORCE	<u>EQ 2MG BASE/ML</u>	<u>A077387</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	SANDOZ	<u>EQ 2MG BASE/ML</u>	<u>A077551</u>	<u>001</u>	Jun 27, 2007
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 2MG BASE/ML</u>	<u>A077173</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	TARO PHARMS IRELAND	<u>EQ 2MG BASE/ML</u>	<u>A078014</u>	<u>001</u>	Mar 21, 2008
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077716</u>	<u>001</u>	Dec 26, 2006

ZOFRAN

<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 2MG BASE/ML</u>	<u>N020007</u>	<u>001</u>	Jan 04, 1991
-----------	---	-----------------	-----------------------	----------------	------------	--------------

ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER

<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 0.64MG BASE/ML</u>	<u>N020403</u>	<u>001</u>	Jan 31, 1995
-----------	---	-----------------	--------------------------	----------------	------------	--------------

ZOFRAN PRESERVATIVE FREE

<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 2MG BASE/ML</u>	<u>N020007</u>	<u>003</u>	Dec 10, 1993
-----------	---	-----------------	-----------------------	----------------	------------	--------------

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AA</u>	APOTEX	<u>EQ 4MG BASE/5ML</u>	<u>A078127</u>	<u>001</u>	Jun 25, 2007
-----------	--------	------------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 297 (of 393)

ONDANSETRON HYDROCHLORIDE

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AA</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE/5ML</u>	<u>A078776</u>	<u>001</u>	Nov 28, 2007
<u>AA</u>	ROXANE	<u>EQ 4MG BASE/5ML</u>	<u>A076960</u>	<u>001</u>	Dec 26, 2006
<u>AA</u>	TARO	<u>EQ 4MG BASE/5ML</u>	<u>A077009</u>	<u>001</u>	Nov 30, 2007
<u>ZOFRAN</u>					
<u>AA</u>	+ GLAXOSMITHKLINE	<u>EQ 4MG BASE/5ML</u>	<u>N020605</u>	<u>001</u>	Jan 24, 1997

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 4MG BASE</u>	<u>A077306</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077306</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE</u>	<u>A078539</u>	<u>001</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078539</u>	<u>002</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078539</u>	<u>003</u>	Jul 31, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A076183</u>	<u>003</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076183</u>	<u>002</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076183</u>	<u>001</u>	Dec 26, 2006
<u>AB</u>	GLENMARK GENERICS	<u>EQ 4MG BASE</u>	<u>A077535</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077535</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077535</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	KALI LABS	<u>EQ 4MG BASE</u>	<u>A077303</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077303</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077303</u>	<u>004</u>	Jun 25, 2007
<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A076930</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076930</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076930</u>	<u>004</u>	Jun 25, 2007
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A077851</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077851</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>EQ 4MG BASE</u>	<u>A077112</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077112</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077112</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	SANDOZ	<u>EQ 4MG BASE</u>	<u>A077517</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077517</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077517</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 4MG BASE</u>	<u>A077050</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077050</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	TEVA	<u>EQ 4MG BASE</u>	<u>A076252</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076252</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076252</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	WEST WARD	<u>EQ 4MG BASE</u>	<u>A077545</u>	<u>001</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077545</u>	<u>002</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077545</u>	<u>003</u>	Sep 06, 2007
<u>ZOFRAN</u>					
<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 4MG BASE</u>	<u>N020103</u>	<u>001</u>	Dec 31, 1992
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N020103</u>	<u>002</u>	Dec 31, 1992
<u>AB</u>	+	<u>EQ 24MG BASE</u>	<u>N020103</u>	<u>003</u>	Aug 27, 1999
<u>ONDANSETRON HYDROCHLORIDE</u>					
	DR REDDYS LABS LTD	<u>EQ 16MG BASE</u>	A076559	001	Dec 26, 2006

ORLISTAT

CAPSULE; ORAL

XENICAL

+	HOFFMANN LA ROCHE	120MG	N020766	001	Apr 23, 1999
---	-------------------	-------	---------	-----	--------------

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

<u>AP</u>	+ GRACEWAY	<u>30MG/ML</u>	<u>N013055</u>	<u>001</u>	
-----------	------------	----------------	----------------	------------	--

## PRESCRIPTION DRUG PRODUCT LIST

3 - 298 (of 393)

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

<u>AP</u>	AKORN	<u>30MG/ML</u>	<u>A040484</u>	<u>001</u>	May 24, 2006
<u>AP</u>	BEDFORD LABS	<u>30MG/ML</u>	<u>A040463</u>	<u>001</u>	Mar 04, 2003
<u>AP</u>	WATSON LABS	<u>30MG/ML</u>	<u>A084779</u>	<u>001</u>	Mar 15, 1982
<u>AP</u>		<u>30MG/ML</u>	<u>A087062</u>	<u>001</u>	

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

<u>AB</u>	ACTAVIS TOTOWA	<u>100MG</u>	<u>A040284</u>	<u>001</u>	Jun 19, 1998
<u>AB</u>	IMPAX PHARMS	<u>100MG</u>	<u>A040368</u>	<u>001</u>	Jun 23, 2000
<u>AB</u>	KIEL	<u>100MG</u>	<u>A040249</u>	<u>001</u>	Jan 29, 1999
<u>AB</u> +	SANDOZ	<u>100MG</u>	<u>A040327</u>	<u>001</u>	Feb 15, 2000

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

TAMIFLU

	ROCHE	EQ 30MG BASE	N021087	003	Jul 02, 2007
		EQ 45MG BASE	N021087	002	Jul 02, 2007
+		EQ 75MG BASE	N021087	001	Oct 27, 1999

FOR SUSPENSION; ORAL

TAMIFLU

+	ROCHE	EQ 12MG BASE/ML	N021246	001	Dec 14, 2000
---	-------	-----------------	---------	-----	--------------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

<u>AP</u> +	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A061490</u>	<u>003</u>	
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062737</u>	<u>001</u>	Dec 23, 1986
<u>AP</u> +		<u>EQ 2GM BASE/VIAL</u>	<u>A061490</u>	<u>004</u>	
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062737</u>	<u>002</u>	Dec 23, 1986
<u>AP</u> +		<u>EQ 10GM BASE/VIAL</u>	<u>A061490</u>	<u>006</u>	May 09, 1991
	BACTOCILL IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640	001	Oct 26, 1989
+		EQ 40MG BASE/ML	N050640	002	Oct 26, 1989

OXALIPLATIN

INJECTABLE; INJECTION

OXALIPLATIN

<u>AP</u>	HOSPIRA INC	<u>50MG/VIAL</u>	<u>A078815</u>	<u>001</u>	Sep 30, 2009
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078815</u>	<u>002</u>	Sep 30, 2009

INJECTABLE; IV (INFUSION)

ELOXATIN

<u>AP</u> +	SANOFI AVENTIS US	<u>50MG/10ML (5MG/ML)</u>	<u>N021759</u>	<u>001</u>	Jan 31, 2005
<u>AP</u> +		<u>100MG/20ML (5MG/ML)</u>	<u>N021759</u>	<u>002</u>	Jan 31, 2005

OXALIPLATIN

<u>AP</u>	EBEWE PHARMA	<u>50MG/10ML (5MG/ML)</u>	<u>A078812</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078812</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>	FRESENIUS KABI ONCOL	<u>50MG/VIAL</u>	<u>A078810</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078810</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>	HOSPIRA WORLDWIDE	<u>50MG/10ML (5MG/ML)</u>	<u>A078813</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078813</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>	SUN PHARM INDS LTD	<u>50MG/VIAL</u>	<u>A078818</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078818</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>	TEVA PARENTERAL	<u>50MG/10ML (5MG/ML)</u>	<u>N022160</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>N022160</u>	<u>002</u>	Aug 07, 2009
	ELOXATIN				
+	SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006

## PRESCRIPTION DRUG PRODUCT LIST

OXANDROLONE

TABLET; ORAL

OXANDRIN

<u>AB</u>	SAVIENT PHARMS	<u>2.5MG</u>	<u>N013718</u>	<u>001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N013718</u>	<u>002</u>	Nov 05, 2001
	<u>OXANDROLONE</u>				
<u>AB</u>	KALI LABS	<u>2.5MG</u>	<u>A077827</u>	<u>001</u>	Jun 22, 2007
<u>AB</u>		<u>10MG</u>	<u>A077827</u>	<u>002</u>	Jun 22, 2007
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076897</u>	<u>001</u>	Dec 01, 2006
<u>AB</u>		<u>10MG</u>	<u>A076897</u>	<u>002</u>	Dec 01, 2006
<u>AB</u>	UPSHER SMITH	<u>2.5MG</u>	<u>A076761</u>	<u>001</u>	Dec 01, 2006
<u>AB</u>		<u>10MG</u>	<u>A078033</u>	<u>001</u>	Mar 22, 2007

OXAPROZIN

TABLET; ORAL

DAYPRO

<u>AB</u>	+	GD SEARLE	<u>600MG</u>	<u>N018841</u>	<u>004</u>	Oct 29, 1992
		<u>OXAPROZIN</u>				
<u>AB</u>		ACTAVIS ELIZABETH	<u>600MG</u>	<u>A075843</u>	<u>001</u>	Oct 03, 2001
<u>AB</u>		APOTEX INC	<u>600MG</u>	<u>A075987</u>	<u>001</u>	Sep 02, 2004
<u>AB</u>		CARACO	<u>600MG</u>	<u>A075844</u>	<u>001</u>	Jan 03, 2002
<u>AB</u>		DR REDDYS LABS LTD	<u>600MG</u>	<u>A075855</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>		GENPHARM	<u>600MG</u>	<u>A075847</u>	<u>001</u>	Feb 28, 2001
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>600MG</u>	<u>A075846</u>	<u>001</u>	May 13, 2002
<u>AB</u>		SANDOZ	<u>600MG</u>	<u>A075845</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>		TEVA	<u>600MG</u>	<u>A075849</u>	<u>001</u>	Jul 03, 2002
<u>AB</u>		WATSON LABS	<u>600MG</u>	<u>A075848</u>	<u>001</u>	Feb 09, 2001

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

<u>AB</u>		ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072251</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>			<u>15MG</u>	<u>A072252</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>			<u>30MG</u>	<u>A072253</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>10MG</u>	<u>A070943</u>	<u>001</u>	Aug 03, 1987
<u>AB</u>			<u>15MG</u>	<u>A070944</u>	<u>001</u>	Aug 03, 1987
<u>AB</u>	+		<u>30MG</u>	<u>A070945</u>	<u>001</u>	Aug 03, 1987
<u>AB</u>		SANDOZ	<u>10MG</u>	<u>A071813</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>			<u>15MG</u>	<u>A071756</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>			<u>30MG</u>	<u>A071814</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>		WATSON LABS	<u>10MG</u>	<u>A072952</u>	<u>001</u>	Sep 28, 1990
<u>AB</u>			<u>15MG</u>	<u>A072953</u>	<u>001</u>	Sep 28, 1990
<u>AB</u>			<u>30MG</u>	<u>A072954</u>	<u>001</u>	Sep 28, 1990

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

<u>AB</u>		RANBAXY	<u>300MG/5ML</u>	<u>A078734</u>	<u>001</u>	Jun 26, 2009
		<u>TRILEPTAL</u>				
<u>AB</u>	+	NOVARTIS	<u>300MG/5ML</u>	<u>N021285</u>	<u>001</u>	May 25, 2001

TABLET; ORAL

OXCARBAZEPINE

<u>AB</u>		APOTEX INC	<u>150MG</u>	<u>A077747</u>	<u>001</u>	Apr 09, 2008
<u>AB</u>			<u>300MG</u>	<u>A077747</u>	<u>002</u>	Apr 09, 2008
<u>AB</u>			<u>600MG</u>	<u>A077747</u>	<u>003</u>	Apr 09, 2008
<u>AB</u>		BRECKENRIDGE PHARM	<u>150MG</u>	<u>A078069</u>	<u>001</u>	Jan 11, 2008
<u>AB</u>			<u>300MG</u>	<u>A078069</u>	<u>002</u>	Jan 11, 2008
<u>AB</u>			<u>600MG</u>	<u>A078069</u>	<u>003</u>	Jan 11, 2008
<u>AB</u>		GLENMARK GENERICS	<u>150MG</u>	<u>A077802</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>			<u>300MG</u>	<u>A077802</u>	<u>002</u>	Oct 09, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 300 (of 393)

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

<u>AB</u>	GLENMARK GENERICS	<u>600MG</u>	<u>A077802</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>	ROXANE	<u>150MG</u>	<u>A077795</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077795</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077795</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>	SUN PHARM INDS	<u>150MG</u>	<u>A077794</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077794</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077794</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>	TARO	<u>150MG</u>	<u>A077801</u>	<u>001</u>	Nov 15, 2007
<u>AB</u>		<u>300MG</u>	<u>A077801</u>	<u>002</u>	Nov 15, 2007
<u>AB</u>		<u>600MG</u>	<u>A077801</u>	<u>003</u>	Nov 15, 2007
<u>AB</u>	TEVA PHARMS	<u>150MG</u>	<u>A078005</u>	<u>001</u>	Dec 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A078005</u>	<u>002</u>	Dec 11, 2007
<u>AB</u>		<u>600MG</u>	<u>A078005</u>	<u>003</u>	Dec 11, 2007
	<u>TRILEPTAL</u>				
<u>AB</u>	NOVARTIS	<u>150MG</u>	<u>N021014</u>	<u>001</u>	Jan 14, 2000
<u>AB</u>		<u>300MG</u>	<u>N021014</u>	<u>002</u>	Jan 14, 2000
<u>AB</u>	+	<u>600MG</u>	<u>N021014</u>	<u>003</u>	Jan 14, 2000

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+ ALTANA EQ 1% BASE N019828 001 Dec 30, 1988

LOTION; TOPICAL

OXISTAT

+ ALTANA EQ 1% BASE N020209 001 Sep 30, 1992

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

+ WARNER CHILCOTT 400MG A087863 001 May 24, 1983

+ 600MG A086742 001

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL

+ WATSON LABS (UTAH) 3.9MG/24HR N021351 002 Feb 26, 2003

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

+ WATSON LABS 10%(100MG/PACKET) N022204 001 Jan 27, 2009

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

<u>AA</u>	MIKART	<u>5MG/5ML</u>	<u>A075039</u>	<u>001</u>	Jan 29, 1999
<u>AA</u>	+ MORTON GROVE	<u>5MG/5ML</u>	<u>A074868</u>	<u>001</u>	Feb 12, 1997
<u>AA</u>	NOVEX	<u>5MG/5ML</u>	<u>A074997</u>	<u>001</u>	Oct 15, 1997
<u>AA</u>	PHARM ASSOC	<u>5MG/5ML</u>	<u>A075137</u>	<u>001</u>	Dec 18, 1998
<u>AA</u>	SILARX	<u>5MG/5ML</u>	<u>A074520</u>	<u>001</u>	Mar 29, 1996
<u>AA</u>	VINTAGE PHARMS	<u>5MG/5ML</u>	<u>A076682</u>	<u>001</u>	Dec 28, 2004

TABLET; ORAL

DITROPANAB + ORTHO MCNEIL JANSSEN 5MG N017577 001OXYBUTYNIN CHLORIDE

<u>AB</u>	PLIVA	<u>5MG</u>	<u>A071655</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>	USL PHARMA	<u>5MG</u>	<u>A074625</u>	<u>001</u>	Jul 31, 1996
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A075079</u>	<u>001</u>	Oct 31, 1997

## PRESCRIPTION DRUG PRODUCT LIST

3 - 301 (of 393)

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DITROPAN XL

<u>AB</u>	ORTHO MCNEIL JANSSEN	<u>5MG</u>	<u>N020897</u>	<u>001</u>	Dec 16, 1998
<u>AB</u>		<u>10MG</u>	<u>N020897</u>	<u>002</u>	Dec 16, 1998
<u>AB</u>	+	<u>15MG</u>	<u>N020897</u>	<u>003</u>	Jun 22, 1999

OXYBUTYNIN CHLORIDE

<u>AB</u>	IMPAX PHARMS	<u>5MG</u>	<u>A076745</u>	<u>002</u>	May 09, 2007
<u>AB</u>		<u>10MG</u>	<u>A076745</u>	<u>003</u>	May 09, 2007
<u>AB</u>		<u>15MG</u>	<u>A076745</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076702</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>		<u>10MG</u>	<u>A076644</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>		<u>15MG</u>	<u>A078293</u>	<u>001</u>	May 10, 2007
<u>AB</u>	OSMOTICA PHARM	<u>5MG</u>	<u>A078503</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>10MG</u>	<u>A078503</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>		<u>15MG</u>	<u>A078503</u>	<u>003</u>	Feb 04, 2009

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>15MG</u>	<u>A076636</u>	<u>001</u>	Feb 06, 2004
<u>AB</u>		<u>30MG</u>	<u>A076636</u>	<u>002</u>	Feb 06, 2004
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A091393</u>	<u>001</u>	Aug 31, 2009
<u>AB</u>		<u>10MG</u>	<u>A091393</u>	<u>002</u>	Aug 31, 2009
<u>AB</u>		<u>15MG</u>	<u>A091393</u>	<u>003</u>	Aug 31, 2009
<u>AB</u>		<u>20MG</u>	<u>A091393</u>	<u>004</u>	Aug 31, 2009
<u>AB</u>		<u>30MG</u>	<u>A091393</u>	<u>005</u>	Aug 31, 2009
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A090895</u>	<u>001</u>	Aug 24, 2009
<u>AB</u>		<u>15MG</u>	<u>A090895</u>	<u>002</u>	Aug 24, 2009
<u>AB</u>		<u>30MG</u>	<u>A090895</u>	<u>003</u>	Aug 24, 2009
<u>AB</u>	KV PHARM	<u>5MG</u>	<u>A077290</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>10MG</u>	<u>A077290</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>15MG</u>	<u>A077290</u>	<u>003</u>	Dec 08, 2005
<u>AB</u>		<u>20MG</u>	<u>A077290</u>	<u>004</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077290</u>	<u>005</u>	Dec 08, 2005
<u>AB</u>	MALLINCKRODT	<u>15MG</u>	<u>A076758</u>	<u>001</u>	Jun 30, 2004
<u>AB</u>		<u>30MG</u>	<u>A076758</u>	<u>002</u>	Jun 30, 2004
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090659</u>	<u>001</u>	Apr 10, 2009
<u>AB</u>		<u>15MG</u>	<u>A090659</u>	<u>002</u>	Apr 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A090659</u>	<u>003</u>	Apr 10, 2009
<u>AB</u>	TYCO HLTHCARE	<u>5MG</u>	<u>A078206</u>	<u>001</u>	Mar 19, 2007
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A077712</u>	<u>003</u>	Mar 02, 2009
<u>AB</u>		<u>15MG</u>	<u>A077712</u>	<u>001</u>	Jan 31, 2007
<u>AB</u>		<u>30MG</u>	<u>A077712</u>	<u>002</u>	Jan 31, 2007
<u>ROXICODONE</u>					
<u>AB</u>	XANODYNE PHARMS	<u>5MG</u>	<u>N021011</u>	<u>003</u>	May 15, 2009
<u>AB</u>	+	<u>15MG</u>	<u>N021011</u>	<u>001</u>	Aug 31, 2000
<u>AB</u>		<u>30MG</u>	<u>N021011</u>	<u>002</u>	Aug 31, 2000

TABLET, EXTENDED RELEASE; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	MALLINCKRODT	<u>10MG</u>	<u>A077822</u>	<u>001</u>	Jul 24, 2008
<u>AB</u>		<u>20MG</u>	<u>A077822</u>	<u>002</u>	Jul 24, 2008
<u>AB</u>		<u>40MG</u>	<u>A077822</u>	<u>003</u>	Jul 24, 2008
<u>AB</u>		<u>80MG</u>	<u>A077822</u>	<u>004</u>	Jul 24, 2008

OXYCONTIN

<u>AB</u>	PURDUE PHARMA LP	<u>10MG</u>	<u>N020553</u>	<u>001</u>	Dec 12, 1995
<u>AB</u>		<u>20MG</u>	<u>N020553</u>	<u>002</u>	Dec 12, 1995
<u>AB</u>	+	<u>40MG</u>	<u>N020553</u>	<u>003</u>	Dec 12, 1995
<u>AB</u>		<u>80MG</u>	<u>N020553</u>	<u>004</u>	Jan 06, 1997



## PRESCRIPTION DRUG PRODUCT LIST

3 - 302 (of 393)

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYCONTIN

PURDUE PHARMA LP	15MG	N020553	006	Sep 18, 2006
	30MG	N020553	007	Sep 18, 2006
	60MG	N020553	008	Sep 18, 2006

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

+ ALAVEN PHARM	50MG	N016848	001	
----------------	------	---------	-----	--

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

+ ENDO PHARMS	1MG/ML	N011707	002	
---------------	--------	---------	-----	--

TABLET; ORAL

OPANA

ENDO PHARMS	5MG	N021611	001	Jun 22, 2006
+	10MG	N021611	002	Jun 22, 2006

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

ENDO PHARMS	5MG	N021610	001	Jun 22, 2006
	7.5MG	N021610	005	Feb 29, 2008
	10MG	N021610	002	Jun 22, 2006
	15MG	N021610	006	Feb 29, 2008
	20MG	N021610	003	Jun 22, 2006
	30MG	N021610	007	Feb 29, 2008
+	40MG	N021610	004	Jun 22, 2006

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

+ PFIZER	EQ 5MG BASE/GM;10,000 UNITS/GM	A061015	001	
----------	--------------------------------	---------	-----	--

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

<u>AP</u>	+ APP PHARMS	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018248</u>	<u>001</u>	
<u>AP</u>	+	<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018248</u>	<u>002</u>	
<u>AP</u>	+ BAXTER HLTHCARE CORP	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018243</u>	<u>001</u>	
<u>AP</u>	+	<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018243</u>	<u>002</u>	Jan 10, 2007
<u>AP</u>	TEVA PARENTERAL	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>A077453</u>	<u>001</u>	Jan 24, 2008
<u>AP</u>		<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>A077453</u>	<u>002</u>	Jan 24, 2008

PITOCIN

<u>AP</u>	+ JHP PHARMS	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018261</u>	<u>001</u>	
<u>AP</u>		<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018261</u>	<u>002</u>	Jul 27, 2007
	OXYTOCIN				
	+ APP PHARMS	300USP UNITS/30ML (10USP UNITS/ML)	N018248	003	Jul 27, 2007

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

+	ABRAXIS BIOSCIENCE	100MG/VIAL	N021660	001	Jan 07, 2005
---	--------------------	------------	---------	-----	--------------

INJECTABLE; INJECTION

PACLITAXEL

<u>AP</u>	ACCORD HLTHCARE INC	<u>6MG/ML</u>	<u>A075436</u>	<u>001</u>	Nov 12, 2004
<u>AP</u>	ACTAVIS TOTOWA	<u>6MG/ML</u>	<u>A090130</u>	<u>001</u>	Dec 09, 2009
<u>AP</u>	BEDFORD	<u>6MG/ML</u>	<u>A075190</u>	<u>001</u>	Jan 28, 2002

PRESCRIPTION DRUG PRODUCT LIST

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

<u>AP</u>	EBEWE PHARMA	<u>6MG/ML</u>	<u>A078167</u>	<u>001</u>	Dec 26, 2007
<u>AP</u>	FRESENIUS KABI ONCOL	<u>6MG/ML</u>	<u>A077574</u>	<u>001</u>	Nov 27, 2006
<u>AP</u>	HOSPIRA	<u>6MG/ML</u>	<u>A076131</u>	<u>001</u>	May 08, 2002
<u>AP</u>	MYLAN	<u>6MG/ML</u>	<u>A075278</u>	<u>001</u>	Jan 25, 2002
<u>AP</u>	PLIVA LACHEMA	<u>6MG/ML</u>	<u>A077413</u>	<u>001</u>	Mar 12, 2008
<u>AP</u>	TEVA PARENTERAL	<u>6MG/ML</u>	<u>A075184</u>	<u>001</u>	Jan 25, 2002

TAXOL

<u>AP</u>	+ BRISTOL MYERS SQUIBB	<u>6MG/ML</u>	<u>N020262</u>	<u>001</u>	Dec 29, 1992
-----------	------------------------	---------------	----------------	------------	--------------

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

	ORTHO MCNEIL JANSSEN	1.5MG	N021999	006	Aug 26, 2008
		3MG	N021999	001	Dec 19, 2006
+		6MG	N021999	002	Dec 19, 2006
		9MG	N021999	003	Dec 19, 2006

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

	JOHNSON AND JOHNSON	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009
		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009
		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009
		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009
		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009

PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

ALOXI

+	HELSSINN HLTHCARE	EQ 0.5MG BASE	N022233	001	Aug 22, 2008
---	-------------------	---------------	---------	-----	--------------

INJECTABLE; INTRAVENOUS

ALOXI

+	HELSSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008
+		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

<u>AP</u>	+ NOVARTIS	<u>30MG/VIAL</u>	<u>N020036</u>	<u>001</u>	Oct 31, 1991
<u>AP</u>	+	<u>90MG/VIAL</u>	<u>N020036</u>	<u>004</u>	May 06, 1993

PAMIDRONATE DISODIUM

<u>AP</u>	AESGEN	<u>30MG/VIAL</u>	<u>A075594</u>	<u>001</u>	May 06, 2002
<u>AP</u>		<u>90MG/VIAL</u>	<u>A075594</u>	<u>002</u>	May 06, 2002
<u>AP</u>	AKORN STRIDES	<u>30MG/10ML (3MG/ML)</u>	<u>A078520</u>	<u>001</u>	Oct 31, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078520</u>	<u>002</u>	Oct 31, 2008
<u>AP</u>	APP PHARMS	<u>30MG/VIAL</u>	<u>A075773</u>	<u>001</u>	May 06, 2002
<u>AP</u>		<u>30MG/10ML (3MG/ML)</u>	<u>A076207</u>	<u>001</u>	May 17, 2002
<u>AP</u>		<u>90MG/VIAL</u>	<u>A075773</u>	<u>002</u>	May 06, 2002
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A076207</u>	<u>002</u>	May 17, 2002
<u>AP</u>	BEDFORD	<u>30MG/VIAL</u>	<u>A075290</u>	<u>001</u>	Apr 30, 2001
<u>AP</u>	+	<u>30MG/10ML (3MG/ML)</u>	<u>N021113</u>	<u>001</u>	Mar 04, 2002
<u>AP</u>		<u>90MG/VIAL</u>	<u>A075290</u>	<u>003</u>	Apr 30, 2001
<u>AP</u>	+	<u>90MG/10ML (9MG/ML)</u>	<u>N021113</u>	<u>002</u>	Mar 04, 2002
<u>AP</u>	CIPLA LTD	<u>30MG/VIAL</u>	<u>A077433</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>		<u>60MG/VIAL</u>	<u>A077433</u>	<u>002</u>	Nov 26, 2008
<u>AP</u>		<u>90MG/VIAL</u>	<u>A077433</u>	<u>003</u>	Nov 26, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 304 (of 393)

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

<u>AP</u>	GENERAMEDIX	<u>30MG/VIAL</u>	<u>A078300</u>	<u>001</u>	Mar 10, 2009
<u>AP</u>		<u>30MG/10ML (3MG/ML)</u>	<u>A078373</u>	<u>001</u>	Dec 23, 2008
<u>AP</u>		<u>90MG/VIAL</u>	<u>A078300</u>	<u>002</u>	Mar 10, 2009
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078373</u>	<u>002</u>	Dec 23, 2008
<u>AP</u>	+ HOSPIRA	<u>30MG/10ML (3MG/ML)</u>	<u>A075841</u>	<u>001</u>	Jun 27, 2002
<u>AP</u>	+	<u>60MG/10ML (6MG/ML)</u>	<u>A075841</u>	<u>002</u>	Jun 27, 2002
<u>AP</u>	+	<u>90MG/10ML (9MG/ML)</u>	<u>A075841</u>	<u>003</u>	Jun 27, 2002
<u>AP</u>	PHARMAFORCE	<u>30MG/10ML (3MG/ML)</u>	<u>A078942</u>	<u>001</u>	Jul 25, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078942</u>	<u>002</u>	Jul 25, 2008
<u>AP</u>	PLIVA LACHEMA	<u>30MG/10ML (3MG/ML)</u>	<u>A078156</u>	<u>001</u>	Aug 19, 2008
<u>AP</u>		<u>60MG/10ML (6MG/ML)</u>	<u>A078156</u>	<u>002</u>	Aug 19, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078156</u>	<u>003</u>	Aug 19, 2008
<u>AP</u>	SUN PHARM INDS	<u>30MG/VIAL</u>	<u>A077703</u>	<u>001</u>	Dec 24, 2008
<u>AP</u>		<u>90MG/VIAL</u>	<u>A077703</u>	<u>002</u>	Dec 24, 2008
<u>AP</u>	TEVA PARENTERAL	<u>30MG/10ML (3MG/ML)</u>	<u>A076153</u>	<u>001</u>	Mar 27, 2002
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A076153</u>	<u>002</u>	Mar 27, 2002

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

	SOLVAY	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725	001	Apr 30, 2009
		60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725	002	Apr 30, 2009
	+	120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725	003	Apr 30, 2009
	ZENPEP				
	EURAND	27,000USP UNITS;5,000USP UNITS;17,000USP UNITS	N022210	001	Aug 27, 2009
		55,000USP UNITS;10,000USP UNITS;34,000USP UNITS	N022210	002	Aug 27, 2009
		82,000USP UNITS;15,000USP UNITS;51,000USP UNITS	N022210	003	Aug 27, 2009
	+	109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210	004	Aug 27, 2009

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

<u>AP</u>	ELKINS SINN	<u>1MG/ML</u>	<u>A072058</u>	<u>001</u>	Mar 23, 1988
<u>AP</u>		<u>2MG/ML</u>	<u>A072059</u>	<u>001</u>	Mar 23, 1988
<u>AP</u>		<u>2MG/ML</u>	<u>A072060</u>	<u>001</u>	Mar 23, 1988
<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A072320</u>	<u>001</u>	Jan 19, 1989
<u>AP</u>	+ TEVA PARENTERAL	<u>1MG/ML</u>	<u>A072759</u>	<u>001</u>	Jul 31, 1990
<u>AP</u>	+	<u>2MG/ML</u>	<u>A072760</u>	<u>001</u>	Jul 31, 1990

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PROTONIX

	+ WYETH PHARMS INC	EQ 40MG BASE	N022020	001	Nov 14, 2007
--	--------------------	--------------	---------	-----	--------------

INJECTABLE; IV (INFUSION)

	+ WYETH PHARMS INC	EQ 40MG BASE/VIAL	N020988	001	Mar 22, 2001
--	--------------------	-------------------	---------	-----	--------------

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

<u>AB</u>	KUDCO IRELAND	<u>EQ 20MG BASE</u>	<u>A078281</u>	<u>001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078281</u>	<u>002</u>	Mar 17, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 305 (of 393)

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

<u>AB</u>	SUN PHARM INDS	<u>EQ 20MG BASE</u>	<u>A077058</u>	<u>001</u>	Sep 10, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077058</u>	<u>002</u>	Sep 10, 2007
<u>AB</u>	TEVA	<u>EQ 20MG BASE</u>	<u>A077056</u>	<u>001</u>	Aug 02, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077056</u>	<u>002</u>	Aug 02, 2007
<u>PROTONIX</u>					
<u>AB</u>	WYETH PHARMS INC	<u>EQ 20MG BASE</u>	<u>N020987</u>	<u>002</u>	Jun 12, 2001
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020987</u>	<u>001</u>	Feb 02, 2000

PARICALCITOL

CAPSULE; ORAL

ZEMPLAR

	ABBOTT	1MCG	N021606	001	May 26, 2005	
		2MCG	N021606	002	May 26, 2005	
	+	4MCG	N021606	003	May 26, 2005	
<u>INJECTABLE; INJECTION</u>						
<u>ZEMPLAR</u>						
	+	ABBOTT	0.002MG/ML	N020819	002	Feb 01, 2000
	+		0.005MG/ML	N020819	001	Apr 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL

PAROMOMYCIN SULFATE

<u>AA</u>	+	CARACO	<u>EQ 250MG BASE</u>	<u>A064171</u>	<u>001</u>	Jun 30, 1997
<u>AA</u>		HERITAGE PHARMS INC	<u>EQ 250MG BASE</u>	<u>A065173</u>	<u>001</u>	Dec 14, 2007

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE/5ML</u>	<u>A077395</u>	<u>001</u>	Dec 05, 2006	
<u>PAXIL</u>						
<u>AB</u>	+	GLAXOSMITHKLINE	<u>EQ 10MG BASE/5ML</u>	<u>N020710</u>	<u>001</u>	Jun 25, 1997

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	ALPHAPHARM	<u>EQ 10MG BASE</u>	<u>A075716</u>	<u>001</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075716</u>	<u>002</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075716</u>	<u>003</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075716</u>	<u>004</u>	Mar 08, 2004
<u>AB</u>	APOTEX	<u>EQ 10MG BASE</u>	<u>A075356</u>	<u>001</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075356</u>	<u>002</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075356</u>	<u>003</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075356</u>	<u>004</u>	Jul 30, 2003
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078406</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078406</u>	<u>002</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078406</u>	<u>003</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078406</u>	<u>004</u>	Jul 25, 2007
<u>AB</u>	CARACO	<u>EQ 10MG BASE</u>	<u>A078194</u>	<u>001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078194</u>	<u>002</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078194</u>	<u>003</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078194</u>	<u>004</u>	Jun 29, 2007
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078902</u>	<u>001</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078902</u>	<u>002</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078902</u>	<u>003</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078902</u>	<u>004</u>	Mar 13, 2008
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A076618</u>	<u>001</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076618</u>	<u>002</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076618</u>	<u>003</u>	Aug 15, 2005

## PRESCRIPTION DRUG PRODUCT LIST

3 - 306 (of 393)

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	TEVA	<u>EQ 40MG BASE</u>	<u>A076618</u>	<u>004</u>	Aug 15, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 10MG BASE</u>	<u>A077584</u>	<u>001</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077584</u>	<u>002</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A077584</u>	<u>003</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077584</u>	<u>004</u>	Mar 07, 2007

PAXIL

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 10MG BASE</u>	<u>N020031</u>	<u>001</u>	Dec 29, 1992
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N020031</u>	<u>002</u>	Dec 29, 1992
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>N020031</u>	<u>003</u>	Dec 29, 1992
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020031</u>	<u>005</u>	Dec 29, 1992

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 12.5MG BASE</u>	<u>A077873</u>	<u>001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A077873</u>	<u>002</u>	Jun 29, 2007

PAXIL CR

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 12.5MG BASE</u>	<u>N020936</u>	<u>001</u>	Feb 16, 1999
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>N020936</u>	<u>002</u>	Feb 16, 1999
	PAXIL CR				
	+ GLAXOSMITHKLINE	EQ 37.5MG BASE	N020936	003	Dec 06, 2000

PAROXETINE MESYLATE

TABLET; ORAL

## PEXEVA

	NOVEN THERAP	EQ 10MG BASE	N021299	001	Jul 03, 2003
		EQ 20MG BASE	N021299	002	Jul 03, 2003
		EQ 30MG BASE	N021299	003	Jul 03, 2003
	+	EQ 40MG BASE	N021299	004	Jul 03, 2003

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

## VOTRIENT

	GLAXOSMITHKLINE	EQ 200MG BASE	N022465	001	Oct 19, 2009
	+	EQ 400MG BASE	N022465	002	Oct 19, 2009

PEGADEMASE BOVINE

INJECTABLE; INJECTION

## ADAGEN

	+ ENZON PHARMS	250 UNITS/ML	N019818	001	Mar 21, 1990
--	----------------	--------------	---------	-----	--------------

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

## MACUGEN

	+ EYETECH INC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004
--	---------------	----------------------	---------	-----	--------------

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS

## SOMAVERT

	+ PHARMACIA AND UPJOHN	10MG/VIAL	N021106	001	Mar 25, 2003
	+	15MG/VIAL	N021106	002	Mar 25, 2003
	+	20MG/VIAL	N021106	003	Mar 25, 2003

PEMETREXED DISODIUM

INJECTABLE; IV (INFUSION)

	+ LILLY	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007
	+	EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 333 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 307 (of 393)

PEMIROLAST POTASSIUM

SOLUTION/DROPS; OPHTHALMIC

+ SANTEN	0.1%	N021079	001	Sep 24, 1999
----------	------	---------	-----	--------------

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

+ SCHWARZ PHARMA	20MG	N018976	004	Jan 05, 1989
------------------	------	---------	-----	--------------

PENCICLOVIR SODIUM

CREAM; TOPICAL

DENA VIR

+ NOVARTIS	1%	N020629	001	Sep 24, 1996
------------	----	---------	-----	--------------

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE

+ ATON	250MG	N019853	001	
--------	-------	---------	-----	--

TABLET; ORAL

DEPEN

+ MEDA PHARMS	250MG	N019854	001	
---------------	-------	---------	-----	--

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

BC + KING PHARMS	600,000 UNITS/ML	N050141	001	
------------------	------------------	---------	-----	--

PERMAPEN

BC PFIZER	600,000 UNITS/ML	A060014	001	
-----------	------------------	---------	-----	--

BICILLIN L-A

+ KING PHARMS	300,000 UNITS/ML	N050141	003	
---------------	------------------	---------	-----	--

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

BICILLIN C-R

+ KING PHARMS	150,000 UNITS/ML;150,000 UNITS/ML	N050138	002	
---------------	-----------------------------------	---------	-----	--

+	300,000 UNITS/ML;300,000 UNITS/ML	N050138	001	
---	-----------------------------------	---------	-----	--

BICILLIN C-R 900/300

+ KING PHARMS	900,000 UNITS/2ML;300,000 UNITS/2ML	N050138	003	
---------------	-------------------------------------	---------	-----	--

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

<u>AP</u> APP PHARMS	<u>5,000,000 UNITS/VIAL</u>	<u>A065448</u>	<u>001</u>	Aug 18, 2009
----------------------	-----------------------------	----------------	------------	--------------

<u>AP</u>	<u>20,000,000 UNITS/VIAL</u>	<u>A065448</u>	<u>002</u>	Aug 18, 2009
-----------	------------------------------	----------------	------------	--------------

<u>AP</u> HANFORD GC	<u>5,000,000 UNITS/VIAL</u>	<u>A065149</u>	<u>002</u>	Jul 23, 2009
----------------------	-----------------------------	----------------	------------	--------------

<u>AP</u>	<u>20,000,000 UNITS/VIAL</u>	<u>A065149</u>	<u>003</u>	Jul 23, 2009
-----------	------------------------------	----------------	------------	--------------

<u>AP</u> SANDOZ	<u>5,000,000 UNITS/VIAL</u>	<u>A065079</u>	<u>002</u>	Aug 30, 2002
------------------	-----------------------------	----------------	------------	--------------

<u>AP</u>	<u>20,000,000 UNITS/VIAL</u>	<u>A065079</u>	<u>003</u>	Aug 30, 2002
-----------	------------------------------	----------------	------------	--------------

PFIZERPEN

<u>AP</u> + PFIZER	<u>5,000,000 UNITS/VIAL</u>	<u>A060657</u>	<u>002</u>	
--------------------	-----------------------------	----------------	------------	--

<u>AP</u> +	<u>20,000,000 UNITS/VIAL</u>	<u>A060657</u>	<u>003</u>	
-------------	------------------------------	----------------	------------	--

PENICILLIN G POTASSIUM

HANFORD GC

1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009
----------------------	---------	-----	--------------

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	20,000 UNITS/ML	N050638	001	Jun 25, 1990
-------------------	-----------------	---------	-----	--------------

+	40,000 UNITS/ML	N050638	002	Jun 25, 1990
---	-----------------	---------	-----	--------------

+	60,000 UNITS/ML	N050638	003	Jun 25, 1990
---	-----------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 308 (of 393)

PENICILLIN G PROCAINE

INJECTABLE; INJECTION  
 PENICILLIN G PROCAINE  
 + KING PHARMS  
 +

300,000 UNITS/ML A060101 002  
 600,000 UNITS/ML A060101 001

PENICILLIN G SODIUM

INJECTABLE; IM-IV  
 PENICILLIN G SODIUM  
 + SANDOZ

5,000,000 UNITS/VIAL A065068 001 Feb 26, 2001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUM

AA DAVA PHARMS INC EQ 125MG BASE/5ML A062981 001 Feb 10, 1989  
AA EQ 250MG BASE/5ML A062981 002 Feb 10, 1989

PENICILLIN-VK

AA TEVA EQ 125MG BASE/5ML A060456 001  
AA + EQ 250MG BASE/5ML A060456 002

TABLET; ORAL

PENICILLIN V POTASSIUM

AB AUROBINDO PHARMA EQ 250MG BASE A065435 001 Apr 29, 2008  
AB EQ 500MG BASE A065435 002 Apr 29, 2008  
AB DAVA PHARMS INC EQ 250MG BASE A062936 001 Nov 25, 1988  
AB EQ 500MG BASE A062935 001 Nov 23, 1988  
AB SANDOZ EQ 250MG BASE A064071 001 Nov 30, 1995  
AB + EQ 500MG BASE A064071 002 Nov 30, 1995

PENICILLIN-VK

AB TEVA EQ 250MG BASE A060711 002  
AB EQ 500MG BASE A060711 003

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION  
 NEBUPENT  
 + APP PHARMS

300MG/VIAL N019887 001 Jun 15, 1989

INJECTABLE; INJECTION

PENTAM

AP + APP PHARMS 300MG/VIAL N019264 001 Oct 16, 1984

PENTAMIDINE ISETHIONATE

AP WATSON LABS 300MG/VIAL A074303 001 Aug 17, 1995

PENTAZOCINE LACTATE

INJECTABLE; INJECTION  
 TALWIN  
 + HOSPIRA

EQ 30MG BASE/ML N016194 001

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS  
 PENTETATE CALCIUM TRISODIUM

+ HAMELN PHARMS EQ 1GM BASE/5ML (EQ 200MG BASE/ML) N021749 001 Aug 11, 2004

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS  
 PENTETATE ZINC TRISODIUM

+ HAMELN PHARMS EQ 1GM BASE/5ML (EQ 200MG BASE/ML) N021751 001 Aug 11, 2004

## PRESCRIPTION DRUG PRODUCT LIST

3 - 309 (of 393)

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+ LUNDBECK INC 50MG/ML A083246 001

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ ORTHO MCNEIL JANSSEN 100MG N020193 001 Sep 26, 1996

PENTOSTATIN

INJECTABLE; INJECTION

NIPENTAP + HOSPIRA INC 10MG/VIAL N020122 001 Oct 11, 1991PENTOSTATINAP BEDFORD LABS 10MG/VIAL A077841 001 Aug 07, 2007PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINEAB APOTEX 400MG A075191 001 Jun 09, 1999AB BIOVAIL 400MG A075028 001 Jul 20, 1998AB IMPAX LABS 400MG A075093 001 Aug 10, 1999AB MYLAN 400MG A074425 001 Jul 08, 1997AB PLIVA 400MG A074874 001 May 25, 1999AB WATSON LABS 400MG A075107 001 Sep 04, 1998PENTOXILAB UPSHER SMITH 400MG A074962 001 Mar 31, 1999TRENTALAB + SANOFI AVENTIS US 400MG N018631 001 Aug 30, 1984PERFLUTREN

INJECTABLE; INTRAVENOUS

DEFINITY

+ LANTHEUS MEDCL 6.52MG/ML N021064 001 Jul 31, 2001

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEONAB SOLVAY PHARMS 2MG N020184 001 Dec 30, 1993AB 4MG N020184 002 Dec 30, 1993AB + 8MG N020184 003 Dec 30, 1993PERINDOPRIL ERBUMINEAB AUROBINDO PHARMA 2MG A079070 001 Nov 10, 2009AB 4MG A079070 002 Nov 10, 2009AB 8MG A079070 003 Nov 10, 2009AB IVAX PHARMS 2MG A078138 001 Nov 10, 2009AB 4MG A078138 002 Nov 10, 2009AB 8MG A078138 003 Nov 10, 2009AB ROXANE 2MG A090072 001 Nov 10, 2009AB 4MG A090072 002 Nov 10, 2009AB 8MG A090072 003 Nov 10, 2009PERMETHRIN

CREAM; TOPICAL

ELIMITEAB + ALLERGAN 5% N019855 001 Aug 25, 1989PERMETHRINAB ACTAVIS MID ATLANTIC 5% A074806 001 Jan 23, 1998



## PRESCRIPTION DRUG PRODUCT LIST

3 - 310 (of 393)

PERMETHRIN

CREAM; TOPICAL

PERMETHRIN

<u>AB</u>	PERRIGO NEW YORK	<u>5%</u>	<u>A076369</u>	<u>001</u>	Apr 21, 2003
-----------	------------------	-----------	----------------	------------	--------------

PERPHENAZINE

CONCENTRATE; ORAL

PERPHENAZINE

	+ PHARM ASSOC	16MG/5ML	A040360	001	May 25, 2001
--	---------------	----------	---------	-----	--------------

TABLET; ORAL

PERPHENAZINE

<u>AB</u>	SANDOZ	<u>2MG</u>	<u>A089683</u>	<u>001</u>	Dec 08, 1988
<u>AB</u>		<u>4MG</u>	<u>A089684</u>	<u>001</u>	Dec 08, 1988
<u>AB</u>		<u>8MG</u>	<u>A089685</u>	<u>001</u>	Dec 08, 1988
<u>AB</u>	+	<u>16MG</u>	<u>A089686</u>	<u>001</u>	Dec 08, 1988
<u>AB</u>	VINTAGE PHARMS	<u>2MG</u>	<u>A040226</u>	<u>001</u>	Dec 31, 1998
<u>AB</u>		<u>4MG</u>	<u>A040226</u>	<u>002</u>	Dec 31, 1998
<u>AB</u>		<u>8MG</u>	<u>A040226</u>	<u>003</u>	Dec 31, 1998
<u>AB</u>		<u>16MG</u>	<u>A040226</u>	<u>004</u>	Dec 31, 1998

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

BONTRIL

BC	MALLINCKRODT	105MG	A088021	001	Sep 21, 1982
----	--------------	-------	---------	-----	--------------

PHENDIMETRAZINE TARTRATE

BC	+ SANDOZ	105MG	N018074	001	
----	----------	-------	---------	-----	--

TABLET; ORAL

BONTRIL PDM

<u>AA</u>	+	VALEANT	<u>35MG</u>	<u>A085272</u>	<u>001</u>
-----------	---	---------	-------------	----------------	------------

PHENDIMETRAZINE TARTRATE

<u>AA</u>	ACTAVIS TOTOWA	<u>35MG</u>	<u>A040762</u>	<u>001</u>	Jan 28, 2008
<u>AA</u>	MIKART	<u>35MG</u>	<u>A089452</u>	<u>001</u>	Oct 30, 1991
<u>AA</u>	SANDOZ	<u>35MG</u>	<u>A085588</u>	<u>001</u>	

PHENELZINE SULFATE

TABLET; ORAL

NARDIL

	+ PARKE DAVIS	EQ 15MG BASE	N011909	002	
--	---------------	--------------	---------	-----	--

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

	+ WELLSRING PHARM	10MG	N008708	001	
--	-------------------	------	---------	-----	--

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

<u>AA</u>	+	TEVA	<u>37.5MG</u>	<u>A088023</u>	<u>001</u>	Aug 02, 1983
-----------	---	------	---------------	----------------	------------	--------------

PHENTERMINE HYDROCHLORIDE

<u>AA</u>	ACTAVIS TOTOWA	<u>15MG</u>	<u>A040460</u>	<u>001</u>	Jan 14, 2003
<u>AA</u>		<u>30MG</u>	<u>A040227</u>	<u>001</u>	Jun 18, 1997
<u>AA</u>		<u>30MG</u>	<u>A040448</u>	<u>001</u>	Jan 22, 2003
<u>AA</u>		<u>37.5MG</u>	<u>A040228</u>	<u>001</u>	Jun 19, 1997
<u>AA</u>	KVK TECH	<u>15MG</u>	<u>A040886</u>	<u>002</u>	Mar 31, 2008
<u>AA</u>		<u>30MG</u>	<u>A040875</u>	<u>001</u>	Mar 21, 2008
<u>AA</u>		<u>30MG</u>	<u>A040886</u>	<u>001</u>	Mar 31, 2008
<u>AA</u>		<u>37.5MG</u>	<u>A040887</u>	<u>001</u>	Apr 24, 2008
<u>AA</u>	LANNETT	<u>30MG</u>	<u>A087022</u>	<u>001</u>	Feb 03, 1983
<u>AA</u>	MUTUAL PHARM	<u>30MG</u>	<u>A040525</u>	<u>001</u>	Oct 23, 2003

## PRESCRIPTION DRUG PRODUCT LIST

3 - 311 (of 393)

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

<u>AA</u>	+	SANDOZ	<u>15MG</u>	<u>A087190</u>	<u>002</u>	
<u>AA</u>	+		<u>30MG</u>	<u>A086945</u>	<u>001</u>	Jul 20, 1983
<u>AA</u>	+		<u>30MG</u>	<u>A087190</u>	<u>001</u>	

TABLET; ORAL

ADIPEX-P

<u>AA</u>	+	TEVA	<u>37.5MG</u>	<u>A085128</u>	<u>001</u>	
-----------	---	------	---------------	----------------	------------	--

PHENTERMINE HYDROCHLORIDE

<u>AA</u>		ACTAVIS ELIZABETH	<u>37.5MG</u>	<u>A040276</u>	<u>001</u>	Nov 25, 1998
<u>AA</u>		ACTAVIS TOTOWA	<u>37.5MG</u>	<u>A040190</u>	<u>001</u>	May 30, 1997
<u>AA</u>		BARR	<u>37.5MG</u>	<u>A090470</u>	<u>001</u>	Aug 31, 2009
<u>AA</u>		CARACO	<u>37.5MG</u>	<u>A040790</u>	<u>001</u>	Aug 21, 2007
<u>AA</u>		KVK TECH	<u>37.5MG</u>	<u>A040876</u>	<u>001</u>	Mar 31, 2008
<u>AA</u>		LANNETT	<u>37.5MG</u>	<u>A040555</u>	<u>001</u>	Apr 15, 2005
<u>AA</u>		MUTUAL PHARM	<u>37.5MG</u>	<u>A040526</u>	<u>001</u>	Oct 23, 2003
<u>AA</u>		VINTAGE PHARMS	<u>37.5MG</u>	<u>A040377</u>	<u>001</u>	Jan 04, 2002

PHENTERMINE HYDROCHLORIDE

	+	SANDOZ	30MG	A088605	001	Sep 28, 1987
--	---	--------	------	---------	-----	--------------

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

<u>AP</u>		BEDFORD	<u>5MG/VIAL</u>	<u>A040235</u>	<u>001</u>	Mar 11, 1998
		<u>REGITINE</u>				
<u>AP</u>	+	NOVARTIS	<u>5MG/VIAL</u>	<u>N008278</u>	<u>003</u>	
		ORAVERSE				
	+	NOVALAR	0.4MG/1.7ML	N022159	001	May 09, 2008

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

<u>AA</u>		VINTAGE	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A040654</u>	<u>001</u>	Dec 07, 2006
		<u>PROMETH VC PLAIN</u>				
<u>AA</u>	+	ACTAVIS MID ATLANTIC	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A088761</u>	<u>001</u>	Nov 08, 1984
		<u>PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE</u>				
<u>AA</u>		AMNEAL PHARMS	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A040902</u>	<u>001</u>	Aug 25, 2009

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125

<u>AB</u>	+	PARKE DAVIS	<u>125MG/5ML</u>	<u>N008762</u>	<u>001</u>	
-----------	---	-------------	------------------	----------------	------------	--

PHENYTOIN

<u>AB</u>		TARO	<u>125MG/5ML</u>	<u>A040521</u>	<u>001</u>	Mar 08, 2004
<u>AB</u>		VISTAPHARM	<u>125MG/5ML</u>	<u>A040342</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>			<u>125MG/5ML</u>	<u>A040610</u>	<u>001</u>	Aug 18, 2005
<u>AB</u>		WOCKHARDT	<u>125MG/5ML</u>	<u>A040420</u>	<u>001</u>	Apr 19, 2002

TABLET, CHEWABLE; ORAL

DILANTIN

	+	PFIZER PHARMS	50MG	A084427	001	
--	---	---------------	------	---------	-----	--

PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN

<u>AB</u>	+	PARKE DAVIS	<u>30MG EXTENDED</u>	<u>A084349</u>	<u>001</u>	
<u>AB</u>	+		<u>100MG EXTENDED</u>	<u>A084349</u>	<u>002</u>	

EXTENDED PHENYTOIN SODIUM

<u>AB</u>		AMNEAL PHARMS NY	<u>100MG EXTENDED</u>	<u>A040765</u>	<u>001</u>	Nov 12, 2008
-----------	--	------------------	-----------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 312 (of 393)

PHENYTOIN SODIUM

CAPSULE; ORAL

EXTENDED PHENYTOIN SODIUM

<u>AB</u>	MYLAN	<u>100MG EXTENDED</u>	<u>A040298</u>	<u>001</u>	Dec 28, 1998
<u>AB</u>	SUN PHARM INDS	<u>200MG EXTENDED</u>	<u>A040731</u>	<u>001</u>	Jun 30, 2008
<u>AB</u>		<u>300MG EXTENDED</u>	<u>A040731</u>	<u>002</u>	Jun 30, 2008
<u>AB</u>	SUN PHARM INDS (IN)	<u>100MG EXTENDED</u>	<u>A040621</u>	<u>001</u>	Dec 11, 2006
<u>AB</u>	TARO	<u>100MG EXTENDED</u>	<u>A040684</u>	<u>001</u>	Sep 05, 2006
<u>AB</u>	WOCKHARDT	<u>30MG EXTENDED</u>	<u>A040759</u>	<u>001</u>	Dec 18, 2007
<u>AB</u>	WOCKHARDT USA	<u>100MG EXTENDED</u>	<u>A040732</u>	<u>001</u>	Jan 30, 2008
	<u>PHENYTEK</u>				
<u>AB</u>	MYLAN	<u>200MG EXTENDED</u>	<u>A040298</u>	<u>002</u>	Dec 06, 2001
<u>AB</u>	+	<u>300MG EXTENDED</u>	<u>A040298</u>	<u>003</u>	Dec 06, 2001

INJECTABLE; INJECTION

PHENYTOIN SODIUM

<u>AP</u>	+	BAXTER HLTHCARE	<u>50MG/ML</u>	<u>A084307</u>	<u>001</u>	
<u>AP</u>		HIKMA FARMACEUTICA	<u>50MG/ML</u>	<u>A040573</u>	<u>001</u>	Sep 13, 2006
<u>AP</u>		HOSPIRA	<u>50MG/ML</u>	<u>A089521</u>	<u>001</u>	Mar 17, 1987
<u>AP</u>			<u>50MG/ML</u>	<u>A089744</u>	<u>001</u>	Dec 18, 1987
<u>AP</u>		PHARMAFORCE	<u>50MG/ML</u>	<u>A040781</u>	<u>001</u>	Dec 04, 2007

PHYTONADIONE

INJECTABLE; INJECTION

## PHYTONADIONE

BP		INTL MEDICATION	1MG/0.5ML	A083722	001	
		VITAMIN K1				
BP	+	HOSPIRA	1MG/0.5ML	A087954	001	Jul 25, 1983
		VITAMIN K1				
	+	HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983
		MEPHYTON				
	+	ATON	5MG	N010104	003	

PILOCARPINE HYDROCHLORIDE

GEL; OPHTHALMIC

## PILOPINE HS

	+	ALCON	4%	N018796	001	Oct 01, 1984
--	---	-------	----	---------	-----	--------------

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

<u>AB</u>		COREPHARMA	<u>5MG</u>	<u>A076746</u>	<u>001</u>	Nov 16, 2004
<u>AB</u>		IMPAX LABS	<u>5MG</u>	<u>A077248</u>	<u>001</u>	Mar 31, 2006
<u>AB</u>			<u>7.5MG</u>	<u>A077248</u>	<u>002</u>	Mar 31, 2006
<u>AB</u>		LANNETT	<u>5MG</u>	<u>A077220</u>	<u>001</u>	Oct 14, 2005
<u>AB</u>			<u>7.5MG</u>	<u>A077220</u>	<u>002</u>	May 06, 2009
<u>AB</u>		ROXANE	<u>5MG</u>	<u>A076963</u>	<u>001</u>	Dec 22, 2004
<u>AB</u>			<u>7.5MG</u>	<u>A076963</u>	<u>002</u>	Feb 27, 2007
		<u>SALAGEN</u>				
<u>AB</u>		EISAI INC	<u>5MG</u>	<u>N020237</u>	<u>001</u>	Mar 22, 1994
<u>AB</u>	+		<u>7.5MG</u>	<u>N020237</u>	<u>002</u>	Apr 18, 2003

PIMECROLIMUS

CREAM; TOPICAL

## ELIDEL

	+	NOVARTIS	1%	N021302	001	Dec 13, 2001
--	---	----------	----	---------	-----	--------------

PIMOZIDE

TABLET; ORAL

## ORAP

		TEVA	1MG	N017473	003	Aug 27, 1997
--	--	------	-----	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 313 (of 393)

PIMOZIDE

TABLET; ORAL

ORAP

+	TEVA	2MG	N017473	001	Jul 31, 1984
---	------	-----	---------	-----	--------------

PINDOLOL

TABLET; ORAL

PINDOLOL

<u>AB</u>	MYLAN	<u>5MG</u>	<u>A074019</u>	<u>001</u>	Sep 03, 1992
<u>AB</u>	+	<u>10MG</u>	<u>A074019</u>	<u>002</u>	Sep 03, 1992
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A074437</u>	<u>001</u>	Feb 27, 1995
<u>AB</u>		<u>10MG</u>	<u>A074437</u>	<u>002</u>	Feb 27, 1995

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

	TAKEDA PHARMS NA	EQ 15MG BASE	N021073	001	Jul 15, 1999
		EQ 30MG BASE	N021073	002	Jul 15, 1999
+		EQ 45MG BASE	N021073	003	Jul 15, 1999

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

+	ISTITUTO BIOCHIMICO	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003
+		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003
+		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003
+		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

<u>AP</u>	ORCHID HLTHCARE	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065386</u>	<u>001</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065386</u>	<u>002</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065386</u>	<u>003</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A065446</u>	<u>001</u>	Sep 15, 2009
	<u>ZOSYN</u>				
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>N050684</u>	<u>001</u>	Oct 22, 1993
<u>AP</u>	+	<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>N050684</u>	<u>002</u>	Oct 22, 1993
<u>AP</u>	+	<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050684</u>	<u>003</u>	Oct 22, 1993
<u>AP</u>	+	<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>N050684</u>	<u>004</u>	Oct 22, 1993
	ZOSYN IN PLASTIC CONTAINER				
+	WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998
+		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998
+		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

+	GRACEWAY	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992
---	----------	-------------------	---------	-----	--------------

PIROXICAM

CAPSULE; ORAL

FELDENE

<u>AB</u>	PFIZER	<u>10MG</u>	<u>N018147</u>	<u>002</u>	Apr 06, 1982
<u>AB</u>	+	<u>20MG</u>	<u>N018147</u>	<u>003</u>	Apr 06, 1982
	<u>PIROXICAM</u>				
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A073535</u>	<u>001</u>	Mar 12, 1993
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A074102</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		<u>20MG</u>	<u>A074102</u>	<u>002</u>	Jul 31, 1992

## PRESCRIPTION DRUG PRODUCT LIST

3 - 314 (of 393)

PIROXICAM

CAPSULE; ORAL

PIROXICAM

<u>AB</u>	NOSTRUM LABS	<u>10MG</u>	<u>A074116</u>	<u>001</u>	Jun 15, 1993
<u>AB</u>		<u>20MG</u>	<u>A074118</u>	<u>001</u>	Jun 15, 1993
<u>AB</u>	TEVA	<u>10MG</u>	<u>A074131</u>	<u>001</u>	Dec 11, 1992
<u>AB</u>		<u>20MG</u>	<u>A074131</u>	<u>002</u>	Dec 11, 1992
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A074287</u>	<u>001</u>	May 16, 1996
<u>AB</u>		<u>10MG</u>	<u>A074460</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>		<u>20MG</u>	<u>A074287</u>	<u>002</u>	May 16, 1996
<u>AB</u>		<u>20MG</u>	<u>A074460</u>	<u>002</u>	Sep 29, 1995

PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

KOWA

		EQ 1MG BASE	N022363	001	Aug 03, 2009
		EQ 2MG BASE	N022363	002	Aug 03, 2009
+		EQ 4MG BASE	N022363	003	Aug 03, 2009

PLERIXAFOR

SOLUTION; SUBCUTANEOUS

MOZOBIL

+	GENZYME	24MG/1.2ML (20MG/ML)	N022311	001	Dec 15, 2008
---	---------	----------------------	---------	-----	--------------

PODOFILOX

GEL; TOPICAL

CONDYLOX

+	WATSON PHARMS	0.5%	N020529	001	Mar 13, 1997
---	---------------	------	---------	-----	--------------

SOLUTION; TOPICAL

CONDYLOX

<u>AT</u>	+	WATSON PHARMS	<u>0.5%</u>	<u>N019795</u>	<u>001</u>	Dec 13, 1990
-----------	---	---------------	-------------	----------------	------------	--------------

PODOFILOX

<u>AT</u>		PADDOCK	<u>0.5%</u>	<u>A075600</u>	<u>001</u>	Jan 29, 2002
-----------	--	---------	-------------	----------------	------------	--------------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAX

<u>AA</u>		SCHWARZ PHARMA	<u>17GM/SCOOPFUL</u>	<u>A076652</u>	<u>001</u>	Jul 02, 2004
-----------	--	----------------	----------------------	----------------	------------	--------------

POLYETHYLENE GLYCOL 3350

<u>AA</u>		BRECKENRIDGE PHARM	<u>17GM/SCOOPFUL</u>	<u>A077736</u>	<u>001</u>	May 26, 2006
-----------	--	--------------------	----------------------	----------------	------------	--------------

<u>AA</u>		NEXGEN PHARMA INC	<u>17GM/SCOOPFUL</u>	<u>A077706</u>	<u>001</u>	Sep 27, 2006
-----------	--	-------------------	----------------------	----------------	------------	--------------

<u>AA</u>		PADDOCK	<u>17GM/SCOOPFUL</u>	<u>A077893</u>	<u>001</u>	May 26, 2006
-----------	--	---------	----------------------	----------------	------------	--------------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

NULYTELY

<u>AA</u>	+	BRAINTREE	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	<u>N019797</u>	<u>001</u>	Apr 22, 1991
-----------	---	-----------	---	----------------	------------	--------------

NULYTELY-FLAVORED

<u>AA</u>	+	BRAINTREE	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	<u>N019797</u>	<u>002</u>	Nov 18, 1994
-----------	---	-----------	---	----------------	------------	--------------

PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE

<u>AA</u>		NOVEL LABS INC	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	<u>A090019</u>	<u>001</u>	May 27, 2009
-----------	--	----------------	---	----------------	------------	--------------

TRILYTE

<u>AA</u>		SCHWARZ PHARMA	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	<u>A076491</u>	<u>001</u>	Feb 05, 2004
-----------	--	----------------	---	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 315 (of 393)

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE;  
SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

<u>AA</u>	+	ALAVEN PHARM	<u>227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT</u>	<u>N018983</u>	<u>010</u>	Jan 31, 1989
-----------	---	--------------	--	----------------	------------	--------------

<u>AA</u>	+		<u>240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT</u>	<u>N018983</u>	<u>007</u>	Jun 12, 1987
-----------	---	--	---	----------------	------------	--------------

COLYTE WITH FLAVOR PACKS

<u>AA</u>	+	ALAVEN PHARM	<u>240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT</u>	<u>N018983</u>	<u>012</u>	Oct 08, 1998
-----------	---	--------------	---	----------------	------------	--------------

COLYTE-FLAVORED

<u>AA</u>	+	ALAVEN PHARM	<u>227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT</u>	<u>N018983</u>	<u>008</u>	Nov 14, 1991
-----------	---	--------------	--	----------------	------------	--------------

<u>AA</u>	+		<u>240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT</u>	<u>N018983</u>	<u>009</u>	Nov 14, 1991
-----------	---	--	---	----------------	------------	--------------

GOLYTELY

<u>AA</u>	+	BRAINTREE	<u>236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT</u>	<u>N019011</u>	<u>001</u>	Jul 13, 1984
-----------	---	-----------	---	----------------	------------	--------------

PEG 3350 AND ELECTROLYTES

<u>AA</u>		NOVEL LABS INC	<u>236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT</u>	<u>A090231</u>	<u>001</u>	Jun 01, 2009
-----------	--	----------------	---	----------------	------------	--------------

<u>AA</u>			<u>240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT</u>	<u>A090186</u>	<u>001</u>	Jun 01, 2009
-----------	--	--	---	----------------	------------	--------------

GOLYTELY

	+	BRAINTREE	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N019011	002	Jun 02, 1992
--	---	-----------	--	---------	-----	--------------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYXIN B SULFATE

<u>AP</u>		APP PHARMS	<u>EQ 500,000 U BASE/VIAL</u>	<u>A065372</u>	<u>001</u>	Jan 10, 2008
-----------	--	------------	-------------------------------	----------------	------------	--------------

<u>AP</u>	+	BEDFORD	<u>EQ 500,000 U BASE/VIAL</u>	<u>A060716</u>	<u>001</u>	
-----------	---	---------	-------------------------------	----------------	------------	--

<u>AP</u>		X GEN PHARMS	<u>EQ 500,000 U BASE/VIAL</u>	<u>A063000</u>	<u>001</u>	Sep 30, 1994
-----------	--	--------------	-------------------------------	----------------	------------	--------------

POWDER; FOR RX COMPOUNDING

POLY-RX

	+	X GEN PHARMS	100,000,000 UNITS/BOT	A061578	001	
--	---	--------------	-----------------------	---------	-----	--

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

POLYTRIM

<u>AT</u>	+	ALLERGAN	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>N050567</u>	<u>001</u>	Oct 20, 1988
-----------	---	----------	---------------------------------------	----------------	------------	--------------

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

<u>AT</u>		BAUSCH AND LOMB	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>A064120</u>	<u>001</u>	Feb 14, 1997
-----------	--	-----------------	---------------------------------------	----------------	------------	--------------

<u>AT</u>		FALCON PHARMS	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>A064211</u>	<u>001</u>	Apr 13, 1998
-----------	--	---------------	---------------------------------------	----------------	------------	--------------

<u>AT</u>		TAYLOR PHARMA	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>A065006</u>	<u>001</u>	Dec 17, 1998
-----------	--	---------------	---------------------------------------	----------------	------------	--------------

PORACTANT ALFA

SUSPENSION; INTRATRACHEAL

CUROSURF

	+	CORNERSTONE THERAP	80MG/ML	N020744	001	Nov 18, 1999
--	---	--------------------	---------	---------	-----	--------------

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

	+	AXCAN	75MG/VIAL	N020451	001	Dec 27, 1995
--	---	-------	-----------	---------	-----	--------------

POSACONAZOLE

SUSPENSION; ORAL

NOXAFIL

	+	SCHERING	40MG/ML	N022003	001	Sep 15, 2006
--	---	----------	---------	---------	-----	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 342 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 316 (of 393)

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE IN PLASTIC CONTAINER

+	HOSPIRA	2MEQ/ML	N018896	001	Jul 20, 1984
---	---------	---------	---------	-----	--------------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

	WATSON LABS FLORIDA	8MEQ	A077419	001	Jun 02, 2008
+		10MEQ	A077419	002	Jun 02, 2008

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

<u>AP</u>	APP PHARMS	<u>2MEQ/ML</u>	<u>A080225</u>	<u>001</u>	
<u>AP</u>	B BRAUN	<u>2MEQ/ML</u>	<u>A085870</u>	<u>001</u>	
<u>AP</u>	BAXTER HLTHCARE	<u>2MEQ/ML</u>	<u>A085499</u>	<u>001</u>	
<u>AP</u>	+ HOSPIRA	<u>2MEQ/ML</u>	<u>A080205</u>	<u>001</u>	
<u>AP</u>	INTL MEDICATION	<u>2MEQ/ML</u>	<u>A083163</u>	<u>001</u>	

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>14.9MG/ML</u>	<u>N019904</u>	<u>001</u>	Dec 26, 1989
<u>AP</u>	+	<u>746MG/100ML</u>	<u>N019904</u>	<u>005</u>	Dec 17, 1990
<u>AP</u>	HOSPIRA	<u>14.9MG/ML</u>	<u>N020161</u>	<u>005</u>	Nov 30, 1992
<u>AP</u>		<u>745MG/100ML</u>	<u>N020161</u>	<u>001</u>	Nov 30, 1992

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>29.8MG/ML</u>	<u>N019904</u>	<u>002</u>	Dec 26, 1989
<u>AP</u>	+	<u>1.49GM/100ML</u>	<u>N019904</u>	<u>006</u>	Dec 17, 1990
<u>AP</u>	+ HOSPIRA	<u>29.8MG/ML</u>	<u>N020161</u>	<u>006</u>	Aug 11, 1998
<u>AP</u>		<u>1.49GM/100ML</u>	<u>N020161</u>	<u>002</u>	Nov 30, 1992

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>2.24GM/100ML</u>	<u>N019904</u>	<u>003</u>	Dec 26, 1989
<u>AP</u>	+ HOSPIRA	<u>2.24GM/100ML</u>	<u>N020161</u>	<u>003</u>	Aug 11, 1998

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>2.98GM/100ML</u>	<u>N019904</u>	<u>004</u>	Dec 26, 1989
<u>AP</u>	+ HOSPIRA	<u>2.98GM/100ML</u>	<u>N020161</u>	<u>004</u>	Aug 11, 1998

POTASSIUM CHLORIDE IN PLASTIC CONTAINER

<u>AP</u>	APP PHARMS	<u>2MEQ/ML</u>	<u>A088901</u>	<u>001</u>	Jan 25, 1985
<u>AP</u>		<u>2MEQ/ML</u>	<u>A088908</u>	<u>001</u>	Jan 25, 1985
	POTASSIUM CHLORIDE				
+	APP PHARMS	3MEQ/ML	A080225	003	

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M10

<u>AB</u>	UPSHER SMITH	<u>10MEQ</u>	<u>A074726</u>	<u>002</u>	Aug 09, 2000
-----------	--------------	--------------	----------------	------------	--------------

KLOR-CON M20

<u>AB</u>	UPSHER SMITH	<u>20MEQ</u>	<u>A074726</u>	<u>001</u>	Nov 20, 1998
-----------	--------------	--------------	----------------	------------	--------------

POTASSIUM CHLORIDE

<u>AB</u>	EURAND	<u>20MEQ</u>	<u>A076368</u>	<u>001</u>	Aug 18, 2004
<u>AB</u>	KV PHARM	<u>20MEQ</u>	<u>A076044</u>	<u>001</u>	Apr 05, 2002
<u>AB</u>	SCHERING	<u>10MEQ</u>	<u>N019439</u>	<u>002</u>	Jun 13, 1986
<u>AB</u>	+	<u>20MEQ</u>	<u>N019439</u>	<u>001</u>	Jun 13, 1986
<u>AB</u>	WATSON LABS FLORIDA	<u>10MEQ</u>	<u>A075604</u>	<u>001</u>	Apr 10, 2002
<u>AB</u>		<u>20MEQ</u>	<u>A075604</u>	<u>002</u>	Apr 10, 2002

K+10

BC	FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987
----	------------	-------	---------	-----	--------------

KAON CL-10

BC	SAVAGE LABS	10MEQ	N017046	002	
----	-------------	-------	---------	-----	--

KLOR-CON

BC	UPSHER SMITH	10MEQ	N019123	002	Apr 17, 1986
----	--------------	-------	---------	-----	--------------

KLOTRIX

BC	APOTHECON	10MEQ	N017850	001	
----	-----------	-------	---------	-----	--

K-TAB

BC	ABBOTT	10MEQ	N018279	001	
----	--------	-------	---------	-----	--

## PRESCRIPTION DRUG PRODUCT LIST

3 - 317 (of 393)

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
 POTASSIUM CHLORIDE

BC	ABBOTT	8MEQ	N018279	002	Aug 01, 1988
	KLOR-CON				
+	UPSHER SMITH	8MEQ	N019123	001	Apr 17, 1986
	KLOR-CON M15				
	UPSHER SMITH	15MEQ	A074726	003	Jun 06, 2003

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>149MG/100ML;450MG/100ML</u>	<u>A078446</u>	<u>001</u>	Sep 10, 2008
-----------	---------	--------------------------------	----------------	------------	--------------

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>150MG/100ML;450MG/100ML</u>	<u>N017648</u>	<u>005</u>	Nov 26, 2002
-----------	-------------------	--------------------------------	----------------	------------	--------------

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>150MG/100ML;900MG/100ML</u>	<u>N019708</u>	<u>004</u>	Sep 29, 1989
<u>AP</u>	BAXTER HLTHCARE	<u>150MG/100ML;900MG/100ML</u>	<u>N017648</u>	<u>001</u>	

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>300MG/100ML;900MG/100ML</u>	<u>N017648</u>	<u>002</u>	
-----------	-----------------	--------------------------------	----------------	------------	--

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>149MG/100ML;900MG/100ML</u>	<u>N019686</u>	<u>001</u>	Oct 17, 1988
-----------	---------	--------------------------------	----------------	------------	--------------

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>298MG/100ML;900MG/100ML</u>	<u>N019686</u>	<u>002</u>	Oct 17, 1988
-----------	---------	--------------------------------	----------------	------------	--------------

	POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%				
	BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N017648	003	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

<u>AB</u>	COREPHARMA	<u>5MEQ</u>	<u>A077440</u>	<u>001</u>	Jun 09, 2006
<u>AB</u>		<u>10MEQ</u>	<u>A077440</u>	<u>002</u>	Jun 09, 2006

UROCIT-K

<u>AB</u>	MISSION PHARMA	<u>5MEQ</u>	<u>N019071</u>	<u>001</u>	Aug 30, 1985
<u>AB</u>	+	<u>10MEQ</u>	<u>N019071</u>	<u>002</u>	Aug 31, 1992

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC

+	ALCON	5%	N018634	001	Dec 17, 1986
---	-------	----	---------	-----	--------------

PRALATREXATE

SOLUTION; INTRAVENOUS

FOLOTYN

	ALLOS	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009
+		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

+	MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983
---	----------------------	----------	---------	-----	--------------

PROTOPAM CHLORIDE

+	BAXTER HLTHCARE CORP	1GM/VIAL	N014134	001	
---	----------------------	----------	---------	-----	--

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.125MG</u>	<u>N020667</u>	<u>001</u>	Jul 01, 1997
<u>AB</u>	+	<u>0.25MG</u>	<u>N020667</u>	<u>002</u>	Jul 01, 1997
<u>AB</u>		<u>0.5MG</u>	<u>N020667</u>	<u>006</u>	Feb 12, 1998



## PRESCRIPTION DRUG PRODUCT LIST

3 - 318 (of 393)

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

<u>AB</u>	BOEHRINGER INGELHEIM	<u>1MG</u>	<u>N020667</u>	<u>003</u>	Jul 01, 1997
<u>AB</u>		<u>1.5MG</u>	<u>N020667</u>	<u>005</u>	Jul 01, 1997
<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>					
<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077724</u>	<u>001</u>	Feb 19, 2008
<u>AB</u>		<u>0.25MG</u>	<u>A077724</u>	<u>002</u>	Feb 19, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077724</u>	<u>003</u>	Feb 19, 2008
<u>AB</u>		<u>1MG</u>	<u>A077724</u>	<u>004</u>	Feb 19, 2008
<u>AB</u>		<u>1.5MG</u>	<u>A077724</u>	<u>005</u>	Feb 19, 2008
<u>MIRAPEX</u>					
	BOEHRINGER INGELHEIM	0.75MG	N020667	007	Jul 30, 2007

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

	AMYLIN	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007
		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007
+		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

EFFIENT

	ELI LILLY AND CO	EQ 5MG BASE	N022307	001	Jul 10, 2009
+		EQ 10MG BASE	N022307	002	Jul 10, 2009

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>10MG</u>	<u>N019898</u>	<u>002</u>	Oct 31, 1991
<u>AB</u>		<u>20MG</u>	<u>N019898</u>	<u>003</u>	Oct 31, 1991
<u>AB</u>		<u>40MG</u>	<u>N019898</u>	<u>004</u>	Mar 22, 1993
<u>AB</u>	+	<u>80MG</u>	<u>N019898</u>	<u>008</u>	Dec 18, 2001
<u>PRAVASTATIN SODIUM</u>					
<u>AB</u>	APOTEX	<u>10MG</u>	<u>A076341</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076341</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076341</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076341</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	COBALT LABS INC	<u>10MG</u>	<u>A076939</u>	<u>004</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076939</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076939</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076939</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>	DR REDDYS LABS INC	<u>10MG</u>	<u>A076714</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076714</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076714</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076714</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	GLENMARK GENERICS	<u>10MG</u>	<u>A077987</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A077987</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A077987</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A077987</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	LEK PHARMS DD	<u>10MG</u>	<u>A076397</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076397</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076397</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077491</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>	LUPIN PHARMS	<u>10MG</u>	<u>A077917</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>		<u>20MG</u>	<u>A077917</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>		<u>40MG</u>	<u>A077917</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>		<u>80MG</u>	<u>A077917</u>	<u>004</u>	Jan 08, 2008
<u>AB</u>	MYLAN	10MG	A077013	001	Oct 23, 2006

## PRESCRIPTION DRUG PRODUCT LIST

3 - 319 (of 393)

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

<u>AB</u>	MYLAN	<u>20MG</u>	<u>A077013</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077013</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077013</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>10MG</u>	<u>A077730</u>	<u>001</u>	Nov 21, 2006
<u>AB</u>		<u>20MG</u>	<u>A077730</u>	<u>002</u>	Nov 21, 2006
<u>AB</u>		<u>40MG</u>	<u>A077730</u>	<u>005</u>	Nov 21, 2006
<u>AB</u>	RANBAXY	<u>10MG</u>	<u>A076445</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>20MG</u>	<u>A076445</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>		<u>40MG</u>	<u>A076445</u>	<u>003</u>	Apr 23, 2007
<u>AB</u>		<u>80MG</u>	<u>A076445</u>	<u>004</u>	Apr 23, 2007
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076056</u>	<u>001</u>	Apr 24, 2006
<u>AB</u>		<u>20MG</u>	<u>A076056</u>	<u>002</u>	Apr 24, 2006
<u>AB</u>		<u>40MG</u>	<u>A076056</u>	<u>003</u>	Apr 24, 2006
<u>AB</u>	TEVA PHARMS	<u>80MG</u>	<u>A077793</u>	<u>001</u>	Jan 15, 2008
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A077904</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077904</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077904</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>10MG</u>	<u>A077751</u>	<u>001</u>	Apr 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A077751</u>	<u>002</u>	Apr 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A077751</u>	<u>003</u>	Apr 30, 2008
<u>AB</u>		<u>80MG</u>	<u>A077751</u>	<u>004</u>	Apr 30, 2008
	PRAVASTATIN SODIUM PLIVA HRVATSKA DOO	30MG	A077730	003	Nov 21, 2006

PRAZIQUANTEL

TABLET; ORAL

BILTRICIDE

+ BAYER HLTHCARE 600MG N018714 001 Dec 29, 1982

PRazosin HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESS

<u>AB</u>	PFIZER	<u>EQ 1MG BASE</u>	<u>N017442</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N017442</u>	<u>003</u>	
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N017442</u>	<u>001</u>	

PRazosin HYDROCHLORIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A071994</u>	<u>001</u>	Sep 12, 1988
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A071995</u>	<u>001</u>	Sep 12, 1988
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A071745</u>	<u>001</u>	Sep 12, 1988
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A072575</u>	<u>003</u>	May 16, 1989
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A072575</u>	<u>002</u>	May 16, 1989
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A072575</u>	<u>001</u>	May 16, 1989
<u>AB</u>	WATSON LABS	<u>EQ 1MG BASE</u>	<u>A072352</u>	<u>001</u>	May 16, 1989
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A072333</u>	<u>001</u>	May 16, 1989

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENTAB + SANOFI AVENTIS US 0.1% N020279 001 Oct 29, 1993PREDNICARBATEAB ALTANA 0.1% A077287 001 Sep 19, 2006

OINTMENT; TOPICAL

DERMATOPAB + SANOFI AVENTIS US 0.1% N019568 001 Sep 23, 1991PREDNICARBATEAB ALTANA 0.1% A077236 001 Mar 09, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 320 (of 393)

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

<u>AA</u>	ALPHARMA	<u>15MG/5ML</u>	<u>A040323</u>	<u>001</u>	May 13, 1999
<u>AA</u>	APOTEX INC	<u>5MG/5ML</u>	<u>A040570</u>	<u>001</u>	Aug 25, 2005
<u>AA</u>		<u>15MG/5ML</u>	<u>A040571</u>	<u>001</u>	Aug 25, 2005
<u>AA</u>	HI TECH PHARMA	<u>15MG/5ML</u>	<u>A040401</u>	<u>001</u>	Feb 27, 2003
<u>AA</u>	IVAX SUB TEVA PHARMS	<u>15MG/5ML</u>	<u>A040287</u>	<u>001</u>	May 28, 1999
<u>AA</u>	+ KV PHARM	<u>5MG/5ML</u>	<u>A040423</u>	<u>001</u>	Oct 22, 2001
<u>AA</u>	+	<u>15MG/5ML</u>	<u>A040364</u>	<u>001</u>	Apr 10, 2002
<u>AA</u>	MORTON GROVE	<u>15MG/5ML</u>	<u>A040313</u>	<u>001</u>	Sep 10, 2003
<u>AA</u>	PHARM ASSOC	<u>15MG/5ML</u>	<u>A040399</u>	<u>001</u>	Mar 05, 2003
<u>AA</u>	VINTAGE	<u>15MG/5ML</u>	<u>A040775</u>	<u>001</u>	Sep 21, 2007
	<u>PRELONE</u>				
<u>AA</u>	TEVA	<u>15MG/5ML</u>	<u>A089081</u>	<u>001</u>	Feb 04, 1986

TABLET; ORAL

PREDNISOLONE

+ WATSON LABS 5MG A080354 001

PREDNISOLONE ACETATE

SUSPENSION; ORAL

FLO-PRED

+ TARO EQ 15MG BASE/5ML N022067 002 Jan 17, 2008

SUSPENSION/DROPS; OPHTHALMIC

OMNIPRED

<u>AB</u>	ALCON	<u>1%</u>	<u>N017469</u>	<u>001</u>	
	<u>PRED FORTE</u>				
<u>AB</u>	+ ALLERGAN	<u>1%</u>	<u>N017011</u>	<u>001</u>	
	PRED MILD				
	+ ALLERGAN	0.12%	N017100	001	

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPHAMIDE S.O.P.

+ ALLERGAN 0.2%;10% A087748 001 Dec 03, 1986

SUSPENSION; OPHTHALMIC

BLEPHAMIDE

+ ALLERGAN 0.2%;10% N012813 002

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

<u>AA</u>	+ SCIELE PHARMA INC	<u>EQ 15MG BASE/5ML</u>	<u>A075117</u>	<u>001</u>	Dec 14, 2000
	<u>PEDIAPRED</u>				
<u>AA</u>	+ UCB INC	<u>EQ 5MG BASE/5ML</u>	<u>N019157</u>	<u>001</u>	May 28, 1986
	<u>PREDNISOLONE SODIUM PHOSPHATE</u>				
<u>AA</u>	AMNEAL PHARMS	<u>EQ 15MG BASE/5ML</u>	<u>A078345</u>	<u>001</u>	Mar 10, 2009
<u>AA</u>	HI TECH PHARMA	<u>EQ 5MG BASE/5ML</u>	<u>A075183</u>	<u>001</u>	Mar 26, 2003
<u>AA</u>	KV PHARM	<u>EQ 5MG BASE/5ML</u>	<u>A076982</u>	<u>001</u>	May 24, 2005
<u>AA</u>		<u>EQ 15MG BASE/5ML</u>	<u>A076988</u>	<u>001</u>	May 24, 2005
<u>AA</u>	MORTON GROVE	<u>EQ 5MG BASE/5ML</u>	<u>A075099</u>	<u>001</u>	Jun 28, 2002
<u>AA</u>		<u>EQ 15MG BASE/5ML</u>	<u>A076895</u>	<u>001</u>	Oct 04, 2004
<u>AA</u>	PADDOCK	<u>EQ 5MG BASE/5ML</u>	<u>A075988</u>	<u>001</u>	May 25, 2004
<u>AA</u>	PHARM ASSOC	<u>EQ 5MG BASE/5ML</u>	<u>A076123</u>	<u>001</u>	Dec 23, 2002
<u>AA</u>		<u>EQ 15MG BASE/5ML</u>	<u>A076913</u>	<u>001</u>	Apr 25, 2005
<u>AA</u>	VINTAGE	<u>EQ 5MG BASE/5ML</u>	<u>A078416</u>	<u>001</u>	Oct 31, 2007
<u>AA</u>		<u>EQ 15MG BASE/5ML</u>	<u>A079010</u>	<u>001</u>	May 26, 2009
<u>AA</u>	WE PHARMS	<u>EQ 15MG BASE/5ML</u>	<u>A075250</u>	<u>001</u>	Jul 12, 2002

## PRESCRIPTION DRUG PRODUCT LIST

3 - 321 (of 393)

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

+	PHARM ASSOC	EQ 10MG BASE/5ML	A078465	001	Mar 07, 2008
+		EQ 20MG BASE/5ML	A078988	001	Jun 09, 2008

SOLUTION/DROPS; OPHTHALMIC

+	BAUSCH AND LOMB	EQ 0.9% PHOSPHATE	A040070	001	Jul 29, 1994
---	-----------------	-------------------	---------	-----	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT

	SCIELE PHARMA INC	EQ 10MG BASE	N021959	001	Jun 01, 2006
		EQ 15MG BASE	N021959	002	Jun 01, 2006
+		EQ 30MG BASE	N021959	003	Jun 01, 2006

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

<u>AT</u>	ALCON	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>A073630</u>	<u>001</u>	May 27, 1993
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>A074449</u>	<u>001</u>	Dec 29, 1995
	<u>VASOCIDIN</u>				
<u>AT</u>	+ NOVARTIS	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>N018988</u>	<u>001</u>	Aug 26, 1988

PREDNISONONE

SOLUTION; ORAL

PREDNISONONE

+	ROXANE	5MG/5ML	A088703	001	Nov 08, 1984
	PREDNISONONE INTENSOL				
+	ROXANE	5MG/ML	A088810	001	Feb 20, 1985

TABLET; ORAL

PREDNISONONE

<u>AB</u>	CADISTA PHARMS	<u>1MG</u>	<u>A040611</u>	<u>001</u>	Jun 06, 2005
<u>AB</u>		<u>5MG</u>	<u>A040362</u>	<u>002</u>	Aug 29, 2001
<u>AB</u>		<u>10MG</u>	<u>A040362</u>	<u>001</u>	Aug 29, 2001
<u>AB</u>		<u>20MG</u>	<u>A040362</u>	<u>003</u>	Jun 29, 2005
<u>AB</u>	LEINER	<u>5MG</u>	<u>A080209</u>	<u>001</u>	
<u>AB</u>	MUTUAL PHARM	<u>5MG</u>	<u>A089245</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>		<u>10MG</u>	<u>A089246</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>		<u>20MG</u>	<u>A089247</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>	+ ROXANE	<u>1MG</u>	<u>A087800</u>	<u>001</u>	Apr 22, 1982
<u>AB</u>	+	<u>2.5MG</u>	<u>A087801</u>	<u>001</u>	Apr 22, 1982
<u>AB</u>	+	<u>5MG</u>	<u>A080352</u>	<u>001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>A084122</u>	<u>001</u>	
<u>AB</u>	+	<u>20MG</u>	<u>A087342</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>A084283</u>	<u>001</u>	
<u>AB</u>	VINTAGE PHARMS	<u>1MG</u>	<u>A040584</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>		<u>2.5MG</u>	<u>A040581</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>		<u>5MG</u>	<u>A040256</u>	<u>001</u>	Jul 12, 2002
<u>AB</u>		<u>10MG</u>	<u>A040256</u>	<u>002</u>	Jul 12, 2002
<u>AB</u>		<u>20MG</u>	<u>A040392</u>	<u>001</u>	Feb 12, 2003
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A080356</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A085162</u>	<u>001</u>	
<u>AB</u>		<u>20MG</u>	<u>A085161</u>	<u>001</u>	
<u>AB</u>	WEST WARD	<u>2.5MG</u>	<u>A040538</u>	<u>001</u>	Jan 08, 2004
<u>AB</u>		<u>5MG</u>	<u>A080292</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A088832</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>		<u>20MG</u>	<u>A083677</u>	<u>001</u>	

## PRESCRIPTION DRUG PRODUCT LIST

3 - 322 (of 393)

PREGABALIN

CAPSULE; ORAL

LYRICA

CP PHARMS

25MG

N021446 001

Dec 30, 2004

50MG

N021446 002

Dec 30, 2004

75MG

N021446 003

Dec 30, 2004

100MG

N021446 004

Dec 30, 2004

150MG

N021446 005

Dec 30, 2004

200MG

N021446 006

Dec 30, 2004

225MG

N021446 007

Dec 30, 2004

+

300MG

N021446 008

Dec 30, 2004

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN DENTAL

+ DENTSPLY PHARM

4%

N021382 001

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE

+ SANOFI AVENTIS US

EQ 15MG BASE

N008316 001

PRIMIDONE

TABLET; ORAL

MYSOLINEAB + VALEANT50MGN009170 003AB250MGN009170 002PRIMIDONEAB AMNEAL PHARM50MGA040866 001

Apr 23, 2008

AB250MGA040866 002

Apr 23, 2008

AB DR REDDYS LABS LTD50MGA040862 001

Oct 03, 2008

AB250MGA040862 002

Oct 03, 2008

AB IMPAX LABS50MGA040717 001

Feb 12, 2008

AB250MGA040717 002

Feb 12, 2008

AB LANNETT50MGA084903 002

May 24, 2001

AB250MGA084903 001AB MUTUAL PHARM50MGA040626 001

Sep 29, 2005

AB250MGA040626 002

Sep 29, 2005

AB VINTAGE PHARMS50MGA040586 001

Feb 24, 2005

AB250MGA040586 002

Feb 24, 2005

AB WATSON LABS250MGA083551 001AB50MGA040667 001

Jul 27, 2006

AB250MGA040667 002

Jul 27, 2006

PROBENECID

TABLET; ORAL

PROBALANAB LANNETT500MGA080966 001PROBENECIDAB IVAX SUB TEVA PHARMS500MGA083740 001

May 09, 1984

AB500MGA084211 002AB WATSON LABS500MGA084442 004

Mar 29, 1983

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDEAP + HOSPIRA100MG/MLA089069 001

Feb 12, 1986

AP500MG/MLA089070 001

Feb 12, 1986

AP INTL MEDICATION100MG/MLA088636 001

Jul 31, 1984

## PRESCRIPTION DRUG PRODUCT LIST

3 - 323 (of 393)

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

<u>AP</u>	INTL MEDICATION	<u>500MG/ML</u>	<u>A088637</u>	<u>001</u>	Jul 31, 1984
-----------	-----------------	-----------------	----------------	------------	--------------

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE

+	WATSON LABS	1%	A080658	001	
---	-------------	----	---------	-----	--

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE

+	SIGMA TAU	EQ 50MG BASE	N016785	001	
---	-----------	--------------	---------	-----	--

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPRO

<u>AB</u>	PADDOCK	<u>25MG</u>	<u>A040246</u>	<u>001</u>	Jun 28, 2000
-----------	---------	-------------	----------------	------------	--------------

PROCHLORPERAZINE

<u>AB</u>	+ G AND W LABS	<u>25MG</u>	<u>A040058</u>	<u>001</u>	Nov 24, 1993
-----------	----------------	-------------	----------------	------------	--------------

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

<u>AP</u>	+ BAXTER HLTHCARE	<u>EQ 5MG BASE/ML</u>	<u>A089903</u>	<u>001</u>	Aug 29, 1989
-----------	-------------------	-----------------------	----------------	------------	--------------

<u>AP</u>	BEDFORD	<u>EQ 5MG BASE/ML</u>	<u>A040540</u>	<u>001</u>	May 28, 2004
-----------	---------	-----------------------	----------------	------------	--------------

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

<u>AB</u>	CADISTA PHARMS	<u>EQ 5MG BASE</u>	<u>A040268</u>	<u>001</u>	Feb 27, 1998
-----------	----------------	--------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040268</u>	<u>002</u>	Feb 27, 1998
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	DURAMED PHARMS BARR	<u>EQ 5MG BASE</u>	<u>A040207</u>	<u>001</u>	May 01, 1997
-----------	---------------------	--------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040207</u>	<u>002</u>	May 01, 1997
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A040185</u>	<u>002</u>	Oct 28, 1996
-----------	-------	--------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040185</u>	<u>001</u>	Oct 28, 1996
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A040101</u>	<u>001</u>	Jul 19, 1996
-----------	--------	--------------------	----------------	------------	--------------

<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>A040101</u>	<u>002</u>	Jul 19, 1996
-----------	---	---------------------	----------------	------------	--------------

<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A040120</u>	<u>001</u>	Jul 11, 1996
-----------	-------------	--------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040120</u>	<u>002</u>	Jul 11, 1996
-----------	--	---------------------	----------------	------------	--------------

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

UNIMED PHARMS LLC 100MG

+		200MG	N019781	001	May 14, 1998
---	--	-------	---------	-----	--------------

			N019781	002	Oct 15, 1999
--	--	--	---------	-----	--------------

GEL; VAGINAL

CRINONE

COLUMBIA LABS 4%

+		8%	N020701	001	Jul 31, 1997
---	--	----	---------	-----	--------------

			N020701	002	Jul 31, 1997
--	--	--	---------	-----	--------------

INJECTABLE; INJECTION

PROGESTERONE

<u>AO</u>	APP PHARMS	<u>50MG/ML</u>	<u>A075906</u>	<u>001</u>	Apr 25, 2001
-----------	------------	----------------	----------------	------------	--------------

<u>AO</u>	PHARMAFORCE	<u>50MG/ML</u>	<u>A090845</u>	<u>001</u>	Jun 22, 2009
-----------	-------------	----------------	----------------	------------	--------------

<u>AO</u>	+ WATSON LABS (UTAH)	<u>50MG/ML</u>	<u>N017362</u>	<u>002</u>	
-----------	----------------------	----------------	----------------	------------	--

INSERT; VAGINAL

ENDOMETRIN

+	FERRING	100MG	N022057	001	Jun 21, 2007
---	---------	-------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 324 (of 393)

PROMETHAZINE HYDROCHLORIDE

## INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

<u>AP</u>	BAXTER HLTHCARE	<u>25MG/ML</u>	<u>A083312</u>	<u>001</u>	
<u>AP</u>		<u>50MG/ML</u>	<u>A083312</u>	<u>002</u>	
<u>AP</u>	HIKMA FARMACEUTICA	<u>25MG/ML</u>	<u>A040737</u>	<u>001</u>	Apr 24, 2008
<u>AP</u>		<u>50MG/ML</u>	<u>A040737</u>	<u>002</u>	Apr 24, 2008
<u>AP</u>	HOSPIRA	<u>25MG/ML</u>	<u>A040372</u>	<u>001</u>	Jun 08, 2000
<u>AP</u>	PHARMAFORCE	<u>25MG/ML</u>	<u>A040515</u>	<u>001</u>	Mar 19, 2003
<u>AP</u> +	TEVA PARENTERAL	<u>25MG/ML</u>	<u>A040454</u>	<u>001</u>	Aug 22, 2002
<u>AP</u> +		<u>50MG/ML</u>	<u>A040454</u>	<u>002</u>	Aug 22, 2002
<u>AP</u>	WOCKHARDT	<u>25MG/ML</u>	<u>A040785</u>	<u>001</u>	Sep 26, 2008
<u>AP</u>		<u>50MG/ML</u>	<u>A040785</u>	<u>002</u>	Sep 26, 2008

## SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>	G AND W LABS	<u>12.5MG</u>	<u>A040428</u>	<u>002</u>	Mar 31, 2003
<u>AB</u> +		<u>25MG</u>	<u>A040428</u>	<u>001</u>	Feb 05, 2002
<u>AB</u>	PADDOCK	<u>12.5MG</u>	<u>A040479</u>	<u>001</u>	Jun 24, 2003
<u>AB</u>		<u>25MG</u>	<u>A040479</u>	<u>002</u>	Jun 24, 2003
<u>AB</u>	PERRIGO NEW YORK	<u>12.5MG</u>	<u>A040500</u>	<u>001</u>	Jun 30, 2003
<u>AB</u>		<u>25MG</u>	<u>A040500</u>	<u>002</u>	Jun 30, 2003
<u>AB</u>	TARO	<u>12.5MG</u>	<u>A040603</u>	<u>001</u>	Oct 26, 2006
<u>AB</u>		<u>25MG</u>	<u>A040603</u>	<u>002</u>	Oct 26, 2006
	PROMETHEGAN				
+	G AND W LABS	50MG	A087165	001	Aug 14, 1987

## SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>6.25MG/5ML</u>	<u>A040882</u>	<u>001</u>	Dec 30, 2009
<u>AA</u>	HI TECH PHARMA	<u>6.25MG/5ML</u>	<u>A040026</u>	<u>001</u>	Sep 25, 1998
<u>AA</u>	SUN PHARM INDS INC	<u>6.25MG/5ML</u>	<u>A040891</u>	<u>001</u>	Mar 13, 2009
<u>AA</u>	TARO	<u>6.25MG/5ML</u>	<u>A040718</u>	<u>001</u>	Apr 04, 2007
<u>AA</u>	VINTAGE	<u>6.25MG/5ML</u>	<u>A040643</u>	<u>001</u>	Apr 26, 2006
	<u>PROMETHAZINE PLAIN</u>				
<u>AA</u> +	MORTON GROVE	<u>6.25MG/5ML</u>	<u>A087953</u>	<u>001</u>	Nov 15, 1982

## TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>12.5MG</u>	<u>A040673</u>	<u>001</u>	Mar 05, 2008
<u>AB</u>		<u>25MG</u>	<u>A040673</u>	<u>002</u>	Mar 05, 2008
<u>AB</u>		<u>50MG</u>	<u>A040673</u>	<u>003</u>	Mar 05, 2008
<u>AB</u>	IMPAX LABS	<u>12.5MG</u>	<u>A040724</u>	<u>001</u>	Feb 12, 2008
<u>AB</u>		<u>25MG</u>	<u>A040724</u>	<u>002</u>	Feb 12, 2008
<u>AB</u>		<u>50MG</u>	<u>A040791</u>	<u>001</u>	May 20, 2008
<u>AB</u>	KVK TECH	<u>12.5MG</u>	<u>A040712</u>	<u>002</u>	May 04, 2007
<u>AB</u>		<u>25MG</u>	<u>A040712</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A040713</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A084234</u>	<u>001</u>	
<u>AB</u> +		<u>50MG</u>	<u>A084176</u>	<u>001</u>	
<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A040863</u>	<u>001</u>	Dec 30, 2008
<u>AB</u>		<u>25MG</u>	<u>A040863</u>	<u>002</u>	Dec 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A040863</u>	<u>003</u>	Dec 30, 2008
<u>AB</u>	VINTAGE PHARMS	<u>12.5MG</u>	<u>A040622</u>	<u>001</u>	Jul 18, 2006
<u>AB</u>		<u>25MG</u>	<u>A040622</u>	<u>002</u>	Jul 18, 2006
<u>AB</u>		<u>50MG</u>	<u>A040622</u>	<u>003</u>	Jul 18, 2006
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A083426</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A083711</u>	<u>001</u>	
<u>AB</u>	ZYDUS PHARMS USA	<u>12.5MG</u>	<u>A040596</u>	<u>001</u>	Nov 18, 2005
<u>AB</u>		<u>25MG</u>	<u>A040596</u>	<u>002</u>	Nov 18, 2005
<u>AB</u>		<u>50MG</u>	<u>A040596</u>	<u>003</u>	Nov 18, 2005

## PRESCRIPTION DRUG PRODUCT LIST

3 - 325 (of 393)

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

RYTHMOL SR

SMITHKLINE BEECHAM 225MG

N021416 001 Sep 04, 2003

325MG

N021416 002 Sep 04, 2003

+ 425MG

N021416 003 Sep 04, 2003

TABLET; ORAL

PROPAFENONE HYDROCHLORIDEAB KV PHARM 150MGA076193 001 Feb 07, 2002AB 225MGA076193 002 Feb 07, 2002AB 300MGA076193 003 Feb 07, 2002AB MUTUAL PHARM 150MGA075998 001 Nov 29, 2001AB 225MGA075998 002 Nov 29, 2001AB 300MGA075998 003 Nov 29, 2001AB PLIVA 150MGA076550 001 Apr 23, 2004AB 225MGA076550 002 Apr 23, 2004AB 300MGA076550 003 Apr 23, 2004AB VINTAGE PHARMS 150MGA075938 001 Oct 17, 2002AB 225MGA075938 002 Oct 17, 2002AB 300MGA075938 003 Oct 17, 2002AB WATSON LABS 150MGA075203 001 Oct 24, 2000AB 225MGA075203 002 Oct 24, 2000RYTHMOLAB SMITHKLINE BEECHAM 150MGN019151 001 Nov 27, 1989AB 225MGN019151 003 Nov 20, 1992AB + 300MGN019151 002 Nov 27, 1989PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALCAINEAT ALCON 0.5%A080027 001OPHTHAINEAT + APOTHECON 0.5%N008883 001OPHTHETICAT + ALLERGAN 0.5%N012583 001PROPARACAINE HYDROCHLORIDEAT BAUSCH AND LOMB 0.5%A040074 001 Sep 29, 1995AT TAYLOR PHARMA 0.5%A040277 001 Mar 16, 2000PROPOFOL

INJECTABLE; INJECTION

DIPRIVANAB + APP PHARMS 10MG/MLN019627 002 Jun 11, 1996PROPOFOLAB HOSPIRA 10MG/MLA077908 001 Mar 17, 2006AB TEVA PARENTERAL 10MG/MLA075102 001 Jan 04, 1999AB 10MG/MLA075392 001 Sep 19, 2000PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVONAA + XANODYNE PHARM 65MGN010997 003DOLENEAA HERITAGE PHARMS INC 65MGA080530 001PROPOXYPHENE HYDROCHLORIDEAA MYLAN 65MGA040569 001 Dec 16, 2004AA PAR PHARM 65MGA080269 001AA TEVA 65MGA088615 001 Oct 22, 1984AA VINTAGE PHARMS 65MGA040908 001 Jul 17, 2009AA WEST WARD 65MGA083501 001**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 352 of 1114**



## PRESCRIPTION DRUG PRODUCT LIST

3 - 326 (of 393)

PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVON-N

+ XANODYNE PHARM 100MG N016862 002

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

<u>AB</u>	AKRIMAX PHARMS	<u>60MG</u>	<u>N018553</u>	<u>004</u>	Mar 18, 1987
<u>AB</u>		<u>80MG</u>	<u>N018553</u>	<u>002</u>	Apr 19, 1983
<u>AB</u>		<u>120MG</u>	<u>N018553</u>	<u>003</u>	Apr 19, 1983
<u>AB</u>	+	<u>160MG</u>	<u>N018553</u>	<u>001</u>	Apr 19, 1983

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>60MG</u>	<u>A078494</u>	<u>001</u>	Aug 10, 2007
<u>AB</u>		<u>80MG</u>	<u>A078494</u>	<u>002</u>	Aug 10, 2007
<u>AB</u>		<u>120MG</u>	<u>A078494</u>	<u>003</u>	Aug 10, 2007
<u>AB</u>		<u>160MG</u>	<u>A078494</u>	<u>004</u>	Aug 10, 2007
<u>AB</u>	MYLAN	<u>60MG</u>	<u>A078022</u>	<u>001</u>	Feb 15, 2007
<u>AB</u>		<u>80MG</u>	<u>A078022</u>	<u>002</u>	Feb 15, 2007
<u>AB</u>		<u>120MG</u>	<u>A078022</u>	<u>003</u>	Feb 15, 2007
<u>AB</u>		<u>160MG</u>	<u>A078022</u>	<u>004</u>	Feb 15, 2007
<u>AB</u>	PAR PHARM	<u>60MG</u>	<u>A078065</u>	<u>001</u>	Jan 26, 2007
<u>AB</u>		<u>80MG</u>	<u>A078065</u>	<u>002</u>	Jan 26, 2007
<u>AB</u>		<u>120MG</u>	<u>A078065</u>	<u>003</u>	Jan 26, 2007
<u>AB</u>		<u>160MG</u>	<u>A078065</u>	<u>004</u>	Jan 26, 2007
<u>AB</u>	UPSHER SMITH	<u>60MG</u>	<u>A078311</u>	<u>001</u>	Mar 06, 2009
<u>AB</u>		<u>80MG</u>	<u>A078311</u>	<u>002</u>	Mar 06, 2009
<u>AB</u>		<u>120MG</u>	<u>A078311</u>	<u>003</u>	Mar 06, 2009
<u>AB</u>		<u>160MG</u>	<u>A078311</u>	<u>004</u>	Mar 06, 2009
	INNOPRAN XL				
BX	SMITHKLINE BEECHAM	80MG	N021438	001	Mar 12, 2003
BX		120MG	N021438	002	Mar 12, 2003

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

<u>AP</u>	APP PHARMS	<u>1MG/ML</u>	<u>A075826</u>	<u>001</u>	Aug 31, 2001
<u>AP</u>	+	<u>1MG/ML</u>	<u>N016419</u>	<u>001</u>	
<u>AP</u>	BEDFORD	<u>1MG/ML</u>	<u>A075792</u>	<u>001</u>	Aug 29, 2000
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077760</u>	<u>001</u>	Jan 31, 2008
<u>AP</u>	SANDOZ	<u>1MG/ML</u>	<u>A076400</u>	<u>001</u>	Feb 26, 2003

SOLUTION; ORAL

PROPRANOLOL HYDROCHLORIDE

	+	ROXANE	20MG/5ML	A070979	001	May 15, 1987
	+		40MG/5ML	A070690	001	May 15, 1987

TABLET; ORAL

INDERAL

<u>AB</u>	AKRIMAX PHARMS	<u>40MG</u>	<u>N016418</u>	<u>002</u>	
<u>AB</u>		<u>60MG</u>	<u>N016418</u>	<u>009</u>	Oct 18, 1982
<u>AB</u>	+	<u>80MG</u>	<u>N016418</u>	<u>004</u>	

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>	IPCA LABS LTD	<u>10MG</u>	<u>A078955</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>		<u>20MG</u>	<u>A078955</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>		<u>40MG</u>	<u>A078955</u>	<u>003</u>	Jun 02, 2008
<u>AB</u>		<u>60MG</u>	<u>A078955</u>	<u>004</u>	Jun 02, 2008
<u>AB</u>		<u>80MG</u>	<u>A078955</u>	<u>005</u>	Jun 02, 2008
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A070213</u>	<u>002</u>	Nov 19, 1985
<u>AB</u>		<u>20MG</u>	<u>A070213</u>	<u>003</u>	Nov 19, 1985
<u>AB</u>		<u>40MG</u>	<u>A070213</u>	<u>001</u>	Nov 19, 1985
<u>AB</u>		<u>80MG</u>	<u>A070213</u>	<u>004</u>	Nov 19, 1985
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078213</u>	<u>001</u>	Jan 10, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 327 (of 393)

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>	NORTHSTAR HLTHCARE	<u>20MG</u>	<u>A078213</u>	<u>002</u>	Jan 10, 2008
<u>AB</u>		<u>40MG</u>	<u>A078213</u>	<u>003</u>	Jan 10, 2008
<u>AB</u>		<u>60MG</u>	<u>A078213</u>	<u>004</u>	Jan 10, 2008
<u>AB</u>		<u>80MG</u>	<u>A078213</u>	<u>005</u>	Jan 10, 2008
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A071972</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>		<u>20MG</u>	<u>A071973</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>		<u>40MG</u>	<u>A071974</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>		<u>60MG</u>	<u>A071975</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>	+	<u>80MG</u>	<u>A071976</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A070175</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>20MG</u>	<u>A070176</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>40MG</u>	<u>A070177</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>80MG</u>	<u>A070178</u>	<u>001</u>	May 13, 1986

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

BD	ACTAVIS ELIZABETH	50MG	A080172	001	
BD	+	DAVA PHARMS INC	N006188	001	
BD	WEST WARD	50MG	A080154	001	

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

+	APP PHARMS	10MG/ML	A089454	001	Apr 07, 1987
---	------------	---------	---------	-----	--------------

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

<u>AB</u>	ROXANE	<u>5MG</u>	<u>A078913</u>	<u>001</u>	Sep 16, 2008
<u>AB</u>		<u>10MG</u>	<u>A078913</u>	<u>002</u>	Sep 16, 2008
	<u>VIVACTIL</u>				
<u>AB</u>	ODYSSEY PHARMS	<u>5MG</u>	<u>A073644</u>	<u>001</u>	Aug 24, 1995
<u>AB</u>	+	<u>10MG</u>	<u>A073645</u>	<u>001</u>	Aug 24, 1995

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

<u>AB</u>	+	DAVA PHARMS INC	<u>500MG</u>	<u>A080157</u>	<u>001</u>
<u>AB</u>		MIKART	<u>500MG</u>	<u>A081319</u>	<u>001</u>

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

<u>AP</u>	+	VALEANT PHARM INTL	<u>5MG/ML</u>	<u>N009830</u>	<u>001</u>
		<u>REGONOL</u>			
<u>AP</u>		SANDOZ	<u>5MG/ML</u>	<u>N017398</u>	<u>001</u>

SYRUP; ORAL

MESTINON

+	VALEANT PHARM INTL	60MG/5ML	N015193	001	
---	--------------------	----------	---------	-----	--

TABLET; ORAL

MESTINON

<u>AB</u>	+	VALEANT PHARM INTL	<u>60MG</u>	<u>N009829</u>	<u>002</u>
-----------	---	--------------------	-------------	----------------	------------

PYRIDOSTIGMINE BROMIDE

<u>AB</u>	COREPHARMA	<u>60MG</u>	<u>A040457</u>	<u>001</u>	Dec 26, 2002
<u>AB</u>	IMPAX LABS	<u>60MG</u>	<u>A040502</u>	<u>001</u>	Apr 24, 2003

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 354 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 328 (of 393)

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE; ORAL  
 MESTINON  
 + VALEANT PHARM INTL 180MG N011665 001

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION  
 PYRIDOXINE HYDROCHLORIDE  
 + APP PHARMS 100MG/ML A080618 001

PYRIMETHAMINE

TABLET; ORAL  
 DARAPRIM  
 + GLAXOSMITHKLINE 25MG N008578 001

QUAZEPAM

TABLET; ORAL  
 DORAL  
 + QUESTCOR PHARMS 15MG N018708 001 Dec 27, 1985

QUETIAPINE FUMARATE

TABLET; ORAL  
 SEROQUEL  
 + ASTRAZENECA EQ 25MG BASE N020639 001 Sep 26, 1997  
 EQ 50MG BASE N020639 007 Oct 04, 2005  
 EQ 100MG BASE N020639 002 Sep 26, 1997  
 EQ 200MG BASE N020639 003 Sep 26, 1997  
 + EQ 300MG BASE N020639 005 Jul 26, 2000  
 EQ 400MG BASE N020639 006 Oct 04, 2005

TABLET, EXTENDED RELEASE; ORAL  
 SEROQUEL XR  
 ASTRAZENECA EQ 50MG BASE N022047 001 May 17, 2007  
 EQ 150MG BASE N022047 005 Aug 11, 2008  
 + EQ 200MG BASE N022047 002 May 17, 2007  
 EQ 300MG BASE N022047 003 May 17, 2007  
 EQ 400MG BASE N022047 004 May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL  
ACCUPRIL  
AB PFIZER PHARMS EQ 5MG BASE N019885 001 Nov 19, 1991  
AB EQ 10MG BASE N019885 002 Nov 19, 1991  
AB EQ 20MG BASE N019885 003 Nov 19, 1991  
AB + EQ 40MG BASE N019885 004 Nov 19, 1991

QUINAPRIL HYDROCHLORIDE  
AB ACTAVIS TOTOWA EQ 5MG BASE A076459 001 Dec 22, 2004  
AB EQ 10MG BASE A076459 002 Dec 22, 2004  
AB EQ 20MG BASE A076459 003 Dec 22, 2004  
AB EQ 40MG BASE A076459 004 Dec 22, 2004  
AB APOTEX EQ 5MG BASE A076240 001 Jan 26, 2006  
AB EQ 10MG BASE A076240 002 Jan 26, 2006  
AB EQ 20MG BASE A076240 003 Jan 26, 2006  
AB EQ 40MG BASE A076240 004 Jan 26, 2006  
AB GENPHARM EQ 5MG BASE A076036 001 Jan 28, 2005  
AB EQ 10MG BASE A076036 002 Jan 28, 2005  
AB EQ 20MG BASE A076036 003 Jan 28, 2005  
AB EQ 40MG BASE A076036 004 Jan 28, 2005  
AB INVAGEN PHARMS EQ 5MG BASE A078457 001 Aug 24, 2007  
AB EQ 10MG BASE A078457 002 Aug 24, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 329 (of 393)

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

<u>AB</u>	INVAGEN PHARMS	<u>EQ 20MG BASE</u>	<u>A078457</u>	<u>003</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078457</u>	<u>004</u>	Aug 24, 2007
<u>AB</u>	LUPIN	<u>EQ 5MG BASE</u>	<u>A077690</u>	<u>001</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077690</u>	<u>002</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077690</u>	<u>003</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077690</u>	<u>004</u>	Jun 20, 2006
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076694</u>	<u>001</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076694</u>	<u>002</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076694</u>	<u>003</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076694</u>	<u>004</u>	Dec 23, 2004
<u>AB</u>	RANBAXY	<u>EQ 5MG BASE</u>	<u>A076607</u>	<u>001</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076607</u>	<u>002</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076607</u>	<u>003</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076607</u>	<u>004</u>	Dec 15, 2004
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A076803</u>	<u>001</u>	Mar 02, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076803</u>	<u>002</u>	Mar 02, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076803</u>	<u>003</u>	Mar 02, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076803</u>	<u>004</u>	Mar 02, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 5MG BASE</u>	<u>A090800</u>	<u>001</u>	Jun 18, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090800</u>	<u>002</u>	Jun 18, 2009
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090800</u>	<u>003</u>	Jun 18, 2009
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090800</u>	<u>004</u>	Jun 18, 2009
<u>AB</u>	TEVA	<u>EQ 5MG BASE</u>	<u>A075504</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075504</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075504</u>	<u>003</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075504</u>	<u>004</u>	Aug 24, 2007
<u>AB</u>	WATSON LABS FLORIDA	<u>EQ 5MG BASE</u>	<u>A076049</u>	<u>001</u>	Jan 14, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076049</u>	<u>002</u>	Jan 14, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076049</u>	<u>003</u>	Jan 14, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076049</u>	<u>004</u>	Jan 14, 2005

QUINIDINE GLUCONATEINJECTABLE; INJECTION  
QUINIDINE GLUCONATE

+ LILLY 80MG/ML N007529 002 Feb 10, 1989

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

BX + MUTUAL PHARM 324MG A089338 001 Feb 11, 1987

BX WATSON LABS 324MG A087810 001 Sep 29, 1982

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATEAB MUTUAL PHARM 200MG A081030 001 Apr 14, 1989AB 300MG A081031 001 Apr 14, 1989AB SANDOZ 200MG A088072 002AB 300MG A088072 001 Sep 26, 1983AB + WATSON LABS 200MG A083288 001AB + 300MG A085583 001

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE SULFATE

+ TEVA PHARMS 300MG A040045 001 Jun 30, 1994

## PRESCRIPTION DRUG PRODUCT LIST

3 - 330 (of 393)

QUININE SULFATE

CAPSULE; ORAL  
 QUALAQUIN  
 + AR HOLDING CO INC 324MG N021799 001 Aug 12, 2005

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL  
 ACIPHEX  
 + EISAI INC 20MG N020973 002 Aug 19, 1999

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL  
 EVISTA  
 + LILLY 60MG N020815 001 Dec 09, 1997

RALTEGRAVIR POTASSIUM

TABLET; ORAL  
 ISENTRESS  
 + MERCK SHARP DOHME EQ 400MG BASE N022145 001 Oct 12, 2007

RAMELTEON

TABLET; ORAL  
 ROZEREM  
 + TAKEDA GLOBAL 8MG N021782 001 Jul 22, 2005

RAMIPRIL

CAPSULE; ORAL  
ALTACE  
AB KING PHARMS 1.25MG N019901 001 Jan 28, 1991  
AB 2.5MG N019901 002 Jan 28, 1991  
AB 5MG N019901 003 Jan 28, 1991  
AB + 10MG N019901 004 Jan 28, 1991  
RAMIPRIL  
AB ACTAVIS ELIZABETH 1.25MG A077513 001 Jun 18, 2008  
AB 2.5MG A077513 002 Jun 18, 2008  
AB 5MG A077513 003 Jun 18, 2008  
AB 10MG A077513 004 Jun 18, 2008  
AB APOTEX 1.25MG A079116 001 Jun 20, 2008  
AB 2.5MG A079116 002 Jun 20, 2008  
AB 5MG A079116 003 Jun 20, 2008  
AB 10MG A079116 004 Jun 20, 2008  
AB CIPLA 1.25MG A077004 001 Aug 07, 2008  
AB 2.5MG A077004 002 Aug 07, 2008  
AB 5MG A077004 003 Aug 07, 2008  
AB 10MG A077004 004 Aug 07, 2008  
AB COBALT LABS INC 1.25MG A076549 001 Oct 24, 2005  
AB 2.5MG A076549 002 Oct 24, 2005  
AB 5MG A076549 003 Oct 24, 2005  
AB 10MG A076549 004 Oct 24, 2005  
AB DR REDDYS LABS LTD 1.25MG A078191 001 Jun 18, 2008  
AB 2.5MG A078191 002 Jun 18, 2008  
AB 5MG A078191 003 Jun 18, 2008  
AB 10MG A078191 004 Jun 18, 2008  
AB INVAGEN PHARMS 1.25MG A078745 001 Jun 18, 2008  
AB 2.5MG A078745 002 Jun 18, 2008  
AB 5MG A078745 003 Jun 18, 2008  
AB 10MG A078745 004 Jun 18, 2008  
AB LUPIN 1.25MG A077626 001 Jun 09, 2008  
AB 2.5MG A077626 002 Jun 09, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 331 (of 393)

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

<u>AB</u>	LUPIN	<u>5MG</u>	<u>A077626</u>	<u>003</u>	Jun 09, 2008
<u>AB</u>		<u>10MG</u>	<u>A077626</u>	<u>004</u>	Jun 09, 2008
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A078849</u>	<u>001</u>	Mar 06, 2009
<u>AB</u>		<u>10MG</u>	<u>A078849</u>	<u>002</u>	Mar 06, 2009
<u>AB</u>	ROXANE	<u>1.25MG</u>	<u>A077900</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077900</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077900</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077900</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	SANDOZ	<u>1.25MG</u>	<u>A077514</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077514</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077514</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077514</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	TEVA PHARMS	<u>1.25MG</u>	<u>A077470</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077470</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077470</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077470</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	ZYDUS PHARMS USA	<u>1.25MG</u>	<u>A078832</u>	<u>001</u>	Sep 02, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A078832</u>	<u>002</u>	Sep 02, 2008
<u>AB</u>		<u>5MG</u>	<u>A078832</u>	<u>003</u>	Sep 02, 2008
<u>AB</u>		<u>10MG</u>	<u>A078832</u>	<u>004</u>	Sep 02, 2008

TABLET; ORAL

ALTACE

<u>AB</u>	KING PHARMS	<u>1.25MG</u>	<u>N022021</u>	<u>001</u>	Feb 27, 2007
<u>AB</u>		<u>2.5MG</u>	<u>N022021</u>	<u>002</u>	Feb 27, 2007
<u>AB</u>		<u>5MG</u>	<u>N022021</u>	<u>003</u>	Feb 27, 2007
<u>AB</u>	+	<u>10MG</u>	<u>N022021</u>	<u>004</u>	Feb 27, 2007

RAMIPRIL

<u>AB</u>	ZYDUS PHARMS USA INC	<u>1.25MG</u>	<u>A090697</u>	<u>001</u>	Sep 24, 2009
<u>AB</u>		<u>2.5MG</u>	<u>A090697</u>	<u>002</u>	Sep 24, 2009
<u>AB</u>		<u>5MG</u>	<u>A090697</u>	<u>003</u>	Sep 24, 2009
<u>AB</u>		<u>10MG</u>	<u>A090697</u>	<u>004</u>	Sep 24, 2009

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A075742</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075742</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074655</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>A074655</u>	<u>002</u>	Oct 22, 1997

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 25MG BASE/ML</u>	<u>A077458</u>	<u>001</u>	Feb 16, 2006	
<u>AP</u>	BEN VENUE	<u>EQ 25MG BASE/ML</u>	<u>A074777</u>	<u>001</u>	Mar 02, 2005	
<u>AP</u>	<u>ZANTAC</u>					
<u>AP</u>	+	<u>GLAXOSMITHKLINE</u>	<u>EQ 25MG BASE/ML</u>	<u>N019090</u>	<u>001</u>	Oct 19, 1984
		ZANTAC IN PLASTIC CONTAINER				
	+	GLAXOSMITHKLINE	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

<u>AA</u>	ALPHARMA US PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A076124</u>	<u>001</u>	Feb 21, 2007
<u>AA</u>	AMNEAL PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078312</u>	<u>001</u>	Sep 02, 2008
<u>AA</u>	APOTEX	<u>EQ 15MG BASE/ML</u>	<u>A077602</u>	<u>001</u>	Sep 17, 2007
<u>AA</u>	CYPRESS PHARM	<u>EQ 15MG BASE/ML</u>	<u>A078684</u>	<u>001</u>	Aug 27, 2009
<u>AA</u>	DR REDDYS LABS LTD	<u>EQ 15MG BASE/ML</u>	<u>A090102</u>	<u>001</u>	May 26, 2009
<u>AA</u>	PHARM ASSOC	<u>EQ 15MG BASE/ML</u>	<u>A077405</u>	<u>001</u>	Sep 21, 2007
<u>AA</u>	RANBAXY	<u>EQ 15MG BASE/ML</u>	<u>A078448</u>	<u>001</u>	Dec 13, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 332 (of 393)

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

<u>AA</u>	WOCKHARDT	<u>EQ 15MG BASE/ML</u>	<u>A079211</u>	<u>001</u>	May 26, 2009
<u>AA</u>		<u>EQ 15MG BASE/ML</u>	<u>A079212</u>	<u>001</u>	Feb 23, 2009
	<u>ZANTAC</u>				
<u>AA</u>	+ GLAXOSMITHKLINE	<u>EQ 15MG BASE/ML</u>	<u>N019675</u>	<u>001</u>	Dec 30, 1988

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 150MG BASE</u>	<u>A077824</u>	<u>001</u>	Oct 13, 2006
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077824</u>	<u>002</u>	Oct 13, 2006
<u>AB</u>	APOTEX	<u>EQ 150MG BASE</u>	<u>A074680</u>	<u>001</u>	Sep 12, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074680</u>	<u>002</u>	Sep 12, 1997
<u>AB</u>	COBALT	<u>EQ 150MG BASE</u>	<u>A077426</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077426</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 150MG BASE</u>	<u>A076705</u>	<u>001</u>	Jul 27, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A076705</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>	GENPHARM	<u>EQ 150MG BASE</u>	<u>A074023</u>	<u>001</u>	Aug 22, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074023</u>	<u>002</u>	Aug 22, 1997
<u>AB</u>	GLENMARK GENERICS	<u>EQ 150MG BASE</u>	<u>A078542</u>	<u>001</u>	Nov 19, 2008
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078542</u>	<u>002</u>	Nov 19, 2008
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 150MG BASE</u>	<u>A075165</u>	<u>001</u>	Sep 30, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075165</u>	<u>002</u>	Sep 30, 1998
<u>AB</u>	PAR PHARM	<u>EQ 150MG BASE</u>	<u>A075180</u>	<u>001</u>	Jan 28, 1999
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075180</u>	<u>002</u>	Jan 28, 1999
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074467</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074467</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A074488</u>	<u>001</u>	Jul 31, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074488</u>	<u>002</u>	Jul 31, 1997
<u>AB</u>	WATSON LABS	<u>EQ 150MG BASE</u>	<u>A074864</u>	<u>001</u>	Oct 20, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074864</u>	<u>002</u>	Oct 20, 1997
<u>AB</u>	WOCKHARDT	<u>EQ 150MG BASE</u>	<u>A075208</u>	<u>001</u>	Dec 17, 1998
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078701</u>	<u>001</u>	Nov 12, 2009
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075208</u>	<u>002</u>	Dec 17, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078701</u>	<u>002</u>	Dec 11, 2009
	<u>ZANTAC 150</u>				
<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 150MG BASE</u>	<u>N018703</u>	<u>001</u>	Jun 09, 1983
	<u>ZANTAC 300</u>				
<u>AB</u>	+ GLAXOSMITHKLINE	<u>EQ 300MG BASE</u>	<u>N018703</u>	<u>002</u>	Dec 09, 1985

TABLET, EFFERVESCENT; ORAL

ZANTAC 25

	+ GLAXOSMITHKLINE	EQ 25MG BASE	N020251	003	Apr 01, 2004
--	-------------------	--------------	---------	-----	--------------

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

	GILEAD	500MG	N021526	002	Jan 27, 2006
	+	1GM	N021526	001	Feb 12, 2007

RASAGILINE MESYLATE

TABLET; ORAL

AZILECT

	TEVA	EQ 0.5MG BASE	N021641	001	May 16, 2006
	+	EQ 1MG BASE	N021641	002	May 16, 2006

REGADENOSON

SOLUTION; INTRAVENOUS

LEXISCAN

	+ ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161	001	Apr 10, 2008
--	------------	-----------------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 333 (of 393)

REMIFENTANIL HYDROCHLORIDEINJECTABLE; INJECTION  
ULTIVA

BIONICHE TEORANTA	EQ 1MG BASE/VIAL	N020630	001	Jul 12, 1996
	EQ 2MG BASE/VIAL	N020630	002	Jul 12, 1996
+	EQ 5MG BASE/VIAL	N020630	003	Jul 12, 1996

REPAGLINIDETABLET; ORAL  
PRANDIN

NOVO NORDISK INC	0.5MG	N020741	001	Dec 22, 1997
	1MG	N020741	002	Dec 22, 1997
+	2MG	N020741	003	Dec 22, 1997

RESERPINETABLET; ORAL  
RESERPINE

BP SANDOZ	0.1MG	N009838	001	
BP +	0.25MG	N009838	002	
SERPALAN				
BP LANNETT	0.1MG	N010124	001	
BP	0.25MG	N010124	002	

RETAPAMULINOINTMENT; TOPICAL  
ALTABAX

+	GLAXO GRP LTD	1%	N022055	001	Apr 12, 2007
---	---------------	----	---------	-----	--------------

RIBAVIRIN

CAPSULE; ORAL

REBETOL

<u>AB</u> +	SCHERING PLOUGH RES	<u>200MG</u>	<u>N020903</u>	<u>002</u>	Jul 25, 2001
-------------	---------------------	--------------	----------------	------------	--------------

RIBASPHERE

<u>AB</u>	THREE RIVERS PHARMS	<u>200MG</u>	<u>A076203</u>	<u>001</u>	Apr 06, 2004
-----------	---------------------	--------------	----------------	------------	--------------

RIBAVARIN

<u>AB</u>	AUROBINDO PHARMA	<u>200MG</u>	<u>A079117</u>	<u>001</u>	Sep 17, 2009
-----------	------------------	--------------	----------------	------------	--------------

RIBAVIRIN

<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A076192</u>	<u>001</u>	Apr 06, 2004
-----------	--------	--------------	----------------	------------	--------------

<u>AB</u>	TEVA	<u>200MG</u>	<u>A076277</u>	<u>001</u>	Oct 04, 2004
-----------	------	--------------	----------------	------------	--------------

<u>AB</u>	ZYDUS PHARMS USA	<u>200MG</u>	<u>A077224</u>	<u>001</u>	Oct 28, 2005
-----------	------------------	--------------	----------------	------------	--------------

## REBETOL

+	SCHERING PLOUGH RES	200MG	N020903	001	Jun 03, 1998
---	---------------------	-------	---------	-----	--------------

FOR SOLUTION; INHALATION  
VIRAZOLE

+	VALEANT PHARM INTL	6GM/VIAL	N018859	001	Dec 31, 1985
---	--------------------	----------	---------	-----	--------------

SOLUTION; ORAL

## REBETOL

+	SCHERING	40MG/ML	N021546	001	Jul 29, 2003
---	----------	---------	---------	-----	--------------

TABLET; ORAL

COPEGUS

<u>AB</u>	ROCHE	<u>200MG</u>	<u>N021511</u>	<u>001</u>	Dec 03, 2002
-----------	-------	--------------	----------------	------------	--------------

RIBAVIRIN

<u>AB</u>	AUROBINDO PHARMA	<u>200MG</u>	<u>A079111</u>	<u>001</u>	Sep 17, 2009
-----------	------------------	--------------	----------------	------------	--------------

<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A077743</u>	<u>001</u>	Oct 03, 2006
-----------	--------	--------------	----------------	------------	--------------

<u>AB</u>	TEVA	<u>200MG</u>	<u>A077053</u>	<u>001</u>	Dec 05, 2005
-----------	------	--------------	----------------	------------	--------------

<u>AB</u>	THREE RIVERS PHARMS	<u>200MG</u>	<u>A077456</u>	<u>001</u>	Dec 05, 2005
-----------	---------------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>400MG</u>	<u>A077456</u>	<u>002</u>	Dec 05, 2005
-----------	--	--------------	----------------	------------	--------------

<u>AB</u> +		<u>600MG</u>	<u>A077456</u>	<u>003</u>	Dec 05, 2005
-------------	--	--------------	----------------	------------	--------------

<u>AB</u>	ZYDUS PHARMS USA	<u>200MG</u>	<u>A077094</u>	<u>001</u>	Dec 05, 2005
-----------	------------------	--------------	----------------	------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

3 - 334 (of 393)

RIBAVIRIN

TABLET; ORAL

RIBAVIRIN

<u>AB</u>	ZYDUS PHARMS USA	<u>400MG</u>	<u>A077094</u>	<u>002</u>	Mar 16, 2007
<u>AB</u>		<u>600MG</u>	<u>A077094</u>	<u>003</u>	Mar 16, 2007
	RIBAVIRIN				
	ZYDUS PHARMS USA	500MG	A077094	004	Apr 18, 2008

RIFABUTIN

CAPSULE; ORAL

## MYCOBUTIN

	+ PHARMACIA AND UPJOHN	150MG	N050689	001	Dec 23, 1992
--	------------------------	-------	---------	-----	--------------

RIFAMPIN

CAPSULE; ORAL

RIFADIN

<u>AB</u>	SANOFI AVENTIS US	<u>150MG</u>	<u>A062303</u>	<u>001</u>	
<u>AB</u>	+	<u>300MG</u>	<u>N050420</u>	<u>001</u>	
	<u>RIFAMPIN</u>				
<u>AB</u>	LANNETT	<u>150MG</u>	<u>A065390</u>	<u>001</u>	Mar 28, 2008
<u>AB</u>		<u>300MG</u>	<u>A065390</u>	<u>002</u>	Mar 28, 2008
<u>AB</u>	SANDOZ	<u>150MG</u>	<u>A064150</u>	<u>002</u>	Jan 02, 1998
<u>AB</u>		<u>300MG</u>	<u>A064150</u>	<u>001</u>	May 28, 1997
<u>AB</u>	VERSAPHARM	<u>150MG</u>	<u>A065028</u>	<u>001</u>	Mar 14, 2001
<u>AB</u>		<u>300MG</u>	<u>A065028</u>	<u>002</u>	Mar 14, 2001
	<u>RIMACTANE</u>				
<u>AB</u>	ACTAVIS TOTOWA	<u>300MG</u>	<u>N050429</u>	<u>001</u>	

INJECTABLE; INJECTION

RIFADIN

<u>AP</u>	+	SANOFI AVENTIS US	<u>600MG/VIAL</u>	<u>N050627</u>	<u>001</u>	May 25, 1989
		<u>RIFAMPIN</u>				
<u>AP</u>		AKORN STRIDES	<u>600MG/VIAL</u>	<u>A065421</u>	<u>001</u>	May 22, 2008
<u>AP</u>		BEDFORD	<u>600MG/VIAL</u>	<u>A064217</u>	<u>001</u>	Oct 29, 1999

RIFAPENTINE

TABLET; ORAL

## PRIFTIN

	+ SANOFI AVENTIS US	150MG	N021024	001	Jun 22, 1998
--	---------------------	-------	---------	-----	--------------

RIFAXIMIN

TABLET; ORAL

## XIFAXAN

	+ SALIX PHARMS	200MG	N021361	001	May 25, 2004
--	----------------	-------	---------	-----	--------------

RILUZOLE

TABLET; ORAL

RILUTEK

<u>AB</u>	+	SANOFI AVENTIS US	<u>50MG</u>	<u>N020599</u>	<u>001</u>	Dec 12, 1995
		<u>RILUZOLE</u>				
<u>AB</u>		IMPAX LABS	<u>50MG</u>	<u>A076173</u>	<u>001</u>	Jan 29, 2003

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

FLUMADINE

<u>AB</u>	+	CARACO	<u>100MG</u>	<u>N019649</u>	<u>001</u>	Sep 17, 1993
		<u>RIMANTADINE HYDROCHLORIDE</u>				
<u>AB</u>		ACTAVIS TOTOWA	<u>100MG</u>	<u>A076375</u>	<u>001</u>	Jan 14, 2003
<u>AB</u>		COREPHARMA	<u>100MG</u>	<u>A075916</u>	<u>001</u>	Nov 02, 2001
<u>AB</u>		IMPAX LABS	<u>100MG</u>	<u>A076132</u>	<u>001</u>	Aug 30, 2002

## PRESCRIPTION DRUG PRODUCT LIST

3 - 335 (of 393)

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

+ ALCON	1%	N020474	001	Dec 30, 1994
---------	----	---------	-----	--------------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

<u>AB</u> PROCTER AND GAMBLE	<u>5MG</u>	<u>N020835</u>	<u>002</u>	Apr 14, 2000
<u>AB</u>	<u>30MG</u>	<u>N020835</u>	<u>001</u>	Mar 27, 1998
<u>AB</u> +	<u>35MG</u>	<u>N020835</u>	<u>003</u>	May 25, 2002

RISEDRONATE SODIUM

<u>AB</u> TEVA PHARMS	<u>5MG</u>	<u>A077132</u>	<u>001</u>	Oct 05, 2007
<u>AB</u>	<u>30MG</u>	<u>A077132</u>	<u>002</u>	Oct 05, 2007
<u>AB</u>	<u>35MG</u>	<u>A077132</u>	<u>003</u>	Oct 05, 2007
ACTONEL				
+ PROCTER AND GAMBLE	150MG	N020835	005	Apr 22, 2008

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

ORTHO MCNEIL JANSSEN	12.5MG/VIAL	N021346	004	Apr 12, 2007
	25MG/VIAL	N021346	001	Oct 29, 2003
	37.5MG/VIAL	N021346	002	Oct 29, 2003
+	50MG/VIAL	N021346	003	Oct 29, 2003

SOLUTION; ORAL

RISPERDAL

<u>AA</u> + ORTHO MCNEIL JANSSEN	<u>1MG/ML</u>	<u>N020588</u>	<u>001</u>	Jun 10, 1996
----------------------------------	---------------	----------------	------------	--------------

RISPERIDONE

<u>AA</u> APOTEX INC	<u>1MG/ML</u>	<u>A077719</u>	<u>001</u>	Jul 29, 2009
<u>AA</u> AUROBINDO PHARMA	<u>1MG/ML</u>	<u>A078452</u>	<u>001</u>	Sep 04, 2009
<u>AA</u> DR REDDYS LABS LTD	<u>1MG/ML</u>	<u>A078909</u>	<u>001</u>	Jul 29, 2009
<u>AA</u> ROXANE	<u>1MG/ML</u>	<u>A076904</u>	<u>001</u>	Jul 29, 2009
<u>AA</u> TEVA	<u>1MG/ML</u>	<u>A076440</u>	<u>001</u>	Jan 30, 2009
<u>AA</u> WOCKHARDT	<u>1MG/ML</u>	<u>A078744</u>	<u>001</u>	Oct 08, 2009

TABLET; ORAL

RISPERDAL

<u>AB</u> ORTHO MCNEIL JANSSEN	<u>0.25MG</u>	<u>N020272</u>	<u>008</u>	May 10, 1999
<u>AB</u>	<u>0.5MG</u>	<u>N020272</u>	<u>007</u>	Jan 27, 1999
<u>AB</u> +	<u>1MG</u>	<u>N020272</u>	<u>001</u>	Dec 29, 1993
<u>AB</u>	<u>2MG</u>	<u>N020272</u>	<u>002</u>	Dec 29, 1993
<u>AB</u>	<u>3MG</u>	<u>N020272</u>	<u>003</u>	Dec 29, 1993
<u>AB</u>	<u>4MG</u>	<u>N020272</u>	<u>004</u>	Dec 29, 1993

RISPERIDONE

<u>AB</u> ACTAVIS TOTOWA	<u>0.25MG</u>	<u>A078071</u>	<u>001</u>	Jun 17, 2009
<u>AB</u>	<u>0.5MG</u>	<u>A078071</u>	<u>002</u>	Jun 17, 2009
<u>AB</u>	<u>1MG</u>	<u>A078071</u>	<u>003</u>	Jun 17, 2009
<u>AB</u>	<u>2MG</u>	<u>A078071</u>	<u>004</u>	Jun 17, 2009
<u>AB</u>	<u>3MG</u>	<u>A078071</u>	<u>005</u>	Jun 17, 2009
<u>AB</u>	<u>4MG</u>	<u>A078071</u>	<u>006</u>	Jun 17, 2009
<u>AB</u> APOTEX INC	<u>0.25MG</u>	<u>A077953</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>	<u>0.5MG</u>	<u>A077953</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>	<u>1MG</u>	<u>A077953</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>	<u>2MG</u>	<u>A077953</u>	<u>004</u>	Sep 15, 2008
<u>AB</u>	<u>3MG</u>	<u>A077953</u>	<u>005</u>	Sep 15, 2008
<u>AB</u>	<u>4MG</u>	<u>A077953</u>	<u>006</u>	Sep 15, 2008
<u>AB</u> AUROBINDO PHARMA	<u>0.25MG</u>	<u>A078269</u>	<u>001</u>	Oct 08, 2008
<u>AB</u>	<u>0.5MG</u>	<u>A078269</u>	<u>002</u>	Oct 08, 2008
<u>AB</u>	<u>1MG</u>	<u>A078269</u>	<u>003</u>	Oct 08, 2008
<u>AB</u>	<u>2MG</u>	<u>A078269</u>	<u>004</u>	Oct 08, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 336 (of 393)

## RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>	AUROBINDO PHARMA	<u>3MG</u>	<u>A078269</u>	<u>005</u>	Oct 08, 2008
<u>AB</u>		<u>4MG</u>	<u>A078269</u>	<u>006</u>	Oct 08, 2008
<u>AB</u>	CADISTA PHARMS	<u>0.25MG</u>	<u>A078828</u>	<u>001</u>	Mar 23, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078828</u>	<u>002</u>	Mar 23, 2009
<u>AB</u>		<u>1MG</u>	<u>A078828</u>	<u>003</u>	Mar 23, 2009
<u>AB</u>		<u>2MG</u>	<u>A078828</u>	<u>004</u>	Mar 23, 2009
<u>AB</u>		<u>3MG</u>	<u>A078828</u>	<u>005</u>	Mar 23, 2009
<u>AB</u>		<u>4MG</u>	<u>A078828</u>	<u>006</u>	Mar 23, 2009
<u>AB</u>	COBALT LABS INC	<u>0.25MG</u>	<u>A077860</u>	<u>001</u>	Dec 05, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077860</u>	<u>002</u>	Dec 05, 2008
<u>AB</u>		<u>1MG</u>	<u>A077860</u>	<u>003</u>	Dec 05, 2008
<u>AB</u>		<u>2MG</u>	<u>A077860</u>	<u>004</u>	Dec 05, 2008
<u>AB</u>		<u>3MG</u>	<u>A077860</u>	<u>005</u>	Dec 05, 2008
<u>AB</u>		<u>4MG</u>	<u>A077860</u>	<u>006</u>	Dec 05, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>0.25MG</u>	<u>A076879</u>	<u>001</u>	Oct 24, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076879</u>	<u>002</u>	Oct 24, 2008
<u>AB</u>		<u>1MG</u>	<u>A076879</u>	<u>003</u>	Oct 24, 2008
<u>AB</u>		<u>2MG</u>	<u>A076879</u>	<u>004</u>	Oct 24, 2008
<u>AB</u>		<u>3MG</u>	<u>A076879</u>	<u>005</u>	Oct 24, 2008
<u>AB</u>		<u>4MG</u>	<u>A076879</u>	<u>006</u>	Oct 24, 2008
<u>AB</u>	MYLAN	<u>0.25MG</u>	<u>A076288</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076288</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>1MG</u>	<u>A076288</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>		<u>2MG</u>	<u>A076288</u>	<u>004</u>	Sep 15, 2008
<u>AB</u>		<u>3MG</u>	<u>A076288</u>	<u>005</u>	Sep 15, 2008
<u>AB</u>		<u>4MG</u>	<u>A076288</u>	<u>006</u>	Sep 15, 2008
<u>AB</u>	PLIVA HRVATSKA DOO	<u>0.25MG</u>	<u>A077769</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077769</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A077769</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A077769</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A077769</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A077769</u>	<u>006</u>	Oct 16, 2008
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A078528</u>	<u>001</u>	Oct 16, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078528</u>	<u>002</u>	Oct 16, 2009
<u>AB</u>		<u>1MG</u>	<u>A078528</u>	<u>003</u>	Oct 16, 2009
<u>AB</u>		<u>2MG</u>	<u>A078528</u>	<u>004</u>	Oct 16, 2009
<u>AB</u>		<u>3MG</u>	<u>A078528</u>	<u>005</u>	Oct 16, 2009
<u>AB</u>		<u>4MG</u>	<u>A078528</u>	<u>006</u>	Oct 16, 2009
<u>AB</u>	SYNTHON PHARMS	<u>0.25MG</u>	<u>A078187</u>	<u>001</u>	Oct 22, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078187</u>	<u>002</u>	Oct 22, 2009
<u>AB</u>		<u>1MG</u>	<u>A078187</u>	<u>003</u>	Oct 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A078187</u>	<u>004</u>	Oct 22, 2009
<u>AB</u>		<u>3MG</u>	<u>A078187</u>	<u>005</u>	Oct 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A078187</u>	<u>006</u>	Oct 22, 2009
<u>AB</u>	TEVA	<u>0.25MG</u>	<u>A076228</u>	<u>001</u>	Jun 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076228</u>	<u>002</u>	Jun 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A076228</u>	<u>003</u>	Jun 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A076228</u>	<u>004</u>	Jun 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A076228</u>	<u>005</u>	Jun 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A076228</u>	<u>006</u>	Jun 30, 2008
<u>AB</u>	TORRENT PHARMS	<u>0.25MG</u>	<u>A079088</u>	<u>001</u>	Oct 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A079088</u>	<u>002</u>	Oct 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A079088</u>	<u>003</u>	Oct 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A079088</u>	<u>004</u>	Oct 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A079088</u>	<u>005</u>	Oct 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A079088</u>	<u>006</u>	Oct 30, 2008
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078707</u>	<u>001</u>	Dec 29, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 337 (of 393)

RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>	VINTAGE	<u>0.5MG</u>	<u>A078707</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>1MG</u>	<u>A078707</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>2MG</u>	<u>A078707</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		<u>3MG</u>	<u>A078707</u>	<u>005</u>	Dec 29, 2008
<u>AB</u>		<u>4MG</u>	<u>A078707</u>	<u>006</u>	Dec 29, 2008
<u>AB</u>	WEST WARD PHARMS	<u>0.25MG</u>	<u>A078740</u>	<u>001</u>	May 29, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078740</u>	<u>002</u>	May 29, 2009
<u>AB</u>		<u>1MG</u>	<u>A078740</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>2MG</u>	<u>A078740</u>	<u>004</u>	May 29, 2009
<u>AB</u>		<u>3MG</u>	<u>A078740</u>	<u>005</u>	May 29, 2009
<u>AB</u>		<u>4MG</u>	<u>A078740</u>	<u>006</u>	May 29, 2009
<u>AB</u>	WOCKHARDT	<u>0.25MG</u>	<u>A078871</u>	<u>001</u>	Oct 09, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078871</u>	<u>002</u>	Oct 09, 2008
<u>AB</u>		<u>1MG</u>	<u>A078871</u>	<u>003</u>	Oct 09, 2008
<u>AB</u>		<u>2MG</u>	<u>A078871</u>	<u>004</u>	Oct 09, 2008
<u>AB</u>		<u>3MG</u>	<u>A078871</u>	<u>005</u>	Oct 09, 2008
<u>AB</u>		<u>4MG</u>	<u>A078871</u>	<u>006</u>	Oct 09, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.25MG</u>	<u>A078040</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078040</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A078040</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A078040</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A078040</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A078040</u>	<u>006</u>	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

<u>AB</u>	ORTHO MCNEIL JANSSEN	<u>0.5MG</u>	<u>N021444</u>	<u>001</u>	Apr 02, 2003
<u>AB</u>	+	<u>1MG</u>	<u>N021444</u>	<u>002</u>	Apr 02, 2003
<u>AB</u>		<u>2MG</u>	<u>N021444</u>	<u>003</u>	Apr 02, 2003
<u>AB</u>		<u>3MG</u>	<u>N021444</u>	<u>004</u>	Dec 23, 2004
<u>AB</u>		<u>4MG</u>	<u>N021444</u>	<u>005</u>	Dec 23, 2004

RISPERIDONE

<u>AB</u>	DR REDDYS LABS LTD	<u>0.5MG</u>	<u>A077328</u>	<u>001</u>	Feb 24, 2009
<u>AB</u>		<u>1MG</u>	<u>A077328</u>	<u>002</u>	Oct 05, 2009
<u>AB</u>		<u>2MG</u>	<u>A077328</u>	<u>003</u>	Feb 24, 2009
<u>AB</u>	PAR PHARM	<u>0.5MG</u>	<u>A077494</u>	<u>002</u>	Apr 30, 2009
<u>AB</u>		<u>1MG</u>	<u>A077494</u>	<u>003</u>	Oct 26, 2009
<u>AB</u>		<u>2MG</u>	<u>A077494</u>	<u>004</u>	Apr 30, 2009
<u>AB</u>		<u>3MG</u>	<u>A077494</u>	<u>005</u>	Apr 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077494</u>	<u>006</u>	Apr 30, 2009
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A078116</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>		<u>1MG</u>	<u>A078116</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A078116</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>		<u>3MG</u>	<u>A078116</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A078116</u>	<u>005</u>	Dec 22, 2009
<u>AB</u>	ZYDUS PHARMS USA	<u>0.5MG</u>	<u>A078516</u>	<u>001</u>	May 01, 2009
<u>AB</u>		<u>2MG</u>	<u>A078516</u>	<u>003</u>	May 01, 2009
	RISPERIDONE				
	PAR PHARM	0.25MG	A077494	001	Apr 30, 2009

RITONAVIR

CAPSULE; ORAL

NORVIR

+ ABBOTT 100MG N020945 001 Jun 29, 1999

SOLUTION; ORAL

NORVIR

+ ABBOTT 80MG/ML N020659 001 Mar 01, 1996

## PRESCRIPTION DRUG PRODUCT LIST

3 - 338 (of 393)

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EXELON

NOVARTIS	4.6MG/24HR	N022083	001	Jul 06, 2007
+	9.5MG/24HR	N022083	002	Jul 06, 2007

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

EXELON

<u>AB</u> + NOVARTIS	<u>EQ 1.5MG BASE</u>	<u>N020823</u>	<u>003</u>	Apr 21, 2000
<u>AB</u>	<u>EQ 3MG BASE</u>	<u>N020823</u>	<u>004</u>	Apr 21, 2000
<u>AB</u>	<u>EQ 4.5MG BASE</u>	<u>N020823</u>	<u>005</u>	Apr 21, 2000
<u>AB</u> +	<u>EQ 6MG BASE</u>	<u>N020823</u>	<u>006</u>	Apr 21, 2000

RIVASTIGMINE TARTRATE

<u>AB</u> DR REDDYS LABS INC	<u>EQ 1.5MG BASE</u>	<u>A077130</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>	<u>EQ 3MG BASE</u>	<u>A077130</u>	<u>002</u>	Oct 31, 2007
<u>AB</u>	<u>EQ 4.5MG BASE</u>	<u>A077130</u>	<u>003</u>	Oct 31, 2007
<u>AB</u>	<u>EQ 6MG BASE</u>	<u>A077130</u>	<u>004</u>	Oct 31, 2007
<u>AB</u> SUN PHARM INDS	<u>EQ 1.5MG BASE</u>	<u>A077131</u>	<u>001</u>	Oct 22, 2007
<u>AB</u>	<u>EQ 3MG BASE</u>	<u>A077131</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>	<u>EQ 4.5MG BASE</u>	<u>A077131</u>	<u>003</u>	Oct 22, 2007
<u>AB</u>	<u>EQ 6MG BASE</u>	<u>A077131</u>	<u>004</u>	Oct 22, 2007
<u>AB</u> WATSON LABS	<u>EQ 1.5MG BASE</u>	<u>A077129</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>	<u>EQ 3MG BASE</u>	<u>A077129</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>	<u>EQ 4.5MG BASE</u>	<u>A077129</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>	<u>EQ 6MG BASE</u>	<u>A077129</u>	<u>004</u>	Jan 08, 2008

SOLUTION; ORAL

EXELON

+	NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000
---	----------	----------------	---------	-----	--------------

RIZATRIPTAN BENZOATE

TABLET; ORAL

MAXALT

MERCK	EQ 5MG BASE	N020864	001	Jun 29, 1998
+	EQ 10MG BASE	N020864	002	Jun 29, 1998

TABLET, ORALLY DISINTEGRATING; ORAL

MAXALT-MLT

MERCK	EQ 5MG BASE	N020865	001	Jun 29, 1998
+	EQ 10MG BASE	N020865	002	Jun 29, 1998

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

<u>AP</u> APP PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A078651</u>	<u>001</u>	Dec 29, 2008
<u>AP</u>	<u>100MG/10ML (10MG/ML)</u>	<u>A078651</u>	<u>002</u>	Dec 29, 2008
<u>AP</u> GENERAMEDIX	<u>50MG/5ML (10MG/ML)</u>	<u>A079199</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>	<u>100MG/10ML (10MG/ML)</u>	<u>A079199</u>	<u>002</u>	Nov 26, 2008
<u>AP</u> HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A078519</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>	<u>100MG/10ML (10MG/ML)</u>	<u>A078519</u>	<u>002</u>	Nov 26, 2008
<u>AP</u> SANDOZ	<u>50MG/5ML (10MG/ML)</u>	<u>A079195</u>	<u>001</u>	Dec 05, 2008
<u>AP</u>	<u>100MG/10ML (10MG/ML)</u>	<u>A079195</u>	<u>002</u>	Dec 05, 2008
<u>AP</u> TEVA PARENTERAL	<u>50MG/5ML (10MG/ML)</u>	<u>A078717</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>	<u>100MG/10ML (10MG/ML)</u>	<u>A078717</u>	<u>002</u>	Nov 26, 2008
<u>ZEMURON</u>				
<u>AP</u> + SCHERING	<u>50MG/5ML (10MG/ML)</u>	<u>N020214</u>	<u>001</u>	Mar 17, 1994
<u>AP</u> +	<u>100MG/10ML (10MG/ML)</u>	<u>N020214</u>	<u>003</u>	Mar 17, 1994

## PRESCRIPTION DRUG PRODUCT LIST

3 - 339 (of 393)

ROMIDEPSIN

POWDER; IV (INFUSION)

+ GLOUCESTER PHARMS 10MG/VIAL N022393 001 Nov 05, 2009

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

<u>AB</u>	+ GLAXOSMITHKLINE	<u>EQ 0.25MG BASE</u>	<u>N020658</u>	<u>001</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>N020658</u>	<u>002</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>N020658</u>	<u>003</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>N020658</u>	<u>004</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>N020658</u>	<u>006</u>	Jan 27, 1999
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N020658</u>	<u>007</u>	Jan 27, 1999
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N020658</u>	<u>005</u>	Sep 19, 1997

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	COREPHARMA	<u>EQ 0.25MG BASE</u>	<u>A078230</u>	<u>001</u>	May 20, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078230</u>	<u>002</u>	May 20, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078230</u>	<u>003</u>	May 20, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078230</u>	<u>004</u>	May 20, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078230</u>	<u>005</u>	May 20, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078230</u>	<u>006</u>	May 20, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078230</u>	<u>007</u>	May 20, 2008
<u>AB</u>	HUAHAI US INC	<u>EQ 0.25MG BASE</u>	<u>A078110</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078110</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078110</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078110</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078110</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078110</u>	<u>006</u>	May 05, 2008
<u>AB</u>	MYLAN	<u>EQ 0.25MG BASE</u>	<u>A078881</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078881</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078881</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078881</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078881</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078881</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078881</u>	<u>007</u>	May 19, 2008
<u>AB</u>	ROXANE	<u>EQ 0.25MG BASE</u>	<u>A077852</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077852</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077852</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077852</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077852</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077852</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077852</u>	<u>007</u>	May 19, 2008
<u>AB</u>	TEVA	<u>EQ 0.25MG BASE</u>	<u>A077460</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077460</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077460</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077460</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077460</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077460</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077460</u>	<u>007</u>	May 19, 2008
<u>AB</u>	WOCKHARDT	<u>EQ 0.25MG BASE</u>	<u>A079050</u>	<u>001</u>	May 29, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079050</u>	<u>002</u>	May 29, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079050</u>	<u>003</u>	May 29, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079050</u>	<u>004</u>	May 29, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079050</u>	<u>005</u>	May 29, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079050</u>	<u>006</u>	May 29, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079050</u>	<u>007</u>	May 29, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 0.25MG BASE</u>	<u>A090411</u>	<u>001</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090411</u>	<u>002</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090411</u>	<u>003</u>	Jun 01, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 340 (of 393)

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 2MG BASE</u>	<u>A090411</u>	<u>004</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090411</u>	<u>005</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090411</u>	<u>006</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090411</u>	<u>007</u>	Jun 01, 2009

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

+	SMITHKLINE BEECHAM	EQ 2MG BASE	N022008	001	Jun 13, 2008
		EQ 4MG BASE	N022008	003	Jun 13, 2008
		EQ 6MG BASE	N022008	006	Apr 10, 2009
		EQ 8MG BASE	N022008	004	Jun 13, 2008
		EQ 12MG BASE	N022008	005	Oct 31, 2008

ROPIVACAINE HYDROCHLORIDE MONOHYDRATE

INJECTABLE; INJECTION

NAROPIN

	APP PHARMS	2MG/ML	N020533	001	Sep 24, 1996
		5MG/ML	N020533	003	Sep 24, 1996
		7.5MG/ML	N020533	004	Sep 24, 1996
+		10MG/ML	N020533	005	Sep 24, 1996

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

	SB PHARMCO	EQ 2MG BASE	N021071	002	May 25, 1999
		EQ 4MG BASE	N021071	003	May 25, 1999
+		EQ 8MG BASE	N021071	004	May 25, 1999

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

	IPR	5MG	N021366	002	Aug 12, 2003
		10MG	N021366	003	Aug 12, 2003
		20MG	N021366	004	Aug 12, 2003
+		40MG	N021366	005	Aug 12, 2003

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION

CARDIOGEN-82

	BRACCO	N/A	N019414	001	Dec 29, 1989
--	--------	-----	---------	-----	--------------

RUFINAMIDE

TABLET; ORAL

BANZEL

	EISAI INC	200MG	N021911	002	Nov 14, 2008
+		400MG	N021911	003	Nov 14, 2008

SACROSIDASE

SOLUTION; ORAL

SUCRAID

+	QOL MEDCL	8,500 IU/ML	N020772	001	Apr 09, 1998
---	-----------	-------------	---------	-----	--------------

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%

+	HOSPIRA	5%;5% (5GM/100ML)	N018997	001	Aug 27, 1984
---	---------	-------------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 341 (of 393)

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 20%

+ HOSPIRA	10%;10% (10GM/100ML)	N018991 001	Aug 27, 1984
-----------	----------------------	-------------	--------------

SALMETEROL XINAFOATE

POWDER; INHALATION

SEREVENT

+ GLAXO GRP LTD	EQ 0.05MG BASE/INH	N020692 001	Sep 19, 1997
-----------------	--------------------	-------------	--------------

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+ EUSA PHARMA USA	50mCi/ML	N020570 001	Mar 28, 1997
-------------------	----------	-------------	--------------

SAPROPTERIN DIHYDROCHLORIDE

TABLET; ORAL

KUVAN

+ BIOMARIN PHARM	100MG	N022181 001	Dec 13, 2007
------------------	-------	-------------	--------------

SAQUINAVIR MESYLATE

CAPSULE; ORAL

INVIRASE

+ HLR	EQ 200MG BASE	N020628 001	Dec 06, 1995
-------	---------------	-------------	--------------

TABLET; ORAL

INVIRASE

+ ROCHE	EQ 500MG BASE	N021785 001	Dec 17, 2004
---------	---------------	-------------	--------------

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

ONGLYZA

BRISTOL MYERS SQUIBB	EQ 2.5MG BASE	N022350 001	Jul 31, 2009
----------------------	---------------	-------------	--------------

+	EQ 5MG BASE	N022350 002	Jul 31, 2009
---	-------------	-------------	--------------

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

TRANSDERM SCOP

+ NOVARTIS	1MG/72HR	N017874 001	
------------	----------	-------------	--

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+ RANBAXY	50MG	A086101 001	Oct 03, 1983
-----------	------	-------------	--------------

+	100MG	A086101 002	Oct 03, 1983
---	-------	-------------	--------------

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

CHIRHOSTIM

+ CHIRHOCLIN	16MCG/VIAL	N021256 001	Apr 09, 2004
--------------	------------	-------------	--------------

	40MCG/VIAL	N021256 002	Jun 21, 2007
--	------------	-------------	--------------

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EMSAM

+ SOMERSET	6MG/24HR	N021336 001	Feb 27, 2006
------------	----------	-------------	--------------

	9MG/24HR	N021336 002	Feb 27, 2006
--	----------	-------------	--------------

	12MG/24HR	N021336 003	Feb 27, 2006
--	-----------	-------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

3 - 342 (of 393)

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

ELDEPRYL

<u>AB</u>	+ SOMERSET	<u>5MG</u>	<u>N020647</u>	<u>001</u>	May 15, 1996
	<u>SELEGILINE HYDROCHLORIDE</u>				
<u>AB</u>	APOTEX	<u>5MG</u>	<u>A075321</u>	<u>001</u>	Dec 04, 1998
<u>AB</u>	DAVA PHARMS INC	<u>5MG</u>	<u>A075352</u>	<u>001</u>	Nov 30, 1998

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

<u>AB</u>	ALPHAPHARM	<u>5MG</u>	<u>A074866</u>	<u>001</u>	Nov 26, 1997
<u>AB</u>	+ APOTEX INC	<u>5MG</u>	<u>A074871</u>	<u>001</u>	Jun 06, 1997
<u>AB</u>	DAVA PHARMS INC	<u>5MG</u>	<u>A074641</u>	<u>001</u>	Aug 02, 1996
<u>AB</u>	STASON	<u>5MG</u>	<u>A074912</u>	<u>001</u>	Apr 30, 1998

TABLET, ORALLY DISINTEGRATING; ORAL

ZELAPAR

	+ VALEANT PHARM INTL	1.25MG	N021479	001	Jun 14, 2006
--	----------------------	--------	---------	-----	--------------

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>2.5%</u>	<u>A084394</u>	<u>001</u>	
<u>AT</u>	MORTON GROVE	<u>2.5%</u>	<u>A088228</u>	<u>001</u>	Sep 01, 1983
<u>AT</u>	PERRIGO NEW YORK	<u>2.5%</u>	<u>A089996</u>	<u>001</u>	Jan 10, 1991
	<u>SELSUN</u>				
<u>AT</u>	+ CHATTEM	<u>2.5%</u>	<u>N007936</u>	<u>001</u>	

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

	+ ORTHO DERMATOLOGICS	2%	N021385	001	Dec 10, 2003
--	-----------------------	----	---------	-----	--------------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

<u>AA</u>	AUROBINDO PHARMA	<u>EQ 20MG BASE/ML</u>	<u>A078861</u>	<u>001</u>	Oct 31, 2008
<u>AA</u>	RANBAXY	<u>EQ 20MG BASE/ML</u>	<u>A078053</u>	<u>001</u>	Feb 05, 2007
<u>AA</u>	ROXANE	<u>EQ 20MG BASE/ML</u>	<u>A076934</u>	<u>001</u>	Jun 30, 2006
	<u>ZOLOFT</u>				
<u>AA</u>	+ PFIZER	<u>EQ 20MG BASE/ML</u>	<u>N020990</u>	<u>001</u>	Dec 07, 1999

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 25MG BASE</u>	<u>A076882</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076882</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076882</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A077206</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077206</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077206</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	AUSTARPHARMA LLC	<u>EQ 25MG BASE</u>	<u>A078677</u>	<u>001</u>	Mar 04, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078677</u>	<u>002</u>	Mar 04, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078677</u>	<u>003</u>	Mar 04, 2009
<u>AB</u>	COBALT	<u>EQ 25MG BASE</u>	<u>A077663</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077663</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077663</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A076442</u>	<u>001</u>	Apr 30, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076442</u>	<u>002</u>	Apr 30, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076442</u>	<u>003</u>	Apr 30, 2007
<u>AB</u>	GENPHARM	<u>EQ 25MG BASE</u>	<u>A076540</u>	<u>001</u>	Mar 20, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076540</u>	<u>002</u>	Mar 20, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076540</u>	<u>003</u>	Mar 20, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 343 (of 393)

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

<u>AB</u>	HIKMA PHARMS	<u>EQ 25MG BASE</u>	<u>A077864</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077864</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077864</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 25MG BASE</u>	<u>A077397</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077397</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077397</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 25MG BASE</u>	<u>A075719</u>	<u>003</u>	Jun 30, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A075719</u>	<u>001</u>	Jun 30, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A075719</u>	<u>002</u>	Jun 30, 2006
<u>AB</u>	LUPIN	<u>EQ 25MG BASE</u>	<u>A077670</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077670</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077670</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	MATRIX LABS LTD	<u>EQ 25MG BASE</u>	<u>A078626</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078626</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078626</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A076671</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076671</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076671</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>EQ 25MG BASE</u>	<u>A077299</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077299</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077299</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	RANBAXY	<u>EQ 25MG BASE</u>	<u>A077977</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077977</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077977</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	ROXANE	<u>EQ 25MG BASE</u>	<u>A076881</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076881</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076881</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE</u>	<u>A077713</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077713</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077713</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 25MG BASE</u>	<u>A078108</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078108</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078108</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076465</u>	<u>001</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076465</u>	<u>002</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076465</u>	<u>003</u>	Aug 11, 2006
<u>AB</u>	TORRENT PHARMS	<u>EQ 25MG BASE</u>	<u>A077765</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077765</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077765</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 25MG BASE</u>	<u>A078403</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078403</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078403</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077106</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077106</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077106</u>	<u>003</u>	Feb 06, 2007
	<u>ZOLOFT</u>				
<u>AB</u>	PFIZER	<u>EQ 25MG BASE</u>	<u>N019839</u>	<u>005</u>	Mar 06, 1996
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N019839</u>	<u>001</u>	Dec 30, 1991
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N019839</u>	<u>002</u>	Dec 30, 1991
	SERTRALINE HYDROCHLORIDE				
	RANBAXY	EQ 150MG BASE	A077977	004	Feb 06, 2007
		EQ 200MG BASE	A077977	005	Feb 06, 2007

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

RENVELA

GENZYME

800MG/PACKET

N022318 001

Aug 12, 2009

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 370 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 344 (of 393)

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

REVELA

+ GENZYME 2.4GM/PACKET N022318 002 Feb 18, 2009

TABLET; ORAL

REVELA

+ GENZYME 800MG N022127 001 Oct 19, 2007

SEVELAMER HYDROCHLORIDE

TABLET; ORAL

RENAGEL

GENZYME 400MG N021179 001 Jul 12, 2000

+ 800MG N021179 002 Jul 12, 2000

SEVOFLURANE

LIQUID; INHALATION

SEVOFLURANEAN BAXTER HLTHCARE 100% A075895 001 Jul 02, 2002AN HALOCARBON PRODS 100% A078650 001 Nov 19, 2007SOJOURNAN MINRAD 100% A077867 001 May 02, 2007ULTANEAN + ABBOTT 100% N020478 001 Jun 07, 1995SIBUTRAMINE HYDROCHLORIDE

CAPSULE; ORAL

MERIDIA

ABBOTT 5MG N020632 001 Nov 22, 1997

10MG N020632 002 Nov 22, 1997

+ 15MG N020632 003 Nov 22, 1997

SILDENAFIL CITRATE

SOLUTION; INTRAVENOUS

REVATIO

+ PFIZER EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML) N022473 001 Nov 18, 2009

TABLET; ORAL

REVATIO

+ PFIZER EQ 20MG BASE N021845 001 Jun 03, 2005

VIAGRA

PFIZER IRELAND EQ 25MG BASE N020895 001 Mar 27, 1998

EQ 50MG BASE N020895 002 Mar 27, 1998

+ EQ 100MG BASE N020895 003 Mar 27, 1998

SILODOSIN

CAPSULE; ORAL

RAPAFLO

WATSON LABS 4MG N022206 001 Oct 08, 2008

+ 8MG N022206 002 Oct 08, 2008

SILVER SULFADIAZINE

CREAM; TOPICAL

SILVADENEAB + KING PHARMS 1% N017381 001SSDAB DR REDDYS LA 1% N018578 001 Feb 25, 1982THERMAZENEAB KENDALL LP 1% N018810 001 Dec 23, 1985

SSD AF

BX DR REDDYS LA 1% N018578 003 Jul 11, 1990

## PRESCRIPTION DRUG PRODUCT LIST

3 - 345 (of 393)

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

<u>AB</u>	ACCORD HLTHCARE	<u>10MG</u>	<u>A078155</u>	<u>002</u>	Feb 26, 2008
<u>AB</u>		<u>20MG</u>	<u>A078155</u>	<u>003</u>	Feb 26, 2008
<u>AB</u>		<u>40MG</u>	<u>A078155</u>	<u>004</u>	Feb 26, 2008
<u>AB</u>		<u>80MG</u>	<u>A078155</u>	<u>001</u>	Feb 26, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A077691</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077691</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077691</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077691</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077691</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	COBALT	<u>5MG</u>	<u>A076685</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076685</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076685</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076685</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076685</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>10MG</u>	<u>A077752</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077752</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077752</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077752</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A078425</u>	<u>001</u>	Aug 16, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076052</u>	<u>001</u>	Jun 23, 2006
<u>AB</u>		<u>10MG</u>	<u>A076052</u>	<u>002</u>	Jun 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076052</u>	<u>003</u>	Jun 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076052</u>	<u>004</u>	Jun 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076052</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	LUPIN	<u>5MG</u>	<u>A078103</u>	<u>005</u>	Apr 14, 2009
<u>AB</u>		<u>10MG</u>	<u>A078103</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A078103</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A078103</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A078103</u>	<u>004</u>	May 11, 2007
<u>AB</u>	PERRIGO R AND D	<u>5MG</u>	<u>A078034</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A078034</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A078034</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A078034</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A078034</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076285</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076285</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076285</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076285</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076285</u>	<u>005</u>	Jun 23, 2006
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A077766</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077766</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077766</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077766</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077766</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077837</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077837</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077837</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077837</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077837</u>	<u>005</u>	Dec 20, 2006
	<u>ZOCOR</u>				
<u>AB</u>	MERCK	<u>5MG</u>	<u>N019766</u>	<u>001</u>	Dec 23, 1991
<u>AB</u>		<u>10MG</u>	<u>N019766</u>	<u>002</u>	Dec 23, 1991
<u>AB</u>		<u>20MG</u>	<u>N019766</u>	<u>003</u>	Dec 23, 1991
<u>AB</u>		<u>40MG</u>	<u>N019766</u>	<u>004</u>	Dec 23, 1991
<u>AB</u>	+	<u>80MG</u>	<u>N019766</u>	<u>005</u>	Jul 10, 1998

## PRESCRIPTION DRUG PRODUCT LIST

3 - 346 (of 393)

SINCALIDE

INJECTABLE; INJECTION  
KINEVAC  
+ BRACCO 0.005MG/VIAL N017697 001

SINECATECHINS

OINTMENT; TOPICAL  
VEREGEN  
+ MEDIGENE 15% N021902 001 Oct 31, 2006

SIROLIMUS

SOLUTION; ORAL  
RAPAMUNE  
+ WYETH PHARMS INC 1MG/ML N021083 001 Sep 15, 1999

TABLET; ORAL  
RAPAMUNE  
WYETH PHARMS INC 1MG N021110 001 Aug 25, 2000  
+ 2MG N021110 002 Aug 22, 2002

SITAGLIPTIN PHOSPHATE

TABLET; ORAL  
JANUVIA  
MERCK CO INC EQ 25MG BASE N021995 001 Oct 16, 2006  
EQ 50MG BASE N021995 002 Oct 16, 2006  
+ EQ 100MG BASE N021995 003 Oct 16, 2006

SODIUM ACETATE ANHYDROUS

INJECTABLE; INJECTION  
SODIUM ACETATE IN PLASTIC CONTAINER  
+ HOSPIRA 2MEQ/ML N018893 001 May 04, 1983

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)  
+ UCYCLYD 10%;10% (5GM/50ML;5GM/50ML) N020645 001 Feb 17, 2005

SODIUM BICARBONATE

INJECTABLE; INJECTION  
SODIUM BICARBONATE  
HOSPIRA 0.9MEQ/ML A077394 001 Nov 09, 2005  
+ 1MEQ/ML A077394 002 Nov 09, 2005

SODIUM CHLORIDE

INJECTABLE; INJECTION  
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP APP PHARMS 9MG/ML A088911 001 Feb 07, 1985  
AP + HOSPIRA 9MG/ML N018800 001 Oct 29, 1982

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP B BRAUN 450MG/100ML N019635 001 Mar 09, 1988  
AP BAXTER HLTHCARE 450MG/100ML N018016 001  
AP HOSPIRA 450MG/100ML N018090 001  
AP 450MG/100ML N019759 001 Jun 08, 1988

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP + APP PHARMS 9MG/ML A088912 001 Jan 10, 1985  
AP + B BRAUN 900MG/100ML N017464 001  
AP + 900MG/100ML N019635 002 Mar 09, 1988  
AP + BAXTER HLTHCARE 9MG/ML N016677 004 Oct 30, 1985  
AP 9MG/ML N020178 002 Dec 07, 1992  
AP + 900MG/100ML N016677 001

## PRESCRIPTION DRUG PRODUCT LIST

3 - 347 (of 393)

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>900MG/100ML</u>	<u>N020178</u>	<u>001</u>	Dec 07, 1992
<u>AP</u>		FRESENIUS MEDCL	<u>900MG/100ML</u>	<u>A078177</u>	<u>001</u>	Apr 12, 2007
<u>AP</u>		HAEMONETICS	<u>900MG/100ML</u>	<u>A076316</u>	<u>001</u>	Oct 27, 2004
<u>AP</u>	+	HOSPIRA	<u>9MG/ML</u>	<u>N018803</u>	<u>001</u>	Oct 29, 1982
<u>AP</u>	+		<u>9MG/ML</u>	<u>N019217</u>	<u>001</u>	Jul 13, 1984
<u>AP</u>			<u>9MG/ML</u>	<u>N019465</u>	<u>002</u>	Jul 15, 1985
<u>AP</u>	+		<u>900MG/100ML</u>	<u>N016366</u>	<u>001</u>	
<u>AP</u>	+		<u>900MG/100ML</u>	<u>N019465</u>	<u>001</u>	Jul 15, 1985
<u>AP</u>	+		<u>900MG/100ML</u>	<u>N019480</u>	<u>001</u>	Sep 17, 1985
<u>AP</u>	+	TARO PHARMS IRELAND	<u>9MG/ML</u>	<u>A077407</u>	<u>001</u>	Aug 11, 2006
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	+	MALLINCKRODT	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006
			112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006
		SODIUM CHLORIDE 3% IN PLASTIC CONTAINER				
		BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983
		SODIUM CHLORIDE 5% IN PLASTIC CONTAINER				
		BAXTER HLTHCARE	5GM/100ML	N019022	002	Nov 01, 1983
		SODIUM CHLORIDE IN PLASTIC CONTAINER				
		HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984

SOLUTION FOR SLUSH; IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

		BAXTER HLTHCARE	900MG/100ML	N019319	002	May 17, 1985
--	--	-----------------	-------------	---------	-----	--------------

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AT</u>		BAXTER HLTHCARE	<u>450MG/100ML</u>	<u>N017864</u>	<u>001</u>	
<u>AT</u>		HOSPIRA	<u>450MG/100ML</u>	<u>N017670</u>	<u>001</u>	
<u>AT</u>			<u>450MG/100ML</u>	<u>N018380</u>	<u>001</u>	
		<u>SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>				
<u>AT</u>		B BRAUN	<u>900MG/100ML</u>	<u>N016733</u>	<u>001</u>	
<u>AT</u>		BAXTER HLTHCARE	<u>900MG/100ML</u>	<u>N017427</u>	<u>001</u>	
<u>AT</u>			<u>900MG/100ML</u>	<u>N017867</u>	<u>001</u>	
<u>AT</u>		HOSPIRA	<u>900MG/100ML</u>	<u>N017514</u>	<u>001</u>	
<u>AT</u>			<u>900MG/100ML</u>	<u>N018314</u>	<u>001</u>	

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPES SODIUM

		BRACCO	200uCi/ML	N013993	001	
--	--	--------	-----------	---------	-----	--

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

	+	SANOFI AVENTIS US	62.5MG/5ML	N020955	001	Feb 18, 1999
--	---	-------------------	------------	---------	-----	--------------

SODIUM IODIDE, I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

<u>AA</u>	+	GE HEALTHCARE	<u>100uCi</u>	<u>N017630</u>	<u>001</u>	
<u>AA</u>		MALLINCKRODT	<u>100uCi</u>	<u>A071909</u>	<u>001</u>	Feb 28, 1989
<u>AA</u>			<u>200uCi</u>	<u>A071910</u>	<u>001</u>	Feb 28, 1989
<u>AA</u>	+	SYNCOR PHARMS	<u>100uCi</u>	<u>N018671</u>	<u>001</u>	May 27, 1982
<u>AA</u>	+		<u>200uCi</u>	<u>N018671</u>	<u>002</u>	May 27, 1982

SOLUTION; ORAL

SODIUM IODIDE I 123

	+	GE HEALTHCARE	2mCi/ML	N017630	002	
--	---	---------------	---------	---------	-----	--

## PRESCRIPTION DRUG PRODUCT LIST

3 - 348 (of 393)

SODIUM IODIDE, I-131

CAPSULE; ORAL

HICON

DRAXIMAGE	100uCi	N021305	004	Nov 18, 2004
SODIUM IODIDE I 131				
+ MALLINCKRODT	0.8-100mCi	N016517	001	
+	15-100uCi	N016517	002	

SOLUTION; ORAL

HICON

+ DRAXIMAGE	1-250mCi/0.25ML	N021305	002	Jan 24, 2003
+	1-500mCi/0.5ML	N021305	003	Jan 24, 2003
SODIUM IODIDE I 131				
+ MALLINCKRODT	3.5-150mCi/VIAL	N016515	001	

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>1.87GM/100ML</u>	<u>N016692</u>	<u>001</u>	
-----------	-----------------	---------------------	----------------	------------	--

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>1.87GM/100ML</u>	<u>N020004</u>	<u>001</u>	Apr 21, 1992
	SODIUM LACTATE IN PLASTIC CONTAINER				
+	HOSPIRA	5MEQ/ML	N018947	001	Sep 05, 1984

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

<u>AP</u>	+ HOSPIRA	<u>25MG/ML</u>	<u>A071961</u>	<u>001</u>	Aug 01, 1988
-----------	-----------	----------------	----------------	------------	--------------

SODIUM NITROPRUSSIDE

<u>AP</u>	TEVA PARENTERAL	<u>25MG/ML</u>	<u>A073465</u>	<u>001</u>	Mar 30, 1992
-----------	-----------------	----------------	----------------	------------	--------------

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+ JAZZ	500MG/ML	N021196	001	Jul 17, 2002
--------	----------	---------	-----	--------------

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYL

+ MEDICIS	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996
-----------	-----------------	---------	-----	--------------

TABLET; ORAL

BUPHENYL

+ MEDICIS	500MG	N020572	001	May 13, 1996
-----------	-------	---------	-----	--------------

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

OSMOPREP

+ SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006
----------------	-----------------	---------	-----	--------------

VISICOL

+ SALIX PHARMS	0.398GM;1.102GM	N021097	001	Sep 21, 2000
----------------	-----------------	---------	-----	--------------

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

HOSPIRA	142MG/ML;276MG/ML	N018892	001	May 10, 1983
---------	-------------------	---------	-----	--------------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KALEXATE

<u>AA</u>	KVK TECH	454GM/BOT	<u>A040905</u>	<u>001</u>	Mar 30, 2009
-----------	----------	-----------	----------------	------------	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 375 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 349 (of 393)

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KAYEXALATE

<u>AA</u>	+	SANOFI AVENTIS US	<u>453.6GM/BOT</u>	<u>N011287</u>	<u>001</u>	
-----------	---	-------------------	--------------------	----------------	------------	--

KIONEX

<u>AA</u>		PADDOCK	<u>454GM/BOT</u>	<u>A040029</u>	<u>001</u>	Feb 06, 1998
-----------	--	---------	------------------	----------------	------------	--------------

SODIUM POLYSTYRENE SULFONATE

<u>AA</u>		CAROLINA MEDCL	<u>454GM/BOT</u>	<u>A089910</u>	<u>001</u>	Jan 19, 1989
-----------	--	----------------	------------------	----------------	------------	--------------

<u>AA</u>		CITRUSPHRMA	<u>454GM/BOT</u>	<u>A040909</u>	<u>001</u>	Dec 03, 2008
-----------	--	-------------	------------------	----------------	------------	--------------

SUSPENSION; ORAL, RECTAL

KIONEX

<u>AA</u>		PADDOCK	<u>15GM/60ML</u>	<u>A040028</u>	<u>001</u>	Sep 17, 2007
-----------	--	---------	------------------	----------------	------------	--------------

SODIUM POLYSTYRENE SULFONATE

<u>AA</u>		ROXANE	<u>15GM/60ML</u>	<u>A089049</u>	<u>001</u>	Nov 17, 1986
-----------	--	--------	------------------	----------------	------------	--------------

SPS

<u>AA</u>	+	CAROLINA MEDCL	<u>15GM/60ML</u>	<u>A087859</u>	<u>001</u>	Dec 08, 1982
-----------	---	----------------	------------------	----------------	------------	--------------

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

## SOTRADECOL

		BIONICHE PHARMA	20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004
	+		60MG/2ML (30MG/ML)	A040541	002	Nov 12, 2004

SOLIFENACIN SUCCINATE

TABLET; ORAL

## VESICARE

		ASTELLAS	5MG	N021518	001	Nov 19, 2004
	+		10MG	N021518	002	Nov 19, 2004

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

## GENOTROPIN

BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280	006	Aug 24, 1995
		GENOTROPIN PRESERVATIVE FREE				

BX		PHARMACIA AND UPJOHN	1.5MG/VIAL	N020280	004	Aug 24, 1995
----	--	----------------------	------------	---------	-----	--------------

## HUMATROPE

BX	+	LILLY	5MG/VIAL	N019640	004	Mar 08, 1987
----	---	-------	----------	---------	-----	--------------

BX			6MG/VIAL	N019640	005	Feb 04, 1999
----	--	--	----------	---------	-----	--------------

## NORDITROPIN

BX		NOVO NORDISK INC	5MG/1.5ML	N021148	001	Jun 20, 2000
----	--	------------------	-----------	---------	-----	--------------

BX			10MG/1.5ML	N021148	002	Jun 20, 2000
----	--	--	------------	---------	-----	--------------

## NORDITROPIN NORDIFLEX

BX		NOVO NORDISK INC	5MG/1.5ML	N021148	004	Oct 01, 2004
----	--	------------------	-----------	---------	-----	--------------

BX			10MG/1.5ML	N021148	005	Oct 01, 2004
----	--	--	------------	---------	-----	--------------

## NUTROPIN

BX		GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993
----	--	-----------	----------	---------	-----	--------------

## OMNITROPE

BX		SANDOZ	1.5MG/VIAL	N021426	002	May 30, 2006
----	--	--------	------------	---------	-----	--------------

BX			5MG/1.5ML	N021426	003	Jan 16, 2008
----	--	--	-----------	---------	-----	--------------

BX			5.8MG/VIAL	N021426	001	May 30, 2006
----	--	--	------------	---------	-----	--------------

BX			10MG/1.5ML	N021426	004	Aug 25, 2008
----	--	--	------------	---------	-----	--------------

## SAIZEN

BX		EMD SERONO	5MG/VIAL	N019764	002	Oct 08, 1996
----	--	------------	----------	---------	-----	--------------

## SEROSTIM

BX		EMD SERONO	4MG/VIAL	N020604	003	Jul 25, 1997
----	--	------------	----------	---------	-----	--------------

BX			5MG/VIAL	N020604	002	Aug 23, 1996
----	--	--	----------	---------	-----	--------------

BX			6MG/VIAL	N020604	001	Aug 23, 1996
----	--	--	----------	---------	-----	--------------

## TEV-TROPIN

BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002
----	---	---------	----------	---------	-----	--------------



## PRESCRIPTION DRUG PRODUCT LIST

3 - 350 (of 393)

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION					
VALTROPIN					
BX	LG LIFE	5MG/VIAL	N021905	001	Apr 19, 2007
GENOTROPIN					
+	PHARMACIA AND UPJOHN	13.8MG/VIAL	N020280	007	Oct 23, 1996
GENOTROPIN PRESERVATIVE FREE					
	PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280	001	Jan 27, 1998
		0.4MG/VIAL	N020280	002	Jan 27, 1998
		0.6MG/VIAL	N020280	003	Jan 27, 1998
		0.8MG/VIAL	N020280	005	Jan 27, 1998
		1MG/VIAL	N020280	008	Jan 27, 1998
		1.2MG/VIAL	N020280	009	Jan 27, 1998
		1.4MG/VIAL	N020280	010	Jan 27, 1998
		1.6MG/VIAL	N020280	011	Jan 27, 1998
		1.8MG/VIAL	N020280	012	Jan 27, 1998
+		2MG/VIAL	N020280	013	Jan 27, 1998
HUMATROPE					
+	LILLY	12MG/VIAL	N019640	006	Feb 04, 1999
+		24MG/VIAL	N019640	007	Feb 04, 1999
NORDITROPIN					
+	NOVO NORDISK INC	15MG/1.5ML	N021148	003	Jun 20, 2000
NORDITROPIN NORDIFLEX					
	NOVO NORDISK INC	15MG/1.5ML	N021148	006	Oct 01, 2004
		30MG/3ML	N021148	007	Mar 10, 2009
NUTROPIN					
+	GENENTECH	10MG/VIAL	N020168	002	Nov 17, 1993
NUTROPIN AQ					
+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008
+		10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995
+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008
NUTROPIN AQ PEN					
+	GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002
SAIZEN					
+	EMD SERONO	8.8MG/VIAL	N019764	003	Aug 29, 2000
ZORBTIVE					
+	EMD SERONO	8.8MG/VIAL	N021597	004	Dec 01, 2003

SORAFENIB TOSYLATE

TABLET; ORAL					
NEXAVAR					
+	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005

SORBITOL

SOLUTION; IRRIGATION					
SORBITOL 3% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	3GM/100ML	N017863	001	
SORBITOL 3.3% IN PLASTIC CONTAINER					
	B BRAUN	3.3GM/100ML	N016741	001	

SOTALOL HYDROCHLORIDE

SOLUTION; INTRAVENOUS					
SOTALOL HYDROCHLORIDE					
+	ACADEMIC PHARMS	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009

TABLET; ORAL

<u>BETAPACE</u>					
<u>AB1</u>	BAYER HLTHCARE	<u>80MG</u>	<u>N019865</u>	<u>001</u>	Oct 30, 1992
<u>AB1</u>		<u>120MG</u>	<u>N019865</u>	<u>005</u>	Apr 20, 1994
<u>AB1</u> +		<u>160MG</u>	<u>N019865</u>	<u>002</u>	Oct 30, 1992
<u>AB1</u>		<u>240MG</u>	<u>N019865</u>	<u>003</u>	Oct 30, 1992

## PRESCRIPTION DRUG PRODUCT LIST

3 - 351 (of 393)

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SORINE

<u>AB1</u>	UPSHER SMITH	<u>80MG</u>	<u>A075500</u>	<u>001</u>	Apr 27, 2001
<u>AB1</u>		<u>120MG</u>	<u>A075500</u>	<u>004</u>	Apr 27, 2001
<u>AB1</u>		<u>160MG</u>	<u>A075500</u>	<u>002</u>	Apr 27, 2001
<u>AB1</u>		<u>240MG</u>	<u>A075500</u>	<u>003</u>	Apr 27, 2001

SOTALOL HYDROCHLORIDE

<u>AB1</u>	APOTEX INC	<u>80MG</u>	<u>A076140</u>	<u>001</u>	Sep 26, 2002
<u>AB1</u>		<u>120MG</u>	<u>A076140</u>	<u>002</u>	Sep 26, 2002
<u>AB1</u>		<u>160MG</u>	<u>A076140</u>	<u>003</u>	Sep 26, 2002
<u>AB1</u>		<u>240MG</u>	<u>A076140</u>	<u>004</u>	Sep 26, 2002
<u>AB1</u>	IMPAX PHARMS	<u>80MG</u>	<u>A075663</u>	<u>001</u>	Nov 07, 2000
<u>AB1</u>		<u>120MG</u>	<u>A075663</u>	<u>002</u>	Nov 07, 2000
<u>AB1</u>		<u>160MG</u>	<u>A075663</u>	<u>003</u>	Nov 07, 2000
<u>AB1</u>		<u>240MG</u>	<u>A075663</u>	<u>004</u>	Nov 07, 2000
<u>AB1</u>	MYLAN	<u>80MG</u>	<u>A075237</u>	<u>001</u>	May 01, 2000
<u>AB1</u>		<u>80MG</u>	<u>A075725</u>	<u>001</u>	Dec 19, 2000
<u>AB1</u>		<u>120MG</u>	<u>A075237</u>	<u>002</u>	May 01, 2000
<u>AB1</u>		<u>120MG</u>	<u>A075725</u>	<u>002</u>	Dec 19, 2000
<u>AB1</u>		<u>160MG</u>	<u>A075237</u>	<u>003</u>	May 01, 2000
<u>AB1</u>		<u>160MG</u>	<u>A075725</u>	<u>003</u>	Dec 19, 2000
<u>AB1</u>		<u>240MG</u>	<u>A075237</u>	<u>004</u>	May 01, 2000
<u>AB1</u>		<u>240MG</u>	<u>A075725</u>	<u>004</u>	Dec 19, 2000
<u>AB1</u>	SANDOZ	<u>80MG</u>	<u>A075366</u>	<u>001</u>	May 01, 2000
<u>AB1</u>		<u>120MG</u>	<u>A075366</u>	<u>002</u>	May 01, 2000
<u>AB1</u>		<u>160MG</u>	<u>A075366</u>	<u>003</u>	May 01, 2000
<u>AB1</u>		<u>240MG</u>	<u>A075366</u>	<u>004</u>	May 01, 2000
<u>AB1</u>	TEVA	<u>80MG</u>	<u>A075429</u>	<u>001</u>	May 01, 2000
<u>AB1</u>		<u>120MG</u>	<u>A075429</u>	<u>002</u>	May 01, 2000
<u>AB1</u>		<u>160MG</u>	<u>A075429</u>	<u>003</u>	May 01, 2000
<u>AB1</u>		<u>240MG</u>	<u>A075429</u>	<u>004</u>	May 01, 2000
<u>AB1</u>	VINTAGE PHARMS	<u>80MG</u>	<u>A075563</u>	<u>001</u>	Nov 07, 2003
<u>AB1</u>		<u>120MG</u>	<u>A075563</u>	<u>002</u>	Nov 07, 2003
<u>AB1</u>		<u>160MG</u>	<u>A075563</u>	<u>003</u>	Nov 07, 2003
<u>AB1</u>		<u>240MG</u>	<u>A075563</u>	<u>004</u>	Nov 07, 2003

BETAPACE AF

<u>AB2</u>	BAYER HLTHCARE	<u>80MG</u>	<u>N021151</u>	<u>001</u>	Feb 22, 2000
<u>AB2</u>		<u>120MG</u>	<u>N021151</u>	<u>002</u>	Feb 22, 2000
<u>AB2</u> +		<u>160MG</u>	<u>N021151</u>	<u>003</u>	Feb 22, 2000

SOTALOL HYDROCHLORIDE

<u>AB2</u>	AMNEAL PHARM	<u>80MG</u>	<u>A077070</u>	<u>001</u>	Nov 04, 2005
<u>AB2</u>		<u>120MG</u>	<u>A077070</u>	<u>002</u>	Nov 04, 2005
<u>AB2</u>		<u>160MG</u>	<u>A077070</u>	<u>003</u>	Nov 04, 2005
<u>AB2</u>	APOTEX	<u>80MG</u>	<u>A076214</u>	<u>001</u>	Aug 27, 2003
<u>AB2</u>		<u>120MG</u>	<u>A076214</u>	<u>002</u>	Aug 27, 2003
<u>AB2</u>		<u>160MG</u>	<u>A076214</u>	<u>003</u>	Aug 27, 2003
<u>AB2</u>	MYLAN	<u>80MG</u>	<u>A077616</u>	<u>001</u>	Feb 07, 2007
<u>AB2</u>		<u>120MG</u>	<u>A077616</u>	<u>002</u>	Feb 07, 2007
<u>AB2</u>		<u>160MG</u>	<u>A077616</u>	<u>003</u>	Feb 07, 2007
<u>AB2</u>	TEVA	<u>80MG</u>	<u>A076883</u>	<u>001</u>	Jul 26, 2004
<u>AB2</u>		<u>120MG</u>	<u>A076883</u>	<u>002</u>	Jul 26, 2004
<u>AB2</u>		<u>160MG</u>	<u>A076883</u>	<u>003</u>	Jul 26, 2004

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 10%

<u>AP</u> +	FRESENIUS	<u>10%</u>	<u>N017643</u>	<u>001</u>	
-------------	-----------	------------	----------------	------------	--

INTRALIPID 20%

<u>AP</u> +	FRESENIUS	<u>20%</u>	<u>N018449</u>	<u>001</u>	
-------------	-----------	------------	----------------	------------	--

## PRESCRIPTION DRUG PRODUCT LIST

3 - 352 (of 393)

SOYBEAN OIL

INJECTABLE; INJECTION

	<u>INTRALIPID 20%</u>				
<u>AP</u>	+ FRESENIUS	<u>20%</u>	<u>N020248</u>	<u>001</u>	Aug 07, 1996
	<u>INTRALIPID 30%</u>				
<u>AP</u>	+ FRESENIUS	<u>30%</u>	<u>N019942</u>	<u>001</u>	Dec 30, 1993
	<u>LIPOSYN III 10%</u>				
<u>AP</u>	+ HOSPIRA	<u>10%</u>	<u>N018969</u>	<u>001</u>	Sep 24, 1984
	<u>LIPOSYN III 20%</u>				
<u>AP</u>	+ HOSPIRA	<u>20%</u>	<u>N018970</u>	<u>001</u>	Sep 25, 1984
	<u>LIPOSYN III 30%</u>				
<u>AP</u>	+ HOSPIRA	<u>30%</u>	<u>N020181</u>	<u>001</u>	Jan 13, 1998
	<u>NUTRILIPID 10%</u>				
<u>AP</u>	+ B BRAUN	<u>10%</u>	<u>N019531</u>	<u>001</u>	May 28, 1993
	<u>NUTRILIPID 20%</u>				
<u>AP</u>	+ B BRAUN	<u>20%</u>	<u>N019531</u>	<u>002</u>	May 28, 1993

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

+ PHARMACIA AND UPJOHN EQ 2GM BASE/VIAL N050347 001

SPIRONOLACTONE

TABLET; ORAL

	<u>ALDACTONE</u>				
<u>AB</u>	GD SEARLE LLC	<u>25MG</u>	<u>N012151</u>	<u>009</u>	Dec 30, 1983
<u>AB</u>		<u>50MG</u>	<u>N012151</u>	<u>008</u>	Dec 30, 1982
<u>AB</u>	+	<u>100MG</u>	<u>N012151</u>	<u>010</u>	Dec 30, 1983
	<u>SPIRONOLACTONE</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>25MG</u>	<u>A040353</u>	<u>003</u>	Mar 15, 2006
<u>AB</u>		<u>50MG</u>	<u>A040353</u>	<u>001</u>	Jul 29, 1999
<u>AB</u>		<u>100MG</u>	<u>A040353</u>	<u>002</u>	Jul 29, 1999
<u>AB</u>	MUTUAL PHARM	<u>25MG</u>	<u>A089424</u>	<u>001</u>	Jul 23, 1986
<u>AB</u>		<u>50MG</u>	<u>A089424</u>	<u>002</u>	Aug 11, 1999
<u>AB</u>		<u>100MG</u>	<u>A089424</u>	<u>003</u>	Aug 11, 1999
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A040424</u>	<u>001</u>	Aug 20, 2001
<u>AB</u>		<u>50MG</u>	<u>A040424</u>	<u>002</u>	Aug 20, 2001
<u>AB</u>		<u>100MG</u>	<u>A040424</u>	<u>003</u>	Aug 20, 2001
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A086809</u>	<u>001</u>	
<u>AB</u>	VINTAGE	<u>25MG</u>	<u>A040750</u>	<u>001</u>	Aug 29, 2006
<u>AB</u>		<u>50MG</u>	<u>A040750</u>	<u>002</u>	Aug 29, 2006
<u>AB</u>		<u>100MG</u>	<u>A040750</u>	<u>003</u>	Aug 29, 2006

STAVUDINE

CAPSULE; ORAL

	<u>STAVUDINE</u>				
<u>AB</u>	AUROBINDO PHARMA	<u>15MG</u>	<u>A077672</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A077672</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A077672</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A077672</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>	HETERO DRUGS	<u>15MG</u>	<u>A078957</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A078957</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A078957</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A078957</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>	MATRIX LABS INC	<u>15MG</u>	<u>A079069</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A079069</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A079069</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A079069</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>	MATRIX LABS LTD	<u>30MG</u>	<u>A078775</u>	<u>001</u>	Jan 05, 2009
<u>AB</u>		<u>40MG</u>	<u>A078775</u>	<u>002</u>	Jan 05, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 353 (of 393)

STAVUDINE

CAPSULE; ORAL

ZERIT

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>15MG</u>	<u>N020412</u>	<u>002</u>	Jun 24, 1994
<u>AB</u>		<u>20MG</u>	<u>N020412</u>	<u>003</u>	Jun 24, 1994
<u>AB</u>		<u>30MG</u>	<u>N020412</u>	<u>004</u>	Jun 24, 1994
<u>AB</u>	+	<u>40MG</u>	<u>N020412</u>	<u>005</u>	Jun 24, 1994

FOR SOLUTION; ORAL

STAVUDINE

<u>AA</u>	AUROBINDO PHARMA	<u>1MG/ML</u>	<u>A077774</u>	<u>001</u>	Dec 29, 2008
<u>AA</u>	CIPLA LTD	<u>1MG/ML</u>	<u>A078030</u>	<u>001</u>	Mar 20, 2009
<u>AA</u>	+	<u>1MG/ML</u>	<u>N020413</u>	<u>001</u>	Sep 06, 1996

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

+	PFIZER	EQ 1GM BASE/2.5ML	A060111	001	
+	X GEN PHARMS	EQ 1GM BASE/VIAL	A064210	001	Jun 30, 1998

STREPTOZOCIN

INJECTABLE; INJECTION

ZANOSAR

+	TEVA PARENTERAL	1GM/VIAL	N050577	001	May 07, 1982
---	-----------------	----------	---------	-----	--------------

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION

METASTRON

<u>AP</u>	+	GE HEALTHCARE	<u>1mCi/ML</u>	<u>N020134</u>	<u>001</u>	Jun 18, 1993
<u>AP</u>		<u>STRONTIUM CHLORIDE SR-89</u>				
<u>AP</u>		BIO NUCLEONICS	<u>1mCi/ML</u>	<u>A075941</u>	<u>001</u>	Jan 06, 2003

SUCCIMER

CAPSULE; ORAL

CHEMET

+	LUNDBECK INC	100MG	N019998	002	Jan 30, 1991
---	--------------	-------	---------	-----	--------------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

<u>AP</u>	+	SANDOZ	<u>20MG/ML</u>	<u>N008453</u>	<u>002</u>	
<u>AP</u>	+	HOSPIRA	<u>20MG/ML</u>	<u>N008845</u>	<u>006</u>	
<u>AP</u>	+	HOSPIRA	<u>20MG/ML</u>	<u>N008845</u>	<u>001</u>	
		QUELICIN PRESERVATIVE FREE				
		+	HOSPIRA	N008845	004	

SUCRALFATE

SUSPENSION; ORAL

CARAFATE

+	AXCAN	1GM/10ML	N019183	001	Dec 16, 1993
---	-------	----------	---------	-----	--------------

TABLET; ORAL

CARAFATE

<u>AB</u>	+	AXCAN	<u>1GM</u>	<u>N018333</u>	<u>001</u>	
<u>AB</u>		<u>SUCRALFATE</u>				
<u>AB</u>		RATIOPHARM	<u>1GM</u>	<u>A074415</u>	<u>001</u>	Jun 08, 1998
<u>AB</u>		TEVA	<u>1GM</u>	<u>A070848</u>	<u>001</u>	Mar 29, 1996

## PRESCRIPTION DRUG PRODUCT LIST

3 - 354 (of 393)

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTA PRESERVATIVE FREE

<u>AP</u>	+	AKORN	<u>EQ 0.05MG BASE/ML</u>	<u>N019050</u>	<u>001</u>	May 04, 1984
<u>AP</u>		<u>SUFENTANIL CITRATE</u>				
<u>AP</u>		BAXTER HLTHCARE	<u>EQ 0.05MG BASE/ML</u>	<u>A074413</u>	<u>001</u>	Dec 15, 1995
<u>AP</u>		HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>A074534</u>	<u>001</u>	Dec 11, 1996

SULCONAZOLE NITRATE

CREAM; TOPICAL

EXELDERM

+	RANBAXY	1%	N018737	001	Feb 28, 1989
---	---------	----	---------	-----	--------------

SOLUTION; TOPICAL

EXELDERM

+	RANBAXY	1%	N018738	001	Aug 30, 1985
---	---------	----	---------	-----	--------------

SULFACETAMIDE SODIUM

LOTION; TOPICAL

KLARON

<u>AB</u>	+	SANOFI AVENTIS US	<u>10%</u>	<u>N019931</u>	<u>001</u>	Dec 23, 1996
<u>AB</u>		<u>SULFACETAMIDE SODIUM</u>				
<u>AB</u>		ALTANA	<u>10%</u>	<u>A077015</u>	<u>001</u>	Nov 17, 2006
<u>AB</u>		PERRIGO CO TENNESSEE	<u>10%</u>	<u>A078649</u>	<u>001</u>	Mar 23, 2009
<u>AB</u>		TARO	<u>10%</u>	<u>A078668</u>	<u>001</u>	May 20, 2009

OINTMENT; OPHTHALMIC

CETAMIDE

<u>AT</u>	+	ALCON	<u>10%</u>	<u>A080021</u>	<u>001</u>	
<u>AT</u>		<u>SULFACETAMIDE SODIUM</u>				
<u>AT</u>		ALTANA	<u>10%</u>	<u>A080029</u>	<u>001</u>	
<u>AT</u>	+	ALLERGAN	<u>10%</u>	<u>A080028</u>	<u>001</u>	
<u>AT</u>		<u>SULFACETAMIDE SODIUM</u>				
<u>AT</u>		ALCON UNIVERSAL	<u>10%</u>	<u>A089560</u>	<u>001</u>	Oct 18, 1988
<u>AT</u>		BAUSCH AND LOMB	<u>10%</u>	<u>A040066</u>	<u>001</u>	Dec 28, 1994

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

+	SANDOZ	500MG	A040091	001	Jul 29, 1994
---	--------	-------	---------	-----	--------------

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

+	TEVA PARENTERAL	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991
---	-----------------	-----------------	---------	-----	--------------

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

<u>AB</u>		HI TECH PHARMA	<u>200MG/5ML;40MG/5ML</u>	<u>A074650</u>	<u>001</u>	Dec 29, 1997
<u>AB</u>	+	TEVA PHARMS	<u>200MG/5ML;40MG/5ML</u>	<u>A077612</u>	<u>001</u>	Nov 13, 2006
<u>AB</u>		VINTAGE	<u>200MG/5ML;40MG/5ML</u>	<u>A077785</u>	<u>001</u>	Jan 24, 2007
<u>AB</u>		<u>SULFATRIM PEDIATRIC</u>				
<u>AB</u>		ACTAVIS MID ATLANTIC	<u>200MG/5ML;40MG/5ML</u>	<u>N018615</u>	<u>001</u>	Jan 07, 1983

TABLET; ORAL

BACTRIM

<u>AB</u>		MUTUAL PHARM	<u>400MG;80MG</u>	<u>N017377</u>	<u>001</u>	
<u>AB</u>	+	<u>BACTRIM DS</u>				
<u>AB</u>		MUTUAL PHARM	<u>800MG;160MG</u>	<u>N017377</u>	<u>002</u>	
<u>AB</u>		<u>SEPTRA</u>				
<u>AB</u>		MONARCH PHARMS	<u>400MG;80MG</u>	<u>N017376</u>	<u>001</u>	

## PRESCRIPTION DRUG PRODUCT LIST

3 - 355 (of 393)

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

<u>SEPTRA DS</u>					
<u>AB</u>	MONARCH PHARMS	<u>800MG;160MG</u>	<u>N017376</u>	<u>002</u>	
<u>SULFAMETHOPRIM</u>					
<u>AB</u>	PAR PHARM	<u>400MG;80MG</u>	<u>A070022</u>	<u>001</u>	Feb 15, 1985
<u>SULFAMETHOPRIM-DS</u>					
<u>AB</u>	PAR PHARM	<u>800MG;160MG</u>	<u>A070032</u>	<u>001</u>	Feb 15, 1985
<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM</u>					
<u>AB</u>	AMNEAL PHARMS NY	<u>400MG;80MG</u>	<u>A076899</u>	<u>001</u>	Jan 27, 2005
<u>AB</u>		<u>800MG;160MG</u>	<u>A076899</u>	<u>002</u>	Jan 27, 2005
<u>AB</u>	MUTUAL PHARM	<u>800MG;160MG</u>	<u>A071017</u>	<u>001</u>	Aug 25, 1986
<u>AB</u>	VINTAGE	<u>400MG;80MG</u>	<u>A078060</u>	<u>002</u>	Jan 25, 2007
<u>AB</u>		<u>800MG;160MG</u>	<u>A078060</u>	<u>001</u>	Jan 25, 2007
<u>AB</u>	VISTA PHARMS	<u>400MG;80MG</u>	<u>A076817</u>	<u>001</u>	Oct 07, 2005
<u>AB</u>		<u>800MG;160MG</u>	<u>A076817</u>	<u>002</u>	Oct 07, 2005
<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH</u>					
<u>AB</u>	SANDOZ	<u>800MG;160MG</u>	<u>N018598</u>	<u>004</u>	May 19, 1982
<u>AB</u>	TEVA	<u>800MG;160MG</u>	<u>A070037</u>	<u>001</u>	Jun 02, 1987
<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH</u>					
<u>AB</u>	PLANTEK	<u>400MG;80MG</u>	<u>A070030</u>	<u>001</u>	Jun 02, 1987

SULFANILAMIDE

CREAM; VAGINAL

AVC

+	AZUR PHARMA	15%	N006530	003	Jan 27, 1987
---	-------------	-----	---------	-----	--------------

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

+	PHARMACIA AND UPJOHN	250MG/5ML	A086983	001	
---	----------------------	-----------	---------	-----	--

TABLET; ORAL

AZULFIDINE

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>500MG</u>	<u>N007073</u>	<u>001</u>	
<u>SULFASALAZINE</u>						
<u>AB</u>		VINTAGE PHARMS	<u>500MG</u>	<u>A040349</u>	<u>001</u>	Jan 11, 2002
<u>AB</u>		WATSON LABS	<u>500MG</u>	<u>A085828</u>	<u>001</u>	
<u>AB</u>			<u>500MG</u>	<u>A087197</u>	<u>001</u>	

TABLET, DELAYED RELEASE; ORAL

AZULFIDINE EN-TABS

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>500MG</u>	<u>N007073</u>	<u>002</u>	Apr 06, 1983
<u>SULFASALAZINE</u>						
<u>AB</u>		VINTAGE PHARMS	<u>500MG</u>	<u>A075339</u>	<u>001</u>	Jan 11, 2002

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

+	IVAX SUB TEVA PHARMS	500MG	A080142	001	
---	----------------------	-------	---------	-----	--

SULINDAC

TABLET; ORAL

CLINORIL

<u>AB</u>	+	MERCK	<u>200MG</u>	<u>N017911</u>	<u>002</u>	
<u>SULINDAC</u>						
<u>AB</u>		EPIC PHARMA	<u>150MG</u>	<u>A072710</u>	<u>001</u>	Mar 25, 1991
<u>AB</u>			<u>200MG</u>	<u>A072711</u>	<u>001</u>	Mar 25, 1991
<u>AB</u>		MUTUAL PHARM	<u>150MG</u>	<u>A072050</u>	<u>001</u>	Apr 17, 1991
<u>AB</u>			<u>200MG</u>	<u>A072051</u>	<u>001</u>	Apr 17, 1991
<u>AB</u>		MYLAN	<u>150MG</u>	<u>A073039</u>	<u>002</u>	Jun 22, 1993

## PRESCRIPTION DRUG PRODUCT LIST

3 - 356 (of 393)

SULINDAC

TABLET; ORAL

SULINDAC

<u>AB</u>	MYLAN	<u>200MG</u>	<u>A073039</u>	<u>001</u>	Jun 22, 1993
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A071891</u>	<u>001</u>	Apr 03, 1990
<u>AB</u>		<u>200MG</u>	<u>A071795</u>	<u>001</u>	Apr 03, 1990

SUMATRIPTAN

SPRAY; NASAL

IMITREX

+	GLAXOSMITHKLINE	5MG/SPRAY	N020626	001	Aug 26, 1997
+		10MG/SPRAY	N020626	002	Aug 26, 1997
+		20MG/SPRAY	N020626	003	Aug 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX

<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080</u>	<u>001</u>	Dec 28, 1992
-----------	---	-----------------	--	----------------	------------	--------------

SUMATRIPTAN SUCCINATE

<u>AP</u>		APP PHARMS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079242</u>	<u>001</u>	Mar 02, 2009
<u>AP</u>			<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079240</u>	<u>002</u>	Sep 18, 2009
<u>AP</u>			<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>A079240</u>	<u>001</u>	Sep 18, 2009
<u>AP</u>		BEDFORD	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079123</u>	<u>001</u>	Feb 06, 2009
<u>AP</u>		JHP PHARMS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077871</u>	<u>001</u>	Jul 09, 2009
<u>AP</u>		PAR PHARM	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077332</u>	<u>001</u>	Oct 09, 2009
<u>AP</u>		SANDOZ	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>A078067</u>	<u>002</u>	Feb 06, 2009
<u>AP</u>			<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078067</u>	<u>001</u>	Feb 06, 2009
<u>AP</u>		TEVA PARENTERAL	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>A078318</u>	<u>001</u>	Feb 06, 2009
<u>AP</u>			<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078318</u>	<u>002</u>	Feb 06, 2009
<u>AP</u>			<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077907</u>	<u>001</u>	Feb 06, 2009
<u>AP</u>		WOCKHARDT	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078593</u>	<u>001</u>	Feb 06, 2009
		IMITREX STATDOSE				
+		GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080	002	Feb 01, 2006
+			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	003	Dec 23, 1996
		SUMAVEL DOSEPRO				
+		ZOGENIX INC	EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N022239	001	Jul 15, 2009

TABLET; ORAL

IMITREX

<u>AB</u>		GLAXOSMITHKLINE	<u>EQ 25MG BASE</u>	<u>N020132</u>	<u>002</u>	Jun 01, 1995
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>N020132</u>	<u>003</u>	Jun 01, 1995
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N020132</u>	<u>001</u>	Jun 01, 1995

SUMATRIPTAN SUCCINATE

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A078327</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A078327</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A078327</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>		COBALT LABS INC	<u>EQ 25MG BASE</u>	<u>A076933</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A076933</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A076933</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 25MG BASE</u>	<u>A076847</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A076847</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A076847</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>		MYLAN	<u>EQ 25MG BASE</u>	<u>A077163</u>	<u>001</u>	Nov 02, 2009
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A077744</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A077163</u>	<u>002</u>	Nov 02, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A077744</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A077163</u>	<u>003</u>	Nov 02, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A077744</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 25MG BASE</u>	<u>A078284</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A078284</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A078284</u>	<u>003</u>	Aug 10, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 357 (of 393)

SUMATRIPTAN SUCCINATE

TABLET; ORAL

SUMATRIPTAN SUCCINATE

<u>AB</u>	RANBAXY	<u>EQ 25MG BASE</u>	<u>A076554</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076554</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076572</u>	<u>001</u>	Feb 09, 2009
<u>AB</u>	ROXANE	<u>EQ 25MG BASE</u>	<u>A078241</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078241</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078241</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE</u>	<u>A076976</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076976</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076976</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	SUN PHARM INDS	<u>EQ 25MG BASE</u>	<u>A078295</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078295</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078295</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076840</u>	<u>001</u>	Feb 09, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076840</u>	<u>002</u>	Feb 09, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076840</u>	<u>003</u>	Feb 09, 2009

SUNITINIB MALATE

CAPSULE; ORAL

SUTENT

CPPI CV

EQ 12.5MG BASE

N021938 001

Jan 26, 2006

EQ 25MG BASE

N021938 002

Jan 26, 2006

EQ 37.5MG BASE

N021938 004

Mar 31, 2009

+

EQ 50MG BASE

N021938 003

Jan 26, 2006

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

COGNEX

SCIELE PHARMA INC

EQ 10MG BASE

N020070 001

Sep 09, 1993

EQ 20MG BASE

N020070 002

Sep 09, 1993

EQ 30MG BASE

N020070 003

Sep 09, 1993

+

EQ 40MG BASE

N020070 004

Sep 09, 1993

TACROLIMUS

CAPSULE; ORAL

PROGRAFAB ASTELLASEQ 0.5MG BASEN050708003 Aug 24, 1998ABEQ 1MG BASEN050708001 Apr 08, 1994AB +EQ 5MG BASEN050708002 Apr 08, 1994TACROLIMUSAB SANDOZEQ 0.5MG BASEA065461001 Aug 10, 2009ABEQ 1MG BASEA065461002 Aug 10, 2009ABEQ 5MG BASEA065461003 Aug 10, 2009

INJECTABLE; INJECTION

PROGRAF

+ ASTELLAS

EQ 5MG BASE/ML

N050709 001

Apr 08, 1994

OINTMENT; TOPICAL

PROTOPIC

ASTELLAS

0.03%

N050777 001

Dec 08, 2000

+

0.1%

N050777 002

Dec 08, 2000

TADALAFIL

TABLET; ORAL

ADCIRCA

+ ELI LILLY CO

20MG

N022332 001

May 22, 2009

CIALIS

LILLY

2.5MG

N021368 004

Jan 07, 2008



## PRESCRIPTION DRUG PRODUCT LIST

3 - 358 (of 393)

TADALAFIL

TABLET; ORAL

CIALIS

LILLY	5MG	N021368	001	Nov 21, 2003
	10MG	N021368	002	Nov 21, 2003
+	20MG	N021368	003	Nov 21, 2003

TALC

AEROSOL, METERED; INTRAPLEURAL

SCLEROSOL

+ BRYAN	400MG/SPRAY	N020587	001	Dec 24, 1997
---------	-------------	---------	-----	--------------

POWDER; INTRAPLEURAL

TALC

+ BRYAN	5GM/BOT	N021388	001	Dec 15, 2003
---------	---------	---------	-----	--------------

TAMOXIFEN CITRATE

TABLET; ORAL

TAMOXIFEN CITRATE

<u>AB</u>	AEGIS PHARMS	<u>EQ 10MG BASE</u>	<u>A076398</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076398</u>	<u>002</u>	Mar 31, 2003
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A074732</u>	<u>002</u>	Feb 20, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A074732</u>	<u>001</u>	Feb 20, 2003
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075797</u>	<u>001</u>	Feb 20, 2003
<u>AB</u> +	TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A074858</u>	<u>001</u>	Feb 20, 2003
<u>AB</u>	WATSON LABS	<u>EQ 10MG BASE</u>	<u>A070929</u>	<u>001</u>	Feb 20, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A070929</u>	<u>002</u>	Feb 20, 2003
<u>AB</u>	WATSON LABS FLORIDA	<u>EQ 10MG BASE</u>	<u>A076179</u>	<u>001</u>	Feb 20, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076179</u>	<u>002</u>	Feb 20, 2003

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

FLOMAX

+ BOEHRINGER INGELHEIM	0.4MG	N020579	001	Apr 15, 1997
------------------------	-------	---------	-----	--------------

TAPENTADOL HYDROCHLORIDE

TABLET; ORAL

NUCYNTA

ORTHO MCNEIL JANSSEN	EQ 50MG BASE	N022304	001	Nov 20, 2008
	EQ 75MG BASE	N022304	002	Nov 20, 2008
+	EQ 100MG BASE	N022304	003	Nov 20, 2008

TAZAROTENE

CREAM; TOPICAL

AVAGE

+ ALLERGAN	0.1%	N021184	003	Sep 30, 2002
------------	------	---------	-----	--------------

TAZORAC

+ ALLERGAN	0.05%	N021184	001	Sep 29, 2000
------------	-------	---------	-----	--------------

+	0.1%	N021184	002	Sep 29, 2000
---	------	---------	-----	--------------

GEL; TOPICAL

TAZORAC

+ ALLERGAN	0.05%	N020600	001	Jun 13, 1997
------------	-------	---------	-----	--------------

+	0.1%	N020600	002	Jun 13, 1997
---	------	---------	-----	--------------

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

PULMOLITE

BS	PHARMALUCENCE	N/A	N017776	001	
	TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT				
BS	DRAXIMAGE	N/A	N017881	001	Dec 30, 1987

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 385 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 359 (of 393)

TECHNETIUM TC-99M BICISATE KITINJECTABLE; INJECTION  
NEUROLITE

LANTHEUS MEDCL N/A

N0120256 001 Nov 23, 1994

TECHNETIUM TC-99M DISOFENIN KITINJECTABLE; INJECTION  
HEPATOLITE

PHARMALUCENCE N/A

N018467 001 Mar 16, 1982

TECHNETIUM TC-99M EXAMETAZIME KITINJECTABLE; INJECTION  
CERETEC

+ GE HEALTHCARE N/A

N019829 001 Dec 30, 1988

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION

CHOLETECAP + BRACCO N/AN018963 001 Jan 21, 1987TECHNETIUM TC-99M MEBROFENINAP PHARMALUCENCE N/AA078242 001 Jan 29, 2008TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

CIS-MDPAP PHARMALUCENCE N/AN018124 001MDP-BRACCOAP BRACCO N/AN018107 001

DRAXIMAGE MDP-10

+ DRAXIMAGE N/A

N018035 001

TECHNETIUM TC-99M MERTIATIDE KITINJECTABLE; INJECTION  
TECHNESCAN MAG3

MALLINCKRODT N/A

N019882 001 Jun 15, 1990

TECHNETIUM TC-99M OXIDRONATE KITINJECTABLE; INJECTION  
TECHNESCAN

+ MALLINCKRODT N/A

N018321 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

AN-DTPAAP PHARMALUCENCE N/AN017714 001DTPAAP DRAXIMAGE N/AN018511 001 Dec 29, 1989TECHNETIUM TC-99M PENTETATE KITAP GE HEALTHCARE N/AN017264 002TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

CIS-PYROAP PHARMALUCENCE N/AN019039 001 Jun 30, 1987TECHNESCAN PYP KITAP MALLINCKRODT N/AN017538 001

## PRESCRIPTION DRUG PRODUCT LIST

3 - 360 (of 393)

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG

MALLINCKRODT

N/A

N019981 001

Jun 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITEAP + LANTHEUS MEDCL N/AN019785 001

Dec 21, 1990

TECHNETIUM TC 99M SESTAMIBIAP CARDINAL HEALTH 414 N/AA078809 001

Apr 28, 2009

AP DRAXIMAGE N/AA078806 001

Apr 29, 2009

AP PHARMALUCENCE 10-30mCiA079157 001

Jul 10, 2009

TECHNETIUM TC-99 SESTAMIBIAP MALLINCKRODT N/AA078098 001

Sep 22, 2008

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

TECHNELITE

LANTHEUS MEDCL

0.0083-2.7 CI/GENERATOR

N017771 001

ULTRA-TECHNEKOW FM

MALLINCKRODT

0.25-3 CI/GENERATOR

N017243 002

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION

MPI DMSA KIDNEY REAGENT

GE HEALTHCARE

N/A

N017944 001

May 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

AN-SULFUR COLLOID

+ PHARMALUCENCE

N/A

N017858 001

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVIEW

+ GE HEALTHCARE

N/A

N020372 001

Feb 09, 1996

MYOVIEW 30ML

+ GE HEALTHCARE

N/A

N020372 002

Jul 07, 2005

TELAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

THERAVANCE INC

EQ 250MG BASE/VIAL

N022110 001

Sep 11, 2009

+

EQ 750MG BASE/VIAL

N022110 002

Sep 11, 2009

TELBIVUDINE

SOLUTION; ORAL

TYZEKA

+ NOVARTIS

100MG/5ML

N022154 001

Apr 28, 2009

TABLET; ORAL

TYZEKA

+ NOVARTIS

600MG

N022011 001

Oct 25, 2006

TELITHROMYCIN

TABLET; ORAL

KETEK

SANOFI AVENTIS US

300MG

N021144 002

Feb 09, 2005

+

400MG

N021144 001

Apr 01, 2004

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 387 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 361 (of 393)

TELMISARTAN

TABLET; ORAL

MICARDIS

BOEHRINGER INGELHEIM	20MG	N020850	003	Apr 04, 2000
	40MG	N020850	001	Nov 10, 1998
+	80MG	N020850	002	Nov 10, 1998

TEMAZEPAM

CAPSULE; ORAL

RESTORIL

<u>AB</u>	TYCO HLTHCARE	<u>7.5MG</u>	<u>N018163</u>	<u>003</u>	Oct 25, 1991
<u>AB</u>		<u>15MG</u>	<u>N018163</u>	<u>001</u>	
<u>AB</u>		<u>22.5MG</u>	<u>N018163</u>	<u>004</u>	Nov 02, 2004
<u>AB</u>	+	<u>30MG</u>	<u>N018163</u>	<u>002</u>	

TEMAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>15MG</u>	<u>A071638</u>	<u>001</u>	Aug 07, 1987
<u>AB</u>		<u>30MG</u>	<u>A071620</u>	<u>001</u>	Aug 07, 1987
<u>AB</u>	MUTUAL PHARM	<u>7.5MG</u>	<u>A078581</u>	<u>001</u>	Sep 08, 2009
<u>AB</u>		<u>22.5MG</u>	<u>A071175</u>	<u>002</u>	Sep 14, 2009
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A070920</u>	<u>004</u>	Jul 07, 1986
<u>AB</u>		<u>22.5MG</u>	<u>A070920</u>	<u>003</u>	Jun 12, 2009
<u>AB</u>		<u>30MG</u>	<u>A070920</u>	<u>001</u>	Jul 10, 1986
<u>AB</u>	NOVEL LABS INC	<u>15MG</u>	<u>A071456</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>		<u>30MG</u>	<u>A071457</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A071427</u>	<u>001</u>	Jan 12, 1988
<u>AB</u>		<u>30MG</u>	<u>A071428</u>	<u>001</u>	Jan 12, 1988
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A071446</u>	<u>001</u>	May 21, 1993
<u>AB</u>		<u>30MG</u>	<u>A071447</u>	<u>001</u>	May 21, 1993

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

SCHERING	5MG	N021029	001	Aug 11, 1999
	20MG	N021029	002	Aug 11, 1999
	100MG	N021029	003	Aug 11, 1999
	140MG	N021029	005	Oct 19, 2006
	180MG	N021029	006	Oct 19, 2006
+	250MG	N021029	004	Aug 11, 1999

POWDER; INTRAVENOUS

TEMODAR

+	SCHERING	100MG/VIAL	N022277	001	Feb 27, 2009
---	----------	------------	---------	-----	--------------

TEMSIROLIMUS

SOLUTION; INTRAVENOUS

TORISEL

+	WYETH PHARMS INC	25MG/ML (25MG/ML)	N022088	001	May 30, 2007
---	------------------	-------------------	---------	-----	--------------

TENIPOSIDE

INJECTABLE; INJECTION

VUMON

+	BRISTOL MYERS SQUIBB	10MG/ML	N020119	001	Jul 14, 1992
---	----------------------	---------	---------	-----	--------------

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

VIREAD

+	GILEAD	300MG	N021356	001	Oct 26, 2001
---	--------	-------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 362 (of 393)

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

HYTRIN

<u>AB</u>	ABBOTT	<u>EQ 1MG BASE</u>	<u>N020347</u>	<u>001</u>	Dec 14, 1994
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N020347</u>	<u>002</u>	Dec 14, 1994
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N020347</u>	<u>003</u>	Dec 14, 1994
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>N020347</u>	<u>004</u>	Dec 14, 1994

TERAZOSIN HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A075498</u>	<u>001</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075498</u>	<u>002</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075498</u>	<u>003</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075498</u>	<u>004</u>	Apr 12, 2001
<u>AB</u>	CADISTA PHARMS	<u>EQ 1MG BASE</u>	<u>A075317</u>	<u>001</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075317</u>	<u>002</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075317</u>	<u>003</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075317</u>	<u>004</u>	Dec 20, 2004
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A075614</u>	<u>002</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075614</u>	<u>001</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075614</u>	<u>003</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075614</u>	<u>004</u>	Jan 30, 2001
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A075140</u>	<u>002</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075140</u>	<u>003</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075140</u>	<u>001</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075140</u>	<u>004</u>	Feb 11, 2000
<u>AB</u>	RANBAXY	<u>EQ 1MG BASE</u>	<u>A076021</u>	<u>001</u>	Aug 22, 2002
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A076021</u>	<u>002</u>	Aug 22, 2002
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076021</u>	<u>003</u>	Aug 22, 2002
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076021</u>	<u>004</u>	Aug 22, 2002
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A074823</u>	<u>001</u>	Mar 30, 1998
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074823</u>	<u>002</u>	Mar 30, 1998
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A074823</u>	<u>003</u>	Mar 30, 1998
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A074823</u>	<u>004</u>	Mar 30, 1998

TABLET; ORAL

## HYTRIN

	ABBOTT	EQ 1MG BASE	N019057	001	Aug 07, 1987
	+	EQ 2MG BASE	N019057	002	Aug 07, 1987
		EQ 5MG BASE	N019057	003	Aug 07, 1987
		EQ 10MG BASE	N019057	004	Aug 07, 1987

TERBINAFINE

GEL; TOPICAL

## LAMISIL

	NOVARTIS	1%	N020846	001	Apr 29, 1998
--	----------	----	---------	-----	--------------

TERBINAFINE HYDROCHLORIDE

GRANULE; ORAL

## LAMISIL

	NOVARTIS	EQ 125MG BASE/PACKET	N022071	001	Sep 28, 2007
	+	EQ 187.5MG BASE/PACKET	N022071	002	Sep 28, 2007

SOLUTION; TOPICAL

## LAMISIL

	NOVARTIS	1%	N020749	001	Oct 17, 1997
--	----------	----	---------	-----	--------------

TABLET; ORAL

LAMISIL

<u>AB</u>	+	NOVARTIS	<u>EQ 250MG BASE</u>	<u>N020539</u>	<u>001</u>	May 10, 1996
-----------	---	----------	----------------------	----------------	------------	--------------

TERBINAFINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 250MG BASE</u>	<u>A078199</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A078297</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 250MG BASE</u>	<u>A076390</u>	<u>001</u>	Jul 02, 2007

## PRESCRIPTION DRUG PRODUCT LIST

3 - 363 (of 393)

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

<u>AB</u>	GEDEON RICHTER USA	<u>EQ 250MG BASE</u>	<u>A077065</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>	GENPHARM	<u>EQ 250MG BASE</u>	<u>A077136</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>	GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078157</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>	HARRIS PHARM	<u>EQ 250MG BASE</u>	<u>A077919</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>	INVAGEN PHARMS	<u>EQ 250MG BASE</u>	<u>A077533</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>	MYLAN	<u>EQ 250MG BASE</u>	<u>A077195</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A078163</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>	ROXANE	<u>EQ 250MG BASE</u>	<u>A077223</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A076377</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>	WATSON LABS	<u>EQ 250MG BASE</u>	<u>A077137</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 250MG BASE</u>	<u>A078229</u>	<u>001</u>	Jul 02, 2007

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

<u>AP</u>	AKORN	<u>1MG/ML</u>	<u>A078151</u>	<u>001</u>	Jan 07, 2008
<u>AP</u>	APP PHARMS	<u>1MG/ML</u>	<u>A076887</u>	<u>001</u>	May 26, 2004
<u>AP</u>	+ BEDFORD	<u>1MG/ML</u>	<u>A076770</u>	<u>001</u>	Apr 23, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078630</u>	<u>001</u>	May 20, 2009
<u>AP</u>	TEVA PARENTERAL	<u>1MG/ML</u>	<u>A076853</u>	<u>001</u>	Jul 20, 2004

TABLET; ORAL

TERBUTALINE SULFATE

<u>AB</u>	IMPAX LABS	<u>2.5MG</u>	<u>A075877</u>	<u>001</u>	Jun 26, 2001
<u>AB</u>		<u>5MG</u>	<u>A075877</u>	<u>002</u>	Jun 26, 2001
<u>AB</u>	LANNETT	<u>2.5MG</u>	<u>A077152</u>	<u>001</u>	Mar 25, 2005
<u>AB</u>		<u>5MG</u>	<u>A077152</u>	<u>002</u>	Mar 25, 2005

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>0.8%</u>	<u>N019964</u>	<u>001</u>	Feb 21, 1991
-----------	------------------------	-------------	----------------	------------	--------------

TERAZOL 7

<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>0.4%</u>	<u>N019579</u>	<u>001</u>	Dec 31, 1987
-----------	------------------------	-------------	----------------	------------	--------------

TERCONAZOLE

<u>AB</u>	ALTANA	<u>0.4%</u>	<u>A076712</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>	TARO	<u>0.4%</u>	<u>A076043</u>	<u>001</u>	Jan 19, 2005
<u>AB</u>		<u>0.8%</u>	<u>A075953</u>	<u>001</u>	Apr 06, 2004
BX	+ ALTANA	0.8%	N021735	001	Oct 01, 2004

SUPPOSITORY; VAGINAL

TERAZOL 3

<u>AB</u>	+ ORTHO MCNEIL JANSSEN	<u>80MG</u>	<u>N019641</u>	<u>001</u>	May 24, 1988
-----------	------------------------	-------------	----------------	------------	--------------

TERCONAZOLE

<u>AB</u>	ALTANA	<u>80MG</u>	<u>A076850</u>	<u>001</u>	Jul 12, 2006
<u>AB</u>	PERRIGO NEW YORK	<u>80MG</u>	<u>A077149</u>	<u>001</u>	Mar 17, 2006
<u>AB</u>	TARO	<u>80MG</u>	<u>A077553</u>	<u>001</u>	Mar 09, 2007

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

## FORTEO

	LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008
+		0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002

## PRESCRIPTION DRUG PRODUCT LIST

3 - 364 (of 393)

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL				
ANDRODERM				
	+ WATSON LABS	2.5MG/24HR	N020489	001 Sep 29, 1995
	+	5MG/24HR	N020489	002 May 02, 1997
GEL; TRANSDERMAL				
ANDROGEL				
BX	+ UNIMED PHARMS	1% (5GM/PACKET)	N021015	002 Feb 28, 2000
TESTIM				
BX	+ AUXILIUM PHARMS	1% (5GM/PACKET)	N021454	001 Oct 31, 2002
ANDROGEL				
	UNIMED PHARMS	1% (2.5GM/PACKET)	N021015	001 Feb 28, 2000
GEL, METERED; TRANSDERMAL				
ANDROGEL				
	+ UNIMED PHARMS	1% (1.25GM/ACTIVATION)	N021015	003 Sep 26, 2003
PELLET; IMPLANTATION				
TESTOPEL				
	+ SLATE PHARMS	75MG	A080911	001
TABLET, EXTENDED RELEASE; BUCCAL				
STRIANT				
	+ COLUMBIA LABS	30MG	N021543	001 Jun 19, 2003

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION				
<u>DEPO-TESTOSTERONE</u>				
<u>AO</u>	+ PHARMACIA AND UPJOHN	<u>100MG/ML</u>	<u>A085635</u>	<u>002</u>
<u>AO</u>	+	<u>200MG/ML</u>	<u>A085635</u>	<u>003</u>
<u>TESTOSTERONE CYPIONATE</u>				
<u>AO</u>	PADDOCK	<u>200MG/ML</u>	<u>A040530</u>	<u>001</u> Jan 31, 2005
<u>AO</u>	SANDOZ	<u>100MG/ML</u>	<u>A040615</u>	<u>001</u> Aug 10, 2006
<u>AO</u>		<u>200MG/ML</u>	<u>A040615</u>	<u>002</u> Aug 10, 2006
<u>AO</u>	SYNERX PHARMA	<u>200MG/ML</u>	<u>A040652</u>	<u>001</u> Dec 11, 2006
<u>AO</u>	WATSON LABS	<u>200MG/ML</u>	<u>A086030</u>	<u>001</u>

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION				
<u>DELATESTRYL</u>				
<u>AO</u>	+ ENDO PHARM	<u>200MG/ML</u>	<u>N009165</u>	<u>003</u>
<u>TESTOSTERONE ENANTHATE</u>				
<u>AO</u>	PADDOCK	<u>200MG/ML</u>	<u>A040575</u>	<u>001</u> Jun 14, 2006
<u>AO</u>	SYNERX PHARMA	<u>200MG/ML</u>	<u>A040647</u>	<u>001</u> Oct 05, 2009
<u>AO</u>	WATSON LABS	<u>200MG/ML</u>	<u>A085598</u>	<u>001</u>

TETRABENAZINE

TABLET; ORAL				
XENAZINE				
	BIOVAIL AMERICAS	12.5MG	N021894	001 Aug 15, 2008
	+	25MG	N021894	002 Aug 15, 2008

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL				
<u>TETRACYCLINE HYDROCHLORIDE</u>				
<u>AB</u>	IMPAX LABS	<u>250MG</u>	<u>A060469</u>	<u>001</u>
<u>AB</u>		<u>500MG</u>	<u>A060469</u>	<u>003</u>
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>250MG</u>	<u>A060704</u>	<u>001</u>
<u>AB</u>	+	<u>500MG</u>	<u>A060704</u>	<u>002</u>
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A061837</u>	<u>001</u>
<u>AB</u>		<u>500MG</u>	<u>A061837</u>	<u>002</u>

## PRESCRIPTION DRUG PRODUCT LIST

3 - 365 (of 393)

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HYDROCHLORIDE

IMPAX LABS 100MG A060469 002

SUSPENSION; ORAL

SUMYCIN

+ PAR PHARM 125MG/5ML A060400 001

TABLET; ORAL

SUMYCIN

PAR PHARM 250MG A061147 001

+ 500MG A061147 004

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+ NYCOMED US 0.05% A086576 002

0.1% A086576 001

SPRAY; NASAL

TYZINE

+ NYCOMED US 0.1% A086576 003

THALIDOMIDE

CAPSULE; ORAL

THALOMID

CELGENE 50MG N020785 001 Jul 16, 1998

100MG N020785 002 Jan 17, 2003

150MG N020785 004 Jan 10, 2007

+ 200MG N020785 003 Jan 17, 2003

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201AP + GE HEALTHCARE 1mCi/ML N018110 002 Feb 27, 1996AP + LANTHEUS MEDCL 1mCi/ML N017806 001AP + MALLINCKRODT 1mCi/ML N018150 001

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201AP + LANTHEUS MEDCL 2mCi/ML N017806 002 Oct 09, 1998AP MALLINCKRODT 2mCi/ML A077698 001 Nov 09, 2006THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

BC UCB INC 100MG A087942 001 Aug 22, 1983

BC 200MG A087943 001 Aug 22, 1983

BC 300MG A087944 001 Aug 22, 1983

THEOPHYLLINE

BC INWOOD LABS 100MG A040052 001 Feb 14, 1994

BC 200MG A040052 003 Feb 14, 1994

BC + 300MG A040052 004 Feb 14, 1994

THEO-24

UCB INC 400MG A081034 001 Feb 28, 1992

THEOPHYLLINE

INWOOD LABS 125MG A040052 002 Feb 14, 1994

ELIXIR; ORAL

ELIXOPHYLLIN

+ FOREST LABS 80MG/15ML A085186 001



## PRESCRIPTION DRUG PRODUCT LIST

3 - 366 (of 393)

THEOPHYLLINE

INJECTABLE; INJECTION

<u>THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	+ B BRAUN	<u>40MG/100ML</u>	<u>N019826 001</u> Aug 14, 1992
<u>THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	+ B BRAUN	<u>80MG/100ML</u>	<u>N019826 002</u> Aug 14, 1992
<u>THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	+ B BRAUN	<u>160MG/100ML</u>	<u>N019826 003</u> Aug 14, 1992
<u>THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	+ B BRAUN	<u>320MG/100ML</u>	<u>N019826 006</u> Aug 14, 1992
<u>THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	+ BAXTER HLTHCARE	<u>4MG/ML</u>	<u>N018649 007</u> Jul 26, 1982
<u>AP</u>	+	<u>40MG/100ML</u>	<u>N018649 001</u> Jul 26, 1982
<u>AP</u>	+	<u>80MG/100ML</u>	<u>N018649 002</u> Jul 26, 1982
<u>AP</u>	+	<u>160MG/100ML</u>	<u>N018649 003</u> Jul 26, 1982
<u>AP</u>	+	<u>200MG/100ML</u>	<u>N018649 004</u> Jul 26, 1982
<u>AP</u>	+	<u>320MG/100ML</u>	<u>N018649 006</u> Nov 13, 1985
<u>AP</u>	+	<u>400MG/100ML</u>	<u>N018649 005</u> Jul 26, 1982
<u>THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	+ HOSPIRA	<u>4MG/ML</u>	<u>N019211 007</u> Dec 14, 1984
<u>AP</u>	+	<u>40MG/100ML</u>	<u>N019211 001</u> Dec 14, 1984
<u>AP</u>	+	<u>80MG/100ML</u>	<u>N019211 002</u> Dec 14, 1984
<u>AP</u>	+	<u>160MG/100ML</u>	<u>N019211 003</u> Dec 14, 1984
<u>AP</u>	+	<u>200MG/100ML</u>	<u>N019211 004</u> Dec 14, 1984
<u>AP</u>	+	<u>320MG/100ML</u>	<u>N019211 006</u> Jan 20, 1988
<u>AP</u>	+	<u>400MG/100ML</u>	<u>N019211 005</u> Dec 14, 1984

TABLET; ORAL

THEOLAIR

+	GRACEWAY	125MG	A086399 001
+		250MG	A086399 002

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

<u>AB</u>	INWOOD LABS	<u>100MG</u>	<u>A088320 001</u> Feb 21, 1985
<u>AB</u>		<u>200MG</u>	<u>A088321 001</u> Feb 21, 1985
<u>AB</u>		<u>300MG</u>	<u>A087400 002</u> Jan 11, 1983
<u>THEOPHYLLINE</u>			
<u>AB</u>	INWOOD LABS	<u>450MG</u>	<u>A040034 001</u> Apr 28, 1995
<u>AB</u>	NOSTRUM	<u>400MG</u>	<u>A040595 001</u> Apr 21, 2006
<u>AB</u>		<u>600MG</u>	<u>A040560 002</u> Apr 21, 2006
<u>AB</u>	+ PLIVA	<u>100MG</u>	<u>A089807 001</u> Apr 30, 1990
<u>AB</u>	+	<u>200MG</u>	<u>A089808 001</u> Apr 30, 1990
<u>AB</u>		<u>300MG</u>	<u>A089763 001</u> Apr 30, 1990
<u>AB</u>	+	<u>450MG</u>	<u>A081236 001</u> Nov 09, 1992
<u>UNIPHYL</u>			
<u>AB</u>	PURDUE PHARM PRODS	<u>400MG</u>	<u>A087571 001</u> Sep 01, 1982
<u>AB</u>	+	<u>600MG</u>	<u>A040086 001</u> Apr 15, 1996

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

<u>AP</u>	+ APP PHARMS	<u>100MG/ML</u>	<u>A080556 001</u>
<u>AP</u>	HOSPIRA	<u>100MG/ML</u>	<u>A040079 001</u> May 03, 1996
<u>AP</u>	WATSON LABS	<u>100MG/ML</u>	<u>A080571 001</u>
	THIAMINE HYDROCHLORIDE		
	+ WATSON LABS	200MG/ML	A080571 002

THIOGUANINE

TABLET; ORAL

THIOGUANINE

+	GLAXOSMITHKLINE	40MG	N012429 001
---	-----------------	------	-------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 393 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 367 (of 393)

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A089431</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>		<u>25MG</u>	<u>A089432</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>		<u>50MG</u>	<u>A089433</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>		<u>100MG</u>	<u>A089953</u>	<u>001</u>	Oct 07, 1988
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A088004</u>	<u>002</u>	Mar 15, 1983
<u>AB</u>		<u>25MG</u>	<u>A088004</u>	<u>003</u>	Mar 15, 1983
<u>AB</u>		<u>50MG</u>	<u>A088004</u>	<u>004</u>	Mar 15, 1983
<u>AB</u>	+	<u>100MG</u>	<u>A088004</u>	<u>001</u>	Nov 18, 1983

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

<u>AP</u>	APP PHARMS	<u>15MG/VIAL</u>	<u>A075698</u>	<u>001</u>	Sep 20, 2001
<u>AP</u>	BEDFORD	<u>15MG/VIAL</u>	<u>A075547</u>	<u>001</u>	Apr 02, 2001
<u>AP</u>	+ TEVA PARENTERAL	<u>15MG/VIAL</u>	<u>A075730</u>	<u>001</u>	Apr 20, 2001
	THIOTEPA				
	+ TEVA PARENTERAL	30MG/VIAL	A075730	002	Apr 20, 2001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

<u>AB</u>	PFIZER	<u>1MG</u>	<u>N016584</u>	<u>001</u>	
<u>AB</u>		<u>2MG</u>	<u>N016584</u>	<u>002</u>	
<u>AB</u>	+	<u>5MG</u>	<u>N016584</u>	<u>003</u>	
<u>AB</u>		<u>10MG</u>	<u>N016584</u>	<u>004</u>	

THIOTHIXENE

<u>AB</u>	MYLAN	<u>1MG</u>	<u>A071093</u>	<u>002</u>	Jun 23, 1987
<u>AB</u>		<u>2MG</u>	<u>A071093</u>	<u>003</u>	Jun 23, 1987
<u>AB</u>		<u>5MG</u>	<u>A071093</u>	<u>004</u>	Jun 23, 1987
<u>AB</u>		<u>10MG</u>	<u>A071093</u>	<u>001</u>	Jun 23, 1987
<u>AB</u>	SANDOZ	<u>1MG</u>	<u>A071610</u>	<u>001</u>	Jun 24, 1987
<u>AB</u>		<u>2MG</u>	<u>A071570</u>	<u>001</u>	Jun 24, 1987
<u>AB</u>		<u>5MG</u>	<u>A071529</u>	<u>001</u>	Jun 24, 1987
<u>AB</u>		<u>10MG</u>	<u>A071530</u>	<u>001</u>	Jun 24, 1987
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A070601</u>	<u>001</u>	Jun 05, 1987
<u>AB</u>		<u>5MG</u>	<u>A070602</u>	<u>001</u>	Jun 05, 1987

THYROTROPIN ALFA

INJECTABLE; INJECTION

THYROGEN

	+ GENZYME	1.1MG/VIAL	N020898	001	Nov 30, 1998
--	-----------	------------	---------	-----	--------------

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

	CEPHALON	2MG	N020646	005	Apr 16, 1999
	+	4MG	N020646	001	Sep 30, 1997
		6MG	N020646	006	Nov 29, 2005
		8MG	N020646	007	Nov 29, 2005
		10MG	N020646	008	Nov 29, 2005
		12MG	N020646	002	Sep 30, 1997
		16MG	N020646	003	Sep 30, 1997

## PRESCRIPTION DRUG PRODUCT LIST

3 - 368 (of 393)

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>250MG</u>	<u>A075253</u>	<u>001</u>	Aug 20, 1999
<u>AB</u>	APOTEX	<u>250MG</u>	<u>A075089</u>	<u>001</u>	Jul 01, 1999
<u>AB</u>	CARACO	<u>250MG</u>	<u>A075526</u>	<u>001</u>	Sep 26, 2002
<u>AB</u>	GENPHARM	<u>250MG</u>	<u>A075161</u>	<u>001</u>	Sep 13, 1999
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A075326</u>	<u>001</u>	Aug 20, 1999
<u>AB</u> +	TEVA	<u>250MG</u>	<u>A075149</u>	<u>001</u>	Aug 20, 1999

TIGECYCLINE

INJECTABLE; IV (INFUSION)

TYGACIL

+	WYETH PHARMS INC	50MG/VIAL	N021821	001	Jun 15, 2005
---	------------------	-----------	---------	-----	--------------

TILUDRONATE DISODIUM

TABLET; ORAL

SKELID

+	SANOFI AVENTIS US	EQ 200MG BASE	N020707	001	Mar 07, 1997
---	-------------------	---------------	---------	-----	--------------

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

+	SANTEN OY	EQ 0.25% BASE	N020439	001	Mar 31, 1995
+		EQ 0.5% BASE	N020439	002	Mar 31, 1995

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

<u>AB</u>	FALCON PHARMS	<u>EQ 0.25% BASE</u>	<u>N020963</u>	<u>001</u>	Oct 21, 1998
<u>AB</u>		<u>EQ 0.5% BASE</u>	<u>N020963</u>	<u>002</u>	Oct 21, 1998
<u>TIMOPTIC-XE</u>					
<u>AB</u> +	ATON	<u>EQ 0.25% BASE</u>	<u>N020330</u>	<u>001</u>	Nov 04, 1993
<u>AB</u> +		<u>EQ 0.5% BASE</u>	<u>N020330</u>	<u>002</u>	Nov 04, 1993

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

<u>AT</u>	AKORN	<u>EQ 0.25% BASE</u>	<u>A074515</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A074466</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A074516</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 0.25% BASE</u>	<u>A074778</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A074776</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>	FALCON PHARMS	<u>EQ 0.25% BASE</u>	<u>A074261</u>	<u>001</u>	Apr 28, 1995
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A074262</u>	<u>001</u>	Apr 28, 1995
<u>AT</u>	FDC LTD	<u>EQ 0.25% BASE</u>	<u>A077259</u>	<u>001</u>	Apr 30, 2008
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A077259</u>	<u>002</u>	Apr 30, 2008
<u>AT</u>	HI TECH PHARMA	<u>EQ 0.5% BASE</u>	<u>A075163</u>	<u>001</u>	Sep 10, 2002
<u>AT</u>	NOVEX	<u>EQ 0.25% BASE</u>	<u>A075411</u>	<u>001</u>	Sep 08, 2000
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A075412</u>	<u>001</u>	Sep 08, 2000
<u>AT</u>	PACIFIC PHARMA	<u>EQ 0.25% BASE</u>	<u>A074746</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A074747</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>	WOCKHARDT	<u>EQ 0.25% BASE</u>	<u>A078771</u>	<u>001</u>	Sep 28, 2009
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A078771</u>	<u>002</u>	Sep 28, 2009
<u>TIMOPTIC</u>					
<u>AT</u> +	ATON	<u>EQ 0.25% BASE</u>	<u>N018086</u>	<u>001</u>	
<u>AT</u> +		<u>EQ 0.5% BASE</u>	<u>N018086</u>	<u>002</u>	
ISTALOL					
BT	ISTA PHARMS	EQ 0.5% BASE	N021516	001	Jun 04, 2004
TIMOPTIC IN OCULOSE					
+	ATON	EQ 0.25% BASE	N019463	001	Nov 05, 1986

## PRESCRIPTION DRUG PRODUCT LIST

3 - 369 (of 393)

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

+ ATON	EQ 0.5% BASE	N019463 002	Nov 05, 1986
--------	--------------	-------------	--------------

TABLET; ORAL

TIMOLOL MALEATE

MYLAN

5MG

A072668 002 Jun 08, 1990

10MG

A072668 003 Jun 08, 1990

+

20MG

A072668 001 Jun 08, 1990

TINIDAZOLE

TABLET; ORAL

TINDAMAX

MISSION PHARMA

250MG

N021618 001 May 17, 2004

+

500MG

N021618 002 May 17, 2004

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

+ CELGENE

20,000 IU/ML

N020484 001 Jul 14, 2000

TIOPRONIN

TABLET; ORAL

TIOPRONIN

+ MISSION PHARMA

100MG

N019569 001 Aug 11, 1988

TIOTROPIUM BROMIDE MONOHYDRATE

POWDER; INHALATION

SPIRIVA

+ BOEHRINGER INGELHEIM EQ 0.018MG BASE/INH

N021395 001 Jan 30, 2004

TIPRANAVIR

CAPSULE; ORAL

APTIVUS

+ BOEHRINGER INGELHEIM 250MG

N021814 001 Jun 22, 2005

SOLUTION; ORAL

APTIVUS

+ BOEHRINGER INGELHEIM 100MG/ML

N022292 001 Jun 23, 2008

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE

EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)

N020913 002 May 17, 2002

+

EQ 12.5MG BASE/250ML (EQ 0.05MG  
BASE/ML)

N020913 003 Apr 20, 2000

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

ZANAFLEX

ACORDA

EQ 2MG BASE

N021447 001 Aug 29, 2002

EQ 4MG BASE

N021447 002 Aug 29, 2002

+

EQ 6MG BASE

N021447 003 Aug 29, 2002

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 2MG BASE</u>	<u>A076283 001</u>	Jul 12, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076283 002</u>	Jul 12, 2002
<u>AB</u>	ACTAVIS TOTOWA	<u>EQ 2MG BASE</u>	<u>A076281 001</u>	Oct 20, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076281 002</u>	Oct 20, 2003

## PRESCRIPTION DRUG PRODUCT LIST

3 - 370 (of 393)

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

<u>AB</u>	ALPHAPHARM	<u>EQ 2MG BASE</u>	<u>A076282</u>	<u>001</u>	Dec 16, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076282</u>	<u>002</u>	Dec 16, 2003
<u>AB</u>	APOTEX	<u>EQ 2MG BASE</u>	<u>A076533</u>	<u>001</u>	Jan 16, 2004
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076533</u>	<u>002</u>	Jan 16, 2004
<u>AB</u>	CARACO	<u>EQ 2MG BASE</u>	<u>A076416</u>	<u>001</u>	Sep 29, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076416</u>	<u>002</u>	Sep 29, 2003
<u>AB</u>	COREPHARMA	<u>EQ 2MG BASE</u>	<u>A076347</u>	<u>001</u>	Oct 11, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076347</u>	<u>002</u>	Oct 11, 2002
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 2MG BASE</u>	<u>A076286</u>	<u>001</u>	Jul 03, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076286</u>	<u>002</u>	Jul 03, 2002
<u>AB</u>	MYLAN	<u>EQ 2MG BASE</u>	<u>A076354</u>	<u>001</u>	Mar 28, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076354</u>	<u>002</u>	Mar 28, 2003
<u>AB</u>	SANDOZ	<u>EQ 2MG BASE</u>	<u>A076399</u>	<u>001</u>	Nov 26, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076280</u>	<u>002</u>	Jun 27, 2002
<u>AB</u>	TEVA	<u>EQ 2MG BASE</u>	<u>A076284</u>	<u>001</u>	Jul 03, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076284</u>	<u>002</u>	Jul 03, 2002
<u>ZANAFLEX</u>					
<u>AB</u>	+ ACORDA	<u>EQ 4MG BASE</u>	<u>N020397</u>	<u>001</u>	Nov 27, 1996

TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBREX

+ ALCON 0.3% N050555 001

SOLUTION; INHALATION

TOBI

+ NOVARTIS PHARMS 300MG/5ML N050753 001 Dec 22, 1997

SOLUTION/DROPS; OPHTHALMIC

AKTOBAT AKORN 0.3% A064096 001 Jan 31, 1996TOBRAMYCINAT ALTANA 0.3% A065026 001 Sep 11, 2001AT BAUSCH AND LOMB 0.3% A064052 001 Nov 29, 1993AT NOVEX 0.3% A065087 001 Feb 25, 2002TOBREXAT ALCON 0.3% A062535 001 Dec 13, 1984AT + FALCON PHARMS 0.3% N050541 001TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATEAP AKORN STRIDES EQ 40MG BASE/ML A065407 001 Mar 11, 2008AP APOTHECON EQ 10MG BASE/ML A064021 001 May 31, 1994AP APP PHARMS EQ 10MG BASE/ML A065122 001 Nov 29, 2002AP + EQ 40MG BASE/ML A065122 002 Nov 29, 2002AP EQ 1.2GM BASE/VIAL N050789 001 Jul 13, 2004AP BAXTER HLTHCARE EQ 40MG BASE/ML A063117 001 Apr 26, 1991AP + HOSPIRA EQ 10MG BASE/ML A063080 001 Apr 30, 1991AP EQ 10MG BASE/ML A063112 001 Apr 30, 1991AP EQ 40MG BASE/ML A063111 001 Apr 30, 1991AP + EQ 40MG BASE/ML A063116 001 May 18, 1992AP MARSAM PHARMS LLC EQ 10MG BASE/ML A062945 001 Aug 09, 1989AP TEVA PARENTERAL EQ 40MG BASE/ML A063100 001 Jan 30, 1992AP + X GEN PHARMS EQ 1.2GM BASE/VIAL A065013 001 Aug 17, 2001TOBRAMYCIN SULFATE (PHARMACY BULK)AP APP PHARMS EQ 40MG BASE/ML A065120 001 Nov 29, 2002

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ HOSPIRA EQ 1.2GM BASE/ML A063081 003 Jul 31, 1990

## PRESCRIPTION DRUG PRODUCT LIST

3 - 371 (of 393)

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	HOSPIRA	EQ 1.6MG BASE/ML	A063081	006	Jun 02, 1993
+		EQ 80MG BASE/100ML	A063081	001	Jul 31, 1990

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

<u>AB</u>	MYLAN	<u>250MG</u>	<u>A070259</u>	<u>001</u>	Jan 02, 1986
<u>AB</u>	+	<u>500MG</u>	<u>A070259</u>	<u>003</u>	Mar 17, 1986
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A070514</u>	<u>001</u>	Jan 09, 1986
<u>AB</u>		<u>500MG</u>	<u>A070515</u>	<u>001</u>	Jan 09, 1986

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

<u>AB</u>	MYLAN	<u>500MG</u>	<u>A086445</u>	<u>001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>A086109</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A087318</u>	<u>001</u>	

TOLCAPONE

TABLET; ORAL

TASMAR

	VALEANT PHARM INTL	100MG	N020697	001	Jan 29, 1998
+		200MG	N020697	002	Jan 29, 1998

TOLMETIN SODIUM

CAPSULE; ORAL

TOLECTIN DS

<u>AB</u>	+	ORTHO MCNEIL JANSSEN	<u>EQ 400MG BASE</u>	<u>N018084</u>	<u>001</u>
-----------	---	----------------------	----------------------	----------------	------------

TOLMETIN SODIUM

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 400MG BASE</u>	<u>A073308</u>	<u>001</u>	Jan 24, 1992
<u>AB</u>	MYLAN	<u>EQ 400MG BASE</u>	<u>A073393</u>	<u>001</u>	May 27, 1993
<u>AB</u>	TEVA	<u>EQ 400MG BASE</u>	<u>A073290</u>	<u>001</u>	Nov 27, 1991

TABLET; ORAL

TOLECTIN

<u>AB</u>	ORTHO MCNEIL JANSSEN	<u>EQ 200MG BASE</u>	<u>N017628</u>	<u>001</u>	
-----------	----------------------	----------------------	----------------	------------	--

TOLECTIN 600

<u>AB</u>	+	ORTHO MCNEIL JANSSEN	<u>EQ 600MG BASE</u>	<u>N017628</u>	<u>002</u>	Mar 08, 1989
-----------	---	----------------------	----------------------	----------------	------------	--------------

TOLMETIN SODIUM

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 600MG BASE</u>	<u>A074399</u>	<u>001</u>	Mar 28, 1996
<u>AB</u>	MUTUAL PHARM	<u>EQ 200MG BASE</u>	<u>A073310</u>	<u>001</u>	Nov 27, 1991
<u>AB</u>	MYLAN	<u>EQ 600MG BASE</u>	<u>A074473</u>	<u>001</u>	Aug 30, 1994

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

DETROL LA

	PHARMACIA AND UPJOHN	2MG	N021228	001	Dec 22, 2000
+		4MG	N021228	002	Dec 22, 2000

TABLET; ORAL

DETROL

	PHARMACIA AND UPJOHN	1MG	N020771	001	Mar 25, 1998
+		2MG	N020771	002	Mar 25, 1998

TOLVAPTAN

TABLET; ORAL

SAMSCA

	OTSUKA AMERICA PHARM	15MG	N022275	001	May 19, 2009
--	----------------------	------	---------	-----	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 398 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 372 (of 393)

TOLVAPTAN

TABLET; ORAL

SAMSCA

+ OTSUKA AMERICA PHARM 30MG N022275 002 May 19, 2009

TOPIRAMATE

CAPSULE; ORAL

TOPAMAXAB ORTHO MCNEIL JANSSEN 15MG N020844 001 Oct 26, 1998AB + 25MG N020844 002 Oct 26, 1998TOPIRAMATEAB COBALT LABS INC 15MG A077868 001 Apr 15, 2009AB 25MG A077868 002 Apr 15, 2009AB MYLAN 15MG A078418 001 Oct 14, 2009AB 25MG A078418 002 Oct 14, 2009AB SANDOZ 15MG A079206 001 Oct 14, 2009AB 25MG A079206 002 Oct 14, 2009AB TEVA 15MG A076575 001 Apr 17, 2009AB 25MG A076575 002 Apr 17, 2009AB ZYDUS PHARMS USA INC 15MG A078877 001 Oct 14, 2009AB 25MG A078877 002 Oct 14, 2009

TABLET; ORAL

TOPAMAXAB + ORTHO MCNEIL JANSSEN 25MG N020505 004 Dec 24, 1996AB 50MG N020505 005 Dec 24, 1996AB 100MG N020505 001 Dec 24, 1996AB 200MG N020505 002 Dec 24, 1996TOPIRAMATEAB ACCORD HLTHCARE 25MG A076311 001 Mar 27, 2009AB 50MG A076311 002 Mar 27, 2009AB 100MG A076311 003 Mar 27, 2009AB 200MG A076311 004 Mar 27, 2009AB APOTEX INC 25MG A077733 001 Mar 27, 2009AB 50MG A077733 002 Mar 27, 2009AB 100MG A077733 003 Mar 27, 2009AB 200MG A077733 004 Mar 27, 2009AB AUROBINDO PHARMA 25MG A078462 001 Mar 27, 2009AB 50MG A078462 002 Mar 27, 2009AB 100MG A078462 003 Mar 27, 2009AB 200MG A078462 004 Mar 27, 2009AB CIPLA LTD 25MG A076343 001 Mar 27, 2009AB 50MG A076343 002 Mar 27, 2009AB 100MG A076343 003 Mar 27, 2009AB 200MG A076343 004 Mar 27, 2009AB COBALT LABS INC 25MG A077643 001 Mar 27, 2009AB 50MG A077643 002 Mar 27, 2009AB 100MG A077643 003 Mar 27, 2009AB 200MG A077643 004 Mar 27, 2009AB GLENMARK GENERICS 25MG A077627 001 Mar 27, 2009AB 50MG A077627 002 Mar 27, 2009AB 100MG A077627 003 Mar 27, 2009AB 200MG A077627 004 Mar 27, 2009AB INVAGEN PHARMS 25MG A079162 001 Mar 27, 2009AB 50MG A079162 002 Mar 27, 2009AB 100MG A079162 003 Mar 27, 2009AB 200MG A079162 004 Mar 27, 2009AB MYLAN 25MG A076314 001 Mar 27, 2009AB 50MG A076314 002 Mar 27, 2009AB 100MG A076314 003 Mar 27, 2009AB 200MG A076314 004 Mar 27, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 373 (of 393)

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

<u>AB</u>	PLIVA HRVATSKA DOO	<u>25MG</u>	<u>A077905</u>	<u>001</u>	Mar 30, 2009
<u>AB</u>		<u>50MG</u>	<u>A077905</u>	<u>002</u>	Mar 30, 2009
<u>AB</u>		<u>100MG</u>	<u>A077905</u>	<u>003</u>	Mar 30, 2009
<u>AB</u>		<u>200MG</u>	<u>A077905</u>	<u>004</u>	Mar 30, 2009
<u>AB</u>	RANBAXY	<u>25MG</u>	<u>A076327</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076327</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076327</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>	ROXANE	<u>25MG</u>	<u>A076306</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076306</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076306</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076306</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>25MG</u>	<u>A090278</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090278</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090278</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090278</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076317</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076317</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076317</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076317</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A079153</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079153</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079153</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079153</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A090162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A078499</u>	<u>001</u>	Jan 07, 2010
<u>AB</u>		<u>50MG</u>	<u>A078499</u>	<u>002</u>	Jan 07, 2010
<u>AB</u>		<u>100MG</u>	<u>A078499</u>	<u>003</u>	Jan 07, 2010
<u>AB</u>		<u>200MG</u>	<u>A078499</u>	<u>004</u>	Jan 07, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078235</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078235</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078235</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078235</u>	<u>004</u>	Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCANTIN

SMITHKLINE BEECHAM	EQ 0.25MG BASE	N020981	001	Oct 11, 2007
+	EQ 1MG BASE	N020981	002	Oct 11, 2007

INJECTABLE; INJECTION

HYCANTIN

+	GLAXOSMITHKLINE	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996
---	-----------------	------------------	---------	-----	--------------

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+	GTX INC	EQ 60MG BASE	N020497	001	May 29, 1997
---	---------	--------------	---------	-----	--------------

TORSEMIDE

INJECTABLE; INJECTION

TORSEMIDE

+	BEDFORD LABS	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008
+		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008



## PRESCRIPTION DRUG PRODUCT LIST

3 - 374 (of 393)

TORSEMIDE

TABLET; ORAL

DEMADEX

<u>AB</u>	MEDA PHARMS	<u>5MG</u>	<u>N020136</u>	<u>001</u>	Aug 23, 1993
<u>AB</u>		<u>10MG</u>	<u>N020136</u>	<u>002</u>	Aug 23, 1993
<u>AB</u>	+	<u>20MG</u>	<u>N020136</u>	<u>003</u>	Aug 23, 1993
<u>AB</u>		<u>100MG</u>	<u>N020136</u>	<u>004</u>	Aug 23, 1993

TORSEMIDE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A076894</u>	<u>001</u>	May 31, 2005
<u>AB</u>		<u>10MG</u>	<u>A076894</u>	<u>002</u>	May 31, 2005
<u>AB</u>		<u>20MG</u>	<u>A076894</u>	<u>003</u>	May 31, 2005
<u>AB</u>		<u>100MG</u>	<u>A076894</u>	<u>004</u>	May 31, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078249</u>	<u>001</u>	Oct 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A078249</u>	<u>002</u>	Oct 17, 2007
<u>AB</u>		<u>20MG</u>	<u>A078249</u>	<u>003</u>	Oct 17, 2007
<u>AB</u>		<u>100MG</u>	<u>A078249</u>	<u>004</u>	Oct 17, 2007
<u>AB</u>	HETERO DRUGS	<u>5MG</u>	<u>A079234</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A079234</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>20MG</u>	<u>A079234</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079234</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A076226</u>	<u>001</u>	May 27, 2003
<u>AB</u>		<u>10MG</u>	<u>A076226</u>	<u>002</u>	May 27, 2003
<u>AB</u>		<u>20MG</u>	<u>A076226</u>	<u>003</u>	May 27, 2003
<u>AB</u>		<u>100MG</u>	<u>A076226</u>	<u>004</u>	May 27, 2003
<u>AB</u>	PLIVA PHARM IND	<u>5MG</u>	<u>A076346</u>	<u>001</u>	May 30, 2003
<u>AB</u>		<u>10MG</u>	<u>A076346</u>	<u>002</u>	May 30, 2003
<u>AB</u>		<u>20MG</u>	<u>A076346</u>	<u>003</u>	May 30, 2003
<u>AB</u>		<u>100MG</u>	<u>A076346</u>	<u>004</u>	Oct 19, 2004
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A076943</u>	<u>001</u>	Mar 01, 2005
<u>AB</u>		<u>10MG</u>	<u>A076943</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>		<u>20MG</u>	<u>A076943</u>	<u>003</u>	Mar 01, 2005
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A078478</u>	<u>001</u>	Feb 26, 2008
<u>AB</u>		<u>10MG</u>	<u>A078478</u>	<u>002</u>	Feb 26, 2008
<u>AB</u>		<u>20MG</u>	<u>A078478</u>	<u>003</u>	Feb 26, 2008
<u>AB</u>		<u>100MG</u>	<u>A078478</u>	<u>004</u>	Feb 26, 2008
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076110</u>	<u>001</u>	May 14, 2002
<u>AB</u>		<u>10MG</u>	<u>A076110</u>	<u>002</u>	May 14, 2002
<u>AB</u>		<u>20MG</u>	<u>A076110</u>	<u>003</u>	May 14, 2002
<u>AB</u>		<u>100MG</u>	<u>A076110</u>	<u>004</u>	May 14, 2002

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>50MG</u>	<u>A075960</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	ALPHAPHARM	<u>50MG</u>	<u>A075980</u>	<u>001</u>	Nov 21, 2002
<u>AB</u>	AMNEAL PHARMS	<u>50MG</u>	<u>A076003</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A075981</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>	CARACO	<u>50MG</u>	<u>A075964</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	MALLINCKRODT	<u>50MG</u>	<u>A075983</u>	<u>001</u>	Jun 25, 2002
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A076100</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075986</u>	<u>001</u>	Jun 21, 2002
<u>AB</u>	PLIVA	<u>50MG</u>	<u>A075982</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A075968</u>	<u>001</u>	Jun 25, 2002
<u>AB</u>	TEVA	<u>50MG</u>	<u>A075977</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A075962</u>	<u>001</u>	Jun 24, 2002

ULTRAM

<u>AB</u>	+	ORTHO MCNEIL JANSSEN	<u>50MG</u>	<u>N020281</u>	<u>002</u>	Mar 03, 1995
-----------	---	----------------------	-------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	PAR PHARM	<u>100MG</u>	<u>A078783</u>	<u>001</u>	Nov 13, 2009
-----------	-----------	--------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

3 - 375 (of 393)

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

<u>TRAMADOL HYDROCHLORIDE</u>					
<u>AB</u>	PAR PHARM	<u>200MG</u>	<u>A078783</u>	<u>002</u>	Nov 13, 2009
<u>ULTRAM ER</u>					
<u>AB</u>	+ BIOVAIL LABS INTL	<u>100MG</u>	<u>N021692</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>		<u>200MG</u>	<u>N021692</u>	<u>002</u>	Sep 08, 2005
RYZOLT					
BC	+ PURDUE PHARMA	100MG	N021745	001	Dec 30, 2008
BC		200MG	N021745	002	Dec 30, 2008
BC		300MG	N021745	003	Dec 30, 2008
ULTRAM ER					
BC	BIOVAIL LABS INTL	300MG	N021692	003	Sep 08, 2005

TRANDOLAPRIL

TABLET; ORAL

<u>MAVIK</u>					
<u>AB</u>	ABBOTT	<u>1MG</u>	<u>N020528</u>	<u>001</u>	Apr 26, 1996
<u>AB</u>		<u>2MG</u>	<u>N020528</u>	<u>002</u>	Apr 26, 1996
<u>AB</u>	+	<u>4MG</u>	<u>N020528</u>	<u>003</u>	Apr 26, 1996
<u>TRANDOLAPRIL</u>					
<u>AB</u>	AUROBINDO PHARMA	<u>1MG</u>	<u>A078438</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078438</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078438</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	CIPLA	<u>1MG</u>	<u>A077307</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077307</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077307</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	COBALT	<u>1MG</u>	<u>A077805</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077805</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077805</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	COREPHARMA	<u>1MG</u>	<u>A077256</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077256</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077256</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A078493</u>	<u>001</u>	Aug 25, 2008
<u>AB</u>		<u>2MG</u>	<u>A078493</u>	<u>002</u>	Aug 25, 2008
<u>AB</u>		<u>4MG</u>	<u>A078493</u>	<u>003</u>	Aug 25, 2008
<u>AB</u>	GLENMARK GENERICS	<u>1MG</u>	<u>A078508</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>2MG</u>	<u>A078508</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>4MG</u>	<u>A078508</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A078320</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078320</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078320</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	LUPIN	<u>1MG</u>	<u>A077522</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077522</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077522</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A078346</u>	<u>001</u>	Apr 28, 2008
<u>AB</u>		<u>2MG</u>	<u>A078346</u>	<u>002</u>	Apr 28, 2008
<u>AB</u>		<u>4MG</u>	<u>A078346</u>	<u>003</u>	Apr 28, 2008
<u>AB</u>	TEVA PHARMS	<u>1MG</u>	<u>A077489</u>	<u>001</u>	Dec 12, 2006
<u>AB</u>		<u>2MG</u>	<u>A077489</u>	<u>002</u>	Dec 12, 2006
<u>AB</u>		<u>4MG</u>	<u>A077489</u>	<u>003</u>	Dec 12, 2006

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARKA					
	ABBOTT	1MG; 240MG	N020591	003	Oct 22, 1996
		2MG; 180MG	N020591	001	Oct 22, 1996
		2MG; 240MG	N020591	004	Oct 22, 1996
+		4MG; 240MG	N020591	002	Oct 22, 1996

## PRESCRIPTION DRUG PRODUCT LIST

3 - 376 (of 393)

TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRON

+ PHARMACIA AND UPJOHN 100MG/ML N019281 001 Dec 30, 1986

TABLET; ORAL

LYSTEDA

+ XANODYNE PHARM 650MG N022430 001 Nov 13, 2009

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATEAB + GLAXOSMITHKLINE EQ 10MG BASE N012342 003 Aug 16, 1985TRANLYCYPROMINE SULFATEAB KALI LABS EQ 10MG BASE A040640 001 Jun 29, 2006TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

+ ALCON 0.004% N021257 001 Mar 16, 2001

TRAVATAN Z

+ ALCON 0.004% N021994 001 Sep 21, 2006

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDEAB ALVOGEN 50MG A071636 001 Apr 18, 1988AB 100MG A071514 001 Apr 18, 1988AB APOTEX 50MG A071258 001 Mar 25, 1987AB + APOTEX INC 100MG A071196 001 Mar 25, 1987AB 150MG A071196 002 Apr 26, 1999AB 300MG A071196 003 Apr 26, 1999AB MATRIX LABS LTD 50MG A090514 001 Jun 02, 2009AB 100MG A090514 002 Jun 02, 2009AB 150MG A090514 003 Jun 02, 2009AB 300MG A090514 004 Jun 02, 2009AB MUTUAL PHARM 50MG A073137 002 Mar 24, 1993AB 100MG A073137 001 Mar 24, 1993AB 150MG A073137 003 Dec 22, 1995AB PLIVA 50MG A071523 001 Dec 11, 1987AB 100MG A071524 001 Dec 11, 1987AB 150MG A071525 001 Mar 09, 1988AB TEVA 50MG A072192 001 Feb 02, 1989AB 100MG A072193 001 Feb 02, 1989AB WATSON LABS 50MG A070857 001 Oct 10, 1986AB 100MG A070858 001 Oct 10, 1986TREPROSTINIL SODIUM

INJECTABLE; IV (INFUSION)-SC

UNITED THERAP

1MG/ML

N021272 001 May 21, 2002

2.5MG/ML

N021272 002 May 21, 2002

5MG/ML

N021272 003 May 21, 2002

+ 10MG/ML

N021272 004 May 21, 2002

SOLUTION; INHALATION

TYVASO

+ UNITED THERAP EQ 0.6MG BASE/ML N022387 001 Jul 30, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 377 (of 393)

TRETINOIN

CAPSULE; ORAL

TRETINOIN

<u>AB</u>	BARR	<u>10MG</u>	<u>A077684</u>	<u>001</u>	Jun 22, 2007
-----------	------	-------------	----------------	------------	--------------

VESANOID

<u>AB</u>	+ ROCHE	<u>10MG</u>	<u>N020438</u>	<u>001</u>	Nov 22, 1995
-----------	---------	-------------	----------------	------------	--------------

CREAM; TOPICAL

AVITA

<u>AB</u>	MYLAN BERTEK	<u>0.025%</u>	<u>N020404</u>	<u>003</u>	Jan 14, 1997
-----------	--------------	---------------	----------------	------------	--------------

RETIN-A

<u>AB</u>	+ JOHNSON AND JOHNSON	<u>0.025%</u>	<u>N019049</u>	<u>001</u>	Sep 16, 1988
-----------	-----------------------	---------------	----------------	------------	--------------

<u>AB</u>	+	<u>0.1%</u>	<u>N017340</u>	<u>001</u>	
-----------	---	-------------	----------------	------------	--

TRETINOIN

<u>AB</u>	TRIAx PHARMS LLC	<u>0.025%</u>	<u>A075264</u>	<u>001</u>	Dec 24, 1998
-----------	------------------	---------------	----------------	------------	--------------

<u>AB</u>		<u>0.1%</u>	<u>A075213</u>	<u>001</u>	Dec 24, 1998
-----------	--	-------------	----------------	------------	--------------

RETIN-A

<u>AB1</u>	+ JOHNSON AND JOHNSON	<u>0.05%</u>	<u>N017522</u>	<u>001</u>	
------------	-----------------------	--------------	----------------	------------	--

TRETINOIN

<u>AB1</u>	TRIAx PHARMS LLC	<u>0.05%</u>	<u>A075265</u>	<u>001</u>	Dec 24, 1998
------------	------------------	--------------	----------------	------------	--------------

RENOVA

<u>AB2</u>	+ ORTHO DERMATOLOGICS	<u>0.05%</u>	<u>N019963</u>	<u>001</u>	Dec 29, 1995
------------	-----------------------	--------------	----------------	------------	--------------

TRETINOIN

<u>AB2</u>	SPEAR PHARMS	<u>0.05%</u>	<u>A076498</u>	<u>001</u>	Sep 15, 2005
------------	--------------	--------------	----------------	------------	--------------

## RENOVA

	+ ORTHO DERMATOLOGICS	0.02%	N021108	001	Aug 31, 2000
--	-----------------------	-------	---------	-----	--------------

GEL; TOPICAL

RETIN-A

<u>AB</u>	+ JOHNSON AND JOHNSON	<u>0.01%</u>	<u>N017955</u>	<u>001</u>	
-----------	-----------------------	--------------	----------------	------------	--

<u>AB</u>	+	<u>0.025%</u>	<u>N017579</u>	<u>002</u>	
-----------	---	---------------	----------------	------------	--

TRETINOIN

<u>AB</u>	TRIAx PHARMS LLC	<u>0.01%</u>	<u>A075589</u>	<u>001</u>	Jun 11, 2002
-----------	------------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>0.025%</u>	<u>A075529</u>	<u>001</u>	Feb 22, 2000
-----------	--	---------------	----------------	------------	--------------

## AVITA

BT	MYLAN BERTEK	0.025%	N020400	001	Jan 29, 1998
----	--------------	--------	---------	-----	--------------

## ATRALIN

	+ DOW PHARM SCIENCES	0.05%	N022070	001	Jul 26, 2007
--	----------------------	-------	---------	-----	--------------

## RETIN-A MICRO

	+ ORTHO DERMATOLOGICS	0.04%	N020475	002	May 10, 2002
--	-----------------------	-------	---------	-----	--------------

	+	0.1%	N020475	001	Feb 07, 1997
--	---	------	---------	-----	--------------

SOLUTION; TOPICAL

RETIN-A

<u>AT</u>	+ JOHNSON AND JOHNSON	<u>0.05%</u>	<u>N016921</u>	<u>001</u>	
-----------	-----------------------	--------------	----------------	------------	--

TRETINOIN

<u>AT</u>	MORTON GROVE	<u>0.05%</u>	<u>A075260</u>	<u>001</u>	Jan 25, 1999
-----------	--------------	--------------	----------------	------------	--------------

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

## AZMACORT

	+ ABBOTT	0.1MG/INH	N018117	001	Apr 23, 1982
--	----------	-----------	---------	-----	--------------

CREAM; TOPICAL

KENALOG

<u>AT</u>	+ APOTHECON	<u>0.025%</u>	<u>N011601</u>	<u>003</u>	
-----------	-------------	---------------	----------------	------------	--

<u>AT</u>	+	<u>0.1%</u>	<u>N011601</u>	<u>006</u>	
-----------	---	-------------	----------------	------------	--

TRIA CET

<u>AT</u>	TEVA	<u>0.025%</u>	<u>A084908</u>	<u>001</u>	
-----------	------	---------------	----------------	------------	--

<u>AT</u>		<u>0.5%</u>	<u>A084908</u>	<u>003</u>	
-----------	--	-------------	----------------	------------	--

TRIAMCINOLONE ACETONIDE

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>0.1%</u>	<u>A087798</u>	<u>001</u>	Jun 04, 1982
-----------	----------------------	-------------	----------------	------------	--------------

<u>AT</u>	ALTANA	<u>0.025%</u>	<u>A085692</u>	<u>001</u>	
-----------	--------	---------------	----------------	------------	--

<u>AT</u>		<u>0.1%</u>	<u>A085692</u>	<u>003</u>	
-----------	--	-------------	----------------	------------	--

## PRESCRIPTION DRUG PRODUCT LIST

3 - 378 (of 393)

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	+	ALTANA	<u>0.5%</u>	<u>A085692</u>	<u>002</u>	
<u>AT</u>		G AND W LABS	<u>0.025%</u>	<u>A089797</u>	<u>001</u>	May 31, 1991
<u>AT</u>		PERRIGO NEW YORK	<u>0.025%</u>	<u>A086415</u>	<u>001</u>	
<u>AT</u>			<u>0.1%</u>	<u>A086414</u>	<u>001</u>	
<u>AT</u>			<u>0.5%</u>	<u>A086413</u>	<u>001</u>	
<u>AT</u>		TARO	<u>0.025%</u>	<u>A086277</u>	<u>001</u>	
<u>AT</u>			<u>0.1%</u>	<u>A040039</u>	<u>001</u>	Nov 26, 1997
<u>AT</u>			<u>0.1%</u>	<u>A086276</u>	<u>001</u>	
<u>AT</u>			<u>0.5%</u>	<u>A086275</u>	<u>001</u>	
<u>AT</u>		VINTAGE	<u>0.025%</u>	<u>A040671</u>	<u>001</u>	Jun 09, 2006
<u>AT</u>			<u>0.1%</u>	<u>A040671</u>	<u>002</u>	Jun 09, 2006
		<u>TRIDERM</u>				
<u>AT</u>		DEL RAY LABS	<u>0.1%</u>	<u>A088042</u>	<u>001</u>	Mar 19, 1984

INJECTABLE; INJECTION

KENALOG-10

<u>AB</u>		APOTHECON	<u>10MG/ML</u>	<u>N012041</u>	<u>001</u>	
-----------	--	-----------	----------------	----------------	------------	--

KENALOG-40

<u>AB</u>	+	APOTHECON	<u>40MG/ML</u>	<u>N014901</u>	<u>001</u>	
-----------	---	-----------	----------------	----------------	------------	--

TRIAMCINOLONE ACETONIDE

<u>AB</u>		SANDOZ	<u>10MG/ML</u>	<u>A090166</u>	<u>001</u>	May 27, 2009
<u>AB</u>			<u>40MG/ML</u>	<u>A090164</u>	<u>001</u>	May 27, 2009

INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL

TRIVARIS

	+	ALLERGAN	8MG/0.1ML (8MG/0.1ML)	N022220	001	Jun 16, 2008
--	---	----------	-----------------------	---------	-----	--------------

INJECTABLE; INTRAVITREAL

TRIESENCE

	+	ALCON	40MG/ML (40MG/ML)	N022048	001	Nov 29, 2007
--	---	-------	-------------------	---------	-----	--------------

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>		ALTANA	<u>0.025%</u>	<u>A040467</u>	<u>001</u>	Apr 21, 2003
<u>AT</u>			<u>0.1%</u>	<u>A040467</u>	<u>002</u>	Apr 21, 2003
<u>AT</u>		MORTON GROVE	<u>0.025%</u>	<u>A088450</u>	<u>001</u>	Apr 01, 1985
<u>AT</u>	+		<u>0.1%</u>	<u>A088451</u>	<u>001</u>	Apr 03, 1985
<u>AT</u>		TARO	<u>0.1%</u>	<u>A089129</u>	<u>001</u>	Aug 14, 1986
<u>AT</u>		VINTAGE	<u>0.1%</u>	<u>A040672</u>	<u>002</u>	Dec 13, 2006

OINTMENT; TOPICAL

KENALOG

<u>AT</u>		APOTHECON	<u>0.025%</u>	<u>N011600</u>	<u>003</u>	
<u>AT</u>			<u>0.1%</u>	<u>N011600</u>	<u>001</u>	

TRIAMCINOLONE ACETONIDE

<u>AT</u>		ACTAVIS MID ATLANTIC	<u>0.1%</u>	<u>A087799</u>	<u>001</u>	Jun 07, 1982
<u>AT</u>		ALTANA	<u>0.025%</u>	<u>A085691</u>	<u>001</u>	
<u>AT</u>			<u>0.1%</u>	<u>A085691</u>	<u>003</u>	
<u>AT</u>			<u>0.5%</u>	<u>A085691</u>	<u>002</u>	
<u>AT</u>	+	PERRIGO NEW YORK	<u>0.025%</u>	<u>A087356</u>	<u>001</u>	
<u>AT</u>	+		<u>0.1%</u>	<u>A087357</u>	<u>001</u>	
<u>AT</u>	+		<u>0.5%</u>	<u>A087385</u>	<u>001</u>	
<u>AT</u>		TARO	<u>0.025%</u>	<u>A040040</u>	<u>001</u>	Sep 30, 1994
<u>AT</u>			<u>0.025%</u>	<u>A040374</u>	<u>001</u>	Jun 05, 2001
<u>AT</u>			<u>0.1%</u>	<u>A040037</u>	<u>001</u>	Sep 30, 1994
<u>AT</u>			<u>0.1%</u>	<u>A087902</u>	<u>001</u>	Dec 27, 1982
<u>AT</u>			<u>0.5%</u>	<u>A040386</u>	<u>001</u>	Jun 05, 2001
		TRIAMCINOLONE ACETONIDE IN ABSORBASE				
	+	CAROLINA MEDCL	0.05%	A089595	001	Mar 23, 1995

## PRESCRIPTION DRUG PRODUCT LIST

3 - 379 (of 393)

TRIAMCINOLONE ACETONIDE

PASTE; DENTAL					
ORACORT					
	+ TARO	0.1%	A070730	001	Oct 01, 1986
SPRAY; TOPICAL					
KENALOG					
	+ RANBAXY	0.147MG/GM	N012104	001	
SPRAY, METERED; NASAL					
<u>NASACORT AQ</u>					
<u>AB</u>	+ SANOFI AVENTIS US	<u>0.055MG/SPRAY</u>	<u>N020468</u>	<u>001</u>	May 20, 1996
<u>TRIAMCINOLONE ACETONIDE</u>					
<u>AB</u>	BARR	<u>0.055MG/SPRAY</u>	<u>A078104</u>	<u>001</u>	Jul 30, 2009

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION					
ARISTOSPAN					
	+ SANDOZ	5MG/ML	N016466	001	
	+	20MG/ML	N016466	002	

TRIAMTERENE

CAPSULE; ORAL					
DYRENIUM					
	WELLSPRING PHARM	50MG	N013174	001	
	+	100MG	N013174	002	

TRIAZOLAM

TABLET; ORAL					
<u>HALCION</u>					
<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.125MG</u>	<u>N017892</u>	<u>003</u>	Apr 26, 1985
<u>AB</u>	+	<u>0.25MG</u>	<u>N017892</u>	<u>001</u>	Nov 15, 1982
<u>TRIAZOLAM</u>					
<u>AB</u>	ALPHAPHARM	<u>0.125MG</u>	<u>A074031</u>	<u>001</u>	Mar 25, 1994
<u>AB</u>		<u>0.25MG</u>	<u>A074031</u>	<u>002</u>	Mar 25, 1994
<u>AB</u>	ROXANE	<u>0.125MG</u>	<u>A074224</u>	<u>001</u>	Jun 01, 1994
<u>AB</u>		<u>0.25MG</u>	<u>A074224</u>	<u>002</u>	Jun 01, 1994
<u>AB</u>	WATSON LABS	<u>0.125MG</u>	<u>A074445</u>	<u>001</u>	Oct 20, 1995
<u>AB</u>		<u>0.25MG</u>	<u>A074445</u>	<u>002</u>	Oct 20, 1995

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL					
SYPRINE					
	+ ATON	250MG	N019194	001	Nov 08, 1985

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL					
<u>TRIFLUOPERAZINE HYDROCHLORIDE</u>					
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A040209</u>	<u>001</u>	Jul 07, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A040209</u>	<u>002</u>	Jul 07, 1997
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A040209</u>	<u>003</u>	Jul 07, 1997
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>A040209</u>	<u>004</u>	Jul 07, 1997
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A085785</u>	<u>001</u>	
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A085786</u>	<u>001</u>	
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A085789</u>	<u>001</u>	
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A085788</u>	<u>001</u>	

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC					
<u>TRIFLURIDINE</u>					
<u>AT</u>	ALCON	1%	A074311	001	Oct 06, 1995
<b>WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 406 of 1114</b>					

## PRESCRIPTION DRUG PRODUCT LIST

3 - 380 (of 393)

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

VIROPTIC

<u>AT</u>	+	MONARCH PHARMS	<u>1%</u>	<u>N018299</u>	<u>001</u>	
-----------	---	----------------	-----------	----------------	------------	--

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

<u>AA</u>		MIKART	<u>2MG/5ML</u>	<u>A040251</u>	<u>001</u>	Sep 27, 1999
<u>AA</u>	+	PHARM ASSOC	<u>2MG/5ML</u>	<u>A040177</u>	<u>001</u>	Apr 17, 1997

TABLET; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

<u>AA</u>		VINTAGE PHARMS	<u>2MG</u>	<u>A040254</u>	<u>001</u>	Dec 24, 1998
<u>AA</u>			<u>5MG</u>	<u>A040254</u>	<u>002</u>	Dec 24, 1998
<u>AA</u>		WATSON LABS	<u>2MG</u>	<u>A040184</u>	<u>001</u>	Feb 06, 1998
<u>AA</u>	+		<u>2MG</u>	<u>A084363</u>	<u>001</u>	
<u>AA</u>			<u>5MG</u>	<u>A040184</u>	<u>002</u>	Feb 06, 1998
<u>AA</u>	+		<u>5MG</u>	<u>A084364</u>	<u>001</u>	
<u>AA</u>		WEST WARD	<u>2MG</u>	<u>A040337</u>	<u>002</u>	Feb 16, 2000
<u>AA</u>			<u>5MG</u>	<u>A040337</u>	<u>001</u>	Feb 16, 2000

TRIMETHADIONE

TABLET; ORAL

TRIDIONE

	+	ABBOTT	150MG	N005856	009	
--	---	--------	-------	---------	-----	--

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN

<u>AB</u>	+	KING PHARMS	<u>300MG</u>	<u>N017531</u>	<u>006</u>	Dec 13, 2001
<u>AB</u>		ACTAVIS TOTOWA	<u>300MG</u>	<u>A076546</u>	<u>001</u>	Aug 20, 2003
<u>AB</u>		MUTUAL PHARMA	<u>300MG</u>	<u>A076570</u>	<u>001</u>	Aug 28, 2003

INJECTABLE; INJECTION

TIGAN

<u>AP</u>	+	JHP PHARMS	<u>100MG/ML</u>	<u>N017530</u>	<u>001</u>	
<u>AP</u>		HOSPIRA	<u>100MG/ML</u>	<u>A088804</u>	<u>001</u>	Apr 03, 1987

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

<u>AB</u>		TEVA	<u>100MG</u>	<u>N018679</u>	<u>001</u>	Jul 30, 1982
<u>AB</u>		WATSON LABS	<u>100MG</u>	<u>A070049</u>	<u>001</u>	Jun 06, 1985
		TRIMETHOPRIM				
	+	TEVA	200MG	A071259	001	Jun 18, 1987

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

	+	FSC	EQ 50MG BASE/5ML	A074973	001	Jan 24, 2000
--	---	-----	------------------	---------	-----	--------------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

<u>AB</u>		ODYSSEY PHARMS	<u>EQ 25MG BASE</u>	<u>N016792</u>	<u>001</u>	
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>N016792</u>	<u>002</u>	
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N016792</u>	<u>003</u>	Sep 15, 1982

## PRESCRIPTION DRUG PRODUCT LIST

3 - 381 (of 393)

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

<u>AB</u>	ACTAVIS TOTOWA	<u>EQ 25MG BASE</u>	<u>A077361</u>	<u>001</u>	Aug 02, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077361</u>	<u>002</u>	Aug 02, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077361</u>	<u>003</u>	Aug 02, 2006

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR DEPOT

+	WATSON LABS	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000
	TRELSTAR LA				
+	WATSON LABS	EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+	HOSPIRA	3.6GM/100ML	N013025	002	
---	---------	-------------	---------	-----	--

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYL

<u>AT</u>	+	ALCON	<u>0.5%</u>	<u>A084305</u>	<u>001</u>	
<u>AT</u>	+		<u>1%</u>	<u>A084306</u>	<u>001</u>	

TROPICACYL

<u>AT</u>		AKORN	<u>0.5%</u>	<u>A040314</u>	<u>001</u>	Sep 29, 2000
<u>AT</u>			<u>1%</u>	<u>A040315</u>	<u>001</u>	Sep 29, 2000

TROPICAMIDE

<u>AT</u>		BAUSCH AND LOMB	<u>0.5%</u>	<u>A040067</u>	<u>001</u>	Jul 27, 1994
<u>AT</u>			<u>1%</u>	<u>A040064</u>	<u>001</u>	Jul 27, 1994

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

+	ALLERGAN	60MG	N022103	001	Aug 03, 2007
---	----------	------	---------	-----	--------------

TABLET; ORAL

SANCTURA

+	ALLERGAN	20MG	N021595	001	May 28, 2004
---	----------	------	---------	-----	--------------

TRYPAN BLUE

SOLUTION; OPHTHALMIC

MEMBRANEBLUE

+	DORC	0.15%	N022278	001	Feb 20, 2009
---	------	-------	---------	-----	--------------

VISIONBLUE

+	DORC	0.06%	N021670	001	Dec 16, 2004
---	------	-------	---------	-----	--------------

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

+	R TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000
---	-----------------	-------	---------	-----	--------------

UREA, C-13

FOR SOLUTION; ORAL

BREATHTEK UBT FOR H-PYLORI

+	OTSUKA AMERICA	EQ 75MG /POUCH	N020586	002	May 10, 2001
---	----------------	----------------	---------	-----	--------------



## PRESCRIPTION DRUG PRODUCT LIST

3 - 382 (of 393)

UREA, C-14

CAPSULE; ORAL

PYTEST

+ BALLARD MEDCL 1uCi N020617 001 May 09, 1997

PYTEST KIT

+ BALLARD MEDCL 1uCi N020617 002 May 09, 1997

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

BRAVELLE

+ FERRING 75 IU/VIAL N021289 001 May 06, 2002

URSODIOL

CAPSULE; ORAL

ACTIGALLAB + WATSON PHARMS 300MG N019594 002 Dec 31, 1987URSODIOLAB ACTAVIS TOTOWA 300MG A075517 001 Mar 14, 2000AB COREPHARMA 300MG A077895 001 Jul 27, 2006AB LANNETT 300MG A079082 001 Dec 15, 2008AB TEVA PHARMS 300MG A075592 001 May 25, 2000

TABLET; ORAL

URSO 250AB AXCAN 250MG N020675 001 Dec 10, 1997URSO FORTEAB + AXCAN 500MG N020675 002 Jul 21, 2004URSODIOLAB TEVA PHARMS 250MG A079184 001 May 13, 2009AB 500MG A079184 002 May 13, 2009VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDEAB RANBAXY EQ 500MG BASE A076588 001 Jan 31, 2007AB EQ 1GM BASE A076588 002 Jan 31, 2007VALTREXAB GLAXOSMITHKLINE EQ 500MG BASE N020487 001 Jun 23, 1995AB + EQ 1GM BASE N020487 002 Jun 23, 1995VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

+ ROCHE PALO 50MG/ML N022257 001 Aug 28, 2009

TABLET; ORAL

VALCYTE

+ ROCHE PALO EQ 450MG BASE N021304 001 Mar 29, 2001

VALPROATE SODIUM

INJECTABLE; INJECTION

DEPACONAP + ABBOTT EQ 100MG BASE/ML N020593 001 Dec 30, 1996VALPROATE SODIUMAP APP PHARMS EQ 100MG BASE/ML A076539 001 Jun 26, 2003AP BEDFORD EQ 100MG BASE/ML A076295 001 Nov 14, 2002VALPROIC ACID

CAPSULE; ORAL

DEPAKENEAB + ABBOTT 250MG N018081 001**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 409 of 1114**

## PRESCRIPTION DRUG PRODUCT LIST

3 - 383 (of 393)

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

<u>AB</u>	BANNER PHARMACAPS	<u>250MG</u>	<u>A073484</u>	<u>001</u>	Jun 29, 1993
<u>AB</u>	CATALENT	<u>250MG</u>	<u>A073229</u>	<u>001</u>	Oct 29, 1991

CAPSULE, DELAYED RELEASE; ORAL

STAVZOR

	BANNER PHARMACAPS	125MG	N022152	001	Jul 29, 2008
		250MG	N022152	002	Jul 29, 2008
+		500MG	N022152	003	Jul 29, 2008

SYRUP; ORAL

DEPAKENE

<u>AA</u>	+ ABBOTT	<u>250MG/5ML</u>	<u>N018082</u>	<u>001</u>	
-----------	----------	------------------	----------------	------------	--

VALPROIC ACID

<u>AA</u>	ALPHARMA	<u>250MG/5ML</u>	<u>A075782</u>	<u>001</u>	Dec 22, 2000
<u>AA</u>	APOTEX INC	<u>250MG/5ML</u>	<u>A077105</u>	<u>001</u>	Jul 29, 2005
<u>AA</u>	HIGH TECH PHARMA	<u>250MG/5ML</u>	<u>A074060</u>	<u>001</u>	Jan 13, 1995
<u>AA</u>	MORTON GROVE	<u>250MG/5ML</u>	<u>A070868</u>	<u>001</u>	Jul 01, 1986
<u>AA</u>	PHARM ASSOC	<u>250MG/5ML</u>	<u>A075379</u>	<u>001</u>	Dec 15, 2000
<u>AA</u>	TEVA PHARMS	<u>250MG/5ML</u>	<u>A073178</u>	<u>001</u>	Aug 25, 1992
<u>AA</u>	VINTAGE	<u>250MG/5ML</u>	<u>A077960</u>	<u>001</u>	Oct 13, 2006

VALRUBICIN

SOLUTION; INTRAVESICAL

VALSTAR PRESERVATIVE FREE

+	ENDO PHARM	40MG/ML	N020892	001	Sep 25, 1998
---	------------	---------	---------	-----	--------------

VALSARTAN

TABLET; ORAL

DIOVAN

	NOVARTIS	40MG	N021283	004	Aug 14, 2002
		80MG	N021283	001	Jul 18, 2001
		160MG	N021283	002	Jul 18, 2001
+		320MG	N021283	003	Jul 18, 2001

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

	VIROPHARMA	EQ 125MG BASE	N050606	001	Apr 15, 1986
+		EQ 250MG BASE	N050606	002	Apr 15, 1986

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

<u>AP</u>	AKORN STRIDES	<u>EQ 500MG BASE/VIAL</u>	<u>A065397</u>	<u>001</u>	Dec 30, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065397</u>	<u>002</u>	Dec 30, 2008
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A065432</u>	<u>001</u>	Dec 30, 2008
<u>AP</u>	+ APP PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A062663</u>	<u>001</u>	Mar 17, 1987
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062663</u>	<u>002</u>	Jul 31, 1987
<u>AP</u>	+	<u>EQ 5GM BASE/VIAL</u>	<u>A062663</u>	<u>003</u>	Jun 03, 1988
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A062663</u>	<u>004</u>	Nov 28, 1997
<u>AP</u>	GENERAMEDIX	<u>EQ 500MG BASE/VIAL</u>	<u>A065401</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065401</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	+ HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A062911</u>	<u>001</u>	Aug 04, 1988
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A062931</u>	<u>001</u>	Oct 29, 1992
<u>AP</u>		<u>EQ 750MG BASE/VIAL</u>	<u>A062912</u>	<u>002</u>	Jan 07, 2009
<u>AP</u>		<u>EQ 750MG BASE/VIAL</u>	<u>A062933</u>	<u>002</u>	May 27, 2009
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062912</u>	<u>001</u>	Aug 04, 1988
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062933</u>	<u>001</u>	Oct 29, 1992
<u>AP</u>	+	<u>EQ 5GM BASE/VIAL</u>	<u>A063076</u>	<u>001</u>	Dec 21, 1990
<u>AP</u>	HOSPIRA INC	<u>EQ 10GM BASE/VIAL</u>	<u>A065455</u>	<u>001</u>	Apr 29, 2009

## PRESCRIPTION DRUG PRODUCT LIST

3 - 384 (of 393)

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993
---	-----------------	---------------------	---------	-----	--------------

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

	BAYER HLTHCARE	2.5MG	N021400	003	Aug 19, 2003
		5MG	N021400	001	Aug 19, 2003
		10MG	N021400	002	Aug 19, 2003
+		20MG	N021400	004	Aug 19, 2003

VARENICLINE TARTRATE

TABLET; ORAL

CHANTIX

	PFIZER INC	EQ 0.5MG BASE	N021928	001	May 10, 2006
+		EQ 1MG BASE	N021928	002	May 10, 2006

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

<u>AP</u>	+	BEDFORD	<u>10MG/VIAL</u>	<u>A075549</u>	<u>001</u>	Jun 13, 2000
<u>AP</u>	+		<u>20MG/VIAL</u>	<u>A075549</u>	<u>002</u>	Jun 13, 2000
<u>AP</u>		GENERAMEDIX	<u>10MG/VIAL</u>	<u>A078274</u>	<u>001</u>	Dec 29, 2008
<u>AP</u>			<u>20MG/VIAL</u>	<u>A078274</u>	<u>002</u>	Dec 29, 2008
<u>AP</u>		HOSPIRA	<u>10MG/VIAL</u>	<u>A075164</u>	<u>001</u>	Oct 21, 1999
<u>AP</u>			<u>20MG/VIAL</u>	<u>A075164</u>	<u>002</u>	Oct 21, 1999
<u>AP</u>		SUN PHARMA GLOBAL	<u>10MG/VIAL</u>	<u>A079001</u>	<u>001</u>	Jun 17, 2009
<u>AP</u>			<u>20MG/VIAL</u>	<u>A079001</u>	<u>002</u>	Jun 17, 2009
<u>AP</u>		TEVA PARENTERAL	<u>10MG/VIAL</u>	<u>A074688</u>	<u>001</u>	Aug 25, 1999
<u>AP</u>			<u>20MG/VIAL</u>	<u>A074688</u>	<u>002</u>	Aug 25, 1999
<u>AP</u>		WATSON LABS	<u>10MG/VIAL</u>	<u>A074334</u>	<u>001</u>	Aug 31, 1995
<u>AP</u>			<u>20MG/VIAL</u>	<u>A074334</u>	<u>002</u>	Aug 31, 1995

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

	WYETH PHARMS INC	EQ 37.5MG BASE	N020699	001	Oct 20, 1997
		EQ 75MG BASE	N020699	002	Oct 20, 1997
+		EQ 150MG BASE	N020699	004	Oct 20, 1997

TABLET; ORAL

EFFEXOR

<u>AB</u>		WYETH PHARMS INC	<u>EQ 25MG BASE</u>	<u>N020151</u>	<u>002</u>	Dec 28, 1993
<u>AB</u>			<u>EQ 37.5MG BASE</u>	<u>N020151</u>	<u>006</u>	Dec 28, 1993
<u>AB</u>	+		<u>EQ 50MG BASE</u>	<u>N020151</u>	<u>003</u>	Dec 28, 1993
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>N020151</u>	<u>004</u>	Dec 28, 1993
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>N020151</u>	<u>005</u>	Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS TOTOWA	<u>EQ 25MG BASE</u>	<u>A078554</u>	<u>001</u>	Jan 09, 2009
<u>AB</u>			<u>EQ 37.5MG BASE</u>	<u>A078554</u>	<u>002</u>	Jan 09, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A078554</u>	<u>003</u>	Jan 09, 2009
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A078554</u>	<u>004</u>	Jan 09, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A078554</u>	<u>005</u>	Jan 09, 2009
<u>AB</u>		CARACO	<u>EQ 25MG BASE</u>	<u>A078627</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>			<u>EQ 37.5MG BASE</u>	<u>A078627</u>	<u>002</u>	Jun 13, 2008
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A078627</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A078627</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A078627</u>	<u>005</u>	Jun 13, 2008

## PRESCRIPTION DRUG PRODUCT LIST

3 - 385 (of 393)

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A078301</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078301</u>	<u>002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078301</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078301</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078301</u>	<u>005</u>	Jun 13, 2008
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077166</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077166</u>	<u>002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077166</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077166</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077166</u>	<u>005</u>	Jun 13, 2008
<u>AB</u>	PLIVA HRVATSKA DOO	<u>EQ 25MG BASE</u>	<u>A078517</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078517</u>	<u>002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078517</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078517</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078517</u>	<u>005</u>	Jun 13, 2008
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076690</u>	<u>001</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A076690</u>	<u>002</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076690</u>	<u>003</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076690</u>	<u>004</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076690</u>	<u>005</u>	Aug 03, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077653</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077653</u>	<u>002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077653</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077653</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077653</u>	<u>005</u>	Jun 13, 2008

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

	OSMOTICA PHARM	EQ 37.5MG BASE	N022104	001	May 20, 2008
		EQ 75MG BASE	N022104	002	May 20, 2008
+		EQ 150MG BASE	N022104	003	May 20, 2008
		EQ 225MG BASE	N022104	004	May 20, 2008

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>100MG</u>	<u>A078306</u>	<u>001</u>	Aug 09, 2007
<u>AB</u>		<u>120MG</u>	<u>A075138</u>	<u>001</u>	Apr 20, 1999
<u>AB</u>		<u>180MG</u>	<u>A075138</u>	<u>002</u>	Apr 20, 1999
<u>AB</u>		<u>200MG</u>	<u>A078306</u>	<u>002</u>	Aug 09, 2007
<u>AB</u>		<u>240MG</u>	<u>A075138</u>	<u>003</u>	Apr 20, 1999
<u>AB</u>		<u>300MG</u>	<u>A078306</u>	<u>003</u>	Aug 09, 2007
	<u>VERELAN</u>				
<u>AB</u>	ELAN DRUG	<u>120MG</u>	<u>N019614</u>	<u>001</u>	May 29, 1990
<u>AB</u>		<u>180MG</u>	<u>N019614</u>	<u>003</u>	Jan 09, 1992
<u>AB</u>		<u>240MG</u>	<u>N019614</u>	<u>002</u>	May 29, 1990
	<u>VERELAN PM</u>				
<u>AB</u>	ELAN DRUG	<u>100MG</u>	<u>N020943</u>	<u>001</u>	Nov 25, 1998
<u>AB</u>		<u>200MG</u>	<u>N020943</u>	<u>002</u>	Nov 25, 1998
<u>AB</u>	+	<u>300MG</u>	<u>N020943</u>	<u>003</u>	Nov 25, 1998
	VERELAN				
+	ELAN DRUG	360MG	N019614	004	May 10, 1996

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>2.5MG/ML</u>	<u>A070577</u>	<u>001</u>	Feb 02, 1987
<u>AP</u>		<u>2.5MG/ML</u>	<u>A070737</u>	<u>001</u>	May 06, 1987
<u>AP</u>		<u>2.5MG/ML</u>	<u>A070738</u>	<u>001</u>	May 06, 1987
<u>AP</u>		<u>2.5MG/ML</u>	<u>A075136</u>	<u>001</u>	Oct 20, 1998

## PRESCRIPTION DRUG PRODUCT LIST

3 - 386 (of 393)

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

<u>AP</u>	INTL MEDICATION	<u>2.5MG/ML</u>	<u>A070451</u>	<u>001</u>	Dec 16, 1985
<u>AP</u>	+ LUITPOLD	<u>2.5MG/ML</u>	<u>A070617</u>	<u>001</u>	Nov 12, 1985

TABLET; ORAL

CALAN

<u>AB</u>	GD SEARLE LLC	<u>40MG</u>	<u>N018817</u>	<u>003</u>	Feb 23, 1988
<u>AB</u>		<u>80MG</u>	<u>N018817</u>	<u>001</u>	Sep 10, 1984
<u>AB</u>	+	<u>120MG</u>	<u>N018817</u>	<u>002</u>	Sep 10, 1984

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>80MG</u>	<u>A071019</u>	<u>001</u>	Sep 24, 1986
<u>AB</u>		<u>120MG</u>	<u>A070468</u>	<u>001</u>	Sep 24, 1986
<u>AB</u>	MYLAN	<u>80MG</u>	<u>A071482</u>	<u>001</u>	Feb 15, 1989
<u>AB</u>		<u>120MG</u>	<u>A071483</u>	<u>001</u>	Feb 15, 1989
<u>AB</u>	WATSON LABS	<u>40MG</u>	<u>A072923</u>	<u>001</u>	Jun 29, 1993
<u>AB</u>		<u>40MG</u>	<u>A072924</u>	<u>001</u>	Jun 29, 1993
<u>AB</u>		<u>80MG</u>	<u>A070855</u>	<u>001</u>	Sep 24, 1986
<u>AB</u>		<u>80MG</u>	<u>A070995</u>	<u>001</u>	Oct 01, 1986
<u>AB</u>		<u>80MG</u>	<u>A071366</u>	<u>001</u>	Oct 01, 1986
<u>AB</u>		<u>120MG</u>	<u>A070856</u>	<u>001</u>	Sep 24, 1986
<u>AB</u>		<u>120MG</u>	<u>A070994</u>	<u>001</u>	Oct 01, 1986
<u>AB</u>		<u>120MG</u>	<u>A071367</u>	<u>001</u>	Oct 01, 1986

TABLET, EXTENDED RELEASE; ORAL

ISOPTIN SR

<u>AB</u>	+ RANBAXY	<u>120MG</u>	<u>N019152</u>	<u>003</u>	Mar 06, 1991
<u>AB</u>	+	<u>180MG</u>	<u>N019152</u>	<u>002</u>	Dec 15, 1989
<u>AB</u>	+	<u>240MG</u>	<u>N019152</u>	<u>001</u>	Dec 16, 1986

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>240MG</u>	<u>A078906</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>120MG</u>	<u>A073568</u>	<u>002</u>	Oct 10, 1997
<u>AB</u>		<u>180MG</u>	<u>A074330</u>	<u>001</u>	Jan 31, 1994
<u>AB</u>		<u>240MG</u>	<u>A073568</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>	KALI LABS	<u>120MG</u>	<u>A075072</u>	<u>001</u>	May 25, 1999
<u>AB</u>		<u>240MG</u>	<u>A075072</u>	<u>003</u>	May 25, 1999
<u>AB</u>	MYLAN	<u>120MG</u>	<u>A074587</u>	<u>002</u>	Feb 21, 1997
<u>AB</u>		<u>180MG</u>	<u>A074587</u>	<u>003</u>	Sep 09, 1997
<u>AB</u>		<u>240MG</u>	<u>A074587</u>	<u>001</u>	Mar 23, 1996

COVERA-HS

BC	+ GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996
BC	+	240MG	N020552	002	Feb 26, 1996

VERTEPORFIN

INJECTABLE; INJECTION

VISUDYNE

	+ QLT	15MG/VIAL	N021119	001	Apr 12, 2000
--	-------	-----------	---------	-----	--------------

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

	+ LUNDBECK INC	500MG/PACKET	N022006	001	Aug 21, 2009
--	----------------	--------------	---------	-----	--------------

TABLET; ORAL

SABRIL

	+ LUNDBECK INC	500MG	N020427	001	Aug 21, 2009
--	----------------	-------	---------	-----	--------------

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

	+ APP PHARMS	1MG/ML	A089515	001	Apr 29, 1987
--	--------------	--------	---------	-----	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 413 of 1114**

PRESCRIPTION DRUG PRODUCT LIST

VINBLASTINE SULFATE

INJECTABLE; INJECTION  
VINBLASTINE SULFATE  
+ BEDFORD

10MG/VIAL

A089395 001

Apr 09, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION  
VINCRISTINE SULFATE

AP APP PHARMS

1MG/ML

A076401 001

Oct 28, 2003

VINCRISTINE SULFATE PFS

AP HOSPIRA

1MG/ML

A071484 001

Apr 19, 1988

AP TEVA PARENTERAL

1MG/ML

A075493 001

Sep 01, 1999

VINORELBINE TARTRATE

INJECTABLE; INJECTION  
NAVELBINE

AP + PIERRE FABRE

EQ 10MG BASE/ML

N020388 001

Dec 23, 1994

VINORELBINE TARTRATE

AP ACTAVIS TOTOWA

EQ 10MG BASE/ML

A078011 001

Jul 22, 2009

AP APP PHARMS

EQ 10MG BASE/ML

A076849 001

Apr 18, 2005

AP BAXTER HLTHCARE

EQ 10MG BASE/ML

A075992 001

Jun 10, 2003

AP BEDFORD

EQ 10MG BASE/ML

A076461 001

Dec 11, 2003

AP EBEWE PHARMA

EQ 10MG BASE/ML

A078408 001

Feb 13, 2008

AP HOSPIRA

EQ 10MG BASE/ML

A076827 001

Jun 02, 2005

AP TEVA PARENTERAL

EQ 10MG BASE/ML

A076028 001

Feb 03, 2003

VITAMIN A PALMITATE

INJECTABLE; INJECTION  
AQUASOL A  
+ HOSPIRA

EQ 50,000 UNITS BASE/ML

N006823 001

VORICONAZOLE

FOR SUSPENSION; ORAL  
VFEND  
+ PFIZER

200MG/5ML

N021630 001

Dec 19, 2003

INJECTABLE; IV (INFUSION)

+ PFIZER

200MG/VIAL

N021267 001

May 24, 2002

TABLET; ORAL

VFEND

PFIZER

50MG

N021266 001

May 24, 2002

+

200MG

N021266 002

May 24, 2002

VORINOSTAT

CAPSULE; ORAL  
ZOLINZA  
+ MERCK

100MG

N021991 001

Oct 06, 2006

WARFARIN SODIUM

INJECTABLE; INJECTION  
COUMADIN  
+ BRISTOL MYERS SQUIBB

5MG/VIAL

N009218 024

Feb 07, 1995

TABLET; ORAL

COUMADIN

AB BRISTOL MYERS SQUIBB

1MG

N009218 022

Mar 01, 1990

AB

2MG

N009218 013

AB

2.5MG

N009218 018

AB

3MG

N009218 025

Nov 18, 1996

AB

4MG

N009218 023

Aug 24, 1993

## PRESCRIPTION DRUG PRODUCT LIST

3 - 388 (of 393)

WARFARIN SODIUM

TABLET; ORAL

COUMADIN

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>5MG</u>	<u>N009218</u>	<u>007</u>	
<u>AB</u>		<u>6MG</u>	<u>N009218</u>	<u>026</u>	Nov 18, 1996
<u>AB</u>		<u>7.5MG</u>	<u>N009218</u>	<u>016</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N009218</u>	<u>005</u>	

JANTOVEN

<u>AB</u>	USL PHARMA	<u>1MG</u>	<u>A040416</u>	<u>001</u>	Oct 02, 2003
<u>AB</u>		<u>2MG</u>	<u>A040416</u>	<u>002</u>	Oct 02, 2003
<u>AB</u>		<u>2.5MG</u>	<u>A040416</u>	<u>003</u>	Oct 02, 2003
<u>AB</u>		<u>3MG</u>	<u>A040416</u>	<u>004</u>	Oct 02, 2003
<u>AB</u>		<u>4MG</u>	<u>A040416</u>	<u>005</u>	Oct 02, 2003
<u>AB</u>		<u>5MG</u>	<u>A040416</u>	<u>006</u>	Oct 02, 2003
<u>AB</u>		<u>6MG</u>	<u>A040416</u>	<u>007</u>	Oct 02, 2003
<u>AB</u>		<u>7.5MG</u>	<u>A040416</u>	<u>008</u>	Oct 02, 2003
<u>AB</u>		<u>10MG</u>	<u>A040416</u>	<u>009</u>	Oct 02, 2003

WARFARIN SODIUM

<u>AB</u>	BARR	<u>1MG</u>	<u>A040145</u>	<u>001</u>	Mar 26, 1997
<u>AB</u>		<u>2MG</u>	<u>A040145</u>	<u>002</u>	Mar 26, 1997
<u>AB</u>		<u>2.5MG</u>	<u>A040145</u>	<u>003</u>	Mar 26, 1997
<u>AB</u>		<u>3MG</u>	<u>A040145</u>	<u>008</u>	Nov 05, 1998
<u>AB</u>		<u>4MG</u>	<u>A040145</u>	<u>004</u>	Mar 26, 1997
<u>AB</u>		<u>5MG</u>	<u>A040145</u>	<u>005</u>	Mar 26, 1997
<u>AB</u>		<u>6MG</u>	<u>A040145</u>	<u>009</u>	Nov 05, 1998
<u>AB</u>		<u>7.5MG</u>	<u>A040145</u>	<u>006</u>	Mar 26, 1997
<u>AB</u>		<u>10MG</u>	<u>A040145</u>	<u>007</u>	Mar 26, 1997
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A040415</u>	<u>001</u>	Sep 27, 2004
<u>AB</u>		<u>2MG</u>	<u>A040415</u>	<u>002</u>	Sep 27, 2004
<u>AB</u>		<u>2.5MG</u>	<u>A040415</u>	<u>003</u>	Sep 29, 2004
<u>AB</u>		<u>3MG</u>	<u>A040415</u>	<u>004</u>	Sep 27, 2004
<u>AB</u>		<u>4MG</u>	<u>A040415</u>	<u>005</u>	Sep 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A040415</u>	<u>006</u>	Sep 27, 2004
<u>AB</u>		<u>6MG</u>	<u>A040415</u>	<u>007</u>	Sep 27, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A040415</u>	<u>008</u>	Sep 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A040415</u>	<u>009</u>	Sep 27, 2004
<u>AB</u>	PLIVA	<u>1MG</u>	<u>A040616</u>	<u>009</u>	Jul 05, 2006
<u>AB</u>		<u>2MG</u>	<u>A040616</u>	<u>001</u>	Jul 05, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040616</u>	<u>002</u>	Jul 05, 2006
<u>AB</u>		<u>3MG</u>	<u>A040616</u>	<u>003</u>	Jul 05, 2006
<u>AB</u>		<u>4MG</u>	<u>A040616</u>	<u>004</u>	Jul 05, 2006
<u>AB</u>		<u>5MG</u>	<u>A040616</u>	<u>005</u>	Jul 05, 2006
<u>AB</u>		<u>6MG</u>	<u>A040616</u>	<u>006</u>	Jul 05, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040616</u>	<u>007</u>	Jul 05, 2006
<u>AB</u>		<u>10MG</u>	<u>A040616</u>	<u>008</u>	Jul 05, 2006
<u>AB</u>	SANDOZ	<u>1MG</u>	<u>A040196</u>	<u>001</u>	Sep 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A040196</u>	<u>002</u>	Sep 30, 1997
<u>AB</u>		<u>2.5MG</u>	<u>A040196</u>	<u>003</u>	Sep 30, 1997
<u>AB</u>		<u>3MG</u>	<u>A040196</u>	<u>008</u>	Jul 26, 2000
<u>AB</u>		<u>4MG</u>	<u>A040196</u>	<u>004</u>	Sep 30, 1997
<u>AB</u>		<u>5MG</u>	<u>A040196</u>	<u>005</u>	Sep 30, 1997
<u>AB</u>		<u>6MG</u>	<u>A040196</u>	<u>009</u>	Jul 26, 2000
<u>AB</u>		<u>7.5MG</u>	<u>A040196</u>	<u>006</u>	Sep 30, 1997
<u>AB</u>		<u>10MG</u>	<u>A040196</u>	<u>007</u>	Sep 30, 1997
<u>AB</u>	TARO	<u>1MG</u>	<u>A040301</u>	<u>002</u>	Jul 15, 1999
<u>AB</u>		<u>2MG</u>	<u>A040301</u>	<u>003</u>	Jul 15, 1999
<u>AB</u>		<u>2.5MG</u>	<u>A040301</u>	<u>004</u>	Jul 15, 1999
<u>AB</u>		<u>3MG</u>	<u>A040301</u>	<u>005</u>	Jul 15, 1999
<u>AB</u>		<u>4MG</u>	<u>A040301</u>	<u>006</u>	Jul 15, 1999
<u>AB</u>		<u>5MG</u>	<u>A040301</u>	<u>007</u>	Jul 15, 1999

## PRESCRIPTION DRUG PRODUCT LIST

3 - 389 (of 393)

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

<u>AB</u>	TARO	<u>6MG</u>	<u>A040301</u>	<u>008</u>	Jul 15, 1999
<u>AB</u>		<u>7.5MG</u>	<u>A040301</u>	<u>009</u>	Jul 15, 1999
<u>AB</u>		<u>10MG</u>	<u>A040301</u>	<u>001</u>	Jul 15, 1999
<u>AB</u>	ZYDUS PHARMS USA	<u>1MG</u>	<u>A040663</u>	<u>001</u>	May 30, 2006
<u>AB</u>		<u>2MG</u>	<u>A040663</u>	<u>002</u>	May 30, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040663</u>	<u>003</u>	May 30, 2006
<u>AB</u>		<u>3MG</u>	<u>A040663</u>	<u>004</u>	May 30, 2006
<u>AB</u>		<u>4MG</u>	<u>A040663</u>	<u>005</u>	May 30, 2006
<u>AB</u>		<u>5MG</u>	<u>A040663</u>	<u>006</u>	May 30, 2006
<u>AB</u>		<u>6MG</u>	<u>A040663</u>	<u>007</u>	May 30, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040663</u>	<u>008</u>	May 30, 2006
<u>AB</u>		<u>10MG</u>	<u>A040663</u>	<u>009</u>	May 30, 2006

WATER FOR INJECTION, STERILE

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+ HOSPIRA	<u>100%</u>	<u>N018802</u>	<u>001</u>	Oct 27, 1982
<u>AP</u>	APP PHARMS	<u>100%</u>	<u>A088400</u>	<u>001</u>	Jan 16, 1984
<u>AP</u>	+ B BRAUN	<u>100%</u>	<u>N019633</u>	<u>001</u>	Feb 29, 1988
<u>AP</u>	+ BAXTER HLTHCARE	<u>100%</u>	<u>N018632</u>	<u>001</u>	Jun 30, 1982
<u>AP</u>	+	<u>100%</u>	<u>N018632</u>	<u>002</u>	Apr 19, 1988
<u>AP</u>	+ HOSPIRA	<u>100%</u>	<u>N018233</u>	<u>001</u>	
<u>AP</u>	+	<u>100%</u>	<u>N018801</u>	<u>001</u>	Oct 27, 1982
<u>AP</u>	+	<u>100%</u>	<u>N019869</u>	<u>001</u>	Dec 26, 1989
<u>AP</u>	TARO PHARMS IRELAND	<u>100%</u>	<u>A077393</u>	<u>001</u>	Aug 11, 2006

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION

STERILE WATER

<u>AT</u>	BAXTER HLTHCARE	<u>100%</u>	<u>N017428</u>	<u>001</u>	
<u>AT</u>	B BRAUN	<u>100%</u>	<u>N016734</u>	<u>001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>100%</u>	<u>N017866</u>	<u>001</u>	
<u>AT</u>	HOSPIRA	<u>100%</u>	<u>N017513</u>	<u>001</u>	
<u>AT</u>		<u>100%</u>	<u>N018313</u>	<u>001</u>	

XENON XE 133

GAS; INHALATION

XENON XE 133

<u>AA</u>	LANTHEUS MEDCL	<u>10mCi/VIAL</u>	<u>N017284</u>	<u>001</u>	
<u>AA</u>		<u>20mCi/VIAL</u>	<u>N017284</u>	<u>002</u>	
<u>AA</u>	MALLINCKRODT	<u>10mCi/VIAL</u>	<u>N018327</u>	<u>001</u>	Mar 09, 1982
<u>AA</u>		<u>20mCi/VIAL</u>	<u>N018327</u>	<u>002</u>	Mar 09, 1982

ZAFIRLUKAST

TABLET; ORAL

ACCOLATE

	ASTRAZENECA	10MG	N020547	003	Sep 17, 1999
+		20MG	N020547	001	Sep 26, 1996

ZALEPLON

CAPSULE; ORAL

SONATA

<u>AB</u>	KING PHARMS	<u>5MG</u>	<u>N020859</u>	<u>001</u>	Aug 13, 1999
<u>AB</u>	+	<u>10MG</u>	<u>N020859</u>	<u>002</u>	Aug 13, 1999



## PRESCRIPTION DRUG PRODUCT LIST

3 - 390 (of 393)

ZALEPLON

CAPSULE; ORAL

ZALEPLON

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078829</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078829</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077505</u>	<u>001</u>	Jun 20, 2008
<u>AB</u>		<u>10MG</u>	<u>A077505</u>	<u>002</u>	Jun 20, 2008
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A077238</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077238</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A090374</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>		<u>10MG</u>	<u>A090374</u>	<u>002</u>	Sep 17, 2009
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A077237</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077237</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A077239</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077239</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A078989</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078989</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UPSHER SMITH	<u>5MG</u>	<u>A078706</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078706</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	WEST WARD	<u>5MG</u>	<u>A078147</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>10MG</u>	<u>A078147</u>	<u>002</u>	Nov 25, 2008

ZANAMIVIR

POWDER; INHALATION

RELENZA

+ GLAXOSMITHKLINE 5MG N021036 001 Jul 26, 1999

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

+ ELAN PHARMS 100MCG/1ML (100MCG/ML) N021060 002 Dec 28, 2004

+ 500MCG/5ML (100MCG/ML) N021060 004 Dec 28, 2004

+ 500MCG/20ML (25MCG/ML) N021060 001 Dec 28, 2004

ZIDOVUDINE

CAPSULE; ORAL

RETROVIRAB + VIIIV HLTHCARE 100MG N019655 001 Mar 19, 1987ZIDOVUDINEAB AUROBINDO PHARMA LTD 100MG A078128 001 Mar 27, 2006AB CIPLA LTD 100MG A078349 001 May 23, 2007

INJECTABLE; INJECTION

RETROVIR

+ VIIIV HLTHCARE 10MG/ML N019951 001 Feb 02, 1990

SYRUP; ORAL

RETROVIRAA + VIIIV HLTHCARE 50MG/5ML N019910 001 Sep 28, 1989ZIDOVUDINEAA AUROBINDO 50MG/5ML A077268 001 Sep 19, 2005AA CIPLA LTD 50MG/5ML A077981 001 Jun 26, 2008

TABLET; ORAL

RETROVIRAB + VIIIV HLTHCARE 300MG N020518 002 Oct 04, 1996ZIDOVUDINEAB AUROBINDO 300MG A077267 001 Sep 19, 2005AB HETERO DRUGS LTD 300MG A090092 001 Apr 25, 2008AB MATRIX LABS LTD 300MG A078922 001 Feb 14, 2008AB RANBAXY 300MG A077327 001 Sep 19, 2005AB ROXANE 300MG A076844 001 Sep 19, 2005

## PRESCRIPTION DRUG PRODUCT LIST

3 - 391 (of 393)

ZILEUTON

TABLET; ORAL				
ZYFLO				
+ CRITICAL	600MG	N020471	003	Dec 09, 1996
TABLET, EXTENDED RELEASE; ORAL				
ZYFLO CR				
+ CRITICAL	600MG	N022052	001	May 30, 2007

ZINC ACETATE

CAPSULE; ORAL				
GALZIN				
TEVA	EQ 25MG ZINC	N020458	001	Jan 28, 1997
+	EQ 50MG ZINC	N020458	002	Jan 28, 1997

ZINC CHLORIDE

INJECTABLE; INJECTION				
ZINC CHLORIDE IN PLASTIC CONTAINER				
+ HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL				
GEODON				
+ PFIZER	EQ 20MG BASE	N020825	001	Feb 05, 2001
	EQ 40MG BASE	N020825	002	Feb 05, 2001
	EQ 60MG BASE	N020825	003	Feb 05, 2001
	EQ 80MG BASE	N020825	004	Feb 05, 2001
SUSPENSION; ORAL				
GEODON				
+ PFIZER INC	EQ 10MG BASE/ML	N021483	001	Mar 29, 2006

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR				
GEODON				
+ PFIZER	EQ 20MG BASE/ML	N020919	001	Jun 21, 2002

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)				
+ NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007
ZOMETA				
+ NOVARTIS	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003

ZOLMITRIPTAN

SPRAY; NASAL				
ZOMIG				
+ ASTRAZENECA	5MG/SPRAY	N021450	004	Sep 30, 2003
TABLET; ORAL				
ZOMIG				
IPR	2.5MG	N020768	001	Nov 25, 1997
+	5MG	N020768	002	Nov 25, 1997
TABLET, ORALLY DISINTEGRATING; ORAL				
ZOMIG-ZMT				
ASTRAZENECA	2.5MG	N021231	001	Feb 13, 2001
+	5MG	N021231	002	Sep 17, 2001

## PRESCRIPTION DRUG PRODUCT LIST

3 - 392 (of 393)

ZOLPIDEM TARTRATE

SPRAY, METERED; ORAL

ZOLPIMIST

+ NOVADEL 5MG/SPRAY N022196 001 Dec 19, 2008

TABLET; ORAL

AMBIENAB SANOFI AVENTIS US 5MG N019908 001 Dec 16, 1992AB + 10MG N019908 002 Dec 16, 1992ZOLPIDEM TARTRATEAB APOTEX INC 5MG A077884 001 Apr 23, 2007AB 10MG A077884 002 Apr 23, 2007AB AUROBINDO PHARMA 5MG A078413 001 May 04, 2007AB 10MG A078413 002 May 04, 2007AB CARACO 5MG A077359 001 Apr 23, 2007AB 10MG A077359 002 Apr 23, 2007AB CARLSBAD 5MG A077990 001 Apr 23, 2007AB 10MG A077990 002 Apr 23, 2007AB DR REDDYS LABS LTD 5MG A077985 001 Apr 23, 2007AB 10MG A077985 002 Apr 23, 2007AB GENPHARM 5MG A078016 001 Apr 23, 2007AB 10MG A078016 002 Apr 23, 2007AB HIKMA 5MG A078129 001 Apr 30, 2008AB 10MG A078129 002 Apr 30, 2008AB INVAGEN PHARMS 5MG A078184 001 Sep 07, 2007AB 10MG A078184 002 Sep 07, 2007AB LEK PHARMS DD 5MG A077322 001 Apr 23, 2007AB 10MG A077322 002 Apr 23, 2007AB MYLAN 5MG A076578 001 Apr 23, 2007AB 10MG A076578 002 Apr 23, 2007AB RANBAXY 5MG A078055 001 Apr 23, 2007AB 10MG A078055 002 Apr 23, 2007AB ROXANE 5MG A077214 001 Apr 23, 2007AB 10MG A077214 002 Apr 23, 2007AB TEVA 5MG A076410 001 Apr 23, 2007AB 10MG A076410 002 Apr 23, 2007AB TORRENT PHARMS 5MG A077903 001 Aug 17, 2007AB 10MG A077903 002 Aug 17, 2007AB VINTAGE 5MG A078616 001 Nov 21, 2008AB 10MG A078616 002 Nov 21, 2008AB WATSON LABS 5MG A077773 001 Apr 23, 2007AB 10MG A077773 002 Apr 23, 2007AB WOCKHARDT 5MG A078426 001 May 15, 2007AB 10MG A078426 002 May 15, 2007

TABLET; SUBLINGUAL

EDLUAR

MEDA PHARMS 5MG N021997 001 Mar 13, 2009

+ 10MG N021997 002 Mar 13, 2009

TABLET, EXTENDED RELEASE; ORAL

AMBIEN CR

SANOFI AVENTIS US 6.25MG N021774 002 Sep 02, 2005

+ 12.5MG N021774 001 Sep 02, 2005

ZONISAMIDE

CAPSULE; ORAL

ZONEGRANAB EISAI INC 25MG N020789 003 Aug 22, 2003AB 50MG N020789 002 Aug 22, 2003AB + 100MG N020789 001 Mar 27, 2000

## PRESCRIPTION DRUG PRODUCT LIST

3 - 393 (of 393)

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

<u>AB</u>	ALPHAPHARM	<u>25MG</u>	<u>A077647</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077647</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077647</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077642</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077642</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077642</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	BANNER PHARMACAPS	<u>25MG</u>	<u>A077813</u>	<u>001</u>	Aug 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077813</u>	<u>002</u>	Aug 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077813</u>	<u>003</u>	Aug 16, 2006
<u>AB</u>	BARR	<u>25MG</u>	<u>A077639</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077639</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077639</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	COREPHARMA	<u>25MG</u>	<u>A077876</u>	<u>001</u>	Feb 21, 2007
<u>AB</u>		<u>50MG</u>	<u>A077876</u>	<u>002</u>	Feb 21, 2007
<u>AB</u>		<u>100MG</u>	<u>A077876</u>	<u>003</u>	Feb 21, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A077645</u>	<u>002</u>	Sep 29, 2006
<u>AB</u>		<u>50MG</u>	<u>A077645</u>	<u>003</u>	Sep 29, 2006
<u>AB</u>		<u>100MG</u>	<u>A077645</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077651</u>	<u>001</u>	Jan 30, 2006
<u>AB</u>		<u>50MG</u>	<u>A077651</u>	<u>002</u>	Jan 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A077651</u>	<u>003</u>	Jan 30, 2006
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A077869</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A077869</u>	<u>002</u>	May 31, 2006
<u>AB</u>		<u>100MG</u>	<u>A077869</u>	<u>003</u>	May 31, 2006
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077637</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077637</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077637</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A077644</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077644</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077644</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	SUN PHARM INDS (IN)	<u>25MG</u>	<u>A077634</u>	<u>001</u>	Mar 17, 2006
<u>AB</u>		<u>50MG</u>	<u>A077634</u>	<u>002</u>	Mar 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A077634</u>	<u>003</u>	Mar 17, 2006
<u>AB</u>	WOCKHARDT	<u>25MG</u>	<u>A077636</u>	<u>003</u>	Jul 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077636</u>	<u>002</u>	Jul 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077636</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077625</u>	<u>001</u>	Oct 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077625</u>	<u>002</u>	Oct 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077625</u>	<u>003</u>	Oct 16, 2006

## OTC DRUG PRODUCT LIST

4 - 1 (of 17)

ACETAMINOPHEN

## SUPPOSITORY; RECTAL

## ACEPHEN

G AND W LABS	120MG	N018060	001	
	325MG	A072344	001	Mar 27, 1992
	325MG	N018060	003	Dec 18, 1986
	650MG	A072237	001	Mar 27, 1992
	650MG	N018060	002	

## ACETAMINOPHEN

ACTAVIS MID ATLANTIC	120MG	N018337	003	Sep 12, 1983
	325MG	N018337	002	
+	650MG	N018337	001	
SUPPOSITORIA	120MG	A070607	001	Apr 06, 1987
	650MG	A070608	001	Dec 01, 1986

## INFANTS' FEVERALL

ACTAVIS MID ATLANTIC	80MG	N018337	004	Aug 26, 1992
----------------------	------	---------	-----	--------------

## NEOPAP

POLYMEDICA	120MG	N016401	001	
------------	-------	---------	-----	--

## TABLET, EXTENDED RELEASE; ORAL

## ACETAMINOPHEN

OHM LABS	650MG	A076200	001	Mar 19, 2002	
PERRIGO	650MG	A075077	001	Feb 25, 2000	
RANBAXY	650MG	A090205	001	Nov 18, 2009	
TYLENOL (CAPLET)					
+	MCNEIL CONS	650MG	N019872	001	Jun 08, 1994
TYLENOL (GELTAB)					
+	MCNEIL CONS	650MG	N019872	002	Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

## TABLET; ORAL

## ACETAMINOPHEN, ASPIRIN AND CAFFEINE

PERRIGO	250MG;250MG;65MG	A075794	001	Nov 26, 2001	
EXCEDRIN (MIGRAINE)					
+	NOVARTIS	250MG;250MG;65MG	N020802	001	Jan 14, 1998

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

## TABLET; ORAL

## TAVIST ALLERGY/SINUS/HEADACHE

+	NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N021082	001	Mar 01, 2001
---	----------	---------------------------	---------	-----	--------------

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

## TABLET, EXTENDED RELEASE; ORAL

## DRIXORAL PLUS

+	SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987
---	-----------------	----------------	---------	-----	--------------

ALCOHOL; CHLORHEXIDINE GLUCONATE

## SOLUTION; TOPICAL

## AVAGARD

+	3M	61%;1%	N021074	001	Jun 07, 2001
---	----	--------	---------	-----	--------------

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

## TABLET, CHEWABLE; ORAL

## FOAMCOAT

GUARDIAN DRUG	80MG;20MG	A071793	001	Sep 04, 1987
---------------	-----------	---------	-----	--------------

## GAVISCON

SANOFI AVENTIS US	80MG;20MG	N018685	001	Dec 09, 1983
+	160MG;40MG	N018685	002	Dec 09, 1983

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

## SOLUTION/DROPS; OPHTHALMIC

## VASOCON-A

+	NOVARTIS	0.5%;0.05%	N018746	002	Jul 11, 1994
---	----------	------------	---------	-----	--------------

## OTC DRUG PRODUCT LIST

4 - 2 (of 17)

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM; TOPICAL				
ANTHELIOS SX				
+ LOREAL USA	2%;2%;10%	N021502	001	Jul 21, 2006
CAPITAL SOLEIL 15				
+ LOREAL USA	2%;3%;10%	N021501	001	Oct 02, 2006

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM; TOPICAL				
ANTHELIOS 20				
+ LOREAL USA	2%;2%;10%;2%	N021471	001	Oct 05, 2006
ANTHELIOS 40				
+ LOREAL USA	2%;3%;10%;5%	N022009	001	Mar 31, 2008
+	2%;3%;10%;5%	N022009	002	Oct 29, 2009

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL				
SHADE UVAGUARD				
+ SCHERING PLOUGH	3%;7.5%;3%	N020045	001	Dec 07, 1992

BENTOQUATAM

LOTION; TOPICAL				
IVY BLOCK				
+ STAND HOMEOPATH	5%	N020532	001	Aug 26, 1996

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL				
LOTRIMIN ULTRA				
+ SCHERING PLOUGH	1%	N021307	001	Dec 07, 2001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL				
FEMSTAT 3				
+ BAYER	2%	N020421	001	Dec 21, 1995

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL				
CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE				
PERRIGO R AND D	800MG;10MG;165MG	A077355	001	Feb 06, 2008
PEPCID COMPLETE				
+ MERCK	800MG;10MG;165MG	N020958	001	Oct 16, 2000

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL				
CETIRIZINE HYDROCHLORIDE ALLERGY				
BANNER PHARMACAPS	5MG	N022429	001	Jul 23, 2009
	10MG	N022429	004	Jul 23, 2009
CETIRIZINE HYDROCHLORIDE HIVES				
BANNER PHARMACAPS	5MG	N022429	003	Jul 23, 2009
+	10MG	N022429	002	Jul 23, 2009
SYRUP; ORAL				
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY				
ACTAVIS MID ATLANTIC	5MG/5ML	A090378	002	May 09, 2008
AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009
APOTEX	5MG/5ML	A090188	002	Apr 22, 2008
CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008
DR REDDYS LABS LTD	5MG/5ML	A090474	002	Mar 30, 2009
PERRIGO R AND D	5MG/5ML	A090254	002	Apr 09, 2008
RANBAXY	5MG/5ML	A090183	002	Apr 24, 2008
TARO	5MG/5ML	A090182	002	Apr 22, 2008
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF				
ACTAVIS MID ATLANTIC	5MG/5ML	A090378	001	May 09, 2008
AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009
APOTEX	5MG/5ML	A090188	001	Apr 22, 2008

## OTC DRUG PRODUCT LIST

4 - 3 (of 17)

CETIRIZINE HYDROCHLORIDE

## SYRUP; ORAL

## CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008
DR REDDYS LABS LTD	5MG/5ML	A090474	001	Mar 30, 2009
PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008
RANBAXY	5MG/5ML	A090183	001	Apr 24, 2008
TARO	5MG/5ML	A090182	001	Apr 22, 2008

## CHILDREN'S ZYRTEC ALLERGY

+ MCNEIL CONSUMER	5MG/5ML	N022155	002	Nov 16, 2007
-------------------	---------	---------	-----	--------------

## CHILDREN'S ZYRTEC HIVES RELIEF

+ MCNEIL CONSUMER	5MG/5ML	N022155	001	Nov 16, 2007
-------------------	---------	---------	-----	--------------

## TABLET, CHEWABLE; ORAL

## CETIRIZINE HYDROCHLORIDE ALLERGY

CARACO	5MG	A077631	004	Jan 11, 2008
	10MG	A077631	003	Jan 11, 2008
SANDOZ	5MG	A078692	001	Feb 14, 2008
	10MG	A078692	002	Feb 14, 2008

## CETIRIZINE HYDROCHLORIDE HIVES RELIEF

CARACO	5MG	A077631	001	Jan 11, 2008
	10MG	A077631	002	Jan 11, 2008

## CHILDREN'S ZYRTEC ALLERGY

PFIZER	5MG	N021621	003	Nov 16, 2007
+	10MG	N021621	004	Nov 16, 2007

## CHILDREN'S ZYRTEC HIVES RELIEF

PFIZER	5MG	N021621	005	Nov 16, 2007
+	10MG	N021621	006	Nov 16, 2007

## TABLET; ORAL

## CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS ELIZABETH	5MG	A078615	003	Dec 28, 2007
	10MG	A078615	004	Dec 28, 2007
APOTEX INC	5MG	A078317	001	Dec 27, 2007
	10MG	A078317	002	Dec 27, 2007
CARACO	5MG	A077499	001	Dec 27, 2007
	10MG	A077499	002	Dec 27, 2007
CONTRACT PHARMA	5MG	A076047	001	Dec 27, 2007
	10MG	A076047	002	Dec 27, 2007
DR REDDYS LABS LTD	5MG	A078343	004	Jan 15, 2008
	10MG	A078343	003	Jan 15, 2008
MYLAN	5MG	A076677	001	Dec 27, 2007
	10MG	A076677	002	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	001	Feb 19, 2009
	10MG	A078862	002	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
	10MG	A078336	002	Dec 27, 2007
RANBAXY	5MG	A077498	001	Dec 27, 2007
	10MG	A077498	002	Dec 27, 2007
SANDOZ	5MG	A077946	001	Dec 27, 2007
	10MG	A077946	002	Dec 27, 2007
TARO	5MG	A078072	001	Jul 22, 2009
	5MG	A078072	003	Jul 22, 2009
UNICHEM	5MG	A078680	003	Jun 26, 2009
	10MG	A078680	004	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	001	Aug 26, 2009
	10MG	A077829	004	Aug 26, 2009
WOCKHARDT	5MG	A078427	003	Dec 28, 2007
	10MG	A078427	004	Dec 28, 2007

## CETIRIZINE HYDROCHLORIDE HIVES

CARACO	5MG	A077499	003	Dec 27, 2007
	10MG	A077499	004	Dec 27, 2007
DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
	10MG	A078343	002	Jan 15, 2008
MYLAN	5MG	A076677	004	Dec 27, 2007
	10MG	A076677	003	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	003	Feb 19, 2009

## OTC DRUG PRODUCT LIST

4 - 4 (of 17)

CETIRIZINE HYDROCHLORIDE

## TABLET; ORAL

## CETIRIZINE HYDROCHLORIDE HIVES

ORCHID HLTHCARE	10MG	A078862	004	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
	10MG	A078336	004	Dec 27, 2007
RANBAXY	5MG	A077498	003	Dec 27, 2007
	10MG	A077498	004	Dec 27, 2007
UNICHEM	5MG	A078680	001	Jun 26, 2009
	10MG	A078680	002	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	003	Aug 26, 2009
	10MG	A077829	002	Aug 26, 2009
CETIRIZINE HYDROCHLORIDE HIVES RELIEF				
TARO	10MG	A078072	002	Jul 22, 2009
	10MG	A078072	004	Jul 22, 2009
Zyrtec Allergy				
MCNEIL CONSUMER	5MG	N019835	003	Nov 16, 2007
+	10MG	N019835	004	Nov 16, 2007
Zyrtec Hives Relief				
MCNEIL CONSUMER	5MG	N019835	005	Nov 16, 2007
+	10MG	N019835	006	Nov 16, 2007

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

## CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SANDOZ	5MG;120MG	A077991	001	Mar 05, 2008	
TEVA PHARMS	5MG;120MG	A077170	001	Feb 25, 2008	
Zyrtec-D 12 Hour					
+	MCNEIL	5MG;120MG	N021150	002	Nov 09, 2007

CHLORHEXIDINE GLUCONATE

## AEROSOL, METERED; TOPICAL

## EXIDINE

+	XTTRIUM	4%	N019127	001	Dec 24, 1984
---	---------	----	---------	-----	--------------

## CLOTH; TOPICAL

## CHLORHEXIDINE GLUCONATE

+	SAGE PRODS	2%	N021669	001	Apr 25, 2005
---	------------	----	---------	-----	--------------

## SOLUTION; TOPICAL

## BRIAN CARE

	SOAPCO	4%	A071419	001	Dec 17, 1987
--	--------	----	---------	-----	--------------

## CHG SCRUB

	ECOLAB	4%	N019258	002	Jul 22, 1986
--	--------	----	---------	-----	--------------

## CIDA-STAT

	ECOLAB	2%	N019258	001	Jul 22, 1986
--	--------	----	---------	-----	--------------

## DYNA-HEX

	XTTRIUM	0.75%	N020111	001	Sep 11, 1997
--	---------	-------	---------	-----	--------------

## EXIDINE

+	XTTRIUM	2%	N019422	001	Dec 17, 1985
---	---------	----	---------	-----	--------------

		4%	N019125	001	Dec 24, 1984
--	--	----	---------	-----	--------------

## HIBICLENS

+	REGENT	4%	N017768	001	
---	--------	----	---------	-----	--

## HIBISTAT

+	REGENT	0.5%	N018300	001	
---	--------	------	---------	-----	--

## SPONGE; TOPICAL

## BIOSCRUB

	GRIFFEN	4%	N019822	001	Mar 31, 1989
--	---------	----	---------	-----	--------------

## CHLORHEXIDINE GLUCONATE

	BECTON DICKINSON	4%	A072525	001	Oct 24, 1989
--	------------------	----	---------	-----	--------------

## PHARMASEAL SCRUB CARE

+	PHARMASEAL	4%	N019793	001	Dec 02, 1988
---	------------	----	---------	-----	--------------



## OTC DRUG PRODUCT LIST

4 - 5 (of 17)

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

## SPONGE; TOPICAL

## CHLORAPREP ONE-STEP

+ ENTURIA INC	2%;70% (3ML)	N020832	001	Jul 14, 2000
+	2%;70% (10.5ML)	N020832	004	Aug 20, 2003
+	2%;70% (26ML)	N020832	006	Nov 21, 2006
CHLORAPREP ONE-STEP FREPP				
+ ENTURIA INC	2%;70% (1.5ML)	N020832	003	Apr 26, 2002
CHLORAPREP WITH TINT				
+ ENTURIA INC	2%;70% (26ML)	N020832	002	May 03, 2005
+	2%;70% (10.5ML)	N020832	005	Apr 03, 2006
+	2%;70% (3ML)	N020832	007	Oct 10, 2006

## SWAB; TOPICAL

## CHLORAPREP ONE-STEP SEPP

+ ENTURIA INC	2%;70% (0.67ML)	N021555	001	Oct 07, 2002
CHLORAPREP SINGLE SWABSTICK				
+ ENTURIA INC	2%;70% (1.75ML)	N021555	002	May 10, 2005
CHLORASCUB MAXI SWABSTICK				
+ SOLUMED	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005
CHLORASCUB SWAB				
+ SOLUMED	3.15%;70% (1ML)	N021524	001	Jun 03, 2005
CHLORASCUB SWABSTICK				
+ SOLUMED	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005

CHLORPHENIRAMINE MALEATE

## TABLET, EXTENDED RELEASE; ORAL

## CHLORPHENIRAMINE MALEATE

AVANTHI INC	12MG	A040829	001	May 13, 2009
CHLOR-TRIMETON				
+ SCHERING PLOUGH	12MG	N007638	002	

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

## SUSPENSION; ORAL

## CHILDREN'S ADVIL ALLERGY SINUS

+ WYETH CONS	1MG/5ML;100MG/5ML;15MG/5ML	N021587	001	Feb 24, 2004
--------------	----------------------------	---------	-----	--------------

## TABLET; ORAL

## ADVIL ALLERGY SINUS

+ WYETH CONS	2MG;200MG;30MG	N021441	001	Dec 19, 2002
--------------	----------------	---------	-----	--------------

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

## TABLET, EXTENDED RELEASE; ORAL

## CHLOR-TRIMETON

+ SCHERING PLOUGH	8MG;120MG	N018397	001	
-------------------	-----------	---------	-----	--

CIMETIDINE

## TABLET; ORAL

## CIMETIDINE

IVAX SUB TEVA PHARMS	200MG	A075345	001	Jun 16, 1999
LEINER	200MG	A074961	001	Jun 19, 1998
	200MG	A074963	001	Jun 19, 1998
PERRIGO	200MG	A075285	001	Oct 29, 1998
WATSON LABS	200MG	A075425	001	Jul 29, 1999
TAGAMET HB				
+ GLAXOSMITHKLINE	200MG	N020238	002	Aug 21, 1996

CLEMASTINE FUMARATE

## TABLET; ORAL

## CLEMASTINE FUMARATE

PERRIGO	1.34MG	A074512	001	Nov 22, 1995
SANDOZ	1.34MG	A073458	001	Oct 31, 1993
TAVIST-1				
+ NOVARTIS	1.34MG	N020925	001	Aug 21, 1992

## OTC DRUG PRODUCT LIST

4 - 6 (of 17)

CLOTRIMAZOLE

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK

+ SCHERING PLOUGH 1%,200MG N020526 002 Jul 29, 1996

GYNE-LOTRIMIN COMBINATION PACK

+ SCHERING PLOUGH 1%,100MG N020289 002 Apr 26, 1993

MYCELEX-7 COMBINATION PACK

BAYER PHARMS 1%,100MG N020389 002 Jun 23, 1994

CREAM; VAGINAL

CLOTRIMAZOLE

ACTAVIS MID ATLANTIC 1% A074165 001 Jul 16, 1993

TARO 1% A072641 001 Dec 04, 1995

GYNE-LOTRIMIN

+ SCHERING PLOUGH 1% N018052 002 Nov 30, 1990

GYNE-LOTRIMIN 3

+ SCHERING PLOUGH 2% N020574 001 Nov 24, 1998

MYCELEX-7

BAYER PHARMS 1% N018230 002 Dec 26, 1991

TRIVAGIZOLE 3

TARO 2% N021143 001 Apr 12, 2000

TABLET; VAGINAL

GYNE-LOTRIMIN

+ SCHERING PLOUGH 100MG N017717 002 Nov 30, 1990

GYNE-LOTRIMIN 3

+ SCHERING PLOUGH 200MG N020525 001 Jul 29, 1996

MYCELEX-7

BAYER PHARMS 100MG N018182 002 Dec 26, 1991

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC 5.2MG/SPRAY A074800 001 Jul 26, 2001

+ BAUSCH AND LOMB 5.2MG/SPRAY A075702 001 Jul 03, 2001

PERRIGO 5.2MG/SPRAY A075427 001 Dec 12, 2001

QPHARMA 5.2MG/SPRAY A077976 001 Sep 07, 2007

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DISOPHROL

SCHERING PLOUGH 6MG;120MG N013483 004 Sep 13, 1982

DRIXORAL

+ SCHERING PLOUGH 6MG;120MG N013483 003 Sep 13, 1982

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX DM

RECKITT BENCKISER 30MG;600MG N021620 002 Apr 29, 2004

+ 60MG;1.2GM N021620 001 Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

+ RECKITT BENCKISER EQ 30MG HBR/5ML N018658 001 Oct 08, 1982

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET; ORAL

ADVIL PM

+ WYETH CONS 38MG;200MG N021394 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

DR REDDYS LABS LTD 38MG;200MG A090619 001 Jul 08, 2009

PERRIGO R AND D 38MG;200MG A079113 001 Dec 22, 2008

## OTC DRUG PRODUCT LIST

4 - 7 (of 17)

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

ADVIL PM

+ WYETH CONS	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	N021393	001	Dec 21, 2005
--------------	--	---------	-----	--------------

DOCOSANOL

CREAM; TOPICAL

ABREVA

+ GLAXOSMITHKLINE	10%	N020941	001	Jul 25, 2000
-------------------	-----	---------	-----	--------------

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE

LNK

25MG

A040564

001

Aug 27, 2004

PERRIGO

25MG

A040167

001

Sep 18, 1996

UNISOM

+ CHATTEM

25MG

N018066

001

EPINEPHRINE

AEROSOL, METERED; INHALATION

EPINEPHRINE

ARMSTRONG PHARMS

0.2MG/INH

A087907

001

May 23, 1984

FAMOTIDINE

TABLET, CHEWABLE; ORAL

FAMOTIDINE

+ PERRIGO

10MG

A075715

001

Aug 22, 2003

PEPCID AC

MERCK

20MG

N020801

002

Dec 17, 2007

TABLET; ORAL

FAMOTIDINE

DR REDDYS LABS LTD

10MG

A075758

001

Aug 17, 2001

20MG

A077367

001

Sep 25, 2006

GENPHARM

10MG

A075674

001

Dec 21, 2001

IVAX SUB TEVA PHARMS

10MG

A075512

001

Jul 26, 2001

PERRIGO

10MG

A075400

001

Mar 18, 2005

20MG

A077351

001

Sep 25, 2006

RANBAXY

10MG

A090283

001

Nov 17, 2009

20MG

A090283

002

Nov 17, 2009

SANDOZ

10MG

A076101

001

Oct 21, 2002

TEVA

10MG

A075312

001

May 31, 2001

WATSON LABS

10MG

A075404

001

Nov 28, 2001

WOCKHARDT

10MG

A077146

001

Mar 07, 2005

PEPCID AC

MERCK

10MG

N020325

001

Apr 28, 1995

+

20MG

N020325

002

Sep 23, 2003

PEPCID AC (GELTAB)

MERCK

10MG

N020902

001

Aug 05, 1999

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX

RECKITT BENCKISER

600MG

N021282

001

Jul 12, 2002

+

1.2GM

N021282

002

Dec 18, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MUCINEX D

RECKITT BENCKISER

600MG;60MG

N021585

001

Jun 22, 2004

+

1.2GM;120MG

N021585

002

Jun 22, 2004

## OTC DRUG PRODUCT LIST

4 - 8 (of 17)

IBUPROFEN

## CAPSULE; ORAL

ADVIL LIQUI-GELS

+ WYETH CONS EQ 200MG FREE ACID AND POTASSIUM SALT N020402 001 Apr 20, 1995

ADVIL MIGRAINE LIQUI-GELS

+ WYETH CONS EQ 200MG FREE ACID AND POTASSIUM SALT N020402 002 Mar 16, 2000

## IBUPROFEN

BANNER PHARMACAPS EQ 200MG FREE ACID AND POTASSIUM SALT A078682 001 Mar 24, 2009

DR REDDYS LABS LTD EQ 200MG FREE ACID AND POTASSIUM SALT A077338 001 Jul 10, 2009

+ LEINER 200MG A074782 001 Jul 06, 1998

MARKSANS PHARMA EQ 200MG FREE ACID AND POTASSIUM SALT A079205 001 Jun 26, 2009

MIDOL LIQUID GELS

+ BANNER PHARMACAPS 200MG N021472 001 Oct 18, 2002

## SUSPENSION/DROPS; ORAL

CHILDREN'S MOTRIN

+ MCNEIL CONS 40MG/ML N020603 001 Jun 10, 1996

## IBUPROFEN

PERRIGO 40MG/ML A075217 001 Dec 16, 1998

TRIS PHARMA INC 40MG/ML A079058 001 Aug 31, 2009

PEDIATRIC ADVIL

+ WYETH CONS 100MG/2.5ML N020812 001 Jan 30, 1998

## SUSPENSION; ORAL

CHILDREN'S ADVIL

WYETH CONS 100MG/5ML N020589 001 Jun 27, 1996

CHILDREN'S ADVIL-FLAVORED

WYETH CONS 100MG/5ML N020589 002 Nov 07, 1997

CHILDREN'S ELIXSURE

ALTERNA TCHP LLC 100MG/5ML N021604 001 Jan 07, 2004

CHILDREN'S IBUPROFEN

PERRIGO 100MG/5ML A074937 001 Dec 22, 1998

CHILDREN'S MOTRIN

+ MCNEIL 100MG/5ML N020516 001 Jun 16, 1995

## IBUPROFEN

ACTAVIS MID ATLANTIC 100MG/5ML A074916 001 Apr 30, 1999

## TABLET, CHEWABLE; ORAL

CHILDREN'S ADVIL

WYETH CONS 50MG N020944 001 Dec 18, 1998

CHILDREN'S MOTRIN

MCNEIL CONS 50MG N020601 001 Nov 15, 1996

## IBUPROFEN

PERRIGO 50MG A076359 001 Jan 16, 2004

100MG A076359 002 Jan 16, 2004

JUNIOR STRENGTH ADVIL

WYETH CONS 100MG N020944 002 Dec 18, 1998

JUNIOR STRENGTH MOTRIN

+ MCNEIL CONS 100MG N020601 003 Nov 15, 1996

## TABLET; ORAL

ADVIL

WYETH CONS 200MG N018989 001 May 18, 1984

## IBUPROFEN

ADVENT PHARMS 200MG A076460 001 Nov 26, 2003

AMNEAL PHARMS NY 200MG A071333 001 Feb 17, 1987

200MG A072199 001 May 23, 1988

DR REDDYS LA 200MG A075661 001 Dec 12, 2001

DR REDDYS LABS INC 100MG A076117 001 Nov 20, 2001

LEINER 200MG A071732 001 Sep 10, 1987

200MG A071735 001 Sep 10, 1987

200MG A072299 001 Jul 01, 1988

200MG A073691 001 Feb 25, 1994

200MG A074931 001 Jul 20, 1998

LNK 100MG A076741 001 Jun 17, 2004

200MG A075010 001 Mar 01, 1999

200MG A075139 001 Mar 01, 1999

MCNEIL 200MG A073019 001 Mar 30, 1994

OHM 200MG A071163 001 Jul 15, 1986

## OTC DRUG PRODUCT LIST

4 - 9 (of 17)

IBUPROFEN

## TABLET; ORAL

## IBUPROFEN

PAR PHARM	200MG	A070481	001	Sep 24, 1986
	200MG	A070985	001	Oct 02, 1987
PERRIGO	200MG	A072096	001	Dec 08, 1987
	200MG	A075995	001	Mar 14, 2002
PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005
SANDOZ	200MG	A071807	001	Feb 25, 1988
	200MG	A074525	001	Dec 15, 1995
	200MG	A074533	001	Dec 15, 1995
VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987
	200MG	A071639	001	Feb 02, 1988
WATSON LABS	200MG	A070435	001	Mar 05, 1986
IBUPROHM				
OHM LABS	200MG	A071214	001	Dec 01, 1986
IBU-TAB 200				
ALRA	200MG	A071057	001	Aug 11, 1988
JUNIOR STRENGTH ADVIL				
WYETH CONS	100MG	N020267	002	Dec 13, 1996
JUNIOR STRENGTH IBUPROFEN				
PERRIGO	100MG	A075367	001	Apr 22, 1999
JUNIOR STRENGTH MOTRIN				
MCNEIL CONS	100MG	N020602	001	Jun 10, 1996
MOTRIN IB				
+ MCNEIL	200MG	N019012	003	Dec 17, 1990
MOTRIN MIGRAINE PAIN				
+ MCNEIL	200MG	N019012	004	Feb 25, 2000
PROFEN				
LEINER	200MG	A071265	001	Oct 15, 1986
TAB-PROFEN				
PERRIGO	200MG	A072095	001	Dec 08, 1987

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

## CAPSULE; ORAL

## ADVIL COLD AND SINUS

+ WYETH CONS	EQ 200MG FREE ACID AND POTASSIUM SALT; 30MG	N021374	001	May 30, 2002
--------------	---	---------	-----	--------------

## SUSPENSION; ORAL

## CHILDREN'S ADVIL COLD

WYETH CONS	100MG/5ML; 15MG/5ML	N021373	001	Apr 18, 2002
------------	---------------------	---------	-----	--------------

## CHILDREN'S MOTRIN COLD

+ MCNEIL CONS	100MG/5ML; 15MG/5ML	N021128	001	Aug 01, 2000
---------------	---------------------	---------	-----	--------------

## IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO	100MG/5ML; 15MG/5ML	A076478	001	Nov 05, 2003
---------	---------------------	---------	-----	--------------

## TABLET; ORAL

## ADVIL COLD AND SINUS

+ WYETH CONS	200MG; 30MG	N019771	001	Sep 19, 1989
--------------	-------------	---------	-----	--------------

## IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD	200MG; 30MG	A077628	001	Aug 14, 2006
--------------------	-------------	---------	-----	--------------

## LEINER

	200MG; 30MG	A075588	001	Apr 08, 2002
--	-------------	---------	-----	--------------

## IBUPROHM COLD AND SINUS

OHM LABS	200MG; 30MG	A074567	001	Apr 17, 2001
----------	-------------	---------	-----	--------------

## SINE-AID IB

MCNEIL CONS	200MG; 30MG	N019899	001	Dec 31, 1992
-------------	-------------	---------	-----	--------------

INSULIN RECOMBINANT HUMAN

## INJECTABLE; INJECTION

## HUMULIN R

+ LILLY	100 UNITS/ML	N018780	001	Oct 28, 1982
---------	--------------	---------	-----	--------------

## HUMULIN R PEN

+ LILLY	100 UNITS/ML	N018780	005	Aug 06, 1998
---------	--------------	---------	-----	--------------

## NOVOLIN R

+ NOVO NORDISK INC	100 UNITS/ML	N019938	001	Jun 25, 1991
--------------------	--------------	---------	-----	--------------

## OTC DRUG PRODUCT LIST

4 - 10 (of 17)

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 70/30

+ LILLY 30 UNITS/ML;70 UNITS/ML N019717 001 Apr 25, 1989

HUMULIN 70/30 PEN

+ LILLY 30 UNITS/ML;70 UNITS/ML N019717 002 Aug 06, 1998

NOVOLIN 70/30

+ NOVO NORDISK INC 30 UNITS/ML;70 UNITS/ML N019991 001 Jun 25, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN N

+ LILLY 100 UNITS/ML N018781 001 Oct 28, 1982

NOVOLIN N

NOVO NORDISK INC 100 UNITS/ML N019959 001 Jul 01, 1991

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

DURAPREP

+ 3M EQ 0.7% IODINE;74% (6ML) N021586 001 Sep 29, 2006

+ EQ 0.7% IODINE;74% (26ML) N021586 002 Sep 29, 2006

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D

+ MCNEIL CONS 1% N020310 001 Oct 10, 1997

KETOPROFEN

FILM; ORAL

NEXCEDE

+ NOVARTIS 12.5MG N022470 001 Nov 25, 2009

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

+ BAUSCH AND LOMB EQ 0.025% BASE N021996 001 Dec 01, 2006

KETOTIFEN FUMARATE

AKORN EQ 0.025% BASE A077958 001 Jul 26, 2007

ALCON EQ 0.025% BASE A077200 001 Sep 02, 2008

APOTEX INC EQ 0.025% BASE A077354 001 May 09, 2006

ZADITOR

+ NOVARTIS EQ 0.025% BASE N021066 002 Oct 19, 2006

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PREVACID 24 HR

+ NOVARTIS 15MG N022327 001 May 18, 2009

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

WATSON LABS 0.75MG A078665 001 Aug 28, 2009

PLAN B

+ DURAMED 0.75MG N021045 002 Aug 24, 2006

PLAN B ONE-STEP

+ DURAMED 1.5MG N021998 001 Jul 10, 2009

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER PHARMACAPS 1MG N021855 001 Aug 04, 2005

+ 2MG N021855 002 Aug 04, 2005

## OTC DRUG PRODUCT LIST

4 - 11 (of 17)

LOPERAMIDE HYDROCHLORIDE

## SOLUTION; ORAL

IMODIUM A-D

+ MCNEIL CONS	1MG/5ML	N019487	001	Mar 01, 1988
LOPERAMIDE HYDROCHLORIDE				
HI TECH PHARMA	1MG/5ML	A074352	001	Nov 17, 1995
MORTON GROVE	1MG/5ML	A074730	001	Aug 28, 1997
PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
ROXANE	1MG/5ML	A073079	001	Apr 30, 1992

## SUSPENSION; ORAL

IMODIUM A-D

+ MCNEIL CONS	1MG/7.5ML	N019487	002	Jul 08, 2004
---------------	-----------	---------	-----	--------------

## TABLET, CHEWABLE; ORAL

IMODIUM A-D EZ CHEWS

+ MCNEIL	2MG	N020448	001	Jul 24, 1997
----------	-----	---------	-----	--------------

## TABLET; ORAL

IMODIUM A-D

+ MCNEIL CONS	2MG	N019860	001	Nov 22, 1989
LOPERAMIDE HYDROCHLORIDE				
LEINER	2MG	A073254	001	Jul 30, 1993
LNK	2MG	A076497	001	Jun 10, 2003
OHM LABS	2MG	A074091	001	Dec 10, 1992
PERRIGO	2MG	A075232	001	Jan 06, 2000

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

## TABLET, CHEWABLE; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ MCNEIL	2MG;125MG	N020606	001	Jun 26, 1996
----------	-----------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002
---------	-----------	---------	-----	--------------

## TABLET; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ MCNEIL CONS	2MG;125MG	N021140	001	Nov 30, 2000
---------------	-----------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

RANBAXY	2MG;125MG	A077500	001	Sep 06, 2006
---------	-----------	---------	-----	--------------

LORATADINE

## CAPSULE; ORAL

CLARITIN

+ SCHERING PLOUGH	10MG	N021952	001	Jun 16, 2008
-------------------	------	---------	-----	--------------

## SUSPENSION; ORAL

LORATADINE

+ TARO	1MG/ML	N021734	001	Oct 04, 2005
--------	--------	---------	-----	--------------

## SYRUP; ORAL

CLARITIN

+ SCHERING PLOUGH	1MG/ML	N020641	002	Nov 27, 2002
-------------------	--------	---------	-----	--------------

LORATADINE

APOTEX INC	1MG/ML	A075565	001	Oct 05, 2004
MORTON GROVE	1MG/ML	A075815	001	Aug 20, 2004
PERRIGO	1MG/ML	A075728	001	Aug 20, 2004
RANBAXY	1MG/ML	A076529	001	Aug 20, 2004
SILARX	1MG/ML	A077421	001	Jun 29, 2006
TARO	1MG/ML	A076805	001	Aug 20, 2004
TEVA	1MG/ML	A075505	001	Nov 07, 2003

## TABLET, CHEWABLE; ORAL

CHILDREN'S CLARITIN

+ SCHERING PLOUGH	5MG	N021891	001	Aug 23, 2006
-------------------	-----	---------	-----	--------------

## TABLET, ORALLY DISINTEGRATING; ORAL

ALAVERT

WYETH CONS	10MG	N021375	001	Dec 19, 2002
------------	------	---------	-----	--------------

CLARITIN HIVES RELIEF REDITAB

+ SCHERING PLOUGH	10MG	N020704	003	Nov 19, 2003
-------------------	------	---------	-----	--------------

CLARITIN REDITABS

+ SCHERING PLOUGH	5MG	N021993	001	Dec 12, 2006
-------------------	-----	---------	-----	--------------

+	10MG	N020704	002	Nov 27, 2002
---	------	---------	-----	--------------

## OTC DRUG PRODUCT LIST

4 - 12 (of 17)

LORATADINE

TABLET, ORALLY DISINTEGRATING; ORAL

LORATADINE

IMPAX LABS	10MG	A076011	001	Sep 29, 2003
WATSON LABS FLORIDA	10MG	A075990	001	Nov 03, 2003
WYETH CONS	10MG	A075822	001	Feb 10, 2003

LORATADINE REDIDOSE

RANBAXY	10MG	A077153	001	Apr 11, 2007
---------	------	---------	-----	--------------

TABLET; ORAL

CLARITIN

+ SCHERING PLOUGH	10MG	N019658	002	Nov 27, 2002
-------------------	------	---------	-----	--------------

CLARITIN HIVES RELIEF

+ SCHERING PLOUGH	10MG	N019658	003	Nov 19, 2003
-------------------	------	---------	-----	--------------

LORATADINE

APOTEX INC	10MG	A076471	001	Feb 14, 2006
------------	------	---------	-----	--------------

MYLAN	10MG	A075790	001	Nov 07, 2008
-------	------	---------	-----	--------------

	10MG	A076154	001	Aug 20, 2003
--	------	---------	-----	--------------

PERRIGO	10MG	A076301	001	Jun 25, 2004
---------	------	---------	-----	--------------

RANBAXY	10MG	A076134	001	Aug 18, 2003
---------	------	---------	-----	--------------

SANDOZ	10MG	A075209	001	Jan 21, 2003
--------	------	---------	-----	--------------

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D 24 HOUR

+ SCHERING PLOUGH	10MG;240MG	N020470	002	Nov 27, 2002
-------------------	------------	---------	-----	--------------

LORATADINE AND PSEUDOEPHEDRINE SULFATE

+ IMPAX LABS	5MG;120MG	A076050	001	Jan 30, 2003
--------------	-----------	---------	-----	--------------

	10MG;240MG	A075989	001	Mar 04, 2004
--	------------	---------	-----	--------------

RANBAXY	10MG;240MG	A076557	001	Sep 22, 2004
---------	------------	---------	-----	--------------

WATSON LABS FLORIDA	5MG;120MG	A076208	001	Jan 28, 2004
---------------------	-----------	---------	-----	--------------

	10MG;240MG	A075706	001	Feb 21, 2003
--	------------	---------	-----	--------------

MENTHOL; METHYL SALICYLATE

PATCH; TOPICAL

SALONPAS

+ HISAMITSU	3%;10%	N022029	001	Feb 20, 2008
-------------	--------	---------	-----	--------------

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MICONAZOLE 7 COMBINATION PACK

G AND W LABS	2%,100MG	A076585	001	Mar 26, 2004
--------------	----------	---------	-----	--------------

MICONAZOLE NITRATE COMBINATION PACK

PERRIGO	2%,200MG	A075329	001	Apr 20, 1999
---------	----------	---------	-----	--------------

MONISTAT 1 COMBINATION PACK

+ JOHNSON AND JOHNSON	1.2GM,2%	N021308	001	Jun 29, 2001
-----------------------	----------	---------	-----	--------------

MONISTAT 7 COMBINATION PACK

+ JOHNSON AND JOHNSON	2%,100MG	N020288	002	Apr 26, 1993
-----------------------	----------	---------	-----	--------------

MONISTAT-3 COMBINATION PACK

+ JOHNSON AND JOHNSON	2%,200MG	N020670	002	Apr 16, 1996
-----------------------	----------	---------	-----	--------------

M-ZOLE 3 COMBINATION PACK

ACTAVIS MID ATLANTIC	2%,200MG	A074926	001	Apr 16, 1999
----------------------	----------	---------	-----	--------------

M-ZOLE 7 DUAL PACK

ACTAVIS MID ATLANTIC	2%,100MG	A074586	001	Jul 17, 1997
----------------------	----------	---------	-----	--------------

CREAM; TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

PERRIGO	2%,4%	A076357	001	Mar 30, 2004
---------	-------	---------	-----	--------------

MONISTAT 3 COMBINATION PACK

JOHNSON AND JOHNSON	2%,4%	N021261	003	Jun 17, 2003
---------------------	-------	---------	-----	--------------

MONISTAT 3 COMBINATION PACK (PREFILLED)

+ JOHNSON AND JOHNSON	2%,4%	N021261	001	Feb 02, 2001
-----------------------	-------	---------	-----	--------------

CREAM; VAGINAL

MICONAZOLE 3

TARO	4%	A076773	001	Mar 02, 2005
------	----	---------	-----	--------------



## OTC DRUG PRODUCT LIST

4-13 (of 17)

MICONAZOLE NITRATE

## CREAM; VAGINAL

## MICONAZOLE 7

ACTAVIS MID ATLANTIC 2%

A074164 001 Mar 29, 1996

## MICONAZOLE NITRATE

G AND W LABS 2%

A074366 001 Feb 22, 1996

PERRIGO 2%

A074760 001 May 15, 1997

TARO 2%

A074444 001 Jan 13, 1997

## MONISTAT 3

+ JOHNSON AND JOHNSON 4%

N020827 001 Mar 30, 1998

## MONISTAT 7

+ JOHNSON AND JOHNSON 2%

N017450 002 Feb 15, 1991

## SUPPOSITORY; VAGINAL

## MICONAZOLE NITRATE

ACTAVIS MID ATLANTIC 100MG

A073507 001 Nov 19, 1993

G AND W LABS 100MG

A074414 001 Apr 30, 1997

+ PERRIGO 100MG

A074395 001 Mar 20, 1997

## MONISTAT 7

+ JOHNSON AND JOHNSON 100MG

N018520 002 Feb 15, 1991

MINOXIDIL

## AEROSOL, FOAM; TOPICAL

## MEN'S ROGAINE

+ JOHNSON AND JOHNSON 5%

N021812 001 Jan 20, 2006

## SOLUTION; TOPICAL

## MINOXIDIL (FOR MEN)

ACTAVIS MID ATLANTIC 2%

A074588 001 Apr 05, 1996

BAUSCH AND LOMB 2%

A074643 001 Apr 09, 1996

HI TECH PHARMA 2%

A074731 001 Dec 24, 1996

MORTON GROVE 2%

A074767 001 Feb 28, 1997

NOVEX 2%

A074924 001 Apr 29, 1998

PERRIGO 2%

A075357 001 Jul 30, 1999

SIGHT PHARMS 2%

A074743 002 Oct 18, 1996

## MINOXIDIL (FOR WOMEN)

HI TECH PHARMA 2%

A074731 002 May 11, 2005

NOVEX 2%

A074924 002 Apr 29, 1998

PERRIGO 2%

A075357 002 Jul 30, 1999

SIGHT PHARMS 2%

A074743 001 Oct 18, 1996

## MINOXIDIL EXTRA STRENGTH (FOR MEN)

ACTAVIS MID ATLANTIC 5%

A075518 001 Nov 17, 2000

MORTON GROVE 5%

A075438 001 Feb 27, 2003

NOVEX 5%

A075839 001 Oct 01, 2001

PERRIGO 5%

A075598 001 Jun 13, 2001

PERRIGO NEW YORK 5%

A075737 001 Mar 15, 2002

## ROGAINE (FOR MEN)

+ JOHNSON AND JOHNSON 2%

N019501 002 Feb 09, 1996

## ROGAINE (FOR WOMEN)

+ JOHNSON AND JOHNSON 2%

N019501 003 Feb 09, 1996

## ROGAINE EXTRA STRENGTH (FOR MEN)

+ JOHNSON AND JOHNSON 5%

N020834 001 Nov 14, 1997

## THEROXIDIL

HARMONY LABS 2%

A078176 001 Nov 09, 2007

5%

A076239 001 Aug 24, 2004

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

## SOLUTION/DROPS; OPHTHALMIC

## NAPHCN-A

+ ALCON 0.025%;0.3%

N020226 001 Jun 08, 1994

## OPCON-A

+ BAUSCH AND LOMB 0.02675%;0.315%

N020065 001 Jun 08, 1994

## VISINE-A

JOHNSON AND JOHNSON 0.025%;0.3%

N020485 001 Jan 31, 1996

## OTC DRUG PRODUCT LIST

4 - 14 (of 17)

NAPROXEN SODIUM

CAPSULE; ORAL

NAPROXEN SODIUM

+ BANNER PHARMACAPS	EQ 200MG BASE	N021920	001	Feb 17, 2006
---------------------	---------------	---------	-----	--------------

TABLET; ORAL

ALEVE

+ BAYER	EQ 200MG BASE	N020204	002	Jan 11, 1994
---------	---------------	---------	-----	--------------

NAPROXEN SODIUM

AMNEAL PHARMS NY EQ 200MG BASE A079096 001 Dec 16, 2008

CONTRACT PHARMACAL EQ 200MG BASE A074635 001 Jan 13, 1997

EQ 200MG BASE A074789 001 Feb 27, 1997

DR REDDYS LABS INC EQ 200MG BASE A075168 001 Jul 28, 1998

PERRIGO EQ 200MG BASE A074661 001 Jan 13, 1997

SANDOZ EQ 200MG BASE A074646 001 Jan 13, 1997

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALEVE-D SINUS &amp; COLD

+ BAYER	200MG;120MG	N021076	001	Nov 29, 1999
---------	-------------	---------	-----	--------------

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS INC	EQ 220MG BASE;120MG	A077381	001	Sep 27, 2006
--------------------	---------------------	---------	-----	--------------

PERRIGO	EQ 200MG BASE;120MG	A076518	001	Mar 17, 2004
---------	---------------------	---------	-----	--------------

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

HABITROL

+ NOVARTIS	7MG/24HR	N020076	004	Nov 12, 1999
------------	----------	---------	-----	--------------

+	14MG/24HR	N020076	005	Nov 12, 1999
---	-----------	---------	-----	--------------

+	21MG/24HR	N020076	006	Nov 12, 1999
---	-----------	---------	-----	--------------

NICODERM CQ

+ SANOFI AVENTIS US	7MG/24HR	N020165	006	Aug 02, 1996
---------------------	----------	---------	-----	--------------

+	14MG/24HR	N020165	005	Aug 02, 1996
---	-----------	---------	-----	--------------

+	21MG/24HR	N020165	004	Aug 02, 1996
---	-----------	---------	-----	--------------

NICOTINE

AVEVA	7MG/24HR	A074645	001	Oct 20, 1997
-------	----------	---------	-----	--------------

	14MG/24HR	A074611	001	Oct 20, 1997
--	-----------	---------	-----	--------------

	21MG/24HR	A074612	001	Oct 20, 1997
--	-----------	---------	-----	--------------

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE

+ GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996
-------------------	-------------	---------	-----	--------------

	EQ 2MG BASE	N018612	004	Sep 25, 2000
--	-------------	---------	-----	--------------

+	EQ 4MG BASE	N020066	002	Feb 09, 1996
---	-------------	---------	-----	--------------

	EQ 4MG BASE	N020066	004	Sep 25, 2000
--	-------------	---------	-----	--------------

NICORETTE (MINT)

GLAXOSMITHKLINE	EQ 2MG BASE	N018612	003	Dec 23, 1998
-----------------	-------------	---------	-----	--------------

	EQ 4MG BASE	N020066	003	Dec 23, 1998
--	-------------	---------	-----	--------------

NICOTINE POLACRILEX

IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009
----------------------	-------------	---------	-----	--------------

	EQ 4MG BASE	A077850	001	Feb 18, 2009
--	-------------	---------	-----	--------------

PERRIGO	EQ 2MG BASE	A076775	001	Sep 16, 2004
---------	-------------	---------	-----	--------------

	EQ 2MG BASE	A076776	001	Sep 16, 2004
--	-------------	---------	-----	--------------

	EQ 2MG BASE	A076777	001	Sep 16, 2004
--	-------------	---------	-----	--------------

	EQ 4MG BASE	A076778	001	Sep 16, 2004
--	-------------	---------	-----	--------------

	EQ 4MG BASE	A076779	001	Sep 16, 2004
--	-------------	---------	-----	--------------

	EQ 4MG BASE	A076789	001	Sep 16, 2004
--	-------------	---------	-----	--------------

PERRIGO R AND D	EQ 2MG BASE	A078325	001	Oct 30, 2006
-----------------	-------------	---------	-----	--------------

	EQ 2MG BASE	A078547	001	May 24, 2007
--	-------------	---------	-----	--------------

	EQ 2MG BASE	A078967	001	Apr 23, 2008
--	-------------	---------	-----	--------------

	EQ 4MG BASE	A078326	001	Oct 30, 2006
--	-------------	---------	-----	--------------

	EQ 4MG BASE	A078546	001	May 24, 2007
--	-------------	---------	-----	--------------

	EQ 4MG BASE	A078968	001	Apr 23, 2008
--	-------------	---------	-----	--------------

WATSON LABS	EQ 2MG BASE	A074507	001	Mar 15, 1999
-------------	-------------	---------	-----	--------------

## OTC DRUG PRODUCT LIST

4 - 15 (of 17)

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL  
 NICOTINE POLACRILEX  
 WATSON LABS

EQ 2MG BASE	A076569	001	Jul 29, 2004
EQ 2MG BASE	A078699	001	Dec 29, 2008
EQ 2MG BASE	A079044	001	Jul 08, 2009
EQ 2MG BASE	A079216	001	Jul 08, 2009
EQ 4MG BASE	A074707	001	Mar 19, 1999
EQ 4MG BASE	A076568	002	Jul 29, 2004
EQ 4MG BASE	A078697	001	Dec 29, 2008
EQ 4MG BASE	A079038	001	Jul 08, 2009
EQ 4MG BASE	A079219	001	Jul 08, 2009

THRIVE

NOVARTIS

EQ 2MG BASE	A077658	001	Jun 19, 2007
EQ 4MG BASE	A077656	001	Jun 19, 2007

TROCHE/LOZENGE; ORAL  
 COMMIT

GLAXOSMITHKLINE CONS

EQ 2MG BASE	N021330	001	Oct 31, 2002
EQ 4MG BASE	N021330	002	Oct 31, 2002

+

NICORETTE

GLAXOSMITHKLINE CONS

EQ 2MG BASE	N022360	001	May 18, 2009
EQ 4MG BASE	N022360	002	May 18, 2009

+

NICOTINE POLACRILEX

PERRIGO R AND D

EQ 2MG BASE	A077007	001	Jan 31, 2006
EQ 2MG BASE	A090711	001	Jul 10, 2009
EQ 2MG BASE	A090821	001	Jul 10, 2009
EQ 4MG BASE	A077007	002	Jan 31, 2006
EQ 4MG BASE	A090711	002	Jul 10, 2009
EQ 4MG BASE	A090821	002	Jul 10, 2009

NIZATIDINE

TABLET; ORAL

AXID AR

+

WYETH CONS

75MG	N020555	001	May 09, 1996
------	---------	-----	--------------

NONOXYNOL-9

SPONGE; VAGINAL

TODAY

+

PAV NOVA

1GM	N018683	001	Apr 01, 1983
-----	---------	-----	--------------

OMEPRAZOLE

TABLET, DELAYED RELEASE; ORAL

OMEPRAZOLE

+

DEXCEL PHARMA

20MG	N022032	001	Dec 04, 2007
------	---------	-----	--------------

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE MAGNESIUM

+

DR REDDYS LABS LTD

EQ 20MG BASE	A078878	001	Jun 05, 2009
--------------	---------	-----	--------------

TABLET, DELAYED RELEASE; ORAL

PRILOSEC OTC

+

ASTRAZENECA

EQ 20MG BASE	N021229	001	Jun 20, 2003
--------------	---------	-----	--------------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

ZEGERID OTC

+

SCHERING PLOUGH

20MG;1.1GM	N022281	001	Dec 01, 2009
------------	---------	-----	--------------

ORLISTAT

CAPSULE; ORAL

ALLI

+

GLAXOSMITHKLINE CONS

60MG	N021887	001	Feb 07, 2007
------	---------	-----	--------------

## OTC DRUG PRODUCT LIST

4 - 16 (of 17)

OXYMETAZOLINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC  
OCUCLEAR

SCHERING PLOUGH	0.025%	N018471	001	May 30, 1986
VISINE L.R.				
+ JOHNSON AND JOHNSON	0.025%	N019407	001	Mar 31, 1989

PERMETHRINLOTION; TOPICAL  
NIX

+ INSIGHT PHARMS	1%	N019918	001	May 02, 1990
PERMETHRIN				
ACTAVIS MID ATLANTIC	1%	A075014	001	Mar 28, 2000
PERRIGO NEW YORK	1%	A076090	001	Dec 20, 2001

PIPERONYL BUTOXIDE; PYRETHRINSAEROSOL; TOPICAL  
RID MOUSSE

+ PFIZER	4%;EQ 0.33% BASE	N021043	001	Mar 07, 2000
----------	------------------	---------	-----	--------------

POLYETHYLENE GLYCOL 3350FOR SOLUTION; ORAL  
GLYCOLAX

KREMERS URBAN DEV	17GM/PACKET	A090600	001	Oct 06, 2009
	17GM/SCOOPFUL	A090600	002	Oct 06, 2009

MIRALAX

+ SCHERING PLOUGH	17GM/SCOOPFUL	N022015	001	Oct 06, 2006
-------------------	---------------	---------	-----	--------------

POLYETHYLENE GLYCOL 3350

MYLAN	17GM/PACKET	A078915	001	Oct 06, 2009
	17GM/SCOOPFUL	A078915	002	Oct 06, 2009
NEXGEN PHARMA	17GM/SCOOPFUL	A090812	001	Oct 07, 2009
NOVEL LABS INC	17GM/SCOOPFUL	A091077	001	Oct 06, 2009
PADDOCK	17GM/SCOOPFUL	A090567	001	Oct 15, 2009
PERRIGO R AND D	17GM/PACKET	A090685	001	Oct 06, 2009
	17GM/SCOOPFUL	A090685	002	Oct 06, 2009

POTASSIUM IODIDESOLUTION; ORAL  
THYROSHIELD

+ FLEMING	65MG/ML	A077218	001	Jan 12, 2005
-----------	---------	---------	-----	--------------

TABLET; ORAL  
IOSAT

+ ANBEX	130MG	N018664	001	Oct 14, 1982
---------	-------	---------	-----	--------------

THYROSAFE

+ RECIPI	65MG	A076350	001	Sep 10, 2002
----------	------	---------	-----	--------------

POVIDONE-IODINESOLUTION; TOPICAL  
POVIDONE IODINE

+ ALLEGIANCE HLTHCARE	1%	N019522	001	Mar 31, 1989
-----------------------	----	---------	-----	--------------

SPONGE; TOPICAL

E-Z SCRUB 201

+ BECTON DICKINSON	20%	N019240	001	Nov 29, 1985
--------------------	-----	---------	-----	--------------

E-Z SCRUB 241

+ BECTON DICKINSON	10%	N019476	001	Jan 07, 1987
--------------------	-----	---------	-----	--------------

PSEUDOEPHEDRINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO	120MG	A075153	001	Feb 26, 1999
---------	-------	---------	-----	--------------

RANBAXY	120MG	A077442	001	Sep 28, 2005
---------	-------	---------	-----	--------------

SUDAFED 12 HOUR

+ MCNEIL CONS	120MG	A073585	001	Oct 31, 1991
---------------	-------	---------	-----	--------------

## OTC DRUG PRODUCT LIST

4 - 17 (of 17)

PSEUDOEPHEDRINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
SUDAFED 24 HOUR

+ ALZA 240MG N020021 002 Dec 15, 1992

PSEUDOEPHEDRINE SULFATETABLET, EXTENDED RELEASE; ORAL  
AFRINOL

+ SCHERING PLOUGH 120MG N018191 001

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

DR REDDYS LABS LTD	EQ 75MG BASE	A075294	001	Mar 28, 2000
	EQ 150MG BASE	A078192	001	Aug 31, 2007
GENPHARM	EQ 75MG BASE	A075497	001	Jan 14, 2000
IVAX SUB TEVA PHARMS	EQ 75MG BASE	A075296	001	Jan 14, 2000
LEINER	EQ 75MG BASE	A075094	001	Jun 21, 1999
PERRIGO	EQ 75MG BASE	A076195	001	Aug 30, 2002
TORPHARM	EQ 75MG BASE	A075167	001	May 04, 2000
WATSON LABS	EQ 75MG BASE	A075212	001	Jan 14, 2000
WOCKHARDT	EQ 75MG BASE	A076760	001	Feb 24, 2006
	EQ 75MG BASE	A078884	001	Jul 31, 2008
	EQ 150MG BASE	A078653	001	Nov 26, 2007

ZANTAC 150

+ BOEHRINGER INGELHEIM	EQ 150MG BASE	N021698	001	Aug 31, 2004
	EQ 150MG BASE	N021698	002	Mar 13, 2007

ZANTAC 75

BOEHRINGER INGELHEIM EQ 75MG BASE N020520 001 Dec 19, 1995

SODIUM CHLORIDEAEROSOL, METERED; INHALATION  
BRONCHO SALINE

+ BLAIREX 0.9% N019912 001 Sep 03, 1992

SODIUM FLUORIDE; TRICLOSANPASTE; DENTAL  
COLGATE TOTAL

+ COLGATE PALMOLIVE 0.24%;0.3% N020231 001 Jul 11, 1997

TERBINAFINEGEL; TOPICAL  
LAMISIL AT

+ NOVARTIS 1% N021958 001 Jul 24, 2006

TERBINAFINE HYDROCHLORIDECREAM; TOPICAL  
LAMISIL

+ NOVARTIS 1% N020980 001 Mar 09, 1999

TERBINAFINE HYDROCHLORIDE

TARO 1% A077511 001 Jul 02, 2007

SOLUTION; TOPICAL

LAMISIL AT

+ NOVARTIS 1% N021124 001 Mar 17, 2000

SPRAY; TOPICAL

LAMISIL AT

+ NOVARTIS 1% N021124 002 Mar 17, 2000

TIOCONAZOLEOINTMENT; VAGINAL  
TIOCONAZOLE

PERRIGO 6.5% A075915 001 Nov 21, 2001

VAGISTAT-1

+ NOVARTIS 6.5% N020676 001 Feb 11, 1997

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

MEDSEP CORPORATION

N760305

Jun 30, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

CYTOSOL

LABORATORIES INC

N020037

Aug 26, 2003

ACD-A SOLUTION

GAMBRO BCT INC

A010228

ANDA

Feb 25, 2002

ADSOL WITH ACD-A

FENWAL INC

N000922

Aug 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A

HAEMONETICS CORP

A980728

ANDA

Feb 06, 2002

AS3 SOLUTION/ACD-A

GAMBRO BCT INC

N001214

May 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N100855

Jun 03, 1959

N160918

Mar 17, 1978

FRESENIUS USA INC

N110912

Sep 02, 1959

MEDSEP CORPORATION

A710497

ANDA

MILES INC

N100102

Dec 14, 1961

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

HAEMONETICS CORP

N000127

Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

FRESENIUS USA INC

N780519

Apr 23, 1980

TERUMO MEDICAL CORP

N820528

Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

FENWAL INC

N770420

May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC

N940404

Jul 28, 1994

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

MEDSEP CORPORATION

N800077

Nov 06, 1980

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION		
ADSOL IN PLASTIC CONTAINER		
FENWAL INC	N900223	Dec 27, 1991
CPD BLOOD BAG UNIT IN PLASTIC CONTAINER		
FENWAL INC	N900224	Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION		
MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB		
MACOPRODUCTIONS SAS	N040083	Nov 21, 2005

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION		
NONE		
FENWAL INC	N170401	Dec 06, 1977
	N811012	Jun 28, 1983
FRESENIUS USA INC	N160907	May 16, 1973
MEDSEP CORPORATION	N800222	Aug 23, 1982
MILES INC	N160527	Jun 22, 1970
TERUMO MEDICAL CORP	N781211	Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1:  
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION		
ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION		
FENWAL INC	N811104	May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5:  
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION		
OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION		
TERUMO MEDICAL CORP	N880217	Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:  
AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;  
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION		
AS-3 NUTRICEL ADDITIVE SYSTEM		
MEDSEP CORP	0.042GM/100ML;0.276GM/100ML; 0.410GM/100ML;0.30GM/100ML; 1.10GM/100ML;0.588GM/100ML	N820915      Oct 19, 1984

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:  
AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;  
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION		
AS-2 NUTRICEL ADDITIVE SYSTEM		
MEDSEP CORP	0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML	N820915      Sep 22, 1983

ANTICOAGULANT ETHYLENEDIAMINE TETRAACETIC ACID (EDTA)

INJECTABLE; INJECTION		
NONE		
FENWAL INC	N090480	Mar 07, 1955

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT HEPARIN SOLUTION USP

INJECTABLE; INJECTION

NONE

FRESENIUS USA INC

N770822

May 17, 1978

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS  
CORPORATION

N980123

Mar 03, 2000

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CYTOSOL  
LABORATORIES INC

N010409

Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC  
FRESENIUS USA INC  
TERUMO MEDICAL CORP

N770923

Jan 20, 1978

N160702

Dec 28, 1970

N781214

Feb 08, 1980

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB

N830715

Oct 30, 1984

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

GENTRAN 40

BAXTER HLTHCARE CORP 10GM/100ML;5GM/100ML  
LMD IN PLASTIC CONTAINER

N840619

Feb 22, 1985

HOSPIRA INC 10GM/100ML;5GM/100ML

A720563

ANDA

Oct 30, 1992

NONE

B BRAUN MEDICAL INC 10GM/100ML;5GM/100ML

N160767

Apr 06, 1970

HOSPIRA INC 10GM/100ML;5GM/100ML

N160375

Jul 25, 1967

MILES INC 10GM/100ML;5GM/100ML

N160653

Sep 23, 1969

PHARMACHEM 10GM/100ML;5GM/100ML

N160836

Nov 14, 1972

RHEOMACRODEX

MEDA AB 10GM/100ML;5GM/100ML

N140716

Jan 18, 1967

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

GENTRAN 40

BAXTER HLTHCARE CORP 10GM/100ML;0.9GM/100ML  
LMD IN PLASTIC CONTAINER

N840620

Feb 22, 1985

HOSPIRA INC 10GM/100ML;0.9GM/100ML

A720562

ANDA

Oct 30, 1992

NONE

HOSPIRA INC 10GM/100ML;0.9GM/100ML

N160375

Jul 25, 1967

MCGAW INC 10GM/100ML;0.9GM/100ML

N160767

Apr 06, 1970

MILES INC 10GM/100ML;0.9GM/100ML

N160653

Sep 23, 1969

PHARMACHEM 10GM/100ML;0.9GM/100ML

N160836

Nov 14, 1972

RHEOMACRODEX

PHARMALINK 10GM/100ML;0.9GM/100ML  
BASLAKEMEDEL AB

N140716

Jan 18, 1967



**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

<u>DEXTRAN 40, 10% W/V DEXTRAN 40 IN 0.8% NAACL 500 ML PVC BAGS</u>			
INJECTABLE; INJECTION			
RHEOMACRODEX			
MEDA AB		N830527	Mar 27, 1985
<u>DEXTRAN 40, 10% W/V DEXTRAN 40 IN 5% DEXTROSE 500 ML PVC BAGS</u>			
INJECTABLE; INJECTION			
RHEOMACRODEX			
MEDA AB		N830627	Mar 27, 1985
<u>DEXTRAN 70, 6% IN DEXTROSE 5%</u>			
INJECTABLE; INJECTION			
MACRODEX			
MEDA AB	6GM/100ML;5GM/100ML	N060826	Jun 08, 1954
NONE			
HOSPIRA INC	6GM/100ML;5GM/100ML	N080819	Mar 31, 1953
<u>DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%</u>			
INJECTABLE; INJECTION			
GENTRAIN 70			
BAXTER HLTHCARE CORP		N160607	Jan 26, 1970
MACRODEX			
PHARMALINK	6GM/100ML;5GM/100ML	N060826	Jun 08, 1954
BASLAKEMEDEL AB			
NONE			
B BRAUN MEDICAL INC	6GM/100ML;0.9 GM/100ML	N090024	Aug 18, 1969
MILES INC	6GM/100ML;0.9 GM/100ML	N080716	Mar 13, 1953
<u>DEXTRAN 70, 6% W/V DEXTRAN 70 IN 0.9% NAACL IN 500 ML PVC BAGS</u>			
INJECTABLE; INJECTION			
MACRODEX			
MEDA AB		N830613	Mar 27, 1985
<u>DEXTRAN 70, 6% W/V DEXTRAN 70 IN 5% DEXTROSE</u>			
INJECTABLE; INJECTION			
MACRODEX			
MEDA AB		N830629	Mar 27, 1985
<u>DEXTRAN 75, 6% IN SODIUM CHLORIDE 0.9%</u>			
INJECTABLE; INJECTION			
NONE			
PHARMACHEM	6GM/100ML;0.9GM/100ML	N080564	Sep 19, 1952
	6GM/100ML;0.9GM/100ML	N160759	Aug 19, 1970
<u>HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION</u>			
INJECTABLE; INJECTION			
HEXTEND			
BIOTIME INC	6GM/100ML	N200952	Mar 31, 1999

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT 6GM/100ML;0.9GM/100ML A740193 ANDA Jan 30, 1995

HESPAN

B BRAUN MEDICAL INC 6GM/100ML;0.9GM/100ML N160889 Jul 17, 1972

HESPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC 6GM/100ML;0.9GM/100ML N890105 Apr 04, 1991

NONE

B BRAUN MEDICAL INC 6GM/100ML;0.9GM/100ML A740283 ANDA Oct 21, 1998

TEVA PARENTERAL 6GM/100ML;0.9GM/100ML A740592 ANDA Nov 12, 1998  
MEDICINES INCHETASTARCH 6% IN SODIUM CHLORIDE 0.9% NACL 500 ML GLASS BOTTLES

INJECTABLE; INJECTION

NONE

HOSPIRA INC 6GM/100ML;0.9 GM/100ML A720746 ANDA Feb 07, 1996

HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

VOLUVEN

FRESNIUS KABI 6GM/100ML;0.9GM/100ML A070012 NDA Dec 27, 2007

CAROLINA RESEARCH  
GROUPPENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

PENTASPAN

B BRAUN MEDICAL INC 10GM/100ML;0.9GM/100ML N841207 May 19, 1987

PENTASPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC 10GM/100ML;0.9GM/100ML N890104 Apr 04, 1991

PERFLUORODECALIN; PERFLUOROTRI-N-PROPYLAMINE

INJECTABLE; INJECTION

FLUOSOL

ALPHA THERPTC CORP 17.5GM/100ML;7.5GM/100ML N860909 Dec 26, 1989

RED BLOOD CELL PROCESSING SOLUTION

INJECTABLE; INJECTION

REJUVESOL

CYTOSOL LABS INC N950522 Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE,  
DIABASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE

INJECTABLE; INJECTION

INTERSOL

FENWAL INC. 2.26G/500ML; 2.21G/500ML; 1.59G/500ML; N080041 NDA Dec 09, 2009  
1.53G/500ML; 0.465G/500ML

## DISCONTINUED DRUG PRODUCT LIST

6 - 1 (of 324)

ABARELIXINJECTABLE; INTRAMUSCULAR  
PLENAXIS

SPECIALITY EUROPEAN 100MG/VIAL N021320 001 Nov 25, 2003

ACETAMINOPHENINJECTABLE; INJECTION  
INJECTAPAP

ORTHO MCNEIL PHARM 100MG/ML N017785 001 Mar 07, 1986

SUPPOSITORY; RECTAL  
ACEPHEN

G AND W LABS 120MG A072218 001 Mar 27, 1992

ACETAMINOPHEN

ABLE 120MG A073106 001 Feb 27, 1995

325MG A073107 001 Feb 27, 1995

650MG A073108 001 Feb 27, 1995

ROXANE 120MG A071010 001 May 12, 1987

650MG A071011 001 May 12, 1987

TYLENOL

MCNEIL CONS 120MG N017756 002

650MG N017756 001

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

MIKART 150MG;180MG;15MG A081095 001 Oct 26, 1990

150MG;180MG;60MG A081097 001 Oct 26, 1990

CODEINE, ASPIRIN, APAP FORMULA NO. 2

SCHERER LABS 150MG;180MG;15MG A085640 001

CODEINE, ASPIRIN, APAP FORMULA NO. 3

SCHERER LABS 150MG;180MG;30MG A085639 001

CODEINE, ASPIRIN, APAP FORMULA NO. 4

SCHERER LABS 150MG;180MG;60MG A085638 001

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BANCAP

FOREST PHARMS 325MG;50MG A088889 001 Jan 16, 1986

BUCET

MALLINCKRODT 650MG;50MG A088991 001 Jun 28, 1985

TENCON

MALLINCKRODT 650MG;50MG A089405 001 May 15, 1990

TRIAPRIN

DUNHALL 325MG;50MG A089268 001 Jul 02, 1987

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

HALSEY 325MG;50MG A089568 001 Oct 05, 1988

WATSON LABS 325MG;50MG A087550 001 Oct 19, 1984

SEDAPAP

MAYRAND 650MG;50MG A088944 001 Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

SHIRE 325MG;50MG;40MG A087628 001 Oct 01, 1986

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GRAHAM DM 325MG;50MG;40MG A088743 001 Jul 18, 1985

325MG;50MG;40MG A088765 001 Mar 27, 1985

325MG;50MG;40MG A089067 001 Apr 19, 1985

MALLINCKRODT 325MG;50MG;40MG A088758 001 Mar 27, 1985

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GILBERT LABS 325MG;50MG;40MG A088825 001 Dec 05, 1984

FEMCET

MALLINCKRODT 325MG;50MG;40MG A089102 001 Jun 19, 1985

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 443 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 2 (of 324)

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

MEDIGESIC PLUS

US CHEM

325MG;50MG;40MG

A089115 001

Jan 14, 1986

TRIAD

MALLINCKRODT

325MG;50MG;40MG

A089023 001

Jun 19, 1985

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ABLE

325MG;50MG;40MG

A040390 001

Jul 23, 2001

500MG;50MG;40MG

A040394 001

Jul 23, 2001

GILBERT LABS

325MG;50MG;40MG

A087629 001

Nov 13, 1984

MUTUAL PHARM

325MG;50MG;40MG

A040601 001

Jul 29, 2005

WATSON LABS

325MG;50MG;40MG

A089536 001

Feb 16, 1988

ESGIC

FOREST PHARMS

325MG;50MG;40MG

A089660 001

Dec 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

ABLE

325MG;50MG;40MG;30MG

A076528 001

Aug 21, 2003

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

DHC PLUS

PHARM RES ASSOC

356.4MG;30MG;16MG

A088584 001

Mar 04, 1986

SYNALGOS-DC-A

LEITNER PHARMS

356.4MG;30MG;16MG

A089166 001

May 14, 1986

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

TEVA

300MG;15MG

A088537 001

Jun 04, 1984

300MG;30MG

A088324 001

Dec 29, 1983

300MG;60MG

A088599 001

Jun 01, 1984

PHENAPHEN W/ CODEINE NO. 2

ROBINS AH

325MG;15MG

A084444 001

PHENAPHEN W/ CODEINE NO. 3

ROBINS AH

325MG;30MG

A084445 001

PHENAPHEN W/ CODEINE NO. 4

ROBINS AH

325MG;60MG

A084446 001

PROVAL #3

SOLVAY

325MG;30MG

A085685 001

TYLENOL W/ CODEINE NO. 3

ORTHO MCNEIL PHARM

300MG;30MG

A087422 001

TYLENOL W/ CODEINE NO. 4

ORTHO MCNEIL PHARM

300MG;60MG

A087421 001

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

CLONMEL

120MG/5ML;12MG/5ML

A040098 001

Sep 20, 1996

ROXANE

120MG/5ML;12MG/5ML

A086366 001

TYLENOL W/ CODEINE

ORTHO MCNEIL PHARM

120MG/5ML;12MG/5ML

A085057 001

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ABLE

300MG;30MG

A040452 001

Aug 01, 2002

300MG;60MG

A040459 001

Aug 01, 2002

AM THERAP

300MG;15MG

A089478 001

Mar 03, 1987

300MG;15MG

A089481 001

Mar 03, 1987

300MG;30MG

A089479 001

Mar 03, 1987

300MG;30MG

A089482 001

Mar 03, 1987

300MG;60MG

A089480 001

Mar 03, 1987

300MG;60MG

A089483 001

Mar 03, 1987

DURAMED PHARMS BARR

300MG;15MG

A088353 001

Feb 06, 1984

300MG;30MG

A088354 001

Feb 06, 1984

## DISCONTINUED DRUG PRODUCT LIST

6 - 3 (of 324)

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

## ACETAMINOPHEN AND CODEINE PHOSPHATE

DURAMED PHARMS BARR	300MG;60MG	A088355	001	Feb 06, 1984
EVERYLIFE	325MG;30MG	A085217	001	
HALSEY	300MG;15MG	A083871	001	
	300MG;30MG	A083872	001	
	300MG;60MG	A086549	001	
KV PHARM	300MG;30MG	A085288	001	
	300MG;60MG	A085365	001	
	325MG;15MG	A085364	001	
	325MG;45MG	A085363	001	
LEDERLE	300MG;30MG	A087141	001	
MIKART	300MG;60MG	A089244	001	Feb 25, 1986
MUTUAL PHARM	300MG;15MG	A085795	001	
	300MG;15MG	A089671	001	Feb 10, 1988
	300MG;30MG	A085794	001	
	300MG;30MG	A089672	001	Feb 10, 1988
	300MG;60MG	A087653	001	Apr 13, 1982
	300MG;60MG	A089673	001	Feb 10, 1988
PHARMERAL	300MG;30MG	A087762	001	Dec 10, 1982
PUREPAC PHARM	300MG;30MG	A086681	001	
	300MG;30MG	A089080	001	Jul 17, 1986
	300MG;60MG	A086683	001	
ROXANE	300MG;15MG	A084659	001	
	300MG;30MG	A084656	001	
	300MG;60MG	A084667	001	
	500MG;15MG	A089511	001	Apr 25, 1989
	500MG;30MG	A089512	001	Apr 25, 1989
	500MG;60MG	A089513	001	Apr 25, 1989
SANDOZ	300MG;15MG	A087433	001	
	300MG;30MG	A081250	001	Jul 16, 1992
	300MG;30MG	A085291	002	
	300MG;30MG	A085917	001	
	300MG;60MG	A081249	001	Jul 16, 1992
	300MG;60MG	A085964	001	
	300MG;60MG	A087423	001	
SUPERPHARM	300MG;15MG	A089183	001	Oct 18, 1985
	300MG;30MG	A089184	001	Oct 18, 1985
	300MG;30MG	A089253	001	May 19, 1986
	300MG;60MG	A089185	001	Oct 18, 1985
	300MG;60MG	A089254	001	May 19, 1986
USL PHARMA	300MG;30MG	A087919	001	Jun 22, 1982
	300MG;60MG	A087920	001	Jun 22, 1982
VALEANT PHARM INTL	300MG;30MG	A085896	001	
VITARINE	300MG;30MG	A085676	001	
WARNER CHILCOTT	300MG;15MG	A085992	001	
	300MG;30MG	A085218	002	
	300MG;60MG	A087306	001	
WATSON LABS	300MG;15MG	A087277	001	May 26, 1982
	300MG;30MG	A087276	001	May 26, 1982
	300MG;60MG	A087275	001	May 26, 1982
WHITEWORTH TOWN PLSN	300MG;30MG	A084360	001	
	300MG;60MG	A085607	001	
CAPITAL AND CODEINE				
CARNRICK	325MG;30MG	A083643	001	
CODRIX				
WATSON LABS FLORIDA	500MG;15MG	A040447	001	Feb 26, 2003
	500MG;30MG	A040441	001	Mar 27, 2003
	500MG;60MG	A040488	001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3				
GLAXOSMITHKLINE	300MG;30MG	A083951	001	
EMPRACET W/ CODEINE PHOSPHATE #4				
GLAXOSMITHKLINE	300MG;60MG	A083951	002	

## DISCONTINUED DRUG PRODUCT LIST

6 - 4 (of 324)

ACETAMINOPHEN; CODEINE PHOSPHATE

## TABLET; ORAL

PAPA-DEINE #3				
VANGARD	300MG; 30MG	A088037	001	Mar 20, 1984
PAPA-DEINE #4				
VANGARD	300MG; 60MG	A088715	001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE				
ROBINS AH	650MG; 30MG	A085856	001	
TYLENOL W/ CODEINE				
ORTHO MCNEIL PHARM	325MG; 7.5MG	A085056	001	
	325MG; 15MG	A085056	002	
	325MG; 30MG	A085056	003	
	325MG; 60MG	A085056	004	
TYLENOL W/ CODEINE NO. 1				
ORTHO MCNEIL JANSSEN	300MG; 7.5MG	A085055	001	
TYLENOL W/ CODEINE NO. 2				
ORTHO MCNEIL JANSSEN	300MG; 15MG	A085055	002	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

## CAPSULE; ORAL

## ACETAMINOPHEN AND HYDROCODONE BITARTRATE

CENT PHARMS	500MG; 5MG	A088898	001	Mar 27, 1985
ALLAY				
IVAX PHARMS	500MG; 5MG	A089907	001	Jan 13, 1989
BANCAP HC				
FOREST PHARMS	500MG; 5MG	A087961	001	Mar 17, 1983
CO-GESIC				
CENT PHARMS	500MG; 5MG	A089360	001	Mar 02, 1988
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MALLINCKRODT	500MG; 5MG	A088956	001	Jul 19, 1985
	500MG; 5MG	A089006	001	Aug 09, 1985
MIKART	500MG; 5MG	A081068	001	Nov 30, 1989
	500MG; 5MG	A081069	001	Nov 30, 1989
	500MG; 5MG	A081070	001	Nov 30, 1989
LORCET-HD				
MALLINCKRODT	500MG; 5MG	A087336	001	Jul 08, 1982
SOLUTION; ORAL				
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MIKART	500MG/15ML; 5MG/15ML	A081226	001	Oct 27, 1992
	500MG/15ML; 5MG/15ML	A089557	001	Apr 29, 1992

## TABLET; ORAL

## DURADYNE DHC

FOREST PHARMS	500MG; 5MG	A087809	001	Mar 17, 1983
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
ABLE	325MG; 5MG	A040478	001	Nov 08, 2002
	325MG; 7.5MG	A040464	001	Oct 23, 2002
	325MG; 10MG	A040464	002	Oct 23, 2002
	500MG; 5MG	A040477	001	Nov 06, 2002
	500MG; 7.5MG	A040490	001	May 21, 2003
	500MG; 10MG	A040473	001	Nov 06, 2002
	650MG; 7.5MG	A040474	001	Jan 02, 2003
	650MG; 10MG	A040476	001	Oct 23, 2002
	750MG; 7.5MG	A040469	001	Oct 25, 2002
BARR	500MG; 2.5MG	A040307	001	Jul 26, 2000
	500MG; 5MG	A040308	001	Jul 26, 2000
	500MG; 5MG	A088577	001	Dec 21, 1984
	500MG; 7.5MG	A040307	002	Jul 26, 2000
	500MG; 10MG	A040309	001	Jul 26, 2000
	650MG; 7.5MG	A040307	003	Jul 26, 2000
	650MG; 10MG	A040307	004	Jul 26, 2000
	750MG; 7.5MG	A040308	002	Jul 26, 2000
ENDO PHARMS	500MG; 5MG	A040281	001	Sep 30, 1998
	500MG; 7.5MG	A040280	001	Sep 30, 1998
	650MG; 7.5MG	A040280	002	Sep 30, 1998

## DISCONTINUED DRUG PRODUCT LIST

6 - 5 (of 324)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

## TABLET; ORAL

## HYDROCODONE BITARTRATE AND ACETAMINOPHEN

ENDO PHARMS	650MG;10MG	A040280	003	Sep 30, 1998
	750MG;7.5MG	A040281	002	Sep 30, 1998
HALSEY	500MG;5MG	A089554	001	Jun 12, 1987
IVAX PHARMS	500MG;5MG	A089696	001	Apr 21, 1988
MIKART	500MG;5MG	A089271	001	Jul 16, 1986
	500MG;5MG	A089697	001	Jan 28, 1992
MUTUAL PHARM	500MG;5MG	A040236	001	Sep 25, 1997
	650MG;7.5MG	A040240	002	Nov 26, 1997
	650MG;10MG	A040240	001	Nov 26, 1997
	750MG;7.5MG	A040236	002	Sep 25, 1997
UCB INC	500MG;10MG	A040210	001	Aug 13, 1997
	650MG;7.5MG	A040134	001	Nov 21, 1996
USL PHARMA	500MG;5MG	A089290	001	May 29, 1987
	500MG;5MG	A089291	001	May 29, 1987
VINTAGE PHARMS	500MG;5MG	A089831	001	Sep 07, 1988
WATSON LABS	325MG;7.5MG	A040248	001	Apr 28, 2000
	500MG;5MG	A040122	001	Mar 04, 1996
	750MG;7.5MG	A040122	002	Mar 04, 1996
HY-PHEN				
ASCHER	500MG;5MG	A087677	001	May 03, 1982
NORCET				
ABANA	500MG;5MG	A088871	001	May 15, 1986
TYCOLET				
ORTHO MCNEIL PHARM	500MG;5MG	A089385	001	Aug 27, 1986
VICODIN				
ABBOTT	500MG;5MG	A085667	001	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

## CAPSULE; ORAL

## OXYCODONE AND ACETAMINOPHEN

BARR	500MG;5MG	A040304	001	Oct 02, 2000
HALSEY	500MG;5MG	A089994	001	May 04, 1989
MUTUAL PHARM	500MG;5MG	A040219	001	Jan 22, 1998
TYLOX-325				
ORTHO MCNEIL PHARM	325MG;5MG	A088246	001	Nov 08, 1984

## TABLET; ORAL

## OXYCODONE 2.5/APAP 500

BRISTOL MYERS SQUIBB	500MG;2.5MG	A085910	001	
OXYCODONE 5/APAP 500				
BRISTOL MYERS SQUIBB	500MG;5MG	A085911	001	
OXYCODONE AND ACETAMINOPHEN				
BARR	325MG;5MG	A087406	001	
DURAMED PHARMS BARR	325MG;5MG	A040272	001	Jun 30, 1998
PERCOCET				
ENDO PHARMS	325MG;5MG	A085106	002	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

## CAPSULE; ORAL

## TYLOX

ORTHO MCNEIL PHARM	500MG;4.5MG;0.38MG	A085375	001	
--------------------	--------------------	---------	-----	--

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

## TABLET; ORAL

## DARVOCET

AAIPHARMA LLC	325MG;32.5MG	N016844	001	
---------------	--------------	---------	-----	--

## DOLENE AP-65

LEDERLE	650MG;65MG	A085100	001	
---------	------------	---------	-----	--

## PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

MYLAN	325MG;32MG	A083689	001	
SANDOZ	650MG;65MG	A089959	001	Jul 18, 1989
WATSON LABS	650MG;65MG	A040139	001	Dec 16, 1996

## DISCONTINUED DRUG PRODUCT LIST

6 - 6 (of 324)

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

WYGESIC

LEITNER PHARMS 650MG;65MG A084999 001

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPACET 100

TEVA 650MG;100MG A070107 001 Jun 12, 1985

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

ABLE 650MG;100MG A075838 001 Jul 11, 2001

ACTAVIS ELIZABETH 650MG;100MG A070910 001 Jan 02, 1987

HALSEY 325MG;50MG A072105 001 May 13, 1988

650MG;100MG A072106 001 May 13, 1988

IVAX SUB TEVA PHARMS 650MG;100MG A070146 001 Aug 02, 1985

MALLINCKRODT 650MG;100MG A075738 001 Feb 02, 2001

MUTUAL PHARM 325MG;50MG A070115 001 Jun 12, 1985

650MG;100MG A070116 001 Jun 12, 1985

650MG;100MG A070615 001 Mar 21, 1986

650MG;100MG A070771 001 Mar 21, 1986

650MG;100MG A070775 001 Mar 21, 1986

MYLAN 650MG;100MG A072195 001 Feb 16, 1988

SANDOZ 650MG;100MG A070443 001 Jan 23, 1986

SUPERPHARM 650MG;100MG A071319 001 Jan 06, 1987

TEVA 650MG;100MG A070732 001 Jan 03, 1986

WATSON LABS 325MG;50MG A070398 001 Dec 18, 1986

650MG;100MG A070399 001 Dec 18, 1986

WATSON LABS FLORIDA 500MG;100MG A077196 001 Jun 28, 2005

650MG;100MG A076609 001 Nov 16, 2004

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

ALRA 250MG A083320 001

ASCOT 250MG A087686 001 Oct 20, 1982

MUTUAL PHARM 250MG A089753 001 Jun 22, 1988

VANGARD 250MG A087654 001 Feb 05, 1982

WATSON LABS 250MG A084498 002

DIAMOX

DURAMED PHARMS BARR 125MG N008943 001

250MG N008943 002

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

HOSPIRA EQ 500MG BASE/VIAL A040108 001 Oct 30, 1995

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETIC ACID

KV PHARM 2% A085493 001

ORLEX

PROCTER AND GAMBLE 2% A086845 001

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

BOROFAIR

PHARMAFAIR 2%;0.79% A088606 001 Aug 21, 1985

DOMEBORO

BAYER PHARMS 2%;0.79% A084476 001



## DISCONTINUED DRUG PRODUCT LIST

6 - 7 (of 324)

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC			
TRIDESILON			
BAYER PHARMS	2%;0.05%	N017914	001

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC			
ACETIC ACID W/ HYDROCORTISONE			
KV PHARM	2%;1%	A085492	001
HYDROCORTISONE AND ACETIC ACID			
BAUSCH AND LOMB	2%;1%	A040097	001 Oct 31, 1994
MORTON GROVE	2%;1%	A040168	001 Aug 30, 1996
ORLEX HC			
PROCTER AND GAMBLE	2%;1%	A086844	001

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC			
NEO-CORT-DOME			
BAYER PHARMS	2%;1%;EQ 0.35% BASE	N050238	001

ACETOHEXAMIDE

TABLET; ORAL			
ACETOHEXAMIDE			
BARR	250MG	A070869	001 Feb 09, 1987
	500MG	A070870	001 Feb 09, 1987
USL PHARMA	250MG	A070753	001 Nov 03, 1986
	500MG	A070754	001 Nov 03, 1986
DYMELOR			
LILLY	250MG	N013378	002
	500MG	N013378	001

ACETOPHENAZINE MALEATE

TABLET; ORAL			
TINDAL			
SCHERING	20MG	N012254	002

ACETRIZOATE SODIUM

SOLUTION; INTRAUTERINE			
SALPIX			
ORTHO MCNEIL PHARM	53%	N009008	001

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC			
MIOCHOL			
NOVARTIS	20MG/VIAL	N016211	001

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL			
ACETYLCYSTEINE			
HOSPIRA	10%	A071364	001 May 01, 1989
	20%	A071365	001 May 01, 1989
ROXANE	10%	A072621	001 Sep 30, 1992
	20%	A072622	001 Sep 30, 1992
MUCOMYST			
APOTHECON	10%	N013601	002
	20%	N013601	001
MUCOSIL-10			
DEY	10%	A070575	001 Oct 14, 1986
MUCOSIL-20			
DEY	20%	A070576	001 Oct 14, 1986

## DISCONTINUED DRUG PRODUCT LIST

6 - 8 (of 324)

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

MUCOMYST W/ ISOPROTERENOL

MEAD JOHNSON 10%;0.05% N017366 001

ACETYLDIGITOXIN

TABLET; ORAL

ACYLANID

NOVARTIS 0.1MG N009436 001

ACRISORCIN

CREAM; TOPICAL

AKRINOL

SCHERING 2MG/GM N012470 001

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

BELCHER PHARMS	200MG	A074889	001	Oct 31, 1997
DAVA PHARMS INC	200MG	A074872	001	Apr 22, 1997
LEK PHARM	200MG	A074750	001	Apr 22, 1997
MYLAN	200MG	A074727	001	Apr 22, 1997
ROXANE	200MG	A074570	002	Apr 22, 1997
TEVA	200MG	A074828	001	Apr 22, 1997
TEVA PHARMS	200MG	A074914	001	Nov 26, 1997

TABLET; ORAL

ACYCLOVIR

BELCHER PHARMS	400MG	A074891	001	Oct 31, 1997
	800MG	A074891	002	Oct 31, 1997
DAVA PHARMS INC	400MG	A074834	001	Apr 24, 1997
	800MG	A074834	002	Apr 24, 1997
LEK PHARM	400MG	A074658	001	Apr 22, 1997
	800MG	A074658	002	Apr 22, 1997
MYLAN	400MG	A075211	001	Sep 28, 1998
	800MG	A075211	002	Sep 28, 1998
TEVA	200MG	A074556	001	Apr 22, 1997
TEVA PHARMS	400MG	A075021	001	Mar 18, 1998
	800MG	A075021	002	Mar 18, 1998

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

ABBOTT EQ 50MG BASE/ML A075114 001 Jul 26, 1999

ACYCLOVIR SODIUM

APOTHECON	EQ 500MG BASE/VIAL	A074897	001	Feb 27, 1998
	EQ 1GM BASE/VIAL	A074897	002	Feb 27, 1998
HOSPIRA	EQ 500MG BASE/VIAL	A074663	001	Apr 22, 1997
	EQ 500MG BASE/VIAL	A074758	001	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074663	002	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074758	002	Apr 22, 1997

ZOVIRAX

GLAXOSMITHKLINE EQ 250MG BASE/VIAL N018603 003 Aug 30, 1983

ADAPALENE

SOLUTION; TOPICAL

DIFFERIN

GALDERMA LABS LP 0.1% N020338 001 May 31, 1996

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

PFIZER	EQ 200MG BASE/VIAL	N020760	001	Dec 18, 1997
	EQ 300MG BASE/VIAL	N020760	002	Dec 18, 1997

## DISCONTINUED DRUG PRODUCT LIST

6 - 9 (of 324)

ALBUMIN CHROMATED CR-51 SERUMINJECTABLE; INJECTION  
CHROMALBIN

ISO TEX	100uCi/VIAL	N017835	001
	250uCi/VIAL	N017835	002
	500uCi/VIAL	N017835	003

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)

BAYER PHARMS	2.5uCi/AMP	N017846	001
--------------	------------	---------	-----

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

MALLINCKRODT	6.67uCi/ML	N017844	003
	10uCi/ML	N017844	001
	100uCi/ML	N017844	002

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

ISO TEX	2mCi/VIAL	N017837	003
	5uCi/AMP	N017837	004
	20uCi/AMP	N017837	005

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

ARMSTRONG PHARMS	0.09MG/INH	A072273	001	Aug 14, 1996
GENPHARM	0.09MG/INH	A073045	001	Aug 19, 1997
IVAX SUB TEVA PHARMS	0.09MG/INH	A073272	001	Dec 28, 1995
PLIVA	0.09MG/INH	A074072	001	Aug 01, 1996
PROVENTIL				
SCHERING	0.09MG/INH	N017559	001	
VENTOLIN				
GLAXOSMITHKLINE	0.09MG/INH	N018473	001	

ALBUTEROL SULFATE

CAPSULE; INHALATION

VENTOLIN ROTACAPS

GLAXOSMITHKLINE	EQ 0.2MG BASE	N019489	001	May 04, 1988
-----------------	---------------	---------	-----	--------------

SOLUTION; INHALATION

ALBUTEROL SULFATE

BAUSCH AND LOMB	EQ 0.083% BASE	A075358	001	Mar 29, 2000
COPLLEY PHARM	EQ 0.083% BASE	A073495	001	May 28, 1993
	EQ 0.5% BASE	A073307	001	Nov 27, 1991
ROXANE	EQ 0.083% BASE	A075129	001	Feb 13, 2001
PROVENTIL				
SCHERING	EQ 0.083% BASE	N019243	002	Jan 14, 1987
	EQ 0.5% BASE	N019243	001	Jan 14, 1987
VENTOLIN				
GLAXOSMITHKLINE	EQ 0.083% BASE	N019773	001	Apr 23, 1992
	EQ 0.5% BASE	N019269	002	Jan 16, 1987

SYRUP; ORAL

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262	001	Mar 30, 1999
MOVA	EQ 2MG BASE/5ML	A074302	001	Sep 30, 1994
WATSON LABS	EQ 2MG BASE/5ML	A073165	001	Apr 29, 1993
PROVENTIL				
SCHERING	EQ 2MG BASE/5ML	N018062	001	Jan 19, 1983
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE/5ML	N019621	001	Jun 10, 1987
TABLET; ORAL				
ALBUTEROL SULFATE				
AM THERAP	EQ 2MG BASE	A072449	001	Dec 05, 1989
	EQ 4MG BASE	A072450	001	Dec 05, 1989

## DISCONTINUED DRUG PRODUCT LIST

6 - 10 (of 324)

ALBUTEROL SULFATE

TABLET; ORAL

ALBUTEROL SULFATE

COPLEY PHARM

EQ 2MG BASE

A072966 001

Nov 22, 1991

EQ 4MG BASE

A072967 001

Nov 22, 1991

DAVA PHARMS INC

EQ 2MG BASE

A072859 001

Dec 20, 1989

EQ 4MG BASE

A072860 001

Dec 20, 1989

PLIVA

EQ 2MG BASE

A072316 001

Dec 05, 1989

EQ 4MG BASE

A072317 001

Dec 05, 1989

SANDOZ

EQ 2MG BASE

A072151 001

Dec 05, 1989

EQ 4MG BASE

A072152 001

Dec 05, 1989

TEVA

EQ 2MG BASE

A072619 001

Dec 05, 1989

EQ 2MG BASE

A072779 001

Jun 25, 1993

EQ 2MG BASE

A072938 001

Mar 30, 1990

EQ 4MG BASE

A072620 001

Dec 05, 1989

EQ 4MG BASE

A072780 001

Jun 25, 1993

EQ 4MG BASE

A072939 001

Mar 30, 1990

UCB INC

EQ 2MG BASE

A073120 001

Sep 29, 1992

EQ 4MG BASE

A073121 001

Sep 29, 1992

WARNER CHILCOTT

EQ 2MG BASE

A072817 001

Jan 09, 1990

EQ 4MG BASE

A072818 001

Jan 09, 1990

WATSON LABS

EQ 2MG BASE

A072629 001

Jan 31, 1991

EQ 4MG BASE

A072630 001

Jan 31, 1991

EQ 4MG BASE

A072765 001

Aug 28, 1991

PROVENTIL

SCHERING

EQ 2MG BASE

N017853 001

May 07, 1982

EQ 4MG BASE

N017853 002

May 07, 1982

VENTOLIN

GLAXOSMITHKLINE

EQ 2MG BASE

N019112 001

Jul 10, 1986

EQ 4MG BASE

N019112 002

Jul 10, 1986

TABLET, EXTENDED RELEASE; ORAL

PROVENTIL

SCHERING

EQ 4MG BASE

N019383 001

Jul 13, 1987

VOLMAX

MURO

EQ 4MG BASE

N019604 002

Dec 23, 1992

EQ 8MG BASE

N019604 001

Dec 23, 1992

ALCOHOL

INJECTABLE; INJECTION

ALCOHOL 5% IN DEXTROSE 5%

MILES

5ML/100ML

A083483 001

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% IN DEXTROSE 5% IN WATER

BAXTER HLTHCARE

5ML/100ML;5GM/100ML

A083256 001

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

GENZYME

10 UNITS/ML

N020057 004

May 08, 1992

ALKAVERVIR

TABLET; ORAL

VERILOID

3M

2MG

N007336 002

3MG

N007336 003

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

MUTUAL PHARM

100MG

A070466 001

Dec 24, 1985

300MG

A070467 001

Dec 24, 1985

PAR PHARM

100MG

A070150 001

Dec 10, 1985

## DISCONTINUED DRUG PRODUCT LIST

6 - 11 (of 324)

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

PAR PHARM	300MG	A070147	001	Dec 10, 1985
PUREPAC PHARM	100MG	A070579	001	Apr 14, 1986
	300MG	A070580	001	Apr 14, 1986
SANDOZ	100MG	A070268	001	Dec 31, 1985
	300MG	A070269	001	Dec 31, 1985
SUPERPHARM	100MG	A070950	001	Nov 30, 1988
	300MG	A070951	001	Nov 30, 1988
WATSON LABS	100MG	N018241	001	Nov 16, 1984
	100MG	N018785	001	Sep 28, 1984
	300MG	N018241	002	Nov 16, 1984
	300MG	N018785	002	Sep 28, 1984
LOPURIN				
ABBOTT	100MG	N018297	001	
	300MG	N018297	002	

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION

CERNEVIT-12

BAXTER HLTHCARE	11.2 IU/VIAL;125MG/VIAL;60MCG/VIAL;200 IU/VIAL;5.5MG/VIAL;414MCG/VIAL;46MG/VIAL;17.25MG/VIAL;4.53MG/VIAL;4.14MG/VIAL;3.51MG/VIAL;3,500 IU/VIAL	N020924	001	Apr 06, 1999
-----------------	--	---------	-----	--------------

ALPRAZOLAM

SOLUTION; ORAL

ALPRAZOLAM

ROXANE	0.5MG/5ML	A074314	001	Oct 31, 1993
--------	-----------	---------	-----	--------------

TABLET; ORAL

ALPRAZOLAM

IVAX SUB TEVA PHARMS	0.25MG	A074294	001	Jul 29, 1994
	0.5MG	A074294	002	Jul 29, 1994
	1MG	A074294	003	Jul 29, 1994
	2MG	A074294	004	Jul 29, 1994
ROXANE	0.25MG	A074199	001	Oct 19, 1993
	0.5MG	A074199	002	Oct 19, 1993
	1MG	A074199	003	Oct 19, 1993
TEVA	0.25MG	A074085	001	Feb 16, 1994
	0.5MG	A074085	002	Feb 16, 1994
	1MG	A074085	003	Feb 16, 1994
	2MG	A074085	004	Feb 26, 1996
WATSON LABS	0.25MG	A074456	001	Aug 31, 1995
	0.25MG	A074479	001	Jan 21, 1997
	0.5MG	A074456	002	Aug 31, 1995
	0.5MG	A074479	002	Jan 21, 1997
	1MG	A074456	003	Aug 31, 1995
	1MG	A074479	003	Jan 21, 1997

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

PFIZER	0.005MG/ML	N020755	001	Oct 31, 1997
	0.01MG/ML	N020755	002	Oct 01, 1997
	0.02MG/ML	N020755	003	Oct 01, 1997

EDEX

SCHWARZ PHARMA	0.005MG/VIAL	N020649	001	Jun 12, 1997
----------------	--------------	---------	-----	--------------

ALSEROXYLON

TABLET; ORAL

RAUTENSIN

NOVARTIS	2MG	N009215	001	
----------	-----	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 12 (of 324)

ALSEROXYLON

TABLET; ORAL				
RAUWILOID				
3M	2MG	N008867	001	

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL				
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE				
PENNEX	80MG;20MG	A089449	001	Nov 27, 1987
FOAMICON				
NOVARTIS	80MG;20MG	A072687	001	Jun 28, 1989

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL				
AMANTADINE HYDROCHLORIDE				
WATSON LABS	100MG	A071382	001	Jan 21, 1987
SYMADINE				
SOLVAY	100MG	A071000	001	Sep 04, 1986
SYMMETREL				
ENDO PHARMS	100MG	N016020	001	
SYRUP; ORAL				
AMANTADINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	50MG/5ML	A072655	001	Oct 30, 1990
TEVA PHARMS	50MG/5ML	A073115	001	Aug 23, 1991
SYMMETREL				
ENDO PHARMS	50MG/5ML	N016023	002	

AMCINONIDE

CREAM; TOPICAL				
CYCLOCORT				
ASTELLAS	0.025%	N018116	001	
	0.1%	N018116	002	
LOTION; TOPICAL				
CYCLOCORT				
ASTELLAS	0.1%	N019729	001	Jun 13, 1988
OINTMENT; TOPICAL				
CYCLOCORT				
ASTELLAS	0.1%	N018498	001	

AMDINOCILLIN

INJECTABLE; INJECTION				
COACTIN				
ROCHE	250MG/VIAL	N050565	001	Dec 21, 1984
	500MG/VIAL	N050565	002	Dec 21, 1984
	1GM/VIAL	N050565	003	Dec 21, 1984

AMIFOSTINE

INJECTABLE; INJECTION				
ETHYOL				
MEDIMMUNE	375MG/VIAL	N020221	002	Sep 10, 1999

AMIKACIN SULFATE

INJECTABLE; INJECTION				
AMIKACIN SULFATE				
ABBOTT	EQ 250MG BASE/ML	A063265	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063266	001	Oct 31, 1994
ASTRAZENECA	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995
	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995
BAXTER HLTHCARE	EQ 50MG BASE/ML	A063274	001	May 18, 1992
	EQ 250MG BASE/ML	A063275	001	May 18, 1992
HOSPIRA	EQ 50MG BASE/ML	A063350	001	Jul 30, 1993
	EQ 62.5MG BASE/ML	A063283	001	Oct 31, 1994
	EQ 250MG BASE/ML	A063350	002	Jul 30, 1993
	EQ 250MG BASE/ML	A064098	001	Jun 26, 1995

## DISCONTINUED DRUG PRODUCT LIST

6 - 13 (of 324)

AMIKACIN SULFATE

## INJECTABLE; INJECTION

## AMIKACIN SULFATE

HOSPIRA	EQ 250MG BASE/ML	A064099	001	Jun 20, 1995
TEVA PARENTERAL	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993

## AMIKIN

APOTHECON	EQ 50MG BASE/ML	A062311	001	
	EQ 50MG BASE/ML	A062562	001	Sep 20, 1984
	EQ 50MG BASE/ML	N050495	001	
	EQ 250MG BASE/ML	A062311	002	
	EQ 250MG BASE/ML	A062562	002	Sep 20, 1984
	EQ 250MG BASE/ML	N050495	002	

## AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

APOTHECON	EQ 5MG BASE/ML	N050618	002	Nov 30, 1987
	EQ 10MG BASE/ML	N050618	001	Nov 30, 1987

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

## TABLET; ORAL

## AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SANDOZ	EQ 5MG ANHYDROUS;50MG	A073357	001	Nov 27, 1991
TEVA	EQ 5MG ANHYDROUS;50MG	A070795	001	Apr 17, 1988
WATSON LABS	EQ 5MG ANHYDROUS;50MG	A073334	001	Jul 19, 1991
HYDRO-RIDE				
PAR PHARM	EQ 5MG ANHYDROUS;50MG	A070347	001	Dec 25, 1990
MODURETIC 5-50				
MERCK	EQ 5MG ANHYDROUS;50MG	N018201	001	

AMINO ACIDS

## INJECTABLE; INJECTION

## AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

HOSPIRA	5.2% (5.2GM/100ML)	N018901	001	Apr 06, 1984
---------	--------------------	---------	-----	--------------

## AMINOSYN 3.5% IN PLASTIC CONTAINER

ABBOTT	3.5% (3.5GM/100ML)	N018804	001	May 15, 1984
	3.5% (3.5GM/100ML)	N018875	001	Aug 08, 1984

## AMINOSYN II 3.5%

HOSPIRA	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986
---------	--------------------	---------	-----	--------------

## AMINOSYN II 3.5% IN PLASTIC CONTAINER

ABBOTT	3.5% (3.5GM/100ML)	N019491	001	Oct 10, 1986
--------	--------------------	---------	-----	--------------

## AMINOSYN II 5%

HOSPIRA	5% (5GM/100ML)	N019438	002	Apr 03, 1986
---------	----------------	---------	-----	--------------

## AMINOSYN-HBC 7% IN PLASTIC CONTAINER

ABBOTT	7% (7GM/100ML)	N019400	001	Jul 23, 1986
--------	----------------	---------	-----	--------------

## BRANCHAMIN 4%

BAXTER HLTHCARE	4% (4GM/100ML)	N018678	001	Sep 28, 1984
-----------------	----------------	---------	-----	--------------

## FREAMINE 8.5%

B BRAUN	8.5% (8.5GM/100ML)	N016822	001	
---------	--------------------	---------	-----	--

## FREAMINE II 8.5%

B BRAUN	8.5% (8.5GM/100ML)	N016822	002	
---------	--------------------	---------	-----	--

## NEOPHAM 6.4%

HOSPIRA	6.4% (6.4GM/100ML)	N018792	001	Jan 17, 1984
---------	--------------------	---------	-----	--------------

## NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER

BAXTER HLTHCARE	15% (15GM/100ML)	N020107	001	Feb 05, 1993
-----------------	------------------	---------	-----	--------------

## NOVAMINE 8.5%

HOSPIRA	8.5% (8.5GM/100ML)	N017957	002	Aug 09, 1982
---------	--------------------	---------	-----	--------------

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

## AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML	N019714	001	Sep 12, 1988
	;22.4MG/100ML;261MG/100ML;205MG/100ML			

## AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	4.25%;36.8MG/100ML;20GM/100ML;51MG/100M	N019714	002	Sep 12, 1988
	L;22.4MG/100ML;261MG/100ML;205MG/100ML			

## DISCONTINUED DRUG PRODUCT LIST

6 - 14 (of 324)

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE;  
POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
ABBOTT	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML; L;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714 004	Sep 12, 1988
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
ABBOTT	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019714 003	Sep 12, 1988
HOSPIRA	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019683 004	Nov 07, 1988

AMINO ACIDS; DEXTROSE

## INJECTABLE; INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER			
ABBOTT	3.5%;25GM/100ML	N019118 001	Oct 11, 1984
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER			
ABBOTT	3.5%;5GM/100ML	N019120 001	Oct 11, 1984
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER			
ABBOTT	4.25%;25GM/100ML	N019119 001	Oct 11, 1984
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER			
ABBOTT	3.5%;25GM/100ML	N019505 002	Nov 07, 1986
	3.5%;25GM/100ML	N019713 006	Sep 09, 1988
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER			
ABBOTT	3.5%;5GM/100ML	N019506 001	Nov 07, 1986
	3.5%;5GM/100ML	N019713 002	Sep 09, 1988
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER			
ABBOTT	4.25%;10GM/100ML	N019713 001	Sep 09, 1988
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER			
ABBOTT	4.25%;20GM/100ML	N019713 004	Sep 09, 1988
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER			
ABBOTT	4.25%;25GM/100ML	N019504 002	Nov 07, 1986
	4.25%;25GM/100ML	N019713 005	Sep 09, 1988
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER			
ABBOTT	5%;25GM/100ML	N019565 001	Dec 17, 1986
	5%;25GM/100ML	N019713 003	Sep 09, 1988
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;10GM/100ML	N019520 002	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;15GM/100ML	N019520 003	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;20GM/100ML	N019520 004	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;25GM/100ML	N019520 005	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;5GM/100ML	N019520 001	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;10GM/100ML	N019520 007	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;15GM/100ML	N019520 008	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;20GM/100ML	N019520 009	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;25GM/100ML	N019520 010	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;5GM/100ML	N019520 006	Sep 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE;  
POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER			
ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100 ML;22.4MG/100ML;104.5MG/100ML;205MG/100 ML	N019712 002	Sep 08, 1988



## DISCONTINUED DRUG PRODUCT LIST

6 - 15 (of 324)

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE;  
POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER  
 HOSPIRA 4.25%;10GM/100ML;51MG/100ML;176.5MG/100 N019682 003 Nov 01, 1988  
 ML;22.4MG/100ML;104.5MG/100ML;205MG/100  
 ML

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE,  
DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER  
 ABBOTT 3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML N019564 002 Dec 16, 1986  
 ;261MG/100ML;205MG/100ML  
 AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER  
 ABBOTT 4.25%;25GM/100ML;51MG/100ML;22.4MG/100M N019564 004 Dec 16, 1986  
 L;261MG/100ML;205MG/100ML

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE;  
SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER  
 ABBOTT 3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 N019564 001 Dec 16, 1986  
 0MG/100ML;49.3MG/100ML  
 3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 N019712 001 Sep 08, 1988  
 0MG/100ML;49.3MG/100ML  
 AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER  
 ABBOTT 4.25%;10GM/100ML;30MG/100ML;97MG/100ML; N019564 003 Dec 16, 1986  
 120MG/100ML;49.3MG/100ML

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM  
ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER  
 BAXTER HLTHCARE 2.75%;10GM/100ML;51MG/100ML;261MG/100ML N020147 002 Oct 23, 1995  
 ;216MG/100ML;112MG/100ML  
 TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER  
 BAXTER HLTHCARE 2.75%;15GM/100ML;51MG/100ML;261MG/100ML N020147 003 Oct 23, 1995  
 ;216MG/100ML;112MG/100ML  
 TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER  
 BAXTER HLTHCARE 2.75%;20GM/100ML;51MG/100ML;261MG/100ML N020147 004 Oct 23, 1995  
 ;216MG/100ML;112MG/100ML  
 TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER  
 BAXTER HLTHCARE 2.75%;25GM/100ML;51MG/100ML;261MG/100ML N020147 005 Oct 23, 1995  
 ;216MG/100ML;112MG/100ML  
 TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER  
 BAXTER HLTHCARE 2.75%;5GM/100ML;51MG/100ML;261MG/100ML; N020147 001 Oct 23, 1995  
 216MG/100ML;112MG/100ML  
 TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER  
 BAXTER HLTHCARE 4.25%;10GM/100ML;51MG/100ML;261MG/100ML N020147 007 Oct 23, 1995  
 ;297MG/100ML;77MG/100ML  
 TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER  
 BAXTER HLTHCARE 4.25%;15GM/100ML;51MG/100ML;261MG/100ML N020147 008 Oct 23, 1995  
 ;297MG/100ML;77MG/100ML  
 TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER  
 BAXTER HLTHCARE 4.25%;20GM/100ML;51MG/100ML;261MG/100ML N020147 009 Oct 23, 1995  
 ;297MG/100ML;77MG/100ML  
 TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER  
 BAXTER HLTHCARE 4.25%;25GM/100ML;51MG/100ML;261MG/100ML N020147 010 Oct 23, 1995  
 ;297MG/100ML;77MG/100ML  
 TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER  
 BAXTER HLTHCARE 4.25%;5GM/100ML;51MG/100ML;261MG/100ML; N020147 006 Oct 23, 1995  
 297MG/100ML;77MG/100ML

## DISCONTINUED DRUG PRODUCT LIST

6 - 16 (of 324)

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N018804 002	May 15, 1984
	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N018875 002	Aug 08, 1984

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

HOSPIRA	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N017789 005	
---------	---	-------------	--

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%;32MG/100ML;128MG/100ML;222MG/100ML ;49MG/100ML	N019493 001	Oct 16, 1986
--------	--	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%

HOSPIRA	8%;61MG/100ML;211MG/100ML;56MG/100ML;38 8MG/100ML	N017957 001	
---------	--	-------------	--

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 7% W/ ELECTROLYTES

HOSPIRA	7%;102MG/100ML;45MG/100ML;522MG/100ML;4 10MG/100ML	N019437 006	Apr 03, 1986
---------	---	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

HOSPIRA	3.5%;30MG/100ML;97MG/100ML;120MG/100ML; 49MG/100ML	N019437 007	Apr 03, 1986
---------	---	-------------	--------------

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

XANODYNE PHARM	250MG/ML	N015229 002	
----------------	----------	-------------	--

AMINOCAPROIC ACID

ABRAXIS PHARM	250MG/ML	A070522 001	Jun 17, 1986
BAXTER HLTHCARE	250MG/ML	N018590 001	Oct 29, 1982
HOSPIRA	250MG/ML	A070888 001	Jun 16, 1988

AMINOGLUTETHIMIDE

TABLET; ORAL

CYTADREN

NOVARTIS	250MG	N018202 001	
----------	-------	-------------	--

AMINOPHYLLINE

ENEMA; RECTAL

SOMOPHYLLIN

FISONS	300MG/5ML	N018232 001	Apr 02, 1982
--------	-----------	-------------	--------------

INJECTABLE; INJECTION

AMINOPHYLLIN

GD SEARLE LLC	25MG/ML	A087243 001	May 24, 1982
	25MG/ML	A087621 001	May 24, 1982

AMINOPHYLLINE

ABRAXIS PHARM	25MG/ML	A084568 001	
	25MG/ML	A087200 001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 17 (of 324)

AMINOPHYLLINE

## INJECTABLE; INJECTION

## AMINOPHYLLINE

ABRAXIS PHARM	25MG/ML	A087250	001	Jan 06, 1982
	25MG/ML	A087431	001	
	25MG/ML	A087886	001	Aug 30, 1983
	25MG/ML	A088407	001	Jan 25, 1984
ELKINS SINN	25MG/ML	A087239	001	
HOSPIRA	25MG/ML	A087601	001	Jul 23, 1982
INTL MEDICATION	25MG/ML	A087867	001	Nov 10, 1983
	25MG/ML	A087868	001	Nov 10, 1983
KING PHARMS	25MG/ML	A086606	001	
PHARMA SERVE NY	25MG/ML	A087387	001	Jun 03, 1983
SMITH AND NEPHEW	25MG/ML	A088429	001	May 30, 1985
	25MG/ML	A088749	001	May 30, 1985

## AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

HOSPIRA	100MG/100ML	A088147	002	May 03, 1983
	200MG/100ML	A088147	003	May 03, 1983

## AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA	100MG/100ML	N018924	001	Dec 12, 1984
	200MG/100ML	N018924	002	Dec 12, 1984
	400MG/100ML	N018924	003	Dec 12, 1984
	500MG/100ML	N018924	004	Dec 12, 1984

## SOLUTION; ORAL

## AMINOPHYLLINE

MORTON GROVE	105MG/5ML	A088156	001	Dec 05, 1983
ROXANE	105MG/5ML	A088126	001	Aug 19, 1983

## AMINOPHYLLINE DYE FREE

ACTAVIS MID ATLANTIC	105MG/5ML	A087727	001	Apr 16, 1982
----------------------	-----------	---------	-----	--------------

## SOMOPHYLLIN

FISONS	105MG/5ML	A086466	001	
--------	-----------	---------	-----	--

## SOMOPHYLLIN-DF

FISONS	105MG/5ML	A087045	001	
--------	-----------	---------	-----	--

## SUPPOSITORY; RECTAL

## TRUPHYLLINE

G AND W LABS	250MG	A085498	001	Mar 23, 1983
	500MG	A085498	002	Jan 03, 1983

## TABLET; ORAL

## AMINOPHYLLIN

GD SEARLE LLC	100MG	N002386	002	
	200MG	N002386	003	

## AMINOPHYLLINE

ASCOT	100MG	A087522	001	Feb 12, 1982
	200MG	A087523	001	Feb 12, 1982
BARR	100MG	A088297	001	Aug 19, 1983
	200MG	A088298	001	Aug 19, 1983
DURAMED PHARMS BARR	100MG	A088182	001	Mar 31, 1983
	200MG	A088183	001	Mar 31, 1983
HALSEY	100MG	A084674	001	
IMPAX LABS	100MG	A084574	001	
	200MG	A084576	001	
KV PHARM	100MG	A085284	001	
	200MG	A085289	001	
LANNETT	100MG	A084588	001	
	200MG	A084588	002	
PAL PAK	100MG	A084533	001	
PANRAY	100MG	A084552	001	
	200MG	A084552	002	
PUREPAC PHARM	100MG	A084699	001	
	200MG	A085333	001	
ROXANE	100MG	A087500	001	Feb 09, 1982
	200MG	A087501	001	Feb 09, 1982
SANDOZ	100MG	A085261	003	
	100MG	A085262	002	
	200MG	A085261	002	

## DISCONTINUED DRUG PRODUCT LIST

6 - 18 (of 324)

AMINOPHYLLINE

## TABLET; ORAL

## AMINOPHYLLINE

VALEANT PHARM INTL	200MG	A084563	001	
VANGARD	100MG	A088314	001	Oct 03, 1983
	200MG	A088319	001	Oct 03, 1983
VINTAGE PHARMS	100MG	A085409	001	
	200MG	A085410	001	
WATSON LABS	100MG	A085567	001	
	200MG	A085564	001	

## TABLET, DELAYED RELEASE; ORAL

## AMINOPHYLLINE

IMPAX LABS	100MG	A084577	001	
	200MG	A084575	001	
TABLICAPS	100MG	A084632	002	
VALE	100MG	A084531	001	
	200MG	A084530	001	

## TABLET, EXTENDED RELEASE; ORAL

## PHYLLOCONTIN

PHARM RES ASSOC	225MG	A086760	001	
-----------------	-------	---------	-----	--

AMINOSALICYLATE SODIUM

## POWDER; ORAL

## P.A.S. SODIUM

CENTURY PHARMS	4GM/PACKET	A080947	001	
SODIUM AMINOSALICYLATE				
HEXCEL	100%	A080097	001	

## TABLET; ORAL

## PARASAL SODIUM

PANRAY	500MG	N006811	006	
	1GM	N006811	011	
SODIUM P.A.S.				
LANNETT	500MG	A080138	002	
TEEBACIN				
CONSOLIDATED MIDLAND	500MG	N007320	002	

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

## TABLET; ORAL

## NEOPASALATE

MEDPOINTE PHARM HLC	846MG;112MG	A080059	002	
---------------------	-------------	---------	-----	--

AMINOSALICYLIC ACID

## TABLET; ORAL

## PARASAL

PANRAY	500MG	N006811	001	
	1GM	N006811	002	

AMINOSALICYLIC ACID RESIN COMPLEX

## POWDER; ORAL

## REZIPAS

BRISTOL MYERS SQUIBB	EQ 500MG BASE/GM	N009052	001	
----------------------	------------------	---------	-----	--

AMIODARONE HYDROCHLORIDE

## INJECTABLE; INJECTION

## AMIODARONE HYDROCHLORIDE

BEN VENUE	50MG/ML	A076088	001	Oct 15, 2002
HOSPIRA	50MG/ML	A076108	001	Oct 15, 2002
INTL MEDICATION SYS	50MG/ML	N021594	001	Feb 04, 2004
CORDARONE				
WYETH PHARMS INC	50MG/ML	N020377	001	Aug 03, 1995

## TABLET; ORAL

## AMIODARONE HYDROCHLORIDE

TEVA	200MG	A074895	001	Apr 16, 1999
------	-------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 19 (of 324)

AMITRIPTYLINE HYDROCHLORIDE

## CONCENTRATE; ORAL

## ENDEP

ROCHE	40MG/ML	A085749	001	
-------	---------	---------	-----	--

## INJECTABLE; INJECTION

## AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS	10MG/ML	A085594	001	
-------------	---------	---------	-----	--

## ELAVIL

ASTRAZENECA	10MG/ML	N012704	001	
-------------	---------	---------	-----	--

## TABLET; ORAL

## AMITID

BRISTOL MYERS SQUIBB	10MG	A086454	001	
----------------------	------	---------	-----	--

	25MG	A086454	002	
--	------	---------	-----	--

	50MG	A086454	003	
--	------	---------	-----	--

	75MG	A086454	004	
--	------	---------	-----	--

	100MG	A086454	005	
--	-------	---------	-----	--

## AMITRIL

WARNER CHILCOTT	10MG	A083939	001	
-----------------	------	---------	-----	--

	25MG	A083937	001	
--	------	---------	-----	--

	50MG	A083938	002	
--	------	---------	-----	--

	75MG	A084957	001	
--	------	---------	-----	--

	100MG	A085093	001	
--	-------	---------	-----	--

	150MG	A086295	001	
--	-------	---------	-----	--

## AMITRIPTYLINE HYDROCHLORIDE

AM THERAP	25MG	A088672	001	Nov 20, 1984
-----------	------	---------	-----	--------------

	50MG	A088673	001	Nov 20, 1984
--	------	---------	-----	--------------

	75MG	A088674	001	Nov 20, 1984
--	------	---------	-----	--------------

	100MG	A088675	001	Nov 20, 1984
--	-------	---------	-----	--------------

COPLEY PHARM	10MG	A088421	001	Apr 30, 1984
--------------	------	---------	-----	--------------

	25MG	A088422	001	Apr 30, 1984
--	------	---------	-----	--------------

	50MG	A088423	001	Apr 30, 1984
--	------	---------	-----	--------------

	75MG	A088424	001	Apr 30, 1984
--	------	---------	-----	--------------

	100MG	A088425	001	Apr 30, 1984
--	-------	---------	-----	--------------

	150MG	A088426	001	Apr 30, 1984
--	-------	---------	-----	--------------

HALSEY	10MG	A085923	001	
--------	------	---------	-----	--

	25MG	A085922	001	
--	------	---------	-----	--

	50MG	A085925	001	
--	------	---------	-----	--

	50MG	A087557	001	Mar 05, 1982
--	------	---------	-----	--------------

	75MG	A085926	001	May 20, 1983
--	------	---------	-----	--------------

	100MG	A085927	001	May 20, 1983
--	-------	---------	-----	--------------

LEDERLE	10MG	A086744	001	
---------	------	---------	-----	--

	10MG	A087366	001	Jan 04, 1982
--	------	---------	-----	--------------

	25MG	A086746	001	
--	------	---------	-----	--

	25MG	A087367	001	May 03, 1982
--	------	---------	-----	--------------

	50MG	A086743	001	
--	------	---------	-----	--

	50MG	A087181	001	Jan 04, 1982
--	------	---------	-----	--------------

	75MG	A086745	001	
--	------	---------	-----	--

	75MG	A087369	001	Jan 04, 1982
--	------	---------	-----	--------------

	100MG	A086747	001	
--	-------	---------	-----	--

	100MG	A087368	001	May 03, 1982
--	-------	---------	-----	--------------

	150MG	A087370	001	Jan 04, 1982
--	-------	---------	-----	--------------

MUTUAL PHARM	10MG	A085744	001	
--------------	------	---------	-----	--

	25MG	A085627	001	
--	------	---------	-----	--

	50MG	A085745	001	
--	------	---------	-----	--

	75MG	A085743	001	
--	------	---------	-----	--

	100MG	A085742	002	May 11, 1982
--	-------	---------	-----	--------------

	150MG	A089423	001	Feb 17, 1987
--	-------	---------	-----	--------------

PAR PHARM	10MG	A088697	001	Sep 25, 1984
-----------	------	---------	-----	--------------

	25MG	A088698	001	Sep 25, 1984
--	------	---------	-----	--------------

	50MG	A088699	001	Sep 25, 1984
--	------	---------	-----	--------------

	75MG	A088700	001	Sep 25, 1984
--	------	---------	-----	--------------

	100MG	A088701	001	Sep 25, 1984
--	-------	---------	-----	--------------

	150MG	A088702	001	Sep 25, 1984
--	-------	---------	-----	--------------

PLIVA	10MG	A088883	001	Sep 26, 1984
-------	------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 20 (of 324)

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

PLIVA	25MG	A088884	001	Sep 26, 1984
	50MG	A088885	001	Sep 26, 1984
	75MG	A088886	001	Sep 26, 1984
	100MG	A088887	001	Sep 26, 1984
	150MG	A088888	001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075	001	Sep 16, 1983
	10MG	A088084	001	Jul 18, 1983
	25MG	A088076	001	May 20, 1983
	25MG	A088085	001	Jul 18, 1983
	50MG	A088077	001	Sep 16, 1983
	50MG	A088105	001	Jul 18, 1983
	75MG	A088078	001	Sep 16, 1983
	75MG	A088106	001	Jul 18, 1983
	100MG	A088079	001	Sep 16, 1983
	100MG	A088107	001	Jul 18, 1983
ROXANE	10MG	A086002	001	
	10MG	A086144	001	
	25MG	A085944	001	
	25MG	A086145	001	
	50MG	A085945	001	
	50MG	A086143	001	
	75MG	A086004	001	
	75MG	A086147	001	
	100MG	A086003	001	
	100MG	A086146	001	
	150MG	A086090	001	
	150MG	A086148	001	
SUPERPHARM	10MG	A088853	001	Nov 13, 1984
	25MG	A088854	001	Nov 13, 1984
	50MG	A088855	001	Nov 13, 1984
	75MG	A088856	001	Nov 13, 1984
	100MG	A088857	001	Nov 13, 1984
TEVA	10MG	A084910	003	
	10MG	A086610	001	
	25MG	A085031	001	
	25MG	A086859	001	
	50MG	A085032	001	
	50MG	A086857	001	
	75MG	A085030	001	
	75MG	A086860	001	
	100MG	A085836	001	
	100MG	A086854	001	
	150MG	A086853	001	
UCB INC	10MG	A085864	001	
	25MG	A085935	001	
	50MG	A085936	001	
	75MG	A086337	001	
	100MG	A086336	001	
	150MG	A086335	001	
USL PHARMA	25MG	A087775	001	Feb 10, 1982
VANGARD	10MG	A087632	001	Feb 01, 1982
	50MG	A087616	001	Feb 08, 1982
	75MG	A087617	001	Feb 05, 1982
	100MG	A087639	001	Feb 08, 1982
WATSON LABS	10MG	A085816	001	
	10MG	A088620	001	Mar 02, 1984
	25MG	A085817	001	
	25MG	A088621	001	Mar 02, 1984
	50MG	A085815	001	
	50MG	A088622	001	Mar 02, 1984
	75MG	A085819	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 21 (of 324)

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

## AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS	75MG	A088633	001	Mar 02, 1984
	100MG	A085820	001	
	100MG	A088634	001	Mar 02, 1984
	150MG	A085821	001	
	150MG	A088635	001	Mar 02, 1984
WEST WARD	10MG	A087647	001	Mar 05, 1982
	25MG	A087278	001	
ELAVIL				
ASTRAZENECA	10MG	N012703	001	
	25MG	N012703	003	
	50MG	N012703	004	
	75MG	N012703	005	
	100MG	N012703	006	
	150MG	N012703	007	
ENDEP				
ROCHE	10MG	A083639	001	
	25MG	A083639	002	
	50MG	A083639	003	
	75MG	A083639	004	
	100MG	A083639	005	
	150MG	A085303	001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

## CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MUTUAL PHARM	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986
	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986
PAR PHARM	EQ 12.5MG BASE;5MG	A072277	001	May 09, 1988
	EQ 25MG BASE;10MG	A072278	001	May 09, 1988
USL PHARMA	EQ 12.5MG BASE;5MG	A070477	001	Jan 12, 1988
	EQ 25MG BASE;10MG	A070478	001	Jan 12, 1988
WATSON LABS	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988
	EQ 25MG BASE;10MG	A072053	001	Dec 16, 1988

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

## ETRAFON 2-10

SCHERING 10MG;2MG N014713 007

## ETRAFON 2-25

SCHERING 25MG;2MG N014713 004

## ETRAFON-A

SCHERING 10MG;4MG N014713 002

## ETRAFON-FORTE

SCHERING 25MG;4MG N014713 006

## PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	10MG;2MG	A070935	001	Sep 11, 1986
	10MG;4MG	A070937	001	Sep 11, 1986
	25MG;2MG	A070936	001	Sep 11, 1986
	25MG;4MG	A070938	001	Sep 11, 1986
	50MG;4MG	A070939	001	Sep 12, 1986
MUTUAL PHARM	10MG;2MG	A071077	001	Nov 12, 1986
	10MG;4MG	A071078	001	Nov 12, 1986
	25MG;2MG	A070297	001	Nov 12, 1986
	25MG;4MG	A071079	001	Nov 12, 1986
PAR PHARM	10MG;2MG	A070565	001	Sep 11, 1986
	10MG;4MG	A070620	001	Sep 11, 1986
	25MG;2MG	A070621	001	Sep 11, 1986
	25MG;4MG	A070595	001	Sep 11, 1986
	50MG;4MG	A070574	001	Sep 11, 1986
SANDOZ	10MG;2MG	A071062	001	Nov 27, 1987
	10MG;4MG	A071862	001	Dec 21, 1987

## DISCONTINUED DRUG PRODUCT LIST

6 - 22 (of 324)

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

SANDOZ	25MG;2MG	A071063	001	Nov 27, 1987
	25MG;4MG	A071064	001	Nov 27, 1987
	50MG;4MG	A071863	001	Dec 21, 1987
WATSON LABS	10MG;2MG	A070373	001	Aug 25, 1986
	10MG;2MG	A072539	001	Feb 15, 1989
	10MG;2MG	A073007	001	Oct 17, 1991
	10MG;4MG	A070375	001	Aug 25, 1986
	10MG;4MG	A072540	001	Feb 15, 1989
	10MG;4MG	A073009	001	Oct 17, 1991
	25MG;2MG	A070374	001	Aug 25, 1986
	25MG;2MG	A072541	001	Feb 15, 1989
	25MG;2MG	A073008	001	Oct 17, 1991
	25MG;4MG	A070376	001	Aug 25, 1986
	25MG;4MG	A072134	001	Feb 15, 1989
	25MG;4MG	A073010	001	Oct 17, 1991
	50MG;4MG	A070377	001	Nov 04, 1986
	50MG;4MG	A071558	001	Mar 02, 1987
	50MG;4MG	A072135	001	Feb 15, 1989
TRIAVIL 2-10 NEW RIVER	10MG;2MG	N014715	004	
TRIAVIL 2-25 NEW RIVER	25MG;2MG	N014715	002	
TRIAVIL 4-10 NEW RIVER	10MG;4MG	N014715	003	
TRIAVIL 4-25 NEW RIVER	25MG;4MG	N014715	005	
TRIAVIL 4-50 NEW RIVER	50MG;4MG	N014715	006	

AMLEXANOX

PATCH; TOPICAL

AMLEXANOX

ULURU	2MG	N021727	001	Sep 29, 2004
-------	-----	---------	-----	--------------

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

GENPHARM	EQ 2.5MG BASE	A077362	001	Jul 09, 2007
	EQ 5MG BASE	A077362	002	Jul 09, 2007
	EQ 10MG BASE	A077362	003	Jul 09, 2007
MUTUAL PHARMA	EQ 2.5MG BASE	A078081	001	Jan 31, 2008
	EQ 5MG BASE	A078081	002	Jan 31, 2008
	EQ 10MG BASE	A078081	003	Jan 31, 2008
TABLET, ORALLY DISINTEGRATING; ORAL				
AMLODIPINE BESYLATE				
SYNTHON PHARMS	EQ 2.5MG BASE	N022026	001	Sep 27, 2007
	EQ 5MG BASE	N022026	002	Sep 27, 2007
	EQ 10MG BASE	N022026	003	Sep 27, 2007

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

DR REDDYS LABS INC	2.5MG	N021435	001	Oct 31, 2003
	5MG	N021435	002	Oct 31, 2003
	10MG	N021435	003	Oct 31, 2003

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE

ABBOTT	5MEQ/ML	A083130	001	
GD SEARLE LLC	3MEQ/ML	A086205	001	



## DISCONTINUED DRUG PRODUCT LIST

6 - 23 (of 324)

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE

MCGAW 900MG/100ML N006580 001

AMMONIUM CHLORIDE 2.14%

B BRAUN 40MEQ/100ML A085734 001

AMODIAQUINE HYDROCHLORIDE

TABLET; ORAL

CAMOQUIN HYDROCHLORIDE

PARKE DAVIS EQ 200MG BASE N006441 001

AMOXAPINE

TABLET; ORAL

AMOXAPINE

SANDOZ 25MG A072943 001 Jun 28, 1991

50MG A072944 001 Jun 28, 1991

100MG A072878 001 Jun 28, 1991

150MG A072879 001 Jun 28, 1991

WATSON LABS 25MG A072418 001 May 11, 1989

50MG A072419 001 May 11, 1989

100MG A072420 001 May 11, 1989

150MG A072421 001 May 11, 1989

ASENDIN

LEDERLE 25MG N018021 001

50MG N018021 002

100MG N018021 003

150MG N018021 004

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AM ANTIBIOTICS 250MG A062058 001

500MG A062058 002

LABS ATRAL 250MG A062528 001 Aug 07, 1985

500MG A062528 002 Aug 07, 1985

MYLAN 250MG A062067 001

500MG A062067 002

TEVA 250MG A062853 001 Dec 22, 1987

250MG A063030 001 Feb 28, 1989

500MG A062854 001 Dec 22, 1987

500MG A063031 001 Feb 28, 1989

AMOXIL

GLAXOSMITHKLINE 250MG A062216 001

250MG A062216 003

250MG N050459 001

500MG A062216 004

500MG N050459 002

TRIMOX

APOTHECON 250MG A061885 001

250MG A062098 001

250MG A062152 001

250MG A063099 001 Mar 20, 1992

500MG A061885 002

500MG A062098 002

500MG A062152 002

500MG A063099 002 Mar 20, 1992

UTIMOX

PARKE DAVIS 250MG A062107 001

500MG A062107 002

WYMOX

WYETH AYERST 250MG A062120 001

500MG A062120 002

## DISCONTINUED DRUG PRODUCT LIST

6 - 24 (of 324)

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

AM ANTIBIOTICS

125MG/5ML

A062059 001

250MG/5ML

A062059 002

MYLAN

125MG/5ML

A062090 001

250MG/5ML

A062090 002

TEVA

125MG/5ML

A062946 001

Nov 01, 1988

250MG/5ML

A063001 001

Jan 06, 1989

AMOXIL

GLAXOSMITHKLINE

50MG/ML

A062226 005

50MG/ML

N050460 005

125MG/5ML

A062226 001

125MG/5ML

N050460 001

200MG/5ML

N050760 001

Apr 15, 1999

250MG/5ML

A062226 002

250MG/5ML

N050460 002

400MG/5ML

N050760 002

Apr 15, 1999

LAROTID

GLAXOSMITHKLINE

50MG/ML

N050460 006

POLYMOX

APOTHECON

125MG/5ML

A061851 001

125MG/5ML

A062323 001

250MG/5ML

A061851 002

250MG/5ML

A062323 002

TRIMOX

APOTHECON

125MG/5ML

A062099 001

125MG/5ML

A062154 001

250MG/5ML

A062099 002

250MG/5ML

A062154 002

UTIMOX

PARKE DAVIS

125MG/5ML

A062127 001

250MG/5ML

A062127 002

WYMOX

WYETH AYERST

125MG/5ML

A062131 001

250MG/5ML

A062131 002

TABLET; ORAL

AMOXIL

GLAXOSMITHKLINE

500MG

N050754 002

Jul 10, 1998

875MG

N050754 001

Jul 10, 1998

TABLET, CHEWABLE; ORAL

AMOXICILLIN

APOTHECON

125MG

A064131 001

May 06, 1996

250MG

A064131 002

May 06, 1996

TEVA

125MG

A064031 001

Dec 19, 1996

250MG

A064031 002

Dec 19, 1996

AMOXIL

GLAXOSMITHKLINE

125MG

N050542 002

200MG

N050761 001

Apr 15, 1999

250MG

N050542 001

400MG

N050761 002

Apr 15, 1999

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AUGMENTIN '125'

GLAXOSMITHKLINE

125MG/5ML;EQ 31.25MG BASE/5ML

N050575 001

Aug 06, 1984

AUGMENTIN '200'

GLAXOSMITHKLINE

200MG/5ML;EQ 28.5MG BASE/5ML

N050725 001

May 31, 1996

AUGMENTIN '250'

GLAXOSMITHKLINE

250MG/5ML;EQ 62.5MG BASE/5ML

N050575 002

Aug 06, 1984

AUGMENTIN '400'

GLAXOSMITHKLINE

400MG/5ML;EQ 57MG BASE/5ML

N050725 002

May 31, 1996

AUGMENTIN ES-600

SMITHKLINE BEECHAM

600MG/5ML;EQ 42.9MG BASE/5ML

N050755 001

Jun 22, 2001

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 466 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 25 (of 324)

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AUGMENTIN '250'

GLAXOSMITHKLINE 250MG;EQ 125MG BASE N050564 001 Aug 06, 1984

AUGMENTIN '500'

GLAXOSMITHKLINE 500MG;EQ 125MG BASE N050564 002 Aug 06, 1984

AUGMENTIN '875'

GLAXOSMITHKLINE 875MG;EQ 125MG BASE N050720 001 Feb 13, 1996

TABLET, CHEWABLE; ORAL

AUGMENTIN '125'

GLAXOSMITHKLINE 125MG;EQ 31.25MG BASE N050597 001 Jul 22, 1985

AUGMENTIN '200'

GLAXOSMITHKLINE 200MG;EQ 28.5MG BASE N050726 001 May 31, 1996

AUGMENTIN '250'

GLAXOSMITHKLINE 250MG;EQ 62.5MG BASE N050597 002 Jul 22, 1985

AUGMENTIN '400'

GLAXOSMITHKLINE 400MG;EQ 57MG BASE N050726 002 May 31, 1996

TABLET, EXTENDED RELEASE; ORAL

AUGMENTIN XR

GLAXOSMITHKLINE 1GM;EQ 62.5MG BASE N050785 001 Sep 25, 2002

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE;  
DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DELCOBESE

TEVA

1.25MG;1.25MG;1.25MG;1.25MG A083564 001

2.5MG;2.5MG;2.5MG;2.5MG A083564 002

3.75MG;3.75MG;3.75MG;3.75MG A083564 003

5MG;5MG;5MG;5MG A083564 004

TABLET; ORAL

DELCOBESE

TEVA

1.25MG;1.25MG;1.25MG;1.25MG A083563 004

2.5MG;2.5MG;2.5MG;2.5MG A083563 003

3.75MG;3.75MG;3.75MG;3.75MG A083563 002

5MG;5MG;5MG;5MG A083563 001

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;  
DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

MUTUAL PHARM

1.25MG;1.25MG;1.25MG;1.25MG A040480 001 Sep 09, 2003

1.875MG;1.875MG;1.875MG;1.875MG A040480 002 Sep 09, 2003

2.5MG;2.5MG;2.5MG;2.5MG A040480 003 Sep 09, 2003

3.125MG;3.125MG;3.125MG;3.125MG A040480 004 Sep 09, 2003

3.75MG;3.75MG;3.75MG;3.75MG A040480 005 Sep 09, 2003

5MG;5MG;5MG;5MG A040480 006 Sep 09, 2003

7.5MG;7.5MG;7.5MG;7.5MG A040480 007 Sep 09, 2003

WATSON LABS

1.25MG;1.25MG;1.25MG;1.25MG A040456 001 May 06, 2003

2.5MG;2.5MG;2.5MG;2.5MG A040456 002 May 06, 2003

5MG;5MG;5MG;5MG A040456 003 May 06, 2003

7.5MG;7.5MG;7.5MG;7.5MG A040456 004 May 06, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

BIPHETAMINE 12.5

UCB INC EQ 6.25MG BASE;EQ 6.25MG BASE N010093 007

BIPHETAMINE 20

UCB INC EQ 10MG BASE;EQ 10MG BASE N010093 003

BIPHETAMINE 7.5

UCB INC EQ 3.75MG BASE;EQ 3.75MG BASE N010093 009

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

LANNETT

5MG

A083901 001 Aug 31, 1984

**WATSON LABORATORIES, INC., IPR2017-01621, Ex. 1085, p. 467 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 26 (of 324)

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

LANNETT

10MG

A083901 002

Aug 31, 1984

AMPHOTERICIN B

CREAM; TOPICAL

FUNGIZONE

APOTHECON

3%

N050314 001

INJECTABLE; INJECTION

AMPHOTERICIN B

ABBOTT

50MG/VIAL

A064141 001

Dec 23, 1996

ABRAXIS PHARM

50MG/VIAL

A062728 001

Apr 13, 1987

LOTION; TOPICAL

FUNGIZONE

APOTHECON

3%

A060570 001

OINTMENT; TOPICAL

FUNGIZONE

APOTHECON

3%

N050313 001

SUSPENSION; ORAL

FUNGIZONE

BRISTOL MYERS SQUIBB

100MG/ML

N050341 003

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

APOTHECON

EQ 125MG BASE/VIAL

A062860 001

Feb 05, 1988

EQ 250MG BASE/VIAL

A062860 002

Feb 05, 1988

EQ 500MG BASE/VIAL

A062860 003

Feb 05, 1988

EQ 1GM BASE/VIAL

A062860 004

Feb 05, 1988

EQ 2GM BASE/VIAL

A062860 005

Feb 05, 1988

BAXTER HLTHCARE

EQ 125MG BASE/VIAL

A062692 001

Jun 24, 1986

EQ 250MG BASE/VIAL

A062692 002

Jun 24, 1986

EQ 500MG BASE/VIAL

A062692 003

Jun 24, 1986

EQ 1GM BASE/VIAL

A062692 004

Jun 24, 1986

EQ 2GM BASE/VIAL

A062692 005

Jun 24, 1986

EQ 10GM BASE/VIAL

A062692 006

Jun 24, 1986

CONSOLIDATED PHARM

EQ 125MG BASE/VIAL

A061936 005

EQ 250MG BASE/VIAL

A061936 001

EQ 500MG BASE/VIAL

A061936 002

EQ 1GM BASE/VIAL

A061936 003

EQ 2GM BASE/VIAL

A061936 004

HANFORD GC

EQ 125MG BASE/VIAL

A063143 001

Apr 15, 1993

EQ 250MG BASE/VIAL

A063145 001

Apr 15, 1993

EQ 500MG BASE/VIAL

A063147 001

Apr 15, 1993

EQ 1GM BASE/VIAL

A063139 001

Apr 15, 1993

EQ 2GM BASE/VIAL

A063141 001

Apr 15, 1993

INTL MEDICATION

EQ 1GM BASE/VIAL

A062634 002

Jan 09, 1987

EQ 2GM BASE/VIAL

A062634 003

Jan 09, 1987

LILLY

EQ 500MG BASE/VIAL

A062565 001

Apr 04, 1985

EQ 1GM BASE/VIAL

A062565 002

Apr 04, 1985

EQ 2GM BASE/VIAL

A062565 003

Jun 24, 1986

MARSAM PHARMS LLC

EQ 125MG BASE/VIAL

A062816 001

Oct 24, 1988

EQ 250MG BASE/VIAL

A062816 002

Oct 24, 1988

EQ 500MG BASE/VIAL

A062816 003

Oct 24, 1988

EQ 1GM BASE/VIAL

A062816 004

Oct 24, 1988

EQ 2GM BASE/VIAL

A062816 005

Oct 24, 1988

EQ 10GM BASE/VIAL

A062994 001

Sep 15, 1988

OMNIPEN-N

WYETH AYERST

EQ 125MG BASE/VIAL

A060626 001

EQ 125MG BASE/VIAL

A062718 001

Dec 16, 1986

EQ 250MG BASE/VIAL

A060626 002

EQ 250MG BASE/VIAL

A062718 002

Dec 16, 1986

EQ 500MG BASE/VIAL

A060626 003

## DISCONTINUED DRUG PRODUCT LIST

6 - 27 (of 324)

AMPICILLIN SODIUM

## INJECTABLE; INJECTION

## OMNIPEN-N

WYETH AYERST	EQ 500MG BASE/VIAL	A062718	003	Dec 16, 1986
	EQ 1GM BASE/VIAL	A060626	004	
	EQ 1GM BASE/VIAL	A062718	004	Dec 16, 1986
	EQ 2GM BASE/VIAL	A060626	005	
	EQ 2GM BASE/VIAL	A062718	005	Dec 16, 1986

## PENBRITIN-S

WYETH AYERST	EQ 125MG BASE/VIAL	N050072	001	
	EQ 250MG BASE/VIAL	N050072	002	
	EQ 500MG BASE/VIAL	N050072	003	
	EQ 1GM BASE/VIAL	N050072	004	
	EQ 2GM BASE/VIAL	N050072	005	
	EQ 4GM BASE/VIAL	N050072	006	

## POLYCILLIN-N

BRISTOL	EQ 125MG BASE/VIAL	N050309	001	
	EQ 250MG BASE/VIAL	N050309	002	
	EQ 500MG BASE/VIAL	N050309	003	
	EQ 1GM BASE/VIAL	N050309	004	
	EQ 2GM BASE/VIAL	N050309	005	

## TOTACILLIN-N

GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	A060677	001	
	EQ 250MG BASE/VIAL	A060677	002	
	EQ 500MG BASE/VIAL	A060677	003	
	EQ 1GM BASE/VIAL	A060677	004	
	EQ 1GM BASE/VIAL	A062727	001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A060677	005	
	EQ 2GM BASE/VIAL	A062727	002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A060677	006	

AMPICILLIN SODIUM; SULBACTAM SODIUM

## INJECTABLE; INJECTION

## UNASYN

PFIZER	EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL	N050608	003	Dec 31, 1986
--------	---------------------------------------	---------	-----	--------------

AMPICILLIN/AMPICILLIN TRIHYDRATE

## CAPSULE; ORAL

## AMCILL

PARKE DAVIS	EQ 250MG BASE	A062041	001	
	EQ 500MG BASE	A062041	002	

## AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS	EQ 250MG BASE	A061602	001	
	EQ 500MG BASE	A061602	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A060765	001	
	EQ 500MG BASE	A060765	002	
LEDERLE	EQ 250MG BASE	A062208	001	
	EQ 500MG BASE	A062208	002	
MYLAN	EQ 250MG BASE	A061755	001	
	EQ 500MG BASE	A061755	002	
PUREPAC PHARM	EQ 250MG BASE	A061853	001	
	EQ 500MG BASE	A061853	002	
TEVA	EQ 250MG BASE	A061502	001	
	EQ 500MG BASE	A061502	002	
VITARINE	EQ 250MG BASE	A061387	001	
	EQ 500MG BASE	A061387	003	

## OMNIPEN (AMPICILLIN)

WYETH AYERST	250MG	A060624	001	
	500MG	A060624	002	

## PENBRITIN

WYETH AYERST	EQ 250MG BASE	A060908	001	
	EQ 500MG BASE	A060908	002	

## PFIZERPEN-A

PFIZER	EQ 250MG BASE	A062050	001	
--------	---------------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 28 (of 324)

AMPICILLIN/AMPICILLIN TRIHYDRATE

## CAPSULE; ORAL

## PFIZERPEN-A

PFIZER

EQ 500MG BASE

A062050 002

## POLYCILLIN

BRISTOL

EQ 250MG BASE

N050310 001

EQ 500MG BASE

N050310 002

## PRINCIPEN

APOTHECON

EQ 250MG BASE

A062888 001

Mar 04, 1988

EQ 500MG BASE

A062888 002

Mar 04, 1988

BRISTOL MYERS SQUIBB

EQ 250MG BASE

A061392 001

EQ 500MG BASE

A061392 002

## PRINCIPEN '250'

APOTHECON

EQ 250MG BASE

A062157 002

EQ 250MG BASE

N050056 001

## PRINCIPEN '500'

APOTHECON

EQ 500MG BASE

A062157 001

EQ 500MG BASE

N050056 002

## TOTACILLIN

GLAXOSMITHKLINE

EQ 250MG BASE

A060060 001

EQ 250MG BASE

A062212 001

EQ 500MG BASE

A060060 002

EQ 500MG BASE

A062212 002

## FOR SUSPENSION; ORAL

## AMCILL

PARKE DAVIS

EQ 125MG BASE/5ML

A062030 001

EQ 250MG BASE/5ML

A062030 002

## AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS

EQ 125MG BASE/5ML

A061601 001

EQ 250MG BASE/5ML

A061601 002

MYLAN

EQ 125MG BASE/5ML

A061829 002

EQ 250MG BASE/5ML

A061829 001

PUREPAC PHARM

EQ 125MG BASE/5ML

A061980 001

EQ 250MG BASE/5ML

A061980 002

TEVA

EQ 125MG BASE/5ML

A061370 001

EQ 250MG BASE/5ML

A061370 002

## OMNIPEN (AMPICILLIN)

WYETH AYERST

100MG/ML

A060625 001

125MG/5ML

A060625 002

250MG/5ML

A060625 003

500MG/5ML

A060625 004

## PENBRITIN

WYETH AYERST

EQ 100MG BASE/ML

N050019 001

EQ 125MG BASE/5ML

N050019 002

EQ 250MG BASE/5ML

N050019 003

## PFIZERPEN-A

PFIZER

EQ 125MG BASE/5ML

A062049 001

EQ 250MG BASE/5ML

A062049 002

## POLYCILLIN

APOTHECON

EQ 125MG BASE/5ML

A062297 001

EQ 250MG BASE/5ML

A062297 002

BRISTOL

EQ 100MG BASE/ML

N050308 004

EQ 125MG BASE/5ML

N050308 001

EQ 250MG BASE/5ML

N050308 002

EQ 500MG BASE/5ML

N050308 003

## PRINCIPEN

APOTHECON

EQ 100MG BASE/ML

A061394 001

EQ 250MG BASE/5ML

A061394 003

## PRINCIPEN '125'

APOTHECON

EQ 125MG BASE/5ML

A060127 002

EQ 125MG BASE/5ML

A062151 001

## PRINCIPEN '250'

APOTHECON

EQ 250MG BASE/5ML

A060127 001

EQ 250MG BASE/5ML

A062151 002

## DISCONTINUED DRUG PRODUCT LIST

6 - 29 (of 324)

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

TOTACILLIN

GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A060666	001
	EQ 125MG BASE/5ML	A062223	001
	EQ 250MG BASE/5ML	A060666	002
	EQ 250MG BASE/5ML	A062223	002

TABLET, CHEWABLE; ORAL

POLYCILLIN

BRISTOL	EQ 125MG BASE	N050093	001
---------	---------------	---------	-----

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE; ORAL

PRINCIPEN W/ PROBENECID

APOTHECON	EQ 389MG BASE;111MG	A062150	001
	EQ 389MG BASE;111MG	N050488	001

FOR SUSPENSION; ORAL

POLYCILLIN-PRB

APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	A061898	001
BRISTOL	EQ 3.5GM BASE/BOT;1GM/BOT	N050457	001
PROBAMPACIN			
TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

GLAXOSMITHKLINE	150MG	N021007	002	Apr 15, 1999
-----------------	-------	---------	-----	--------------

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

SHIRE	EQ 1MG BASE	N020333	002	Mar 14, 1997
-------	-------------	---------	-----	--------------

ANAGRELIDE HYDROCHLORIDE

ROXANE	EQ 0.5MG BASE	A076489	001	Apr 18, 2005
	EQ 1MG BASE	A076489	002	Apr 18, 2005

ANILERIDINE HYDROCHLORIDE

TABLET; ORAL

LERITINE

MERCK	EQ 25MG BASE	N010585	002
-------	--------------	---------	-----

ANILERIDINE PHOSPHATE

INJECTABLE; INJECTION

LERITINE

MERCK	25MG/ML	N010520	003
-------	---------	---------	-----

ANISINDIONE

TABLET; ORAL

MIRADON

SCHERING	50MG	N010909	003
----------	------	---------	-----

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL

ANISOTROPINE METHYLBROMIDE

WATSON LABS	50MG	A086046	001
-------------	------	---------	-----

VALPIN 50

ENDO PHARMS	50MG	N013428	001
-------------	------	---------	-----

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

IPSEN LTD	20MG/2ML (10MG/ML)	N021264	001	Apr 20, 2004
-----------	--------------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 30 (of 324)

ARBUTAMINE HYDROCHLORIDEINJECTABLE; INJECTION  
GENESA

GENSIA AUTOMEDICS 0.05MG/ML N020420 001 Sep 12, 1997

ARDEPARIN SODIUMINJECTABLE; INJECTION  
NORMIFLOPHARMACIA AND UPJOHN 5,000 UNITS/0.5ML N020227 002 May 23, 1997  
10,000 UNITS/0.5ML N020227 001 May 23, 1997ARIPIPIRAZOLETABLET, ORALLY DISINTEGRATING; ORAL  
ABILIFYOTSUKA 20MG N021729 004 Jun 07, 2006  
30MG N021729 005 Jun 07, 2006ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.C. 9+3

ABRAXIS PHARM 10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 N018440 002 Aug 08, 1985  
0  
IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/  
ML;0.3MG/ML;330 UNITS/ML;1 IU/ML

M.V.I.-12

HOSPIRA 10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 N008809 004 Aug 08, 1985  
0  
IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/  
ML;0.3MG/ML;330 UNITS/ML;1 IU/ML

MVC PLUS

WATSON LABS 10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 N018439 002 Aug 08, 1985  
0  
IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/  
ML;0.3MG/ML;330 UNITS/ML;1 IU/MLASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

BEROCCA PN

ROCHE 50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML; N006071 003 Oct 10, 1985  
100  
IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;  
1.5MG/ML;1,650 IU/ML;5 IU/MLASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

HOSPIRA 20MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 N008809 005 Apr 22, 2004  
0  
IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/M  
L;0.6MG/ML;330 UNITS/ML;1 IU/MLASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

ASTRAZENECA 100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15M N018933 002 Aug 08, 1985  
G/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4  
MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10  
MG/VIAL



## DISCONTINUED DRUG PRODUCT LIST

6 - 31 (of 324)

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE;  
PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A  
PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

HOSPIRA	N/A, 80MG/VIAL; N/A, 0.02MG/VIAL; N/A, 0.001 MG/VIAL; 400 IU/10ML, N/A; N/A, 0.14MG/VIAL; N/A, 17MG/VI AL; N/A, 5MG/VIAL; 0.2MG/10ML, N/A; N/A, 1MG/ VIAL; N/A, 1.4MG/VIAL; N/A, 1.2MG/VIAL; EQ 2,300 UNITS BASE/10ML, N/A; 7 IU/10ML, N/A	N020176	001	Dec 29, 1993
---------	---	---------	-----	--------------

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER	500MG	N021317	001	Oct 18, 2001
-------	-------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER

BAYER	650MG	N016030	001	
-------	-------	---------	-----	--

MEASURIN

BAYER	650MG	N016030	002	
-------	-------	---------	-----	--

ASPIRIN; BUTALBITAL

TABLET; ORAL

AXOTAL

SAVAGE LABS	650MG; 50MG	A088305	001	Oct 13, 1983
-------------	-------------	---------	-----	--------------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

MUTUAL PHARM	325MG; 50MG; 40MG	A078149	001	Jun 13, 2007
--------------	-------------------	---------	-----	--------------

WATSON LABS	325MG; 50MG; 40MG	A086231	002	Feb 12, 1985
-------------	-------------------	---------	-----	--------------

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

HALSEY	325MG; 50MG; 40MG	A089448	001	Dec 01, 1986
--------	-------------------	---------	-----	--------------

IVAX PHARMS	325MG; 50MG; 40MG	A085441	002	Oct 31, 1984
-------------	-------------------	---------	-----	--------------

PHARMERAL	325MG; 50MG; 40MG	A087048	002	Dec 09, 1983
-----------	-------------------	---------	-----	--------------

QUANTUM PHARMICS	325MG; 50MG; 40MG	A088972	001	Jun 18, 1985
------------------	-------------------	---------	-----	--------------

SANDOZ	325MG; 50MG; 40MG	A086398	002	Apr 06, 1984
--------	-------------------	---------	-----	--------------

WATSON LABS	325MG; 50MG; 40MG	A086237	002	Mar 23, 1984
-------------	-------------------	---------	-----	--------------

FIORINAL

WATSON PHARMS	325MG; 50MG; 40MG	N017534	003	Apr 16, 1986
---------------	-------------------	---------	-----	--------------

LANORINAL

LANNETT	325MG; 50MG; 40MG	A086986	002	Oct 18, 1985
---------	-------------------	---------	-----	--------------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

ENDO PHARMS	325MG; 50MG; 40MG; 30MG	A075351	001	Mar 05, 1999
-------------	-------------------------	---------	-----	--------------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

SOLCO HLTHCARE	385MG; 30MG; 25MG	A075141	001	May 29, 1998
----------------	-------------------	---------	-----	--------------

ORPHENGESIC FORTE

SOLCO HLTHCARE	770MG; 60MG; 50MG	A075141	002	May 29, 1998
----------------	-------------------	---------	-----	--------------

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

COMPOUND 65

ALRA	389MG; 32.4MG; 65MG	A084553	002	Aug 17, 1983
------	---------------------	---------	-----	--------------

DARVON COMPOUND

XANODYNE PHARM	389MG; 32.4MG; 32MG	N010996	006	Mar 08, 1983
----------------	---------------------	---------	-----	--------------

DARVON COMPOUND-65

XANODYNE PHARM	389MG; 32.4MG; 65MG	N010996	007	Mar 08, 1983
----------------	---------------------	---------	-----	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 473 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 32 (of 324)

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE COMPOUND 65

IVAX SUB TEVA PHARMS 389MG;32.4MG;65MG

A083077 002 Dec 07, 1984

SANDOZ 389MG;32.4MG;65MG

A080044 002 Sep 16, 1983

TEVA 389MG;32.4MG;65MG

A089025 001 Mar 29, 1985

PROPOXYPHENE COMPOUND-65

SANDOZ 389MG;32.4MG;65MG

A083101 002 Jun 24, 1985

PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE

WATSON LABS 389MG;32.4MG;65MG

A085732 002 Sep 03, 1984

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL COMPOUND

WATSON LABS 325MG;200MG

A088809 001 Oct 03, 1985

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

SCHWARZ PHARMA 500MG;5MG

A089420 001 Jan 25, 1988

VICOPRIN

ABBOTT 500MG;5MG

A086333 001 Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

CARACO 325MG;200MG

N011702 003 Dec 29, 1983

MEPRO-ASPIRIN

SANDOZ 325MG;200MG

A089127 001 Mar 02, 1987

MEPROBAMATE AND ASPIRIN

PAR PHARM 325MG;200MG

A089126 001 Aug 19, 1986

MICRAININ

MEDPOINTE PHARM HLC 325MG;200MG

A084978 001

Q-GESIC

QUANTUM PHARMICS 325MG;200MG

A088740 001 Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

MCNEIL 325MG;400MG

A089193 001 Feb 12, 1986

PAR PHARM 325MG;400MG

A089657 001 Nov 04, 1988

ROBAXISAL

ROBINS AH 325MG;400MG

N012281 001

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

CODOXY

HALSEY 325MG;4.5MG;0.38MG

A087464 001 Jul 01, 1982

OXYCODONE AND ASPIRIN

MUTUAL PHARM 325MG;4.5MG;0.38MG

A040260 001 Jul 17, 1998

325MG;4.5MG;0.38MG

A087794 001 May 26, 1982

OXYCODONE AND ASPIRIN (HALF-STRENGTH)

ROXANE 325MG;2.25MG;0.19MG

A087742 001 Jun 04, 1982

PERCODAN-DEMI

ENDO PHARMS 325MG;2.25MG;0.19MG

N007337 005

ROXIPRIN

ROXANE 325MG;4.5MG;0.38MG

A087743 001 Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

SANOFI AVENTIS US 325MG;EQ 12.5MG BASE

N016891 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 33 (of 324)

ASPIRIN; PRAVASTATIN SODIUM

TABLET, TABLET; ORAL				
PRAVIGARD PAC (COPACKAGED)				
BRISTOL MYERS SQUIBB	325MG,N/A;N/A,80MG	N021387	006	Jun 24, 2003
TABLET; TABLET, TABLET; ORAL				
PRAVIGARD PAC (COPACKAGED)				
BRISTOL MYERS SQUIBB	81MG,N/A;N/A,20MG	N021387	001	Jun 24, 2003
	81MG,N/A;N/A,40MG	N021387	002	Jun 24, 2003
	81MG,N/A;N/A,80MG	N021387	003	Jun 24, 2003
	325MG,N/A;N/A,20MG	N021387	004	Jun 24, 2003
	325MG,N/A;N/A,40MG	N021387	005	Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL				
DARVON W/ ASA				
XANODYNE PHARM	325MG;65MG	N010996	005	

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL				
DARVON-N W/ ASA				
AAIPHARMA LLC	325MG;100MG	N016829	001	
TABLET; ORAL				
DARVON-N W/ ASA				
AAIPHARMA LLC	325MG;100MG	N016863	001	

ATENOLOL

INJECTABLE; INJECTION				
TENORMIN				
ASTRAZENECA	0.5MG/ML	N019058	001	Sep 13, 1989
TABLET; ORAL				
ATENOLOL				
ABLE	25MG	A076907	001	Jul 30, 2004
	50MG	A076907	002	Jul 30, 2004
	100MG	A076907	003	Jul 30, 2004
APOTHECON	50MG	A073317	001	Mar 20, 1992
	100MG	A073318	001	Mar 20, 1992
NOSTRUM LABS	50MG	A074127	001	Feb 21, 1995
	100MG	A074127	002	Feb 21, 1995
PLIVA	25MG	A074101	001	Jul 17, 1997
	50MG	A074101	002	Jul 17, 1997
	100MG	A074101	003	Jul 17, 1997
SANDOZ	25MG	A074265	001	Feb 28, 1994
	50MG	A074265	002	Feb 28, 1994
	100MG	A074265	003	Feb 28, 1994
SCS	50MG	A073676	001	Oct 30, 1992
	100MG	A073676	002	Oct 30, 1992
TEVA	50MG	A073315	001	May 28, 1993
	100MG	A073316	001	May 28, 1993
TEVA PHARMS	50MG	A074120	001	Feb 24, 1995
	100MG	A074120	002	Feb 24, 1995

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL				
ATENOLOL AND CHLORTHALIDONE				
NOSTRUM LABS	50MG;25MG	A074404	001	May 14, 1998
	100MG;25MG	A074404	002	May 14, 1998
PLIVA	50MG;25MG	A074107	001	Sep 24, 1997
	100MG;25MG	A074107	002	Sep 24, 1997

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL				
STRATTERA				
LILLY	5MG	N021411	001	Nov 26, 2002

## DISCONTINUED DRUG PRODUCT LIST

6 - 34 (of 324)

ATOVAQUONE

TABLET; ORAL

MEPRON

GLAXOSMITHKLINE	250MG	N020259	001	Nov 25, 1992
-----------------	-------	---------	-----	--------------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

BAXTER HLTHCARE	10MG/ML	A074824	001	Sep 30, 1997
-----------------	---------	---------	-----	--------------

BAXTER HLTHCARE CORP	10MG/ML	A074753	001	Jan 23, 1997
----------------------	---------	---------	-----	--------------

HOSPIRA	10MG/ML	A074632	001	Dec 23, 1996
---------	---------	---------	-----	--------------

	10MG/ML	A074740	001	Mar 28, 1997
--	---------	---------	-----	--------------

MARSAM PHARMS LLC	10MG/ML	A074945	001	Jul 28, 1998
-------------------	---------	---------	-----	--------------

TEVA PARENTERAL	10MG/ML	A074784	001	Jun 11, 1997
-----------------	---------	---------	-----	--------------

ATRACURIUM BESYLATE PRESERVATIVE FREE

BAXTER HLTHCARE	10MG/ML	A074825	001	Sep 30, 1997
-----------------	---------	---------	-----	--------------

BAXTER HLTHCARE CORP	10MG/ML	A074768	001	Jan 23, 1997
----------------------	---------	---------	-----	--------------

HOSPIRA	10MG/ML	A074633	001	Dec 23, 1996
---------	---------	---------	-----	--------------

	10MG/ML	A074639	001	Mar 25, 1997
--	---------	---------	-----	--------------

	10MG/ML	A074741	001	Mar 28, 1997
--	---------	---------	-----	--------------

MARSAM PHARMS LLC	10MG/ML	A074944	001	Jul 28, 1998
-------------------	---------	---------	-----	--------------

TRACRIUM

HOSPIRA	10MG/ML	N018831	002	Jun 20, 1985
---------	---------	---------	-----	--------------

TRACRIUM PRESERVATIVE FREE

HOSPIRA	10MG/ML	N018831	001	Nov 23, 1983
---------	---------	---------	-----	--------------

ATROPINE

INJECTABLE; INJECTION

ATROPINE

SOLVAY	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987
--------	----------------------	---------	-----	--------------

ATROPINE SULFATE

AEROSOL, METERED; INHALATION

ATROPINE SULFATE

US ARMY	EQ 0.36MG BASE/INH	N020056	001	Sep 19, 1990
---------	--------------------	---------	-----	--------------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN HALF-STRENGTH

VALEANT	0.025MG;0.5MG	N017744	001	
---------	---------------	---------	-----	--

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE

SCHERER RP	0.025MG;2.5MG	A086440	001	
------------	---------------	---------	-----	--

SOLUTION; ORAL

COLONAIID

MEDPOINTE PHARM HLC	0.025MG/5ML;2.5MG/5ML	A085735	001	
---------------------	-----------------------	---------	-----	--

LOMANATE

ALPHARMA US PHARMS	0.025MG/5ML;2.5MG/5ML	A085746	001	
--------------------	-----------------------	---------	-----	--

TABLET; ORAL

COLONAIID

MEDPOINTE PHARM HLC	0.025MG;2.5MG	A085737	001	
---------------------	---------------	---------	-----	--

DI-ATRO

MD PHARM	0.025MG;2.5MG	A085266	001	
----------	---------------	---------	-----	--

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

ABLE	0.025MG;2.5MG	A040395	001	Nov 27, 2000
------	---------------	---------	-----	--------------

ASCOT	0.025MG;2.5MG	A087934	001	Jul 19, 1983
-------	---------------	---------	-----	--------------

HEATHER	0.025MG;2.5MG	A086798	001	
---------	---------------	---------	-----	--

INWOOD LABS	0.025MG;2.5MG	A085509	001	
-------------	---------------	---------	-----	--

IVAX PHARMS	0.025MG;2.5MG	A086727	001	
-------------	---------------	---------	-----	--

KV PHARM	0.025MG;2.5MG	A085659	001	
----------	---------------	---------	-----	--

LEDERLE	0.025MG;2.5MG	A086950	001	
---------	---------------	---------	-----	--

MUTUAL PHARM	0.025MG;2.5MG	A085506	001	
--------------	---------------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 35 (of 324)

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

## TABLET; ORAL

## DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

PARKE DAVIS	0.025MG;2.5MG	A087131	001	
PVT FORM	0.025MG;2.5MG	A085766	001	
R AND S PHARMA	0.025MG;2.5MG	A085035	001	
ROXANE	0.025MG;2.5MG	A086057	001	
SANDOZ	0.025MG;2.5MG	A086173	001	
USL PHARMA	0.025MG;2.5MG	A087842	001	Mar 29, 1982
VALEANT PHARM INTL	0.025MG;2.5MG	A087195	001	Feb 16, 1982
WATSON LABS	0.025MG;2.5MG	A085876	001	
WEST WARD	0.025MG;2.5MG	A087765	001	Mar 15, 1982
LOGEN				
SUPERPHARM	0.025MG;2.5MG	A088962	001	May 10, 1985
LO-TROL				
VANGARD	0.025MG;2.5MG	A088009	001	Mar 25, 1983
LOW-QUEL				
HALSEY	0.025MG;2.5MG	A085211	001	

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## ATROPINE AND DEMEROL

ABBOTT	0.4MG/ML;50MG/ML	A087853	001	Nov 26, 1982
	0.4MG/ML;75MG/ML	A087847	001	Nov 26, 1982
	0.4MG/ML;100MG/ML	A087848	001	Nov 26, 1982

## MEPERIDINE AND ATROPINE SULFATE

WYETH AYERST	0.4MG/ML;50MG/ML	A085121	001	
	0.4MG/ML;75MG/ML	A085121	002	
	0.4MG/ML;100MG/ML	A085121	003	

ATROPINE; PRALIDOXIME CHLORIDE

## INJECTABLE; INTRAMUSCULAR

## ATNAA

US ARMY	2.1MG/0.7ML;600MG/0.7ML	N021175	001	Jan 17, 2002
---------	-------------------------	---------	-----	--------------

AZATADINE MALEATE

## TABLET; ORAL

## OPTIMINE

SCHERING	1MG	N017601	001	
----------	-----	---------	-----	--

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

## TABLET, EXTENDED RELEASE; ORAL

## TRINALIN

SCHERING	1MG;120MG	N018506	001	Mar 23, 1982
----------	-----------	---------	-----	--------------

AZATHIOPRINE

## TABLET; ORAL

## IMURAN

PROMETHEUS LABS	25MG	N016324	002	
-----------------	------	---------	-----	--

AZATHIOPRINE SODIUM

## INJECTABLE; INJECTION

## IMURAN

PROMETHEUS LABS	EQ 100MG BASE/VIAL	N017391	001	
-----------------	--------------------	---------	-----	--

AZELASTINE HYDROCHLORIDE

## SPRAY, METERED; NASAL

## AZELASTINE HYDROCHLORIDE

APOTEX INC	EQ 0.125MG BASE/SPRAY	A077954	001	Apr 30, 2009
------------	-----------------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 36 (of 324)

AZITHROMYCINCAPSULE; ORAL  
ZITHROMAX  
PFIZER

EQ 250MG BASE

N050670 001 Nov 01, 1991

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATEFOR SUSPENSION, TABLET; ORAL  
TROVAN/ZITHROMAX COMPLIANCE PAK  
PFIZER

EQ 1GM BASE,N/A;N/A,EQ 100MG BASE

N050762 001 Dec 18, 1998

AZLOCILLIN SODIUMINJECTABLE; INJECTION  
AZLIN

BAYER PHARMS

EQ 2GM BASE/VIAL  
EQ 2GM BASE/VIAL  
EQ 2GM BASE/VIAL  
EQ 3GM BASE/VIAL  
EQ 3GM BASE/VIAL  
EQ 3GM BASE/VIAL  
EQ 4GM BASE/VIAL  
EQ 4GM BASE/VIAL  
EQ 4GM BASE/VIALA062388 001 Sep 08, 1982  
A062417 001 Oct 12, 1982  
N050562 001 Sep 03, 1982  
A062388 002 Sep 08, 1982  
A062417 002 Oct 12, 1982  
N050562 002 Sep 03, 1982  
A062388 003 Sep 08, 1982  
A062417 003 Oct 12, 1982  
N050562 003 Sep 03, 1982AZTREONAMINJECTABLE; INJECTION  
AZACTAMBRISTOL MYERS SQUIBB 500MG/VIAL  
AZACTAM IN PLASTIC CONTAINER  
BRISTOL MYERS SQUIBB 10MG/MLN050580 001 Dec 31, 1986  
N050632 003 May 24, 1989BACAMPICILLIN HYDROCHLORIDEFOR SUSPENSION; ORAL  
SPECTROBID

PFIZER

125MG/5ML

N050556 001 Mar 23, 1982

TABLET; ORAL  
SPECTROBID

PFIZER

400MG  
800MGN050520 001  
N050520 002 Sep 12, 1983BACITRACININJECTABLE; INJECTION  
BACITRACIN

PFIZER

50,000 UNITS/VIAL

A060282 001

OINTMENT; OPHTHALMIC  
BACIGUENT

PHARMACIA AND UPJOHN

500 UNITS/GM

A060734 001

BACITRACIN

LILLY

500 UNITS/GM

A060687 001

PHARMADERM

500 UNITS/GM

A062158 001

PHARMAFAIR

500 UNITS/GM

A062453 001 Mar 28, 1984

OINTMENT; TOPICAL  
BACITRACIN

COMBE

500 UNITS/GM

A062799 001 May 14, 1987

NASKA

500 UNITS/GM

A062857 001 Nov 13, 1987

POWDER; FOR RX COMPOUNDING  
BACITRACIN

APOTHEKERNES

5,000,000 UNITS/BOT

A061699 001

PADDOCK

5,000,000 UNITS/BOT

A062456 001 Jul 27, 1983

BACITRACIN ZINCPOWDER; FOR RX COMPOUNDING  
ZIBA-RX

X GEN PHARMS

500,000 UNITS/BOT

A061737 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 37 (of 324)

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
CORTISPORIN				
MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050416	002	
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE				
PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062389	001	Jul 02, 1982
OINTMENT; TOPICAL				
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE				
PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062381	001	Sep 06, 1985

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL				
LANABIOTIC				
COMBE	400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM	A062499	001	Jun 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE				
PHARMAFAIR	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062386	001	Sep 09, 1982
BACITRACIN-NEOMYCIN-POLYMYXIN				
PHARMADERM	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062167	001	
NEO-POLYCIN				
DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060647	001	
NEOSPORIN				
MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001	
OINTMENT; TOPICAL				
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE				
NASKA	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062833	001	Nov 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL; TOPICAL				
POLYSPORIN				
GLAXOSMITHKLINE	10,000 UNITS/GM;2,000,000 UNITS/GM	N050167	002	Mar 01, 1985
OINTMENT; OPHTHALMIC				
OCUMYCIN				
PHARMAFAIR	500 UNITS/GM;10,000 UNITS/GM	A062430	001	Apr 08, 1983
POLYSPORIN				
MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM	A061229	001	
OINTMENT; TOPICAL				
BACITRACIN ZINC-POLYMYXIN B SULFATE				
NASKA	500 UNITS/GM;10,000 UNITS/GM	A062849	001	Nov 13, 1987

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE				
ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060731	002	

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
MYCITRACIN				
PHARMACIA AND UPJOHN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A061048	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 38 (of 324)

BACITRACIN; POLYMYXIN B SULFATEDISC; TOPICAL  
LANABIOTIC

COMBE	500 UNITS/GM;5,000 UNITS/GM	N050598	001	Sep 22, 1986
-------	-----------------------------	---------	-----	--------------

BACLOFENTABLET; ORAL  
BACLOFEN

TEVA	10MG	A073043	001	Feb 27, 1992
	20MG	A073044	001	Feb 27, 1992
USL PHARMA	10MG	A071260	001	May 06, 1988
	20MG	A071261	001	May 06, 1988
WATSON LABS	10MG	A073092	001	Jan 28, 1994
	10MG	A074698	001	Aug 20, 1996
	20MG	A073093	001	Jan 28, 1994
	20MG	A074698	002	Aug 20, 1996
LIORESAL				
NOVARTIS	10MG	N017851	001	
	20MG	N017851	003	Jan 20, 1982

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

BECLOVENT

GLAXOSMITHKLINE	0.042MG/INH	N018153	001	
VANCERIL				
SCHERING	0.042MG/INH	N017573	001	
VANCERIL DOUBLE STRENGTH				
SCHERING	0.084MG/INH	N020486	001	Dec 24, 1996

AEROSOL, METERED; NASAL

BECONASE

GLAXOSMITHKLINE	0.042MG/INH	N018584	001	
VANCENASE				
SCHERING	0.042MG/INH	N018521	001	

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

VANCENASE AQ

SCHERING	EQ 0.042MG DIPROP/SPRAY	N019589	001	Dec 23, 1987
	EQ 0.084MG DIPROP/SPRAY	N020469	001	Jun 26, 1996

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

GENPHARM	5MG	A076476	001	Feb 11, 2004
	10MG	A076476	002	Feb 11, 2004
	20MG	A076476	003	Feb 11, 2004
	40MG	A076476	004	Feb 11, 2004

BENDROFLUMETHIAZIDE

TABLET; ORAL

NATURETIN-10

APOTHECON	10MG	N012164	003	
-----------	------	---------	-----	--

NATURETIN-2.5

APOTHECON	2.5MG	N012164	001	
-----------	-------	---------	-----	--

NATURETIN-5

APOTHECON	5MG	N012164	002	
-----------	-----	---------	-----	--

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BENOXINATE HYDROCHLORIDE

SOLA BARNES HIND	0.4%	A084149	001	
------------------	------	---------	-----	--



## DISCONTINUED DRUG PRODUCT LIST

6 - 39 (of 324)

BENTIROMIDESOLUTION; ORAL  
CHYMEX

SAVAGE LABS 500MG/7.5ML N018366 001 Dec 29, 1983

BENZPHETAMINE HYDROCHLORIDETABLET; ORAL  
DIDREX

PHARMACIA AND UPJOHN 25MG N012427 003

BENZQUINAMIDE HYDROCHLORIDEINJECTABLE; INJECTION  
EMETE-CON

PFIZER EQ 50MG BASE/VIAL N016820 001

SUPPOSITORY; RECTAL

EMETE-CON

ROERIG EQ 100MG BASE N016818 006

BENZTHIAZIDETABLET; ORAL  
AQUATAG

SOLVAY 25MG N016001 001

50MG N016001 002

BENZTHIAZIDE

PVT FORM 50MG A083206 001

EXNA

AH ROBINS INC 50MG N012489 001

FOVANE

PFIZER 50MG N012128 002

URESE

PFIZER 25MG N012128 003

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

MUTUAL PHARM 1MG A081264 001 Jan 23, 1992

2MG A081265 001 Jan 23, 1992

QUANTUM PHARMICS 0.5MG A088514 001 Jan 31, 1984

1MG A088510 001 Jan 31, 1984

2MG A088511 001 Jan 31, 1984

USL PHARMA 0.5MG A089211 001 Jun 14, 1988

1MG A089212 001 Jun 14, 1988

2MG A089213 001 Jun 14, 1988

COGENTIN

MERCK 0.5MG N009193 004

1MG N009193 003

2MG N009193 002

BENZYL BENZOATEEMULSION; TOPICAL  
BENZYL BENZOATE

LANNETT 50% A084535 001

BENZYL PENICILLOYL-POLYLYSINEINJECTABLE; INJECTION  
PRE-PEN

ALLERQUEST 60UMOLAR N050114 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

BEPADIN

MEDPOINTE PHARM HLC 200MG N019001 001 Dec 28, 1990

300MG N019001 002 Dec 28, 1990

## DISCONTINUED DRUG PRODUCT LIST

6 - 40 (of 324)

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

BEPADIN

MEDPOINTE PHARM HLC 400MG

N019001 003 Dec 28, 1990

VASCOR

JOHNSON AND JOHNSON 200MG

N019002 001 Dec 28, 1990

300MG

N019002 002 Dec 28, 1990

400MG

N019002 003 Dec 28, 1990

BETA CAROTENE

CAPSULE; ORAL

SOLATENE

ROCHE 30MG

N017589 001

BETAMETHASONE

CREAM; TOPICAL

CELESTONE

SCHERING 0.2%

N014762 001

TABLET; ORAL

CELESTONE

SCHERING 0.6MG

N012657 003

BETAMETHASONE BENZOATE

CREAM; TOPICAL

UTICORT

PARKE DAVIS 0.025%

N016998 002

GEL; TOPICAL

UTICORT

PARKE DAVIS 0.025%

N017244 001

LOTION; TOPICAL

UTICORT

PARKE DAVIS 0.025%

N017528 001

OINTMENT; TOPICAL

UTICORT

PARKE DAVIS 0.025%

N018089 001

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

SAVAGE LABS EQ 0.05% BASE

N019138 001 Jun 26, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK EQ 0.05% BASE

A072536 001 Jan 31, 1990

EQ 0.05% BASE

A074579 001 Nov 26, 1997

PHARMADERM EQ 0.05% BASE

N019136 001 Jun 26, 1984

TARO EQ 0.05% BASE

A071143 001 Jun 17, 1987

TEVA EQ 0.05% BASE

A071476 001 Aug 10, 1987

DIPROSONE

SCHERING EQ 0.05% BASE

N017536 001

CREAM, AUGMENTED; TOPICAL

DIPROLENE

SCHERING EQ 0.05% BASE

N019408 001 Jan 31, 1986

DISC; TOPICAL

DIPROSONE

SCHERING EQ 0.1% BASE

N017829 001

GEL, AUGMENTED; TOPICAL

DIPROLENE

SCHERING EQ 0.05% BASE

N019408 002 Nov 22, 1991

LOTION; TOPICAL

ALPHATREX

SAVAGE LABS EQ 0.05% BASE

A070273 001 Aug 12, 1985

BETAMETHASONE DIPROPIONATE

ALPHARMA US PHARMS EQ 0.05% BASE

A071085 001 Feb 03, 1987

PHARMADERM EQ 0.05% BASE

A070274 001 Aug 12, 1985

TARO EQ 0.05% BASE

A072276 001 Aug 24, 1988

EQ 0.05% BASE

A074272 001 Sep 30, 1994

## DISCONTINUED DRUG PRODUCT LIST

6 - 41 (of 324)

BETAMETHASONE DIPROPIONATE

## LOTION; TOPICAL

## BETAMETHASONE DIPROPIONATE

TEVA PHARMS EQ 0.05% BASE

A071882 001 Jun 06, 1988

## DIPROSONE

SCHERING EQ 0.05% BASE

N017781 001

## OINTMENT; TOPICAL

## ALPHATREX

SAVAGE LABS EQ 0.05% BASE

N019143 001 Sep 04, 1984

## BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK EQ 0.05% BASE

A072526 001 Jan 31, 1990

PHARMADERM EQ 0.05% BASE

N019140 001 Sep 04, 1984

TEVA EQ 0.05% BASE

A071477 001 Aug 10, 1987

## DIPROSONE

SCHERING EQ 0.05% BASE

N017691 001

BETAMETHASONE SODIUM PHOSPHATE

## INJECTABLE; INJECTION

## BETAMETHASONE SODIUM PHOSPHATE

WATSON LABS EQ 3MG BASE/ML

A085738 001

## CELESTONE

SCHERING EQ 3MG BASE/ML

N017561 001

BETAMETHASONE VALERATE

## CREAM; TOPICAL

## BETADERM

ROACO EQ 0.1% BASE

N018839 001 Jun 30, 1983

## BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE

A070053 001 Jun 10, 1986

PHARMADERM EQ 0.1% BASE

N018860 002 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE

A070485 001 May 29, 1987

TARO EQ 0.1% BASE

A070062 001 May 14, 1985

## BETATREX

SAVAGE LABS EQ 0.1% BASE

N018862 001 Aug 31, 1983

## VALISONE

SCHERING EQ 0.01% BASE

N016322 002

EQ 0.1% BASE

N016322 001

## LOTION; TOPICAL

## BETAMETHASONE VALERATE

PHARMADERM EQ 0.1% BASE

N018870 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE

A070484 001 May 29, 1987

TEVA PHARMS EQ 0.1% BASE

A071883 001 Apr 22, 1988

## BETATREX

SAVAGE LABS EQ 0.1% BASE

N018867 001 Aug 31, 1983

## VALISONE

SCHERING EQ 0.1% BASE

N016932 001

## OINTMENT; TOPICAL

## BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE

A071478 001 Dec 23, 1987

PHARMADERM EQ 0.1% BASE

N018864 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE

A070486 001 May 29, 1987

## BETATREX

SAVAGE LABS EQ 0.1% BASE

N018863 001 Aug 31, 1983

## BETA-VAL

TEVA EQ 0.1% BASE

A070069 001 Dec 19, 1985

## VALISONE

SCHERING EQ 0.1% BASE

N016740 001

BETAXOLOL HYDROCHLORIDE

## TABLET; ORAL

## KERLONE

SANOFI AVENTIS US 10MG

N019507 001 Oct 27, 1989

20MG

N019507 002 Oct 27, 1989

## DISCONTINUED DRUG PRODUCT LIST

6 - 42 (of 324)

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

KERLEDEX

SANOFI AVENTIS US	5MG;12.5MG	N019807	001	Oct 30, 1992
	10MG;12.5MG	N019807	002	Oct 30, 1992

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC PILO

ALCON	EQ 0.25% BASE;1.75%	N020619	001	Apr 17, 1997
-------	---------------------	---------	-----	--------------

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

HISTALOG

LILLY	50MG/ML	N009344	001	
-------	---------	---------	-----	--

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

ODYSSEY PHARMS	5MG/ML	N006536	001	
----------------	--------	---------	-----	--

TABLET; ORAL

BETHANECHOL CHLORIDE

ABLE	5MG	A040492	001	Jul 27, 2004
	10MG	A040483	001	Jul 27, 2004
	25MG	A040485	001	Jul 27, 2004
	50MG	A040509	001	Jul 27, 2004
ACTAVIS TOTOWA	50MG	A040551	001	Oct 28, 2004
ASCOT	10MG	A088288	001	Jun 08, 1983
	25MG	A088289	001	Jun 08, 1983
IVAX SUB TEVA PHARMS	25MG	A084689	001	
LANNETT	5MG	A084702	001	
	10MG	A084712	001	
	25MG	A084074	001	
SANDOZ	5MG	A084353	001	
	10MG	A084378	001	
	10MG	A084379	001	
	25MG	A084383	001	
	25MG	A084384	001	
WATSON LABS	5MG	A084402	001	
	5MG	A085230	002	
	5MG	A085841	001	
	10MG	A084408	001	
	10MG	A085228	001	
	10MG	A085842	001	
	25MG	A084441	001	
	25MG	A085229	001	
	25MG	A085839	001	
	50MG	A087397	001	
	50MG	A087444	001	
MYOTONACHOL				
GLENWOOD	5MG	A084188	001	
	10MG	A084188	003	
	25MG	A084188	004	
URECHOLINE				
ODYSSEY PHARMS	5MG	N006536	003	
	10MG	N006536	002	
	25MG	N006536	004	
	50MG	N006536	005	

BETHANIDINE SULFATE

TABLET; ORAL

TENATHAN

ROBINS AH	10MG	N017675	001	
	25MG	N017675	002	

## DISCONTINUED DRUG PRODUCT LIST

6 - 43 (of 324)

BIPERIDEN LACTATEINJECTABLE; INJECTION  
AKINETON

ABBOTT

5MG/ML

N012418 002

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDEFOR SOLUTION; ORAL  
HALFLYTELY

BRAINTREE

5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM  
;N/A,5.6GM

N021551 001 May 10, 2004

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

MUTUAL PHARM

5MG

A075474 001 Oct 25, 2002

10MG

A075474 002 Oct 25, 2002

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

APOTHECON

2.5MG;6.25MG

A075642 002 Dec 27, 2000

5MG;6.25MG

A075642 001 Dec 27, 2000

10MG;6.25MG

A075642 003 Dec 27, 2000

IVAX SUB TEVA PHARMS

2.5MG;6.25MG

A075632 001 Sep 27, 2000

5MG;6.25MG

A075632 002 Sep 27, 2000

10MG;6.25MG

A075632 003 Sep 27, 2000

SANDOZ

2.5MG;6.25MG

A075527 001 Sep 25, 2000

5MG;6.25MG

A075527 003 Sep 25, 2000

10MG;6.25MG

A075527 002 Sep 25, 2000

TEVA

2.5MG;6.25MG

A075686 001 Jan 19, 2001

5MG;6.25MG

A075686 002 Jan 19, 2001

10MG;6.25MG

A075686 003 Jan 19, 2001

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

SANOFI AVENTIS US

0.37MG/INH

N018770 001 Dec 28, 1984

SOLUTION; INHALATION

TORNALATE

SANOFI AVENTIS US

0.2%

N019548 001 Feb 19, 1992

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

TEVA PARENTERAL

EQ 15 UNITS BASE/VIAL

A064084 001 Jun 01, 1996

EQ 30 UNITS BASE/VIAL

A064084 002 Jun 01, 1996

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

ABRAXIS PHARM

50MG/ML

A070134 001 Apr 29, 1986

100MG/ML

A071298 001 Feb 13, 1987

ASTRAZENECA

50MG/ML

A071151 001 Aug 10, 1987

50MG/ML

A071152 001 Aug 10, 1987

50MG/ML

A071153 001 Aug 10, 1987

BAXTER HLTHCARE

50MG/ML

A070545 001 May 14, 1986

50MG/ML

A070546 001 May 14, 1986

HOSPIRA

50MG/ML

N019033 001 Apr 29, 1986

INTL MEDICATION

50MG/ML

A070119 001 Apr 29, 1986

BRETYLIUM TOSYLATE IN DEXTROSE 5%

ABBOTT

200MG/100ML

N019005 002 Apr 29, 1986

400MG/100ML

N019005 003 Apr 29, 1986

800MG/100ML

N019005 001 Apr 29, 1986

## DISCONTINUED DRUG PRODUCT LIST

6 - 44 (of 324)

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	200MG/100ML	N019837	002	Apr 12, 1989
	400MG/100ML	N019837	001	Apr 12, 1989
HOSPIRA	800MG/100ML	N019008	001	Apr 29, 1986
BRETYLLOL				
HOSPIRA	50MG/ML	N017954	001	

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

ALLERGAN	0.2%	N020613	001	Sep 06, 1996
	0.5%	N020490	001	Mar 13, 1997

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

LEK PHARM	EQ 5MG BASE	A075100	001	Dec 10, 1998
-----------	-------------	---------	-----	--------------

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

AMBODRYL

PARKE DAVIS	25MG	N007984	001	
-------------	------	---------	-----	--

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

AMBENYL

FOREST LABS	12.5MG/5ML;10MG/5ML	N009319	006	Jan 10, 1984
-------------	---------------------	---------	-----	--------------

BROMANYL

ALPHARMA US PHARMS	12.5MG/5ML;10MG/5ML	A088343	001	Aug 15, 1984
--------------------	---------------------	---------	-----	--------------

BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE

MORTON GROVE	12.5MG/5ML;10MG/5ML	A088626	001	Oct 12, 1984
--------------	---------------------	---------	-----	--------------

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL

BROMPHENIRAMINE MALEATE

ALPHARMA US PHARMS	2MG/5ML	A086936	001	
KV PHARM	2MG/5ML	A085466	001	
PHARM ASSOC	2MG/5ML	A087517	001	
USL PHARMA	2MG/5ML	A087964	001	Jan 25, 1983

INJECTABLE; INJECTION

BROMPHENIRAMINE MALEATE

WATSON LABS	10MG/ML	A083821	001	
	100MG/ML	A083820	001	

DIMETANE-TEN

WYETH AYERST	10MG/ML	N011418	002	
--------------	---------	---------	-----	--

TABLET; ORAL

BROMPHENIRAMINE MALEATE

BARR	4MG	A084468	001	
IVAX SUB TEVA PHARMS	4MG	A084351	001	
NEWTRON PHARMS	4MG	A086987	001	
NEXGEN PHARMA INC	4MG	A086187	001	
PAR PHARM	4MG	A087009	001	
PIONEER PHARMS	4MG	A088604	001	Jul 13, 1984
SANDOZ	4MG	A083215	001	
VITARINE	4MG	A085850	001	
WATSON LABS	4MG	A083123	001	
	4MG	A085769	001	

DIMETANE

WYETH CONS	4MG	N010799	003	
------------	-----	---------	-----	--

TABLET, EXTENDED RELEASE; ORAL

DIMETANE

WYETH CONS	8MG	N010799	010	Jun 10, 1983
------------	-----	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 45 (of 324)

BROMPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

DIMETANE

WYETH CONS

12MG

N010799 011

Jun 10, 1983

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DC

ALPHARMA US PHARMS

2MG/5ML;10MG/5ML;12.5MG/5ML

A088723 001

Feb 25, 1985

DIMETANE-DC

ROBINS AH

2MG/5ML;10MG/5ML;12.5MG/5ML

N011694 006

Mar 29, 1984

MYPHETANE DC

MORTON GROVE

2MG/5ML;10MG/5ML;12.5MG/5ML

A088904 001

Feb 21, 1985

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DM

ALPHARMA US PHARMS

2MG/5ML;10MG/5ML;30MG/5ML

A088722 001

Mar 07, 1985

BROMFED-DM

WOCKHARDT

2MG/5ML;10MG/5ML;30MG/5ML

A089681 001

Dec 22, 1988

DIMETANE-DX

ROBINS AH

2MG/5ML;10MG/5ML;30MG/5ML

N019279 001

Aug 24, 1984

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL

BIPHETAP

MORTON GROVE

4MG/5ML;25MG/5ML

A088687 001

Sep 26, 1984

BROMANATE

ALPHARMA US PHARMS

4MG/5ML;25MG/5ML

A088688 001

Feb 06, 1985

DIMETAPP

WYETH CONS

2MG/5ML;12.5MG/5ML

N013087 003

Mar 29, 1984

TABLET, EXTENDED RELEASE; ORAL

BROMATAPP

COPLLEY PHARM

12MG;75MG

A071099 001

Jul 02, 1987

DIMETAPP

WYETH CONS

12MG;75MG

N012436 003

May 14, 1985

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

ALZA

16MG;240MG

N019672 001

Mar 29, 1996

BUCLIZINE HYDROCHLORIDE

TABLET; ORAL

BUCLADIN-S

STUART PHARMS

50MG

N010911 006

BUDESONIDE

AEROSOL, METERED; NASAL

RHINOCORT

ASTRAZENECA

0.032MG/INH

N020233 001

Feb 14, 1994

POWDER, METERED; INHALATION

PULMICORT

ASTRAZENECA

0.32MG/INH

N020441 003

Jun 24, 1997

SPRAY, METERED; NASAL

RHINOCORT

ASTRAZENECA

0.064MG/INH

N020746 002

Oct 01, 1999

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

HOSPIRA

0.25MG/ML

A074160 001

Oct 30, 1997

BUMEX

VALIDUS PHARMS INC

0.25MG/ML

N018226 001

Feb 28, 1983

## DISCONTINUED DRUG PRODUCT LIST

6 - 46 (of 324)

BUMETANIDE

TABLET; ORAL

BUMEX

VALIDUS PHARMS INC	0.5MG	N018225	002	Feb 28, 1983
	1MG	N018225	001	Feb 28, 1983
	2MG	N018225	003	Jun 14, 1985

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE KIT

HOSPIRA	0.075%	N019978	001	Sep 03, 1992
	0.114%	N019978	002	Sep 03, 1992
	0.23%	N019978	003	Sep 03, 1992

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

HOSPIRA	0.25%;0.005MG/ML	A071166	001	Jun 16, 1988
	0.5%;0.005MG/ML	A071169	001	Jun 16, 1988
	0.5%;0.005MG/ML	A071170	001	Jun 16, 1988
	0.75%;0.005MG/ML	A071171	001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

AMPHASTAR	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496	001	May 23, 2003
-----------	--	---------	-----	--------------

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

SANDOZ	75MG	A075613	002	Oct 10, 2000
	100MG	A075613	001	Oct 10, 2000

WELLBUTRIN

GLAXOSMITHKLINE	50MG	N018644	001	Dec 30, 1985
-----------------	------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

SANDOZ	100MG	A076845	001	Jul 14, 2005
	150MG	A076834	001	Jul 14, 2005
	150MG	A076845	002	Jul 14, 2005

ZYBAN

GLAXOSMITHKLINE	100MG	N020711	002	May 14, 1997
-----------------	-------	---------	-----	--------------

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUSPAR

BRISTOL MYERS SQUIBB	5MG	N021190	001	Dec 20, 2000
	7.5MG	N021190	002	Dec 20, 2000
	10MG	N021190	003	Dec 20, 2000
	15MG	N021190	004	Dec 20, 2000

TABLET; ORAL

BUSPAR

BRISTOL MYERS SQUIBB	30MG	N018731	004	Apr 22, 1996
----------------------	------	---------	-----	--------------

BUSPIRONE HYDROCHLORIDE

SANDOZ	5MG	A075413	001	Mar 19, 2002
	10MG	A075413	002	Mar 19, 2002
	15MG	A075413	003	Mar 19, 2002

BUTABARBITAL SODIUM

CAPSULE; ORAL

BUTICAPS

MEDPOINTE PHARM HLC	15MG	A085381	001
	30MG	A085381	002
	50MG	A085381	003



## DISCONTINUED DRUG PRODUCT LIST

6 - 47 (of 324)

BUTABARBITAL SODIUM

CAPSULE; ORAL

BUTICAPS

MEDPOINTE PHARM HLC 100MG A085381 004

ELIXIR; ORAL

BUTABARB

ALPHARMA US PHARMS 30MG/5ML A085873 001

BUTABARBITAL SODIUM

MORTON GROVE 30MG/5ML A085383 001

BUTALAN

LANNETT 33.3MG/5ML A085880 001

SARISOL

HALSEY 30MG/5ML A084723 001

TABLET; ORAL

BUTABARBITAL

BUNDY 30MG A085550 001

BUTABARBITAL SODIUM

SANDOZ 15MG A084292 003 Feb 09, 1982

15MG A085938 001

30MG A084272 002

30MG A085934 001

SOLVAY 16.2MG A083606 001

32.4MG A083898 001

48.6MG A083897 001

97.2MG A083896 001

TEVA 15MG A088632 001 May 18, 1985

30MG A088631 001 May 01, 1985

WATSON LABS 15MG A085764 001

30MG A085772 001

WHITWORTH TOWN PLSN 15MG A083325 002

30MG A083337 001

BUTISOL SODIUM

MEDA PHARMS 15MG N000793 002

100MG N000793 005

SARISOL NO. 1

HALSEY 15MG A084719 001

SARISOL NO. 2

HALSEY 30MG A084719 002

SODIUM BUTABARBITAL

IVAX SUB TEVA PHARMS 15MG A083484 001

30MG A084040 001

LANNETT 15MG A085849 001

30MG A085866 001

100MG A085881 001

MARSHALL PHARMA 16.2MG A083524 001

32.4MG A083858 001

WEST WARD 15MG A085418 001

30MG A085432 001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT

ROCHE PALO 2% N019215 001 Nov 25, 1985

SUPPOSITORY; VAGINAL

FEMSTAT

ROCHE PALO 100MG N019359 001 Nov 25, 1985

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

HOSPIRA 1MG/ML A075342 001 Nov 04, 1999

1MG/ML A075559 001 Mar 20, 2000

2MG/ML A075342 002 Nov 04, 1999

2MG/ML A075559 002 Mar 20, 2000

## DISCONTINUED DRUG PRODUCT LIST

6 - 48 (of 324)

BUTORPHANOL TARTRATE

## INJECTABLE; INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

HOSPIRA	1MG/ML	A074620	001	Jan 22, 1997
	1MG/ML	A075170	001	Sep 28, 1998
	2MG/ML	A074620	002	Jan 22, 1997
	2MG/ML	A075170	002	Sep 28, 1998

## SPRAY, METERED; NASAL

STADOL

BRISTOL MYERS SQUIBB	1MG/SPRAY	N019890	001	Dec 12, 1991
----------------------	-----------	---------	-----	--------------

CABERGOLINE

## TABLET; ORAL

DOSTINEX

PHARMACIA AND UPJOHN	0.5MG	N020664	001	Dec 23, 1996
----------------------	-------	---------	-----	--------------

CAFFEINE; ERGOTAMINE TARTRATE

## SUPPOSITORY; RECTAL

CAFERGOT

NOVARTIS	100MG; 2MG	N009000	002	
----------	------------	---------	-----	--

## TABLET; ORAL

CAFERGOT

NOVARTIS	100MG; 1MG	N006620	001	
----------	------------	---------	-----	--

WIGRAINE

ORGANON USA INC	100MG; 1MG	A086562	001	
-----------------	------------	---------	-----	--

CALCIFEDIOL

## CAPSULE; ORAL

CALDEROL

ORGANON USA INC	0.02MG	N018312	001	
-----------------	--------	---------	-----	--

	0.05MG	N018312	002	
--	--------	---------	-----	--

CALCIPOTRIENE

## OINTMENT; TOPICAL

DOVONEX

LEO PHARM	0.005%	N020273	001	Dec 29, 1993
-----------	--------	---------	-----	--------------

CALCITONIN HUMAN

## INJECTABLE; INJECTION

CIBACALCIN

NOVARTIS	0.5MG/VIAL	N018470	001	Oct 31, 1986
----------	------------	---------	-----	--------------

CALCITONIN, SALMON

## INJECTABLE; INJECTION

CALCIMAR

SANOFI AVENTIS US	200 IU/ML	N017769	001	
-------------------	-----------	---------	-----	--

	400 IU/VIAL	N017497	001	
--	-------------	---------	-----	--

CALCITONIN-SALMON

ASTRAZENECA	200 IU/ML	A073690	001	Apr 14, 1995
-------------	-----------	---------	-----	--------------

MIACALCIN

NOVARTIS	100 IU/ML	N017808	001	Jul 03, 1986
----------	-----------	---------	-----	--------------

CALCITRIOL

## INJECTABLE; INJECTION

CALCITRIOL

HOSPIRA	0.001MG/ML	A075816	001	Jan 16, 2004
---------	------------	---------	-----	--------------

	0.002MG/ML	A075816	002	Jan 16, 2004
--	------------	---------	-----	--------------

CALCIUM ACETATE

## CAPSULE; ORAL

PHOSLO

FRESENIUS MEDCL	EQ 84.5MG CALCIUM	N021160	001	Apr 02, 2001
-----------------	-------------------	---------	-----	--------------

	EQ 169MG CALCIUM	N021160	002	Apr 02, 2001
--	------------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 49 (of 324)

CALCIUM ACETATE

TABLET; ORAL

CALCIUM ACETATE

ROXANE	EQ 169MG CALCIUM	A077693	001	Jan 30, 2008
PHOSLO				
FRESENIUS MEDCL	EQ 169MG CALCIUM	N019976	001	Dec 10, 1990

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET, TABLET; ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

PROCTER AND GAMBLE	EQ 500MG BASE,N/A;N/A,35MG	N021823	001	Aug 12, 2005
--------------------	----------------------------	---------	-----	--------------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML; 3.05GM/1000ML;0.157GM/1000ML;2.21GM/100 0ML;7.07GM/1000ML	N021703	012	Oct 10, 2008
--------------------	---	---------	-----	--------------

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.0 5GM/1000ML;0.314GM/1000ML;3.09GM/1000ML ;6.46GM/1000ML	N021703	005	Oct 25, 2006
--------------------	--	---------	-----	--------------

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML; 2.03GM/1000ML;0.314GM/1000ML;3.09GM/100 0ML;6.46GM/1000ML	N021703	008	Oct 25, 2006
--------------------	---	---------	-----	--------------

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05 GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46 GM/1000ML	N021703	007	Oct 25, 2006
--------------------	---	---------	-----	--------------

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3 .05GM/1000ML;0.314GM/1000ML;3.09GM/1000 ML;6.46GM/1000ML	N021703	009	Oct 25, 2006
--------------------	--	---------	-----	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/1 00ML;330MG/100ML;88MG/100ML	N018271	001	
---------	--	---------	-----	--

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/10 0ML;640MG/100ML;500MG/100ML;74MG/100ML	N018269	002	Jan 17, 1983
---------	---	---------	-----	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;2.5GM/100ML;15MG/100ML;610MG /100ML;560MG/100ML	N018460	006	Jan 29, 1986
---------	---	---------	-----	--------------

DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;1.5GM/100ML;15MG/100ML;610MG /100ML;560MG/100ML	N018460	001	
---------	---	---------	-----	--

DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;4.25GM/100ML;15MG/100ML;610M G/100ML;560MG/100ML	N018460	003	
---------	--	---------	-----	--

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML;1.5GM/100ML;15MG/100ML;560MG /100ML;390MG/100ML	N018460	002	
---------	---	---------	-----	--

**DISCONTINUED DRUG PRODUCT LIST**

6 - 50 (of 324)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML;5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	008	Jan 29, 1986
---------	--	---------	-----	--------------

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML;4.25GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N018460	004	
---------	--	---------	-----	--

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N018256	001	
---------	---	---------	-----	--

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	4MG/100ML;4GM/100ML;6MG/100ML;120MG/100ML;62MG/100ML	N019634	002	Feb 24, 1988
---------	--	---------	-----	--------------

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N017510	001	
---------	---	---------	-----	--

MILES	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018499	001	
-------	---	---------	-----	--

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	005	Oct 17, 1988
---------	--	---------	-----	--------------

	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685	006	Oct 17, 1988
--	--	---------	-----	--------------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	007	Oct 17, 1988
---------	--	---------	-----	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	003	Oct 17, 1988
---------	--	---------	-----	--------------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	001	Oct 17, 1988
---------	--	---------	-----	--------------

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;538MG/100ML;448MG/100ML	N019395	001	Mar 26, 1986
-----------------	--	---------	-----	--------------

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;538MG/100ML;448MG/100ML	N019395	002	Mar 26, 1986
-----------------	--	---------	-----	--------------

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;538MG/100ML;448MG/100ML	N019395	003	Mar 26, 1986
-----------------	---	---------	-----	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N019399	001	Jun 16, 1986
--------	--	---------	-----	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018899	001	Oct 31, 1983
---------	---	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 51 (of 324)

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION  
 ACETATED RINGER'S IN PLASTIC CONTAINER  
 B BRAUN 20MG/100ML; 30MG/100ML; 380MG/100ML; 600MG /100ML N018725 001 Nov 29, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION  
 RINGER'S IN PLASTIC CONTAINER  
 B BRAUN 33MG/100ML; 30MG/100ML; 860MG/100ML N018721 001 Nov 09, 1982  
 SOLUTION; IRRIGATION  
 RINGER'S IN PLASTIC CONTAINER  
 ABBOTT 33MG/100ML; 30MG/100ML; 860MG/100ML N018462 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION  
 LACTATED RINGER'S IN PLASTIC CONTAINER  
 ABBOTT 20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG /100ML N019485 001 Oct 24, 1985  
 B BRAUN 20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG /100ML N018023 001  
 MILES 20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG /100ML N018417 001

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION  
 CALCIUM GLUCEPTATE  
 ABBOTT EQ 90MG CALCIUM/5ML A080001 001  
 EQ 90MG CALCIUM/5ML A083159 001  
 ABRAXIS PHARM EQ 90MG CALCIUM/5ML A089373 001 Apr 30, 1987  
 LILLY EQ 90MG CALCIUM/5ML N006470 001

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE; INJECTION  
 ISOPAQUE 440  
 GE HEALTHCARE 0.78MG/ML; 75.9MG/ML; 0.15MG/ML; 16.6MG/ML N016847 001

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE; INJECTION  
 ISOPAQUE 280  
 GE HEALTHCARE 0.35MG/ML; 140.1MG/ML; 461.8MG/ML N017506 001

CANDICIDIN

OINTMENT; VAGINAL  
 VANOVID  
 SANOFI AVENTIS US 0.6MG/GM A061596 001  
 TABLET; VAGINAL  
 VANOVID  
 SANOFI AVENTIS US 3MG A061613 001

CAPTOPRIL

TABLET; ORAL  
 CAPOTEN  
 PAR PHARM 37.5MG N018343 006 Sep 17, 1986  
 75MG N018343 007 Jun 13, 1995  
 150MG N018343 004 Jun 13, 1995  
 CAPTOPRIL  
 APOTHECON 12.5MG A074472 001 Mar 31, 1995  
 25MG A074472 002 Mar 31, 1995  
 50MG A074472 003 Mar 31, 1995  
 100MG A074472 004 Mar 31, 1995  
 CLONMEL HLTHCARE 12.5MG A074423 001 Feb 13, 1996  
 25MG A074423 002 Feb 13, 1996  
 50MG A074423 003 Feb 13, 1996

## DISCONTINUED DRUG PRODUCT LIST

6 - 52 (of 324)

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

CLONMEL HLTHCARE	100MG	A074423	004	Feb 13, 1996
EGIS PHARMS	12.5MG	A074748	004	May 29, 1997
	25MG	A074748	002	May 29, 1997
	50MG	A074748	001	May 29, 1997
	100MG	A074748	003	May 29, 1997
ENDO LABS	12.5MG	A074418	001	Feb 13, 1996
	25MG	A074418	002	Feb 13, 1996
	50MG	A074418	003	Feb 13, 1996
	100MG	A074418	004	Feb 13, 1996
IVAX SUB TEVA PHARMS	12.5MG	A074590	004	Aug 30, 1996
	25MG	A074590	002	Aug 30, 1996
	50MG	A074590	001	Aug 30, 1996
	100MG	A074590	003	Aug 30, 1996
PAR PHARM	12.5MG	A074493	001	Feb 13, 1996
	25MG	A074493	002	Feb 13, 1996
	50MG	A074493	003	Feb 13, 1996
	100MG	A074493	004	Feb 13, 1996
PUREPAC PHARM	12.5MG	A074640	001	Mar 31, 1997
	25MG	A074640	002	Mar 31, 1997
	50MG	A074640	003	Mar 31, 1997
	100MG	A074640	004	Mar 31, 1997
SANDOZ	12.5MG	A074481	001	Feb 13, 1996
	12.5MG	A074519	001	Feb 13, 1996
	25MG	A074481	002	Feb 13, 1996
	25MG	A074519	002	Feb 13, 1996
	50MG	A074481	003	Feb 13, 1996
	50MG	A074519	003	Feb 13, 1996
	100MG	A074481	004	Feb 13, 1996
	100MG	A074519	004	Feb 13, 1996
TEVA	12.5MG	A074433	001	Feb 13, 1996
	25MG	A074433	002	Feb 13, 1996
	50MG	A074433	003	Feb 13, 1996
	100MG	A074433	004	Feb 13, 1996
TEVA PHARMS	12.5MG	A074462	001	Feb 13, 1996
	25MG	A074462	002	Feb 13, 1996
	50MG	A074462	003	Feb 13, 1996
	100MG	A074462	004	Feb 13, 1996
WATSON LABS	12.5MG	A074576	001	Apr 23, 1996
	25MG	A074576	002	Apr 23, 1996
	50MG	A074576	003	Apr 23, 1996
	100MG	A074576	004	Apr 23, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

ENDO LABS	25MG;15MG	A074788	001	Dec 29, 1997
	25MG;25MG	A074788	002	Dec 29, 1997
	50MG;15MG	A074788	004	Dec 29, 1997
	50MG;25MG	A074788	003	Dec 29, 1997
WATSON LABS	50MG;25MG	A074832	001	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

CARBACHOL

PHARMAFAIR	0.01%	A070292	001	May 21, 1986
CARBASTAT				
NOVARTIS	0.01%	A073677	001	Apr 28, 1995

## DISCONTINUED DRUG PRODUCT LIST

6 - 53 (of 324)

CARBAMAZEPINE

SUSPENSION; ORAL

CARBAMAZEPINE

TARO

100MG/5ML

A075875 001

Dec 21, 2000

TABLET; ORAL

CARBAMAZEPINE

ACTAVIS ELIZABETH

200MG

A071696 001

Nov 09, 1987

PLIVA

200MG

A071479 001

Jul 24, 1987

USL PHARMA

200MG

A070300 001

May 15, 1986

WARNER CHILCOTT

200MG

A070429 001

Jan 02, 1987

TERIL

TARO

200MG

A076525 001

Sep 26, 2003

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

CADISTA PHARMS

100MG

A071940 001

Feb 01, 1988

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN

ROERIG

EQ 1GM BASE/VIAL

N050306 001

EQ 2GM BASE/VIAL

N050306 004

EQ 5GM BASE/VIAL

N050306 002

EQ 10GM BASE/VIAL

N050306 006

EQ 30GM BASE/VIAL

N050306 007

PYOPEN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

N050298 001

EQ 2GM BASE/VIAL

N050298 002

EQ 5GM BASE/VIAL

N050298 003

EQ 10GM BASE/VIAL

N050298 006

EQ 20GM BASE/VIAL

N050298 007

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN

PFIZER

EQ 382MG BASE

N050435 001

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

SANDOZ

10MG;100MG

A073586 001

Jun 29, 1995

25MG;100MG

A073587 001

Jun 29, 1995

25MG;250MG

A073620 001

Jun 29, 1995

SCS

10MG;100MG

A074080 001

Mar 25, 1994

25MG;100MG

A074080 002

Mar 25, 1994

25MG;250MG

A074080 003

Mar 25, 1994

WATSON LABS

10MG;100MG

A073381 001

Sep 28, 1993

25MG;100MG

A073382 001

Sep 28, 1993

25MG;250MG

A073383 001

Sep 28, 1993

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

KV PHARM

50MG;200MG

A076663 001

Jun 24, 2004

TABLET, FOR SUSPENSION; ORAL

CARBILEV

RANBAXY

10MG;100MG

A076643 001

Jun 10, 2005

25MG;100MG

A076643 002

Jun 10, 2005

25MG;250MG

A076643 003

Jun 10, 2005

CARBINOXAMINE MALEATE

ELIXIR; ORAL

CLISTIN

MCNEIL

4MG/5ML

N008955 001

TABLET; ORAL

CLISTIN

ORTHO MCNEIL PHARM

4MG

N008915 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 54 (of 324)

CARBOPLATIN

## INJECTABLE; INJECTION

## CARBOPLATIN

HOSPIRA	50MG/VIAL	A076473	001	Oct 27, 2004
	150MG/VIAL	A076473	002	Oct 27, 2004
	450MG/VIAL	A076473	003	Oct 27, 2004

## PARAPLATIN

BRISTOL MYERS SQUIBB	50MG/VIAL	N019880	001	Mar 03, 1989
	150MG/VIAL	N019880	002	Mar 03, 1989
	450MG/VIAL	N019880	003	Mar 03, 1989

## INJECTABLE; IV (INFUSION)

## CARBOPLATIN

APP PHARMS	50MG/5ML (10MG/ML)	A077247	001	Oct 21, 2004
	150MG/15ML (10MG/ML)	A077247	002	Oct 21, 2004
SPECTRUM PHARMS	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005
	150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005
	450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005

CARISOPRODOL

## CAPSULE; ORAL

## SOMA

MEDA PHARMS	250MG	N011792	003	
-------------	-------	---------	-----	--

## TABLET; ORAL

## CARISOPRODOL

ABLE	350MG	A040421	001	Jun 21, 2001
PIONEER PHARMS	350MG	A089390	001	Oct 13, 1988
SANDOZ	350MG	A081025	001	Apr 13, 1989
	350MG	A089566	001	Aug 30, 1988
WATSON LABS	350MG	A040152	001	Dec 03, 1996
	350MG	A085433	001	
	350MG	A086179	001	

## RELA

SCHERING	350MG	N012155	001	
----------	-------	---------	-----	--

CARPENAZINE MALEATE

## CONCENTRATE; ORAL

## PROKETAZINE

WYETH AYERST	50MG/ML	N014173	001	
--------------	---------	---------	-----	--

## TABLET; ORAL

## PROKETAZINE

WYETH AYERST	12.5MG	N012768	001	
	25MG	N012768	002	
	50MG	N012768	004	

CARPROFEN

## TABLET; ORAL

## RIMADYL

ROCHE	100MG	N018550	002	Dec 31, 1987
	150MG	N018550	003	Dec 31, 1987

CARTEOLOL HYDROCHLORIDE

## TABLET; ORAL

## CARTROL

ABBOTT	2.5MG	N019204	001	Dec 28, 1988
	5MG	N019204	002	Dec 28, 1988
	10MG	N019204	003	Dec 28, 1988

CEFACLOR

## CAPSULE; ORAL

## CECLOR

LILLY	EQ 250MG BASE	N050521	001	
	EQ 500MG BASE	N050521	002	

## CEFACLOR

CEPH INTL	EQ 250MG BASE	A062205	001	
-----------	---------------	---------	-----	--



## DISCONTINUED DRUG PRODUCT LIST

6 - 55 (of 324)

CEFACLOR

CAPSULE; ORAL

CEFACLOR

CEPH INTL	EQ 500MG BASE	A062205	002	
CLONMEL HLTHCARE	EQ 250MG BASE	A064107	001	Apr 27, 1995
	EQ 500MG BASE	A064107	002	Apr 27, 1995
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A064061	001	Apr 27, 1995
	EQ 500MG BASE	A064061	002	Apr 27, 1995
MARSAM PHARMS LLC	EQ 250MG BASE	A064148	001	May 23, 1996
	EQ 500MG BASE	A064148	002	May 23, 1996
TEVA	EQ 250MG BASE	A064081	001	Sep 16, 1996
	EQ 250MG BASE	A064145	001	Jun 24, 1996
	EQ 500MG BASE	A064081	002	Sep 16, 1996
	EQ 500MG BASE	A064145	002	Jun 24, 1996

FOR SUSPENSION; ORAL

CECLOR

LILLY	EQ 125MG BASE/5ML	N050522	001	
	EQ 250MG BASE/5ML	N050522	002	

CEFACLOR

CEPH INTL	EQ 125MG BASE/5ML	A062206	001	
	EQ 187MG BASE/5ML	A062206	003	Apr 20, 1988
	EQ 250MG BASE/5ML	A062206	002	
	EQ 375MG BASE/5ML	A062206	004	Apr 20, 1988
CLONMEL HLTHCARE	EQ 125MG BASE/5ML	A064114	001	Apr 28, 1995
	EQ 187MG BASE/5ML	A064115	001	Apr 28, 1995
	EQ 250MG BASE/5ML	A064116	001	Apr 28, 1995
	EQ 375MG BASE/5ML	A064110	001	Apr 28, 1995
IVAX SUB TEVA PHARMS	EQ 125MG BASE/5ML	A064087	001	Apr 28, 1995
	EQ 187MG BASE/5ML	A064086	001	Apr 28, 1995
	EQ 250MG BASE/5ML	A064085	001	Apr 28, 1995
	EQ 375MG BASE/5ML	A064070	001	Apr 28, 1995
MARSAM PHARMS LLC	EQ 125MG BASE/5ML	A064204	001	Feb 18, 1998
	EQ 187MG BASE/5ML	A064205	001	Feb 18, 1998
	EQ 250MG BASE/5ML	A064206	001	Feb 18, 1998
	EQ 375MG BASE/5ML	A064207	001	Feb 18, 1998

TABLET, EXTENDED RELEASE; ORAL

CECLOR CD

LILLY	EQ 375MG BASE	N050673	001	Jun 28, 1996
	EQ 500MG BASE	N050673	002	Jun 28, 1996

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

IVAX SUB TEVA PHARMS	EQ 500MG BASE	A062766	001	Mar 03, 1987
PUREPAC PHARM	EQ 500MG BASE	A063017	001	Jan 05, 1989
TEVA	EQ 500MG BASE	A062695	001	Feb 10, 1989

DURICEF

WARNER CHILCOTT	EQ 250MG BASE	N050512	002	
	EQ 500MG BASE	N050512	001	

ULTRACEF

BRISTOL	EQ 500MG BASE	A062378	001	Mar 16, 1982
---------	---------------	---------	-----	--------------

FOR SUSPENSION; ORAL

CEFADROXIL

APOTHECON	EQ 125MG BASE/5ML	A062334	001	
	EQ 250MG BASE/5ML	A062334	002	
	EQ 500MG BASE/5ML	A062334	003	
TEVA	EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989
	EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989
	EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989

DURICEF

WARNER CHILCOTT	EQ 125MG BASE/5ML	N050527	002	
-----------------	-------------------	---------	-----	--

ULTRACEF

BRISTOL	EQ 125MG BASE/5ML	A062376	001	Mar 16, 1982
	EQ 250MG BASE/5ML	A062376	002	Mar 16, 1982

## DISCONTINUED DRUG PRODUCT LIST

6 - 56 (of 324)

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

ULTRACEF

BRISTOL

EQ 500MG BASE/5ML

A062376 003

Mar 16, 1982

TABLET; ORAL

DURICEF

WARNER CHILCOTT

EQ 1GM BASE

N050528 001

ULTRACEF

APOTHECON

EQ 1GM BASE

A062390 001

Jun 10, 1982

BRISTOL

EQ 1GM BASE

A062408 001

Aug 31, 1982

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

LILLY

EQ 500MG BASE/VIAL

N050504 001

EQ 1GM BASE/VIAL

A062560 001

Sep 10, 1985

EQ 1GM BASE/VIAL

N050504 002

EQ 2GM BASE/VIAL

A062560 002

Sep 10, 1985

EQ 2GM BASE/VIAL

N050504 003

EQ 10GM BASE/VIAL

N050504 004

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

GLAXOSMITHKLINE

EQ 250MG BASE/VIAL

N050461 001

EQ 500MG BASE/VIAL

N050461 002

EQ 1GM BASE/VIAL

N050461 003

EQ 5GM BASE/VIAL

N050461 004

EQ 10GM BASE/VIAL

N050461 005

ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 10MG BASE/ML

N050566 003

Jun 08, 1983

EQ 20MG BASE/ML

N050566 004

Jun 08, 1983

ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 10MG BASE/ML

N050566 001

Jun 08, 1983

EQ 20MG BASE/ML

N050566 002

Jun 08, 1983

CEFAZOLIN AND DEXTROSE

B BRAUN

EQ 500MG BASE/VIAL

N050779 001

Jul 27, 2000

CEFAZOLIN SODIUM

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A062688 002

Nov 17, 1986

EQ 1GM BASE/VIAL

A062688 003

Nov 17, 1986

EQ 10GM BASE/VIAL

A062688 004

Nov 17, 1986

EQ 20GM BASE/VIAL

A062688 005

Aug 03, 1987

BEDFORD

EQ 250MG BASE/VIAL

A062894 001

Jul 21, 1988

EQ 500MG BASE/VIAL

A062894 002

Jul 21, 1988

EQ 1GM BASE/VIAL

A062894 003

Jul 21, 1988

EQ 5GM BASE/VIAL

A062894 004

Jul 21, 1988

EQ 10GM BASE/VIAL

A062894 005

Jul 21, 1988

ELKINS SINN

EQ 250MG BASE/VIAL

A062807 001

Jan 12, 1988

EQ 500MG BASE/VIAL

A062807 002

Jan 12, 1988

EQ 1GM BASE/VIAL

A062807 003

Jan 12, 1988

EQ 5GM BASE/VIAL

A062807 004

Jan 12, 1988

EQ 10GM BASE/VIAL

A062807 005

Jan 12, 1988

EQ 20GM BASE/VIAL

A062807 006

Jan 12, 1988

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A064033 001

Oct 31, 1993

HANFORD GC

EQ 500MG BASE/VIAL

A063214 001

Dec 27, 1991

EQ 500MG BASE/VIAL

A063216 001

Dec 27, 1991

MARSAM PHARMS LLC

EQ 250MG BASE/VIAL

A062988 001

Dec 29, 1989

EQ 500MG BASE/VIAL

A062988 002

Dec 29, 1989

EQ 1GM BASE/VIAL

A062988 003

Dec 29, 1989

EQ 5GM BASE/VIAL

A062989 001

Dec 29, 1989

EQ 10GM BASE/VIAL

A062989 002

Dec 29, 1989

EQ 20GM BASE/VIAL

A062989 003

Dec 29, 1989

TEVA

EQ 250MG BASE/VIAL

A063016 001

Mar 14, 1989

EQ 500MG BASE/VIAL

A063016 002

Mar 14, 1989

## DISCONTINUED DRUG PRODUCT LIST

6 - 57 (of 324)

CEFAZOLIN SODIUMINJECTABLE; INJECTION  
CEFAZOLIN SODIUM

TEVA	EQ 1GM BASE/VIAL	A063016	003	Mar 14, 1989
	EQ 5GM BASE/VIAL	A063018	001	Mar 05, 1990
	EQ 10GM BASE/VIAL	A063018	002	Mar 05, 1990
KEFZOL				
ACS DOBFAR	EQ 250MG BASE/VIAL	A061773	001	
	EQ 20GM BASE/VIAL	A061773	005	Sep 08, 1987
LILLY	EQ 500MG BASE/VIAL	A062557	001	Sep 10, 1985
	EQ 1GM BASE/VIAL	A062557	002	Sep 10, 1985

CEFIXIMEFOR SUSPENSION; ORAL  
SUPRAX

LEDERLE	100MG/5ML	N050622	001	Apr 28, 1989
TABLET; ORAL SUPRAX				
LEDERLE	200MG	N050621	001	Apr 28, 1989
	400MG	N050621	002	Apr 28, 1989

CEFMENOXIME HYDROCHLORIDEINJECTABLE; INJECTION  
CEFMAX

TAP PHARM	EQ 500MG BASE/VIAL	N050571	001	Dec 30, 1987
	EQ 1GM BASE/VIAL	N050571	002	Dec 30, 1987
	EQ 2GM BASE/VIAL	N050571	003	Dec 30, 1987

CEFMETAZOLE SODIUMINJECTABLE; INJECTION  
ZEFAZONE

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N050637	001	Dec 11, 1989
	EQ 2GM BASE/VIAL	N050637	002	Dec 11, 1989
ZEFAZONE IN PLASTIC CONTAINER				
PHARMACIA AND UPJOHN	EQ 20MG BASE/ML	N050683	001	Dec 29, 1992
	EQ 40MG BASE/ML	N050683	002	Dec 29, 1992

CEFONICID SODIUMINJECTABLE; INJECTION  
MONOCID

GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N050579	001	May 23, 1984
	EQ 1GM BASE/VIAL	A063295	001	Jul 26, 1993
	EQ 1GM BASE/VIAL	N050579	002	May 23, 1984
	EQ 2GM BASE/VIAL	N050579	003	May 23, 1984
	EQ 10GM BASE/VIAL	N050579	004	May 23, 1984

CEFOPERAZONE SODIUMINJECTABLE; INJECTION  
CEFOBID

PFIZER	EQ 1GM BASE/VIAL	A063333	001	Mar 31, 1995
	EQ 1GM BASE/VIAL	N050551	001	Nov 18, 1982
	EQ 2GM BASE/VIAL	A063333	002	Mar 31, 1995
	EQ 2GM BASE/VIAL	N050551	002	Nov 18, 1982
	EQ 10GM BASE/VIAL	N050551	003	Mar 05, 1990
CEFOBID IN PLASTIC CONTAINER				
PFIZER	EQ 20MG BASE/ML	N050613	002	Jul 31, 1987
	EQ 40MG BASE/ML	N050613	001	Jul 23, 1986

CEFORANIDEINJECTABLE; INJECTION  
PRECEF

APOTHECON	500MG/VIAL	A062579	001	Nov 26, 1984
	1GM/VIAL	A062579	002	Nov 26, 1984
	2GM/VIAL	A062579	003	Nov 26, 1984

## DISCONTINUED DRUG PRODUCT LIST

6 - 58 (of 324)

CEFORANIDEINJECTABLE; INJECTION  
PRECEF

APOTHECON	10GM/VIAL	A062579	004	Nov 26, 1984
	20GM/VIAL	A062579	005	Nov 26, 1984
BRISTOL	500MG/VIAL	N050554	001	May 24, 1984
	1GM/VIAL	N050554	002	May 24, 1984
	2GM/VIAL	N050554	003	May 24, 1984
	10GM/VIAL	N050554	004	May 24, 1984
	20GM/VIAL	N050554	005	May 24, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER				
B BRAUN	EQ 2GM BASE	N050792	001	Jul 29, 2004
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER				
B BRAUN	EQ 1GM BASE	N050792	002	Jul 29, 2004
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
SANOFI AVENTIS US	EQ 20MG BASE/ML	N050596	001	May 20, 1985
	EQ 40MG BASE/ML	N050596	003	May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN				
ASTRAZENECA	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993
	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985
	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993
	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985
	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988
CEFOTAN IN PLASTIC CONTAINER				
ASTRAZENECA	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993
	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993

CEFOTIAM HYDROCHLORIDE

INJECTABLE; INJECTION

CERADON				
TAKEDA	EQ 1GM BASE/VIAL	N050601	001	Dec 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION

MEFOXIN				
BIONICHE PHARMA	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987
	EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987
MERCK	EQ 1GM BASE/VIAL	N050517	001	
	EQ 2GM BASE/VIAL	N050517	002	
	EQ 10GM BASE/VIAL	N050517	003	
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
MERCK	EQ 20MG BASE/ML	N050581	003	Sep 20, 1984
	EQ 40MG BASE/ML	N050581	004	Sep 20, 1984
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
MERCK	EQ 20MG BASE/ML	N050581	002	Sep 20, 1984
	EQ 40MG BASE/ML	N050581	001	Sep 20, 1984

CEFPYRAMIDE SODIUM

INJECTABLE; INJECTION

CEFPYRAMIDE SODIUM				
WYETH AYERST	EQ 1GM BASE/VIAL	N050633	002	Jan 31, 1989
	EQ 2GM BASE/VIAL	N050633	003	Jan 31, 1989
	EQ 10GM BASE/VIAL	N050633	005	Jan 31, 1989

## DISCONTINUED DRUG PRODUCT LIST

6 - 59 (of 324)

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

BANAN

SANKYO	EQ 50MG BASE/5ML	N050688	002	Aug 07, 1992
	EQ 100MG BASE/5ML	N050688	001	Aug 07, 1992

VANTIN

PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML	N050675	001	Aug 07, 1992
	EQ 100MG BASE/5ML	N050675	002	Aug 07, 1992

TABLET; ORAL

BANAN

SANKYO	EQ 100MG BASE	N050687	001	Aug 07, 1992
	EQ 200MG BASE	N050687	002	Aug 07, 1992

CEFTAZIDIME

INJECTABLE; INJECTION

CEPTAZ

GLAXOSMITHKLINE	500MG/VIAL	N050646	001	Sep 27, 1990
	1GM/VIAL	N050646	002	Sep 27, 1990
	2GM/VIAL	N050646	003	Sep 27, 1990
	10GM/VIAL	N050646	004	Sep 27, 1990

PENTACEF

GLAXOSMITHKLINE	1GM/VIAL	A063322	001	Nov 07, 1995
	1GM/VIAL	A064006	001	Mar 31, 1992
	2GM/VIAL	A063322	002	Nov 07, 1995
	2GM/VIAL	A064006	002	Mar 31, 1992
	6GM/VIAL	A064008	001	Mar 31, 1992
	10GM/VIAL	A064008	002	Mar 31, 1992

TAZIDIME

LILLY	1GM/VIAL	A062655	001	Nov 20, 1985
	2GM/VIAL	A062655	002	Nov 20, 1985

TAZIDIME IN PLASTIC CONTAINER

LILLY	1GM/VIAL	A062739	001	Jul 10, 1986
	2GM/VIAL	A062739	002	Jul 10, 1986

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	A063221	001	Apr 29, 1993
	EQ 20MG BASE/ML	A063221	002	Apr 29, 1993
	EQ 40MG BASE/ML	A063221	003	Apr 29, 1993

FORTAZ IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989
-----------------	-----------------	---------	-----	--------------

CEFTIBUTEN DIHYDRATE

FOR SUSPENSION; ORAL

CEDAX

SCIELE PHARMA INC	EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995
-------------------	-------------------	---------	-----	--------------

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

ASTELLAS	EQ 500MG BASE/VIAL	N050560	001	Sep 15, 1983
	EQ 1GM BASE/VIAL	A063294	002	Mar 31, 1994
	EQ 1GM BASE/VIAL	N050560	002	Sep 15, 1983
	EQ 2GM BASE/VIAL	A063294	003	Mar 31, 1994
	EQ 2GM BASE/VIAL	N050560	003	Sep 15, 1983
	EQ 10GM BASE/VIAL	N050560	005	Mar 19, 1993

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589	001	Oct 03, 1984
	EQ 40MG BASE/ML	N050589	002	Oct 03, 1984

CEFIZOX IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589	003	Apr 13, 1995
	EQ 40MG BASE/ML	N050589	004	Apr 13, 1995

## DISCONTINUED DRUG PRODUCT LIST

6 - 60 (of 324)

CEFTRIAXONE SODIUMINJECTABLE; IM-IV  
ROCEPHIN

HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	N050585	001	Dec 21, 1984
	EQ 500MG BASE/VIAL	N050585	002	Dec 21, 1984
	EQ 1GM BASE/VIAL	N050585	003	Dec 21, 1984
	EQ 2GM BASE/VIAL	N050585	004	Dec 21, 1984

INJECTABLE; INJECTION  
ROCEPHIN

HLR	EQ 250MG BASE/VIAL	A063239	001	Aug 13, 1993
	EQ 500MG BASE/VIAL	A062654	001	Apr 30, 1987
	EQ 1GM BASE/VIAL	A062654	002	Apr 30, 1987
	EQ 2GM BASE/VIAL	A062654	003	Apr 30, 1987
HOFFMANN LA ROCHE	EQ 10GM BASE/VIAL	N050585	005	Dec 21, 1984
ROCHE	EQ 250MG BASE/VIAL	A062510	001	Mar 12, 1985
	EQ 500MG BASE/VIAL	A062510	002	Mar 12, 1985
	EQ 1GM BASE/VIAL	A062510	003	Mar 12, 1985
ROCEPHIN W/ DEXTROSE IN	PLASTIC CONTAINER			
HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624	001	Feb 11, 1987
	EQ 20MG BASE/ML	N050624	002	Feb 11, 1987
	EQ 40MG BASE/ML	N050624	003	Feb 11, 1987

CEFTRIAXONE SODIUM; LIDOCAINEINJECTABLE; INJECTION  
ROCEPHIN KIT

HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL,N/A;N/A,1%	N050585	007	May 08, 1996
	EQ 1GM BASE/VIAL,N/A;N/A,1%	N050585	006	May 08, 1996

CEFUROXIME SODIUMINJECTABLE; IM-IV  
CEFUROXIME SODIUM

MARSAM PHARMS LLC	EQ 750MG BASE/VIAL	A064035	001	Feb 26, 1993
KEFUROX				
ACS DOBFAR	EQ 750MG BASE/VIAL	A062591	001	Jan 10, 1986

INJECTABLE; INJECTION  
CEFUROXIME SODIUM

MARSAM PHARMS LLC	EQ 1.5GM BASE/VIAL	A064035	002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036	001	Feb 26, 1993
KEFUROX				
ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591	002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591	003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592	002	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 1.5GM BASE/VIAL	A062590	002	Jan 10, 1986
-------	--------------------	---------	-----	--------------

INJECTABLE; INTRAVENOUS

KEFUROX				
LILLY	EQ 750MG BASE/VIAL	A062592	001	Jan 10, 1986
KEFUROX IN PLASTIC CONTAINER				
LILLY	EQ 750MG BASE/VIAL	A062590	001	Jan 10, 1986

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

MISSION PHARMA	2.5GM/PACKET	N018757	002	Dec 28, 1982
	300GM/BOT	N018757	003	Oct 16, 1984

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

APOTHECON	EQ 250MG BASE	A062973	001	Nov 08, 1988
	EQ 250MG BASE	A063063	001	Sep 29, 1989
	EQ 250MG BASE	A063186	001	Dec 30, 1994
	EQ 500MG BASE	A062974	001	Nov 23, 1988
	EQ 500MG BASE	A063063	002	Sep 29, 1989

## DISCONTINUED DRUG PRODUCT LIST

6 - 61 (of 324)

CEPHALEXIN

## CAPSULE; ORAL

## CEPHALEXIN

APOTHECON	EQ 500MG BASE	A063186	002	Dec 30, 1994
BARR	EQ 250MG BASE	A062773	001	Jun 26, 1987
	EQ 500MG BASE	A062775	001	Apr 22, 1987
PUREPAC PHARM	EQ 250MG BASE	A062809	001	Apr 22, 1987
	EQ 500MG BASE	A062809	002	Apr 22, 1987
STEVENS J	EQ 500MG BASE	A062869	001	Mar 17, 1988
TEVA	EQ 250MG BASE	A062760	001	Apr 24, 1987
	EQ 250MG BASE	A062821	001	Feb 05, 1988
	EQ 500MG BASE	A062761	001	Apr 24, 1987
	EQ 500MG BASE	A062823	001	Feb 05, 1988
YOSHITOMI	EQ 250MG BASE	A062872	001	Jun 20, 1988
	EQ 500MG BASE	A062871	001	Jul 05, 1988

## KEFLEX

## MIDDLEBROOK PHARMS

## FOR SUSPENSION; ORAL

## CEPHALEXIN

APOTHECON	EQ 125MG BASE/5ML	A062986	001	Apr 18, 1991
	EQ 250MG BASE/5ML	A062987	001	Jul 25, 1989
BARR	EQ 125MG BASE/5ML	A062778	001	Aug 06, 1987
	EQ 250MG BASE/5ML	A062777	001	Aug 06, 1987
CEPH INTL	EQ 100MG BASE/ML	A062117	001	
TEVA	EQ 125MG BASE/5ML	A062767	001	Jun 16, 1987
	EQ 125MG BASE/5ML	A062873	001	May 23, 1988
	EQ 250MG BASE/5ML	A062768	001	Jun 16, 1987
	EQ 250MG BASE/5ML	A062867	001	Apr 15, 1988
VITARINE	EQ 125MG BASE/5ML	A062779	001	Dec 22, 1987
	EQ 250MG BASE/5ML	A062781	001	Dec 22, 1987

## KEFLEX

## LEX PHARMS

EQ 100MG BASE/ML	N050406	003	
EQ 125MG BASE/5ML	N050406	001	
EQ 250MG BASE/5ML	N050406	002	

## TABLET; ORAL

## CEPHALEXIN

BARR	EQ 250MG BASE	A062826	001	Aug 17, 1987
	EQ 500MG BASE	A062827	001	Aug 17, 1987
VITARINE	EQ 250MG BASE	A062863	001	Aug 11, 1988
	EQ 500MG BASE	A062863	002	Aug 11, 1988
	EQ 1GM BASE	A062863	003	Aug 11, 1988

## KEFLET

## LILLY

EQ 250MG BASE	A062745	001	Dec 01, 1986
EQ 250MG BASE	N050440	003	Feb 26, 1987
EQ 500MG BASE	A062745	002	Dec 01, 1986
EQ 500MG BASE	N050440	001	
EQ 1GM BASE	N050440	002	

CEPHALEXIN HYDROCHLORIDE

## TABLET; ORAL

## KEFTAB

## LILLY

EQ 250MG BASE	N050614	001	Oct 29, 1987
EQ 333MG BASE	N050614	003	May 16, 1988
EQ 500MG BASE	N050614	002	Oct 29, 1987

CEPHALOGLYCIN

## CAPSULE; ORAL

## KAFOCIN

## LILLY

250MG	N050219	001	
-------	---------	-----	--

CEPHALOTHIN SODIUM

## INJECTABLE; INJECTION

## CEPHALOTHIN

## INTL MEDICATION

EQ 500MG BASE/VIAL

A062426 001 May 03, 1985

## DISCONTINUED DRUG PRODUCT LIST

6 - 62 (of 324)

CEPHALOTHIN SODIUM

## INJECTABLE; INJECTION

## CEPHALOTHIN

INTL MEDICATION	EQ 1GM BASE/VIAL	A062426 002	May 03, 1985
	EQ 2GM BASE/VIAL	A062426 003	May 03, 1985
	EQ 4GM BASE/VIAL	A062426 004	May 03, 1985

## CEPHALOTHIN SODIUM

## ABBOTT

EQ 1GM BASE/VIAL	A062547 001	Sep 11, 1985
EQ 1GM BASE/VIAL	A062548 001	Sep 11, 1985
EQ 2GM BASE/VIAL	A062547 002	Sep 11, 1985
EQ 2GM BASE/VIAL	A062548 002	Sep 11, 1985

## ABRAXIS PHARM

EQ 1GM BASE/VIAL	A062666 002	Jun 10, 1987
EQ 2GM BASE/VIAL	A062666 001	Jun 10, 1987

## BRISTOL

EQ 1GM BASE/VIAL	A062464 001	May 07, 1984
EQ 2GM BASE/VIAL	A062464 002	May 07, 1984
EQ 4GM BASE/VIAL	A062464 003	May 07, 1984

## CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

## BAXTER HLTHCARE

EQ 20MG BASE/ML	A062422 003	Jan 31, 1984
EQ 20MG BASE/ML	A062422 005	Jul 16, 1991
EQ 20MG BASE/ML	A062730 001	Mar 05, 1987
EQ 40MG BASE/ML	A062422 004	Jan 31, 1984
EQ 40MG BASE/ML	A062422 006	Jul 16, 1991
EQ 40MG BASE/ML	A062730 002	Mar 05, 1987

## CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

## BAXTER HLTHCARE

EQ 20MG BASE/ML	A062422 001	Jan 31, 1984
EQ 40MG BASE/ML	A062422 002	Jan 31, 1984

## KEFLIN

## LILLY

EQ 1GM BASE/VIAL	N050482 001
EQ 2GM BASE/VIAL	N050482 002
EQ 4GM BASE/VIAL	N050482 003
EQ 20GM BASE/VIAL	N050482 007

## KEFLIN IN PLASTIC CONTAINER

## LILLY

EQ 1GM BASE/VIAL	A062549 001	Sep 10, 1985
EQ 2GM BASE/VIAL	A062549 002	Sep 10, 1985

## SEFFIN

## GLAXOSMITHKLINE

EQ 1GM BASE/VIAL	A062435 001	Nov 15, 1983
EQ 2GM BASE/VIAL	A062435 002	Nov 15, 1983
EQ 10GM BASE/VIAL	A062435 003	Nov 15, 1983

CEPHAPIRIN SODIUM

## INJECTABLE; INJECTION

## CEFADYL

## APOTHECON

EQ 500MG BASE/VIAL	A062961 001	Sep 20, 1988
EQ 500MG BASE/VIAL	N050446 005	
EQ 1GM BASE/VIAL	A061769 001	
EQ 1GM BASE/VIAL	A062724 001	Dec 23, 1986
EQ 1GM BASE/VIAL	A062961 002	Sep 20, 1988
EQ 1GM BASE/VIAL	N050446 001	
EQ 2GM BASE/VIAL	A061769 002	
EQ 2GM BASE/VIAL	A062724 002	Dec 23, 1986
EQ 2GM BASE/VIAL	A062961 003	Sep 20, 1988
EQ 2GM BASE/VIAL	N050446 002	
EQ 4GM BASE/VIAL	A061769 003	
EQ 4GM BASE/VIAL	A062961 004	Sep 20, 1988
EQ 4GM BASE/VIAL	N050446 003	
EQ 20GM BASE/VIAL	N050446 004	

## CEPHAPIRIN SODIUM

## ABRAXIS PHARM

EQ 500MG BASE/VIAL	A062723 001	Nov 17, 1986
EQ 1GM BASE/VIAL	A062723 002	Nov 17, 1986
EQ 2GM BASE/VIAL	A062723 003	Nov 17, 1986
EQ 4GM BASE/VIAL	A062723 004	Nov 17, 1986
EQ 20GM BASE/VIAL	A062723 005	Nov 17, 1986

## BAXTER HLTHCARE

EQ 500MG BASE/VIAL	A062720 001	Jul 02, 1987
EQ 1GM BASE/VIAL	A062720 002	Jul 02, 1987



## DISCONTINUED DRUG PRODUCT LIST

6 - 63 (of 324)

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEPHAPIRIN SODIUM

BAXTER HLTHCARE	EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987
	EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987

CEPHRADINE

CAPSULE; ORAL

ANSPOR

GLAXOSMITHKLINE	250MG	A061859	001	
	500MG	A061859	002	

CEPHRADINE

BARR	250MG	A062850	001	Apr 22, 1988
	500MG	A062851	001	Apr 22, 1988
IVAX SUB TEVA PHARMS	250MG	A062762	001	Mar 06, 1987
	500MG	A062762	002	Mar 06, 1987
TEVA	250MG	A062683	001	Jan 09, 1987
	500MG	A062683	002	Jan 09, 1987
VITARINE	250MG	A062813	001	Feb 25, 1988
	500MG	A062813	002	Feb 25, 1988

VELOSEF

APOTHECON	250MG	A061764	001	
	500MG	A061764	002	

VELOSEF '250'

ERSANA	250MG	N050548	001	
--------	-------	---------	-----	--

VELOSEF '500'

ERSANA	500MG	N050548	002	
--------	-------	---------	-----	--

FOR SUSPENSION; ORAL

ANSPOR

GLAXOSMITHKLINE	125MG/5ML	A061866	001	
	250MG/5ML	A061866	002	

CEPHRADINE

BARR	125MG/5ML	A062858	001	May 19, 1988
	250MG/5ML	A062859	001	May 19, 1988
TEVA	125MG/5ML	A062693	001	Jan 09, 1987
	250MG/5ML	A062693	002	Jan 09, 1987

VELOSEF '125'

APOTHECON	125MG/5ML	A061763	001	
-----------	-----------	---------	-----	--

VELOSEF '250'

APOTHECON	250MG/5ML	A061763	002	
-----------	-----------	---------	-----	--

INJECTABLE; INJECTION

VELOSEF

APOTHECON	250MG/VIAL	A061976	001	
	500MG/VIAL	A061976	002	
	1GM/VIAL	A061976	004	
	2GM/VIAL	A061976	003	
	4GM/VIAL	A061976	005	

TABLET; ORAL

VELOSEF

BRISTOL MYERS SQUIBB	1GM	N050530	001	
----------------------	-----	---------	-----	--

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

BAYER PHARMS	0.05MG	N020740	001	Jun 26, 1997
	0.1MG	N020740	002	Jun 26, 1997
	0.2MG	N020740	003	Jun 26, 1997
	0.3MG	N020740	004	Jun 26, 1997
	0.4MG	N020740	005	May 24, 1999
	0.8MG	N020740	006	Jul 24, 2000

## DISCONTINUED DRUG PRODUCT LIST

6 - 64 (of 324)

CERULETIDE DIETHYLAMINEINJECTABLE; INJECTION  
TYMTRAN

PHARMACIA AND UPJOHN 0.02MG/ML N018296 001

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOLFOR SUSPENSION; INTRATRACHEAL  
EXOSURF NEONATAL

GLAXOSMITHKLINE 12MG/VIAL;108MG/VIAL;8MG/VIAL N020044 001 Aug 02, 1990

CHENODIOLTABLET; ORAL  
CHENIX

SIGMA TAU 250MG N018513 002 Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDESYRUP; ORAL  
ULO

3M 25MG/5ML N012126 001

CHLORAMPHENICOLCAPSULE; ORAL  
AMPHICOLFERRANTE 100MG A060058 001  
250MG A060058 002

CHLORAMPHENICOL

IVAX SUB TEVA PHARMS 250MG A062247 001

CHLOROMYCETIN

PARKEDALE 50MG A060591 001  
100MG A060591 003  
250MG A060591 002

MYCHEL

ARMENPHARM 250MG A060851 001

CREAM; TOPICAL  
CHLOROMYCETIN

PARKE DAVIS 1% N050183 001

FOR SOLUTION; OPHTHALMIC  
CHLOROMYCETIN

PARKEDALE 25MG/VIAL N050143 001

INJECTABLE; INJECTION  
CHLOROMYCETIN

PARKE DAVIS 250MG/ML N050153 001

OINTMENT; OPHTHALMIC  
CHLORAMPHENICOL

ALTANA 1% A060133 001

CHLOROFAIR

PHARMAFAIR 1% A062439 001 Apr 21, 1983

CHLOROMYCETIN

PARKEDALE 1% N050156 001

CHLOROPTIC S.O.P.

ALLERGAN 1% A061187 001

ECONOCHLOR

ALCON 1% A061648 001

SOLUTION/DROPS; OPHTHALMIC  
CHLORAMPHENICOL

AKORN 0.5% A062042 001

ALCON 0.5% A062628 001 Sep 25, 1985

CHLOROFAIR

PHARMAFAIR 0.5% A062437 001 Apr 14, 1983

CHLOROPTIC

ALLERGAN 0.5% N050091 001

ECONOCHLOR

ALCON 0.5% A061645 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 65 (of 324)

CHLORAMPHENICOL

SOLUTION/DROPS; OPHTHALMIC

OPHTHOCHLOR

PARKEDALE 0.5% A061220 001

OPTOMYCIN

OPTOPICS 0.5% A062171 001 Mar 31, 1982

SOLUTION/DROPS; OTIC

CHLOROMYCETIN

PARKEDALE 0.5% N050205 001

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL

CHLOROMYCETIN PALMITATE

PARKE DAVIS EQ 150MG BASE/5ML A062301 001

EQ 150MG BASE/5ML N050152 001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL

ELKINS SINN EQ 1GM BASE/VIAL A062406 001 Nov 09, 1982

CHLORAMPHENICOL SODIUM SUCCINATE

GRUPPO LEPETIT EQ 1GM BASE/VIAL A062278 001

CHLOROMYCETIN

PARKEDALE EQ 1GM BASE/VIAL N050155 001

MYCHEL-S

ANGUS EQ 1GM BASE/VIAL A060132 001

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL

ELASE-CHLOROMYCETIN

PARKE DAVIS 10MG/GM;666 UNITS/GM;1 UNITS/GM N050294 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

PARKEDALE 12.5MG/VIAL;25MG/VIAL N050202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

OPHTHOCORT

PARKEDALE 10MG/GM;5MG/GM;10,000 UNITS/GM N050201 002

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CHLOROMYXIN

PARKE DAVIS 1%;10,000 UNITS/GM N050203 002

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT; OPHTHALMIC

CHLOROPTIC-P S.O.P.

ALLERGAN 1%;0.5% A061188 001

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE; ORAL

LIBRELEASE

VALEANT PHARM INTL 30MG N017813 001 Sep 12, 1983

TABLET; ORAL

LIBRITABS

VALEANT PHARM INTL 5MG A085482 001

10MG A085481 001

25MG A085488 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 66 (of 324)

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

A-POXIDE

ABBOTT

5MG

A085447 001

5MG

A085517 001

10MG

A085447 002

10MG

A085518 001

25MG

A085447 003

25MG

A085513 001

CHLORDIAZACHEL

RACHELLE

5MG

A085086 001

10MG

A084639 001

25MG

A085087 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

ASCOT

5MG

A087525 001

Jan 07, 1982

10MG

A087524 001

Jan 07, 1982

25MG

A087512 001

Jan 07, 1982

FERRANTE

5MG

A085118 001

10MG

A085119 001

25MG

A085120 001

HALSEY

5MG

A085340 001

10MG

A085339 001

25MG

A084685 001

IMPAX LABS

5MG

A086213 001

10MG

A085113 001

25MG

A086212 001

IVAX SUB TEVA PHARMS

5MG

A083741 001

10MG

A083742 001

25MG

A083570 001

LEDERLE

5MG

A086892 001

5MG

A087234 001

10MG

A086876 001

10MG

A087037 001

25MG

A086893 001

25MG

A087231 001

MAST MM

10MG

A086217 001

MYLAN

5MG

A084886 001

10MG

A084601 001

25MG

A084887 001

PARKE DAVIS

5MG

A085163 001

10MG

A084598 001

25MG

A085164 001

PIONEER PHARMS

10MG

A089533 001

Jul 15, 1988

25MG

A089558 001

Jul 15, 1988

PUREPAC PHARM

5MG

A085155 001

10MG

A084939 002

25MG

A085144 001

ROXANE

5MG

A084706 001

10MG

A084700 001

25MG

A084705 001

SANDOZ

5MG

A084678 001

5MG

A084919 001

10MG

A084041 001

10MG

A084920 001

25MG

A084679 002

25MG

A084823 001

SUPERPHARM

5MG

A088987 001

Apr 25, 1985

10MG

A088986 001

Apr 25, 1985

25MG

A088988 001

Apr 25, 1985

TEVA

5MG

A088705 001

Jan 18, 1985

10MG

A088706 001

Jan 18, 1985

25MG

A086494 001

25MG

A088707 001

Jan 18, 1985

USL PHARMA

5MG

A084644 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 67 (of 324)

CHLORDIAZEPOXIDE HYDROCHLORIDE

## CAPSULE; ORAL

## CHLORDIAZEPOXIDE HYDROCHLORIDE

USL PHARMA	25MG	A084645	001	
VANGARD	5MG	A088129	001	Mar 28, 1983
	10MG	A088010	001	Mar 28, 1983
	25MG	A088130	001	Mar 28, 1983
WEST WARD	5MG	A085014	001	
	10MG	A085000	001	
	25MG	A085294	001	

## LIBRIUM

VALEANT PHARM INTL	5MG	N012249	002	
	10MG	N012249	001	
	25MG	N012249	003	

## LYGEN

ALRA	5MG	A085107	001	
	10MG	A085009	001	
	25MG	A085108	001	

## INJECTABLE; INJECTION

## LIBRIUM

VALEANT PHARM INTL	100MG/AMP	N012301	001	
--------------------	-----------	---------	-----	--

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

## TABLET; ORAL

MENRIUM 10-4				
ROCHE	10MG;0.4MG	N014740	006	
MENRIUM 5-2				
ROCHE	5MG;0.2MG	N014740	002	
MENRIUM 5-4				
ROCHE	5MG;0.4MG	N014740	004	

CHLORHEXIDINE GLUCONATE

## SOLUTION; TOPICAL

## EXIDINE

XTTRIUM	2.5%	N019421	001	Dec 17, 1985
MICRODERM				
J AND J	4%	A072255	001	Apr 15, 1991
PREVACARE R				
J AND J	0.5%	A072292	001	Jan 28, 1992
STERI-STAT				
MATRIX MEDCL	4%	A070104	001	Jul 24, 1986

## SPONGE; TOPICAL

## CHLORHEXIDINE GLUCONATE

KENDALL IL	4%	N019490	001	Mar 27, 1987
E-Z SCRUB				
BECTON DICKINSON	4%	A073416	001	Mar 14, 2000
HIBICLENS				
MOLNLYCKE HLTH	4%	N018423	001	
MICRODERM				
J AND J	4%	A072295	001	Feb 28, 1991

CHLORMERODRIN, HG-197

## INJECTABLE; INJECTION

## CHLORMERODRIN HG 197

BRACCO	0.6-1.4mCi/ML	N017269	001	
--------	---------------	---------	-----	--

CHLORMEZANONE

## TABLET; ORAL

## TRANCOPAL

SANOFI AVENTIS US	100MG	N011467	003	
	200MG	N011467	005	

## DISCONTINUED DRUG PRODUCT LIST

6 - 68 (of 324)

CHLOROPROCAINE HYDROCHLORIDEINJECTABLE; INJECTION  
NESACAINE-MPF

APP PHARMS	2%	N009435	003	
	3%	N009435	004	

CHLOROQUINE HYDROCHLORIDEINJECTABLE; INJECTION  
ARALEN HYDROCHLORIDE

SANOFI AVENTIS US	EQ 40MG BASE/ML	N006002	002	
-------------------	-----------------	---------	-----	--

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

MD PHARM	EQ 150MG BASE	A087228	001	
PUREPAC PHARM	EQ 150MG BASE	A080886	001	
TEVA	EQ 150MG BASE	A087504	001	Jan 13, 1982
WATSON LABS	EQ 150MG BASE	A087979	001	Dec 21, 1982
	EQ 300MG BASE	A088030	001	Dec 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET; ORAL

ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE

SANOFI AVENTIS US	EQ 300MG BASE;EQ 45MG BASE	N014860	002	
-------------------	----------------------------	---------	-----	--

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

ABC HOLDING	250MG	A085569	001	
LEDERLE	250MG	A086940	001	
	500MG	A086938	001	
SANDOZ	250MG	A085485	001	
WATSON LABS	250MG	A085165	001	
	250MG	A085173	001	
	250MG	A086795	001	Aug 15, 1983
	500MG	A084026	001	Sep 01, 1982
	500MG	A086796	001	Aug 15, 1983
DIURIL				
LUNDBECK INC	250MG	N011145	004	
	500MG	N011145	002	

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

MERCK	150MG; 250MG	N016016	001	
-------	--------------	---------	-----	--

ALDOCLOR-250

MERCK	250MG; 250MG	N016016	002	
-------	--------------	---------	-----	--

METHYLDOPA AND CHLOROTHIAZIDE

PAR PHARM	150MG; 250MG	A070783	001	Nov 06, 1987
	250MG; 250MG	A070654	001	Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE AND RESERPINE

WEST WARD	250MG; 0.125MG	A088557	001	Dec 22, 1983
	500MG; 0.125MG	A088365	001	Dec 22, 1983

CHLOROTHIAZIDE W/ RESERPINE

WATSON LABS	250MG; 0.125MG	A084853	001	
	500MG; 0.125MG	A088151	001	Jun 09, 1983

CHLOROTHIAZIDE-RESERPINE

MYLAN	250MG; 0.125MG	A087744	001	May 06, 1982
	500MG; 0.125MG	A087745	001	May 06, 1982

## DISCONTINUED DRUG PRODUCT LIST

6 - 69 (of 324)

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

DIUPRES-250

MERCK

250MG;0.125MG

N011635 003

Aug 26, 1987

DIUPRES-500

MERCK

500MG;0.125MG

N011635 006

Aug 26, 1987

CHLOROTRIANISENE

CAPSULE; ORAL

CHLOROTRIANISENE

BANNER PHARMACAPS

12MG

A084652 001

TACE

SANOFI AVENTIS US

12MG

N008102 004

25MG

N011444 001

72MG

N016235 001

CHLOROXINE

SHAMPOO; TOPICAL

CAPITROL

WESTWOOD SQUIBB

2%

N017594 001

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

PHARMACIA AND UPJOHN

400MG

N014217 002

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

SANDOZ

12MG

A070797 001

Aug 12, 1988

TELDRIN

GLAXOSMITHKLINE

8MG

N017369 001

12MG

N017369 002

INJECTABLE; INJECTION

CHLORPHENIRAMINE MALEATE

BEL MAR

10MG/ML

A080821 001

ELKINS SINN

10MG/ML

A080797 001

WATSON LABS

10MG/ML

A083593 001

10MG/ML

A086096 001

100MG/ML

A086095 001

CHLOR-TRIMETON

SCHERING PLOUGH

10MG/ML

N008826 001

100MG/ML

N008794 001

PYRIDAMAL 100

BEL MAR

100MG/ML

A083733 001

SYRUP; ORAL

CHLORPHENIRAMINE MALEATE

PHARM ASSOC

2MG/5ML

A087520 001

Feb 10, 1982

CHLOR-TRIMETON

SCHERING

2MG/5ML

N006921 006

TABLET; ORAL

ANTAGONATE

BAYER PHARMS

4MG

A083381 001

CHLORPHENIRAMINE MALEATE

ANABOLIC

4MG

A083078 001

BELL PHARMA

4MG

A083062 001

ELKINS SINN

4MG

A080938 001

IMPAX LABS

4MG

A080809 001

IVAX SUB TEVA PHARMS

4MG

A080779 001

KV PHARM

4MG

A087164 001

LEDERLE

4MG

A086941 001

MUTUAL PHARM

4MG

A080700 001

NEWTRON PHARMS

4MG

A086519 001

PANRAY

4MG

A083243 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 70 (of 324)

CHLORPHENIRAMINE MALEATE

## TABLET; ORAL

## CHLORPHENIRAMINE MALEATE

PHARMAVITE	4MG	A085104	001	
PHARMERAL	4MG	A083753	001	
PIONEER PHARMS	4MG	A088556	001	Jul 13, 1984
PUREPAC PHARM	4MG	A086306	001	
PVT FORM	4MG	A080786	001	
ROXANE	4MG	A080626	001	
SANDOZ	4MG	A080961	001	
VITARINE	4MG	A085837	001	
WATSON LABS	4MG	A080696	001	
	4MG	A080791	001	
	4MG	A085139	001	
WEST WARD	4MG	A083787	001	

## CHLOR-TRIMETON

SCHERING	4MG	N006921	002	
----------	-----	---------	-----	--

## KLOROMIN

HALSEY	4MG	A083629	001	
--------	-----	---------	-----	--

## PHENETRON

LANNETT	4MG	A080846	001	
---------	-----	---------	-----	--

## TABLET, EXTENDED RELEASE; ORAL

## CHLOR-TRIMETON

SCHERING PLOUGH	8MG	N007638	001	
-----------------	-----	---------	-----	--

## EFIDAC 24 CHLORPHENIRAMINE MALEATE

ALZA	16MG	N019746	002	Nov 18, 1994
------	------	---------	-----	--------------

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HYDROCHLORIDE

WATSON LABS	12MG;75MG	A088681	001	Sep 29, 1987
-------------	-----------	---------	-----	--------------

## CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HYDROCHLORIDE

SANDOZ	12MG;75MG	A088940	001	Jan 26, 1989
--------	-----------	---------	-----	--------------

## COLD CAPSULE IV

GRAHAM DM	12MG;75MG	N018793	001	Apr 25, 1985
-----------	-----------	---------	-----	--------------

## COLD CAPSULE V

GRAHAM DM	8MG;75MG	N018794	001	Apr 23, 1985
-----------	----------	---------	-----	--------------

## CONTAC 12 HOUR

GLAXOSMITHKLINE	8MG;75MG	N018099	001	
-----------------	----------	---------	-----	--

## DRIZE

ASCHER	12MG;75MG	A088359	001	Feb 13, 1986
--------	-----------	---------	-----	--------------

## ORNADE

GLAXOSMITHKLINE	12MG;75MG	N012152	004	
-----------------	-----------	---------	-----	--

## PHENYLPROPANOLAMINE HYDROCHLORIDE W/ CHLORPHENIRAMINE MALEATE

CENT PHARMS	8MG;75MG	N018809	001	May 07, 1984
-------------	----------	---------	-----	--------------

## TABLET, EXTENDED RELEASE; ORAL

## CONTAC

NOVARTIS	12MG;75MG	N019613	001	Jun 13, 1986
----------	-----------	---------	-----	--------------

## DEMAZIN

SCHERING PLOUGH	4MG;25MG	N018556	001	May 14, 1984
-----------------	----------	---------	-----	--------------

## TRIAMINIC-12

NOVARTIS	12MG;75MG	N018115	001	
----------	-----------	---------	-----	--

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## CODIMAL-L.A. 12

SCHWARZ PHARMA	12MG;120MG	N018935	001	Apr 15, 1985
----------------	------------	---------	-----	--------------

## ISOCLOR

FISONS	8MG;120MG	N018747	001	Mar 06, 1986
--------	-----------	---------	-----	--------------

## PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE

CENT PHARMS	8MG;120MG	N019428	001	Aug 02, 1988
-------------	-----------	---------	-----	--------------

GRAHAM DM	8MG;120MG	N018844	001	Mar 20, 1985
-----------	-----------	---------	-----	--------------

	12MG;120MG	N018843	001	Mar 18, 1985
--	------------	---------	-----	--------------

KV PHARM	12MG;120MG	A071455	001	Mar 01, 1989
----------	------------	---------	-----	--------------



## DISCONTINUED DRUG PRODUCT LIST

6 - 71 (of 324)

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

UCB INC EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML N021369 001 Jun 21, 2004

PENNTUSS

FISONS EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML N018928 001 Aug 14, 1985

CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CORSYM

UCB INC EQ 4MG MALEATE/5ML;EQ 37.5MG HCL/5ML N018050 001 Jan 04, 1984

CHLORPHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PRE-SATE

PARKE DAVIS EQ 65MG BASE N014696 001

CHLORPROMAZINE

SUPPOSITORY; RECTAL

THORAZINE

GLAXOSMITHKLINE 25MG N009149 024

100MG N009149 033

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

THORAZINE

GLAXOSMITHKLINE 30MG N011120 016

75MG N011120 017

150MG N011120 018

200MG N011120 019

300MG N011120 020

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC 100MG/ML A086863 001

MORTON GROVE 30MG/ML A087032 001 Jul 08, 1982

100MG/ML A087053 001

PHARM ASSOC 30MG/ML A040231 001 Dec 30, 1999

100MG/ML A040224 001 Jan 26, 1999

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

ROXANE 30MG/ML A088157 001 Apr 27, 1983

100MG/ML A088158 001 Apr 27, 1983

SONAZINE

SANDOZ 30MG/ML A080983 004

100MG/ML A080983 005

THORAZINE

GLAXOSMITHKLINE 30MG/ML N009149 032

100MG/ML N009149 043

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

ABRAXIS PHARM 25MG/ML A084911 001

MARSAM PHARMS LLC 25MG/ML A089563 001 Apr 15, 1988

WATSON LABS 25MG/ML A080365 001

25MG/ML A085591 001

WYETH AYERST 25MG/ML A080370 001

THORAZINE

GLAXOSMITHKLINE 25MG/ML N009149 011

SYRUP; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ALPHARMA US PHARMS 10MG/5ML A086712 001

SONAZINE

SANDOZ 10MG/5ML A083040 001

THORAZINE

GLAXOSMITHKLINE 10MG/5ML N009149 022

## DISCONTINUED DRUG PRODUCT LIST

6 - 72 (of 324)

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ABBOTT	10MG	A084414	001	
	25MG	A084415	001	
	50MG	A084411	001	
	100MG	A084412	001	
	200MG	A084413	001	
IVAX SUB TEVA PHARMS	10MG	A083549	001	
	25MG	A083549	002	
	50MG	A083549	003	
	100MG	A083574	001	
	200MG	A083575	001	
KV PHARM	10MG	A085750	002	Jan 04, 1982
	25MG	A085751	001	
	50MG	A085484	001	
	100MG	A085752	001	
	200MG	A085748	002	Jan 04, 1982
LEDERLE	10MG	A084803	001	
	25MG	A084801	001	
	50MG	A084800	001	
	100MG	A084789	001	
	200MG	A084802	001	
PUREPAC PHARM	10MG	A080403	004	
	25MG	A080403	001	
	50MG	A080403	002	
	100MG	A080403	003	
	200MG	A080403	005	
PVT FORM	25MG	A080340	001	
	50MG	A080340	002	
	200MG	A080340	003	
ROXANE	10MG	A085331	001	
	25MG	A085331	002	
	50MG	A085331	003	
	100MG	A085331	004	
	200MG	A085331	005	
VANGARD	10MG	A088038	001	Aug 16, 1982
	25MG	A087645	001	
	50MG	A087646	001	
WATSON LABS	10MG	A085959	001	
	25MG	A085956	001	
	50MG	A085960	001	
	100MG	A085957	001	
	200MG	A085958	001	
WEST WARD	10MG	A087783	001	Sep 16, 1982
	25MG	A087865	001	Sep 16, 1982
	50MG	A087878	001	Sep 15, 1982
	100MG	A087884	001	Sep 15, 1982
	200MG	A087880	001	Sep 16, 1982
PROMAPAR				
PARKE DAVIS	10MG	A086886	001	
	25MG	A084423	001	
	50MG	A086887	001	
	100MG	A086888	001	
	200MG	A086885	001	
THORAZINE				
GLAXOSMITHKLINE	10MG	N009149	002	
	25MG	N009149	007	
	50MG	N009149	013	
	100MG	N009149	018	
	200MG	N009149	020	

## DISCONTINUED DRUG PRODUCT LIST

6 - 73 (of 324)

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

BARR	100MG	A088812	001	Oct 19, 1984
	100MG	A089446	001	Nov 17, 1986
	250MG	A088813	001	Oct 19, 1984
	250MG	A089447	001	Nov 17, 1986
CLONMEL HLTHCARE	100MG	A089561	001	Sep 04, 1987
	250MG	A089562	001	Sep 04, 1987
DURAMED PHARMS BARR	100MG	A088918	001	Oct 16, 1984
	250MG	A088919	001	Oct 16, 1984
HALSEY	100MG	A089321	001	Jan 16, 1986
	250MG	A088662	001	Jan 09, 1986
IVAX PHARMS	100MG	A088840	001	Oct 25, 1984
	250MG	A087353	001	
PAR PHARM	100MG	A088175	001	Feb 27, 1984
	250MG	A088176	001	Feb 27, 1984
SANDOZ	100MG	A088725	001	Aug 31, 1984
	250MG	A084669	001	
	250MG	A088726	001	Aug 31, 1984
SUPERPHARM	100MG	A088694	001	Sep 17, 1984
	250MG	A088695	001	Sep 17, 1984
TEVA	100MG	A088768	001	Oct 11, 1984
USL PHARMA	100MG	A088708	001	Aug 30, 1984
	250MG	A088709	001	Aug 30, 1984
WATSON LABS	100MG	A086865	001	Sep 24, 1984
	100MG	A088608	001	Apr 12, 1984
	250MG	A086866	001	
	250MG	A088568	001	Apr 12, 1984
GLUCAMIDE				
TEVA	250MG	A088641	001	Oct 11, 1984

CHLORPROTHIXENE

CONCENTRATE; ORAL

TARACTAN

ROCHE 100MG/5ML

N016149 002

INJECTABLE; INJECTION

TARACTAN

ROCHE 12.5MG/ML

N012487 001

TABLET; ORAL

TARACTAN

ROCHE 10MG

N012486 005

25MG

N012486 004

50MG

N012486 003

100MG

N012486 001

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

LEDERLE 1%

N050404 001

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

ABBOTT 25MG

A087364 001

50MG

A087384 001

ASCOT 25MG

A087698 001 Oct 20, 1982

50MG

A087699 001 Oct 20, 1982

CLONMEL HLTHCARE 25MG

A087451 001

50MG

A087450 001

IVAX PHARMS 25MG

A087555 001

25MG

A088164 001 Jan 09, 1984

50MG

A087176 001

50MG

A087947 001 Feb 27, 1984

## DISCONTINUED DRUG PRODUCT LIST

6 - 74 (of 324)

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

KV PHARM	25MG	A087311	001	
	50MG	A087312	001	
MUTUAL PHARM	25MG	A087292	001	
	25MG	A089285	001	Jul 21, 1986
	25MG	A089738	001	Sep 19, 1988
	50MG	A087293	001	
	50MG	A089286	001	Jul 21, 1986
	50MG	A089739	001	Sep 19, 1988
PIONEER PHARMS	50MG	A089591	001	Jul 21, 1988
PUREPAC PHARM	25MG	A088139	001	Jul 16, 1986
	50MG	A088140	001	Aug 11, 1983
SANDOZ	25MG	A087380	001	
	50MG	A087118	001	
	50MG	A087381	001	
SUPERPHARM	25MG	A087473	001	Feb 09, 1983
	50MG	A087247	001	Feb 09, 1983
TEVA	50MG	A088651	001	May 30, 1985
USL PHARMA	25MG	A089051	001	Jun 01, 1987
	50MG	A089052	001	Jun 01, 1987
VANGARD	25MG	A088012	001	Jul 14, 1982
	50MG	A088073	001	Mar 25, 1983
WARNER CHILCOTT	25MG	A087515	001	Jan 24, 1983
	50MG	A087516	001	Feb 09, 1983
WATSON LABS	25MG	A087050	001	
	25MG	A087100	001	
	25MG	A087296	001	
	25MG	A087706	001	
	50MG	A087029	001	
	50MG	A087082	001	
	50MG	A087521	001	
	50MG	A087689	001	
HYGROTON				
SANOFI AVENTIS US	25MG	N012283	004	
	50MG	N012283	003	
THALITONE				
MONARCH PHARMS	25MG	A088051	001	Nov 12, 1982
	25MG	N019574	002	Feb 12, 1992

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM	15MG;0.1MG	A071179	001	Dec 16, 1987
	15MG;0.2MG	A071178	001	Dec 16, 1987
	15MG;0.3MG	A071142	001	Dec 16, 1987
COMBIPRES				
BOEHRINGER INGELHEIM	15MG;0.1MG	N017503	001	
	15MG;0.2MG	N017503	002	
	15MG;0.3MG	N017503	003	Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL

LOPRESSIDONE

NOVARTIS	25MG;100MG	N019451	001	Dec 31, 1987
	25MG;200MG	N019451	002	Dec 31, 1987

CHLORTHALIDONE; RESERPINE

TABLET; ORAL

DEMI-REGROTON

SANOFI AVENTIS US	25MG;0.125MG	N015103	002	
-------------------	--------------	---------	-----	--

REGROTON

SANOFI AVENTIS US	50MG;0.25MG	N015103	001	
-------------------	-------------	---------	-----	--

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 516 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 75 (of 324)

CHLORZOXAZONE

## TABLET; ORAL

## CHLORZOXAZONE

MUTUAL PHARM	500MG	A089970	001	Sep 27, 1990
PAR PHARM	250MG	A087981	001	Sep 20, 1983
PIONEER PHARMS	250MG	A089592	001	Jan 06, 1989
	500MG	A089948	001	Jan 06, 1989
SANDOZ	250MG	A089852	001	May 04, 1988
	500MG	A089853	001	May 04, 1988
WATSON LABS	250MG	A086901	001	
	250MG	A086948	001	Aug 09, 1982
	500MG	A081019	001	Jul 29, 1991
PARAFLEX				
ORTHO MCNEIL PHARM	250MG	N011300	003	
STRIFON FORTE DSC				
FERNDAL LABS	500MG	A081008	001	Dec 23, 1988

CHOLESTYRAMINE

## BAR, CHEWABLE; ORAL

## CHOLYBAR

PARKE DAVIS	EQ 4GM RESIN/BAR	A071621	001	May 26, 1988
	EQ 4GM RESIN/BAR	A071739	001	May 26, 1988

## POWDER; ORAL

## CHOLESTYRAMINE

IVAX SUB TEVA PHARMS	EQ 4GM RESIN/PACKET	A074771	001	Jul 09, 1997
	EQ 4GM RESIN/SCOOPFUL	A074771	002	Jul 09, 1997
TEVA	EQ 4GM RESIN/PACKET	A074347	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074347	002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996
	EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996
CHOLESTYRAMINE LIGHT				
TEVA	EQ 4GM RESIN/PACKET	A074348	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074348	002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074555	001	Sep 30, 1998
	EQ 4GM RESIN/SCOOPFUL	A074555	002	Sep 30, 1998

## TABLET; ORAL

## QUESTRAN

APOTHECON	EQ 800MG RESIN	A073403	002	Dec 27, 1999
	EQ 1GM RESIN	A073403	001	Apr 28, 1994

CHORIOGONADOTROPIN ALFA

## INJECTABLE; INJECTION

## OVIDREL

EMD SERONO	0.25MG/VIAL	N021149	001	Sep 20, 2000
------------	-------------	---------	-----	--------------

CHROMIC CHLORIDE

## INJECTABLE; INJECTION

## CHROMIC CHLORIDE

ABRAXIS PHARM	EQ 0.004MG CHROMIUM/ML	N019271	001	May 05, 1987
---------------	------------------------	---------	-----	--------------

CHROMIC PHOSPHATE P-32

## INJECTABLE; INJECTION

## PHOSPHOCOL P32

MALLINCKRODT	5mCi/ML	N017084	001	
--------------	---------	---------	-----	--

CHYMOPAPAIN

## INJECTABLE; INJECTION

## CHYMODIACTIN

CHART MEDCL	4,000 UNITS/VIAL	N018663	002	Aug 21, 1984
	10,000 UNITS/VIAL	N018663	001	Nov 10, 1982
DISCASE				
ABBOTT	12,500 UNITS/VIAL	N018625	001	Jan 18, 1984

## DISCONTINUED DRUG PRODUCT LIST

6 - 76 (of 324)

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC

ALPHA CHYMAR

SOLA BARNES HIND 750 UNITS/VIAL N011837 001

CATARASE

CIBA 300 UNITS/VIAL N016938 001

NOVARTIS 150 UNITS/VIAL N018121 001

ZOLYSE

ALCON 750 UNITS/VIAL N011903 001

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION

PRIMAXIN

MERCK EQ 750MG BASE/VIAL;750MG/VIAL N050630 002 Dec 14, 1990

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

MUTUAL PHARM 50MG A077208 002 Mar 29, 2006

100MG A077208 001 Mar 29, 2006

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200

GLAXOSMITHKLINE 200MG/20ML N020951 001 Jul 09, 1999

TABLET; ORAL

CIMETIDINE

APOTEX 100MG A074948 001 Jun 19, 1998

200MG A074948 002 Jul 26, 2002

ENDO PHARMS 200MG A074281 001 May 17, 1994

300MG A074281 002 May 17, 1994

400MG A074281 003 May 17, 1994

800MG A074329 001 May 17, 1994

IVAX SUB TEVA PHARMS 200MG A074401 001 May 30, 1995

300MG A074401 002 May 30, 1995

400MG A074401 003 May 30, 1995

800MG A074402 001 May 30, 1995

LEK PHARMS 100MG A075122 001 Jun 19, 1998

200MG A074250 001 Jun 29, 1995

200MG A075122 002 Jun 19, 1998

300MG A074250 002 Jun 29, 1995

400MG A074250 003 Jun 29, 1995

800MG A074250 004 Jun 29, 1995

PERRIGO 100MG A074972 001 Jun 19, 1998

ROXANE 300MG A074361 001 Dec 23, 1994

400MG A074361 002 Dec 23, 1994

800MG A074371 001 Dec 23, 1994

SANDOZ 200MG A074100 001 Jan 31, 1995

300MG A074100 002 Jan 31, 1995

400MG A074100 003 Jan 31, 1995

800MG A074100 004 Jan 31, 1995

TEVA 200MG A074365 001 Feb 28, 1995

300MG A074365 002 Feb 28, 1995

400MG A074365 003 Feb 28, 1995

800MG A074365 004 Feb 28, 1995

TAGAMET HB

GLAXOSMITHKLINE 100MG N020238 001 Jun 19, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

ENDO PHARMS EQ 300MG BASE/2ML A074005 001 Aug 31, 1994

HOSPIRA EQ 300MG BASE/2ML A074296 001 Mar 28, 1997

EQ 300MG BASE/2ML A074412 001 Mar 28, 1997

## DISCONTINUED DRUG PRODUCT LIST

6 - 77 (of 324)

CIMETIDINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## CIMETIDINE HYDROCHLORIDE

HOSPIRA EQ 300MG BASE/2ML A074422 001 Jan 31, 1995

LUITPOLD EQ 300MG BASE/2ML A074353 001 Dec 20, 1994

## CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA EQ 90MG BASE/100ML A074468 005 Dec 29, 1994

EQ 120MG BASE/100ML A074468 006 Dec 29, 1994

EQ 180MG BASE/100ML A074468 003 Dec 29, 1994

EQ 240MG BASE/100ML A074468 004 Dec 29, 1994

EQ 360MG BASE/100ML A074468 001 Dec 29, 1994

EQ 480MG BASE/100ML A074468 002 Dec 29, 1994

## TAGAMET

GLAXOSMITHKLINE EQ 300MG BASE/2ML N017939 002

## TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

GLAXOSMITHKLINE EQ 6MG BASE/ML N019434 001 Oct 31, 1985

## SOLUTION; ORAL

## CIMETIDINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC EQ 300MG BASE/5ML A074176 001 Jun 01, 1994

DURAMED PHARMS BARR EQ 300MG BASE/5ML A075110 001 Jun 18, 1998

ENDO PHARMS EQ 300MG BASE/5ML A074251 001 Dec 22, 1994

ROXANE EQ 300MG BASE/5ML A074541 001 Aug 05, 1997

TEVA PHARMS EQ 300MG BASE/5ML A074859 001 Jul 09, 1998

## TAGAMET

GLAXOSMITHKLINE EQ 300MG BASE/5ML N017924 001

CINOXACIN

## CAPSULE; ORAL

## CINOBAC

LILLY 250MG N018067 001

500MG N018067 002

## CINOXACIN

TEVA 250MG A073005 001 Feb 28, 1992

500MG A073006 001 Feb 28, 1992

CIPROFLOXACIN

## INJECTABLE; INJECTION

## CIPRO

BAYER HLTHCARE 1200MG/120ML (10MG/ML) N019847 003 Dec 26, 1990

## CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAYER PHARMS 200MG/100ML N019858 001 Dec 26, 1990

## CIPROFLOXACIN

APP PHARMS 200MG/20ML (10MG/ML) A076484 001 Aug 28, 2006

400MG/40ML (10MG/ML) A076484 002 Aug 28, 2006

BEDFORD LABS 200MG/20ML (10MG/ML) A076992 001 Aug 28, 2006

400MG/40ML (10MG/ML) A076992 002 Aug 28, 2006

1200MG/120ML (10MG/ML) A076993 001 Aug 28, 2006

## CIPROFLOXACIN IN DEXTROSE 5%

HIKMA FARMACEUTICA 200MG/100ML A076757 001 Apr 21, 2008

## CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

BEDFORD 200MG/100ML A078114 001 Mar 18, 2008

400MG/200ML A078114 002 Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

## TABLET; ORAL

## CIPROFLOXACIN HYDROCHLORIDE

BARR EQ 250MG BASE A074124 001 Jun 09, 2004

EQ 500MG BASE A074124 002 Jun 09, 2004

EQ 750MG BASE A074124 003 Jun 09, 2004

NOSTRUM LABS EQ 250MG BASE A076138 001 Jun 09, 2004

EQ 500MG BASE A076138 002 Jun 09, 2004

EQ 750MG BASE A076138 003 Jun 09, 2004

SANDOZ EQ 100MG BASE A075939 001 Mar 03, 2005

EQ 250MG BASE A075939 002 Jun 09, 2004

## DISCONTINUED DRUG PRODUCT LIST

6 - 78 (of 324)

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

SANDOZ	EQ 250MG BASE	A076593	002	Jun 09, 2004
	EQ 500MG BASE	A075939	003	Jun 09, 2004
	EQ 500MG BASE	A076593	003	Jun 09, 2004
	EQ 750MG BASE	A075939	004	Jun 09, 2004
	EQ 750MG BASE	A076593	004	Jun 09, 2004
TEVA	EQ 250MG BASE	A076136	001	Jun 09, 2004
	EQ 500MG BASE	A076136	002	Jun 09, 2004
	EQ 750MG BASE	A076136	003	Jun 09, 2004

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007
	425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007
SANDOZ	212.6MG;EQ 287.5MG BASE	A078712	001	Dec 11, 2007

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL

PROPULSID

ORTHO MCNEIL JANSSEN	EQ 1MG BASE/ML	N020398	001	Sep 15, 1995
----------------------	----------------	---------	-----	--------------

TABLET; ORAL

PROPULSID

ORTHO MCNEIL JANSSEN	EQ 10MG BASE	N020210	001	Jul 29, 1993
	EQ 20MG BASE	N020210	002	Dec 23, 1993

TABLET, ORALLY DISINTEGRATING; ORAL

PROPULSID QUICKSOLV

JANSSEN PHARMA	EQ 20MG BASE	N020767	001	Nov 07, 1997
----------------	--------------	---------	-----	--------------

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

BEDFORD	10MG/VIAL	A074713	001	Nov 14, 2000
	50MG/VIAL	A074713	002	Nov 14, 2000

PLATINOL-AQ

BRISTOL MYERS	0.5MG/ML	N018057	003	Jul 18, 1984
---------------	----------	---------	-----	--------------

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

APOTEX INC	EQ 10MG BASE/5ML	A077601	001	Nov 15, 2005
------------	------------------	---------	-----	--------------

TABLET; ORAL

CELEXA

FOREST LABS	EQ 60MG BASE	N020822	004	Jul 17, 1998
-------------	--------------	---------	-----	--------------

CITALOPRAM HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 10MG BASE	A077033	001	Oct 28, 2004
	EQ 20MG BASE	A077033	002	Oct 28, 2004
	EQ 40MG BASE	A077033	003	Oct 28, 2004
AMNEAL PHARMS	EQ 10MG BASE	A077045	003	Apr 29, 2005
	EQ 20MG BASE	A077045	002	Apr 29, 2005
	EQ 40MG BASE	A077045	001	Apr 29, 2005
MUTUAL PHARM	EQ 10MG BASE	A077052	001	Jul 03, 2006
	EQ 20MG BASE	A077052	002	Jul 03, 2006
	EQ 40MG BASE	A077052	003	Jul 03, 2006
ROXANE	EQ 10MG BASE	A077041	001	Nov 23, 2004
	EQ 20MG BASE	A077041	002	Nov 23, 2004
	EQ 40MG BASE	A077041	003	Nov 23, 2004
SANDOZ	EQ 10MG BASE	A077040	001	Aug 17, 2005
	EQ 20MG BASE	A077040	002	Aug 17, 2005
	EQ 40MG BASE	A077040	003	Aug 17, 2005
TARO	EQ 10MG BASE	A077278	001	Mar 22, 2006
	EQ 20MG BASE	A077278	002	Mar 22, 2006



## DISCONTINUED DRUG PRODUCT LIST

6 - 79 (of 324)

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

TARO	EQ 40MG BASE	A077278	003	Mar 22, 2006
TEVA PHARMS	EQ 10MG BASE	A077213	001	Mar 31, 2006
	EQ 20MG BASE	A077213	002	Mar 31, 2006
	EQ 40MG BASE	A077213	003	Mar 31, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

CITALOPRAM HYDROBROMIDE

BIOVAIL LABS INTL	EQ 10MG BASE	N021763	001	Dec 20, 2005
	EQ 20MG BASE	N021763	002	Dec 20, 2005
	EQ 40MG BASE	N021763	003	Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

IRRIGATING SOLUTION G IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.24GM/100ML;380MG/100ML;430MG/100ML	N018519	001	Jun 22, 1982
UROLOGIC G IN PLASTIC CONTAINER				
HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N018904	001	May 27, 1983

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

ABBOTT	187MG/5ML	N050698	003	Sep 30, 1998
--------	-----------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

RANBAXY	1GM	A065210	001	Jan 26, 2005
---------	-----	---------	-----	--------------

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

TEVA PHARMS	EQ 0.5MG BASE/5ML	A073095	001	Apr 21, 1992
TAVIST				
NOVARTIS	EQ 0.5MG BASE/5ML	N018675	001	Jun 28, 1985

TABLET; ORAL

CLEMASTINE FUMARATE

TEVA	1.34MG	A073282	001	Jan 31, 1992
	1.34MG	A073282	002	Dec 03, 1992
TAVIST				
NOVARTIS	2.68MG	N017661	001	
TAVIST-1				
NOVARTIS	1.34MG	N017661	002	
	1.34MG	N017661	003	Aug 21, 1992

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TAVIST-D

NOVARTIS	EQ 1MG BASE;75MG	N018298	001	Dec 15, 1982
	1.34MG;75MG	N018298	002	Aug 21, 1992
	1.34MG;75MG	N020640	001	Aug 09, 1996

CLIDINIUM BROMIDE

CAPSULE; ORAL

QUARZAN

ROCHE	2.5MG	N010355	001	
	5MG	N010355	002	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN

PHARMACIA AND UPJOHN	EQ 75MG BASE	A061809	001	
	EQ 150MG BASE	A061809	002	

CLINDAMYCIN HYDROCHLORIDE

TEVA	EQ 75MG BASE	A063027	001	Sep 20, 1989
------	--------------	---------	-----	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 521 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 80 (of 324)

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

WATSON LABS EQ 75MG BASE A063082 001 Jul 31, 1991

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

PHARMACIA AND UPJOHN EQ 75MG BASE/5ML A061827 001

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLEOCIN

PHARMACIA AND UPJOHN EQ 2% BASE N050680 001 Aug 11, 1992

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

PHARMACIA AND UPJOHN EQ 150MG BASE/ML A061839 001

CLINDAMYCIN PHOSPHATE

ABRAXIS PHARM EQ 150MG BASE/ML A062747 001 Jun 03, 1988

ASTRAZENECA EQ 150MG BASE/ML A062928 001 Feb 13, 1989

BAXTER HLTHCARE EQ 150MG BASE/ML A062806 001 Oct 15, 1987

EQ 150MG BASE/ML A062953 001 Apr 21, 1988

EQ 150MG BASE/ML A063068 001 Aug 28, 1989

BEDFORD EQ 150MG BASE/ML A063163 001 Jun 30, 1994

BRISTOL MYERS SQUIBB EQ 150MG BASE/ML A062908 001 Feb 01, 1989

LOCH EQ 150MG BASE/ML A062905 001 May 09, 1988

MARSAM PHARMS LLC EQ 150MG BASE/ML A062913 001 Oct 20, 1988

SOLOPAK EQ 150MG BASE/ML A062819 001 Mar 15, 1988

EQ 150MG BASE/ML A062852 001 Mar 17, 1988

TEVA PARENTERAL EQ 150MG BASE/ML A063041 001 Dec 29, 1989

EQ 150MG BASE/ML A063282 001 May 29, 1992

WATSON LABS EQ 150MG BASE/ML A062900 001 Jun 08, 1988

EQ 150MG BASE/ML A063079 001 Mar 05, 1990

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

ABRAXIS PHARM EQ 12MG BASE/ML N050636 001 Dec 22, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT EQ 6MG BASE/ML A065027 001 Jun 29, 2001

EQ 12MG BASE/ML A065027 002 Jun 29, 2001

EQ 18MG BASE/ML A065027 003 Jun 29, 2001

BAXTER HLTHCARE EQ 6MG BASE/ML N050648 001 Dec 29, 1989

EQ 12MG BASE/ML N050648 002 Dec 29, 1989

EQ 900MG BASE/100ML N050648 003 Dec 29, 1989

SOLUTION; TOPICAL

CLEOCIN T

PHARMACIA AND UPJOHN EQ 1% BASE A062363 001 Feb 08, 1982

CLINDAMYCIN PHOSPHATE

BOCA PHARMA EQ 1% BASE A062930 001 Jun 28, 1989

COPLY PHARM EQ 1% BASE A062944 001 Jan 11, 1989

STIEFEL GSK EQ 1% BASE A064108 001 Sep 27, 1996

CLIOQUINOL; NYSTATIN

OINTMENT; TOPICAL

NYSTAFORM

BAYER PHARMS 10MG/GM;100,000 UNITS/GM N050235 001

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

STIEFEL 0.05% A075338 001 Feb 09, 2001

CLOBETASOL PROPIONATE (EMOLLIENT)

STIEFEL GSK 0.05% A075733 001 Aug 22, 2001

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

STIEFEL GSK 0.05% A075057 001 Aug 12, 1998

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 522 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 81 (of 324)

CLOFAZIMINECAPSULE; ORAL  
LAMPRENE

NOVARTIS 100MG N019500 001 Dec 15, 1986

CLOFIBRATECAPSULE; ORAL  
ATROMID-S

WYETH AYERST 500MG N016099 002

CLOFIBRATE

BANNER PHARMACAPS 500MG A073396 001 Mar 20, 1992

SANDOZ 500MG A072191 001 May 02, 1988

TEVA 500MG A072600 001 Jul 25, 1991

USL PHARMA 500MG A070531 001 Jun 16, 1986

WATSON LABS 500MG A071603 001 Sep 18, 1987

CLOMIPHENE CITRATETABLET; ORAL  
MILOPHENE

MILEX 50MG A072196 001 Dec 20, 1988

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

SANDOZ 25MG A074953 001 Jun 25, 1997

50MG A074953 002 Jun 25, 1997

75MG A074953 003 Jun 25, 1997

TEVA 25MG A074849 001 Apr 04, 1997

50MG A074849 002 Apr 04, 1997

75MG A074849 003 Apr 04, 1997

WATSON LABS 25MG A074600 001 Nov 27, 1996

25MG A074751 001 Sep 30, 1998

50MG A074600 002 Nov 27, 1996

50MG A074751 002 Sep 30, 1998

75MG A074600 003 Nov 27, 1996

75MG A074751 003 Sep 30, 1998

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

KALI LABS 0.5MG A077147 001 May 02, 2005

1MG A077147 002 May 02, 2005

2MG A077147 003 May 02, 2005

SANDOZ 0.5MG A074925 001 Sep 30, 1997

1MG A074925 002 Sep 30, 1997

2MG A074925 003 Sep 30, 1997

TEVA 0.5MG A074920 001 Aug 04, 1998

1MG A074920 002 Aug 04, 1998

2MG A074920 003 Aug 04, 1998

KLONOPIN

ROCHE 0.125MG N017533 005 Apr 09, 1997

0.25MG N017533 006 Apr 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

KLONOPIN RAPIDLY DISINTEGRATING

ROCHE 0.125MG N020813 001 Dec 23, 1997

0.25MG N020813 002 Dec 23, 1997

0.5MG N020813 003 Dec 23, 1997

1MG N020813 004 Dec 23, 1997

2MG N020813 005 Dec 23, 1997

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AM THERAP 0.1MG A070881 001 Jul 08, 1986

## DISCONTINUED DRUG PRODUCT LIST

6 - 82 (of 324)

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AM THERAP	0.2MG	A070882	001	Jul 08, 1986
	0.3MG	A070883	001	Jul 08, 1986
AMNEAL PHARMS NY	0.1MG	A071252	001	Oct 01, 1986
	0.2MG	A071253	001	Oct 01, 1986
	0.3MG	A071254	001	Oct 01, 1986
DURAMED PHARMS BARR	0.1MG	A071103	001	Aug 14, 1986
	0.2MG	A071102	001	Aug 14, 1986
	0.3MG	A071101	001	Aug 14, 1986
PAR PHARM	0.1MG	A070461	001	Jul 08, 1986
	0.2MG	A070460	001	Jul 08, 1986
	0.3MG	A070459	001	Jul 08, 1986
SANDOZ	0.1MG	A070887	001	Aug 31, 1988
	0.2MG	A070886	001	Aug 31, 1988
	0.3MG	A071294	001	Aug 31, 1988
TEVA	0.1MG	A070747	001	Jul 08, 1986
	0.2MG	A070702	001	Jul 08, 1986
	0.3MG	A070659	001	Jul 08, 1986
WARNER CHILCOTT	0.1MG	A072138	001	Jun 13, 1988
	0.2MG	A072139	001	Jun 13, 1988
	0.3MG	A072140	001	Jun 13, 1988
WATSON LABS	0.1MG	A070395	001	Mar 23, 1987
	0.1MG	A070965	001	Jul 08, 1986
	0.2MG	A070396	001	Mar 23, 1987
	0.2MG	A070964	001	Jul 08, 1986
	0.3MG	A070397	001	Mar 23, 1987

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

DR REDDYS LABS INC	EQ 75MG BASE	A076273	001	Jan 14, 2008
--------------------	--------------	---------	-----	--------------

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071777	001	Jul 14, 1987
	7.5MG	A071778	001	Jul 14, 1987
	15MG	A071779	001	Jul 14, 1987
AM THERAP	3.75MG	A071429	001	Jun 23, 1987
	7.5MG	A071430	001	Jun 23, 1987
	15MG	A071431	001	Jun 23, 1987
CLONMEL HLTHCARE	3.75MG	A071742	001	Dec 14, 1987
	7.5MG	A071743	001	Dec 14, 1987
	15MG	A071744	001	Dec 14, 1987
GD SEARLE LLC	3.75MG	A071727	001	Dec 18, 1987
	7.5MG	A071728	001	Dec 18, 1987
	15MG	A071729	001	Dec 18, 1987
MYLAN	3.75MG	A071509	001	Oct 19, 1987
	7.5MG	A071510	001	Oct 19, 1987
	15MG	A071511	001	Oct 19, 1987
PUREPAC PHARM	3.75MG	A071924	001	Apr 25, 1988
	7.5MG	A071925	001	Apr 25, 1988
	15MG	A071926	001	Apr 25, 1988
QUANTUM PHARMICS	3.75MG	A071549	001	Sep 12, 1988
	7.5MG	A071550	001	Sep 12, 1988
	15MG	A071522	001	Sep 12, 1988
SANDOZ	3.75MG	A072219	001	Aug 26, 1988
	7.5MG	A072220	001	Aug 26, 1988
	15MG	A072112	001	Aug 26, 1988
USL PHARMA	3.75MG	A071242	001	Jun 23, 1987
	7.5MG	A071243	001	Jun 23, 1987
	15MG	A071244	001	Jun 23, 1987

## DISCONTINUED DRUG PRODUCT LIST

6 - 83 (of 324)

CLOAZEPATE DIPOTASSIUM

## CAPSULE; ORAL

## CLOAZEPATE DIPOTASSIUM

WARNER CHILCOTT	3.75MG	A071774	001	Mar 01, 1988
	7.5MG	A071775	001	Mar 01, 1988
	15MG	A071776	001	Mar 01, 1988
WATSON LABS	3.75MG	A071878	001	Mar 15, 1988
	7.5MG	A071879	001	Mar 15, 1988
	15MG	A071860	001	Mar 15, 1988

## TRANXENE

LUNDBECK INC	3.75MG	N017105	001	
	7.5MG	N017105	002	
	15MG	N017105	003	

## TABLET; ORAL

## CLOAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071780	001	Jun 26, 1987
	7.5MG	A071781	001	Jun 26, 1987
	15MG	A071782	001	Jun 26, 1987
AM THERAP	3.75MG	A071747	001	Jun 23, 1987
	7.5MG	A071748	001	Jun 23, 1987
	15MG	A071749	001	Jun 23, 1987
LEDERLE	3.75MG	A072013	001	Dec 15, 1987
	7.5MG	A072014	001	Dec 15, 1987
	15MG	A072015	001	Dec 15, 1987
PUREPAC PHARM	3.75MG	A072330	001	Aug 08, 1988
	7.5MG	A072331	001	Aug 08, 1988
	15MG	A072332	001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG	A071730	001	Oct 26, 1987
	7.5MG	A071731	001	Oct 26, 1987
	15MG	A071702	001	Oct 26, 1987
SANDOZ	3.75MG	A072512	001	May 11, 1990
	7.5MG	A072513	001	May 11, 1990
	15MG	A072514	001	May 11, 1990
WARNER CHILCOTT	3.75MG	A071828	001	Mar 03, 1988
	7.5MG	A071829	001	Mar 03, 1988
	15MG	A071830	001	Mar 03, 1988
TRANXENE SD				
LUNDBECK INC	11.25MG	N017105	005	
	22.5MG	N017105	004	

CLOTRIMAZOLE

## CREAM; TOPICAL

## LOTRIMIN

SCHERING PLOUGH	1%	N017619	001	
MYCELEX				
BAYER PHARMS	1%	N018183	001	

## LOTION; TOPICAL

## LOTRIMIN

SCHERING	1%	N018813	001	Feb 17, 1984
----------	----	---------	-----	--------------

## SOLUTION; TOPICAL

## LOTRIMIN

SCHERING PLOUGH	1%	N017613	001	
-----------------	----	---------	-----	--

## TABLET; VAGINAL

## GYNIX

TEVA PHARMS	100MG	A073249	001	Feb 13, 1998
MYCELEX-G				
BAYER PHARMS	500MG	N019069	001	Apr 19, 1985

CLOXACILLIN SODIUM

## CAPSULE; ORAL

## CLOXACILLIN SODIUM

APOTHECON	EQ 250MG BASE	A061452	001	
	EQ 500MG BASE	A061452	002	
TEVA	EQ 250MG BASE	A062240	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 84 (of 324)

CLOXACILLIN SODIUM

CAPSULE; ORAL

CLOXACILLIN SODIUM

TEVA

EQ 500MG BASE

A062240 002

CLOXAPEN

GLAXOSMITHKLINE

EQ 250MG BASE

A061806 001

EQ 250MG BASE

A062233 001

EQ 500MG BASE

A061806 002

EQ 500MG BASE

A062233 002

FOR SOLUTION; ORAL

CLOXACILLIN SODIUM

TEVA

EQ 125MG BASE/5ML

A062268 001

EQ 125MG BASE/5ML

A062978 001

Apr 06, 1989

TEGOPEN

APOTHECON

EQ 125MG BASE/5ML

A061453 001

EQ 125MG BASE/5ML

N050192 001

CLOZAPINE

TABLET; ORAL

CLOZAPINE

PAR PHARM

25MG

A075162 001

Apr 26, 2005

100MG

A075162 002

Apr 26, 2005

SANDOZ

25MG

A074546 001

Aug 30, 1996

100MG

A074546 002

Aug 30, 1996

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

AZUR PHARMA INTL

50MG

N021590 003

Jun 03, 2005

COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A; N/A

RUBRATOPE-57 KIT

BRACCO

N/A;N/A;N/A;N/A

N016089 001

COBALT CHLORIDE, CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-60; INTRINSIC FACTOR

N/A; N/A

RUBRATOPE-60 KIT

BRACCO

N/A;N/A;N/A;N/A

N016090 001

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC W/ CODEINE

ANI PHARMS

10MG/5ML;5MG/5ML;6.25MG/5ML

N008306 005

Apr 02, 1984

PHERAZINE VC W/ CODEINE

HALSEY

10MG/5ML;5MG/5ML;6.25MG/5ML

A088870 001

Mar 02, 1987

PROMETHAZINE VC W/ CODEINE

CENCI

10MG/5ML;5MG/5ML;6.25MG/5ML

A088816 001

Nov 22, 1985

MORTON GROVE

10MG/5ML;5MG/5ML;6.25MG/5ML

A088896 001

Jan 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN W/ CODEINE

ANI PHARMS

10MG/5ML;6.25MG/5ML

N008306 004

Apr 02, 1984

PHERAZINE W/ CODEINE

HALSEY

10MG/5ML;6.25MG/5ML

A088739 001

Dec 23, 1988

PROMETHAZINE W/ CODEINE

CENCI

10MG/5ML;6.25MG/5ML

A088814 001

Nov 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTIFED W/ CODEINE

GLAXOSMITHKLINE

10MG/5ML;30MG/5ML;1.25MG/5ML

N012575 003

Apr 04, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE

CENCI

10MG/5ML;30MG/5ML;1.25MG/5ML

A089018 001

Jul 23, 1986

## DISCONTINUED DRUG PRODUCT LIST

6 - 85 (of 324)

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE			
MORTON GROVE	10MG/5ML;30MG/5ML;1.25MG/5ML	A088833 001	Nov 16, 1984

COLCHICINE; PROBENECID

TABLET; ORAL

COLBENEMID			
MERCK	0.5MG;500MG	N012383 001	
PROBEN-C			
WATSON LABS	0.5MG;500MG	A085552 001	
PROBENECID AND COLCHICINE			
BEECHAM	0.5MG;500MG	A084321 001	
IMPAX LABS	0.5MG;500MG	A083720 002	
SANDOZ	0.5MG;500MG	A086130 001	
PROBENECID W/ COLCHICINE			
LEDERLE	0.5MG;500MG	A086954 001	
WATSON LABS	0.5MG;500MG	A083221 001	

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL

WELCHOL			
DAIICHI SANKYO	375MG	N021141 001	May 26, 2000

COLISTIN SULFATE

SUSPENSION; ORAL

COLY-MYCIN S			
PARKE DAVIS	EQ 25MG BASE/5ML	N050355 001	

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL			
ASTELLAS	20MG/4ML (5MG/ML)	N021697 001	Dec 29, 2005

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

CU-7			
GD SEARLE LLC	89MG	N017408 001	
TATUM-T			
GD SEARLE LLC	120MG	N018205 001	

CORTICOTROPIN

INJECTABLE; INJECTION

ACTH			
PARKEDALE	25 UNITS/VIAL	N008317 002	
	40 UNITS/VIAL	N008317 004	
ACTHAR			
SANOFI AVENTIS US	25 UNITS/VIAL	N007504 002	
	40 UNITS/VIAL	N007504 003	
CORTICOTROPIN			
ORGANICS LAGRANGE	40 UNITS/ML	N010831 001	
	80 UNITS/ML	N010831 002	
WATSON LABS	40 UNITS/VIAL	A088772 001	Nov 21, 1984
H.P. ACTHAR GEL			
QUESTCOR PHARMS	40 UNITS/ML	N008372 006	
PURIFIED CORTROPHIN GEL			
ORGANON USA INC	40 UNITS/ML	N008975 001	
	80 UNITS/ML	N008975 002	

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION

CORTROPHIN-ZINC			
ORGANON USA INC	40 UNITS/ML	N009854 001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 86 (of 324)

CORTISONE ACETATE

## INJECTABLE; INJECTION

## CORTISONE ACETATE

PHARMACIA AND UPJOHN	25MG/ML	N008126	002
WATSON LABS	25MG/ML	A083147	003
	25MG/ML	A085677	001
	50MG/ML	A083147	004
	50MG/ML	A085677	002

## CORTONE

MERCK	25MG/ML	N007110	002
	50MG/ML	N007110	003

## TABLET; ORAL

## CORTISONE ACETATE

BARR	25MG	A083471	001
ELKINS SINN	25MG	A080836	001
EVERYLIFE	25MG	A084246	001
HEATHER	25MG	A085736	001
IMPAX LABS	25MG	N009458	001
INWOOD LABS	25MG	A080731	001
IVAX SUB TEVA PHARMS	25MG	A080630	001
	25MG	A083536	001
LANNETT	25MG	A080694	001
PANRAY	5MG	N008284	002
	25MG	N008284	001
PHARMACIA AND UPJOHN	5MG	N008126	003
	10MG	N008126	004
	25MG	N008126	001
PUREPAC PHARM	25MG	A080493	001
VITARINE	25MG	A080333	001
WATSON LABS	25MG	A085884	001
WHITTEWORTH TOWN PLSN	25MG	A080341	001

## CORTONE

MERCK	25MG	N007750	003
-------	------	---------	-----

CROMOLYN SODIUM

## CAPSULE; INHALATION

## INTAL

SANOFI AVENTIS US	20MG	N016990	001
-------------------	------	---------	-----

## CAPSULE; ORAL

## GASTROCROM

UCB INC	100MG	N019188	001	Dec 22, 1989
---------	-------	---------	-----	--------------

## SOLUTION; INHALATION

## CROMOLYN SODIUM

PHARMASCIENCE INC	10MG/ML	A075437	001	Apr 21, 2000
-------------------	---------	---------	-----	--------------

ROXANE	10MG/ML	A075175	001	Sep 30, 1999
--------	---------	---------	-----	--------------

## INTAL

KING PHARMS	10MG/ML	N018596	001	May 28, 1982
-------------	---------	---------	-----	--------------

## SOLUTION/DROPS; OPHTHALMIC

## CROMOPTIC

KING PHARMS	4%	A075088	001	Apr 27, 1999
-------------	----	---------	-----	--------------

## SPRAY, METERED; NASAL

## NASALCROM

MCNEIL CONS	5.2MG/SPRAY	N020463	001	Jan 03, 1997
-------------	-------------	---------	-----	--------------

CRYPTENAMINE ACETATES

## INJECTABLE; INJECTION

## UNITENSEN

MEDPOINTE PHARM HLC	260CSR UNIT/ML	N008814	001
---------------------	----------------	---------	-----

CRYPTENAMINE TANNATES

## TABLET; ORAL

## UNITENSEN

MEDPOINTE PHARM HLC	260CSR UNIT	N009217	001
---------------------	-------------	---------	-----



## DISCONTINUED DRUG PRODUCT LIST

6 - 87 (of 324)

CUPRIC SULFATEINJECTABLE; INJECTION  
CUPRIC SULFATE

ABRAXIS PHARM EQ 0.4MG COPPER/ML N019350 001 May 05, 1987

CYANOCOBALAMINGEL, METERED; NASAL  
NASCOBAL

PAR PHARM 0.5MG/INH N019722 001 Nov 05, 1996

INJECTABLE; INJECTION

BERUBIGEN

PHARMACIA AND UPJOHN 1MG/ML N006798 001

BETALIN 12

LILLY 0.1MG/ML A080855 001

1MG/ML A080855 002

COBAVITE

WATSON LABS 0.1MG/ML A083013 001

1MG/ML A083064 001

CYANOCOBALAMIN

ABRAXIS PHARM 0.03MG/ML A080510 003

0.1MG/ML A080510 001

1MG/ML A080510 002

1MG/ML A083075 001

AKORN 1MG/ML A087969 001 Nov 10, 1983

APP PHARMS 0.1MG/ML A080557 002

BAXTER HLTHCARE 1MG/ML A080515 002

BIONICHE PHARMA 1MG/ML A040451 001 Sep 23, 2003

DELL LABS 0.03MG/ML A080689 001

0.1MG/ML A080689 002

1MG/ML A080689 003

LUITPOLD 0.03MG/ML A080668 001

SANOFI AVENTIS US 1MG/ML A080564 001

SOLOPAK 1MG/ML A087551 001 Feb 29, 1984

WARNER CHILCOTT 1MG/ML N007085 002

WATSON LABS 0.1MG/ML A080573 002

0.1MG/ML A083120 001

1MG/ML A080573 001

1MG/ML A083120 002

WYETH AYERST 0.1MG/ML A080554 001

1MG/ML A080554 002

REDISOL

MERCK 1MG/ML N006668 010

RUBIVITE

BEL MAR 0.03MG/ML N010791 004

0.05MG/ML N010791 001

0.1MG/ML N010791 002

0.12MG/ML N010791 005

1MG/ML N010791 003

RUBRAMIN PC

BRISTOL MYERS SQUIBB 0.1MG/ML N006799 002

1MG/ML N006799 004

1MG/ML N006799 010 Apr 28, 1988

RUVITE

SAVAGE LABS 1MG/ML A080570 002

VI-TWEL

BAYER HLTHCARE 1MG/ML N007012 002

TABLET; ORAL

CYANOCOBALAMIN

WEST WARD 1MG A084264 001

CYANOCOBALAMIN, CO-57

CAPSULE; ORAL

RUBRATOPE-57

BRACCO 0.5-1uCi N016089 002

## DISCONTINUED DRUG PRODUCT LIST

6 - 88 (of 324)

CYANOCOBALAMIN, CO-60

CAPSULE; ORAL				
RUBRATOPE-60				
BRACCO	0.5-1uCi		N016090	002

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A				
DICOPAC KIT				
GE HEALTHCARE	N/A;N/A;N/A		N017406	001

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A; N/A				
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT				
MALLINCKRODT	0.1MG;0.5uCi;60MG		N016635	001

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE; INJECTION				
DEPINAR				
ARMOUR PHARM	0.5MG/ML;2.3MG/ML;1MG/ML		N011208	001

CYCLACILLIN

FOR SUSPENSION; ORAL				
CYCLAPEN-W				
WYETH AYERST	125MG/5ML		N050508	001
	250MG/5ML		N050508	002
	500MG/5ML		N050508	003
TABLET; ORAL				
CYCLACILLIN				
TEVA	250MG		A062895	001 Aug 04, 1988
	500MG		A062895	002 Aug 04, 1988
CYCLAPEN-W				
WYETH AYERST	250MG		N050509	001
	500MG		N050509	002

CYCLIZINE LACTATE

INJECTABLE; INJECTION				
MAREZINE				
GLAXOSMITHKLINE	50MG/ML		N009495	001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL				
CYCLOBENZAPRINE HYDROCHLORIDE				
SANDOZ	10MG		A073683	001 Feb 26, 1993
WATSON LABS	10MG		A073143	001 Nov 27, 1991
	10MG		A074436	001 Nov 30, 1994

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC				
AK-PENTOLATE				
AKORN	1%		A085555	001
CYCLOPENTOLATE HYDROCHLORIDE				
ALCON UNIVERSAL	1%		A089162	001 Jan 24, 1991
SOLA BARNES HIND	1%		A084150	001
	1%		A084863	001
PENTOLAIR				
PHARMAFAIR	0.5%		A088643	001 Feb 09, 1987
	1%		A088150	001 Feb 25, 1983

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION				
CYCLOPHOSPHAMIDE				
BAXTER HLTHCARE	100MG/VIAL		A088371	001 Jul 03, 1986
	200MG/VIAL		A088372	001 Jul 03, 1986

## DISCONTINUED DRUG PRODUCT LIST

6 - 89 (of 324)

CYCLOPHOSPHAMIDE

## INJECTABLE; INJECTION

## CYCLOPHOSPHAMIDE

BAXTER HLTHCARE	500MG/VIAL	A088373	001	Jul 03, 1986
	1GM/VIAL	A088374	001	Sep 24, 1986

## CYTOXAN

BAXTER HLTHCARE	100MG/VIAL	N012142	001	
	200MG/VIAL	N012142	002	
	500MG/VIAL	N012142	003	
	1GM/VIAL	N012142	004	Aug 30, 1982
	2GM/VIAL	N012142	005	Aug 30, 1982

## NEOSAR

TEVA PARENTERAL	100MG/VIAL	A040015	001	Apr 29, 1993
	100MG/VIAL	A087442	001	Feb 16, 1982
	200MG/VIAL	A040015	002	Apr 29, 1993
	200MG/VIAL	A087442	002	Feb 16, 1982
	500MG/VIAL	A040015	003	Apr 29, 1993
	500MG/VIAL	A087442	003	Feb 16, 1982
	1GM/VIAL	A040015	004	Apr 29, 1993
	1GM/VIAL	A087442	004	Jul 08, 1983
	2GM/VIAL	A040015	005	Apr 29, 1993
	2GM/VIAL	A087442	005	Mar 30, 1989

## TABLET; ORAL

## CYTOXAN

BAXTER HLTHCARE	25MG	N012141	002	
	50MG	N012141	001	

CYCLOSPORINE

## CAPSULE; ORAL

## NEORAL

NOVARTIS	50MG	N050715	003	Jul 14, 1995
----------	------	---------	-----	--------------

CYCLOTHIAZIDE

## TABLET; ORAL

## ANHYDRON

LILLY	2MG	N013157	002	
-------	-----	---------	-----	--

## FLUIDIL

PHARMACIA AND UPJOHN	2MG	N018173	001	
----------------------	-----	---------	-----	--

CYCRIMINE HYDROCHLORIDE

## TABLET; ORAL

## PAGITANE

LILLY	1.25MG	N008951	001	
	2.5MG	N008951	002	

CYPROHEPTADINE HYDROCHLORIDE

## SYRUP; ORAL

## CYPROHEPTADINE HYDROCHLORIDE

HALSEY	2MG/5ML	A089199	001	Jul 03, 1986
MORTON GROVE	2MG/5ML	A087001	001	Nov 04, 1982
NASKA	2MG/5ML	A089021	001	Dec 21, 1987

## PERIACTIN

MERCK	2MG/5ML	N013220	002	
-------	---------	---------	-----	--

## TABLET; ORAL

## CYPROHEPTADINE HYDROCHLORIDE

AM THERAP	4MG	A088798	001	Feb 15, 1985
ASCOT	4MG	A087685	001	Oct 25, 1982
DURAMED PHARMS BARR	4MG	A088232	001	Oct 25, 1983
HALSEY	4MG	A089057	001	Jul 03, 1986
KV PHARM	4MG	A086737	001	
MD PHARM	4MG	A087566	001	Nov 10, 1982
MYLAN	4MG	A086678	001	
PIONEER PHARMS	4MG	A087839	001	Feb 08, 1984
SANDOZ	4MG	A086808	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 90 (of 324)

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

SUPERPHARM 4MG

A087405 001

TG UNITED LABS 4MG

A088212 001

May 26, 1983

VITARINE 4MG

A087284 001

WATSON LABS 4MG

A085245 001

4MG

A086165 001

4MG

A086580 001

PERIACTIN

MERCK 4MG

N012649 001

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HYDROCHLORIDE

HOSPIRA 7.25%

N019523 001

Oct 22, 1986

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

TEVA PARENTERAL 100MG/VIAL

N016793 001

500MG/VIAL

N016793 002

1GM/VIAL

N016793 003

Dec 21, 1987

2GM/VIAL

N016793 004

Dec 21, 1987

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

ABRAXIS PHARM 100MG/VIAL

A070962 001

Aug 28, 1986

200MG/VIAL

A070990 001

Aug 28, 1986

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

KING PHARMS 420MG/VIAL; 180MG/VIAL

N050748 002

Aug 24, 2000

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

EISAI INC 7,500 IU/0.75ML

N020287 008

Apr 04, 2002

DANAPAROID SODIUM

INJECTABLE; INJECTION

ORGARAN

ORGANON USA INC 750 UNITS/0.6ML

N020430 001

Dec 24, 1996

DANAZOL

CAPSULE; ORAL

DANAZOL

AM THERAP 200MG

A071569 001

Dec 30, 1987

DANOCRINE

SANOFI AVENTIS US 50MG

N017557 003

100MG

N017557 004

200MG

N017557 002

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

REV-EYES

ANGELINI 0.5%

N019849 001

Dec 31, 1990

## DISCONTINUED DRUG PRODUCT LIST

6 - 91 (of 324)

DAPTOMYCIN

INJECTABLE; IV (INFUSION)

CUBICIN

CUBIST

250MG/VIAL

N021572 001

Sep 12, 2003

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

GILEAD

EQ 2MG BASE/ML

N050704 002

Apr 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

SANOFI AVENTIS US

EQ 20MG BASE/VIAL

A061876 001

WYETH AYERST

EQ 20MG BASE/VIAL

N050484 001

DAUNORUBICIN HYDROCHLORIDE

TEVA PARENTERAL

EQ 20MG BASE/VIAL

A064212 001

Jun 23, 1998

EQ 50MG BASE/VIAL

A064212 002

May 03, 1999

DECAMETHONIUM BROMIDE

INJECTABLE; INJECTION

SYNCURINE

GLAXOSMITHKLINE

1MG/ML

N006931 002

DEMECARIUM BROMIDE

SOLUTION/DROPS; OPHTHALMIC

HUMORSOL

MERCK

0.125%

N011860 002

0.25%

N011860 001

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DECLOMYCIN

LEDERLE

150MG

N050262 001

SYRUP; ORAL

DECLOMYCIN

LEDERLE

75MG/5ML

N050257 001

TABLET; ORAL

DECLOMYCIN

STIEFEL

75MG

N050261 001

DESERPIDINE

TABLET; ORAL

HARMONYL

ABBOTT

0.1MG

N010796 001

0.25MG

N010796 002

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ORETICYL 25

ABBOTT

0.125MG; 25MG

N012148 001

ORETICYL 50

ABBOTT

0.125MG; 50MG

N012148 003

ORETICYL FORTE

ABBOTT

0.25MG; 25MG

N012148 002

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

ABBOTT

0.25MG; 5MG

N012775 001

ENDURONYL FORTE

ABBOTT

0.5MG; 5MG

N012775 002

## DISCONTINUED DRUG PRODUCT LIST

6 - 92 (of 324)

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE AND DESERPIDINE

WATSON LABS	0.25MG;5MG	A088486	001	Aug 10, 1984
	0.5MG;5MG	A088452	001	Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

PERTOFRANE

SANOFI AVENTIS US	25MG	N013621	001	
	50MG	N013621	002	

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

PLIVA	25MG	A071800	001	Dec 08, 1987
	50MG	A071801	001	Dec 08, 1987
	75MG	A071802	001	Dec 08, 1987
	100MG	A071803	001	May 29, 1997
	150MG	A071804	001	May 29, 1997
USL PHARMA	25MG	A071864	001	Sep 09, 1987
	50MG	A071865	001	Sep 09, 1987
	75MG	A071866	001	Sep 09, 1987
	100MG	A071867	001	Sep 09, 1987

DESLANOSIDE

INJECTABLE; INJECTION

CEDILANID-D

NOVARTIS	0.2MG/ML	N009282	002	
----------	----------	---------	-----	--

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

SANOFI AVENTIS US	0.015MG/ML	N018938	002	Apr 25, 1995
DESMOPRESSIN ACETATE BEDFORD	0.004MG/ML	A074575	001	Feb 18, 2000
	DESMOPRESSIN ACETATE PRESERVATIVE FREE BEDFORD	0.004MG/ML	A074574	001

SOLUTION; NASAL

CONCENTRAID

FERRING	0.01%	N019776	001	Dec 26, 1990
---------	-------	---------	-----	--------------

SPRAY, METERED; NASAL

DDAVP

SANOFI AVENTIS US	0.01MG/SPRAY	N017922	002	Feb 06, 1989
-------------------	--------------	---------	-----	--------------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGEN

ORGANON USA INC	0.15MG;0.03MG	N020071	001	Dec 10, 1992
DESOGESTREL AND ETHINYL ESTRADIOL DURAMED PHARMS BARR	0.15MG;0.03MG	A075256	001	Aug 12, 1999
	ORTHO-CEPT ORTHO MCNEIL JANSSEN	0.15MG;0.03MG	N020301	001

DESONIDE

CREAM; TOPICAL

DESONIDE

TEVA PHARMS	0.05%	A074027	001	Sep 28, 1992
-------------	-------	---------	-----	--------------

DESOXIMETASONE

OINTMENT; TOPICAL

DESOXIMETASONE

ALTANA	0.25%	A073440	001	Apr 01, 1998
TOPICORT TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985

## DISCONTINUED DRUG PRODUCT LIST

6 - 93 (of 324)

DESOXYCORTICOSTERONE ACETATE

INJECTABLE; INJECTION

DOCA

ORGANON USA INC 5MG/ML N001104 001

PELLET; IMPLANTATION

PERCORTEN

NOVARTIS 125MG N005151 001

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION

PERCORTEN

NOVARTIS 25MG/ML N008822 001

DEXAMETHASONE

AEROSOL; TOPICAL

AEROSEB-DEX

ALLERGAN HERBERT 0.01% A083296 002

DECASPRAY

MERCK 0.04% N012731 002

ELIXIR; ORAL

DECADRON

MERCK 0.5MG/5ML N012376 002

DEXAMETHASONE

ALPHARMA US PHARMS 0.5MG/5ML A088997 001 Oct 10, 1986

HEXADROL

ORGANON USA INC 0.5MG/5ML N012674 001

GEL; TOPICAL

DECADERM

MERCK 0.1% N013538 001

SUSPENSION/DROPS; OPHTHALMIC

DEXAMETHASONE

WATSON LABS 0.1% A089170 001 May 09, 1989

TABLET; ORAL

DECADRON

MERCK 0.25MG N011664 004

0.5MG N011664 001

0.75MG N011664 002

1.5MG N011664 003

4MG N011664 005

6MG N011664 006 Jul 30, 1982

DEXAMETHASONE

IMPAX LABS 0.75MG A085376 001

MUTUAL PHARM 0.25MG A084013 001

0.25MG A084764 001

0.5MG A084084 001

0.5MG A084766 001

0.75MG A084081 001

0.75MG A084765 001

1.5MG A084086 001

1.5MG A084763 001

PAR PHARM 0.25MG A088149 001 Apr 28, 1983

0.5MG A088148 001 Apr 28, 1983

0.75MG A088160 001 Apr 28, 1983

1.5MG A088237 001 Apr 28, 1983

4MG A088238 001 Apr 28, 1983

6MG A088481 001 Nov 28, 1983

PHOENIX LABS NY 0.75MG A083806 001

PVT FORM 0.75MG A083420 001

ROXANE 0.25MG A084614 001

SANDOZ 0.75MG A080399 001

UPSHER SMITH 0.75MG A087534 001

1.5MG A087533 001

WATSON LABS 0.25MG A085455 001

0.5MG A085458 001

0.75MG A080968 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 94 (of 324)

DEXAMETHASONE

## TABLET; ORAL

## DEXAMETHASONE

WATSON LABS	0.75MG	A084457	001
	0.75MG	A085818	001
	1.5MG	A085456	001
	1.5MG	A085840	001
WHITEWORTH TOWN PLSN	0.75MG	A084327	001
DEXONE 0.5			
SOLVAY	0.5MG	A084991	001
DEXONE 0.75			
SOLVAY	0.75MG	A084993	001
DEXONE 1.5			
SOLVAY	1.5MG	A084990	001
DEXONE 4			
SOLVAY	4MG	A084992	001
HEXADROL			
ORGANON USA INC	0.5MG	N012675	004
	0.75MG	N012675	007
	1.5MG	N012675	009
	4MG	N012675	010

DEXAMETHASONE ACETATE

## INJECTABLE; INJECTION

## DECADRON-LA

MERCK	EQ 8MG BASE/ML	N016675	001
-------	----------------	---------	-----

## DEXAMETHASONE ACETATE

WATSON LABS	EQ 8MG BASE/ML	A084315	001
	EQ 16MG BASE/ML	A087711	001

May 24, 1982

DEXAMETHASONE SODIUM PHOSPHATE

## AEROSOL; NASAL

## DEXACORT

UCB INC	EQ 0.1MG PHOSPHATE/INH	N014242	001
---------	------------------------	---------	-----

## AEROSOL, METERED; INHALATION

## DEXACORT

UCB INC	EQ 0.1MG PHOSPHATE/INH	N013413	001
---------	------------------------	---------	-----

## CREAM; TOPICAL

## DECADRON

MERCK	EQ 0.1% PHOSPHATE	N011983	002
-------	-------------------	---------	-----

## INJECTABLE; INJECTION

## DECADRON

MERCK	EQ 4MG PHOSPHATE/ML	N012071	002
	EQ 24MG PHOSPHATE/ML	N012071	004

## DEXACEN-4

CENT PHARMS	EQ 4MG PHOSPHATE/ML	A084342	001
-------------	---------------------	---------	-----

## DEXAMETHASONE

ABRAXIS PHARM	EQ 4MG PHOSPHATE/ML	A088448	001
---------------	---------------------	---------	-----

Jan 25, 1984

APP PHARMS	EQ 10MG PHOSPHATE/ML	A088469	001
------------	----------------------	---------	-----

Jan 25, 1984

## DEXAMETHASONE SODIUM PHOSPHATE

ABRAXIS PHARM	EQ 4MG PHOSPHATE/ML	A087065	001
---------------	---------------------	---------	-----

AKORN	EQ 4MG PHOSPHATE/ML	A084493	001
-------	---------------------	---------	-----

BAXTER HLTHCARE	EQ 4MG PHOSPHATE/ML	A084282	001
-----------------	---------------------	---------	-----

BEL MAR	EQ 4MG PHOSPHATE/ML	A084752	001
---------	---------------------	---------	-----

DELL LABS	EQ 4MG PHOSPHATE/ML	A083161	001
-----------	---------------------	---------	-----

INTL MEDICATION	EQ 20MG PHOSPHATE/ML	A088522	001
-----------------	----------------------	---------	-----

Feb 17, 1984

TEVA PARENTERAL	EQ 4MG PHOSPHATE/ML	A081125	001
-----------------	---------------------	---------	-----

Aug 31, 1990

WATSON LABS	EQ 4MG PHOSPHATE/ML	A083702	001
-------------	---------------------	---------	-----

	EQ 4MG PHOSPHATE/ML	A084355	001
--	---------------------	---------	-----

	EQ 4MG PHOSPHATE/ML	A089169	001
--	---------------------	---------	-----

Apr 09, 1986

	EQ 10MG PHOSPHATE/ML	A087668	001
--	----------------------	---------	-----

Jul 01, 1982

	EQ 24MG PHOSPHATE/ML	A085606	001
--	----------------------	---------	-----

WYETH AYERST	EQ 4MG PHOSPHATE/ML	A085641	001
--------------	---------------------	---------	-----



## DISCONTINUED DRUG PRODUCT LIST

6 - 95 (of 324)

DEXAMETHASONE SODIUM PHOSPHATE

## INJECTABLE; INJECTION

## HEXADROL

ORGANON USA INC	EQ 4MG PHOSPHATE/ML	N014694	002
	EQ 10MG PHOSPHATE/ML	N014694	003
	EQ 20MG PHOSPHATE/ML	N014694	004

## OINTMENT; OPHTHALMIC

## DECADRON

MERCK	EQ 0.05% PHOSPHATE	N011977	001
-------	--------------------	---------	-----

## DEXAIR

PHARMAFAIR	EQ 0.05% PHOSPHATE	A088071	001	Dec 28, 1982
------------	--------------------	---------	-----	--------------

## MAXIDEX

ALCON	EQ 0.05% PHOSPHATE	A083342	001
-------	--------------------	---------	-----

## SOLUTION/DROPS; OPHTHALMIC

## DEXAIR

PHARMAFAIR	EQ 0.1% PHOSPHATE	A088433	001	Dec 15, 1983
------------	-------------------	---------	-----	--------------

## DEXAMETHASONE SODIUM PHOSPHATE

SOLA BARNES HIND	EQ 0.1% PHOSPHATE	A084170	001
------------------	-------------------	---------	-----

	EQ 0.1% PHOSPHATE	A084173	001
--	-------------------	---------	-----

## SOLUTION/DROPS; OPHTHALMIC, OTIC

## DECADRON

MERCK	EQ 0.1% PHOSPHATE	N011984	001
-------	-------------------	---------	-----

## SOLUTION/DROPS; OTIC

## DEXAMETHASONE SODIUM PHOSPHATE

AKORN	EQ 0.1% PHOSPHATE	A084855	001
-------	-------------------	---------	-----

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## DECADRON W/ XYLOCAINE

MERCK	EQ 4MG PHOSPHATE/ML;10MG/ML	N013334	002
-------	-----------------------------	---------	-----

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

## OINTMENT; OPHTHALMIC

## NEODECADRON

MERCK	EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM	N050324	001
-------	-------------------------------------	---------	-----

## SOLUTION/DROPS; OPHTHALMIC

## NEODECADRON

MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N050322	001
-------	------------------------------------	---------	-----

## NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

BAUSCH AND LOMB	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A064055	001	Oct 30, 1995
-----------------	------------------------------------	---------	-----	--------------

## NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

ALCON UNIVERSAL	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062714	001	Jul 21, 1986
-----------------	------------------------------------	---------	-----	--------------

PHARMAFAIR	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062539	001	Jan 10, 1985
------------	------------------------------------	---------	-----	--------------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

## OINTMENT; OPHTHALMIC

## DEXACIDIN

NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062566	001	Feb 22, 1985
----------	---------------------------------------	---------	-----	--------------

## DEXASPORIN

PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062411	001	May 16, 1983
------------	---------------------------------------	---------	-----	--------------

## SUSPENSION/DROPS; OPHTHALMIC

## DEXACIDIN

NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062544	001	Oct 29, 1984
----------	---------------------------------------	---------	-----	--------------

## DEXASPORIN

PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062428	001	May 18, 1983
------------	---------------------------------------	---------	-----	--------------

DEXBROMPHENIRAMINE MALEATE

## SYRUP; ORAL

## DISOMER

SCHERING	2MG/5ML	N011814	002
----------	---------	---------	-----

## TABLET; ORAL

## DISOMER

SCHERING	2MG	N011814	001
----------	-----	---------	-----

## DISCONTINUED DRUG PRODUCT LIST

6 - 96 (of 324)

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET; ORAL				
DISOPHROL				
SCHERING	2MG;60MG	N012394	002	
TABLET, EXTENDED RELEASE; ORAL				
BROMPHERIL				
COPLY PHARM	6MG;120MG	A089116	001	Jan 22, 1987
DISOBROM				
SANDOZ	6MG;120MG	A070770	001	Sep 30, 1991
RESPORAL				
PIONEER PHARMS	6MG;120MG	A089139	001	Jun 16, 1988

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL				
POLARAMINE				
SCHERING	2MG/5ML	A086837	001	Jul 19, 1982
TABLET; ORAL				
DEXCHLORPHENIRAMINE MALEATE				
PLIVA	2MG	A088682	001	Jan 17, 1986
POLARAMINE				
SCHERING	2MG	A086835	001	

DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL				
DEXAMPEX				
TEVA	15MG	A085355	001	
CAPSULE, EXTENDED RELEASE; ORAL				
DEXTROAMPHETAMINE SULFATE				
ABLE	5MG	A076814	001	Aug 25, 2004
	10MG	A076814	002	Aug 25, 2004
	15MG	A076814	003	Aug 25, 2004
ELIXIR; ORAL				
DEXEDRINE				
GLAXOSMITHKLINE	5MG/5ML	A083902	001	
TABLET; ORAL				
DEXAMPEX				
TEVA	5MG	A083735	001	
	10MG	A083735	002	
DEXEDRINE				
GLAXOSMITHKLINE	5MG	A084935	001	
DEXTROAMPHETAMINE SULFATE				
ENDO PHARMS	5MG	A040299	001	May 13, 1999
HALSEY	10MG	A083930	001	
LANNETT	5MG	A083903	001	
	10MG	A083903	003	
	15MG	A085652	001	
MAST MM	5MG	A086521	001	
PUREPAC PHARM	5MG	A084125	001	
SANDOZ	5MG	A085370	001	
	10MG	A085371	001	
VITARINE	5MG	A084986	001	
	10MG	A085892	001	
DEXTROSTAT				
SHIRE	5MG	A084051	001	
	10MG	A084051	002	
FERNDEX				
FERNDALE LABS	5MG	A084001	001	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL				
PHERAZINE DM				
HALSEY	15MG/5ML;6.25MG/5ML	A088913	001	Mar 02, 1987
PROMETHAZINE HYDROCHLORIDE AND DESTROMETHORPHAN HYDROBROMIDE				
ANI PHARMS	15MG/5ML;6.25MG/5ML	N011265	002	Apr 02, 1984

## DISCONTINUED DRUG PRODUCT LIST

6 - 97 (of 324)

DEXTROSE

## INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML	N018046	001
MILES	10GM/100ML	N018504	001
DEXTROSE 2.5% IN PLASTIC CONTAINER			
B BRAUN	2.5GM/100ML	N018358	001
	2.5GM/100ML	N019626	001 Feb 02, 1988
DEXTROSE 38.5% IN PLASTIC CONTAINER			
ABBOTT	38.5GM/100ML	N018923	001 Sep 19, 1984
DEXTROSE 5% IN PLASTIC CONTAINER			
DHL	5GM/100ML	N019971	001 Sep 28, 1995
DEXTROSE 60%			
B BRAUN	60GM/100ML	N017995	002 Sep 22, 1982
DEXTROSE 60% IN PLASTIC CONTAINER			
B BRAUN	60GM/100ML	N017995	001
BAXTER HLTHCARE	60GM/100ML	N020047	002 Jul 02, 1991
HOSPIRA	60GM/100ML	N019346	001 Jan 25, 1985
DEXTROSE 7.7% IN PLASTIC CONTAINER			
B BRAUN	7.7GM/100ML	N019626	003 Feb 02, 1988

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

## INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019025	001 Dec 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N018273	001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

## INJECTABLE; INJECTION

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018274	001

DEXTROSE; POTASSIUM CHLORIDE

## INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;37MG/100ML	N019699	001 Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;75MG/100ML	N019699	002 Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML	N019699	003 Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML	N019699	005 Sep 29, 1989

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML	N018270	001

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%			
B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N018268	009
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N018268	004

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 539 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 98 (of 324)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N018268	005
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N018268	006
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N018268	011 Jan 18, 1986
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N018268	012 Jan 18, 1986
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N018268	013 Jan 18, 1986
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N018268	014 Jan 18, 1986
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%			
B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML	N018268	010
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N018268	001
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N018268	002
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N018268	003
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008	003
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008	001
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008	002

DEXTROSE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;200MG/100ML	N018386	001
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;450MG/100ML	N018229	001
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;900MG/100ML	N018047	001
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	2.5GM/100ML;450MG/100ML	N018030	001
HOSPIRA	2.5GM/100ML;450MG/100ML	N018096	001
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	2.5GM/100ML;900MG/100ML	N018376	001
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ABBOTT	3.3GM/100ML;300MG/100ML	N018055	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML	N018030	005
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;200MG/100ML	N018030	004
MILES	5GM/100ML;200MG/100ML	N018399	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;225MG/100ML	N019482	001 Oct 04, 1985
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;300MG/100ML	N019486	001 Oct 04, 1985
MILES	5GM/100ML;300MG/100ML	N018501	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;330MG/100ML	N018030	003
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;450MG/100ML	N019484	001 Oct 04, 1985
B BRAUN	5GM/100ML;450MG/100ML	N018030	002
MILES	5GM/100ML;450MG/100ML	N018400	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;900MG/100ML	N019483	001 Oct 04, 1985
B BRAUN	5GM/100ML;900MG/100ML	N018026	001
MILES	5GM/100ML;900MG/100ML	N018500	001

## DISCONTINUED DRUG PRODUCT LIST

6 - 99 (of 324)

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN

ABBOTT

1MG	N012302	005
2MG	N012302	002
4MG	N012302	004
6MG	N012302	006

DEZOCINE

INJECTABLE; INJECTION

DALGAN

ASTRAZENECA

5MG/ML	N019082	001	Dec 29, 1989
10MG/ML	N019082	002	Dec 29, 1989
15MG/ML	N019082	003	Dec 29, 1989

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

ANGIOVIST 282

BAYER HLTHCARE

60%	A087726	001	Sep 23, 1982
-----	---------	-----	--------------

CARDIOGRAFIN

BRACCO

85%	N011620	002
-----	---------	-----

DIATRIZOATE MEGLUMINE

BRACCO

76%	N010040	017
-----	---------	-----

HYPAQUE

GE HEALTHCARE

30%	N016403	002
60%	N016403	001

RENO-60

BRACCO

60%	N010040	016
-----	---------	-----

RENO-DIP

BRACCO

30%	N010040	012
-----	---------	-----

UROVIST MEGLUMINE DIU/CT

BAYER HLTHCARE

30%	A087739	001	Sep 23, 1982
-----	---------	-----	--------------

SOLUTION; URETERAL

RENO-30

BRACCO

30%	N010040	021
-----	---------	-----

UROVIST CYSTO

BAYER HLTHCARE

30%	A087729	001	Sep 23, 1982
-----	---------	-----	--------------

UROVIST CYSTO PEDIATRIC

BAYER HLTHCARE

30%	A087731	001	Sep 23, 1982
-----	---------	-----	--------------

SOLUTION; URETHRAL

HYPAQUE-CYSTO

GE HEALTHCARE

30%	N016403	003
-----	---------	-----

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

ANGIOVIST 292

BAYER HLTHCARE

52%;8%	A087724	001	Sep 23, 1982
--------	---------	-----	--------------

ANGIOVIST 370

BAYER HLTHCARE

66%;10%	A087723	001	Sep 23, 1982
---------	---------	-----	--------------

DIATRIZOATE-60

INTL MEDICATION

52%;8%	A088166	001	Jun 17, 1983
--------	---------	-----	--------------

HYPAQUE-76

GE HEALTHCARE

66%;10%	A086505	001
---------	---------	-----

HYPAQUE-M, 75%

GE HEALTHCARE

50%;25%	N010220	003
---------	---------	-----

HYPAQUE-M, 90%

GE HEALTHCARE

60%;30%	N010220	002
---------	---------	-----

MD-60

MALLINCKRODT

52%;8%	A087074	001
--------	---------	-----

MD-76

MALLINCKRODT

66%;10%	A087073	001
---------	---------	-----

RENOCAL-76

BRACCO

66%;10%	A089347	001	Jun 01, 1988
---------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 100 (of 324)

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

## INJECTABLE; INJECTION

RENOGRAFIN-60

BRACCO 52%;8% N010040 006

RENOVIST

BRACCO 34.3%;35% N010040 020

RENOVIST II

BRACCO 28.5%;29.1% N010040 019

## SOLUTION; ORAL, RECTAL

GASTROVIST

BAYER HLTHCARE 66%;10% A087728 001 Sep 23, 1982

DIATRIZOATE SODIUM

## INJECTABLE; INJECTION

HYPAQUE

GE HEALTHCARE 25% N009561 003

50% N009561 001

MD-50

MALLINCKRODT 50% A087075 001

UROVIST SODIUM 300

BAYER HLTHCARE 50% A087725 001 Sep 23, 1982

## SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE 40% N011386 003

## SOLUTION; URETERAL

HYPAQUE SODIUM 20%

GE HEALTHCARE 20% N009561 002

DIAZEPAM

## CAPSULE, EXTENDED RELEASE; ORAL

VALRELEASE

ROCHE 15MG N018179 001

## GEL; RECTAL

DIASTAT

VALEANT 5MG/ML (5MG/ML) N020648 002 Jul 29, 1997

10MG/2ML (5MG/ML) N020648 003 Jul 29, 1997

15MG/3ML (5MG/ML) N020648 004 Jul 29, 1997

20MG/4ML (5MG/ML) N020648 005 Jul 29, 1997

## INJECTABLE; INJECTION

DIAZEPAM

ABRAXIS PHARM 5MG/ML A070662 001 Jun 25, 1986

BAXTER HLTHCARE 5MG/ML A070311 001 Dec 16, 1985

5MG/ML A070312 001 Dec 16, 1985

5MG/ML A070313 001 Dec 16, 1985

5MG/ML A071308 001 Jul 17, 1987

5MG/ML A071309 001 Jul 17, 1987

5MG/ML A071310 001 Jul 17, 1987

MARSAM PHARMS LLC 5MG/ML A072370 001 Jan 29, 1993

5MG/ML A072371 001 Jan 29, 1993

5MG/ML A072397 001 Jan 29, 1993

PARENTA PHARMS 5MG/ML A076815 001 Apr 15, 2004

US ARMY 5MG/ML N020124 001 Dec 05, 1990

WARNER CHILCOTT 5MG/ML A071613 001 Oct 22, 1987

5MG/ML A071614 001 Oct 22, 1987

WATSON LABS 5MG/ML A070911 001 Aug 28, 1986

5MG/ML A070912 001 Aug 28, 1986

5MG/ML A070930 001 Dec 01, 1986

DIZAC

PHARMACIA AND UPJOHN 5MG/ML N019287 001 Jun 18, 1993

VALIUM

ROCHE 5MG/ML N016087 001

## TABLET; ORAL

DIAZEPAM

DAVA PHARMS INC 5MG A070227 001 Sep 26, 1985

10MG A070228 001 Sep 26, 1985

## DISCONTINUED DRUG PRODUCT LIST

6 - 101 (of 324)

DIAZEPAM

TABLET; ORAL

DIAZEPAM

DURAMED PHARMS BARR	2MG	A070894	001	Aug 27, 1986
	5MG	A070895	001	Aug 27, 1986
	10MG	A070896	001	Aug 27, 1986
FERNDALE LABS	2MG	A070903	001	Apr 01, 1987
	5MG	A070904	001	Apr 01, 1987
	10MG	A070905	001	Apr 01, 1987
HALSEY	2MG	A070987	001	Aug 15, 1986
	5MG	A070996	001	Aug 15, 1986
	10MG	A070956	001	Aug 15, 1986
IVAX SUB TEVA PHARMS	2MG	A070360	001	Sep 04, 1985
	5MG	A070361	001	Sep 04, 1985
	10MG	A070362	001	Sep 04, 1985
MARTEC USA LLC	10MG	A072402	001	Apr 25, 1989
PAR PHARM	2MG	A070462	001	Feb 25, 1986
	5MG	A070463	001	Feb 25, 1986
	10MG	A070464	001	Feb 25, 1986
PIONEER PHARMS	2MG	A070787	001	Aug 02, 1988
	5MG	A070788	001	Aug 02, 1988
	10MG	A070776	001	Aug 02, 1988
ROXANE	2MG	A070356	001	Jun 17, 1986
	5MG	A070357	001	Jun 17, 1986
	10MG	A070358	001	Jun 17, 1986
SANDOZ	2MG	A070302	001	Dec 20, 1985
	5MG	A070303	001	Dec 20, 1985
	10MG	A070304	001	Dec 20, 1985
WARNER CHILCOTT	2MG	A070209	001	Sep 04, 1985
	5MG	A070210	001	Sep 04, 1985
	10MG	A070222	001	Sep 04, 1985
WATSON LABS	2MG	A070456	001	Nov 01, 1985
	5MG	A070457	001	Nov 01, 1985
	10MG	A070458	001	Nov 01, 1985
Q-PAM				
QUANTUM PHARMICS	2MG	A070423	001	Dec 12, 1985
	2MG	A072431	001	Apr 29, 1988
	5MG	A070424	001	Dec 12, 1985
	5MG	A072432	001	Apr 29, 1988
	10MG	A070425	001	Dec 12, 1985
	10MG	A072433	001	Apr 29, 1988

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

TEVA GLOBAL

50MG

N017425 001

100MG

N017425 002

INJECTABLE; INJECTION

DIAZOXIDE

ABRAXIS PHARM

15MG/ML

A071519 001

Aug 26, 1987

HYPERSTAT

SCHERING

15MG/ML

N016996 001

DIBUCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

HEAVY SOLUTION NUPERCAINE

NOVARTIS

2.5MG/ML

N006203 001

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

TARO

50MG

N011366 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 102 (of 324)

DICLOFENAC POTASSIUM

TABLET; ORAL

CATAFLAM

NOVARTIS

25MG

N020142 001

Nov 24, 1993

DICLOFENAC POTASSIUM

MUTUAL PHARM

50MG

A075470 001

Feb 21, 2002

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

FALCON PHARMS

0.1%

N020809 001

May 04, 1998

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

PLIVA

50MG

A074432 002

Jul 29, 1999

75MG

A074432 003

Jul 29, 1999

ROXANE

25MG

A074391 001

Jun 29, 1995

50MG

A074391 002

Jun 29, 1995

75MG

A074391 003

Jun 29, 1995

TEVA

50MG

A074723 001

Mar 30, 1999

75MG

A074390 001

Aug 15, 1996

TEVA PHARMS

25MG

A074459 001

Jun 25, 1997

50MG

A074459 002

Jun 25, 1997

75MG

A074459 003

Jun 25, 1997

VOLTAREN

NOVARTIS

25MG

N019201 001

Jul 28, 1988

50MG

N019201 002

Jul 28, 1988

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DYCILL

GLAXOSMITHKLINE

EQ 250MG BASE

A060254 002

EQ 250MG BASE

A062238 001

EQ 500MG BASE

A060254 003

EQ 500MG BASE

A062238 002

PATHOCIL

WYETH AYERST

EQ 250MG BASE

N050011 002

EQ 500MG BASE

N050011 003

Mar 28, 1983

FOR SUSPENSION; ORAL

DICLOXACILLIN SODIUM

APOTHECON

EQ 62.5MG BASE/5ML

A061455 001

DYNAPEN

APOTHECON

EQ 62.5MG BASE/5ML

N050337 002

PATHOCIL

WYETH AYERST

EQ 62.5MG BASE/5ML

N050092 001

DICUMAROL

CAPSULE; ORAL

DICUMAROL

LILLY

25MG

N005509 003

50MG

N005509 001

TABLET; ORAL

DICUMAROL

ABBOTT

25MG

N005545 003

50MG

N005545 004

100MG

N005545 005

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HYDROCHLORIDE

MUTUAL PHARM

10MG

A084505 001

Oct 21, 1986

PIONEER PHARMS

10MG

A089361 001

Jan 10, 1989

WATSON LABS

10MG

A083179 001

Feb 12, 1986



## DISCONTINUED DRUG PRODUCT LIST

6 - 103 (of 324)

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE

WATSON LABS 10MG/ML

A080614 001 Feb 11, 1986

SYRUP; ORAL

DICYCLOMINE HYDROCHLORIDE

ALPHARMA US PHARMS 10MG/5ML

A084479 001

TABLET; ORAL

DICYCLOMINE HYDROCHLORIDE

MUTUAL PHARM 20MG

A084600 001 Jul 29, 1985

PIONEER PHARMS 20MG

A088585 001 Aug 20, 1986

WATSON LABS 20MG

A084361 001 Feb 06, 1986

DIDANOSINE

FOR SOLUTION; ORAL

VIDEX

BRISTOL MYERS SQUIBB 100MG/PACKET

N020155 003 Oct 09, 1991

167MG/PACKET

N020155 004 Oct 09, 1991

250MG/PACKET

N020155 005 Oct 09, 1991

375MG/PACKET

N020155 006 Oct 09, 1991

TABLET, CHEWABLE; ORAL

VIDEX

BRISTOL MYERS SQUIBB 25MG

N020154 002 Oct 09, 1991

50MG

N020154 003 Oct 09, 1991

100MG

N020154 004 Oct 09, 1991

150MG

N020154 005 Oct 09, 1991

200MG

N020154 006 Oct 28, 1999

DIENESTROL

CREAM; VAGINAL

DIENESTROL

ORTHO MCNEIL PHARM 0.01%

N006110 005

DV

SANOFI AVENTIS US 0.01%

A083518 001

ESTRAGUARD

SOLVAY 0.01%

A084436 001

SUPPOSITORY; VAGINAL

DV

SANOFI AVENTIS US 0.7MG

A083517 001

DIETHYLCARBAMAZINE CITRATE

TABLET; ORAL

HETRAZAN

LEDERLE 50MG

N006459 001

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

SANDOZ 25MG

A085916 001

TEVA 25MG

A088642 001 Sep 20, 1984

TG UNITED LABS 25MG

A088267 001 Aug 25, 1983

25MG

A088268 001 Aug 25, 1983

UCB INC 25MG

A085544 001

WATSON LABS 25MG

A085741 001

TENUATE

SANOFI AVENTIS US 25MG

N017668 001

TEPANIL

3M 25MG

N011673 001

TABLET, EXTENDED RELEASE; ORAL

TENUATE

SANOFI AVENTIS US 75MG

N017669 001

TEPANIL TEN-TAB

3M 75MG

N017956 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 104 (of 324)

DIETHYLSTILBESTROL

## INJECTABLE; INJECTION

## STILBESTROL

BRISTOL MYERS SQUIBB	0.2MG/ML	N004056	003
	0.5MG/ML	N004056	004
	1MG/ML	N004056	005
	5MG/ML	N004056	006

## SUPPOSITORY; VAGINAL

## DIETHYLSTILBESTROL

LILLY	0.1MG	N004040	001
	0.5MG	N004040	002

## STILBESTROL

BRISTOL MYERS SQUIBB	0.1MG	N004056	001
	0.5MG	N004056	002

## TABLET; ORAL

## DIETHYLSTILBESTROL

LILLY	0.1MG	N004041	002
	0.5MG	N004041	003
	1MG	N004041	004
	5MG	N004041	005

## STILBESTROL

TABLICAPS	0.5MG	A083004	001
	1MG	A083002	001
	5MG	A083006	001

## STILBETIN

BRISTOL MYERS SQUIBB	0.1MG	N004056	007
	0.25MG	N004056	017
	0.5MG	N004056	008
	1MG	N004056	009
	5MG	N004056	010

## TABLET, DELAYED RELEASE; ORAL

## DIETHYLSTILBESTROL

LILLY	0.1MG	N004039	002
	0.25MG	N004039	005
	0.5MG	N004039	003
	1MG	N004039	004
	5MG	N004039	006

## STILBESTROL

TABLICAPS	0.5MG	A083003	001
	1MG	A083005	001
	5MG	A083007	001

## STILBETIN

BRISTOL MYERS SQUIBB	0.1MG	N004056	011
	0.5MG	N004056	012
	1MG	N004056	013
	5MG	N004056	014

DIETHYLSTILBESTROL DIPHOSPHATE

## INJECTABLE; INJECTION

## STILPHOSTROL

BAYER PHARMS	250MG/5ML	N010010	001
--------------	-----------	---------	-----

## TABLET; ORAL

## STILPHOSTROL

BAYER PHARMS	50MG	N010010	002
--------------	------	---------	-----

DIFLORASONE DIACETATE

## CREAM; TOPICAL

## FLORONE

PHARMACIA AND UPJOHN	0.05%	N017741	001
----------------------	-------	---------	-----

## FLORONE E

PHARMACIA AND UPJOHN	0.05%	N019259	001	Aug 28, 1985
----------------------	-------	---------	-----	--------------

## OINTMENT; TOPICAL

## PSORCON

PHARMACIA AND UPJOHN	0.05%	N019260	001	Aug 28, 1985
----------------------	-------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 105 (of 324)

DIFLORASONE DIACETATE

OINTMENT; TOPICAL

PSORCON E

PHARMACIA AND UPJOHN 0.05% N017994 001

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

PUREPAC PHARM 250MG A074285 001 May 07, 1996

500MG A074285 002 May 07, 1996

ROXANE 250MG A073562 001 Nov 27, 1992

500MG A073563 001 Nov 27, 1992

SANDOZ 500MG A074604 001 Jun 10, 1996

TEVA 250MG A073679 001 Jul 31, 1992

WATSON LABS 250MG A074400 001 Jul 17, 1997

500MG A074400 002 Jul 17, 1997

DOLOBID

MERCK 250MG N018445 001 Apr 19, 1982

500MG N018445 002 Apr 19, 1982

DIGITOXIN

INJECTABLE; INJECTION

CRYSTODIGIN

LILLY 0.2MG/ML A084100 005

DIGOXIN

CAPSULE; ORAL

LANOXICAPS

SMITHKLINE BEECHAM 0.15MG N018118 004 Sep 24, 1984

INJECTABLE; INJECTION

DIGOXIN

ABRAXIS PHARM 0.25MG/ML A083217 001

HOSPIRA 0.25MG/ML A040206 001 Aug 28, 1998

WYETH AYERST 0.25MG/ML A084386 001

DIGOXIN PEDIATRIC

HOSPIRA 0.1MG/ML A040092 001 Apr 25, 1996

TABLET; ORAL

LANOXIN

SMITHKLINE BEECHAM 0.0625MG N020405 001 Sep 30, 1997

0.1875MG N020405 003 Sep 30, 1997

0.375MG N020405 005 Sep 30, 1997

0.5MG N020405 006 Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

EMBOLEX

NOVARTIS 0.5MG/0.5ML; 2,500 N018885 001 Nov 30, 1984

UNITS/0.5ML; 5.33MG/0.5ML

0.5MG/0.7ML; 5,000 N018885 002 Nov 30, 1984

UNITS/0.7ML; 7.46MG/0.7ML

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM SR

BIOVAIL 60MG N019471 001 Jan 23, 1989

90MG N019471 002 Jan 23, 1989

120MG N019471 003 Jan 23, 1989

180MG N019471 004 Jan 23, 1989

DILTIAZEM HYDROCHLORIDE

BIOVAIL 60MG A074845 001 Sep 15, 1999

90MG A074845 002 Sep 15, 1999

120MG A074845 003 Sep 15, 1999

120MG N020939 001 Jan 28, 2000

180MG N020939 002 Jan 28, 2000

## DISCONTINUED DRUG PRODUCT LIST

6 - 106 (of 324)

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

BIOVAIL	240MG	N020939	003	Jan 28, 2000
	300MG	N020939	004	Jan 28, 2000
	360MG	N020939	005	Sep 14, 2001
	420MG	N020939	006	Sep 14, 2001
TEVA	60MG	A074079	001	Nov 30, 1993
	90MG	A074079	002	Nov 30, 1993
	120MG	A074079	003	Nov 30, 1993

INJECTABLE; INJECTION

CARDIZEM

BIOVAIL	100MG/VIAL	N020792	001	Sep 05, 1997
BIOVAIL LABS INTL	5MG/ML	N020027	001	Oct 24, 1991
	25MG/VIAL	N020027	003	Aug 18, 1995

DILTIAZEM HYDROCHLORIDE

HOSPIRA	5MG/ML	A075004	001	Feb 16, 2000
	5MG/ML	A075106	001	Apr 29, 1999

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

APOTHECON	30MG	A074051	001	Mar 31, 1993
	60MG	A074051	002	Mar 31, 1993
	90MG	A074051	003	Mar 31, 1993
	120MG	A074051	004	Mar 31, 1993
IVAX SUB TEVA PHARMS	30MG	A074168	001	Mar 03, 1995
	60MG	A074168	002	Mar 03, 1995
	90MG	A074168	003	Mar 03, 1995
	120MG	A074168	004	Mar 03, 1995
TEVA	30MG	A074084	001	Feb 25, 1994
	60MG	A074084	002	Feb 25, 1994
TEVA PHARMS	30MG	A074067	001	Nov 05, 1992
	60MG	A074067	002	Nov 05, 1992
	90MG	A074067	003	Nov 05, 1992
	120MG	A074067	004	Nov 05, 1992

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL

TIAMATE

MERCK	EQ 120MG HCL	N020506	001	Oct 04, 1996
	EQ 180MG HCL	N020506	002	Oct 04, 1996
	EQ 240MG HCL	N020506	003	Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL

TECZEM

BIOVAIL	EQ 180MG HCL;5MG	N020507	001	Oct 04, 1996
---------	------------------	---------	-----	--------------

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

BAXTER HLTHCARE	50MG/ML	A084767	001	
WATSON LABS	50MG/ML	A083531	001	
WYETH AYERST	50MG/ML	A084316	001	

LIQUID; ORAL

DIMENHYDRINATE

ALRA	12.5MG/4ML	A080715	001	
------	------------	---------	-----	--

TABLET; ORAL

DIMENHYDRINATE

HEATHER	50MG	A080841	001	
NEXGEN PHARMA INC	50MG	A085985	001	
WATSON LABS	50MG	A085166	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 107 (of 324)

DIMYRISTOYL LECITHIN; PERFLEXANEINJECTABLE; INTRAVENOUS  
IMAGENT

IMCOR PHARMS CO 0.92MG/VIAL;0.092MG/VIAL N021191 001 May 31, 2002

DINOPROST TROMETHAMINEINJECTABLE; INJECTION  
PROSTIN F2 ALPHA

PHARMACIA AND UPJOHN EQ 5MG BASE/ML N017434 001

DIPHEMANIL METHYLSULFATETABLET; ORAL  
PRANTAL

SCHERING 100MG N008114 004

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

BENADRYL

MCNEIL CONS 25MG N005845 007

50MG N005845 001

DIPHENHYDRAMINE HYDROCHLORIDE

ALRA 25MG A080519 004

50MG A080519 003

ANABOLIC 50MG A083275 001

ELKINS SINN 25MG A085701 001

50MG A085701 002

HALSEY 50MG A087914 001 Jun 04, 1984

HEATHER 25MG A084524 001

50MG A083953 001

IMPAX LABS 25MG A080807 001

50MG A080807 002

IVAX SUB TEVA PHARMS 25MG A080762 001

50MG A080762 002

LANNETT 25MG A080868 001

50MG A080868 002

LEDERLE 25MG A086874 001

50MG A086875 001

LNK 25MG A087977 001 Jan 27, 1983

50MG A087978 001 Jan 27, 1983

MK LABS 25MG A083087 001

50MG A083087 002

MUTUAL PHARM 25MG A084506 001

25MG A089488 001 Jan 02, 1987

50MG A089489 001 Jan 02, 1987

NEWTRON PHARMS 25MG A086543 001

50MG A086544 001

NEXGEN PHARMA INC 25MG A083634 001

PERRIGO 25MG A083061 001

50MG A083061 002

PIONEER PHARMS 25MG A089101 001 Dec 20, 1985

50MG A088880 001 Dec 20, 1985

PUREPAC PHARM 25MG A085156 001

50MG A085150 001

PVT FORM 25MG A083027 001

50MG A083027 002

ROXANE 50MG A080635 001

SANDOZ 25MG A080832 001

25MG A080845 002

50MG A080832 002

50MG A080845 001

SUPERPHARM 25MG A089040 001 May 15, 1985

50MG A089041 001 May 15, 1985

TEVA 25MG A085874 001

50MG A085874 002

## DISCONTINUED DRUG PRODUCT LIST

6 - 108 (of 324)

DIPHENHYDRAMINE HYDROCHLORIDE

## CAPSULE; ORAL

## DIPHENHYDRAMINE HYDROCHLORIDE

VALEANT PHARM INTL	25MG	A080596	001	
	50MG	A080592	001	
VANGARD	25MG	A088034	001	Oct 27, 1982
	50MG	A087630	001	
WATSON LABS	25MG	A080728	001	
	25MG	A083797	001	
	25MG	A085138	001	
	50MG	A080727	001	
	50MG	A083797	002	
	50MG	A085083	001	
WEST WARD	50MG	A083567	001	
WHITEWORTH TOWN PLSN	25MG	A083441	001	
	50MG	A080800	001	

## ELIXIR; ORAL

## BELIX

HALSEY	12.5MG/5ML	A086586	001	Oct 03, 1983
--------	------------	---------	-----	--------------

## BENADRYL

MCNEIL CONS	12.5MG/5ML	N005845	004	
-------------	------------	---------	-----	--

## DIBENIL

CENCI	12.5MG/5ML	A088304	001	Dec 16, 1983
-------	------------	---------	-----	--------------

## DIPHEN

USL PHARMA	12.5MG/5ML	A084640	001	
------------	------------	---------	-----	--

## DIPHENHYDRAMINE HYDROCHLORIDE

BUNDY	12.5MG/5ML	A083674	001	
CENCI	12.5MG/5ML	A087941	001	Dec 17, 1982
KV PHARM	12.5MG/5ML	A085621	001	
LANNETT	12.5MG/5ML	A080939	002	
LEDERLE	12.5MG/5ML	A086937	001	
MK LABS	12.5MG/5ML	A083088	002	
NASKA	12.5MG/5ML	A088680	001	May 31, 1985
PERRIGO	12.5MG/5ML	A083063	001	
PUREPAC PHARM	12.5MG/5ML	A083237	001	Jan 25, 1982
PVT FORM	12.5MG/5ML	A085287	001	
ROXANE	12.5MG/5ML	A080643	001	

## HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A080763	002	
--------------------	------------	---------	-----	--

## INJECTABLE; INJECTION

## BENADRYL

MCNEIL CONS	10MG/ML	N006146	001	
-------------	---------	---------	-----	--

## DIPHENHYDRAMINE HYDROCHLORIDE

ABRAXIS PHARM	10MG/ML	A087066	001	
BAXTER HLTHCARE	50MG/ML	A083183	001	
BEL MAR	10MG/ML	A080822	001	
WATSON LABS	10MG/ML	A083533	001	
WYETH AYERST	50MG/ML	A080577	001	

## DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

ABRAXIS PHARM	50MG/ML	A080586	002	
---------------	---------	---------	-----	--

## SYRUP; ORAL

## ANTITUSSIVE

PERRIGO	12.5MG/5ML	A071292	001	Apr 10, 1987
---------	------------	---------	-----	--------------

## BELDIN

HALSEY	12.5MG/5ML	A089179	001	Jun 05, 1986
--------	------------	---------	-----	--------------

## BENYLIN

PARKE DAVIS	12.5MG/5ML	N006514	004	
-------------	------------	---------	-----	--

## DIPHEN

MORTON GROVE	12.5MG/5ML	A070118	001	Oct 01, 1985
--------------	------------	---------	-----	--------------

## DIPHENHYDRAMINE HYDROCHLORIDE

ALPHARMA US PHARMS	12.5MG/5ML	A070497	001	Apr 25, 1989
CUMBERLAND SWAN	12.5MG/5ML	A073611	001	Aug 20, 1992
HI TECH PHARMA	12.5MG/5ML	A072416	001	Sep 28, 1990

## HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A070205	001	Jan 28, 1986
--------------------	------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 109 (of 324)

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL

SILPHEN

SILARX

12.5MG/5ML

A072646 001

Feb 27, 1992

VICKS FORMULA 44

PROCTER AND GAMBLE

12.5MG/5ML

A070524 001

Jan 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

BENYLIN

PARKE DAVIS

12.5MG/5ML; 30MG/5ML

N019014 001

Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET; ORAL

VONTROL

GLAXOSMITHKLINE

EQ 25MG BASE

N016033 001

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

HISPRIL

GLAXOSMITHKLINE

5MG

N011945 001

DIPYRIDAMOLE

INJECTABLE; INJECTION

IV PERSANTINE

BOEHRINGER INGELHEIM

5MG/ML

N019817 001

Dec 13, 1990

TABLET; ORAL

DIPYRIDAMOLE

PUREPAC PHARM

50MG

A089426 001

Jul 12, 1990

75MG

A089427 001

Jul 12, 1990

SANDOZ

25MG

A086944 002

Apr 16, 1991

50MG

A087562 001

Feb 25, 1992

75MG

A087561 001

Feb 25, 1992

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

LILLY RES LABS

250MG

N050678 001

Jun 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

AMNEAL PHARMS NY

EQ 100MG BASE

A071190 001

Jan 15, 1987

EQ 150MG BASE

A071191 001

Jan 15, 1987

IVAX SUB TEVA PHARMS

EQ 100MG BASE

A070186 001

Nov 18, 1985

EQ 150MG BASE

A070187 001

Nov 18, 1985

MUTUAL PHARM

EQ 100MG BASE

A070351 001

Dec 17, 1985

EQ 150MG BASE

A070352 001

Dec 17, 1985

MYLAN

EQ 100MG BASE

A070138 001

Jun 14, 1985

EQ 150MG BASE

A070139 001

Jun 14, 1985

SANDOZ

EQ 100MG BASE

A070470 001

Dec 10, 1985

EQ 150MG BASE

A070471 001

Dec 10, 1985

SUPERPHARM

EQ 100MG BASE

A070940 001

Feb 09, 1987

EQ 150MG BASE

A070941 001

Feb 09, 1987

WATSON LABS

EQ 100MG BASE

A070240 001

Feb 02, 1986

EQ 150MG BASE

A070241 001

Feb 02, 1986

DISULFIRAM

TABLET; ORAL

ANTABUSE

ODYSSEY PHARMS

250MG

N007883 003

500MG

N007883 002

## DISCONTINUED DRUG PRODUCT LIST

6 - 110 (of 324)

DISULFIRAM

TABLET; ORAL

DISULFIRAM

PAR PHARM	250MG	A088792	001	Aug 14, 1984
	500MG	A088793	001	Aug 14, 1984
WATSON LABS	250MG	A086889	001	
	250MG	A087973	001	Aug 05, 1983
	500MG	A086890	001	
	500MG	A087974	001	Aug 05, 1983

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE CP

ABBOTT	EQ 250MG BASE	N019794	001	Jul 11, 1990
	EQ 500MG BASE	N019794	002	Jul 11, 1990

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

ASTRAZENECA	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995
BAXTER HLTHCARE	EQ 12.5MG BASE/ML	A074381	001	Sep 26, 1996
HOSPIRA	EQ 1.25GM BASE/100ML	A074634	001	Sep 27, 1996
LUITPOLD	EQ 12.5MG BASE/ML	A074545	001	Jun 25, 1998
MARSAM PHARMS LLC	EQ 12.5MG BASE/ML	A074279	001	Feb 18, 1998
	EQ 12.5MG BASE/ML	A074995	001	Mar 31, 1998
DOBUTREX				
LILLY	EQ 12.5MG BASE/ML	N017820	002	

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL

ARICEPT

EISAI INC	5MG/5ML	N021719	001	Oct 18, 2004
-----------	---------	---------	-----	--------------

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

ABBOTT	40MG/ML	A070656	001	Jan 24, 1989
	80MG/ML	A070657	001	Jan 24, 1989
ABRAXIS PHARM	40MG/ML	A070012	001	Jun 12, 1985
	40MG/ML	A070058	001	Mar 20, 1985
	40MG/ML	N018549	001	Mar 11, 1983
	80MG/ML	A070013	001	Jun 12, 1985
	80MG/ML	A070059	001	Mar 20, 1985
	160MG/ML	A070364	001	Dec 04, 1985
ASTRAZENECA	40MG/ML	A070087	001	Oct 23, 1985
	40MG/ML	N018656	001	Jun 28, 1983
	80MG/ML	A070089	001	Oct 23, 1985
	80MG/ML	A070090	001	Oct 23, 1985
	80MG/ML	A070091	001	Oct 23, 1985
	160MG/ML	A070092	001	Oct 23, 1985
	160MG/ML	A070093	001	Oct 23, 1985
	160MG/ML	A070094	001	Oct 23, 1985
BAXTER HLTHCARE	40MG/ML	N018398	001	
	80MG/ML	N018398	002	Mar 22, 1982
HOSPIRA	40MG/ML	A074403	001	May 23, 1996
INTL MEDICATION	40MG/ML	N018014	001	
SMITH AND NEPHEW	40MG/ML	A070011	001	Aug 29, 1985
	40MG/ML	A070046	001	Aug 29, 1985
	80MG/ML	A070047	001	Aug 29, 1985
TEVA PARENTERAL	40MG/ML	A072999	001	Oct 23, 1991
	80MG/ML	A073000	001	Oct 23, 1991
WARNER CHILCOTT	40MG/ML	A070558	001	Sep 20, 1985
	40MG/ML	N018138	001	
	80MG/ML	A070559	001	Sep 20, 1985



## DISCONTINUED DRUG PRODUCT LIST

6 - 111 (of 324)

DOPAMINE HYDROCHLORIDE

## INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE	IN DEXTROSE 5%			
HOSPIRA	1.6MG/ML	N020542	001	Aug 30, 1995
INTROPIN				
HOSPIRA	40MG/ML	N017395	001	
	80MG/ML	N017395	002	
	160MG/ML	N017395	003	

DOXACURIUM CHLORIDE

## INJECTABLE; INJECTION

NUROMAX				
ABBOTT	EQ 1MG BASE/ML	N019946	001	Mar 07, 1991

DOXAZOSIN MESYLATE

## TABLET; ORAL

DOXAZOSIN MESYLATE				
GENPHARM	EQ 1MG BASE	A075466	001	Oct 18, 2000
	EQ 2MG BASE	A075466	002	Oct 18, 2000
	EQ 4MG BASE	A075466	003	Oct 18, 2000
	EQ 8MG BASE	A075466	004	Oct 18, 2000
SANDOZ	EQ 1MG BASE	A075646	001	Oct 18, 2000
	EQ 2MG BASE	A075646	002	Oct 18, 2000
	EQ 4MG BASE	A075646	003	Oct 18, 2000
	EQ 8MG BASE	A075646	004	Oct 18, 2000
TEVA	EQ 1MG BASE	A075353	001	Jan 12, 2001
	EQ 2MG BASE	A075353	002	Jan 12, 2001
	EQ 4MG BASE	A075353	003	Jan 12, 2001
	EQ 8MG BASE	A075353	004	Jan 12, 2001

DOXEPIN HYDROCHLORIDE

## CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE				
CLONMEL HLTHCARE	EQ 10MG BASE	A071685	001	Jan 05, 1988
	EQ 25MG BASE	A071686	001	Jan 05, 1988
	EQ 50MG BASE	A071673	001	Jan 05, 1988
	EQ 75MG BASE	A071674	001	Jan 05, 1988
	EQ 100MG BASE	A071675	001	Jan 05, 1988
	EQ 150MG BASE	A071676	001	Jan 05, 1988
MUTUAL PHARM	EQ 25MG BASE	A071502	001	Feb 18, 1988
	EQ 50MG BASE	A071653	001	Feb 18, 1988
	EQ 75MG BASE	A071654	001	Feb 18, 1988
	EQ 100MG BASE	A071521	001	Feb 18, 1988
NEW RIVER	EQ 10MG BASE	N016987	001	
	EQ 25MG BASE	N016987	002	
	EQ 50MG BASE	N016987	003	
	EQ 75MG BASE	N016987	006	
	EQ 100MG BASE	N016987	004	
	EQ 150MG BASE	N016987	007	Apr 13, 1987
PUREPAC PHARM	EQ 10MG BASE	A073054	001	Dec 28, 1990
	EQ 25MG BASE	A072109	001	Dec 28, 1990
	EQ 50MG BASE	A073055	001	Dec 28, 1990
	EQ 75MG BASE	A072386	001	Sep 08, 1988
	EQ 100MG BASE	A072110	001	Sep 08, 1988
	EQ 150MG BASE	A072387	001	Sep 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	A070972	001	Sep 29, 1987
	EQ 25MG BASE	A070973	001	Sep 29, 1987
	EQ 50MG BASE	A070931	001	Sep 29, 1987
	EQ 75MG BASE	A070932	001	Sep 29, 1987
	EQ 100MG BASE	A072375	001	Mar 15, 1989
	EQ 150MG BASE	A072376	001	Mar 15, 1989
SANDOZ	EQ 10MG BASE	A071487	001	Mar 02, 1987
	EQ 25MG BASE	A070827	001	May 15, 1986
	EQ 50MG BASE	A070828	001	May 15, 1986

## DISCONTINUED DRUG PRODUCT LIST

6 - 112 (of 324)

DOXEPIN HYDROCHLORIDE

## CAPSULE; ORAL

## DOXEPIN HYDROCHLORIDE

SANDOZ

EQ 75MG BASE	A070825	001	May 15, 1986	
EQ 100MG BASE	A071562	001	Mar 02, 1987	
WATSON LABS	EQ 10MG BASE	A070952	001	Mar 04, 1987
EQ 10MG BASE	A072985	001	Mar 29, 1991	
EQ 25MG BASE	A070953	001	May 15, 1986	
EQ 25MG BASE	A072986	001	Mar 29, 1991	
EQ 50MG BASE	A070954	001	May 15, 1986	
EQ 50MG BASE	A072987	001	Mar 29, 1991	
EQ 75MG BASE	A071763	001	Feb 09, 1988	
EQ 100MG BASE	A070955	001	May 15, 1986	
EQ 150MG BASE	A071764	001	Feb 09, 1988	

SINEQUAN

PFIZER

EQ 10MG BASE	N016798	003	
EQ 25MG BASE	N016798	001	
EQ 50MG BASE	N016798	002	
EQ 75MG BASE	N016798	006	
EQ 100MG BASE	N016798	005	
EQ 150MG BASE	N016798	007	

## CONCENTRATE; ORAL

SINEQUAN

PFIZER

EQ 10MG BASE/ML	N017516	001	
-----------------	---------	-----	--

DOXORUBICIN HYDROCHLORIDE

## INJECTABLE; INJECTION

ADRIAMYCIN PFS

PHARMACIA AND UPJOHN

2MG/ML	A063165	001	Jan 30, 1991
2MG/ML	N050629	001	Dec 23, 1987
200MG/100ML	A063165	002	Jan 30, 1991
200MG/100ML	N050629	002	May 03, 1988

ADRIAMYCIN RDF

PHARMACIA AND UPJOHN

10MG/VIAL	N050467	001	
20MG/VIAL	N050467	003	May 20, 1985
50MG/VIAL	N050467	002	
150MG/VIAL	N050467	004	Jul 22, 1987

RUBEX

BRISTOL MYERS SQUIBB

10MG/VIAL	A062926	001	Apr 13, 1989
50MG/VIAL	A062926	002	Apr 13, 1989
100MG/VIAL	A062926	003	Apr 13, 1989

DOXYCYCLINE

## CAPSULE; ORAL

DOXYCYCLINE

PAR PHARM

EQ 75MG BASE	A065055	004	Apr 18, 2005
--------------	---------	-----	--------------

## FOR SUSPENSION; ORAL

DOXYCHEL

RACHELLE

EQ 25MG BASE/5ML	A061720	001	
------------------	---------	-----	--

DOXYCYCLINE HYCLATE

## CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AMNEAL PHARMS NY

EQ 50MG BASE	A062763	001	Sep 02, 1988
EQ 100MG BASE	A062763	002	Sep 02, 1988

HALSEY

EQ 50MG BASE	A062119	002	May 24, 1985
EQ 100MG BASE	A062119	001	May 24, 1985

HEATHER

EQ 50MG BASE	A062463	001	Dec 07, 1983
EQ 100MG BASE	A062463	002	Dec 07, 1983

MUTUAL PHARM

EQ 50MG BASE	A062418	001	Jan 28, 1983
EQ 100MG BASE	A062418	002	Jan 28, 1983

MYLAN

EQ 50MG BASE	A062337	001	Mar 29, 1982
EQ 100MG BASE	A062337	002	Mar 29, 1982

PAR PHARM

EQ 50MG BASE	A062434	001	Oct 19, 1984
--------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 113 (of 324)

DOXYCYCLINE HYCLATE

## CAPSULE; ORAL

## DOXYCYCLINE HYCLATE

PAR PHARM	EQ 100MG BASE	A062442	001	Dec 22, 1983
PVT FORM	EQ 50MG BASE	A062631	001	Jul 24, 1986
	EQ 100MG BASE	A062631	002	Jul 24, 1986
RANBAXY	EQ 50MG BASE	A062479	001	Dec 23, 1983
	EQ 100MG BASE	A062479	002	Dec 23, 1983
SUPERPHARM	EQ 50MG BASE	A062469	001	Oct 31, 1984
	EQ 100MG BASE	A062469	002	Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	A062594	001	Dec 05, 1985
	EQ 100MG BASE	A062594	002	Dec 05, 1985
WATSON LABS	EQ 50MG BASE	A061717	001	
	EQ 50MG BASE	A062142	001	
	EQ 100MG BASE	A061717	002	
	EQ 100MG BASE	A062142	002	

## DOXY-LEMMON

TEVA	EQ 50MG BASE	A062497	001	Aug 23, 1984
	EQ 100MG BASE	A062497	002	Jun 15, 1984

## PERIOSTAT

COLLAGENEX	EQ 20MG BASE	N050744	001	Sep 30, 1998
------------	--------------	---------	-----	--------------

## CAPSULE, COATED PELLETS; ORAL

## DOXYCYCLINE HYCLATE

PLIVA	EQ 100MG BASE	A063187	001	Jun 30, 1992
-------	---------------	---------	-----	--------------

## CAPSULE, DELAYED RELEASE; ORAL

## DORYX

MAYNE PHARMA INTL	EQ 75MG BASE	N050582	002	Aug 13, 2001
	EQ 100MG BASE	N050582	001	Jul 22, 1985
WARNER CHILCOTT	EQ 100MG BASE	A062653	001	Oct 30, 1985

## INJECTABLE; INJECTION

## DOXYCHEL HYCLATE

RACHELLE	EQ 100MG BASE/VIAL	A061953	001	
----------	--------------------	---------	-----	--

## DOXYCYCLINE

BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983
BEDFORD	EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988

## DOXYCYCLINE HYCLATE

BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989
	EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989

## VIBRAMYCIN

PFIZER	EQ 100MG BASE/VIAL	N050442	002	
	EQ 200MG BASE/VIAL	N050442	001	

## TABLET; ORAL

## DOXYCYCLINE HYCLATE

AMNEAL PHARMS NY	EQ 100MG BASE	A062764	001	Sep 02, 1988
HEATHER	EQ 100MG BASE	A062462	001	May 11, 1983
MUTUAL PHARM	EQ 100MG BASE	A062391	001	Sep 30, 1982
MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983
PAR PHARM	EQ 20MG BASE	A065287	001	Feb 28, 2006
SUPERPHARM	EQ 100MG BASE	A062494	001	Feb 20, 1985
TRUXTON INC	EQ 50MG BASE	A062269	003	
	EQ 100MG BASE	A062269	002	Nov 08, 1982
WARNER CHILCOTT	EQ 100MG BASE	A062593	001	Aug 28, 1985
WATSON LABS	EQ 50MG BASE	A062392	001	Mar 31, 1983
	EQ 100MG BASE	A062392	002	Mar 31, 1983

## DOXY-LEMMON

TEVA	EQ 100MG BASE	A062581	001	Mar 15, 1985
------	---------------	---------	-----	--------------

DOXYLAMINE SUCCINATE

## CAPSULE; ORAL

## UNISOM

PFIZER	25MG	N019440	001	Feb 05, 1986
--------	------	---------	-----	--------------

## TABLET; ORAL

## DECAPRYN

SANOFI AVENTIS US	12.5MG	N006412	015	
-------------------	--------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 114 (of 324)

DOXYLAMINE SUCCINATE

TABLET; ORAL

DECAPRYN

SANOFI AVENTIS US 25MG N006412 014

DOXYLAMINE SUCCINATE

COPLEY PHARM 25MG A088900 002 Feb 12, 1988

QUANTUM PHARMICS 25MG A088603 001 Aug 07, 1984

DOXY-SLEEP-AID

PAR PHARM 25MG A070156 001 Jul 02, 1987

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BENDECTIN

SANOFI AVENTIS US 10MG;10MG N010598 002

DROMOSTANOLONE PROPIONATE

INJECTABLE; INJECTION

DROLBAN

LILLY 50MG/ML N012936 001

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

ABRAXIS PHARM 2.5MG/ML A070992 001 Nov 17, 1986

2.5MG/ML A070993 001 Nov 17, 1986

ASTRAZENECA 2.5MG/ML A072018 001 Oct 20, 1988

2.5MG/ML A072019 001 Oct 19, 1988

2.5MG/ML A072020 001 Oct 19, 1988

2.5MG/ML A072021 001 Oct 19, 1988

HOSPIRA 2.5MG/ML A071645 001 Apr 07, 1988

2.5MG/ML A072272 001 Aug 31, 1995

SMITH AND NEPHEW 2.5MG/ML A071750 001 Sep 06, 1988

SOLOPAK 2.5MG/ML A071754 001 Sep 06, 1988

WATSON LABS 2.5MG/ML A071755 001 Sep 06, 1988

2.5MG/ML A073520 001 Nov 27, 1991

2.5MG/ML A073521 001 Nov 27, 1991

2.5MG/ML A073523 001 Nov 27, 1991

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA 2.5MG/ML;EQ 0.05MG BASE/ML A072026 001 Apr 13, 1989

2.5MG/ML;EQ 0.05MG BASE/ML A072027 001 Apr 13, 1989

2.5MG/ML;EQ 0.05MG BASE/ML A072028 001 Apr 13, 1989

HOSPIRA 2.5MG/ML;EQ 0.05MG BASE/ML A071982 001 May 04, 1988

INNOVAR

AKORN MFG 2.5MG/ML;EQ 0.05MG BASE/ML N016049 001

DYCLONINE HYDROCHLORIDE

SOLUTION; TOPICAL

DYCLONE

ASTRAZENECA 0.5% N009925 002

1% N009925 001

DYDROGESTERONE

TABLET; ORAL

GYNOREST

SOLVAY 5MG N017388 001

10MG N017388 002

## DISCONTINUED DRUG PRODUCT LIST

6 - 115 (of 324)

DYPHYLLINE

ELIXIR; ORAL NEOTHYLLINE TEVA	160MG/15ML	N007794	003
INJECTABLE; INJECTION NEOTHYLLINE TEVA	250MG/ML	N009088	001
TABLET; ORAL DILOR SAVAGE LABS	200MG	A084514	001
DILOR-400 SAVAGE LABS	400MG	A084751	001
NEOTHYLLINE TEVA	200MG	N007794	001
	400MG	N007794	002

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC PHOSPHOLINE IODIDE WYETH PHARMS INC	0.03%	N011963	002
	0.06%	N011963	004
	0.25%	N011963	003

ECONAZOLE NITRATE

CREAM; TOPICAL SPECTAZOLE ORTHONEUTROGENA	1%	N018751	001	Dec 23, 1982
---	----	---------	-----	--------------

EDETATE CALCIUM DISODIUM

TABLET; ORAL CALCIUM DISODIUM VERSENATE GRACEWAY	500MG	N008922	002
--	-------	---------	-----

EDETATE DISODIUM

INJECTABLE; INJECTION DISODIUM EDETATE WATSON LABS	150MG/ML	A084356	001
EDETATE DISODIUM WATSON LABS	150MG/ML	A080391	001
SODIUM VERSENATE 3M	200MG/ML	N010573	001

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION EDROPHONIUM CHLORIDE WATSON LABS	10MG/ML	A040044	001	Mar 20, 1996
EDROPHONIUM CHLORIDE PRESERVATIVE FREE WATSON LABS	10MG/ML	A040043	001	Mar 20, 1996
REVERSOL ORGANON USA INC	10MG/ML	A089624	001	May 13, 1988

EFAVIRENZ

CAPSULE; ORAL SUSTIVA BRISTOL MYERS SQUIBB	100MG	N020972	002	Sep 17, 1998
TABLET; ORAL SUSTIVA BRISTOL MYERS SQUIBB	300MG	N021360	001	Feb 01, 2002

EFLORNITHINE HYDROCHLORIDE

INJECTABLE; INJECTION ORNIDYL SANOFI AVENTIS US	200MG/ML	N019879	002	Nov 28, 1990
---	----------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 116 (of 324)

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

APOTHECON	2.5MG	A075583	001	Aug 22, 2000
	5MG	A075583	002	Aug 22, 2000
	10MG	A075583	003	Aug 22, 2000
	20MG	A075583	004	Aug 22, 2000
IVAX SUB TEVA PHARMS	2.5MG	A075482	001	Aug 22, 2000
	5MG	A075482	002	Aug 22, 2000
	10MG	A075482	003	Aug 22, 2000
	20MG	A075482	004	Aug 22, 2000
SANDOZ	2.5MG	A075048	001	Aug 22, 2000
	5MG	A075048	002	Aug 22, 2000
	10MG	A075048	003	Aug 22, 2000
	20MG	A075048	004	Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXXEL

ASTRAZENECA	5MG; 2.5MG	N020668	002	Oct 28, 1998
-------------	------------	---------	-----	--------------

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS	5MG; 12.5MG	A075736	001	Mar 25, 2003
	10MG; 25MG	A075736	002	Mar 25, 2003

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

HOSPIRA	1.25MG/ML	A075456	001	Aug 22, 2000
	1.25MG/ML	A075571	001	Aug 22, 2000
VASOTEC				
BIOVAIL LABS INTL	1.25MG/ML	N019309	001	Feb 09, 1988

ENFLURANE

LIQUID; INHALATION

ENFLURANE

ABBOTT	99.9%	A070803	001	Sep 08, 1987
--------	-------	---------	-----	--------------

ENOXACIN

TABLET; ORAL

PENETREX

SANOFI AVENTIS US	200MG	N019616	004	Dec 31, 1991
	400MG	N019616	005	Dec 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX (PRESERVATIVE FREE)

SANOFI AVENTIS US	90MG/0.6ML (150MG/ML)	N020164	006	Jun 02, 2000
-------------------	-----------------------	---------	-----	--------------

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST

STERLING	0.25MG/INH	N016803	001	
----------	------------	---------	-----	--

PRIMATENE MIST

WYETH CONS	0.2MG/INH	N016126	001	
------------	-----------	---------	-----	--

INJECTABLE; INJECTION

SUS-PHRINE SULFITE-FREE

FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999
	5MG/ML	N007942	001	

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N019430	004	Aug 03, 1995
----------------------	-----------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 117 (of 324)

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR

EPIPEN E Z PEN

MERIDIAN MEDCL TECHN 0.3MG/DELIVERY

N019430 003 Aug 03, 1995

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

BRONITIN MIST

WYETH CONS 0.3MG/INH

N016126 002

MEDIHALER-EPI

3M 0.3MG/INH

N010374 003

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA 0.005MG/ML;1%

N017751 006

0.005MG/ML;1.5%

N017751 007

DENTSPLY PHARM 0.005MG/ML;1.5%

N021384 001

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

ASTRAZENECA 0.005MG/ML;4%

N014763 008

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA 0.005MG/ML;0.5%

N017751 004

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE

CARLISLE 0.01MG/ML;2%

A084720 001

0.02MG/ML;2%

A084732 001

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

ELKINS SINN 0.01MG/ML;1%

A080406 001

0.01MG/ML;2%

A080406 002

GRAHAM CHEM 0.01MG/ML;2%

A080504 004

Oct 19, 1983

0.02MG/ML;2%

A080504 005

Oct 19, 1983

HOSPIRA 0.005MG/ML;1.5%

A089650 001

Jun 21, 1988

LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

ABBOTT 0.01MG/ML;1%

A083154 001

BEL MAR 0.01MG/ML;1%

A080820 001

0.01MG/ML;2%

A080757 001

DELL LABS 0.01MG/ML;1%

A083389 001

0.01MG/ML;2%

A083390 001

INTL MEDICATION 0.01MG/ML;1%

A086402 001

WATSON LABS 0.01MG/ML;1%

A080377 003

0.01MG/ML;1%

A085463 001

0.01MG/ML;2%

A080377 004

LIDOCATON

PHARMATON 0.01MG/ML;2%

A084729 001

Aug 17, 1983

0.02MG/ML;2%

A084728 001

Aug 17, 1983

XYLOCAINE W/ EPINEPHRINE

APP PHARMS 0.01MG/ML;2%

N006488 003

ASTRAZENECA 0.005MG/ML;1%

N010418 006

0.005MG/ML;1.5%

N010418 010

0.005MG/ML;2%

N010418 008

PATCH; IONTOPHORESIS, TOPICAL

LIDOSITE TOPICAL SYSTEM KIT

VYTERIS 1.05MG/PATCH;100MG/PATCH

N021504 001

May 06, 2004

SOLUTION; IONTOPHORESIS

IONTOCAINE

IOMED 0.01MG/ML;2%

N020530 001

Dec 21, 1995

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 559 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 118 (of 324)

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

SOLUTION; IONTOPHORESIS, TOPICAL				
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
EMPI	0.01MG/ML; 2%	N021486	001	Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
PROCAINE HYDROCHLORIDE W/ EPINEPHRINE				
BEL MAR	0.02MG/ML; 1%	A080758	001	
	0.02MG/ML; 2%	A080759	001	

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)				
EPIRUBICIN HYDROCHLORIDE				
HOSPIRA	200MG/VIAL	N050807	002	Sep 15, 2006

EPLERENONE

TABLET; ORAL				
INSPRA				
GD SEARLE LLC	100MG	N021437	003	Sep 27, 2002

EPROSARTAN MESYLATE

TABLET; ORAL				
TEVETEN				
ABBOTT	EQ 300MG BASE	N020738	004	Dec 22, 1997

ERGOCALCIFEROL

CAPSULE; ORAL				
DELTALIN				
LILLY	50,000 IU	A080884	001	
VITAMIN D				
CHASE CHEM	50,000 IU	A080747	001	
EVERYLIFE	50,000 IU	A080956	001	
IMPAX LABS	50,000 IU	A080951	001	
LANNETT	50,000 IU	A080825	001	
VITARINE	50,000 IU	A084053	001	
WEST WARD	50,000 IU	A083102	001	

ERGOLOID MESYLATES

CAPSULE; ORAL				
HYDERGINE LC				
NOVARTIS	1MG	N018706	001	Jan 18, 1983
SOLUTION; ORAL				
HYDERGINE				
NOVARTIS	1MG/ML	N018418	001	
TABLET; ORAL				
ERGOLOID MESYLATES				
MUTUAL PHARM	1MG	A088891	001	Nov 01, 1985
WATSON LABS	1MG	A086433	001	May 27, 1982
	1MG	A087244	001	Aug 16, 1982
GERIMAL				
WATSON LABS	1MG	A088207	001	Mar 22, 1984
HYDERGINE				
NOVARTIS	0.5MG	N017993	003	
TABLET; SUBLINGUAL				
ALKERGOT				
SANDOZ	0.5MG	A085153	001	
	1MG	A087417	001	
CIRCANOL				
3M	0.5MG	A084868	001	
	1MG	A085809	001	
DEAPRIL-ST				
BRISTOL MYERS SQUIBB	1MG	A085020	002	



## DISCONTINUED DRUG PRODUCT LIST

6 - 119 (of 324)

ERGOLOID MESYLATES

## TABLET; SUBLINGUAL

## ERGOLOID MESYLATES

KV PHARM	0.5MG	A085899	001	
	0.5MG	A086265	001	
	1MG	A085900	001	
	1MG	A086264	001	
LEDERLE	0.5MG	A086984	001	
	1MG	A086985	001	
MUTUAL PHARM	0.5MG	A087407	001	
	1MG	A087552	001	
SUPERPHARM	0.5MG	A089233	001	Sep 23, 1986
	1MG	A089234	001	Sep 23, 1986
VANGARD	0.5MG	A088013	001	Sep 20, 1982
	1MG	A088014	001	Sep 20, 1982
WATSON LABS	0.5MG	A084930	001	
	1MG	A085177	001	
	1MG	A087183	001	
GERIMAL				
WATSON LABS	0.5MG	A086189	001	
	1MG	A086188	001	
HYDERGINE				
NOVARTIS	0.5MG	N009087	002	
	1MG	N009087	001	
HYDROGENATED ERGOT ALKALOIDS				
IVAX PHARMS	0.5MG	A087186	001	
	1MG	A087185	001	

ERGOTAMINE TARTRATE

## AEROSOL, METERED; INHALATION

## MEDIHALER ERGOTAMINE

3M 0.36MG/INH N012102 001

## TABLET; SUBLINGUAL

## ERGOSTAT

PARKE DAVIS 2MG A088337 001 Jun 08, 1984

## WIGRETTES

ORGANON USA INC 2MG A086750 001 Jul 29, 1982

ERYTHROMYCIN

## CAPSULE, DELAYED REL PELLETS; ORAL

## ERYC

PARKE DAVIS 250MG A062546 001 Jul 25, 1985

250MG A062618 001 Sep 25, 1985

## ERYC 125

PARKE DAVIS 125MG A062648 001 Oct 24, 1985

## ERYC SPRINKLES

HOSPIRA 125MG N050593 001 Jul 22, 1985

## ERYTHROMYCIN

BARR 250MG A063098 001 May 04, 1989

## GEL; TOPICAL

## EMGEL

ALTANA 2% A063107 001 Aug 23, 1991

## LOTION; TOPICAL

## E-SOLVE 2

SYOSSET 2% A062467 001 Jul 03, 1985

## OINTMENT; OPHTHALMIC

## ERYTHROMYCIN

AKORN 0.5% A064030 001 Jul 18, 1996

PHARMADERM 5MG/GM A062446 001 Sep 26, 1983

PHARMAFAIR 5MG/GM A062481 001 Apr 05, 1984

## ILOTYCIN

DISTA 0.5% N050368 001

## POWDER; FOR RX COMPOUNDING

## ERYTHROMYCIN

PADDOCK 100% N050610 001 Nov 07, 1986

## DISCONTINUED DRUG PRODUCT LIST

6 - 120 (of 324)

ERYTHROMYCIN

## SOLUTION; TOPICAL

## A/T/S

TARO PHARMS NORTH	2%	A062405	001	Nov 18, 1982
C-SOLVE-2				
BIOGLAN PHARMA	2%	A062468	001	Jul 03, 1985
ERYDERM				
ABBOTT	2%	A062290	001	
ERYMAX				
MERZ PHARMS	2%	A062508	002	Jul 11, 1985
ERYTHROMYCIN				
ALPHARMA US PHARMS	1.5%	A062328	001	Apr 19, 1982
	2%	A062326	001	Apr 19, 1982
	2%	A062327	001	Apr 19, 1982
	2%	A062342	001	Feb 25, 1982
	2%	A062957	001	Jul 21, 1988
BAUSCH AND LOMB	2%	A064039	001	Jan 27, 1994
LILLY	2%	N050532	001	
PHARMAFAIR	1.5%	A062485	001	Jul 11, 1984
	2%	A062616	001	Jul 25, 1985
STIEFEL	2%	A064127	001	Feb 14, 1997
SANSAC				
DOW PHARM SCIENCES	2%	A062522	001	Jan 24, 1985
STATICIN				
WESTWOOD SQUIBB	1.5%	N050526	001	
T-STAT				
WESTWOOD SQUIBB	2%	A062436	001	Mar 09, 1983
SWAB; TOPICAL				
C-SOLVE-2				
IVAX SUB TEVA PHARMS	2%	A062751	001	Jul 30, 1993
ERYCETTE				
ORTHONEUTROGENA	2%	N050594	001	Feb 15, 1985
ERYTHROMYCIN				
STIEFEL	2%	A064128	001	Jul 03, 1996
T-STAT				
WESTWOOD SQUIBB	2%	A062748	001	Jul 23, 1987
TABLET, DELAYED RELEASE; ORAL				
E-BASE				
BARR	333MG	A063028	001	May 15, 1990
	333MG	A063086	001	May 15, 1990
	500MG	A062999	001	Nov 25, 1988
E-MYCIN				
ABBOTT	250MG	A060272	001	
	333MG	A060272	002	
ILOTYCIN				
DISTA	250MG	A061910	001	
ROBIMYCIN				
ROBINS AH	250MG	A061633	001	
R-P MYCIN				
SOLVAY	250MG	A061659	001	

ERYTHROMYCIN ESTOLATE

## CAPSULE; ORAL

## ERYTHROMYCIN ESTOLATE

BARR	EQ 125MG BASE	A062162	001	
	EQ 250MG BASE	A062162	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A062237	001	
WATSON LABS	EQ 250MG BASE	A062087	001	
ILOSONE				
LILLY	EQ 125MG BASE	A061897	001	
	EQ 250MG BASE	A061897	002	
FOR SUSPENSION; ORAL				
ILOSONE				
DISTA	EQ 125MG BASE/5ML	A061893	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 121 (of 324)

ERYTHROMYCIN ESTOLATE

## SUSPENSION; ORAL

## ERYTHROMYCIN ESTOLATE

ALPHARMA US PHARMS	EQ 125MG BASE/5ML	A062353	001	Nov 18, 1982
	EQ 250MG BASE/5ML	A062409	001	Dec 16, 1982
BARR	EQ 125MG BASE/5ML	A062169	001	Oct 17, 1990
	EQ 250MG BASE/5ML	A062169	002	Oct 17, 1990
LIFE LABS	EQ 250MG BASE/5ML	A062362	001	Dec 17, 1982
ILOSONE				
LILLY	EQ 125MG BASE/5ML	A061894	001	
	EQ 125MG BASE/5ML	N050010	001	
	EQ 250MG BASE/5ML	A061894	002	
	EQ 250MG BASE/5ML	N050010	002	

## SUSPENSION/DROPS; ORAL

## ILOSONE

LILLY	EQ 100MG BASE/ML	A061894	003	
-------	------------------	---------	-----	--

## TABLET; ORAL

## ILOSONE

LILLY	EQ 500MG BASE	A061896	001	
-------	---------------	---------	-----	--

## TABLET, CHEWABLE; ORAL

## ILOSONE

DISTA	EQ 125MG BASE	A061895	001	
	EQ 250MG BASE	A061895	002	

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

## SUSPENSION; ORAL

## ILOSONE SULFA

LILLY	EQ 125MG BASE/5ML;EQ 600MG BASE/5ML	N050599	001	Sep 29, 1989
-------	-------------------------------------	---------	-----	--------------

ERYTHROMYCIN ETHYLSUCCINATE

## GRANULE; ORAL

## ERYTHROMYCIN ETHYLSUCCINATE

BARR	EQ 200MG BASE/5ML	A062055	001	
------	-------------------	---------	-----	--

## PEDIAMYCIN

ROSS LABS	EQ 200MG BASE/5ML	A062305	001	
-----------	-------------------	---------	-----	--

## SUSPENSION; ORAL

## E-MYCIN E

PHARMACIA AND UPJOHN	EQ 200MG BASE/5ML	A062198	001	
	EQ 400MG BASE/5ML	A062198	002	

## ERYTHROMYCIN ETHYLSUCCINATE

ALPHARMA US PHARMS	EQ 200MG BASE/5ML	A062200	001	
--------------------	-------------------	---------	-----	--

	EQ 400MG BASE/5ML	A062200	002	
--	-------------------	---------	-----	--

DISTA	EQ 200MG BASE/5ML	A062177	001	
-------	-------------------	---------	-----	--

	EQ 400MG BASE/5ML	A062177	002	
--	-------------------	---------	-----	--

NASKA	EQ 400MG BASE/5ML	A062674	001	Mar 10, 1987
-------	-------------------	---------	-----	--------------

PARKE DAVIS	EQ 200MG BASE/5ML	A062231	001	
-------------	-------------------	---------	-----	--

	EQ 400MG BASE/5ML	A062231	002	
--	-------------------	---------	-----	--

PHARMAFAIR	EQ 200MG BASE/5ML	A062559	001	Mar 15, 1985
------------	-------------------	---------	-----	--------------

	EQ 400MG BASE/5ML	A062558	001	Mar 15, 1985
--	-------------------	---------	-----	--------------

## WYAMYCIN E

WYETH AYERST	EQ 200MG BASE/5ML	A062123	002	
--------------	-------------------	---------	-----	--

	EQ 400MG BASE/5ML	A062123	001	
--	-------------------	---------	-----	--

## SUSPENSION/DROPS; ORAL

## PEDIAMYCIN

ROSS LABS	EQ 100MG BASE/2.5ML	A062305	002	
-----------	---------------------	---------	-----	--

## TABLET; ORAL

## E.E.S. 400

ABBOTT	EQ 400MG BASE	A061905	001	
--------	---------------	---------	-----	--

## ERYTHROMYCIN ETHYLSUCCINATE

BARR	EQ 400MG BASE	A062256	001	
------	---------------	---------	-----	--

MYLAN	EQ 400MG BASE	A062847	001	Sep 14, 1988
-------	---------------	---------	-----	--------------

## TABLET, CHEWABLE; ORAL

## E.E.S.

ABBOTT	EQ 200MG BASE	N050297	002	
--------	---------------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 122 (of 324)

ERYTHROMYCIN ETHYLSUCCINATE

TABLET, CHEWABLE; ORAL

ERYPED

ABBOTT EQ 200MG BASE N050297 003 Jul 05, 1988

PEDIAMYCIN

ROSS LABS EQ 200MG BASE A062306 001

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYZOLE

ALRA EQ 200MG BASE/5ML;EQ 600MG BASE/5ML A062758 001 Jun 15, 1988

PEDIAZOLE

ROSS LABS EQ 200MG BASE/5ML;EQ 600MG BASE/5ML N050529 001

ERYTHROMYCIN GLUCEPTATE

INJECTABLE; INJECTION

ILOTYCIN GLUCEPTATE

DISTA EQ 250MG BASE/VIAL N050370 001

EQ 500MG BASE/VIAL N050370 002

EQ 1GM BASE/VIAL N050370 003

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

ABBOTT EQ 500MG BASE/VIAL A062586 001 Jan 04, 1988

EQ 1GM BASE/VIAL A062586 002 Jan 04, 1988

HOSPIRA EQ 500MG BASE/VIAL N050182 002

EQ 1GM BASE/VIAL N050182 003

EQ 1GM BASE/VIAL N050609 002 Sep 24, 1986

ERYTHROMYCIN

ELKINS SINN EQ 500MG BASE/VIAL A062563 001 Mar 28, 1985

EQ 1GM BASE/VIAL A062563 002 Mar 28, 1985

ERYTHROMYCIN LACTOBIONATE

ABRAXIS PHARM EQ 500MG BASE/VIAL A062604 001 Nov 24, 1986

EQ 1GM BASE/VIAL A062604 002 Nov 24, 1986

BAXTER HLTHCARE EQ 500MG BASE/VIAL A062993 001 May 09, 1989

EQ 1GM BASE/VIAL A062993 002 May 09, 1989

ERYTHROMYCIN STEARATE

TABLET; ORAL

BRISTAMYCIN

BRISTOL EQ 250MG BASE A061304 001

EQ 250MG BASE A061887 001

ERYPAR

PARKE DAVIS EQ 250MG BASE A062032 001

EQ 500MG BASE A062032 002

WARNER CHILCOTT EQ 250MG BASE A062322 001

ERYTHROCIN STEARATE

ABBOTT EQ 125MG BASE A060359 002

ERYTHROMYCIN STEARATE

BARR EQ 250MG BASE A061591 001

EQ 500MG BASE A063179 001 May 15, 1990

IVAX SUB TEVA PHARMS EQ 250MG BASE A061461 001

EQ 500MG BASE A061461 002

LEDERLE EQ 250MG BASE A062089 001

EQ 500MG BASE A062089 002

MYLAN EQ 250MG BASE A061505 001

EQ 500MG BASE A061505 002

PUREPAC PHARM EQ 250MG BASE A061743 001

WATSON LABS EQ 250MG BASE A062121 002

EQ 500MG BASE A062121 001

ETHRIL 250

BRISTOL MYERS SQUIBB EQ 250MG BASE A061605 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 123 (of 324)

ERYTHROMYCIN STEARATE

TABLET; ORAL

ETHRIL 500

BRISTOL MYERS SQUIBB EQ 500MG BASE

A061605 002

PFIZER-E

PFIZER EQ 250MG BASE

A061791 001

EQ 500MG BASE

A061791 002

WYAMYCIN S

WYETH AYERST EQ 250MG BASE

A061675 001

EQ 500MG BASE

A061675 002

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

BAXTER HLTHCARE CORP 10MG/ML

N019386 003

Aug 15, 1988

250MG/ML

N019386 002

Dec 31, 1986

ESTAZOLAM

TABLET; ORAL

PROSOM

ABBOTT 1MG

N019080 001

Dec 26, 1990

2MG

N019080 002

Dec 26, 1990

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESCLIM

WOMEN FIRST HLTHCARE 0.025MG/24HR

N020847 001

Aug 04, 1998

0.0375MG/24HR

N020847 002

Aug 04, 1998

0.05MG/24HR

N020847 003

Aug 04, 1998

0.075MG/24HR

N020847 004

Aug 04, 1998

0.1MG/24HR

N020847 005

Aug 04, 1998

ESTRADIOL

ORTHO MCNEIL PHARM 0.05MG/24HR

N021048 001

Sep 20, 1999

0.075MG/24HR

N021048 002

Sep 20, 1999

0.1MG/24HR

N021048 003

Sep 20, 1999

FEMPATCH

PARKE DAVIS 0.025MG/24HR

N020417 001

Dec 03, 1996

VIVELLE

NOVARTIS 0.025MG/24HR

N020323 005

Aug 16, 2000

0.0375MG/24HR

N020323 001

Oct 28, 1994

0.075MG/24HR

N020323 003

Oct 28, 1994

GEL; TOPICAL

ESTROGEL

ASCEND 0.06%

N021166 001

Feb 09, 2004

TABLET; ORAL

ESTRADIOL

AAI PHARMA INC 0.5MG

A040138 001

Jan 30, 1998

1MG

A040138 002

Jan 30, 1998

2MG

A040138 003

Jan 30, 1998

HERITAGE PHARMS INC 0.5MG

A040275 001

Dec 29, 1998

1MG

A040275 002

Dec 29, 1998

2MG

A040275 003

Dec 29, 1998

GYNODIOL

DURAMED PHARMS BARR 0.5MG

A040212 001

Dec 29, 1997

1MG

A040212 002

Dec 29, 1997

1.5MG

A040212 003

Dec 29, 1997

2MG

A040212 004

Dec 29, 1997

INNOFEM

NOVO NORDISK INC 0.5MG

A040312 001

Nov 19, 1999

1MG

A040312 002

Nov 19, 1999

2MG

A040312 003

Nov 19, 1999

## DISCONTINUED DRUG PRODUCT LIST

6 - 124 (of 324)

ESTRADIOL CYPIONATEINJECTABLE; INJECTION  
DEPO-ESTRADIOL

PHARMACIA AND UPJOHN	1MG/ML	A085470	001
	3MG/ML	A085470	002

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATEINJECTABLE; INTRAMUSCULAR  
LUNELLE

PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N020874	001	Oct 05, 2000
----------------------	----------------------	---------	-----	--------------

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATEINJECTABLE; INJECTION  
DEPO-TESTADIOL

PHARMACIA AND UPJOHN	2MG/ML;50MG/ML	N017968	001
----------------------	----------------	---------	-----

TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

WATSON LABS	2MG/ML;50MG/ML	A085603	001	Mar 13, 1986
-------------	----------------	---------	-----	--------------

ESTRADIOL VALERATEINJECTABLE; INJECTION  
ESTRADIOL VALERATE

WATSON LABS	10MG/ML	A083546	001
-------------	---------	---------	-----

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATEINJECTABLE; INJECTION  
DITATE-DS

SAVAGE LABS	8MG/ML;180MG/ML	A086423	001
-------------	-----------------	---------	-----

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

WATSON LABS	4MG/ML;90MG/ML	A085865	001
-------------	----------------	---------	-----

	8MG/ML;180MG/ML	A085860	001
--	-----------------	---------	-----

ESTROGENS, CONJUGATEDTABLET; ORAL  
PREMARIN

WYETH PHARMS INC	2.5MG	N004782	002
------------------	-------	---------	-----

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN;CYCRIN 14/14)

WYETH PHARMS INC	0.625MG,0.625MG;N/A,5MG	N020303	002	Dec 30, 1994
------------------	-------------------------	---------	-----	--------------

PREMPRO (PREMARIN;CYCRIN)

WYETH PHARMS INC	0.625MG,0.625MG;2.5MG,2.5MG	N020303	001	Dec 30, 1994
------------------	-----------------------------	---------	-----	--------------

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

MILPREM-200

MEDPOINTE PHARM HLC	0.45MG;200MG	N011045	002
---------------------	--------------	---------	-----

MILPREM-400

MEDPOINTE PHARM HLC	0.45MG;400MG	N011045	001
---------------------	--------------	---------	-----

PMB 200

WYETH AYERST	0.45MG;200MG	N010971	005
--------------	--------------	---------	-----

PMB 400

WYETH AYERST	0.45MG;400MG	N010971	003
--------------	--------------	---------	-----

ESTROGENS, ESTERIFIED

TABLET; ORAL

AMNESTROGEN

BRISTOL MYERS SQUIBB	0.3MG	A083266	001
----------------------	-------	---------	-----

	0.625MG	A083266	002
--	---------	---------	-----

	1.25MG	A083266	003
--	--------	---------	-----

	2.5MG	A083266	004
--	-------	---------	-----

ESTERIFIED ESTROGENS

PVT FORM	0.625MG	A083414	001
----------	---------	---------	-----

## DISCONTINUED DRUG PRODUCT LIST

6 - 125 (of 324)

ESTROGENS, ESTERIFIED

## TABLET; ORAL

## ESTERIFIED ESTROGENS

PVT FORM	1.25MG	A083765	001
	2.5MG	A085907	001
SANDOZ	1.25MG	A085302	001
ESTRATAB			
SOLVAY	0.3MG	A086715	001
	0.625MG	A083209	001
	1.25MG	A083856	001
	2.5MG	A083857	001
EVEX			
ROCHE PALO	0.625MG	A084215	001
	1.25MG	A083376	002
FEMOGEN			
PVT FORM	0.625MG	A085076	001
	1.25MG	A085008	001
	2.5MG	A085007	001

ESTRONE

## INJECTABLE; INJECTION

## ESTROGENIC SUBSTANCE

WYETH AYERST	2MG/ML	A083488	001
ESTRONE			
WATSON LABS	2MG/ML	A083397	001
NATURAL ESTROGENIC SUBSTANCE-ESTRONE			
WATSON LABS	2MG/ML	A085237	001
			Nov 23, 1982
THEELIN			
PARKEDALE	1MG/ML	N003977	001
	2MG/ML	N003977	002
	5MG/ML	N003977	003

ESTROPIPATE

## TABLET; ORAL

## ESTROPIPATE

DURAMED PHARMS BARR	0.75MG	A040296	001	Nov 01, 1999
	1.5MG	A040296	002	Nov 01, 1999
	3MG	A040296	003	Nov 01, 1999
MYLAN	3MG	A040359	003	Aug 26, 1999

ETHACRYNIC ACID

## TABLET; ORAL

## EDECIN

ATON	50MG	N016092	002
------	------	---------	-----

ETHAMBUTOL HYDROCHLORIDE

## TABLET; ORAL

## MYAMBUTOL

STI PHARMA LLC	200MG	N016320	002
	500MG	N016320	004

ETHCHLORVYNOL

## CAPSULE; ORAL

## ETHCHLORVYNOL

BANNER PHARMACAPS	100MG	A084463	001
	200MG	A084463	002
	500MG	A084463	003
	750MG	A084463	004
PLACIDYL			
ABBOTT	100MG	N010021	004
	200MG	N010021	007
	500MG	N010021	002
	750MG	N010021	010

## DISCONTINUED DRUG PRODUCT LIST

6 - 126 (of 324)

ETHINAMATECAPSULE; ORAL  
VALMID  
DISTA

500MG

N009750 001

ETHINYL ESTRADIOLTABLET; ORAL  
ESTINYL

SCHERING

0.02MG

N005292 001

0.05MG

N005292 002

0.5MG

N005292 003

FEMINONE

PHARMACIA AND UPJOHN

0.05MG

N016649 001

LYNORAL

ORGANON USA INC

0.01MG

N005490 003

0.05MG

N005490 002

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

DEMULEN 1/35-21

GD SEARLE LLC

0.035MG;1MG

N018168 001

DEMULEN 1/50-21

GD SEARLE LLC

0.05MG;1MG

N016927 001

ZOVIA 1/35E-21

WATSON LABS

0.035MG;1MG

A072720 001

Dec 30, 1991

ZOVIA 1/50E-21

WATSON LABS

0.05MG;1MG

A072722 001

Dec 30, 1991

TABLET; ORAL-28

DEMULEN 1/35-28

GD SEARLE LLC

0.035MG;1MG

N018160 001

DEMULEN 1/50-28

GD SEARLE LLC

0.05MG;1MG

N016936 001

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET; ORAL-28

NORQUEST FE

GD SEARLE LLC

0.035MG;75MG;1MG

N018926 001

Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET; ORAL-28

NORLESTRIN FE 1/50

PARKE DAVIS

0.05MG;75MG;1MG

N016766 001

NORLESTRIN FE 2.5/50

PARKE DAVIS

0.05MG;75MG;2.5MG

N016854 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

PREVEN EMERGENCY CONTRACEPTIVE KIT

DURAMED

0.05MG;0.25MG

N020946 001

Sep 01, 1998

TABLET; ORAL-21

ALESSE

WYETH PHARMS INC

0.02MG;0.1MG

N020683 001

Mar 27, 1997

AVIANE-21

DURAMED PHARMS BARR

0.02MG;0.1MG

A075796 002

Apr 30, 2001

ENPRESSE-21

DURAMED PHARMS BARR

0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG

A075809 001

Jul 16, 2001

LESSINA-21

BARR

0.02MG;0.1MG

A075803 001

Mar 20, 2002

LEVLITE

BAYER HLTHCARE

0.02MG;0.1MG

N020860 001

Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR

0.02MG;0.1MG

A075862 001

Apr 29, 2003



## DISCONTINUED DRUG PRODUCT LIST

6 - 127 (of 324)

ETHINYL ESTRADIOL; LEVONORGESTREL

## TABLET; ORAL-21

LEVORA 0.15/30-21

WATSON LABS 0.03MG;0.15MG A073592 001 Dec 13, 1993

NORDETTE-21

DURAMED RES 0.03MG;0.15MG N018668 001 May 10, 1982

PORTIA-21

BARR 0.03MG;0.15MG A075866 001 May 23, 2002

TRIPHASIL-21

AKRIMAX PHARMS 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG N019192 001 Nov 01, 1984

TRIVORA-21

WATSON LABS 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG A074538 001 Dec 18, 1997

## TABLET; ORAL-28

ALESSE

WYETH PHARMS INC 0.02MG;0.1MG N020683 002 Mar 27, 1997

LEVLITE

BAYER HLTHCARE 0.02MG;0.1MG N020860 002 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR 0.02MG;0.1MG A075862 002 Apr 29, 2003

TRIPHASIL-28

WYETH PHARMS INC 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG N019190 001 Nov 01, 1984

ETHINYL ESTRADIOL; NORETHINDRONE

## TABLET; ORAL-21

BALZIVA-21

BARR 0.035MG;0.4MG A076198 001 Apr 22, 2004

BREVICON 21-DAY

WATSON LABS 0.035MG;0.5MG N017566 001

GENCEPT 10/11-21

BARR 0.035MG,0.035MG;0.5MG,1MG A072694 001 Feb 28, 1992

MODICON 21

ORTHO MCNEIL PHARM 0.035MG;0.5MG N017488 001

N.E.E. 1/35 21

LPI 0.035MG;1MG A071541 001 Dec 14, 1987

NORCEPT-E 1/35 21

ORTHO MCNEIL PHARM 0.035MG;1MG A071545 001 Feb 09, 1989

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS 0.035MG;0.5MG A070684 001 Jan 29, 1987

NORTREL 0.5/35-21

BARR 0.035MG;0.5MG A072692 001 Feb 28, 1992

ORTHO-NOVUM 1/35-21

ORTHO MCNEIL PHARM 0.035MG;1MG N017489 002

ORTHO-NOVUM 10/11-21

ORTHO MCNEIL JANSSEN 0.035MG,0.035MG;0.5MG,1MG N018354 001 Jan 11, 1982

ORTHO-NOVUM 7/14-21

ORTHO MCNEIL PHARM 0.035MG,0.035MG;0.5MG,1MG N019004 001 Apr 04, 1984

ORTHO-NOVUM 7/7/7-21

ORTHO MCNEIL JANSSEN 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG N018985 001 Apr 04, 1984

OVCON-35

WARNER CHILCOTT 0.035MG;0.4MG N018127 001

OVCON-50

WARNER CHILCOTT 0.05MG;1MG N018128 001

TRI-NORINYL 21-DAY

WATSON LABS 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG N018977 001 Apr 13, 1984

## TABLET; ORAL-28

GENCEPT 10/11-28

BARR 0.035MG,0.035MG;0.5MG,1MG A072697 001 Feb 28, 1992

N.E.E. 1/35 28

LPI 0.035MG;1MG A071542 001 Dec 14, 1987

NORCEPT-E 1/35 28

ORTHO MCNEIL PHARM 0.035MG;1MG A071546 001 Feb 09, 1989

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 569 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 128 (of 324)

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28					
ORTHO-NOVUM 10/11-28					
ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG	N018354	002	Jan 11, 1982	
ORTHO-NOVUM 7/14-28					
ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N019004	002	Apr 04, 1984	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21					
ESTROSTEP 21					
WARNER CHILCOTT	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	001	Oct 09, 1996	
NORLESTRIN 21 1/50					
PARKE DAVIS	0.05MG;1MG	N016749	001		
NORLESTRIN 21 2.5/50					
PARKE DAVIS	0.05MG;2.5MG	N016852	001		
TABLET; ORAL-28					
NORLESTRIN 28 1/50					
PARKE DAVIS	0.05MG;1MG	N016723	001		

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-21					
ORTHO CYCLEN-21					
ORTHO MCNEIL JANSSEN	0.035MG;0.25MG	N019653	001	Dec 29, 1989	
ORTHO TRI-CYCLEN					
ORTHO MCNEIL JANSSEN	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N019697	002	Jul 03, 1992	

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21					
LO/OVRAL					
WYETH PHARMS INC	0.03MG;0.3MG	N017612	001		
OGESTREL 0.5/50-21					
WATSON LABS	0.05MG;0.5MG	A075406	001	Dec 15, 1999	
OVRAL					
AKRIMAX PHARMS	0.05MG;0.5MG	N016672	001		
TABLET; ORAL-28					
OVRAL-28					
WYETH PHARMS INC	0.05MG;0.5MG	N016806	001		

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL					
PARSIDOL					
PARKE DAVIS	10MG	N009078	003		
	50MG	N009078	006		
	100MG	N009078	008		

ETHOTOIN

TABLET; ORAL					
PEGANONE					
LUNDBECK INC	500MG	N010841	003		

ETHOXZOLAMIDE

TABLET; ORAL					
CARDRASE					
PHARMACIA AND UPJOHN	62.5MG	N011047	002		
	125MG	N011047	001		
ETHAMIDE					
ALLERGAN	125MG	N016144	001		

ETHYLESTRENOL

ELIXIR; ORAL					
MAXIBOLIN					
ORGANON USA INC	2MG/5ML	N014006	002		

## DISCONTINUED DRUG PRODUCT LIST

6 - 129 (of 324)

ETHYLESTRENOLTABLET; ORAL  
MAXIBOLIN

ORGANON USA INC 2MG N014005 002

ETHYNODIOL DIACETATE; MESTRANOLTABLET; ORAL-20  
OVULEN

GD SEARLE LLC 1MG;0.1MG N016029 002

TABLET; ORAL-21  
OVULEN-21

GD SEARLE LLC 1MG;0.1MG N016029 003

TABLET; ORAL-28  
OVULEN-28

GD SEARLE LLC 1MG;0.1MG N016705 001

ETIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION  
DURANEST

ASTRAZENECA 0.5% N017751 003

1% N017751 005

ETIDRONATE DISODIUMINJECTABLE; INJECTION  
DIDRONEL

MGI PHARMA INC 50MG/ML N019545 001 Apr 20, 1987

ETODOLACCAPSULE; ORAL  
ETODOLAC

AAIPHARMA LLC 300MG A074929 001 Jan 30, 1998

ENDO PHARMS 200MG A074842 001 Jul 17, 1997

300MG A074842 002 Jul 17, 1997

GENPHARM 200MG A075071 001 Sep 30, 1998

300MG A075071 002 Sep 30, 1998

IVAX SUB TEVA PHARMS 200MG A074899 001 Jul 08, 1997

300MG A074899 002 Jul 08, 1997

MYLAN 200MG A074932 001 May 16, 1997

300MG A074932 002 May 16, 1997

SANDOZ 200MG A074840 001 Aug 29, 1997

200MG A074942 001 Sep 30, 1997

300MG A074840 002 Aug 29, 1997

300MG A074942 002 Sep 30, 1997

TEVA 200MG A075126 001 Sep 16, 1999

WATSON LABS 200MG A074844 001 Dec 23, 1997

300MG A074844 002 Dec 23, 1997

LODINE

WYETH PHARMS INC 200MG N018922 002 Jan 31, 1991

300MG N018922 003 Jan 31, 1991

TABLET; ORAL

ETODOLAC

AAIPHARMA LLC 400MG A074927 001 Oct 30, 1997

ENDO PHARMS 400MG A074841 001 Jun 27, 1997

GENPHARM 400MG A075012 001 Sep 30, 1998

500MG A075012 002 Sep 30, 1998

IVAX SUB TEVA PHARMS 400MG A074883 001 Feb 28, 1997

500MG A074883 002 Nov 20, 1998

RANBAXY 400MG A075226 001 Nov 24, 1998

500MG A075226 002 Nov 24, 1998

SANDOZ 400MG A074839 001 Jul 11, 1997

400MG A074846 001 Feb 28, 1997

TEVA 400MG A074847 001 Apr 23, 1999

500MG A074847 002 Apr 23, 1999

WATSON LABS 400MG A074892 001 Apr 16, 1997

## DISCONTINUED DRUG PRODUCT LIST

6 - 130 (of 324)

ETODOLAC

## TABLET; ORAL

## ETODOLAC

WATSON LABS	400MG	A075069	001	Apr 16, 1998
	500MG	A074892	002	Oct 29, 1998

## LODINE

WYETH PHARMS INC	400MG	N018922	004	Jul 29, 1993
	500MG	N018922	005	Jun 28, 1996

## TABLET, EXTENDED RELEASE; ORAL

## ETODOLAC

POINT HOLDINGS	400MG	A075696	001	Jul 31, 2000
SANDOZ	400MG	A075943	001	Jul 26, 2002
	500MG	A075943	002	Jul 26, 2002
	600MG	A075943	003	Jul 26, 2002
WATSON LABS FLORIDA	400MG	A075829	001	Nov 30, 2001
	500MG	A075829	002	Nov 30, 2001

## LODINE XL

WYETH PHARMS INC	400MG	N020584	001	Oct 25, 1996
	500MG	N020584	003	Jan 20, 1998
	600MG	N020584	002	Oct 25, 1996

ETOPOSIDE

## CAPSULE; ORAL

## VEPESID

BRISTOL MYERS SQUIBB	50MG	N019557	001	Dec 30, 1986
	100MG	N019557	002	Dec 30, 1986

## INJECTABLE; INJECTION

## ETOPOSIDE

HOSPIRA	20MG/ML	A074320	001	Aug 30, 1995
	20MG/ML	A074351	001	Aug 30, 1995
MARSAM PHARMS LLC	20MG/ML	A074968	001	Jan 09, 1998
PIERRE FABRE	20MG/ML	A074813	001	Jul 09, 1997
TEVA PARENTERAL	20MG/ML	A074510	001	Jun 29, 1995
WATSON LABS	20MG/ML	A074228	001	Oct 15, 1996

## TOPOSAR

TEVA PARENTERAL	20MG/ML	A074166	001	Feb 27, 1995
-----------------	---------	---------	-----	--------------

ETOPOSIDE PHOSPHATE

## INJECTABLE; INJECTION

## ETOPOPHOS PRESERVATIVE FREE

BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N020906	001	Feb 27, 1998
	EQ 1GM BASE/VIAL	N020906	002	Feb 27, 1998

ETRETINATE

## CAPSULE; ORAL

## TEGISON

ROCHE	10MG	N019369	001	Sep 30, 1986
	25MG	N019369	002	Sep 30, 1986

EVANS BLUE

## INJECTABLE; INJECTION

## EVANS BLUE

PARKE DAVIS	0.5%	N008041	001	
-------------	------	---------	-----	--

FAMOTIDINE

## INJECTABLE; INJECTION

## FAMOTIDINE

APOTEX INC	10MG/ML	A075942	001	Aug 02, 2002
APOTHECON	10MG/ML	A075707	001	Apr 16, 2001
HOSPIRA	10MG/ML	A075705	001	Apr 16, 2001
	10MG/ML	A075905	001	Nov 23, 2001

## FAMOTIDINE PRESERVATIVE FREE

APOTHECON	10MG/ML	A075708	001	Apr 16, 2001
HOSPIRA	10MG/ML	A075669	001	Apr 16, 2001

## DISCONTINUED DRUG PRODUCT LIST

6 - 131 (of 324)

FAMOTIDINE

## INJECTABLE; INJECTION

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

ABBOTT 0.4MG/ML

A075729 001 Dec 17, 2001

## TABLET; ORAL

FAMOTIDINE

APOTEX 10MG

A075610 001 Mar 12, 2002

MUTUAL PHARM 20MG

A075639 002 Dec 12, 2001

40MG

A075639 001 Dec 12, 2001

SANDOZ 20MG

A075302 001 Apr 16, 2001

20MG

A075793 001 Apr 16, 2001

40MG

A075302 002 Apr 16, 2001

40MG

A075793 002 Apr 16, 2001

## TABLET, CHEWABLE; ORAL

PEPCID AC

MERCK 10MG

N020801 001 Sep 24, 1998

## TABLET, ORALLY DISINTEGRATING; ORAL

PEPCID RPD

MERCK 20MG

N020752 001 May 28, 1998

40MG

N020752 002 May 28, 1998

FELODIPINE

## TABLET, EXTENDED RELEASE; ORAL

PLENDIL

ASTRAZENECA 2.5MG

N019834 004 Sep 22, 1994

5MG

N019834 001 Jul 25, 1991

10MG

N019834 002 Jul 25, 1991

FENOFIBRATE

## CAPSULE; ORAL

ANTARA (MICRONIZED)

OSCIENT 87MG

N021695 002 Nov 30, 2004

LIPIDIL

ABBOTT 100MG

N019304 001 Dec 31, 1993

TRICOR (MICRONIZED)

ABBOTT 67MG

N019304 002 Feb 09, 1998

134MG

N019304 003 Jun 30, 1999

200MG

N019304 004 Jun 30, 1999

## TABLET; ORAL

FENOFIBRATE

MYLAN 107MG

A076520 002 Dec 29, 2005

TRICOR

ABBOTT 54MG

N021203 001 Sep 04, 2001

160MG

N021203 003 Sep 04, 2001

FENOPROFEN CALCIUM

## CAPSULE; ORAL

FENOPROFEN CALCIUM

AM THERAP EQ 200MG BASE

A072307 001 Aug 22, 1988

EQ 300MG BASE

A072308 001 Aug 22, 1988

HALSEY EQ 200MG BASE

A072355 001 Aug 17, 1988

EQ 300MG BASE

A072356 001 Aug 17, 1988

PAR PHARM EQ 200MG BASE

A072437 001 Aug 22, 1988

EQ 300MG BASE

A072438 001 Aug 22, 1988

QUANTUM PHARMICS EQ 200MG BASE

A072214 001 Aug 17, 1988

EQ 300MG BASE

A071738 001 Aug 17, 1988

SANDOZ EQ 200MG BASE

A072394 001 Oct 17, 1988

EQ 300MG BASE

A072395 001 Oct 17, 1988

WARNER CHILCOTT EQ 200MG BASE

A072946 001 Apr 30, 1991

EQ 300MG BASE

A072472 001 Apr 30, 1991

WATSON LABS EQ 200MG BASE

A072294 001 Aug 17, 1988

EQ 200MG BASE

A072981 001 Aug 19, 1991

EQ 300MG BASE

A072293 001 Aug 17, 1988

EQ 300MG BASE

A072982 001 Aug 19, 1991

## DISCONTINUED DRUG PRODUCT LIST

6 - 132 (of 324)

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

PEDINOL	EQ 300MG BASE	N017604	002	
---------	---------------	---------	-----	--

TABLET; ORAL

FENOPROFEN CALCIUM

ACTAVIS ELIZABETH	EQ 600MG BASE	A072274	001	May 02, 1988
AM THERAP	EQ 600MG BASE	A072309	001	Aug 17, 1988
CLONMEL HLTHCARE	EQ 600MG BASE	A072326	001	Aug 17, 1988
HALSEY	EQ 600MG BASE	A072357	001	Aug 17, 1988
MUTUAL PHARM	EQ 600MG BASE	A072902	001	Dec 21, 1990
PAR PHARM	EQ 600MG BASE	A072429	001	Aug 17, 1988
QUANTUM PHARMICS	EQ 600MG BASE	A072194	001	Aug 17, 1988
SANDOZ	EQ 600MG BASE	A072396	001	Oct 17, 1988
USL PHARMA	EQ 600MG BASE	A072362	001	Aug 17, 1988
WATSON LABS	EQ 600MG BASE	A072165	001	Aug 17, 1988
	EQ 600MG BASE	A072407	001	Aug 17, 1988
	EQ 600MG BASE	A072602	001	Oct 11, 1988

NALFON

DISTA	EQ 600MG BASE	N017710	001	
-------	---------------	---------	-----	--

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

ABBOTT	EQ 0.05MG BASE/ML	A070636	001	Apr 30, 1990
	EQ 0.05MG BASE/ML	A070637	001	Apr 30, 1990
WATSON LABS	EQ 0.05MG BASE/ML	A073488	001	Jun 30, 1992
FENTANYL CITRATE PRESERVATIVE FREE				
MARSAM PHARMS LLC	EQ 0.05MG BASE/ML	A074917	001	Feb 03, 1998

TROCHE/LOZENGE; ORAL

FENTANYL

CEPHALON	EQ 0.1MG BASE	N020195	007	Oct 30, 1995
	EQ 0.2MG BASE	N020195	001	Oct 04, 1993
	EQ 0.3MG BASE	N020195	002	Oct 04, 1993
	EQ 0.4MG BASE	N020195	003	Oct 04, 1993

FENTANYL HYDROCHLORIDE

SYSTEM; IONTOPHORESIS, TRANSDERMAL

IONSYS

ALZA	10.8MCG	N021338	001	May 22, 2006
------	---------	---------	-----	--------------

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL

FERRISELTZ

OTSUKA	600MG/PACKET	N020292	001	Oct 14, 1997
--------	--------------	---------	-----	--------------

FERROUS CITRATE, FE-59

INJECTABLE; INJECTION

FERROUS CITRATE FE 59

MALLINCKRODT	25uCi/ML	N016729	001	
--------------	----------	---------	-----	--

FERROUS SULFATE; FOLIC ACID

CAPSULE; ORAL

FOLVRON

LEDERLE	182MG;0.33MG	N006012	003	
---------	--------------	---------	-----	--

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL

ALLEGRA

SANOFI AVENTIS US	60MG	N020625	001	Jul 25, 1996
-------------------	------	---------	-----	--------------

FEXOFENADINE HYDROCHLORIDE

BARR	60MG	A076169	001	Jul 13, 2005
------	------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 133 (of 324)

FIBRINOGEN, I-125INJECTABLE; INJECTION  
IBRIN

GE HEALTHCARE	154uCi/VIAL	N017879	001	
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR				
ABBOTT	140uCi/ML	N017787	001	

FINASTERIDETABLET; ORAL  
FINASTERIDE

IVAX SUB TEVA PHARMS	5MG	A076340	001	Jun 19, 2006
----------------------	-----	---------	-----	--------------

FLECAINIDE ACETATETABLET; ORAL  
FLECAINIDE ACETATE

SANDOZ	50MG	A076030	001	Oct 28, 2002
	100MG	A076030	002	Oct 28, 2002
	150MG	A076030	003	Oct 28, 2002
TAMBOCOR				
GRACEWAY	200MG	N018830	002	Oct 31, 1985

FLOXURIDINEINJECTABLE; INJECTION  
FUDR

HOSPIRA	500MG/VIAL	N016929	001	
---------	------------	---------	-----	--

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
APOTEX INC	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005

TABLET; ORAL

FLUCONAZOLE

GEDEON RICHTER USA	50MG	A076432	001	Jul 29, 2004
	100MG	A076432	002	Jul 29, 2004
	150MG	A076432	003	Jul 29, 2004
	200MG	A076432	004	Jul 29, 2004
ROXANE	50MG	A076213	001	Jul 29, 2004
	100MG	A076213	002	Jul 29, 2004
	150MG	A076213	003	Jul 29, 2004
	200MG	A076213	004	Jul 29, 2004
SANDOZ	50MG	A076086	001	Jul 29, 2004
	100MG	A076086	002	Jul 29, 2004
	150MG	A076086	003	Jul 29, 2004
	200MG	A076086	004	Jul 29, 2004

FLUDEOXYGLUCOSE F-18INJECTABLE; INJECTION  
FLUDEOXYGLUCOSE F 18

DOWNSTATE CLINCL	4-40mCi/ML	N020306	001	Aug 19, 1994
	4-90mCi/ML	N020306	002	Sep 25, 2001

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF

KING PHARMS	0.1MG	N010060	001	
-------------	-------	---------	-----	--

FLUMETHASONE PIVALATE

CREAM; TOPICAL

LOCORTEN

NOVARTIS	0.03%	N016379	001	
----------	-------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 134 (of 324)

FLUNISOLIDESPRAY, METERED; NASAL  
NASALIDE

IVAX RES 0.025MG/SPRAY N018148 001

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCET

ALPHARMA US PHARMS 0.025% A088360 001 Jan 16, 1984

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS 0.01% A088361 001 Jan 16, 1984

G AND W LABS 0.01% A089526 001 Jul 26, 1988

0.025% A089525 001 Jul 26, 1988

PERRIGO NEW YORK 0.01% A086810 001 Mar 04, 1982

0.025% A086811 001 Mar 04, 1982

PHARMADERM 0.01% A088047 001 Dec 16, 1982

0.025% A088045 001 Dec 16, 1982

PHARMAFAIR 0.01% A088499 001 Aug 02, 1984

0.025% A088506 001 Aug 02, 1984

TARO 0.01% A040035 001 Oct 31, 1994

0.01% A087102 001 Apr 27, 1982

0.025% A040042 001 Oct 31, 1994

USL PHARMA 0.01% A088757 001 Feb 11, 1985

0.025% A088756 001 Mar 28, 1985

FLUONID

ALLERGAN HERBERT 0.025% A087156 002 Sep 06, 1984

FLUOTREX

SAVAGE LABS 0.01% A088174 001 May 06, 1983

0.025% A088173 001 Mar 09, 1983

SYNALAR-HP

MEDICIS 0.2% N016161 002

GEL; TOPICAL

FLUONID

ALLERGAN HERBERT 0.025% A087300 001 May 27, 1982

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

G AND W LABS 0.025% A089524 001 Jul 26, 1988

PHARMADERM 0.025% A088046 001 Dec 16, 1982

PHARMAFAIR 0.025% A088507 001 Feb 27, 1984

USL PHARMA 0.025% A088742 001 Feb 08, 1985

FLUONID

ALLERGAN HERBERT 0.025% A087157 001 Sep 06, 1984

FLUOTREX

SAVAGE LABS 0.025% A088172 001 Mar 09, 1983

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS 0.01% A087159 001 Jun 16, 1982

BAUSCH AND LOMB 0.01% A040059 001 Dec 20, 1993

MORTON GROVE 0.01% A088312 001 Jan 27, 1984

PHARMADERM 0.01% A088048 001 Dec 16, 1982

PHARMAFAIR 0.01% A088449 001 Feb 08, 1984

FLUONID

ALLERGAN HERBERT 0.01% A087158 001 Mar 17, 1983

FLUOTREX

SAVAGE LABS 0.01% A088171 001 Mar 09, 1983

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

MEDICIS 0.025%;EQ 3.5MG BASE/GM A060700 001



## DISCONTINUED DRUG PRODUCT LIST

6 - 135 (of 324)

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

PERRIGO NEW YORK 0.05%

A071790 001 Jul 13, 1988

TARO 0.05%

A071500 001 Jun 10, 1987

FLUOCINONIDE EMULSIFIED BASE

ACTAVIS MID ATLANTIC 0.05%

A074204 001 Jun 13, 1995

SOLUTION; TOPICAL

FLUOCINONIDE

TARO 0.05%

A072857 001 Aug 02, 1989

TEVA PHARMS 0.05%

A072522 001 Sep 28, 1990

FLUORESCEIN SODIUM

INJECTABLE; INJECTION

FUNDUSCEIN-25

NOVARTIS 25%

N017869 001

FLUOROMETHOLONE

CREAM; TOPICAL

OXYLONE

PHARMACIA AND UPJOHN 0.025%

N011748 001

SUSPENSION/DROPS; OPHTHALMIC

FLUOR-OP

NOVARTIS 0.1%

A070185 001 Feb 27, 1986

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRASONE

ALCON 0.1%;0.3%

N050628 001 Jul 21, 1989

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

FML-S

ALLERGAN 0.1%;10%

N019525 001 Sep 29, 1989

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

PHARMACIA AND UPJOHN 50MG/ML

A081222 001 Jun 28, 1991

50MG/ML

N017959 001

TEVA PARENTERAL 50MG/ML

A040023 001 Oct 18, 1991

50MG/ML

A081225 001 Aug 28, 1991

FLUOROURACIL

ABIC 50MG/ML

A088929 001 Mar 04, 1986

ABRAXIS PHARM 50MG/ML

A089152 001 Mar 21, 1986

50MG/ML

A089428 001 Jan 12, 1987

50MG/ML

A089519 001 Mar 12, 1987

APP PHARMS 50MG/ML

A040291 001 Mar 24, 1999

50MG/ML

A040379 001 Nov 15, 2000

BEDFORD 50MG/ML

A089508 001 Jan 26, 1988

MARCHAR 50MG/ML

A087791 001 Jan 18, 1983

SMITH AND NEPHEW 50MG/ML

A088766 001 Dec 28, 1984

50MG/ML

A088767 001 Dec 28, 1984

50MG/ML

A089434 001 Mar 26, 1987

WATSON LABS 50MG/ML

A087792 001 Oct 13, 1982

SOLUTION; TOPICAL

FLUOROPLEX

ELORAC 1%

N016765 001

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

MUTUAL PHARMA EQ 10MG BASE

A075787 001 Jan 29, 2002

EQ 20MG BASE

A075787 002 Jan 29, 2002

## DISCONTINUED DRUG PRODUCT LIST

6 - 136 (of 324)

FLUOXETINE HYDROCHLORIDE

## CAPSULE; ORAL

## FLUOXETINE

WATSON LABS	EQ 10MG BASE	A075662	001	Jan 29, 2002
	EQ 20MG BASE	A075662	002	Jan 29, 2002

## FLUOXETINE HYDROCHLORIDE

BARR	EQ 40MG BASE	A076251	001	May 18, 2005
CARLSBAD	EQ 10MG BASE	A076022	001	Jan 30, 2002
	EQ 20MG BASE	A076022	002	Jan 30, 2002
PAR PHARM	EQ 10MG BASE	A076922	001	Dec 16, 2004
	EQ 20MG BASE	A076922	002	Dec 16, 2004
	EQ 40MG BASE	A076922	003	Dec 16, 2004
SANDOZ	EQ 10MG BASE	A075807	001	Jan 29, 2002
	EQ 20MG BASE	A075807	002	Jan 29, 2002

## PROZAC

LILLY	EQ 60MG BASE	N018936	004	Jun 15, 1999
-------	--------------	---------	-----	--------------

## SOLUTION; ORAL

## FLUOXETINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690	001	Jan 31, 2002
HI TECH PHARMA	EQ 20MG BASE/5ML	A075525	001	Jun 27, 2002

## PROZAC

LILLY	EQ 20MG BASE/5ML	N020101	001	Apr 24, 1991
-------	------------------	---------	-----	--------------

## TABLET; ORAL

## FLUOXETINE HYDROCHLORIDE

BARR	EQ 10MG BASE	A075810	001	Feb 01, 2002
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865	001	Feb 28, 2002
	EQ 40MG BASE	A075865	003	Aug 30, 2004
SANDOZ	EQ 10MG BASE	A076024	001	Jan 29, 2002

## PROZAC

LILLY	EQ 10MG BASE	N020974	001	Mar 09, 1999
	EQ 20MG BASE	N020974	002	Mar 09, 1999

FLUOXYMESTERONE

## TABLET; ORAL

## ANDROID-F

VALEANT PHARM INTL	10MG	A087196	001	
FLUOXYMESTERONE				
VALEANT PHARM INTL	10MG	A088221	001	May 05, 1983
WATSON LABS	2MG	A088260	001	Dec 06, 1983
	5MG	A088265	001	Dec 06, 1983
	10MG	A088309	001	Dec 06, 1983

## HALOTESTIN

PHARMACIA AND UPJOHN	2MG	N010611	002	
	5MG	N010611	006	
	10MG	N010611	010	

## ORA-TESTRYL

BRISTOL MYERS SQUIBB	2MG	N011359	001	
	5MG	N011359	002	

FLUPHENAZINE DECANOATE

## INJECTABLE; INJECTION

## FLUPHENAZINE DECANOATE

HOSPIRA	25MG/ML	A074966	001	Apr 16, 1998
PROLIXIN DECANOATE				
BRISTOL MYERS SQUIBB	25MG/ML	N016727	001	

FLUPHENAZINE ENANTHATE

## INJECTABLE; INJECTION

## PROLIXIN ENANTHATE

APOTHECON	25MG/ML	N016110	001	
-----------	---------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 137 (of 324)

FLUPHENAZINE HYDROCHLORIDE

## CONCENTRATE; ORAL

## FLUPHENAZINE HYDROCHLORIDE

TEVA PHARMS 5MG/ML A073058 001 Aug 30, 1991

## PERMITIL

SCHERING 5MG/ML N016008 001

## PROLIXIN

APOTHECON 5MG/ML A070533 001 Nov 07, 1985

## ELIXIR; ORAL

## FLUPHENAZINE HYDROCHLORIDE

TEVA PHARMS 2.5MG/5ML A081310 001 Apr 29, 1993

## PROLIXIN

APOTHECON 2.5MG/5ML N012145 003

## INJECTABLE; INJECTION

## PROLIXIN

APOTHECON 2.5MG/ML N011751 005

## TABLET; ORAL

## FLUPHENAZINE HYDROCHLORIDE

WATSON LABS 1MG A088555 001 Dec 18, 1987

2.5MG A088544 001 Dec 18, 1987

5MG A088527 001 Dec 18, 1987

10MG A088550 001 Dec 18, 1987

## PERMITIL

SCHERING 0.25MG N012034 001

2.5MG N012034 004

5MG N012034 005

10MG N012034 006

## PROLIXIN

APOTHECON 1MG N011751 004

2.5MG N011751 001

5MG N011751 003

10MG N011751 002

## TABLET, EXTENDED RELEASE; ORAL

## PERMITIL

SCHERING 1MG N012419 004

FLUPREDNISOLONE

## TABLET; ORAL

## ALPHADROL

PHARMACIA AND UPJOHN 1.5MG N012259 002

FLURANDRENOLIDE

## LOTION; TOPICAL

## FLURANDRENOLIDE

ALPHARMA US PHARMS 0.05% A087203 001 Apr 29, 1982

FLURANDRENOLIDE; NEOMYCIN SULFATE

## CREAM; TOPICAL

## CORDRAN-N

LILLY 0.05%;EQ 3.5MG BASE/GM N050346 001

## OINTMENT; TOPICAL

## CORDRAN-N

LILLY 0.05%;EQ 3.5MG BASE/GM N050345 001

FLURAZEPAM HYDROCHLORIDE

## CAPSULE; ORAL

## FLURAZEPAM HYDROCHLORIDE

HALSEY 15MG A071808 001 Jan 07, 1988

30MG A071809 001 Jan 07, 1988

MUTUAL PHARM 15MG A070454 001 Aug 04, 1986

30MG A070455 001 Aug 04, 1986

PAR PHARM 15MG A070444 001 Mar 20, 1986

30MG A070445 001 Mar 20, 1986

PUREPAC PHARM 15MG A071927 001 Sep 09, 1987

## DISCONTINUED DRUG PRODUCT LIST

6 - 138 (of 324)

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

PUREPAC PHARM	30MG	A071551	001	Sep 09, 1987
SANDOZ	15MG	A071716	001	Jul 31, 1991
	30MG	A071717	001	Jul 31, 1991
SUPERPHARM	15MG	A071659	001	Aug 04, 1988
	30MG	A071660	001	Aug 04, 1988
USL PHARMA	15MG	A070562	001	Jul 09, 1987
	30MG	A070563	001	Jul 09, 1987
WARNER CHILCOTT	15MG	A071767	001	Dec 04, 1987
	30MG	A071768	001	Dec 04, 1987
WATSON LABS	15MG	A072368	001	Mar 30, 1989

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

IVAX SUB TEVA PHARMS	50MG	A074411	001	May 31, 1995
	100MG	A074411	002	May 31, 1995
PLIVA	50MG	A074647	001	Apr 01, 1997
	100MG	A074647	002	Apr 01, 1997
SANDOZ	50MG	A074448	001	Jul 28, 1995
	100MG	A074448	002	Jul 28, 1995
TEVA	50MG	A074405	002	May 24, 1995
	100MG	A074405	001	May 24, 1995
THERAGEN	100MG	A074560	002	May 16, 1997

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

SCHERING	125MG	N018554	001	Jan 27, 1989
----------	-------	---------	-----	--------------

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT

GLAXOSMITHKLINE	0.044MG/INH	N020548	001	Mar 27, 1996
	0.11MG/INH	N020548	002	Mar 27, 1996
	0.22MG/INH	N020548	003	Mar 27, 1996

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

TARO PHARM INDS	0.005%	A077145	001	Jun 14, 2005
-----------------	--------	---------	-----	--------------

POWDER; INHALATION

FLOVENT

GLAXOSMITHKLINE	0.044MG/INH	N020549	001	Nov 07, 1997
	0.088MG/INH	N020549	002	Nov 07, 1997
	0.22MG/INH	N020549	003	Nov 07, 1997

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

ACTAVIS ELIZABETH	25MG	A075901	001	Dec 28, 2000
	50MG	A075901	002	Dec 28, 2000
	100MG	A075901	003	Dec 28, 2000
GENPHARM	50MG	A075950	001	Oct 15, 2001
	100MG	A075950	002	Oct 15, 2001
IVAX SUB TEVA PHARMS	25MG	A075898	001	Mar 12, 2001
	50MG	A075898	002	Mar 12, 2001
	100MG	A075898	003	Mar 12, 2001
MUTUAL PHARM	25MG	A076125	001	Apr 29, 2002
	50MG	A076125	002	Apr 29, 2002
	100MG	A076125	003	Apr 29, 2002
SANDOZ	25MG	A075887	001	Jan 05, 2001
	50MG	A075887	002	Jan 05, 2001
	100MG	A075887	003	Jan 05, 2001

## DISCONTINUED DRUG PRODUCT LIST

6 - 139 (of 324)

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

SYNTHON PHARMS	25MG	A075899	001	Jan 17, 2001
	50MG	A075899	002	Jan 17, 2001
	100MG	A075899	003	Jan 17, 2001
WATSON LABS	25MG	A075894	001	Apr 18, 2001
	50MG	A075894	002	Apr 18, 2001
	100MG	A075894	003	Apr 18, 2001

LUVOX

SOLVAY

	25MG	N020243	001	Dec 05, 1994
	50MG	N020243	002	Dec 05, 1994
	100MG	N020243	003	Dec 05, 1994
	150MG	N020243	004	Dec 05, 1994

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

BEN VENUE	5MG/ML	A081066	001	Dec 29, 1993
-----------	--------	---------	-----	--------------

FOLVITE

WYETH PHARMS INC	5MG/ML	N005897	008	
------------------	--------	---------	-----	--

TABLET; ORAL

FOLIC ACID

BARR	1MG	A089177	001	Jan 08, 1986
EVERYLIFE	1MG	A080755	001	
HALSEY	1MG	A083598	001	
IMPAX LABS	1MG	A080686	001	
IVAX SUB TEVA PHARMS	1MG	A083000	001	
LANNETT	1MG	A080816	001	
LILLY	1MG	N006135	003	
MK LABS	1MG	A083526	001	
NEXGEN PHARMA INC	1MG	A084915	001	
PHARMERAL	1MG	A084158	001	
PIONEER PHARMS	1MG	A088949	001	Sep 13, 1985
PUREPAC PHARM	1MG	A080784	001	
SANDOZ	1MG	A084472	001	
TABLICAPS	1MG	A083133	002	
UDL	1MG	A088199	001	Mar 29, 1983
USL PHARMA	1MG	A087828	001	May 13, 1982
VALEANT PHARM INTL	1MG	A080903	001	
VANGARD	1MG	A088730	001	Mar 23, 1984
VINTAGE PHARMS	1MG	A086296	001	
WATSON LABS	1MG	A080680	001	
	1MG	A083141	001	
	1MG	A085141	002	
WHITEWORTH TOWN PLSN	1MG	A080691	002	
FOLICET				
MISSION PHARMA	1MG	A087438	001	
FOLVITE				
WYETH PHARMS INC	1MG	N005897	004	

FOLLITROPIN ALFA/BETA

INJECTABLE; IM-SC

FOLLISTIM

ORGANON USA INC	75 IU/VIAL	N020582	001	Sep 29, 1997
	150 IU/VIAL	N020582	002	Sep 29, 1997

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

ORGANON USA INC	150 IU/0.18ML	N021211	003	Feb 11, 2004
-----------------	---------------	---------	-----	--------------

GONAL-F

EMD SERONO	37.5 IU/VIAL	N020378	003	May 25, 2000
	37.5 IU/VIAL	N021765	001	Mar 25, 2004
	75 IU/VIAL	N020378	001	Sep 29, 1997
	150 IU/VIAL	N020378	002	Sep 29, 1997

## DISCONTINUED DRUG PRODUCT LIST

6 - 140 (of 324)

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

GONAL-F

EMD SERONO

150 IU/VIAL

N021765 003

Mar 25, 2004

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

NOVARTIS

6.6MG/ML

N020961 001

Aug 26, 1998

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

SANDOZ

10MG

A076188 001

Oct 08, 2004

20MG

A076188 002

Oct 08, 2004

40MG

A076188 003

Oct 08, 2004

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

TEVA

10MG;12.5MG

A076945 001

Jul 05, 2006

20MG;12.5MG

A076945 002

Jul 05, 2006

WATSON LABS

10MG;12.5MG

A077144 001

Aug 16, 2005

20MG;12.5MG

A077144 002

Aug 16, 2005

MONOPRIL-HCT

BRISTOL MYERS SQUIBB

10MG;12.5MG

N020286 002

Nov 30, 1994

20MG;12.5MG

N020286 001

Nov 30, 1994

FURAZOLIDONE

SUSPENSION; ORAL

FUROXONE

SHIRE

50MG/15ML

N011323 002

TABLET; ORAL

FUROXONE

SHIRE

100MG

N011270 002

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

ABRAXIS PHARM

10MG/ML

N018507 001

Jul 30, 1982

10MG/ML

N019036 001

Aug 13, 1984

ASTRAZENECA

10MG/ML

A070014 001

Sep 09, 1985

10MG/ML

A070095 001

Sep 09, 1985

10MG/ML

A070096 001

Sep 09, 1985

BAXTER HLTHCARE

10MG/ML

A071439 001

Sep 14, 1990

10MG/ML

N018267 001

HOSPIRA

10MG/ML

A072080 001

Aug 13, 1991

10MG/ML

A074337 001

Oct 31, 1994

MARSAM PHARMS LLC

10MG/ML

A074017 001

Jun 30, 1994

ORGANON USA INC

10MG/ML

A070017 001

Dec 15, 1986

SMITH AND NEPHEW

10MG/ML

A070023 001

Feb 05, 1986

10MG/ML

A070078 001

Feb 05, 1986

WARNER CHILCOTT

10MG/ML

N018420 001

Feb 26, 1982

WATSON LABS

10MG/ML

A070019 001

Sep 22, 1986

10MG/ML

A070604 001

Jan 02, 1987

WYETH AYERST

10MG/ML

N018670 001

Jul 20, 1982

LASIX

SANOFI AVENTIS US

10MG/ML

N016363 001

SOLUTION; ORAL

LASIX

SANOFI AVENTIS US

10MG/ML

N017688 001

TABLET; ORAL

FUROSEMIDE

INTL MEDICATION

20MG

N018753 001

Feb 28, 1984

## DISCONTINUED DRUG PRODUCT LIST

6 - 141 (of 324)

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

INTL MEDICATION	40MG	N018753	002	Feb 28, 1984
KALAPHARM	20MG	N018868	001	Jun 28, 1983
	40MG	N018868	002	Jun 28, 1983
MUTUAL PHARM	20MG	A070043	001	Sep 26, 1985
	40MG	N018790	001	Nov 29, 1983
	80MG	A070100	001	Jan 26, 1988
SANDOZ	40MG	N018750	002	Jul 30, 1984
SUPERPHARM	20MG	N018370	002	Jun 26, 1984
	40MG	N018370	001	Feb 10, 1983
WARNER CHILCOTT	20MG	N018419	001	Jan 31, 1983
	40MG	N018419	002	Jan 31, 1983
	80MG	N018419	003	Nov 13, 1984
WATSON LABS	20MG	N018369	001	May 14, 1982
	40MG	A070413	001	Feb 26, 1986
	40MG	N018369	002	May 14, 1982

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

IVAX SUB TEVA PHARMS	100MG	A075477	001	Mar 23, 2005
	300MG	A075477	002	Mar 23, 2005
	400MG	A075477	003	Mar 23, 2005
MUTUAL PHARM	100MG	A076537	001	Jun 30, 2005
	300MG	A076537	002	Jun 30, 2005
	400MG	A076537	003	Jun 30, 2005
SANDOZ	100MG	A075428	001	Jan 24, 2006
	300MG	A075428	002	Jan 24, 2006
	400MG	A075428	003	Jan 24, 2006

TABLET; ORAL

GABAPENTIN

RANBAXY	600MG	A076605	001	Sep 14, 2005
	800MG	A076605	002	Sep 14, 2005
SANDOZ	600MG	A076120	001	Jan 27, 2006
	800MG	A076120	002	Jan 27, 2006

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007
---------------	-------------------------	---------	-----	--------------

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION

FLAXEDIL

DAVIS AND GECK	20MG/ML	N007842	001	
	100MG/ML	N007842	002	

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

GE HEALTHCARE	1mCi/ML	N017700	001	
NEOSCAN				
GE HEALTHCARE	2mCi/ML	N017655	001	

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

ROCHE PALO	250MG	N020460	001	Dec 22, 1994
	500MG	N020460	002	Dec 12, 1997

## DISCONTINUED DRUG PRODUCT LIST

6 - 142 (of 324)

GANCICLOVIR SODIUMINJECTABLE; INJECTION  
CYTOVENE

ROCHE PALO	EQ 500MG BASE/VIAL	N019661	001	Jun 23, 1989
------------	--------------------	---------	-----	--------------

GEMFIBROZIL

CAPSULE; ORAL

GEMFIBROZIL

MYLAN	300MG	A073466	001	Jan 25, 1993
-------	-------	---------	-----	--------------

PUREPAC PHARM	300MG	A072929	001	Jan 29, 1993
---------------	-------	---------	-----	--------------

LOPID

PFIZER PHARMS	200MG	N018422	001	
---------------	-------	---------	-----	--

	300MG	N018422	002	
--	-------	---------	-----	--

TABLET; ORAL

GEMFIBROZIL

DAVA PHARMS INC	600MG	A074270	001	Sep 27, 1993
-----------------	-------	---------	-----	--------------

MYLAN	600MG	A074452	001	Feb 16, 1995
-------	-------	---------	-----	--------------

PUREPAC PHARM	600MG	A074360	001	Aug 31, 1994
---------------	-------	---------	-----	--------------

SANDOZ	600MG	A074615	001	Sep 29, 1995
--------	-------	---------	-----	--------------

WATSON LABS	600MG	A074156	001	Oct 24, 1994
-------------	-------	---------	-----	--------------

GENTAMICIN SULFATE

CREAM; TOPICAL

GARAMYCIN

SCHERING	EQ 0.1% BASE	A060462	001	
----------	--------------	---------	-----	--

GENTAFAIR

PHARMAFAIR	EQ 0.1% BASE	A062458	001	Sep 01, 1983
------------	--------------	---------	-----	--------------

GENTAMICIN SULFATE

ALPHARMA US PHARMS	EQ 0.1% BASE	A062471	001	Sep 27, 1983
--------------------	--------------	---------	-----	--------------

BAUSCH AND LOMB	EQ 0.1% BASE	A064056	001	Apr 29, 1994
-----------------	--------------	---------	-----	--------------

PHARMADERM	EQ 1MG BASE/GM	A062530	001	Jul 05, 1984
------------	----------------	---------	-----	--------------

INJECTABLE; INJECTION

APOGEN

KING PHARMS	EQ 10MG BASE/ML	A062289	001	
-------------	-----------------	---------	-----	--

	EQ 40MG BASE/ML	A062289	002	
--	-----------------	---------	-----	--

BRISTAGEN

BRISTOL	EQ 40MG BASE/ML	A062288	001	
---------	-----------------	---------	-----	--

GARAMYCIN

SCHERING	EQ 1MG BASE/ML	A061716	002	
----------	----------------	---------	-----	--

	EQ 10MG BASE/ML	A061739	001	
--	-----------------	---------	-----	--

	EQ 40MG BASE/ML	A061716	001	
--	-----------------	---------	-----	--

GENTAFAIR

PHARMAFAIR	EQ 40MG BASE/ML	A062493	001	Aug 28, 1985
------------	-----------------	---------	-----	--------------

GENTAMICIN

INTL MEDICATION	EQ 1MG BASE/ML	A062325	003	Jun 23, 1982
-----------------	----------------	---------	-----	--------------

	EQ 40MG BASE/ML	A062325	001	
--	-----------------	---------	-----	--

	EQ 100MG BASE/100ML	A062325	004	Jun 23, 1982
--	---------------------	---------	-----	--------------

GENTAMICIN SULFATE

ABBOTT	EQ 1.2MG BASE/ML	A062413	001	Aug 11, 1983
--------	------------------	---------	-----	--------------

	EQ 1.4MG BASE/ML	A062413	002	Aug 11, 1983
--	------------------	---------	-----	--------------

	EQ 1.6MG BASE/ML	A062413	003	Aug 11, 1983
--	------------------	---------	-----	--------------

	EQ 1.8MG BASE/ML	A062413	004	Aug 11, 1983
--	------------------	---------	-----	--------------

	EQ 2MG BASE/ML	A062413	005	Aug 11, 1983
--	----------------	---------	-----	--------------

	EQ 60MG BASE/100ML	A062413	006	Aug 11, 1983
--	--------------------	---------	-----	--------------

	EQ 70MG BASE/100ML	A062413	007	Aug 11, 1983
--	--------------------	---------	-----	--------------

	EQ 80MG BASE/100ML	A062413	008	Aug 11, 1983
--	--------------------	---------	-----	--------------

	EQ 90MG BASE/100ML	A062413	009	Aug 11, 1983
--	--------------------	---------	-----	--------------

	EQ 100MG BASE/100ML	A062413	010	Aug 11, 1983
--	---------------------	---------	-----	--------------

BAXTER HLTHCARE	EQ 10MG BASE/ML	A062251	002	
-----------------	-----------------	---------	-----	--

	EQ 40MG BASE/ML	A062251	001	
--	-----------------	---------	-----	--

KALAPHARM	EQ 40MG BASE/ML	A062354	001	Apr 05, 1982
-----------	-----------------	---------	-----	--------------

PHARM SPEC	EQ 40MG BASE/ML	A062340	001	Mar 28, 1983
------------	-----------------	---------	-----	--------------

SOLOPAK	EQ 10MG BASE/ML	A062507	001	Jun 06, 1985
---------	-----------------	---------	-----	--------------

	EQ 40MG BASE/ML	A062507	002	Jun 06, 1985
--	-----------------	---------	-----	--------------



## DISCONTINUED DRUG PRODUCT LIST

6 - 143 (of 324)

GENTAMICIN SULFATE

## INJECTABLE; INJECTION

## GENTAMICIN SULFATE

TEVA PARENTERAL	EQ 10MG BASE/ML	A063149	001	Nov 21, 1991
	EQ 40MG BASE/ML	A063106	002	Nov 21, 1991
WATSON LABS	EQ 10MG BASE/ML	A062318	002	
	EQ 40MG BASE/ML	A062318	001	
WYETH AYERST	EQ 10MG BASE/ML	A062264	001	
	EQ 40MG BASE/ML	A062264	002	

## GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 1.2MG BASE/ML	A062588	001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062588	002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062588	003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062588	004	Jan 06, 1986
	EQ 2MG BASE/ML	A062588	005	Jan 06, 1986
	EQ 60MG BASE/100ML	A062588	006	Jan 06, 1986
	EQ 70MG BASE/100ML	A062588	007	Jan 06, 1986
	EQ 80MG BASE/100ML	A062588	008	Jan 06, 1986
	EQ 90MG BASE/100ML	A062588	009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062588	010	Jan 06, 1986

## U-GENCIN

PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248	001	
	EQ 40MG BASE/ML	A062248	002	

## INJECTABLE; INTRATHECAL

## GARAMYCIN

SCHERING	EQ 2MG BASE/ML	N050505	001	
----------	----------------	---------	-----	--

## OINTMENT; OPHTHALMIC

## GARAMYCIN

SCHERING	EQ 0.3% BASE	N050425	001	
----------	--------------	---------	-----	--

## GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062501	001	Jul 26, 1984
----------	--------------	---------	-----	--------------

## GENTAFAIR

PHARMAFAIR	EQ 3MG BASE/GM	A062443	001	May 26, 1983
------------	----------------	---------	-----	--------------

## OINTMENT; TOPICAL

## GARAMYCIN

SCHERING	EQ 0.1% BASE	A060463	001	
----------	--------------	---------	-----	--

## GENTAFAIR

PHARMAFAIR	EQ 0.1% BASE	A062444	001	May 26, 1983
------------	--------------	---------	-----	--------------

## GENTAMICIN SULFATE

ALPHARMA US PHARMS	EQ 0.1% BASE	A062496	001	Mar 14, 1984
--------------------	--------------	---------	-----	--------------

BAUSCH AND LOMB	EQ 0.1% BASE	A064054	001	Apr 29, 1994
-----------------	--------------	---------	-----	--------------

PHARMADERM	EQ 0.1% BASE	A062534	001	Oct 10, 1984
------------	--------------	---------	-----	--------------

## SOLUTION/DROPS; OPHTHALMIC

## GARAMYCIN

SCHERING	EQ 0.3% BASE	N050039	002	
----------	--------------	---------	-----	--

## GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062480	001	Mar 30, 1984
----------	--------------	---------	-----	--------------

## GENTAFAIR

PHARMAFAIR	EQ 0.3% BASE	A062440	001	May 03, 1983
------------	--------------	---------	-----	--------------

## GENTAMICIN SULFATE

ALCON UNIVERSAL	EQ 0.3% BASE	A062523	001	Nov 25, 1985
-----------------	--------------	---------	-----	--------------

PACO	EQ 3MG BASE/ML	A062932	001	Nov 07, 1988
------	----------------	---------	-----	--------------

GENTIAN VIOLET

## SUPPOSITORY; VAGINAL

## GVS

SAVAGE LABS	0.4%	A083513	001	
-------------	------	---------	-----	--

## TAMPON; VAGINAL

## GENAPAX

KEY PHARMS	5MG	A085017	001	
------------	-----	---------	-----	--

GLATIRAMER ACETATE

## FOR SOLUTION; SUBCUTANEOUS

## COPAXONE

## TEVA

	20MG/VIAL	N020622	001	Dec 20, 1996
--	-----------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 144 (of 324)

GLIMEPIRIDETABLET; ORAL  
GLIMEPIRIDE

RANBAXY	3MG	A077366	001	Oct 06, 2005
	6MG	A077366	002	Oct 06, 2005
VINTAGE	1MG	A077370	001	Dec 23, 2005
	2MG	A077370	002	Dec 23, 2005
	4MG	A077370	003	Dec 23, 2005
	8MG	A077370	004	Dec 23, 2005

GLIPIZIDETABLET; ORAL  
GLIPIZIDE

ENDO PHARMS	5MG	A074378	001	Nov 28, 1994
	10MG	A074378	002	Nov 28, 1994
PLIVA	5MG	A074619	001	Apr 04, 1997
	10MG	A074619	002	Apr 04, 1997
SANDOZ	5MG	A074542	001	Jun 20, 1995
	10MG	A074542	002	Jun 20, 1995
TEVA	5MG	A074387	001	Mar 04, 1996
	10MG	A074387	002	Mar 04, 1996
GLUCOTROL				
PFIZER	2.5MG	N017783	003	May 11, 1993

GLUCAGON HYDROCHLORIDEINJECTABLE; INJECTION  
GLUCAGON

LILLY	EQ 1MG BASE/VIAL	N012122	001	
	EQ 10MG BASE/VIAL	N012122	002	

GLUTETHIMIDECAPSULE; ORAL  
DORIDEN

SANOFI AVENTIS US	500MG	N009519	008	
-------------------	-------	---------	-----	--

TABLET; ORAL  
DORIDEN

SANOFI AVENTIS US	250MG	N009519	002	
	500MG	N009519	005	

GLUTETHIMIDE

HALSEY	250MG	A089458	001	Oct 10, 1986
	500MG	A089459	001	Oct 10, 1986
LANNETT	250MG	A083475	001	
	500MG	A085571	001	
SANDOZ	500MG	A083234	002	
UCB INC	500MG	A085171	001	
VITARINE	500MG	A087297	001	
WATSON LABS	500MG	A084362	001	
	500MG	A085763	001	

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

SANDOZ	1.5MG	A075174	001	Jun 22, 1998
	3MG	A075174	002	Jun 22, 1998
SANOFI AVENTIS US	1.5MG	N020055	001	Apr 17, 1992
	3MG	N020055	002	Apr 17, 1992
	6MG	N020055	003	Mar 08, 2000

GLYNASE

PHARMACIA AND UPJOHN	4.5MG	N020051	003	Sep 24, 1993
----------------------	-------	---------	-----	--------------

MICRONASE

PHARMACIA AND UPJOHN	1.25MG	N017498	001	May 01, 1984
	2.5MG	N017498	002	May 01, 1984
	5MG	N017498	003	May 01, 1984

## DISCONTINUED DRUG PRODUCT LIST

6 - 145 (of 324)

GLYCINE

## SOLUTION; IRRIGATION

## GLYCINE 1.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	1.5GM/100ML	N018522	001	Feb 19, 1982
HOSPIRA	1.5GM/100ML	N017633	001	

GLYCOPYRROLATE

## INJECTABLE; INJECTION

## GLYCOPYRROLATE

ABRAXIS PHARM	0.2MG/ML	A088475	001	Jun 12, 1984
HOSPIRA	0.2MG/ML	A089393	001	Jun 15, 1988
TEVA PARENTERAL	0.2MG/ML	A081169	001	Sep 10, 1991
WATSON LABS	0.2MG/ML	A086947	001	Jun 24, 1983
ROBINUL				
ROBINS AH	0.2MG/ML	N014764	001	

## TABLET; ORAL

## GLYCOPYRROLATE

WATSON LABS	1MG	A085562	001	
	1MG	A086902	001	
	2MG	A085563	001	
	2MG	A086178	001	
	2MG	A086900	001	

GONADORELIN ACETATE

## INJECTABLE; INJECTION

## LUTREPULSE KIT

FERRING	0.8MG/VIAL	N019687	001	Oct 10, 1989
	3.2MG/VIAL	N019687	002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE

## INJECTABLE; INJECTION

## FACTREL

BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982
	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982
	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982

GONADOTROPIN, CHORIONIC

## INJECTABLE; INJECTION

## A.P.L.

FERRING	5,000 UNITS/VIAL	N017055	001	
	10,000 UNITS/VIAL	N017055	002	
	20,000 UNITS/VIAL	N017055	003	

## CHORIONIC GONADOTROPIN

APP PHARMS	5,000 UNITS/VIAL	N017067	001	
	15,000 UNITS/VIAL	N017067	004	
	20,000 UNITS/VIAL	N017067	003	
BEL MAR	5,000 UNITS/VIAL	N017054	001	
	10,000 UNITS/VIAL	N017054	002	
FERRING	2,000 UNITS/VIAL	N017016	009	Dec 27, 1984
	2,000 UNITS/VIAL	N017016	011	Feb 16, 1990
	5,000 UNITS/VIAL	N017016	006	
	15,000 UNITS/VIAL	N017016	010	Feb 15, 1985
	20,000 UNITS/VIAL	N017016	004	

## FOLLUTEIN

BRISTOL MYERS SQUIBB	10,000 UNITS/VIAL	N017056	001	
----------------------	-------------------	---------	-----	--

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

## SOLUTION/DROPS; OPHTHALMIC

## NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

IPHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062818	001	Oct 11, 1988
WATSON LABS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062788	001	Jun 11, 1987

## DISCONTINUED DRUG PRODUCT LIST

6 - 146 (of 324)

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

## SOLUTION/DROPS; OPHTHALMIC

## NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062383	001	Aug 31, 1982
------------	--	---------	-----	--------------

## NEO-POLYCIN

DOW PHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A060427	001	
-----------	--	---------	-----	--

GRANISETRON HYDROCHLORIDE

## INJECTABLE; INJECTION

## KYTRIL

ROCHE	EQ 3MG BASE/ML	N020239	001	Dec 29, 1993
-------	----------------	---------	-----	--------------

## SOLUTION; ORAL

## KYTRIL

ROCHE	EQ 2MG BASE/10ML	N021238	001	Jun 27, 2001
-------	------------------	---------	-----	--------------

## TABLET; ORAL

## KYTRIL

ROCHE	EQ 2MG BASE	N020305	002	Jun 15, 1998
-------	-------------	---------	-----	--------------

GREPAFLOXACIN HYDROCHLORIDE

## TABLET; ORAL

## RAXAR

OTSUKA	EQ 200MG BASE	N020695	001	Nov 06, 1997
--------	---------------	---------	-----	--------------

	EQ 400MG BASE	N020695	002	May 14, 1998
--	---------------	---------	-----	--------------

	EQ 600MG BASE	N020695	003	May 14, 1998
--	---------------	---------	-----	--------------

GRISEOFULVIN, MICROCRYSTALLINE

## CAPSULE; ORAL

## GRISACTIN

WYETH AYERST	125MG	N050051	002	
--------------	-------	---------	-----	--

	250MG	N050051	001	
--	-------	---------	-----	--

## SUSPENSION; ORAL

## GRIFULVIN V

JOHNSON AND JOHNSON	125MG/5ML	N050448	001	
---------------------	-----------	---------	-----	--

## TABLET; ORAL

## FULVICIN-U/F

SCHERING	250MG	A060569	002	
----------	-------	---------	-----	--

	500MG	A060569	001	
--	-------	---------	-----	--

## GRIFULVIN V

J AND J	125MG	A060618	001	
---------	-------	---------	-----	--

	250MG	A060618	002	
--	-------	---------	-----	--

	500MG	A060618	003	
--	-------	---------	-----	--

ORTHONEUTROGENA	125MG	A062279	001	
-----------------	-------	---------	-----	--

	250MG	A062279	002	
--	-------	---------	-----	--

## GRISACTIN

WYETH AYERST	500MG	A060212	001	
--------------	-------	---------	-----	--

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

## TABLET; ORAL

## FULVICIN P/G

SCHERING	125MG	A061996	001	
----------	-------	---------	-----	--

	250MG	A061996	002	
--	-------	---------	-----	--

## FULVICIN P/G 165

SCHERING	165MG	A061996	003	Apr 06, 1982
----------	-------	---------	-----	--------------

## FULVICIN P/G 330

SCHERING	330MG	A061996	004	Apr 06, 1982
----------	-------	---------	-----	--------------

## GRISACTIN ULTRA

WYETH AYERST	125MG	A062178	001	
--------------	-------	---------	-----	--

	165MG	A062438	001	Nov 17, 1983
--	-------	---------	-----	--------------

	250MG	A062178	002	
--	-------	---------	-----	--

	330MG	A062438	002	Nov 17, 1983
--	-------	---------	-----	--------------

## ULTRAGRIS-165

PLIVA	165MG	A062645	001	Jun 30, 1992
-------	-------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 147 (of 324)

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL				
ULTRAGRIS-330				
PLIVA	330MG	A062646	001	Jun 30, 1992

GUANABENZ ACETATE

TABLET; ORAL				
GUANABENZ ACETATE				
SANDOZ	EQ 4MG BASE	A074517	001	Sep 30, 1998
	EQ 8MG BASE	A074517	002	Sep 30, 1998
TEVA PHARMS	EQ 4MG BASE	A074267	001	Jun 01, 1994
	EQ 8MG BASE	A074267	002	Jun 01, 1994
WATSON LABS	EQ 4MG BASE	A074025	001	Feb 28, 1994
	EQ 8MG BASE	A074025	002	Feb 28, 1994
WYTENSIN				
WYETH AYERST	EQ 4MG BASE	N018587	001	Sep 07, 1982
	EQ 8MG BASE	N018587	002	Sep 07, 1982
	EQ 16MG BASE	N018587	003	Sep 07, 1982

GUANADREL SULFATE

TABLET; ORAL				
HYLOREL				
PHARMACIA AND UPJOHN	10MG	N018104	001	Dec 29, 1982
	25MG	N018104	002	Dec 29, 1982

GUANETHIDINE MONOSULFATE

TABLET; ORAL				
GUANETHIDINE MONOSULFATE				
WATSON LABS	EQ 10MG SULFATE	A086113	001	Mar 26, 1985
	EQ 25MG SULFATE	A086114	001	Mar 26, 1985
ISMELIN				
NOVARTIS	EQ 10MG SULFATE	N012329	001	
	EQ 25MG SULFATE	N012329	002	

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL				
ESIMIL				
NOVARTIS	10MG;25MG	N013553	001	

GUANFACINE HYDROCHLORIDE

TABLET; ORAL				
GUANFACINE HYDROCHLORIDE				
WATSON LABS	EQ 1MG BASE	A074762	001	Jun 25, 1997
	EQ 2MG BASE	A074762	002	Jun 25, 1997
TENEX				
PROMIUS PHARMA	EQ 3MG BASE	N019032	003	Nov 07, 1988

HALAZEPAM

TABLET; ORAL				
PAXIPAM				
SCHERING	20MG	N017736	003	
	40MG	N017736	004	

HALCINONIDE

CREAM; TOPICAL				
HALOG				
WESTWOOD SQUIBB	0.025%	N017818	001	
HALOG-E				
RANBAXY	0.1%	N018234	001	
OINTMENT; TOPICAL				
HALOG				
BRISTOL MYERS SQUIBB	0.025%	N018125	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 148 (of 324)

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL

HALFAN

GLAXOSMITHKLINE 250MG N020250 001 Jul 24, 1992

HALOPERIDOL

TABLET; ORAL

HALDOL

ORTHO MCNEIL 0.5MG N015921 001  
 1MG N015921 002  
 2MG N015921 003  
 5MG N015921 004  
 10MG N015921 005  
 20MG N015921 006 Feb 02, 1982

HALDOL SOLUTAB

ORTHO MCNEIL PHARM 1MG N017079 001

HALOPERIDOL

DURAMED PHARMS BARR 0.5MG A071216 001 Dec 04, 1986  
 1MG A071217 001 Dec 04, 1986  
 2MG A071218 001 Dec 04, 1986  
 5MG A071219 001 Dec 04, 1986  
 10MG A071220 001 Jul 07, 1987  
 20MG A071221 001 Jul 07, 1987  
 LEDERLE 0.5MG A072727 001 Sep 19, 1989  
 1MG A072728 001 Sep 19, 1989  
 2MG A072729 001 Sep 19, 1989  
 5MG A072730 001 Sep 19, 1989  
 10MG A072731 001 Sep 19, 1989  
 20MG A072732 001 Sep 19, 1989  
 MUTUAL PHARM 0.5MG A071156 001 Jan 02, 1987  
 1MG A071157 001 Jan 02, 1987  
 2MG A071172 001 Jan 02, 1987  
 5MG A071212 001 Jan 07, 1988  
 10MG A071173 001 Jan 07, 1988  
 20MG A071177 001 Jan 07, 1988  
 PAR PHARM 20MG A071328 001 Jul 20, 1987  
 PUREPAC PHARM 0.5MG A071071 001 Nov 03, 1986  
 1MG A071072 001 Nov 03, 1986  
 2MG A071073 001 Nov 03, 1986  
 5MG A071074 001 Nov 03, 1986  
 10MG A071075 001 Aug 04, 1987  
 20MG A071076 001 Aug 04, 1987  
 QUANTUM PHARMICS 0.5MG A071255 001 Feb 17, 1987  
 1MG A071269 001 Feb 17, 1987  
 2MG A071256 001 Feb 17, 1987  
 5MG A071257 001 Feb 17, 1987  
 ROXANE 0.5MG A071128 001 Feb 17, 1987  
 1MG A071129 001 Feb 17, 1987  
 2MG A071130 001 Feb 17, 1987  
 5MG A071131 001 Feb 17, 1987  
 10MG A071132 001 May 12, 1987  
 20MG A071133 001 May 12, 1987  
 ROYCE LABS 0.5MG A071722 001 Dec 24, 1987  
 1MG A071723 001 Dec 24, 1987  
 2MG A071724 001 Dec 24, 1987  
 5MG A071725 001 Dec 24, 1987  
 10MG A072121 001 Dec 24, 1987  
 20MG A072122 001 Dec 24, 1987  
 SCS 0.5MG A070720 001 Jun 10, 1986  
 1MG A070721 001 Jun 10, 1986  
 2MG A070722 001 Jun 10, 1986  
 5MG A070723 001 Jun 10, 1986  
 10MG A070724 001 Jun 10, 1986  
 20MG A070725 001 Sep 24, 1986

## DISCONTINUED DRUG PRODUCT LIST

6 - 149 (of 324)

HALOPERIDOL

## TABLET; ORAL

## HALOPERIDOL

VINTAGE	0.5MG	A071233	001	Nov 03, 1986
	1MG	A071234	001	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071236	001	Nov 03, 1986
	10MG	A071237	001	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991

HALOPERIDOL DECANOATE

## INJECTABLE; INJECTION

## HALOPERIDOL DECANOATE

HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176	002	Feb 09, 2000
SANDOZ	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005

HALOPERIDOL LACTATE

## CONCENTRATE; ORAL

## HALDOL

ORTHO MCNEIL	EQ 2MG BASE/ML	N015922	001	
HALOPERIDOL				
ALPHARMA	EQ 2MG BASE/ML	A070318	001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710	001	Mar 07, 1986
SCS	EQ 2MG BASE/ML	A070726	001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015	001	Aug 25, 1987

## HALOPERIDOL INTENSOL

ROXANE	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988
--------	----------------	---------	-----	--------------

## INJECTABLE; INJECTION

## HALOPERIDOL

ABRAXIS PHARM	EQ 5MG BASE/ML	A071187	001	Jan 20, 1987
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A072516	001	Feb 25, 1993
	EQ 5MG BASE/ML	A072517	001	Feb 25, 1993
SANDOZ	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070802	001	Dec 14, 1987
SOLOPAK	EQ 5MG BASE/ML	A070800	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070801	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070864	001	Dec 14, 1987
WATSON LABS	EQ 5MG BASE/ML	A070713	001	May 17, 1988
	EQ 5MG BASE/ML	A070714	001	May 17, 1988
	EQ 5MG BASE/ML	A070744	001	May 17, 1988

## SOLUTION; ORAL

## HALOPERIDOL LACTATE

ACTAVIS MID ATLANTIC	EQ 1MG BASE/ML	A074536	001	Nov 02, 1995
----------------------	----------------	---------	-----	--------------

HALOPROGIN

## CREAM; TOPICAL

## HALOTEX

WESTWOOD SQUIBB	1%	N016942	001	
-----------------	----	---------	-----	--

## SOLUTION; TOPICAL

## HALOTEX

WESTWOOD SQUIBB	1%	N016943	001	
-----------------	----	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 150 (of 324)

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

WYETH AYERST

99.99%

N011338 001

HALOTHANE

BH

99.99%

A084977 001

HALOCARBON

99.99%

A080810 001

HOSPIRA

99.99%

A083254 001

HEPARIN CALCIUM

INJECTABLE; INJECTION

CALCIPARINE

SANOFI AVENTIS US

25,000 UNITS/ML

N018237 001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

HOSPIRA

100 UNITS/ML

N005264 010

INTL MEDICATION

10 UNITS/ML

A086357 001

500 UNITS/ML

A086357 002

LUITPOLD

10 UNITS/ML

A089063 001

Oct 09, 1985

100 UNITS/ML

A089064 001

Oct 09, 1985

PARKE DAVIS

10 UNITS/ML

N017346 006

SMITH AND NEPHEW

10 UNITS/ML

A087904 001

Apr 20, 1983

10 UNITS/ML

A087958 001

Apr 20, 1983

10 UNITS/ML

A088458 001

Jul 26, 1984

10 UNITS/ML

A088580 001

Oct 25, 1984

100 UNITS/ML

A087906 001

Apr 20, 1983

100 UNITS/ML

A087959 001

Apr 20, 1983

100 UNITS/ML

A088460 001

Jul 26, 1984

100 UNITS/ML

A088581 001

Oct 25, 1984

SOLOPAK

10 UNITS/ML

A087903 001

Apr 20, 1983

10 UNITS/ML

A088457 001

Oct 25, 1984

100 UNITS/ML

A087905 001

Apr 20, 1983

100 UNITS/ML

A088459 001

Jul 26, 1984

HEPARIN SODIUM

ABRAXIS PHARM

1,000 UNITS/ML

N017033 001

1,000 UNITS/ML

N017979 001

5,000 UNITS/ML

N017979 003

10,000 UNITS/ML

N017979 002

AKORN

1,000 UNITS/ML

N017486 001

5,000 UNITS/ML

N017486 002

10,000 UNITS/ML

N017486 003

20,000 UNITS/ML

N017486 004

40,000 UNITS/ML

N017486 005

APP PHARMS

1,000 UNITS/ML

N017651 005

5,000 UNITS/ML

N017029 002

10,000 UNITS/ML

N017651 003

20,000 UNITS/ML

N017651 008

BAXTER HLTHCARE

5,000 UNITS/0.5ML

N017037 013

Apr 07, 1986

BAXTER HLTHCARE CORP

1,000 UNITS/ML

N017007 001

2,500 UNITS/ML

N017007 007

5,000 UNITS/ML

N017007 002

5,000 UNITS/0.5ML

N017007 010

7,500 UNITS/ML

N017007 003

10,000 UNITS/ML

N017007 004

15,000 UNITS/ML

N017007 005

20,000 UNITS/ML

N017007 006

CHAMBERLIN PARENTERL

1,000 UNITS/ML

N017130 001

5,000 UNITS/ML

N017130 002

10,000 UNITS/ML

N017130 003

20,000 UNITS/ML

N017130 004

DELL LABS

1,000 UNITS/ML

N017540 001

5,000 UNITS/ML

N017540 002



## DISCONTINUED DRUG PRODUCT LIST

6 - 151 (of 324)

HEPARIN SODIUM

## INJECTABLE; INJECTION

## HEPARIN SODIUM

DELL LABS	10,000 UNITS/ML	N017540	003	
	20,000 UNITS/ML	N017540	004	
	40,000 UNITS/ML	N017540	005	
HOSPIRA	2,500 UNITS/ML	A088099	001	Apr 28, 1983
	10,000 UNITS/ML	A040095	001	Jul 26, 1996
LILLY	1,000 UNITS/ML	N005521	001	
	10,000 UNITS/ML	N005521	002	
	20,000 UNITS/ML	N005521	004	
LUITPOLD	1,000 UNITS/ML	A087452	001	Oct 31, 1983
MARSAM PHARMS LLC	1,000 UNITS/ML	A040007	001	Jun 07, 1996
	1,000 UNITS/ML	A040008	001	Oct 10, 1995
ORGANON USA INC	1,000 UNITS/ML	N000552	008	
	5,000 UNITS/ML	N000552	009	
	10,000 UNITS/ML	N000552	010	
PARKE DAVIS	1,000 UNITS/ML	N017346	001	
	5,000 UNITS/ML	N017346	002	
	7,500 UNITS/ML	N017346	003	
	10,000 UNITS/ML	N017346	004	
	20,000 UNITS/ML	N017346	005	
PHARM SPEC	1,000 UNITS/ML	N017780	001	
	5,000 UNITS/ML	N017780	002	
	10,000 UNITS/ML	N017780	003	
	20,000 UNITS/ML	N017780	004	
	40,000 UNITS/ML	N017780	005	
PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570	001	
	5,000 UNITS/ML	N004570	002	
	10,000 UNITS/ML	N004570	003	
SMITH AND NEPHEW	1,000 UNITS/ML	A088239	001	Jul 26, 1984
SOLOPAK	1,000 UNITS/ML	A087043	001	
	5,000 UNITS/ML	A087077	001	
	5,000 UNITS/0.5ML	A087395	001	
	10,000 UNITS/ML	A087107	001	
	10,000 UNITS/0.5ML	A087363	001	
WATSON LABS	1,000 UNITS/ML	N017064	002	
	2,500 UNITS/ML	N017064	015	
	3,000 UNITS/ML	N017064	016	
	4,000 UNITS/ML	N017064	017	
	5,000 UNITS/ML	N017064	003	
	6,000 UNITS/ML	N017064	018	
	7,500 UNITS/ML	N017064	019	
	10,000 UNITS/ML	N017064	004	
	20,000 UNITS/ML	N017064	005	
	40,000 UNITS/ML	N017064	006	
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	200 UNITS/100ML	N019042	001	Mar 29, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%				
HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%				
HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
	10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
	10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992

## DISCONTINUED DRUG PRODUCT LIST

6 - 152 (of 324)

HEPARIN SODIUM

## INJECTABLE; INJECTION

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
	5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
	10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019802	005	Jul 20, 1992
	10,000 UNITS/100ML	N019802	002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019135	001	Mar 29, 1985
	5,000 UNITS/100ML	N019802	003	Jul 20, 1992
HOSPIRA	5,000 UNITS/100ML	N018916	009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	500 UNITS/100ML	N018609	003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	1,000 UNITS/100ML	N019130	002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%				
HOSPIRA	100 UNITS/ML	N018911	002	Jan 30, 1985
	100 UNITS/ML	N018916	004	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	1,000 UNITS/100ML	N018916	001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	1,000 UNITS/100ML	N019042	004	Mar 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE				
MARSAM PHARMS LLC	1,000 UNITS/ML	A089464	001	Jun 03, 1986
PHARMA SERVE NY	1,000 UNITS/ML	A086129	001	
LIPO-HEPIN				
3M	1,000 UNITS/0.5ML	N017027	001	
	1,000 UNITS/ML	N017027	006	
	5,000 UNITS/0.5ML	N017027	002	
	5,000 UNITS/ML	N017027	008	
	7,500 UNITS/0.5ML	N017027	010	
	10,000 UNITS/0.5ML	N017027	003	
	10,000 UNITS/ML	N017027	009	
	15,000 UNITS/0.5ML	N017027	011	
	20,000 UNITS/0.5ML	N017027	004	
	20,000 UNITS/ML	N017027	007	
	40,000 UNITS/ML	N017027	005	
LIQUAEMIN LOCK FLUSH				
ORGANON USA INC	100 UNITS/ML	N000552	007	
LIQUAEMIN SODIUM				
ORGANON USA INC	1,000 UNITS/ML	N000552	004	
	5,000 UNITS/ML	N000552	003	
	10,000 UNITS/ML	N000552	005	
	20,000 UNITS/ML	N000552	001	
	40,000 UNITS/ML	N000552	002	
LIQUAEMIN SODIUM PRESERVATIVE FREE				
ORGANON USA INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986
	5,000 UNITS/ML	N000552	012	Apr 11, 1986
	10,000 UNITS/ML	N000552	013	Apr 11, 1986
PANHEPRIN				
HOSPIRA	1,000 UNITS/ML	N005264	004	
	5,000 UNITS/ML	N005264	006	

## DISCONTINUED DRUG PRODUCT LIST

6 - 153 (of 324)

HEPARIN SODIUM

INJECTABLE; INJECTION

PANHEPRIN

HOSPIRA

10,000 UNITS/ML

N005264 007

20,000 UNITS/ML

N005264 008

40,000 UNITS/ML

N005264 009

SODIUM HEPARIN

ABRAXIS PHARM

5,000 UNITS/ML

N017033 002

10,000 UNITS/ML

N017033 003

20,000 UNITS/ML

N017033 004

BAXTER HLTHCARE

1,000 UNITS/ML

N017036 001

Mar 04, 1988

HETACILLIN

FOR SUSPENSION; ORAL

VERSAPEN

BRISTOL

EQ 112.5MG AMPICIL/ML

A061398 001

EQ 112.5MG AMPICIL/5ML

N050060 001

EQ 112.5MG AMPICIL/ML

N050060 003

EQ 225MG AMPICIL/5ML

A061398 002

HETACILLIN POTASSIUM

CAPSULE; ORAL

VERSAPEN-K

BRISTOL

EQ 225MG AMPICIL

A061396 001

EQ 450MG AMPICIL

A061396 002

HEXACHLOROPHENE

AEROSOL; TOPICAL

SEPTISOL

VESTAL LABS

0.23%

N017424 001

TURGEX

XTTRIUM

3%

N018375 001

EMULSION; TOPICAL

HEXA-GERM

HUNTINGTON LABS

3%

N017411 001

PHISOHEX

SANOFI AVENTIS US

3%

N008402 001

SOY-DOME

BAYER PHARMS

3%

N017405 001

TURGEX

XTTRIUM

3%

N019055 001

Nov 30, 1984

SOAP; TOPICAL

GAMOPHEN

ARBROOK

2%

N006270 003

SOLUTION; TOPICAL

DIAL

DIAL

0.25%

N017421 002

GERMA-MEDICA

HUNTINGTON LABS

1%

N017412 001

GERMA-MEDICA "MG"

HUNTINGTON LABS

0.25%

N017412 002

SEPTI-SOFT

CALGON

0.25%

N017460 001

SEPTISOL

VESTAL LABS

0.25%

N017423 001

SPONGE; TOPICAL

E-Z SCRUB

BECTON DICKINSON

450MG

N017452 001

HEXASCRUB

PROF DSPLS

3%

N018363 001

PHISO-SCRUB

SANOFI AVENTIS US

3%

N017446 001

SCRUBTEAM SURGICAL SPONGEBRUSH

3M

330MG

N017413 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 154 (of 324)

HEXAFLUORENIUM BROMIDEINJECTABLE; INJECTION  
MYLAXEN

MEDPOINTE PHARM HLC 20MG/ML N009789 003

HEXOCYCLIUM METHYLSULFATETABLET; ORAL  
TRAL

ABBOTT 25MG N010599 001

HEXYLCAINE HYDROCHLORIDESOLUTION; TOPICAL  
CYCLAINA

MERCK 5% N008472 001

HISTAMINE PHOSPHATEINJECTABLE; INJECTION  
HISTAMINE PHOSPHATE

LILLY EQ 0.1MG BASE/ML N000734 003

EQ 0.2MG BASE/ML N000734 002

EQ 1MG BASE/ML N000734 001

HISTRELIN ACETATEINJECTABLE; INJECTION  
SUPPRELIN

SHIRE EQ 0.2MG BASE/ML N019836 001 Dec 24, 1991

EQ 0.5MG BASE/ML N019836 002 Dec 24, 1991

EQ 1MG BASE/ML N019836 003 Dec 24, 1991

HOMATROPINE METHYLBROMIDETABLET; ORAL  
HOMAPIN-10

MISSION PHARMA 10MG A086308 001

HOMAPIN-5

MISSION PHARMA 5MG A086309 001

TABLET, CHEWABLE; ORAL

EQUIPIN

MISSION PHARMA 3MG A086310 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

ENDO PHARMS 1.5MG/5ML;5MG/5ML N005213 002 Jul 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

IVAX SUB TEVA PHARMS 1.5MG/5ML;5MG/5ML A040285 001 Jul 19, 1999

HYDROPANE

HALSEY 1.5MG/5ML;5MG/5ML A088066 001 Jun 28, 1985

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS TOTOWA 1.5MG;5MG A040295 001 Dec 01, 2000

HYCODAN

ENDO PHARMS 1.5MG;5MG N005213 001 Jul 26, 1988

HYALURONIDASE

INJECTABLE; INJECTION

VITRASE

ISTA PHARMS 6,200 UNITS/VIAL N021640 001 May 05, 2004

WYDASE

BAXTER HLTHCARE 150 UNITS/ML N006343 002

150 UNITS/VIAL N006343 006

1,500 UNITS/VIAL N006343 005

## DISCONTINUED DRUG PRODUCT LIST

6 - 155 (of 324)

HYDRALAZINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## APRESOLINE

NOVARTIS 20MG/ML N008303 003

## HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM 20MG/ML A089532 001 Aug 11, 1987

SMITH AND NEPHEW 20MG/ML A088518 001 Apr 20, 1984

SOLOPAK 20MG/ML A088517 001 Aug 22, 1985

TEVA PARENTERAL 20MG/ML A040373 001 Feb 23, 2000

## TABLET; ORAL

## APRESOLINE

NOVARTIS 10MG N008303 004

25MG N008303 001

50MG N008303 002

100MG N008303 005

## DRALZINE

TEVA 25MG A084301 001

## HYDRALAZINE HYDROCHLORIDE

ACTAVIS TOTOWA 25MG A088560 001 Oct 04, 1984

50MG A088649 001 Oct 18, 1984

ASCOT 25MG A088310 001 Dec 19, 1984

50MG A088311 001 Dec 19, 1984

HALSEY 10MG A089218 001 Jan 22, 1986

25MG A089130 001 Jan 15, 1986

50MG A089222 001 Jan 22, 1986

100MG A089178 001 Jan 15, 1986

IMPAX LABS 25MG A084922 001

50MG A084923 001

IVAX SUB TEVA PHARMS 10MG A084443 001

25MG A084437 001

50MG A084469 002

100MG A084581 001

MUTUAL PHARM 10MG A088728 001 Apr 11, 1985

10MG A089359 001 Jul 25, 1986

25MG A084106 002

25MG A089258 001 May 05, 1986

50MG A084107 002

50MG A089259 001 May 05, 1986

100MG A088729 001 Apr 11, 1985

PUREPAC PHARM 25MG A088177 001 Jul 29, 1983

50MG A088178 001 Aug 15, 1983

QUANTUM PHARMICS 10MG A088671 001 May 01, 1984

25MG A088657 001 Jun 15, 1984

50MG A088652 001 May 08, 1984

100MG A088686 001 May 01, 1984

SANDOZ 10MG A083241 001

25MG A083560 001

50MG A083561 001

50MG A085088 001

SUPERPHARM 10MG A088787 001 Aug 28, 1984

25MG A088788 001 Aug 28, 1984

50MG A088789 001 Aug 28, 1984

TG UNITED LABS 10MG A088846 001 Feb 26, 1985

25MG A088847 001 Feb 26, 1985

50MG A088848 001 Feb 26, 1985

100MG A088849 001 Feb 26, 1985

USL PHARMA 25MG A087780 001 Mar 29, 1982

50MG A087751 001 Mar 29, 1982

VANGARD 25MG A087712 001

50MG A087908 001 May 07, 1982

VITARINE 25MG A086088 001

WATSON LABS 25MG A085532 002 May 24, 1982

50MG A085533 002 May 25, 1982

WEST WARD 25MG A088240 001 May 27, 1983

## DISCONTINUED DRUG PRODUCT LIST

6 - 156 (of 324)

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

WEST WARD 50MG A088241 001 May 27, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

APRESAZIDE

NOVARTIS 25MG;25MG A084735 001

50MG;50MG A084810 001

100MG;50MG A084811 001

HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY 25MG;25MG A087608 001 Feb 08, 1982

50MG;50MG A087213 001 Feb 08, 1982

100MG;50MG A087609 001 Feb 08, 1982

SUPERPHARM 25MG;25MG A089200 001 Feb 09, 1987

50MG;50MG A089201 001 Feb 09, 1987

WATSON LABS 25MG;25MG A085457 001 Mar 04, 1982

50MG;50MG A085446 001 Mar 04, 1982

100MG;50MG A085440 001 Mar 04, 1982

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50

IVAX PHARMS 100MG;50MG A088358 001 Apr 10, 1984

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25

IVAX PHARMS 25MG;25MG A088356 001 Apr 10, 1984

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50

IVAX PHARMS 50MG;50MG A088357 001 Apr 10, 1984

HYDRA-ZIDE

PAR PHARM 100MG;50MG A088961 001 Oct 21, 1985

TABLET; ORAL

APRESOLINE-ESIDRIX

NOVARTIS 25MG;15MG N012026 002

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

WATSON LABS 25MG;15MG A085827 001

HYDROCHLOROTHIAZIDE W/ HYDRALAZINE

WATSON LABS 25MG;15MG A085373 001

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CAM-AP-ES

TG UNITED LABS 25MG;15MG;0.1MG A084897 001

HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE

IVAX SUB TEVA PHARMS 25MG;15MG;0.1MG A084291 001

HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE

MYLAN 25MG;15MG;0.1MG A087085 001

HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE

WATSON LABS 25MG;15MG;0.1MG A085771 001

HYDRAP-ES

SANDOZ 25MG;15MG;0.1MG A084876 001

HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

WATSON LABS 25MG;15MG;0.1MG A083770 001

HYDROSERPINE PLUS (R-H-H)

IVAX SUB TEVA PHARMS 25MG;15MG;0.1MG A083877 001

RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MUTUAL PHARM 25MG;15MG;0.1MG A088570 001 Apr 10, 1984

SOLVAY 25MG;15MG;0.1MG A088376 001 Oct 28, 1983

WATSON LABS 25MG;15MG;0.1MG A085549 001

25MG;15MG;0.1MG A087556 001

RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE

LEDERLE 25MG;15MG;0.1MG A087709 001 May 13, 1982

SER-A-GEN

SOLVAY 25MG;15MG;0.1MG A087210 001

SER-AP-ES

NOVARTIS 25MG;15MG;0.1MG N012193 005

## DISCONTINUED DRUG PRODUCT LIST

6 - 157 (of 324)

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

UNIPRES

SOLVAY	25MG;15MG;0.1MG	A085893	001
	25MG;15MG;0.1MG	A086298	001

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL

DRALSERP

SANDOZ	25MG;0.1MG	A084617	001
--------	------------	---------	-----

SERPASIL-APRESOLINE

NOVARTIS	25MG;0.1MG	N009296	004
	50MG;0.2MG	N009296	002

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE

MORTON GROVE	50MG/5ML	A089661	001	Jun 20, 1988
--------------	----------	---------	-----	--------------

ROXANE	50MG/5ML	A088587	001	Jul 02, 1984
--------	----------	---------	-----	--------------

HYDROCHLOROTHIAZIDE INTENSOL

ROXANE	100MG/ML	A088588	001	Jul 02, 1984
--------	----------	---------	-----	--------------

TABLET; ORAL

ESIDRIX

NOVARTIS	25MG	N011793	005
	50MG	N011793	008
	100MG	N011793	009

HYDROCHLOROTHIAZIDE

ABC HOLDING	50MG	A085672	001
-------------	------	---------	-----

ALRA	25MG	A086369	001
------	------	---------	-----

	50MG	A083554	001
--	------	---------	-----

ASCOT	25MG	A087539	001	Feb 03, 1982
-------	------	---------	-----	--------------

	50MG	A087540	001	Feb 03, 1982
--	------	---------	-----	--------------

BARR	50MG	A084771	001
------	------	---------	-----

DAVA PHARMS INC	100MG	A087060	001
-----------------	-------	---------	-----

ELKINS SINN	50MG	A085152	002
-------------	------	---------	-----

HEATHER	50MG	A084135	001
---------	------	---------	-----

IMPAX LABS	25MG	A084029	001
------------	------	---------	-----

	50MG	A083607	002
--	------	---------	-----

	100MG	A085098	001
--	-------	---------	-----

INWOOD LABS	25MG	A084776	001
-------------	------	---------	-----

	25MG	A085067	001
--	------	---------	-----

	50MG	A084776	002
--	------	---------	-----

IVAX SUB TEVA PHARMS	50MG	A084658	001
----------------------	------	---------	-----

	100MG	A085022	001
--	-------	---------	-----

MAST MM	25MG	A086192	001
---------	------	---------	-----

	50MG	A086192	002
--	------	---------	-----

MUTUAL PHARM	25MG	A083972	001
--------------	------	---------	-----

	50MG	A083972	002
--	------	---------	-----

	100MG	A083972	003
--	-------	---------	-----

MYLAN	25MG	A084880	001
-------	------	---------	-----

	50MG	A085112	001
--	------	---------	-----

PVT FORM	50MG	A086597	001
----------	------	---------	-----

ROXANE	25MG	A085004	001
--------	------	---------	-----

	50MG	A084536	002
--	------	---------	-----

	50MG	A085005	001
--	------	---------	-----

SANDOZ	25MG	A083899	001
--------	------	---------	-----

	25MG	A087565	001	Mar 09, 1982
--	------	---------	-----	--------------

	50MG	A084912	001
--	------	---------	-----

SOLVAY	25MG	A085323	001
--------	------	---------	-----

SUPERPHARM	25MG	A088827	001	Dec 28, 1984
------------	------	---------	-----	--------------

	50MG	A088828	001	Dec 28, 1984
--	------	---------	-----	--------------

	100MG	A088829	001	Dec 28, 1984
--	-------	---------	-----	--------------

TEVA	25MG	A088924	001	Feb 07, 1985
------	------	---------	-----	--------------

	50MG	A088923	001	Feb 07, 1985
--	------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 158 (of 324)

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

TG UNITED LABS	25MG	A085683	001	
	50MG	A083965	001	
USL PHARMA	25MG	A087827	001	Apr 19, 1982
	50MG	A087752	001	Apr 19, 1982
VANGARD	25MG	A087638	001	
	50MG	A087610	001	
WARNER CHILCOTT	25MG	A087586	001	May 03, 1982
	50MG	A087587	001	May 03, 1982
WATSON LABS	25MG	A083458	001	
	25MG	A085232	002	
	50MG	A083232	001	
	50MG	A083456	001	
	50MG	A085233	001	
	50MG	A086087	001	
	50MG	A086594	001	
	100MG	A081190	001	Jan 24, 1992
	100MG	A085099	001	
	100MG	A087002	001	
WEST WARD	25MG	A084899	001	
WHITEWORTH TOWN PLSN	25MG	A083809	002	
	50MG	A083809	001	
	100MG	A085347	001	
HYDRO-D				
HALSEY	25MG	A086504	001	
	50MG	A083891	002	
HYDRODIURIL				
MERCK	25MG	N011835	003	
	50MG	N011835	006	
	100MG	N011835	007	
ORETIC				
ABBOTT	25MG	N011971	001	
ZIDE				
SOLVAY	50MG	A083925	001	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

SANOFI AVENTIS US	12.5MG; 75MG	N020758	001	Sep 30, 1997
-------------------	--------------	---------	-----	--------------

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

SCHERING	25MG; 100MG	N019046	001	Apr 06, 1987
	25MG; 200MG	N019046	002	Apr 06, 1987
	25MG; 300MG	N019046	003	Apr 06, 1987
	25MG; 400MG	N019046	004	Apr 06, 1987
TRANDATE HCT				
GLAXOSMITHKLINE	25MG; 100MG	N019174	001	Apr 10, 1987
	25MG; 200MG	N019174	002	Apr 10, 1987
	25MG; 300MG	N019174	003	Apr 10, 1987
	25MG; 400MG	N019174	004	Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

SANDOZ	12.5MG; 10MG	A075926	001	Jul 01, 2002
	12.5MG; 20MG	A075926	002	Jul 01, 2002
	25MG; 20MG	A075926	003	Jul 01, 2002
PRINZIDE				
MERCK	25MG; 20MG	N019778	002	Feb 16, 1989



## DISCONTINUED DRUG PRODUCT LIST

6 - 159 (of 324)

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15				
MERCK	15MG;250MG	N013402	001	
ALDORIL 25				
MERCK	25MG;250MG	N013402	002	
ALDORIL D30				
MERCK	30MG;500MG	N013402	003	
ALDORIL D50				
MERCK	50MG;500MG	N013402	004	
METHYLDOPA AND HYDROCHLOROTHIAZIDE				
CLONMEL HLTHCARE	15MG;250MG	A072507	001	Jun 02, 1989
	25MG;250MG	A072508	001	Jun 02, 1989
	30MG;500MG	A072509	001	Jun 02, 1989
	50MG;500MG	A072510	001	Jun 02, 1989
IVAX SUB TEVA PHARMS	15MG;250MG	A071458	001	Mar 08, 1988
	25MG;250MG	A071459	001	Mar 08, 1988
	30MG;500MG	A071460	001	Mar 08, 1988
	50MG;500MG	A071461	001	Mar 08, 1988
PAR PHARM	15MG;250MG	A070616	001	Feb 02, 1987
	25MG;250MG	A070612	001	Feb 02, 1987
	30MG;500MG	A070613	001	Feb 02, 1987
	50MG;500MG	A070614	001	Feb 02, 1987
PARKE DAVIS	15MG;250MG	A071897	001	Nov 23, 1987
	25MG;250MG	A071898	001	Nov 23, 1987
	30MG;500MG	A071899	001	Nov 23, 1987
	50MG;500MG	A071900	001	Nov 23, 1987
PUREPAC PHARM	15MG;250MG	A070853	001	Oct 08, 1986
	25MG;250MG	A070688	001	Apr 24, 1986
	30MG;500MG	A070854	001	Oct 08, 1986
	50MG;500MG	A070689	001	Apr 24, 1986
SANDOZ	15MG;250MG	A070182	001	Jan 15, 1986
	15MG;250MG	A070829	001	Mar 09, 1987
	25MG;250MG	A070183	001	Jan 15, 1986
	25MG;250MG	A070830	001	Mar 09, 1987
	30MG;500MG	A070543	001	Jan 15, 1986
	50MG;500MG	A070544	001	Jan 15, 1986
TEVA	15MG;250MG	A071819	001	Apr 08, 1988
	25MG;250MG	A071820	001	Apr 08, 1988
	30MG;500MG	A071821	001	Apr 08, 1988
	50MG;500MG	A071822	001	Apr 08, 1988
WATSON LABS	15MG;250MG	A070365	001	Mar 19, 1986
	15MG;250MG	A070958	001	Feb 06, 1989
	15MG;250MG	A071920	001	Aug 29, 1988
	25MG;250MG	A070366	001	Apr 16, 1986
	25MG;250MG	A070959	001	Jan 19, 1989
	25MG;250MG	A071921	001	Aug 29, 1988
	30MG;500MG	A070367	001	Mar 19, 1986
	30MG;500MG	A071069	001	Jan 19, 1989
	30MG;500MG	A071922	001	Aug 29, 1988
	50MG;500MG	A070368	001	Apr 16, 1986
	50MG;500MG	A070960	001	Feb 06, 1989
	50MG;500MG	A071923	001	Aug 29, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006
	12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006
	12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006

## DISCONTINUED DRUG PRODUCT LIST

6 - 160 (of 324)

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL  
LOPRESSOR HCT  
NOVARTIS

50MG;100MG

N018303 003 Dec 31, 1984

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL  
VISKAZIDE

NOVARTIS

25MG;5MG

N018872 001 Jul 22, 1987

25MG;10MG

N018872 002 Jul 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50

WYETH AYERST

50MG;120MG

N019059 002 Jul 03, 1985

INDERIDE LA 160/50

WYETH AYERST

50MG;160MG

N019059 003 Jul 03, 1985

INDERIDE LA 80/50

WYETH AYERST

50MG;80MG

N019059 001 Jul 03, 1985

TABLET; ORAL

INDERIDE-80/25

AKRIMAX PHARMS

25MG;80MG

N018031 002

PROPRANOLOL HYDROCHLORIDE &amp; HYDROCHLOROTHIAZIDE

DURAMED PHARMS BARR

25MG;40MG

A071126 001 Mar 02, 1987

25MG;80MG

A071127 001 Mar 02, 1987

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH

25MG;40MG

A070851 001 May 15, 1986

25MG;80MG

A070852 001 May 15, 1986

BARR

25MG;40MG

A070704 001 Oct 01, 1986

25MG;80MG

A070705 001 Oct 01, 1986

IVAX SUB TEVA PHARMS

25MG;40MG

A071552 001 Dec 01, 1988

25MG;80MG

A071553 001 Dec 01, 1988

SANDOZ

25MG;40MG

A071060 001 Aug 26, 1987

25MG;80MG

A071061 001 Aug 26, 1987

WARNER CHILCOTT

25MG;40MG

A071771 001 Jan 26, 1988

25MG;80MG

A071772 001 Jan 26, 1988

WATSON LABS

25MG;40MG

A071498 001 Dec 18, 1991

25MG;80MG

A071501 001 Dec 18, 1991

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

H.R. -50

WHITETHORNTOWN TOWN PLSN

50MG;0.125MG

A085338 001

HYDROCHLOROTHIAZIDE W/ RESERPINE

IVAX SUB TEVA PHARMS

25MG;0.1MG

A083572 001

25MG;0.125MG

A083571 001

50MG;0.1MG

A083568 001

50MG;0.125MG

A083573 001

PHARMERAL

25MG;0.125MG

A085421 001

50MG;0.125MG

A085420 001

ROXANE

50MG;0.125MG

A084603 001

WATSON LABS

25MG;0.125MG

A084466 001

25MG;0.125MG

A085317 001

25MG;0.125MG

A086330 002

50MG;0.125MG

A083666 001

50MG;0.125MG

A084467 001

50MG;0.125MG

A086331 001

HYDROPRES 25

MERCK

25MG;0.125MG

N011958 002

HYDROPRES 50

MERCK

50MG;0.125MG

N011958 003

HYDRO-RESERP

ABC HOLDING

50MG;0.125MG

A084714 002 Jun 29, 1982

## DISCONTINUED DRUG PRODUCT LIST

6 - 161 (of 324)

HYDROCHLOROTHIAZIDE; RESERPINE

## TABLET; ORAL

HYDRO-SERP "25"				
SANDOZ	25MG;0.125MG	A084827	001	
HYDRO-SERP "50"				
SANDOZ	50MG;0.125MG	A085213	001	
RESERPINE AND HYDROCHLOROTHIAZIDE				
BARR	25MG;0.125MG	A084580	001	
	50MG;0.125MG	A084579	001	
SANDOZ	50MG;0.125MG	A088200	001	Jan 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50				
WEST WARD	50MG;0.125MG	A088189	001	May 10, 1984
SERPASIL-ESIDRIX #1				
NOVARTIS	25MG;0.1MG	N011878	003	
SERPASIL-ESIDRIX #2				
NOVARTIS	50MG;0.1MG	N011878	005	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

## TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE				
ASCOT	25MG;25MG	A088025	001	Nov 23, 1984
MUTUAL PHARM	25MG;25MG	A087267	001	
PUREPAC PHARM	25MG;25MG	A087999	001	Nov 06, 1985
SANDOZ	25MG;25MG	A086881	001	
SUPERPHARM	25MG;25MG	A089137	001	Aug 26, 1985
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE				
IVAX PHARMS	25MG;25MG	A087004	002	May 24, 1982
LEDERLE	25MG;25MG	A087511	001	
PARKE DAVIS	25MG;25MG	A087948	001	Feb 22, 1983
PUREPAC PHARM	25MG;25MG	A088054	001	Aug 18, 1983
UPSHER SMITH	25MG;25MG	A087553	001	
USL PHARMA	25MG;25MG	A087651	001	
VANGARD	25MG;25MG	A087655	001	
WATSON LABS	25MG;25MG	A085974	001	
	25MG;25MG	A086026	001	

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

## TABLET; ORAL

TIMOLIDE 10-25				
MERCK	25MG;10MG	N018061	001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

## CAPSULE; ORAL

DYAZIDE				
GLAXOSMITHKLINE	25MG;50MG	N016042	002	
TRIAMTERENE AND HYDROCHLOROTHIAZIDE				
BARR	25MG;37.5MG	A074970	001	Jan 06, 1998
NOVARTIS	25MG;37.5MG	A074857	001	Sep 09, 1997
VITARINE	25MG;50MG	A071737	001	Feb 12, 1988

## TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE				
AM THERAP	50MG;75MG	A072022	001	Apr 17, 1988
QUANTUM PHARMICS	50MG;75MG	A071980	001	Apr 17, 1988

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

## SYRUP; ORAL

CODAMINE				
ALPHARMA US PHARMS	5MG/5ML;25MG/5ML	A075103	001	Sep 29, 2000
HYCOMINE				
ENDO PHARMS	5MG/5ML;25MG/5ML	N019410	001	Aug 17, 1990
HYCOMINE PEDIATRIC				
ENDO PHARMS	2.5MG/5ML;12.5MG/5ML	N019411	001	Aug 17, 1990

## DISCONTINUED DRUG PRODUCT LIST

6 - 162 (of 324)

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT; TOPICAL

MAGNACORT

PFIZER

0.5%

N010554 001

HYDROCORTISONE

AEROSOL; TOPICAL

AEROSEB-HC

ALLERGAN HERBERT

0.5%

A085805 001

CREAM; TOPICAL

CORT-DOME

BAYER PHARMS

0.5%

N009585 003

1%

N009585 001

DERMACORT

MONARCH PHARMS

1%

A083011 002

ELDECORT

VALEANT PHARM INTL

1%

A080459 001

2.5%

A084055 001

FLEXICORT

WESTWOOD SQUIBB

0.5%

A087136 003

Apr 08, 1982

1%

A087136 002

Apr 08, 1982

2.5%

A087136 001

Apr 08, 1982

HC #1

BAYER PHARMS

0.5%

A080438 001

HC #4

BAYER PHARMS

1%

A080438 002

HC (HYDROCORTISONE)

C AND M PHARMA

0.5%

A080482 003

1%

A080482 004

H-CORT

PHARM ASSOC

0.5%

A086823 001

HI-COR

C AND M PHARMA

2.5%

A080483 001

HYDROCORTISONE

ALPHARMA US PHARMS

2.5%

A089754 001

Feb 01, 1989

ALTANA

0.5%

A080848 002

1%

A080848 003

AMBIX

1%

A086080 001

2.5%

A086271 001

EVERYLIFE

0.5%

A080452 001

1%

A080452 002

G AND W LABS

1%

A084059 001

INGRAM PHARM

0.5%

A080456 002

1%

A080456 003

IVAX PHARMS

1%

A085733 001

NASKA

1%

A089706 001

Mar 10, 1988

PERRIGO NEW YORK

0.5%

A084970 002

1%

A085026 001

PHARMADERM

1%

A088845 001

Feb 27, 1986

2.5%

A089413 001

Dec 16, 1986

PHARMAFAIR

1%

A087838 001

Jul 28, 1982

STIEFEL

1%

A086170 001

SYOSSET

0.5%

A085527 001

TARO

0.5%

A086154 001

TEVA

0.5%

A080400 002

1%

A080400 003

1%

A085191 001

2.5%

A080400 004

TOPIDERM

1%

A089273 001

Feb 17, 1989

USL PHARMA

1%

A088027 001

Sep 27, 1983

2.5%

A088029 001

Sep 27, 1983

WHITEWORTH TOWN PLSN

1%

A080496 002

NOGENIC HC

IVAX PHARMS

1%

A087427 001

Apr 04, 1988

## DISCONTINUED DRUG PRODUCT LIST

6 - 163 (of 324)

HYDROCORTISONE

## CREAM; TOPICAL

## NUTRACORT

CORIA	0.5%	A080442	002	
	1%	A080442	003	

## PENECORT

ALLERGAN HERBERT	1%	A088216	001	Jun 06, 1984
------------------	----	---------	-----	--------------

## PROCTOCORT

MONARCH PHARMS	1%	A083011	001	
----------------	----	---------	-----	--

## SYNACORT

MEDICIS	0.5%	A087459	001	
---------	------	---------	-----	--

## GEL; TOPICAL

## NUTRACORT

HEALTHPOINT	1%	A084698	001	
-------------	----	---------	-----	--

## PENECORT

ALLERGAN HERBERT	1%	A088215	001	Jun 06, 1984
------------------	----	---------	-----	--------------

## INJECTABLE; INJECTION

## CORTEF

PHARMACIA AND UPJOHN	50MG/ML	N009864	001	
----------------------	---------	---------	-----	--

## LOTION; TOPICAL

## ACTICORT

BAKER NORTON	1%	A086535	001	
--------------	----	---------	-----	--

## BALNEOL-HC

SOLVAY	1%	A088041	001	Dec 03, 1982
--------	----	---------	-----	--------------

## BETA-HC

BETA DERMAC	1%	A089495	001	Jan 25, 1988
-------------	----	---------	-----	--------------

## CETACORT

CORIA	0.5%	A080426	002	
-------	------	---------	-----	--

	1%	A080426	001	
--	----	---------	-----	--

## CORT-DOME

BAYER PHARMS	0.5%	N009895	003	
--------------	------	---------	-----	--

	1%	N009895	001	
--	----	---------	-----	--

## DERMACORT

SOLVAY	0.5%	A084573	002	
--------	------	---------	-----	--

	1%	A086462	001	
--	----	---------	-----	--

## EPICORT

BLULINE	0.5%	A083219	002	
---------	------	---------	-----	--

## GLYCORT

HERAN	1%	A087489	001	Oct 03, 1983
-------	----	---------	-----	--------------

## H-CORT

PHARM ASSOC	0.5%	A086824	001	
-------------	------	---------	-----	--

## HYDROCORTISONE

ALPHARMA US PHARMS	0.5%	A087317	001	Jun 07, 1982
--------------------	------	---------	-----	--------------

	1%	A087315	001	Jun 07, 1982
--	----	---------	-----	--------------

MERICON	0.5%	A085282	001	
---------	------	---------	-----	--

	1%	A085282	002	Feb 26, 1987
--	----	---------	-----	--------------

NASKA	1%	A089705	001	Apr 25, 1988
-------	----	---------	-----	--------------

PERRIGO NEW YORK	0.5%	A085662	001	
------------------	------	---------	-----	--

	1%	A085663	001	
--	----	---------	-----	--

TARO	1%	A089024	001	Feb 12, 1986
------	----	---------	-----	--------------

## NUTRACORT

CORIA	0.5%	A080443	002	
-------	------	---------	-----	--

## OINTMENT; TOPICAL

## CORTRIL

PFIZER GLOBAL	1%	N009176	001	
---------------	----	---------	-----	--

	2.5%	N009176	002	
--	------	---------	-----	--

## HC (HYDROCORTISONE)

C AND M PHARMA	0.5%	A080481	001	
----------------	------	---------	-----	--

	1%	A080481	002	
--	----	---------	-----	--

## HYDROCORTISONE

ALTANA	0.5%	A080489	002	
--------	------	---------	-----	--

	1%	A080489	003	
--	----	---------	-----	--

AMBIX	1%	A086079	001	
-------	----	---------	-----	--

	2.5%	A086272	001	
--	------	---------	-----	--

NASKA	1%	A089704	001	Mar 10, 1988
-------	----	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 164 (of 324)

HYDROCORTISONE

## OINTMENT; TOPICAL

## HYDROCORTISONE

PERRIGO NEW YORK	0.5%	A084969	003	
	1%	A085028	001	
PHARMADERM	1%	A088842	001	Feb 09, 1987
TARO	0.5%	A086256	001	
USL PHARMA	1%	A088061	001	Sep 27, 1983
	2.5%	A088039	001	Sep 27, 1983

## HYTONE

DERMIK LABS	1%	A080474	003	
	2.5%	A080474	004	

## PENECORT

ALLERGAN HERBERT	2.5%	A088217	001	Jun 06, 1984
------------------	------	---------	-----	--------------

## POWDER; FOR RX COMPOUNDING

## H-CORT

TORCH	100%	A087834	001	Mar 29, 1982
-------	------	---------	-----	--------------

## HYDROCORTISONE

PADDOCK	100%	A088082	001	Apr 08, 1983
---------	------	---------	-----	--------------

## SOLUTION; TOPICAL

## PENECORT

ALLERGAN HERBERT	1%	A088214	001	Jun 06, 1984
------------------	----	---------	-----	--------------

## TEXACORT

JSJ PHARMS	1%	A080425	001	
	2.5%	A081271	001	Apr 17, 1992

## TABLET; ORAL

## CORTRIL

PFIZER	10MG	N009127	005	
	20MG	N009127	003	

## HYDROCORTISONE

BARR	20MG	A083999	001	
ELKINS SINN	20MG	A080624	001	
FERRANTE	10MG	A080568	001	
	20MG	A080568	002	
IMPAX LABS	20MG	A080781	001	
INWOOD LABS	20MG	A080732	001	
LANNETT	20MG	A085070	001	
NEXGEN PHARMA INC	20MG	A083140	001	
PANRAY	10MG	N009659	001	
	20MG	N009659	002	
PARKE DAVIS	20MG	A084243	001	
PUREPAC PHARM	10MG	A084247	003	Aug 31, 1982
	20MG	A080395	001	
	20MG	A084247	002	
ROXANE	10MG	A088539	001	Mar 21, 1984
SANDOZ	20MG	A080642	002	
WATSON LABS	20MG	A080355	001	
WHITEWORTH TOWN PLSN	10MG	A080344	001	
	20MG	A080344	002	

## HYDROCORTONE

MERCK	10MG	N008506	007	
	20MG	N008506	011	

## TABLET; VAGINAL

## CORTRIL

PFIPHARMECS	10MG	N009796	001	
-------------	------	---------	-----	--

HYDROCORTISONE ACETATE

## CREAM; TOPICAL

## HEMSOL-HC

ABLE	1%	A081274	001	Jun 19, 1992
------	----	---------	-----	--------------

## HYDROCORTISONE ACETATE

CENCI	1%	A080419	001	Jan 25, 1982
PARKE DAVIS	1%	A089914	001	Jan 03, 1989
PUREPAC PHARM	0.5%	A086050	001	
	1%	A086052	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 165 (of 324)

HYDROCORTISONE ACETATE

## INJECTABLE; INJECTION

## CORTEF ACETATE

PHARMACIA AND UPJOHN	50MG/ML	N009378	002
----------------------	---------	---------	-----

## CORTRIL

PFIZER	25MG/ML	N009164	001
--------	---------	---------	-----

## HYDROCORTISONE ACETATE

AKORN	25MG/ML	N009637	001
-------	---------	---------	-----

	50MG/ML	N009637	002
--	---------	---------	-----

BEL MAR	25MG/ML	A083739	001
---------	---------	---------	-----

	50MG/ML	A083739	002
--	---------	---------	-----

WATSON LABS	25MG/ML	A083128	001
-------------	---------	---------	-----

	25MG/ML	A083759	001
--	---------	---------	-----

	50MG/ML	A083759	002
--	---------	---------	-----

	50MG/ML	A085214	001
--	---------	---------	-----

## HYDROCORTONE

MERCK	25MG/ML	N008228	001
-------	---------	---------	-----

	50MG/ML	N008228	004
--	---------	---------	-----

## LOTION; TOPICAL

## DRICORT

INGRAM PHARM	0.5%	A086207	001
--------------	------	---------	-----

## OINTMENT; OPHTHALMIC

## HYDROCORTISONE ACETATE

ALTANA	0.5%	A080828	001
--------	------	---------	-----

## OINTMENT; OPHTHALMIC, OTIC

## HYDROCORTONE

MERCK	1.5%	N009018	003
-------	------	---------	-----

## OINTMENT; TOPICAL

## CORTEF ACETATE

PHARMACIA AND UPJOHN	1%	N008917	002
----------------------	----	---------	-----

	2.5%	N008917	001
--	------	---------	-----

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

## CREAM; TOPICAL

## NEO-CORTEF

PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	A061049	001
----------------------	---------------------	---------	-----

	2.5%;EQ 3.5MG BASE/GM	A061049	002
--	-----------------------	---------	-----

## OINTMENT; OPHTHALMIC

## NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060610	001
----------------------	-----------------------	---------	-----

	1.5%;EQ 3.5MG BASE/GM	A060610	002
--	-----------------------	---------	-----

## OINTMENT; TOPICAL

## NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060751	001
----------------------	-----------------------	---------	-----

	1%;EQ 3.5MG BASE/GM	A060751	002
--	---------------------	---------	-----

	2.5%;EQ 3.5MG BASE/GM	A060751	003
--	-----------------------	---------	-----

## SUSPENSION/DROPS; OPHTHALMIC

## COR-OTICIN

AKORN	1.5%;EQ 3.5MG BASE/ML	A060188	001
-------	-----------------------	---------	-----

## NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/ML	A060612	002
----------------------	-----------------------	---------	-----

	1.5%;EQ 3.5MG BASE/ML	A060612	001
--	-----------------------	---------	-----

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

## SUSPENSION; OPHTHALMIC

## TERRA-CORTRIL

PFIZER	1.5%;EQ 5MG BASE/ML	A061016	001
--------	---------------------	---------	-----

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

## AEROSOL, METERED; TOPICAL

## HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

BOCA PHARMA	1%;1%	A089440	001	May 17, 1988
-------------	-------	---------	-----	--------------

## LOTION; TOPICAL

## PRAMOSONE

FERNDAL LABS	0.5%;1%	A083213	002
--------------	---------	---------	-----

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 607 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 166 (of 324)

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

YAMANOUCHI

0.1%

N018795 001

Jan 07, 1983

OINTMENT; TOPICAL

LOCOID

YAMANOUCHI

0.1%

N019106 001

Jul 03, 1984

SOLUTION; TOPICAL

LOCOID

YAMANOUCHI

0.1%

N019819 001

Sep 15, 1988

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL

CORTEF

PHARMACIA AND UPJOHN EQ 10MG BASE/5ML

N009900 001

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTONE

MERCK

EQ 50MG BASE/ML

N012052 001

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

ABBOTT

EQ 100MG BASE/VIAL

A085928 001

EQ 100MG BASE/VIAL

A089577 001

Apr 11, 1989

EQ 250MG BASE/VIAL

A089578 001

Apr 11, 1989

EQ 500MG BASE/VIAL

A089579 001

Apr 11, 1989

EQ 1GM BASE/VIAL

A089580 001

Apr 11, 1989

HOSPIRA

EQ 100MG BASE/VIAL

A085929 001

HYDROCORTISONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 100MG BASE/VIAL

A088667 001

Jun 08, 1984

EQ 100MG BASE/VIAL

A088712 001

Jun 08, 1984

EQ 250MG BASE/VIAL

A088668 001

Jun 08, 1984

EQ 500MG BASE/VIAL

A088669 001

Jun 08, 1984

EQ 1GM BASE/VIAL

A088670 001

Jun 08, 1984

BAXTER HLTHCARE

EQ 100MG BASE/VIAL

A086619 001

EQ 250MG BASE/VIAL

A087567 001

EQ 500MG BASE/VIAL

A087568 001

EQ 1GM BASE/VIAL

A087569 001

INTL MEDICATION

EQ 100MG BASE/VIAL

A087532 001

Mar 19, 1982

WATSON LABS

EQ 100MG BASE/VIAL

A084737 002

EQ 100MG BASE/VIAL

A084738 001

EQ 250MG BASE/VIAL

A084737 001

EQ 500MG BASE/VIAL

A084747 001

EQ 1GM BASE/VIAL

A084748 001

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

TEVA PHARMS

0.2%

A074489 001

Aug 12, 1998

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORT-DOME

BAYER PHARMS

0.5%;EQ 3.5MG BASE/GM

N050237 006

Jun 05, 1984

1%;EQ 3.5MG BASE/GM

N050237 005

Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062394 001

Sep 29, 1982

OTOCORT

WATSON LABS

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A060730 002

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 608 of 1114**



## DISCONTINUED DRUG PRODUCT LIST

6 - 167 (of 324)

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

## SUSPENSION/DROPS; OPHTHALMIC

## CORTISPORIN

MONARCH PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML N050169 001

## NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062623 001 Sep 24, 1985

## SUSPENSION/DROPS; OTIC

## NEOMYCIN SULFATE, POLYMYXIN B SULFATE &amp; HYDROCORTISONE

PHARMAFAIR 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062617 001 Sep 18, 1985

## OTICAIR

PHARMAFAIR 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062399 001 Nov 18, 1982

## OTOBIONE

SCHERING 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A061816 001

## OTOCORT

WATSON LABS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062521 001 Jul 11, 1985

HYDROCORTISONE; POLYMYXIN B SULFATE

## SOLUTION/DROPS; OTIC

## OTOBIOIC

SCHERING 5MG/ML;EQ 10,000 UNITS BASE/ML A062302 001

## PYOCIDIN

FOREST LABS 5MG/ML;EQ 10,000 UNITS BASE/ML A061606 001

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

## OINTMENT; OPHTHALMIC

## ACHROMYCIN

LEDERLE 1.5%;1% N050272 001

HYDROCORTISONE; UREA

## CREAM; TOPICAL

## ALPHADERM

BIOGLAN 1%;10% A086008 001

## CALMURID HC

PHARMACIA AND UPJOHN 1%;10% A083947 001

HYDROFLUMETHIAZIDE

## TABLET; ORAL

## DIUCARDIN

WYETH AYERST 50MG A083383 001

## HYDROFLUMETHIAZIDE

WATSON LABS 50MG A088031 001 Apr 06, 1983

50MG A088528 001 Aug 15, 1984

HYDROFLUMETHIAZIDE; RESERPINE

## TABLET; ORAL

## HYDROFLUMETHIAZIDE AND RESERPINE

USL PHARMA 50MG;0.125MG A088195 001 Oct 26, 1983

WATSON LABS 25MG;0.125MG A088127 001 Mar 22, 1983

50MG;0.125MG A088110 001 Mar 22, 1983

## RESERPINE AND HYDROFLUMETHIAZIDE

IVAX PHARMS 50MG;0.125MG A088932 001 Jan 11, 1985

PAR PHARM 50MG;0.125MG A088907 001 Sep 20, 1985

## SALUTENSIN

SHIRE 50MG;0.125MG N012359 003

## SALUTENSIN-DEMI

SHIRE 25MG;0.125MG N012359 004

HYDROMORPHONE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## PALLADONE

PURDUE PHARMA LP 12MG N021044 001 Sep 24, 2004

16MG N021044 002 Sep 24, 2004

24MG N021044 003 Sep 24, 2004

32MG N021044 004 Sep 24, 2004

## DISCONTINUED DRUG PRODUCT LIST

6 - 168 (of 324)

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

WATSON LABS 10MG/ML A074317 001 Aug 23, 1995

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

ALPHAREDISOL

MERCK 1MG/ML A080778 001

HYDROXOCOBALAMIN

ABRAXIS PHARM 1MG/ML A084921 001

WATSON LABS 1MG/ML A085528 001

HYDROXOMIN

BEL MAR 1MG/ML A084629 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRINE

AKORN 1% N000004 004

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

DELALUTIN

BRISTOL MYERS SQUIBB 125MG/ML N010347 004

125MG/ML N016911 001

250MG/ML N010347 002

250MG/ML N016911 002

HYDROXYPROGESTERONE CAPROATE

AKORN 125MG/ML N018004 001

WATSON LABS 125MG/ML N017439 001

250MG/ML N017439 002

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE; INJECTION

HYDROXYSTILBAMIDINE ISETHIONATE

SANOFI AVENTIS US 225MG/AMP N009166 001

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

BARR 250MG A075143 002 Sep 21, 2000

DURAMED PHARMS BARR 250MG A075020 002 Jun 26, 2000

500MG A075020 001 Jul 30, 1998

ROXANE 500MG A074476 001 Aug 18, 1995

TABLET; ORAL

HYDROXYUREA

BARR 1GM A075734 001 Aug 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

BAXTER HLTHCARE 50MG/ML A085551 002

HYDROXYZINE HYDROCHLORIDE

ALTANA 25MG/ML A087273 001 Apr 20, 1982

50MG/ML A087273 002 Apr 20, 1982

APP PHARMS 25MG/ML A088184 001 Mar 31, 1983

50MG/ML A088185 001 Mar 31, 1983

BAXTER HLTHCARE 25MG/ML A085551 001

HOSPIRA 25MG/ML A087416 001

50MG/ML A086821 001

50MG/ML A087546 001

PHARMAFAIR 25MG/ML A088862 001 Feb 14, 1986

25MG/ML A089106 001 Feb 14, 1986

50MG/ML A088881 001 Feb 14, 1986

## DISCONTINUED DRUG PRODUCT LIST

6 - 169 (of 324)

HYDROXYZINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## HYDROXYZINE HYDROCHLORIDE

PHARMAFAIR	50MG/ML	A089107	001	Feb 14, 1986
SMITH AND NEPHEW	25MG/ML	A087592	001	
SOLOPAK	25MG/ML	A086822	001	
	25MG/ML	A087591	001	
	50MG/ML	A087310	001	
	50MG/ML	A087593	001	
	50MG/ML	A087595	001	
	50MG/ML	A087596	001	
WATSON LABS	25MG/ML	A085778	001	
	25MG/ML	A087274	001	
	50MG/ML	A085779	001	
	50MG/ML	A087274	002	
WYETH AYERST	25MG/ML	A086258	001	
	50MG/ML	A086258	002	

## ORGATRAX

ORGANON USA INC	25MG/ML	A087014	001	
	50MG/ML	A087014	002	

## VISTARIL

PFIZER	25MG/ML	N011111	001	
	50MG/ML	N011111	002	

## SYRUP; ORAL

## ATARAX

ROERIG	10MG/5ML	N010485	001	
--------	----------	---------	-----	--

## HYDROXYZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	10MG/5ML	A086880	001	
ALPHARMA US PHARMS	10MG/5ML	A088785	001	Feb 03, 1988
KV PHARM	10MG/5ML	A087730	001	Jul 01, 1982

## TABLET; ORAL

## ATARAX

PFIZER	10MG	N010392	001	
	25MG	N010392	004	
	50MG	N010392	006	
	100MG	N010392	005	

## HYDROXYZINE HYDROCHLORIDE

ABLE	10MG	A040559	001	Jul 22, 2004
	25MG	A040562	001	Jul 22, 2004
	50MG	A040563	001	Jul 22, 2004
ACTAVIS TOTOWA	10MG	A089071	001	Jul 22, 1986
	25MG	A089072	001	Jul 22, 1986
	50MG	A089073	001	Jul 22, 1986
HALSEY	10MG	A089366	001	May 02, 1988
	25MG	A089117	001	May 02, 1988
	50MG	A089396	001	May 02, 1988
IVAX PHARMS	10MG	A087216	001	
	25MG	A087410	001	
	50MG	A087411	001	
KV PHARM	10MG	A087819	001	Jun 23, 1982
	25MG	A087820	001	Jun 23, 1982
	50MG	A087821	001	Jun 23, 1982
	100MG	A087822	001	Jun 23, 1982
MUTUAL PHARM	10MG	A088409	001	Nov 15, 1983
	25MG	A087857	001	Apr 18, 1983
	50MG	A087860	001	Apr 18, 1983
	100MG	A087862	001	Apr 18, 1983
PLIVA	100MG	A081054	001	Sep 25, 1995
PUREPAC PHARM	10MG	A088120	001	Sep 25, 1984
	25MG	A088121	001	Sep 25, 1984
	50MG	A088122	001	Sep 25, 1984
QUANTUM PHARMICS	10MG	A088540	001	Oct 22, 1985
	25MG	A088551	001	Oct 22, 1985
	50MG	A088529	001	Oct 22, 1985

## DISCONTINUED DRUG PRODUCT LIST

6 - 170 (of 324)

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

SANDOZ	10MG	A087246	002	
	10MG	A087869	001	Dec 20, 1982
	25MG	A085247	001	
	25MG	A087870	001	Dec 20, 1982
	50MG	A087245	001	
SUPERPHARM	50MG	A087871	001	Dec 20, 1982
	10MG	A088794	001	Dec 05, 1984
	25MG	A088795	001	Dec 05, 1984
USL PHARMA	50MG	A088796	001	Dec 05, 1984
	10MG	A089121	001	Mar 20, 1986
	25MG	A089122	001	Mar 20, 1986
VINTAGE	50MG	A089123	001	Mar 20, 1986
	10MG	A087602	001	Jan 22, 1982
	25MG	A087603	001	Jan 22, 1982
WATSON LABS	50MG	A087604	001	Jan 22, 1982
	10MG	A086827	001	
	25MG	A086829	001	
	50MG	A086836	001	

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

DURAMED PHARMS BARR	EQ 25MG HCL	A088593	001	Feb 29, 1984
	EQ 50MG HCL	A088594	001	Feb 29, 1984
	EQ 100MG HCL	A088595	001	Feb 29, 1984
PAR PHARM	EQ 25MG HCL	A087656	001	Jun 11, 1982
	EQ 25MG HCL	A089145	001	Mar 17, 1986
	EQ 50MG HCL	A087657	001	Jun 11, 1982
	EQ 50MG HCL	A089146	001	Mar 17, 1986
	EQ 100MG HCL	A087658	001	Jun 11, 1982
SANDOZ	EQ 25MG HCL	A081127	001	Jun 28, 1991
	EQ 50MG HCL	A081128	001	Jun 28, 1991
	EQ 100MG HCL	A081129	001	Jun 28, 1991
SUPERPHARM	EQ 25MG HCL	A089031	001	Jan 02, 1987
	EQ 50MG HCL	A089032	001	Jan 02, 1987
	EQ 100MG HCL	A089033	001	Jan 02, 1987
VANGARD	EQ 25MG HCL	A088392	001	Sep 19, 1983
	EQ 50MG HCL	A088393	001	Sep 19, 1983
	EQ 25MG HCL	A086698	001	
WATSON LABS	EQ 25MG HCL	A086840	001	Jul 01, 1982
	EQ 50MG HCL	A086695	001	
	EQ 50MG HCL	A086705	001	Jul 01, 1982
	EQ 50MG HCL	A087767	001	Aug 16, 1982
	EQ 100MG HCL	A086697	001	
	EQ 100MG HCL	A086728	001	Oct 05, 1982
	EQ 100MG HCL	A087790	001	Aug 16, 1982
HY-PAM "25"				
TEVA	EQ 25MG HCL	A088713	001	Mar 04, 1985
VISTARIL				
PFIZER	EQ 100MG HCL	N011459	006	

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

ROCHE	EQ 2.5MG BASE	N021455	001	May 16, 2003
-------	---------------	---------	-----	--------------

IBUPROFEN

CAPSULE; ORAL

MIDOL

BAYER	200MG	A070626	001	Sep 02, 1987
	200MG	A071002	001	Sep 02, 1987

## DISCONTINUED DRUG PRODUCT LIST

6 - 171 (of 324)

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ADVIL

WYETH CONS

100MG/5ML

N019833 002

Sep 19, 1989

IBU

ABBOTT

100MG/5ML

N019784 001

Dec 18, 1989

MOTRIN

MCNEIL CONSUMER

100MG/5ML

N019842 001

Sep 19, 1989

SUSPENSION/DROPS; ORAL

MOTRIN

MCNEIL

40MG/ML

N020476 001

May 25, 1995

TABLET; ORAL

ACHES-N-PAIN

LEDERLE

200MG

A071065 001

May 28, 1987

CAP-PROFEN

PERRIGO

200MG

A072097 001

Dec 08, 1987

IBU

BASF

400MG

A070083 001

Feb 22, 1985

400MG

N018197 001

600MG

A070088 001

Feb 08, 1985

600MG

A070099 001

Mar 29, 1985

800MG

A070745 001

Jul 23, 1986

IBUPRIN

PLIVA

200MG

A071773 001

Jul 16, 1987

IBUPROFEN

ABBOTT

600MG

A070556 001

Jun 14, 1985

800MG

A071264 001

Jul 25, 1986

HALSEY

200MG

A071027 001

Sep 29, 1987

300MG

A071028 001

Mar 23, 1987

400MG

A071029 001

Mar 23, 1987

600MG

A071030 001

Mar 23, 1987

800MG

A072137 001

Feb 05, 1988

IVAX SUB TEVA PHARMS

200MG

A071144 001

Jan 20, 1987

200MG

A071154 001

Oct 27, 1987

200MG

A072040 001

Apr 29, 1988

200MG

A072901 001

Dec 19, 1991

200MG

A072903 001

Dec 19, 1991

400MG

A071145 001

Sep 23, 1986

600MG

A071146 001

Sep 23, 1986

800MG

A071769 001

May 08, 1987

LEDERLE

400MG

A070629 001

Sep 19, 1986

600MG

A070630 001

Sep 19, 1986

LEINER

300MG

A071266 001

Oct 15, 1986

MCNEIL

400MG

A070081 001

Jun 16, 1986

600MG

A070476 001

Jun 16, 1986

MUTUAL PHARM

200MG

A070493 001

Dec 24, 1985

200MG

A070908 001

Sep 26, 1986

200MG

A071462 001

Oct 02, 1986

400MG

A070079 001

Jul 24, 1985

600MG

A070080 001

Jul 24, 1985

800MG

A071448 001

Feb 18, 1987

MYLAN

200MG

A071870 001

May 05, 1988

400MG

A070045 001

Sep 24, 1985

600MG

A070057 001

Sep 24, 1985

800MG

A071999 001

Dec 03, 1987

PAR PHARM

200MG

A071575 001

May 08, 1987

300MG

A070328 001

Aug 06, 1985

400MG

A070329 001

Aug 06, 1985

600MG

A070330 001

Aug 06, 1985

800MG

A070986 001

Jul 25, 1986

PERRIGO

200MG

A072098 001

Dec 08, 1987

PLIVA

400MG

A071666 001

Jun 18, 1987

600MG

A071667 001

Jun 18, 1987

800MG

A071668 001

Jun 18, 1987

## DISCONTINUED DRUG PRODUCT LIST

6 - 172 (of 324)

IBUPROFEN

TABLET; ORAL

IBUPROFEN

PUREPAC PHARM	200MG	A071122	001	Oct 03, 1986
	200MG	A071664	001	Feb 03, 1987
	300MG	A071123	001	Sep 19, 1986
	400MG	A071124	001	Sep 19, 1986
	600MG	A071125	001	Sep 19, 1986
	800MG	A071964	001	Feb 01, 1988
SANDOZ	200MG	A070733	001	Sep 19, 1986
	300MG	A070734	001	Jun 12, 1986
	400MG	A070735	001	Jun 12, 1986
	400MG	A072064	001	Jan 14, 1988
	600MG	A070736	001	Jun 12, 1986
	600MG	A072065	001	Jan 14, 1988
	800MG	A071938	001	Jan 14, 1988
	800MG	A072169	001	Dec 11, 1987
SUPERPHARM	600MG	A070709	001	Apr 25, 1986
TEVA	200MG	A073141	001	May 29, 1992
	400MG	A073343	001	Jun 30, 1992
	600MG	A073344	001	Jun 30, 1992
	800MG	A073345	001	Jun 30, 1992
VINTAGE PHARMS	200MG	A072249	001	Jan 10, 1989
WATSON LABS	200MG	A071765	001	Sep 04, 1987
	200MG	A071905	001	Mar 08, 1988
	300MG	A071338	001	Dec 01, 1986
	400MG	A070038	001	Sep 06, 1985
	600MG	A070041	001	Sep 06, 1985
	800MG	A071547	001	Jul 02, 1987
	800MG	A071911	001	Oct 13, 1987
IBU-TAB				
ALRA	800MG	A071965	001	Aug 11, 1988
MEDIPREN				
MCNEIL	200MG	A070475	001	Feb 06, 1986
	200MG	A071215	001	Jun 26, 1986
MIDOL				
BAYER	200MG	A070591	001	Sep 02, 1987
	200MG	A071001	001	Sep 02, 1987
MOTRIN				
MCNEIL CONSUMER	300MG	N017463	003	
	400MG	N017463	002	
	600MG	N017463	004	
	800MG	N017463	005	May 22, 1985
MCNEIL PED	100MG	N020418	001	Nov 16, 1994
NUPRIN				
BRISTOL MYERS	200MG	A072035	001	Feb 16, 1988
	200MG	A072036	001	Feb 16, 1988
MCNEIL	200MG	N019012	001	May 18, 1984
	200MG	N019012	002	Jul 29, 1987
RUFEN				
BASF	600MG	N018197	002	Mar 05, 1984
TABLET, CHEWABLE; ORAL				
MOTRIN				
MCNEIL PED	50MG	N020135	001	Nov 16, 1994
	100MG	N020135	002	Nov 16, 1994

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN

PHARMACIA AND UPJOHN	5MG/VIAL	N050661	002	Sep 27, 1990
	10MG/VIAL	N050661	001	Sep 27, 1990
	20MG/VIAL	N050661	003	Apr 25, 1995

## DISCONTINUED DRUG PRODUCT LIST

6 - 173 (of 324)

IDOXURIDINE

OINTMENT; OPHTHALMIC

STOXIL

GLAXOSMITHKLINE 0.5% N015868 001

SOLUTION/DROPS; OPHTHALMIC

STOXIL

GLAXOSMITHKLINE 0.1% N013934 001

IFOSFAMIDE

INJECTABLE; INJECTION

IFEX

BAXTER HLTHCARE 1GM/VIAL N019763 001 Dec 30, 1988

3GM/VIAL N019763 002 Dec 30, 1988

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

NOVARTIS EQ 50MG BASE N021335 001 May 10, 2001

EQ 100MG BASE N021335 002 May 10, 2001

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE; ORAL

IMIPRAMINE HYDROCHLORIDE

NOVARTIS 25MG/ML A086765 001

INJECTABLE; INJECTION

TOFRANIL

NOVARTIS 12.5MG/ML N011838 002

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

LEDERLE 10MG A086269 001

25MG A086267 001

50MG A086268 001

PAR PHARM 25MG A089497 001 Jul 14, 1987

50MG A088276 001 Oct 21, 1983

ROXANE 10MG A083799 001

25MG A083799 002

50MG A083799 003

SANDOZ 10MG A085200 001

25MG A084869 002

50MG A085133 001

TEVA 10MG A083729 001

25MG A083729 004

50MG A083729 003

USL PHARMA 25MG A087776 001 Feb 10, 1982

VANGARD 10MG A088036 001 Nov 03, 1982

25MG A087619 001 Feb 09, 1982

50MG A087631 001 Jan 04, 1982

WATSON LABS 10MG A085220 001

10MG A085875 001

25MG A084252 002

25MG A085878 001

50MG A085221 001

50MG A085877 001

WEST WARD 25MG A088222 001 May 26, 1983

50MG A088223 001 May 26, 1983

JANIMINE

ABBOTT 10MG N017895 001

25MG N017895 002

50MG N017895 003

PRAMINE

ALRA 10MG A083827 001

25MG A083827 002

50MG A083827 003

## DISCONTINUED DRUG PRODUCT LIST

6 - 174 (of 324)

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

PRESAMINE

SANOFI AVENTIS US	10MG	N011836	006
	25MG	N011836	003
	50MG	N011836	007

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

HOSPIRA	EQ 5MG BASE/ML	A074616	001	Aug 03, 1998
---------	----------------	---------	-----	--------------

INOCOR

SANOFI AVENTIS US	EQ 5MG BASE/ML	N018700	001	Jul 31, 1984
-------------------	----------------	---------	-----	--------------

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

CADISTA PHARMS	1.25MG	A075201	001	Dec 04, 1998
	2.5MG	A075201	002	Dec 04, 1998
TEVA	1.25MG	A074498	002	Feb 12, 1998
	1.25MG	A074665	001	Apr 04, 1997
	2.5MG	A074498	001	Oct 31, 1996
	2.5MG	A074665	002	Apr 04, 1997

LOZOL

SANOFI AVENTIS US	1.25MG	N018538	002	Apr 29, 1993
	2.5MG	N018538	001	Jul 06, 1983

INDECANIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DECABID

LILLY	EQ 50MG BASE	N019693	001	Dec 29, 1989
	EQ 75MG BASE	N019693	002	Dec 29, 1989
	EQ 100MG BASE	N019693	003	Dec 29, 1989

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

MERCK SHARP DOHME	EQ 333MG BASE	N020685	005	Dec 17, 1998
-------------------	---------------	---------	-----	--------------

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

AKORN	10MG/VIAL	N011525	003
	40MG/VIAL	N011525	004
	50MG/VIAL	N011525	002

INDOMETHACIN

CAPSULE; ORAL

INDOCIN

IROKO PHARMS	25MG	N016059	001
	50MG	N016059	002

INDO-LEMMON

TEVA	25MG	A070266	001	Nov 07, 1985
	50MG	A070267	001	Nov 07, 1985

INDOMETHACIN

ABLE	25MG	A076666	001	Dec 17, 2003
	50MG	A076666	002	Dec 17, 2003
DURAMED PHARMS BARR	25MG	A070326	001	Oct 18, 1985
	50MG	A070327	001	Oct 18, 1985
	25MG	A070782	001	Jun 03, 1987
HALSEY	50MG	A070635	001	Jun 03, 1987
	25MG	N018851	001	May 18, 1984
HERITAGE PHARMS INC	25MG	N018851	002	May 18, 1984



## DISCONTINUED DRUG PRODUCT LIST

6 - 175 (of 324)

INDOMETHACIN

## CAPSULE; ORAL

## INDOMETHACIN

IVAX SUB TEVA PHARMS	25MG	N018730	001	May 04, 1984
	50MG	N018730	002	May 04, 1984
MUTUAL PHARM	25MG	A070067	001	Oct 03, 1986
	25MG	A070899	001	Feb 09, 1987
	50MG	A070068	001	Oct 03, 1986
	50MG	A070900	001	Feb 09, 1987
MYLAN	50MG	N018858	002	Apr 20, 1984
PARKE DAVIS	25MG	N018806	001	Nov 23, 1984
	50MG	N018806	002	Nov 23, 1984
PIONEER PHARMS	25MG	A070813	001	Aug 11, 1986
	50MG	A070592	001	Aug 11, 1986
PLIVA	25MG	A071148	001	Mar 18, 1987
	50MG	A071149	001	Mar 18, 1987
ROXANE	25MG	A070353	001	Jun 18, 1985
	50MG	A070354	001	Jun 18, 1985
SUPERPHARM	25MG	A070487	001	Oct 10, 1986
	50MG	A070488	001	Oct 10, 1986
TEVA	25MG	A071342	001	Apr 18, 1988
	50MG	A071343	001	Apr 18, 1988
VINTAGE	25MG	N018829	002	Aug 06, 1984
	50MG	A070651	001	Mar 05, 1986
	50MG	N018829	001	Aug 06, 1984
WATSON LABS	25MG	A070529	001	Oct 18, 1985
	25MG	A070784	001	Aug 20, 1986
	25MG	A072996	001	Jul 31, 1991
	25MG	N018690	001	Jul 31, 1984
	50MG	A070530	001	Oct 18, 1985
	50MG	A070785	001	Aug 20, 1986
	50MG	A071635	001	May 18, 1987
	50MG	A072997	001	Jul 31, 1991
	50MG	N018690	002	Jul 31, 1984
CAPSULE, EXTENDED RELEASE; ORAL				
INDOCIN SR				
IROKO PHARMS	75MG	N018185	001	Feb 23, 1982
INDOMETHACIN				
ABLE	75MG	A076114	001	Feb 06, 2002
INWOOD LABS	75MG	A072410	001	Mar 15, 1989
SUPPOSITORY; RECTAL				
INDOCIN				
IROKO PHARMS	50MG	N017814	001	Aug 13, 1984
SUSPENSION; ORAL				
INDOMETHACIN				
ROXANE	25MG/5ML	A071412	001	Mar 18, 1987

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

## INJECTABLE; SUBCUTANEOUS

## NOVOLOG MIX 50/50

NOVO NORDISK INC	50 UNITS/ML;50 UNITS/ML	N021810	001	Aug 26, 2008
------------------	-------------------------	---------	-----	--------------

INSULIN PORK

## INJECTABLE; INJECTION

## ILETIN I

LILLY	500 UNITS/ML	N017931	001	
-------	--------------	---------	-----	--

## INSULIN

NOVO NORDISK INC	40 UNITS/ML	N017926	001	
------------------	-------------	---------	-----	--

## REGULAR INSULIN

NOVO NORDISK INC	100 UNITS/ML	N017926	003	
------------------	--------------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 176 (of 324)

INSULIN PURIFIED BEEF

INJECTABLE; INJECTION

REGULAR ILETIN II

LILLY

100 UNITS/ML

N018478 001

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

ILETIN II

LILLY

500 UNITS/ML

N018344 002

REGULAR ILETIN II (PORK)

LILLY

100 UNITS/ML

N018344 001

REGULAR PURIFIED PORK INSULIN

NOVO NORDISK INC

100 UNITS/ML

N018381 001

VELOSULIN

NOVO NORDISK INC

100 UNITS/ML

N018193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN NORDISK MIXTARD (PORK)

NOVO NORDISK INC

30 UNITS/ML;70 UNITS/ML

N018195 001

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN BR

LILLY

100 UNITS/ML

N019529 001

Apr 28, 1986

VELOSULIN BR

NOVO NORDISK INC

100 UNITS/ML

N021028 001

Jul 19, 1999

POWDER; INHALATION

EXUBERA

PFIZER

1MG/INH

N021868 001

Jan 27, 2006

3MG/INH

N021868 002

Jan 27, 2006

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

LILLY

50 UNITS/ML;50 UNITS/ML

N020100 001

Apr 29, 1992

INSULIN RECOMBINANT PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN R

NOVO NORDISK INC

100 UNITS/ML

N018778 001

Aug 30, 1983

VELOSULIN BR HUMAN

NOVO NORDISK INC

100 UNITS/ML

N019450 001

May 30, 1986

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

MIXTARD HUMAN 70/30

BAYER PHARMS

30 UNITS/ML;70 UNITS/ML

N019585 001

Mar 11, 1988

NOVOLIN 70/30

NOVO NORDISK INC

30 UNITS/ML;70 UNITS/ML

N019441 001

Jul 11, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION

NPH INSULIN

NOVO NORDISK INC

40 UNITS/ML

N017929 001

100 UNITS/ML

N017929 003

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION

NPH ILETIN I (BEEF-PORK)

LILLY

40 UNITS/ML

N017936 001

100 UNITS/ML

N017936 002

## DISCONTINUED DRUG PRODUCT LIST

6 - 177 (of 324)

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION

NPH ILETIN II

LILLY

100 UNITS/ML

N018479 001

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN INSULATARD NPH NORDISK

NOVO NORDISK INC

100 UNITS/ML

N018194 001

NPH ILETIN II (PORK)

LILLY

100 UNITS/ML

N018345 001

NPH PURIFIED PORK ISOPHANE INSULIN

NOVO NORDISK INC

100 UNITS/ML

N018623 001

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

INSULATARD NPH HUMAN

NOVO NORDISK INC

100 UNITS/ML

N019449 001

May 30, 1986

NOVOLIN N

NOVO NORDISK INC

100 UNITS/ML

N019065 001

Jan 23, 1985

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

INJECTABLE; INJECTION

PROTAMINE ZINC &amp; ILETIN I (BEEF-PORK)

LILLY

40 UNITS/ML

N017932 001

100 UNITS/ML

N017932 002

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II

LILLY

100 UNITS/ML

N018476 001

PROTAMINE ZINC INSULIN

BRISTOL MYERS SQUIBB

40 UNITS/ML

N017928 001

100 UNITS/ML

N017928 003

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II (PORK)

LILLY

100 UNITS/ML

N018346 001

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION

LENTE INSULIN

NOVO NORDISK INC

40 UNITS/ML

N017998 001

100 UNITS/ML

N017998 003

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE; INJECTION

ULTRALENTE INSULIN

NOVO NORDISK INC

100 UNITS/ML

N017997 003

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION

ULTRALENTE

NOVO NORDISK INC

100 UNITS/ML

N018385 001

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN U

LILLY

40 UNITS/ML

N019571 001

Jun 10, 1987

100 UNITS/ML

N019571 002

Jun 10, 1987

## DISCONTINUED DRUG PRODUCT LIST

6 - 178 (of 324)

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE; INJECTION			
SEMILENTE INSULIN			
NOVO NORDISK INC	100 UNITS/ML	N017996	003

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE; INJECTION			
SEMILENTE			
NOVO NORDISK INC	100 UNITS/ML	N018382	001

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION			
LENTE ILETIN II			
LILLY	100 UNITS/ML	N018477	001

INSULIN ZINC SUSP PURIFIED BEEF/PORK

INJECTABLE; INJECTION			
LENTARD			
NOVO NORDISK INC	100 UNITS/ML	N018384	001

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION			
LENTE			
NOVO NORDISK INC	100 UNITS/ML	N018383	001
LENTE ILETIN II (PORK)			
LILLY	100 UNITS/ML	N018347	001

INSULIN ZINC SUSP RECOMBINANT HUMAN

INJECTABLE; INJECTION				
HUMULIN L				
LILLY	100 UNITS/ML	N019377	002	Sep 30, 1985
NOVOLIN L				
NOVO NORDISK INC	100 UNITS/ML	N019965	001	Jun 25, 1991

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION				
NOVOLIN L				
NOVO NORDISK INC	100 UNITS/ML	N018777	001	Aug 30, 1983

INULIN

INJECTABLE; INJECTION				
INULIN AND SODIUM CHLORIDE				
ISO TEX	100MG/ML	N002282	001	

INVERT SUGAR

INJECTABLE; INJECTION				
TRAVERT 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	10GM/100ML	N016717	001	

IOBENGUANE SULFATE I-131

INJECTABLE; INJECTION				
IOBENGUANE SULFATE I 131				
PHARMALUCENCE	2.3mCi/ML	N020084	001	Mar 25, 1994

IO CETAMIC ACID

TABLET; ORAL				
CHOLEBRINE				
MALLINCKRODT	750MG	N017129	001	

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION				
RENOVUE-65				
BRACCO	65%	N017902	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 179 (of 324)

IODAMIDE MEGLUMINEINJECTABLE; INJECTION  
RENOVUE-DIP

BRACCO 24% N017903 001

IODIPAMIDE MEGLUMINEINJECTABLE; INJECTION  
CHOLOGRAFIN MEGLUMINE

BRACCO 10.3% N009321 007

IODIPAMIDE SODIUMINJECTABLE; INJECTION  
CHOLOGRAFIN SODIUM

BRACCO 20% N009321 001

IODOHIPPURATE SODIUM, I-123INJECTABLE; INJECTION  
NEPHROFLOW

GE HEALTHCARE 1mCi/ML N018289 001 Dec 28, 1984

IODOHIPPURATE SODIUM, I-131INJECTABLE; INJECTION  
HIPURAN I 131

MALLINCKRODT 0.25mCi/ML N016666 001

HIPPUTOPE

BRACCO 1-2mCi/VIAL N015419 002

IODOHIPPURATE SODIUM I 131

PHARMALUCENCE 0.2mCi/ML N017313 001

IOOXAMATE MEGLUMINEINJECTABLE; INJECTION  
CHOLOVUE

BRACCO 9.9% N018077 001

40.3% N018076 001

IOFETAMINE HYDROCHLORIDE I-123INJECTABLE; INJECTION  
SPECTAMINE

IMP 1mCi/ML N019432 001 Dec 24, 1987

IOHEXOLINJECTABLE; INJECTION  
OMNIPAQUE 210

GE HEALTHCARE 45.3% N018956 006 Jun 30, 1989

SOLUTION; URETHRAL  
OMNIPAQUE 70

GE HEALTHCARE 15.1% N018956 007 Jun 01, 1994

IOPAMIDOLINJECTABLE; INJECTION  
IOPAMIDOL

BAXTER HLTHCARE 41% A074629 001 Nov 06, 1996

51% A074629 004 Mar 31, 1998

61% A074629 002 Nov 06, 1996

76% A074629 003 Nov 06, 1996

HOSPIRA 61% A074734 001 Dec 10, 1996

76% A074734 002 Dec 10, 1996

IOPAMIDOL-200

COOK IMAGING 41% A074881 001 Jul 28, 2000

IOPAMIDOL-250

COOK IMAGING 51% A074881 002 Jul 28, 2000

IOPAMIDOL-300

ABBOTT 61% A074638 001 Apr 30, 1997

## DISCONTINUED DRUG PRODUCT LIST

6 - 180 (of 324)

IOPAMIDOL

INJECTABLE; INJECTION				
IOPAMIDOL-300				
COOK IMAGING	61%	A074881	003	Jul 28, 2000
IOPAMIDOL-370				
COOK IMAGING	76%	A074881	004	Jul 28, 2000
ISOVUE-128				
BRACCO	26%	N018735	005	Oct 21, 1986
ISOVUE-200				
BRACCO	41%	N020327	001	Oct 12, 1994

IOPANOIC ACID

TABLET; ORAL				
TELEPAQUE				
GE HEALTHCARE	500MG	N008032	001	

IOPHENDYLATE

INJECTABLE; INJECTION				
PANTOPAQUE				
ALCON	100%	N005319	001	

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION				
VASCORAY				
MALLINCKRODT	52%;26%	N016783	001	

IOTHALAMATE SODIUM

INJECTABLE; INJECTION				
ANGIO-CONRAY				
MALLINCKRODT	80%	N013319	001	
CONRAY 325				
MALLINCKRODT	54.3%	N017685	001	
CONRAY 400				
MALLINCKRODT	66.8%	N014295	001	

IOTHALAMATE SODIUM, I-125

INJECTABLE; INJECTION				
GLOFIL-125				
ISOTEX	250-300uCi/ML	N017279	001	

IOTROLAN

INJECTABLE; INTRATHECAL				
OSMOVIST 190				
BAYER HLTHCARE	40.6%	N019580	001	Dec 07, 1989
OSMOVIST 240				
BAYER HLTHCARE	51.3%	N019580	002	Dec 07, 1989

IOVERSOL

INJECTABLE; INJECTION				
OPTIRAY 240				
MALLINCKRODT	51%	N020923	001	May 28, 1998
OPTIRAY 320				
MALLINCKRODT	68%	N020923	002	May 29, 1998

IPODATE CALCIUM

GRANULE; ORAL				
ORAGRAFIN CALCIUM				
BRACCO	3GM/PACKET	N012968	001	

IPODATE SODIUM

CAPSULE; ORAL				
BILIVIST				
BAYER HLTHCARE	500MG	A087768	001	Aug 11, 1982

## DISCONTINUED DRUG PRODUCT LIST

6 - 181 (of 324)

IPODATE SODIUM

CAPSULE; ORAL  
ORAGRAFIN SODIUM  
BRACCO

500MG N012967 001

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION  
ATROVENT

BOEHRINGER INGELHEIM 0.018MG/INH

N019085 001 Dec 29, 1986

SOLUTION; INHALATION

ATROVENT

BOEHRINGER INGELHEIM 0.02%

N020228 001 Sep 29, 1993

IPRATROPIUM BROMIDE

PHARMASCIENCE INC 0.02%

A075507 001 Jan 19, 2001

ROXANE 0.02%

A075867 001 Jul 22, 2002

IRON DEXTRAN

INJECTABLE; INJECTION  
IRON DEXTRAN

SANOFI AVENTIS US EQ 50MG IRON/ML

N010787 002

IRON SUCROSE

INJECTABLE; INTRAVENOUS  
VENOFER

LUITPOLD EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)

N021135 002 Mar 20, 2005

EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)

N021135 003 Mar 29, 2005

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION  
BETA-2

NEPHRON 1%

A086711 001

BRONKOSOL

SANOFI AVENTIS US 0.25%

N012339 009

1%

N012339 008

ISOETHARINE HYDROCHLORIDE

ALPHARMA US PHARMS 1%

A087101 001

ASTRAZENECA 0.062%

A087937 001 Nov 15, 1982

0.062%

A089614 001 Jun 13, 1991

0.125%

A087938 001 Nov 15, 1982

0.125%

A089615 001 Jun 13, 1991

0.167%

A088470 001 Mar 14, 1984

0.167%

A089616 001 Jun 13, 1991

0.2%

A088471 001 Mar 14, 1984

0.2%

A089617 001 Jun 13, 1991

0.25%

A088472 001 Mar 14, 1984

0.25%

A089618 001 Jun 13, 1991

BAXTER HLTHCARE

0.08%

A088144 001 Jul 29, 1983

0.14%

A088145 001 Mar 26, 1984

0.25%

A088146 001 Aug 01, 1983

DEY

0.08%

A088187 001 Dec 03, 1982

0.1%

A087389 001

0.17%

A087390 001

0.25%

A088188 001 Dec 03, 1982

1%

A086763 001

INTL MEDICATION

0.077%

A086651 001

0.08%

A086651 002

0.1%

A086651 003

0.143%

A086651 004

0.167%

A086651 005

0.2%

A086651 006

0.25%

A086651 007

1%

A086651 008

PARKE DAVIS

0.5%

A085997 001

1%

A085889 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 182 (of 324)

ISOETHARINE HYDROCHLORIDE

## SOLUTION; INHALATION

## ISOETHARINE HYDROCHLORIDE

ROXANE	0.1%	A087396	001	
	0.125%	A087025	001	
	0.167%	A088226	001	Sep 16, 1983
	0.2%	A087324	001	
	0.25%	A088275	001	Jun 03, 1983
	1%	A086899	001	
ISOETHARINE HYDROCHLORIDE S/F				
DEY	0.08%	A089817	001	Nov 22, 1988
	0.1%	A089818	001	Nov 22, 1988
	0.17%	A089819	001	Nov 22, 1988
	0.25%	A089820	001	Nov 22, 1988
	1%	A089252	001	Sep 15, 1986

ISOETHARINE MESYLATE

## AEROSOL, METERED; INHALATION

## BRONKOMETER

SANOVI AVENTIS US	0.34MG/INH	N012339	007	
ISOETHARINE MESYLATE				
ALPHARMA US PHARMS	0.34MG/INH	A087858	001	Aug 21, 1984

ISOFLURANE

## LIQUID; INHALATION

## ISOFLURANE

MARSAM PHARMS LLC	99.9%	A074393	001	May 12, 1995
-------------------	-------	---------	-----	--------------

ISOFLUROPHATE

## OINTMENT; OPHTHALMIC

## FLOROPRYL

MERCK	0.025%	N010656	001	
-------	--------	---------	-----	--

ISONIAZID

## INJECTABLE; INJECTION

## NYDRAZID

SANDOZ	100MG/ML	N008662	001	
--------	----------	---------	-----	--

## RIMIFON

ROCHE	25MG/ML	N008420	002	
	100MG/ML	N008420	003	

## SYRUP; ORAL

## ISONIAZID

MIKART	50MG/5ML	A081118	001	Jul 21, 1997
--------	----------	---------	-----	--------------

## LANIAZID

LANNETT	50MG/5ML	A089243	001	Feb 03, 1986
---------	----------	---------	-----	--------------

## RIMIFON

ROCHE	50MG/5ML	N008420	001	
-------	----------	---------	-----	--

## TABLET; ORAL

## DOW-ISONIAZID

DOW PHARM	300MG	A080330	002	
-----------	-------	---------	-----	--

## HYZYD

MEDPOINTE PHARM HLC	100MG	A080134	003	
	300MG	A080134	004	

## INH

NOVARTIS	300MG	A080935	001	
----------	-------	---------	-----	--

## ISONIAZID

DURAMED PHARMS BARR	100MG	A088231	001	Mar 17, 1983
	300MG	A088119	001	Mar 17, 1983

HALSEY	50MG	A083632	001	
--------	------	---------	-----	--

IMPAX LABS	100MG	A080153	001	
------------	-------	---------	-----	--

IVAX SUB TEVA PHARMS	100MG	A080270	001	
----------------------	-------	---------	-----	--

	300MG	A083610	001	
--	-------	---------	-----	--

LILLY	100MG	N008499	002	
-------	-------	---------	-----	--

	300MG	N008499	003	
--	-------	---------	-----	--



## DISCONTINUED DRUG PRODUCT LIST

6 - 183 (of 324)

ISONIAZID

TABLET; ORAL

ISONIAZID

MK LABS	100MG	A080941	001	
MUTUAL PHARM	100MG	A080136	001	
	300MG	A083633	001	
NEXGEN PHARMA INC	100MG	A084050	001	
PANRAY	50MG	N008428	001	
	100MG	N008428	002	
	300MG	N008428	003	
PERRIGO	100MG	A083060	001	
PHARMAVITE	100MG	A085091	001	
PHOENIX LABS NY	50MG	A080368	001	
	100MG	A080368	002	
PUREPAC PHARM	50MG	A080132	003	Jul 14, 1982
	100MG	A080132	004	Jul 14, 1982
WATSON LABS	50MG	A080522	001	
	100MG	A080401	001	
	100MG	A080523	001	
	100MG	A085790	001	
	300MG	A083178	001	
	300MG	A085784	001	
WHITEWORTH TOWN PLSN	100MG	A080120	002	
<u>LANIAZID</u>				
LANNETT	50MG	A080140	001	
	100MG	A080140	002	
	300MG	A089776	001	Jun 13, 1988
<u>NYDRAZID</u>				
BRISTOL MYERS SQUIBB	100MG	N008392	003	
<u>STANOZIDE</u>				
EVERYLIFE	100MG	A080126	001	
	300MG	A080126	002	

ISOPROPAMIDE IODIDE

TABLET; ORAL

DARBID

GLAXOSMITHKLINE	EQ 5MG BASE	N010744	001	
-----------------	-------------	---------	-----	--

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HYDROCHLORIDE

3M	0.12MG/INH	N010375	004	
ALPHARMA US PHARMS	0.12MG/INH	A085904	001	
<u>ISUPREL</u>				
SANOFI AVENTIS US	0.103MG/INH	N011178	001	
<u>DISC; INHALATION</u>				
<u>NORISODRINE AEROTROL</u>				
ABBOTT	0.25%	N016814	001	
<u>INJECTABLE; INJECTION</u>				
<u>ISOPROTERENOL HYDROCHLORIDE</u>				
ABRAXIS PHARM	0.2MG/ML	A083431	001	
BAXTER HLTHCARE	0.2MG/ML	A083486	001	
HOSPIRA	0.02MG/ML	A083283	001	
	0.2MG/ML	A083346	001	
<u>SOLUTION; INHALATION</u>				
<u>AEROLONE</u>				
LILLY	0.25%	N007245	001	
<u>ISOPROTERENOL HYDROCHLORIDE</u>				
ARMOUR PHARM	0.031%	A087935	001	Nov 18, 1982
	0.062%	A087936	001	Nov 18, 1982
DEY	0.5%	A086764	001	Jan 04, 1982
PARKE DAVIS	0.25%	A085994	001	
	0.5%	A085540	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 184 (of 324)

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

ISUPREL

SANOFI AVENTIS US	0.5%	N006327	002
	1%	N006327	003

VAPO-ISO

FISONS	0.5%	N016813	001
--------	------	---------	-----

TABLET; RECTAL, SUBLINGUAL

ISUPREL

SANOFI AVENTIS US	10MG	N006328	001
	15MG	N006328	002

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

DUO-MEDIHALER

3M	0.16MG/INH; 0.24MG/INH	N013296	001
----	------------------------	---------	-----

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

MEDIHALER-ISO

3M	0.08MG/INH	N010375	003
----	------------	---------	-----

POWDER; INHALATION

NORISODRINE

ABBOTT	10%	N006905	003
	25%	N006905	002

ISOSORBIDE

SOLUTION; ORAL

ISMOTIC

ALCON	100GM/220ML	N017063	001
-------	-------------	---------	-----

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

ISORDIL

WYETH AYERST	40MG	N012882	002	Jul 29, 1988
--------------	------	---------	-----	--------------

TABLET; ORAL

ISOSORBIDE DINITRATE

MUTUAL PHARM	5MG	A086166	002	Sep 19, 1986
	10MG	A086169	001	Sep 19, 1986
	20MG	A086167	001	Sep 19, 1986
	30MG	A087564	001	Sep 18, 1986
SUPERPHARM	5MG	A089190	001	Feb 17, 1987
	10MG	A089191	001	Feb 17, 1987
	20MG	A089192	001	Feb 17, 1987

SORBITRATE

ASTRAZENECA	5MG	N016192	001	Apr 01, 1996
	10MG	N016192	002	Apr 01, 1996
	20MG	A086405	002	Aug 21, 1990
	30MG	A088124	001	Aug 21, 1990
	40MG	A088125	001	Aug 21, 1990

TABLET; SUBLINGUAL

ISORDIL

BIOVAIL	2.5MG	N012940	004	Jul 29, 1988
	5MG	N012940	003	Jul 29, 1988
	10MG	N012940	005	Jul 29, 1988

ISOSORBIDE DINITRATE

MUTUAL PHARM	2.5MG	A084204	001	Sep 18, 1986
	5MG	A086168	001	Sep 18, 1986
	10MG	A087545	001	Sep 18, 1986
SANDOZ	2.5MG	A086225	001	Feb 19, 1988
	5MG	A086222	001	Feb 19, 1988

SORBITRATE

ASTRAZENECA	2.5MG	N016191	002	Apr 01, 1996
	5MG	N016191	001	Apr 01, 1996

## DISCONTINUED DRUG PRODUCT LIST

6 - 185 (of 324)

ISOSORBIDE DINITRATETABLET, CHEWABLE; ORAL  
SORBITRATE

ASTRAZENECA	5MG	N016776	002	Apr 01, 1996
	10MG	N016776	003	Apr 01, 1996

TABLET, EXTENDED RELEASE; ORAL

ISORDIL

WYETH AYERST	40MG	N012882	001	Jul 29, 1988
--------------	------	---------	-----	--------------

ISOSORBIDE MONONITRATETABLET, EXTENDED RELEASE; ORAL  
IMDUR

SCHERING PLOUGH	30MG	N020225	001	Aug 12, 1993
	60MG	N020225	002	Aug 12, 1993
	120MG	N020225	003	Mar 30, 1995

ISOSORBIDE MONONITRATE

IVAX SUB TEVA PHARMS	30MG	A075448	002	Aug 07, 2001
	60MG	A075448	001	Jun 19, 2000
	120MG	A075448	003	Aug 07, 2001

ISOTRETINOIN

CAPSULE; ORAL

ACCUTANE

HOFFMANN LA ROCHE	10MG	N018662	002	May 07, 1982
	20MG	N018662	004	Mar 28, 1983
	40MG	N018662	003	May 07, 1982

ISRADIPINE

CAPSULE; ORAL

DYNACIRC

SMITHKLINE BEECHAM	2.5MG	N019546	001	Dec 20, 1990
	5MG	N019546	002	Dec 20, 1990

IVERMECTIN

TABLET; ORAL

STROMEKTOL

MERCK	6MG	N050742	001	Nov 22, 1996
-------	-----	---------	-----	--------------

KANAMYCIN SULFATE

CAPSULE; ORAL

KANTREX

APOTHECON	EQ 500MG BASE	A060516	001	
	EQ 500MG BASE	A061911	001	
	EQ 500MG BASE	A062726	001	Mar 06, 1987

INJECTABLE; INJECTION

KANAMYCIN

BAXTER HLTHCARE	EQ 75MG BASE/2ML	A062324	001	
	EQ 500MG BASE/2ML	A062324	002	
	EQ 1GM BASE/3ML	A062324	003	

KANAMYCIN SULFATE

ABRAXIS PHARM	EQ 75MG BASE/2ML	A062504	001	Apr 05, 1984
	EQ 500MG BASE/2ML	A062504	002	Apr 05, 1984
	EQ 1GM BASE/3ML	A062504	003	Apr 05, 1984
INTL MEDICATION	EQ 500MG BASE/2ML	A062466	001	Sep 30, 1983
	EQ 1GM BASE/3ML	A062466	002	Sep 30, 1983
LOCH	EQ 75MG BASE/2ML	A063021	001	Jul 31, 1992
	EQ 500MG BASE/2ML	A063022	001	Jul 31, 1992
	EQ 1GM BASE/3ML	A063025	001	Jul 31, 1992
PHARMAFAIR	EQ 75MG BASE/2ML	A062668	001	May 07, 1987
	EQ 500MG BASE/2ML	A062672	001	May 07, 1987
	EQ 1GM BASE/3ML	A062669	001	May 07, 1987
SOLOPAK	EQ 75MG BASE/2ML	A062605	003	Feb 26, 1986
	EQ 500MG BASE/2ML	A062605	001	Feb 26, 1986
	EQ 1GM BASE/3ML	A062605	002	Feb 26, 1986

## DISCONTINUED DRUG PRODUCT LIST

6 - 186 (of 324)

KANAMYCIN SULFATE

## INJECTABLE; INJECTION

## KANAMYCIN SULFATE

WARNER CHILCOTT

EQ 1GM BASE/3ML

A063092 001

Oct 11, 1989

WATSON LABS

EQ 1GM BASE/3ML

A062520 003

May 09, 1985

## KANTREX

APOTHECON

EQ 75MG BASE/2ML

A061655 003

EQ 75MG BASE/2ML

A061901 003

EQ 75MG BASE/2ML

A062564 001

Sep 21, 1984

EQ 500MG BASE/2ML

A061655 001

EQ 500MG BASE/2ML

A061901 001

EQ 500MG BASE/2ML

A062564 002

Sep 21, 1984

EQ 1GM BASE/3ML

A061655 002

EQ 1GM BASE/3ML

A061901 002

EQ 1GM BASE/3ML

A062564 003

Sep 21, 1984

## KLEBCIL

KING PHARMS

EQ 75MG BASE/2ML

A062170 001

EQ 500MG BASE/2ML

A062170 002

EQ 1GM BASE/3ML

A062170 003

KETOCONAZOLE

## CREAM; TOPICAL

## NIZORAL

JANSSEN PHARMA

2%

N019084 001

Dec 31, 1985

## SUSPENSION; ORAL

## NIZORAL

JANSSEN PHARMA

100MG/5ML

A070767 001

Nov 07, 1986

## TABLET; ORAL

## KETOCONAZOLE

AAIPHARMA LLC

200MG

A075341 001

Jul 27, 1999

TEVA

200MG

A074971 001

Jun 15, 1999

KETOPROFEN

## CAPSULE; ORAL

## KETOPROFEN

SANDOZ

50MG

A074024 001

Dec 29, 1995

75MG

A074024 002

Dec 29, 1995

TEVA

25MG

A073515 001

Dec 22, 1992

## ORUDIS

WYETH AYERST

25MG

N018754 001

Jul 31, 1987

50MG

N018754 002

Jan 09, 1986

75MG

N018754 003

Jan 09, 1986

## CAPSULE, EXTENDED RELEASE; ORAL

## ORUVAIL

WYETH PHARMS INC

100MG

N019816 003

Feb 08, 1995

150MG

N019816 002

Feb 08, 1995

200MG

N019816 001

Sep 24, 1993

## TABLET; ORAL

## ACTRON

BAYER

12.5MG

N020499 001

Oct 06, 1995

## KETOPROFEN

PERRIGO

12.5MG

A075364 001

Feb 07, 2002

## ORUDIS KT

WYETH CONS

12.5MG

N020429 001

Oct 06, 1995

KETOROLAC TROMETHAMINE

## INJECTABLE; INJECTION

## KETOROLAC TROMETHAMINE

AMPHASTAR PHARM

15MG/ML

A076209 001

Jul 21, 2004

30MG/ML

A076209 002

Jul 21, 2004

APOTEX INC

30MG/ML

A075626 001

Jul 24, 2001

30MG/ML

A077201 001

Oct 14, 2005

APOTHECON

15MG/ML

A075348 001

Nov 28, 2000

30MG/ML

A075348 002

Nov 28, 2000

## DISCONTINUED DRUG PRODUCT LIST

6 - 187 (of 324)

KETOROLAC TROMETHAMINE

## INJECTABLE; INJECTION

## KETOROLAC TROMETHAMINE

BEDFORD	15MG/ML	A075230	002	Oct 25, 1999
	30MG/ML	A075230	001	Oct 25, 1999
GLAND PHARMA LTD	15MG/ML	A076722	001	Jul 27, 2004
	30MG/ML	A076722	002	Jul 27, 2004
HOSPIRA	15MG/ML	A074801	001	Jun 05, 1997
	30MG/ML	A074801	002	Jun 05, 1997
TORADOL				
ROCHE PALO	15MG/ML	N019698	001	Nov 30, 1989
	30MG/ML	N019698	002	Nov 30, 1989

## TABLET; ORAL

## KETOROLAC TROMETHAMINE

ROXANE	10MG	A074790	001	Jun 26, 1997
WATSON LABS	10MG	A074955	001	Sep 19, 1997
TORADOL				
ROCHE PALO	10MG	N019645	001	Dec 20, 1991

KRYPTON, KR-81M

## GAS; INHALATION

## MPI KRYPTON 81M GENERATOR

GE HEALTHCARE	N/A	N018088	001	
---------------	-----	---------	-----	--

LABETALOL HYDROCHLORIDE

## INJECTABLE; INJECTION

## LABETALOL HYDROCHLORIDE

APOTHECON	5MG/ML	A075355	001	Nov 29, 1999
HOSPIRA	5MG/ML	A075242	001	Sep 30, 1999
NORMODYNE				
SCHERING	5MG/ML	N018686	001	Aug 01, 1984
TRANDATE				
PROMETHEUS LABS	5MG/ML	N019425	001	Dec 31, 1985

## TABLET; ORAL

## LABETALOL HYDROCHLORIDE

APOTHECON	100MG	A075223	001	Nov 20, 1998
	200MG	A075223	002	Nov 20, 1998
	300MG	A075223	003	Nov 20, 1998
MUTUAL PHARM	100MG	A075215	001	Jul 29, 1999
	200MG	A075215	002	Jul 29, 1999
	300MG	A075215	003	Jul 29, 1999
TEVA	100MG	A074989	001	Sep 30, 1998
	200MG	A074989	002	Sep 30, 1998
	300MG	A074989	003	Sep 30, 1998
NORMODYNE				
SCHERING	100MG	N018687	001	Aug 31, 1987
	200MG	N018687	002	Aug 01, 1984
	300MG	N018687	003	Aug 01, 1984
	400MG	N018687	004	Aug 01, 1984
TRANDATE				
PROMETHEUS LABS	400MG	N018716	004	Aug 01, 1984

LACTULOSE

## SOLUTION; ORAL

## CHRONULAC

SANOFI AVENTIS US	10GM/15ML	N017884	001	
DUPHALAC				
SOLVAY	10GM/15ML	A072372	001	Mar 22, 1989
EVALOSE				
TEVA PHARMS	10GM/15ML	A073497	001	May 28, 1993
LACTULOSE				
MORTON GROVE	10GM/15ML	A071841	001	Sep 22, 1988
PACO	10GM/15ML	A073160	001	Aug 25, 1992

## DISCONTINUED DRUG PRODUCT LIST

6 - 188 (of 324)

LACTULOSE

SOLUTION; ORAL

LAXILOSE

NOSTRUM LABS

10GM/15ML

A073686 001

May 28, 1993

SOLUTION; ORAL, RECTAL

ACILAC

NOSTRUM LABS

10GM/15ML

A073685 001

May 28, 1993

CEPHULAC

SANOFI AVENTIS US

10GM/15ML

N017657 001

GENERLAC

MORTON GROVE

10GM/15ML

A071842 001

Sep 27, 1988

HEPTALAC

TEVA PHARMS

10GM/15ML

A073504 001

May 28, 1993

LACTULOSE

PACO

10GM/15ML

A072029 001

Aug 25, 1992

ROXANE

10GM/15ML

A073590 001

May 29, 1992

SOLVAY

10GM/15ML

N017906 001

PORTALAC

SOLVAY

10GM/15ML

A072374 001

Mar 22, 1989

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

GLAXOSMITHKLINE

50MG

N020241 006

Dec 27, 1994

250MG

N020241 004

Dec 27, 1994

LAMOTRIGINE

MYLAN

25MG

A077428 001

Jan 27, 2009

100MG

A077428 002

Jan 27, 2009

150MG

A077428 003

Jan 27, 2009

200MG

A077428 004

Jan 27, 2009

TABLET, CHEWABLE; ORAL

LAMICTAL CD

GLAXOSMITHKLINE

100MG

N020764 003

Aug 24, 1998

LAMOTRIGINE

SANDOZ

5MG

A078409 002

Jan 22, 2009

25MG

A078409 003

Jan 22, 2009

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE; ORAL

PREVACID

TAKEDA PHARMS NA

15MG/PACKET

N021281 001

May 03, 2001

30MG/PACKET

N021281 002

May 03, 2001

INJECTABLE; INTRAVENOUS

PREVACID IV

TAKEDA PHARMS NA

30MG/VIAL

N021566 001

May 27, 2004

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

TAKEDA PHARMS NA

15MG,N/A;N/A,250MG

N021507 002

Nov 14, 2003

PREVACID NAPRAPAC 375 (COPACKAGED)

TAKEDA PHARMS NA

15MG,N/A;N/A,375MG

N021507 003

Nov 14, 2003

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVACID NAPRAPAC 500 (COPACKAGED)

TAKEDA PHARMS NA

15MG,N/A;N/A,500MG

N021507 004

Nov 14, 2003

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

SHIRE

EQ 250MG BASE

N021468 001

Oct 26, 2004

## DISCONTINUED DRUG PRODUCT LIST

6 - 189 (of 324)

LEFLUNOMIDE

TABLET; ORAL  
LEFLUNOMIDE  
SANDOZ

10MG	A077085	001	Sep 13, 2005
20MG	A077085	002	Sep 13, 2005

LEUCOVORIN CALCIUM

FOR SOLUTION; ORAL  
LEUCOVORIN CALCIUM

HOSPIRA	EQ 60MG BASE/VIAL	N008107	003	Jan 30, 1987
---------	-------------------	---------	-----	--------------

INJECTABLE; INJECTION  
LEUCOVORIN CALCIUM

ABIC	EQ 3MG BASE/ML	A089352	001	Jun 01, 1988
	EQ 50MG BASE/VIAL	A089353	001	Jun 01, 1988
ABRAXIS PHARM	EQ 50MG BASE/VIAL	A088939	001	Dec 01, 1986
ELKINS SINN	EQ 50MG BASE/VIAL	A070480	001	Jan 02, 1987
	EQ 100MG BASE/VIAL	A081224	001	Jun 03, 1994
HOSPIRA	EQ 3MG BASE/ML	N008107	001	
	EQ 50MG BASE/VIAL	N008107	002	
	EQ 100MG BASE/VIAL	N008107	004	May 23, 1988
PHARMACHEMIE	EQ 350MG BASE/VIAL	A040262	001	Dec 15, 1999
PHARMACHEMIE USA	EQ 50MG BASE/VIAL	A089628	001	Apr 17, 1997
	EQ 100MG BASE/VIAL	A089915	001	Apr 17, 1997

LEUCOVORIN CALCIUM PRESERVATIVE FREE

HOSPIRA	EQ 10MG BASE/ML	A040147	001	Jun 25, 1997
TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999

WELLCOVORIN

GLAXOSMITHKLINE	EQ 5MG BASE/ML	A087439	001	Oct 19, 1982
	EQ 25MG BASE/VIAL	A089833	001	Jan 23, 1989
	EQ 50MG BASE/VIAL	A089465	001	Jan 23, 1989
	EQ 100MG BASE/VIAL	A089834	001	Jan 23, 1989

TABLET; ORAL

LEUCOVORIN CALCIUM

COREPHARMA	EQ 5MG BASE	A074544	001	Aug 28, 1997
	EQ 25MG BASE	A074544	002	Aug 28, 1997
PAR PHARM	EQ 5MG BASE	A071600	001	Oct 14, 1987
	EQ 25MG BASE	A071598	001	Oct 14, 1987
PHARMACHEMIE	EQ 5MG BASE	A073099	001	Mar 28, 1997
	EQ 25MG BASE	A073101	001	Mar 28, 1997
XANODYNE PHARM	EQ 5MG BASE	N018459	001	Jan 30, 1986
	EQ 10MG BASE	A071962	001	Nov 19, 1987
	EQ 15MG BASE	A071104	001	Mar 04, 1987

WELLCOVORIN

GLAXOSMITHKLINE	EQ 5MG BASE	N018342	001	Jul 08, 1983
	EQ 25MG BASE	N018342	002	Jul 08, 1983

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION

VIADUR

ORTHO MCNEIL JANSSEN	EQ 65MG BASE	N021088	001	Mar 03, 2000
----------------------	--------------	---------	-----	--------------

INJECTABLE; INJECTION

LUPRON DEPOT-PED

ABBOTT LABS	3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993
	7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993

LEVALLORPHAN TARTRATE

INJECTABLE; INJECTION

LORFAN

ROCHE	1MG/ML	N010423	001	
-------	--------	---------	-----	--

LEVAMISOLE HYDROCHLORIDE

TABLET; ORAL

ERGAMISOL

JANSSEN PHARMA	EQ 50MG BASE	N020035	001	Jun 18, 1990
----------------	--------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 190 (of 324)

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

MYLAN	250MG	A078731	001	Feb 10, 2009
	500MG	A078731	002	Feb 10, 2009
	750MG	A078731	003	Feb 10, 2009
	1GM	A078731	004	Feb 10, 2009
WATSON LABS FLORIDA	250MG	A077408	001	Mar 02, 2009
	500MG	A077408	002	Mar 02, 2009
	750MG	A077408	003	Mar 02, 2009

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

ALCON	EQ 0.5% BASE	N021114	001	Feb 23, 2000
-------	--------------	---------	-----	--------------

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N020997	001	Aug 05, 1999
	EQ 5MG BASE/ML	N020997	002	Aug 05, 1999
	EQ 7.5MG BASE/ML	N020997	003	Aug 05, 1999

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

NOVARTIS	EQ 0.05% BASE	N020219	001	Nov 10, 1993
----------	---------------	---------	-----	--------------

LEVOCARNITINE

SOLUTION; ORAL

CARNITOR

SIGMA TAU	1GM/10ML	N018948	002	Apr 27, 1988
-----------	----------	---------	-----	--------------

LEVODOPA

CAPSULE; ORAL

BENDOPA

VALEANT PHARM INTL	100MG	N016948	003	
	250MG	N016948	001	
	500MG	N016948	002	

DOPAR

SHIRE	100MG	N016913	003	
	250MG	N016913	001	
	500MG	N016913	002	

LARODOPA

ROCHE	100MG	N016912	002	
	250MG	N016912	001	
	500MG	N016912	006	

TABLET; ORAL

DOPAR

SHIRE	250MG	N016913	004	
	500MG	N016913	005	

LARODOPA

ROCHE	100MG	N016912	005	
	250MG	N016912	003	
	500MG	N016912	004	

LEVOMEPRMAZINE

INJECTABLE; INJECTION

LEVOPROME

IMMUNEX	20MG/ML	N015865	001	
---------	---------	---------	-----	--



## DISCONTINUED DRUG PRODUCT LIST

6 - 191 (of 324)

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM

ROXANE

10MG/ML

N020315 001

Jul 09, 1993

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN

SOLVAY

0.05MG/ML;2%

A085010 001

CARBOCAINE W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML;2%

N012125 002

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN

GRAHAM CHEM

0.05MG/ML;2%

A084850 002

Oct 21, 1983

POLOCAINE W/ LEVONORDEFRIN

DENTSPLY PHARM

0.05MG/ML;2%

A089517 001

Apr 14, 1988

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML;2%;0.4%

N008592 007

LEVONORGESTREL

IMPLANT; IMPLANTATION

LEVONORGESTREL

WYETH PHARMS INC

75MG/IMPLANT

N020627 001

Aug 15, 1996

NORPLANT

POPULATION COUNCIL

36MG/IMPLANT

N019897 001

Dec 10, 1990

NORPLANT II

POPULATION COUNCIL

75MG/IMPLANT

N020544 001

Nov 01, 1996

NORPLANT SYSTEM IN PLASTIC CONTAINER

WYETH PHARMS INC

36MG/IMPLANT

N020088 001

Dec 10, 1990

TABLET; ORAL

PLAN B

DURAMED

0.75MG

N021045 001

Jul 28, 1999

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

CAPSULE; ORAL

NOVRAD

LILLY

EQ 50MG BASE

N012928 006

EQ 100MG BASE

N012928 004

SUSPENSION; ORAL

NOVRAD

LILLY

EQ 50MG BASE/5ML

N012928 002

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION

LEVO-DROMORAN

VALEANT PHARM INTL

2MG/ML

N008719 001

Dec 19, 1991

LEVOTHYROXINE SODIUM\*\*

CAPSULE; ORAL

TIROSINT

INST BIOCHIMIQUE

0.013MG

N022121 001

Aug 01, 2007

0.025MG

N021924 002

Oct 13, 2006

0.05MG

N021924 003

Oct 13, 2006

0.075MG

N021924 004

Oct 13, 2006

0.1MG

N021924 005

Oct 13, 2006

0.125MG

N021924 006

Oct 13, 2006

0.15MG

N021924 007

Oct 13, 2006

TABLET; ORAL

LEVOLET

VINTAGE

0.025MG

N021137 001

Jun 06, 2003

0.05MG

N021137 002

Jun 06, 2003

0.075MG

N021137 003

Jun 06, 2003

## DISCONTINUED DRUG PRODUCT LIST

6 - 192 (of 324)

LEVOTHYROXINE SODIUM\*\*

TABLET; ORAL				
LEVOLET				
VINTAGE	0.088MG		N021137 004	Jun 06, 2003
	0.1MG		N021137 005	Jun 06, 2003
	0.112MG		N021137 006	Jun 06, 2003
	0.125MG		N021137 007	Jun 06, 2003
	0.137MG		N021137 008	Jun 06, 2003
	0.15MG		N021137 009	Jun 06, 2003
	0.175MG		N021137 010	Jun 06, 2003
	0.2MG		N021137 011	Jun 06, 2003
	0.3MG		N021137 012	Jun 06, 2003
LEVOXYL				
--> KING PHARMS	--> 0.3MG		N021301 012	May 25, 2001
NOVOTHYROX				
MERCK KGAA	0.025MG		N021292 001	May 31, 2002
	0.05MG		N021292 002	May 31, 2002
	0.075MG		N021292 003	May 31, 2002
	0.088MG		N021292 004	May 31, 2002
	0.1MG		N021292 005	May 31, 2002
	0.112MG		N021292 006	May 31, 2002
	0.125MG		N021292 007	May 31, 2002
	0.137MG		N021292 008	May 31, 2002
	0.15MG		N021292 009	May 31, 2002
	0.175MG		N021292 010	May 31, 2002
	0.2MG		N021292 011	May 31, 2002
	0.3MG		N021292 012	May 31, 2002

LIDOCAINE

AEROSOL; ORAL				
XYLOCAINE				
ASTRAZENECA	10%		N014394 001	
FILM, EXTENDED RELEASE; BUCCAL				
DENTIPATCH				
NOVEN	23MG/PATCH		N020575 001	May 21, 1996
OINTMENT; TOPICAL				
ALPHACAINE				
CARLISLE	5%		A084944 001	
	5%		A084946 001	
	5%		A084947 001	
LIDOCAINE				
GRAHAM CHEM	5%		A080210 001	
XYLOCAINE				
ASTRAZENECA	5%		N008048 001	
PATCH; TOPICAL				
DENTIPATCH				
NOVEN	46.1MG/PATCH		N020575 002	May 21, 1996
SOLUTION; TOPICAL				
XYLOCAINE				
ASTRAZENECA	5%		N014127 001	
SUPPOSITORY; RECTAL				
XYLOCAINE				
ASTRAZENECA	100MG		N013077 001	

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
ALPHACAINE HYDROCHLORIDE				
CARLISLE	2%		A084721 001	
LIDOCAINE HYDROCHLORIDE				
ABBOTT	10%		A087980 001	Feb 02, 1983
	20%		A089362 001	May 25, 1988
ABRAXIS PHARM	1%		A080390 001	
	1%		A080420 001	
	1%		A086761 001	
	1.5%		A080420 005	

## DISCONTINUED DRUG PRODUCT LIST

6 - 193 (of 324)

LIDOCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## LIDOCAINE HYDROCHLORIDE

ABRAXIS PHARM	2%	A080390	002	
	2%	A080420	002	
	2%	A080420	004	
	2%	A086761	002	
	2%	N017508	001	
	4%	N017508	002	
	20%	N017508	004	
AKORN	1%	A085037	001	
	2%	A085037	002	
BAXTER HLTHCARE	1%	A080407	001	
	2%	A080407	002	
BEL MAR	1%	A080710	001	
	2%	A080760	001	
DELL LABS	1%	A083387	001	
	2%	A083388	001	
ELKINS SINN	0.5%	A085131	001	
	4%	A084626	001	
GD SEARLE LLC	1%	A083135	001	
	2%	A083135	002	
GRAHAM CHEM	2%	A080504	001	
HOSPIRA	1.5%	A088330	001	May 17, 1984
	2%	A088331	001	May 17, 1984
INTL MEDICATION	1%	N017701	002	
	2%	N017701	001	
	1GM/VIAL	N018543	001	
	2GM/VIAL	N018543	002	
MILES	1%	A080414	001	
	2%	A080414	002	
WATSON LABS	1%	A080377	001	
	1%	A083627	001	
	2%	A080377	002	
	2%	A083627	002	
WYETH AYERST	1%	A083083	001	
	2%	A083083	002	
LIDOCAINE HYDROCHLORIDE	0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	100MG/100ML	N018461	001	
LIDOCAINE HYDROCHLORIDE	0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	200MG/100ML	N018967	001	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE	0.2% IN DEXTROSE 5%			
HOSPIRA	200MG/100ML	A083158	005	
LIDOCAINE HYDROCHLORIDE	0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER			
ABBOTT	200MG/100ML	N018954	001	Jul 09, 1985
HOSPIRA	200MG/100ML	N018388	001	
LIDOCAINE HYDROCHLORIDE	0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	400MG/100ML	N018967	002	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE	0.4% IN DEXTROSE 5%			
HOSPIRA	400MG/100ML	A083158	006	
LIDOCAINE HYDROCHLORIDE	0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	800MG/100ML	N018967	003	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE	IN PLASTIC CONTAINER			
HOSPIRA	1.5%	A088326	001	Jul 31, 1984
	10%	A088367	001	Jul 31, 1984
	20%	A088368	001	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE	PRESERVATIVE FREE			
BAXTER HLTHCARE	1%	A084625	001	
	2%	A084625	002	
INTL MEDICATION	4%	N017702	002	
LIDOCATON				
PHARMATON	2%	A084727	001	Aug 17, 1983
XYLOCAINE				
ASTRAZENECA	1%	N010418	005	

## DISCONTINUED DRUG PRODUCT LIST

6 - 194 (of 324)

LIDOCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## XYLOCAINE

ASTRAZENECA	1.5%	N010418	009	
	2%	N010418	007	

## INJECTABLE; SPINAL

## XYLOCAINE 1.5% W/ DEXTROSE 7.5%

APP PHARMS	1.5%	N016297	001	
------------	------	---------	-----	--

## XYLOCAINE 5% W/ GLUCOSE 7.5%

ASTRAZENECA	5%	N010496	002	Jul 07, 1982
-------------	----	---------	-----	--------------

## SOLUTION; ORAL

## LIDOCAINE HYDROCHLORIDE VISCOUS

INTL MEDICATION	2%	A086389	001	Feb 02, 1982
-----------------	----	---------	-----	--------------

## SOLUTION; TOPICAL

## LARYNGOTRACHEAL ANESTHESIA KIT

KENDALL IL	4%	A087931	001	Jun 10, 1983
------------	----	---------	-----	--------------

## LIDOCAINE HYDROCHLORIDE

PACO	4%	A089688	001	Jun 30, 1989
------	----	---------	-----	--------------

## LTA II KIT

HOSPIRA	4%	A088542	001	Jul 31, 1984
---------	----	---------	-----	--------------

## PEDIATRIC LTA KIT

ABBOTT	2%	A088572	001	Jul 31, 1984
--------	----	---------	-----	--------------

## SYSTEM; INTRADERMAL

## ZINGO

ANESIVA	0.5MG	N022114	001	Aug 16, 2007
---------	-------	---------	-----	--------------

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

## INJECTABLE; INJECTION

## TERRAMYCIN

PFIZER	2%;50MG/ML	A060567	001	
	2%;125MG/ML	A060567	002	

LIDOCAINE; PRILOCAINE

## DISC; TOPICAL

## EMLA

ASTRAZENECA	2.5%;2.5%	N020962	001	Feb 04, 1998
-------------	-----------	---------	-----	--------------

LINCOMYCIN HYDROCHLORIDE

## CAPSULE; ORAL

## LINCOCIN

PHARMACIA AND UPJOHN	EQ 250MG BASE	N050316	001	
	EQ 500MG BASE	N050316	002	

## INJECTABLE; INJECTION

## LINCOMYCIN HYDROCHLORIDE

WATSON LABS	EQ 300MG BASE/ML	A063180	001	Apr 16, 1991
-------------	------------------	---------	-----	--------------

LINDANE

## CREAM; TOPICAL

## KWELL

REED AND CARNRICK	1%	A084218	001	
	1%	N006309	001	

## LOTION; TOPICAL

## GAMENE

SOLA BARNES HIND	1%	A084989	001	
------------------	----	---------	-----	--

## KWELL

REED AND CARNRICK	1%	A084218	002	
	1%	N006309	003	

## LINDANE

OLTA PHARMS	1%	A087313	001	
-------------	----	---------	-----	--

## SCABENE

STIEFEL	1%	A086769	001	
---------	----	---------	-----	--

## SHAMPOO; TOPICAL

## GAMENE

SOLA BARNES HIND	1%	A084988	001	
------------------	----	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 195 (of 324)

LINDANE

SHAMPOO; TOPICAL

KWELL

REED AND CARNRICK

1%

A084219 001

1%

N010718 001

SCABENE

STIEFEL

1%

A087940 001

Apr 08, 1983

LINEZOLID

TABLET; ORAL

ZYVOX

PHARMACIA AND UPJOHN 400MG

N021130 001

Apr 18, 2000

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

WATSON LABS

EQ 0.025MG BASE

A085755 001

Jan 25, 1982

EQ 0.05MG BASE

A085753 001

Feb 03, 1982

LIOTRIX (T4;T3)

TABLET; ORAL

EUTHROID-0.5

PARKE DAVIS

0.03MG;0.0075MG

N016680 001

EUTHROID-1

PARKE DAVIS

0.06MG;0.015MG

N016680 002

EUTHROID-2

PARKE DAVIS

0.12MG;0.03MG

N016680 003

EUTHROID-3

PARKE DAVIS

0.18MG;0.045MG

N016680 004

THYROLAR-5

FOREST LABS

0.25MG;0.0625MG

N016807 006

LISINAPRIL

TABLET; ORAL

PRINIVIL

MERCK

2.5MG

N019558 006

Jan 28, 1994

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

ABLE

150MG

A076823 001

Jun 29, 2004

300MG

A076121 001

Sep 27, 2001

300MG

A076823 002

Jun 29, 2004

600MG

A076823 003

Jun 29, 2004

USL PHARMA

300MG

A072542 001

Feb 01, 1989

WATSON LABS

300MG

A070407 001

Mar 19, 1987

LITHONATE

SOLVAY

300MG

N016782 001

TABLET; ORAL

ESKALITH

JDS PHARMS

300MG

N017971 001

LITHANE

BAYER PHARMS

300MG

N018833 001

Jul 18, 1985

LITHIUM CARBONATE

PFIZER

300MG

N016834 001

LITHOTABS

SOLVAY

300MG

N016980 001

TABLET, EXTENDED RELEASE; ORAL

ESKALITH CR

JDS PHARMS

450MG

N018152 001

Mar 29, 1982

LITHIUM CARBONATE

ABLE

300MG

A076382 001

Apr 21, 2003

BARR

300MG

A076170 001

Jun 10, 2002

450MG

A076366 001

Aug 21, 2003

## DISCONTINUED DRUG PRODUCT LIST

6 - 196 (of 324)

LITHIUM CITRATE

SYRUP; ORAL				
LITHONATE				
SOLVAY	EQ 300MG CARBONATE/5ML	N017672	001	

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL				
MAXAQUIN				
PHARMACIA	EQ 400MG BASE	N020013	001	Feb 21, 1992

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL				
IMODIUM				
MCNEIL PED	2MG	N017690	001	
LOPERAMIDE HYDROCHLORIDE				
ROXANE	2MG	A073080	001	Nov 27, 1991
SANDOZ	2MG	A072993	001	Aug 28, 1992
TEVA	2MG	A073122	001	Aug 30, 1991
SOLUTION; ORAL				
IMODIUM				
JANSSEN PHARMA	1MG/5ML	N019037	001	Jul 31, 1984
LOPERAMIDE HYDROCHLORIDE				
ALPHARMA US PHARMS	1MG/5ML	A073187	001	Sep 15, 1992
DURAMED PHARMS BARR	1MG/5ML	A074991	001	Dec 29, 1997
TEVA	1MG/5ML	A073478	001	Jun 23, 1995
WATSON LABS	1MG/5ML	A073062	001	May 28, 1993
TABLET; ORAL				
LOPERAMIDE HYDROCHLORIDE				
ABLE	2MG	A073528	001	Nov 30, 1993
PERRIGO	2MG	A074194	001	Oct 30, 1992

LORACARBEF

CAPSULE; ORAL				
LORABID				
KING PHARMS	200MG	N050668	001	Dec 31, 1991
	400MG	N050668	002	Apr 05, 1996
FOR SUSPENSION; ORAL				
LORABID				
KING PHARMS	100MG/5ML	N050667	001	Dec 31, 1991
	200MG/5ML	N050667	002	Dec 31, 1991

LORATADINE

SYRUP; ORAL				
CLARITIN HIVES RELIEF				
SCHERING PLOUGH	1MG/ML	N020641	003	Nov 19, 2003
TABLET; ORAL				
LORATADINE				
PERRIGO	10MG	N021512	001	Jun 24, 2004

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL				
CLARITIN-D				
SCHERING PLOUGH	5MG;120MG	N019670	002	Nov 27, 2002

LORAZEPAM

INJECTABLE; INJECTION				
LORAZEPAM				
AKORN	2MG/ML	A074974	001	Jul 23, 1998
BAXTER HLTHCARE	2MG/ML	A074496	001	Sep 28, 1998
	4MG/ML	A074496	002	Sep 28, 1998
DAVA PHARMS INC	2MG/ML	A074793	001	Mar 16, 2000
	4MG/ML	A074793	002	Mar 16, 2000
HOSPIRA	2MG/ML	A074280	001	May 27, 1994
	4MG/ML	A074280	002	May 27, 1994

## DISCONTINUED DRUG PRODUCT LIST

6 - 197 (of 324)

LORAZEPAM

## INJECTABLE; INJECTION

## LORAZEPAM

HOSPIRA	4MG/ML	A074300	003	Mar 19, 1997
MARSAM PHARMS LLC	1MG/0.5ML	A074551	003	Sep 12, 1996
	2MG/ML	A074535	001	Sep 12, 1996
	2MG/ML	A074551	001	Sep 12, 1996
	4MG/ML	A074535	002	Sep 12, 1996
	4MG/ML	A074551	002	Sep 12, 1996
TAYLOR	2MG/ML	A075025	001	Jul 23, 1998

## SOLUTION; ORAL

## LORAZEPAM

ROXANE	0.5MG/5ML	A074648	001	Mar 18, 1997
--------	-----------	---------	-----	--------------

## TABLET; ORAL

## LORAZ

QUANTUM PHARMICS	0.5MG	A070200	001	Aug 09, 1985
	1MG	A070201	001	Aug 09, 1985
	2MG	A070202	001	Aug 09, 1985

## LORAZEPAM

AM THERAP	0.5MG	A070727	001	Mar 07, 1986
	1MG	A070728	001	Mar 07, 1986
	2MG	A070729	001	Mar 07, 1986
HALSEY	0.5MG	A071434	001	Sep 01, 1987
	1MG	A071435	001	Sep 01, 1987
	2MG	A071436	001	Sep 01, 1987
MUTUAL PHARM	0.5MG	A070472	001	Dec 10, 1985
	1MG	A070473	001	Dec 10, 1985
	2MG	A070474	001	Dec 10, 1985
PAR PHARM	0.5MG	A070675	001	Dec 01, 1986
	1MG	A070676	001	Dec 01, 1986
	2MG	A070677	001	Dec 01, 1986
SUPERPHARM	0.5MG	A071245	001	Feb 09, 1987
	1MG	A071246	001	Feb 09, 1987
	2MG	A071247	001	Feb 09, 1987
USL PHARMA	1MG	A070539	001	Dec 22, 1986
	2MG	A070540	001	Dec 22, 1986
WARNER CHILCOTT	1MG	A071038	001	Jan 12, 1988
	2MG	A071039	001	Jan 12, 1988
WATSON LABS	0.5MG	A071086	001	Mar 23, 1987
	0.5MG	A071117	001	Jul 24, 1986
	1MG	A071087	001	Mar 23, 1987
	2MG	A071088	001	Mar 23, 1987
	2MG	A071110	001	Jul 24, 1986

LOTEPREDNOL ETABONATE

## SUSPENSION/DROPS; OPHTHALMIC

## LOTEMAX

PHARMOS	0.5%	N020841	001	Mar 09, 1998
---------	------	---------	-----	--------------

LOVASTATIN

## TABLET; ORAL

## MEVACOR

MERCK	10MG	N019643	002	Mar 28, 1991
-------	------	---------	-----	--------------

## TABLET, EXTENDED RELEASE; ORAL

## ALTOPREV

ANDRX LABS LLC	10MG	N021316	001	Jun 26, 2002
----------------	------	---------	-----	--------------

LOXAPINE HYDROCHLORIDE

## CONCENTRATE; ORAL

## LOXITANE C

WATSON LABS	EQ 25MG BASE/ML	N017658	001	
-------------	-----------------	---------	-----	--

## INJECTABLE; INJECTION

## LOXITANE IM

WATSON LABS	EQ 50MG BASE/ML	N018039	001	
-------------	-----------------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 198 (of 324)

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

ACTAVIS TOTOWA

EQ 5MG BASE  
EQ 10MG BASE  
EQ 25MG BASE  
EQ 50MG BASEA076868 001 Aug 04, 2005  
A076868 002 Aug 04, 2005  
A076868 003 Aug 04, 2005  
A076868 004 Aug 04, 2005

LOXITANE

WATSON LABS

EQ 5MG BASE  
EQ 10MG BASE  
EQ 25MG BASE  
EQ 50MG BASEN017525 001  
N017525 002  
N017525 003  
N017525 004

TABLET; ORAL

LOXITANE

WATSON LABS

EQ 10MG BASE  
EQ 25MG BASE  
EQ 50MG BASEN017525 006  
N017525 007  
N017525 008LYPRESSIN

SOLUTION; NASAL

DIAPID

NOVARTIS

0.185MG/ML

N016755 001

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN

30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML

N019006 001 Apr 04, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN

30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML

N018252 001

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA

14MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML

N018406 001

SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE

30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML

N019326 001 Jan 25, 1985

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

GE HEALTHCARE

37.9MG/ML

N020652 001 Nov 26, 1997

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL

LUMENHANCE

BRACCO

3.49MG/GM

N020686 001 Dec 19, 1997

MANGANESE SULFATE

INJECTABLE; INJECTION

MANGANESE SULFATE

ABRAXIS PHARM

EQ 0.1MG MANGANESE/ML

N019228 001 May 05, 1987

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

HOSPIRA

10GM/100ML

N016269 002

MILES

10GM/100ML

N016472 002



## DISCONTINUED DRUG PRODUCT LIST

6 - 199 (of 324)

MANNITOL

## INJECTABLE; INJECTION

## MANNITOL 15%

HOSPIRA	15GM/100ML	N016269	003	
MILES	15GM/100ML	N016472	005	

## MANNITOL 20%

HOSPIRA	20GM/100ML	N016269	004	
MILES	20GM/100ML	N016472	004	

## MANNITOL 25%

ABRAXIS PHARM	12.5GM/50ML	A086754	001	
ASTRAZENECA	12.5GM/50ML	A089239	001	May 06, 1987
	12.5GM/50ML	A089240	001	May 06, 1987
HOSPIRA	12.5GM/50ML	N016269	005	
MERCK	12.5GM/50ML	N005620	001	
WATSON LABS	12.5GM/50ML	A087460	001	Jun 27, 1983

## MANNITOL 5%

HOSPIRA	5GM/100ML	N016269	001	
---------	-----------	---------	-----	--

## SOLUTION; IRRIGATION

## RESECTISOL

B BRAUN	5GM/100ML	N016704	002	
---------	-----------	---------	-----	--

MANNITOL; SORBITOL

## SOLUTION; IRRIGATION

## SORBITOL-MANNITOL

HOSPIRA	540MG/100ML; 2.7GM/100ML	A080224	001	
---------	--------------------------	---------	-----	--

## SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA	540MG/100ML; 2.7GM/100ML	N017636	001	
---------	--------------------------	---------	-----	--

MAPROTILINE HYDROCHLORIDE

## TABLET; ORAL

## LUDIOMIL

NOVARTIS	25MG	N017543	001	
	50MG	N017543	002	
	75MG	N017543	003	Sep 30, 1982

## MAPROTILINE HYDROCHLORIDE

AM THERAP	25MG	A072129	001	Jan 14, 1988
	50MG	A072130	001	Jan 14, 1988
	75MG	A072131	001	Jan 14, 1988
WATSON LABS	25MG	A071943	001	Dec 30, 1987
	25MG	A072162	001	Jun 01, 1988
	50MG	A071944	001	Dec 30, 1987
	50MG	A072163	001	Jun 01, 1988
	75MG	A071945	001	Dec 30, 1987
	75MG	A072164	001	Jun 01, 1988

MASOPROCOL

## CREAM; TOPICAL

## ACTINEX

UNIV AZ CANCER CTR	10%	N019940	001	Sep 04, 1992
--------------------	-----	---------	-----	--------------

MAZINDOL

## TABLET; ORAL

## MAZANOR

WYETH AYERST	1MG	N017980	002	
	2MG	N017980	001	

## SANOREX

NOVARTIS	1MG	N017247	001	
	2MG	N017247	002	

MEBENDAZOLE

## TABLET, CHEWABLE; ORAL

## VERMOX

MCNEIL PED	100MG	N017481	001	
------------	-------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 200 (of 324)

MEBUTAMATE

TABLET; ORAL

DORMATE

MEDPOINTE PHARM HLC 600MG N017374 001

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

INVERSINE

TARGACEPT 2.5MG N010251 001

MECASERMIN RINFABATE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPLEX

INSMED 36MG/0.6ML N021884 001 Dec 12, 2005

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

PFIZER 50MG N010721 001 Jan 20, 1982

MECLIZINE HYDROCHLORIDE

ABC HOLDING 12.5MG A085253 001

25MG A085252 001

ANABOLIC 25MG A085891 001

BUNDY 12.5MG A084382 001

25MG A084872 001

IVAX SUB TEVA PHARMS 12.5MG A083784 001

12.5MG A084975 001

25MG A084657 001

KV PHARM 12.5MG A085524 001

25MG A085523 001

PLIVA 12.5MG A088732 001 Dec 11, 1985

25MG A088734 001 Dec 11, 1985

SUPERPHARM 12.5MG A089113 001 Aug 20, 1985

25MG A089114 001 Aug 20, 1985

UDL 12.5MG A088256 001 Jun 13, 1983

25MG A088257 001 Jun 13, 1983

VANGARD 12.5MG A087877 001 Apr 20, 1982

25MG A087620 001 Jan 04, 1982

WATSON LABS 12.5MG A085195 001

12.5MG A085269 001

TABLET, CHEWABLE; ORAL

ANTIVERT

PFIZER 25MG N010721 005

MECLIZINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS 25MG A084976 001

NEXGEN PHARMA INC 25MG A086392 001

PLIVA 25MG A088733 001 Dec 11, 1985

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL

MECLAN

JOHNSON AND JOHNSON 1% N050518 001

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLODIUM

QUANTUM PHARMICS EQ 50MG BASE A071380 001 Jul 14, 1987

EQ 100MG BASE A071381 001 Jul 14, 1987

MECLOFENAMATE SODIUM

AM THERAP EQ 50MG BASE A071362 001 Feb 10, 1987

EQ 100MG BASE A071363 001 Feb 10, 1987

BARR EQ 50MG BASE A072848 001 Mar 20, 1989

EQ 100MG BASE A072809 001 Mar 20, 1989

PAR PHARM EQ 50MG BASE A072077 001 Mar 10, 1988

## DISCONTINUED DRUG PRODUCT LIST

6 - 201 (of 324)

MECLOFENAMATE SODIUM

## CAPSULE; ORAL

## MECLOFENAMATE SODIUM

PAR PHARM	EQ 100MG BASE	A072078	001	Mar 10, 1988
SANDOZ	EQ 50MG BASE	A072262	001	Nov 29, 1988
	EQ 100MG BASE	A072263	001	Nov 29, 1988
USL PHARMA	EQ 50MG BASE	A071007	001	Mar 25, 1988
	EQ 100MG BASE	A071008	001	Mar 25, 1988
VITARINE	EQ 50MG BASE	A071710	001	Jun 15, 1988
	EQ 100MG BASE	A071684	001	Jun 15, 1988
WATSON LABS	EQ 50MG BASE	A070400	001	Nov 25, 1986
	EQ 50MG BASE	A071640	001	Aug 11, 1987
	EQ 100MG BASE	A070401	001	Nov 25, 1986
	EQ 100MG BASE	A071641	001	Aug 11, 1987
MECLOMEN				
PARKE DAVIS	EQ 50MG BASE	N018006	001	
	EQ 100MG BASE	N018006	002	

MEDROXYPROGESTERONE ACETATE

## INJECTABLE; INJECTION

## DEPO-PROVERA

PHARMACIA AND UPJOHN	100MG/ML	N012541	002	
----------------------	----------	---------	-----	--

## TABLET; ORAL

## AMEN

AMARIN PHARMS	10MG	A083242	001	
---------------	------	---------	-----	--

## CURRETAB

SOLVAY	10MG	A085686	001	
--------	------	---------	-----	--

## CYCRIN

ESI	2.5MG	A081239	001	Oct 30, 1992
	5MG	A081240	001	Oct 30, 1992
	10MG	A089386	001	Sep 09, 1987

## MEDROXYPROGESTERONE ACETATE

DURAMED PHARMS BARR	2.5MG	A040311	001	Dec 01, 1999
	5MG	A040311	002	Dec 01, 1999
	10MG	A040311	003	Dec 01, 1999

MEDRYSONE

## SUSPENSION; OPHTHALMIC

## HMS

ALLERGAN	1%	N016624	003	
----------	----	---------	-----	--

MEFLOQUINE HYDROCHLORIDE

## TABLET; ORAL

## LARIAM

ROCHE	250MG	N019591	001	May 02, 1989
-------	-------	---------	-----	--------------

## MEFLOQUINE HYDROCHLORIDE

US ARMY WALTER REED	250MG	N019578	001	May 02, 1989
---------------------	-------	---------	-----	--------------

MEGESTROL ACETATE

## TABLET; ORAL

## MEGESTROL ACETATE

TEVA	40MG	A074745	001	Feb 27, 1998
USL PHARMA	20MG	A070646	001	Oct 02, 1987
	40MG	A070647	001	Oct 02, 1987

MELOXICAM

## TABLET; ORAL

## MELOXICAM

MUTUAL PHARM	7.5MG	A077935	001	Jul 19, 2006
	15MG	A077935	002	Jul 19, 2006
ROXANE	7.5MG	A077925	001	Jul 19, 2006
	15MG	A077925	002	Jul 19, 2006

## DISCONTINUED DRUG PRODUCT LIST

6 - 202 (of 324)

MENADIOL SODIUM DIPHOSPHATE

## INJECTABLE; INJECTION

## KAPPADIONE

LILLY 10MG/ML N005725 001

## SYNKAYVITE

ROCHE 5MG/ML N003718 004

10MG/ML N003718 006

37.5MG/ML N003718 008

## TABLET; ORAL

## SYNKAYVITE

ROCHE 5MG N003718 010

MENADIONE

## TABLET; ORAL

## MENADIONE

LILLY 5MG N002139 003

MENOTROPINS (FSH;LH)

## INJECTABLE; INJECTION

## HUMEGON

ORGANON USA INC 75 IU/VIAL;75 IU/VIAL N020328 001 Sep 01, 1994

150 IU/VIAL;150 IU/VIAL N020328 002 Sep 01, 1994

## MENOTROPINS

FERRING 75 IU/VIAL;75 IU/VIAL A073598 001 Jan 30, 1997

150 IU/VIAL;150 IU/VIAL A073599 001 Jan 30, 1997

## PERGONAL

SERONO 75 IU/AMP;75 IU/AMP N017646 001

150 IU/AMP;150 IU/AMP N017646 002 May 20, 1985

## REPRONEX

FERRING 150 IU/VIAL;150 IU/VIAL N021047 002 Aug 27, 1999

MEPENZOLATE BROMIDE

## SOLUTION; ORAL

## CANTIL

SANOFI AVENTIS US 25MG/5ML N010679 004

MEPERIDINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## DEMEROL

SANOFI AVENTIS US 25MG/ML N005010 007

50MG/ML N005010 002

75MG/ML N005010 009

100MG/ML N005010 003

## MEPERIDINE HYDROCHLORIDE

ABBOTT 25MG/ML A080388 001

50MG/ML A080385 001

50MG/ML A080387 001

75MG/ML A080389 001

100MG/ML A080386 001

ASTRAZENECA 25MG/ML A089781 001 Mar 31, 1989

50MG/ML A089782 001 Mar 31, 1989

50MG/ML A089783 001 Mar 31, 1989

50MG/ML A089784 001 Mar 31, 1989

75MG/ML A089785 001 Mar 31, 1989

100MG/ML A089786 001 Mar 31, 1989

100MG/ML A089787 001 Mar 31, 1989

100MG/ML A089788 001 Mar 31, 1989

BAXTER HLTHCARE 25MG/ML A088279 001 Jun 15, 1984

50MG/ML A088280 001 Jun 15, 1984

75MG/ML A088281 001 Jun 15, 1984

100MG/ML A088282 001 Jun 15, 1984

INTL MEDICATION 10MG/ML A086332 001

PARKE DAVIS 50MG/ML A080364 002

75MG/ML A080364 003

## DISCONTINUED DRUG PRODUCT LIST

6 - 203 (of 324)

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

PARKE DAVIS 100MG/ML

A080364 001

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

HOSPIRA 10MG/ML

A040305 001

Mar 10, 1999

MALLINCKRODT 10MG/ML

A040163 001

May 12, 1997

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

DURAMED PHARMS BARR 50MG

A040318 001

Oct 05, 1999

100MG

A040318 002

Oct 05, 1999

MUTUAL PHARM 50MG

A080448 001

100MG

A080448 002

WYETH AYERST 50MG

A080454 001

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

BAXTER HLTHCARE CORP 25MG/ML; 25MG/ML

N011730 001

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

BAXTER HLTHCARE CORP EQ 15MG BASE/ML

N008248 002

EQ 30MG BASE/ML

N008248 001

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

NOVARTIS 100MG

N006008 001

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE

SOLVAY 3%

A084777 002

Apr 18, 1982

CARBOCAINE

EASTMAN KODAK 3%

N012125 003

MEPIVACAINE HYDROCHLORIDE

GRAHAM CHEM 3%

A083559 001

INTL MEDICATION 1%

A087509 001

Oct 05, 1982

MEPREDNISONE

TABLET; ORAL

BETAPAR

SCHERING 4MG

N016053 002

MEPROBAMATE

CAPSULE; ORAL

EQUANIL

WYETH AYERST 400MG

N012455 002

CAPSULE, EXTENDED RELEASE; ORAL

MEPROSPAN

MEDPOINTE PHARM HLC 200MG

N011284 001

400MG

N011284 002

TABLET; ORAL

AMOSENE

FERNDAL LABS 400MG

A084030 001

BAMATE

ALRA 200MG

A080380 001

400MG

A080380 002

EQUANIL

WYETH AYERST 200MG

N010028 005

400MG

N010028 004

## DISCONTINUED DRUG PRODUCT LIST

6 - 204 (of 324)

MEPROBAMATE

TABLET; ORAL

MEPRIAM

TEVA 400MG

N016069 001

MEPROBAMATE

BARR 600MG

A084230 001

ELKINS SINN 200MG

N015426 002

400MG

N015426 001

HEATHER 400MG

N016928 003

600MG

A084329 001

IMPAX LABS 200MG

N014322 002

400MG

N014322 001

IVAX SUB TEVA PHARMS 200MG

N015438 001

400MG

N015438 002

600MG

A084181 001

IVC INDS 400MG

A084153 001

LANNETT 200MG

N014882 002

400MG

N014882 001

LEDERLE 400MG

A086299 001

LEE KM 400MG

A089538 001

Nov 25, 1987

MALLARD 400MG

N015072 002

MK LABS 200MG

N014368 004

400MG

N014368 002

MUTUAL PHARM 200MG

A080699 001

400MG

A080699 002

MYLAN 400MG

A083618 001

NEXGEN PHARMA INC 200MG

A084220 001

400MG

A084589 001

PARKE DAVIS 200MG

A084744 001

400MG

A084744 002

PERRIGO 200MG

A084546 001

400MG

A084547 001

PHARMAVITE 400MG

A084438 001

PUREPAC PHARM 200MG

A084804 001

400MG

A084804 002

PVT FORM 400MG

N014601 001

ROXANE 600MG

A084332 001

SANDOZ 200MG

N014547 002

400MG

A080655 001

400MG

N014547 001

SCHERER LABS 400MG

A083343 001

SOLVAY 200MG

A084435 001

STANLABS PHARM 200MG

N014474 002

400MG

N014474 004

TABLICAPS 400MG

A083494 001

USL PHARMA 200MG

A087825 001

Mar 18, 1982

400MG

A087826 001

Mar 18, 1982

VALEANT PHARM INTL 200MG

N015139 006

400MG

N015139 005

VANGARD 400MG

A088011 001

Jul 14, 1982

WATSON LABS 200MG

A085720 001

400MG

A085721 001

600MG

A084274 001

600MG

A085719 001

WEST WARD 200MG

N015417 003

400MG

N015417 002

WHITEWORTH TOWN PLSN 200MG

A083830 001

400MG

A083442 001

MILTOWN

MEDPOINTE PHARM HLC 200MG

N009698 004

400MG

N009698 002

600MG

A083919 001

NEURAMATE

HALSEY 200MG

N014359 002

## DISCONTINUED DRUG PRODUCT LIST

6 - 205 (of 324)

MEPROBAMATE

TABLET; ORAL			
NEURAMATE			
HALSEY	400MG	N014359	001
TRANMEP			
SOLVAY	400MG	A084369	001
	400MG	N016249	001

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION			
MERSALYL-THEOPHYLLINE			
WATSON LABS	100MG/ML;50MG/ML	A084875	001

MESALAMINE

SUPPOSITORY; RECTAL			
CANASA			
AXCAN SCANDIPHARM	500MG	N021252	001 Jan 05, 2001
ROWASA			
ALAVEN PHARM	500MG	N019919	001 Dec 18, 1990

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL			
SERENTIL			
NOVARTIS	EQ 25MG BASE/ML	N016997	001
INJECTABLE; INJECTION			
SERENTIL			
NOVARTIS	EQ 25MG BASE/ML	N016775	001
TABLET; ORAL			
SERENTIL			
NOVARTIS	EQ 10MG BASE	N016774	001
	EQ 25MG BASE	N016774	002
	EQ 50MG BASE	N016774	003
	EQ 100MG BASE	N016774	004

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20			
NORINYL			
WATSON LABS	0.1MG;2MG	N013625	004
TABLET; ORAL-21			
NORETHIN 1/50M-21			
WATSON LABS	0.05MG;1MG	A071539	001 Apr 12, 1988
NORETHINDRONE AND MESTRANOL			
WATSON LABS	0.05MG;1MG	A070758	001 Jul 01, 1988
NORINYL 1+50 21-DAY			
WATSON LABS	0.05MG;1MG	N013625	002
NORINYL 1+80 21-DAY			
GD SEARLE LLC	0.08MG;1MG	N016724	001
ORTHO-NOVUM 1/50 21			
ORTHO MCNEIL PHARM	0.05MG;1MG	N012728	004
ORTHO-NOVUM 1/80 21			
ORTHO MCNEIL PHARM	0.08MG;1MG	N016715	001
ORTHO-NOVUM 10-21			
ORTHO MCNEIL PHARM	0.06MG;10MG	N012728	001
ORTHO-NOVUM 2-21			
ORTHO MCNEIL PHARM	0.1MG;2MG	N012728	005
TABLET; ORAL-28			
NORETHIN 1/50M-28			
WATSON LABS	0.05MG;1MG	A071540	001 Apr 12, 1988
NORETHINDRONE AND MESTRANOL			
WATSON LABS	0.05MG;1MG	A070759	001 Jul 01, 1988
NORINYL 1+80 28-DAY			
GD SEARLE LLC	0.08MG;1MG	N016725	001
ORTHO-NOVUM 1/50 28			
ORTHO MCNEIL JANSSEN	0.05MG;1MG	N016709	001

## DISCONTINUED DRUG PRODUCT LIST

6 - 206 (of 324)

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28				
ORTHO-NOVUM 1/80 28				
ORTHO MCNEIL PHARM	0.08MG;1MG		N016715	002

MESTRANOL; NORETHYNODREL

TABLET; ORAL				
ENOVID				
GD SEARLE LLC	0.075MG;5MG		N010976	008
	0.15MG;9.85MG		N010976	005
TABLET; ORAL-20				
ENOVID				
GD SEARLE LLC	0.075MG;5MG		N010976	004
ENOVID-E				
GD SEARLE LLC	0.1MG;2.5MG		N010976	006
TABLET; ORAL-21				
ENOVID-E 21				
GD SEARLE LLC	0.1MG;2.5MG		N010976	007

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION				
ALUPENT				
BOEHRINGER INGELHEIM	0.65MG/INH		N016402	001
SOLUTION; INHALATION				
ALUPENT				
BOEHRINGER INGELHEIM	0.4%		N018761	002
	0.6%		N018761	001
	5%		N017659	001
METAPROTERENOL SULFATE				
ASTRAZENECA	0.4%		A071275	001
	0.6%		A071018	001
DEY	0.33%		A071806	001
	0.5%		A071805	001
	5%		A070805	001
MORTON GROVE	5%		A072190	001
PROMETA				
MURO	5%		A073340	001
SYRUP; ORAL				
ALUPENT				
BOEHRINGER INGELHEIM	10MG/5ML		N017571	001
METAPROTERENOL SULFATE				
MORTON GROVE	10MG/5ML		A071656	001
	10MG/5ML		A074702	001
TEVA	10MG/5ML		A072761	001
TEVA PHARMS	10MG/5ML		A073034	001
PROMETA				
MURO	10MG/5ML		A072023	001
TABLET; ORAL				
ALUPENT				
BOEHRINGER INGELHEIM	10MG		N015874	002
	20MG		N015874	001
METAPROTERENOL SULFATE				
AM THERAP	10MG		A072054	001
	20MG		A072055	001
TEVA	10MG		A072519	001
	20MG		A072520	001
USL PHARMA	10MG		A071013	001
	20MG		A071014	001

METARAMINOL BITARTRATE

INJECTABLE; INJECTION				
ARAMINE				
MERCK	EQ 10MG BASE/ML		N009509	002
				Dec 22, 1987



## DISCONTINUED DRUG PRODUCT LIST

6 - 207 (of 324)

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

ABRAXIS PHARM	EQ 10MG BASE/ML	A080431	001	
ELKINS SINN	EQ 10MG BASE/ML	A083363	001	
GD SEARLE LLC	EQ 10MG BASE/ML	A086418	001	
	EQ 20MG BASE/ML	A086418	002	

METAXALONE

TABLET; ORAL

SKELAXIN

KING PHARMS	400MG	N013217	001	
-------------	-------	---------	-----	--

METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOPHAGE

BRISTOL MYERS SQUIBB	625MG	N020357	003	Nov 05, 1998
	750MG	N020357	004	Nov 05, 1998

METFORMIN HYDROCHLORIDE

BARR	500MG	A075971	001	Jan 25, 2002
	850MG	A075971	002	Jan 25, 2002
	1GM	A075971	003	Jan 25, 2002
TEVA	500MG	A076328	001	Dec 16, 2002
	850MG	A076328	002	Dec 16, 2002
	1GM	A076328	003	Dec 16, 2002

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

BARR	500MG	A076496	001	Nov 25, 2005
MUTUAL PHARM	500MG	A077124	001	Dec 21, 2005
SANDOZ	500MG	A076223	001	Dec 14, 2004

METHACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC	EQ 140MG BASE	A060641	001	
	EQ 280MG BASE	A060641	002	

SYRUP; ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML	A060641	003	
---------------------	------------------	---------	-----	--

METHADONE HYDROCHLORIDE

SYRUP; ORAL

DOLOPHINE HYDROCHLORIDE

ROXANE	10MG/30ML	N006134	004	
--------	-----------	---------	-----	--

TABLET; ORAL

METHADONE HYDROCHLORIDE

ROXANE	5MG	A088108	001	Mar 08, 1983
	10MG	A088109	001	Mar 08, 1983
	40MG	A074081	001	Apr 28, 1995
SANDOZ	5MG	A040241	001	May 29, 1998

TABLET, DISPERSIBLE; ORAL

WESTADONE

SANDOZ	2.5MG	N017108	001	
--------	-------	---------	-----	--

TABLET, EFFERVESCENT; ORAL

WESTADONE

SANDOZ	5MG	N017108	002	
	10MG	N017108	003	
	40MG	N017108	004	

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

METHAMPEX

TEVA	10MG	A083889	001	
------	------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 208 (of 324)

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

METHAMPHETAMINE HYDROCHLORIDE

ABLE 5MG A040529 001 Feb 25, 2004

REXAR 5MG A084931 001

10MG A084931 002

TEVA 5MG A086359 001

TABLET, EXTENDED RELEASE; ORAL

DESOXYN

LUNDBECK INC 5MG N005378 004

10MG N005378 003

15MG N005378 005

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

SHIRE 50MG N007390 001

METHARBITAL

TABLET; ORAL

GEMONIL

ABBOTT 100MG N008322 001

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

APPLIED ANAL 25MG A040011 001 Jul 17, 1997

50MG A040011 002 Jul 17, 1997

SANDOZ 25MG A040102 001 Aug 28, 1996

50MG A040102 002 Aug 28, 1996

NEPTAZANE

LEDERLE 25MG N011721 002 Nov 25, 1991

50MG N011721 001

METHDILAZINE

TABLET, CHEWABLE; ORAL

TACARYL

WESTWOOD SQUIBB 3.6MG N011950 009

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL

METHDILAZINE HYDROCHLORIDE

ALPHARMA US PHARMS 4MG/5ML A087122 001

TACARYL

WESTWOOD SQUIBB 4MG/5ML N011950 007

TABLET; ORAL

TACARYL

WESTWOOD SQUIBB 8MG N011950 006

METHICILLIN SODIUM

INJECTABLE; INJECTION

STAPHICILLIN

APOTHECON EQ 900MG BASE/VIAL A061449 001

EQ 900MG BASE/VIAL N050117 001

EQ 3.6GM BASE/VIAL A061449 002

EQ 3.6GM BASE/VIAL N050117 002

EQ 5.4GM BASE/VIAL A061449 003

EQ 5.4GM BASE/VIAL N050117 003

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

CEDAR PHARMS 15MG A040619 003 Jul 12, 2005

20MG A040547 004 Feb 18, 2005

## DISCONTINUED DRUG PRODUCT LIST

6 - 209 (of 324)

METHIMAZOLETABLET; ORAL  
METHIMAZOLE

MYLAN 20MG A040350 003 Jun 07, 2001

TAPAZOLE

KING PHARMS 5MG N007517 002

10MG N007517 004

METHIXENE HYDROCHLORIDETABLET; ORAL  
TREST

NOVARTIS 1MG N013420 001

METHOCARBAMOLINJECTABLE; INJECTION  
METHOCARBAMOL

MARSAM PHARMS LLC 100MG/ML A089849 001 Dec 27, 1991

TABLET; ORAL  
DELAXIN

FERNDALE LABS 500MG A085454 001

FORBAXIN

FOREST LABS 750MG A085136 001

METHOCARBAMOL

ABLE 500MG A040413 001 Mar 17, 2003

750MG A040413 002 Mar 17, 2003

AM THERAP 500MG A089417 001 Feb 11, 1987

750MG A089418 001 Feb 11, 1987

ASCOT 500MG A087660 001 Oct 27, 1982

750MG A087661 001 Oct 27, 1982

CLONMEL HLTHCARE 500MG A085961 001

750MG A085963 001

HEATHER 500MG A084675 001

750MG A084924 001

IMPAX LABS 500MG A084927 001

750MG A084928 001

INWOOD LABS 500MG A085137 001

IVAX SUB TEVA PHARMS 500MG A084648 001

750MG A084649 001

KV PHARM 500MG A085660 001

750MG A085658 001

MUTUAL PHARM 500MG A084488 001

750MG A084486 001

MYLAN 500MG A084259 001

750MG A084323 001

NYLOS 750MG A085033 001

PHARMERAL 500MG A084231 002

750MG A084471 001

PIONEER PHARMS 500MG A088731 001 Dec 13, 1985

750MG A089082 001 Dec 13, 1985

PUREPAC PHARM 500MG A085718 001

750MG A085718 002

ROXANE 500MG A088646 001 Feb 29, 1984

750MG A088647 001 Feb 29, 1984

SANDOZ 500MG A087283 001

750MG A087282 001

SOLCO HLTHCARE 500MG A086989 001

750MG A086988 001

SOLVAY 500MG A084448 001

750MG A084449 001

SUPERPHARM 500MG A087589 001 Jan 22, 1982

750MG A087590 001 Jan 22, 1982

TABLICAPS 500MG A084846 001

UPSHER SMITH 500MG A087453 001

750MG A087454 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 210 (of 324)

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

WATSON LABS

500MG

A083605 001

750MG

A083605 002

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

JHP PHARMS

5GM/VIAL

N011559 003

METHOTREXATE SODIUM

INJECTABLE; INJECTION

ABITREXATE

ABIC

EQ 25MG BASE/ML

A089161 001

Mar 10, 1987

EQ 50MG BASE/VIAL

A089354 001

Jul 17, 1987

EQ 100MG BASE/VIAL

A089355 001

Jul 17, 1987

EQ 250MG BASE/VIAL

A089356 001

Jul 17, 1987

FOLEX

PHARMACIA AND UPJOHN

EQ 25MG BASE/VIAL

A087695 001

Apr 08, 1983

EQ 50MG BASE/VIAL

A087695 002

Apr 08, 1983

EQ 100MG BASE/VIAL

A087695 003

Apr 08, 1983

EQ 250MG BASE/VIAL

A088954 001

Oct 24, 1985

FOLEX PFS

PHARMACIA AND UPJOHN

EQ 25MG BASE/ML

A081242 001

Aug 23, 1991

EQ 25MG BASE/ML

A089180 001

Jan 03, 1986

METHOTREXATE LPF

HOSPIRA

EQ 25MG BASE/ML

N011719 007

Mar 31, 1982

METHOTREXATE PRESERVATIVE FREE

APP PHARMS

EQ 25MG BASE/ML

A040265 001

Feb 26, 1999

EQ 1GM BASE/VIAL

A040266 001

Feb 26, 1999

HOSPIRA

EQ 20MG BASE/2ML (EQ 10MG BASE/ML)

N011719 014

Apr 13, 2005

EQ 500MG BASE/20ML (EQ 25MG BASE/ML)

N011719 013

Apr 13, 2005

EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)

N011719 011

Apr 13, 2005

METHOTREXATE SODIUM

ABRAXIS PHARM

EQ 2.5MG BASE/ML

A089323 001

Jun 13, 1986

EQ 20MG BASE/VIAL

A088935 001

Oct 11, 1985

EQ 25MG BASE/ML

A089263 001

Jun 13, 1986

EQ 25MG BASE/ML

A089322 001

Jun 13, 1986

EQ 50MG BASE/VIAL

A088936 001

Oct 11, 1985

EQ 100MG BASE/VIAL

A088937 001

Oct 11, 1985

HOSPIRA

EQ 2.5MG BASE/ML

N011719 004

EQ 20MG BASE/VIAL

N011719 001

EQ 25MG BASE/ML

N011719 005

EQ 50MG BASE/VIAL

N011719 003

EQ 100MG BASE/VIAL

N011719 006

NORBROOK

EQ 25MG BASE/ML

A088648 001

May 09, 1986

PHARMACHEMIE USA

EQ 25MG BASE/ML

A089158 001

Jul 08, 1988

METHOTREXATE SODIUM PRESERVATIVE FREE

HOSPIRA

EQ 1GM BASE/VIAL

N011719 009

Apr 07, 1988

MEXATE

BRISTOL

EQ 20MG BASE/VIAL

A086358 001

EQ 50MG BASE/VIAL

A086358 002

EQ 100MG BASE/VIAL

A086358 003

EQ 250MG BASE/VIAL

A086358 004

MEXATE-AQ

BRISTOL MYERS

EQ 25MG BASE/ML

A088760 001

Feb 14, 1985

MEXATE-AQ PRESERVED

BRISTOL MYERS SQUIBB

EQ 25MG BASE/ML

A089887 001

Apr 14, 1989

TABLET; ORAL

METHOTREXATE SODIUM

DURAMED PHARMS BARR

EQ 2.5MG BASE

A040233 001

Jun 17, 1999

## DISCONTINUED DRUG PRODUCT LIST

6 - 211 (of 324)

METHOXAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

VASOXYL

GLAXOSMITHKLINE	10MG/ML	N006772	002	
	20MG/ML	N006772	001	

METHOXSALEN

CAPSULE; ORAL

METHOXSALEN

SANDOZ	10MG	A087781	001	Jun 08, 1982
--------	------	---------	-----	--------------

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

PVT FORM	2.5MG	A080970	001	
----------	-------	---------	-----	--

METHYCLOTHIAZIDE

TABLET; ORAL

AQUATENSEN

MEDPOINTE PHARM HLC	5MG	N017364	001	
---------------------	-----	---------	-----	--

METHYCLOTHIAZIDE

IVAX PHARMS	2.5MG	A087913	001	Jun 03, 1982
-------------	-------	---------	-----	--------------

	5MG	A087786	001	May 18, 1982
--	-----	---------	-----	--------------

MYLAN	2.5MG	A087671	001	Aug 17, 1982
-------	-------	---------	-----	--------------

PAR PHARM	2.5MG	A089135	001	Feb 12, 1986
-----------	-------	---------	-----	--------------

	5MG	A089136	001	Feb 12, 1986
--	-----	---------	-----	--------------

SANDOZ	2.5MG	A089835	001	Aug 18, 1988
--------	-------	---------	-----	--------------

	5MG	A089837	001	Aug 18, 1988
--	-----	---------	-----	--------------

USL PHARMA	5MG	A088745	001	Mar 21, 1985
------------	-----	---------	-----	--------------

WATSON LABS	2.5MG	A085487	001	Mar 11, 1982
-------------	-------	---------	-----	--------------

	2.5MG	A088750	001	Sep 06, 1984
--	-------	---------	-----	--------------

	5MG	A085476	001	Mar 11, 1982
--	-----	---------	-----	--------------

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTRON

ABBOTT	5MG;25MG	N016047	001	
--------	----------	---------	-----	--

METHYCLOTHIAZIDE; RESERPINE

TABLET; ORAL

DIUTENSEN-R

MEDPOINTE PHARM HLC	2.5MG;0.1MG	N012708	005	
---------------------	-------------	---------	-----	--

METHYLDOPA

SUSPENSION; ORAL

ALDOMET

MERCK	250MG/5ML	N018389	001	
-------	-----------	---------	-----	--

TABLET; ORAL

ALDOMET

MERCK	125MG	N013400	003	
-------	-------	---------	-----	--

	250MG	N013400	001	
--	-------	---------	-----	--

	500MG	N013400	002	
--	-------	---------	-----	--

METHYLDOPA

ACCORD HLTH	125MG	A070070	003	Oct 15, 1985
-------------	-------	---------	-----	--------------

DURAMED PHARMS BARR	250MG	A071006	001	Dec 16, 1986
---------------------	-------	---------	-----	--------------

	500MG	A071009	001	Dec 16, 1986
--	-------	---------	-----	--------------

HALSEY	125MG	A071751	001	Mar 28, 1988
--------	-------	---------	-----	--------------

	250MG	A071752	001	Mar 28, 1988
--	-------	---------	-----	--------------

	500MG	A071753	001	Mar 28, 1988
--	-------	---------	-----	--------------

MUTUAL PHARM	125MG	A070073	001	Oct 09, 1986
--------------	-------	---------	-----	--------------

	250MG	A070060	001	Oct 09, 1986
--	-------	---------	-----	--------------

	500MG	A070074	001	Oct 09, 1986
--	-------	---------	-----	--------------

PAR PHARM	125MG	A070535	001	Jan 02, 1987
-----------	-------	---------	-----	--------------

	250MG	A070536	001	Jan 02, 1987
--	-------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 212 (of 324)

METHYLDOPA

TABLET; ORAL

METHYLDOPA

PAR PHARM	500MG	A070537	001	Jan 02, 1987
PARKE DAVIS	125MG	A070331	001	Apr 15, 1986
	250MG	A070332	001	Apr 15, 1986
	500MG	A070333	001	Apr 15, 1986
PLIVA	125MG	A072126	001	Jul 07, 1988
	250MG	A072127	001	Jul 07, 1988
	500MG	A072128	001	Jul 07, 1988
PUREPAC PHARM	125MG	A070749	001	Feb 07, 1986
	250MG	A070750	001	Feb 07, 1986
	500MG	A070452	001	Feb 07, 1986
ROXANE	125MG	A070192	001	Apr 25, 1986
	250MG	A070193	001	Apr 25, 1986
	500MG	A070194	001	Apr 25, 1986
SANDOZ	125MG	A071700	001	Mar 02, 1988
	250MG	N018934	001	Jun 29, 1984
	500MG	N018934	002	Jun 29, 1984
SUPERPHARM	250MG	A070669	001	Jun 23, 1989
	500MG	A070670	001	Jun 23, 1989
TEVA	125MG	A071105	001	Dec 05, 1986
	250MG	A071106	001	Dec 05, 1986
	500MG	A071067	001	Dec 05, 1986
WATSON LABS	125MG	A070245	001	Feb 25, 1986
	125MG	A070260	001	Jun 24, 1985
	250MG	A070246	001	Feb 25, 1986
	250MG	A070261	001	Jun 24, 1985
	250MG	A070703	001	Jun 06, 1986
	500MG	A070247	001	Feb 25, 1986
	500MG	A070262	001	Jun 24, 1985

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

ALDOMET

MERCK 50MG/ML

N013401 001

METHYLDOPATE HYDROCHLORIDE

ABRAXIS PHARM 50MG/ML

A070652 001 Jun 03, 1986

BAXTER HLTHCARE 50MG/ML

A070291 001 Jul 01, 1986

HOSPIRA 50MG/ML

A070691 001 Jun 19, 1987

50MG/ML

A070698 001 Jun 15, 1987

50MG/ML

A070699 001 Jun 15, 1987

50MG/ML

A070849 001 Jun 19, 1987

MARSAM PHARMS LLC 50MG/ML

A071812 001 Dec 22, 1987

SMITH AND NEPHEW 50MG/ML

A070841 001 Jan 02, 1987

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

ABLE 5MG

A040404 001 Mar 29, 2001

10MG

A040404 002 Mar 29, 2001

20MG

A040404 003 Mar 29, 2001

TABLET, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

ABLE 20MG

A076032 001 May 09, 2001

METHYLPREDNISOLONE

TABLET; ORAL

MEDROL

PHARMACIA AND UPJOHN 2MG

N011153 002

24MG

N011153 005

METHYLPREDNISOLONE

HEATHER 4MG

A085650 001

PAR PHARM 16MG

A089207 001 Apr 25, 1988

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 654 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 213 (of 324)

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

PAR PHARM	24MG	A089208	001	Apr 25, 1988
	32MG	A089209	001	Apr 25, 1988
SANDOZ	4MG	A087341	001	
WATSON LABS	4MG	A086161	001	Feb 09, 1982
	16MG	A086159	001	Feb 09, 1982

METHYLPREDNISOLONE ACETATE

ENEMA; RECTAL

MEDROL

PHARMACIA AND UPJOHN	40MG/BOT	N018102	001	
----------------------	----------	---------	-----	--

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AKORN	40MG/ML	A086903	001	Oct 20, 1982
	80MG/ML	A086903	002	Oct 20, 1982
WATSON LABS	20MG/ML	A085597	001	
	20MG/ML	A087248	001	
	40MG/ML	A085374	001	
	40MG/ML	A085600	001	
	80MG/ML	A085595	001	
	80MG/ML	A086507	001	
M-PREDROL				
BEL MAR	40MG/ML	A086666	001	
	80MG/ML	A087135	001	

OINTMENT; TOPICAL

MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%	N012421	001	
	1%	N012421	002	

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	A060611	002	
	1%;EQ 3.5MG BASE/GM	A060611	001	

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

ABBOTT	EQ 40MG BASE/VIAL	A089573	001	Feb 22, 1991
	EQ 125MG BASE/VIAL	A089574	001	Feb 22, 1991
	EQ 500MG BASE/VIAL	A089575	001	Feb 22, 1991
	EQ 1GM BASE/VIAL	A089576	001	Feb 22, 1991
HOSPIRA	EQ 40MG BASE/VIAL	A085853	001	
	EQ 125MG BASE/VIAL	A085855	001	
	EQ 500MG BASE/VIAL	A085854	001	
	EQ 1GM BASE/VIAL	A085852	001	

METHYLPREDNISOLONE

ELKINS SINN	EQ 125MG BASE/VIAL	A086906	002	
	EQ 500MG BASE/VIAL	A086906	003	
	EQ 1GM BASE/VIAL	A086906	004	
ORGANON USA INC	EQ 500MG BASE/VIAL	A087535	001	Jun 25, 1982
	EQ 1GM BASE/VIAL	A087535	002	Jun 25, 1982

METHYLPREDNISOLONE SODIUM SUCCINATE

ABRAXIS PHARM	EQ 40MG BASE/VIAL	A088676	001	Jun 08, 1984
	EQ 40MG BASE/VIAL	A089143	001	Mar 28, 1986
	EQ 125MG BASE/VIAL	A088677	001	Jun 08, 1984
	EQ 125MG BASE/VIAL	A089144	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A088678	001	Jun 08, 1984
	EQ 500MG BASE/VIAL	A089186	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A089187	001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A088679	001	Jun 08, 1984
	EQ 1GM BASE/VIAL	A089188	001	Mar 28, 1986

## DISCONTINUED DRUG PRODUCT LIST

6 - 214 (of 324)

METHYLPREDNISOLONE SODIUM SUCCINATE

## INJECTABLE; INJECTION

## METHYLPREDNISOLONE SODIUM SUCCINATE

ABRAXIS PHARM	EQ 1GM BASE/VIAL	A089189	001	Mar 28, 1986
ELKINS SINN	EQ 40MG BASE/VIAL	A086906	001	
INTL MEDICATION	EQ 40MG BASE/VIAL	A087812	001	Feb 09, 1983
	EQ 125MG BASE/VIAL	A087813	001	Feb 09, 1983
	EQ 500MG BASE/VIAL	A087851	001	Feb 09, 1983
	EQ 1GM BASE/VIAL	A087852	001	Feb 09, 1983
TEVA PARENTERAL	EQ 500MG BASE/VIAL	A081267	001	Nov 30, 1992
	EQ 1GM BASE/VIAL	A081268	001	Nov 30, 1992
WATSON LABS	EQ 40MG BASE/VIAL	A086953	001	Jul 22, 1982
	EQ 125MG BASE/VIAL	A087030	001	Jul 22, 1982
	EQ 500MG BASE/VIAL	A088523	001	Jul 24, 1984
	EQ 1GM BASE/VIAL	A088524	001	Jul 24, 1984

METHYLPREDNISOLONE; NEOMYCIN SULFATE

## OINTMENT; OPHTHALMIC

## NEO-MEDROL

PHARMACIA AND UPJOHN	0.1%;EQ 3.5MG BASE/GM	A060645	001	
----------------------	-----------------------	---------	-----	--

METHYLTESTOSTERONE

## CAPSULE; ORAL

## METHYLTESTOSTERONE

HEATHER	10MG	A084967	001	
---------	------	---------	-----	--

## VIRILON

STAR PHARMS FL	10MG	A087750	001	Nov 24, 1982
----------------	------	---------	-----	--------------

## TABLET; BUCCAL

## ANDROID 5

VALEANT PHARM INTL	5MG	A087222	001	
--------------------	-----	---------	-----	--

## ORETON

SCHERING	10MG	A080281	001	
----------	------	---------	-----	--

## TABLET; BUCCAL/SUBLINGUAL

## METANDREN

NOVARTIS	5MG	N003240	004	
----------	-----	---------	-----	--

	10MG	N003240	005	
--	------	---------	-----	--

## METHYLTESTOSTERONE

IMPAX LABS	10MG	A084287	001	
------------	------	---------	-----	--

LILLY	10MG	A080256	001	
-------	------	---------	-----	--

PUREPAC PHARM	10MG	A080308	001	
---------------	------	---------	-----	--

	10MG	A080475	001	
--	------	---------	-----	--

PVT FORM	5MG	A083836	001	
----------	-----	---------	-----	--

TABLICAPS	10MG	A085125	001	
-----------	------	---------	-----	--

USL PHARMA	10MG	A080271	001	
------------	------	---------	-----	--

## TABLET; ORAL

## METANDREN

NOVARTIS	10MG	N003240	001	
----------	------	---------	-----	--

	25MG	N003240	003	
--	------	---------	-----	--

## METHYLTESTOSTERONE

INWOOD LABS	10MG	A080839	001	
-------------	------	---------	-----	--

	25MG	A080973	001	
--	------	---------	-----	--

KV PHARM	10MG	A084312	001	
----------	------	---------	-----	--

LANNETT	10MG	A087092	001	Nov 05, 1982
---------	------	---------	-----	--------------

	25MG	A087111	001	Jan 27, 1983
--	------	---------	-----	--------------

LILLY	25MG	A080256	002	
-------	------	---------	-----	--

PARKE DAVIS	10MG	A084244	001	
-------------	------	---------	-----	--

	25MG	A084241	001	
--	------	---------	-----	--

PUREPAC PHARM	10MG	A080309	001	
---------------	------	---------	-----	--

	10MG	A080475	002	
--	------	---------	-----	--

	25MG	A080310	001	
--	------	---------	-----	--

	25MG	A080475	003	
--	------	---------	-----	--

PVT FORM	5MG	A080214	001	
----------	-----	---------	-----	--

	10MG	A080214	002	
--	------	---------	-----	--

	25MG	A080214	003	
--	------	---------	-----	--



## DISCONTINUED DRUG PRODUCT LIST

6 - 215 (of 324)

METHYLTESTOSTERONE

TABLET; ORAL

METHYLTESTOSTERONE

TABLICAPS	10MG	A080313	001
	25MG	A085270	001
WATSON LABS	10MG	A080933	001
	25MG	A080931	001
WEST WARD	10MG	A084331	001
	25MG	A084331	002
	25MG	A084642	001
ORETON METHYL			
SCHERING	10MG	N003158	001
	25MG	N003158	002

METHYPRYLON

CAPSULE; ORAL

NOLUDAR

ROCHE	300MG	N009660	008
-------	-------	---------	-----

ELIXIR; ORAL

NOLUDAR

ROCHE	50MG/5ML	N009660	007
-------	----------	---------	-----

TABLET; ORAL

NOLUDAR

ROCHE	50MG	N009660	002
	200MG	N009660	004

METHYSERGIDE MALEATE

TABLET; ORAL

SANSERT

NOVARTIS	2MG	N012516	001
----------	-----	---------	-----

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL

METOCLOPRAMIDE INTENSOL

ROXANE	EQ 10MG BASE/ML	A072995	001	Jan 30, 1992
--------	-----------------	---------	-----	--------------

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

ABRAXIS PHARM	EQ 10MG BASE/2ML	A070293	001	Jan 24, 1986
BEDFORD	EQ 5MG BASE/ML	A072155	001	Mar 30, 1992
	EQ 5MG BASE/ML	A072244	001	Mar 30, 1992
	EQ 5MG BASE/ML	A072247	001	May 18, 1992
HOSPIRA	EQ 5MG BASE/ML	A070505	001	Jun 23, 1989
	EQ 5MG BASE/ML	A070506	001	Jun 22, 1989
	EQ 5MG BASE/ML	A070847	001	Nov 07, 1988
	EQ 5MG BASE/ML	A071291	001	Mar 03, 1989
	EQ 5MG BASE/ML	A071990	001	Jan 18, 1989
NORBROOK	EQ 10MG BASE/2ML	A070892	001	Aug 26, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070623	001	Mar 02, 1987
	EQ 10MG BASE/2ML	A070622	001	Mar 02, 1987

REGLAN

BAXTER HLTHCARE CORP	EQ 10MG BASE/ML	N017862	004	May 28, 1987
----------------------	-----------------	---------	-----	--------------

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 5MG BASE/5ML	A071340	001	Aug 18, 1988
MORTON GROVE	EQ 5MG BASE/5ML	A070949	001	Mar 06, 1987
PACO	EQ 5MG BASE/5ML	A071665	001	Dec 05, 1988
ROXANE	EQ 5MG BASE/5ML	A072038	001	Dec 05, 1988
TEVA	EQ 5MG BASE/5ML	A070819	001	Jul 10, 1987
	EQ 5MG BASE/5ML	A071315	001	Jun 30, 1993

REGLAN

ROBINS AH	EQ 5MG BASE/5ML	N018821	001	Mar 25, 1983
-----------	-----------------	---------	-----	--------------

TABLET; ORAL

CLOPRA

QUANTUM PHARMICS	EQ 5MG BASE	A072384	001	Jun 02, 1988
------------------	-------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 216 (of 324)

METOCLOPRAMIDE HYDROCHLORIDE

## TABLET; ORAL

## CLOPRA

QUANTUM PHARMICS	EQ 10MG BASE	A070294	001	Jul 29, 1985
CLOPRA-"YELLOW"				
QUANTUM PHARMICS	EQ 10MG BASE	A070632	001	Oct 28, 1985
MAXOLON				
KING PHARMS	EQ 10MG BASE	A070106	001	Mar 04, 1986
METOCLOPRAMIDE HYDROCHLORIDE				
AMNEAL PHARMS NY	EQ 10MG BASE	A071213	001	Sep 24, 1986
CLONMEL HLTHCARE	EQ 10MG BASE	A072639	001	May 09, 1991
HALSEY	EQ 10MG BASE	A070906	001	Oct 28, 1986
MUTUAL PHARM	EQ 10MG BASE	A070660	001	Feb 10, 1987
	EQ 10MG BASE	A071536	001	Apr 28, 1993
PAR PHARM	EQ 10MG BASE	A070342	001	Mar 25, 1986
SANDOZ	EQ 5MG BASE	A072436	001	Jun 22, 1989
	EQ 5MG BASE	A074478	001	Oct 05, 1995
	EQ 10MG BASE	A070850	001	Feb 03, 1987
	EQ 10MG BASE	A072215	001	Jan 30, 1990
SCHERING	EQ 10MG BASE	A070598	001	Feb 02, 1987
SUPERPHARM	EQ 10MG BASE	A070926	001	Jun 26, 1987
USL PHARMA	EQ 10MG BASE	A070339	001	Jul 29, 1985
WATSON LABS	EQ 10MG BASE	A070363	001	Mar 02, 1987
	EQ 10MG BASE	A070453	001	Jun 06, 1986
	EQ 10MG BASE	A070645	001	May 11, 1987

## TABLET, ORALLY DISINTEGRATING; ORAL

## REGLAN ODT

ALAVEN PHARM	EQ 5MG BASE	N021793	001	Jun 10, 2005
	EQ 10MG BASE	N021793	002	Jun 10, 2005

METOCURINE IODIDE

## INJECTABLE; INJECTION

## METUBINE IODIDE

LILLY	2MG/ML	N006632	003	
-------	--------	---------	-----	--

METOLAZONE

## TABLET; ORAL

## DIULO

GD SEARLE LLC	2.5MG	N018535	001	
	5MG	N018535	002	
	10MG	N018535	003	
METOLAZONE				
ROXANE	10MG	A076482	002	Apr 29, 2004
WATSON LABS	10MG	A076891	001	Jul 21, 2004
MYKROX				
UCB INC	0.5MG	N019532	001	Oct 30, 1987

METOPROLOL FUMARATE

## TABLET, EXTENDED RELEASE; ORAL

## LOPRESSOR

NOVARTIS	EQ 100MG TARTRATE	N019786	001	Dec 27, 1989
	EQ 200MG TARTRATE	N019786	002	Dec 27, 1989
	EQ 300MG TARTRATE	N019786	003	Dec 27, 1989
	EQ 400MG TARTRATE	N019786	004	Dec 27, 1989

METOPROLOL TARTRATE

## TABLET; ORAL

## METOPROLOL TARTRATE

APOTHECON	50MG	A074258	001	Jan 27, 1994
	100MG	A074258	002	Jan 27, 1994
MYLAN	50MG	A073666	001	Dec 21, 1993
	100MG	A073666	002	Dec 21, 1993
PUREPAC PHARM	50MG	A074380	001	Jul 29, 1994
	100MG	A074380	002	Jul 29, 1994

## DISCONTINUED DRUG PRODUCT LIST

6 - 217 (of 324)

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

SOLCO HLTHCARE	50MG	A074453	001	Apr 27, 1995
	100MG	A074453	002	Apr 27, 1995
TEVA	50MG	A074143	001	Sep 30, 1994
	100MG	A074143	002	Sep 30, 1994
TEVA PHARMS	50MG	A074333	001	Jan 27, 1994
	100MG	A074333	002	Jan 27, 1994

METRIZAMIDE

INJECTABLE; INJECTION

AMIPAQUE

GE HEALTHCARE	2.5GM/VIAL	N017982	003	Sep 12, 1983
	3.75GM/VIAL	N017982	001	
	6.75GM/VIAL	N017982	002	
	13.5GM/VIAL	N017982	004	Sep 12, 1983

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

ABLE	375MG	A076505	001	Nov 13, 2003
------	-------	---------	-----	--------------

INJECTABLE; INJECTION

METRO I.V.

B BRAUN	500MG/100ML	N018674	001	Aug 31, 1982
---------	-------------	---------	-----	--------------

METRONIDAZOLE

ABBOTT	500MG/100ML	N018889	001	Nov 18, 1983
ABRAXIS PHARM	500MG/100ML	A070071	001	Dec 03, 1984
ELKINS SINN	500MG/100ML	N018907	001	Mar 30, 1984
INTL MEDICATION	500MG/100ML	A070004	001	May 08, 1985
WATSON LABS	500MG/100ML	A070042	001	Dec 20, 1984
	500MG/100ML	A070170	001	Apr 01, 1986

TABLET; ORAL

METROMIDOL

LABS AF	250MG	A074523	001	Oct 24, 1996
	500MG	A074523	002	Oct 24, 1996

METRONIDAZOLE

ABLE	250MG	A076519	001	Jun 27, 2003
	500MG	A076519	002	Jun 27, 2003
HALSEY	250MG	A070021	001	Apr 02, 1985
	500MG	A070593	001	Feb 27, 1986
LNK	250MG	N019029	001	Apr 10, 1984
MUTUAL PHARM	250MG	N018818	001	Feb 16, 1983
	500MG	N018818	002	Feb 16, 1983
PAR PHARM	250MG	A070040	001	Jan 29, 1985
	250MG	N018845	001	Aug 18, 1983
	500MG	A070039	001	Jan 29, 1985
	500MG	N018930	001	Aug 18, 1983
SANDOZ	250MG	N018740	001	Oct 22, 1982
	500MG	N018740	002	Oct 22, 1982
SUPERPHARM	250MG	A070008	001	Dec 11, 1984
	500MG	A070009	001	Dec 11, 1984
WATSON LABS	250MG	N018599	001	Sep 17, 1982
	500MG	N018599	002	Feb 13, 1984

PROTOSTAT

ORTHO MCNEIL PHARM	250MG	N018871	001	Mar 02, 1983
	500MG	N018871	002	Mar 02, 1983

SATRIC

SAVAGE LABS	250MG	A070029	001	Mar 19, 1985
	500MG	A070731	001	Jun 08, 1987

TABLET, EXTENDED RELEASE; ORAL

METRONIDAZOLE

ABLE	750MG	A076462	001	Jun 25, 2003
------	-------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 218 (of 324)

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

METRONIDAZOLE HYDROCHLORIDE

ABRAXIS PHARM	EQ 500MG BASE/VIAL	A070295	001	Oct 15, 1985
---------------	--------------------	---------	-----	--------------

METYRAPONE

TABLET; ORAL

METOPIRONE

NOVARTIS	250MG	N012911	001	
----------	-------	---------	-----	--

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

SANDOZ	150MG	A074450	001	May 16, 1996
	200MG	A074450	002	May 16, 1996
	250MG	A074450	003	May 16, 1996

MEXITIL

BOEHRINGER INGELHEIM	150MG	N018873	002	Dec 30, 1985
	200MG	N018873	003	Dec 30, 1985
	250MG	N018873	004	Dec 30, 1985

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

BAYER PHARMS	EQ 1GM BASE/VIAL	A062333	001	
	EQ 1GM BASE/VIAL	A062372	005	Jan 13, 1983
	EQ 1GM BASE/VIAL	N050549	001	
	EQ 2GM BASE/VIAL	A062333	002	
	EQ 2GM BASE/VIAL	A062372	001	May 13, 1982
	EQ 2GM BASE/VIAL	N050549	002	
	EQ 3GM BASE/VIAL	A062333	003	
	EQ 3GM BASE/VIAL	A062372	002	May 13, 1982
	EQ 3GM BASE/VIAL	A062697	001	Jan 22, 1987
	EQ 3GM BASE/VIAL	N050549	003	
	EQ 4GM BASE/VIAL	A062333	004	
	EQ 4GM BASE/VIAL	A062372	003	May 13, 1982
	EQ 4GM BASE/VIAL	A062697	002	Jan 22, 1987
	EQ 4GM BASE/VIAL	N050549	004	
	EQ 20GM BASE/VIAL	A062372	004	Mar 02, 1988
	EQ 20GM BASE/VIAL	N050549	005	Mar 02, 1988

MICONAZOLE

INJECTABLE; INJECTION

MONISTAT

JANSSEN PHARMA	10MG/ML	N018040	001	
----------------	---------	---------	-----	--

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

ORTHONEUTROGENA	2%	N017494	001	
-----------------	----	---------	-----	--

CREAM; VAGINAL

MICONAZOLE NITRATE

TEVA	2%	A074136	001	Jan 04, 1995
TEVA PHARMS	2%	A074030	001	Oct 30, 1992

LOTION; TOPICAL

MONISTAT-DERM

JOHNSON AND JOHNSON	2%	N017739	001	
---------------------	----	---------	-----	--

TAMPON; VAGINAL

MONISTAT 5

PERSONAL PRODS	100MG	N018592	001	Oct 27, 1989
----------------	-------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 219 (of 324)

MIDAZOLAM HYDROCHLORIDE

## INJECTABLE; INJECTION

## MIDAZOLAM HYDROCHLORIDE

APOTHECON	EQ 1MG BASE/ML	A075620	001	Nov 01, 2000
	EQ 5MG BASE/ML	A075620	002	Nov 01, 2000
	EQ 5MG BASE/ML	A075641	001	Oct 19, 2000
ASTRAZENECA	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000
BEDFORD	EQ 5MG BASE/ML	A075249	001	Jun 23, 2000
BEN VENUE	EQ 5MG BASE/ML	A075455	001	Jun 20, 2000
HOSPIRA	EQ 1MG BASE/ML	A075396	001	Jun 20, 2000
	EQ 5MG BASE/ML	A075396	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075409	001	Jun 20, 2000
	EQ 5MG BASE/ML	A075484	001	Jun 20, 2000
VERSED				
HLR	EQ 1MG BASE/ML	N018654	002	May 26, 1987
	EQ 5MG BASE/ML	N018654	001	Dec 20, 1985

## SYRUP; ORAL

## VERSED

ROCHE	EQ 2MG BASE/ML	N020942	001	Oct 15, 1998
-------	----------------	---------	-----	--------------

MILRINONE LACTATE

## INJECTABLE; INJECTION

## MILRINONE LACTATE

BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075852	001	May 28, 2002
BIONICHE PHARMA	EQ 1MG BASE/ML	A076428	001	Jun 16, 2003
HOSPIRA	EQ 1MG BASE/ML	A075830	001	May 28, 2002

## MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002
	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076259	001	Aug 08, 2002

## PRIMACOR

SANOFI AVENTIS US	EQ 1MG BASE/ML	N019436	001	Dec 31, 1987
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER				
SANOFI AVENTIS US	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994
	EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994

MINOCYCLINE HYDROCHLORIDE

## CAPSULE; ORAL

## DYNACIN

MEDICIS	EQ 50MG BASE	A063066	001	Aug 14, 1990
---------	--------------	---------	-----	--------------

## MINOCIN

TRIAx PHARMS	EQ 50MG BASE	N050315	002	
	EQ 100MG BASE	N050315	001	
TRIAx PHARMS LLC	EQ 75MG BASE	N050649	003	Feb 12, 2001

## INJECTABLE; INJECTION

## MINOCIN

LEDERLE	EQ 100MG BASE/VIAL	A062139	001	
---------	--------------------	---------	-----	--

## SUSPENSION; ORAL

## MINOCIN

TRIAx PHARMS	EQ 50MG BASE/5ML	N050445	001	
--------------	------------------	---------	-----	--

## TABLET; ORAL

## MINOCYCLINE HYDROCHLORIDE

TRIAx PHARMS	EQ 50MG BASE	N050451	003	Aug 10, 1982
	EQ 100MG BASE	N050451	002	Aug 10, 1982

MINOXIDIL

## SOLUTION; TOPICAL

## MINOXIDIL (FOR MEN)

COPLEY PHARM	2%	A074500	001	May 23, 1996
TEVA	2%	A074589	001	Apr 05, 1996
MINOXIDIL EXTRA STRENGTH (FOR MEN)				
TEVA	5%	A075619	001	Nov 17, 2000

## TABLET; ORAL

## LONITEN

PHARMACIA AND UPJOHN	2.5MG	N018154	001	
----------------------	-------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 220 (of 324)

MINOXIDIL

TABLET; ORAL

LONITEN

PHARMACIA AND UPJOHN 10MG

N018154 003

MINODYL

QUANTUM PHARMICS 2.5MG

A072153 001 Jul 13, 1988

10MG

A071534 001 Mar 19, 1987

MINOXIDIL

ROYCE LABS 2.5MG

A071799 001 Nov 10, 1987

10MG

A071796 001 Nov 10, 1987

USL PHARMA 2.5MG

A071537 001 Dec 16, 1988

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

IVAX SUB TEVA PHARMS 15MG

A076244 001 Dec 22, 2003

30MG

A076244 002 Dec 22, 2003

45MG

A076244 003 Dec 22, 2003

ROXANE 15MG

A076270 001 Jun 19, 2003

30MG

A076270 002 Jun 19, 2003

45MG

A076270 003 Jun 19, 2003

SANDOZ 15MG

A076189 001 Jun 19, 2003

30MG

A076189 002 Jun 19, 2003

45MG

A076189 003 Jun 19, 2003

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

HOSPIRA 20MG/VIAL

A064106 001 Nov 29, 1995

MITOZYTREX

SUPERGEN 5MG/VIAL

N050763 001 Nov 14, 2002

MUTAMYCIN

BRISTOL 5MG/VIAL

N050450 001

20MG/VIAL

N050450 002

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVANTRONE

EMD SERONO EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)

N019297 002 Dec 23, 1987

EQ 30MG BASE/15ML (EQ 2MG BASE/ML)

N019297 003 Dec 23, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACRON

ABBOTT EQ 2MG BASE/ML

N020098 001 Jan 22, 1992

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT EQ 0.5MG BASE/ML

N020098 002 Jan 22, 1992

EQ 50MG BASE/100ML

N020098 003 Jan 22, 1992

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL

MOBAN

ENDO PHARMS 5MG

N017111 001

10MG

N017111 002

25MG

N017111 003

CONCENTRATE; ORAL

MOBAN

ENDO PHARMS 20MG/ML

N017938 001

TABLET; ORAL

MOBAN

ENDO PHARMS 100MG

N017111 008

## DISCONTINUED DRUG PRODUCT LIST

6 - 221 (of 324)

MONOBENZONECREAM; TOPICAL  
BENOQUIN

VALEANT PHARM INTL 20% N008173 003

MONOCTANOINLIQUID; PERFUSION, BILIARY  
MOCTANIN

ETHITEK 100% N019368 001 Oct 29, 1985

MORICIZINE HYDROCHLORIDETABLET; ORAL  
ETHMOZINESHIRE 200MG N019753 001 Jun 19, 1990  
250MG N019753 002 Jun 19, 1990  
300MG N019753 003 Jun 19, 1990MORPHINE SULFATEINJECTABLE; INJECTION  
MORPHINE SULFATEHOSPIRA 0.5MG/ML N019917 001 Oct 30, 1992  
MALLINCKRODT 1MG/ML N020631 001 Jul 03, 1996  
2MG/ML N020631 002 Jul 03, 1996

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

PACIRA PHARMS INC 20MG/2ML (10MG/ML) N021671 003 May 18, 2004

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB GENERICS 15MG A074862 001 Jul 07, 1998  
30MG A074862 002 Jul 07, 1998  
60MG A074862 003 Jul 07, 1998  
100MG A074769 001 Jul 02, 1998  
200MG A074769 002 Jul 02, 1998  
CLONMEL HLTHCARE 15MG A075407 001 Jan 28, 2000MOXALACTAM DISODIUM

INJECTABLE; INJECTION

MOXAM

LILLY EQ 250MG BASE/VIAL N050550 001  
EQ 500MG BASE/VIAL N050550 002  
EQ 1GM BASE/VIAL N050550 003  
EQ 2GM BASE/VIAL N050550 004  
EQ 10GM BASE/VIAL N050550 008NABUMETONE

TABLET; ORAL

NABUMETONE

COPLLEY PHARM 750MG A075179 001 Jun 06, 2000  
SANDOZ 500MG A075590 001 Feb 25, 2002  
750MG A075590 002 Feb 25, 2002

RELAFEN

SMITHKLINE BEECHAM 500MG N019583 001 Dec 24, 1991  
750MG N019583 002 Dec 24, 1991NADOLOL

TABLET; ORAL

CORCARD

KING PHARMS 120MG N018063 003  
160MG N018063 004

NADOLOL

IVAX SUB TEVA PHARMS 120MG A074255 002 Jan 24, 1996  
160MG A074255 003 Jan 24, 1996  
TEVA PHARMS 80MG A074368 001 Aug 31, 1994  
120MG A074368 002 Aug 31, 1994

## DISCONTINUED DRUG PRODUCT LIST

6 - 222 (of 324)

NADOLOL

TABLET; ORAL

NADOLOL

TEVA PHARMS

160MG

A074368 003

Aug 31, 1994

NAFCILLIN SODIUM

CAPSULE; ORAL

UNIPEN

WYETH AYERST

EQ 250MG BASE

N050111 001

FOR SOLUTION; ORAL

UNIPEN

WYETH AYERST

EQ 250MG BASE/5ML

N050199 001

INJECTABLE; INJECTION

NAFCILLIN SODIUM

APOTHECON

EQ 500MG BASE/VIAL

A061984 001

EQ 1GM BASE/VIAL

A061984 002

EQ 2GM BASE/VIAL

A061984 003

EQ 4GM BASE/VIAL

A061984 005

MARSAM PHARMS LLC

EQ 500MG BASE/VIAL

A062844 001

Oct 26, 1988

EQ 1GM BASE/VIAL

A062844 002

Oct 26, 1988

EQ 1.5GM BASE/VIAL

A062844 003

Oct 26, 1988

EQ 2GM BASE/VIAL

A062844 004

Oct 26, 1988

EQ 4GM BASE/VIAL

A062844 005

Oct 26, 1988

EQ 10GM BASE/VIAL

A063008 001

Sep 29, 1988

SANDOZ

EQ 500MG BASE/VIAL

A062527 001

Aug 02, 1984

NALLPEN

GLAXOSMITHKLINE

EQ 500MG BASE/VIAL

A061999 001

EQ 1GM BASE/VIAL

A061999 002

EQ 1GM BASE/VIAL

A062755 001

Dec 19, 1986

EQ 2GM BASE/VIAL

A061999 003

EQ 2GM BASE/VIAL

A062755 002

Dec 19, 1986

EQ 10GM BASE/VIAL

A061999 004

UNIPEN

WYETH AYERST

EQ 500MG BASE/VIAL

A062717 001

Dec 16, 1986

EQ 500MG BASE/VIAL

N050320 001

EQ 1GM BASE/VIAL

A062717 002

Dec 16, 1986

EQ 2GM BASE/VIAL

A062717 004

Dec 16, 1986

EQ 2GM BASE/VIAL

N050320 003

EQ 4GM BASE/VIAL

N050320 004

EQ 10GM BASE/VIAL

N050320 005

EQ 20GM BASE/VIAL

N050320 006

UNIPEN IN PLASTIC CONTAINER

WYETH AYERST

EQ 1GM BASE/VIAL

N050320 002

TABLET; ORAL

UNIPEN

WYETH AYERST

EQ 500MG BASE

N050462 001

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE

ABRAXIS PHARM

10MG/ML

A070751 001

Jul 02, 1986

20MG/ML

A070752 001

Sep 24, 1986

NALBUPHINE HYDROCHLORIDE

ABBOTT

1.5MG/ML

N020200 001

Mar 12, 1993

20MG/ML

A070917 001

Feb 03, 1989

ASTRAZENECA

10MG/ML

A072070 001

Apr 10, 1989

10MG/ML

A072071 001

Apr 10, 1989

10MG/ML

A072072 001

Apr 10, 1989

20MG/ML

A072073 001

Apr 10, 1989

20MG/ML

A072074 001

Apr 10, 1989

20MG/ML

A072075 001

Apr 10, 1989

BARR

10MG/ML

A074471 001

Mar 19, 1998

20MG/ML

A074471 002

Mar 19, 1998



## DISCONTINUED DRUG PRODUCT LIST

6 - 223 (of 324)

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NUBAIN

ENDO PHARMS	10MG/ML	N018024	001	
	20MG/ML	N018024	002	May 27, 1982

NALIDIXIC ACID

SUSPENSION; ORAL

NEGGRAM

SANOFI AVENTIS US	250MG/5ML	N017430	001	
-------------------	-----------	---------	-----	--

TABLET; ORAL

NALIDIXIC ACID

MUTUAL PHARM	250MG	A070270	001	Jun 29, 1988
	500MG	A070271	001	Jun 29, 1988
	1GM	A070272	001	Jun 29, 1988
WATSON LABS	250MG	A071936	001	Jun 29, 1988
	500MG	A072061	001	Jun 29, 1988
	1GM	A071919	001	Jun 29, 1988

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX

BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995
	EQ 1MG BASE/ML	N020459	002	Apr 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

BAXTER HLTHCARE	0.4MG/ML	A070298	001	Sep 24, 1986
	0.4MG/ML	A070299	001	Sep 24, 1986
	0.4MG/ML	A070496	001	Sep 24, 1986
WYETH AYERST	0.02MG/ML	A070188	001	Sep 24, 1986
	0.02MG/ML	A070189	001	Sep 24, 1986
	0.4MG/ML	A070190	001	Sep 24, 1986
	0.4MG/ML	A070191	001	Sep 24, 1986

NALOXONE HYDROCHLORIDE

ABRAXIS PHARM	0.02MG/ML	A070648	001	Nov 17, 1986
	0.02MG/ML	A070661	001	Nov 17, 1986
	0.4MG/ML	A070649	001	Nov 17, 1986
	1MG/ML	A071604	001	Dec 16, 1988
ASTRAZENECA	0.02MG/ML	A072081	001	Apr 11, 1989
	0.02MG/ML	A072082	001	Apr 11, 1989
	0.02MG/ML	A072083	001	Apr 11, 1989
	0.02MG/ML	A072084	001	Apr 11, 1989
	0.02MG/ML	A072085	001	Apr 11, 1989
	0.4MG/ML	A072086	001	Apr 11, 1989
	0.4MG/ML	A072087	001	Apr 11, 1989
	0.4MG/ML	A072088	001	Apr 11, 1989
	0.4MG/ML	A072089	001	Apr 11, 1989
	0.4MG/ML	A072090	001	Apr 11, 1989
	1MG/ML	A072091	001	Apr 11, 1989
	1MG/ML	A072092	001	Apr 11, 1989
	1MG/ML	A072093	001	Apr 11, 1989
BAXTER HLTHCARE	0.02MG/ML	A071272	001	May 24, 1988
	1MG/ML	A071273	001	May 24, 1988
	1MG/ML	A071274	001	May 24, 1988
	1MG/ML	A071287	001	May 24, 1988
HOSPIRA	0.02MG/ML	A070171	001	Sep 24, 1986
	0.02MG/ML	A070252	001	Jan 16, 1987
	0.02MG/ML	A070253	001	Jan 16, 1987
	0.4MG/ML	A070255	001	Jan 07, 1987
INTL MEDICATION	0.4MG/ML	A070417	001	Sep 24, 1986
	1MG/ML	A072115	001	Apr 27, 1988
MARSAM PHARMS LLC	0.4MG/ML	A071811	001	Jul 19, 1988

## DISCONTINUED DRUG PRODUCT LIST

6 - 224 (of 324)

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

SMITH AND NEPHEW	0.02MG/ML	A071671	001	Nov 17, 1987
	0.4MG/ML	A071681	001	Nov 17, 1987
	0.4MG/ML	A071682	001	Nov 17, 1987
SOLOPAK	0.02MG/ML	A071672	001	Nov 17, 1987
	0.4MG/ML	A071683	001	Nov 17, 1987
WATSON LABS	0.4MG/ML	A071339	001	Nov 18, 1987
NARCAN				
BRISTOL MYERS SQUIBB	0.4MG/ML	A071083	001	Jul 28, 1988
	1MG/ML	A071084	001	Jul 28, 1988
	1MG/ML	A071311	001	Jul 28, 1988
ENDO PHARMS	0.02MG/ML	N016636	002	
	0.4MG/ML	N016636	001	
	1MG/ML	N016636	003	Jun 14, 1982

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

ORGANON USA INC	50MG/ML	N013132	001	Jun 12, 1986
	100MG/ML	N013132	002	Jun 12, 1986
	200MG/ML	N013132	003	Jun 12, 1986

NANDROLONE DECANOATE

ABRAXIS PHARM	100MG/ML	A088290	001	Oct 03, 1983
	200MG/ML	A088317	001	Oct 14, 1983
AKORN	100MG/ML	A087519	001	Sep 28, 1983
WATSON LABS	50MG/ML	A086385	001	Jan 13, 1984
	50MG/ML	A087598	001	Oct 06, 1983
	50MG/ML	A088554	001	Feb 10, 1986
	100MG/ML	A086598	001	Jan 13, 1984
	100MG/ML	A087599	001	Oct 06, 1983
	200MG/ML	A088128	001	Dec 05, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

DURABOLIN

ORGANON USA INC	25MG/ML	N011891	001	
	50MG/ML	N011891	002	

NANDROLONE PHENPROPIONATE

WATSON LABS	25MG/ML	A086386	001	Jun 17, 1983
	50MG/ML	A087488	001	Jun 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAFAZAIR

PHARMAFAIR	0.1%	A088101	001	Apr 15, 1983
NAPHCN FORTE				
ALCON	0.1%	A080229	001	
OPCON				
BAUSCH AND LOMB	0.1%	A087506	001	
VASOCON				
NOVARTIS	0.1%	A080235	002	Mar 24, 1983

NAPROXEN

TABLET; ORAL

NAPROXEN

BAXTER HLTHCARE	250MG	A074105	001	Dec 21, 1993
	375MG	A074105	002	Dec 21, 1993
	500MG	A074105	003	Dec 21, 1993
HAMILTON PHARMS	250MG	A074110	001	Oct 30, 1992
	375MG	A074110	002	Oct 30, 1992
	500MG	A074110	003	Oct 30, 1992
IVAX SUB TEVA PHARMS	250MG	A074111	001	Feb 28, 1995

## DISCONTINUED DRUG PRODUCT LIST

6 - 225 (of 324)

NAPROXEN

TABLET; ORAL

NAPROXEN

IVAX SUB TEVA PHARMS	375MG	A074111	002	Feb 28, 1995
	500MG	A074111	003	Feb 28, 1995
PLIVA	250MG	A074182	001	Jun 27, 1996
	375MG	A074182	002	Jun 27, 1996
	500MG	A074182	003	Jun 27, 1996
PUREPAC PHARM	250MG	A074263	001	Dec 21, 1993
	375MG	A074263	002	Dec 21, 1993
	500MG	A074263	003	Dec 21, 1993
ROXANE	250MG	A074211	001	Feb 28, 1994
	375MG	A074211	002	Feb 28, 1994
	500MG	A074211	003	Feb 28, 1994
TEVA	250MG	A074129	001	Dec 21, 1993
	250MG	A074216	001	Apr 11, 1996
	375MG	A074129	002	Dec 21, 1993
	375MG	A074216	002	Apr 11, 1996
	500MG	A074129	003	Dec 21, 1993
	500MG	A074216	003	Apr 11, 1996
TEVA PHARMS	250MG	A074207	001	Dec 21, 1993
	375MG	A074207	002	Dec 21, 1993
	500MG	A074207	003	Dec 21, 1993
WATSON LABS	250MG	A074163	001	Feb 10, 1995
	375MG	A074163	002	Feb 10, 1995
	500MG	A074163	003	Feb 10, 1995

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

ABLE	EQ 250MG BASE	A076544	001	Aug 22, 2003
	EQ 500MG BASE	A076544	002	Aug 22, 2003
HAMILTON PHARMS	EQ 250MG BASE	A074106	001	Aug 31, 1993
	EQ 500MG BASE	A074106	002	Aug 31, 1993
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A074230	001	Mar 14, 1995
	EQ 500MG BASE	A074230	002	Mar 14, 1995
MYLAN	EQ 250MG BASE	A074367	001	Aug 31, 1994
	EQ 500MG BASE	A074367	002	Aug 31, 1994
PLIVA	EQ 250MG BASE	A074242	001	Jun 20, 1996
	EQ 500MG BASE	A074242	002	Jun 20, 1996
PUREPAC PHARM	EQ 250MG BASE	A074319	001	Mar 20, 1995
	EQ 500MG BASE	A074319	002	Mar 20, 1995
ROXANE	EQ 250MG BASE	A074257	001	Dec 21, 1993
	EQ 500MG BASE	A074257	002	Dec 21, 1993
TEVA	EQ 250MG BASE	A074142	001	Dec 21, 1993
	EQ 500MG BASE	A074142	002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289	001	Jan 27, 1994
	EQ 500MG BASE	A074289	002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195	001	Dec 21, 1993
	EQ 500MG BASE	A074195	002	Dec 21, 1993
TABLET, EXTENDED RELEASE; ORAL				
NAPROXEN SODIUM				
WATSON LABS FLORIDA	EQ 375MG BASE	A075416	002	Apr 23, 2003
	EQ 500MG BASE	A075416	001	Aug 27, 2002

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

KING PHARMS	1.75MG/INH	N019660	001	Dec 30, 1992
-------------	------------	---------	-----	--------------

SOLUTION; INHALATION

TILADE

SANOFI AVENTIS US	0.5%	N020750	001	Oct 01, 1997
-------------------	------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 226 (of 324)

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

MYLAN	100MG	A076129	002	Sep 16, 2003
	150MG	A076129	003	Sep 16, 2003
	200MG	A076129	004	Sep 16, 2003
	250MG	A076129	005	Sep 16, 2003
ROXANE	50MG	A076196	001	Sep 16, 2003
	100MG	A076196	002	Sep 16, 2003
	150MG	A076196	003	Sep 16, 2003
	200MG	A076196	004	Sep 16, 2003
	250MG	A076196	005	Sep 16, 2003
SANDOZ	50MG	A076072	001	Sep 16, 2003
	100MG	A076072	002	Sep 16, 2003
	150MG	A076072	003	Sep 16, 2003
	200MG	A076072	004	Sep 16, 2003
	250MG	A076072	005	Sep 16, 2003
WATSON LABS	100MG	A076073	002	Sep 16, 2003
	150MG	A076073	003	Sep 16, 2003
	200MG	A076073	004	Sep 16, 2003
	250MG	A076073	005	Sep 16, 2003
SERZONE				
BRISTOL MYERS SQUIBB	50MG	N020152	001	Dec 22, 1994
	100MG	N020152	002	Dec 22, 1994
	150MG	N020152	003	Dec 22, 1994
	200MG	N020152	004	Dec 22, 1994
	250MG	N020152	005	Dec 22, 1994
	300MG	N020152	006	Dec 22, 1994

NEOMYCIN SULFATE

SOLUTION; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N050285	001	
----------------------	--------------------	---------	-----	--

TABLET; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 350MG BASE	A060520	001	
----------------------	---------------	---------	-----	--

NEOBIOTIC

PFIZER	EQ 350MG BASE	A060475	001	
--------	---------------	---------	-----	--

NEOMYCIN SULFATE

BRISTOL MYERS SQUIBB	500MG	A060365	001	
LANNETT	500MG	A060607	001	
LILLY	500MG	A060385	001	
ROXANE	500MG	A062173	001	
SANDOZ	500MG	A061586	001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

NEOSPORIN

GLAXOSMITHKLINE	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050176	002	Jan 14, 1985
-----------------	----------------------------------	---------	-----	--------------

OINTMENT; OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050344	002	
-------	----------------------------------	---------	-----	--

SOLUTION/DROPS; OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	A062339	001	Nov 30, 1984
	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N050456	001	

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/GM;0.25%	A061039	002	
	EQ 3.5MG BASE/GM;0.5%	A061039	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 227 (of 324)

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN EQ 3.5MG BASE/ML;0.25% A061037 001

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC

NEO-HYDELTRASOL

MERCCK EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE N050378 001

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYTREX A

SAVAGE LABS EQ 3.5MG BASE/GM;0.1% A062598 001 Jul 21, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA EQ 3.5MG BASE/GM;0.1% A062600 001 Jul 21, 1986

PHARMADERM EQ 3.5MG BASE/GM;0.1% A062595 001 Jul 21, 1986

OINTMENT; TOPICAL

MYTREX A

SAVAGE LABS EQ 3.5MG BASE/GM;0.1% A062609 001 May 23, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA EQ 3.5MG BASE/GM;0.1% A062608 001 May 23, 1986

PHARMADERM EQ 3.5MG BASE/GM;0.1% A062607 001 May 23, 1986

NETILMICIN SULFATE

INJECTABLE; INJECTION

NETROMYCIN

SCHERING EQ 10MG BASE/ML N050544 001 Feb 28, 1983

EQ 25MG BASE/ML N050544 002 Feb 28, 1983

EQ 100MG BASE/ML N050544 003 Feb 28, 1983

NIACIN

CAPSULE; ORAL

WAMPOCAP

MEDPOINTE PHARM HLC 500MG N011073 003

TABLET; ORAL

NIACIN

EVERYLIFE 500MG A083203 001

HALSEY 500MG A083453 001

IMPAX LABS 500MG A083115 001

IVAX SUB TEVA PHARMS 500MG A083180 001

MK LABS 500MG A083525 001

PUREPAC PHARM 500MG A083271 001

SANDOZ 500MG A083306 001

TABLICAPS 500MG A084237 001

WATSON LABS 500MG A083136 001

500MG A083305 001

500MG A085172 001

WEST WARD 500MG A083718 001

NICOLAR

SANOFI AVENTIS US 500MG A083823 001

TABLET, EXTENDED RELEASE; ORAL

NIACIN

BARR 500MG A076378 001 Apr 26, 2005

750MG A076378 002 Apr 26, 2005

1GM A076250 001 Apr 14, 2005

NIASPAN

ABBOTT 375MG N020381 001 Jul 28, 1997

NIASPAN TITRATION STARTER PACK

ABBOTT 375MG;500MG;750MG N020381 005 Jul 28, 1997

## DISCONTINUED DRUG PRODUCT LIST

6 - 228 (of 324)

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL

TPN

INTL MINERALS 15MG/5ML; 3.75MG/5ML; 600MG/5ML N008378 003

NICLOSAMIDE

TABLET, CHEWABLE; ORAL

NICLOCID

BAYER PHARMS 500MG N018669 001 May 14, 1982

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTROL

MCNEIL CONS 15MG/16HR N020536 001 Jul 03, 1996

PROSTEP

AVEVA 11MG/24HR N019983 003 Dec 23, 1998

22MG/24HR N019983 004 Dec 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

WATSON LABS EQ 2MG BASE A076568 001 Jul 29, 2004

EQ 4MG BASE A076569 002 Jul 29, 2004

NIFEDIPINE

CAPSULE; ORAL

ADALAT

BAYER PHARMS 10MG N019478 001 Nov 27, 1985

20MG N019478 002 Sep 17, 1986

NIFEDIPINE

CATALENT 20MG A074045 001 Apr 30, 1992

CHASE LABS NJ 10MG A072409 001 Jul 04, 1990

20MG A073421 001 Jun 19, 1991

TEVA 10MG A072651 001 Feb 19, 1992

PROCARDIA

PFIZER 20MG N018482 002 Jul 24, 1986

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

MARTEC USA LLC 90MG A075414 003 Mar 23, 2004

MYLAN 30MG A075108 001 Dec 17, 1999

NILUTAMIDE

TABLET; ORAL

NILANDRON

SANOFI AVENTIS US 50MG N020169 001 Sep 19, 1996

NIMODIPINE

CAPSULE; ORAL

NIMOTOP

BAYER PHARMS 30MG N018869 001 Dec 28, 1988

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

SCIELE PHARMA INC 10MG N020356 001 Feb 02, 1995

20MG N020356 002 Feb 02, 1995

30MG N020356 003 Feb 02, 1995

40MG N020356 004 Feb 02, 1995

NITROFURANTOIN

CAPSULE; ORAL

NITROFURANTOIN

WATSON LABS 50MG A084326 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 229 (of 324)

NITROFURANTOIN

CAPSULE; ORAL

NITROFURANTOIN

WATSON LABS

100MG

A084326 002

TABLET; ORAL

FURADANTIN

PROCTER AND GAMBLE

50MG

N008693 001

100MG

N008693 002

FURALAN

LANNETT

50MG

A080017 001

100MG

A080017 002

NITROFURANTOIN

ELKINS SINN

50MG

A080003 001

100MG

A080003 002

IVAX SUB TEVA PHARMS

50MG

A080078 002

100MG

A080078 001

SANDOZ

50MG

A080043 001

100MG

A080043 002

WATSON LABS

50MG

A080447 001

50MG

A085797 001

100MG

A080447 002

100MG

A085796 001

WHITEWORTH TOWN PLSN

100MG

A084085 002

NITROFURANTOIN SODIUM

INJECTABLE; INJECTION

IVADANTIN

PROCTER AND GAMBLE

EQ 180MG BASE/VIAL

N012402 001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

MYLAN

100MG

A074967 002

Jul 09, 1997

SANDOZ

25MG

A074336 001

Jan 25, 1995

50MG

A074336 002

Jan 25, 1995

100MG

A074336 003

Jan 25, 1995

NITROFURANTOIN MACROCRYSTALLINE

WATSON LABS

50MG

A070248 001

Jun 24, 1988

100MG

A070249 001

Jun 24, 1988

NITROFURAZONE

CREAM; TOPICAL

FURACIN

SHIRE

0.2%

A083789 001

DRESSING; TOPICAL

ACTIN-N

SHERWOOD MEDCL

0.2%

N017343 001

OINTMENT; TOPICAL

FURACIN

SHIRE

0.2%

N005795 001

NITROFURAZONE

AMBIX

0.2%

A086077 001

LANNETT

0.2%

A084393 001

PERRIGO NEW YORK

0.2%

A084968 001

TARO

0.2%

A086156 001

WENDT

0.2%

A086766 001

POWDER; TOPICAL

FURACIN

SHIRE

0.2%

A083791 001

SOLUTION; TOPICAL

NITROFURAZONE

PERRIGO NEW YORK

0.2%

A085130 001

WENDT

0.2%

A087081 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 230 (of 324)

NITROGLYCERIN

AEROSOL; SUBLINGUAL				
NITROLINGUAL				
POHL BOSKAMP	0.4MG/SPRAY	N018705	001	Oct 31, 1985
FILM, EXTENDED RELEASE; TRANSDERMAL				
NITROGLYCERIN				
MYLAN TECHNOLOGIES	0.1MG/HR	A074992	004	Nov 12, 1999
	0.2MG/HR	A074992	003	Nov 12, 1999
	0.4MG/HR	A074992	002	Nov 12, 1999
	0.6MG/HR	A074992	001	Nov 12, 1999
TRANSDERM-NITRO				
NOVARTIS	0.1MG/HR	N020144	001	Feb 27, 1996
	0.2MG/HR	N020144	002	Feb 27, 1996
	0.4MG/HR	N020144	003	Feb 27, 1996
	0.6MG/HR	N020144	004	Feb 27, 1996
	0.8MG/HR	N020144	005	Feb 27, 1996
INJECTABLE; INJECTION				
NITRO IV				
POHL BOSKAMP	5MG/ML	N018672	002	Aug 30, 1983
NITRO-BID				
SANOFI AVENTIS US	5MG/ML	N018621	001	Jan 05, 1982
	10MG/ML	A071159	001	Feb 28, 1990
NITROGLYCERIN				
ABRAXIS PHARM	5MG/ML	A070077	001	Dec 13, 1985
	5MG/ML	A071203	001	May 08, 1987
INTL MEDICATION	5MG/ML	A070026	001	Sep 10, 1985
LUITPOLD	5MG/ML	A071492	001	May 24, 1988
SMITH AND NEPHEW	5MG/ML	A070633	001	Jun 19, 1986
	5MG/ML	A070634	001	Jun 19, 1986
NITROGLYCERIN IN DEXTROSE 5%				
HOSPIRA	0.1MG/ML	A074083	001	Oct 26, 1994
NITROL				
RORER	0.8MG/ML	N018774	001	Jan 19, 1983
NITRONAL				
POHL BOSKAMP	1MG/ML	N018672	001	Aug 30, 1983
NITROSTAT				
PARKE DAVIS	0.8MG/ML	N018588	001	
	5MG/ML	A070863	001	Jan 08, 1987
	5MG/ML	N018588	002	Dec 23, 1983
	10MG/ML	A070871	001	Jan 08, 1987
	10MG/ML	A070872	001	Jan 08, 1987
TRIDIL				
HOSPIRA	0.5MG/ML	N018537	002	Jun 16, 1983
	5MG/ML	N018537	001	

NIZATIDINE

CAPSULE; ORAL				
NIZATIDINE				
ZENITH GOLDLINE	150MG	A075461	001	Jul 08, 2002
	300MG	A075461	002	Jul 08, 2002

NONOXYNOL-9

AEROSOL; VAGINAL				
DELFEN				
PERSONAL PRODS	12.5%	N014349	002	

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
RAVOCAINE AND NOVOCAIN W/ LEVOPHED				
EASTMAN KODAK	EQ 0.033MG BASE/ML; 2%; 0.4%	N008592	003	



## DISCONTINUED DRUG PRODUCT LIST

6 - 231 (of 324)

NORETHINDRONE

TABLET; ORAL

NORLUTIN

PARKE DAVIS

5MG

N010895 002

NORETHINDRONE ACETATE

TABLET; ORAL

NORLUTATE

PARKE DAVIS

5MG

N012184 002

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN

MERCK

0.3%

N019757 001 Jun 17, 1991

NORGESTREL

TABLET; ORAL

OVRETTE

WYETH PHARMS INC

0.075MG

N017031 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HYDROCHLORIDE

LILLY

EQ 10MG BASE

N014684 001

EQ 25MG BASE

N014684 002

NORTRIPTYLINE HYDROCHLORIDE

SANDOZ

EQ 10MG BASE

A074054 001 Dec 31, 1992

EQ 10MG BASE

A074835 001 Jun 30, 1997

EQ 25MG BASE

A074054 002 Dec 31, 1992

EQ 25MG BASE

A074835 002 Jun 30, 1997

EQ 50MG BASE

A074054 003 Dec 31, 1992

EQ 50MG BASE

A074835 003 Jun 30, 1997

EQ 75MG BASE

A074054 004 Dec 31, 1992

EQ 75MG BASE

A074835 004 Jun 30, 1997

TEVA

EQ 10MG BASE

A073667 001 Apr 11, 1996

EQ 25MG BASE

A073667 002 Apr 11, 1996

EQ 50MG BASE

A073667 003 Apr 11, 1996

EQ 75MG BASE

A073667 004 Apr 11, 1996

NOVOBIOCIN SODIUM

CAPSULE; ORAL

ALBAMYCIN

PHARMACIA AND UPJOHN

EQ 250MG BASE

N050339 001

NYSTATIN

CREAM; TOPICAL

CANDEX

BAYER PHARMS

100,000 UNITS/GM

A061810 001

MYKINAC

ALPHARMA US PHARMS

100,000 UNITS/GM

A062387 001 Jul 29, 1982

NILSTAT

LEDERLE

100,000 UNITS/GM

A061445 001

NYSTATIN

TARO

100,000 UNITS/GM

A062457 001 Jul 28, 1983

TEVA

100,000 UNITS/GM

A061966 001

LOTION; TOPICAL

CANDEX

BAYER PHARMS

100,000 UNITS/ML

N050233 001

OINTMENT; TOPICAL

MYCOSTATIN

WESTWOOD SQUIBB

100,000 UNITS/GM

A060571 001

MYKINAC

ALPHARMA US PHARMS

100,000 UNITS/GM

A062731 001 Sep 22, 1986

## DISCONTINUED DRUG PRODUCT LIST

6 - 232 (of 324)

NYSTATIN

OINTMENT; TOPICAL				
NILSTAT				
LEDERLE	100,000 UNITS/GM	A061444	001	
PASTILLE; ORAL				
MYCOSTATIN				
BRISTOL MYERS SQUIBB	200,000 UNITS	N050619	001	Apr 09, 1987
POWDER; ORAL				
BARSTATIN 100				
BARLAN	100%	A062489	001	Apr 27, 1988
NILSTAT				
DAVA PHARMS INC	100%	N050576	001	Dec 22, 1983
NYSTATIN				
PADDOCK	100%	A062613	001	Nov 26, 1985
SUPPOSITORY; VAGINAL				
NYSERT				
PROCTER AND GAMBLE	100,000 UNITS	N050478	001	
SUSPENSION; ORAL				
MYCOSTATIN				
APOTHECON	100,000 UNITS/ML	A061533	001	
NYSTATIN				
ALPHARMA US PHARMS	100,000 UNITS/ML	A062571	001	Oct 29, 1985
MORTON GROVE	100,000 UNITS/ML	A062835	001	Nov 19, 1987
PHARMADERM	100,000 UNITS/ML	A062518	001	Jul 06, 1984
PHARMAFAIR	100,000 UNITS/ML	A062541	001	Jan 16, 1985
ROXANE	100,000 UNITS/ML	A062832	001	Dec 27, 1991
TEVA	100,000 UNITS/ML	A062670	001	Jun 18, 1987
	100,000 UNITS/ML	A062776	001	Dec 17, 1987
NYSTEX				
SAVAGE LABS	100,000 UNITS/ML	A062519	001	Jul 06, 1984
TABLET; ORAL				
MYCOSTATIN				
BRISTOL MYERS SQUIBB	500,000 UNITS	A060574	001	
NILSTAT				
LEDERLE	500,000 UNITS	A061151	001	
NYSTATIN				
PAR PHARM	500,000 UNITS	A062474	001	Dec 22, 1983
QUANTUM PHARMICS	500,000 UNITS	A062525	001	Oct 29, 1984
SANDOZ	500,000 UNITS	A062065	001	
USL PHARMA	500,000 UNITS	A062524	001	Nov 26, 1985
WATSON LABS	500,000 UNITS	A062402	001	Dec 16, 1982
TABLET; VAGINAL				
KOROSTATIN				
HOLLAND RANTOS	100,000 UNITS	A061718	001	
MYCOSTATIN				
BRISTOL MYERS SQUIBB	100,000 UNITS	A060577	001	
NILSTAT				
LEDERLE	100,000 UNITS	A061325	001	
NYSTATIN				
FOUGERA	100,000 UNITS	A062459	001	Nov 09, 1983
PHARMADERM	100,000 UNITS	A062460	001	Nov 09, 1983
QUANTUM PHARMICS	100,000 UNITS	A062509	001	Apr 03, 1984
SANDOZ	100,000 UNITS	A061965	001	
TEVA	100,000 UNITS	A062502	001	Dec 23, 1983
WATSON LABS	100,000 UNITS	A062176	001	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL				
MYCOLOG-II				
APOTHECON	100,000 UNITS/GM;0.1%	A060576	002	May 01, 1985
	100,000 UNITS/GM;0.1%	A062606	001	May 15, 1985
MYCO-TRIACET II				
TEVA	100,000 UNITS/GM;0.1%	A061954	002	Sep 20, 1985
MYTREX F				
SAVAGE LABS	100,000 UNITS/GM;0.1%	A062597	001	Oct 08, 1985

## DISCONTINUED DRUG PRODUCT LIST

6 - 233 (of 324)

NYSTATIN; TRIAMCINOLONE ACETONIDE

## CREAM; TOPICAL

## NYSTATIN AND TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	A063010	001	Dec 20, 1988
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062186	002	Jun 06, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	A062657	001	Jul 30, 1986
TARO	100,000 UNITS/GM;0.1%	A062347	001	Mar 30, 1987

## NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062596	001	Oct 08, 1985
------------	-----------------------	---------	-----	--------------

## OINTMENT; TOPICAL

## MYCOLOG-II

APOTHECON	100,000 UNITS/GM;0.1%	A060572	001	Jun 28, 1985
-----------	-----------------------	---------	-----	--------------

## MYCO-TRIACET II

TEVA	100,000 UNITS/GM;0.1%	A062045	002	Nov 26, 1985
------	-----------------------	---------	-----	--------------

## MYTREX F

SAVAGE LABS	100,000 UNITS/GM;0.1%	A062601	001	Oct 09, 1985
-------------	-----------------------	---------	-----	--------------

## NYSTATIN AND TRIAMCINOLONE ACETONIDE

PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062280	002	Oct 10, 1985
------------------	-----------------------	---------	-----	--------------

PHARMAFAIR	100,000 UNITS/GM;0.1%	A062656	001	Jul 30, 1986
------------	-----------------------	---------	-----	--------------

## NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062603	001	Oct 09, 1985
------------	-----------------------	---------	-----	--------------

OFLOXACIN

## INJECTABLE; INJECTION

## FLOXIN

ORTHO MCNEIL PHARM	20MG/ML	N020087	002	Mar 31, 1992
	40MG/ML	N020087	003	Mar 31, 1992

## FLOXIN IN DEXTROSE 5%

ORTHO MCNEIL PHARM	400MG/100ML	N020087	001	Mar 31, 1992
--------------------	-------------	---------	-----	--------------

## FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

ORTHO MCNEIL PHARM	4MG/ML	N020087	004	Mar 31, 1992
--------------------	--------	---------	-----	--------------

	400MG/100ML	N020087	005	Mar 31, 1992
--	-------------	---------	-----	--------------

## OFLOXACIN

BEDFORD	40MG/ML	A075762	001	Jan 16, 2002
---------	---------	---------	-----	--------------

## TABLET; ORAL

## FLOXIN

ORTHO MCNEIL JANSSEN	200MG	N019735	001	Dec 28, 1990
	300MG	N019735	002	Dec 28, 1990
	400MG	N019735	003	Dec 28, 1990

## OFLOXACIN

PAR PHARM	200MG	A076093	001	Sep 02, 2003
-----------	-------	---------	-----	--------------

	300MG	A076093	002	Sep 02, 2003
--	-------	---------	-----	--------------

	400MG	A076093	003	Sep 02, 2003
--	-------	---------	-----	--------------

ONDANSETRON HYDROCHLORIDE

## INJECTABLE; INJECTION

## ONDANSETRON HYDROCHLORIDE

HOSPIRA	EQ 2MG BASE/ML	A076695	001	Dec 26, 2006
---------	----------------	---------	-----	--------------

TEVA	EQ 2MG BASE/ML	A076876	001	Nov 22, 2006
------	----------------	---------	-----	--------------

## ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

HOSPIRA	EQ 0.64MG BASE/ML	A076978	001	Feb 26, 2007
---------	-------------------	---------	-----	--------------

## ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

HOSPIRA	EQ 2MG BASE/ML	A076696	001	Dec 26, 2006
---------	----------------	---------	-----	--------------

TEVA	EQ 2MG BASE/ML	A076759	001	Nov 22, 2006
------	----------------	---------	-----	--------------

ORPHENADRINE CITRATE

## TABLET, EXTENDED RELEASE; ORAL

## NORFLEX

GRACEWAY	100MG	N012157	001	
----------	-------	---------	-----	--

## ORPHENADRINE CITRATE

ASCOT	100MG	A088067	001	Apr 06, 1983
-------	-------	---------	-----	--------------

SANDOZ	100MG	A085046	001	
--------	-------	---------	-----	--

WATSON LABS	100MG	A084303	001	
-------------	-------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 234 (of 324)

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL

DISIPAL

3M

50MG

N010653 001

OXACILLIN SODIUM

CAPSULE; ORAL

BACTOCILL

GLAXOSMITHKLINE

EQ 250MG BASE

A061336 001

EQ 250MG BASE

A062241 001

EQ 500MG BASE

A061336 002

EQ 500MG BASE

A062241 002

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE

A061450 002

EQ 500MG BASE

A061450 001

TEVA

EQ 250MG BASE

A062222 001

EQ 500MG BASE

A062222 002

PROSTAPHLIN

APOTHECON

EQ 500MG BASE

N050118 002

FOR SOLUTION; ORAL

BACTOCILL

GLAXOSMITHKLINE

EQ 250MG BASE/5ML

A062321 001

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE/5ML

A061457 001

TEVA

EQ 250MG BASE/5ML

A062252 001

PROSTAPHLIN

APOTHECON

EQ 250MG BASE/5ML

N050194 001

INJECTABLE; INJECTION

BACTOCILL

GLAXOSMITHKLINE

EQ 500MG BASE/VIAL

A061334 009

Mar 26, 1982

EQ 1GM BASE/VIAL

A061334 006

Mar 26, 1982

EQ 1GM BASE/VIAL

A062736 001

Dec 19, 1986

EQ 2GM BASE/VIAL

A061334 007

Mar 26, 1982

EQ 2GM BASE/VIAL

A062736 002

Dec 19, 1986

EQ 4GM BASE/VIAL

A061334 008

Mar 26, 1982

EQ 10GM BASE/VIAL

A061334 010

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE/VIAL

N050195 001

EQ 500MG BASE/VIAL

N050195 002

EQ 1GM BASE/VIAL

N050195 003

EQ 2GM BASE/VIAL

N050195 004

EQ 4GM BASE/VIAL

N050195 005

ELKINS SINN

EQ 250MG BASE/VIAL

A062711 001

Feb 03, 1989

EQ 500MG BASE/VIAL

A062711 002

Feb 03, 1989

EQ 1GM BASE/VIAL

A062711 003

Feb 03, 1989

EQ 2GM BASE/VIAL

A062711 004

Feb 03, 1989

EQ 4GM BASE/VIAL

A062711 005

Feb 03, 1989

EQ 10GM BASE/VIAL

A062711 006

Feb 03, 1989

IBI

EQ 125MG BASE/VIAL

A062798 003

Dec 11, 1995

EQ 250MG BASE/VIAL

A062798 004

Dec 11, 1995

EQ 500MG BASE/VIAL

A062798 005

Dec 11, 1995

EQ 1GM BASE/VIAL

A062798 001

Dec 11, 1995

EQ 2GM BASE/VIAL

A062798 002

Dec 11, 1995

MARSAM PHARMS LLC

EQ 10GM BASE/VIAL

A062984 001

Sep 29, 1988

SANDOZ

EQ 250MG BASE/VIAL

A061490 001

EQ 500MG BASE/VIAL

A061490 002

WATSON LABS

EQ 250MG BASE/VIAL

A062856 001

Oct 26, 1988

EQ 500MG BASE/VIAL

A062856 002

Oct 26, 1988

EQ 1GM BASE/VIAL

A062856 003

Oct 26, 1988

EQ 2GM BASE/VIAL

A062856 004

Oct 26, 1988

EQ 4GM BASE/VIAL

A062856 005

Oct 26, 1988

## DISCONTINUED DRUG PRODUCT LIST

6 - 235 (of 324)

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

SANOFI AVENTIS US	50MG/VIAL	N021492	001	Aug 09, 2002
	100MG/VIAL	N021492	002	Aug 09, 2002

OXAMNIQUINE

CAPSULE; ORAL

VANSIL

PFIZER	250MG	N018069	001	
--------	-------	---------	-----	--

OXANDROLONE

TABLET; ORAL

OXANDROLONE

ROXANE	2.5MG	A077249	001	Jul 10, 2007
	10MG	A077249	002	Jul 10, 2007

OXAPROZIN

TABLET; ORAL

OXAPROZIN

MYLAN	600MG	A075851	001	Aug 17, 2001
SANDOZ	600MG	A075842	001	Apr 12, 2001
	600MG	A075850	001	Apr 27, 2001

OXAPROZIN POTASSIUM

TABLET; ORAL

DAYPRO ALTA

GD SEARLE	600MG	N020776	001	Oct 17, 2002
-----------	-------	---------	-----	--------------

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AM THERAP	10MG	A071955	001	Mar 03, 1988
	15MG	A071956	001	Mar 03, 1988
	30MG	A071957	001	Mar 03, 1988
MUTUAL PHARM	10MG	A071026	002	Aug 10, 1987
	15MG	A071026	003	Aug 10, 1987
	30MG	A071026	001	Aug 10, 1987
MYLAN	10MG	A071713	001	Oct 20, 1987
	15MG	A071714	001	Oct 20, 1987
	30MG	A071715	001	Oct 20, 1987
SERAX				
ALPHARMA US PHARMS	10MG	N015539	002	
	15MG	N015539	004	
	30MG	N015539	006	
ZAXOPAM				
QUANTUM PHARMICS	10MG	A070650	001	Mar 01, 1988
	15MG	A070640	001	Mar 01, 1988
	30MG	A070641	001	Mar 01, 1988

TABLET; ORAL

OXAZEPAM

MUTUAL PHARM	15MG	A070683	001	Jan 16, 1987
PARKE DAVIS	15MG	A071508	001	Feb 02, 1987
WATSON LABS	15MG	A071494	001	Apr 21, 1987
SERAX				
ALPHARMA US PHARMS	15MG	N015539	008	

OXPRENOLOL HYDROCHLORIDE

CAPSULE; ORAL

TRASICOR

NOVARTIS	20MG	N018166	001	Dec 28, 1983
	40MG	N018166	002	Dec 28, 1983
	80MG	N018166	003	Dec 28, 1983
	160MG	N018166	004	Dec 28, 1983

## DISCONTINUED DRUG PRODUCT LIST

6 - 236 (of 324)

OXTRIPHYLLINE

SOLUTION; ORAL

CHOLEDYL

PARKE DAVIS 100MG/5ML N009268 012 Nov 27, 1984

OXTRIPHYLLINE

MORTON GROVE 100MG/5ML A088243 001 Dec 05, 1983

SYRUP; ORAL

CHOLEDYL

PARKE DAVIS 50MG/5ML N009268 011

OXTRIPHYLLINE PEDIATRIC

MORTON GROVE 50MG/5ML A088242 001 Dec 05, 1983

TABLET, DELAYED RELEASE; ORAL

CHOLEDYL

PARKE DAVIS 100MG N009268 003

200MG N009268 007

OXTRIPHYLLINE

WATSON LABS 100MG A087866 001 Aug 25, 1983

200MG A087835 001 Aug 25, 1983

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

DITROPAN

ORTHO MCNEIL JANSSEN 5MG/5ML N018211 001

TABLET; ORAL

OXYBUTYNIN CHLORIDE

QUANTUM PHARMICS 5MG A072296 001 Dec 08, 1988

USL PHARMA 5MG A070746 001 Mar 10, 1988

WATSON LABS 5MG A072485 001 Apr 19, 1989

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYCODONE HYDROCHLORIDE

TEVA 10MG A076610 001 Dec 06, 2005

20MG A076610 002 Dec 06, 2005

40MG A076610 003 Dec 06, 2005

80MG A076168 001 Mar 23, 2004

OXYCONTIN

PURDUE PHARMA LP 160MG N020553 005 Mar 15, 2000

ROXICODONE

ROXANE 10MG N020932 001 Oct 26, 1998

30MG N020932 002 Oct 26, 1998

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

ENDO PHARMS 1.5MG/ML N011707 001

SUPPOSITORY; RECTAL

NUMORPHAN

ENDO PHARMS 5MG N011738 004

OXYPHENBUTAZONE

TABLET; ORAL

OXYPHENBUTAZONE

WATSON LABS 100MG A088399 001 Sep 17, 1984

TANDEARIL

NOVARTIS 100MG N012542 004 Sep 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL

DARICON

PFIZER 10MG N011612 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 237 (of 324)

OXYPHENONIUM BROMIDE

TABLET; ORAL				
ANTRENYL				
NOVARTIS	5MG		N008492	002

OXYTETRACYCLINE

TABLET; ORAL				
TERRAMYCIN				
PFIZER	250MG		N050287	001

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL				
TERRAMYCIN				
PFIZER	EQ 125MG BASE/5ML		A060595	001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL				
OXY-KESSO-TETRA				
FERRANTE	EQ 250MG BASE		A060179	001
OXYTETRACYCLINE HYDROCHLORIDE				
IMPAX LABS	EQ 250MG BASE		A060760	001
PROTER	EQ 250MG BASE		A060869	001
PUREPAC PHARM	EQ 250MG BASE		A060634	001
WEST WARD	EQ 250MG BASE		A060770	001
TERRAMYCIN				
PFIZER	EQ 125MG BASE		N050286	001
	EQ 250MG BASE		N050286	002
INJECTABLE; INJECTION				
TERRAMYCIN				
PFIZER	EQ 250MG BASE/VIAL		A060586	001
	EQ 500MG BASE/VIAL		A060586	002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC				
TERRAMYCIN W/ POLYMYXIN				
PFIZER	EQ 5MG BASE/GM;10,000 UNITS/GM		A061841	001
TABLET; VAGINAL				
TERRAMYCIN-POLYMYXIN				
PFIZER	EQ 100MG BASE;100,000 UNITS		A061009	001

OXYTOCIN

INJECTABLE; INJECTION				
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%				
ABBOTT	1USP UNITS/100ML		N019185	004 Mar 29, 1985
	2USP UNITS/100ML		N019185	003 Mar 29, 1985
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%				
ABBOTT	2USP UNITS/100ML		N019185	002 Mar 29, 1985
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%				
ABBOTT	1USP UNITS/100ML		N019185	001 Mar 29, 1985
SYNTOCINON				
NOVARTIS	10USP UNITS/ML		N018245	001
SOLUTION; NASAL				
SYNTOCINON				
NOVARTIS	40USP UNITS/ML		N012285	001

PACLITAXEL

INJECTABLE; INJECTION				
PACLITAXEL				
HOSPIRA	6MG/ML		A076233	001 Aug 01, 2002
TEVA PARENTERAL	6MG/ML		A075297	001 Jan 25, 2002

## DISCONTINUED DRUG PRODUCT LIST

6 - 238 (of 324)

PALIPERIDONETABLET, EXTENDED RELEASE; ORAL  
INVEGA

ORTHO MCNEIL JANSSEN 12MG N021999 004 Dec 19, 2006

PAMIDRONATE DISODIUMINJECTABLE; INJECTION  
AREDIA

NOVARTIS 60MG/VIAL N020036 003 May 06, 1993

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)CAPSULE; ORAL  
COTAZYMORGANON USA INC 30,000USP UNITS;8,000USP  
UNITS;30,000USP UNITS N020580 001 Dec 09, 1996PANCURONIUM BROMIDEINJECTABLE; INJECTION  
PANCURONIUM BROMIDE

ASTRAZENECA	1MG/ML	A072210	001	Mar 31, 1988
	2MG/ML	A072211	001	Mar 31, 1988
	2MG/ML	A072212	001	Mar 31, 1988
	2MG/ML	A072213	001	Mar 31, 1988
HOSPIRA	2MG/ML	A072321	001	Jan 19, 1989
PAVULON				
ORGANON USA INC	1MG/ML	N017015	002	
	2MG/ML	N017015	001	

PARAMETHADIONECAPSULE; ORAL  
PARADIONE

ABBOTT	150MG	N006800	003	
	300MG	N006800	001	

SOLUTION; ORAL  
PARADIONE

ABBOTT 300MG/ML N006800 002

PARAMETHASONE ACETATETABLET; ORAL  
HALDRONE

LILLY	1MG	N012772	005	
	2MG	N012772	006	

PARGYLINE HYDROCHLORIDETABLET; ORAL  
EUTONYL

ABBOTT	10MG	N013448	002	
	25MG	N013448	003	
	50MG	N013448	004	

PAROMOMYCIN SULFATECAPSULE; ORAL  
HUMATIN

KING PHARMS	EQ 250MG BASE	A062310	001	
PARKEDALE	EQ 250MG BASE	A060521	001	

SYRUP; ORAL  
HUMATIN

PARKE DAVIS EQ 125MG BASE/5ML A060522 001

PAROXETINE HYDROCHLORIDECAPSULE; ORAL  
PAXIL

GLAXOSMITHKLINE	EQ 10MG BASE	N020885	001	Oct 09, 1998
	EQ 20MG BASE	N020885	002	Oct 09, 1998



## DISCONTINUED DRUG PRODUCT LIST

6 - 239 (of 324)

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL

PAXIL

GLAXOSMITHKLINE	EQ 30MG BASE	N020885	003	Oct 09, 1998
	EQ 40MG BASE	N020885	004	Oct 09, 1998

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

ROXANE	EQ 10MG BASE	A078026	001	Jun 29, 2007
	EQ 20MG BASE	A078026	002	Jun 29, 2007
	EQ 30MG BASE	A078026	003	Jun 29, 2007
	EQ 40MG BASE	A078026	004	Jun 29, 2007
SANDOZ	EQ 10MG BASE	A075566	001	Mar 08, 2004
	EQ 20MG BASE	A075566	002	Mar 08, 2004
	EQ 30MG BASE	A075566	003	Mar 08, 2004
	EQ 40MG BASE	A075566	004	Mar 08, 2004
TEVA PHARMS	EQ 10MG BASE	A077082	001	Jun 29, 2007
	EQ 20MG BASE	A077082	002	Jun 29, 2007
	EQ 30MG BASE	A077082	003	Jun 29, 2007
	EQ 40MG BASE	A077082	004	Jun 29, 2007
PAXIL				
GLAXOSMITHKLINE	EQ 50MG BASE	N020031	004	Dec 29, 1992

PEMOLINE

TABLET; ORAL

CYLERT

ABBOTT	18.75MG	N016832	001	
	37.5MG	N016832	002	
	75MG	N016832	003	

PEMOLINE

ACTAVIS TOTOWA	18.75MG	A075595	001	Feb 28, 2000
	37.5MG	A075595	002	Feb 28, 2000
	75MG	A075595	003	Feb 28, 2000
MALLINCKRODT	18.75MG	A075726	003	Mar 30, 2001
	37.5MG	A075726	002	Mar 30, 2001
	75MG	A075726	001	Mar 30, 2001
SANDOZ	18.75MG	A075286	001	Dec 27, 1999
	37.5MG	A075286	002	Jun 30, 1999
	75MG	A075286	003	Jun 30, 1999
TEVA PHARMS	18.75MG	A075030	003	Feb 22, 2000
	37.5MG	A075030	001	Jan 29, 1999
	75MG	A075030	002	Jan 29, 1999
VINTAGE PHARMS	18.75MG	A075328	001	Apr 19, 2000
	37.5MG	A075328	002	Apr 19, 2000
	75MG	A075328	003	Apr 19, 2000
WATSON LABS	18.75MG	A075287	001	Jun 13, 2001
	37.5MG	A075287	002	Sep 18, 2000
	75MG	A075287	003	Sep 18, 2000

TABLET, CHEWABLE; ORAL

CYLERT

ABBOTT	37.5MG	N017703	001	
--------	--------	---------	-----	--

PEMOLINE

ACTAVIS TOTOWA	37.5MG	A075678	001	Jul 26, 2000
TEVA PHARMS	37.5MG	A075555	001	Feb 18, 2000

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

SCHWARZ PHARMA	10MG	N018976	001	Dec 30, 1987
----------------	------	---------	-----	--------------

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE

ATON	125MG	N019853	002	
------	-------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 240 (of 324)

PENICILLIN G BENZATHINE

## INJECTABLE; INJECTION

## BICILLIN L-A

WYETH AYERST

300,000 UNITS/ML

N050131 001

## SUSPENSION; ORAL

## BICILLIN

WYETH AYERST

300,000 UNITS/5ML

N050126 002

## TABLET; ORAL

## BICILLIN

WYETH AYERST

200,000 UNITS

N050128 001

PENICILLIN G POTASSIUM

## FOR SOLUTION; ORAL

## PENICILLIN

TEVA

200,000 UNITS/5ML

A060307 002

400,000 UNITS/5ML

A060307 004

## PENICILLIN G POTASSIUM

MYLAN

200,000 UNITS/5ML

A060752 003

250,000 UNITS/5ML

A060752 002

400,000 UNITS/5ML

A060752 001

PUREPAC PHARM

250,000 UNITS/5ML

A061740 001

400,000 UNITS/5ML

A061740 002

## PENICILLIN-2

TEVA

250,000 UNITS/5ML

A060307 003

## PENTIDS '200'

APOTHECON

200,000 UNITS/5ML

A062149 001

## PENTIDS '400'

APOTHECON

400,000 UNITS/5ML

A062149 002

## PFIZERPEN G

PFIZER

400,000 UNITS/5ML

A060587 001

## INJECTABLE; INJECTION

## PENICILLIN G POTASSIUM

APOTHECON

1,000,000 UNITS/VIAL

A060362 001

5,000,000 UNITS/VIAL

A060362 003

10,000,000 UNITS/VIAL

A060362 004

20,000,000 UNITS/VIAL

A060362 002

CONSOLIDATED PHARM

500,000 UNITS/VIAL

A060806 001

1,000,000 UNITS/VIAL

A060806 002

5,000,000 UNITS/VIAL

A060806 003

10,000,000 UNITS/VIAL

A060806 004

LILLY

200,000 UNITS/VIAL

A060384 004

500,000 UNITS/VIAL

A060384 003

1,000,000 UNITS/VIAL

A060384 002

5,000,000 UNITS/VIAL

A060384 001

20,000,000 UNITS/VIAL

A060384 005

20,000,000 UNITS/VIAL

A060601 001

MARSAM PHARMS LLC

1,000,000 UNITS/VIAL

A062991 001

Sep 13, 1988

5,000,000 UNITS/VIAL

A062991 002

Sep 13, 1988

10,000,000 UNITS/VIAL

A062991 003

Sep 13, 1988

20,000,000 UNITS/VIAL

A062991 004

Sep 13, 1988

PARKE DAVIS

1,000,000 UNITS/VIAL

A062003 001

5,000,000 UNITS/VIAL

A062003 002

PFIZER

20,000,000 UNITS/VIAL

A060074 003

SANDOZ

1,000,000 UNITS/VIAL

A065079 001

Aug 30, 2002

## PFIZERPEN

PFIZER

1,000,000 UNITS/VIAL

A060657 001

## TABLET; ORAL

## PENICILLIN G POTASSIUM

APOTHECON

250,000 UNITS

A060392 003

IVAX SUB TEVA PHARMS

400,000 UNITS

A060073 004

LILLY

250,000 UNITS

A060403 001

MYLAN

200,000 UNITS

A060781 001

250,000 UNITS

A060781 002

400,000 UNITS

A060781 003

500,000 UNITS

A060781 005

## DISCONTINUED DRUG PRODUCT LIST

6 - 241 (of 324)

PENICILLIN G POTASSIUM

TABLET; ORAL

PENICILLIN G POTASSIUM

MYLAN	800,000 UNITS	A060781	004
PUREPAC PHARM	200,000 UNITS	A061588	001
	250,000 UNITS	A061588	002
	400,000 UNITS	A061588	003
TEVA	200,000 UNITS	A060306	001
	250,000 UNITS	A060306	002
	400,000 UNITS	A060306	003
	500,000 UNITS	A060306	004
WYETH AYERST	200,000 UNITS	A060413	001
	250,000 UNITS	A060413	002
	400,000 UNITS	A060413	003
PENTIDS '200'			
APOTHECON	200,000 UNITS	A062155	001
PENTIDS '250'			
APOTHECON	250,000 UNITS	A062155	002
PENTIDS '400'			
APOTHECON	400,000 UNITS	A060392	004
	400,000 UNITS	A062155	003
PENTIDS '800'			
APOTHECON	800,000 UNITS	A060392	005
	800,000 UNITS	A062155	004
PFIZERPEN G			
PFIZER	50,000 UNITS	A060075	001
	100,000 UNITS	A060075	002
	200,000 UNITS	A060075	003
	250,000 UNITS	A060075	004
	400,000 UNITS	A060075	005
	800,000 UNITS	A060075	006

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

DURACILLIN A.S.

LILLY	300,000 UNITS/ML	A060093	001
PENICILLIN G PROCAINE			
CONSOLIDATED PHARM	300,000 UNITS/ML	A060800	001
	600,000 UNITS/1.2ML	A060800	002
PARKE DAVIS	300,000 UNITS/ML	A062029	001
PFIZER	300,000 UNITS/VIAL	A060099	001
	1,500,000 UNITS/VIAL	A060099	002
PFIZERPEN-AS			
PFIZER	300,000 UNITS/ML	A060286	001
	600,000 UNITS/ML	A060286	002

PENICILLIN G SODIUM

INJECTABLE; IM-IV

PENICILLIN G SODIUM

MARSAM PHARMS LLC	5,000,000 UNITS/VIAL	A063014	001	Sep 13, 1988
INJECTABLE; INJECTION				
PENICILLIN G SODIUM				
BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL	A061935	001	
COPANOS	5,000,000 UNITS/VIAL	A061051	001	
PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL	A061046	001	

PENICILLIN V

FOR SUSPENSION; ORAL

V-CILLIN

LILLY	125MG/0.6ML	A060002	001
-------	-------------	---------	-----

## DISCONTINUED DRUG PRODUCT LIST

6 - 242 (of 324)

PENICILLIN V POTASSIUM

## FOR SOLUTION; ORAL

## BEEPEN-VK

GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A062270	001
	EQ 250MG BASE/5ML	A062270	002

## BETAPEN-VK

APOTHECON	EQ 125MG BASE/5ML	A061149	001
	EQ 250MG BASE/5ML	A061149	002

## LEDERCILLIN VK

LEDERLE	EQ 125MG BASE/5ML	A060136	001
	EQ 250MG BASE/5ML	A060136	002

## PENAPAR-VK

PARKE DAVIS	EQ 125MG BASE/5ML	A062002	001
	EQ 250MG BASE/5ML	A062002	002

## PENICILLIN V POTASSIUM

AM ANTIBIOTICS	EQ 125MG BASE/5ML	A061529	001
	EQ 250MG BASE/5ML	A061529	002
MYLAN	EQ 125MG BASE/5ML	A061624	002
	EQ 250MG BASE/5ML	A061624	001
PUREPAC PHARM	EQ 125MG BASE/5ML	A061758	001
	EQ 250MG BASE/5ML	A061758	002

## PEN-VEE K

WYETH AYERST	EQ 125MG BASE/5ML	A060007	001
	EQ 250MG BASE/5ML	A060007	002

## PFIZERPEN VK

PFIZER	EQ 125MG BASE/5ML	A061815	001
	EQ 250MG BASE/5ML	A061815	002

## V-CILLIN K

LILLY	EQ 125MG BASE/5ML	A060004	001
	EQ 250MG BASE/5ML	A060004	002

## VEETIDS

APOTHECON	EQ 125MG BASE/5ML	A061410	001
	EQ 250MG BASE/5ML	A061410	002

## VEETIDS '125'

APOTHECON	EQ 125MG BASE/5ML	A061206	001
	EQ 125MG BASE/5ML	A062153	001

## VEETIDS '250'

APOTHECON	EQ 250MG BASE/5ML	A061206	002
	EQ 250MG BASE/5ML	A062153	002

## TABLET; ORAL

## BEEPEN-VK

GLAXOSMITHKLINE	EQ 250MG BASE	A062273	001
	EQ 500MG BASE	A062273	002

## BETAPEN-VK

BRISTOL	EQ 250MG BASE	A061150	001
	EQ 500MG BASE	A061150	002

## LEDERCILLIN VK

LEDERLE	EQ 250MG BASE	A060134	001
	EQ 500MG BASE	A060134	002

## PENAPAR-VK

PARKE DAVIS	EQ 250MG BASE	A062001	001
	EQ 500MG BASE	A062001	002

## PENICILLIN V POTASSIUM

AM ANTIBIOTICS	EQ 250MG BASE	A061528	001
	EQ 500MG BASE	A061528	002
IVAX SUB TEVA PHARMS	EQ 125MG BASE	A060518	001
	EQ 250MG BASE	A060518	002
	EQ 500MG BASE	A060518	003
MYLAN	EQ 250MG BASE	A061530	001
	EQ 500MG BASE	A061530	002
PUREPAC PHARM	EQ 125MG BASE	A061571	001
	EQ 250MG BASE	A061571	002
	EQ 500MG BASE	A061571	003

## DISCONTINUED DRUG PRODUCT LIST

6 - 243 (of 324)

PENICILLIN V POTASSIUM

TABLET; ORAL

PEN-VEE K

WYETH AYERST

EQ 125MG BASE

A060006 001

EQ 250MG BASE

A060006 002

EQ 500MG BASE

A060006 003

PFIZERPEN VK

PFIZER

EQ 250MG BASE

A061836 001

EQ 500MG BASE

A061836 002

UTICILLIN VK

PHARMACIA AND UPJOHN

EQ 250MG BASE

A061651 001

EQ 500MG BASE

A061651 002

V-CILLIN K

LILLY

EQ 125MG BASE

A060003 001

EQ 250MG BASE

A060003 002

EQ 500MG BASE

A060003 003

VEETIDS

APOTHECON

EQ 250MG BASE

A061411 001

EQ 500MG BASE

A061411 002

VEETIDS '250'

APOTHECON

EQ 250MG BASE

A061164 001

EQ 250MG BASE

A062156 002

VEETIDS '500'

APOTHECON

EQ 500MG BASE

A061164 002

EQ 500MG BASE

A062156 001

PENTAGASTRIN

INJECTABLE; INJECTION

PEPTAVLON

WYETH AYERST

0.25MG/ML

N017048 001

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

APP PHARMS

600MG/VIAL

N019887 002

Mar 22, 1996

INJECTABLE; INJECTION

PENTACARINAT

ARMOUR PHARM

300MG/VIAL

A073447 001

Apr 28, 1994

PENTAMIDINE ISETHIONATE

BAXTER HLTHCARE

300MG/VIAL

A073617 001

Dec 18, 1995

HOSPIRA

300MG/VIAL

A073479 001

Jun 30, 1992

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN 50

SANOFI AVENTIS US

EQ 50MG BASE

N016732 001

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE; INJECTION

YTTERBIUM YB 169 DTPA

3M

2mCi/ML

N017518 001

PENTOBARBITAL

ELIXIR; ORAL

NEMBUTAL

OVATION PHARMS

18.2MG/5ML

A083244 001

PENTOBARBITAL SODIUM

CAPSULE; ORAL

NEMBUTAL SODIUM

OVATION PHARMS

30MG

A084095 001

50MG

A084093 001

100MG

A083245 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 244 (of 324)

PENTOBARBITAL SODIUM

## CAPSULE; ORAL

## PENTOBARBITAL SODIUM

LANNETT	50MG	A085937	001	
	100MG	A085915	001	
VITARINE	100MG	A083284	001	
WHITEWORTH TOWN PLSN	100MG	A083338	001	

## SODIUM PENTOBARBITAL

ANABOLIC	100MG	A084590	001	
ELKINS SINN	100MG	A083368	001	
EVERYLIFE	100MG	A083259	001	
HALSEY	100MG	A084677	001	
IVAX SUB TEVA PHARMS	50MG	A083461	001	
	100MG	A083461	002	
PARKE DAVIS	100MG	A084156	001	
PERRIGO	100MG	A084560	001	
PUREPAC PHARM	100MG	A083301	001	
VALEANT PHARM INTL	100MG	A083264	001	
WATSON LABS	100MG	A085791	001	
WYETH AYERST	100MG	A083239	001	

## INJECTABLE; INJECTION

## PENTOBARBITAL SODIUM

ELKINS SINN	50MG/ML	A083270	001	
-------------	---------	---------	-----	--

## SODIUM PENTOBARBITAL

WYETH AYERST	50MG/ML	A083261	001	
--------------	---------	---------	-----	--

## SUPPOSITORY; RECTAL

## NEMBUTAL

OVATION PHARMS	30MG	A083247	001	Jan 25, 1982
	60MG	A083247	002	Jan 25, 1982
	120MG	A083247	003	Jan 25, 1982
	200MG	A083247	004	Jan 25, 1982

## TABLET; ORAL

## PENTOBARBITAL SODIUM

VITARINE	100MG	A083285	001	
----------	-------	---------	-----	--

## SODIUM PENTOBARBITAL

NEXGEN PHARMA INC	100MG	A084238	001	
-------------------	-------	---------	-----	--

PENTOLINIUM TARTRATE

## INJECTABLE; INJECTION

## ANSOLYSEN

WYETH AYERST	10MG/ML	N009372	001	
--------------	---------	---------	-----	--

PENTOXIFYLLINE

## TABLET, EXTENDED RELEASE; ORAL

## PENTOXIFYLLINE

ACTAVIS ELIZABETH	400MG	A074878	001	Jul 09, 1997
HERITAGE PHARMS INC	400MG	A074877	001	Jul 08, 1997
TEVA	400MG	A075199	001	Sep 03, 1999

PERFLUBRON

## LIQUID; ORAL

## IMAGENT

ALLIANCE PHARM	100%	N020091	001	Aug 13, 1993
----------------	------	---------	-----	--------------

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

## PASTE; TOPICAL

## SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

US ARMY	50%;50%	N021084	001	Feb 17, 2000
---------	---------	---------	-----	--------------

PERGOLIDE MESYLATE

## TABLET; ORAL

## PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS	EQ 0.05MG BASE	A076094	001	Sep 04, 2003
	EQ 0.25MG BASE	A076094	002	Sep 04, 2003

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 686 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 245 (of 324)

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS	EQ 1MG BASE	A076094	003	Sep 04, 2003
PAR PHARM	EQ 0.05MG BASE	A076061	001	Nov 27, 2002
	EQ 0.25MG BASE	A076061	002	Nov 27, 2002
	EQ 1MG BASE	A076061	003	Nov 27, 2002

PERMAX

VALEANT PHARM INTL	EQ 0.05MG BASE	N019385	001	Dec 30, 1988
	EQ 0.25MG BASE	N019385	002	Dec 30, 1988
	EQ 1MG BASE	N019385	003	Dec 30, 1988

PERMETHRIN

LOTION; TOPICAL

NIX

GLAXOSMITHKLINE	1%	N019435	001	Mar 31, 1986
-----------------	----	---------	-----	--------------

PERPHENAZINE

CONCENTRATE; ORAL

TRILAFON

SCHERING	16MG/5ML	N011557	001	
----------	----------	---------	-----	--

INJECTABLE; INJECTION

TRILAFON

SCHERING	5MG/ML	N011213	002	
----------	--------	---------	-----	--

SYRUP; ORAL

TRILAFON

SCHERING	2MG/5ML	N011294	002	
----------	---------	---------	-----	--

TABLET; ORAL

PERPHENAZINE

IVAX PHARMS	2MG	A089707	001	Sep 10, 1987
	4MG	A089708	001	Sep 10, 1987
	8MG	A089456	001	Sep 10, 1987
	16MG	A089457	001	Sep 10, 1987

TRILAFON

SCHERING	2MG	N010775	001	
	4MG	N010775	002	
	8MG	N010775	003	
	16MG	N010775	004	

TABLET, EXTENDED RELEASE; ORAL

TRILAFON

SCHERING	8MG	N011361	002	
----------	-----	---------	-----	--

PHENACEMIDE

TABLET; ORAL

PHENURONE

ABBOTT	500MG	N007707	001	
--------	-------	---------	-----	--

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL

AZO GANTANOL

ROCHE	100MG;500MG	N013294	001	Sep 10, 1987
-------	-------------	---------	-----	--------------

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HYDROCHLORIDE

ABLE	200MG,N/A,N/A;N/A,800MG,160MG	N021105	001	Jun 26, 2001
------	-------------------------------	---------	-----	--------------

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL

AZO GANTRISIN

ROCHE	50MG;500MG	N019358	001	Aug 31, 1990
-------	------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 246 (of 324)

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL			
PHENAZINE			
MAST MM	35MG	A086523	001
	35MG	A086524	001
	35MG	A086525	001
PHENDIMETRAZINE TARTRATE			
SANDOZ	35MG	A085633	001
	35MG	A085694	001
	35MG	A085695	001
	35MG	A085702	001
VITARINE	35MG	A085634	001
	35MG	A085645	001
	35MG	A085670	001
	35MG	A086403	001
	35MG	A086408	001
	35MG	A086410	001
	35MG	A087424	001
SPRX-3			
SOLVAY	35MG	A085897	001
STATOBEX			
TEVA	35MG	A085507	001
X-TROZINE			
SHIRE RICHWOOD	35MG	A087394	001 Sep 22, 1982
CAPSULE, EXTENDED RELEASE; ORAL			
MELFIAT-105			
NUMARK	105MG	A087487	001 Oct 13, 1982
PHENDIMETRAZINE TARTRATE			
GRAHAM DM	105MG	A087214	001 May 26, 1982
	105MG	A088020	001 Aug 16, 1982
	105MG	A088028	001 Aug 16, 1982
	105MG	A088062	001 Sep 13, 1982
	105MG	A088063	001 Sep 10, 1982
	105MG	A088111	001 Oct 18, 1982
SANDOZ	105MG	A087378	001
SPRX-105			
NUMARK	105MG	A088024	001 Dec 22, 1982
X-TROZINE L.A.			
SHIRE RICHWOOD	105MG	A087371	001 Aug 24, 1982
TABLET; ORAL			
ADPHEN			
FERNDAL LABS	35MG	A083655	001
ALPHAZINE			
SANDOZ	35MG	A085034	001
CAM-METRAZINE			
ABC HOLDING	35MG	A085511	001
CAMALL	35MG	A085756	001
TG UNITED LABS	35MG	A083922	001
	35MG	A085318	001
	35MG	A085320	001
	35MG	A085321	001
DI-METREX			
PVT FORM	35MG	A085698	001
MELFIAT			
NUMARK	35MG	A083790	002
METRA			
FOREST PHARMS	35MG	A083754	001
PHENAZINE			
MAST MM	35MG	A087305	001
PHENAZINE-35			
ABC HOLDING	35MG	A085512	001
PHENDIMETRAZINE TARTRATE			
BARR	35MG	A083644	001
	35MG	A083684	001



## DISCONTINUED DRUG PRODUCT LIST

6 - 247 (of 324)

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

BARR	35MG	A083686	001	
	35MG	A083687	001	
	35MG	A084831	001	
	35MG	A084834	001	
	35MG	A084835	001	
FERNDALE LABS	35MG	A086834	001	Sep 15, 1983
INWOOD LABS	35MG	A084740	001	
	35MG	A084741	001	
	35MG	A084742	001	
	35MG	A084743	001	
IVAX PHARMS	35MG	A085611	001	
	35MG	A085612	001	
IVAX SUB TEVA PHARMS	35MG	A083682	001	
KV PHARM	35MG	A084138	001	
	35MG	A084141	001	
	35MG	A085525	001	
MFG CHEMISTS	35MG	A085914	001	
NEXGEN PHARMA INC	35MG	A086020	001	
NUMARK	35MG	A083790	001	
PVT FORM	35MG	A085199	001	
	35MG	A085697	001	
SANDOZ	35MG	A085402	001	
	35MG	A085497	001	
	35MG	A085830	001	
	35MG	A086365	001	
	35MG	A086370	001	
SOLVAY	35MG	A083993	001	
TG UNITED LABS	35MG	A085761	001	
	35MG	A085941	001	Jun 27, 1983
USL PHARMA	35MG	A083805	001	
	35MG	A084398	001	
	35MG	A084399	001	
VITARINE	35MG	A085519	001	
	35MG	A086005	001	
	35MG	A086106	001	
WATSON LABS	35MG	A085767	001	
	35MG	A085768	001	
	35MG	A085770	001	
	35MG	A085773	001	
PLEGINE				
WYETH AYERST	35MG	N012248	001	
STATOBEX				
TEVA	35MG	A086013	001	
STATOBEX-G				
TEVA	35MG	A085095	001	
X-TROZINE				
SHIRE RICHWOOD	35MG	A086550	001	
	35MG	A086551	001	
	35MG	A086552	001	
	35MG	A086553	001	
	35MG	A086554	001	

PHENINDIONE

TABLET; ORAL

HEDULIN

SANOFI AVENTIS US	50MG	N008767	002
-------------------	------	---------	-----

PHENMETRAZINE HYDROCHLORIDE

TABLET; ORAL

PRELUDIN

BOEHRINGER INGELHEIM	25MG	N010460	005
----------------------	------	---------	-----

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 689 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 248 (of 324)

PHENMETRAZINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
PRELUDIN

BOEHRINGER INGELHEIM	50MG	N011752	004
	75MG	N011752	003

PHENPROCOUMON

TABLET; ORAL

LIQUAMAR

ORGANON USA INC	3MG	N011228	001
-----------------	-----	---------	-----

PHENSUXIMIDE

CAPSULE; ORAL

MILONTIN

PARKE DAVIS	500MG	N008855	004
-------------	-------	---------	-----

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

FASTIN

GLAXOSMITHKLINE	30MG	N017352	001
-----------------	------	---------	-----

OBESTIN-30

FERNDAL LABS	30MG	A087144	001
--------------	------	---------	-----

OBY-TRIM

SHIRE RICHWOOD	30MG	A087764	001	Mar 18, 1982
----------------	------	---------	-----	--------------

ONA-MAST

MAST MM	30MG	A086511	001
---------	------	---------	-----

	30MG	A086516	001
--	------	---------	-----

PHENTERMINE HYDROCHLORIDE

ABC HOLDING	30MG	A085411	001
-------------	------	---------	-----

ABLE	15MG	A040497	001	Mar 13, 2003
------	------	---------	-----	--------------

	30MG	A040403	001	Aug 30, 2001
--	------	---------	-----	--------------

	30MG	A040427	001	Aug 30, 2001
--	------	---------	-----	--------------

CAMALL	15MG	A086735	001
--------	------	---------	-----

	30MG	A087226	001
--	------	---------	-----

DURAMED PHARMS BARR	30MG	A088948	001	Apr 25, 1986
---------------------	------	---------	-----	--------------

IVAX PHARMS	30MG	A086329	001
-------------	------	---------	-----

MUTUAL PHARM	37.5MG	A040527	001	Oct 23, 2003
--------------	--------	---------	-----	--------------

SANDOZ	30MG	A087208	001
--------	------	---------	-----

	30MG	A087223	001
--	------	---------	-----

	37.5MG	A088414	001	Oct 19, 1983
--	--------	---------	-----	--------------

TEVA	30MG	A086911	001
------	------	---------	-----

	30MG	A087126	001
--	------	---------	-----

	30MG	A087777	001	Nov 01, 1985
--	------	---------	-----	--------------

	30MG	A088612	001	Apr 04, 1984
--	------	---------	-----	--------------

	30MG	A088613	001	Apr 09, 1984
--	------	---------	-----	--------------

	30MG	A088614	001	Apr 09, 1984
--	------	---------	-----	--------------

TG UNITED INC	30MG	A040083	001	Mar 07, 1997
---------------	------	---------	-----	--------------

TG UNITED LABS	18.75MG	A088576	001	May 23, 1984
----------------	---------	---------	-----	--------------

	30MG	A085417	001
--	------	---------	-----

	30MG	A086732	002
--	------	---------	-----

	30MG	A087215	001
--	------	---------	-----

	37.5MG	A087915	001	Dec 22, 1983
--	--------	---------	-----	--------------

	37.5MG	A087918	001	Dec 22, 1983
--	--------	---------	-----	--------------

	37.5MG	A087930	001	Oct 14, 1983
--	--------	---------	-----	--------------

	37.5MG	A088610	001	Jun 04, 1984
--	--------	---------	-----	--------------

	37.5MG	A088611	001	Jun 04, 1984
--	--------	---------	-----	--------------

	37.5MG	A088625	001	Aug 23, 1984
--	--------	---------	-----	--------------

USL PHARMA	30MG	A084487	001	Apr 09, 1982
------------	------	---------	-----	--------------

	30MG	A088430	001	Mar 27, 1984
--	------	---------	-----	--------------

	30MG	A088797	001	Dec 10, 1984
--	------	---------	-----	--------------

VITARINE	30MG	A087202	001
----------	------	---------	-----

	30MG	A087235	001
--	------	---------	-----

WATSON LABS	30MG	A086740	001	Mar 21, 1985
-------------	------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 249 (of 324)

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

ONA-MAST

MAST MM 8MG A086260 001

PHENTERMINE HYDROCHLORIDE

ABLE 37.5MG A040402 001 Aug 30, 2001

IVAX PHARMS 8MG A085553 001

SANDOZ 8MG A085671 001

8MG A085689 001

TG UNITED LABS 8MG A083923 001

8MG A085319 001

37.5MG A087805 001 Dec 06, 1982

37.5MG A088596 001 Apr 04, 1984

USL PHARMA 8MG A083804 001

37.5MG A088910 001 Jul 17, 1985

37.5MG A088917 001 Jul 17, 1985

VITARINE 8MG A086453 001

8MG A086456 001

WATSON LABS 8MG A085739 001

TORA

SOLVAY 8MG A084035 001

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

IONAMIN

UCB INC EQ 15MG BASE N011613 004

EQ 30MG BASE N011613 002

PHENTERMINE RESIN 30

QUANTUM PHARMICS EQ 30MG BASE A089120 001 Feb 04, 1988

PHENYL AMINOSALICYLATE

POWDER; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC 50% N011695 002

TABLET; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC 500MG N011695 003

PHENYLBUTAZONE

CAPSULE; ORAL

AZOLID

SANOFI AVENTIS US 100MG A087260 001

BUTAZOLIDIN

NOVARTIS 100MG N008319 009

PHENYLBUTAZONE

IVAX PHARMS 100MG A088218 001 Jun 24, 1983

MUTUAL PHARM 100MG A088994 001 Dec 04, 1985

SANDOZ 100MG A087774 001 Jun 16, 1982

WATSON LABS 100MG A087756 001 Dec 17, 1982

TABLET; ORAL

AZOLID

SANOFI AVENTIS US 100MG A087091 001

BUTAZOLIDIN

NOVARTIS 100MG N008319 008

PHENYLBUTAZONE

MUTUAL PHARM 100MG A088863 001 Dec 04, 1985

SANDOZ 100MG A084339 001

WATSON LABS 100MG A086151 001

100MG A087674 001 Apr 21, 1982

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC

ANI PHARMS 5MG/5ML; 6.25MG/5ML N008604 003 Apr 02, 1984

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 691 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 250 (of 324)

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE VC

HALSEY

5MG/5ML; 6.25MG/5ML

A088868 001

Mar 02, 1987

PROMETHAZINE VC PLAIN

CENCI

5MG/5ML; 6.25MG/5ML

A088815 001

Nov 22, 1985

MORTON GROVE

5MG/5ML; 6.25MG/5ML

A088897 001

Jan 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

PREFRIN-A

ALLERGAN

0.12%; 0.1%

N007953 001

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-30

PARKE DAVIS

30MG/5ML

N008762 002

PHENYTOIN

ACTAVIS MID ATLANTIC

125MG/5ML

A089892 001

Sep 25, 1992

PHENYTOIN SODIUM

CAPSULE; ORAL

DIPHENYLAN SODIUM

LANNETT

30MG PROMPT

A080857 001

100MG PROMPT

A080857 002

EXTENDED PHENYTOIN SODIUM

BARR

100MG EXTENDED

A040435 001

Jun 20, 2003

PLIVA

100MG EXTENDED

A089441 001

Dec 18, 1986

PHENYTEX

WATSON LABS

100MG EXTENDED

A088711 001

Dec 21, 1984

PHENYTOIN SODIUM

PHARMERAL

100MG PROMPT

A085435 001

WATSON LABS

100MG PROMPT

A085894 001

PROMPT PHENYTOIN SODIUM

IVAX SUB TEVA PHARMS

100MG PROMPT

A080259 001

WATSON LABS

100MG PROMPT

A080905 001

INJECTABLE; INJECTION

DILANTIN

PARKE DAVIS

50MG/ML

N010151 001

PHENYTOIN SODIUM

APP PHARMS

50MG/ML

A089003 001

May 31, 1985

MARSAM PHARMS LLC

50MG/ML

A089501 001

Oct 13, 1987

50MG/ML

A089779 001

Nov 27, 1992

SMITH AND NEPHEW

50MG/ML

A088519 001

Dec 19, 1984

50MG/ML

A088521 001

Dec 18, 1984

SOLOPAK

50MG/ML

A088520 001

Dec 17, 1984

WARNER CHILCOTT

50MG/ML

A089900 001

Mar 30, 1990

WATSON LABS

50MG/ML

A085434 001

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

ATON

1MG/0.5ML

N012223 002

10MG/ML

N012223 001

KONAKION

ROCHE

1MG/0.5ML

N011745 001

10MG/ML

N011745 003

PHYTONADIONE

GLAXOSMITHKLINE

1MG/0.5ML

A084060 001

10MG/ML

A084060 002

VITAMIN K1

HOSPIRA

10MG/ML

A087956 001

Jul 25, 1983

## DISCONTINUED DRUG PRODUCT LIST

6 - 251 (of 324)

PILOCARPINE

INSERT, EXTENDED RELEASE; OPHTHALMIC

OCUSERT PILO-20

AKORN 5MG N017431 001

OCUSERT PILO-40

AKORN 11MG N017548 001

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL

PINDAC

LEO PHARM 12.5MG N019456 001 Dec 28, 1989

25MG N019456 002 Dec 28, 1989

PINDOLOL

TABLET; ORAL

PINDOLOL

GENPHARM 5MG A074013 001 Sep 24, 1992

10MG A074018 001 Sep 24, 1992

IVAX SUB TEVA PHARMS 5MG A073687 001 Feb 26, 1993

10MG A073687 002 Feb 26, 1993

MUTUAL PHARM 5MG A074063 001 Jan 27, 1994

10MG A074063 002 Jan 27, 1994

NOSTRUM LABS 5MG A074474 001 Oct 28, 1996

10MG A074474 002 Oct 28, 1996

PUREPAC PHARM 5MG A074125 001 Apr 28, 1993

10MG A074125 002 Apr 28, 1993

SANDOZ 5MG A073608 001 Mar 29, 1993

10MG A073609 001 Mar 29, 1993

TEVA 5MG A073661 001 Oct 31, 1993

5MG A074123 001 Apr 17, 1997

10MG A073661 002 Oct 31, 1993

10MG A074123 002 Apr 17, 1997

VISKEN

NOVARTIS 5MG N018285 001 Sep 03, 1982

10MG N018285 002 Sep 03, 1982

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION

ARDUAN

ORGANON USA INC 10MG/VIAL N019638 001 Jun 26, 1990

PIPERACETAZINE

TABLET; ORAL

QUIDE

DOW PHARM 10MG N013615 001

25MG N013615 002

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPRACIL

WYETH PHARMS INC EQ 2GM BASE/VIAL A062750 001 Oct 13, 1987

EQ 2GM BASE/VIAL N050545 002

EQ 3GM BASE/VIAL A062750 002 Oct 13, 1987

EQ 3GM BASE/VIAL N050545 003

EQ 4GM BASE/VIAL A062750 003 Oct 13, 1987

EQ 4GM BASE/VIAL N050545 004

EQ 40GM BASE/VIAL N050545 006 Sep 30, 1985

PIPERAZINE CITRATE

SYRUP; ORAL

ANTEPAR

GLAXOSMITHKLINE EQ 500MG BASE/5ML N009102 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 252 (of 324)

PIPERAZINE CITRATE

SYRUP; ORAL

BRYREL

SANOFI AVENTIS US EQ 500MG BASE/5ML N017796 001

MULTIFUGE

BLULINE EQ 500MG BASE/5ML N009452 001

PIPERAZINE CITRATE

ALPHARMA US PHARMS EQ 500MG BASE/5ML A080774 001

LANNETT EQ 500MG BASE/5ML A080963 001

LUITPOLD EQ 500MG BASE/5ML A080671 001

VERMIDOL

SOLVAY EQ 500MG BASE/5ML A080992 001

TABLET; ORAL

ANTEPAR

GLAXOSMITHKLINE EQ 500MG BASE N009102 003

PIPERAZINE CITRATE

IMPAX LABS EQ 250MG BASE A080874 001

PIPOBROMAN

TABLET; ORAL

VERCYTE

ABBOTT 10MG N016245 001

25MG N016245 002

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

GRACEWAY EQ 0.2MG BASE/INH N019009 001 Dec 30, 1986

PIROXICAM

CAPSULE; ORAL

PIROXICAM

EGIS 10MG A074808 001 Jul 08, 1997

20MG A074808 002 Jul 08, 1997

GENPHARM 10MG A074043 001 Sep 22, 1992

20MG A074043 002 Sep 22, 1992

IVAX SUB TEVA PHARMS 10MG A074148 001 Jun 03, 1996

20MG A074148 002 Jun 03, 1996

MUTUAL PHARM 20MG A073536 001 Mar 12, 1993

ROXANE 10MG A073651 001 Feb 26, 1993

20MG A073651 002 Feb 26, 1993

SCS 10MG A074036 001 May 29, 1992

20MG A074036 002 May 29, 1992

TEVA 10MG A073637 001 Jan 28, 1994

20MG A073638 001 Jan 28, 1994

TEVA PHARMS 10MG A074103 001 Aug 28, 1992

20MG A074103 002 Aug 28, 1992

PLICAMYCIN

INJECTABLE; INJECTION

MITHRACIN

PFIZER 2.5MG/VIAL N050109 001

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION

ESTRADURIN

WYETH AYERST 40MG/AMP N010753 001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

TEVA PHARMS 17GM/SCOOPFUL A077445 001 May 04, 2006

## DISCONTINUED DRUG PRODUCT LIST

6 - 253 (of 324)

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE;  
SODIUM SULFATE

SOLUTION; ORAL

OCL

HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML;146MG/ 100ML;1.29GM/100ML	N019284	001	Apr 30, 1986
---------	---	---------	-----	--------------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE;  
SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

ALAVEN PHARM	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKE T;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984
	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PAC KET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984
	360GM/PACKET;4.47GM/PACKET;10.08GM/PACK ET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984

FOR SUSPENSION; ORAL

CO-LAV

BOCA PHARMA	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/ BOT;22.72GM/BOT	A073428	001	Jan 28, 1992
-------------	--	---------	-----	--------------

COLOVAGE

DYNAPHARM	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PAC KET;5.53GM/PACKET;21.5GM/PACKET	A071320	001	Apr 20, 1988
-----------	--	---------	-----	--------------

E-Z-EM PREP LYTE

E Z EM	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/ BOT;22.74GM/BOT	A071278	001	Nov 21, 1988
--------	--	---------	-----	--------------

GLYCOPREP

GOLDLINE	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/ BOT;22.74GM/BOT	A072319	001	Dec 23, 1988
----------	--	---------	-----	--------------

GO-EVAC

BOCA PHARMA	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/ BOT;22.74GM/BOT	A073433	001	Apr 28, 1992
-------------	--	---------	-----	--------------

PEG-LYTE

SANDOZ	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/ BOT;22.74GM/BOT	A073098	001	Aug 31, 1993
--------	--	---------	-----	--------------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

AEROSPORIN

GLAXOSMITHKLINE	EQ 500,000 U BASE/VIAL	A062036	001	
-----------------	------------------------	---------	-----	--

POWDER; FOR RX COMPOUNDING

POLYMYXIN B SULFATE

PADDOCK	100,000,000 UNITS/BOT	A062455	001	Jul 27, 1983
---------	-----------------------	---------	-----	--------------

POLYTHIAZIDE

TABLET; ORAL

RENESE

PFIZER	1MG	N012845	001	
	2MG	N012845	002	
	4MG	N012845	003	

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIZIDE

PFIZER	0.5MG;EQ 1MG BASE	N017986	001	
	0.5MG;EQ 2MG BASE	N017986	002	
	0.5MG;EQ 5MG BASE	N017986	003	

POLYTHIAZIDE; RESERPINE

TABLET; ORAL

RENESE-R

PFIZER	2MG;0.25MG	N013636	001	
--------	------------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 254 (of 324)

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL

PASKALIUM

GLENWOOD

500MG

N009395 004

POWDER; ORAL

POTASSIUM AMINOSALICYLATE

HEXCEL

100%

A080098 001

TABLET; ORAL

PASKALIUM

GLENWOOD

1GM

N009395 003

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

SAVAGE LABS

8MEQ

A073398 001

Jan 28, 1992

10MEQ

A072427 001

Mar 28, 1990

MICRO-K

KV PHARM

8MEQ

N018238 001

MICRO-K 10

KV PHARM

10MEQ

N018238 002

May 14, 1984

POTASSIUM CHLORIDE

KV PHARM

10MEQ

A070980 001

Feb 17, 1987

TEVA

8MEQ

A073531 001

Apr 26, 1996

10MEQ

A073532 001

Apr 26, 1996

FOR SUSPENSION, EXTENDED RELEASE; ORAL

MICRO-K LS

KV PHARM

20MEQ/PACKET

N019561 003

Aug 26, 1988

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

ABRAXIS PHARM

2MEQ/ML

A080204 001

2MEQ/ML

A084290 001

2MEQ/ML

A086713 001

2MEQ/ML

A086714 001

2MEQ/ML

A087787 001

Apr 20, 1982

2MEQ/ML

A087885 001

Feb 03, 1983

AKORN

2MEQ/ML

A088286 001

Sep 05, 1985

APP PHARMS

2MEQ/ML

A087817 001

Oct 20, 1982

BAXTER HLTHCARE

2MEQ/ML

A080203 001

GD SEARLE LLC

1MEQ/ML

A086219 001

2MEQ/ML

A086219 002

2MEQ/ML

A086220 002

3MEQ/ML

A086219 003

3MEQ/ML

A086220 001

4MEQ/ML

A086219 004

HOSPIRA

1MEQ/ML

A080205 003

1MEQ/ML

A083345 003

1.5MEQ/ML

A083345 001

2MEQ/ML

A083345 002

2.4MEQ/ML

A080205 004

3.2MEQ/ML

A080205 005

LILLY

2MEQ/ML

N007865 002

LUITPOLD

2MEQ/ML

A080221 001

2MEQ/ML

A080736 001

2MEQ/ML

A087584 001

2MEQ/ML

A087585 001

MILES

1MEQ/ML

A080195 002

2MEQ/ML

A080195 001

3MEQ/ML

A080195 003

4MEQ/ML

A080195 004

PHARMA SERVE NY

2MEQ/ML

A086297 001

2MEQ/ML

A087362 001

Mar 08, 1983

WATSON LABS

2MEQ/ML

A086208 001

2MEQ/ML

A089163 001

Mar 10, 1988

2MEQ/ML

A089421 001

Jan 02, 1987

3MEQ/ML

A086210 001



## DISCONTINUED DRUG PRODUCT LIST

6 - 255 (of 324)

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
K+8

FUTURE PAK	8MEQ	A070998	001	Jan 25, 1993
KAON CL				
SAVAGE LABS	6.7MEQ	N017046	001	
POTASSIUM CHLORIDE				
COPLY PHARM	8MEQ	A070618	001	Sep 09, 1987
SLOW-K				
NOVARTIS	8MEQ	N017476	002	
TEN-K				
NOVARTIS	10MEQ	N019381	001	Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	37MG/100ML;900MG/100ML	N019708	001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	75MG/100ML;900MG/100ML	N019708	002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	110MG/100ML;900MG/100ML	N019708	003	Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	220MG/100ML;900MG/100ML	N019708	005	Sep 29, 1989
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	300MG/100ML;900MG/100ML	N019708	006	Sep 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER				
B BRAUN	75MG/100ML;900MG/100ML	N018722	001	Nov 09, 1982
BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N017648	004	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
B BRAUN	150MG/100ML;900MG/100ML	N018722	002	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER				
B BRAUN	220MG/100ML;900MG/100ML	N018722	003	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
B BRAUN	300MG/100ML;900MG/100ML	N018722	004	Nov 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E				
HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N013025	001	

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE				
MISSION PHARMA	10MEQ/PACKET	N019647	002	Oct 13, 1988
	20MEQ/PACKET	N019647	001	Oct 13, 1988

POTASSIUM IODIDE

SOLUTION; ORAL

POTASSIUM IODIDE				
ROXANE	1GM/ML	N018551	001	Feb 19, 1982

TABLET; ORAL

THYRO-BLOCK				
MEDPOINTE PHARM HLC	130MG	N018307	001	

POTASSIUM PERCHLORATE

CAPSULE; ORAL

PERCHLORACAP				
MALLINCKRODT	200MG	N017551	001	

POVIDONE-IODINE

SOLUTION; TOPICAL

E-Z PREP				
CLINIPAD	10%	N019382	001	Jul 25, 1989

## DISCONTINUED DRUG PRODUCT LIST

6 - 256 (of 324)

POVIDONE-IODINE

SPONGE; TOPICAL

E-Z PREP

CLINIPAD

5%

N019382 002 Jul 25, 1989

E-Z PREP 220

CLINIPAD

5%

N019382 003 Jul 25, 1989

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

BAXTER HLTHCARE CORP 300MG/ML

N018799 001 Dec 13, 1982

TABLET; ORAL

PROTOPAM CHLORIDE

WYETH AYERST 500MG

N014122 002

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

BOEHRINGER INGELHEIM 1.25MG

N020667 004 Jul 01, 1997

PRAZEPAM

CAPSULE; ORAL

CENTRAX

PARKE DAVIS

5MG

N018144 001

10MG

N018144 002

20MG

N018144 003 May 10, 1982

PRAZEPAM

USL PHARMA

5MG

A070427 001

Nov 06, 1987

10MG

A070428 001

Nov 06, 1987

TABLET; ORAL

CENTRAX

PARKE DAVIS

10MG

N017415 001

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

AM THERAP

EQ 1MG BASE

A072782 001

May 16, 1989

EQ 2MG BASE

A072783 001

May 16, 1989

EQ 5MG BASE

A072784 001

May 16, 1989

CLONMEL HLTHCARE

EQ 1MG BASE

A072705 001

May 16, 1989

EQ 2MG BASE

A072706 001

May 16, 1989

EQ 5MG BASE

A072707 001

May 16, 1989

PUREPAC PHARM

EQ 1MG BASE

A072991 001

May 16, 1989

EQ 2MG BASE

A072921 001

May 16, 1989

EQ 5MG BASE

A072992 001

May 16, 1989

SANDOZ

EQ 1MG BASE

A072576 001

May 16, 1989

EQ 2MG BASE

A072577 001

May 16, 1989

EQ 5MG BASE

A072578 001

May 16, 1989

WATSON LABS

EQ 5MG BASE

A072609 001

May 16, 1989

TABLET, EXTENDED RELEASE; ORAL

MINIPRESS XL

PFIZER

2.5MG

N019775 001

Jan 29, 1992

5MG

N019775 002

Jan 29, 1992

PREDNISOLONE

CREAM; TOPICAL

METI-DERM

SCHERING

0.5%

N010209 002

SYRUP; ORAL

PREDNISOLONE

TEVA PHARMS

15MG/5ML

A040322 001

Jan 19, 2000

WE PHARMS

15MG/5ML

A040192 001

May 28, 1998

PRELONE

MURO

5MG/5ML

A089654 001

Jan 17, 1989

## DISCONTINUED DRUG PRODUCT LIST

6 - 257 (of 324)

PREDNISOLONE

TABLET; ORAL

CORTALONE

HALSEY	1MG	A080304	003
	2.5MG	A080304	002
	5MG	A080304	001

DELTA-CORTEF

PHARMACIA AND UPJOHN	5MG	N009987	004
----------------------	-----	---------	-----

FERNISOLONE-P

FERNDALÉ LABS	5MG	A083941	001
---------------	-----	---------	-----

PREDNISOLONE

BARR	5MG	A084426	002
------	-----	---------	-----

BUNDY	5MG	A083675	001
-------	-----	---------	-----

ELKINS SINN	5MG	A080625	001
-------------	-----	---------	-----

EVERYLIFE	1MG	A084439	001
-----------	-----	---------	-----

	2.5MG	A084439	002
--	-------	---------	-----

	5MG	A084439	003
--	-----	---------	-----

FERRANTE	2.5MG	A080562	001
----------	-------	---------	-----

	5MG	A080562	002
--	-----	---------	-----

HEATHER	5MG	A080326	001
---------	-----	---------	-----

IMPAX LABS	5MG	A080780	001
------------	-----	---------	-----

INWOOD LABS	5MG	A080748	001
-------------	-----	---------	-----

IVAX SUB TEVA PHARMS	5MG	A080378	001
----------------------	-----	---------	-----

LANNETT	5MG	A080531	002
---------	-----	---------	-----

MARSHALL PHARMA	5MG	A080307	001
-----------------	-----	---------	-----

PANRAY	1MG	A080351	001
--------	-----	---------	-----

	5MG	A080351	002
--	-----	---------	-----

PERRIGO	5MG	A084542	001
---------	-----	---------	-----

PHOENIX LABS NY	5MG	A080322	001
-----------------	-----	---------	-----

PUREPAC PHARM	5MG	A080325	001
---------------	-----	---------	-----

PVT FORM	5MG	A080211	001
----------	-----	---------	-----

ROXANE	5MG	A080327	002
--------	-----	---------	-----

SANDOZ	5MG	A080339	001
--------	-----	---------	-----

	5MG	A084773	001
--	-----	---------	-----

SPERTI	1MG	A080358	001
--------	-----	---------	-----

	2.5MG	A080358	002
--	-------	---------	-----

	5MG	A080358	003
--	-----	---------	-----

SUPERPHARM	5MG	A088892	001
------------	-----	---------	-----

Feb 26, 1985

TABLICAPS	5MG	A085170	001
-----------	-----	---------	-----

TEVA	5MG	A080398	001
------	-----	---------	-----

UDL	5MG	A087987	001
-----	-----	---------	-----

Jan 18, 1983

VALEANT PHARM INTL	5MG	A080236	001
--------------------	-----	---------	-----

VITARINE	5MG	A080534	001
----------	-----	---------	-----

WATSON LABS	5MG	A085085	002
-------------	-----	---------	-----

	5MG	A085415	001
--	-----	---------	-----

	5MG	A085416	001
--	-----	---------	-----

WEST WARD	5MG	A080324	001
-----------	-----	---------	-----

WHITEWORTH TOWN PLSN	5MG	A080342	001
----------------------	-----	---------	-----

STERANE

PFIZER	5MG	N009996	001
--------	-----	---------	-----

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

METICORTELONE

SCHERING	25MG/ML	N010255	002
----------	---------	---------	-----

PREDNISOLONE ACETATE

AKORN	25MG/ML	A083032	001
-------	---------	---------	-----

	50MG/ML	A084492	001
--	---------	---------	-----

BEL MAR	25MG/ML	A083738	001
---------	---------	---------	-----

	50MG/ML	A083738	002
--	---------	---------	-----

CENT PHARMS	25MG/ML	A084717	001
-------------	---------	---------	-----

	50MG/ML	A084717	002
--	---------	---------	-----

WATSON LABS	25MG/ML	A083398	001
-------------	---------	---------	-----

	25MG/ML	A083654	001
--	---------	---------	-----

## DISCONTINUED DRUG PRODUCT LIST

6 - 258 (of 324)

PREDNISOLONE ACETATEINJECTABLE; INJECTION  
PREDNISOLONE ACETATE

WATSON LABS	40MG/ML	A083767	001
	50MG/ML	A083764	001
	50MG/ML	A085781	001

STERANE

PFIZER	25MG/ML	N011446	001
--------	---------	---------	-----

SUSPENSION; ORAL  
FLO-PRED

TARO	EQ 5MG BASE/5ML	N022067	001	Jan 17, 2008
------	-----------------	---------	-----	--------------

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

ALCON	0.125%	N017468	001
-------	--------	---------	-----

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

CETAPRED

ALCON	0.25%;10%	A087771	001	Aug 06, 1993
-------	-----------	---------	-----	--------------

METIMYD

SCHERING	0.5%;10%	N010210	002	Sep 09, 1984
----------	----------	---------	-----	--------------

PREDSULFAIR

PHARMAFAIR	0.5%;10%	A088032	001	Apr 15, 1983
------------	----------	---------	-----	--------------

VASOCIDIN

NOVARTIS	0.5%;10%	A088791	001	Oct 05, 1984
----------	----------	---------	-----	--------------

SUSPENSION; OPHTHALMIC

ISOPTO CETAPRED

ALCON	0.25%;10%	A087547	001
-------	-----------	---------	-----

SUSPENSION/DROPS; OPHTHALMIC

METIMYD

SCHERING	0.5%;10%	N010210	001
----------	----------	---------	-----

PREDAMIDE

AKORN	0.5%;10%	A088059	001	Jul 29, 1983
-------	----------	---------	-----	--------------

PREDSULFAIR

PHARMAFAIR	0.5%;10%	A088007	001	Apr 19, 1983
------------	----------	---------	-----	--------------

PREDSULFAIR II

PHARMAFAIR	0.2%;10%	A088837	001	Dec 24, 1985
------------	----------	---------	-----	--------------

SULPHRIN

BAUSCH AND LOMB	0.5%;10%	A088089	001	Dec 28, 1982
-----------------	----------	---------	-----	--------------

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDELTRASOL

MERCK	EQ 20MG PHOSPHATE/ML	N011583	002
-------	----------------------	---------	-----

PREDNISOLONE SODIUM PHOSPHATE

WATSON LABS	EQ 20MG PHOSPHATE/ML	A080517	001
-------------	----------------------	---------	-----

OINTMENT; OPHTHALMIC, OTIC

HYDELTRASOL

MERCK	EQ 0.25% PHOSPHATE	N011028	001
-------	--------------------	---------	-----

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

WE PHARMS	EQ 5MG BASE/5ML	A075181	001	Dec 23, 2002
-----------	-----------------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

INFLAMASE FORTE

NOVARTIS	EQ 0.9% PHOSPHATE	A080751	002
----------	-------------------	---------	-----

INFLAMASE MILD

NOVARTIS	EQ 0.11% PHOSPHATE	A080751	001
----------	--------------------	---------	-----

METRETON

SCHERING	EQ 0.5% PHOSPHATE	A083834	001
----------	-------------------	---------	-----

PREDAIR

PHARMAFAIR	EQ 0.11% PHOSPHATE	A088415	001	Feb 29, 1984
------------	--------------------	---------	-----	--------------

PREDAIR FORTE

PHARMAFAIR	EQ 0.9% PHOSPHATE	A088165	001	Mar 28, 1983
------------	-------------------	---------	-----	--------------

PREDNISOLONE SODIUM PHOSPHATE

AKORN	EQ 0.11% PHOSPHATE	A083358	001
-------	--------------------	---------	-----

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 700 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 259 (of 324)

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

AKORN	EQ 0.9% PHOSPHATE	A083358	002	
ALCON UNIVERSAL	EQ 0.11% PHOSPHATE	A081043	001	Oct 24, 1991
	EQ 0.9% PHOSPHATE	A081044	001	Oct 24, 1991
BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	A040065	001	Jul 29, 1994
SOLA BARNES HIND	EQ 0.11% PHOSPHATE	A084171	001	
	EQ 0.9% PHOSPHATE	A084168	001	
	EQ 0.9% PHOSPHATE	A084169	001	
	EQ 0.9% PHOSPHATE	A084172	001	

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULSTER

AKORN	EQ 0.23% PHOSPHATE;10%	A074511	001	Jul 30, 1996
-------	------------------------	---------	-----	--------------

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION

HYDELTRA-TBA

MERCK	20MG/ML	N010562	001	
-------	---------	---------	-----	--

PREDNISOLONE TEBUTATE

WATSON LABS	20MG/ML	A083362	001	Feb 17, 1984
-------------	---------	---------	-----	--------------

PREDNISONE

SOLUTION; ORAL

PREDNISONE

MORTON GROVE	5MG/5ML	A089726	001	Aug 02, 1988
--------------	---------	---------	-----	--------------

SYRUP; ORAL

LIQUID PRED

MURO	5MG/5ML	A087611	002	Sep 07, 1982
------	---------	---------	-----	--------------

TABLET; ORAL

CORTAN

HALSEY	20MG	A087480	001	
--------	------	---------	-----	--

DELTA-DOME

BAYER PHARMS	5MG	A080293	001	
--------------	-----	---------	-----	--

DELTASONE

PHARMACIA AND UPJOHN	2.5MG	N009986	005	
	5MG	N009986	002	
	10MG	N009986	006	
	20MG	N009986	007	
	50MG	N009986	008	

FERNISONE

FERNDAL LABS	5MG	A083364	001	
--------------	-----	---------	-----	--

METICORTEN

SCHERING	1MG	N009766	002	
----------	-----	---------	-----	--

	5MG	N009766	001	
--	-----	---------	-----	--

ORASONE

SOLVAY	1MG	A083009	001	
--------	-----	---------	-----	--

	5MG	A083009	002	
--	-----	---------	-----	--

	10MG	A083009	003	
--	------	---------	-----	--

	20MG	A083009	004	
--	------	---------	-----	--

	50MG	A085999	001	
--	------	---------	-----	--

PARACORT

PARKE DAVIS	5MG	N010962	002	
-------------	-----	---------	-----	--

PREDNICEN-M

SCHWARZ PHARMA	5MG	A084655	001	
----------------	-----	---------	-----	--

PREDNISONE

AM THERAP	5MG	A089387	001	Nov 06, 1986
-----------	-----	---------	-----	--------------

	10MG	A089388	001	Nov 06, 1986
--	------	---------	-----	--------------

	20MG	A089389	001	Nov 06, 1986
--	------	---------	-----	--------------

AMNEAL PHARMS NY	5MG	A089597	001	Oct 05, 1987
------------------	-----	---------	-----	--------------

	10MG	A089598	001	Oct 05, 1987
--	------	---------	-----	--------------

	20MG	A089599	001	Oct 05, 1987
--	------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 260 (of 324)

PREDNISONE

TABLET; ORAL

PREDNISONE

BUNDY	5MG	A083676	001	
DURAMED PHARMS BARR	5MG	A088394	001	Oct 04, 1983
	10MG	A088395	001	Oct 04, 1983
	20MG	A088396	001	Oct 04, 1983
ELKINS SINN	5MG	A080491	001	
	20MG	A085811	001	
EVERYLIFE	1MG	A084440	001	
	2.5MG	A084440	002	
	5MG	A084440	003	
FERRANTE	2.5MG	A080563	001	
	5MG	A080563	002	
HALSEY	5MG	A080300	001	
HEATHER	5MG	A080320	001	
	10MG	A084341	001	
	20MG	A084417	001	
	20MG	A085543	001	
	50MG	A086946	001	
IMPAX LABS	5MG	A080782	001	
INWOOD LABS	1MG	A080328	001	
	2.5MG	A080306	001	
	5MG	A080279	001	
IVAX SUB TEVA PHARMS	5MG	A080283	001	
	10MG	A084133	001	
	20MG	A084134	001	
KV PHARM	5MG	A084236	001	
LANNETT	5MG	A080514	001	
	20MG	A084275	001	
LEDERLE	5MG	A086968	001	
MARSHALL PHARMA	5MG	A080301	001	
MUTUAL PHARM	5MG	A080701	001	
	10MG	A086595	001	
	20MG	A084634	001	
	50MG	A086596	001	
NYLOS	5MG	A085115	001	
PANRAY	1MG	A080350	001	
	2.5MG	A080350	002	
	5MG	A080350	003	
PERRIGO	5MG	A083059	001	
PHARMAVITE	5MG	A084662	002	
PHOENIX LABS NY	5MG	A080321	001	
	20MG	A083807	001	
PUREPAC PHARM	5MG	A080353	001	
	10MG	A086062	001	
	20MG	A086061	001	
PVT FORM	20MG	A085151	001	
REXALL	5MG	A080232	001	
ROXANE	20MG	N017109	001	
	25MG	A087833	001	May 04, 1982
SANDOZ	5MG	A080336	002	
	5MG	A084774	001	
	10MG	A089983	001	Jan 12, 1989
	20MG	A085813	001	
	50MG	A089984	001	Jan 12, 1989
SCHERER LABS	5MG	A080371	001	
SPERTI	1MG	A080359	001	
	2.5MG	A080359	002	
	5MG	A080359	003	
SUPERPHARM	5MG	A088865	001	Oct 25, 1984
	10MG	A088866	001	Oct 25, 1984
	20MG	A088867	001	Oct 25, 1984
TEVA	5MG	A080397	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 261 (of 324)

PREDNISONE

TABLET; ORAL

PREDNISONE

UDL	5MG	A087984	001	Jan 18, 1983
	10MG	A087985	001	Jan 18, 1983
	20MG	A087986	001	Jan 18, 1983
UPSHER SMITH	5MG	A087471	001	
	20MG	A087470	001	
VALEANT PHARM INTL	5MG	A080237	001	
VANGARD	5MG	A087682	001	Jan 15, 1982
	20MG	A087701	001	Jan 15, 1982
VITARINE	5MG	A080334	001	
	5MG	A080506	001	
WATSON LABS	5MG	A085084	002	
	10MG	A087773	001	Jul 13, 1982
	20MG	A086813	001	
	50MG	A086867	001	
	50MG	A087772	001	Jul 13, 1982
WEST WARD	50MG	A088465	001	Jun 01, 1984
WHITEWORTH TOWN PLSN	2.5MG	A084913	001	
	5MG	A080343	001	
	10MG	A089028	001	Jul 24, 1986
	20MG	A084913	002	
SERVISONE				
LEDERLE	5MG	A080223	001	

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST

ASTRAZENECA	1%	N014763	004	
	2%	N014763	005	
	3%	N014763	003	
CITANEST PLAIN				
ASTRAZENECA	4%	N014763	007	

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

XCEL PHARMS	250MG/5ML	N010401	001	
-------------	-----------	---------	-----	--

TABLET; ORAL

PRIMIDONE

WATSON LABS	250MG	A085052	001	
-------------	-------	---------	-----	--

PROBENECID

TABLET; ORAL

BENEMID

MERCK	500MG	N007898	004	
-------	-------	---------	-----	--

PROBENECID

LEDERLE	500MG	A086917	001	
---------	-------	---------	-----	--

WATSON LABS	500MG	A086150	002	Apr 23, 1982
-------------	-------	---------	-----	--------------

PROBUCOL

TABLET; ORAL

LORELCO

SANOFI AVENTIS US	250MG	N017535	001	
	500MG	N017535	002	Jul 06, 1988

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ASCOT	250MG	A087542	001	Jan 08, 1982
	375MG	A087697	001	Mar 01, 1983
	500MG	A087543	001	Jan 08, 1982
IVAX SUB TEVA PHARMS	250MG	A084604	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 262 (of 324)

PROCAINAMIDE HYDROCHLORIDE

## CAPSULE; ORAL

## PROCAINAMIDE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	375MG	A084595	001	
	500MG	A084606	001	
LANNETT	250MG	A083693	001	
	500MG	A084696	001	
LEDERLE	250MG	A086942	001	
	375MG	A086952	001	
	500MG	A086943	001	
ROXANE	250MG	A088989	001	Apr 26, 1985
	500MG	A088990	001	Apr 26, 1985
SANDOZ	250MG	A089219	001	Jul 01, 1986
	375MG	A089220	001	Jul 01, 1986
	500MG	A089221	001	Jul 01, 1986
VANGARD	250MG	A087643	001	Jun 01, 1982
	500MG	A087875	001	Jun 01, 1982
WATSON LABS	250MG	A083287	001	
	250MG	A083795	001	
	250MG	A085167	001	
	375MG	A084403	001	
	375MG	A087020	001	
	500MG	A084280	001	
	500MG	A084357	001	
	500MG	A087021	001	
PROCAN				
PARKE DAVIS	250MG	A085804	001	
	375MG	A087502	001	
	500MG	A085079	001	
PROCAPAN				
PANRAY	250MG	A083553	002	
PRONESTYL				
APOTHECON	250MG	N007335	001	
	375MG	N007335	004	
	500MG	N007335	003	

## INJECTABLE; INJECTION

## PROCAINAMIDE HYDROCHLORIDE

ABRAXIS PHARM	100MG/ML	A089415	001	Nov 17, 1986
	500MG/ML	A089416	001	Nov 17, 1986
BAXTER HLTHCARE	100MG/ML	A089029	001	Apr 17, 1986
	500MG/ML	A089030	001	Apr 17, 1986
HOSPIRA	500MG/ML	A089537	001	Aug 25, 1987
PHARMAFAIR	100MG/ML	A088824	001	Nov 20, 1985
	500MG/ML	A088830	001	Nov 20, 1985
SMITH AND NEPHEW	100MG/ML	A088530	001	Mar 04, 1985
	500MG/ML	A088531	001	Mar 04, 1985
SOLOPAK	500MG/ML	A088532	001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML	A089528	001	May 03, 1988
	500MG/ML	A089529	001	May 03, 1988
WATSON LABS	100MG/ML	A087079	001	
	500MG/ML	A087080	001	
PRONESTYL				
APOTHECON	100MG/ML	N007335	002	
	500MG/ML	N007335	005	

## TABLET; ORAL

## PRONESTYL

APOTHECON	250MG	N017371	001	
	375MG	N017371	002	
	500MG	N017371	003	

## TABLET, EXTENDED RELEASE; ORAL

## PROCAINAMIDE HYDROCHLORIDE

COPLLEY PHARM	500MG	A088974	001	Jul 22, 1985
	750MG	A089438	001	Mar 23, 1987
	1GM	A040111	001	Dec 13, 1996
INWOOD LABS	500MG	A089840	001	Mar 06, 1989



## DISCONTINUED DRUG PRODUCT LIST

6 - 263 (of 324)

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HYDROCHLORIDE

PLIVA	250MG	A088958	001	Dec 02, 1985
	500MG	A088959	001	Dec 02, 1985
SANDOZ	250MG	A089369	001	Aug 14, 1987
	500MG	A089284	001	Jun 23, 1986
	500MG	A089370	001	Jan 09, 1987
	750MG	A089371	001	Aug 14, 1987
WATSON LABS	250MG	A088533	001	Dec 03, 1984
	250MG	A089026	001	Oct 22, 1985
	500MG	A088534	001	Dec 03, 1984
	500MG	A089027	001	Oct 22, 1985
	750MG	A088535	001	Nov 03, 1984
	750MG	A089042	001	Oct 22, 1985
	1GM	A089520	001	Jan 15, 1987
PROCAN SR				
PARKE DAVIS	250MG	A086468	001	
PARKEDALE	500MG	A086065	001	
	750MG	A087510	001	Apr 01, 1982
	1GM	A088489	001	Jan 16, 1985
PROCANBID				
KING PHARMS	500MG	N020545	001	Jan 31, 1996
	1GM	N020545	002	Jan 31, 1996
PRONESTYL-SR				
APOTHECON	500MG	A087361	001	

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

HOSPIRA	1%	A085362	003	
	2%	A085362	004	
	10%	A086797	001	

PROCAINE HYDROCHLORIDE

ABRAXIS PHARM	1%	A080384	002	
	1%	A080421	001	
	2%	A080384	003	
	2%	A080421	002	
BEL MAR	1%	A080711	001	
	2%	A080756	001	
ELKINS SINN	1%	A083315	001	
	2%	A083315	002	
GD SEARLE LLC	1%	A086202	001	
	2%	A086202	002	
HOSPIRA	1%	A080416	001	
	2%	A080416	002	
MILES	1%	A080415	001	
	2%	A080415	002	
WATSON LABS	1%	A083535	001	
	2%	A080658	002	
	2%	A083535	002	

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE	40MG/VIAL;100MG/VIAL	N050276	001	
	40MG/VIAL;250MG/VIAL	N050276	003	

TETRACYN

PFIZER	40MG/VIAL;100MG/VIAL	A060285	002	
	40MG/VIAL;250MG/VIAL	A060285	003	

## DISCONTINUED DRUG PRODUCT LIST

6 - 264 (of 324)

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE; INJECTION

DICURIN PROCAINE

LILLY

100MG/ML; 50MG/ML

N008869 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPAZINE

GLAXOSMITHKLINE

2.5MG

N011127 003

5MG

N011127 001

25MG

N011127 002

PROCHLORPERAZINE

ABLE

2.5MG

A040407 001

Jul 11, 2001

5MG

A040407 002

Jul 11, 2001

25MG

A040407 003

Jul 11, 2001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 10MG BASE/ML

N011276 001

PROCHLORPERAZINE

ALPHARMA US PHARMS

EQ 10MG BASE/ML

A087153 001

Jun 08, 1982

PROCHLORPERAZINE EDISYLATE

MORTON GROVE

EQ 10MG BASE/ML

A088598 001

Oct 25, 1984

INJECTABLE; INJECTION

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE/ML

N010742 002

PROCHLORPERAZINE

BAXTER HLTHCARE

EQ 5MG BASE/ML

A087759 001

Oct 01, 1982

PROCHLORPERAZINE EDISYLATE

BAXTER HLTHCARE

EQ 5MG BASE/ML

A089523 001

May 03, 1988

HOSPIRA

EQ 5MG BASE/ML

A089703 001

Apr 07, 1988

MARSAM PHARMS LLC

EQ 5MG BASE/ML

A089675 001

Dec 05, 1988

SMITH AND NEPHEW

EQ 5MG BASE/ML

A089251 001

Dec 04, 1986

TEVA PARENTERAL

EQ 5MG BASE/ML

A040505 001

May 30, 2003

WATSON LABS

EQ 5MG BASE/ML

A089530 001

Jul 08, 1987

EQ 5MG BASE/ML

A089605 001

Jul 08, 1987

EQ 5MG BASE/ML

A089606 001

Jul 08, 1987

WYETH AYERST

EQ 5MG BASE/ML

A086348 001

SYRUP; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE/5ML

N011188 001

PROCHLORPERAZINE EDISYLATE

ALPHARMA US PHARMS

EQ 5MG BASE/5ML

A087154 001

Sep 01, 1982

MORTON GROVE

EQ 5MG BASE/5ML

A088597 001

Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 10MG BASE

N011000 001

EQ 10MG BASE

N021019 001

Oct 06, 1999

EQ 15MG BASE

N011000 002

EQ 15MG BASE

N021019 002

Oct 06, 1999

EQ 30MG BASE

N011000 003

EQ 75MG BASE

N011000 004

TABLET; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE

N010571 001

EQ 10MG BASE

N010571 002

EQ 25MG BASE

N010571 003

PROCHLORPERAZINE

WATSON LABS

EQ 5MG BASE

A085580 001

EQ 10MG BASE

A085178 001

EQ 25MG BASE

A085579 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 265 (of 324)

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

DURAMED PHARMS BARR	EQ 5MG BASE	A089484	001	Jan 20, 1987
	EQ 10MG BASE	A089485	001	Jan 20, 1987
	EQ 25MG BASE	A089486	001	Jan 20, 1987
IVAX SUB TEVA PHARMS	EQ 5MG BASE	A040162	001	Jan 20, 1998
	EQ 10MG BASE	A040162	002	Jan 20, 1998
SANDOZ	EQ 25MG BASE	A040101	003	Jul 19, 1996

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

MONARCH PHARMS	2MG	N009818	005	
	5MG	N009818	003	

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

UNIMED PHARMS LLC	300MG	N019781	003	Oct 15, 1999
-------------------	-------	---------	-----	--------------

INJECTABLE; INJECTION

PROGESTERONE

LILLY	25MG/ML	N009238	002	
	50MG/ML	N009238	001	

INSERT, EXTENDED RELEASE; INTRAUTERINE

PROGESTASERT

ALZA	38MG	N017553	001	
------	------	---------	-----	--

PROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SPARINE

WYETH AYERST	30MG/ML	N010942	001	
	100MG/ML	N010942	004	

INJECTABLE; INJECTION

PROMAZINE HYDROCHLORIDE

WATSON LABS	25MG/ML	A084510	001	
	50MG/ML	A084517	001	

SPARINE

BAXTER HLTHCARE CORP	25MG/ML	N010349	008	
	50MG/ML	N010349	006	

SYRUP; ORAL

SPARINE

WYETH AYERST	10MG/5ML	N010942	003	
--------------	----------	---------	-----	--

TABLET; ORAL

SPARINE

WYETH AYERST	10MG	N010348	006	
	25MG	N010348	001	
	50MG	N010348	002	
	100MG	N010348	003	
	200MG	N010348	004	

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PHENERGAN

WYETH AYERST	25MG/ML	N008857	002	
	50MG/ML	N008857	003	

PROMETHAZINE HYDROCHLORIDE

ABBOTT	25MG/ML	A084223	001	
	50MG/ML	A084222	001	
AKORN	25MG/ML	A083955	002	
	50MG/ML	A083955	001	
BEDFORD LABS	25MG/ML	A040524	001	Mar 17, 2004
	50MG/ML	A040524	002	Mar 17, 2004
BIONICHE PHARMA	25MG/ML	A040471	001	Nov 21, 2002

## DISCONTINUED DRUG PRODUCT LIST

6 - 266 (of 324)

PROMETHAZINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## PROMETHAZINE HYDROCHLORIDE

HOSPIRA	50MG/ML	A040372	002	Jun 08, 2000
	50MG/ML	A083838	002	
MARSAM PHARMS LLC	25MG/ML	A089463	001	May 02, 1988
	50MG/ML	A089477	001	May 02, 1988
SANDOZ	25MG/ML	A040593	001	Nov 08, 2006
	50MG/ML	A040593	002	Nov 08, 2006
WATSON LABS	25MG/ML	A083532	001	
	25MG/ML	A084591	001	
	50MG/ML	A080629	002	
	50MG/ML	A083532	002	
ZIPAN-25				
ALTANA	25MG/ML	A083997	001	
ZIPAN-50				
ALTANA	50MG/ML	A083997	002	

## SUPPOSITORY; RECTAL

## PHENERGAN

VICTORY PHARMA	12.5MG	N010926	002	
	25MG	N010926	001	
	50MG	N011689	001	

## PROMETHACON

POLYMEDICA	25MG	A084901	001	
	50MG	A084902	001	

## PROMETHAZINE HYDROCHLORIDE

ABLE	12.5MG	A040504	001	Apr 11, 2003
	25MG	A040504	002	Apr 11, 2003
	50MG	A040449	001	Feb 27, 2003

## SYRUP; ORAL

## MYMETHAZINE FORTIS

USL PHARMA	25MG/5ML	A087996	001	Jan 18, 1983
------------	----------	---------	-----	--------------

## PROMETH FORTIS

ALPHARMA US PHARMS	25MG/5ML	A084772	001	
--------------------	----------	---------	-----	--

## PROMETH PLAIN

ACTAVIS MID ATLANTIC	6.25MG/5ML	A085953	001	
----------------------	------------	---------	-----	--

## PROMETHAZINE

CENCI	6.25MG/5ML	A089013	001	Sep 20, 1985
-------	------------	---------	-----	--------------

## PROMETHAZINE HYDROCHLORIDE

KV PHARM	6.25MG/5ML	A085388	001	
	25MG/5ML	A085385	001	
PHARM ASSOC	6.25MG/5ML	A087518	001	
WHITEWORTH TOWN PLSN	6.25MG/5ML	A086395	001	

## PROMETHAZINE HYDROCHLORIDE PLAIN

ANI PHARMS	6.25MG/5ML	N008381	004	Apr 18, 1984
	25MG/5ML	N008381	003	

## TABLET; ORAL

## PHENERGAN

WYETH PHARMS INC	12.5MG	N007935	002	
	25MG	N007935	003	
	50MG	N007935	004	

## PROMETHAZINE HYDROCHLORIDE

ABBOTT	12.5MG	A084160	001	
	25MG	A084166	001	
	50MG	A084539	001	
ABLE	12.5MG	A040558	001	Jul 01, 2004
	25MG	A040558	002	Jul 01, 2004
	50MG	A040558	003	Jul 01, 2004
IMPAX LABS	25MG	A084214	002	Jul 07, 1982
IVAX SUB TEVA PHARMS	12.5MG	A083604	001	
	25MG	A083603	001	
	50MG	A083613	001	
LANNETT	12.5MG	A080949	001	
	25MG	A080949	002	
	50MG	A080949	003	

## DISCONTINUED DRUG PRODUCT LIST

6 - 267 (of 324)

PROMETHAZINE HYDROCHLORIDE

## TABLET; ORAL

## PROMETHAZINE HYDROCHLORIDE

MUTUAL PHARM	12.5MG	A084555	001	
	25MG	A084554	001	
	50MG	A084557	001	
PVT FORM	12.5MG	A083214	001	
	25MG	A083658	001	
SANDOZ	12.5MG	A084176	002	May 22, 2009
	12.5MG	A084233	001	
	25MG	A085146	001	
	50MG	A085146	002	
TABLICAPS	12.5MG	A084080	001	
	25MG	A084027	001	
TEVA	25MG	A089109	001	Sep 10, 1985
WATSON LABS	12.5MG	A083401	001	
	12.5MG	A083712	001	
	12.5MG	A085986	001	
	25MG	A083204	001	
	25MG	A085684	001	
	50MG	A083403	001	
	50MG	A085664	001	
REMSED				
BRISTOL MYERS SQUIBB	25MG	A083176	002	
	50MG	A083176	001	

PROPANTHELINE BROMIDE

## INJECTABLE; INJECTION

## PRO-BANTHINE

GD SEARLE LLC	30MG/VIAL	N008843	001	
---------------	-----------	---------	-----	--

## TABLET; ORAL

## PRO-BANTHINE

SHIRE	7.5MG	N008732	003	
	15MG	N008732	002	

## PROPANTHELINE BROMIDE

ASCOT	15MG	A087663	001	Oct 25, 1982
HEATHER	15MG	A085780	001	
IMPAX LABS	15MG	A084541	002	
MYLAN	15MG	A083706	001	
PAR PHARM	15MG	A088377	001	Dec 08, 1983
PVT FORM	15MG	A080977	001	
ROXANE	7.5MG	A080927	001	
	15MG	A080927	002	
SANDOZ	15MG	A080928	001	
TABLICAPS	15MG	A084428	001	
WATSON LABS	15MG	A083029	002	
	15MG	A083151	001	

PROPARACAINE HYDROCHLORIDE

## SOLUTION/DROPS; OPHTHALMIC

## KAINAIR

PHARMAFAIR	0.5%	A088087	001	Jun 07, 1983
------------	------	---------	-----	--------------

## PARACAINE

OPTOPICS	0.5%	A087681	001	Aug 05, 1982
----------	------	---------	-----	--------------

## PROPARACAINE HYDROCHLORIDE

SOLA BARNES HIND	0.5%	A084144	001	
	0.5%	A084151	001	

PROPIOLACTONE

## SOLUTION; IRRIGATION

## BETAPRONE

FOREST LABS	N/A	N011657	001	
-------------	-----	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 268 (of 324)

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

BAXTER HLTHCARE CORP 20MG/ML N012382 002

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

APP PHARMS 10MG/ML N019627 001 Oct 02, 1989

PROPOFOL

BEDFORD 10MG/ML A074848 001 Apr 19, 2005

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

XANODYNE PHARM 32MG N010997 001

KESSO-GESIC

MK LABS 65MG A083544 001

PROPHENE 65

HALSEY 65MG A083538 002

PROPOXYPHENE HYDROCHLORIDE

ALRA 65MG A083184 001

IMPAX LABS 65MG A083317 001

IVAX SUB TEVA PHARMS 32MG A083597 001

MUTUAL PHARM 65MG A083186 001

MYLAN 32MG A083528 001

65MG A083299 001

NEXGEN PHARMA INC 65MG A083185 001

PUREPAC PHARM 65MG A083278 001

PVT FORM 32MG A083464 001

65MG A083113 001

ROXANE 32MG A083089 001

65MG A083089 002

SANDOZ 32MG A084014 001

65MG A083125 002

65MG A083688 001

65MG A083870 002

65MG A086495 001

VALEANT PHARM INTL 65MG A080783 001

WATSON LABS 65MG A080908 002

65MG A085190 001

WHITEWORTH TOWN PLSN 65MG A084551 001

PROPOXYPHENE HYDROCHLORIDE 65

WARNER CHILCOTT 65MG A083786 001

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL

DARVON-N

AAIPHARMA LLC 50MG/5ML N016861 001

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

INWOOD LABS 60MG A072499 001 Apr 11, 1989

80MG A072500 001 Apr 11, 1989

120MG A072501 001 Apr 11, 1989

160MG A072502 001 Apr 11, 1989

CONCENTRATE; ORAL

PROPRANOLOL HYDROCHLORIDE INTENSOL

ROXANE 80MG/ML A071388 001 May 15, 1987

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

SMITH AND NEPHEW 1MG/ML A070135 001 Apr 15, 1986

1MG/ML A070137 001 Apr 15, 1986

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 710 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 269 (of 324)

PROPRANOLOL HYDROCHLORIDE

## INJECTABLE; INJECTION

## PROPRANOLOL HYDROCHLORIDE

SOLOPAK 1MG/ML A070136 001 Apr 15, 1986

## SOLUTION; ORAL

## PROPRANOLOL HYDROCHLORIDE

MORTON GROVE 20MG/5ML A071984 001 Mar 03, 1989

40MG/5ML A071985 001 Mar 03, 1989

## SUSPENSION; ORAL

## INDERAL

WYETH AYERST 10MG/ML N019536 001 Dec 12, 1986

## TABLET; ORAL

## INDERAL

AKRIMAX PHARMS 10MG N016418 001

20MG N016418 003

90MG N016418 010 Oct 18, 1982

## PROPRANOLOL HYDROCHLORIDE

AMNEAL PHARMS NY 10MG A071368 001 May 05, 1987

20MG A071369 001 May 05, 1987

40MG A071370 001 May 05, 1987

80MG A071371 001 May 05, 1987

CLONMEL HLTHCARE 10MG A070125 001 Jul 30, 1985

20MG A070126 001 Jul 30, 1985

40MG A070127 001 Jul 30, 1985

60MG A071495 001 Dec 31, 1987

80MG A070128 001 Jul 30, 1985

90MG A071496 001 Dec 31, 1987

DURAMED PHARMS BARR 10MG A070306 001 Sep 09, 1985

20MG A070307 001 Sep 09, 1985

40MG A070308 001 Sep 09, 1985

60MG A070309 001 Oct 01, 1986

80MG A070310 001 Sep 09, 1985

90MG A071327 001 Oct 01, 1986

IVAX SUB TEVA PHARMS 10MG A072063 001 Jul 29, 1988

20MG A072066 001 Jul 29, 1988

40MG A072067 001 Jul 29, 1988

60MG A072068 001 Jul 29, 1988

80MG A072069 001 Jul 29, 1988

LEDERLE 10MG A072117 001 Jun 23, 1988

20MG A072118 001 Jun 23, 1988

40MG A072119 001 Jun 23, 1988

80MG A072120 001 Jun 23, 1988

MUTUAL PHARM 10MG A070319 001 Oct 22, 1985

20MG A070320 001 Oct 22, 1985

40MG A070103 001 Oct 22, 1985

60MG A070321 001 Sep 24, 1986

80MG A070322 001 Aug 04, 1986

MYLAN 60MG A072275 001 Jun 09, 1989

PAR PHARM 90MG A071288 001 Oct 22, 1986

PLIVA 90MG A071977 001 Apr 06, 1988

PUREPAC PHARM 10MG A070814 001 Nov 03, 1986

20MG A070815 001 Nov 03, 1986

40MG A070816 001 Nov 03, 1986

60MG A070817 001 Nov 03, 1986

80MG A070757 001 Nov 03, 1986

ROXANE 10MG A070516 001 Jul 07, 1986

20MG A070517 001 Jul 07, 1986

40MG A070518 001 Jul 07, 1986

60MG A070519 001 Sep 24, 1986

80MG A070520 001 Jul 07, 1986

90MG A070521 001 Sep 24, 1986

SANDOZ 10MG A070663 001 Jun 13, 1986

10MG A071658 001 Jul 05, 1988

20MG A070664 001 Jun 13, 1986

20MG A071687 001 Jul 05, 1988

## DISCONTINUED DRUG PRODUCT LIST

6 - 270 (of 324)

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

SANDOZ	40MG	A070665	001	Jun 13, 1986
	40MG	A071688	001	Jul 05, 1988
	60MG	A070666	001	Oct 10, 1986
	60MG	A072197	001	Jul 05, 1988
	80MG	A070667	001	Jun 13, 1986
	80MG	A071689	001	Jul 05, 1988
	90MG	A072198	001	Jul 05, 1988
SCHERING	10MG	A070120	001	Aug 06, 1985
	20MG	A070121	001	Aug 06, 1985
	40MG	A070122	001	Aug 06, 1985
	60MG	A070123	001	Oct 29, 1986
	80MG	A070124	001	Aug 06, 1985
SUPERPHARM	10MG	A071515	001	Jun 08, 1988
	20MG	A071516	001	Jun 08, 1988
	40MG	A071517	001	Jun 08, 1988
	80MG	A071518	001	Jun 08, 1988
TEVA	10MG	A070232	001	Oct 07, 1987
	20MG	A070233	001	Jun 23, 1986
	40MG	A070234	001	Jun 23, 1986
VINTAGE	10MG	A070217	001	Aug 01, 1986
	20MG	A070218	001	Aug 01, 1986
	40MG	A070219	001	Aug 01, 1986
	60MG	A070220	001	Sep 24, 1986
	80MG	A070221	001	Apr 14, 1986
WARNER CHILCOTT	10MG	A070438	001	Sep 15, 1986
	20MG	A070439	001	Sep 15, 1986
	40MG	A070440	001	Sep 15, 1986
	60MG	A070441	001	Sep 24, 1986
	80MG	A070442	001	Sep 15, 1986
WATSON LABS	10MG	A070140	001	Jul 30, 1985
	10MG	A070378	001	Mar 19, 1987
	10MG	A070548	001	Jul 10, 1986
	20MG	A070141	001	Jul 30, 1985
	20MG	A070379	001	Mar 19, 1987
	20MG	A070549	001	Apr 11, 1986
	40MG	A070142	001	Jul 30, 1985
	40MG	A070380	001	Mar 19, 1987
	40MG	A070550	001	Apr 11, 1986
	60MG	A070143	001	Jan 15, 1987
	60MG	A070381	001	Mar 19, 1987
	60MG	A071098	001	Oct 06, 1986
	60MG	A071791	001	Jul 15, 1987
	80MG	A070144	001	Jul 30, 1985
	80MG	A070382	001	Mar 19, 1987
	80MG	A070551	001	Jul 10, 1986
	90MG	A071183	001	Oct 06, 1986
	90MG	A071792	001	Jul 15, 1987

PROPYLIODONE

SUSPENSION; INTRATRACHEAL

DIONOSIL AQUEOUS

GLAXOSMITHKLINE 50% N009309 001

DIONOSIL OILY

GLAXOSMITHKLINE 60% N009309 002

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

ABBOTT 50MG A084075 001

ANABOLIC 50MG A080285 001

HALSEY 50MG A080015 001

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 712 of 1114**



## DISCONTINUED DRUG PRODUCT LIST

6 - 271 (of 324)

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

IMPAX LABS	50MG	A080159	001
IVAX SUB TEVA PHARMS	50MG	A080215	001
LANNETT	50MG	A080016	001
LILLY	50MG	N006213	001
MUTUAL PHARM	50MG	A083982	001
PERRIGO	50MG	A084543	001
TABLICAPS	50MG	A080840	001
WATSON LABS	50MG	A080932	001
	50MG	A085201	001

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

BAXTER HLTHCARE	10MG/ML	A089474	001	Nov 05, 1986
	10MG/ML	A089475	001	Nov 05, 1986
LILLY	10MG/ML	N006460	002	
PHARMACIA AND UPJOHN	50MG/VIAL	N007413	001	
	250MG/VIAL	N007413	002	Aug 02, 1984

PROTEIN HYDROLYSATE

INJECTABLE; INJECTION

AMINOSOL 5%

ABBOTT	5%	N005932	012	Jan 31, 1985
HYPROTIGEN 5%				
B BRAUN	5%	N006170	003	Jan 10, 1984

PROTIRELIN

INJECTABLE; INJECTION

THYPINONE

ABBOTT	0.5MG/ML	N017638	001
THYREL TRH			
FERRING	0.5MG/ML	N018087	001

PROTOKYLOL HYDROCHLORIDE

TABLET; ORAL

VENTAIRE

SANOFI AVENTIS US	2MG	A083459	001
-------------------	-----	---------	-----

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

ODYSSEY PHARMS	5MG	N016012	001
	10MG	N016012	002

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NOVAFED

SANOFI AVENTIS US	120MG	N017603	001
SUDAFED 12 HOUR			
GLAXOSMITHKLINE	120MG	N017941	002

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACTIFED

GLAXOSMITHKLINE	120MG;5MG	N018996	001	Jun 17, 1985
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES				
KV PHARM	120MG;5MG	A071798	001	Mar 16, 1989

SYRUP; ORAL

ACTAHLST

CENCI	30MG/5ML;1.25MG/5ML	A088344	001	Feb 09, 1984
-------	---------------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 272 (of 324)

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

HISTAFED

CENCI

30MG/5ML;1.25MG/5ML

A088283 001 Apr 20, 1984

MYFED

USL PHARMA

30MG/5ML;1.25MG/5ML

A088116 001 Mar 04, 1983

TRILITRON

NEWTRON PHARMS

30MG/5ML;1.25MG/5ML

A088474 001 Feb 12, 1985

TABLET; ORAL

ALLERFED

PVT FORM

60MG;2.5MG

A088860 001 Jan 31, 1985

CORPHED

SANDOZ

60MG;2.5MG

A088602 001 Apr 11, 1985

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

SANDOZ

60MG;2.5MG

A088193 001 May 17, 1983

TRILITRON

NEWTRON PHARMS

60MG;2.5MG

A088515 001 Jan 09, 1985

TRIPHED

TEVA

60MG;2.5MG

A088630 001 May 17, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE

WATSON LABS

60MG;2.5MG

A088318 002 Jan 13, 1984

WEST WARD

60MG;2.5MG

A088117 001 Apr 19, 1983

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS

60MG;2.5MG

A085273 001 Dec 12, 1984

SUPERPHARM

60MG;2.5MG

A088578 001 Feb 21, 1985

TABLET, EXTENDED RELEASE; ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM

120MG;5MG

A072758 001 Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

PSEUDO-12

UCB INC

EQ 60MG HCL/5ML

N019401 001 Jun 19, 1987

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

BARR

30MG

A040512 002 Jul 20, 2005

60MG

A040512 001 Oct 08, 2003

SOLVAY

30MG

A089572 001 Nov 27, 1990

US ARMY

30MG

N020414 001 Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

HEXA-BETALIN

LILLY

100MG/ML

A080854 001

PYRIDOXINE HYDROCHLORIDE

AKORN

100MG/ML

A087967 001 Oct 01, 1982

BEL MAR

100MG/ML

A080761 001

DELL LABS

50MG/ML

A083771 001

100MG/ML

A083772 001

ELKINS SINN

100MG/ML

A080581 001

LUITPOLD

100MG/ML

A080669 001

WATSON LABS

100MG/ML

A080572 001

100MG/ML

A083760 001

PYRILAMINE MALEATE

TABLET; ORAL

PYRILAMINE MALEATE

IMPAX LABS

25MG

A080808 001

WATSON LABS

25MG

A085231 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 273 (of 324)

PYRIMETHAMINE; SULFADOXINE

TABLET; ORAL				
FANSIDAR				
ROCHE	25MG;500MG		N018557	001

PYRITHIONE ZINC

LOTION; TOPICAL				
HEAD & SHOULDERS CONDITIONER				
PROCTER AND GAMBLE	0.3%		N019412	002 Mar 10, 1986

PYRVINIUM PAMOATE

SUSPENSION; ORAL				
POVAN				
PARKE DAVIS	EQ 50MG BASE/5ML		N011964	001
TABLET; ORAL				
POVAN				
PARKE DAVIS	EQ 50MG BASE		N012485	002

QUAZEPAM

TABLET; ORAL				
DORAL				
QUESTCOR PHARMS	7.5MG		N018708	003 Feb 26, 1987

QUETIAPINE FUMARATE

TABLET; ORAL				
SEROQUEL				
ASTRAZENECA	EQ 150MG BASE		N020639	004 Dec 20, 1998

QUINESTROL

TABLET; ORAL				
ESTROVIS				
PARKE DAVIS	0.1MG		N016768	002
	0.2MG		N016768	003

QUINETHAZONE

TABLET; ORAL				
HYDROMOX				
LEDERLE	50MG		N013264	001

QUINETHAZONE; RESERPINE

TABLET; ORAL				
HYDROMOX R				
LEDERLE	50MG;0.125MG		N013927	001

QUINIDINE GLUCONATE

TABLET; ORAL				
QUINACT				
BAYER HLTHCARE	266MG		A085978	001
	400MG		A086099	001
TABLET, EXTENDED RELEASE; ORAL				
DURAQUIN				
WARNER CHILCOTT	330MG		N017917	001
QUINAGLUTE				
BAYER HLTHCARE	324MG		N016647	001
QUINALAN				
LANNETT	324MG		A088081	001 Feb 10, 1986
QUINATIME				
WATSON LABS	324MG		A087448	001
QUINIDINE GLUCONATE				
ASCOT	324MG		A088582	001 Jun 17, 1985
HALSEY	324MG		A089476	001 Apr 10, 1987
ROXANE	324MG		A088431	001 Jan 06, 1984
SANDOZ	324MG		A089894	001 Dec 15, 1988

## DISCONTINUED DRUG PRODUCT LIST

6 - 274 (of 324)

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

SUPERPHARM	324MG	A089164	001	Nov 21, 1985
WATSON LABS	324MG	A087785	001	Jan 24, 1983

QUINIDINE POLYGALACTURONATE

TABLET; ORAL

CARDIOQUIN

PHARM RES ASSOC	275MG	N011642	002	
-----------------	-------	---------	-----	--

QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

SOLVAY	200MG	A085296	001	
	300MG	A085297	001	

QUINIDINE SULFATE

LILLY	200MG	A085103	001	
-------	-------	---------	-----	--

TABLET; ORAL

CIN-QUIN

SOLVAY	100MG	A085299	001	
	200MG	A084932	001	
	300MG	A085298	001	

QUINIDINE SULFATE

BARR	200MG	A084177	001	
------	-------	---------	-----	--

CLONMEL HLTHCARE	200MG	A087011	001	
------------------	-------	---------	-----	--

ELKINS SINN	200MG	A083622	001	
-------------	-------	---------	-----	--

EVERYLIFE	200MG	A083439	001	
-----------	-------	---------	-----	--

HALSEY	200MG	A083583	001	
--------	-------	---------	-----	--

IMPAX LABS	200MG	A083347	001	
------------	-------	---------	-----	--

IVAX SUB TEVA PHARMS	200MG	A084549	001	
----------------------	-------	---------	-----	--

KING PHARMS	200MG	A085175	001	
-------------	-------	---------	-----	--

KV PHARM	200MG	A085276	001	
----------	-------	---------	-----	--

LANNETT	200MG	A083743	001	
---------	-------	---------	-----	--

LEDERLE	200MG	A086176	001	
---------	-------	---------	-----	--

LEINER	200MG	A083808	001	
--------	-------	---------	-----	--

LILLY	200MG	A085038	001	
-------	-------	---------	-----	--

MUTUAL PHARM	100MG	A081029	001	Apr 14, 1989
--------------	-------	---------	-----	--------------

PERRIGO	200MG	A085322	001	
---------	-------	---------	-----	--

PHARMAVITE	200MG	A084627	001	
------------	-------	---------	-----	--

PUREPAC PHARM	200MG	A084003	001	
---------------	-------	---------	-----	--

ROXANE	200MG	A083640	001	
--------	-------	---------	-----	--

	300MG	A085632	001	
--	-------	---------	-----	--

SANDOZ	200MG	A084631	001	
--------	-------	---------	-----	--

	200MG	A084914	001	
--	-------	---------	-----	--

	300MG	A089839	001	Sep 29, 1988
--	-------	---------	-----	--------------

SCHERER LABS	200MG	A085068	001	
--------------	-------	---------	-----	--

SUPERPHARM	200MG	A088973	001	Apr 10, 1985
------------	-------	---------	-----	--------------

USL PHARMA	200MG	A087837	001	Apr 14, 1982
------------	-------	---------	-----	--------------

VALEANT PHARM INTL	200MG	A083393	001	
--------------------	-------	---------	-----	--

VANGARD	200MG	A087909	001	Jul 13, 1982
---------	-------	---------	-----	--------------

VINTAGE PHARMS	200MG	A083963	001	
----------------	-------	---------	-----	--

WARNER CHILCOTT	200MG	A083879	001	
-----------------	-------	---------	-----	--

WATSON LABS	100MG	A085584	001	
-------------	-------	---------	-----	--

	200MG	A085140	002	
--	-------	---------	-----	--

WEST WARD	200MG	A083862	001	
-----------	-------	---------	-----	--

WHITETHORTH TOWN PLSN	200MG	A085444	001	
-----------------------	-------	---------	-----	--

QUINORA

KEY PHARMS	200MG	A083576	001	
------------	-------	---------	-----	--

SCHERING	300MG	A085222	001	
----------	-------	---------	-----	--

TABLET, EXTENDED RELEASE; ORAL

QUINIDEX

WYETH PHARMS INC	300MG	N012796	002	
------------------	-------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 275 (of 324)

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

ACIPHEX

EISAI INC

10MG

N020973 001

May 29, 2002

RABEPRAZOLE SODIUM

TEVA

20MG

A076822 001

Feb 21, 2007

RANITIDINE BISMUTH CITRATE

TABLET; ORAL

TRITEC

GLAXOSMITHKLINE

400MG

N020559 001

Aug 08, 1996

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

GENPHARM

EQ 150MG BASE

A075564 001

Oct 27, 2000

EQ 300MG BASE

A075564 002

Oct 27, 2000

TEVA

EQ 150MG BASE

A075557 001

Oct 31, 2003

EQ 300MG BASE

A075557 002

Oct 31, 2003

ZANTAC 150

GLAXOSMITHKLINE

EQ 150MG BASE

N020095 001

Mar 08, 1994

ZANTAC 300

GLAXOSMITHKLINE

EQ 300MG BASE

N020095 002

Mar 08, 1994

GRANULE, EFFERVESCENT; ORAL

ZANTAC 150

GLAXOSMITHKLINE

EQ 150MG BASE/PACKET

N020251 002

Mar 31, 1994

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

BEDFORD

EQ 25MG BASE/ML

A074764 001

Nov 19, 2004

ZANTAC IN PLASTIC CONTAINER

GLAXOSMITHKLINE

EQ 50MG BASE/100ML

N019593 001

Dec 17, 1986

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

BOEHRINGER INGELHEIM

EQ 150MG BASE

A074662 001

Aug 29, 1997

EQ 300MG BASE

A074662 002

Aug 29, 1997

MYLAN

EQ 150MG BASE

A074552 001

Jul 30, 1998

EQ 300MG BASE

A074552 002

Jul 30, 1998

RANBAXY

EQ 75MG BASE

A075132 001

Jan 14, 2000

EQ 75MG BASE

A075254 001

Jan 14, 2000

EQ 150MG BASE

A075000 001

Jan 30, 1998

EQ 150MG BASE

A075439 001

Apr 19, 2000

EQ 300MG BASE

A075000 002

Jan 30, 1998

EQ 300MG BASE

A075439 002

Apr 19, 2000

EQ 75MG BASE

A075519 001

Sep 26, 2002

SANDOZ

TABLET, EFFERVESCENT; ORAL

ZANTAC 150

GLAXOSMITHKLINE

EQ 150MG BASE

N020251 001

Mar 31, 1994

ZANTAC 75

BOEHRINGER INGELHEIM

EQ 75MG BASE

N020745 001

Feb 26, 1998

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION

RAPLON

ORGANON USA INC

100MG/VIAL

N020984 001

Aug 18, 1999

200MG/VIAL

N020984 002

Aug 18, 1999

RAUWOLFIA SERPENTINA

TABLET; ORAL

HIWOLFIA

BOWMAN PHARMS

50MG

N009276 003

50MG

N009276 005

100MG

N009276 004

HYSERPIN

PHYS PRODS VA

50MG

N010581 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 276 (of 324)

RAUWOLFIA SERPENTINA

TABLET; ORAL

KOGLUCOID

PANRAY

50MG

N009278 001

100MG

N009278 002

RAUDIXIN

APOTHECON

50MG

N008842 001

100MG

N008842 002

RAUSERPIN

FERNDALE LABS

50MG

N009926 002

100MG

N009926 004

RAUVAL

PAL PAK

50MG

N009108 002

100MG

N009108 004

RAUWOLFIA SERPENTINA

BUNDY

50MG

N009477 001

100MG

N009477 002

HALSEY

50MG

A080498 001

100MG

A080498 002

IMPAX LABS

50MG

N009273 001

100MG

N009273 002

IVAX SUB TEVA PHARMS

50MG

N011521 001

100MG

N011521 002

PUREPAC PHARM

50MG

A080842 001

100MG

A080842 002

PVT FORM

50MG

A080583 001

100MG

A080583 002

SOLVAY

50MG

A080500 001

100MG

A080500 002

TABLICAPS

50MG

A083867 001

100MG

A083444 001

VALEANT PHARM INTL

50MG

N009668 001

100MG

N009668 002

WATSON LABS

50MG

A080907 001

100MG

A080914 001

WOLFINA

FOREST PHARMS

50MG

N009255 008

100MG

N009255 006

RESCINNAMINE

CAPSULE; ORAL

CINNASIL

PANRAY

0.5MG

A084736 001

TABLET; ORAL

MODERIL

PFIZER

0.25MG

N010686 003

0.5MG

N010686 006

RESERPINE

ELIXIR; ORAL

SERPASIL

NOVARTIS

0.2MG/4ML

N009115 005

INJECTABLE; INJECTION

SANDRIL

LILLY

2.5MG/ML

N010012 001

SERPASIL

NOVARTIS

2.5MG/ML

N009434 002

TABLET; ORAL

HISERPIA

BOWMAN PHARMS

0.1MG

N009631 002

0.25MG

N009631 004

RAU-SED

BRISTOL MYERS SQUIBB

0.1MG

N009357 001

0.25MG

N009357 004

## DISCONTINUED DRUG PRODUCT LIST

6 - 277 (of 324)

RESERPINE

TABLET; ORAL

RAU-SED

BRISTOL MYERS SQUIBB	0.5MG	N009357	006
	1MG	N009357	008

RESERPINE

BARR	0.25MG	A080721	002	
BELL PHARMA	0.1MG	A083058	001	
	0.25MG	A083058	002	
BUNDY	0.1MG	N009663	001	
	0.25MG	N009663	003	
ELKINS SINN	0.1MG	A083145	001	
	0.25MG	A083145	002	
EVERYLIFE	0.1MG	N010441	001	
	0.25MG	N010441	002	
	0.5MG	N010441	003	
	1MG	N010441	004	
HALSEY	0.1MG	A080457	002	
	0.25MG	A080457	001	
	1MG	A080457	003	
IMPAX LABS	0.1MG	N009627	001	
	0.25MG	N009627	002	
IVAX SUB TEVA PHARMS	0.1MG	N011185	001	
	0.25MG	N011185	002	
MARSHALL PHARMA	0.1MG	A080492	001	
	0.25MG	A080492	002	
MK LABS	0.1MG	A080525	002	
	0.25MG	A080525	001	
MYLAN	1MG	A084974	001	
PHARMAVITE	0.25MG	A084663	001	
PUREPAC PHARM	0.1MG	A080753	002	
	0.25MG	A080753	001	
PVT FORM	0.1MG	A086117	001	
	0.25MG	A080582	001	
	0.25MG	A085775	001	
	1MG	A080582	002	
REXALL	0.25MG	A080637	001	
ROXANE	0.1MG	N009859	001	
	0.25MG	N009859	002	
SOLVAY	0.25MG	A080446	001	
TABLICAPS	0.25MG	A085207	001	
TEVA	0.1MG	A089020	001	Mar 07, 1985
	0.25MG	A089019	001	Mar 07, 1985
VALEANT PHARM INTL	0.1MG	N009667	001	
	0.25MG	N009667	002	
WATSON LABS	0.1MG	A080679	001	
	0.25MG	A080393	001	
	0.25MG	A085401	001	
	1MG	A080749	001	
WEST WARD	0.1MG	A080975	001	
	0.25MG	A080975	002	
	1MG	A080975	003	
WHITEWORTH TOWN PLSN	0.1MG	A080723	001	
	0.25MG	A080723	002	
	1MG	A080723	003	
SANDRIL				
LILLY	0.1MG	N009376	004	
	0.25MG	N009376	001	
SERPANRAY				
PANRAY	0.1MG	N009391	001	
	0.25MG	N009391	002	
	1MG	N009391	004	
SERPASIL				
NOVARTIS	0.1MG	N009115	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 278 (of 324)

RESERPINE

TABLET; ORAL

SERPASIL

NOVARTIS

0.25MG

N009115 003

1MG

N009115 004

SERPATE

VALE

0.1MG

N009453 001

0.25MG

N009453 002

SERPIVITE

VITARINE

0.25MG

N009645 002

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

METATENSIN #2

SANOFI AVENTIS US

0.1MG; 2MG

N012972 001

METATENSIN #4

SANOFI AVENTIS US

0.1MG; 4MG

N012972 002

NAQUIVAL

SCHERING

0.1MG; 4MG

N012265 003

TRICHLORMETHIAZIDE W/ RESERPINE

WATSON LABS

0.1MG; 4MG

A085248 001

RIBAVIRIN

TABLET; ORAL

COPEGUS

ROCHE

400MG

N021511 002

Jun 21, 2005

RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL

FLUMADINE

FOREST LABS

50MG/5ML

N019650 001

Sep 17, 1993

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

PROCTER AND GAMBLE

75MG

N020835 004

Apr 16, 2007

RISPERIDONE

TABLET; ORAL

RISPERDAL

ORTHO MCNEIL JANSSEN

5MG

N020272 005

Dec 29, 1993

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HYDROCHLORIDE

ABRAXIS PHARM

10MG/ML

A071188 001

Jul 23, 1987

15MG/ML

A071189 001

Jul 23, 1987

HOSPIRA

10MG/ML

A071618 001

Feb 28, 1991

15MG/ML

A071619 001

Feb 28, 1991

RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

30MG/100ML

A071438 001

Jan 22, 1991

YUTOPAR

ASTRAZENECA

10MG/ML

N018580 001

15MG/ML

N018580 002

TABLET; ORAL

YUTOPAR

ASTRAZENECA

10MG

N018555 001

RITONAVIR

CAPSULE; ORAL

NORVIR

ABBOTT

100MG

N020680 001

Mar 01, 1996



## DISCONTINUED DRUG PRODUCT LIST

6 - 279 (of 324)

ROCURONIUM BROMIDEINJECTABLE; INJECTION  
ZEMURON

SCHERING 10MG/ML (10MG/ML) N020214 002 Mar 17, 1994

ROFECOXIBSUSPENSION; ORAL  
VIOXXMERCK 12.5MG/5ML N021052 001 May 20, 1999  
25MG/5ML N021052 002 May 20, 1999TABLET; ORAL  
VIOXXMERCK 12.5MG N021042 001 May 20, 1999  
25MG N021042 002 May 20, 1999  
50MG N021042 003 Feb 25, 2000ROPINIROLE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
REQUIP XL

SMITHKLINE BEECHAM EQ 3MG BASE N022008 002 Jun 13, 2008

ROSE BENGAL SODIUM, I-131INJECTABLE; INJECTION  
ROBENGATOPEBRACCO 0.5mCi/VIAL N016224 001  
1mCi/VIAL N016224 002  
2mCi/VIAL N016224 003

SODIUM ROSE BENGAL I 131

SORIN 0.5mCi/ML N017318 001

ROTIGOTINEFILM, EXTENDED RELEASE; TRANSDERMAL  
NEUPROSCHWARZ BIOSCIENCES 2MG/24HR N021829 001 May 09, 2007  
4MG/24HR N021829 002 May 09, 2007  
6MG/24HR N021829 003 May 09, 2007RUFINAMIDETABLET; ORAL  
BANZEL

EISAI INC 100MG N021911 001 Nov 14, 2008

SAFFLOWER OILINJECTABLE; INJECTION  
LIPOSYN 10%

ABBOTT 10% (10GM/100ML) N018203 001

LIPOSYN 20%

ABBOTT 20% (20GM/100ML) N018614 001

SALMETEROL XINAFOATEAEROSOL, METERED; INHALATION  
SEREVENT

GLAXOSMITHKLINE EQ 0.021MG BASE/INH N020236 001 Feb 04, 1994

SAQUINAVIRCAPSULE; ORAL  
FORTOVASE

HLR 200MG N020828 001 Nov 07, 1997

SARALASIN ACETATEINJECTABLE; INJECTION  
SARENIN

PROCTER AND GAMBLE EQ 0.6MG BASE/ML N018009 001

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 721 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 280 (of 324)

SECOBARBITAL SODIUM

## CAPSULE; ORAL

## SECOBARBITAL SODIUM

ANABOLIC	100MG	A084422	001
BARR	100MG	A084225	001
EVERYLIFE	100MG	A085895	001
HALSEY	100MG	A084676	001
IVAX PHARMS	100MG	A085869	001
KV PHARM	100MG	A085285	001
LANNETT	50MG	A085909	001
	100MG	A085903	001
PARKE DAVIS	100MG	A084762	001
PERRIGO	100MG	A084561	001
PUREPAC PHARM	100MG	A085867	001
VALEANT PHARM INTL	100MG	A085477	001
VITARINE	100MG	A085898	001
	100MG	A086273	001
WATSON LABS	100MG	A085792	001
WEST WARD	100MG	A084926	001
WHITWORTH TOWN PLSN	100MG	A085798	001
WYETH AYERST	100MG	A086390	001

## INJECTABLE; INJECTION

## SECOBARBITAL SODIUM

ELKINS SINN	100MG/VIAL	A083281	001
WYETH AYERST	50MG/ML	A083262	001

## SECONAL SODIUM

LILLY	50MG/ML	N007392	002
-------	---------	---------	-----

## SUPPOSITORY; RECTAL

## SECONAL SODIUM

LILLY	30MG	A086530	001
	60MG	A086530	002
	120MG	A086530	003
	200MG	A086530	004

SECRETIN

## INJECTABLE; INJECTION

## SECRETIN-FERRING

FERRING	75CU/VIAL	N018290	001
---------	-----------	---------	-----

SECRETIN SYNTHETIC PORCINE

## FOR SOLUTION; INTRAVENOUS

## SECFLO

CHIRHOCLIN	16MCG/VIAL	N021136	001	Apr 04, 2002
------------	------------	---------	-----	--------------

SELEGILINE HYDROCHLORIDE

## CAPSULE; ORAL

## SELEGILINE HYDROCHLORIDE

AAIPHARMA LLC	5MG	A075145	001	Sep 15, 2003
---------------	-----	---------	-----	--------------

## TABLET; ORAL

## SELEGILINE HYDROCHLORIDE

ENDO PHARMS	5MG	A074565	001	Aug 02, 1996
IVAX SUB TEVA PHARMS	5MG	A074756	001	Nov 25, 1998
SIEGFRIED	5MG	A074672	001	Apr 01, 1997
SOMERSET	5MG	N019334	001	Jun 05, 1989
TEVA	5MG	A074537	001	Aug 02, 1996
	5MG	A074744	001	Jan 27, 1997

SELENIUM SULFIDE

## LOTION/SHAMPOO; TOPICAL

## EXSEL

ALLERGAN HERBERT	2.5%	A083892	001
------------------	------	---------	-----

## SELENIUM SULFIDE

IVAX PHARMS	2.5%	A085777	001
TARO	2.5%	A086209	001

## DISCONTINUED DRUG PRODUCT LIST

6 - 281 (of 324)

SELENOMETHIONINE, SE-75

INJECTABLE; INJECTION			
SELENOMETHIONINE SE 75			
GE HEALTHCARE	250uCi/ML	N017257	001
MALLINCKRODT	100uCi/ML	N017098	001
PHARMALUCENCE	500uCi/ML	N017322	001
SETHOTOPE			
BRACCO	85-550uCi/ML	N017047	001

SERACTIDE ACETATE

INJECTABLE; INJECTION			
ACTHAR GEL-SYNTHETIC			
ARMOUR PHARM	40 UNITS/ML	N017861	001
	80 UNITS/ML	N017861	002

SERMORELIN ACETATE

INJECTABLE; INJECTION			
GEREF			
EMD SERONO	EQ 0.05MG BASE/AMP	N019863	001 Dec 28, 1990
	EQ 0.5MG BASE/VIAL	N020443	001 Sep 26, 1997
	EQ 1MG BASE/VIAL	N020443	002 Sep 26, 1997

SERTRALINE HYDROCHLORIDE

TABLET; ORAL			
SERTRALINE HYDROCHLORIDE			
ACTAVIS ELIZABETH	EQ 25MG BASE	A077345	001 Feb 06, 2007
	EQ 50MG BASE	A077345	002 Feb 06, 2007
	EQ 100MG BASE	A077345	003 Feb 06, 2007
MUTUAL PHARM	EQ 25MG BASE	A077818	001 Feb 06, 2007
	EQ 50MG BASE	A077818	002 Feb 06, 2007
	EQ 100MG BASE	A077818	003 Feb 06, 2007
WATSON LABS	EQ 25MG BASE	A077162	001 Feb 06, 2007
	EQ 50MG BASE	A077162	002 Feb 06, 2007
	EQ 100MG BASE	A077162	003 Feb 06, 2007
ZOLOFT			
PFIZER	EQ 150MG BASE	N019839	003 Dec 30, 1991
	EQ 200MG BASE	N019839	004 Dec 30, 1991

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL			
RENAGEL			
GENZYME	403MG	N020926	001 Oct 30, 1998

SILVER SULFADIAZINE

DRESSING; TOPICAL			
SILDAFLO			
FRANKLIN PHARMS	1%	N019608	001 Nov 30, 1989

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL			
SONORX			
BRACCO	7.5MG/ML	N020773	001 Oct 29, 1998

SIMVASTATIN

TABLET, ORALLY DISINTEGRATING; ORAL			
SIMVASTATIN			
SYNTHON PHARMS	10MG	N021961	001 Oct 09, 2007
	20MG	N021961	002 Oct 09, 2007
	40MG	N021961	003 Oct 09, 2007
	80MG	N021961	004 Oct 09, 2007

## DISCONTINUED DRUG PRODUCT LIST

6 - 282 (of 324)

SIROLIMUSTABLET; ORAL  
RAPAMUNE

WYETH PHARMS INC 5MG N021110 003 Feb 23, 2004

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION; ORAL  
UCEPHAN

B BRAUN 100MG/ML;100MG/ML N019530 001 Dec 23, 1987

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE IN PLASTIC CONTAINER

ABBOTT 0.9MEQ/ML N019443 001 Jun 03, 1986  
1MEQ/ML N019443 002 Jun 03, 1986SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

LAFAYETTE PHARMS 460MG/GM;420MG/GM N018509 001 Aug 07, 1985

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABRAXIS PHARM 9MG/ML A088909 001 Feb 07, 1985

SODIUM CHLORIDE

ABBOTT 20GM/100ML N017013 001

B BRAUN 20GM/100ML N017038 001

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 450MG/100ML N018184 001

MILES 450MG/100ML N018503 001

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT 9MG/ML N019218 001 Jul 13, 1984

MILES 900MG/100ML N018502 001

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

ABRAXIS PHARM 234MG/ML N019329 001 Apr 22, 1987

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

B BRAUN 3GM/100ML N019635 003 Mar 09, 1988

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML N019635 004 Mar 09, 1988

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

BAXTER HLTHCARE 450MG/100ML N018497 001 Feb 19, 1982

SODIUM CHLORIDE IN PLASTIC CONTAINER

MILES 900MG/100ML N018247 001

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPE SODIUM

BRACCO 2mCi/VIAL N013993 002

SODIUM CHROMATE CR 51

MALLINCKRODT 100uCi/ML N016708 001

SODIUM FLUORIDE, F-18

INJECTABLE; INTRAVENOUS

FLUORINE F-18

GE HEALTHCARE 2mCi/ML N017042 001

SODIUM IODIDE, I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

SYNCOR PHARMS 400uCi N018671 003 May 27, 1982

## DISCONTINUED DRUG PRODUCT LIST

6 - 283 (of 324)

SODIUM IODIDE, I-131

CAPSULE; ORAL

IODOTOPE

BRACCO

1-130mCi

N010929 001

1-150mCi

N010929 003

SODIUM IODIDE I 131

CIS

50uCi

N017316 001

100uCi

N017316 002

MALLINCKRODT

0.8-100mCi

N016515 002

SOLUTION; ORAL

IODOTOPE

BRACCO

7-106mCi/BOT

N010929 002

SODIUM IODIDE I 131

CIS

50mCi/ML

N017315 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

B BRAUN

1.87GM/100ML

N018186 001

HOSPIRA

1.87GM/100ML

N018249 001

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 002

Aug 06, 1986

PASTE; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 001

Jun 03, 1987

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NIPRIDE

ROCHE

50MG/VIAL

N017546 001

NITROPRESS

ABBOTT

50MG/VIAL

A071555 001

Nov 16, 1987

50MG/VIAL

N018450 001

HOSPIRA

50MG/VIAL

A070566 001

Jun 09, 1986

SODIUM NITROPRUSSIDE

ABRAXIS PHARM

50MG/VIAL

A070031 001

Jan 17, 1985

BAXTER HLTHCARE

50MG/VIAL

N018581 001

Jul 28, 1982

SODIUM PHOSPHATE, P-32

SOLUTION; INJECTION, ORAL

PHOSPHOTOPE

BRACCO

1-8mCi/VIAL

N010927 001

SODIUM PHOSPHATE P 32

MALLINCKRODT

0.67mCi/ML

N011777 001

1.5mCi/VIAL

N011777 002

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

MORTON GROVE

453.6GM/BOT

A088786 001

Sep 11, 1984

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

MORTON GROVE

15GM/60ML

A088717 001

Sep 11, 1984

ROXANE

15GM/60ML

A088453 001

Nov 17, 1983

SODIUM SUCCINATE

INJECTABLE; INJECTION

SODIUM SUCCINATE

ELKINS SINN

30%

A080516 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 284 (of 324)

SODIUM TETRADECYL SULFATEINJECTABLE; INJECTION  
SOTRADECOL

ELKINS SINN	1%	N005970	004	
	3%	N005970	005	

SODIUM THIOSULFATEINJECTABLE; INJECTION  
SODIUM THIOSULFATE

US ARMY	250MG/ML	N020166	001	Feb 14, 1992
---------	----------	---------	-----	--------------

SOMATREMINJECTABLE; INJECTION  
PROTROPIN

GENENTECH	5MG/VIAL	N019107	001	Oct 17, 1985
	10MG/VIAL	N019107	002	Oct 24, 1989

SOMATROPININJECTABLE; INJECTION  
ASELLACRIN 10

SERONO	10 IU/VIAL	N017726	001	
--------	------------	---------	-----	--

ASELLACRIN 2

SERONO	2 IU/VIAL	N017726	002	Jul 21, 1983
--------	-----------	---------	-----	--------------

CRESCORMON

GENENTECH	4 IU/VIAL	N017992	001	
-----------	-----------	---------	-----	--

SOMATROPIN RECOMBINANTINJECTABLE; INJECTION  
ACCRETROPIN

CANGENE	5MG/ML (5MG/ML)	N021538	001	Jan 23, 2008
---------	-----------------	---------	-----	--------------

BIO-TROPIN

FERRING	4.8MG/VIAL	N019774	001	May 25, 1995
---------	------------	---------	-----	--------------

HUMATROPE

LILLY	2MG/VIAL	N019640	001	Jun 23, 1987
-------	----------	---------	-----	--------------

NORDITROPIN

NOVO NORDISK INC	4MG/VIAL	N019721	001	May 08, 1995
------------------	----------	---------	-----	--------------

	8MG/VIAL	N019721	002	May 08, 1995
--	----------	---------	-----	--------------

NUTROPIN DEPOT

GENENTECH	13.5MG/VIAL	N021075	001	Dec 22, 1999
-----------	-------------	---------	-----	--------------

	18MG/VIAL	N021075	002	Dec 22, 1999
--	-----------	---------	-----	--------------

	22.5MG/VIAL	N021075	003	Dec 22, 1999
--	-------------	---------	-----	--------------

SAIZEN

EMD SERONO	4MG/VIAL	N019764	005	Jan 16, 2007
------------	----------	---------	-----	--------------

	6MG/VIAL	N019764	001	Oct 08, 1996
--	----------	---------	-----	--------------

SEROSTIM

EMD SERONO	8.8MG/VIAL	N020604	004	Sep 06, 2001
------------	------------	---------	-----	--------------

ZORBTIVE

EMD SERONO	4MG/VIAL	N021597	001	Dec 01, 2003
------------	----------	---------	-----	--------------

	5MG/VIAL	N021597	002	Dec 01, 2003
--	----------	---------	-----	--------------

	6MG/VIAL	N021597	003	Dec 01, 2003
--	----------	---------	-----	--------------

INJECTABLE; SUBCUTANEOUS

SEROSTIM LQ

EMD SERONO	6MG/0.5ML (6MG/0.5ML)	N020604	005	Feb 11, 2005
------------	-----------------------	---------	-----	--------------

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE	3GM/100ML	N018512	001	May 27, 1982
-----------------	-----------	---------	-----	--------------

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

BAYER HLTHCARE	320MG	N019865	004	Oct 30, 1992
----------------	-------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 285 (of 324)

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE AF

BAYER HLTHCARE	40MG	N021151	006	Apr 02, 2003
	60MG	N021151	007	Apr 02, 2003
	100MG	N021151	005	Mar 14, 2003

SOTALOL HYDROCHLORIDE

MUTUAL PHARM

	80MG	A075515	001	Oct 15, 2001
	80MG	A076576	001	Apr 08, 2004
	120MG	A075515	004	Oct 15, 2001
	120MG	A076576	002	Apr 08, 2004
	160MG	A075515	002	Oct 15, 2001
	160MG	A076576	003	Apr 08, 2004
	240MG	A075515	003	Oct 15, 2001

WATSON LABS

	80MG	A075238	001	Jul 13, 2000
	120MG	A075238	002	Jul 13, 2000
	160MG	A075238	003	Jul 13, 2000
	240MG	A075238	004	Jul 13, 2000

SOYBEAN OIL

INJECTABLE; INJECTION

SOYACAL 10%

ALPHA THERA	10%	N018465	001	Jun 29, 1983
-------------	-----	---------	-----	--------------

SOYACAL 20%

ALPHA THERA	20%	N018786	001	Jun 29, 1983
-------------	-----	---------	-----	--------------

TRAVAMULSION 10%

BAXTER HLTHCARE	10%	N018660	001	Feb 26, 1982
-----------------	-----	---------	-----	--------------

TRAVAMULSION 20%

BAXTER HLTHCARE	20%	N018758	001	Feb 15, 1983
-----------------	-----	---------	-----	--------------

SPARFLOXACIN

TABLET; ORAL

ZAGAM

MYLAN	200MG	N020677	001	Dec 19, 1996
-------	-------	---------	-----	--------------

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

PHARMACIA AND UPJOHN	EQ 4GM BASE/VIAL	N050347	002	
----------------------	------------------	---------	-----	--

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL

RENORMAX

SCHERING	3MG	N020240	001	Dec 29, 1994
	6MG	N020240	002	Dec 29, 1994
	12MG	N020240	003	Dec 29, 1994
	24MG	N020240	004	Dec 29, 1994

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

ASCOT	25MG	A087687	001	Oct 20, 1982
IVAX PHARMS	25MG	A087108	001	
LEDERLE	25MG	A087634	001	
MUTUAL PHARM	25MG	A087265	001	
MYLAN	25MG	A087086	001	
PUREPAC PHARM	25MG	A087998	001	Oct 14, 1983
	25MG	A088053	001	Aug 25, 1983
SUPERPHARM	25MG	A089364	001	Nov 07, 1986
UPSHER SMITH	25MG	A087554	001	
VANGARD	25MG	A087648	001	Feb 01, 1982
WARNER CHILCOTT	25MG	A087952	001	Nov 18, 1982
WATSON LABS	25MG	A086898	002	Mar 02, 1982
	25MG	A087078	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 286 (of 324)

STANOZOLOL

TABLET; ORAL

WINSTROL

LUNDBECK INC

2MG

N012885 001

May 14, 1984

STAVUDINE

CAPSULE; ORAL

ZERIT

BRISTOL MYERS SQUIBB 5MG

N020412 001

Jun 24, 1994

CAPSULE, EXTENDED RELEASE; ORAL

ZERIT XR

BRISTOL MYERS SQUIBB 37.5MG

N021453 001

Dec 31, 2002

50MG

N021453 002

Dec 31, 2002

75MG

N021453 003

Dec 31, 2002

100MG

N021453 004

Dec 31, 2002

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

COPANOS

EQ 500MG BASE/ML

A060684 001

LILLY

EQ 1GM BASE/VIAL

A060107 001

EQ 1GM BASE/2ML

A060404 001

EQ 5GM BASE/VIAL

A060107 002

PFIZER

EQ 1GM BASE/VIAL

A060076 001

EQ 5GM BASE/VIAL

A060076 002

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

SANDOZ

50MG/ML

N008453 003

500MG/VIAL

N008453 001

1GM/VIAL

N008453 004

QUELICIN PRESERVATIVE FREE

HOSPIRA

50MG/ML

N008845 002

SUCCINYLCHOLINE CHLORIDE

INTL MEDICATION

100MG/VIAL

A085400 001

Feb 04, 1982

ORGANON USA INC

20MG/ML

A080997 001

SUCOSTRIN

APOTHECON

20MG/ML

N008847 001

100MG/ML

N008847 003

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

WATSON LABS

EQ 0.05MG BASE/ML

A074406 001

Dec 15, 1995

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPH-10

ALLERGAN

10%

A084015 001

SODIUM SULAMYD

SCHERING

10%

N005963 002

SULFAIR 10

PHARMAFAIR

10%

A088000 001

Dec 22, 1982

SOLUTION/DROPS; OPHTHALMIC

BLEPH-30

ALLERGAN

30%

A080028 002

ISOPTO CETAMIDE

ALCON

15%

A080020 002

OCUSULF-10

MIZA PHARMS USA

10%

A080660 001

OCUSULF-30

MIZA PHARMS USA

30%

A080660 002



## DISCONTINUED DRUG PRODUCT LIST

6 - 287 (of 324)

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SODIUM SULAMYD

SCHERING	10%	N005963	001
	30%	N005963	003

SODIUM SULFACETAMIDE

AKORN	10%	A083021	001
	15%	A083021	002
	30%	A083021	003
SOLA BARNES HIND	10%	A084143	001
	10%	A084145	001
	30%	A084146	001
	30%	A084147	001

SULF-10

NOVARTIS	10%	A080025	001
----------	-----	---------	-----

SULF-15

NOVARTIS	15%	A089047	001	Oct 31, 1995
----------	-----	---------	-----	--------------

SULFACEL-15

OPTOPICS	15%	A080024	001
----------	-----	---------	-----

SULFACETAMIDE SODIUM

AKORN	10%	A040215	001	May 25, 1999
	30%	A040216	001	May 25, 1999
ALCON	30%	A089068	001	May 05, 1987
PHARMAFAIR	10%	A088947	001	May 17, 1985

SULFAIR 10

PHARMAFAIR	10%	A087949	001	Dec 13, 1982
------------	-----	---------	-----	--------------

SULFAIR FORTE

PHARMAFAIR	30%	A088385	001	Oct 13, 1983
------------	-----	---------	-----	--------------

SULFAIR-15

PHARMAFAIR	15%	A088186	001	May 25, 1983
------------	-----	---------	-----	--------------

SULTEN-10

BAUSCH AND LOMB	10%	A087818	001	Feb 03, 1983
-----------------	-----	---------	-----	--------------

SULFACYTINE

TABLET; ORAL

RENOQUID

GLENWOOD	250MG	N017569	001
----------	-------	---------	-----

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

ABBOTT	300MG	N004125	005
EVERYLIFE	500MG	A080088	001
IMPAX LABS	500MG	A080081	001
LANNETT	500MG	A080084	001
LEDERLE	500MG	N004054	001
LILLY	500MG	N004122	002

SULFADIAZINE SODIUM

INJECTABLE; INJECTION

SULFADIAZINE SODIUM

LEDERLE	250MG/ML	N004054	002
---------	----------	---------	-----

SULFADIAZINE; SULFAMERAZINE

SUSPENSION; ORAL

SULFONAMIDES DUPLEX

LILLY	250MG/5ML; 250MG/5ML	N006317	007
-------	----------------------	---------	-----

SULFAMETER

TABLET; ORAL

SULLA

BAYER HLTHCARE	500MG	N016000	002
----------------	-------	---------	-----

## DISCONTINUED DRUG PRODUCT LIST

6 - 288 (of 324)

SULFAMETHIZOLE

## TABLET; ORAL

## MICROSUL

FOREST PHARMS 1GM A086012 001

## PROKLAR

FOREST PHARMS 500MG A080273 001

## THIOSULFIL

WYETH AYERST 250MG N008565 001

500MG N008565 004

SULFAMETHOXAZOLE

## SUSPENSION; ORAL

## GANTANOL

ROCHE 500MG/5ML N013664 002

## TABLET; ORAL

## GANTANOL

ROCHE 500MG N012715 002

## GANTANOL-DS

ROCHE 1GM N012715 003

## SULFAMETHOXAZOLE

ASCOT 500MG A087662 001 Oct 20, 1982

BARR 500MG A087189 001 Jul 25, 1983

HEATHER 500MG A086163 001

SANDOZ 500MG A085844 001

WATSON LABS 500MG A085053 001

1GM A086000 001

## UROBAK

SHIONOGI 500MG A087307 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

## INJECTABLE; INJECTION

## BACTRIM

MUTUAL PHARM 80MG/ML;16MG/ML N018374 001

## SEPTRA

MONARCH PHARMS 80MG/ML;16MG/ML N018452 001

## SULFAMETHOXAZOLE AND TRIMETHOPRIM

ABRAXIS PHARM 80MG/ML;16MG/ML A070223 001 Dec 29, 1987

BAXTER HLTHCARE 80MG/ML;16MG/ML A070627 001 Dec 29, 1987

80MG/ML;16MG/ML A070628 001 Dec 29, 1987

BEDFORD 80MG/ML;16MG/ML A072383 001 Apr 29, 1992

HOSPIRA 80MG/ML;16MG/ML A073199 001 Sep 11, 1992

WATSON LABS 80MG/ML;16MG/ML A071556 001 Dec 29, 1987

## SUSPENSION; ORAL

## BACTRIM

MUTUAL PHARM 200MG/5ML;40MG/5ML N017560 001

## BACTRIM PEDIATRIC

MUTUAL PHARM 200MG/5ML;40MG/5ML N017560 002

## SEPTRA

MONARCH PHARMS 200MG/5ML;40MG/5ML N017598 001

## SEPTRA GRAPE

MONARCH PHARMS 200MG/5ML;40MG/5ML N017598 002 Feb 12, 1986

## SULFAMETHOXAZOLE AND TRIMETHOPRIM

TEVA 200MG/5ML;40MG/5ML A070028 001 Jun 02, 1987

200MG/5ML;40MG/5ML N018812 001 Jan 28, 1983

200MG/5ML;40MG/5ML N018812 002 Jun 10, 1983

## SULFATRIM

ACTAVIS MID ATLANTIC 200MG/5ML;40MG/5ML N018615 002 Jan 07, 1983

## SULMEPRIM

USL PHARMA 200MG/5ML;40MG/5ML A070063 001 Aug 01, 1986

## SULMEPRIM PEDIATRIC

USL PHARMA 200MG/5ML;40MG/5ML A070064 001 Aug 01, 1986

## TRIMETH/SULFA

ALPHARMA US PHARMS 200MG/5ML;40MG/5ML A072289 001 May 23, 1988

200MG/5ML;40MG/5ML A072398 001 May 23, 1988

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 730 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 289 (of 324)

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

TRIMETH/SULFA

NASKA

200MG/5ML;40MG/5ML

A072399 001

May 23, 1988

TABLET; ORAL

COTRIM

TEVA

400MG;80MG

A070034 001

May 16, 1985

COTRIM D.S.

TEVA

800MG;160MG

A070048 001

Mar 18, 1985

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AMNEAL PHARMS NY

400MG;80MG

A071299 001

Oct 27, 1987

800MG;160MG

A071300 001

Oct 27, 1987

HEATHER

400MG;80MG

N018946 001

Aug 10, 1984

800MG;160MG

N018946 002

Aug 10, 1984

MARTEC USA LLC

400MG;80MG

A072408 001

Dec 07, 1988

MUTUAL PHARM

400MG;80MG

A070006 001

Nov 14, 1984

400MG;80MG

A071016 001

Aug 25, 1986

PLIVA

400MG;80MG

A070215 001

Sep 10, 1985

800MG;160MG

A070216 001

Sep 10, 1985

ROXANE

400MG;80MG

A072768 001

Aug 30, 1991

SANDOZ

400MG;80MG

A070889 001

Nov 13, 1986

400MG;80MG

N018598 003

May 19, 1982

800MG;160MG

A070890 001

Nov 13, 1986

TEVA

400MG;80MG

N018242 001

800MG;160MG

N018242 002

USL PHARMA

400MG;80MG

A070203 001

Nov 08, 1985

800MG;160MG

A070204 001

Nov 08, 1985

WATSON LABS

400MG;80MG

A070002 001

Nov 07, 1984

400MG;80MG

N018852 001

May 09, 1983

800MG;160MG

A070000 001

Nov 07, 1984

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

MARTEC USA LLC

800MG;160MG

A072417 001

Dec 07, 1988

MUTUAL PHARM

800MG;160MG

A070007 001

Nov 14, 1984

ROXANE

800MG;160MG

A072769 001

Aug 30, 1991

WATSON LABS

800MG;160MG

N018854 001

May 09, 1983

SULFATRIM-DS

SUPERPHARM

800MG;160MG

A070066 001

Jun 24, 1985

SULFATRIM-SS

SUPERPHARM

400MG;80MG

A070065 002

Jun 24, 1985

UROPLUS DS

SHIONOGI

800MG;160MG

A071816 001

Sep 28, 1987

UROPLUS SS

SHIONOGI

400MG;80MG

A071815 001

Sep 28, 1987

SULFANILAMIDE

CREAM; VAGINAL

SULFANILAMIDE

TEVA

15%

A088718 001

Sep 19, 1985

SUPPOSITORY; VAGINAL

AVC

AZUR PHARMA

1.05GM

N006530 004

Jan 27, 1987

SULFAPHENAZOLE

SUSPENSION; ORAL

SULFABID

PHARM RES ASSOC

500MG/5ML

N013093 001

TABLET; ORAL

SULFABID

PURDUE FREDERICK

500MG

N013092 002

SULFAPYRIDINE

TABLET; ORAL

SULFAPYRIDINE

LILLY

500MG

N000159 001

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 731 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 290 (of 324)

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

PHARMACIA AND UPJOHN 250MG/5ML

N018605 001

TABLET; ORAL

S.A.S.-500

SOLVAY 500MG

A083450 001

SULFASALAZINE

HERITAGE PHARMS INC 500MG

A080197 001

MUTUAL PHARM 500MG

A089590 001

Oct 19, 1987

SANDOZ 500MG

A086184 001

SUPERPHARM 500MG

A089339 001

Oct 26, 1987

WATSON LABS 500MG

A084964 001

TABLET, DELAYED RELEASE; ORAL

SULFASALAZINE

WATSON LABS 500MG

A088052 001

May 24, 1983

SULFINPYRAZONE

CAPSULE; ORAL

ANTURANE

NOVARTIS 200MG

N011556 004

SULFINPYRAZONE

BARR 200MG

A087666 001

Sep 17, 1982

IVAX PHARMS 200MG

A087770 001

Nov 19, 1982

PAR PHARM 200MG

A088934 001

Sep 06, 1985

VANGARD 200MG

A088666 001

Feb 17, 1984

TABLET; ORAL

ANTURANE

NOVARTIS 100MG

N011556 003

SULFINPYRAZONE

BARR 100MG

A087665 001

Sep 17, 1982

IVAX PHARMS 100MG

A087769 001

Jun 01, 1982

PAR PHARM 100MG

A088933 001

Sep 06, 1985

WATSON LABS 100MG

A087667 001

May 26, 1982

SULFISOXAZOLE

TABLET; ORAL

GANTRISIN

ROCHE 500MG

N006525 001

SOSOL

MK LABS 500MG

A080036 001

SOXAZOLE

ALRA 500MG

A080366 001

SULFALAR

PARKE DAVIS 500MG

A084955 001

SULFISOXAZOLE

BARR 500MG

A084031 001

HEATHER 500MG

A080189 001

IMPAX LABS 500MG

A080109 001

LANNETT 500MG

A080085 001

LEDERLE 500MG

A087649 001

PHARMERAL 500MG

A084385 001

PUREPAC PHARM 500MG

A080087 001

ROXANE 500MG

A080082 001

SANDOZ 500MG

A085628 001

VALEANT PHARM INTL 500MG

A080268 002

VITARINE 500MG

A087332 001

WATSON LABS 500MG

A085534 001

WEST WARD 500MG

A080379 001

SULSOXIN

SOLVAY 500MG

A080040 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 291 (of 324)

SULFISOXAZOLE ACETYL

EMULSION; ORAL				
LIPO GANTRISIN				
ROCHE	EQ 1GM BASE/5ML		N009182	009
SUSPENSION; ORAL				
GANTRISIN PEDIATRIC				
ROCHE	EQ 500MG BASE/5ML		N009182	004
SYRUP; ORAL				
GANTRISIN				
ROCHE	EQ 500MG BASE/5ML		N009182	002

SULFISOXAZOLE DIOLAMINE

INJECTABLE; INJECTION				
GANTRISIN				
ROCHE	EQ 400MG BASE/ML		N006917	001
OINTMENT; OPHTHALMIC				
GANTRISIN				
ROCHE	EQ 4% BASE		N008414	002
SOLUTION/DROPS; OPHTHALMIC				
GANTRISIN				
ROCHE	EQ 4% BASE		N007757	002
SULFISOXAZOLE DIOLAMINE				
SOLA BARNES HIND	EQ 4% BASE		A084148	001

SULFOXONE SODIUM

TABLET, DELAYED RELEASE; ORAL				
DIASONE SODIUM				
ABBOTT	165MG		N006044	003

SULFUR

POWDER; TOPICAL				
BENSULFOID				
POYTHRESS	33.32%		N002918	001

SULINDAC

TABLET; ORAL				
CLINORIL				
MERCK	150MG		N017911	001
SULINDAC				
HERITAGE PHARMS INC	150MG		A073262	002
	200MG		A073262	001
				Sep 06, 1991
SANDOZ	150MG		A072712	001
	200MG		A072713	001
				Aug 30, 1991
TEVA	150MG		A072972	001
	200MG		A072973	001
				Feb 28, 1992

SUPROFEN

SOLUTION/DROPS; OPHTHALMIC				
PROFENAL				
ALCON	1%		N019387	001
				Dec 23, 1988

SUTILAINS

OINTMENT; TOPICAL				
TRAVASE				
ABBOTT	82,000 UNITS/GM		N012828	001

TALBUTAL

TABLET; ORAL				
LOTUSATE				
SANOFI AVENTIS US	120MG		N009410	005

## DISCONTINUED DRUG PRODUCT LIST

6 - 292 (of 324)

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

ROSEMONT

EQ 10MG BASE/5ML

N021807 001

Oct 29, 2005

TABLET; ORAL

NOLVADEX

ASTRAZENECA

EQ 10MG BASE

N017970 001

EQ 20MG BASE

N017970 002

Mar 21, 1994

TAMOXIFEN CITRATE

IVAX SUB TEVA PHARMS

EQ 10MG BASE

A075740 001

Feb 20, 2003

EQ 20MG BASE

A075740 002

Feb 20, 2003

PHARMACHEMIE

EQ 10MG BASE

A074539 001

Mar 31, 2003

ROXANE

EQ 10MG BASE

A076027 001

Feb 20, 2003

EQ 20MG BASE

A076027 002

Feb 20, 2003

TEVA

EQ 10MG BASE

A074504 001

Apr 28, 2003

EQ 20MG BASE

A074504 002

Apr 28, 2003

TECHNETIUM TC-99M ALBUMIN AGGREGATED

INJECTABLE; INJECTION

TC 99M-LUNGAGGREGATE

GE HEALTHCARE

5mCi/ML

N017848 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

A-N STANNOUS AGGREGATED ALBUMIN

SYNCOR PHARMS

N/A

N017916 001

AN-MAA

PHARMALUCENCE

N/A

N017792 001

LUNGAGGREGATE REAGENT

GE HEALTHCARE

N/A

N017838 001

MACROTEC

BRACCO

N/A

N017833 001

TECHNESCAN MAA

MALLINCKRODT

N/A

N017842 001

TECHNETIUM TC 99M MAA

GE HEALTHCARE

N/A

N017773 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION

MICROLITE

PHARMALUCENCE

N/A

N018263 001

Mar 25, 1983

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M HSA

GE HEALTHCARE

N/A

N017775 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

INJECTABLE; INJECTION

INSTANT MICROSPHERES

3M

N/A

N017832 001

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

CIS BIO INTL SA

N/A

N020887 001

Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

CIS BIO INTL SA

N/A

N021012 001

Aug 03, 1999

## DISCONTINUED DRUG PRODUCT LIST

6 - 293 (of 324)

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION		
CINTICHEM TECHNETIUM 99M HEDSPA		
GE HEALTHCARE	N/A	N017653 001
MPI STANNOUS DIPHOSPHONATE		
GE HEALTHCARE	N/A	N017667 001
OSTEOSCAN		
MALLINCKRODT	N/A	N017454 001
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT		
GE HEALTHCARE	N/A	N017562 001

TECHNETIUM TC-99M FERPENTETATE KIT

INJECTABLE; INJECTION		
RENOTEC		
BRACCO	N/A	N017045 001

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION		
GLUCOSCAN		
BRISTOL MYERS SQUIBB	N/A	N017907 001
TECHNESCAN GLUCEPTATE		
DRAXIMAGE	N/A	N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION		
TECHNESCAN HIDA		
DRAXIMAGE	N/A	N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION		
AMERSCAN MDP KIT		
GE HEALTHCARE	N/A	N018335 001 Aug 05, 1982
DRAXIMAGE MDP-25		
DRAXIMAGE	N/A	N018035 002 Feb 27, 2004
OSTEOLITE		
PHARMALUCENCE	N/A	N017972 001
TECHNETIUM TC 99M MPI MDP		
GE HEALTHCARE	N/A	N018141 001
	N/A	N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION		
MPI DTPA KIT - CHELATE		
GE HEALTHCARE	N/A	N017255 001

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE; INJECTION		
SODIUM POLYPHOSPHATE-TIN KIT		
GE HEALTHCARE	N/A	N017664 001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION		
PYROLITE		
PHARMALUCENCE	N/A	N017684 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION		
PHOSPHOTEC		
BRACCO	N/A	N017680 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 294 (of 324)

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

RBC-SCAN

CADEMA

N/A

N020063 001

Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

MIRALUMA

LANTHEUS MEDCL

N/A

N019785 003

May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

GE HEALTHCARE

2-100mCi/ML

N017471 001

MALLINCKRODT

10-60mCi/ML

N017725 001

PHARMALUCENCE

12mCi/ML

N017321 001

24mCi/ML

N017321 002

48mCi/ML

N017321 003

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

MINITEC

BRACCO

0.22-2.22 CI/GENERATOR

N017339 001

TECHNETIUM TC 99M GENERATOR

GE HEALTHCARE

830-16600mCi/GENERATOR

N017693 001

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION; INJECTION, ORAL

TECHNETIUM TC 99M SULFUR COLLOID

GE HEALTHCARE

4mCi/ML

N017456 001

SOLUTION; ORAL

TECHNETIUM TC 99M SULFUR COLLOID

MALLINCKRODT

3mCi/ML

N017724 001

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

TECHNECOLL

MALLINCKRODT

N/A

N017059 001

TECHNETIUM TC 99M TSC

GE HEALTHCARE

N/A

N017784 001

TESULOID

BRACCO

N/A

N016923 001

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE; INJECTION

CARDIOTEC

BRACCO

N/A

N019928 001

Dec 19, 1990

TEGASEROD MALEATE

TABLET; ORAL

ZELNORM

NOVARTIS

EQ 2MG BASE

N021200 001

Jul 24, 2002

EQ 6MG BASE

N021200 002

Jul 24, 2002

TEMAZEPAM

CAPSULE; ORAL

TEMAZ

QUANTUM PHARMICS

15MG

A070564 001

Oct 15, 1985

30MG

A070547 001

Oct 15, 1985

TEMAZEPAM

DURAMED PHARMS BARR

15MG

A071708 001

Sep 29, 1988

30MG

A071709 001

Sep 29, 1988

MUTUAL PHARM

15MG

A071174 001

Jul 10, 1986



## DISCONTINUED DRUG PRODUCT LIST

6 - 295 (of 324)

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

MUTUAL PHARM	30MG	A071175	001	Jul 10, 1986
USL PHARMA	15MG	A070489	001	Jul 07, 1986
	30MG	A070490	001	Jul 07, 1986
WATSON LABS	15MG	A070383	001	Mar 23, 1987
	30MG	A070384	001	Mar 23, 1987

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

MYLAN TECHNOLOGIES	EQ 1MG BASE	A075384	001	Dec 01, 2000
	EQ 2MG BASE	A075384	002	Dec 01, 2000
	EQ 5MG BASE	A075384	003	Dec 01, 2000
	EQ 10MG BASE	A075384	004	Dec 01, 2000
SANDOZ	EQ 1MG BASE	A075667	001	Jul 28, 2000
	EQ 2MG BASE	A075667	002	Jul 28, 2000
	EQ 5MG BASE	A075667	003	Jul 28, 2000
	EQ 10MG BASE	A075667	004	Jul 28, 2000

TABLET; ORAL

TERAZOSIN HYDROCHLORIDE

IVAX SUB TEVA PHARMS	EQ 1MG BASE	A074530	001	Apr 21, 2000
	EQ 2MG BASE	A074530	002	Apr 21, 2000
	EQ 5MG BASE	A074530	003	Apr 21, 2000
	EQ 10MG BASE	A074530	004	Apr 21, 2000
SANDOZ	EQ 1MG BASE	A074315	001	Dec 31, 1998
	EQ 1MG BASE	A074657	001	Apr 28, 2000
	EQ 2MG BASE	A074315	002	Dec 31, 1998
	EQ 2MG BASE	A074657	002	Apr 28, 2000
	EQ 5MG BASE	A074315	003	Dec 31, 1998
	EQ 5MG BASE	A074657	003	Apr 28, 2000
	EQ 10MG BASE	A074315	004	Dec 31, 1998
	EQ 10MG BASE	A074657	004	Apr 28, 2000
TEVA	EQ 1MG BASE	A074446	001	May 18, 2000
	EQ 2MG BASE	A074446	002	May 18, 2000
	EQ 5MG BASE	A074446	003	May 18, 2000
	EQ 10MG BASE	A074446	004	May 18, 2000

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

NOVARTIS	1%	N020192	001	Dec 30, 1992
----------	----	---------	-----	--------------

TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION

BRETHAIRE

NOVARTIS	0.2MG/INH	N018762	001	Aug 17, 1984
----------	-----------	---------	-----	--------------

BRICANYL

SANOFI AVENTIS US	0.2MG/INH	N018000	001	Mar 19, 1985
-------------------	-----------	---------	-----	--------------

INJECTABLE; INJECTION

BRETHINE

AAIPHARMA LLC	1MG/ML	N018571	001	
---------------	--------	---------	-----	--

BRICANYL

SANOFI AVENTIS US	1MG/ML	N017466	001	
-------------------	--------	---------	-----	--

TABLET; ORAL

BRETHINE

AAIPHARMA LLC	2.5MG	N017849	001	
---------------	-------	---------	-----	--

	5MG	N017849	002	
--	-----	---------	-----	--

BRICANYL

SANOFI AVENTIS US	2.5MG	N017618	001	
-------------------	-------	---------	-----	--

	5MG	N017618	002	
--	-----	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 296 (of 324)

TERIPARATIDE ACETATEINJECTABLE; INJECTION  
PARATHAR

SANOFI AVENTIS US 200 UNITS/VIAL N019498 001 Dec 23, 1987

TESTOLACTONEINJECTABLE; INJECTION  
TESLAC

BRISTOL MYERS SQUIBB 100MG/ML N016119 001

TABLET; ORAL

TESLAC

BRISTOL MYERS SQUIBB 50MG N016118 001

250MG N016118 002

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

TESTODERM

ALZA 4MG/24HR N019762 001 Oct 12, 1993

6MG/24HR N019762 002 Oct 12, 1993

TESTODERM TTS

ALZA 5MG/24HR N020791 001 Dec 18, 1997

GEL; TRANSDERMAL

TESTOSTERONE

PAR PHARM 1% (2.5GM/PACKET) A076744 001 May 23, 2007

1% (5GM/PACKET) A076744 002 May 23, 2007

WATSON LABS 1% (2.5GM/PACKET) A076737 001 Jan 27, 2006

1% (5GM/PACKET) A076737 002 Jan 27, 2006

INJECTABLE; INJECTION

TESTOSTERONE

WATSON LABS 25MG/ML A086420 001 May 10, 1983

50MG/ML A086419 001 Aug 23, 1983

100MG/ML A086417 001 Jul 07, 1983

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

PHARMACIA AND UPJOHN 50MG/ML A085635 001

TESTOSTERONE CYPIONATE

WATSON LABS 100MG/ML A084401 001

100MG/ML A086029 001

200MG/ML A084401 002

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

ENDO PHARM 200MG/ML N009165 001

TESTOSTERONE ENANTHATE

WATSON LABS 100MG/ML A083667 001

100MG/ML A085599 001

200MG/ML A083667 002

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

BEL MAR 25MG/ML A080741 001

50MG/ML A080742 001

100MG/ML A080743 001

ELKINS SINN 25MG/ML A080276 001

LILLY 50MG/ML A080254 002

WATSON LABS 25MG/ML A080188 001

25MG/ML A085490 001

50MG/ML A080188 002

50MG/ML A085490 002

100MG/ML A080188 003

## DISCONTINUED DRUG PRODUCT LIST

6 - 297 (of 324)

TESTOSTERONE PROPIONATEINJECTABLE; INJECTION  
TESTOSTERONE PROPIONATE

WATSON LABS 100MG/ML A083595 003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

HERITAGE PHARMS INC 250MG N050278 003  
500MG N050278 001

BRISTACYCLINE

BRISTOL 250MG A061658 001  
250MG A061888 001  
500MG A061658 002  
500MG A061888 002

CYCLOPAR

WARNER CHILCOTT 250MG A061725 001  
250MG A062175 001  
250MG A062332 001  
500MG A061725 002  
500MG A062332 002

PANMYCIN

PHARMACIA AND UPJOHN 250MG A060347 001

RETET

SOLVAY 250MG A061443 001  
500MG A061443 002

ROBITET

WYETH AYERST 250MG A061734 001  
500MG A061734 002

SUMYCIN

APOTHECON 100MG A060429 002  
125MG A060429 004  
250MG A060429 001  
500MG A060429 003

TETRACHEL

ANGUS 250MG A060343 001  
500MG A060343 003

TETRACYCLINE HYDROCHLORIDE

ABBOTT 250MG A061802 001  
500MG A061802 002

ELKINS SINN 250MG A060059 001

FERRANTE 125MG A060173 001

250MG A060173 002

HEATHER 250MG A061148 001

500MG A061148 002

LABS ATRAL 250MG A062752 001 Aug 12, 1988

500MG A062752 002 Aug 12, 1988

MAST MM 250MG A062085 001

MUTUAL PHARM 250MG A060736 001

500MG A060736 002

MYLAN 250MG A060783 001

500MG A060783 002

PUREPAC PHARM 250MG A060290 001

500MG A060290 002

PVT FORM 250MG A062686 001 Jul 24, 1986

500MG A062686 002 Jul 24, 1986

ROXANE 500MG A061214 002

SANDOZ 250MG A061471 001

SUPERPHARM 250MG A062540 001 Mar 21, 1985

500MG A062540 002 Mar 21, 1985

VALEANT PHARM INTL 250MG A060471 001

500MG A060471 002

WARNER CHILCOTT 250MG A062300 001

500MG A062300 002

## DISCONTINUED DRUG PRODUCT LIST

6 - 298 (of 324)

TETRACYCLINE HYDROCHLORIDE

## CAPSULE; ORAL

## TETRACYCLINE HYDROCHLORIDE

WATSON LABS	250MG	A062103	001
	250MG	A062343	001
	500MG	A062103	002
	500MG	A062343	002
WEST WARD	250MG	A060768	001
	500MG	A060768	002
WYETH AYERST	250MG	A061685	001
	500MG	A061685	002

## TETRACYN

PFIPHARMECS	250MG	A060082	003
	500MG	A060082	004

## FIBER, EXTENDED RELEASE; PERIODONTAL

## ACTISITE

ON SITE	12.7MG/FIBER	N050653	001	Mar 25, 1994
---------	--------------	---------	-----	--------------

## FOR SOLUTION; TOPICAL

## TOPICYCLINE

SHIRE	2.2MG/ML	N050493	001
-------	----------	---------	-----

## INJECTABLE; INJECTION

## ACHROMYCIN

LEDERLE	250MG/VIAL	N050273	002
	500MG/VIAL	N050273	003

## TETRACYN

PFIZER	250MG/VIAL	A060096	001
	500MG/VIAL	A060096	002

## OINTMENT; OPHTHALMIC

## ACHROMYCIN

STORZ	10MG/GM	N050266	001
-------	---------	---------	-----

## SUSPENSION; ORAL

## ACHROMYCIN V

LEDERLE	125MG/5ML	N050263	002
---------	-----------	---------	-----

## TETRACYCLINE HYDROCHLORIDE

ALPHARMA US PHARMS	125MG/5ML	A060633	001
FERRANTE	125MG/5ML	A060174	001
PROTER	125MG/5ML	A060446	001
PUREPAC PHARM	125MG/5ML	A060291	001

## TETRACYN

PFIPHARMECS	125MG/5ML	A060095	001
-------------	-----------	---------	-----

## TETRAMED

IVAX SUB TEVA PHARMS	125MG/5ML	A061468	001
----------------------	-----------	---------	-----

## SUSPENSION/DROPS; OPHTHALMIC

## ACHROMYCIN

STORZ	1%	N050268	001
-------	----	---------	-----

## TABLET; ORAL

## PANMYCIN

PHARMACIA AND UPJOHN	250MG	A061705	001
	500MG	A061705	002

## SUMYCIN

PAR PHARM	50MG	A061147	003
	100MG	A061147	002

TETRACYCLINE PHOSPHATE COMPLEX

## CAPSULE; ORAL

## TETREX

BRISTOL	EQ 100MG HCL	A061653	001
	EQ 250MG HCL	A061653	002
	EQ 250MG HCL	A061889	002
	EQ 250MG HCL	N050212	002
	EQ 500MG HCL	A061653	003
	EQ 500MG HCL	A061889	001
	EQ 500MG HCL	N050212	003

## DISCONTINUED DRUG PRODUCT LIST

6 - 299 (of 324)

THALLOUS CHLORIDE, TL-201

## INJECTABLE; INJECTION

## THALLOUS CHLORIDE TL 201

BRACCO	1mCi/ML	N018548	001	Dec 30, 1982
TRACE LIFE	1mCi/ML	A075569	001	Nov 21, 2001

THEOPHYLLINE

## CAPSULE; ORAL

## BRONKODYL

SANOFI AVENTIS US	100MG	A085264	001	
	200MG	A085264	002	

## ELIXOPHYLLIN

FOREST LABS	100MG	A085545	001	Jul 31, 1984
	200MG	A083921	001	Jul 31, 1984

## SOMOPHYLLIN-T

FISONS	100MG	A087155	001	Feb 25, 1985
	200MG	A087155	002	Feb 25, 1985
	250MG	A087155	003	Feb 25, 1985

## THEOPHYLLINE

KV PHARM	100MG	A085263	001	
	200MG	A085263	002	
SCHERER RP	100MG	A084731	002	Nov 07, 1986
	200MG	A084731	001	Nov 07, 1986
	250MG	A084731	003	Nov 07, 1986

## CAPSULE, EXTENDED RELEASE; ORAL

## AEROLATE III

FLEMING PHARMS	65MG	A085075	003	Nov 24, 1986
----------------	------	---------	-----	--------------

## AEROLATE JR

FLEMING PHARMS	130MG	A085075	002	Nov 24, 1986
----------------	-------	---------	-----	--------------

## AEROLATE SR

FLEMING PHARMS	260MG	A085075	001	Nov 24, 1986
----------------	-------	---------	-----	--------------

## ELIXOPHYLLIN SR

FOREST LABS	125MG	A086826	001	Jan 29, 1985
	250MG	A086826	002	Jan 29, 1985

## SLO-BID

SANOFI AVENTIS US	50MG	A088269	001	Jan 31, 1985
	75MG	A089539	001	May 10, 1989
	100MG	A087892	001	Jan 31, 1985
	125MG	A089540	001	May 10, 1989
	200MG	A087893	001	Jan 31, 1985
	300MG	A087894	001	Jan 31, 1985

## SLO-PHYLLIN

SANOFI AVENTIS US	60MG	A085206	001	May 24, 1982
	125MG	A085203	001	May 24, 1982
	250MG	A085205	001	May 24, 1982

## SOMOPHYLLIN-CRT

GRAHAM DM	50MG	A087763	001	Feb 27, 1985
	100MG	A087194	001	
	200MG	A088382	001	Feb 27, 1985
	250MG	A087193	001	
	300MG	A088383	001	Feb 27, 1985

## THEOBID

WHITBY	260MG	A085983	001	Mar 20, 1985
--------	-------	---------	-----	--------------

## THEOBID JR.

WHITBY	130MG	A087854	001	Mar 20, 1985
--------	-------	---------	-----	--------------

## THEOCLEAR L.A.-130

SCHWARZ PHARMA	130MG	A086569	001	May 27, 1982
----------------	-------	---------	-----	--------------

## THEOCLEAR L.A.-260

SCHWARZ PHARMA	260MG	A086569	002	May 27, 1982
----------------	-------	---------	-----	--------------

## THEO-DUR

SCHERING	50MG	A088022	001	Sep 10, 1985
	75MG	A088015	001	Sep 10, 1985
	125MG	A088016	001	Sep 10, 1985
	200MG	A087995	001	Sep 10, 1985

## DISCONTINUED DRUG PRODUCT LIST

6 - 300 (of 324)

THEOPHYLLINE

## CAPSULE, EXTENDED RELEASE; ORAL

## THEOPHYLLINE

CENT PHARMS	125MG	A088654	001	Feb 12, 1985
	250MG	A088689	001	Feb 12, 1985
HOSPIRA	100MG	A089976	001	Jan 04, 1995
	200MG	A089977	001	Jan 04, 1995
	300MG	A089932	001	Jan 04, 1995
SANDOZ	260MG	A087462	001	May 11, 1982

## THEOPHYLLINE-SR

SCHERER RP	300MG	A088255	001	Jun 12, 1986
------------	-------	---------	-----	--------------

## THEOPHYL-SR

ORTHO MCNEIL PHARM	125MG	A086480	001	Feb 08, 1985
	250MG	A086471	001	Feb 08, 1985

## THEOVENT

SCHERING	125MG	A087010	001	Jan 31, 1985
	250MG	A087910	001	Jan 31, 1985

## ELIXIR; ORAL

## ELIXOMIN

CENCI	80MG/15ML	A088303	001	Jan 25, 1984
-------	-----------	---------	-----	--------------

## LANOPHYLLIN

LANNETT	80MG/15ML	A084578	001	
---------	-----------	---------	-----	--

## THEOLIXIR

PANRAY	80MG/15ML	A084559	001	
--------	-----------	---------	-----	--

## THEOPHYL-225

ORTHO MCNEIL PHARM	112.5MG/15ML	A086485	001	
--------------------	--------------	---------	-----	--

## THEOPHYLLINE

ALPHARMA US PHARMS	80MG/15ML	A089223	001	May 27, 1988
CENCI	80MG/15ML	A087679	001	Apr 15, 1982
HALSEY	80MG/15ML	A085169	001	
MORTON GROVE	80MG/15ML	A086748	001	
PERRIGO	80MG/15ML	A085952	001	
PHARM ASSOC	80MG/15ML	A086720	001	
PRECISION DOSE	80MG/15ML	A085863	001	
ROXANE	80MG/15ML	A084739	001	
TARO	80MG/15ML	A089626	001	Oct 28, 1988

## INJECTABLE; INJECTION

## THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	40MG/100ML	N019083	001	Nov 07, 1984
---------	------------	---------	-----	--------------

## THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	80MG/100ML	N019083	002	Nov 07, 1984
---------	------------	---------	-----	--------------

## THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	160MG/100ML	N019083	003	Nov 07, 1984
---------	-------------	---------	-----	--------------

## THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	200MG/100ML	N019212	001	Nov 07, 1984
	200MG/100ML	N019826	004	Aug 14, 1992

## THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	4MG/ML	N019212	003	Nov 07, 1984
	400MG/100ML	N019212	002	Nov 07, 1984
	400MG/100ML	N019826	005	Aug 14, 1992

## SOLUTION; ORAL

## AEROLATE

FLEMING PHARMS	150MG/15ML	A089141	001	Dec 03, 1986
----------------	------------	---------	-----	--------------

## THEOLAIR

3M	80MG/15ML	A086107	001	
----	-----------	---------	-----	--

## THEOPHYLLINE

ROXANE	80MG/15ML	A087449	001	Sep 15, 1983
--------	-----------	---------	-----	--------------

## SUSPENSION; ORAL

## ELIXICON

FOREST LABS	100MG/5ML	A085502	001	
-------------	-----------	---------	-----	--

## SYRUP; ORAL

## ACCURBRON

SANOFI AVENTIS US	150MG/15ML	A088746	001	Nov 22, 1985
-------------------	------------	---------	-----	--------------

## AQUAPHYLLIN

FERNDAL LABS	80MG/15ML	A087917	001	Jan 18, 1983
--------------	-----------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 301 (of 324)

THEOPHYLLINE

## SYRUP; ORAL

## SLO-PHYLLIN

SANOFI AVENTIS US 80MG/15ML A085187 001

## THEOCLEAR-80

CENT PHARMS 80MG/15ML A087095 001 Mar 01, 1982

## THEOPHYLLINE

ALPHARMA US PHARMS 80MG/15ML A086001 001

150MG/15ML A086545 001

## TABLET; ORAL

## QUIBRON-T

MONARCH PHARMS 300MG A088656 001 Aug 22, 1985

## SLO-PHYLLIN

SANOFI AVENTIS US 100MG A085202 001

200MG A085204 001

## THEOCLEAR-100

CENT PHARMS 100MG A085353 002

## THEOCLEAR-200

CENT PHARMS 200MG A085353 001

## THEOPHYL-225

ORTHO MCNEIL PHARM 225MG A084726 001

## TABLET, CHEWABLE; ORAL

## THEOPHYL

ORTHO MCNEIL PHARM 100MG A086506 001 Sep 12, 1985

## TABLET, EXTENDED RELEASE; ORAL

## DURAPHYL

FOREST LABS 100MG A088503 001 Apr 03, 1985

200MG A088504 001 Apr 03, 1985

300MG A088505 001 Apr 03, 1985

## LABID

PROCTER AND GAMBLE 250MG A087225 001

## QUIBRON-T/SR

MONARCH PHARMS 300MG A087563 001 Jun 21, 1983

## SUSTAIRE

ROERIG 100MG A085665 001

300MG A085665 002

## THEO-DUR

SCHERING 100MG A085328 001

200MG A086998 001

300MG A085328 002

450MG A089131 001 Jun 25, 1986

## THEOLAIR-SR

3M 200MG A088369 001 Jul 16, 1987

250MG A086363 002 Jul 16, 1987

300MG A088364 001 Jul 16, 1987

500MG A089132 001 Jul 16, 1987

## THEOPHYLLINE

ABLE 300MG A040548 001 Apr 30, 2004

400MG A040543 001 Apr 27, 2004

450MG A040546 001 Apr 30, 2004

600MG A040539 001 Apr 27, 2004

## T-PHYL

PHARM RES ASSOC 200MG A088253 001 Aug 17, 1983

## UNI-DUR

SCHERING 400MG A089822 001 Jan 04, 1995

600MG A089823 001 Jan 04, 1995

THEOPHYLLINE SODIUM GLYCINATE

## ELIXIR; ORAL

## SYNOPHYLATE

CENT PHARMS EQ 165MG BASE/15ML N006333 008

## TABLET; ORAL

## ASBRON

NOVARTIS EQ 150MG BASE A085148 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 302 (of 324)

THIABENDAZOLE

SUSPENSION; ORAL

MINTEZOL

MERCK

500MG/5ML

N016097 001

TABLET, CHEWABLE; ORAL

MINTEZOL

MERCK

500MG

N016096 001

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BETALIN S

LILLY

100MG/ML

A080853 001

THIAMINE HYDROCHLORIDE

ABRAXIS PHARM

100MG/ML

A080509 001

AKORN

100MG/ML

A087968 001

Oct 01, 1982

BAXTER HLTHCARE

100MG/ML

A080575 001

BEL MAR

100MG/ML

A080718 001

200MG/ML

A080712 001

DELL LABS

100MG/ML

A083775 001

LUITPOLD

100MG/ML

A080667 001

PARKE DAVIS

100MG/ML

A080770 001

WATSON LABS

100MG/ML

A083534 001

200MG/ML

A083534 002

WYETH AYERST

100MG/ML

A080553 001

THIAMYLAL SODIUM

INJECTABLE; INJECTION

SURITAL

PARKEDALE

1GM/VIAL

N007600 003

5GM/VIAL

N007600 005

10GM/VIAL

N007600 009

THIETHYLPERAZINE MALATE

INJECTABLE; INJECTION

TORECAN

NOVARTIS

5MG/ML

N012754 002

THIETHYLPERAZINE MALEATE

SUPPOSITORY; RECTAL

TORECAN

NOVARTIS

10MG

N013247 001

TABLET; ORAL

TORECAN

NOVARTIS

10MG

N012753 001

THIOPENTAL SODIUM

SUSPENSION; RECTAL

PENTOTHAL

ABBOTT

400MG/GM

N011679 001

THIORIDAZINE

SUSPENSION; ORAL

MELLARIL-S

NOVARTIS

EQ 25MG HCL/5ML

N017923 001

EQ 100MG HCL/5ML

N017923 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

MELLARIL

NOVARTIS

30MG/ML

N011808 012

100MG/ML

N011808 018

THIORIDAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

A088229 001

Aug 23, 1983

ALPHARMA US PHARMS

30MG/ML

A087766 001

Apr 26, 1983



## DISCONTINUED DRUG PRODUCT LIST

6 - 303 (of 324)

THIORIDAZINE HYDROCHLORIDE

## CONCENTRATE; ORAL

## THIORIDAZINE HYDROCHLORIDE

HI TECH PHARMA	30MG/ML	A040125	001	Aug 16, 1996
	100MG/ML	A040126	001	Aug 16, 1996
MORTON GROVE	30MG/ML	A088258	001	Jul 25, 1983
	100MG/ML	A088227	001	Jul 05, 1983
PHARM ASSOC	30MG/ML	A040187	001	Aug 28, 1997
	100MG/ML	A040213	001	May 29, 1998
SANDOZ	30MG/ML	A088307	001	Nov 23, 1983
	100MG/ML	A088308	001	Nov 23, 1983
TEVA PHARMS	30MG/ML	A089602	001	Nov 09, 1987
	100MG/ML	A089603	001	Nov 09, 1987
THIORIDAZINE HYDROCHLORIDE INTENSOL				
ROXANE	30MG/ML	A088941	001	Dec 16, 1985
	100MG/ML	A088942	001	Dec 16, 1985

## TABLET; ORAL

## MELLARIL

NOVARTIS	10MG	N011808	003	
	15MG	N011808	016	
	25MG	N011808	006	
	50MG	N011808	011	
	100MG	N011808	009	
	150MG	N011808	017	
	200MG	N011808	015	

## THIORIDAZINE HYDROCHLORIDE

IVAX PHARMS	10MG	A088270	001	Apr 14, 1983
	15MG	A088271	001	Apr 14, 1983
	25MG	A088272	001	Apr 14, 1983
	50MG	A088194	001	Apr 14, 1983
	100MG	A088273	001	Oct 03, 1983
MUTUAL PHARM	10MG	A088375	001	Nov 18, 1983
	15MG	A088461	001	Nov 18, 1983
	25MG	A087264	001	Nov 18, 1983
	50MG	A088370	001	Nov 18, 1983
	100MG	A088379	001	Nov 16, 1983
	150MG	A088737	001	Sep 26, 1984
	200MG	A088738	001	Oct 16, 1984
MYLAN	10MG	A088332	001	Jun 27, 1983
	25MG	A088333	001	Jun 27, 1983
	50MG	A088334	001	Jun 27, 1983
	100MG	A088335	001	Nov 18, 1983
PAR PHARM	10MG	A088351	001	Dec 05, 1983
	15MG	A088352	001	Dec 05, 1983
	25MG	A088336	001	Dec 05, 1983
	50MG	A088322	001	Dec 05, 1983
	100MG	A088480	001	Dec 29, 1983
	150MG	A089764	001	Feb 09, 1988
	200MG	A089765	001	Feb 09, 1988
ROXANE	10MG	A088663	001	Mar 15, 1984
	25MG	A088664	001	Mar 15, 1984
	50MG	A088665	001	Mar 15, 1984
	100MG	A089048	001	Feb 26, 1985
SANDOZ	10MG	A088131	001	Aug 30, 1983
	15MG	A088132	001	Aug 30, 1983
	25MG	A088133	001	Aug 30, 1983
	50MG	A088134	001	Aug 30, 1983
	100MG	A088135	001	Nov 20, 1984
	150MG	A088136	001	Sep 17, 1986
	200MG	A088137	001	Sep 17, 1986
SUPERPHARM	10MG	A089103	001	Jul 02, 1985
	25MG	A089104	001	Jul 02, 1985
	50MG	A089105	001	Jul 02, 1985
TEVA	10MG	A088493	001	May 17, 1985

## DISCONTINUED DRUG PRODUCT LIST

6 - 304 (of 324)

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

TEVA	100MG	A088456	001	May 17, 1985
WATSON LABS	10MG	A088412	001	Sep 12, 1983
	10MG	A088476	001	Nov 08, 1983
	10MG	A088561	001	May 11, 1984
	15MG	A088345	001	Jul 28, 1983
	15MG	A088477	001	Nov 08, 1983
	15MG	A088562	001	May 11, 1984
	25MG	A088296	001	Jul 28, 1983
	25MG	A088478	001	Nov 08, 1983
	25MG	A088567	001	May 11, 1984
	25MG	A088755	001	Jul 24, 1984
	50MG	A088323	001	Jul 28, 1983
	50MG	A088479	001	Nov 08, 1983
	50MG	A088563	001	May 11, 1984
	100MG	A088284	001	Aug 25, 1983
	100MG	A088564	001	May 11, 1984
	100MG	A088736	001	Jul 24, 1984
	150MG	A088410	001	Mar 05, 1984
	150MG	A088869	001	Jun 28, 1985
	200MG	A088381	001	Mar 14, 1984
	200MG	A088872	001	Apr 26, 1985
WEST WARD	10MG	A088658	001	Mar 26, 1984
	15MG	A088659	001	Mar 26, 1984
	25MG	A088660	001	Mar 26, 1984
	50MG	A088661	001	Mar 26, 1984

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

IMMUNEX	15MG/VIAL	N020058	001	Dec 22, 1994
---------	-----------	---------	-----	--------------

THIOTEPA

IMMUNEX	15MG/VIAL	N011683	001	
---------	-----------	---------	-----	--

THIOTHIXENE

CAPSULE; ORAL

NAVANE

PFIZER	20MG	N016584	005	
--------	------	---------	-----	--

THIOTHIXENE

AM THERAP	1MG	A071884	001	Aug 12, 1987
	2MG	A071885	001	Aug 12, 1987
	5MG	A071886	001	Aug 12, 1987
	10MG	A071887	001	Aug 12, 1987
	20MG	A072200	001	Dec 17, 1987
WATSON LABS	1MG	A070600	001	Jun 05, 1987
	2MG	A071626	001	Jun 25, 1987
	5MG	A071627	001	Jun 25, 1987
	10MG	A070603	001	Jun 05, 1987
	10MG	A071628	001	Jun 25, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

NAVANE

PFIZER	EQ 5MG BASE/ML	N016758	001	
--------	----------------	---------	-----	--

THIOTHIXENE HYDROCHLORIDE

ALPHARMA US PHARMS	EQ 5MG BASE/ML	A070969	001	Oct 16, 1987
PACO	EQ 1MG BASE/ML	A071917	001	Sep 20, 1989
	EQ 5MG BASE/ML	A071939	001	Dec 16, 1988
TEVA	EQ 5MG BASE/ML	A071184	001	Jun 22, 1987
TEVA PHARMS	EQ 5MG BASE/ML	A071554	001	Oct 16, 1987

THIOTHIXENE HYDROCHLORIDE INTENSOL

ROXANE	EQ 5MG BASE/ML	A073494	001	Jun 30, 1992
--------	----------------	---------	-----	--------------

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 746 of 1114**

## DISCONTINUED DRUG PRODUCT LIST

6 - 305 (of 324)

THIOTHIXENE HYDROCHLORIDE

INJECTABLE; INJECTION

NAVANE

PFIZER

EQ 2MG BASE/ML  
EQ 10MG BASE/VIALN016904 001  
N016904 002THYROGLOBULIN

TABLET; ORAL

PROLOID

PARKE DAVIS

16MG  
32MG  
65MG  
100MG  
130MG  
200MG  
325MGN002245 009  
N002245 005  
N002245 002  
N002245 008  
N002245 010  
N002245 007  
N002245 004

THYROGLOBULIN

IMPAX LABS

64.8MG

A080151 001

THYROTROPIN

INJECTABLE; INJECTION

THYTROPAR

SANOFI AVENTIS US

10 IU/VIAL

N008682 001

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

CEPHALON

20MG

N020646 004 Sep 30, 1997

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL  
EQ 3GM BASE/VIAL  
EQ 3GM BASE/VIAL  
EQ 6GM BASE/VIAL  
EQ 20GM BASE/VIAL  
EQ 30GM BASE/VIALN050497 001  
A062690 001 Dec 19, 1986  
N050497 002  
N050497 003  
N050497 004  
N050497 005 Apr 04, 1984TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

ROCHE PALO

125MG  
250MGN019979 001 Mar 24, 1993  
N019979 002 Oct 31, 1991

TICLOPIDINE HYDROCHLORIDE

MYLAN

250MG

A075316 001 Nov 02, 1999

SANDOZ

250MG

A075318 001 Aug 20, 1999

WATSON LABS

250MG

A075309 001 Apr 26, 2000

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AKORN

EQ 0.25% BASE

A074465 001 Mar 25, 1997

FOUGERA

EQ 0.25% BASE

A074667 001 Mar 25, 1997

EQ 0.5% BASE

A074668 001 Mar 25, 1997

TABLET; ORAL

BLOCADREN

MERCK

5MG  
10MG  
20MGN018017 001  
N018017 002  
N018017 004

TIMOLOL MALEATE

QUANTUM PHARMICS

5MG

A072466 001 May 19, 1989

10MG

A072467 001 May 19, 1989

20MG

A072468 001 May 19, 1989

## DISCONTINUED DRUG PRODUCT LIST

6 - 306 (of 324)

TIMOLOL MALEATE

TABLET; ORAL

TIMOLOL MALEATE

SANDOZ

5MG

A072550 001

Apr 13, 1989

10MG

A072551 001

Apr 13, 1989

20MG

A072552 001

Apr 13, 1989

TEVA

5MG

A072648 001

Jun 16, 1993

10MG

A072649 001

Jun 16, 1993

20MG

A072650 001

Jun 16, 1993

USL PHARMA

5MG

A072001 001

Apr 11, 1989

10MG

A072002 001

Apr 11, 1989

20MG

A072003 001

Apr 11, 1989

WATSON LABS

5MG

A072269 001

Apr 11, 1989

5MG

A072917 001

Jul 31, 1991

10MG

A072270 001

Apr 11, 1989

10MG

A072918 001

Jul 31, 1991

20MG

A072271 001

Apr 11, 1989

20MG

A072919 001

Jul 31, 1991

TIOCONAZOLE

CREAM; TOPICAL

TZ-3

PFIZER

1%

N018682 001

Feb 18, 1983

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE

EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)

N020912 001

May 14, 1998

EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)

N020913 001

May 14, 1998

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

BARR

EQ 2MG BASE

A076371 001

Apr 09, 2003

EQ 4MG BASE

A076371 002

Apr 09, 2003

IVAX SUB TEVA PHARMS

EQ 2MG BASE

A076321 001

Sep 30, 2004

EQ 4MG BASE

A076321 002

Sep 30, 2004

ZANAFLEX

ACORDA

EQ 2MG BASE

N020397 002

Feb 04, 2000

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

ALCON UNIVERSAL

0.3%

A063176 001

May 25, 1994

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

LILLY

EQ 10MG BASE/ML

A062008 004

EQ 10MG BASE/ML

A062707 001

Apr 29, 1987

EQ 10MG BASE/ML

N050477 005

EQ 40MG BASE/ML

A062008 001

EQ 1.2GM BASE/VIAL

N050519 001

TOBRAMYCIN SULFATE

APOTHECON

EQ 40MG BASE/ML

A064021 002

May 31, 1994

EQ 40MG BASE/ML

A064026 001

May 31, 1994

ASTRAZENECA

EQ 10MG BASE/ML

A063119 001

Oct 31, 1994

EQ 40MG BASE/ML

A063120 001

Oct 31, 1994

EQ 40MG BASE/ML

A063121 001

Oct 31, 1994

EQ 40MG BASE/ML

A063122 001

Oct 31, 1994

BAXTER HLTHCARE

EQ 10MG BASE/ML

A063113 001

Apr 26, 1991

EQ 10MG BASE/ML

A063128 001

Nov 27, 1991

EQ 40MG BASE/ML

A063118 001

Jul 29, 1991

EQ 40MG BASE/ML

A063127 001

Nov 27, 1991

## DISCONTINUED DRUG PRODUCT LIST

6 - 307 (of 324)

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

HOSPIRA	EQ 40MG BASE/ML	A063161	001	May 29, 1991
MARSAM PHARMS LLC	EQ 40MG BASE/ML	A062945	002	Aug 09, 1989

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

TONOCARD

ASTRAZENECA	400MG	N018257	001	Nov 09, 1984
	600MG	N018257	002	Nov 09, 1984

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

AMNEAL PHARMS NY	250MG	A071270	001	Sep 23, 1986
	500MG	A071271	001	Sep 23, 1986
BARR	100MG	A070162	001	Jan 14, 1986
	250MG	A070163	001	Jan 14, 1986
	500MG	A070164	001	Jan 14, 1986
DURAMED PHARMS BARR	100MG	A070165	001	Jan 10, 1986
	250MG	A070166	001	Jan 10, 1986
	500MG	A070167	001	Jan 10, 1986
IVAX SUB TEVA PHARMS	100MG	N018894	001	Nov 02, 1984
	250MG	N018894	002	Nov 02, 1984
	500MG	N018894	003	Nov 02, 1984
MUTUAL PHARM	100MG	A071357	001	Jul 16, 1987
	250MG	A071358	001	Jul 16, 1987
	500MG	A071359	001	Jul 16, 1987
PAR PHARM	100MG	A070159	001	Jan 06, 1986
	250MG	A070160	001	Jan 06, 1986
	500MG	A070161	001	Jan 06, 1986
SANDOZ	100MG	A071633	001	Dec 09, 1987
	250MG	A070289	001	Mar 13, 1986
	500MG	A070290	001	Mar 13, 1986
SUPERPHARM	250MG	A070763	001	Jun 16, 1986
	500MG	A070764	001	Jun 16, 1986
USL PHARMA	100MG	A071355	001	Jan 11, 1988
	250MG	A070168	001	Apr 02, 1986
	500MG	A070169	001	Apr 02, 1986
WATSON LABS	100MG	A070242	001	Aug 01, 1986
	100MG	A070513	001	Jan 09, 1986
	250MG	A070243	001	Aug 01, 1986
	500MG	A070244	001	Aug 01, 1986
TOLINASE				
PHARMACIA AND UPJOHN	100MG	N015500	002	
	250MG	N015500	004	
	500MG	N015500	005	

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRISCOLINE

NOVARTIS	25MG/ML	N006403	005	Feb 22, 1985
----------	---------	---------	-----	--------------

TOLBUTAMIDE

TABLET; ORAL

ORINASE

PHARMACIA AND UPJOHN	250MG	N010670	002	
	500MG	N010670	001	

TOLBUTAMIDE

ALRA	500MG	A086141	001	
ASCOT	500MG	A087541	001	Mar 01, 1983
BARR	500MG	A087121	001	
CLONMEL HLTHCARE	500MG	A086926	001	

## DISCONTINUED DRUG PRODUCT LIST

6 - 308 (of 324)

TOLBUTAMIDE

## TABLET; ORAL

## TOLBUTAMIDE

IVAX PHARMS	500MG	A087093	001	
PARKE DAVIS	500MG	A086047	001	
PUREPAC PHARM	500MG	A088950	001	Jun 17, 1985
SANDOZ	500MG	A086574	001	
	500MG	N012678	001	
SUPERPHARM	500MG	A088893	001	Nov 19, 1984
VANGARD	500MG	A087876	001	Apr 20, 1982
WATSON LABS	250MG	A089110	001	May 29, 1987
	500MG	A089111	001	May 29, 1987

TOLBUTAMIDE SODIUM

## INJECTABLE; INJECTION

## ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N012095	001	
----------------------	------------------	---------	-----	--

TOLMETIN SODIUM

## CAPSULE; ORAL

## TOLMETIN SODIUM

IVAX SUB TEVA PHARMS	EQ 400MG BASE	A073392	001	Jan 24, 1992
MUTUAL PHARM	EQ 400MG BASE	A073311	001	Nov 27, 1991
SANDOZ	EQ 400MG BASE	A073462	001	Apr 30, 1992
TEVA	EQ 400MG BASE	A073519	001	May 29, 1992

## TABLET; ORAL

## TOLMETIN SODIUM

ACTAVIS ELIZABETH	EQ 600MG BASE	A073527	001	Jun 30, 1992
SANDOZ	EQ 200MG BASE	A073588	001	Jul 31, 1992
	EQ 600MG BASE	A074002	001	Sep 27, 1993
TEVA	EQ 600MG BASE	A074729	001	Feb 27, 1997

TOLVAPTAN

## TABLET; ORAL

## SAMSCA

OTSUKA AMERICA PHARM	60MG	N022275	003	May 19, 2009
----------------------	------	---------	-----	--------------

TOPIRAMATE

## CAPSULE; ORAL

## TOPAMAX SPRINKLE

ORTHO MCNEIL JANSSEN	50MG	N020844	003	Oct 26, 1998
----------------------	------	---------	-----	--------------

## TOPIRAMATE

BARR	15MG	A076448	001	Apr 15, 2009
	25MG	A076448	002	Apr 15, 2009

## TABLET; ORAL

## TOPAMAX

ORTHO MCNEIL JANSSEN	300MG	N020505	003	Dec 24, 1996
	400MG	N020505	006	Dec 24, 1996

## TOPIRAMATE

BARR	25MG	A076315	001	Mar 27, 2009
	100MG	A076315	002	Mar 27, 2009
	200MG	A076315	003	Mar 27, 2009

TORSEMIDE

## INJECTABLE; INJECTION

## DEMADEX

ROCHE	50MG/5ML (10MG/ML)	N020137	002	Aug 23, 1993
	20MG/2ML (10MG/ML)	N020137	001	Aug 23, 1993

TRAMADOL HYDROCHLORIDE

## TABLET; ORAL

## TRAMADOL HYDROCHLORIDE

ASTA	50MG	A075974	001	Jul 12, 2002
IVAX SUB TEVA PHARMS	50MG	A075963	001	Jul 03, 2002

## DISCONTINUED DRUG PRODUCT LIST

6 - 309 (of 324)

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

ULTRAM

ORTHO MCNEIL JANSSEN 100MG

N020281 001 Mar 03, 1995

TABLET, ORALLY DISINTEGRATING; ORAL

TRAMADOL HYDROCHLORIDE

VICTORY PHARMA 50MG

N021693 001 May 05, 2005

TRANEXAMIC ACID

TABLET; ORAL

CYKLOKAPRON

PHARMACIA AND UPJOHN 500MG

N019280 001 Dec 30, 1986

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

DESYREL

APOTHECON 50MG

N018207 001

100MG

N018207 002

150MG

N018207 003 Mar 25, 1985

300MG

N018207 004 Nov 07, 1988

TRAZODONE HYDROCHLORIDE

AM THERAP 50MG

A071139 001 Oct 29, 1986

100MG

A071140 001 Oct 29, 1986

MYLAN

50MG

A071405 001 Feb 27, 1991

100MG

A071406 001 Feb 27, 1991

QUANTUM PHARMICS

100MG

A070921 001 Dec 01, 1986

SANDOZ

50MG

A072484 001 Apr 30, 1990

100MG

A072483 001 Apr 30, 1990

TEVA

150MG

A074357 001 Apr 30, 1997

USL PHARMA

50MG

A070491 001 Apr 29, 1987

100MG

A070492 001 Apr 29, 1987

WATSON LABS

50MG

A071112 001 Nov 17, 1986

100MG

A071113 001 Nov 17, 1986

TRIALODINE

QUANTUM PHARMICS 50MG

A070942 001 Dec 01, 1986

TRETINOIN

SOLUTION; TOPICAL

TRETINOIN

TEVA PHARMS 0.05%

A074873 001 Jun 19, 1998

SWAB; TOPICAL

RETIN-A

JOHNSON AND JOHNSON 0.05%

N016921 002

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

ASTELLAS 1MG

N011161 009

2MG

N011161 004

4MG

N011161 007

8MG

N011161 011

16MG

N011161 010

KENACORT

BRISTOL MYERS SQUIBB 1MG

N011283 003

2MG

N011283 008

4MG

N011283 006

8MG

N011283 010

TRIAMCINOLONE

BARR 2MG

A084286 001

2MG

A084318 001

4MG

A084267 001

4MG

A084319 001

8MG

A084268 001

8MG

A084320 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 310 (of 324)

TRIAMCINOLONE

## TABLET; ORAL

## TRIAMCINOLONE

IMPAX LABS	4MG	A084340	001
IVAX SUB TEVA PHARMS	4MG	A083750	001
MYLAN	2MG	A084406	001
PUREPAC PHARM	2MG	A084020	002
	4MG	A084020	003
ROXANE	2MG	A084708	001
	4MG	A084709	001
	8MG	A084707	001
SANDOZ	4MG	A085601	001
TEVA	4MG	A084775	001
WATSON LABS	4MG	A084270	001
	4MG	A085834	001

TRIAMCINOLONE ACETONIDEAEROSOL, METERED; NASAL  
NASACORT

SANOVI AVENTIS US	0.055MG/INH	N019798	001	Jul 11, 1991
-------------------	-------------	---------	-----	--------------

## CREAM; TOPICAL

## ARISTOCORT

ASTELLAS	0.025%	A083017	003
	0.1%	A083016	004
	0.5%	A083015	002

## ARISTOCORT A

ASTELLAS	0.025%	A083017	004	
	0.025%	A088818	001	Oct 16, 1984
	0.1%	A083016	005	
	0.1%	A088819	001	Oct 16, 1984
	0.5%	A083015	003	
	0.5%	A088820	001	Oct 16, 1984

## FLUTEX

IVAX PHARMS	0.025%	A085539	001
	0.1%	A085539	002
	0.5%	A085539	003

## KENALOG

APOTHECON	0.5%	A083943	001
-----------	------	---------	-----

## KENALOG-H

APOTHECON	0.1%	A086240	001
-----------	------	---------	-----

## TRACET

TEVA	0.1%	A084908	002
------	------	---------	-----

## TRACORT

SOLVAY	0.1%	A087113	001
--------	------	---------	-----

## TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS	0.025%	A087797	001	Jun 07, 1982
AMBIX	0.025%	A087932	001	May 09, 1983
G AND W LABS	0.1%	A089798	001	May 31, 1991
MORTON GROVE	0.025%	A088094	001	Sep 01, 1983
	0.1%	A088095	001	Sep 01, 1983
	0.5%	A088096	001	Sep 01, 1983
PHARMADERM	0.025%	A087990	001	Jul 07, 1983
	0.1%	A087991	001	Jul 07, 1983
	0.5%	A087992	001	Jul 07, 1983
PHARMAFAIR	0.025%	A087921	001	Aug 10, 1982
	0.1%	A087912	001	Aug 10, 1982
	0.5%	A087922	001	Aug 10, 1982
TARO	0.025%	A040038	001	Oct 26, 1994
TOPIDERM	0.025%	A089274	001	Feb 21, 1989
	0.1%	A089275	001	Feb 21, 1989
	0.5%	A089276	001	Feb 21, 1989

## TRIALEX

IVAX PHARMS	0.025%	A087430	001	Nov 01, 1988
	0.1%	A087429	001	Nov 01, 1988



## DISCONTINUED DRUG PRODUCT LIST

6 - 311 (of 324)

TRIAMCINOLONE ACETONIDE

## CREAM; TOPICAL

## TRIALEX

IVAX PHARMS 0.5% A087428 001 Nov 01, 1988

## TRYMEX

SAVAGE LABS 0.025% A088196 001 Mar 25, 1983

0.1% A088197 001 Mar 25, 1983

0.5% A088198 001 Mar 25, 1983

## GEL; TOPICAL

## ARISTOGEL

ASTELLAS 0.1% A083380 001

## INJECTABLE; INJECTION

## TRIAMCINOLONE ACETONIDE

PARNELL 3MG/ML N019503 001 Oct 16, 1987

WATSON LABS 40MG/ML A085825 001

## LOTION; TOPICAL

## KENALOG

APOTHECON 0.025% A084343 001

0.1% A084343 002

BRISTOL MYERS SQUIBB 0.025% N011602 003

0.1% N011602 001

## TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS 0.025% A087191 001 Sep 08, 1982

0.1% A087192 001 Sep 08, 1982

## OINTMENT; TOPICAL

## ARISTOCORT

ASTELLAS 0.1% A080750 004

0.5% A080745 002

## ARISTOCORT A

ASTELLAS 0.1% A080750 003

0.1% A088780 001 Oct 01, 1984

0.5% A080745 003

0.5% A088781 001 Oct 05, 1984

## FLUTEX

IVAX PHARMS 0.025% A087375 001 Nov 01, 1988

0.1% A087377 001 Nov 01, 1988

0.5% A087376 001 Nov 01, 1988

## KENALOG

APOTHECON 0.5% A083944 001

## TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS 0.5% A089913 001 Dec 23, 1988

G AND W LABS 0.025% A089795 001 Dec 23, 1988

0.1% A089796 001 Dec 23, 1988

MORTON GROVE 0.025% A088090 001 Sep 01, 1983

0.1% A088091 001 Sep 01, 1983

0.5% A088092 001 Sep 01, 1983

PHARMADERM 0.025% A088692 001 Aug 02, 1984

0.1% A088690 001 Aug 02, 1984

## TRYMEX

SAVAGE LABS 0.025% A088693 001 Aug 02, 1984

0.1% A088691 001 Aug 02, 1984

## PASTE; DENTAL

## KENALOG IN ORABASE

APOTHECON 0.1% N012097 001

## ORALONE

TARO 0.1% A071383 001 Jul 06, 1987

## SPRAY, METERED; NASAL

## ALLERNAZE

LUPIN ATLANTIS 0.05MG/SPRAY N020120 001 Feb 04, 2000

## NASACORT HFA

SANOFI AVENTIS US 0.055MG/SPRAY N020784 001 Apr 07, 2004

## DISCONTINUED DRUG PRODUCT LIST

6 - 312 (of 324)

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

SANDOZ

25MG/ML

N011685 003

40MG/ML

N012802 001

TRIAMCINOLONE DIACETATE

AKORN

25MG/ML

A085122 001

40MG/ML

A086394 001

WATSON LABS

40MG/ML

A084072 001

40MG/ML

A085529 001

SYRUP; ORAL

ARISTOCORT

ASTELLAS

2MG/5ML

N011960 004

KENACORT

BRISTOL MYERS SQUIBB EQ 4MG BASE/5ML

N012515 001

TRIAZOLAM

TABLET; ORAL

HALCION

PHARMACIA AND UPJOHN 0.5MG

N017892 002

Nov 15, 1982

TRICHLORMETHIAZIDE

TABLET; ORAL

METAHYDRIN

SANOFI AVENTIS US

2MG

N012594 001

Jun 16, 1988

4MG

N012594 002

Jun 16, 1988

NAQUA

SCHERING

2MG

N012265 001

4MG

N012265 002

TRICHLOREX

LANNETT

4MG

A083436 001

4MG

A085630 001

TRICHLORMAS

MAST MM

4MG

A086259 001

TRICHLORMETHIAZIDE

IMPAX LABS

4MG

A083967 001

PAR PHARM

2MG

A087007 001

4MG

A087005 001

SANDOZ

4MG

A086171 001

TG UNITED LABS

4MG

A085568 001

WATSON LABS

2MG

A083847 001

2MG

A086458 001

4MG

A083462 001

4MG

A083855 001

4MG

A085962 001

TRICLOFOS SODIUM

SOLUTION; ORAL

TRICLOS

SANOFI AVENTIS US

1.5GM/15ML

N016830 001

TABLET; ORAL

TRICLOS

SANOFI AVENTIS US

750MG

N016809 002

TRIDIHEXETHYL CHLORIDE

INJECTABLE; INJECTION

PATHILON

LEDERLE

10MG/ML

N009729 001

TABLET; ORAL

PATHILON

LEDERLE

25MG

N009489 005

## DISCONTINUED DRUG PRODUCT LIST

6 - 313 (of 324)

TRIFLUOPERAZINE HYDROCHLORIDE

## CONCENTRATE; ORAL

## STELAZINE

GLAXOSMITHKLINE EQ 10MG BASE/ML N011552 006

## TRIFLUOPERAZINE HYDROCHLORIDE

MORTON GROVE EQ 10MG BASE/ML A088143 001 Jul 26, 1983

SANDOZ EQ 10MG BASE/ML A085787 001 Apr 15, 1982

## INJECTABLE; INJECTION

## STELAZINE

GLAXOSMITHKLINE EQ 2MG BASE/ML N011552 005

## TABLET; ORAL

## STELAZINE

GLAXOSMITHKLINE EQ 1MG BASE N011552 001

EQ 2MG BASE N011552 002

EQ 5MG BASE N011552 003

EQ 10MG BASE N011552 004

## TRIFLUOPERAZINE HYDROCHLORIDE

DURAMED PHARMS BARR EQ 1MG BASE A088967 001 Apr 23, 1985

EQ 2MG BASE A088968 001 Apr 23, 1985

EQ 5MG BASE A088969 001 Apr 23, 1985

EQ 10MG BASE A088970 001 Apr 23, 1985

IVAX PHARMS EQ 1MG BASE A087612 001 Nov 19, 1982

EQ 2MG BASE A087613 001 Nov 19, 1982

EQ 5MG BASE A087328 001 Nov 19, 1982

EQ 10MG BASE A087614 001 Nov 19, 1982

SANDOZ EQ 1MG BASE A040153 001 Oct 25, 1996

EQ 2MG BASE A040153 002 Oct 25, 1996

EQ 5MG BASE A040153 003 Oct 25, 1996

EQ 10MG BASE A040153 004 Oct 25, 1996

WATSON LABS EQ 1MG BASE A085975 001 Jun 23, 1988

EQ 2MG BASE A085976 001 Jun 23, 1988

EQ 5MG BASE A085973 001 Jun 23, 1988

EQ 10MG BASE A088710 001 Jun 23, 1988

TRIFLUPROMAZINE

## SUSPENSION; ORAL

## VESPRIN

APOTHECON EQ 50MG HCL/5ML N011491 004

TRIFLUPROMAZINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## VESPRIN

APOTHECON 3MG/ML N011325 005

10MG/ML N011325 004

20MG/ML N011325 001

## TABLET; ORAL

## VESPRIN

BRISTOL MYERS SQUIBB 10MG N011123 001

25MG N011123 002

50MG N011123 003

TRIHEXYPHENIDYL HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## ARTANE

LEDERLE 5MG N006773 010

5MG N012947 001

## ELIXIR; ORAL

## ARTANE

LEDERLE 2MG/5ML N006773 009

## TRIHEXYPHENIDYL HYDROCHLORIDE

PHARM VENTURES 2MG/5ML A089514 001 Apr 07, 1989

## TABLET; ORAL

## ARTANE

LEDERLE 2MG N006773 005

## DISCONTINUED DRUG PRODUCT LIST

6 - 314 (of 324)

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

ARTANE

LEDERLE 5MG N006773 003

TREMIN

SCHERING 2MG A080381 001

5MG A080381 003

TRIHEXYPHENIDYL HYDROCHLORIDE

NYLOS 5MG A085622 001

VANGARD 2MG A088035 001 Jul 30, 1982

WATSON LABS 2MG A085117 001

5MG A085105 001

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

BIOENVISION 30MG N018719 002 Dec 31, 1984

60MG N018719 001 Dec 31, 1984

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TEMARIL

ALLERGAN HERBERT EQ 5MG BASE N011316 004

SYRUP; ORAL

TEMARIL

ALLERGAN HERBERT EQ 2.5MG BASE/5ML N011316 003

TRIMEPRAZINE TARTRATE

ALPHARMA US PHARMS EQ 2.5MG BASE/5ML A085015 001 Feb 18, 1982

MORTON GROVE EQ 2.5MG BASE/5ML A088285 001 Apr 11, 1985

TABLET; ORAL

TEMARIL

ALLERGAN HERBERT EQ 2.5MG BASE N011316 001

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE

ABBOTT 300MG N005856 005

SOLUTION; ORAL

TRIDIONE

ABBOTT 200MG/5ML N005856 002

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION

ARFONAD

ROCHE 50MG/ML N008983 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

SMITH AND NEPHEW 100MG/ML A088960 001 Apr 04, 1986

100MG/ML A089043 001 Apr 04, 1986

SOLOPAK 100MG/ML A089094 001 Apr 04, 1986

WATSON LABS 100MG/ML A086577 001 Oct 19, 1982

100MG/ML A087939 001 Dec 28, 1982

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

MONARCH PHARMS 100MG N017943 001

200MG N017943 003 Jul 14, 1982

TRIMETHOPRIM

MUTUAL PHARM 100MG A070494 001 Jan 22, 1986

200MG A070495 001 Sep 24, 1986

## DISCONTINUED DRUG PRODUCT LIST

6 - 315 (of 324)

TRIMETHOPRIM

TABLET; ORAL

TRIMPEX

ROCHE

100MG

N017952 001

TRIMPEX 200

ROCHE

200MG

N017952 002

Nov 09, 1982

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

FSC

EQ 25MG BASE/5ML

A074374 001

Jun 23, 1995

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

NEUTREXIN

MEDIMMUNE ONCOLOGY

EQ 25MG BASE/VIAL

N020326 001

Dec 17, 1993

EQ 200MG BASE/VIAL

N020326 002

Jul 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

USL PHARMA

EQ 25MG BASE

A071283 001

Dec 08, 1987

EQ 50MG BASE

A071284 001

Dec 08, 1987

EQ 100MG BASE

A071285 001

Dec 08, 1987

TRIOXSALEN

TABLET; ORAL

TRISORALEN

VALEANT PHARM INTL

5MG

N012697 001

TRIPELENNAMINE CITRATE

ELIXIR; ORAL

PBZ

NOVARTIS

EQ 25MG HCL/5ML

N005914 004

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

NOVARTIS

25MG

A083149 001

50MG

N005914 002

TRIPELENNAMINE HYDROCHLORIDE

ANABOLIC

50MG

A083037 001

BARR

50MG

A080744 001

HEATHER

50MG

A083989 001

IMPAX LABS

50MG

A080785 001

LANNETT

50MG

A083557 001

NYLOS

50MG

A085412 001

PARKE DAVIS

25MG

A083625 001

50MG

A083626 001

WATSON LABS

50MG

A080713 001

50MG

A080790 001

50MG

A085188 001

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

NOVARTIS

50MG

N010533 002

100MG

N010533 001

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL

GYNE-SULF

G AND W LABS

3.7%;2.86%;3.42%

A088607 001

Jun 09, 1986

SULTRIN

ORTHO MCNEIL PHARM

3.7%;2.86%;3.42%

N005794 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 316 (of 324)

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

## CREAM; VAGINAL

## TRIPLE SULFA

ALPHARMA US PHARMS	3.7%;2.86%;3.42%	A087864	001	Sep 01, 1982
FOUGERA	3.7%;2.86%;3.42%	A086424	001	
PERRIGO NEW YORK	3.7%;2.86%;3.42%	A087285	001	Nov 15, 1982
TRYSUL				
SAVAGE LABS	3.7%;2.86%;3.42%	A087887	001	Jul 23, 1982
VAGILIA				
TEVA	3.7%;2.86%;3.42%	A088821	001	Nov 09, 1987

## TABLET; VAGINAL

## SULTRIN

ORTHO MCNEIL PHARM	184MG;143.75MG;172.5MG	N005794	002	
--------------------	------------------------	---------	-----	--

## TRIPLE SULFA

FOUGERA	184MG;143.75MG;172.5MG	A088463	001	Jan 03, 1985
PHARMADERM	184MG;143.75MG;172.5MG	A088462	001	Jan 03, 1985

TRIPROLIDINE HYDROCHLORIDE

## SYRUP; ORAL

## ACTIDIL

GLAXOSMITHKLINE	1.25MG/5ML	N011496	002	Jul 01, 1983
-----------------	------------	---------	-----	--------------

## MYIDYL

USL PHARMA	1.25MG/5ML	A087963	001	Jan 18, 1983
------------	------------	---------	-----	--------------

## TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARMS	1.25MG/5ML	A085940	001	
HALSEY	1.25MG/5ML	A088735	001	Jan 17, 1985
PHARM ASSOC	1.25MG/5ML	A087514	001	Feb 10, 1982

## TABLET; ORAL

## ACTIDIL

GLAXOSMITHKLINE	2.5MG	N011110	002	Jul 01, 1983
-----------------	-------	---------	-----	--------------

## TRIPROLIDINE HYDROCHLORIDE

VITARINE	2.5MG	A085610	001	
WATSON LABS	2.5MG	A085094	001	

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

## SUSPENSION; ORAL

## LANTRISUL

LANNETT	167MG/5ML;167MG/5ML;167MG/5ML	A080123	002	
---------	-------------------------------	---------	-----	--

## NEOTRIZINE

LILLY	167MG/5ML;167MG/5ML;167MG/5ML	N006317	012	
-------	-------------------------------	---------	-----	--

## SULFALOID

FOREST PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	A080100	001	
---------------	-------------------------------	---------	-----	--

## SULFOSE

WYETH AYERST	167MG/5ML;167MG/5ML;167MG/5ML	A080013	002	
--------------	-------------------------------	---------	-----	--

## TERFONYL

BRISTOL MYERS SQUIBB	167MG/5ML;167MG/5ML;167MG/5ML	N006904	002	
----------------------	-------------------------------	---------	-----	--

## TRIPLE SULFA

ALPHARMA US PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	A080280	001	
--------------------	-------------------------------	---------	-----	--

## TRIPLE SULFAS

LEDERLE	167MG/5ML;167MG/5ML;167MG/5ML	N006920	003	
---------	-------------------------------	---------	-----	--

## TABLET; ORAL

## NEOTRIZINE

LILLY	167MG;167MG;167MG	N006317	011	
-------	-------------------	---------	-----	--

## SULFALOID

FOREST PHARMS	167MG;167MG;167MG	A080099	001	
---------------	-------------------	---------	-----	--

## SULFA-TRIPLE #2

IMPAX LABS	167MG;167MG;167MG	A080079	001	
------------	-------------------	---------	-----	--

## SULFOSE

WYETH AYERST	167MG;167MG;167MG	A080013	001	
--------------	-------------------	---------	-----	--

## TERFONYL

BRISTOL MYERS SQUIBB	167MG;167MG;167MG	N006904	001	
----------------------	-------------------	---------	-----	--

## TRIPLE SULFA

PUREPAC PHARM	167MG;167MG;167MG	A080086	001	
---------------	-------------------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 317 (of 324)

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET; ORAL

TRIPLE SULFAS

LEDERLE

167MG;167MG;167MG

N006920 002

TRIPLE SULFOID

PAL PAK

167MG;167MG;167MG

A080094 001

TROGLITAZONE

TABLET; ORAL

PRELAY

SANKYO

200MG

N020719 001

Jan 29, 1997

300MG

N020719 003

Aug 04, 1997

400MG

N020719 002

Jan 29, 1997

REZULIN

PFIZER PHARMS

200MG

N020720 001

Jan 29, 1997

300MG

N020720 003

Aug 04, 1997

400MG

N020720 002

Jan 29, 1997

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC

CERUMENEX

PHARM RES ASSOC

10%

N011340 002

TROLEANDOMYCIN

CAPSULE; ORAL

TAO

PFIZER

EQ 250MG BASE

N050336 002

SUSPENSION; ORAL

TAO

PFIZER

EQ 125MG BASE/5ML

N050332 001

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYL

ALCON

0.5%

N012111 002

1%

N012111 004

MYDRIAFAIR

PHARMAFAIR

0.5%

A088274 001

Sep 16, 1983

1%

A088230 001

Sep 16, 1983

TROPICAMIDE

AKORN

1%

A088447 001

Aug 28, 1985

ALCON UNIVERSAL

1%

A089172 001

Dec 28, 1990

MIZA PHARMS USA

0.5%

A087636 001

Jul 30, 1982

1%

A087637 001

Aug 09, 1982

WATSON LABS

0.5%

A089171 001

Dec 28, 1990

TROVAFLOXACIN MESYLATE

TABLET; ORAL

TROVAN

PFIZER

EQ 100MG BASE

N020759 001

Dec 18, 1997

EQ 200MG BASE

N020759 002

Dec 18, 1997

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION

TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB

3MG/ML

N005657 001

HOSPIRA

3MG/ML

N006095 001

LILLY

3MG/ML

N006325 001

TYROPANOATE SODIUM

CAPSULE; ORAL

BILOPAQUE

GE HEALTHCARE

750MG

N013731 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 318 (of 324)

UNDECOYLIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX

SOLUTION; TOPICAL

VIRAC REX

CHESEBROUGH PONDS 0.5%;1.8% N011914 001

URACIL MUSTARD

CAPSULE; ORAL

URACIL MUSTARD

SHIRE 1MG N012892 001

UREA

INJECTABLE; INJECTION

STERILE UREA

HOSPIRA 40GM/VIAL N017698 001

UREAPHIL

HOSPIRA 40GM/VIAL N012154 001

UREA, C-13

FOR SOLUTION; ORAL

HELICOSOL

METABOLIC SOLUTIONS 125MG/VIAL N021092 001 Dec 17, 1999

MERETEK UBT KIT (W/ PRANACTIN)

OTSUKA AMERICA 125MG/VIAL N020586 001 Sep 17, 1996

PYLORI-CHEK BREATH TEST

DXS DEVICES 100MG/VIAL N020900 001 Feb 04, 1999

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR

METRODIN

SERONO 75 IU/AMP N019415 002 Sep 18, 1986

150 IU/AMP N019415 003 Sep 18, 1986

INJECTABLE; SUBCUTANEOUS

FERTINEX

SERONO 75 IU/AMP N019415 005 Aug 23, 1996

150 IU/AMP N019415 004 Aug 23, 1996

UROKINASE

INJECTABLE; INJECTION

KINLYTIC

MICROBIX BIOSYSTEMS 5,000 IU/VIAL N021846 003

9,000 IU/VIAL N021846 002

250,000 IU/VIAL N021846 001

URSODIOL

CAPSULE; ORAL

ACTIGALL

WATSON PHARMS 150MG N019594 001 Dec 31, 1987

VALDECOXIB

TABLET; ORAL

BEXTRA

GD SEARLE 10MG N021341 002 Nov 16, 2001

20MG N021341 003 Nov 16, 2001

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

PAR PHARM 250MG A070431 001 Feb 28, 1986

SCHERER RP 250MG A070195 001 Jul 02, 1987

USL PHARMA 250MG A070631 001 Jun 11, 1987



## DISCONTINUED DRUG PRODUCT LIST

6 - 319 (of 324)

VALSARTANCAPSULE; ORAL  
DIOVAN

NOVARTIS	80MG	N020665	001	Dec 23, 1996
	160MG	N020665	002	Dec 23, 1996

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOVIN HYDROCHLORIDE

VIROPHARMA	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983
	EQ 500MG BASE/6ML	A061667	001	

VANCOLED

LEDERLE

	EQ 250MG BASE/5ML	A063321	002	Oct 15, 1993
	EQ 500MG BASE/6ML	A063321	003	Oct 15, 1993

INJECTABLE; INJECTION

VANCOVIN HYDROCHLORIDE

VIROPHARMA

	EQ 500MG BASE/VIAL	A060180	001	
	EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984
	EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987
	EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987
	EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986
	EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986
	EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987
	EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987
	EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987

VANCOLED

BAXTER HLTHCARE

	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986
	EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988
	EQ 2GM BASE/VIAL	A062682	003	May 11, 1988
	EQ 5GM BASE/VIAL	A062682	004	May 11, 1988
	EQ 10GM BASE/VIAL	A062682	005	May 11, 1988

VANCOMYCIN HYDROCHLORIDE

BAXTER HLTHCARE

	EQ 500MG BASE/VIAL	A062879	001	Aug 02, 1988
	EQ 1GM BASE/VIAL	A062879	002	Aug 02, 1988

VANCOR

PHARMACIA AND UPJOHN

	EQ 500MG BASE/VIAL	A062956	001	Aug 01, 1988
	EQ 1GM BASE/VIAL	A062956	002	Aug 01, 1988

VASOPRESSIN TANNATE

INJECTABLE; INJECTION

PITRESSIN TANNATE

PARKE DAVIS

	5PRESSOR UNITS/ML	N003402	001	
--	-------------------	---------	-----	--

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

ORGANON USA INC

	10MG/VIAL	N018776	002	Apr 30, 1984
	20MG/VIAL	N018776	003	Jan 03, 1992

VECURONIUM BROMIDE

BAXTER HLTHCARE

	10MG/VIAL	A075218	001	Aug 23, 1999
	20MG/VIAL	A075218	002	Aug 23, 1999

HOSPIRA

	4MG/VIAL	A075558	001	Sep 11, 2001
--	----------	---------	-----	--------------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

WYETH PHARMS INC

	EQ 100MG BASE	N020699	003	Oct 20, 1997
--	---------------	---------	-----	--------------

TABLET; ORAL

EFFEXOR

WYETH PHARMS INC

	EQ 12.5MG BASE	N020151	001	Dec 28, 1993
--	----------------	---------	-----	--------------

VENLAFAXINE HYDROCHLORIDE

SANDOZ

	EQ 25MG BASE	A077515	001	Jun 13, 2008
	EQ 37.5MG BASE	A077515	002	Jun 13, 2008
	EQ 50MG BASE	A077515	003	Jun 13, 2008

## DISCONTINUED DRUG PRODUCT LIST

6 - 320 (of 324)

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

SANDOZ	EQ 75MG BASE	A077515	004	Jun 13, 2008
	EQ 100MG BASE	A077515	005	Jun 13, 2008

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

CALAN

GD SEARLE LLC	2.5MG/ML	N018925	001	Mar 30, 1984
	2.5MG/ML	N019038	001	Mar 30, 1984

ISOPTIN

FSC	2.5MG/ML	N018485	001	
-----	----------	---------	-----	--

VERAPAMIL HYDROCHLORIDE

ABRAXIS PHARM	2.5MG/ML	A070348	001	May 01, 1986
BEDFORD	2.5MG/ML	A072888	001	Jul 28, 1995
HOSPIRA	2.5MG/ML	A070739	001	May 06, 1987
	2.5MG/ML	A070740	001	May 06, 1987
LUITPOLD	2.5MG/ML	A070225	001	Nov 12, 1985
MARSAM PHARMS LLC	2.5MG/ML	A072233	001	Feb 26, 1993
	2.5MG/ML	A073485	001	Sep 27, 1993
SMITH AND NEPHEW	2.5MG/ML	A070696	001	Jul 31, 1987
	2.5MG/ML	A070697	001	Jul 31, 1987
SOLOPAK	2.5MG/ML	A070695	001	Jul 31, 1987

TABLET; ORAL

CALAN

GD SEARLE LLC	160MG	N018817	004	Feb 23, 1988
---------------	-------	---------	-----	--------------

ISOPTIN

FSC	40MG	N018593	003	Nov 23, 1987
	80MG	N018593	001	Mar 08, 1982
	120MG	N018593	002	Mar 08, 1982

VERAPAMIL HYDROCHLORIDE

HERITAGE PHARMS INC	80MG	A071880	001	Apr 05, 1988
	120MG	A071881	001	Apr 05, 1988
MUTUAL PHARM	80MG	A070482	001	Sep 24, 1986
	80MG	A071489	002	Jan 13, 1988
	120MG	A070483	001	Sep 24, 1986
	120MG	A071489	001	Jan 13, 1988
PLIVA	40MG	A072751	001	Feb 23, 1996
	80MG	A072124	001	Jan 26, 1989
	120MG	A072125	001	Jan 26, 1989
SANDOZ	40MG	A073168	001	Jul 31, 1992
	80MG	A071423	001	May 24, 1988
	120MG	A071424	001	May 25, 1988
WARNER CHILCOTT	80MG	A070340	001	Sep 24, 1986
	120MG	A070341	001	Sep 24, 1986
WATSON LABS	40MG	A072799	001	Apr 28, 1989

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

PLIVA	240MG	A072922	001	Mar 01, 1996
-------	-------	---------	-----	--------------

VERATRUM VIRIDE

TABLET; ORAL

VERTAVIS

MEDPOINTE PHARM HLC	130CSR UNIT	N005691	002	
---------------------	-------------	---------	-----	--

VIDARABINE

INJECTABLE; INJECTION

VIRA-A

PARKEDALE	EQ 187.4MG BASE/ML	N050523	001	
-----------	--------------------	---------	-----	--

OINTMENT; OPHTHALMIC

VIRA-A

PARKEDALE	3%	N050486	001	
-----------	----	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

6 - 321 (of 324)

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VELBAN

LILLY 10MG/VIAL N012665 001

VINBLASTINE SULFATE

ABRAXIS PHARM 10MG/VIAL A089011 001 Nov 18, 1985

HOSPIRA 10MG/VIAL A089565 001 Aug 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

LILLY 1MG/VIAL N014103 001

1MG/ML N014103 003 Mar 07, 1984

5MG/VIAL N014103 002

VINCASAR PFS

TEVA PARENTERAL 1MG/ML A071426 001 Jul 17, 1987

VINCUREX

BRISTOL MYERS SQUIBB 5MG/VIAL A070867 001 Jul 12, 1988

VINCRISTINE SULFATE

ABIC 1MG/ML A070873 001 Feb 19, 1987

ABRAXIS PHARM 1MG/ML A070411 001 Sep 10, 1986

APP PHARMS 1MG/ML A076296 001 Dec 20, 2002

HOSPIRA 1MG/VIAL A071559 001 Apr 11, 1988

2MG/VIAL A071560 001 Apr 11, 1988

5MG/VIAL A071561 001 Apr 11, 1988

VIOMYCIN SULFATE

INJECTABLE; INJECTION

VIOCIN SULFATE

PFIZER EQ 1GM BASE/VIAL A061086 001

EQ 5GM BASE/VIAL A061086 002

VITAMIN A

CAPSULE; ORAL

AQUASOL A

ASTRAZENECA 25,000USP UNITS A083080 002

50,000USP UNITS A083080 001

VITAMIN A

BANNER PHARMACAPS 50,000USP UNITS A083973 001

CHASE CHEM 50,000 IU A083351 001

EVERYLIFE 50,000 IU A083134 001

IMPAX LABS 50,000USP UNITS A080952 001

WEST WARD 50,000USP UNITS A080985 001

VITAMIN A PALMITATE

CAPSULE; ORAL

AFAXIN

STERLING WINTHROP EQ 50,000 UNITS BASE A083187 001

ALPHALIN

LILLY EQ 50,000 UNITS BASE A080883 001

DEL-VI-A

DEL RAY LABS EQ 50,000 UNITS BASE A080830 001

VI-DOM-A

BAYER PHARMS EQ 50,000 UNITS BASE A080972 001

VITAMIN A

BANNER PHARMACAPS EQ 50,000 UNITS BASE A080702 001

BRISTOL MYERS SQUIBB EQ 50,000 UNITS BASE A080860 001

CHASE CHEM EQ 50,000 UNITS BASE A080746 001

EQ 50,000 UNITS BASE A083207 001

ELKINS SINN EQ 50,000 UNITS BASE A085479 001

EVERYLIFE EQ 50,000 UNITS BASE A080943 001

EQ 50,000 UNITS BASE A083114 001

IMPAX LABS EQ 50,000 UNITS BASE A080953 001

EQ 50,000 UNITS BASE A080955 001

## DISCONTINUED DRUG PRODUCT LIST

6 - 322 (of 324)

VITAMIN A PALMITATE

CAPSULE; ORAL

VITAMIN A

IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035	001
	EQ 50,000 UNITS BASE	A083190	001
MK LABS	EQ 25,000 UNITS BASE	A083457	002
	EQ 50,000 UNITS BASE	A083457	001
WEST WARD	EQ 50,000 UNITS BASE	A080967	001
WHARTON LABS	EQ 50,000 UNITS BASE	A083665	001

VITAMIN A PALMITATE

ARCUM	EQ 50,000 UNITS BASE	A083311	001
	EQ 50,000 UNITS BASE	A083321	001
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948	001
	EQ 50,000 UNITS BASE	A083981	001

VITAMIN A SOLUBILIZED

TEVA	EQ 50,000 UNITS BASE	A080921	001
------	----------------------	---------	-----

INJECTABLE; INJECTION

VITAMIN A PALMITATE

BEL MAR	EQ 50,000 UNITS BASE/ML	A080819	001
---------	-------------------------	---------	-----

WARFARIN POTASSIUM

TABLET; ORAL

ATHROMBIN-K

PHARM RES ASSOC	2MG	N011771	007
	5MG	N011771	004
	10MG	N011771	005
	25MG	N011771	006

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

BRISTOL MYERS SQUIBB	50MG/VIAL	N009218	020
	75MG/VIAL	N009218	012

TABLET; ORAL

ATHROMBIN

PHARM RES ASSOC	5MG	N011771	003
	10MG	N011771	002
	25MG	N011771	001

PANWARFIN

ABBOTT	2MG	N017020	001
	2.5MG	N017020	002
	5MG	N017020	003
	7.5MG	N017020	004
	10MG	N017020	005

WARFARIN SODIUM

USL PHARMA	2MG	A088719	001	Jun 27, 1985
	2.5MG	A088720	001	Aug 06, 1985
	5MG	A088721	001	Jul 02, 1985
WATSON LABS	2MG	A086123	001	Aug 17, 1982
	2.5MG	A086120	001	Aug 17, 1982
	5MG	A086119	001	Aug 17, 1982
	7.5MG	A086118	001	Aug 17, 1982
	10MG	A086122	001	Aug 17, 1982

WATER FOR INJECTION, STERILE

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

ABRAXIS PHARM	100%	A089099	001	Dec 29, 1987
	100%	A089100	001	Dec 29, 1987

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

B BRAUN	100%	N019077	001	Mar 02, 1984
---------	------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

6 - 323 (of 324)

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION				
STERILE WATER IN PLASTIC CONTAINER				
MILES	100%	N018246	001	

XENON XE 127

GAS; INHALATION				
XENON XE 127				
MALLINCKRODT	5mCi/VIAL	N018536	001	Oct 01, 1982
	10mCi/VIAL	N018536	002	Oct 01, 1982

XENON XE 133

GAS; INHALATION				
XENON XE 133				
GE HEALTHCARE	1 CI/AMP	N017256	002	
	10mCi/VIAL	N017687	002	
	20mCi/VIAL	N017687	003	
GEN ELECTRIC	5-100 CI/CYLINDER	N017550	001	
	0.25-5 CI/AMP	N017550	003	
XENON XE 133-V.S.S.				
GE HEALTHCARE	10mCi/VIAL	N017687	001	
INJECTABLE; INJECTION				
XENON XE 133				
GE HEALTHCARE	1.3-1.7 CI/AMP	N017256	001	
LANTHEUS MEDCL	6.3mCi/ML	N017283	001	
SOLUTION; INHALATION, INJECTION				
XENEISOL				
MALLINCKRODT	18-25mCi/AMP	N017262	002	

XYLOSE

POWDER; ORAL				
XYLO-PFAN				
SAVAGE LABS	25GM/BOT	N017605	001	
XYLOSE				
LYNE	25GM/BOT	N018856	001	Mar 26, 1987

ZALCITABINE

TABLET; ORAL				
HIVID				
ROCHE	0.375MG	N020199	001	Jun 19, 1992
	0.75MG	N020199	002	Jun 19, 1992

ZALEPLON

CAPSULE; ORAL				
ZALEPLON				
SANDOZ	5MG	A078095	001	Jun 06, 2008
	10MG	A078095	002	Jun 06, 2008

ZICONOTIDE

INJECTABLE; INTRATHECAL				
PRIALT				
ELAN PHARMS	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004

ZIDOVUDINE

TABLET; ORAL				
RETROVIR				
VIIV HLTHCARE	200MG	N020518	001	Dec 19, 1995
ZIDOVUDINE				
AUROBINDO PHARMA	60MG	N022294	001	Jul 23, 2009

## DISCONTINUED DRUG PRODUCT LIST

6 - 324 (of 324)

ZILEUTON

TABLET; ORAL

ZYFLO

CRITICAL

300MG

N020471 001

Dec 09, 1996

ZINC SULFATE

INJECTABLE; INJECTION

ZINC SULFATE

ABRAXIS PHARM

EQ 1MG ZINC/ML

N019229 002

May 05, 1987

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

NOVARTIS

EQ 4MG BASE/VIAL

N021223 001

Aug 20, 2001

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

MUTUAL PHARMA

5MG

A077288 001

Apr 23, 2007

10MG

A077288 002

Apr 23, 2007

PAR PHARM

5MG

A076062 001

Apr 23, 2007

10MG

A076062 002

Apr 23, 2007

SYNTHON PHARMS

5MG

A077540 001

Apr 23, 2007

10MG

A077540 002

Apr 23, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

TOVALT ODT

BIOVAIL LABS INTL

5MG

N021412 001

Apr 25, 2007

10MG

N021412 002

Apr 25, 2007

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

MUTUAL PHARM

25MG

A077635 001

Dec 22, 2005

50MG

A077635 002

Dec 22, 2005

100MG

A077635 003

Dec 22, 2005

ROXANE

25MG

A077648 001

Dec 22, 2005

50MG

A077648 002

Dec 22, 2005

100MG

A077648 003

Dec 22, 2005

TEVA PHARMS

25MG

A077641 003

Dec 22, 2005

50MG

A077641 002

Dec 22, 2005

100MG

A077641 001

Dec 22, 2005

WATSON LABS

25MG

A077650 001

Apr 20, 2006

50MG

A077650 002

Apr 20, 2006

100MG

A077650 003

Apr 20, 2006

**ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST**

The list of List of Orphan Designations and Approvals is available at:  
<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

ACETAMINOPHEN; ASPIRIN; BUTALBITAL CAPSULE OR TABLET; ORAL 160-165MG; 160-165MG; 50MG	ASPIRIN; CAFFEINE; CARISOPRODOL TABLET; ORAL 160MG; 32MG; 200MG
ACETAMINOPHEN; ASPIRIN; BUTALBITAL CAPSULE OR TABLET; ORAL 325MG; 325MG; 50MG	ASPIRIN; CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE TABLET; ORAL 160MG; 32MG; 200MG; 16MG
ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAFFEINE CAPSULE OR TABLET; ORAL 160-165MG; 160-165MG; 50MG; 40MG	ASPIRIN; CARISOPRODOL TABLET; ORAL 325MG; 200MG
ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAFFEINE CAPSULE OR TABLET; ORAL 325MG; 325MG; 50MG; 40MG	ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE TABLET; ORAL 325MG; 200MG; 16MG
ACETAMINOPHEN; BUTALBITAL CAPSULE OR TABLET; ORAL 325MG; 50MG 650MG; 50MG	ASPIRIN; MEPROBAMATE TABLET; ORAL 325MG; 200MG
ACETAMINOPHEN; BUTALBITAL; CAFFEINE CAPSULE OR TABLET; ORAL 325MG; 50MG; 40MG 650MG; 50MG; 40MG 500MG; 50MG; 40MG	ASPIRIN; METHOCARBAMOL TABLET; ORAL 325MG; 400MG
AMINOPHYLLINE TABLET; ORAL 100MG; 200MG	CHLOROTHIAZIDE TABLET; ORAL 250MG
ASPIRIN; BUTALBITAL CAPSULE OR TABLET; ORAL 325MG; 50MG 650MG; 50MG	HYDROXYZINE HYDROCHLORIDE TABLET; ORAL 10MG; 25MG; 50MG; 100MG
ASPIRIN; BUTALBITAL; CAFFEINE CAPSULE OR TABLET; ORAL 325MG; 50MG; 40MG 650MG; 50MG; 40MG	PREDNISONE TABLET; ORAL 1MG; 2.5MG; 5MG; 10MG; 20MG; 25MG; 50MG



## APPENDIX A - PRODUCT NAME INDEX

A - 1

\*\* 8 \*\*

8-MOP, METHOXSALEN

\*\* A \*\*

ABELCET, AMPHOTERICIN B  
 ABILIFY, ARIPIPIRAZOLE  
 ABLAVAR, GADOFOSVESET TRISODIUM  
 ABRAXANE, PACLITAXEL  
 ABREVA, DOCOSANOL (OTC)  
 ACANYA, BENZOYL PEROXIDE  
 ACCOLATE, ZAFIRLUKAST  
 ACCUNEB, ALBUTEROL SULFATE  
 ACCUPRIL, QUINAPRIL HYDROCHLORIDE  
 ACCURETIC, HYDROCHLOROTHIAZIDE  
 ACEON, PERINDOPRIL ERBUMINE  
 ACEPHEN, ACETAMINOPHEN (OTC)  
 ACETADOTE, ACETYLCYSTEINE  
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)  
 ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL  
 ACIPHEX, RABEPRAZOLE SODIUM  
 ACLOVATE, ALCLOMETASONE DIPROPIONATE  
 ACTHREL, CORTICORELIN OVINE TRIFLUTATE  
 ACTIGALL, URSODIOL  
 ACTIQ, FENTANYL CITRATE  
 ACTIVELLA, ESTRADIOL  
 ACTONEL, RISEDRONATE SODIUM  
 ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE  
 ACTOPLUS MET, METFORMIN HYDROCHLORIDE  
 ACTOS, PIOGLITAZONE HYDROCHLORIDE  
 ACULAR LS, KETOROLAC TROMETHAMINE  
 ACULAR PRESERVATIVE FREE, KETOROLAC TROMETHAMINE  
 ACULAR, KETOROLAC TROMETHAMINE  
 ACUVAIL, KETOROLAC TROMETHAMINE  
 ACYCLOVIR AND HYDROCORTISONE, ACYCLOVIR  
 ACZONE, DAPSONE  
 ADAGEN, PEGADEMASE BOVINE  
 ADALAT CC, NIFEDIPINE  
 ADCIRCA, TADALAFIL  
 ADDERALL 10, AMPHETAMINE ASPARTATE  
 ADDERALL 12.5, AMPHETAMINE ASPARTATE  
 ADDERALL 15, AMPHETAMINE ASPARTATE  
 ADDERALL 20, AMPHETAMINE ASPARTATE  
 ADDERALL 30, AMPHETAMINE ASPARTATE  
 ADDERALL 5, AMPHETAMINE ASPARTATE  
 ADDERALL 7.5, AMPHETAMINE ASPARTATE  
 ADDERALL XR 10, AMPHETAMINE ASPARTATE  
 ADDERALL XR 15, AMPHETAMINE ASPARTATE  
 ADDERALL XR 20, AMPHETAMINE ASPARTATE  
 ADDERALL XR 25, AMPHETAMINE ASPARTATE  
 ADDERALL XR 30, AMPHETAMINE ASPARTATE  
 ADDERALL XR 5, AMPHETAMINE ASPARTATE  
 ADENOCARD, ADENOSINE  
 ADENOSCAN, ADENOSINE  
 ADREVIEW, IOBENGUANE SULFATE I 123  
 ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE  
 ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE  
 ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE  
 ADVAIR HFA, FLUTICASONE PROPIONATE  
 ADVICOR, LOVASTATIN  
 ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)  
 ADVIL COLD AND SINUS, IBUPROFEN (OTC)  
 ADVIL LIQUI-GELS, IBUPROFEN (OTC)  
 ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)  
 ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)

## APPENDIX A - PRODUCT NAME INDEX

A - 2

\*\* A \*\*

ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)  
ADVIL, IBUPROFEN (OTC)  
AEROBID, FLUNISOLIDE  
AEROSPAN HFA, FLUNISOLIDE  
AFINITOR, EVEROLIMUS  
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)  
AGENERASE, AMPRENAVIR  
AGGRASTAT, TIROFIBAN HYDROCHLORIDE  
AGGRENOLX, ASPIRIN  
AGRYLIN, ANAGRELIDE HYDROCHLORIDE  
AK-FLUOR 10%, FLUORESCEIN SODIUM  
AK-FLUOR 25%, FLUORESCEIN SODIUM  
AKINETON, BIPERIDEN HYDROCHLORIDE  
AKNE-MYCIN, ERYTHROMYCIN  
AKTEN, LIDOCAINE HYDROCHLORIDE  
ALAMAST, PEMIROLAST POTASSIUM  
ALAVERT, LORATADINE (OTC)  
ALAWAY, KETOTIFEN FUMARATE (OTC)  
ALBENZA, ALBENDAZOLE  
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL  
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL  
ALDACTAZIDE, HYDROCHLOROTHIAZIDE  
ALDACTONE, SPIRONOLACTONE  
ALDARA, IMIQUIMOD  
ALEVE, NAPROXEN SODIUM (OTC)  
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)  
ALFENTA, ALFENTANIL HYDROCHLORIDE  
ALIMTA, PEMETREXED DISODIUM  
ALINIA, NITAZOXANIDE  
ALKERAN, MELPHALAN  
ALKERAN, MELPHALAN HYDROCHLORIDE  
ALLEGRA D 24 HOUR, FEXOFENADINE HYDROCHLORIDE  
ALLEGRA, FEXOFENADINE HYDROCHLORIDE  
ALLEGRA-D 12 HOUR, FEXOFENADINE HYDROCHLORIDE  
ALLI, ORLISTAT (OTC)  
ALLOPURINOL, ALLOPURINOL  
ALOCRIL, NEDOCROMIL SODIUM  
ALOMIDE, LODOXAMIDE TROMETHAMINE  
ALOPRIM, ALLOPURINOL SODIUM  
ALORA, ESTRADIOL  
ALOXI, PALONOSETRON HYDROCHLORIDE  
ALPHAGAN P, BRIMONIDINE TARTRATE  
ALREX, LOTEPREDNOL ETABONATE  
ALTABAX, RETAPAMULIN  
ALTACE, RAMIPRIL  
ALTOPREV, LOVASTATIN  
ALVESCO, CICLESONIDE  
AMARYL, GLIMEPIRIDE  
AMBIEN CR, ZOLPIDEM TARTRATE  
AMBIEN, ZOLPIDEM TARTRATE  
AMBISOME, AMPHOTERICIN B  
AMERGE, NARATRIPTAN HYDROCHLORIDE  
AMICAR, AMINOCAPROIC ACID  
AMIDATE, ETOMIDATE  
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE  
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM  
AMINOSYN 10% (PH6), AMINO ACIDS  
AMINOSYN 10%, AMINO ACIDS  
AMINOSYN 3.5% M, AMINO ACIDS  
AMINOSYN 3.5%, AMINO ACIDS  
AMINOSYN 5%, AMINO ACIDS  
AMINOSYN 7% (PH6), AMINO ACIDS  
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS

## APPENDIX A - PRODUCT NAME INDEX

A - 3

\*\* A \*\*

AMINOSYN 7%, AMINO ACIDS  
AMINOSYN 8.5% (PH6), AMINO ACIDS  
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS  
AMINOSYN 8.5%, AMINO ACIDS  
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS  
AMINOSYN II 10%, AMINO ACIDS  
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 7%, AMINO ACIDS  
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS  
AMINOSYN II 8.5%, AMINO ACIDS  
AMINOSYN-HBC 7%, AMINO ACIDS  
AMINOSYN-HF 8%, AMINO ACIDS  
AMINOSYN-PF 10%, AMINO ACIDS  
AMINOSYN-PF 7%, AMINO ACIDS  
AMINOSYN-RF 5.2%, AMINO ACIDS  
AMITIZA, LUBIPROSTONE  
AMMONIA N 13, AMMONIA, N-13  
AMMONUL, SODIUM BENZOATE  
AMPHADASE, HYALURONIDASE  
AMPHOTEC, AMPHOTERICIN B  
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE  
ANADROL-50, OXYMETHOLONE  
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE  
ANAPROX DS, NAPROXEN SODIUM  
ANAPROX, NAPROXEN SODIUM  
ANCOBON, FLUCYTOSINE  
ANDRODERM, TESTOSTERONE  
ANDROGEL, TESTOSTERONE  
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT  
ANECTINE, SUCCINYLCHOLINE CHLORIDE  
ANGELIQ, DROSPIRENONE  
ANGIOMAX, BIVALIRUDIN  
ANSAID, FLURBIPROFEN  
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT  
ANTARA (MICRONIZED), FENOFIBRATE  
ANTHELIOS 20, AVOBENZONE (OTC)  
ANTHELIOS 40, AVOBENZONE (OTC)  
ANTHELIOS SX, AVOBENZONE (OTC)  
ANTIVERT, MECLIZINE HYDROCHLORIDE  
ANTIZOL, FOMEPIZOLE  
ANZEMET, DOLASETRON MESYLATE  
APHTHASOL, AMLEXANOX  
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT  
APIDRA, INSULIN GLULISINE RECOMBINANT  
APLENZIN, BUPROPION HYDROBROMIDE  
APOKYN, APOMORPHINE HYDROCHLORIDE  
APRISO, MESALAMINE  
APTIVUS, TIPRANAVIR  
AQUASOL A, VITAMIN A PALMITATE  
ARALEN, CHLOROQUINE PHOSPHATE  
ARAVAL, LEFLUNOMIDE

## APPENDIX A - PRODUCT NAME INDEX

A - 4

\*\* A \*\*

AREDIA, PAMIDRONATE DISODIUM  
 ARESTIN, MINOCYCLINE HYDROCHLORIDE  
 ARGATROBAN, ARGATROBAN  
 ARICEPT ODT, DONEPEZIL HYDROCHLORIDE  
 ARICEPT, DONEPEZIL HYDROCHLORIDE  
 ARIMIDEX, ANASTROZOLE  
 ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE  
 ARIXTRA, FONDAPARINUX SODIUM  
 AROMASIN, EXEMESTANE  
 ARRANON, NELARABINE  
 ARTHROTEC, DICLOFENAC SODIUM  
 ASACOL HD, MESALAMINE  
 ASACOL, MESALAMINE  
 ASMANEX TWISTHALER, MOMETASONE FUROATE  
 ASTELIN, AZELASTINE HYDROCHLORIDE  
 ASTEPRO, AZELASTINE HYDROCHLORIDE  
 ATACAND HCT, CANDESARTAN CILEXETIL  
 ATACAND, CANDESARTAN CILEXETIL  
 ATIVAN, LORAZEPAM  
 ATRALIN, TRETINOIN  
 ATRIDOX, DOXYCYCLINE HYCLATE  
 ATRIPLA, EFAVIRENZ  
 ATROPEN, ATROPINE  
 ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE  
 ATROVENT HFA, IPRATROPIUM BROMIDE  
 ATROVENT, IPRATROPIUM BROMIDE  
 AVAGARD, ALCOHOL (OTC)  
 AVAGE, TAZAROTENE  
 AVALIDE, HYDROCHLOROTHIAZIDE  
 AVANDAMET, METFORMIN HYDROCHLORIDE  
 AVANDARYL, GLIMEPIRIDE  
 AVANDIA, ROSIGLITAZONE MALEATE  
 AVAPRO, IRBESARTAN  
 AVC, SULFANILAMIDE  
 AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE  
 AVELOX, MOXIFLOXACIN HYDROCHLORIDE  
 AVENTYL HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE  
 AVINZA, MORPHINE SULFATE  
 AVITA, TRETINOIN  
 AVODART, DUTASTERIDE  
 AXERT, ALMOTRIPTAN MALATE  
 AXID AR, NIZATIDINE (OTC)  
 AXID, NIZATIDINE  
 AYGESTIN, NORETHINDRONE ACETATE  
 AZACTAM IN PLASTIC CONTAINER, AZTREONAM  
 AZACTAM, AZTREONAM  
 AZASITE, AZITHROMYCIN  
 AZELEX, AZELAIC ACID  
 AZILECT, RASAGILINE MESYLATE  
 AZITHROMYCIN, AZITHROMYCIN  
 AZMACORT, TRIAMCINOLONE ACETONIDE  
 AZOPT, BRINZOLAMIDE  
 AZOR, AMLODIPINE BESYLATE  
 AZULFIDINE EN-TABS, SULFASALAZINE  
 AZULFIDINE, SULFASALAZINE

\*\* B \*\*

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE  
 BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM  
 BACTRIM DS, SULFAMETHOXAZOLE  
 BACTRIM, SULFAMETHOXAZOLE  
 BACTROBAN, MUPIROCIN

## APPENDIX A - PRODUCT NAME INDEX

A - 5

\*\* B \*\*

BACTROBAN, MUPIROCIIN CALCIUM  
BAL, DIMERCAPROL  
BANZEL, RUFINAMIDE  
BARACLUDE, ENTECAVIR  
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE  
BENADRYL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE  
BENADRYL, DIPHENHYDRAMINE HYDROCHLORIDE  
BENICAR HCT, HYDROCHLOROTHIAZIDE  
BENICAR, OLMESARTAN MEDOXOMIL  
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE  
BENTYL, DICYCLOMINE HYDROCHLORIDE  
BENZAFLIN, BENZOYL PEROXIDE  
BENZAMYCIN PAK, BENZOYL PEROXIDE  
BENZAMYCIN, BENZOYL PEROXIDE  
BEPREVE, BEPOTASTINE BESILATE  
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE  
BETADINE, POVIDONE-IODINE  
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE  
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE  
BETAPACE AF, SOTALOL HYDROCHLORIDE  
BETAPACE, SOTALOL HYDROCHLORIDE  
BETA-VAL, BETAMETHASONE VALERATE  
BETIMOL, TIMOLOL  
BETOPTIC S, BETAXOLOL HYDROCHLORIDE  
BETOPTIC, BETAXOLOL HYDROCHLORIDE  
BIAXIN XL, CLARITHROMYCIN  
BIAXIN, CLARITHROMYCIN  
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE  
BICILLIN C-R, PENICILLIN G BENZATHINE  
BICILLIN L-A, PENICILLIN G BENZATHINE  
BICNU, CARMUSTINE  
BIDIL, HYDRALAZINE HYDROCHLORIDE  
BILTRICIDE, PRAZIQUANTEL  
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)  
BLENOXANE, BLEOMYCIN SULFATE  
BLEPHAMIDE, PREDNISOLONE ACETATE  
BONIVA, IBANDRONATE SODIUM  
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS  
BRAVELLE, UROFOLLITROPIN  
BREATHTEK UBT FOR H-PYLORI, UREA, C-13  
BRETILIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETILIUM TOSYLATE  
BRETILIUM TOSYLATE, BRETILIUM TOSYLATE  
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE  
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE  
BREVIBLOC, ESMOLOL HYDROCHLORIDE  
BREVICON 28-DAY, ETHINYL ESTRADIOL  
BREVITAL SODIUM, METHOHEXITAL SODIUM  
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE  
BRONCHO SALINE, SODIUM CHLORIDE (OTC)  
BROVANA, ARFORMOTEROL TARTRATE  
BSS PLUS, CALCIUM CHLORIDE  
BSS, CALCIUM CHLORIDE  
BUPHENYL, SODIUM PHENYLBUTYRATE  
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE  
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE  
BUSPAR, BUSPIRONE HYDROCHLORIDE  
BUSULFEX, BUSULFAN  
BUTISOL SODIUM, BUTABARBITAL SODIUM  
BYETTA, EXENATIDE SYNTHETIC  
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

A - 6

\*\* C \*\*

CADUET, AMLODIPINE BESYLATE  
CAFCIT, CAFFEINE CITRATE  
CALAN, VERAPAMIL HYDROCHLORIDE  
CALCIJEX, CALCITRIOL  
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM  
CALDOLOR, IBUPROFEN  
CALOMIST, CYANOCOBALAMIN  
CAMBIA, DICLOFENAC POTASSIUM  
CAMPRAL, ACAMPROSATE CALCIUM  
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE  
CANASA, MESALAMINE  
CANCIDAS, CASPOFUNGIN ACETATE  
CANTIL, MEPENZOLATE BROMIDE  
CAPASTAT SULFATE, CAPREOMYCIN SULFATE  
CAPEX, FLUOCINOLONE ACETONIDE  
CAPITAL SOLEIL 15, AVOBENZONE (OTC)  
CAPOTEN, CAPTOPRIL  
CAPOZIDE 25/15, CAPTOPRIL  
CAPOZIDE 25/25, CAPTOPRIL  
CAPOZIDE 50/15, CAPTOPRIL  
CAPOZIDE 50/25, CAPTOPRIL  
CARAC, FLUOROURACIL  
CARAFATE, SUCRALFATE  
CARBATROL, CARBAMAZEPINE  
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE  
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
CARDENE SR, NICARDIPINE HYDROCHLORIDE  
CARDENE, NICARDIPINE HYDROCHLORIDE  
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82  
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT  
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE  
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE  
CARDIZEM, DILTIAZEM HYDROCHLORIDE  
CARDURA XL, DOXAZOSIN MESYLATE  
CARDURA, DOXAZOSIN MESYLATE  
CARNITOR SF, LEVOCARNITINE  
CARNITOR, LEVOCARNITINE  
CASODEX, BICALUTAMIDE  
CATAFLAM, DICLOFENAC POTASSIUM  
CATAPRES, CLONIDINE HYDROCHLORIDE  
CATAPRES-TTS-1, CLONIDINE  
CATAPRES-TTS-2, CLONIDINE  
CATAPRES-TTS-3, CLONIDINE  
CAVERJECT IMPULSE, ALPROSTADIL  
CAVERJECT, ALPROSTADIL  
CEDAX, CEFTIBUTEN DIHYDRATE  
CEENU, LOMUSTINE  
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM  
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE  
CEFTIN, CEFUROXIME AXETIL  
CEFTRIAZONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAZONE SODIUM  
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM  
CEFZIL, CEFPROZIL  
CELEBREX, CELECOXIB  
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE  
CELESTONE, BETAMETHASONE  
CELEXA, CITALOPRAM HYDROBROMIDE  
CELLCEPT, MYCOPHENOLATE MOFETIL  
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

A - 7

\*\* C \*\*

CELONTIN, METHSUXIMIDE  
 CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A  
 CENTANY, MUPIROCIN  
 CEREBYX, FOSPHENYTOIN SODIUM  
 CEREDASE, ALGLUCERASE  
 CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT  
 CEREZYME, IMIGLUCERASE  
 CERVIDIL, DINOPROSTONE  
 CESAMET, NABILONE  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE  
 CETROTIDE, CETRORELIX  
 CHANTIX, VARENICLINE TARTRATE  
 CHEMET, SUCCIMER  
 CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)  
 CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)  
 CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)  
 CHILDREN'S ADVIL, IBUPROFEN (OTC)  
 CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)  
 CHILDREN'S CLARITIN, LORATADINE (OTC)  
 CHILDREN'S ELIXSURE, IBUPROFEN (OTC)  
 CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)  
 CHILDREN'S MOTRIN, IBUPROFEN (OTC)  
 CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN  
 CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)  
 CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)  
 CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)  
 CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
 CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)  
 CHLORASCRUB MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
 CHLORASCRUB SWAB, CHLORHEXIDINE GLUCONATE (OTC)  
 CHLORASCRUB SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)  
 CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)  
 CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT  
 CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE  
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC  
 CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE  
 CHROMITOPE SODIUM, SODIUM CHROMATE CR-51  
 CIALIS, TADALAFIL  
 CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)  
 CILOXAN, CIPROFLOXACIN HYDROCHLORIDE  
 CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE  
 CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
 CIPRO XR, CIPROFLOXACIN  
 CIPRO, CIPROFLOXACIN  
 CIPRO, CIPROFLOXACIN HYDROCHLORIDE  
 CIPRODEX, CIPROFLOXACIN  
 CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT  
 CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT  
 CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE  
 CITANEST PLAIN DENTAL, PRILOCAINE HYDROCHLORIDE  
 CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM  
 CLAFORAN, CEFOTAXIME SODIUM  
 CLARINEX D 24 HOUR, DESLORATADINE  
 CLARINEX, DESLORATADINE  
 CLARINEX-D 12 HOUR, DESLORATADINE  
 CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)  
 CLARITIN HIVES RELIEF, LORATADINE (OTC)  
 CLARITIN REDITABS, LORATADINE (OTC)

## APPENDIX A - PRODUCT NAME INDEX

A - 8

\*\* C \*\*

CLARITIN, LORATADINE (OTC)  
 CLARITIN-D 24 HOUR, LORATADINE (OTC)  
 CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE  
 CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLEOCIN T, CLINDAMYCIN PHOSPHATE  
 CLEOCIN, CLINDAMYCIN PHOSPHATE  
 CLEVIPREX, CLEVIDIPINE BUTYRATE  
 CLIMARA PRO, ESTRADIOL  
 CLIMARA, ESTRADIOL  
 CLINDAGEL, CLINDAMYCIN PHOSPHATE  
 CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE  
 CLINDESSE, CLINDAMYCIN PHOSPHATE  
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINORIL, SULINDAC  
 CLOBEX, CLOBETASOL PROPIONATE  
 CLODERM, CLOCORTOLONE PIVALATE  
 CLOLAR, CLOFARABINE  
 CLOMID, CLOMIPHENE CITRATE  
 CLONIDINE, CLONIDINE  
 CLOZARIL, CLOZAPINE  
 COARTEM, ARTEMETHER  
 CODEINE SULFATE, CODEINE SULFATE  
 COGENTIN, BENZTROPINE MESYLATE  
 COGNEX, TACRINE HYDROCHLORIDE  
 COLAZAL, BALSALAZIDE DISODIUM  
 COLCRYS, COLCHICINE  
 COLESTID, COLESTIPOL HYDROCHLORIDE  
 COLGATE TOTAL, SODIUM FLUORIDE (OTC)  
 COLY-MYCIN M, COLISTIMETHATE SODIUM



## APPENDIX A - PRODUCT NAME INDEX

A - 9

\*\* C \*\*

COLY-MYCIN S, COLISTIN SULFATE  
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350  
COLYTE, POLYETHYLENE GLYCOL 3350  
COLYTE-FLAVORED, POLYETHYLENE GLYCOL 3350  
COMBIGAN, BRIMONIDINE TARTRATE  
COMBIPATCH, ESTRADIOL  
COMBIVENT, ALBUTEROL SULFATE  
COMBIVIR, LAMIVUDINE  
COMBUNOX, IBUPROFEN  
COMMIT, NICOTINE POLACRILEX (OTC)  
COMTAN, ENTACAPONE  
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE  
CONDYLOX, PODOFILOX  
CONRAY 30, IOTHALAMATE MEGLUMINE  
CONRAY 43, IOTHALAMATE MEGLUMINE  
CONRAY, IOTHALAMATE MEGLUMINE  
COPAXONE, GLATIRAMER ACETATE  
COPEGUS, RIBAVIRIN  
CORDARONE, AMIODARONE HYDROCHLORIDE  
CORDRAN SP, FLURANDRENOLIDE  
CORDRAN, FLURANDRENOLIDE  
COREG CR, CARVEDILOL PHOSPHATE  
COREG, CARVEDILOL  
CORGARD, NADOLOL  
CORLOPAM, FENOLDOPAM MESYLATE  
CORTEF, HYDROCORTISONE  
CORTENEMA, HYDROCORTISONE  
CORTIFOAM, HYDROCORTISONE ACETATE  
CORTISPORIN, BACITRACIN ZINC  
CORTISPORIN, HYDROCORTISONE  
CORTISPORIN, HYDROCORTISONE ACETATE  
CORTROSYN, COSYNTROPIN  
CORVERT, IBUTILIDE FUMARATE  
CORZIDE, BENDROFLUMETHIAZIDE  
COSMEGEN, DACTINOMYCIN  
COSOPT, DORZOLAMIDE HYDROCHLORIDE  
COSYNTROPIN, COSYNTROPIN  
COUMADIN, WARFARIN SODIUM  
COVERA-HS, VERAPAMIL HYDROCHLORIDE  
COZAAR, LOSARTAN POTASSIUM  
CREON, LIPASE  
CRESTOR, ROSUVASTATIN CALCIUM  
CRINONE, PROGESTERONE  
CRIXIVAN, INDINAVIR SULFATE  
CUBICIN, DAPTOMYCIN  
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE  
CUPRIMINE, PENICILLAMINE  
CUROSURF, PORACTANT ALFA  
CUTIVATE, FLUTICASONE PROPIONATE  
CYANOKIT, HYDROXOCOBALAMIN  
CYCLESSA, DESOGESTREL  
CYCLOSET, BROMOCRIPTINE MESYLATE  
CYKLOKAPRON, TRANEXAMIC ACID  
CYMBALTA, DULOXETINE HYDROCHLORIDE  
CYSTADANE, BETAINE HYDROCHLORIDE  
CYSTAGON, CYSTEAMINE BITARTRATE  
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE  
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE  
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE  
CYTOMEL, LIOTHYRONINE SODIUM  
CYTOTEC, MISOPROSTOL

\*\* D \*\*

## APPENDIX A - PRODUCT NAME INDEX

A - 10

\*\* D \*\*

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE  
 DACOGEN, DECITABINE  
 DALMANE, FLURAZEPAM HYDROCHLORIDE  
 DANTRIUM, DANTROLENE SODIUM  
 DARAPRIM, PYRIMETHAMINE  
 DARVOCET-N 100, ACETAMINOPHEN  
 DARVOCET-N 50, ACETAMINOPHEN  
 DARVON, PROPOXYPHENE HYDROCHLORIDE  
 DARVON-N, PROPOXYPHENE NAPSYLATE  
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE  
 DAYPRO, OXAPROZIN  
 DAYTRANA, METHYLPHENIDATE  
 DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE  
 DDAVP, DESMOPRESSIN ACETATE  
 DECLOMYCIN, DEMECLOCYCLINE HYDROCHLORIDE  
 DEFINITY, PERFLUTREN  
 DELATESTRYL, TESTOSTERONE ENANTHATE  
 DELESTROGEN, ESTRADIOL VALERATE  
 DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)  
 DEMADEx, TORSEMIDE  
 DEMEROL, MEPERIDINE HYDROCHLORIDE  
 DEMSER, METYROSINE  
 DENAVIR, PENCICLOVIR SODIUM  
 DENDRID, IDOXURIDINE  
 DEPACON, VALPROATE SODIUM  
 DEPAKENE, VALPROIC ACID  
 DEPAKOTE ER, DIVALPROEX SODIUM  
 DEPAKOTE, DIVALPROEX SODIUM  
 DEPEN, PENICILLAMINE  
 DEPOCYT, CYTARABINE  
 DEPODUR, MORPHINE SULFATE  
 DEPO-MEDROL, METHYLPREDNISOLONE ACETATE  
 DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE  
 DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE  
 DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE  
 DERMATOP E EMOLLIENT, PREDNICARBATE  
 DERMATOP, PREDNICARBATE  
 DERMOTIC, FLUOCINOLONE ACETONIDE  
 DESFERAL, DEFEROXAMINE MESYLATE  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DESOGEN, DESOGESTREL  
 DESONATE, DESONIDE  
 DESONIDE, DESONIDE  
 DESOWEN, DESONIDE  
 DESOXYN, METHAMPHETAMINE HYDROCHLORIDE  
 DETROL LA, TOLTERODINE TARTRATE  
 DETROL, TOLTERODINE TARTRATE  
 DEXEDRINE, DEXTROAMPHETAMINE SULFATE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE

## APPENDIX A - PRODUCT NAME INDEX

A - 11

## \*\* D \*\*

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 25%, DEXTROSE  
 DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,  
 DEXTROSE  
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE  
 DIABETA, GLYBURIDE  
 DIABINESE, CHLORPROPAMIDE  
 DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

A - 12

## \*\* D \*\*

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIAMOX, ACETAZOLAMIDE  
 DIAMOX, ACETAZOLAMIDE SODIUM  
 DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIASTAT ACUDIAL, DIAZEPAM  
 DIASTAT, DIAZEPAM  
 DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE  
 DIDREX, BENZPHETAMINE HYDROCHLORIDE  
 DIDRONEL, ETIDRONATE DISODIUM  
 DIFFERIN, ADAPALENE  
 DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE  
 DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
 DIFLUCAN, FLUCONAZOLE  
 DIGOXIN, DIGOXIN  
 DILACOR XR, DILTIAZEM HYDROCHLORIDE  
 DILANTIN-125, PHENYTOIN  
 DILATRATE-SR, ISOSORBIDE DINITRATE  
 DILAUDID, HYDROMORPHONE HYDROCHLORIDE  
 DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE  
 DIOVAN HCT, HYDROCHLOROTHIAZIDE  
 DIOVAN, VALSARTAN  
 DIPENTUM, OLSALAZINE SODIUM  
 DIPRIVAN, PROPOFOL  
 DIPROLENE AF, BETAMETHASONE DIPROPIONATE  
 DIPROLENE, BETAMETHASONE DIPROPIONATE  
 DISOPHROL, DEKBROMPHENIRAMINE MALEATE (OTC)  
 DITROPAN XL, OXYBUTYNIN CHLORIDE  
 DITROPAN, OXYBUTYNIN CHLORIDE  
 DIURIL, CHLOROTHIAZIDE  
 DIURIL, CHLOROTHIAZIDE SODIUM  
 DIVIGEL, ESTRADIOL  
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE  
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE  
 DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE  
 DOPRAM, DOXAPRAM HYDROCHLORIDE  
 DORAL, QUAZEPAM  
 DORIBAX, DORIPENEM  
 DORYX, DOXYCYCLINE HYCLATE  
 DOVONEX, CALCIPOTRIENE  
 DOXIL, DOXORUBICIN HYDROCHLORIDE  
 DRAXIMAGE MDP-10, TECHNETIUM TC-99M MEDRONATE KIT  
 DRISDOL, ERGOCALCIFEROL  
 DRIXORAL PLUS, ACETAMINOPHEN (OTC)

## APPENDIX A - PRODUCT NAME INDEX

A - 13

## \*\* D \*\*

DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)  
 DROXIA, HYDROXYUREA  
 DTIC-DOME, DACARBAZINE  
 DTPA, TECHNETIUM TC-99M PENTETATE KIT  
 DUAC, BENZOYL PEROXIDE  
 DUETACT, GLIMEPIRIDE  
 DUODOTE, ATROPINE  
 DUONEB, ALBUTEROL SULFATE  
 DURACLON, CLONIDINE HYDROCHLORIDE  
 DURAGESIC-100, FENTANYL  
 DURAGESIC-12, FENTANYL  
 DURAGESIC-25, FENTANYL  
 DURAGESIC-50, FENTANYL  
 DURAGESIC-75, FENTANYL  
 DURAMORPH PF, MORPHINE SULFATE  
 DURAPREP, IODINE POVACRYLEX (OTC)  
 DUREZOL, DIFLUPREDNATE  
 DURICEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 DYAZIDE, HYDROCHLOROTHIAZIDE  
 DYNACIRC CR, ISRADIPINE  
 DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)  
 DYRENIUM, TRIAMTERENE

## \*\* E \*\*

E.E.S., ERYTHROMYCIN ETHYLSUCCINATE  
 EC-NAPROSYN, NAPROXEN  
 EDECRIN, ETHACRYNATE SODIUM  
 EDECRIN, ETHACRYNIC ACID  
 EDEX, ALPROSTADIL  
 EDLUAR, ZOLPIDEM TARTRATE  
 EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE  
 EFFEXOR, VENLAFAXINE HYDROCHLORIDE  
 EFFIENT, PRASUGREL HYDROCHLORIDE  
 EFUDEX, FLUOROURACIL  
 ELDEPRYL, SELEGILINE HYDROCHLORIDE  
 ELESTAT, EPINASTINE HYDROCHLORIDE  
 ELESTRIN, ESTRADIOL  
 ELIDEL, PIMECROLIMUS  
 ELIGARD, LEUPROLIDE ACETATE  
 ELIMITE, PERMETHRIN  
 ELLENCE, EPIRUBICIN HYDROCHLORIDE  
 ELLIOTTS B SOLUTION, CALCIUM CHLORIDE  
 ELMIRON, PENTOSAN POLYSULFATE SODIUM  
 ELOCON, MOMETASONE FUROATE  
 ELOXATIN, OXALIPLATIN  
 EMADINE, EMEDASTINE DIFUMARATE  
 EMBEDA, MORPHINE SULFATE  
 EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM  
 EMEND, APREPITANT  
 EMEND, FOSAPREPITANT DIMEGLUMINE  
 EMLA, LIDOCAINE  
 EMSAM, SELEGILINE  
 EMTRIVA, EMTRICITABINE  
 ENABLEX, DARIFENACIN HYDROBROMIDE  
 ENDOMETRIN, PROGESTERONE  
 ENDOSOL EXTRA, CALCIUM CHLORIDE  
 ENDURON, METHYLOTHIAZIDE  
 ENJUWIA, ESTROGENS, CONJUGATED SYNTHETIC B  
 ENLON-PLUS, ATROPINE SULFATE  
 ENTEREG, ALVIMOPAN  
 ENTOCORT EC, BUDESONIDE  
 EOVIAT, GADOXETATE DISODIUM  
 EPIDUO, ADAPALENE

## APPENDIX A - PRODUCT NAME INDEX

A - 14

\*\* E \*\*

EPIPEN JR., EPINEPHRINE  
 EPIPEN, EPINEPHRINE  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 EPIVIR, LAMIVUDINE  
 EPIVIR-HBV, LAMIVUDINE  
 EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM  
 EPZICOM, ABACAVIR SULFATE  
 EQUETRO, CARBAMAZEPINE  
 ERAXIS, ANIDULAFUNGIN  
 ERTACZO, SERTACONAZOLE NITRATE  
 ERYC, ERYTHROMYCIN  
 ERYGEL, ERYTHROMYCIN  
 ERYPED, ERYTHROMYCIN ETHYLSUCCINATE  
 ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE  
 ESKALITH, LITHIUM CARBONATE  
 ESTRADERM, ESTRADIOL  
 ESTRASORB, ESTRADIOL HEMIHYDRATE  
 ESTRING, ESTRADIOL  
 ESTROGEL, ESTRADIOL  
 ESTROSTEP FE, ETHINYL ESTRADIOL  
 ETHAMOLIN, ETHANOLAMINE OLEATE  
 ETHIODOL, ETHIODIZED OIL  
 ETHRANE, ENFLURANE  
 ETHYOL, AMIFOSTINE  
 ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE  
 EURAX, CROTAMITON  
 EVAMIST, ESTRADIOL  
 EVISTA, RALOXIFENE HYDROCHLORIDE  
 EVOCLIN, CLINDAMYCIN PHOSPHATE  
 EVOXAC, CEVIMELINE HYDROCHLORIDE  
 EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)  
 EXELDERM, SULCONAZOLE NITRATE  
 EXELON, RIVASTIGMINE  
 EXELON, RIVASTIGMINE TARTRATE  
 EXFORGE HCT, AMLODIPINE  
 EXFORGE, AMLODIPINE BESYLATE  
 EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)  
 EXJADE, DEFERASIROX  
 EXTINA, KETOCONAZOLE  
 EXTRANEAL, ICODEXTRIN  
 E-Z SCRUB 201, POVIDONE-IODINE (OTC)  
 E-Z SCRUB 241, POVIDONE-IODINE (OTC)

\*\* F \*\*

FACTIVE, GEMIFLOXACIN MESYLATE  
 FAMVIR, FAMCICLOVIR  
 FANAPT, ILOPERIDONE  
 FARESTON, TOREMIFENE CITRATE  
 FASLODEX, FULVESTRANT  
 FAZACLO ODT, CLOZAPINE  
 FELBATOL, FELBAMATE  
 FELDENE, PIROXICAM  
 FEMARA, LETROZOLE  
 FEMCON FE, ETHINYL ESTRADIOL  
 FEMHRT, ETHINYL ESTRADIOL  
 FEMRING, ESTRADIOL ACETATE  
 FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)  
 FEMTRACE, ESTRADIOL ACETATE  
 FENOGLIDE, FENOFIBRATE  
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE  
 FENTANYL CITRATE, FENTANYL CITRATE  
 FENTORA, FENTANYL CITRATE  
 FERAHEME, FERUMOXYTOL

## APPENDIX A - PRODUCT NAME INDEX

A - 15

\*\* F \*\*

FERIDEX I.V., FERUMOXIDES  
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX  
FIBRICOR, FENOFIBRIC ACID  
FINACEA, AZELAIC ACID  
FIORICET W/ CODEINE, ACETAMINOPHEN  
FIORINAL W/CODEINE, ASPIRIN  
FIORINAL, ASPIRIN  
FIRMAGON, DEGARELIX ACETATE  
FLAGYL ER, METRONIDAZOLE  
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE  
FLAGYL I.V., METRONIDAZOLE HYDROCHLORIDE  
FLAGYL, METRONIDAZOLE  
FLAREX, FLUOROMETHOLONE ACETATE  
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE  
FLECTOR, DICLOFENAC EPOLAMINE  
FLEXERIL, CYCLOBENZAPRINE HYDROCHLORIDE  
FLOLAN, EPOPROSTENOL SODIUM  
FLOMAX, TAMSULOSIN HYDROCHLORIDE  
FLONASE, FLUTICASONE PROPIONATE  
FLO-PRED, PREDNISOLONE ACETATE  
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE  
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE  
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE  
FLOVENT HFA, FLUTICASONE PROPIONATE  
FLOXIN OTIC, OFLOXACIN  
FLUDARA, FLUDARABINE PHOSPHATE  
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE F-18  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
FLUMADINE, RIMANTADINE HYDROCHLORIDE  
FLUOCINONIDE, FLUOCINONIDE  
FLUORESCITE, FLUORESCEIN SODIUM  
FLUOROPLEX, FLUOROURACIL  
FLUOROURACIL, FLUOROURACIL  
FLUXID, FAMOTIDINE  
FML FORTE, FLUOROMETHOLONE  
FML, FLUOROMETHOLONE  
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE  
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE  
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA  
FOLOTYN, PRALATREXATE  
FORADIL CERTIHALER, FORMOTEROL FUMARATE  
FORADIL, FORMOTEROL FUMARATE  
FORANE, ISOFLURANE  
FORTAMET, METFORMIN HYDROCHLORIDE  
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM  
FORTAZ, CEFTAZIDIME  
FORTEO, TERIPARATIDE RECOMBINANT HUMAN  
FORTICAL, CALCITONIN SALMON RECOMBINANT  
FOSAMAX PLUS D, ALENDRONATE SODIUM  
FOSAMAX, ALENDRONATE SODIUM  
FOSCAVIR, FOSCARNET SODIUM  
FOSRENOL, LANTHANUM CARBONATE  
FRAGMIN, DALTEPARIN SODIUM  
FREAMINE HBC 6.9%, AMINO ACIDS  
FREAMINE III 10%, AMINO ACIDS  
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS  
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS  
FREAMINE III 8.5%, AMINO ACIDS  
FROVA, FROVATRIPTAN SUCCINATE  
FURADANTIN, NITROFURANTOIN  
FUROSEMIDE, FUROSEMIDE  
FUSILEV, LEVOLEUCOVORIN CALCIUM

## APPENDIX A - PRODUCT NAME INDEX

A - 16

## \*\* F \*\*

FUZEON, ENFUVIRTIDE

## \*\* G \*\*

GABITRIL, TIAGABINE HYDROCHLORIDE  
 GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67  
 GALZIN, ZINC ACETATE  
 GANIRELIX ACETATE INJECTION, GANIRELIX ACETATE  
 GANITE, GALLIUM NITRATE  
 GASTROCROM, CROMOLYN SODIUM  
 GASTROGRAFIN, DIATRIZOATE MEGLUMINE  
 GASTROMARK, FERUMOXASIL  
 GAVISCON, ALUMINUM HYDROXIDE (OTC)  
 GELNIQUE, OXYBUTYNIN CHLORIDE  
 GEMZAR, GEMCITABINE HYDROCHLORIDE  
 GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT  
 GENOTROPIN, SOMATROPIN RECOMBINANT  
 GEODON, ZIPRASIDONE HYDROCHLORIDE  
 GEODON, ZIPRASIDONE MESYLATE  
 GLEEVEC, IMATINIB MESYLATE  
 GLIADEL, CARMUSTINE  
 GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT  
 GLUCAGON, GLUCAGON RECOMBINANT  
 GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE  
 GLUCOPHAGE, METFORMIN HYDROCHLORIDE  
 GLUCOTROL XL, GLIPIZIDE  
 GLUCOTROL, GLIPIZIDE  
 GLUCOVANCE, GLYBURIDE  
 GLUMETZA, METFORMIN HYDROCHLORIDE  
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE  
 GLYNASE, GLYBURIDE  
 GLYSET, MIGLITOL  
 GOLYTELY, POLYETHYLENE GLYCOL 3350  
 GONAL-F RFF PEN, FOLLITROPIN ALFA/BETA  
 GONAL-F RFF, FOLLITROPIN ALFA/BETA  
 GONAL-F, FOLLITROPIN ALFA/BETA  
 GRIS-PEG, GRISEOFULVIN, ULTRAMICROCRYSTALLINE  
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE  
 GYNAZOLE-1, BUTOCONAZOLE NITRATE  
 GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)  
 GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)  
 GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)  
 GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)

## \*\* H \*\*

H.P. ACTHAR GEL, CORTICOTROPIN  
 HABITROL, NICOTINE (OTC)  
 HALCION, TRIAZOLAM  
 HALDOL, HALOPERIDOL DECANOATE  
 HALDOL, HALOPERIDOL LACTATE  
 HALFLYTELY, BISACODYL  
 HALOG, HALCINONIDE  
 HECTOROL, DOXERCALCIFEROL  
 HELIDAC, BISMUTH SUBSALICYLATE  
 HEMABATE, CARBOPROST TROMETHAMINE  
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM



## APPENDIX A - PRODUCT NAME INDEX

A - 17

## \*\* H \*\*

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
 HEPARIN SODIUM, HEPARIN SODIUM  
 HEPATAMINE 8%, AMINO ACIDS  
 HEPATASOL 8%, AMINO ACIDS  
 HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT  
 HEPSERA, ADEFOVIR DIPIVOXIL  
 HERPLEX, IDOXURIDINE  
 HEXABRIX, IOXAGLATE MEGLUMINE  
 HEXALEN, ALTRETAMINE  
 HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)  
 HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)  
 HICON, SODIUM IODIDE, I-131  
 HIPREX, METHENAMINE HIPPURATE  
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT  
 HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG PEN, INSULIN LISPRO RECOMBINANT  
 HUMALOG, INSULIN LISPRO RECOMBINANT  
 HUMATROPE, SOMATROPIN RECOMBINANT  
 HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)  
 HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN R, INSULIN RECOMBINANT HUMAN  
 HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)  
 Hycamtin, Topotecan Hydrochloride  
 HYDASE, HYALURONIDASE  
 HYDERGINE, ERGOLOID MESYLATES  
 HYDREA, HYDROXYUREA  
 HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN  
 HYPAQUE, DIATRIZOATE SODIUM  
 HYTRIN, TERAZOSIN HYDROCHLORIDE  
 HYZAAR, HYDROCHLOROTHIAZIDE

## \*\* I \*\*

IC-GREEN, INDOCYANINE GREEN  
 IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE  
 IDKIT:HP, UREA C-13  
 IFEX/MESNEX KIT, IFOSFAMIDE  
 IMITREX STATDOSE, SUMATRIPTAN SUCCINATE  
 IMITREX, SUMATRIPTAN  
 IMITREX, SUMATRIPTAN SUCCINATE  
 IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)  
 IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)  
 IMODIUM MULTI-SYMPOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)  
 IMODIUM, LOPERAMIDE HYDROCHLORIDE  
 IMPLANON, ETONOGESTREL  
 IMURAN, AZATHIOPRINE  
 INAPSINE, DROPERIDOL  
 INCRELEX, MECASERMIN RECOMBINANT  
 INDERAL LA, PROPRANOLOL HYDROCHLORIDE  
 INDERAL, PROPRANOLOL HYDROCHLORIDE  
 INDERIDE-40/25, HYDROCHLOROTHIAZIDE  
 INDICLOR, INDIUM IN-111 CHLORIDE  
 INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE  
 INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE

## APPENDIX A - PRODUCT NAME INDEX

A - 18

\*\* I \*\*

INDOCIN, INDOMETHACIN  
INDOCIN, INDOMETHACIN SODIUM  
INDOMETHACIN, INDOMETHACIN  
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)  
INFASURF PRESERVATIVE FREE, CALFACTANT  
INFED, IRON DEXTRAN  
INFUMORPH, MORPHINE SULFATE  
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE  
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID  
INFUVITE PEDIATRIC, ASCORBIC ACID  
INNOHEP, TINZAPARIN SODIUM  
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE  
INOMAX, NITRIC OXIDE  
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
INSPRA, EPLERENONE  
INTAL, CROMOLYN SODIUM  
INTEGRILIN, EPTIFIBATIDE  
INTELENCE, ETRAVIRINE  
INTRALIPID 10%, SOYBEAN OIL  
INTRALIPID 20%, SOYBEAN OIL  
INTRALIPID 30%, SOYBEAN OIL  
INTUNIV, GUANFACINE HYDROCHLORIDE  
INVANZ, ERTAPENEM SODIUM  
INVEGA SUSTENNA, PALIPERIDONE PALMITATE  
INVEGA, PALIPERIDONE  
INVIRASE, SAQUINAVIR MESYLATE  
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
IOPIDINE, APRACLONIDINE HYDROCHLORIDE  
IOSAT, POTASSIUM IODIDE (OTC)  
I PRIVASK, DESIRUDIN RECOMBINANT  
IQIUX, LEVOFLOXACIN  
IRESSA, GEFITINIB  
ISENTRESS, RALTEGRAVIR POTASSIUM  
ISMO, ISOSORBIDE MONONITRATE  
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
ISONIAZID, ISONIAZID  
ISOPTIN SR, VERAPAMIL HYDROCHLORIDE  
ISORDIL, ISOSORBIDE DINITRATE  
ISOVUE-200, IOPAMIDOL  
ISOVUE-250, IOPAMIDOL  
ISOVUE-300, IOPAMIDOL  
ISOVUE-370, IOPAMIDOL  
ISOVUE-M 200, IOPAMIDOL  
ISOVUE-M 300, IOPAMIDOL  
ISTALOL, TIMOLOL MALEATE  
ISTODAX, ROMIDEPSIN  
ISUPREL, ISOPROTERENOL HYDROCHLORIDE  
IVY BLOCK, BENTOQUATAM (OTC)  
IXEMPRA KIT, IXABEPILONE

## APPENDIX A - PRODUCT NAME INDEX

A - 19

## \*\* J \*\*

JANUMET, METFORMIN HYDROCHLORIDE  
 JANUVIA, SITAGLIPTIN PHOSPHATE  
 JEANATOPE, ALBUMIN IODINATED I-125 SERUM  
 JENLOGA, CLONIDINE HYDROCHLORIDE  
 JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)  
 JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)

## \*\* K \*\*

KADIAN, MORPHINE SULFATE  
 KALETRA, LOPINAVIR  
 KAON CL-10, POTASSIUM CHLORIDE  
 KAPIDEX, DEXLANSOPRAZOLE  
 KAYEXALATE, SODIUM POLYSTYRENE SULFONATE  
 KEFLEX, CEPHALEXIN  
 KEMSTRO, BACLOFEN  
 KENALOG, TRIAMCINOLONE ACETONIDE  
 KENALOG-10, TRIAMCINOLONE ACETONIDE  
 KENALOG-40, TRIAMCINOLONE ACETONIDE  
 KEPRA XR, LEVETIRACETAM  
 KEPRA, LEVETIRACETAM  
 KETALAR, KETAMINE HYDROCHLORIDE  
 KETEK, TELITHROMYCIN  
 KINEVAC, SINCALIDE  
 KLARON, SULFACETAMIDE SODIUM  
 KLONOPIN, CLONAZEPAM  
 KLOR-CON, POTASSIUM CHLORIDE  
 KLOTRIX, POTASSIUM CHLORIDE  
 K-TAB, POTASSIUM CHLORIDE  
 KUVAN, SAPROPTERIN DIHYDROCHLORIDE  
 KYTRIL, GRANISETRON HYDROCHLORIDE

## \*\* L \*\*

LAC-HYDRIN, AMMONIUM LACTATE  
 LACRISERT, HYDROXYPROPYL CELLULOSE  
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LAMICTAL CD, LAMOTRIGINE  
 LAMICTAL ODT, LAMOTRIGINE  
 LAMICTAL XR, LAMOTRIGINE  
 LAMICTAL, LAMOTRIGINE  
 LAMISIL AT, TERBINAFINE (OTC)  
 LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)  
 LAMISIL, TERBINAFINE  
 LAMISIL, TERBINAFINE HYDROCHLORIDE  
 LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)  
 LAMPRENE, CLOFAZIMINE  
 LANOXICAPS, DIGOXIN  
 LANOXIN PEDIATRIC, DIGOXIN  
 LANOXIN, DIGOXIN  
 LANTUS, INSULIN GLARGINE RECOMBINANT  
 LASIX, FUROSEMIDE  
 LATISSE, BIMATOPROST  
 LESCOL XL, FLUVASTATIN SODIUM  
 LESCOL, FLUVASTATIN SODIUM  
 LETAIRIS, AMBRISENTAN  
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM  
 LEUKERAN, CHLORAMBUCIL  
 LEUSTATIN, CLADRIBINE  
 LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 LEVAQUIN, LEVOFLOXACIN  
 LEVATOL, PENBUTOLOL SULFATE  
 LEVEMIR, INSULIN DETEMIR RECOMBINANT

## APPENDIX A - PRODUCT NAME INDEX

A - 20

\*\* L \*\*

LEVITRA, VARDENAFIL HYDROCHLORIDE  
 LEVO-DROMORAN, LEVORPHANOL TARTRATE  
 LEVOPHED, NOREPINEPHRINE BITARTRATE  
 LEVO-T, LEVOTHYROXINE SODIUM  
 LEVOTHROID, LEVOTHYROXINE SODIUM  
 LEVOXYL, LEVOTHYROXINE SODIUM  
 LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE  
 LEXAPRO, ESCITALOPRAM OXALATE  
 LEXISCAN, REGADENOSON  
 LEXIVA, FOSAMPRENAVIR CALCIUM  
 LEXXEL, ENALAPRIL MALEATE  
 LIALDA, MESALAMINE  
 LIDEX, FLUOCINONIDE  
 LIDEX-E, FLUOCINONIDE  
 LIDOCAINE AND TETRACAINE, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 LIDODERM, LIDOCAINE  
 LIDOPEN, LIDOCAINE HYDROCHLORIDE  
 LIMBITROL DS, AMITRIPTYLINE HYDROCHLORIDE  
 LIMBITROL, AMITRIPTYLINE HYDROCHLORIDE  
 LINCOCIN, LINCOMYCIN HYDROCHLORIDE  
 LIORESAL, BACLOFEN  
 LIPITOR, ATORVASTATIN CALCIUM  
 LIPOFEN, FENOFIBRATE  
 LIPOSYN II 10%, SAFFLOWER OIL  
 LIPOSYN II 20%, SAFFLOWER OIL  
 LIPOSYN III 10%, SOYBEAN OIL  
 LIPOSYN III 20%, SOYBEAN OIL  
 LIPOSYN III 30%, SOYBEAN OIL  
 LITHIUM CARBONATE, LITHIUM CARBONATE  
 LITHIUM CITRATE, LITHIUM CITRATE  
 LITHOBID, LITHIUM CARBONATE  
 LITHOSTAT, ACETOHYDROXAMIC ACID  
 LIVALO, PITAVASTATIN CALCIUM  
 LO/OVRAL-28, ETHINYL ESTRADIOL  
 LOCROID LIPOCREAM, HYDROCORTISONE BUTYRATE  
 LOCROID, HYDROCORTISONE BUTYRATE  
 LODOSYN, CARBIDOPA  
 LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL  
 LOESTRIN 21 1/20, ETHINYL ESTRADIOL  
 LOESTRIN 24 FE, ETHINYL ESTRADIOL  
 LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL  
 LOESTRIN FE 1/20, ETHINYL ESTRADIOL  
 LOMOTIL, ATROPINE SULFATE  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 LOPID, GEMFIBROZIL  
 LOPRESSOR HCT, HYDROCHLOROTHIAZIDE  
 LOPRESSOR, METOPROLOL TARTRATE  
 LOPROX, CICLOPIROX  
 LORATADINE, LORATADINE (OTC)  
 LOSEASONIQUE, ETHINYL ESTRADIOL  
 LOTEMAX, LOTEPREDNOL ETABONATE  
 LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE  
 LOTENSIN, BENAZEPRIL HYDROCHLORIDE  
 LOTREL, AMLODIPINE BESYLATE  
 LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)  
 LOTRISONE, BETAMETHASONE DIPROPIONATE  
 LOTRONEX, ALOSETRON HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

A - 21

## \*\* L \*\*

LOVAZA, OMEGA-3-ACID ETHYL ESTERS  
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM  
 LOVENOX, ENOXAPARIN SODIUM  
 LUMIGAN, BIMATOPROST  
 LUNESTA, ESZOPICLONE  
 LUPRON DEPOT, LEUPROLIDE ACETATE  
 LUPRON DEPOT-3, LEUPROLIDE ACETATE  
 LUPRON DEPOT-4, LEUPROLIDE ACETATE  
 LUPRON DEPOT-PED, LEUPROLIDE ACETATE  
 LUPRON, LEUPROLIDE ACETATE  
 LUSEDRA, FOSPROPOFOL DISODIUM  
 LUVERIS, LUTROPIN ALFA  
 LUVOX CR, FLUVOXAMINE MALEATE  
 LUVOX, FLUVOXAMINE MALEATE  
 LUXIQ, BETAMETHASONE VALERATE  
 LYBREL, ETHINYL ESTRADIOL  
 LYMPHAZURIN, ISOSULFAN BLUE  
 LYOPHILIZED CYTOXAN, CYCLOPHOSPHAMIDE  
 LYRICA, PREGABALIN  
 LYSODREN, MITOTANE  
 LYSTEDA, TRANEXAMIC ACID

## \*\* M \*\*

M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID  
 M.V.I. ADULT, ASCORBIC ACID  
 M.V.I. PEDIATRIC, ASCORBIC ACID  
 M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID  
 MACROBID, NITROFURANTOIN  
 MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE  
 MACUGEN, PEGAPTANIB SODIUM  
 MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE, MAGNESIUM HYDROXIDE  
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 MAGNESIUM SULFATE, MAGNESIUM SULFATE  
 MAGNEVIST, GADOPENTETATE DIMEGLUMINE  
 MALARONE PEDIATRIC, ATOVAQUONE  
 MALARONE, ATOVAQUONE  
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE  
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL  
 MANNITOL 10%, MANNITOL  
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL  
 MANNITOL 15%, MANNITOL  
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 20%, MANNITOL  
 MANNITOL 25%, MANNITOL  
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL  
 MANNITOL 5%, MANNITOL  
 MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE, BUPIVACAINE HYDROCHLORIDE  
 MARINOL, DRONABINOL  
 MARPLAN, ISOCARBOXAZID  
 MATULANE, PROCARBAZINE HYDROCHLORIDE  
 MAVIK, TRANDOLAPRIL  
 MAXAIR, PIRBUTEROL ACETATE  
 MAXALT, RIZATRIPTAN BENZOATE  
 MAXALT-MLT, RIZATRIPTAN BENZOATE  
 MAXIDEX, DEXAMETHASONE

## APPENDIX A - PRODUCT NAME INDEX

A - 22

\*\* M \*\*

MAXIPIME, CEFEPIME HYDROCHLORIDE  
MAXITROL, DEXAMETHASONE  
MAXZIDE, HYDROCHLOROTHIAZIDE  
MAXZIDE-25, HYDROCHLOROTHIAZIDE  
MD-76R, DIATRIZOATE MEGLUMINE  
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT  
MEDROL, METHYLPREDNISOLONE  
MEGACE ES, MEGESTROL ACETATE  
MEGACE, MEGESTROL ACETATE  
MEGATOPE, ALBUMIN IODINATED I-131 SERUM  
MEMBRANEBLUE, TRYPAN BLUE  
MENOPUR, LUTEINIZING HORMONE  
MENOSTAR, ESTRADIOL  
MEN'S ROGAINE, MINOXIDIL (OTC)  
MENTAX, BUTENAFINE HYDROCHLORIDE  
MENTAX-TC, BUTENAFINE HYDROCHLORIDE  
MEPHYTON, PHYTONADIONE  
MEPRON, ATOVAQUONE  
MERIDIA, SIBUTRAMINE HYDROCHLORIDE  
MERREM I.V., MEROPENEM  
MESNEX, MESNA  
MESTINON, PYRIDOSTIGMINE BROMIDE  
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE  
METAGLIP, GLIPIZIDE  
METASTRON, STRONTIUM CHLORIDE, SR-89  
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
METHADOSE, METHADONE HYDROCHLORIDE  
METHERGINE, METHYLERGONOVINE MALEATE  
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM  
METHOTREXATE SODIUM, METHOTREXATE SODIUM  
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE  
METOPIRONE, METYRAPONE  
METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE  
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE  
METROCREAM, METRONIDAZOLE  
METROGEL, METRONIDAZOLE  
METROGEL-VAGINAL, METRONIDAZOLE  
METROLOTION, METRONIDAZOLE  
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE  
METRONIDAZOLE, METRONIDAZOLE  
METVIXIA, METHYL AMINOLEVULINATE HYDROCHLORIDE  
MEVACOR, LOVASTATIN  
MIACALCIN, CALCITONIN, SALMON  
MICARDIS HCT, HYDROCHLOROTHIAZIDE  
MICARDIS, TELMISARTAN  
MICRONOR, NORETHINDRONE  
MICROZIDE, HYDROCHLOROTHIAZIDE  
MIDAMOR, AMILORIDE HYDROCHLORIDE  
MIDOL LIQUID GELS, IBUPROFEN (OTC)  
MIFEPREX, MIFEPRISTONE  
MIGRANAL, DIHYDROERGOTAMINE MESYLATE  
MINIPRESS, PRAZOSIN HYDROCHLORIDE  
MINIRIN, DESMOPRESSIN ACETATE  
MINOCIN, MINOCYCLINE HYDROCHLORIDE  
MIOCHOL-E, ACETYLCHOLINE CHLORIDE  
MIOSTAT, CARBACHOL  
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)  
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE  
MIRCETTE, DESOGESTREL  
MIRENA, LEVONORGESTREL  
MOBAN, MOLINDONE HYDROCHLORIDE  
MOBIC, MELOXICAM  
MODICON 28, ETHINYL ESTRADIOL

## APPENDIX A - PRODUCT NAME INDEX

A - 23

## \*\* M \*\*

MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)  
 MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 MONISTAT 3, MICONAZOLE NITRATE  
 MONISTAT 3, MICONAZOLE NITRATE (OTC)  
 MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 MONISTAT 7, MICONAZOLE NITRATE (OTC)  
 MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 MONODOX, DOXYCYCLINE  
 MONOKET, ISOSORBIDE MONONITRATE  
 MONOPRIL, FOSINOPRIL SODIUM  
 MONUROL, FOSFOMYCIN TROMETHAMINE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 MOTOFEN, ATROPINE SULFATE  
 MOTRIN IB, IBUPROFEN (OTC)  
 MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)  
 MOVIPREP, ASCORBIC ACID  
 MOXATAG, AMOXICILLIN  
 MOZOBIL, PLERIXAFOR  
 MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT  
 MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM  
 MS CONTIN, MORPHINE SULFATE  
 MUCINEX D, GUAIFENESIN (OTC)  
 MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)  
 MUCINEX, GUAIFENESIN (OTC)  
 MULTAQ, DRONEDARONE HYDROCHLORIDE  
 MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE  
 MULTIHANCE, GADOBENATE DIMEGLUMINE  
 MUSE, ALPROSTADIL  
 MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE  
 MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE  
 MYCAMINE, MICAFUNGIN SODIUM  
 MYCELEX, CLOTRIMAZOLE  
 MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)  
 MYCELEX-7, CLOTRIMAZOLE (OTC)  
 MYCOBUTIN, RIFABUTIN  
 MYFORTIC, MYCOPHENOLIC ACID  
 MYLERAN, BUSULFAN  
 MYLOTARG, GEMTUZUMAB OZOGAMICIN  
 MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT  
 MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT  
 MYSOLINE, PRIMIDONE  
 MYTELASE, AMBENONIUM CHLORIDE

## \*\* N \*\*

NAFTIN, NAFTIFINE HYDROCHLORIDE  
 NALFON, FENOPROFEN CALCIUM  
 NALLPEN IN PLASTIC CONTAINER, NAFICILLIN SODIUM  
 NAMENDA, MEMANTINE HYDROCHLORIDE  
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 NAPRELAN, NAPROXEN SODIUM  
 NAPROSYN, NAPROXEN  
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)  
 NARDIL, PHENELZINE SULFATE  
 NAROPIN, ROPIVACAINE HYDROCHLORIDE MONOHYDRATE  
 NASACORT AQ, TRIAMCINOLONE ACETONIDE  
 NASAREL, FLUNISOLIDE  
 NASCOBAL, CYANOCOBALAMIN  
 NASONEX, MOMETASONE FUROATE MONOHYDRATE  
 NATACYN, NATAMYCIN  
 NATRECOR, NESIRITIDE RECOMBINANT  
 NAVANE, THIOTHIXENE  
 NAVELBINE, VINORELBINE TARTRATE

## APPENDIX A - PRODUCT NAME INDEX

A - 24

\*\* N \*\*

NAVSTEL, CALCIUM CHLORIDE  
 NEBUPENT, PENTAMIDINE ISETHIONATE  
 NEGRAM, NALIDIXIC ACID  
 NEOPAP, ACETAMINOPHEN (OTC)  
 NEOPROFEN, IBUPROFEN LYSINE  
 NEORAL, CYCLOSPORINE  
 NEPHRAMINE 5.4%, AMINO ACIDS  
 NESACAINE, CHLOROPROCAINE HYDROCHLORIDE  
 NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE  
 NEUROLITE, TECHNETIUM TC-99M BICISATE KIT  
 NEURONTIN, GABAPENTIN  
 NEVANAC, NEPAFENAC  
 NEXAVAR, SORAFENIB TOSYLATE  
 NEXCEDE, KETOPROFEN (OTC)  
 NEXIUM IV, ESOMEPRAZOLE SODIUM  
 NEXIUM, ESOMEPRAZOLE MAGNESIUM  
 NEXTERONE, AMLODARONE HYDROCHLORIDE  
 NIASPAN, NIACIN  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
 NICODERM CQ, NICOTINE (OTC)  
 NICORETTE (MINT), NICOTINE POLACRILEX (OTC)  
 NICORETTE, NICOTINE POLACRILEX (OTC)  
 NICOTROL, NICOTINE  
 NILANDRON, NILUTAMIDE  
 NILSTAT, NYSTATIN  
 NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE  
 NIMBEX, CISATRACURIUM BESYLATE  
 NIPENT, PENTOSTATIN  
 NIRAVAM, ALPRAZOLAM  
 NITRO-DUR, NITROGLYCERIN  
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN  
 NITROGLYCERIN, NITROGLYCERIN  
 NITROLINGUAL PUMPSPRAY, NITROGLYCERIN  
 NITROMIST, NITROGLYCERIN  
 NITROSTAT, NITROGLYCERIN  
 NIX, PERMETHRIN (OTC)  
 NIZORAL A-D, KETOCONAZOLE (OTC)  
 NIZORAL, KETOCONAZOLE  
 NORDETTE-28, ETHINYL ESTRADIOL  
 NORDITROPIN NORDIFLEX, SOMATROPIN RECOMBINANT  
 NORDITROPIN, SOMATROPIN RECOMBINANT  
 NORFLEX, ORPHENADRINE CITRATE  
 NORGESIC FORTE, ASPIRIN  
 NORGESIC, ASPIRIN  
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL  
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL  
 NORINYL 1+50 28-DAY, MESTRANOL  
 NORITATE, METRONIDAZOLE  
 NORMOCARB HF 25, MAGNESIUM CHLORIDE  
 NORMOCARB HF 35, MAGNESIUM CHLORIDE  
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 NOROXIN, NORFLOXACIN  
 NORPACE CR, DISOPYRAMIDE PHOSPHATE  
 NORPACE, DISOPYRAMIDE PHOSPHATE  
 NORPRAMIN, DESIPRAMINE HYDROCHLORIDE  
 NOR-QD, NORETHINDRONE  
 NORVASC, AMLODIPINE BESYLATE  
 NORVIR, RITONAVIR  
 NOVAMINE 11.4%, AMINO ACIDS  
 NOVAMINE 15%, AMINO ACIDS  
 NOVANTRONE, MITOXANTRONE HYDROCHLORIDE



## APPENDIX A - PRODUCT NAME INDEX

A - 25

## \*\* N \*\*

NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)  
 NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)  
 NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)  
 NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT  
 NOVOLOG, INSULIN ASPART RECOMBINANT  
 NOXAFIL, POSACONAZOLE  
 NUCYNTA, TAPENTADOL HYDROCHLORIDE  
 NULYTELY, POLYETHYLENE GLYCOL 3350  
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350  
 NUTRESTORE, GLUTAMINE  
 NUTRILIPID 10%, SOYBEAN OIL  
 NUTRILIPID 20%, SOYBEAN OIL  
 NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT  
 NUTROPIN AQ, SOMATROPIN RECOMBINANT  
 NUTROPIN, SOMATROPIN RECOMBINANT  
 NUVARING, ETHINYL ESTRADIOL  
 NUVIGIL, ARMODAFINIL

## \*\* O \*\*

OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT  
 OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)  
 OCUFEN, FLURBIPROFEN SODIUM  
 OCUFLOX, OFLOXACIN  
 OCUPRESS, CARTEOLOL HYDROCHLORIDE  
 OFORTA, FLUDARABINE PHOSPHATE  
 OLUX E, CLOBETASOL PROPIONATE  
 OLUX, CLOBETASOL PROPIONATE  
 OMEPRAZOLE, OMEPRAZOLE (OTC)  
 OMNARIS, CICLESONIDE  
 OMNICEF, CEFDINIR  
 OMNIPAQUE 140, IOHEXOL  
 OMNIPAQUE 180, IOHEXOL  
 OMNIPAQUE 240, IOHEXOL  
 OMNIPAQUE 300, IOHEXOL  
 OMNIPAQUE 350, IOHEXOL  
 OMNIPRED, PREDNISOLONE ACETATE  
 OMNISCAN, GADODIAMIDE  
 OMNITROPE, SOMATROPIN RECOMBINANT  
 ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE  
 ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE  
 ONSOLIS, FENTANYL CITRATE  
 OPANA ER, OXYMORPHONE HYDROCHLORIDE  
 OPANA, OXYMORPHONE HYDROCHLORIDE  
 OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 OPTHAINA, PROPARACAINE HYDROCHLORIDE  
 OPTHETIC, PROPARACAINE HYDROCHLORIDE  
 OPTICROM, CROMOLYN SODIUM  
 OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE  
 OPTIMARK, GADOVERSETAMIDE  
 OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE  
 OPTIRAY 160, IOVERSOL  
 OPTIRAY 240, IOVERSOL  
 OPTIRAY 300, IOVERSOL  
 OPTIRAY 320, IOVERSOL  
 OPTIRAY 350, IOVERSOL  
 OPTISON, ALBUMIN HUMAN  
 OPTIVAR, AZELASTINE HYDROCHLORIDE  
 ORACEA, DOXYCYCLINE  
 ORAMORPH SR, MORPHINE SULFATE  
 ORAP, PIMOZIDE  
 ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE  
 ORAQIX, LIDOCAINE  
 ORAVERSE, PHENTOLAMINE MESYLATE

## APPENDIX A - PRODUCT NAME INDEX

A - 26

\*\* O \*\*

ORETIC, HYDROCHLOROTHIAZIDE  
 ORFADIN, NITISINONE  
 ORTHO CYCLEN-28, ETHINYL ESTRADIOL  
 ORTHO EVRA, ETHINYL ESTRADIOL  
 ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL  
 ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL  
 ORTHO-CEPT, DESOGESTREL  
 ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL  
 ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL  
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 10% IN WATER, MANNITOL  
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 15% IN WATER, MANNITOL  
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 20% IN WATER, MANNITOL  
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 5% IN WATER, MANNITOL  
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC ANHYDROUS  
 OVCON-35, ETHINYL ESTRADIOL  
 OVCON-50, ETHINYL ESTRADIOL  
 OVIDE, MALATHION  
 OVIDREL, CHORIOGONADOTROPIN ALFA  
 OXALIPLATIN, OXALIPLATIN  
 OXANDRIN, OXANDROLONE  
 OXILAN-300, IOXILAN  
 OXILAN-350, IOXILAN  
 OXISTAT, OXICONAZOLE NITRATE  
 OXSORALEN, METHOXSALEN  
 OXSORALEN-ULTRA, METHOXSALEN  
 OXYCONTIN, OXYCODONE HYDROCHLORIDE  
 OXYTOCIN, OXYTOCIN  
 OXYTROL, OXYBUTYNIN  
 OZURDEX, DEXAMETHASONE

\*\* P \*\*

PAMELOR, NORTRIPTYLINE HYDROCHLORIDE  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
 PAMINE FORTE, METHSCOPOLAMINE BROMIDE  
 PAMINE, METHSCOPOLAMINE BROMIDE  
 PANDEL, HYDROCORTISONE PROBUTATE  
 PANRETIN, ALITRETINOIN  
 PARAFON FORTE DSC, CHLORZOXAZONE  
 PARAGARD T 380A, COPPER  
 PARAPLATIN, CARBOPLATIN  
 PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE  
 PARLODEL, BROMOCRIPTINE MESYLATE  
 PARNATE, TRANLYCYPROMINE SULFATE  
 PATADAY, OLOPATADINE HYDROCHLORIDE  
 PATANASE, OLOPATADINE HYDROCHLORIDE  
 PATANOL, OLOPATADINE HYDROCHLORIDE  
 PAXIL CR, PAROXETINE HYDROCHLORIDE  
 PAXIL, PAROXETINE HYDROCHLORIDE  
 PCE, ERYTHROMYCIN  
 PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE  
 PEDIATRIC ADVIL, IBUPROFEN (OTC)  
 PEGANONE, ETHOTOIN  
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM  
 PENLAC, CICLOPIROX  
 PENNSAID, DICLOFENAC SODIUM  
 PENTAM, PENTAMIDINE ISETHIONATE  
 PENTASA, MESALAMINE  
 PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM  
 PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM

## APPENDIX A - PRODUCT NAME INDEX

A - 27

\*\* P \*\*

PEPCID AC (GELTAB), FAMOTIDINE (OTC)  
 PEPCID AC, FAMOTIDINE (OTC)  
 PEPCID COMPLETE, CALCIUM CARBONATE (OTC)  
 PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE  
 PEPCID PRESERVATIVE FREE, FAMOTIDINE  
 PEPCID, FAMOTIDINE  
 PERCODAN, ASPIRIN  
 PERFOROMIST, FORMOTEROL FUMARATE  
 PERIDEX, CHLORHEXIDINE GLUCONATE  
 PERIOCHIP, CHLORHEXIDINE GLUCONATE  
 PERIOSTAT, DOXYCYCLINE HYCLATE  
 PERSANTINE, DIPYRIDAMOLE  
 PEXEVA, PAROXETINE MESYLATE  
 PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)  
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE  
 PHISOHEX, HEXACHLOROPHENE  
 PHOSLO GELCAPS, CALCIUM ACETATE  
 PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE  
 PHOTOFRIN, PORFIMER SODIUM  
 PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PILOPINE HS, PILOCARPINE HYDROCHLORIDE  
 PITOCIN, OXYTOCIN  
 PLAN B ONE-STEP, LEVONORGESTREL  
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)  
 PLAN B, LEVONORGESTREL  
 PLAN B, LEVONORGESTREL (OTC)  
 PLAQUENIL, HYDROXYCHLOROQUINE SULFATE  
 PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE  
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PLATINOL, CISPLATIN  
 PLATINOL-AQ, CISPLATIN  
 PLAVIX, CLOPIDOGREL BISULFATE  
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PLETAL, CILOSTAZOL  
 POLY-PRED, NEOMYCIN SULFATE  
 POLYTRIM, POLYMYXIN B SULFATE  
 PONSTEL, MEFENAMIC ACID  
 POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE



## APPENDIX A - PRODUCT NAME INDEX

A - 29

\*\* P \*\*

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 POVIDONE IODINE, POVIDONE-IODINE (OTC)  
 PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE  
 PRANDIMET, METFORMIN HYDROCHLORIDE  
 PRANDIN, REPAGLINIDE  
 PRAVACHOL, PRAVASTATIN SODIUM  
 PRECEDEX, DEXMEDETOMIDINE  
 PRECOSE, ACARBOSE  
 PRED FORTE, PREDNISOLONE ACETATE  
 PRED MILD, PREDNISOLONE ACETATE  
 PRED-G, GENTAMICIN SULFATE  
 PREFEST, ESTRADIOL  
 PREGNYL, GONADOTROPIN, CHORIONIC  
 PREMARIN, ESTROGENS, CONJUGATED  
 PREMPHASE 14/14, ESTROGENS, CONJUGATED  
 PREMPRO, ESTROGENS, CONJUGATED  
 PRE-OP II, HEXACHLOROPHENE  
 PRE-OP, HEXACHLOROPHENE  
 PREPIDIL, DINOPROSTONE  
 PREVACID 24 HR, LANSOPRAZOLE (OTC)  
 PREVACID, LANSOPRAZOLE  
 PREVPAC, AMOXICILLIN  
 PREZISTA, DARUNAVIR ETHANOLATE  
 PRIALT, ZICONOTIDE  
 PRIFTIN, RIFAPENTINE  
 PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)  
 PRILOSEC, OMEPRAZOLE  
 PRILOSEC, OMEPRAZOLE MAGNESIUM  
 PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE  
 PRIMAQUINE, PRIMAQUINE PHOSPHATE  
 PRIMAXIN, CILASTATIN SODIUM  
 PRINIVIL, LISINAPRIL  
 PRINZIDE, HYDROCHLOROTHIAZIDE  
 PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL B22GK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

A - 30

## \*\* P \*\*

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISTIQ, DESVENLAFAXINE SUCCINATE  
 PROAIR HFA, ALBUTEROL SULFATE  
 PROAMATINE, MIDODRINE HYDROCHLORIDE  
 PROCALAMINE, AMINO ACIDS  
 PROCARDIA XL, NIFEDIPINE  
 PROCARDIA, NIFEDIPINE  
 PROFERDEX, IRON DEXTRAN  
 PROGESTERONE, PROGESTERONE  
 PROGLYCEM, DIAZOXIDE  
 PROGRAF, TACROLIMUS  
 PROHANCE MULTIPACK, GADOTERIDOL  
 PROHANCE, GADOTERIDOL  
 PROMACTA, ELTROMBOPAG OLAMINE  
 PROMETRIUM, PROGESTERONE  
 PROPECIA, FINASTERIDE  
 PROPINE, DIPIVEFRIN HYDROCHLORIDE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 PROPYLTHIOURACIL, PROPYLTHIOURACIL  
 PROQUIN XR, CIPROFLOXACIN HYDROCHLORIDE  
 PROSCAR, FINASTERIDE  
 PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS  
 PROSTIN E2, DINOPROSTONE  
 PROSTIN VR PEDIATRIC, ALPROSTADIL  
 PROTONIX IV, PANTOPRAZOLE SODIUM  
 PROTONIX, PANTOPRAZOLE SODIUM  
 PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE  
 PROTOPIC, TACROLIMUS  
 PROVENTIL-HFA, ALBUTEROL SULFATE  
 PROVERA, MEDROXYPROGESTERONE ACETATE  
 PROVIGIL, MODAFINIL  
 PROVOCHOLINE, METHACHOLINE CHLORIDE  
 PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE  
 PROZAC, FLUOXETINE HYDROCHLORIDE  
 PSORCON, DIFLORASONE DIACETATE  
 PULMICORT FLEXHALER, BUDESONIDE  
 PULMICORT RESPULES, BUDESONIDE  
 PULMICORT, BUDESONIDE  
 PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT  
 PURINETHOL, MERCAPTOPYRIMIDINE  
 PYLERA, BISMUTH SUBCITRATE POTASSIUM  
 PYTEST KIT, UREA, C-14  
 PYTEST, UREA, C-14

## \*\* Q \*\*

QUADRAMET, SAMARIUM SM 153 LEXIDRONAM PENTASODIUM  
 QUALAQUIN, QUININE SULFATE  
 QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE  
 QUELICIN, SUCCINYLCHOLINE CHLORIDE  
 QUESTRAN LIGHT, CHOLESTYRAMINE  
 QUESTRAN, CHOLESTYRAMINE  
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE  
 QUIXIN, LEVOFLOXACIN  
 QUTENZA, CAPSAICIN  
 QVAR 40, BECLOMETHASONE DIPROPIONATE  
 QVAR 80, BECLOMETHASONE DIPROPIONATE

## APPENDIX A - PRODUCT NAME INDEX

A - 31

\*\* R \*\*

RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE (II)  
RANEXA, RANOLAZINE  
RAPAFLO, SILODOSIN  
RAPAMUNE, SIROLIMUS  
RAZADYNE ER, GALANTAMINE HYDROBROMIDE  
RAZADYNE, GALANTAMINE HYDROBROMIDE  
REBETOL, RIBAVIRIN  
RECLAST, ZOLEDRONIC ACID  
REFLUDAN, LEPHRUDIN RECOMBINANT  
REGITINE, PHENTOLAMINE MESYLATE  
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE  
REGONOL, PYRIDOSTIGMINE BROMIDE  
RELENZA, ZANAMIVIR  
RELISTOR, METHYLNALTREXONE BROMIDE  
RELPAX, ELETRIPTAN HYDROBROMIDE  
REMERON SOLTAB, MIRTAZAPINE  
REMERON, MIRTAZAPINE  
REMODULIN, TREPROSTINIL SODIUM  
RENACIDIN, CITRIC ACID  
RENAGEL, SEVELAMER HYDROCHLORIDE  
RENAMIN W/O ELECTROLYTES, AMINO ACIDS  
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE  
RENOVA, TRETINOIN  
RENVELA, SEVELAMER CARBONATE  
REPRONEX, LUTEINIZING HORMONE  
REQUIP XL, ROPINIROLE HYDROCHLORIDE  
REQUIP, ROPINIROLE HYDROCHLORIDE  
RESCRIPTOR, DELAVIRDINE MESYLATE  
RESCULA, UNOPROSTONE ISOPROPYL  
RESECTISOL IN PLASTIC CONTAINER, MANNITOL  
RESERPINE, RESERPINE  
RESTASIS, CYCLOSPORINE  
RESTORIL, TEMAZEPAM  
RETIN-A MICRO, TRETINOIN  
RETIN-A, TRETINOIN  
RETISERT, FLUOCINOLONE ACETONIDE  
RETROVIR, ZIDOVUDINE  
REVATIO, SILDENAFIL CITRATE  
REVIA, NALTREXONE HYDROCHLORIDE  
REVLIMID, LENALIDOMIDE  
REYATAZ, ATAZANAVIR SULFATE  
R-GENE 10, ARGININE HYDROCHLORIDE  
RHINOCORT, BUDESONIDE  
RID MOUSSE, PIPERONYL BUTOXIDE (OTC)  
RIDAURA, AURANOFIN  
RIFADIN, RIFAMPIN  
RIFATER, ISONIAZID  
RILUTEK, RILUZOLE  
RIMACTANE, RIFAMPIN  
RIMSO-50, DIMETHYL SULFOXIDE  
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
RIOMET, METFORMIN HYDROCHLORIDE  
RISPERDAL CONSTA, RISPERIDONE  
RISPERDAL, RISPERIDONE  
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE  
RITALIN, METHYLPHENIDATE HYDROCHLORIDE  
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE  
ROBAXIN, METHOCARBAMOL  
ROBAXIN-750, METHOCARBAMOL  
ROBINUL FORTE, GLYCOPYRROLATE  
ROBINUL, GLYCOPYRROLATE  
ROCALTROL, CALCITRIOL  
ROGAINE (FOR MEN), MINOXIDIL (OTC)

## APPENDIX A - PRODUCT NAME INDEX

A - 32

## \*\* R \*\*

ROGAINE (FOR WOMEN), MINOXIDIL (OTC)  
 ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)  
 ROMAZICON, FLUMAZENIL  
 ROWASA, MESALAMINE  
 ROXICODONE, OXYCODONE HYDROCHLORIDE  
 ROZEREM, RAMELTEON  
 RYTHMOL SR, PROPAFENONE HYDROCHLORIDE  
 RYTHMOL, PROPAFENONE HYDROCHLORIDE  
 RYZOLT, TRAMADOL HYDROCHLORIDE

## \*\* S \*\*

SABRIL, VIGABATRIN  
 SAIZEN, SOMATROPIN RECOMBINANT  
 SALAGEN, PILOCARPINE HYDROCHLORIDE  
 SALONPAS, MENTHOL (OTC)  
 SALURON, HYDROFLUMETHIAZIDE  
 SAMSCA, TOLVAPTAN  
 SANCTURA XR, TROSPIMUM CHLORIDE  
 SANCTURA, TROSPIMUM CHLORIDE  
 SANCUSO, GRANISETRON  
 SANDIMMUNE, CYCLOSPORINE  
 SANDOSTATIN LAR, OCTREOTIDE ACETATE  
 SANDOSTATIN, OCTREOTIDE ACETATE  
 SAPHRIS, ASENAPINE MALEATE  
 SARAFEM, FLUOXETINE HYDROCHLORIDE  
 SAVELLA, MILNACIPRAN HYDROCHLORIDE  
 SCLEROSOL, TALC  
 SEASONALE, ETHINYL ESTRADIOL  
 SEASONIQUE, ETHINYL ESTRADIOL  
 SECTRAL, ACEBUTOLOL HYDROCHLORIDE  
 SELSUN, SELENIUM SULFIDE  
 SELZENTRY, MARAVIROC  
 SEMPREX-D, ACRIVASTINE  
 SENSIPAR, CINACALCET HYDROCHLORIDE  
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE  
 SEPTOCAINE, ARTICAINE HYDROCHLORIDE  
 SEPTRA DS, SULFAMETHOXAZOLE  
 SEPTRA, SULFAMETHOXAZOLE  
 SEREVENT, SALMETEROL XINAFOATE  
 SEROPHENE, CLOMIPHENE CITRATE  
 SEROQUEL XR, QUETIAPINE FUMARATE  
 SEROQUEL, QUETIAPINE FUMARATE  
 SEROSTIM, SOMATROPIN RECOMBINANT  
 SERPALAN, RESERPINE  
 SFROWASA, MESALAMINE  
 SHADE UVAGUARD, AVOBENZONE (OTC)  
 SILVADENE, SILVER SULFADIAZINE  
 SIMCOR, NIACIN  
 SINE-AID IB, IBUPROFEN (OTC)  
 SINEMET CR, CARBIDOPA  
 SINEMET, CARBIDOPA  
 SINGULAIR, MONTELUKAST SODIUM  
 SINOGRAFIN, DIATRIZOATE MEGLUMINE  
 SKELAXIN, METAXALONE  
 SKELID, TILUDRONATE DISODIUM  
 SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS  
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM IODIDE I-123, SODIUM IODIDE, I-123



## APPENDIX A - PRODUCT NAME INDEX

A - 33

\*\* S \*\*

SODIUM IODIDE I 131, SODIUM IODIDE, I-131  
 SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE  
 SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE  
 SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE  
 SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE  
 SOLAGE, MEQUINOL  
 SOLARAZE, DICLOFENAC SODIUM  
 SOLODYN, MINOCYCLINE HYDROCHLORIDE  
 SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE  
 SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE  
 SOMA COMPOUND W/ CODEINE, ASPIRIN  
 SOMA COMPOUND, ASPIRIN  
 SOMA, CARISOPRODOL  
 SOMATULINE DEPOT, LANREOTIDE ACETATE  
 SOMAVERT, PEGVISOMANT  
 SONATA, ZALEPLON  
 SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL  
 SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL  
 SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL  
 SORIATANE, ACITRETIN  
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE  
 SPECTRACEF, CEFDITOREN PIVOXIL  
 SPIRIVA, TIOTROPIUM BROMIDE MONOHYDRATE  
 SPORANOX, ITRACONAZOLE  
 SPRYCEL, DASATINIB  
 SSD AF, SILVER SULFADIAZINE  
 SSD, SILVER SULFADIAZINE  
 STADOL PRESERVATIVE FREE, BUTORPHANOL TARTRATE  
 STADOL, BUTORPHANOL TARTRATE  
 STALEVO 100, CARBIDOPA  
 STALEVO 125, CARBIDOPA  
 STALEVO 150, CARBIDOPA  
 STALEVO 200, CARBIDOPA  
 STALEVO 50, CARBIDOPA  
 STALEVO 75, CARBIDOPA  
 STARLIX, NATEGLINIDE  
 STAVZOR, VALPROIC ACID  
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE  
 STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE  
 STERILE WATER, WATER FOR IRRIGATION, STERILE  
 STIMATE, DESMOPRESSIN ACETATE  
 STRATTERA, ATOMOXETINE HYDROCHLORIDE  
 STRIANT, TESTOSTERONE  
 STROMEKTOL, IVERMECTIN  
 SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE  
 SUBOXONE, BUPRENORPHINE HYDROCHLORIDE  
 SUBUTEX, BUPRENORPHINE HYDROCHLORIDE  
 SUCRAID, SACROSIDASE  
 SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)  
 SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE  
 SULAR, NISOLDIPINE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE  
 SULFAMYLON, MAFENIDE ACETATE  
 SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE  
 SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE  
 SUPPRELIN LA, HISTRELIN ACETATE  
 SUPRANE, DESFLURANE  
 SURMONTIL, TRIMIPRAMINE MALEATE  
 SURVANTA, BERACTANT  
 SUSTIVA, EFAVIRENZ  
 SUTENT, SUNITINIB MALATE  
 SYMBICORT, BUDESONIDE  
 SYMBYAX, FLUOXETINE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

A - 34

\*\* S \*\*

SYMLIN, PRAMLINTIDE ACETATE  
 SYMMETREL, AMANTADINE HYDROCHLORIDE  
 SYNALAR, FLUOCINOLONE ACETONIDE  
 SYNALGOS-DC, ASPIRIN  
 SYNAREL, NAFARELIN ACETATE  
 SYNERA, LIDOCAINE  
 SYNERCID, DALFOPRISTIN  
 SYNTHETIC CONJUGATED ESTROGENS A, ESTROGENS, CONJUGATED SYNTHETIC A  
 SYNTHROID, LEVOTHYROXINE SODIUM  
 SYPRINE, TRIENTINE HYDROCHLORIDE

\*\* T \*\*

TACLONEX SCALP, BETAMETHASONE DIPROPIONATE  
 TACLONEX, BETAMETHASONE DIPROPIONATE  
 TAGAMET HB, CIMETIDINE (OTC)  
 TAGAMET, CIMETIDINE  
 TALACEN, ACETAMINOPHEN  
 TALC, TALC  
 TALWIN NX, NALOXONE HYDROCHLORIDE  
 TALWIN, PENTAZOCINE LACTATE  
 TAMBOCOR, FLECAINIDE ACETATE  
 TAMIFLU, OSELTAMIVIR PHOSPHATE  
 TARCEVA, ERLOTINIB HYDROCHLORIDE  
 TARGRETIN, BEXAROTENE  
 TARKA, TRANDOLAPRIL  
 TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE  
 TASMAR, TOLCAPONE  
 TAVIST ALLERGY/SINUS/HEADACHE, ACETAMINOPHEN (OTC)  
 TAVIST-1, CLEMASTINE FUMARATE (OTC)  
 TAXOL, PACLITAXEL  
 TAXOTERE, DOCETAXEL  
 TAZORAC, TAZAROTENE  
 TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
 TECHNISCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT  
 TECHNISCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT  
 TECHNISCAN, TECHNETIUM TC-99M OXIDRONATE KIT  
 TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT  
 TECHNETIUM TC-99M PENTETATE KIT, TECHNETIUM TC-99M PENTETATE KIT  
 TEGRETOL, CARBAMAZEPINE  
 TEGRETOL-XR, CARBAMAZEPINE  
 TEKTRNA HCT, ALISKIREN HEMIFUMARATE  
 TEKTRNA, ALISKIREN HEMIFUMARATE  
 TEMODAR, TEMOZOLOMIDE  
 TEMOVATE E, CLOBETASOL PROPIONATE  
 TEMOVATE, CLOBETASOL PROPIONATE  
 TENEX, GUANFACINE HYDROCHLORIDE  
 TENORETIC 100, ATENOLOL  
 TENORETIC 50, ATENOLOL  
 TENORMIN, ATENOLOL  
 TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE  
 TENSILON, EDROPHONIUM CHLORIDE  
 TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE  
 TENUATE, DIETHYLPROPION HYDROCHLORIDE  
 TERAZOL 3, TERCONAZOLE  
 TERAZOL 7, TERCONAZOLE  
 TERCONAZOLE, TERCONAZOLE  
 TESSALON, BENZONATATE  
 TESTIM, TESTOSTERONE  
 TEVETEN HCT, EPROSARTAN MESYLATE  
 TEVETEN, EPROSARTAN MESYLATE  
 TEV-TROPIN, SOMATROPIN RECOMBINANT  
 THALITONE, CHLORTHALIDONE  
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201

## APPENDIX A - PRODUCT NAME INDEX

A - 35

\*\* T \*\*

THALOMID, THALIDOMIDE  
 THAM, TROMETHAMINE  
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THERMAZENE, SILVER SULFADIAZINE  
 THIIOGUANINE, THIIOGUANINE  
 THYROGEN, THYROTROPIN ALFA  
 THYROLAR-0.25, LIOETHYRONINE SODIUM  
 THYROLAR-0.5, LIOETHYRONINE SODIUM  
 THYROLAR-1, LIOETHYRONINE SODIUM  
 THYROLAR-2, LIOETHYRONINE SODIUM  
 THYROLAR-3, LIOETHYRONINE SODIUM  
 TIAZAC, DILTIAZEM HYDROCHLORIDE  
 TIGAN, TRIMETHOENZAMIDE HYDROCHLORIDE  
 TIKOSYN, DOFETILIDE  
 TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM  
 TIMENTIN, CLAVULANATE POTASSIUM  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE  
 TIMOPTIC, TIMOLOL MALEATE  
 TIMOPTIC-XE, TIMOLOL MALEATE  
 TINDAMAX, TINIDAZOLE  
 TIOPRONIN, TIOPRONIN  
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 TIS-U-SOL, MAGNESIUM SULFATE  
 TOBI, TOBRAMYCIN  
 TOBRADEX ST, DEXAMETHASONE  
 TOBRADEX, DEXAMETHASONE  
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
 TOBREX, TOBRAMYCIN  
 TODAY, NONOXYNOL-9 (OTC)  
 TOFRANIL-PM, IMIPRAMINE PAMOATE  
 TOLECTIN 600, TOLMETIN SODIUM  
 TOLECTIN DS, TOLMETIN SODIUM  
 TOLECTIN, TOLMETIN SODIUM  
 TOPAMAX, TOPIRAMATE  
 TOPICORT LP, DESOXIMETASONE  
 TOPICORT, DESOXIMETASONE  
 TOPROL-XL, METOPROLOL SUCCINATE  
 TORISEL, TEMSIROLIMUS  
 TOTECT, DEXRAZOXANE HYDROCHLORIDE  
 TOVIAZ, FESOTERODINE FUMARATE  
 TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 TRACLEER, BOSENTAN  
 TRANDATE, LABETALOL HYDROCHLORIDE  
 TRANSDERM SCOP, SCOPOLAMINE  
 TRANXENE, CLORAZEPATE DIPOTASSIUM  
 TRASYLOL, APROTININ  
 TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS  
 TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS  
 TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS  
 TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS  
 TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS

## APPENDIX A - PRODUCT NAME INDEX

A - 36

## \*\* T \*\*

TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS  
 TRAVATAN Z, TRAVOPROST  
 TRAVATAN, TRAVOPROST  
 TREANDA, BENDAMUSTINE HYDROCHLORIDE  
 TRECATOR, ETHIONAMIDE  
 TRELSTAR DEPOT, TRIPTORELIN PAMOATE  
 TRELSTAR LA, TRIPTORELIN PAMOATE  
 TRENTAL, PENTOXIFYLLINE  
 TREXIMET, NAPROXEN SODIUM  
 TRICOR, FENOFIBRATE  
 TRIDIONE, TRIMETHADIONE  
 TRISENCE, TRIAMCINOLONE ACETONIDE  
 TRIGLIDE, FENOFIBRATE  
 TRILEPTAL, OXCARBAZEPINE  
 TRILIPIX, CHOLINE FENOFIBRATE  
 TRI-LUMA, FLUOCINOLONE ACETONIDE  
 TRIMETHOPRIM, TRIMETHOPRIM  
 TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL  
 TRIOSTAT, LIOTHYRONINE SODIUM  
 TRISENOX, ARSENIC TRIOXIDE  
 TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)  
 TRIVARIS, TRIAMCINOLONE ACETONIDE  
 TRIZIVIR, ABACAVIR SULFATE  
 TROBICIN, SPECTINOMYCIN HYDROCHLORIDE  
 TROPHAMINE 10%, AMINO ACIDS  
 TROPHAMINE, AMINO ACIDS  
 TRUSOPT, DORZOLAMIDE HYDROCHLORIDE  
 TRUVADA, EMTRICITABINE  
 TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLYSTIREX  
 TWINJECT 0.15, EPINEPHRINE  
 TWINJECT 0.3, EPINEPHRINE  
 TWYNSTA, AMLODIPINE BESYLATE  
 TYGACIL, TIGECYCLINE  
 TYKERB, LAPATINIB DITOSYLATE  
 TYLENOL (CAPLET), ACETAMINOPHEN (OTC)  
 TYLENOL (GELTAB), ACETAMINOPHEN (OTC)  
 TYVASO, TREPROSTINIL SODIUM  
 TYZEKA, TELBIVUDINE

## \*\* U \*\*

ULESFIA, BENZYL ALCOHOL  
 ULORIC, FEBUXOSTAT  
 ULTANE, SEVOFLURANE  
 ULTIVA, REMIFENTANIL HYDROCHLORIDE  
 ULTRACET, ACETAMINOPHEN  
 ULTRAM ER, TRAMADOL HYDROCHLORIDE  
 ULTRAM, TRAMADOL HYDROCHLORIDE  
 ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT  
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
 ULTRAVATE, HALOBETASOL PROPIONATE  
 ULTRAVIST (PHARMACY BULK), IOPROMIDE  
 ULTRAVIST 150, IOPROMIDE  
 ULTRAVIST 240, IOPROMIDE  
 ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE  
 ULTRAVIST 300, IOPROMIDE  
 ULTRAVIST 370, IOPROMIDE  
 UNASYN, AMPICILLIN SODIUM  
 UNIRETIC, HYDROCHLOROTHIAZIDE  
 UNISOM, DOXYLAMINE SUCCINATE (OTC)  
 UNITHROID, LEVOTHYROXINE SODIUM  
 UNIVASC, MOEXIPRIL HYDROCHLORIDE  
 UREX, METHENAMINE HIPPURATE  
 URISPAS, FLAVOXATE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

A - 37

## \*\* U \*\*

UROCIT-K, POTASSIUM CITRATE  
 UROXATRAL, ALFUZOSIN HYDROCHLORIDE  
 URSO 250, URSODIOL  
 URSO FORTE, URSODIOL  
 UVADEX, METHOXSALEN

## \*\* V \*\*

VAGIFEM, ESTRADIOL  
 VAGISTAT-1, TIOCONAZOLE (OTC)  
 VALCYTE, VALGANCICLOVIR HYDROCHLORIDE  
 VALIUM, DIAZEPAM  
 VALSTAR PRESERVATIVE FREE, VALRUBICIN  
 VALTREX, VALACYCLOVIR HYDROCHLORIDE  
 VALTROPIN, SOMATROPIN RECOMBINANT  
 VALTURNA, ALISKIREN HEMIFUMARATE  
 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE  
 VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 VANDAZOLE, METRONIDAZOLE  
 VANIQA, EFLORNITHINE HYDROCHLORIDE  
 VANOS, FLUOCINONIDE  
 VANTAS, HISTRELIN ACETATE  
 VANTIN, CEFPODOXIME PROXETIL  
 VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE  
 VASERETIC, ENALAPRIL MALEATE  
 VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE  
 VASOCON-A, ANTAZOLINE PHOSPHATE (OTC)  
 VASOTEC, ENALAPRIL MALEATE  
 VECTICAL, CALCITRIOL  
 VELCADE, BORTEZOMIB  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 VENOFER, IRON SUCROSE  
 VENTAVIS, ILOPROST  
 VENTOLIN HFA, ALBUTEROL SULFATE  
 VEPESID, ETOPOSIDE  
 VERAMYST, FLUTICASONE FUROATE  
 VERDESO, DESONIDE  
 VEREGEN, SINECATECHINS  
 VERELAN PM, VERAPAMIL HYDROCHLORIDE  
 VERELAN, VERAPAMIL HYDROCHLORIDE  
 VESANOID, TRETINOIN  
 VESICARE, SOLIFENACIN SUCCINATE  
 VEXOL, RIMEXOLONE  
 VFEND, VORICONAZOLE  
 VIAGRA, SILDENAFIL CITRATE  
 VIBATIV, TELAVANCIN HYDROCHLORIDE  
 VIBRAMYCIN, DOXYCYCLINE  
 VIBRAMYCIN, DOXYCYCLINE CALCIUM  
 VIBRAMYCIN, DOXYCYCLINE HYCLATE  
 VIBRA-TABS, DOXYCYCLINE HYCLATE  
 VICOPROFEN, HYDROCODONE BITARTRATE  
 VIDAZA, AZACITIDINE  
 VIDEX EC, DIDANOSINE  
 VIDEX, DIDANOSINE  
 VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE  
 VIMPAT, LACOSAMIDE  
 VIRACEPT, NELFINAVIR MESYLATE  
 VIRAMUNE, NEVIRAPINE  
 VIRAZOLE, RIBAVIRIN  
 VIREAD, TENOFOVIR DISOPROXIL FUMARATE  
 VIROPTIC, TRIFLURIDINE  
 VISICOL, SODIUM PHOSPHATE, DIBASIC ANHYDROUS  
 VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)  
 VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)

## APPENDIX A - PRODUCT NAME INDEX

A - 38

\*\* V \*\*

VISIONBLUE, TRYPAN BLUE  
 VISIPAQUE 270, IODIXANOL  
 VISIPAQUE 320, IODIXANOL  
 VISTARIL, HYDROXYZINE PAMOATE  
 VISTIDE, CIDOFOVIR  
 VISUDYNE, VERTEPORFIN  
 VITRASE, HYALURONIDASE  
 VITRASERT, GANCICLOVIR  
 VIVELLE, ESTRADIOL  
 VIVELLE-DOT, ESTRADIOL  
 VIVITROL, NALTREXONE  
 VOLTAREN, DICLOFENAC SODIUM  
 VOLTAREN-XR, DICLOFENAC SODIUM  
 VOSOL HC, ACETIC ACID, GLACIAL  
 VOSOL, ACETIC ACID, GLACIAL  
 VOTRIENT, PAZOPANIB HYDROCHLORIDE  
 VUMON, TENIPOSIDE  
 VUSION, MICONAZOLE NITRATE  
 VYTORIN, EZETIMIBE  
 VYVANSE, LISDEXAMFETAMINE DIMESYLATE

\*\* W \*\*

WELCHOL, COLESEVELAM HYDROCHLORIDE  
 WELLBUTRIN SR, BUPROPION HYDROCHLORIDE  
 WELLBUTRIN XL, BUPROPION HYDROCHLORIDE  
 WELLBUTRIN, BUPROPION HYDROCHLORIDE  
 WESTCORT, HYDROCORTISONE VALERATE

\*\* X \*\*

XALATAN, LATANOPROST  
 XANAX XR, ALPRAZOLAM  
 XANAX, ALPRAZOLAM  
 XELODA, CAPECITABINE  
 XENAZINE, TETRABENAZINE  
 XENICAL, ORLISTAT  
 XENON XE 133, XENON XE 133  
 XIBROM, BROMFENAC SODIUM  
 XIFAXAN, RIFAXIMIN  
 XOLEGEL, KETOCONAZOLE  
 XOPENEX HFA, LEVALBUTEROL TARTRATE  
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE  
 XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE DENTAL WITH EPINEPHRINE, EPINEPHRINE  
 XYLOCAINE DENTAL, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE  
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE  
 XYREM, SODIUM OXYBATE  
 XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

\*\* Y \*\*

YASMIN, DROSPIRENONE  
 YAZ, DROSPIRENONE

\*\* Z \*\*

ZADITOR, KETOTIFEN FUMARATE (OTC)  
 ZANAFLEX, TIZANIDINE HYDROCHLORIDE  
 ZANOSAR, STREPTOZOCIN  
 ZANTAC 150, RANITIDINE HYDROCHLORIDE  
 ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)  
 ZANTAC 25, RANITIDINE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

A - 39

\*\* Z \*\*

ZANTAC 300, RANITIDINE HYDROCHLORIDE  
 ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)  
 ZANTAC IN PLASTIC CONTAINER, RANITIDINE HYDROCHLORIDE  
 ZANTAC, RANITIDINE HYDROCHLORIDE  
 ZARONTIN, ETHOSUXIMIDE  
 ZAROXOLYN, METOLAZONE  
 ZAVESCA, MIGLUSTAT  
 ZEBETA, BISOPROLOL FUMARATE  
 ZEGERID OTC, OMEPRAZOLE (OTC)  
 ZEGERID, MAGNESIUM HYDROXIDE  
 ZEGERID, OMEPRAZOLE  
 ZELAPAR, SELEGILINE HYDROCHLORIDE  
 ZEMPLAR, PARICALCITOL  
 ZEMURON, ROCURONIUM BROMIDE  
 ZENPEP, LIPASE  
 ZERIT, STAVUDINE  
 ZESTORETIC, HYDROCHLOROTHIAZIDE  
 ZESTRIL, LISINAPRIL  
 ZETIA, EZETIMIBE  
 ZIAC, BISOPROLOL FUMARATE  
 ZIAGEN, ABACAVIR SULFATE  
 ZIANA, CLINDAMYCIN PHOSPHATE  
 ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM  
 ZINACEF, CEFUROXIME SODIUM  
 ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE  
 ZINECARD, DEXRAZOXANE HYDROCHLORIDE  
 ZIPSOR, DICLOFENAC POTASSIUM  
 ZIRGAN, GANCICLOVIR  
 ZITHROMAX, AZITHROMYCIN  
 ZMAX, AZITHROMYCIN  
 ZOCOR, SIMVASTATIN  
 ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE  
 ZOFRAN ODT, ONDANSETRON  
 ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ZOFRAN, ONDANSETRON HYDROCHLORIDE  
 ZOLADEX, GOSERELIN ACETATE  
 ZOLINZA, VORINOSTAT  
 ZOLOFT, SERTRALINE HYDROCHLORIDE  
 ZOLPIMIST, ZOLPIDEM TARTRATE  
 ZOMETA, ZOLEDRONIC ACID  
 ZOMIG, ZOLMITRIPTAN  
 ZOMIG-ZMT, ZOLMITRIPTAN  
 ZONALON, DOXEPIN HYDROCHLORIDE  
 ZONEGRAN, ZONISAMIDE  
 ZORBTIVE, SOMATROPIN RECOMBINANT  
 ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM  
 ZOSYN, PIPERACILLIN SODIUM  
 ZOVIRAX, ACYCLOVIR  
 ZOVIRAX, ACYCLOVIR SODIUM  
 ZYBAN, BUPROPION HYDROCHLORIDE  
 ZYFLO CR, ZILEUTON  
 ZYFLO, ZILEUTON  
 ZYLET, LOTEPREDNOL ETABONATE  
 ZYLOPRIM, ALLOPURINOL  
 ZYMAR, GATIFLOXACIN  
 ZYPREXA RELPREVV, OLANZAPINE PAMOATE  
 ZYPREXA ZYDIS, OLANZAPINE  
 ZYPREXA, OLANZAPINE  
 ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 ZYRTEC, CETIRIZINE HYDROCHLORIDE  
 ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)  
 ZYVOX, LINEZOLID

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* 3 \*\*****3M**

- \* 3M CO  
PERIDEX, CHLORHEXIDINE GLUCONATE
- \* 3M HEALTH CARE INC  
AVAGARD, ALCOHOL (OTC)  
DURAPREP, IODINE POVACRYLEX (OTC)
- \* 3M PHARMACEUTICALS INC  
PROVENTIL-HFA, ALBUTEROL SULFATE

**ABBOTT**

- \* ABBOTT LABORATORIES  
ADVICOR, LOVASTATIN  
AKINETON, BIPERIDEN HYDROCHLORIDE  
AZMACORT, TRIAMCINOLONE ACETONIDE  
BIAXIN XL, CLARITHROMYCIN  
BIAXIN, CLARITHROMYCIN  
DEPAKOTE ER, DIVALPROEX SODIUM  
DEPAKOTE, DIVALPROEX SODIUM  
KALETRA, LOPINAVIR  
NIASPAN, NIACIN  
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE  
NIMBEX, CISATRACURIUM BESYLATE  
NORVIR, RITONAVIR  
OMNICEF, CEFDINIR  
SIMCOR, NIACIN  
SYNTHROID, LEVOTHYROXINE SODIUM  
TEVETEN HCT, EPROSARTAN MESYLATE  
TEVETEN, EPROSARTAN MESYLATE  
ULTANE, SEVOFLURANE  
ZEMPLAR, PARICALCITOL
- \* ABBOTT LABORATORIES HOSP PRODUCTS DIV  
CALCIJEX, CALCITRIOL
- \* ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV  
BIAXIN, CLARITHROMYCIN  
DEPACON, VALPROATE SODIUM  
DEPAKENE, VALPROIC ACID  
DEPAKOTE, DIVALPROEX SODIUM  
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE  
ENDURON, METHYCLOTHIAZIDE  
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE  
HYTRIN, TERAZOSIN HYDROCHLORIDE  
K-TAB, POTASSIUM CHLORIDE  
MAVIK, TRANDOLAPRIL  
MERIDIA, SIBUTRAMINE HYDROCHLORIDE  
NORVIR, RITONAVIR  
ORETIC, HYDROCHLOROTHIAZIDE  
PCE, ERYTHROMYCIN  
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
TARKA, TRANDOLAPRIL  
TRICOR, FENOFIBRATE  
TRIDIONE, TRIMETHADIONE  
VICOPROFEN, HYDROCODONE BITARTRATE  
ZEMPLAR, PARICALCITOL

**ABBOTT LABS**

- \* ABBOTT ENDOCRINE INC SUB ABBOTT LABORATORIES  
LUPRON DEPOT, LEUPROLIDE ACETATE  
LUPRON DEPOT-3, LEUPROLIDE ACETATE  
LUPRON DEPOT-4, LEUPROLIDE ACETATE  
LUPRON DEPOT-PED, LEUPROLIDE ACETATE  
LUPRON, LEUPROLIDE ACETATE
- \* ABBOTT LABORATORIES  
TRILIPIX, CHOLINE FENOFIBRATE



## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* A \*\*

ABRAXIS BIOSCIENCE

\* ABRAXIS BIOSCIENCE LLC  
ABRAXANE, PACLITAXEL

ABRAXIS PHARM

\* ABRAXIS PHARMACEUTICAL PRODUCTS  
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE  
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
MAGNESIUM SULFATE, MAGNESIUM SULFATE

ACADEMIC PHARMS

\* ACADEMIC PHARMACEUTICALS INC  
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ACORDA

\* ACORDA THERAPEUTICS INC  
ZANAFLEX, TIZANIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH

\* ACTAVIS ELIZABETH LLC  
KADIAN, MORPHINE SULFATE

ACTAVIS MID ATLANTIC

\* ACTAVIS MID ATLANTIC LLC  
ACETAMINOPHEN, ACETAMINOPHEN (OTC)  
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)  
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE

ACTAVIS TOTOWA

\* ACTAVIS TOTOWA LLC  
RIMACTANE, RIFAMPIN

ACTELION

\* ACTELION LTD  
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM  
TRACLEER, BOSENTAN

ACTELION PHARMS LTD

\* ACTELION PHARMACEUTICALS LTD  
VENTAVIS, ILOPROST  
ZAVESCA, MIGLUSTAT

ADOLOR

\* ADOLOR CORP  
ENTEREG, ALVIMOPAN

AGOURON

\* AGOURON PHARMACEUTICALS INC  
VIRACEPT, NELFINAVIR MESYLATE

AKORN

\* AKORN INC  
AK-FLUOR 10%, FLUORESCEIN SODIUM  
AK-FLUOR 25%, FLUORESCEIN SODIUM  
AKTEN, LIDOCAINE HYDROCHLORIDE  
ALFENTA, ALFENTANIL HYDROCHLORIDE  
BAL, DIMERCAPROL  
CAPASTAT SULFATE, CAPREOMYCIN SULFATE  
ENDOSOL EXTRA, CALCIUM CHLORIDE  
IC-GREEN, INDOCYANINE GREEN  
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE  
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE  
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE

AKORN INC

\* AKORN INC  
INAPSINE, DROPERIDOL

AKRIMAX PHARMS

\* AKRIMAX PHARMACEUTICALS LLC  
INDERAL LA, PROPRANOLOL HYDROCHLORIDE  
INDERAL, PROPRANOLOL HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* AKRIMAX PHARMACEUTICALS LLC  
 INDERIDE-40/25, HYDROCHLOROTHIAZIDE  
 LO/OVRAL-28, ETHINYL ESTRADIOL  
 NITROMIST, NITROGLYCERIN

**ALARA PHARM**

\* ALARA PHARMACEUTICAL CORPORATION  
 LEVO-T, LEVOTHYROXINE SODIUM

**ALAVEN PHARM**

\* ALAVEN PHARMACEUTICAL LLC  
 ANADROL-50, OXYMETHOLONE  
 COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350  
 COLYTE, POLYETHYLENE GLYCOL 3350  
 COLYTE-FLAVORED, POLYETHYLENE GLYCOL 3350  
 REGLAN, METOCLOPRAMIDE HYDROCHLORIDE  
 ROWASA, MESALAMINE  
 SFROWASA, MESALAMINE

**ALCON**

\* ALCON INC  
 AZOPT, BRINZOLAMIDE  
 CILOXAN, CIPROFLOXACIN HYDROCHLORIDE  
 CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE  
 CIPRODEX, CIPROFLOXACIN  
 FLUORESCITE, FLUORESCIN SODIUM  
 NAVSTEL, CALCIUM CHLORIDE  
 NEVANAC, NEPAFENAC  
 PATADAY, OLOPATADINE HYDROCHLORIDE  
 PATANASE, OLOPATADINE HYDROCHLORIDE  
 TOBRADEX ST, DEXAMETHASONE  
 TRAVATAN Z, TRAVOPROST  
 TRAVATAN, TRAVOPROST  
 TRISENCE, TRIAMCINOLONE ACETONIDE  
 VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE

\* ALCON LABORATORIES INC  
 ALOMIDE, LODOXAMIDE TROMETHAMINE  
 BETADINE, POVIDONE-IODINE  
 BETOPTIC S, BETAXOLOL HYDROCHLORIDE  
 BETOPTIC, BETAXOLOL HYDROCHLORIDE  
 BSS PLUS, CALCIUM CHLORIDE  
 BSS, CALCIUM CHLORIDE  
 DENDRID, IDOXURIDINE  
 EMADINE, EMEDASTINE DIFUMARATE  
 FLAREX, FLUOROMETHOLONE ACETATE  
 IOPIDINE, APRACLONIDINE HYDROCHLORIDE  
 MAXIDEX, DEXAMETHASONE  
 MIOSTAT, CARBACHOL  
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 NATACYN, NATAMYCIN  
 OMNIPRED, PREDNISOLONE ACETATE  
 PATANOL, OLOPATADINE HYDROCHLORIDE  
 PILOPINE HS, PILOCARPINE HYDROCHLORIDE  
 TOBRADEX, DEXAMETHASONE  
 TOBEX, TOBRAMYCIN  
 VEXOL, RIMEXOLONE

**ALCON RES**

\* ALCON RESEARCH LTD  
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE

**ALKERMES**

\* ALKERMES INC  
 VIVITROL, NALTREXONE

**ALLEGIANCE HLTHCARE**

\* ALLEGIANCE HEALTHCARE CORP  
 POVIDONE IODINE, POVIDONE-IODINE (OTC)

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 810 of 1114**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****ALLERGAN**

- \* ALLERGAN
  - ACULAR LS, KETOROLAC TROMETHAMINE
  - ALPHAGAN P, BRIMONIDINE TARTRATE
- \* ALLERGAN INC
  - ACULAR PRESERVATIVE FREE, KETOROLAC TROMETHAMINE
  - ACULAR, KETOROLAC TROMETHAMINE
  - ACUVAIL, KETOROLAC TROMETHAMINE
  - ACZONE, DAPSONE
  - ALOCRIIL, NEDOCROMIL SODIUM
  - ALPHAGAN P, BRIMONIDINE TARTRATE
  - AVAGE, TAZAROTENE
  - AZELEX, AZELAIC ACID
  - COMBIGAN, BRIMONIDINE TARTRATE
  - ELESTAT, EPINASTINE HYDROCHLORIDE
  - ELIMITE, PERMETHRIN
  - LATISSE, BIMATOPROST
  - LUMIGAN, BIMATOPROST
  - OCUFLOX, OFLOXACIN
  - OPTICROM, CROMOLYN SODIUM
  - OZURDEX, DEXAMETHASONE
  - POLYTRIM, POLYMYXIN B SULFATE
  - RESTASIS, CYCLOSPORINE
  - SANCTURA XR, TROSPIMUM CHLORIDE
  - SANCTURA, TROSPIMUM CHLORIDE
  - TAZORAC, TAZAROTENE
  - TRIVARIS, TRIAMCINOLONE ACETONIDE
  - ZYMAR, GATIFLOXACIN
- \* ALLERGAN PHARMACEUTICAL
  - BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
  - BLEPHAMIDE, PREDNISOLONE ACETATE
  - FML FORTE, FLUOROMETHOLONE
  - FML, FLUOROMETHOLONE
  - HERPLEX, IDOXURIDINE
  - OCUFEN, FLURBIPROFEN SODIUM
  - OPHTHETIC, PROPARACAINE HYDROCHLORIDE
  - POLY-PRED, NEOMYCIN SULFATE
  - PRED FORTE, PREDNISOLONE ACETATE
  - PRED MILD, PREDNISOLONE ACETATE
  - PRED-G, GENTAMICIN SULFATE
  - PROPINE, DIPIVEFRIN HYDROCHLORIDE

**ALLERGAN HERBERT**

- \* ALLERGAN HERBERT SKIN CARE DIV ALLERGAN INC
  - FLUOROPLEX, FLUOROURACIL

**ALLOS**

- \* ALLOS THERAPEUTICS INC
  - FOLOTYN, PRALATREXATE

**ALPHARMA KING**

- \* ALPHARMA PHARMACEUTICALS LLC KING PHARMACEUTICALS
  - EMBEDA, MORPHINE SULFATE

**ALTANA**

- \* ALTANA INC
  - CUTIVATE, FLUTICASONE PROPIONATE
  - OXISTAT, OXICONAZOLE NITRATE
  - TEMOVATE E, CLOBETASOL PROPIONATE
  - TEMOVATE, CLOBETASOL PROPIONATE
  - TERCONAZOLE, TERCONAZOLE

**ALTERNA TCHP LLC**

- \* ALTERNA TCHP LLC
  - CHILDREN'S ELIXSURE, IBUPROFEN (OTC)

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****ALZA**

\* ALZA CORP  
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

**AMAG PHARMS INC**

\* AMAG PHARMACEUTICALS INC  
FERAHEME, FERUMOXYTOL  
FERIDEX I.V., FERUMOXIDES  
GASTROMARK, FERUMOXSIL

**AMGEN**

\* AMGEN INC  
SENSIPAR, CINACALCET HYDROCHLORIDE

**AMPHASTAR**

\* AMPHASTAR PHARMACEUTICALS INC  
CORTROSYN, COSYNTROPIN

**AMPHASTAR PHARM**

\* AMPHASTAR PHARMACEUTICAL INC  
AMPHADASE, HYALURONIDASE

**AMYLIN**

\* AMYLIN PHARMACEUTICALS INC  
BYETTA, EXENATIDE SYNTHETIC  
SYMLIN, PRAMLINTIDE ACETATE

**ANBEX**

\* ANBEX INC  
IOSAT, POTASSIUM IODIDE (OTC)

**ANDRX LABS LLC**

\* ANDRX LABS LLC  
ALTOPREV, LOVASTATIN  
FORTAMET, METFORMIN HYDROCHLORIDE

**ANESTA AG**

\* ANESTA AG  
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE

**ANI PHARMS**

\* ANI PHARMACEUTICALS INC  
CORTENEMA, HYDROCORTISONE

**APOTHECON**

\* APOTHECON INC DIV BRISTOL MYERS SQUIBB  
CAPOZIDE 25/15, CAPTOPRIL  
CAPOZIDE 25/25, CAPTOPRIL  
CAPOZIDE 50/15, CAPTOPRIL  
CAPOZIDE 50/25, CAPTOPRIL  
KENALOG, TRIAMCINOLONE ACETONIDE  
KENALOG-10, TRIAMCINOLONE ACETONIDE  
KENALOG-40, TRIAMCINOLONE ACETONIDE  
KLOTRIX, POTASSIUM CHLORIDE  
OPHTHAINE, PROPARACAINE HYDROCHLORIDE  
STADOL PRESERVATIVE FREE, BUTORPHANOL TARTRATE  
STADOL, BUTORPHANOL TARTRATE

**APP PHARMS**

\* APP PHARMACEUTICALS LLC  
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC  
DIPRIVAN, PROPOFOL  
EMLA, LIDOCAINE  
FUROSEMIDE, FUROSEMIDE  
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM  
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
HEPARIN SODIUM, HEPARIN SODIUM  
NAROPIN, ROPIVACAINE HYDROCHLORIDE MONOHYDRATE  
NEBUPENT, PENTAMIDINE ISETHIONATE  
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* APP PHARMACEUTICALS LLC  
 NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE  
 OXYTOCIN, OXYTOCIN  
 PENTAM, PENTAMIDINE ISETHIONATE  
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE  
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
 XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE  
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE

**AR HOLDING CO INC**

\* AR HOLDING CO INC  
 COLCRYS, COLCHICINE  
 FIBRICOR, FENOFIBRIC ACID  
 QUALAQUIN, QUININE SULFATE

**ASCEND**

\* ASCEND THERAPEUTICS INC  
 ESTROGEL, ESTRADIOL

**ASTELLAS**

\* ASTELLAS PHARMA US INC  
 ADENOCARD, ADENOSINE  
 ADENOSCAN, ADENOSINE  
 AMBISOME, AMPHOTERICIN B  
 LEXISCAN, REGADENOSON  
 MYCAMINE, MICAFUNGIN SODIUM  
 PROGRAF, TACROLIMUS  
 PROTOPIC, TACROLIMUS  
 VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE  
 VESICARE, SOLIFENACIN SUCCINATE

**ASTRAZENECA**

\* ASTRAZENECA LP  
 ENTOCORT EC, BUDESONIDE  
 FOSCAVIR, FOSCARNET SODIUM  
 NEXIUM IV, ESOMEPRAZOLE SODIUM  
 NEXIUM, ESOMEPRAZOLE MAGNESIUM  
 PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)  
 PRILOSEC, OMEPRAZOLE  
 PRILOSEC, OMEPRAZOLE MAGNESIUM  
 PULMICORT FLEXHALER, BUDESONIDE  
 PULMICORT RESPULES, BUDESONIDE  
 RHINOCORT, BUDESONIDE  
 SEROQUEL, QUETIAPINE FUMARATE  
 SYMBICORT, BUDESONIDE  
 TENORMIN, ATENOLOL  
 TOPROL-XL, METOPROLOL SUCCINATE

\* ASTRAZENECA PHARMACEUTICALS LP  
 ATACAND HCT, CANDESARTAN CILEXETIL  
 ATACAND, CANDESARTAN CILEXETIL  
 FASLODEX, FULVESTRANT  
 LEXXEL, ENALAPRIL MALEATE  
 PULMICORT, BUDESONIDE  
 SEROQUEL XR, QUETIAPINE FUMARATE  
 TENORETIC 100, ATENOLOL  
 TENORETIC 50, ATENOLOL  
 ZOMIG, ZOLMITRIPTAN  
 ZOMIG-ZMT, ZOLMITRIPTAN

\* ASTRAZENECA UK LTD  
 ACCOLATE, ZAFIRLUKAST  
 ARIMIDEX, ANASTROZOLE  
 CASODEX, BICALUTAMIDE  
 IRESSA, GEFITINIB  
 MERREM I.V., MEROPENEM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ASTRAZENECA UK LTD  
 ZESTORETIC, HYDROCHLOROTHIAZIDE  
 ZESTRIL, LISINOPRIL  
 ZOLADEX, GOSERELIN ACETATE

**ATON**

\* ATON PHARMA INC  
 CUPRIMINE, PENICILLAMINE  
 DEMSER, METYROSINE  
 EDECRIN, ETHACRYNATE SODIUM  
 EDECRIN, ETHACRYNIC ACID  
 LACRISERT, HYDROXYPROPYL CELLULOSE  
 MEPHYTON, PHYTONADIONE  
 SYPRINE, TRIENTINE HYDROCHLORIDE  
 TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE  
 TIMOPTIC, TIMOLOL MALEATE  
 TIMOPTIC-XE, TIMOLOL MALEATE

**AUXILIUM PHARMS**

\* AUXILIUM PHARMACEUTICALS  
 TESTIM, TESTOSTERONE

**AXCAN**

\* AXCAN PHARMA US INC  
 BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE  
 BENTYL, DICYCLOMINE HYDROCHLORIDE  
 CARAFATE, SUCRALFATE  
 PHOTOFRIN, PORFIMER SODIUM  
 URSO 250, URSODIOL  
 URSO FORTE, URSODIOL

**AXCAN SCANDIPHARM**

\* AXCAN SCANDIPHARM INC  
 CANASA, MESALAMINE  
 PYLERA, BISMUTH SUBCITRATE POTASSIUM

**AZUR PHARMA**

\* AZUR PHARMA INTERNATIONAL LTD  
 AVC, SULFANILAMIDE  
 GASTROCROM, CROMOLYN SODIUM

**AZUR PHARMA II**

\* AZUR PHARMA INTERNATIONAL II LTD  
 ELESTRIN, ESTRADIOL

**AZUR PHARMA INTL**

\* AZUR PHARMA INTERNATIONAL III LTD  
 FAZACLO ODT, CLOZAPINE

**B BRAUN**

\* B BRAUN MEDICAL INC  
 ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL  
 ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL  
 ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL  
 BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE  
 CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM  
 CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM  
 CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* B \*\*

\* B BRAUN MEDICAL INC  
 DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE  
 FREAMINE HBC 6.9%, AMINO ACIDS  
 FREAMINE III 10%, AMINO ACIDS  
 FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS  
 FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS  
 FREAMINE III 8.5%, AMINO ACIDS  
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE  
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPATAMINE 8%, AMINO ACIDS  
 ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 HYDROCHLORIDE  
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL  
 MANNITOL 10%, MANNITOL  
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL  
 MANNITOL 15%, MANNITOL  
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 20%, MANNITOL  
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL  
 MANNITOL 5%, MANNITOL  
 METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE  
 NEPHRAMINE 5.4%, AMINO ACIDS  
 NUTRILIPID 10%, SOYBEAN OIL  
 NUTRILIPID 20%, SOYBEAN OIL  
 PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
 CONTAINER, DEXTROSE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

\* B BRAUN MEDICAL INC  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

\* B BRAUN MEDICAL INC  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 PROCALAMINE, AMINO ACIDS  
 RESECTISOL IN PLASTIC CONTAINER, MANNITOL  
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE  
 SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL  
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE  
 STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE  
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 TROPHAMINE 10%, AMINO ACIDS  
 TROPHAMINE, AMINO ACIDS

**BALLARD MEDCL**

\* BALLARD MEDICAL PRODUCTS INC  
 PYTEST KIT, UREA, C-14  
 PYTEST, UREA, C-14

**BANNER PHARMACAPS**

\* BANNER PHARMACAPS INC  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 MIDOL LIQUID GELS, IBUPROFEN (OTC)  
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)  
 STAVZOR, VALPROIC ACID

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\*****BAUSCH AND LOMB**

- \* BAUSCH AND LOMB INC
  - ALAWAY, KETOTIFEN FUMARATE (OTC)
  - ALREX, LOTEPIREDNOL ETABONATE
  - BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
  - LOTEMAX, LOTEPIREDNOL ETABONATE
  - OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
  - RETISERT, FLUOCINOLONE ACETONIDE
  - VITRASERT, GANCICLOVIR
  - ZYLET, LOTEPIREDNOL ETABONATE
- \* BAUSCH AND LOMB PHARMACEUTICALS INC
  - OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE

**BAXTER HLTHCARE**

- \* BAXTER HEALTHCARE CORP
  - ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
  - AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
  - BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
  - BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
  - CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
  - CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
  - CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
  - DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
  - DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
  - DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
  - DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
  - DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
  - DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
  - DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
  - DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
  - DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
  - DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* B \*\*

\* BAXTER HEALTHCARE CORP  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,  
 DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,  
 DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,  
 DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,  
 DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,  
 DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,  
 DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC  
 CONTAINER, DEXTROSE  
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE  
 DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE  
 EXTRANEAL, ICODEXTRIN  
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE  
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPATASOL 8%, AMINO ACIDS  
 IFEX/MESNEX KIT, IFOSFAMIDE  
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 HYDROCHLORIDE  
 LYOPHILIZED CYTOXAN, CYCLOPHOSPHAMIDE  
 MESNEX, MESNA  
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* B \*\*

\* BAXTER HEALTHCARE CORP  
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN  
 ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER, ONDANSETRON  
 HYDROCHLORIDE  
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 10% IN WATER, MANNITOL  
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 15% IN WATER, MANNITOL  
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 20% IN WATER, MANNITOL  
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 5% IN WATER, MANNITOL  
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM  
 PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE  
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM  
 CHLORIDE  
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 CALCIUM CHLORIDE  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 CALCIUM CHLORIDE  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 CALCIUM CHLORIDE  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 CALCIUM CHLORIDE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 CALCIUM CHLORIDE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 CALCIUM CHLORIDE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 DEXTROSE  
 RENAMIN W/O ELECTROLYTES, AMINO ACIDS  
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 820 of 1114**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

- \* BAXTER HEALTHCARE CORP
  - SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
  - SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
  - SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
  - STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
  - STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
  - STERILE WATER, WATER FOR IRRIGATION, STERILE
  - THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
  - TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
  - TIS-U-SOL, MAGNESIUM SULFATE
  - TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
  - TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
  - TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
  - TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
  - TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
  - TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
  - TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
  - TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
  - TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
  - TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
  - TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
  - TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
  - VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
- \* BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
  - DOPRAM, DOXAPRAM HYDROCHLORIDE
  - DURAMORPH PF, MORPHINE SULFATE
  - FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
  - HEPARIN SODIUM, HEPARIN SODIUM
  - INFUMORPH, MORPHINE SULFATE
  - ROBINUL, GLYCOPYRROLATE
- \* BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV
  - PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

**BAXTER HLTHCARE CORP**

- \* BAXTER HEALTHCARE CORP ANESTHESIA CRITICAL CARE
  - ATIVAN, LORAZEPAM
  - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
  - BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
  - BREVIBLOC, ESMOLOL HYDROCHLORIDE
  - ETHRANE, ENFLURANE
  - FORANE, ISOFLURANE
  - OXYTOCIN, OXYTOCIN
  - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
  - PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
  - REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
  - ROBAXIN, METHOCARBAMOL
  - SUPRANE, DESFLURANE

**BAYER**

- \* BAYER HEALTHCARE LLC
  - ALEVE, NAPROXEN SODIUM (OTC)
  - ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
  - FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)

**BAYER HLTHCARE**

- \* BAYER HEALTHCARE PHARMACEUTICALS INC
  - ADALAT CC, NIFEDIPINE
  - ANGELIQ, DROSPIRENONE
  - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
  - AVELOX, MOXIFLOXACIN HYDROCHLORIDE
  - BETAPACE AF, SOTALOL HYDROCHLORIDE
  - BETAPACE, SOTALOL HYDROCHLORIDE
  - BILTRICIDE, PRAZIQUANTEL
  - CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
  - CIPRO XR, CIPROFLOXACIN
  - CIPRO, CIPROFLOXACIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

\* BAYER HEALTHCARE PHARMACEUTICALS INC  
 CIPRO, CIPROFLOXACIN HYDROCHLORIDE  
 CLIMARA PRO, ESTRADIOL  
 CLIMARA, ESTRADIOL  
 DTIC-DOME, DACARBAZINE  
 EOVIIST, GADOXETATE DISODIUM  
 LEVITRA, VARDENAFIL HYDROCHLORIDE  
 MAGNEVIST, GADOPENTETATE DIMEGLUMINE  
 MENOSTAR, ESTRADIOL  
 MIRENA, LEVONORGESTREL  
 MYCELEX, CLOTRIMAZOLE  
 NEXAVAR, SORAFENIB TOSYLATE  
 PRECOSE, ACARBOSE  
 REFLUDAN, LEPYRUDIN RECOMBINANT  
 TRASYLOL, APROTININ  
 ULTRAVIST (PHARMACY BULK), IOPROMIDE  
 ULTRAVIST 150, IOPROMIDE  
 ULTRAVIST 240, IOPROMIDE  
 ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE  
 ULTRAVIST 300, IOPROMIDE  
 ULTRAVIST 370, IOPROMIDE  
 YASMIN, DROSPIRENONE  
 YAZ, DROSPIRENONE

**BAYER PHARMS**

\* BAYER PHARMACEUTICALS CORP  
 MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)  
 MYCELEX-7, CLOTRIMAZOLE (OTC)

**BEAUFOR IPSEN**

\* BEAUFOR IPSEN PHARMA  
 SOMATULINE DEPOT, LANREOTIDE ACETATE

**BECTON DICKINSON**

\* BECTON DICKINSON AND CO  
 E-Z SCRUB 201, POVIDONE-IODINE (OTC)  
 E-Z SCRUB 241, POVIDONE-IODINE (OTC)

**BEDFORD**

\* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC  
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

**BIOMARIN PHARM**

\* BIOMARIN PHARMACEUTICAL INC  
 KUVAN, SAPROPTERIN DIHYDROCHLORIDE

**BIONICHE PHARMA**

\* BIONICHE PHARMA USA LLC  
 ALOPRIM, ALLOPURINOL SODIUM  
 ENLON-PLUS, ATROPINE SULFATE  
 RIMSO-50, DIMETHYL SULFOXIDE

**BIONICHE TEORANTA**

\* BIONICHE TEORANTA  
 ULTIVA, REMIFENTANIL HYDROCHLORIDE

**BIOVAIL**

\* BIOVAIL CORP INTERNATIONAL  
 TIAZAC, DILTIAZEM HYDROCHLORIDE  
 \* BIOVAIL LABORATORIES INC  
 ATIVAN, LORAZEPAM  
 CARDIZEM CD, DILTIAZEM HYDROCHLORIDE  
 ISORDIL, ISOSORBIDE DINITRATE

**BIOVAIL AMERICAS**

\* BIOVAIL AMERICAS CORP  
 XENAZINE, TETRABENAZINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\*****BIOVAIL LABS INTL**

\* BIOVAIL LABORATORIES INTERNATIONAL SRL  
 APLENZIN, BUPROPION HYDROBROMIDE  
 CARDIZEM LA, DILTIAZEM HYDROCHLORIDE  
 CARDIZEM, DILTIAZEM HYDROCHLORIDE  
 ULTRAM ER, TRAMADOL HYDROCHLORIDE  
 VASERETIC, ENALAPRIL MALEATE  
 VASOTEC, ENALAPRIL MALEATE  
 WELLBUTRIN XL, BUPROPION HYDROCHLORIDE

**BLAIREX**

\* BLAIREX LABORATORIES INC  
 BRONCHO SALINE, SODIUM CHLORIDE (OTC)

**BOEHRINGER INGELHEIM**

\* BOEHRINGER INGELHEIM  
 CATAPRES, CLONIDINE HYDROCHLORIDE  
 CATAPRES-TTS-1, CLONIDINE  
 CATAPRES-TTS-2, CLONIDINE  
 CATAPRES-TTS-3, CLONIDINE  
 MICARDIS HCT, HYDROCHLOROTHIAZIDE  
 MICARDIS, TELMISARTAN  
 MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE  
 ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)  
 ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)

\* BOEHRINGER INGELHEIM PHARMACEUTICALS INC  
 AGGRENOX, ASPIRIN  
 APTIVUS, TIPRANAVIR  
 ATROVENT HFA, IPRATROPIUM BROMIDE  
 ATROVENT, IPRATROPIUM BROMIDE  
 COMBIVENT, ALBUTEROL SULFATE  
 FLOMAX, TAMSULOSIN HYDROCHLORIDE  
 MOBIC, MELOXICAM  
 PERSANTINE, DIPYRIDAMOLE  
 SPIRIVA, TIOTROPIUM BROMIDE MONOHYDRATE  
 TWYNSTA, AMLODIPINE BESYLATE  
 VIRAMUNE, NEVIRAPINE

**BRACCO**

\* BRACCO DIAGNOSTICS INC  
 CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82  
 CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT  
 CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE  
 CHROMITOPE SODIUM, SODIUM CHROMATE CR-51  
 CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE  
 CYSTOGRAFIN, DIATRIZOATE MEGLUMINE  
 GASTROGRAFIN, DIATRIZOATE MEGLUMINE  
 ISOVUE-200, IOPAMIDOL  
 ISOVUE-250, IOPAMIDOL  
 ISOVUE-300, IOPAMIDOL  
 ISOVUE-370, IOPAMIDOL  
 ISOVUE-M 200, IOPAMIDOL  
 ISOVUE-M 300, IOPAMIDOL  
 KINEVAC, SINCALIDE  
 MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT  
 MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE  
 MULTIHANCE, GADOBENATE DIMEGLUMINE  
 PROHANCE MULTIPACK, GADOTERIDOL  
 PROHANCE, GADOTERIDOL  
 RENOGRAFIN-76, DIATRIZOATE MEGLUMINE  
 SINOGRAFIN, DIATRIZOATE MEGLUMINE

**BRAINTREE**

\* BRAINTREE LABORATORIES INC  
 AXID, NIZATIDINE  
 GOLYTELY, POLYETHYLENE GLYCOL 3350

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 823 of 1114**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

- \* BRAINTREE LABORATORIES INC  
HALFLYTELY, BISACODYL  
NULYTELY, POLYETHYLENE GLYCOL 3350  
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

**BRISTOL**

- \* BRISTOL LABORATORIES INC DIV BRISTOL MYERS CO  
BICNU, CARMUSTINE

**BRISTOL MYERS**

- \* BRISTOL MYERS CO  
PLATINOL, CISPLATIN  
PLATINOL-AQ, CISPLATIN  
QUESTRAN LIGHT, CHOLESTYRAMINE  
QUESTRAN, CHOLESTYRAMINE

**BRISTOL MYERS SQUIBB**

- \* BRISTOL MYERS SQUIBB  
AZACTAM, AZTREONAM  
BARACLUDE, ENTECAVIR  
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
GLUCOVANCE, GLYBURIDE  
LYSODREN, MITOTANE  
MEGACE, MEGESTROL ACETATE  
PRAVACHOL, PRAVASTATIN SODIUM
- \* BRISTOL MYERS SQUIBB CO  
AZACTAM IN PLASTIC CONTAINER, AZTREONAM  
CEENU, LOMUSTINE  
DROXIA, HYDROXYUREA  
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE  
HYDREA, HYDROXYUREA  
IXEMPRA KIT, IXABEPILONE  
METAGLIP, GLIPIZIDE  
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE  
PARAPLATIN, CARBOPLATIN  
REYATAZ, ATAZANAVIR SULFATE  
SPRYCEL, DASATINIB  
SUSTIVA, EFAVIRENZ  
VEPESID, ETOPOSIDE  
VIDEX EC, DIDANOSINE
- \* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE  
BLENOXANE, BLEOMYCIN SULFATE  
BUSPAR, BUSPIRONE HYDROCHLORIDE  
CEFZIL, CEFPROZIL  
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE  
GLUCOPHAGE, METFORMIN HYDROCHLORIDE  
MAXIPIME, CEFEPIME HYDROCHLORIDE  
MONOPRIL, FOSINOPRIL SODIUM  
TAXOL, PACLITAXEL  
VIDEX, DIDANOSINE  
VUMON, TENIPOSIDE  
ZERIT, STAVUDINE
- \* BRISTOL MYERS SQUIBB PHARMA CO  
COUMADIN, WARFARIN SODIUM  
LODOSYN, CARBIDOPA  
SINEMET CR, CARBIDOPA  
SINEMET, CARBIDOPA  
SUSTIVA, EFAVIRENZ

**BRYAN**

- \* BRYAN CORP  
SCLEROSOL, TALC  
TALC, TALC



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* C \*\*****CANYON**

\* CANYON PHARMACEUTICALS INC  
IPRIVASK, DESIRUDIN RECOMBINANT

**CARACO**

\* CARACO PHARMACEUTICAL LABORATORIES LTD  
FLUMADINE, RIMANTADINE HYDROCHLORIDE  
SYNALGOS-DC, ASPIRIN

**CELGENE**

\* CELGENE CORP  
INNOHEP, TINZAPARIN SODIUM  
REVLIMID, LENALIDOMIDE  
THALOMID, THALIDOMIDE  
VIDAZA, AZACITIDINE

**CENTOCOR ORTHO**

\* CENTOCOR ORTHO BIOTECH INC  
PREZISTA, DARUNAVIR ETHANOLATE

**CEPHALON**

\* CEPHALON INC  
ACTIQ, FENTANYL CITRATE  
FENTORA, FENTANYL CITRATE  
GABITRIL, TIAGABINE HYDROCHLORIDE  
NUVIGIL, ARMODAFINIL  
PROVIGIL, MODAFINIL  
TREANDA, BENDAMUSTINE HYDROCHLORIDE  
TRISENOX, ARSENIC TRIOXIDE

**CHATTEM**

\* CHATTEM INC  
SELSUN, SELENIUM SULFIDE  
UNISOM, DOXYLAMINE SUCCINATE (OTC)

**CHIRHOCLIN**

\* CHIRHOCLIN INC  
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

**CIPHER PHARMS INC**

\* CIPHER PHARMACEUTICALS INC  
LIPOFEN, FENOFIBRATE

**COLGATE PALMOLIVE**

\* COLGATE PALMOLIVE  
COLGATE TOTAL, SODIUM FLUORIDE (OTC)

**COLUMBIA LABS**

\* COLUMBIA LABORATORIES INC  
CRINONE, PROGESTERONE  
STRIANT, TESTOSTERONE

**CONNECTICS**

\* CONNECTICS CORP  
LUXIQ, BETAMETHASONE VALERATE

**CONNETICS**

\* CONNETICS CORP  
OLUX, CLOBETASOL PROPIONATE

**CONTROLLED THERAP**

\* CONTROLLED THERAPEUTICS (SCOTLAND) LTD  
CERVIDIL, DINOPROSTONE

**CORNERSTONE**

\* CORNERSTONE BIOPHARMA INC  
SPECTRACEF, CEFDITOREN PIVOXIL

**CORNERSTONE THERAP**

\* CORNERSTONE THERAPEUTICS INC  
CUROSURF, PORACTANT ALFA

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* C \*\*****CP PHARMS**

\* CP PHARMACEUTICALS CV  
LYRICA, PREGABALIN

**CPPI CV**

\* CP PHARMACEUTICALS INTERNATIONAL CV  
SUTENT, SUNITINIB MALATE

**CRITICAL**

\* CRITICAL THERAPEUTICS INC  
ZYFLO CR, ZILEUTON  
ZYFLO, ZILEUTON

**CSL BEHRING**

\* CSL BEHRING LLC  
STIMATE, DESMOPRESSIN ACETATE

**CUBIST**

\* CUBIST PHARMACEUTICALS INC  
CUBICIN, DAPTOMYCIN

**CUMBERLAND PHARMS**

\* CUMBERLAND PHARMACEUTICALS INC  
ACETADOTE, ACETYLCYSTEINE  
CALDOLOR, IBUPROFEN

**CYPRESS BIOSCIENCE**

\* CYPRESS BIOSCIENCE INC  
SAVELLA, MILNACIPRAN HYDROCHLORIDE

**DAIICHI**

\* DAIICHI PHARMACEUTICAL CORP  
FLOXIN OTIC, OFLOXACIN

**DAIICHI SANKYO**

\* DAIICHI SANKYO INC  
AZOR, AMLODIPINE BESYLATE  
BENICAR HCT, HYDROCHLOROTHIAZIDE  
BENICAR, OLMESARTAN MEDOXOMIL  
WELCHOL, COLESEVELAM HYDROCHLORIDE

**DAIICHI SANKYO CO**

\* DAIICHI SANKYO CO LTD  
EVOXAC, CEVIMELINE HYDROCHLORIDE

**DANCO LABS LLC**

\* DANCO LABORATORIES LLC  
MIFEPREX, MIFEPRISTONE

**DAVA PHARMS INC**

\* DAVA PHARMACEUTICALS INC  
FUROSEMIDE, FUROSEMIDE  
METHOTREXATE SODIUM, METHOTREXATE SODIUM  
PROPYLTHIOURACIL, PROPYLTHIOURACIL

**DAVIS AND GECK**

\* DAVIS AND GECK DIV AMERICAN CYANAMID CO  
PRE-OP II, HEXACHLOROPHENE  
PRE-OP, HEXACHLOROPHENE

**DENTSPLY PHARM**

\* DENTSPLY PHARMACEUTICAL  
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE  
CITANEST PLAIN DENTAL, PRILOCAINE HYDROCHLORIDE  
ORAQIX, LIDOCAINE  
XYLOCAINE DENTAL WITH EPINEPHRINE, EPINEPHRINE  
XYLOCAINE DENTAL, LIDOCAINE HYDROCHLORIDE

**DEPOMED INC**

\* DEPOMED INC  
GLUMETZA, METFORMIN HYDROCHLORIDE  
PROQUIN XR, CIPROFLOXACIN HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* D \*\*****DEPROCO**

\* DEPROCO INC  
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

**DEXCEL PHARMA**

\* DEXCEL PHARMA TECHNOLOGIES LTD  
OMEPRAZOLE, OMEPRAZOLE (OTC)  
PERIOCHIP, CHLORHEXIDINE GLUCONATE

**DEY**

\* DEY LP  
ACCUNEB, ALBUTEROL SULFATE  
DUONEB, ALBUTEROL SULFATE

**DEY LP**

\* DEY LP  
PERFOROMIST, FORMOTEROL FUMARATE

**DIALYSIS SUPS**

\* DIALYSIS SUPPLIES INC  
NORMOCARB HF 25, MAGNESIUM CHLORIDE  
NORMOCARB HF 35, MAGNESIUM CHLORIDE

**DORC**

\* DORC INTERNATIONAL BV  
MEMBRANEBLUE, TRYPAN BLUE  
VISIONBLUE, TRYPAN BLUE

**DOW PHARM SCI**

\* DOW PHARMACEUTICAL SCIENCES  
ACANYA, BENZOYL PEROXIDE

**DOW PHARM SCIENCES**

\* DOW PHARMACEUTICAL SCIENCES INC  
AKNE-MYCIN, ERYTHROMYCIN  
ATRALIN, TRETINOIN  
CLODERM, CLOCORTOLONE PIVALATE

**DR REDDYS LA**

\* DR REDDYS LABORATORIES LOUISIANA LLC  
SSD AF, SILVER SULFADIAZINE  
SSD, SILVER SULFADIAZINE

**DRAXIMAGE**

\* DRAXIMAGE INC  
DRAXIMAGE MDP-10, TECHNETIUM TC-99M MEDRONATE KIT  
DTPA, TECHNETIUM TC-99M PENTETATE KIT  
HICON, SODIUM IODIDE, I-131  
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

**DURAMED**

\* DURAMED PHARMACEUTICALS INC  
CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A  
ENJUVA, ESTROGENS, CONJUGATED SYNTHETIC B  
LOSEASONIQUE, ETHINYL ESTRADIOL  
MIRCETTE, DESOGESTREL  
NORDETTE-28, ETHINYL ESTRADIOL  
PLAN B ONE-STEP, LEVONORGESTREL  
PLAN B ONE-STEP, LEVONORGESTREL (OTC)  
PLAN B, LEVONORGESTREL  
PLAN B, LEVONORGESTREL (OTC)  
REVIA, NALTREXONE HYDROCHLORIDE

**DURAMED PHARMS BARR**

\* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC  
DIAMOX, ACETAZOLAMIDE  
DIAMOX, ACETAZOLAMIDE SODIUM  
ZEBETA, BISOPROLOL FUMARATE  
ZIAC, BISOPROLOL FUMARATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* D \*\*****DURAMED RES**

\* DURAMED RESEARCH INC  
 ADDERALL 10, AMPHETAMINE ASPARTATE  
 ADDERALL 12.5, AMPHETAMINE ASPARTATE  
 ADDERALL 15, AMPHETAMINE ASPARTATE  
 ADDERALL 20, AMPHETAMINE ASPARTATE  
 ADDERALL 30, AMPHETAMINE ASPARTATE  
 ADDERALL 5, AMPHETAMINE ASPARTATE  
 ADDERALL 7.5, AMPHETAMINE ASPARTATE  
 AYGESTIN, NORETHINDRONE ACETATE  
 PARAGARD T 380A, COPPER  
 PREFEST, ESTRADIOL  
 SEASONALE, ETHINYL ESTRADIOL  
 SEASONIQUE, ETHINYL ESTRADIOL  
 SYNTHETIC CONJUGATED ESTROGENS A, ESTROGENS, CONJUGATED SYNTHETIC A

**DUSA**

\* DUSA PHARMACEUTICALS INC  
 LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

**EBEWE PHARMA**

\* EBEWE PHARMA GES MBH NFG KG  
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE

**ECOLAB**

\* ECOLAB INC  
 CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)  
 CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

**EISAI INC**

\* EISAI INC  
 ACIPHEX, RABEPRAZOLE SODIUM  
 ARICEPT ODT, DONEPEZIL HYDROCHLORIDE  
 ARICEPT, DONEPEZIL HYDROCHLORIDE  
 BANZEL, RUFINAMIDE  
 DACOGEN, DECITABINE  
 FRAGMIN, DALTEPARIN SODIUM  
 GLIADEL, CARMUSTINE  
 HEXALEN, ALTRETAMINE  
 LUSEDRA, FOSPROPOFOL DISODIUM  
 PANRETIN, ALITRETINOIN  
 SALAGEN, PILOCARPINE HYDROCHLORIDE  
 TARGRETIN, BEXAROTENE  
 ZONEGRAN, ZONISAMIDE

**EKR THERAP**

\* EKR THERAPEUTICS INC  
 CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
 CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
 CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
 CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
 CARDENE SR, NICARDIPINE HYDROCHLORIDE  
 CARDENE, NICARDIPINE HYDROCHLORIDE

**ELAN DRUG**

\* ELAN DRUG DELIVERY INC  
 VERELAN PM, VERAPAMIL HYDROCHLORIDE  
 VERELAN, VERAPAMIL HYDROCHLORIDE

**ELAN PHARMS**

\* ELAN PHARMACEUTICALS INC  
 PRIALT, ZICONOTIDE

**ELI LILLY AND CO**

\* ELI LILLY AND CO  
 EFFIENT, PRASUGREL HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* E \*\*****ELI LILLY CO**

\* ELI LILLY CO  
 ADCIRCA, TADALAFIL  
 ZYPREXA RELPREVV, OLANZAPINE PAMOATE

**EMD SERONO**

\* EMD SERONO INC  
 CETROTIDE, CETRORELIX  
 GONAL-F RFF PEN, FOLLITROPIN ALFA/BETA  
 GONAL-F RFF, FOLLITROPIN ALFA/BETA  
 GONAL-F, FOLLITROPIN ALFA/BETA  
 LUVERIS, LUTROPIN ALFA  
 NOVANTRONE, MITOXANTRONE HYDROCHLORIDE  
 OVIDREL, CHORIOGONADOTROPIN ALFA  
 SAIZEN, SOMATROPIN RECOMBINANT  
 SEROPHENE, CLOMIPHENE CITRATE  
 SEROSTIM, SOMATROPIN RECOMBINANT  
 ZORBTIVE, SOMATROPIN RECOMBINANT

**ENDO PHARM**

\* ENDO PHARMACEUTICAL SOLUTIONS INC  
 DELATESTRYL, TESTOSTERONE ENANTHATE  
 SUPPRELIN LA, HISTRELIN ACETATE  
 VALSTAR PRESERVATIVE FREE, VALRUBICIN  
 VANTAS, HISTRELIN ACETATE

**ENDO PHARMS**

\* ENDO PHARMACEUTICALS INC  
 FROVA, FROVATRIPTAN SUCCINATE  
 MOBAN, MOLINDONE HYDROCHLORIDE  
 OPANA ER, OXYMORPHONE HYDROCHLORIDE  
 OPANA, OXYMORPHONE HYDROCHLORIDE  
 PERCODAN, ASPIRIN  
 SYMMETREL, AMANTADINE HYDROCHLORIDE

**ENTURIA INC**

\* ENTURIA INC  
 CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)  
 CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)  
 CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)  
 CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
 CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)

**ENZON**

\* ENZON INC  
 ABELCET, AMPHOTERICIN B

**ENZON PHARMS**

\* ENZON PHARMACEUTICALS INC  
 ADAGEN, PEGADEMASE BOVINE

**EURAND**

\* EURAND INC  
 ZENPEP, LIPASE

**EUSA PHARMA USA**

\* EUSA PHARMA (USA) INC  
 QUADRAMET, SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

**EXALENZ BIOSCIENCE**

\* EXALENZ BIOSCIENCE LTD  
 IDKIT:HP, UREA C-13

**EYETECH INC**

\* EYETECH INC  
 MACUGEN, PEGAPTANIB SODIUM

**FALCON PHARMS**

\* FALCON PHARMACEUTICALS LTD  
 MAXITROL, DEXAMETHASONE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* F \*\***

\* FALCON PHARMACEUTICALS LTD  
TIMOLOL MALEATE, TIMOLOL MALEATE  
TOBREX, TOBRAMYCIN

**FEINSTEIN**

\* FEINSTEIN INSTITUTE MEDICAL RESEARCH  
AMMONIA N 13, AMMONIA, N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**FERRING**

\* FERRING PHARMACEUTICALS INC  
ACTHREL, CORTICORELIN OVINE TRIFLUTATE  
BRAVELLE, UROFOLLITROPIN  
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC  
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
ENDOMETRIN, PROGESTERONE  
FIRMAGON, DEGARELIX ACETATE  
MENOPUR, LUTEINIZING HORMONE  
MINIRIN, DESMOPRESSIN ACETATE  
REPRONEX, LUTEINIZING HORMONE  
TEV-TROPIN, SOMATROPIN RECOMBINANT

**FLEMING**

\* FLEMING AND CO  
CALOMIST, CYANOCOBALAMIN

**FOREST LABS**

\* FOREST LABORATORIES INC  
AEROSPAN HFA, FLUNISOLIDE  
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE  
CAMPRAL, ACAMPROSATE CALCIUM  
CELEXA, CITALOPRAM HYDROBROMIDE  
COMBUNOX, IBUPROFEN  
LEXAPRO, ESCITALOPRAM OXALATE  
NAMENDA, MEMANTINE HYDROCHLORIDE  
TESSALON, BENZONATATE  
THYROLAR-0.25, LIOETHYRONINE SODIUM  
THYROLAR-0.5, LIOETHYRONINE SODIUM  
THYROLAR-1, LIOETHYRONINE SODIUM  
THYROLAR-2, LIOETHYRONINE SODIUM  
THYROLAR-3, LIOETHYRONINE SODIUM

**FOUGERA**

\* E FOUGERA DIV ALTANA INC  
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE

**FRESENIUS**

\* FRESENIUS KABI DEUTSCHLAND GMBH  
INTRALIPID 10%, SOYBEAN OIL  
INTRALIPID 20%, SOYBEAN OIL  
INTRALIPID 30%, SOYBEAN OIL  
\* FRESENIUS USA INC  
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

**FRESENIUS MEDCL**

\* FRESENIUS MEDICAL CARE NORTH AMERICA  
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* F \*\***

- \* FRESENIUS MEDICAL CARE NORTH AMERICA  
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PHOSLO GELCAPS, CALCIUM ACETATE

**G AND W LABS**

- \* G AND W LABORATORIES INC  
 ACEPHEN, ACETAMINOPHEN (OTC)

**GALDERMA LABS**

- \* GALDERMA LABORATORIES INC  
 CLOBEX, CLOBETASOL PROPIONATE  
 EPIDUO, ADAPALENE

**GALDERMA LABS LP**

- \* GALDERMA LABORATORIES L P  
 CLOBEX, CLOBETASOL PROPIONATE
- \* GALDERMA LABORATORIES LP  
 CAPEX, FLUOCINOLONE ACETONIDE  
 CLINDAGEL, CLINDAMYCIN PHOSPHATE  
 CLOBEX, CLOBETASOL PROPIONATE  
 DESOWEN, DESONIDE  
 DIFFERIN, ADAPALENE  
 LIDOCAINE AND TETRACAINE, LIDOCAINE  
 METROCREAM, METRONIDAZOLE  
 METROGEL, METRONIDAZOLE  
 METROLOTION, METRONIDAZOLE  
 METVIXIA, METHYL AMINOLEVULINATE HYDROCHLORIDE  
 ORACEA, DOXYCYCLINE  
 PERIOSTAT, DOXYCYCLINE HYCLATE  
 TRI-LUMA, FLUOCINOLONE ACETONIDE  
 VECTICAL, CALCITRIOL

**GALEN LTD**

- \* GALEN LTD  
 FEMRING, ESTRADIOL ACETATE

**GAMBRO RENAL PRODS**

- \* GAMBRO RENAL PRODUCTS  
 PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

**GD SEARLE**

- \* GD SEARLE LLC  
 CELEBREX, CELECOXIB  
 DAYPRO, OXAPROZIN

**GD SEARLE LLC**

- \* GD SEARLE LLC  
 ALDACTAZIDE, HYDROCHLOROTHIAZIDE  
 ALDACTONE, SPIRONOLACTONE  
 ARTHROTEC, DICLOFENAC SODIUM  
 CALAN, VERAPAMIL HYDROCHLORIDE  
 COVERA-HS, VERAPAMIL HYDROCHLORIDE  
 CYTOTEC, MISOPROSTOL  
 FLAGYL ER, METRONIDAZOLE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* G \*\***

\* GD SEARLE LLC  
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE  
 FLAGYL I.V., METRONIDAZOLE HYDROCHLORIDE  
 FLAGYL, METRONIDAZOLE  
 INSPRA, EPLERENONE  
 LOMOTIL, ATROPINE SULFATE  
 NORPACE CR, DISOPYRAMIDE PHOSPHATE  
 NORPACE, DISOPYRAMIDE PHOSPHATE  
 SYNAREL, NAFARELIN ACETATE

**GE HEALTHCARE**

\* GE HEALTHCARE  
 ADREVIEW, IOBENGUANE SULFATE I 123  
 CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT  
 HYPAAQUE, DIATRIZOATE SODIUM  
 INDICLOR, INDIUM IN-111 CHLORIDE  
 INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE  
 METASTRON, STRONTIUM CHLORIDE, SR-89  
 MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT  
 MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM  
 MYOVIEV 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT  
 MYOVIEV, TECHNETIUM TC-99M TETROFOSMIN KIT  
 OMNIPAQUE 140, IOHEXOL  
 OMNIPAQUE 180, IOHEXOL  
 OMNIPAQUE 240, IOHEXOL  
 OMNIPAQUE 300, IOHEXOL  
 OMNIPAQUE 350, IOHEXOL  
 OMNISCAN, GADODIAMIDE  
 OPTISON, ALBUMIN HUMAN  
 SODIUM IODIDE I 123, SODIUM IODIDE, I-123  
 TECHNETIUM TC-99M PENTETATE KIT, TECHNETIUM TC-99M PENTETATE KIT  
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201  
 VISIPAQUE 270, IODIXANOL  
 VISIPAQUE 320, IODIXANOL

**GENENTECH**

\* GENENTECH INC  
 NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT  
 NUTROPIN AQ, SOMATROPIN RECOMBINANT  
 NUTROPIN, SOMATROPIN RECOMBINANT

**GENTA**

\* GENTA INC  
 GANITE, GALLIUM NITRATE

**GENZYME**

\* GENZYME CORP  
 CEREDASE, ALGLUCERASE  
 CEREZYME, IMIGLUCERASE  
 CLOLAR, CLOFARABINE  
 FLUDARA, FLUDARABINE PHOSPHATE  
 HECTOROL, DOXERCALCIFEROL  
 MOZOBIL, PLERIXAFOR  
 RENAGEL, SEVELAMER HYDROCHLORIDE  
 RENVELA, SEVELAMER CARBONATE  
 THYROGEN, THYROTROPIN ALFA

**GILEAD**

\* GILEAD SCIENCES INC  
 ATRIPLA, EFAVIRENZ  
 EMTRIVA, EMTRICITABINE  
 HEPSERA, ADEFOVIR DIPIVOXIL  
 LETAIRIS, AMBRISENTAN  
 RANEXA, RANOLAZINE  
 TRUVADA, EMTRICITABINE  
 VIREAD, TENOFOVIR DISOPROXIL FUMARATE  
 VISTIDE, CIDOFOVIR



## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* G \*\*

GLAXO GRP LTD

\* GLAXO GROUP LTD DBA GLAXOSMITHKLINE  
 ALTABAX, RETAPAMULIN  
 FLOVENT HFA, FLUTICASONE PROPIONATE  
 SEREVENT, SALMETEROL XINAFOATE

GLAXOSMITHKLINE

\* GLAXOSMITHKLINE  
 ABREVA, DOCOSANOL (OTC)  
 ACLOVATE, ALCLOMETASONE DIPROPIONATE  
 ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE  
 ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE  
 ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE  
 ADVAIR HFA, FLUTICASONE PROPIONATE  
 AGENERASE, AMPRENAVIR  
 ALBENZA, ALBENDAZOLE  
 ALKERAN, MELPHALAN  
 ALKERAN, MELPHALAN HYDROCHLORIDE  
 AMERGE, NARATRIPTAN HYDROCHLORIDE  
 ARIXTRA, FONDAPARINUX SODIUM  
 AVODART, DUTASTERIDE  
 BACTROBAN, MUPIROCIN  
 BACTROBAN, MUPIROCIN CALCIUM  
 BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE  
 CEFTIN, CEFUROXIME AXETIL  
 DARAPRIM, PYRIMETHAMINE  
 DYAZIDE, HYDROCHLOROTHIAZIDE  
 EPIVIR-HBV, LAMIVUDINE  
 FLOLAN, EPOPROSTENOL SODIUM  
 FLONASE, FLUTICASONE PROPIONATE  
 FLOVENT DISKUS 100, FLUTICASONE PROPIONATE  
 FLOVENT DISKUS 250, FLUTICASONE PROPIONATE  
 FLOVENT DISKUS 50, FLUTICASONE PROPIONATE  
 FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM  
 FORTAZ, CEFTAZIDIME  
 HYCAMTIN, TOPOTECAN HYDROCHLORIDE  
 IMITREX STATDOSE, SUMATRIPTAN SUCCINATE  
 IMITREX, SUMATRIPTAN  
 IMITREX, SUMATRIPTAN SUCCINATE  
 LAMICTAL CD, LAMOTRIGINE  
 LAMICTAL, LAMOTRIGINE  
 LANOXIN PEDIATRIC, DIGOXIN  
 LANOXIN, DIGOXIN  
 MALARONE PEDIATRIC, ATOVAQUONE  
 MALARONE, ATOVAQUONE  
 MEPRON, ATOVAQUONE  
 MYLERAN, BUSULFAN  
 NICORETTE (MINT), NICOTINE POLACRILEX (OTC)  
 NICORETTE, NICOTINE POLACRILEX (OTC)  
 PARNATE, TRANYLCPROMINE SULFATE  
 PAXIL CR, PAROXETINE HYDROCHLORIDE  
 PAXIL, PAROXETINE HYDROCHLORIDE  
 PROMACTA, ELTROMBOPAG OLAMINE  
 RELENZA, ZANAMIVIR  
 REQUIP, ROPINIROLE HYDROCHLORIDE  
 TAGAMET HB, CIMETIDINE (OTC)  
 TAGAMET, CIMETIDINE  
 THIOGUANINE, THIOGUANINE  
 TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM  
 TIMENTIN, CLAVULANATE POTASSIUM  
 TREXIMET, NAPROXEN SODIUM  
 VALTREX, VALACYCLOVIR HYDROCHLORIDE  
 VENTOLIN HFA, ALBUTEROL SULFATE  
 VERAMYST, FLUTICASONE FUROATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* G \*\*****\* GLAXOSMITHKLINE**

VOTRIENT, PAZOPANIB HYDROCHLORIDE  
 WELLBUTRIN SR, BUPROPION HYDROCHLORIDE  
 WELLBUTRIN, BUPROPION HYDROCHLORIDE  
 ZANTAC 150, RANITIDINE HYDROCHLORIDE  
 ZANTAC 25, RANITIDINE HYDROCHLORIDE  
 ZANTAC 300, RANITIDINE HYDROCHLORIDE  
 ZANTAC IN PLASTIC CONTAINER, RANITIDINE HYDROCHLORIDE  
 ZANTAC, RANITIDINE HYDROCHLORIDE  
 ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM  
 ZINACEF, CEFUROXIME SODIUM  
 ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE  
 ZOFRAN ODT, ONDANSETRON  
 ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ZOFRAN, ONDANSETRON HYDROCHLORIDE  
 ZOVIRAX, ACYCLOVIR  
 ZOVIRAX, ACYCLOVIR SODIUM  
 ZYBAN, BUPROPION HYDROCHLORIDE

**GLAXOSMITHKLINE CONS**

\* GLAXOSMITHKLINE CONSUMER HEALTHCARE  
 ALLI, ORLISTAT (OTC)  
 COMMIT, NICOTINE POLACRILEX (OTC)  
 NICORETTE, NICOTINE POLACRILEX (OTC)

**GLENMARK GENERICS**

\* GLENMARK GENERICS INC USA  
 NILSTAT, NYSTATIN

**GLOUCESTER PHARMS**

\* GLOUCESTER PHARMACEUTICALS INC  
 ISTODAX, ROMIDEPSIN

**GRACEWAY**

\* GRACEWAY PHARMACEUTICALS LLC  
 ALDARA, IMIQUIMOD  
 CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM  
 ESTRASORB, ESTRADIOL HEMIHYDRATE  
 MAXAIR, PIRBUTEROL ACETATE  
 METROGEL-VAGINAL, METRONIDAZOLE  
 NORFLEX, ORPHENADRINE CITRATE  
 NORGESIC FORTE, ASPIRIN  
 NORGESIC, ASPIRIN  
 TAMBOCOR, FLECAINIDE ACETATE

**GRIFFEN**

\* KW GRIFFEN CO  
 BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

**GTX INC**

\* GTX INC  
 FARESTON, TOREMIFENE CITRATE

**GUERBET**

\* GUERBET LLC  
 HEXABRIX, IOXAGLATE MEGLUMINE  
 OXILAN-300, IOXILAN  
 OXILAN-350, IOXILAN

**HALOZYME THERAP**

\* HALOZYME THERAPEUTICS INC  
 HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN

**HAMELN PHARMS**

\* HAMELN PHARMACEUTICALS GMBH  
 PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM  
 PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\*****HELSINN HLTHCARE**

\* HELSINN HEALTHCARE SA  
ALOXI, PALONOSETRON HYDROCHLORIDE

**HEYL CHEMISCH**

\* HEYL CHEMISCH PHARMAZEUTISCHE FABRIK  
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

**HI TECH PHARMA**

\* HI TECH PHARMACAL CO INC  
VOSOL HC, ACETIC ACID, GLACIAL  
VOSOL, ACETIC ACID, GLACIAL

**HILL DERMAC**

\* HILL DERMACEUTICALS INC  
DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE  
DERMOTIC, FLUOCINOLONE ACETONIDE

**HISAMITSU**

\* HISAMITSU PHARMACEUTICAL CO INC  
SALONPAS, MENTHOL (OTC)

**HLR**

\* HLR TECHNOLOGY  
INVIRASE, SAQUINAVIR MESYLATE  
ROMAZICON, FLUMAZENIL

**HOFFMANN LA ROCHE**

\* HOFFMANN LA ROCHE INC  
XELODA, CAPECITABINE  
XENICAL, ORLISTAT

**HOSPIRA**

\* HOSPIRA INC  
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL  
AMIDATE, ETOMIDATE  
AMINOSYN 10% (PH6), AMINO ACIDS  
AMINOSYN 10%, AMINO ACIDS  
AMINOSYN 3.5% M, AMINO ACIDS  
AMINOSYN 3.5%, AMINO ACIDS  
AMINOSYN 5%, AMINO ACIDS  
AMINOSYN 7% (PH6), AMINO ACIDS  
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS  
AMINOSYN 7%, AMINO ACIDS  
AMINOSYN 8.5% (PH6), AMINO ACIDS  
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS  
AMINOSYN 8.5%, AMINO ACIDS  
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS  
AMINOSYN II 10%, AMINO ACIDS  
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 7%, AMINO ACIDS  
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS  
AMINOSYN II 8.5%, AMINO ACIDS

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* H \*\*

\* HOSPIRA INC

AMINOSYN-HBC 7%, AMINO ACIDS  
 AMINOSYN-HF 8%, AMINO ACIDS  
 AMINOSYN-PF 10%, AMINO ACIDS  
 AMINOSYN-PF 7%, AMINO ACIDS  
 AMINOSYN-RF 5.2%, AMINO ACIDS  
 AQUASOL A, VITAMIN A PALMITATE  
 ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE  
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE  
 BRETILUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETILUM TOSYLATE  
 BRETILUM TOSYLATE, BRETILUM TOSYLATE  
 BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE  
 CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 CARBOCAINE, MEPIVACAINE HYDROCHLORIDE  
 CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE  
 CORLOPAM, FENOLDOPAM MESYLATE  
 CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE  
 DEMEROL, MEPERIDINE HYDROCHLORIDE  
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 25%, DEXTROSE  
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE  
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE  
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 ERYC, ERYTHROMYCIN  
 ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE  
 FENTANYL CITRATE, FENTANYL CITRATE  
 FUROSEMIDE, FUROSEMIDE  
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE  
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
 IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISUPREL, ISOPROTERENOL HYDROCHLORIDE  
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM  
 LEVOPHED, NOREPINEPHRINE BITARTRATE  
 LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIPOSYN II 10%, SAFFLOWER OIL  
 LIPOSYN II 20%, SAFFLOWER OIL

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 836 of 1114**

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* H \*\*

\* HOSPIRA INC

LIPOSYN III 10%, SOYBEAN OIL  
 LIPOSYN III 20%, SOYBEAN OIL  
 LIPOSYN III 30%, SOYBEAN OIL  
 M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID  
 M.V.I. ADULT, ASCORBIC ACID  
 M.V.I. PEDIATRIC, ASCORBIC ACID  
 M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID  
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE  
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 25%, MANNITOL  
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL  
 MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE, BUPIVACAINE HYDROCHLORIDE  
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM  
 METHOTREXATE SODIUM, METHOTREXATE SODIUM  
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NITROGLYCERIN, NITROGLYCERIN  
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 NOVAMINE 11.4%, AMINO ACIDS  
 NOVAMINE 15%, AMINO ACIDS  
 PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 CALCIUM CHLORIDE  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\***

\* HOSPIRA INC  
 POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 CALCIUM CHLORIDE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 DEXTROSE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 DEXTROSE  
 PRECEDEX, DEXMEDETOMIDINE  
 QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE  
 QUELICIN, SUCCINYLCHOLINE CHLORIDE  
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS  
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE  
 SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE  
 SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL  
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE  
 STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE  
 TALWIN, PENTAZOCINE LACTATE  
 THAM, TROMETHAMINE  
 THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

**HOSPIRA INC**

\* HOSPIRA INC  
 NIPENT, PENTOSTATIN

**INO**

\* INO THERAPEUTICS INC  
 INOMAX, NITRIC OXIDE

**INSIGHT PHARMS**

\* INSIGHT PHARMACEUTICALS CORP  
 NIX, PERMETHRIN (OTC)

**INSPIRE**

\* INSPIRE PHARMACEUTICALS INC  
 AZASITE, AZITHROMYCIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* I \*\*****INST BIOCHEM**

\* INSTITUT BIOCHEMIQUE SA  
FLECTOR, DICLOFENAC EPOLAMINE

**INTENDIS**

\* INTENDIS INC  
DESONATE, DESONIDE  
FINACEA, AZELAIC ACID

**INTL MEDICATION**

\* INTERNATIONAL MEDICATION SYSTEM  
FUROSEMIDE, FUROSEMIDE  
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE

**IPR**

\* IPR PHARMACEUTICALS INC  
CRESTOR, ROSUVASTATIN CALCIUM  
ZOMIG, ZOLMITRIPTAN

**IPSEN LTD**

\* IPSEN LTD  
APOKYN, APOMORPHINE HYDROCHLORIDE

**IROKO PHARMS**

\* IROKO PHARMACEUTICALS LLC  
INDOCIN, INDOMETHACIN

**ISO TEX**

\* ISO TEX DIAGNOSTICS INC  
JEANATOPE, ALBUMIN IODINATED I-125 SERUM  
MEGATOPE, ALBUMIN IODINATED I-131 SERUM

**ISTA PHARMS**

\* ISTA PHARMACEUTICALS  
BEPREVE, BEPOTASTINE BESILATE  
ISTALOL, TIMOLOL MALEATE  
VITRASE, HYALURONIDASE  
XIBROM, BROMFENAC SODIUM

**IVAX SUB TEVA PHARMS**

\* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA  
FUROSEMIDE, FUROSEMIDE  
METRONIDAZOLE, METRONIDAZOLE

**JAZZ**

\* JAZZ PHARMACEUTICALS  
LUVOX CR, FLUVOXAMINE MALEATE  
LUVOX, FLUVOXAMINE MALEATE  
XYREM, SODIUM OXYBATE

**JHP PHARMS**

\* JHP PHARMACEUTICALS LLC  
BREVITAL SODIUM, METHOHEXITAL SODIUM  
COLY-MYCIN M, COLISTIMETHATE SODIUM  
COLY-MYCIN S, COLISTIN SULFATE  
DANTRIUM, DANTROLENE SODIUM  
DELESTROGEN, ESTRADIOL VALERATE  
KETALAR, KETAMINE HYDROCHLORIDE  
PITOCIN, OXYTOCIN  
TIGAN, TRIMETHOENZAMIDE HYDROCHLORIDE  
TRIOSTAT, LIOTHYRONINE SODIUM

**JOHNSON AND JOHNSON**

\* JOHNSON AND JOHNSON CONSUMER COMPANIES INC  
RETIN-A, TRETINOIN  
\* JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES  
MEN'S ROGAINE, MINOXIDIL (OTC)  
ROGAINE (FOR MEN), MINOXIDIL (OTC)  
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)  
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* J \*\***

- \* JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES  
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)  
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
- \* JOHNSON AND JOHNSON HEALTHCARE PRODUCTS  
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MONISTAT 3 COMBINATION PACK (REFILLED), MICONAZOLE NITRATE (OTC)  
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MONISTAT 3, MICONAZOLE NITRATE (OTC)  
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MONISTAT 7, MICONAZOLE NITRATE (OTC)  
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
- \* JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT LLC  
INVEGA SUSTENNA, PALIPERIDONE PALMITATE

**KENDALL LP**

- \* KENDALL CO LP  
THERMAZENE, SILVER SULFADIAZINE

**KEY PHARMS**

- \* KEY PHARMACEUTICALS INC SUB SCHERING PLOUGH CORP  
NITRO-DUR, NITROGLYCERIN

**KING PHARMS**

- \* KING PHARMACEUTICALS INC  
ALTACE, RAMIPRIL  
AVINZA, MORPHINE SULFATE  
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE  
BICILLIN C-R, PENICILLIN G BENZATHINE  
BICILLIN L-A, PENICILLIN G BENZATHINE  
CORGARD, NADOLOL  
CORZIDE, BENDROFLUMETHIAZIDE  
CYTOMEL, LIOTHYRONINE SODIUM  
INTAL, CROMOLYN SODIUM  
LEVOXYL, LEVOTHYROXINE SODIUM  
SILVADENE, SILVER SULFADIAZINE  
SKELAXIN, METAXALONE  
SYNERCID, DALFOPRISTIN  
TIGAN, TRIMETHOENZAMIDE HYDROCHLORIDE
- \* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC SUB KING PHARMACEUTICALS INC  
SONATA, ZALEPLON

**KOWA**

- \* KOWA RESEARCH INSTITUTE INC  
LIVALO, PITAVASTATIN CALCIUM

**KOWA PHARMS**

- \* KOWA PHARMACEUTICALS AMERICA INC  
CAMBIA, DICLOFENAC POTASSIUM

**KV PHARM**

- \* KV PHARMACEUTICAL CO  
CLINDESSE, CLINDAMYCIN PHOSPHATE  
EVAMIST, ESTRADIOL  
GYNAZOLE-1, BUTOCONAZOLE NITRATE

**LANNETT**

- \* LANNETT CO INC  
SERPALAN, RESERPINE

**LANTHEUS MEDCL**

- \* LANTHEUS MEDICAL IMAGING INC  
ABLAVAR, GADOFOSVESET TRISODIUM  
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT  
DEFINITY, PERFLUTREN  
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67  
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT  
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201  
XENON XE 133, XENON XE 133



## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* L \*\*

LEO PHARM

\* LEO PHARMACEUTICAL PRODUCTS LTD  
DOVONEX, CALCIPOTRIENE  
TACLONEX, BETAMETHASONE DIPROPIONATE

LEO PHARM PRODS

\* LEO PHARMACEUTICAL PRODUCTS LTD  
TACLONEX SCALP, BETAMETHASONE DIPROPIONATE

LG LIFE

\* LG LIFE SCIENCES LTD  
VALTROPIN, SOMATROPIN RECOMBINANT

LILLY

\* ELI LILLY AND CO  
ALIMTA, PEMETREXED DISODIUM  
CIALIS, TADALAFIL  
CYMBALTA, DULOXETINE HYDROCHLORIDE  
EVISTA, RALOXIFENE HYDROCHLORIDE  
FORTEO, TERIPARATIDE RECOMBINANT HUMAN  
GEMZAR, GEMCITABINE HYDROCHLORIDE  
GLUCAGON, GLUCAGON RECOMBINANT  
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT  
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT  
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT  
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT  
HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT  
HUMALOG PEN, INSULIN LISPRO RECOMBINANT  
HUMALOG, INSULIN LISPRO RECOMBINANT  
HUMATROPE, SOMATROPIN RECOMBINANT  
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)  
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)  
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)  
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)  
HUMULIN R, INSULIN RECOMBINANT HUMAN  
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)  
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE  
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE  
STRATTERA, ATOMOXETINE HYDROCHLORIDE  
SYMBYAX, FLUOXETINE HYDROCHLORIDE  
ZYPREXA ZYDIS, OLANZAPINE  
ZYPREXA, OLANZAPINE

\* LILLY RESEARCH LABORATORIES DIV ELI LILLY AND CO  
PROZAC, FLUOXETINE HYDROCHLORIDE  
SARAFEM, FLUOXETINE HYDROCHLORIDE

LLOYD

\* LLOYD INC  
LEVOTHROID, LEVOTHYROXINE SODIUM

LOREAL USA

\* LOREAL USA PRODUCTS INC  
ANTHELIOS 20, AVOBENZONE (OTC)  
ANTHELIOS 40, AVOBENZONE (OTC)  
ANTHELIOS SX, AVOBENZONE (OTC)  
CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LUITPOLD

\* LUITPOLD PHARMACEUTICALS INC  
FUROSEMIDE, FUROSEMIDE  
VENOFER, IRON SUCROSE

LUNDBECK INC

\* LUNDBECK INC  
CHEMET, SUCCIMER  
COGENTIN, BENZTROPINE MESYLATE  
COSMEGEN, DACTINOMYCIN  
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 841 of 1114**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* L \*\***

\* LUNDBECK INC  
 DIURIL, CHLOROTHIAZIDE SODIUM  
 INDOCIN, INDOMETHACIN SODIUM  
 MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE  
 NEOPROFEN, IBUPROFEN LYSINE  
 PEGANONE, ETHOTOIN  
 SABRIL, VIGABATRIN  
 TRANXENE, CLORAZEPATE DIPOTASSIUM

**MALLINCKRODT**

\* MALLINCKRODT CHEMICAL INC  
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
 METHADOSE, METHADONE HYDROCHLORIDE

\* MALLINCKRODT INC  
 METHYLIN, METHYLPHENIDATE HYDROCHLORIDE  
 OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE  
 OPTIMARK, GADOVERSETAMIDE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

\* MALLINCKRODT MEDICAL INC  
 CONRAY 30, IOTHALAMATE MEGLUMINE  
 CONRAY 43, IOTHALAMATE MEGLUMINE  
 CONRAY, IOTHALAMATE MEGLUMINE  
 CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE  
 GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67  
 INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE  
 MD-76R, DIATRIZOATE MEGLUMINE  
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT  
 OPTIRAY 160, IOVERSOL  
 OPTIRAY 240, IOVERSOL  
 OPTIRAY 300, IOVERSOL  
 OPTIRAY 320, IOVERSOL  
 OPTIRAY 350, IOVERSOL  
 SODIUM IODIDE I 131, SODIUM IODIDE, I-131  
 TECHNISCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT  
 TECHNISCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT  
 TECHNISCAN, TECHNETIUM TC-99M OXIDRONATE KIT  
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201  
 ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT  
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
 XENON XE 133, XENON XE 133

**MAYNE PHARMA INTL**

\* MAYNE PHARMA INTERNATIONAL FAULDING PHARM  
 DORYX, DOXYCYCLINE HYCLATE

**MCNEIL**

\* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC  
 CHILDREN'S MOTRIN, IBUPROFEN (OTC)  
 IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)  
 IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)  
 MOTRIN IB, IBUPROFEN (OTC)  
 MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)  
 ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

**MCNEIL CONS**

\* MCNEIL CONSUMER HEALTHCARE  
 BENADRYL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE  
 BENADRYL, DIPHENHYDRAMINE HYDROCHLORIDE  
 CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)  
 CHILDREN'S MOTRIN, IBUPROFEN (OTC)  
 IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)  
 IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)  
 IMODIUM, LOPERAMIDE HYDROCHLORIDE  
 JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)  
 NIZORAL A-D, KETOCONAZOLE (OTC)  
 SINE-AID IB, IBUPROFEN (OTC)  
 TYLENOL (CAPLET), ACETAMINOPHEN (OTC)

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MCNEIL CONSUMER HEALTHCARE  
 TYLENOL (GELTAB), ACETAMINOPHEN (OTC)

**MCNEIL CONSUMER**

\* MCNEIL CONSUMER HEALTHCARE DIV MCNEIL PPC INC  
 CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 ZYRTEC, CETIRIZINE HYDROCHLORIDE

**MCNEIL PED**

\* MCNEIL PEDIATRICS  
 FLEXERIL, CYCLOBENZAPRINE HYDROCHLORIDE

**MEAD JOHNSON**

\* MEAD JOHNSON AND CO  
 CAFKIT, CAFFEINE CITRATE

**MEDA PHARMS**

\* MEDA PHARMACEUTICALS  
 EDLUAR, ZOLPIDEM TARTRATE

\* MEDA PHARMACEUTICALS INC  
 ASTELIN, AZELASTINE HYDROCHLORIDE  
 ASTEPRO, AZELASTINE HYDROCHLORIDE  
 BUTISOL SODIUM, BUTABARBITAL SODIUM  
 CESAMET, NABILONE  
 DEMADDEX, TORSEMIDE  
 DEPEN, PENICILLAMINE  
 FELBATOL, FELBAMATE  
 ONSOLIS, FENTANYL CITRATE  
 OPTIVAR, AZELASTINE HYDROCHLORIDE

\* MEDA PHARMACEUTICALS MEDA PHARMACEUTICALS INC  
 ASTEPRO, AZELASTINE HYDROCHLORIDE  
 SOMA COMPOUND W/ CODEINE, ASPIRIN  
 SOMA COMPOUND, ASPIRIN  
 SOMA, CARISOPRODOL

**MEDICINES CO**

\* THE MEDICINES CO  
 ANGIOMAX, BIVALIRUDIN  
 CLEVIPREX, CLEVIDIPINE BUTYRATE

**MEDICIS**

\* MEDICIS PHARMACEUTICAL CORP  
 BUPHENYL, SODIUM PHENYLBUTYRATE  
 LIDEX, FLUOCINONIDE  
 LIDEX-E, FLUOCINONIDE  
 LOPROX, CICLOPIROX  
 SOLODYN, MINOCYCLINE HYDROCHLORIDE  
 SYNALAR, FLUOCINOLONE ACETONIDE  
 VANOS, FLUOCINONIDE  
 ZIANA, CLINDAMYCIN PHOSPHATE

**MEDICURE**

\* MEDICURE INTERNATIONAL INC  
 AGGRASTAT, TIROFIBAN HYDROCHLORIDE

**MEDIGENE**

\* MEDIGENE INC  
 VEREGEN, SINECATECHINS

**MEDIMMUNE**

\* MEDIMMUNE  
 ETHYOL, AMIFOSTINE

**MEDIVIR**

\* MEDIVIR AB  
 ACYCLOVIR AND HYDROCORTISONE, ACYCLOVIR

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* M \*\*

MEDTRONIC

\* MEDTRONIC INC  
LIORESAL, BACLOFEN

MERCK

\* MERCK AND CO INC  
AMINOHIPURATE SODIUM, AMINOHIPURATE SODIUM  
CANCIDAS, CASPOFUNGIN ACETATE  
EMEND, APREPITANT  
FOSAMAX PLUS D, ALENDRONATE SODIUM  
FOSAMAX, ALENDRONATE SODIUM  
HYZAAR, HYDROCHLOROTHIAZIDE  
INVANZ, ERTAPENEM SODIUM  
JANUMET, METFORMIN HYDROCHLORIDE  
MAXALT, RIZATRIPTAN BENZOATE  
MAXALT-MLT, RIZATRIPTAN BENZOATE  
PRIMAXIN, CILASTATIN SODIUM  
PROSCAR, FINASTERIDE  
SINGULAIR, MONTELUKAST SODIUM  
STROMEKTOL, IVERMECTIN  
ZOLINZA, VORINOSTAT

\* MERCK RESEARCH LABORATORIES DIV MERCK CO INC  
CLINORIL, SULINDAC  
COSOPT, DORZOLAMIDE HYDROCHLORIDE  
COZAAR, LOSARTAN POTASSIUM  
MEVACOR, LOVASTATIN  
NOROXIN, NORFLOXACIN  
PEPCID AC (GELTAB), FAMOTIDINE (OTC)  
PEPCID AC, FAMOTIDINE (OTC)  
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)  
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE  
PEPCID PRESERVATIVE FREE, FAMOTIDINE  
PEPCID, FAMOTIDINE  
PRINIVIL, LISINAPRIL  
PRINZIDE, HYDROCHLOROTHIAZIDE  
PROPECIA, FINASTERIDE  
SINGULAIR, MONTELUKAST SODIUM  
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE  
ZOCOR, SIMVASTATIN

MERCK AND CO INC

\* MERCK AND CO INC  
EMEND, FOSAPREPITANT DIMEGLUMINE  
FOSAMAX, ALENDRONATE SODIUM

MERCK CO INC

\* MERCK CO INC  
JANUVIA, SITAGLIPTIN PHOSPHATE

MERCK SANTE SAS

\* MERCK SANTE SAS  
CYANOKIT, HYDROXOCOBALAMIN

MERCK SHARP DOHME

\* MERCK SHARP AND DOHME CORP  
CRIXIVAN, INDINAVIR SULFATE  
ISENTRESS, RALTEGRAVIR POTASSIUM

MERIDIAN MEDCL

\* MERIDIAN MEDICAL TECHNOLOGIES INC  
DUODOTE, ATROPINE

MERIDIAN MEDCL TECHN

\* MERIDIAN MEDICAL TECHNOLOGIES INC  
ATROPEN, ATROPINE  
EPIPEN JR., EPINEPHRINE  
EPIPEN, EPINEPHRINE  
LIDOPEN, LIDOCAINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MERIDIAN MEDICAL TECHNOLOGIES INC  
MORPHINE SULFATE, MORPHINE SULFATE  
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

**MERZ PHARMS**

\* MERZ PHARMACEUTICALS LLC  
ERYGEL, ERYTHROMYCIN  
NAFTIN, NAFTIFINE HYDROCHLORIDE

**METHAPHARM**

\* METHAPHARM INC  
PROVOCHOLINE, METHACHOLINE CHLORIDE

**MIDDLEBROOK PHARMS**

\* MIDDLEBROOK PHARMACEUTICALS INC  
KEFLEX, CEPHALEXIN  
MOXATAG, AMOXICILLIN

**MILLENNIUM PHARMS**

\* MILLENNIUM PHARMACEUTICALS INC  
VELCADE, BORTEZOMIB

**MISSION PHARMA**

\* MISSION PHARMACAL CO  
LITHOSTAT, ACETOHYDROXAMIC ACID  
TINDAMAX, TINIDAZOLE  
TIOPRONIN, TIOPRONIN  
UROCIT-K, POTASSIUM CITRATE

**MONARCH PHARMS**

\* MONARCH PHARMACEUTICALS INC  
CORTISPORIN, BACITRACIN ZINC  
CORTISPORIN, HYDROCORTISONE  
CORTISPORIN, HYDROCORTISONE ACETATE  
SEPTRA DS, SULFAMETHOXAZOLE  
SEPTRA, SULFAMETHOXAZOLE  
THALITONE, CHLORTHALIDONE  
VIROPTIC, TRIFLURIDINE

**MSP SINGAPORE**

\* MSP SINGAPORE CO LLC  
VYTORIN, EZETIMIBE  
ZETIA, EZETIMIBE

**MUTUAL PHARM**

\* MUTUAL PHARMACEUTICAL CO INC  
BACTRIM DS, SULFAMETHOXAZOLE  
BACTRIM, SULFAMETHOXAZOLE

**MYLAN**

\* MYLAN PHARMACEUTICALS INC  
ALLOPURINOL, ALLOPURINOL  
CYSTAGON, CYSTEAMINE BITARTRATE  
FUROSEMIDE, FUROSEMIDE  
INDOMETHACIN, INDOMETHACIN

**MYLAN BERTEK**

\* MYLAN BERTEK PHARMACEUTICALS INC  
AVITA, TRETINOIN  
MAXZIDE, HYDROCHLOROTHIAZIDE  
MAXZIDE-25, HYDROCHLOROTHIAZIDE  
MENTAX, BUTENAFINE HYDROCHLORIDE  
MENTAX-TC, BUTENAFINE HYDROCHLORIDE

**NEUROGESX**

\* NEUROGESX INC  
QUTENZA, CAPSAICIN

**NEW RIVER**

\* NEW RIVER PHARMACEUTICALS INC  
PROFERDEX, IRON DEXTRAN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* N \*\*****NITROMED**

\* NITROMED INC  
 BIDIL, HYDRALAZINE HYDROCHLORIDE

**NOVADEL**

\* NOVADEL PHARMA INC  
 ZOLPIMIST, ZOLPIDEM TARTRATE

**NOVALAR**

\* NOVALAR PHARMACEUTICALS INC  
 ORAVERSE, PHENTOLAMINE MESYLATE

**NOVARTIS**

\* NOVARTIS CONSUMER HEALTH INC  
 DENAVIR, PENCICLOVIR SODIUM  
 EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)  
 HABITROL, NICOTINE (OTC)  
 LAMISIL AT, TERBINAFFINE (OTC)  
 LAMISIL AT, TERBINAFFINE HYDROCHLORIDE (OTC)  
 LAMISIL, TERBINAFFINE  
 LAMISIL, TERBINAFFINE HYDROCHLORIDE  
 LAMISIL, TERBINAFFINE HYDROCHLORIDE (OTC)  
 NEXCEDE, KETOPROFEN (OTC)  
 PREVACID 24 HR, LANSOPRAZOLE (OTC)  
 TAVIST ALLERGY/SINUS/HEADACHE, ACETAMINOPHEN (OTC)  
 TRANSDERM SCOP, SCOPOLAMINE  
 VAGISTAT-1, TIOCONAZOLE (OTC)  
 VOLTAREN, DICLOFENAC SODIUM

\* NOVARTIS PHARMACEUTICALS CORP  
 AFINITOR, EVEROLIMUS  
 AREDIA, PAMIDRONATE DISODIUM  
 CATAFLAM, DICLOFENAC POTASSIUM  
 CLOZARIL, CLOZAPINE  
 COARTEM, ARTEMETHER  
 COMBIPATCH, ESTRADIOL  
 DESFERAL, DEFEROXAMINE MESYLATE  
 DIOVAN HCT, HYDROCHLOROTHIAZIDE  
 DIOVAN, VALSARTAN  
 ELIDEL, PIMECROLIMUS  
 ENABLEX, DARIFENACIN HYDROBROMIDE  
 ESTRADERM, ESTRADIOL  
 EXELON, RIVASTIGMINE  
 EXELON, RIVASTIGMINE TARTRATE  
 EXFORGE HCT, AMLODIPINE  
 EXFORGE, AMLODIPINE BESYLATE  
 EXJADE, DEFERASIROX  
 FAMVIR, FAMCICLOVIR  
 FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE  
 FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE  
 FORADIL CERTIHALER, FORMOTEROL FUMARATE  
 FORADIL, FORMOTEROL FUMARATE  
 GLEEVEC, IMATINIB MESYLATE  
 HYDERGINE, ERGOLOID MESYLATES  
 LAMISIL, TERBINAFFINE HYDROCHLORIDE  
 LAMPRENE, CLOFAZIMINE  
 LESCOL XL, FLUVASTATIN SODIUM  
 LESCOL, FLUVASTATIN SODIUM  
 LOPRESSOR HCT, HYDROCHLOROTHIAZIDE  
 LOPRESSOR, METOPROLOL TARTRATE  
 LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE  
 LOTENSIN, BENAZEPRIL HYDROCHLORIDE  
 LOTREL, AMLODIPINE BESYLATE  
 METHERGINE, METHYLERGONOVINE MALEATE  
 METOPIRONE, METYRAPONE  
 MIACALCIN, CALCITONIN, SALMON

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* N \*\***

\* NOVARTIS PHARMACEUTICALS CORP  
 MIOCHOL-E, ACETYLCHOLINE CHLORIDE  
 MYFORTIC, MYCOPHENOLIC ACID  
 NEORAL, CYCLOSPORINE  
 OCUPRESS, CARTEOLOL HYDROCHLORIDE  
 PARLODEL, BROMOCRIPTINE MESYLATE  
 RECLAST, ZOLEDRONIC ACID  
 REGITINE, PHENTOLAMINE MESYLATE  
 RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE  
 RITALIN, METHYLPHENIDATE HYDROCHLORIDE  
 RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE  
 SANDIMMUNE, CYCLOSPORINE  
 SANDOSTATIN LAR, OCTREOTIDE ACETATE  
 SANDOSTATIN, OCTREOTIDE ACETATE  
 STARLIX, NATEGLINIDE  
 TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE  
 TAVIST-1, CLEMASTINE FUMARATE (OTC)  
 TEGRETOL, CARBAMAZEPINE  
 TEGRETOL-XR, CARBAMAZEPINE  
 TEKTURNA HCT, ALISKIREN HEMIFUMARATE  
 TEKTURNA, ALISKIREN HEMIFUMARATE  
 TRILEPTAL, OXCARBAZEPINE  
 TYZEKA, TELBIVUDINE  
 VALTURNA, ALISKIREN HEMIFUMARATE  
 VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE  
 VASOCON-A, ANTAZOLINE PHOSPHATE (OTC)  
 VIVELLE, ESTRADIOL  
 VIVELLE-DOT, ESTRADIOL  
 VOLTAREN, DICLOFENAC SODIUM  
 VOLTAREN-XR, DICLOFENAC SODIUM  
 ZADITOR, KETOTIFEN FUMARATE (OTC)  
 ZOMETA, ZOLEDRONIC ACID

**NOVARTIS PHARMS**

\* NOVARTIS PHARMACEUTICALS CORP  
 FEMARA, LETROZOLE  
 TOBI, TOBRAMYCIN

**NOVEN THERAP**

\* NOVEN THERAPEUTICS LLC  
 ESKALITH, LITHIUM CARBONATE  
 LITHOBID, LITHIUM CARBONATE  
 PEKEVA, PAROXETINE MESYLATE

**NOVO NORDISK**

\* NOVO NORDISK PHARMACEUTICALS INC  
 GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT

**NOVO NORDISK INC**

\* NOVO NORDISK INC  
 ACTIVELLA, ESTRADIOL  
 LEVEMIR, INSULIN DETEMIR RECOMBINANT  
 NORDITROPIN NORDIFLEX, SOMATROPIN RECOMBINANT  
 NORDITROPIN, SOMATROPIN RECOMBINANT  
 NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)  
 NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)  
 NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)  
 NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT  
 NOVOLOG, INSULIN ASPART RECOMBINANT  
 PRANDIMET, METFORMIN HYDROCHLORIDE  
 PRANDIN, REPAGLINIDE  
 VAGIFEM, ESTRADIOL

**NUTRITIONAL RESTART**

\* NUTRITIONAL RESTART PHARMACEUTICAL LP  
 NUTRESTORE, GLUTAMINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* N \*\*****NUVO RES**

\* NUVO RESEARCH INC  
PENNSAID, DICLOFENAC SODIUM

**NYCOMED US**

\* NYCOMED US INC  
ALVESCO, CICLESONIDE  
CUTIVATE, FLUTICASON PROPIONATE  
OMNARIS, CICLESONIDE  
PAMINE FORTE, METHSCOPOLAMINE BROMIDE  
PAMINE, METHSCOPOLAMINE BROMIDE  
SOLARAZE, DICLOFENAC SODIUM  
ZONALON, DOXEPIN HYDROCHLORIDE

**ODYSSEY PHARMS**

\* ODYSSEY PHARMACEUTICALS INC  
SURMONTIL, TRIMIPRAMINE MALEATE

**ONY**

\* ONY INC  
INFASURF PRESERVATIVE FREE, CALFACTANT

**ORAPHARMA**

\* ORAPHARMA INC  
ARESTIN, MINOCYCLINE HYDROCHLORIDE

**ORGANON USA INC**

\* ORGANON USA INC  
CYCLESSA, DESOGESTREL  
DESOGEN, DESOGESTREL  
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA  
GANIRELIX ACETATE INJECTION, GANIRELIX ACETATE  
IMPLANON, ETONOGESTREL  
NUVARING, ETHINYL ESTRADIOL  
PREGNYL, GONADOTROPIN, CHORIONIC  
REMERON SOLTAB, MIRTAZAPINE  
REMERON, MIRTAZAPINE  
SAPHRIS, ASENAPINE MALEATE

**ORION**

\* ORION CORP  
COMTAN, ENTACAPONE  
STALEVO 100, CARBIDOPA  
STALEVO 125, CARBIDOPA  
STALEVO 150, CARBIDOPA  
STALEVO 200, CARBIDOPA  
STALEVO 50, CARBIDOPA  
STALEVO 75, CARBIDOPA

**ORTHO BIOTECH**

\* ORTHO BIOTECH PRODUCTS LP  
DOXIL, DOXORUBICIN HYDROCHLORIDE  
LEUSTATIN, CLADRIBINE

**ORTHO DERMATOLOGICS**

\* ORTHO DERMATOLOGICS  
ERTACZO, SERTACONAZOLE NITRATE  
RENOVA, TRETINOIN  
RETIN-A MICRO, TRETINOIN

**ORTHO MCNEIL JANSSEN**

\* ORTHO MCNEIL JANSSEN PHARMACEUTICAL INC  
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE  
DORIBAX, DORIPENEM  
HALDOL, HALOPERIDOL DECANOATE  
RAZADYNE, GALANTAMINE HYDROBROMIDE  
RISPERDAL, RISPERIDONE  
TERAZOL 3, TERCONAZOLE  
ULTRACET, ACETAMINOPHEN



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* O \*\***

\* ORTHO MCNEIL JANSSEN PHARMACEUTICALS INC  
 AXERT, ALMOTRIPTAN MALATE  
 DITROPAN XL, OXYBUTYNIN CHLORIDE  
 DITROPAN, OXYBUTYNIN CHLORIDE  
 DURAGESIC-100, FENTANYL  
 DURAGESIC-12, FENTANYL  
 DURAGESIC-25, FENTANYL  
 DURAGESIC-50, FENTANYL  
 DURAGESIC-75, FENTANYL  
 ELMIRON, PENTOSAN POLYSULFATE SODIUM  
 HALDOL, HALOPERIDOL LACTATE  
 INVEGA, PALIPERIDONE  
 LEVAQUIN, LEVOFLOXACIN  
 MICRONOR, NORETHINDRONE  
 MODICON 28, ETHINYL ESTRADIOL  
 NIZORAL, KETOCONAZOLE  
 NUCYNTA, TAPENTADOL HYDROCHLORIDE  
 ORTHO CYCLEN-28, ETHINYL ESTRADIOL  
 ORTHO EVRA, ETHINYL ESTRADIOL  
 ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL  
 ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL  
 ORTHO-CEPT, DESOGESTREL  
 ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL  
 ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL  
 PARAFON FORTE DSC, CHLORZOXAZONE  
 RAZADYNE ER, GALANTAMINE HYDROBROMIDE  
 RAZADYNE, GALANTAMINE HYDROBROMIDE  
 RISPERDAL CONSTA, RISPERIDONE  
 RISPERDAL, RISPERIDONE  
 SPORANOX, ITRACONAZOLE  
 TERAZOL 3, TERCONAZOLE  
 TERAZOL 7, TERCONAZOLE  
 TOLECTIN 600, TOLMETIN SODIUM  
 TOLECTIN DS, TOLMETIN SODIUM  
 TOLECTIN, TOLMETIN SODIUM  
 TOPAMAX, TOPIRAMATE  
 ULTRAM, TRAMADOL HYDROCHLORIDE  
 URISPAS, FLAVOXATE HYDROCHLORIDE

**ORTHO MCNEIL PHARM**

\* ORTHO MCNEIL PHARMACEUTICAL INC  
 LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 LEVAQUIN, LEVOFLOXACIN

**OSCIENT**

\* OSCIENT PHARMACEUTICALS  
 ANTARA (MICRONIZED), FENOFIBRATE  
 FACTIVE, GEMIFLOXACIN MESYLATE

**OSI PHARMS**

\* OSI PHARMACEUTICALS INC  
 TARCEVA, ERLOTINIB HYDROCHLORIDE

**OSMOTICA PHARM**

\* OSMOTICA PHARMACEUTICAL CORP  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

**OTSUKA**

\* OTSUKA PHARMACEUTICAL CO LTD  
 ABILIFY, ARIPIPIRAZOLE  
 PLETAL, CILOSTAZOL  
 \* OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC  
 ABILIFY, ARIPIPIRAZOLE

**OTSUKA AMERICA**

\* OTSUKA AMERICA PHARMACEUTICALS INC  
 BREATHTEK UBT FOR H-PYLORI, UREA, C-13

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* O \*\*

OTSUKA AMERICA PHARM

- \* OTSUKA AMERICA PHARMACEUTICAL INC  
SAMSCA, TOLVAPTAN

OTSUKA PHARM

- \* OTSUKA PHARMACEUTICAL CO LTD  
BUSULFEX, BUSULFAN

PACIRA PHARMS INC

- \* PACIRA PHARMACEUTICALS INC  
DEPOCYT, CYTARABINE  
DEPODUR, MORPHINE SULFATE

PADDOCK LABS

- \* PADDOCK LABORATORIES INC  
MIDAMOR, AMILORIDE HYDROCHLORIDE

PALADIN LABS

- \* PALADIN LABS USA INC  
ANTIZOL, FOMEPIZOLE

PAR PHARM

- \* PAR PHARMACEUTICAL INC  
CAPOTEN, CAPTOPRIL  
MEGACE ES, MEGESTROL ACETATE  
NASCOBAL, CYANOCOBALAMIN

PARKE DAVIS

- \* PARKE DAVIS DIV WARNER LAMBERT CO  
CELONTIN, METHSUXIMIDE  
CEREBYX, FOSPHENYTOIN SODIUM  
DILANTIN-125, PHENYTOIN  
NARDIL, PHENELZINE SULFATE  
NEURONTIN, GABAPENTIN  
ZARONTIN, ETHOSUXIMIDE

PAV NOVA

- \* PAV NOVA INC  
TODAY, NONOXYNOL-9 (OTC)

PEDINOL

- \* PEDINOL PHARMACAL INC  
GRIS-PEG, GRISEOFULVIN, ULTRAMICROCRYSTALLINE  
NALFON, FENOPROFEN CALCIUM

PERRIGO NEW YORK

- \* PERRIGO NEW YORK INC  
CENTANY, MUPIROCIN  
DESONIDE, DESONIDE

PERSONAL PRODS

- \* PERSONAL PRODUCTS CO  
MONISTAT 3, MICONAZOLE NITRATE

PFIZER

- \* PFIZER CENTRAL RESEARCH  
DIFLUCAN, FLUCONAZOLE  
ZITHROMAX, AZITHROMYCIN
- \* PFIZER CHEMICALS DIV PFIZER INC  
DIFLUCAN, FLUCONAZOLE  
ZITHROMAX, AZITHROMYCIN
- \* PFIZER INC  
ANTIVERT, MECLIZINE HYDROCHLORIDE  
ARGATROBAN, ARGATROBAN  
CADUET, AMLODIPINE BESYLATE  
CARDURA XL, DOXAZOSIN MESYLATE  
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE  
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

- \* PFIZER INC
  - GEODON, ZIPRASIDONE HYDROCHLORIDE
  - GEODON, ZIPRASIDONE MESYLATE
  - GLUCOTROL XL, GLIPIZIDE
  - GLUCOTROL, GLIPIZIDE
  - LIPITOR, ATORVASTATIN CALCIUM
  - NAVANE, THIOTHIXENE
  - NORVASC, AMLODIPINE BESYLATE
  - PROCARDIA, NIFEDIPINE
  - REVATIO, SILDENAFIL CITRATE
  - RID MOUSSE, PIPERONYL BUTOXIDE (OTC)
  - TOVIAZ, FESOTERODINE FUMARATE
  - UNASYN, AMPICILLIN SODIUM
  - VFEND, VORICONAZOLE
  - ZITHROMAX, AZITHROMYCIN
- \* PFIZER LABORATORIES DIV PFIZER INC
  - CARDURA, DOXAZOSIN MESYLATE
  - DIABINESE, CHLORPROPAMIDE
  - FELDENE, PIROXICAM
  - MINIPRESS, PRAZOSIN HYDROCHLORIDE
  - PROCARDIA XL, NIFEDIPINE
  - VIBRAMYCIN, DOXYCYCLINE
  - VIBRAMYCIN, DOXYCYCLINE CALCIUM
  - VIBRAMYCIN, DOXYCYCLINE HYCLATE
  - VIBRA-TABS, DOXYCYCLINE HYCLATE
  - VISTARIL, HYDROXYZINE PAMOATE
- \* PFIZER PHARMACEUTICALS INC
  - ZOLOFT, SERTRALINE HYDROCHLORIDE
- \* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
  - TIKOSYN, DOFETILIDE

**PFIZER GLOBAL**

- \* PFIZER GLOBAL RESEARCH DEVELOPMENT
  - ZMAX, AZITHROMYCIN

**PFIZER INC**

- \* PFIZER INC
  - CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
  - CHANTIX, VARENICLINE TARTRATE
  - ELLENCEN, EPIRUBICIN HYDROCHLORIDE
  - GEODON, ZIPRASIDONE HYDROCHLORIDE
  - NICOTROL, NICOTINE

**PFIZER IRELAND**

- \* PFIZER IRELAND PHARMACEUTICALS
  - RELPAK, ELETRIPTAN HYDROBROMIDE
  - VIAGRA, SILDENAFIL CITRATE

**PFIZER PHARMS**

- \* PFIZER PHARMACEUTICALS LTD
  - ACCUPRIL, QUINAPRIL HYDROCHLORIDE
  - ACCURETIC, HYDROCHLOROTHIAZIDE
  - LOPID, GEMFIBROZIL
  - NEURONTIN, GABAPENTIN
  - NITROSTAT, NITROGLYCERIN

**PHARMACIA AND UPJOHN**

- \* PHARMACIA AND UPJOHN
  - XANAX XR, ALPRAZOLAM
- \* PHARMACIA AND UPJOHN CO
  - ANSAID, FLURBIPROFEN
  - AROMASIN, EXEMESTANE
  - AZULFIDINE EN-TABS, SULFASALAZINE
  - AZULFIDINE, SULFASALAZINE
  - CAVERJECT IMPULSE, ALPROSTADIL
  - CAVERJECT, ALPROSTADIL
  - CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
  - CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

- \* PHARMACIA AND UPJOHN CO  
 CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLEOCIN T, CLINDAMYCIN PHOSPHATE  
 CLEOCIN, CLINDAMYCIN PHOSPHATE  
 COLESTID, COLESTIPOL HYDROCHLORIDE  
 CORTEF, HYDROCORTISONE  
 CORVERT, IBUTILIDE FUMARATE  
 CYKLOKAPRON, TRANEXAMIC ACID  
 DEPO-MEDROL, METHYLPREDNISOLONE ACETATE  
 DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE  
 DETROL LA, TOLTERODINE TARTRATE  
 DETROL, TOLTERODINE TARTRATE  
 DIDREX, BENZPHETAMINE HYDROCHLORIDE  
 EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM  
 ESTRING, ESTRADIOL  
 FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE  
 GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT  
 GENOTROPIN, SOMATROPIN RECOMBINANT  
 GLYNASE, GLYBURIDE  
 GLYSET, MIGLITOL  
 HALCION, TRIAZOLAM  
 HEMABATE, CARBOPROST TROMETHAMINE  
 IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE  
 LINCOCIN, LINCOMYCIN HYDROCHLORIDE  
 MEDROL, METHYLPREDNISOLONE  
 MYCOBUTIN, RIFABUTIN  
 NICOTROL, NICOTINE  
 PREPIDIL, DINOPROSTONE  
 PROSTIN E2, DINOPROSTONE  
 PROSTIN VR PEDIATRIC, ALPROSTADIL  
 PROVERA, MEDROXYPROGESTERONE ACETATE  
 R-GENE 10, ARGININE HYDROCHLORIDE  
 SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE  
 SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE  
 SOMAVERT, PEGVISOMANT  
 TROBICIN, SPECTINOMYCIN HYDROCHLORIDE  
 VANTIN, CEFPODOXIME PROXETIL  
 XALATAN, LATANOPROST  
 XANAX, ALPRAZOLAM  
 ZINECARD, DEXRAZOXANE HYDROCHLORIDE  
 ZYVOX, LINEZOLID
- \* PHARMACIA AND UPJOHN SUB PFIZER INC  
 DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE

**PHARMALUCENCE**

- \* PHARMALUCENCE INC  
 AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT  
 AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT  
 CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT  
 CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT  
 HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT  
 PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

**PHARMASEAL**

- \* PHARMASEAL DIV BAXTER HEALTHCARE CORP  
 PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)

**PIERRE FABRE**

- \* PIERRE FABRE MEDICAMENT  
 NAVELBINE, VINORELBINE TARTRATE

**POHL BOSKAMP**

- \* POHL BOSKAMP  
 NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\*****POLYMEDICA**

- \* POLYMEDICA INDUSTRIES INC  
NEOPAP, ACETAMINOPHEN (OTC)

**PRIMAPHARM**

- \* PRIMAPHARM INC  
HYDASE, HYALURONIDASE

**PRISM PHARMS**

- \* PRISM PHARMACEUTICALS INC  
NEXTERONE, AMIODARONE HYDROCHLORIDE

**PROCTER AND GAMBLE**

- \* PROCTER AND GAMBLE CO  
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
- \* PROCTER AND GAMBLE PHARMACEUTICALS INC  
ASACOL HD, MESALAMINE
- \* PROCTER AND GAMBLE PHARMACEUTICALS INC SUB PROCTER AND GAMBLE CO  
ACTONEL, RISEDRONATE SODIUM  
ASACOL, MESALAMINE  
DIDRONEL, ETIDRONATE DISODIUM  
MACROBID, NITROFURANTOIN

**PROGENICS**

- \* PROGENICS PHARMACEUTICALS INC  
RELISTOR, METHYLNALTREXONE BROMIDE

**PROMETHEUS LABS**

- \* PROMETHEUS LABORATORIES INC  
HELIDAC, BISMUTH SUBSALICYLATE  
IMURAN, AZATHIOPRINE  
LOTRONEX, ALOSETRON HYDROCHLORIDE  
RIDAURA, AURANOFIN  
TRANDATE, LABETALOL HYDROCHLORIDE  
ZYLOPRIM, ALLOPURINOL

**PROMIUS PHARMA**

- \* PROMIUS PHARMA LLC  
ISMO, ISOSORBIDE MONONITRATE  
SECTRAL, ACEBUTOLOL HYDROCHLORIDE  
TENEX, GUANFACINE HYDROCHLORIDE

**PURDUE PHARM PRODS**

- \* PURDUE PHARMACEUTICAL PRODUCTS LP  
DILAUDID, HYDROMORPHONE HYDROCHLORIDE  
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE

**PURDUE PHARMA**

- \* PURDUE PHARMA PRODUCTS LP  
RYZOLT, TRAMADOL HYDROCHLORIDE

**PURDUE PHARMA LP**

- \* PURDUE PHARMA LP  
MS CONTIN, MORPHINE SULFATE  
OXYCONTIN, OXYCODONE HYDROCHLORIDE

**QLT**

- \* QLT INC  
VISUDYNE, VERTEPORFIN

**QOL MEDCL**

- \* QOL MEDICAL LLC  
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE  
ETHAMOLIN, ETHANOLAMINE OLEATE  
SUCRAID, SACROSIDASE

**QUESTCOR PHARMS**

- \* QUESTCOR PHARMACEUTICALS INC  
DORAL, QUAZEPAM  
H.P. ACTHAR GEL, CORTICOTROPIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* R \*\*****R TECH UENO LTD**

- \* R TECH UENO LTD  
RESCULA, UNOPROSTONE ISOPROPYL

**RANBAXY**

- \* RANBAXY LABORATORIES INC  
EURAX, CROTAMITON  
EXELDERM, SULCONAZOLE NITRATE  
HALOG, HALCINONIDE  
ISOPTIN SR, VERAPAMIL HYDROCHLORIDE  
KENALOG, TRIAMCINOLONE ACETONIDE  
LAC-HYDRIN, AMMONIUM LACTATE  
ULTRAVATE, HALOBETASOL PROPIONATE  
WESTCORT, HYDROCORTISONE VALERATE
- \* RANBAXY PHARMACEUTICALS INC  
AVENTYL HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE  
RIOMET, METFORMIN HYDROCHLORIDE

**RARE DIS**

- \* RARE DISEASE THERAPEUTICS INC  
ORFADIN, NITISINONE

**RARE DIS THERAP**

- \* RARE DISEASE THERAPEUTICS INC  
CYSTADANE, BETAINE HYDROCHLORIDE

**RECKITT BENCKISER**

- \* RECKITT BENCKISER  
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
- \* RECKITT BENCKISER INC  
MUCINEX D, GUAIFENESIN (OTC)  
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)  
MUCINEX, GUAIFENESIN (OTC)
- \* RECKITT BENCKISER PHARMACEUTICALS INC  
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE  
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE  
SUBUTEX, BUPRENORPHINE HYDROCHLORIDE

**REGENT**

- \* REGENT MEDICAL AMERICAS LLC  
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)  
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

**ROCHE**

- \* HOFFMANN LA ROCHE INC  
BONIVA, IBANDRONATE SODIUM  
COPEGUS, RIBAVIRIN  
FUZEON, ENFUVIRTIDE  
INVIRASE, SAQUINAVIR MESYLATE  
KLONOPIN, CLONAZEPAM  
KYTRIL, GRANISETRON HYDROCHLORIDE  
TAMIFLU, OSELTAMIVIR PHOSPHATE  
VALIUM, DIAZEPAM  
VESANOID, TRETINOIN

**ROCHE PALO**

- \* ROCHE PALO ALTO LLC  
AEROBID, FLUNISOLIDE  
ANAPROX DS, NAPROXEN SODIUM  
ANAPROX, NAPROXEN SODIUM  
CELLCEPT, MYCOPHENOLATE MOFETIL  
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE  
EC-NAPROSYN, NAPROXEN  
NAPROSYN, NAPROXEN  
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE

**ROMARK**

- \* ROMARK LABORATORIES  
ALINIA, NITAZOXANIDE

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 854 of 1114**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* R \*\*****ROSS LABS**

\* ROSS LABORATORIES DIV ABBOTT LABORATORIES INC  
SURVANTA, BERACTANT

**ROXANE**

\* ROXANE LABORATORIES INC  
CODEINE SULFATE, CODEINE SULFATE  
DIGOXIN, DIGOXIN  
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
FUROSEMIDE, FUROSEMIDE  
LITHIUM CARBONATE, LITHIUM CARBONATE  
LITHIUM CITRATE, LITHIUM CITRATE  
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
MORPHINE SULFATE, MORPHINE SULFATE

**SAGE PRODS**

\* SAGE PRODUCTS INC  
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

**SALIX PHARMS**

\* SALIX PHARMACEUTICALS INC  
APRISO, MESALAMINE  
COLAZAL, BALSALAZIDE DISODIUM  
DIURIL, CHLOROTHIAZIDE  
METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE  
MOVIPREP, ASCORBIC ACID  
OSMOPREP, SODIUM PHOSPHATE, DIBASIC ANHYDROUS  
PEPCID, FAMOTIDINE  
VISICOL, SODIUM PHOSPHATE, DIBASIC ANHYDROUS  
XIFAXAN, RIFAXIMIN

**SANDOZ**

\* SANDOZ CANADA INC  
ANECTINE, SUCCINYLCHOLINE CHLORIDE  
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE  
COSYNTROPIN, COSYNTROPIN  
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE  
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID  
INFUVITE PEDIATRIC, ASCORBIC ACID  
REGONOL, PYRIDOSTIGMINE BROMIDE

\* SANDOZ INC  
FUROSEMIDE, FUROSEMIDE  
ISONIAZID, ISONIAZID  
METRONIDAZOLE, METRONIDAZOLE  
OMNITROPE, SOMATROPIN RECOMBINANT  
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE  
RESERPINE, RESERPINE  
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE

**SANOFI AVENTIS US**

\* SANOFI AVENTIS US LLC  
ALLEGRA D 24 HOUR, FEXOFENADINE HYDROCHLORIDE  
ALLEGRA, FEXOFENADINE HYDROCHLORIDE  
ALLEGRA-D 12 HOUR, FEXOFENADINE HYDROCHLORIDE  
AMARYL, GLIMEPIRIDE  
AMBIEN CR, ZOLPIDEM TARTRATE  
AMBIEN, ZOLPIDEM TARTRATE  
ANZEMET, DOLASETRON MESYLATE  
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT  
APIDRA, INSULIN GLULISINE RECOMBINANT  
ARALEN, CHLOROQUINE PHOSPHATE  
ARAVAL, LEFLUNOMIDE  
AVALIDE, HYDROCHLOROTHIAZIDE  
AVAPRO, IRBESARTAN  
BENZACLIN, BENZOYL PEROXIDE  
BENZAMYCIN PAK, BENZOYL PEROXIDE  
BENZAMYCIN, BENZOYL PEROXIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SANOFI AVENTIS US LLC  
 CANTIL, MEPENZOLATE BROMIDE  
 CARAC, FLUOROURACIL  
 CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM  
 CLAFORAN, CEFOTAXIME SODIUM  
 CLOMID, CLOMIPHENE CITRATE  
 DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE  
 DDAVP, DESMOPRESSIN ACETATE  
 DEMEROL, MEPERIDINE HYDROCHLORIDE  
 DERMATOP E EMOLLIENT, PREDNICARBATE  
 DERMATOP, PREDNICARBATE  
 DIABETA, GLYBURIDE  
 DRISDOL, ERGOCALCIFEROL  
 ELOXATIN, OXALIPLATIN  
 FERRELECIT, SODIUM FERRIC GLUCONATE COMPLEX  
 GAVISCON, ALUMINUM HYDROXIDE (OTC)  
 HIPREX, METHENAMINE HIPPURATE  
 KAYEXALATE, SODIUM POLYSTYRENE SULFONATE  
 KETEK, TELITHROMYCIN  
 KLARON, SULFACETAMIDE SODIUM  
 LANTUS, INSULIN GLARGINE RECOMBINANT  
 LASIX, FUROSEMIDE  
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM  
 LOVENOX, ENOXAPARIN SODIUM  
 MULTAQ, DRONEDARONE HYDROCHLORIDE  
 MYTELASE, AMBENONIUM CHLORIDE  
 NASACORT AQ, TRIAMCINOLONE ACETONIDE  
 NEGGRAM, NALIDIXIC ACID  
 NICODERM CQ, NICOTINE (OTC)  
 NILANDRON, NILUTAMIDE  
 NORITATE, METRONIDAZOLE  
 NORPRAMIN, DESIPRAMINE HYDROCHLORIDE  
 OFORTA, FLUDARABINE PHOSPHATE  
 PENLAC, CICLOPIROX  
 PHISOHEX, HEXACHLOROPHENE  
 PLAQUENIL, HYDROXYCHLOROQUINE SULFATE  
 PLAVIX, CLOPIDOGREL BISULFATE  
 PRIFTIN, RIFAPENTINE  
 PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE  
 PRIMAQUINE, PRIMAQUINE PHOSPHATE  
 PSORCON, DIFLORASONE DIACETATE  
 RIFADIN, RIFAMPIN  
 RIFATER, ISONIAZID  
 RILUTEK, RILUZOLE  
 SKELID, TILUDRONATE DISODIUM  
 TALACEN, ACETAMINOPHEN  
 TALWIN NX, NALOXONE HYDROCHLORIDE  
 TAXOTERE, DOCETAXEL  
 TRENAL, PENTOXIFYLLINE  
 UROXATRAL, ALFUZOSIN HYDROCHLORIDE

**SANTARUS**

\* SANTARUS INC  
 MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE, MAGNESIUM HYDROXIDE  
 ZEGERID, MAGNESIUM HYDROXIDE  
 ZEGERID, OMEPRAZOLE

**SANTEN**

\* SANTEN INC  
 ALAMAST, PEMIROLAST POTASSIUM  
 IQUIX, LEVOFLOXACIN  
 QUIXIN, LEVOFLOXACIN

**SANTEN OY**

\* SANTEN OY  
 BETIMOL, TIMOLOL



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\*****SAVAGE LABS**

- \* SAVAGE LABORATORIES INC DIV ALTANA INC  
ETHIODOL, ETHIODIZED OIL  
KAON CL-10, POTASSIUM CHLORIDE  
PANDEL, HYDROCORTISONE PROBUTATE

**SAVIENT PHARMS**

- \* SAVIENT PHARMACEUTICALS INC  
OXANDRIN, OXANDROLONE

**SB PHARMCO**

- \* SB PHARMCO PUERTO RICO INC  
AVANDAMET, METFORMIN HYDROCHLORIDE  
AVANDARYL, GLIMEPIRIDE  
AVANDIA, ROSIGLITAZONE MALEATE  
COREG CR, CARVEDILOL PHOSPHATE

**SCHERING**

- \* SCHERING  
CLARINEX-D 12 HOUR, DESLORATADINE
- \* SCHERING CORP  
ASMANEX TWISTHALER, MOMETASONE FUROATE  
CLARINEX D 24 HOUR, DESLORATADINE  
CLARINEX, DESLORATADINE  
DIPROLENE AF, BETAMETHASONE DIPROPIONATE  
GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE  
INTEGRILIN, EPTIFIBATIDE  
LOTRISONE, BETAMETHASONE DIPROPIONATE  
NOXAFIL, POSACONAZOLE  
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
REBETOL, RIBAVIRIN  
TEMODAR, TEMOZOLOMIDE  
ZEMURON, ROCURONIUM BROMIDE
- \* SCHERING CORP SUB SCHERING PLOUGH CORP  
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE  
CELESTONE, BETAMETHASONE  
DIPROLENE, BETAMETHASONE DIPROPIONATE  
ELOCON, MOMETASONE FUROATE

**SCHERING PLOUGH**

- \* SCHERING PLOUGH CORP  
CLARINEX, DESLORATADINE
- \* SCHERING PLOUGH HEALTHCARE PRODUCTS INC  
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)  
CHILDREN'S CLARITIN, LORATADINE (OTC)  
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)  
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)  
CLARITIN HIVES RELIEF, LORATADINE (OTC)  
CLARITIN REDITABS, LORATADINE (OTC)  
CLARITIN, LORATADINE (OTC)  
CLARITIN-D 24 HOUR, LORATADINE (OTC)  
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)  
DRIXORAL PLUS, ACETAMINOPHEN (OTC)  
DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)  
GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)  
GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)  
GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)  
GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)  
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)  
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)  
NASONEX, MOMETASONE FUROATE MONOHYDRATE  
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)  
SHADE UVAGUARD, AVOBENZONE (OTC)  
ZEGERID OTC, OMEPRAZOLE (OTC)

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* S \*\*

SCHERING PLOUGH RES

- \* SCHERING PLOUGH RESEARCH INSTITUTE  
LOTTRISONE, BETAMETHASONE DIPROPIONATE  
REBETOL, RIBAVIRIN

SCHWARZ

- \* SCHWARZ GMBH  
MONOKET, ISOSORBIDE MONONITRATE

SCHWARZ BIOSCIENCES

- \* SCHWARZ BIOSCIENCES INC  
VIMPAT, LACOSAMIDE

SCHWARZ PHARMA

- \* SCHWARZ PHARMA AG  
EDEX, ALPROSTADIL
- \* SCHWARZ PHARMA INC  
CORTIFOAM, HYDROCORTISONE ACETATE  
DILATRATE-SR, ISOSORBIDE DINITRATE  
FLUXID, FAMOTIDINE  
KEMSTRO, BACLOFEN  
LEVATOL, PENBUTOLOL SULFATE  
NIRAVAM, ALPRAZOLAM  
ROBAXIN, METHOCARBAMOL  
ROBAXIN-750, METHOCARBAMOL  
UNIRETIC, HYDROCHLOROTHIAZIDE  
UNIVASC, MOEXIPRIL HYDROCHLORIDE

SCIELE PHARMA INC

- \* SCIELE PHARMA INC  
CEDAX, CEFTIBUTEN DIHYDRATE  
COGNEX, TACRINE HYDROCHLORIDE  
FENOGLIDE, FENOFIBRATE  
FURADANTIN, NITROFURANTOIN  
JENLOGA, CLONIDINE HYDROCHLORIDE  
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE  
PONSTEL, MEFENAMIC ACID  
ROBINUL FORTE, GLYCOPYRROLATE  
ROBINUL, GLYCOPYRROLATE  
SULAR, NISOLDIPINE  
TWINJECT 0.15, EPINEPHRINE  
TWINJECT 0.3, EPINEPHRINE  
ULESFIA, BENZYL ALCOHOL

SCIOS

- \* SCIOS INC  
NATRECOR, NESIRITIDE RECOMBINANT

SEPRACOR

- \* SEPRACOR INC  
BROVANA, ARFORMOTEROL TARTRATE  
LUNESTA, ESZOPICLONE  
XOPENEX HFA, LEVALBUTEROL TARTRATE  
XOPENEX, LEVALBUTEROL HYDROCHLORIDE

SHIRE

- \* SHIRE DEVELOPMENT INC  
ADDERALL XR 10, AMPHETAMINE ASPARTATE  
ADDERALL XR 15, AMPHETAMINE ASPARTATE  
ADDERALL XR 20, AMPHETAMINE ASPARTATE  
ADDERALL XR 25, AMPHETAMINE ASPARTATE  
ADDERALL XR 30, AMPHETAMINE ASPARTATE  
ADDERALL XR 5, AMPHETAMINE ASPARTATE  
AGRYLIN, ANAGRELIDE HYDROCHLORIDE  
CARBATROL, CARBAMAZEPINE  
DAYTRANA, METHYLPHENIDATE  
FOSRENOL, LANTHANUM CARBONATE  
INTUNIV, GUANFACINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SHIRE DEVELOPMENT INC  
LIALDA, MESALAMINE  
PENTASA, MESALAMINE  
PROAMATINE, MIDODRINE HYDROCHLORIDE  
SALURON, HYDROFLUMETHIAZIDE

**SHIRE DEVELOPMENT**

\* SHIRE DEVELOPMENT INC  
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

**SIGMA TAU**

\* SIGMA TAU PHARMACEUTICALS INC  
CARNITOR SF, LEVOCARNITINE  
CARNITOR, LEVOCARNITINE  
MATULANE, PROCARBAZINE HYDROCHLORIDE

**SIRION THERAP**

\* SIRION THERAPEUTICS INC  
DUREZOL, DIFLUPREDNATE  
ZIRGAN, GANCICLOVIR

**SKINMEDICA**

\* SKINMEDICA INC  
VANIQA, EFLORNITHINE HYDROCHLORIDE

**SKYEPHARMA AG**

\* SKYEPHARMA AG  
TRIGLIDE, FENOFIBRATE

**SMITHKLINE BEECHAM**

\* SMITHKLINE BEECHAM  
LOVAZA, OMEGA-3-ACID ETHYL ESTERS

\* SMITHKLINE BEECHAM CORP  
LAMICTAL XR, LAMOTRIGINE

\* SMITHKLINE BEECHAM CORP DBA GLAXOSMITHKLINE  
ARRANON, NELARABINE  
AXID, NIZATIDINE  
COREG, CARVEDILOL  
DEXEDRINE, DEXTROAMPHETAMINE SULFATE  
DYNACIRC CR, ISRADIPINE  
HYCANTIN, TOPOTECAN HYDROCHLORIDE  
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE  
LAMICTAL ODT, LAMOTRIGINE  
LANOXICAPS, DIGOXIN  
LANOXIN, DIGOXIN  
LEUKERAN, CHLORAMBUCIL  
REQUIP XL, ROPINIROLE HYDROCHLORIDE  
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE  
RYTHMOL, PROPAFENONE HYDROCHLORIDE  
TYKERB, LAPATINIB DITOSYLATE

**SOLUMED**

\* LES ENTREPRISES SOLUMED INC  
CHLORASCRUB MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORASCRUB SWAB, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORASCRUB SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

**SOLVAY**

\* SOLVAY PHARMACEUTICALS  
CREON, LIPASE

**SOLVAY PHARMS**

\* SOLVAY PHARMACEUTICALS INC  
ACEON, PERINDOPRIL ERBUMINE

**SOMERSET**

\* SOMERSET PHARMACEUTICALS INC  
ELDEPRYL, SELEGILINE HYDROCHLORIDE  
EMSAM, SELEGILINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\*****SPECTRUM PHARMS**

\* SPECTRUM PHARMACEUTICALS INC  
FUSILEV, LEVOLEUCOVORIN CALCIUM

**STAND HOMEOPATH**

\* STANDARD HOMEOPATHIC CO  
IVY BLOCK, BENTOQUATAM (OTC)

**STAT TRADE**

\* STAT TRADE INC  
NAPRELAN, NAPROXEN SODIUM

**STEVENS J**

\* JEROME STEVENS PHARMACEUTICALS INC  
UNITHROID, LEVOTHYROXINE SODIUM

**STI PHARMA LLC**

\* STI PHARMA LLC  
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE

**STIEFEL**

\* STIEFEL LABORATORIES INC  
DECLOMYCIN, DEMECLOCYCLINE HYDROCHLORIDE  
DUAC, BENZOYL PEROXIDE

**STIEFEL LABS INC**

\* STIEFEL LABORATORIES INC  
EVOCLIN, CLINDAMYCIN PHOSPHATE  
EXTINA, KETOCONAZOLE  
OLUX E, CLOBETASOL PROPIONATE  
SOLAGE, MEQUINOL  
SORIATANE, ACITRETIN  
VERDESO, DESONIDE  
VUSION, MICONAZOLE NITRATE  
XOLEGEL, KETOCONAZOLE

**STRAKAN**

\* STRAKAN INTERNATIONAL LTD  
SANCUSO, GRANISETRON

**SUCAMPO PHARMS**

\* SUCAMPO PHARMACEUTICALS INC  
AMITIZA, LUBIPROSTONE

**SYNCOR PHARMS**

\* SYNCOR PHARMACEUTICALS INC  
SODIUM IODIDE I 123, SODIUM IODIDE, I-123

**TAKEDA GLOBAL**

\* TAKEDA GLOBAL RESEARCH DEVELOPMENT CENTER INC  
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE  
ACTOPLUS MET, METFORMIN HYDROCHLORIDE  
DUETACT, GLIMEPIRIDE  
ROZEREM, RAMELTEON

**TAKEDA PHARMS**

\* TAKEDA PHARMACEUTICALS NORTH AMERICA INC  
KAPIDEX, DEXLANSOPRAZOLE  
ULORIC, FEBUXOSTAT

**TAKEDA PHARMS NA**

\* TAKEDA PHARMACEUTICALS NORTH AMERICA INC  
ACTOS, PIOGLITAZONE HYDROCHLORIDE  
PREVACID, LANSOPRAZOLE  
PREVPAC, AMOXICILLIN

**TARO**

\* TARO PHARMACEUTICALS USA INC  
FLO-PRED, PREDNISOLONE ACETATE  
FLUOCINONIDE, FLUOCINONIDE  
LORATADINE, LORATADINE (OTC)  
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\*****TARO PHARMS NORTH**

\* TARO PHARMACEUTICALS NORTH AMERICA INC  
OVIDE, MALATHION  
TOPICORT LP, DESOXIMETASONE  
TOPICORT, DESOXIMETASONE

**TEIKOKU PHARMA USA**

\* TEIKOKU PHARMA USA INC  
LIDODERM, LIDOCAINE

**TERCICA**

\* TERCICA INC  
INCRELEX, MECASERMIN RECOMBINANT

**TEVA**

\* TEVA NEUROSCIENCE INC  
AZILECT, RASAGILINE MESYLATE  
COPAXONE, GLATIRAMER ACETATE  
\* TEVA PHARMACEUTICALS USA INC  
BETA-VAL, BETAMETHASONE VALERATE  
GALZIN, ZINC ACETATE  
ORAP, PIMOZIDE  
PURINETHOL, MERCAPTOPYRINE  
TRIMETHOPRIM, TRIMETHOPRIM

**TEVA GLOBAL**

\* TEVA GLOBAL RESPIRATORY RESEARCH LLC  
NASAREL, FLUNISOLIDE  
PROAIR HFA, ALBUTEROL SULFATE  
PROGLYCEM, DIAZOXIDE  
QVAR 40, BECLOMETHASONE DIPROPIONATE  
QVAR 80, BECLOMETHASONE DIPROPIONATE

**TEVA PARENTERAL**

\* TEVA PARENTERAL MEDICINES INC  
AZITHROMYCIN, AZITHROMYCIN  
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
OXALIPLATIN, OXALIPLATIN  
ZANOSAR, STREPTOZOCIN

**TEVA PHARMS**

\* TEVA PHARMACEUTICALS USA  
VANDAZOLE, METRONIDAZOLE

**THERAKOS**

\* THERAKOS INC  
UVADEX, METHOXSALEN

**THERAVANCE INC**

\* THERAVANCE INC  
VIBATIV, TELAVANCIN HYDROCHLORIDE

**THREE RIVERS PHARMS**

\* THREE RIVERS PHARMACEUTICALS LLC  
AMPHOTEC, AMPHOTERICIN B

**TIBOTEC**

\* TIBOTEC INC  
INTELENCE, ETRAVIRINE

**TOLMAR**

\* TOLMAR INC  
ATRIDOX, DOXYCYCLINE HYCLATE

**TOLMAR THERAP**

\* TOLMAR THERAPEUTICS INC  
ELIGARD, LEUPROLIDE ACETATE

**TOPOTARGET**

\* TOPOTARGET AS  
TOTECT, DEXRAZOXANE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\*****TRIAx PHARMS LLC**

\* TRIAX PHARMACEUTICALS LLC  
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE  
LOCOID, HYDROCORTISONE BUTYRATE  
MINOCIN, MINOCYCLINE HYDROCHLORIDE

**TRIS PHARMA**

\* TRIS PHARMA INC  
CLONIDINE, CLONIDINE

**TYCO HLTHCARE**

\* TYCO HEALTHCARE GROUP LP  
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE  
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE  
RESTORIL, TEMAZEPAM  
TOFRANIL-PM, IMIPRAMINE PAMOATE

**UCB INC**

\* UCB INC  
DIPENTUM, OLSALAZINE SODIUM  
KEPPRA XR, LEVETIRACETAM  
KEPPRA, LEVETIRACETAM  
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE  
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE  
SEMPREX-D, ACRIVASTINE  
TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLYSTIREX  
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE  
ZAROXOLYN, METOLAZONE

**UCYCLYD**

\* UCYCLYD PHARMA INC  
AMMONUL, SODIUM BENZOATE

**UDL LABS**

\* UDL LABORATORIES  
SULFAMYLON, MAFENIDE ACETATE

**ULURU**

\* ULURU INC  
APHTHASOL, AMLEXANOX

**UNIMED**

\* UNIMED INC  
MARINOL, DRONABINOL

**UNIMED PHARMS**

\* UNIMED PHARMACEUTICALS INC  
ANDROGEL, TESTOSTERONE

**UNIMED PHARMS LLC**

\* UNIMED PHARMACEUTICALS LLC  
PROMETRIUM, PROGESTERONE

**UNITED GUARDIAN**

\* UNITED GUARDIAN INC  
RENACIDIN, CITRIC ACID

**UNITED THERAP**

\* UNITED THERAPEUTICS CORP  
REMODULIN, TREPROSTINIL SODIUM  
TYVASO, TREPROSTINIL SODIUM

**UPSHER SMITH**

\* UPSHER SMITH LABORATORIES INC  
DIVIGEL, ESTRADIOL  
FORTICAL, CALCITONIN SALMON RECOMBINANT  
KLOR-CON, POTASSIUM CHLORIDE

**US SURGCL**

\* UNITED STATES SURGICAL DIV TYCO HEALTHCARE GROUP LP  
LYMPHAZURIN, ISOSULFAN BLUE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* V \*\*****VALEANT**

\* VALEANT PHARMACEUTICALS INTERNATIONAL  
 ANCOBON, FLUCYOSINE  
 D.H.E. 45, DIHYDROERGOTAMINE MESYLATE  
 DIASTAT ACUDIAL, DIAZEPAM  
 DIASTAT, DIAZEPAM  
 FLUOROURACIL, FLUOROURACIL  
 MIGRANAL, DIHYDROERGOTAMINE MESYLATE  
 MOTOFEN, ATROPINE SULFATE  
 MYSOLINE, PRIMIDONE

**VALEANT PHARM INTL**

\* VALEANT PHARMACEUTICALS INTERNATIONAL  
 8-MOP, METHOXSALEN  
 DALMANE, FLURAZEPAM HYDROCHLORIDE  
 EFUDEX, FLUOROURACIL  
 LEVO-DROMORAN, LEVORPHANOL TARTRATE  
 LIMBITROL DS, AMITRIPTYLINE HYDROCHLORIDE  
 LIMBITROL, AMITRIPTYLINE HYDROCHLORIDE  
 MESTINON, PYRIDOSTIGMINE BROMIDE  
 OXSORALEN, METHOXSALEN  
 OXSORALEN-ULTRA, METHOXSALEN  
 TASMAR, TOLCAPONE  
 TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE  
 TENSILON, EDROPHONIUM CHLORIDE  
 VIRAZOLE, RIBAVIRIN  
 ZELAPAR, SELEGILINE HYDROCHLORIDE

**VALIDUS PHARMS**

\* VALIDUS PHARMACEUTICALS LLC  
 ROCALTROL, CALCITRIOL

**VALIDUS PHARMS INC**

\* VALIDUS PHARMACEUTICALS INC  
 EQUETRO, CARBAMAZEPINE  
 MARPLAN, ISOCARBOXAZID

**VANDA PHARMS INC**

\* VANDA PHARMACEUTICALS INC  
 FANAPT, ILOPERIDONE

**VATRING PHARMS**

\* VATRING PHARMACEUTICALS LP  
 UREX, METHENAMINE HIPPURATE

**VEROSCIENCE**

\* VEROSCIENCE LLC  
 CYCLOSET, BROMOCRIPTINE MESYLATE

**VICURON**

\* VICURON PHARMACEUTICALS INC  
 ERAXIS, ANIDULAFUNGIN

**VIIV HLTHCARE**

\* VIIV HEALTHCARE CO  
 COMBIVIR, LAMIVUDINE  
 EPIVIR, LAMIVUDINE  
 EPZICOM, ABACAVIR SULFATE  
 LEXIVA, FOSAMPRENAVIR CALCIUM  
 RESCRIPTOR, DELAVIRDINE MESYLATE  
 RETROVIR, ZIDOVUDINE  
 SELZENTRY, MARAVIROC  
 TRIZIVIR, ABACAVIR SULFATE  
 ZIAGEN, ABACAVIR SULFATE

**VIROPHARMA**

\* VIROPHARMA INC  
 VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* V \*\*****VIVUS**

\* VIVUS INC  
MUSE, ALPROSTADIL

**WARNER CHILCOTT**

\* WARNER CHILCOTT INC  
DURICEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
ESTROSTEP FE, ETHINYL ESTRADIOL  
FEMCON FE, ETHINYL ESTRADIOL  
FEMHRT, ETHINYL ESTRADIOL  
FEMTRACE, ESTRADIOL ACETATE  
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL  
LOESTRIN 21 1/20, ETHINYL ESTRADIOL  
LOESTRIN 24 FE, ETHINYL ESTRADIOL  
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL  
LOESTRIN FE 1/20, ETHINYL ESTRADIOL  
OVCON-35, ETHINYL ESTRADIOL  
OVCON-50, ETHINYL ESTRADIOL  
SARAFEM, FLUOXETINE HYDROCHLORIDE

**WATSON LABS**

\* WATSON LABORATORIES INC  
ALLOPURINOL, ALLOPURINOL  
ALORA, ESTRADIOL  
ANDRODERM, TESTOSTERONE  
BREVICON 28-DAY, ETHINYL ESTRADIOL  
CORDRAN, FLURANDRENOLIDE  
DILACOR XR, DILTIAZEM HYDROCHLORIDE  
GELNIQUE, OXYBUTYNIN CHLORIDE  
METRONIDAZOLE, METRONIDAZOLE  
MICROZIDE, HYDROCHLOROTHIAZIDE  
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL  
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL  
NORINYL 1+50 28-DAY, MESTRANOL  
RAPAFLO, SILODOSIN  
TRELSTAR DEPOT, TRIPTORELIN PAMOATE  
TRELSTAR LA, TRIPTORELIN PAMOATE  
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL

**WATSON LABS (UTAH)**

\* WATSON LABORATORIES INC  
INFED, IRON DEXTRAN  
NOR-QD, NORETHINDRONE  
OXYTROL, OXYBUTYNIN  
PROGESTERONE, PROGESTERONE

**WATSON PHARMS**

\* WATSON PHARMACEUTICALS  
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE  
TENUATE, DIETHYLPROPION HYDROCHLORIDE

\* WATSON PHARMACEUTICALS INC  
ACTIGALL, URSODIOL  
CONDYLOX, PODOFILOX  
CORDRAN SP, FLURANDRENOLIDE  
CORDRAN, FLURANDRENOLIDE  
FIORICET W/ CODEINE, ACETAMINOPHEN  
FIORINAL W/CODEINE, ASPIRIN  
FIORINAL, ASPIRIN  
MONODOX, DOXYCYCLINE

**WEILL MEDCL COLL**

\* WEILL MEDICAL COLLEGE CORNELL UNIV  
FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE F-18

**WELLSPRING PHARM**

\* WELLSPRING PHARMACEUTICAL CORP  
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE

**WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1085, p. 864 of 1114**



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* W \*\***

\* WELLSPRING PHARMACEUTICAL CORP  
DYRENIUM, TRIAMTERENE

**WRASER PHARMS**

\* WRASER PHARMACEUTICALS LLC  
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

**WYETH CONS**

\* WYETH CONSUMER HEALTHCARE  
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)  
ADVIL COLD AND SINUS, IBUPROFEN (OTC)  
ADVIL LIQUI-GELS, IBUPROFEN (OTC)  
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)  
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)  
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)  
ADVIL, IBUPROFEN (OTC)  
ALAVERT, LORATADINE (OTC)  
AXID AR, NIZATIDINE (OTC)  
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)  
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)  
CHILDREN'S ADVIL, IBUPROFEN (OTC)  
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)  
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)  
PEDIATRIC ADVIL, IBUPROFEN (OTC)

**WYETH PHARMS INC**

\* WYETH PHARMACEUTICALS INC  
CORDARONE, AMIODARONE HYDROCHLORIDE  
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE  
EFFEXOR, VENLAFAXINE HYDROCHLORIDE  
LYBREL, ETHINYL ESTRADIOL  
MYLOTARG, GEMTUZUMAB OZOGAMICIN  
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE  
PREMARIN, ESTROGENS, CONJUGATED  
PREMPHASE 14/14, ESTROGENS, CONJUGATED  
PREMPRO, ESTROGENS, CONJUGATED  
PRISTIQ, DESVENLAFAXINE SUCCINATE  
PROTONIX IV, PANTOPRAZOLE SODIUM  
PROTONIX, PANTOPRAZOLE SODIUM  
RAPAMUNE, SIROLIMUS  
TORISEL, TEMSIROLIMUS  
TRECATOR, ETHIONAMIDE  
TYGACIL, TIGECYCLINE  
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM  
ZOSYN, PIPERACILLIN SODIUM

**XANODYNE PHARM**

\* XANODYNE PHARMACEUTICS INC  
AMICAR, AMINOCAPROIC ACID  
DARVOCET-N 100, ACETAMINOPHEN  
DARVOCET-N 50, ACETAMINOPHEN  
DARVON, PROPOXYPHENE HYDROCHLORIDE  
DARVON-N, PROPOXYPHENE NAPSYLATE  
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
DURACLON, CLONIDINE HYDROCHLORIDE  
LYSTEDA, TRANEXAMIC ACID  
ORAMORPH SR, MORPHINE SULFATE  
ZIPSOR, DICLOFENAC POTASSIUM

**XANODYNE PHARMS**

\* XANODYNE PHARMACEUTICALS INC  
ROXICODONE, OXYCODONE HYDROCHLORIDE

**XTTRIUM**

\* XTTRIUM LABORATORIES INC  
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)  
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* Z \*\*

ZAMBON SPA

\* ZAMBON SPA ITALY  
MONUROL, FOSFOMYCIN TROMETHAMINE

ZARS PHARM

\* ZARS PHARMA INC  
SYNERA, LIDOCAINE

ZOGENIX INC

\* ZOGENIX INC  
SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE

**APPENDIX C****UNIFORM TERMS*****DOSAGE FORMS***

AEROSOL	LOTION/SHAMPOO
AEROSOL, FOAM	OIL
AEROSOL, METERED	OIL/DROPS
CAPSULE	OINTMENT
CAPSULE, DELAYED REL PELLETS	OINTMENT, AUGMENTED
CAPSULE, DELAYED RELEASE	PASTE
CAPSULE, EXTENDED RELEASE	PATCH
CLOTH	PELLET
CONCENTRATE	POWDER
CREAM	POWDER, EXTENDED RELEASE
CREAM, AUGMENTED	POWDER, METERED
ELIXIR	RING
EMULSION	SHAMPOO
ENEMA	SOLUTION
FILM	SOLUTION FOR SLUSH
FILM, EXTENDED RELEASE	SOLUTION, GEL FORMING/DROPS
FOR SOLUTION	SOLUTION/DROPS
FOR SOLUTION; TABLET, FOR SOLUTION	SPONGE
FOR SUSPENSION	SPRAY
FOR SUSPENSION, DELAYED RELEASE	SPRAY, METERED
FOR SUSPENSION, EXTENDED RELEASE	SUPPOSITORY
GAS	SUSPENSION
GEL	SUSPENSION, EXTENDED RELEASE
GEL, AUGMENTED	SUSPENSION/DROPS
GEL, METERED	SWAB
GRANULE	SYRUP
GRANULE, DELAYED RELEASE	SYSTEM, EXTENDED RELEASE
GUM, CHEWING	TABLET
IMPLANT	TABLET, CHEWABLE
INHALANT	TABLET, COATED PARTICLES
INJECTABLE	TABLET, DELAYED RELEASE
INJECTABLE, LIPID COMPLEX	TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING
INJECTABLE, LIPOSOMAL	TABLET, EFFERVESCENT
INSERT	TABLET, EXTENDED RELEASE
INSERT, EXTENDED RELEASE	TABLET, FOR SUSPENSION
INTRAUTERINE DEVICE	TABLET, ORALLY DISINTEGRATING
JELLY	TAPE
LIQUID	TROCHE/LOZENGE
LOTION	
LOTION, AUGMENTED	

Note: Terms comprise currently marketed products

**APPENDIX C****UNIFORM TERMS*****ROUTES OF ADMINISTRATION***

BUCCAL	INTRAVITREAL
DENTAL	IRRIGATION
ENDOCERVICAL	IV (INFUSION)
EPIDURAL	IV (INFUSION)-SC
FOR RX COMPOUNDING	IV-SC
IM-IV	N/A
IM-IV-SC	NASAL
IMPLANTATION	OPHTHALMIC
IM-SC	ORAL
INHALATION	ORAL-21
INJECTION	ORAL-28
INTRA-ARTICULAR, INTRAMUSCULAR,	OTIC
INTRAVITREAL	PERFUSION, CARDIAC
INTRACRANIAL	PERIODONTAL
INTRALYMPHATIC	RECTAL
INTRAMUSCULAR	SPINAL
INTRAOCULAR	SUBCUTANEOUS
INTRAPERITONEAL	SUBLINGUAL
INTRAPLEURAL	TOPICAL
INTRATHECAL	TRANSDERMAL
INTRATRACHEAL	TRANSMUCOSAL
INTRAUTERINE	URETHRAL
INTRAVENOUS	VAGINAL
INTRAVESICAL	

Note: Terms comprise currently marketed products

**APPENDIX C****UNIFORM TERMS****ABBREVIATIONS**

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
INH	INHALATION
IU	INTERNATIONAL UNITS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
MCI	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SQ CM	SQUARE CENTIMETER
U	UNITS
UCI	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

## PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act (1984 Amendments) for periods of exclusivity, during which abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (the Act) for those drug products may, in some instances, not be submitted or made effective as described below, and provides patent information concerning the listed drug products. Those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the Act and those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A are also included in this *Addendum*. This section is arranged in alphabetical order by active ingredient name followed the trade name. Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. Exclusivity prevents the submission or effective approval of ANDAs or applications described in Section 505(b)(2) of the Act. It does not prevent the submission or approval of a second 505(b)(1) application except in the case of Orphan Drug exclusivity. Applications qualifying for periods of exclusivity are:

- (1) A new drug application approved after September 24, 1984, for a drug product all active ingredients (including any ester or salt of the active ingredient) of which had never been approved in any other new drug application under Section 505 (b) of the Act. No subsequent ANDA or application described in Section 505(b)(2) of the Act for the same drug may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought.
- (2) A new drug application approved after September 24, 1984, for a drug product containing an active ingredient (including any ester or salt of that active ingredient) that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, the approval of a subsequent ANDA or an application described in Section 505(b)(2) of the Act may not be *made effective* for the same drug or use, if for a new indication, before the expiration of *three years* from the date of approval of the original application. If an applicant has exclusivity for a new application or 505(b)(2) application for the drug product with indications or use, this does not preclude the approval of an ANDA or 505(b)(2) application not covered by the exclusivity.
- (3) A supplement to a new drug application for a drug containing a previously approved active ingredient including (any ester or salt of the active ingredient) approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant. The approval of a subsequent ANDA or 505(b)(2) application for a change approved in the supplement may not be

*made effective for three years from the date of approval of the original supplement.*

The Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. No NDA may be approved after September 24, 1984, without the submission of patent information to the Agency. Effective August 18, 2003, this information must be filed using FDA Form 3524a "Patent Information Submitted with the Filing of an NDA, Amendment or Supplement".

Effective August 18, 2003, upon approval of an application, patent information for purposes of listing in the Orange Book must be submitted to the agency within 30 days of approval on FDA Form 3542 "Patent Information Submitted Upon and After Approval of an NDA or Supplement". Patent information on unapproved applications or on patents beyond the scope of the Act (i.e., process or manufacturing patents) will not be published. FDA form 3542 will be the only form used for the purposes of this publication.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient(s); drug product patents which include formulation/composition patents; use patents for a particular approved indication or method of using the product; and certain other patents as detailed on FDA Form 3542. This information, as provided by the sponsor on FDA form 3542, will be published as described above.

A requirement for submission of patent information to FDA for certain old antibiotics became effective October 7, 2008 under section 4(b)(1) of the Q1 Act. A guidance for industry on this subject is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM048345.pdf>

Upon approval, patent numbers and expiration dates, in addition to certain other information on appropriate patents claiming drug products that are the subject of approved applications, will be published on a daily basis in the Electronic Orange Book, <http://www.fda.gov/cder/ob/default.htm>. The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the annual edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Electronic Orange Book, updated daily, should be consulted for the most recent patent and exclusivity information.

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N020977 001	5034394	Dec 18, 2011	DS DP			
	5034394*PED	Jun 18, 2012				
	5089500*PED	Dec 26, 2009				
	6294540	May 14, 2018	DS DP		U-65	
	6294540*PED	Nov 14, 2018			U-65	
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N020978 001	5034394	Dec 18, 2011	DS DP			
	5034394*PED	Jun 18, 2012				
	5089500*PED	Dec 26, 2009				
	6294540	May 14, 2018	DS DP		U-65	
	6294540*PED	Nov 14, 2018			U-65	
	6641843	Feb 04, 2020	DP			
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N021652 001	5034394	Dec 18, 2011	DS DP			
	5034394*PED	Jun 18, 2012				
	5047407	Nov 17, 2009	DS DP		U-257	
	5047407*PED	May 17, 2010				
	5089500*PED	Dec 26, 2009				
	5905082	May 18, 2016	DS DP			
	5905082*PED	Nov 18, 2016				
	6294540	May 14, 2018	DS DP		U-257	
	6294540*PED	Nov 14, 2018				
	6417191	Mar 28, 2016	DP		U-257	
	7119202*PED	Aug 08, 2009				
<u>ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - TRIZIVIR</u>						
N021205 001	5034394	Dec 18, 2011	DS DP			
	5034394*PED	Jun 18, 2012				
	5047407	Nov 17, 2009	DS DP		U-248	
	5047407*PED	May 17, 2010				
	5089500*PED	Dec 26, 2009			U-248	
	5905082	May 18, 2016	DS DP		U-248	
	5905082*PED	Nov 18, 2016				
	6294540	May 14, 2018	DS DP		U-65	
	6294540*PED	Nov 14, 2018			U-65	
	6417191	Mar 28, 2016	DP		U-248	
	7119202*PED	Aug 08, 2009				
<u>ABARELIX - PLENAXIS</u>						
N021320 001	5843901	Dec 01, 2015	DS DP			
	5968895	Dec 11, 2016				
	6180608	Dec 11, 2016			U-549	
	6423686	Jun 07, 2015	DS			
	6455499	Jun 07, 2015			U-549	
	6699833	Dec 11, 2016	DP			
<u>ACAMPROSATE CALCIUM - CAMPRAL</u>						
N021431 001					NCE	Jul 29, 2009
<u>ACETAMINOPHEN; ASPIRIN; CAFFEINE - EXCEDRIN (MIGRAINE)</u>						
N020802 001	5972916	Jul 14, 2017				U-296
<u>ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE - ULTRACET</u>						
N021123 001	RE39221	Aug 09, 2011	DS DP			U-55
<u>ACETYLCHOLINE CHLORIDE - MIOCHOL-E</u>						
N020213 001	6261546	Apr 29, 2019				U-506
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539 001					ODE	Jan 23, 2011
<u>ACYCLOVIR; HYDROCORTISONE - ACYCLOVIR AND HYDROCORTISONE</u>						
N022436 001	6514980	Jan 24, 2017	DP			U-1006
	7223387	Feb 28, 2021	DP			U-1006
	RE39264	Feb 02, 2016	DP			U-1006



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE - DIFFERIN</u>						
N020338 001	4717720	May 31, 2010				
	RE34440	May 31, 2010		U-275		
<u>ADAPALENE - DIFFERIN</u>						
N020380 001	4717720	May 31, 2010				
	RE34440	May 31, 2010		U-275		
<u>ADAPALENE - DIFFERIN</u>						
N020748 001	4717720	May 31, 2010				
	RE34440	May 31, 2010		U-275		
<u>ADAPALENE - DIFFERIN</u>						
N021753 001	4717720	May 31, 2010	DS DP		NP	Jun 19, 2010
	7579377	Feb 23, 2025		U-818		
	RE34440	May 31, 2010		U-818		
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	4717720	May 31, 2010	DS DP		NC	Dec 08, 2011
	RE34440	May 31, 2010		U-818		
<u>ADEFOVIR DIPIVOXIL - HEPSERA</u>						
N021449 001	5663159	Sep 02, 2014	DS DP		NPP	Dec 19, 2010
	6451340	Jul 23, 2018	DS DP	U-470		
<u>ADENOSINE - ADENOSCAN</u>						
N020059 001	5731296	Mar 24, 2015		U-221		
<u>ALATROFLOXACIN MESYLATE - TROVAN PRESERVATIVE FREE</u>						
N020760 001	5164402	Nov 17, 2009		U-282		
	5763454	Jun 15, 2015		U-282		
	6080756	Jul 05, 2016				
	6194429	Jul 23, 2018				
<u>ALATROFLOXACIN MESYLATE - TROVAN PRESERVATIVE FREE</u>						
N020760 002	5164402	Nov 17, 2009		U-282		
	5763454	Jun 15, 2015		U-282		
	6080756	Jul 05, 2016				
	6194429	Jul 23, 2018				
<u>ALBUMIN HUMAN - OPTISON</u>						
N020899 001	5529766	Jun 25, 2013		U-505		
	5558094	Feb 28, 2012		U-505		
	5573751	Apr 25, 2012				
	6723303	Apr 20, 2021	DP			
<u>ALBUTEROL SULFATE - ACCUNEB</u>						
N020949 001	6702997	Dec 28, 2021		U-558		
<u>ALBUTEROL SULFATE - ACCUNEB</u>						
N020949 002	6702997	Dec 28, 2021		U-558		
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	5605674	Feb 25, 2014	DP		NPP	Sep 16, 2011
	5695743	Jul 06, 2010	DP	U-491		
	5766573	Nov 28, 2009		U-356		
	6352684	Nov 28, 2009	DP	U-716		
	7105152	Sep 12, 2023	DP			
	7566445	Jun 04, 2017	DP			
<u>ALBUTEROL SULFATE - PROVENTIL-HFA</u>						
N020503 001	5225183	Jul 06, 2010				
	5439670	Jul 06, 2010				
	5605674	Feb 25, 2014				
	5695743	Jul 06, 2010		U-491		
	5766573	Jun 16, 2015				
	6352684	Nov 28, 2009				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N020983 001	6131566	Apr 14, 2015	DP U-716			
	6131566	Apr 14, 2015	DP U-589			
	6131566*PED	Oct 14, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6532955	Apr 14, 2015	DP			
	6532955*PED	Oct 14, 2015				
	6558651	Dec 19, 2016	DP U-716			
	6558651*PED	Jun 19, 2017				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-716		
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 06, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT</u>						
N020291 001	5603918	Jun 09, 2015				
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEB</u>						
N020950 001	6632842	Dec 28, 2021		U-532		
<u>ALCOHOL; CHLORHEXIDINE GLUCONATE - AVAGARD</u>						
N021074 001	5897031	Jun 21, 2016				
	6090395	Jun 22, 2015	DP			
	6534069	Jun 22, 2015	DP			
	6623744	Jun 23, 2015		U-1008		
	7081246	Aug 03, 2016	DP			
	7566460	Jun 22, 2015	DP U-1008			
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 001	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	5849726	Jun 06, 2015				
	5849726*PED	Dec 06, 2015				
	6008207	Jun 06, 2015		U-303		
	6008207*PED	Dec 06, 2015		U-303		
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
	6194004	Dec 02, 2012				
	6194004*PED	Jun 02, 2013				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 002	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	5849726	Jun 06, 2015				
	5849726*PED	Dec 06, 2015				
	6008207	Jun 06, 2015		U-303		
	6008207*PED	Jun 06, 2015		U-303		
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 003	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	5849726	Jun 06, 2015				
	5849726*PED	Dec 06, 2015				
	6008207	Jun 06, 2015		U-303		
	6008207*PED	Dec 06, 2015		U-303		
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 004	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	5849726	Jun 06, 2015				
	5849726*PED	Dec 06, 2015				
	5994329	Jul 17, 2018				
	5994329*PED	Jan 17, 2019				
	6008207	Jun 06, 2015				
	6008207*PED	Dec 06, 2015				
	6015801	Jul 17, 2018		U-353		
	6015801*PED	Jan 17, 2019		U-353		
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
	6225294	Jul 17, 2018				
	6225294*PED	Jan 17, 2019				
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 005	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	5849726	Jun 06, 2015				
	5849726*PED	Dec 06, 2015				
	5994329	Jul 17, 2018				
	5994329*PED	Jan 17, 2019				
	6008207	Jun 06, 2015				
	6008207*PED	Dec 06, 2015				
	6015801	Jul 17, 2018		U-353		
	6015801*PED	Jan 17, 2019		U-353		
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
	6225294	Jul 17, 2018				
	6225294*PED	Jan 17, 2019				
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N021575 001	5462932	May 17, 2014				
	5462932*PED	Nov 17, 2014				
	5994329	Jul 17, 2018				
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018				
	6015801*PED	Jan 17, 2019				
	6225294	Jul 17, 2018				
	6225294*PED	Jan 17, 2019				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>						
N021762 001	5358941	Dec 02, 2012	DP			
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012	DP			
	5681590*PED	Jun 02, 2013				
	5994329	Jul 17, 2018		U-647		
	5994329*PED	Jan 17, 2019				
	6090410	Dec 02, 2012	DP			
	6090410*PED	Jun 02, 2013	DP			
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>						
N021762 002	5358941	Dec 02, 2012	DP		D-107	Apr 26, 2010
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012	DP			
	5681590*PED	Jun 02, 2013				
	6090410	Dec 02, 2012	DP			
	6090410*PED	Jun 02, 2013	DP			
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>						
N021287 001	4661491	Jan 18, 2011		U-706		
	6149940	Aug 22, 2017				
<u>ALISKIREN HEMIFUMARATE - TEKTURNIA</u>						
N021985 001	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE - TEKTURNIA</u>						
N021985 002	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNIA HCT</u>						
N022107 001	5559111	Apr 04, 2015	DS DP U-3		I-600	Jul 16, 2012
					NCE	Mar 05, 2012
					NC	Jan 18, 2011
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNIA HCT</u>						
N022107 002	5559111	Apr 04, 2015	DS DP U-3		I-600	Jul 16, 2012
					NCE	Mar 05, 2012
					NC	Jan 18, 2011
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNIA HCT</u>						
N022107 003	5559111	Apr 04, 2015	DS DP U-3		I-600	Jul 16, 2012
					NCE	Mar 05, 2012
					NC	Jan 18, 2011
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNIA HCT</u>						
N022107 004	5559111	Apr 04, 2015	DS DP U-3		I-600	Jul 16, 2012
					NCE	Mar 05, 2012
					NC	Jan 18, 2011
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNIA</u>						
N022217 001	5399578	Mar 21, 2012	DS DP U-3		NC	Sep 16, 2012
	5559111	Jul 21, 2018	DS DP U-3			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNIA</u>						
N022217 002	5399578	Mar 21, 2012	DS DP U-3		NC	Sep 16, 2012
	5559111	Jul 21, 2018	DS DP U-3			
<u>ALITRETINOIN - PANRETIN</u>						
N020886 001	5932622	Aug 03, 2016		U-562		
<u>ALMOTRIPTAN MALATE - AXERT</u>						
N021001 001	5565447	May 07, 2015	DS DP U-969			
	5565447*PED	Nov 07, 2015				
<u>ALMOTRIPTAN MALATE - AXERT</u>						
N021001 002	5565447	May 07, 2015	DS DP U-969			
	5565447*PED	Nov 07, 2015				
<u>ALOSETRON HYDROCHLORIDE - LOTRONEX</u>						
N021107 001	5368800	Jan 12, 2013	DS DP U-405		D-113	Apr 01, 2011

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOSETRON HYDROCHLORIDE - LOTRONEX</u>						
N021107 002	5360800	Jan 13, 2013	DS DP U-405		D-113	Apr 01, 2011
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
A078088 001					PC	Jul 13, 2009
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
A078088 002					PC	Jul 13, 2009
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
A078088 003					PC	Jul 13, 2009
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
A078088 004					PC	Jul 13, 2009
<u>ALPRAZOLAM - NIRAVAM</u>						
N021726 001	6024981	Apr 09, 2018		DP		
	6221392	Apr 09, 2018		DP		
<u>ALPRAZOLAM - NIRAVAM</u>						
N021726 002	6024981	Apr 09, 2018		DP		
	6221392	Apr 09, 2018		DP		
<u>ALPRAZOLAM - NIRAVAM</u>						
N021726 003	6024981	Apr 09, 2018		DP		
	6221392	Apr 09, 2018		DP		
<u>ALPRAZOLAM - NIRAVAM</u>						
N021726 004	6024981	Apr 09, 2018		DP		
	6221392	Apr 09, 2018		DP		
<u>ALPROSTADIL - CAVERJECT</u>						
N020379 001	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N020379 002	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N020379 003	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N020379 004	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT IMPULSE</u>						
N021212 001	5501673	Apr 16, 2013		DP		
	5716338	Feb 10, 2015		DP		
<u>ALPROSTADIL - CAVERJECT IMPULSE</u>						
N021212 002	5501673	Apr 16, 2013		DP		
	5716338	Feb 10, 2015		DP		
<u>ALPROSTADIL - MUSE</u>						
N020700 001	5242391	Sep 07, 2010				U-155
	5474535	Dec 12, 2012				U-155
	5773020	Apr 25, 2010		DP		
	5886039	Mar 23, 2016		DP		U-155
<u>ALPROSTADIL - MUSE</u>						
N020700 002	5242391	Sep 07, 2010				U-155
	5474535	Dec 12, 2012				U-155
	5773020	Apr 25, 2010		DP		
	5886039	Mar 23, 2016		DP		U-155
<u>ALPROSTADIL - MUSE</u>						
N020700 003	5242391	Sep 07, 2010				U-155
	5474535	Dec 12, 2012				U-155
	5773020	Apr 25, 2010		DP		
	5886039	Mar 23, 2016		DP		U-155

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALPROSTADIL - MUSE</u>						
N020700 004	5242391	Sep 07, 2010				
	5474535	Dec 12, 2012				
	5773020	Apr 25, 2010	DP			
	5886039	Mar 23, 2016	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	5250542	Mar 29, 2011	DS DP		NCE	May 20, 2013
	5434171	Dec 08, 2013	DS DP			
	6469030	Nov 29, 2020				
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 001	5703017	Dec 30, 2014	DS		NCE	Jun 15, 2012
	5840722	Nov 24, 2015			ODE	Jun 15, 2014
	5932730	Oct 07, 2015	DS			
	7109205	Oct 07, 2015	DS DP			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 002	5703017	Dec 30, 2014	DS		NCE	Jun 15, 2012
	5840722	Nov 24, 2015			ODE	Jun 15, 2014
	5932730	Oct 07, 2015	DS			
	7109205	Oct 07, 2015	DS DP			
<u>AMIFOSTINE - ETHYOL</u>						
N020221 001	5424471	Jul 31, 2012				
	5591731	Jul 31, 2012				
	5994409	Dec 08, 2017				
<u>AMIFOSTINE - ETHYOL</u>						
N020221 002	5424471	Jul 31, 2012				
	5591731	Jul 31, 2012				
	5994409	Dec 08, 2017				
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N020965 001	5079262	Sep 30, 2013				
	5211938	May 18, 2010				
	5422093	Jul 28, 2009				
	5954703	Oct 31, 2017				
	6709446	May 01, 2018				
	6710066	Jul 28, 2009				
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N022325 001	5134127	Jan 23, 2010				
	5376645	Jan 23, 2010				
	6869939	May 04, 2022				
	7635773	Mar 13, 2029				
<u>AMLEXANOX - APHTHASOL</u>						
N020511 001	5362737	Nov 08, 2011				
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N022026 001	6828339	Nov 20, 2022	DS			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N022026 002	6828339	Nov 20, 2022	DS			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N022026 003	6828339	Nov 20, 2022	DS			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 001	4681893	Sep 24, 2009	DS DP U-161			
	4681893*PED	Mar 24, 2010				
	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018			U-552	
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 002	4681893	Sep 24, 2009	DS DP U-161			
	4681893*PED	Mar 24, 2010				
	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018			U-552	
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 003	4681893	Sep 24, 2009	DS DP U-161			
	4681893*PED	Mar 24, 2010				
	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018			U-552	
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 004	4681893	Sep 24, 2009	DS DP U-161			
	4681893*PED	Mar 24, 2010				
	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018			U-552	
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 005	4681893	Sep 24, 2009	DS DP U-161			
	4681893*PED	Mar 24, 2010				
	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018			U-552	
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 006	4681893	Sep 24, 2009	DS DP U-161			
	4681893*PED	Mar 24, 2010				
	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018			U-552	
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 007	4681893	Sep 24, 2009	DS DP U-161			
	4681893*PED	Mar 24, 2010				
	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018			U-552	
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 008	4681893	Sep 24, 2009	DS DP U-161			
	4681893*PED	Mar 24, 2010				
	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018			U-552	
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 009	4681893	Sep 24, 2009	DS DP U-161			
	4681893*PED	Mar 24, 2010				
	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018			U-552	
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 010	4681893	Sep 24, 2009	DS DP U-161			
	4681893*PED	Mar 24, 2010				
	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018			U-552	
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 011	4681893	Sep 24, 2009	DS DP U-161			
	4681893*PED	Mar 24, 2010				
	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011				
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018			U-552	
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 002	6162802	Dec 19, 2017				U-367
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 003	6162802	Dec 19, 2017				U-367
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 004	6162802	Dec 19, 2017				U-367
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 005	6162802	Dec 19, 2017				U-367
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 006	6162802	Dec 19, 2017	DS DP			U-185
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 007	6162802	Dec 19, 2017	DS DP			U-185
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N022100 001	5616599	Apr 25, 2016	DS DP U-3		NC	Sep 26, 2010
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N022100 002	5616599	Apr 25, 2016	DS DP U-3		NC	Sep 26, 2010
	5616599*PED	Oct 25, 2016				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N022100 003	5616599	Apr 25, 2016	DS DP U-3		NC	Sep 26, 2010
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N022100 004	5616599	Apr 25, 2016	DS DP U-3		NC	Sep 26, 2010
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N022401 001	5591762	Jan 07, 2014	DS DP U-3		NC	Oct 16, 2012
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N022401 002	5591762	Jan 07, 2014	DS DP U-3		NC	Oct 16, 2012
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N022401 003	5591762	Jan 07, 2014	DS DP U-3		NC	Oct 16, 2012
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N022401 004	5591762	Jan 07, 2014	DS DP U-3		NC	Oct 16, 2012
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N021990 002	5399578	Mar 21, 2012	DS DP U-3		I-567	Jun 23, 2011
	5399578*PED	Sep 21, 2012			NC	Jun 20, 2010
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N021990 003	5399578	Mar 21, 2012	DS DP U-3		I-567	Jun 23, 2011
	5399578*PED	Sep 21, 2012			NC	Jun 20, 2010
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N021990 004	5399578	Mar 21, 2012	DS DP U-3		I-567	Jun 23, 2011
	5399578*PED	Sep 21, 2012			NC	Jun 20, 2010
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N021990 005	5399578	Mar 21, 2012	DS DP U-3		I-567	Jun 23, 2011
	5399578*PED	Sep 21, 2012			NC	Jun 20, 2010
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMMONIA, N-13 - AMMONIA N 13</u>						
N022119 001					NCE	Aug 23, 2012
					W	Aug 23, 2012
<u>AMOXICILLIN - MOXATAG</u>						
N050813 001	6544555	Oct 13, 2020	DS DP U-897			
	6669948	Oct 13, 2020	DS DP U-897			
	6723341	Oct 13, 2020	DS DP U-897			
<u>AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE - PREVPAC</u>						
N050757 001	4628098*PED	Nov 10, 2009				
	5013743	Feb 12, 2010		U-452		
	5013743*PED	Aug 12, 2010				
<u>AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR</u>						
N050785 001	6746692	Apr 04, 2020		DP		
	6783773	Apr 04, 2020		DP		
	6878386	Apr 04, 2020			U-926	
	7217430	Apr 04, 2020		DP	U-926	
	7250176	Apr 04, 2020			U-926	
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10</u>						
N011522 007	6384020	Jul 06, 2020				
	6384020*PED	Jan 06, 2021				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5</u>						
N011522 012	6384020	Jul 06, 2020				
	6384020*PED	Jan 06, 2021				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15</u>						
N011522 013	6384020	Jul 06, 2020				
	6384020*PED	Jan 06, 2021				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20</u>						
N011522 008	6384020	Jul 06, 2020				
	6384020*PED	Jan 06, 2021				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30</u>						
N011522 010	6384020	Jul 06, 2020				
	6384020*PED	Jan 06, 2021				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5</u>						
N011522 009	6384020	Jul 06, 2020				
	6384020*PED	Jan 06, 2021				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5</u>						
N011522 011	6384020	Jul 06, 2020				
	6384020*PED	Jan 06, 2021				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N021303 001	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N021303 006	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N021303 002	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N021303 004	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N021303 003	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N021303 005	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
<u>AMPHOTERICIN B - AMBISOME</u>						
N050740 001	5874104	Feb 23, 2016	DP	U-922		
	5965156	Oct 12, 2016	DP	U-922		
<u>AMPRENAVIR - AGENERASE</u>						
N021007 001	5585397	Dec 17, 2013				
	5646180	Jul 08, 2014		U-257		
	5723490	Mar 03, 2015		U-257		
	6730679	Nov 11, 2017	DP			
<u>AMPRENAVIR - AGENERASE</u>						
N021007 002	5585397	Dec 17, 2013				
	5646180	Jul 08, 2014		U-257		
	5723490	Mar 03, 2015		U-257		
	6730679	Nov 11, 2017	DP			
<u>AMPRENAVIR - AGENERASE</u>						
N021039 001	5585397	Dec 17, 2013				
	5646180	Jul 08, 2014		U-257		
	5723490	Mar 03, 2015		U-257		
<u>ANASTROZOLE - ARIMIDEX</u>						
N020541 001	RE36617	Dec 27, 2009	DS DP	U-946	M-61	Dec 05, 2011
	RE36617*PED	Jun 27, 2010			PED	Jun 05, 2012

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ANIDULAFUNGIN - ERAXIS</u>						
N021632 001	5965525	Feb 17, 2020	DS DP U-540		NCE	Feb 17, 2011
	6384013	Mar 19, 2012	DS			
	6743777	Mar 19, 2012	DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7198796	Jun 13, 2022	DP			
<u>ANIDULAFUNGIN - ERAXIS</u>						
N021632 002	5965525	Feb 17, 2020	DS DP U-540		NCE	Feb 17, 2011
	6384013	Mar 19, 2012	DS			
	6743777	Mar 19, 2012	DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7198796	Jun 13, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - APOKYN</u>						
N021264 001					ODE	Apr 20, 2011
<u>APOMORPHINE HYDROCHLORIDE - APOKYN</u>						
N021264 002					ODE	Apr 20, 2011
<u>APRACLONIDINE HYDROCHLORIDE - IOPIDINE</u>						
N019779 001	5212196	May 18, 2010		U-120		
<u>APREPITANT - EMEND</u>						
N021549 001	5145684	Jan 25, 2011		DP		
	5538982	Jul 23, 2013		U-745		
	5719147	Apr 17, 2015	DS DP	U-853		
	6048859	Jun 29, 2012		U-745		
	6096742	Jul 01, 2018	DS DP	U-745		
	6235735	Jun 29, 2012		U-747		
	6235735	Jun 29, 2012		U-746		
	7214692	Sep 18, 2012		U-853		
<u>APREPITANT - EMEND</u>						
N021549 002	5145684	Jan 25, 2011		DP		
	5538982	Jul 23, 2013		U-745		
	5719147	Jun 29, 2012	DS DP			
	6048859	Jun 29, 2012		U-745		
	6096742	Jul 01, 2018	DS DP	U-745		
	6235735	Jun 29, 2012		U-746		
	6235735	Jun 29, 2012		U-747		
	7214692	Sep 18, 2012		U-853		
<u>APREPITANT - EMEND</u>						
N021549 003	5145684	Jan 25, 2011		DP		
	5538982	Jul 23, 2013		U-745		
	5719147	Jun 29, 2012	DS DP			
	6048859	Jun 29, 2012		U-745		
	6096742	Jul 01, 2018	DS DP	U-745		
	6235735	Jun 29, 2012		U-747		
	6235735	Jun 29, 2012		U-746		
	7214692	Sep 18, 2012		U-853		
<u>ARBUTAMINE HYDROCHLORIDE - GENESA</u>						
N020420 001	5234404	Aug 10, 2010		U-220		
	5395970	Mar 07, 2012				
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	5795564	Apr 03, 2012		U-793	NP	Oct 06, 2009
	6040344	Nov 12, 2016	DS			
	6068833	Apr 03, 2012		U-793		
	6472563	Nov 09, 2021	DS			
	6589508	Apr 03, 2012		U-793		
	6720453	Nov 09, 2021	DS			
	6866839	Apr 03, 2012		U-793		
	7145036	Nov 09, 2021	DS			
<u>ARGATROBAN - ARGATROBAN</u>						
N020883 001	5214052	Jun 30, 2014			M-75	May 05, 2011

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>ARIPIPRAZOLE - ABILIFY</u>							
N021436 001	5006528	Oct 20, 2014	DS DP U-761			D-115	May 06, 2011
	5006528*PED	Apr 20, 2015				D-110	Oct 29, 2010
						I-616	Nov 19, 2012
						I-559	May 06, 2011
						I-555	Feb 27, 2011
						I-545	Nov 16, 2010
						PED	Aug 27, 2011
						PED	Apr 29, 2011
<u>ARIPIPRAZOLE - ABILIFY</u>							
N021436 002	5006528	Oct 20, 2014	DS DP U-761			D-115	May 06, 2011
	5006528*PED	Apr 20, 2015				D-110	Oct 29, 2010
						I-616	Nov 19, 2012
						I-559	May 06, 2011
						I-555	Feb 27, 2011
						I-545	Nov 16, 2010
						PED	Aug 27, 2011
						PED	Apr 29, 2011
<u>ARIPIPRAZOLE - ABILIFY</u>							
N021436 003	5006528	Oct 20, 2014	DS DP U-761			D-115	May 06, 2011
	5006528*PED	Apr 20, 2015				D-110	Oct 29, 2010
						I-616	Nov 19, 2012
						I-559	May 06, 2011
						I-555	Feb 27, 2011
						I-545	Nov 16, 2010
						PED	Aug 27, 2011
						PED	Apr 29, 2011
<u>ARIPIPRAZOLE - ABILIFY</u>							
N021436 004	5006528	Oct 20, 2014	DS DP U-761			D-115	May 06, 2011
	5006528*PED	Apr 20, 2015				D-110	Oct 29, 2010
						I-616	Nov 19, 2012
						I-559	May 06, 2011
						I-555	Feb 27, 2011
						I-545	Nov 16, 2010
						PED	Aug 27, 2011
						PED	Apr 29, 2011
<u>ARIPIPRAZOLE - ABILIFY</u>							
N021436 005	5006528	Oct 20, 2014	DS DP U-761			D-115	May 06, 2011
	5006528*PED	Apr 20, 2015				D-110	Oct 29, 2010
						I-616	Nov 19, 2012
						I-559	May 06, 2011
						I-555	Feb 27, 2011
						I-545	Nov 16, 2010
						PED	Aug 27, 2011
						PED	Apr 29, 2011
<u>ARIPIPRAZOLE - ABILIFY</u>							
N021436 006	5006528	Oct 20, 2014	DS DP U-761			D-115	May 06, 2011
	5006528*PED	Apr 20, 2015				D-110	Oct 29, 2010
						I-616	Nov 19, 2012
						I-559	May 06, 2011
						I-555	Feb 27, 2011
						I-545	Nov 16, 2010
						PED	Aug 27, 2011
						PED	Apr 29, 2011

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021713 001	5006528	Oct 20, 2014	DS DP U-761		D-115	May 06, 2011
	5006528*PED	Apr 20, 2015			D-110	Oct 29, 2010
	6977257	Apr 24, 2022	DS DP		I-559	May 06, 2011
	6977257*PED	Oct 24, 2022			I-555	Feb 27, 2011
					I-545	Nov 16, 2010
					PED	Aug 27, 2011
					PED	Apr 29, 2011
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021729 002	5006528	Oct 20, 2014	DS DP U-761		D-115	May 06, 2011
	5006528*PED	Apr 20, 2015			D-110	Oct 29, 2010
					I-559	May 06, 2011
					I-555	Feb 27, 2011
					I-545	Nov 16, 2010
					PED	Aug 27, 2011
					PED	Apr 29, 2011
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021729 003	5006528	Oct 20, 2014	DS DP U-761		D-115	May 06, 2011
	5006528*PED	Apr 20, 2015			D-110	Oct 29, 2010
					I-559	May 06, 2011
					I-555	Feb 27, 2011
					I-545	Nov 16, 2010
					PED	Aug 27, 2011
					PED	Apr 29, 2011
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021729 004	5006528	Oct 20, 2014	DS DP U-761		D-115	May 06, 2011
	5006528*PED	Apr 20, 2015			D-110	Oct 29, 2010
					I-559	May 06, 2011
					I-555	Feb 27, 2011
					I-545	Nov 16, 2010
					PED	Aug 27, 2011
					PED	Apr 29, 2011
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021729 005	5006528	Oct 20, 2014	DS DP U-761		D-115	May 06, 2011
	5006528*PED	Apr 20, 2015			D-110	Oct 29, 2010
					I-559	May 06, 2011
					I-555	Feb 27, 2011
					I-545	Nov 16, 2010
					PED	Aug 27, 2011
					PED	Apr 29, 2011
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021866 001	5006528	Oct 20, 2014	DS DP U-763		D-115	May 06, 2011
	5006528*PED	Apr 20, 2015			D-110	Oct 29, 2010
	7115587	Jul 21, 2024	DS DP U-764		I-559	May 06, 2011
	7115587*PED	Jan 21, 2025			I-555	Feb 27, 2011
	7550445	Jul 21, 2024	DP		I-545	Nov 16, 2010
	7550445*PED	Jan 21, 2025			NDF	Sep 20, 2009
					PED	Aug 27, 2011
					PED	Apr 29, 2011
					PED	Mar 20, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARMODAFINIL - NUVIGIL</u>						
N021875 001	4927855	Apr 22, 2010	DS DP U-820		NP	Jun 15, 2010
	4927855*PED	Oct 22, 2010				
	7132570	Dec 18, 2023	DS DP			
	7132570*PED	Jun 18, 2024				
	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014	DP U-820			
	RE37516*PED	Apr 06, 2015				
<u>ARMODAFINIL - NUVIGIL</u>						
N021875 002	4927855	Apr 22, 2010	DS DP U-820		NP	Jun 15, 2010
	4927855*PED	Oct 22, 2010				
	7132570	Dec 18, 2023	DS DP			
	7132570*PED	Jun 18, 2024				
	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014	DP U-820			
	RE37516*PED	Apr 06, 2015				
<u>ARMODAFINIL - NUVIGIL</u>						
N021875 003	4927855	Apr 22, 2010	DS DP U-820		NP	Jun 15, 2010
	4927855*PED	Oct 22, 2010				
	7132570	Dec 18, 2023	DS DP			
	7132570*PED	Jun 18, 2024				
	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014	DP U-820			
	RE37516*PED	Apr 06, 2015				
<u>ARMODAFINIL - NUVIGIL</u>						
N021875 004	4927855	Apr 22, 2010	DS DP U-820		NP	Jun 15, 2010
	4927855*PED	Oct 22, 2010				
	7132570	Dec 18, 2023	DS DP			
	7132570*PED	Jun 18, 2024				
	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014	DP U-820			
	RE37516*PED	Apr 06, 2015				
<u>ARMODAFINIL - NUVIGIL</u>						
N021875 005	4927855	Apr 22, 2010	DS DP U-820		NP	Jun 15, 2010
	4927855*PED	Oct 22, 2010				
	7132570	Dec 18, 2023	DS DP			
	7132570*PED	Jun 18, 2024				
	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014	DP U-820			
	RE37516*PED	Apr 06, 2015				
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N021248 001	6723351	Nov 10, 2018		U-573		
	6855339	Nov 10, 2018		U-617		
	6861076	Nov 10, 2018		U-617		
	6884439	Nov 10, 2018		U-651		
	6982096	Nov 10, 2018		U-651		
<u>ARTEMETHER; LUMEFANTRINE - COARTEM</u>						
N022268 001	5677331	Oct 14, 2014	DP U-977		NCE	Apr 07, 2014
					ODE	Apr 07, 2016
<u>ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E - M.V.I.-12 (WITHOUT VITAMIN K)</u>						
N008809 006					ODE	Sep 09, 2011
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>						
N021881 001	7169381	Sep 01, 2024	DS DP		NP	Aug 02, 2009



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N022117 001	5763476	Jun 09, 2015	DP U-326		NCE	Aug 13, 2014
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N022117 002	5763476	Jun 09, 2015	DP U-326		NCE	Aug 13, 2014
<u>ASPIRIN; DIPYRIDAMOLE - AGGRENOX</u>						
N020884 001	6015577	Jan 18, 2017	U-302			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 001	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 002	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 003	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 004	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 005	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 006	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 001	5849911	Jun 20, 2017	DS DP U-167		D-116	Sep 30, 2011
	6087383	Dec 21, 2018	DS DP		NPP	Mar 25, 2011
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 002	5849911	Jun 20, 2017	DS DP U-167		D-116	Sep 30, 2011
	6087383	Dec 21, 2018	DS DP		NPP	Mar 25, 2011
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 003	5849911	Jun 20, 2017	DS DP U-167		D-116	Sep 30, 2011
	6087383	Dec 21, 2018	DS DP		NPP	Mar 25, 2011
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 004	5849911	Jun 20, 2017	DS DP U-167		D-116	Sep 30, 2011
	6087383	Dec 21, 2018	DS DP		NPP	Mar 25, 2011
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 001	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 002	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 003	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 004	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 005	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 006	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 007	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 008	5658590	Nov 26, 2016	U-494		I-562	May 07, 2011
	5658590*PED	May 26, 2017	U-494		M-78	Jul 23, 2011
					M-66	Sep 28, 2010
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N020702 001	4681893	Sep 24, 2009	DS DP U-161		I-523	Mar 02, 2010
	4681893*PED	Mar 24, 2010	U-161			
	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011	U-162			
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015	U-213			
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N020702 002	4681893	Sep 24, 2009	DS DP U-161		I-523	Mar 02, 2010
	4681893*PED	Mar 24, 2010	U-161			
	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011	U-162			
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015	U-213			
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N020702 003	4681893	Sep 24, 2009	DS DP U-161		I-523	Mar 02, 2010
	4681893*PED	Mar 24, 2010	U-161			
	5273995	Dec 28, 2010	DS DP U-162			
	5273995*PED	Jun 28, 2011	U-162			
	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015	U-213			
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N020702 004	4681893	Sep 24, 2009	DS DP	U-161	I-523	Mar 02, 2010
	4681893*PED	Mar 24, 2010		U-161		
	5273995	Dec 28, 2010	DS DP	U-162		
	5273995*PED	Jun 28, 2011		U-162		
	5686104	Nov 11, 2014		DP U-213		
	5686104*PED	May 11, 2015		U-213		
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013		DP		
	6126971*PED	Jul 19, 2013				
	RE40667	Dec 28, 2010	DS DP	U-162		
	RE40667*PED	Jun 28, 2011				
<u>ATOVAQUONE - MEPRON</u>						
N020259 001	4981874	Aug 15, 2009		U-69		
	4981874*PED	Feb 15, 2010		U-69		
<u>ATOVAQUONE - MEPRON</u>						
N020500 001	4981874	Aug 15, 2009		U-69		
	4981874*PED	Feb 15, 2010		U-69		
	6649659	Jul 10, 2016	DS DP	U-69		
	6649659*PED	Jan 10, 2017				
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - MALARONE</u>						
N021078 001	5998449	Nov 25, 2013		U-990		
	5998449*PED	May 25, 2014				
	6166046	Nov 25, 2013		U-406		
	6166046*PED	May 25, 2014				
	6291488	Nov 25, 2013		U-406		
	6291488*PED	May 25, 2014				
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - MALARONE PEDIATRIC</u>						
N021078 002	5998449	Nov 25, 2013		U-990		
	5998449*PED	May 25, 2014				
	6166046	Nov 25, 2013				
	6166046*PED	May 25, 2014				
	6291488	Nov 25, 2013		U-406		
	6291488*PED	May 25, 2014				
<u>ATROPINE; PRALIDOXIME CHLORIDE - DUODOTE</u>						
N021983 001	5092843	Apr 12, 2010		DP		
<u>AVOBENZONE; ECAMSULE; OCTOCRYLENE - ANTHELIOS SX</u>						
N021502 001	5587150	Dec 24, 2013	DP	U-752	NC	Jul 21, 2009
<u>AVOBENZONE; ECAMSULE; OCTOCRYLENE - CAPITAL SOLEIL 15</u>						
N021501 001					NC	Jul 21, 2009
					NP	Oct 02, 2009
<u>AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE - ANTHELIOS 20</u>						
N021471 001					NC	Oct 05, 2009
<u>AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE - ANTHELIOS 40</u>						
N022009 001					NP	Mar 31, 2011
					NC	Oct 05, 2009
<u>AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE - ANTHELIOS 40</u>						
N022009 002					NP	Oct 29, 2012
<u>AZACITIDINE - VIDAZA</u>						
N050794 001					ODE	May 19, 2011
<u>AZELAIC ACID - FINACEA</u>						
N021470 001	6534070	Nov 18, 2018				
<u>AZELASTINE HYDROCHLORIDE - ASTELIN</u>						
N020114 001	5164194	Nov 01, 2010		U-730		
	5164194	Nov 01, 2010		U-207		
	5164194*PED	May 01, 2011				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N022203	001				NP	Oct 15, 2011
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N022371	001				NP	Aug 31, 2012
<u>AZELASTINE HYDROCHLORIDE - AZELASTINE HYDROCHLORIDE</u>						
A078621	001				PC	May 30, 2010
<u>AZELASTINE HYDROCHLORIDE - OPTIVAR</u>						
N021127	001	5164194	Nov 01, 2010			
		5164194*PED	May 01, 2011			
<u>AZITHROMYCIN - AZASITE</u>						
N050810	001	5192535	Mar 09, 2010	DP U-709		
		6159458	Nov 04, 2017	DP U-709		
		6239113	Mar 31, 2019	U-709		
		6569443	Mar 31, 2019	DP U-709		
		6861411	Nov 25, 2018	U-709		
		7056893	Mar 31, 2019	DP U-709		
<u>AZITHROMYCIN - AZITHROMYCIN</u>						
A065500	001				PC	Nov 07, 2009
<u>AZITHROMYCIN - AZITHROMYCIN</u>						
A065506	001				PC	Nov 07, 2009
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050693	001	6268489	Jul 31, 2018	DS		
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050710	001	6268489	Jul 31, 2018	DS		
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050710	002	6268489	Jul 31, 2018	DS		
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050711	001	6268489	Jul 31, 2018	DS		
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050730	001	6268489	Jul 31, 2018	DS		
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050733	001	6268489	Jul 31, 2018	DS		
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050784	001	6268489	Jul 31, 2018	DS		
<u>AZITHROMYCIN - ZMAX</u>						
N050797	001	6068859	May 30, 2017	DP		
		6268489	Jul 31, 2018	DS		
		6984403	Feb 14, 2024	DP U-282		
<u>BACLOFEN - KEMSTRO</u>						
N021589	001	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>BACLOFEN - KEMSTRO</u>						
N021589	002	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
N020610	001				NPP	Dec 20, 2009
					ODE	Dec 20, 2013
					PED	Jun 20, 2014
					PED	Jun 20, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N020911 002	5605674	Feb 25, 2014				
	5683677	Nov 04, 2014				
	5695743	Jul 06, 2010				
	5766573	Nov 28, 2009	U-356			
	5776432	Jul 07, 2015				
	6352684	Nov 28, 2009				
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N020911 001	5605674	Feb 25, 2014				
	5683677	Nov 04, 2014				
	5695743	Jul 06, 2010				
	5766573	Nov 28, 2009	U-356			
	5776432	Jul 07, 2015				
	6352684	Nov 28, 2009				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 001					I-580	Oct 31, 2011
					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 002					I-580	Oct 31, 2011
					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N050819 001	5733886	Mar 31, 2015	DP	U-124		
	6117843	Feb 18, 2012	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - DUAC</u>						
N050741 001	5466446	Feb 16, 2014	DS	DP		
<u>BENZYL ALCOHOL - ULESFIA</u>						
N022129 001	5858383	Aug 11, 2017		U-970	NCE	Apr 09, 2014
	6139859	Aug 11, 2017		U-970		
	6793931	Jul 11, 2022	DP	U-970		
	7294342	May 19, 2024		U-970		
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N022288 001					NCE	Sep 08, 2014
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N022308 001	5447926	Sep 05, 2012	DS	DP	U-80	NCE
	6685958	Jun 29, 2021		DP	U-80	May 28, 2014
	6699492	Mar 31, 2019		DP	U-80	
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N021852 001	5763426	Jun 09, 2015	DS	DP		
	6753013	Jan 27, 2020		DP	U-193	
	6753013	Jan 27, 2020		DP	U-88	
	RE39706	Jun 09, 2015	DS	DP		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX SCALP</u>						
N022185 001	6753013	Jan 27, 2020		DP	U-88	NDF
	6753013	Jan 27, 2020		DP	U-193	May 09, 2011
	6787529	Jan 27, 2020		DP	U-88	
	6787529	Jan 27, 2020		DP	U-193	
	RE39706	Jun 09, 2015	DS	DP		
<u>BETAMETHASONE VALERATE - LUXIQ</u>						
N020934 001	6126920	Mar 01, 2016			U-484	
	7078058	May 24, 2017		DP		
<u>BETAXOLOL HYDROCHLORIDE - BETOPTIC S</u>						
N019845 001					M-14	Jun 08, 2010
					PED	Dec 08, 2010
<u>BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE - BETOPTIC PILO</u>						
N020619 001						

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BEXAROTENE - TARGRETIN</u>						
N021055 001	5780676	Jul 14, 2015		U-509		
	5962731	Oct 05, 2016		U-475		
	6043279	Apr 22, 2012		U-509		
	6320074	Apr 22, 2012	DS	U-509		
<u>BEXAROTENE - TARGRETIN</u>						
N021056 001	5780676	Jul 14, 2015		U-510		
	5962731	Oct 05, 2016				
	6043279	Apr 22, 2012		U-510		
	6320074	Apr 22, 2012	DS	U-510		
<u>BICALUTAMIDE - CASODEX</u>						
N020498 001					M-81	Dec 19, 2011
					PED	Jun 19, 2012
<u>BIMATOPROST - LATISSE</u>						
N022369 001	6403649	Sep 21, 2012	DS		NP	Dec 24, 2011
	7351404	May 25, 2024		U-939		
	7388029	Jan 21, 2022		U-938		
<u>BIMATOPROST - LUMIGAN</u>						
N021275 001	5688819	Aug 19, 2014		U-446		
	6403649	Sep 21, 2012	DS DP	U-446		
<u>BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY</u>						
N021551 001	7291324	Oct 22, 2022		U-837		
<u>BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY</u>						
N021551 002	7291324	Oct 22, 2022		U-837	NP	Sep 24, 2010
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLEERA</u>						
N050786 001	5196205	Mar 23, 2010		U-933		
	5476669	Mar 23, 2010		U-933		
	6350468	Dec 14, 2018		U-932		
	6350468	Dec 14, 2018		U-956		
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Mar 23, 2010				
	5196404*PED	Sep 23, 2010				
	7582727	Jul 27, 2028		DP		
	7582727*PED	Jan 27, 2029				
	7598343	Jul 27, 2028		DP		
	7598343*PED	Jan 27, 2029				
<u>BORTEZOMIB - VELCADE</u>						
N021602 001	5780454	May 03, 2017		DP	I-564	Jun 20, 2011
	6083903	Oct 28, 2014		DP	U-515	I-521 Dec 08, 2009
	6297217	Oct 28, 2014			U-515	ODE Mar 25, 2012
	6297217	Oct 28, 2014			U-884	ODE May 13, 2010
	6297217	Oct 28, 2014			U-885	
	6617317	Oct 28, 2014	DS	DP		
	6713446	Jan 25, 2022		DP		
	6747150	Oct 28, 2014		DP		
	6958319	Jan 25, 2022		DP		
	7119080	Oct 28, 2014		DP		
<u>BOSENTAN - TRACLEER</u>						
N021290 001	5292740	Nov 20, 2015			I-607	Aug 07, 2012
					M-64	Feb 15, 2010
<u>BOSENTAN - TRACLEER</u>						
N021290 002	5292740	Nov 20, 2015			I-607	Aug 07, 2012
					M-64	Feb 15, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N021262 001	5424078	Jun 13, 2012				
	5424078*PED	Dec 13, 2012				
	6562873	Jul 10, 2021				
	6562873*PED	Jan 10, 2022				
	6627210	Jul 18, 2021	DP			
	6627210*PED	Jan 18, 2022				
	6641834	Jul 28, 2021	DP			
	6641834*PED	Jan 28, 2022				
	6673337	Jul 26, 2021	DP			
	6673337*PED	Jan 26, 2022				
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N021770 001	5424078	Jun 13, 2012	DP			
	5424078*PED	Dec 13, 2012				
	6562873	Jul 10, 2021	DP			
	6562873*PED	Jan 10, 2022				
	6627210	Jul 18, 2021	DP			
	6627210*PED	Jan 18, 2022				
	6641834	Jul 28, 2021	DP			
	6641834*PED	Jan 28, 2022				
	6673337	Jul 26, 2021	DP			
	6673337*PED	Jan 26, 2022				
<u>BRIMONIDINE TARTRATE - BRIMONIDINE TARTRATE</u>						
N021764 001	7265117	Aug 19, 2025	DP			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	7030149	Apr 19, 2022		U-849	NC	Oct 30, 2010
	7320976	Apr 19, 2022		U-849		
	7323463	Jan 19, 2023	DP			
	7642258	Apr 19, 2022	DS DP	U-1024		
<u>BRINZOLAMIDE - AZOPT</u>						
N020816 001	5240923	Aug 31, 2010	DS DP	U-224	M-54	Sep 28, 2009
	5240923*PED	Mar 01, 2011			PED	Mar 28, 2010
	5378703	Apr 01, 2012	DS DP	U-224		
	5378703*PED	Oct 01, 2012				
	5461081	Oct 24, 2012	DP	U-225		
	5461081*PED	Apr 24, 2013				
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N020866 001	5468755	Nov 21, 2012		U-976	NP	May 05, 2012
	5679685	Oct 21, 2014	DP			
	5716957	Feb 10, 2015		U-976		
	5756513	Nov 21, 2012		U-976		
	5866584	Nov 21, 2012		U-976		
<u>BUDESONIDE - ENTOCORT EC</u>						
N021324 001	5643602	Jul 01, 2014		U-655		
	5643602*PED	Jan 01, 2015	DP			
	6423340	Nov 15, 2010				
	6423340*PED	May 15, 2011				
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N021949 001	6027714	Jan 09, 2018	DP	U-787	NP	Jul 12, 2009
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N021949 002	6027714	Jan 09, 2018	DP	U-787	NP	Jul 12, 2009
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N020929 001	6598603	Dec 23, 2018				
	6598603*PED	Jun 23, 2019				
	6899099	Dec 23, 2018				
	6899099*PED	Jun 23, 2019				
	7524834	Nov 11, 2018	DP			
	7524834*PED	May 11, 2019				
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N020929 002	6598603	Dec 23, 2018				
	6598603*PED	Jun 23, 2019				
	6899099	Dec 23, 2018				
	6899099*PED	Jun 23, 2019				
	7524834	Nov 11, 2018	DP			
	7524834*PED	May 11, 2019				
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N020929 003	6598603	Dec 23, 2018				
	6598603*PED	Jun 23, 2019				
	6899099	Dec 23, 2018				
	6899099*PED	Jun 23, 2019				
	7524834	Nov 11, 2018	DP			
	7524834*PED	May 11, 2019				
<u>BUDESONIDE - RHINOCORT</u>						
N020746 001	6291445	Apr 29, 2017				
	6291445*PED	Oct 29, 2017				
	6686346	Apr 29, 2017	DP			
	6986904	Apr 29, 2017	DP			
<u>BUDESONIDE - RHINOCORT</u>						
N020746 002	6291445	Apr 29, 2017				
	6291445*PED	Oct 29, 2017				
	6686346	Apr 29, 2017	DP			
	6986904	Apr 29, 2017	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	5349945	Sep 27, 2011	DP		I-582	Feb 27, 2012
	5674860	Oct 07, 2014	DP		NC	Jul 21, 2009
	5972919	Dec 17, 2012	DP			
	6123924	Sep 26, 2017	DP			
	6641800	Sep 23, 2012	DP			
	7367333	Nov 11, 2018	DP			
	7587988	Apr 10, 2026	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	5349945	Sep 27, 2011	DP		I-582	Feb 27, 2012
	5674860	Oct 07, 2014	DP		NC	Jul 21, 2009
	5972919	Dec 17, 2012	DP			
	6123924	Sep 26, 2017	DP			
	6641800	Sep 23, 2012	DP			
	7367333	Nov 11, 2018	DP			
	7587988	Apr 10, 2026	DP			
<u>BUPRENORPHINE HYDROCHLORIDE - SUBUTEX</u>						
N020732 002					ODE	Oct 08, 2009
<u>BUPRENORPHINE HYDROCHLORIDE - SUBUTEX</u>						
N020732 003					ODE	Oct 08, 2009
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N020733 001					ODE	Oct 08, 2009
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N020733 002					ODE	Oct 08, 2009
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 001	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026				
	7572935	Jun 27, 2026	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 002	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026		U-997		
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 003	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026		U-997		
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N020358 001	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N020358 002	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N020358 003	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N020358 004	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N021515 001	6096341	Oct 30, 2018				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N021515 002	6096341	Oct 30, 2018				
<u>BUPROPION HYDROCHLORIDE - ZYBAN</u>						
N020711 002	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - ZYBAN</u>						
N020711 003	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUSULFAN - BUSULFEX</u>						
N020954 001	5430057	Sep 30, 2013		U-263		
	5430057*PED	Mar 30, 2014		U-263		
	5559148	Sep 30, 2013		U-264		
	5559148*PED	Mar 30, 2014		U-264		
<u>BUTENAFINE HYDROCHLORIDE - MENTAX</u>						
N020524 001	5021458	Oct 18, 2010		U-177		
<u>BUTOCONAZOLE NITRATE - GYNAZOLE-1</u>						
N019881 001	5266329	Nov 30, 2010		U-457		
	5993856	Nov 17, 2017	DP	U-457		
<u>CALCIPOTRIENE - DOVONEX</u>						
N020554 001	5763426	Jun 09, 2015	DS DP			
	RE39706	Jun 09, 2015	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIPOTRIENE - DOVONEX</u>						
N020611 001	5763426	Jun 09, 2015	DS DP			
	RE39706	Jun 09, 2015	DS DP			
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N021406 001	6440392	Feb 02, 2021	DP U-227			
	RE40812	Feb 02, 2021	DP			
<u>CALCITONIN, SALMON - MIACALCIN</u>						
N020313 002	5733569	Mar 31, 2015		U-227		
	5759565	Mar 31, 2015				
<u>CALCITRIOL - CALCIJEX</u>						
N018874 001	6051567	Aug 02, 2019				
	6051567*PED	Feb 02, 2020				
	6265392	Aug 02, 2019				
	6265392*PED	Feb 02, 2020				
	6274169	Aug 02, 2019				
	6274169*PED	Feb 02, 2020				
<u>CALCITRIOL - CALCIJEX</u>						
N018874 002	6051567	Aug 02, 2019				
	6051567*PED	Feb 02, 2020				
	6265392	Aug 02, 2019				
	6265392*PED	Feb 02, 2020				
	6274169	Aug 02, 2019				
	6274169*PED	Feb 02, 2020				
<u>CALCITRIOL - VECTICAL</u>						
N022087 001					NDF	Jan 23, 2012
<u>CALCIUM ACETATE - PHOSLO</u>						
N021160 002	6576665	Apr 03, 2021				
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N021160 003	6576665	Apr 03, 2021				
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE</u>						
N020958 001	5075114	May 23, 2010	DP			
	5075114*PED	Nov 23, 2010				
	5229137	May 16, 2012			U-349	
	5229137*PED	Nov 16, 2012				
	5989588	Sep 30, 2015			U-349	
	5989588*PED	Mar 30, 2016			U-349	
	6814978	Aug 26, 2021	DP			
	6814978*PED	Feb 26, 2022				
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>						
N021823 001	5583122	Dec 10, 2013	DS DP U-353			
	5583122*PED	Jun 10, 2014				
	5994329	Jul 17, 2018			U-353	
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018			U-353	
	6015801*PED	Jan 17, 2019				
	6096342	Nov 21, 2011	DP			
	6096342*PED	May 21, 2012				
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
	6432932	Jul 17, 2018			U-595	
	6432932*PED	Jan 17, 2019				
	6465443	Aug 14, 2018	DP			
	6465443*PED	Feb 14, 2019				
<u>CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL</u>						
N022193 001	5409904	Apr 25, 2012	DP U-891		NP	Jul 24, 2011
	5578578	Apr 25, 2012	DP			
	7084130	Nov 29, 2021	DP U-891			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N020838 001	5196444	Jun 04, 2012	DS DP U-3			
	5196444	Jun 04, 2012	DS DP U-660			
	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5705517	Apr 18, 2011	DS DP U-660			
	5705517*PED	Oct 18, 2011				
	7538133	Apr 18, 2011	DS			
	7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N020838 002	5196444	Jun 04, 2012	DS DP U-3			
	5196444	Jun 04, 2012	DS DP U-660			
	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5705517	Apr 18, 2011	DS DP U-660			
	5705517*PED	Oct 18, 2011				
	7538133	Apr 18, 2011	DS			
	7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N020838 003	5196444	Jun 04, 2012	DS DP U-660			
	5196444	Jun 04, 2012	DS DP U-3			
	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5705517	Apr 18, 2011	DS DP U-660			
	5705517*PED	Oct 18, 2011				
	7538133	Apr 18, 2011	DS			
	7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N020838 004	5196444	Jun 04, 2012	DS DP U-660			
	5196444	Jun 04, 2012	DS DP U-3			
	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5705517	Apr 18, 2011	DS DP U-660			
	5705517*PED	Oct 18, 2011				
	7538133	Apr 18, 2011	DS			
	7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N021093 001	5196444	Jun 04, 2012	DS DP U-3			
	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5705517	Apr 18, 2011	DS DP U-3			
	5705517*PED	Oct 18, 2011				
	5721263	Feb 24, 2015	DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7538133	Apr 18, 2011	DS			
	7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N021093 002	5196444	Jun 04, 2012	DS DP U-3			
	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5705517	Apr 18, 2011	DS DP U-3			
	5705517*PED	Oct 18, 2011				
	5721263	Feb 24, 2015	DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7538133	Apr 18, 2011	DS			
	7538133*PED	Oct 18, 2011				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N021093 003	5196444	Jun 04, 2012	DS DP U-3			
	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5705517	Apr 18, 2011	DS DP U-3			
	5705517*PED	Oct 18, 2011				
	5721263	Feb 24, 2015	DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7538133	Apr 18, 2011	DS			
	7538133*PED	Oct 18, 2011				
<u>CAPECITABINE - XELODA</u>						
N020896 001	4966891	Jan 13, 2011			U-272	
	5472949	Dec 14, 2013			U-271	
<u>CAPECITABINE - XELODA</u>						
N020896 002	4966891	Jan 13, 2011			U-272	
	5472949	Dec 14, 2013			U-271	
<u>CAPSAICIN - QUTENZA</u>						
N022395 001	6239180	Nov 06, 2016	DP		NCE	Nov 16, 2014
<u>CAPTOPRIL - CAPOTEN</u>						
N018343 001	5238924	Aug 24, 2010			U-92	
<u>CAPTOPRIL - CAPOTEN</u>						
N018343 002	5238924	Aug 24, 2010			U-92	
<u>CAPTOPRIL - CAPOTEN</u>						
N018343 003	5238924	Aug 24, 2010			U-92	
<u>CAPTOPRIL - CAPOTEN</u>						
N018343 004	5238924	Aug 24, 2010			U-92	
<u>CAPTOPRIL - CAPOTEN</u>						
N018343 005	5238924	Aug 24, 2010			U-92	
<u>CAPTOPRIL - CAPOTEN</u>						
N018343 006	5238924	Aug 24, 2010			U-92	
<u>CAPTOPRIL - CAPOTEN</u>						
N018343 007	5238924	Aug 24, 2010			U-92	
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 001	5326570	Jul 05, 2011			U-215	
	5912013	Jun 15, 2016			U-277	
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 002	5326570	Jul 05, 2011			U-215	
	5912013	Jun 15, 2016			U-277	
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 003	5326570	Jul 05, 2011			U-215	
	5912013	Jun 15, 2016			U-277	
<u>CARBAMAZEPINE - EQUETRO</u>						
N021710 001	5326570	Jul 23, 2011	DP U-627			
	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024			U-693	
<u>CARBAMAZEPINE - EQUETRO</u>						
N021710 002	5326570	Jul 23, 2011	DP U-627			
	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024			U-693	
<u>CARBAMAZEPINE - EQUETRO</u>						
N021710 003	5326570	Jul 23, 2011	DP U-627			
	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024			U-693	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBAMAZEPINE - TEGRETOL-XR</u>						
N020234 001	5284662	Feb 08, 2011				
<u>CARBAMAZEPINE - TEGRETOL-XR</u>						
N020234 002	5284662	Feb 08, 2011				
<u>CARBAMAZEPINE - TEGRETOL-XR</u>						
N020234 003	5284662	Feb 08, 2011				
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100</u>						
N021485 002	5135950	Oct 31, 2010	DS DP	U-219		
	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020		DP	U-219	
	6797732	Jun 29, 2020		DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125</u>						
N021485 006	5135950	Oct 31, 2010	DS DP	U-219		
	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020		DP	U-219	
	6797732	Jun 29, 2020		DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>						
N021485 003	5135950	Oct 31, 2010	DS DP	U-219		
	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020		DP	U-219	
	6797732	Jun 29, 2020		DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200</u>						
N021485 004	5135950	Oct 31, 2010	DS DP	U-219		
	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020		DP	U-219	
	6797732	Jun 29, 2020		DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50</u>						
N021485 001	5135950	Oct 31, 2010	DS DP	U-219		
	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020		DP	U-219	
	6797732	Jun 29, 2020		DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75</u>						
N021485 005	5135950	Oct 31, 2010	DS DP	U-219		
	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020		DP	U-219	
	6797732	Jun 29, 2020		DP		
<u>CARISOPRODOL - SOMA</u>						
N011792 004					NP	Sep 13, 2010
<u>CARMUSTINE - GLIADEL</u>						
N020637 001					ODE	Feb 25, 2010
<u>CARVEDILOL - COREG</u>						
N020297 001	RE40000	Jun 07, 2015		U-233	M-61	Feb 23, 2010
	RE40000*PED	Dec 07, 2015			M-56	Aug 28, 2009
					PED	Aug 23, 2010
					PED	Feb 28, 2010
<u>CARVEDILOL - COREG</u>						
N020297 002	RE40000	Jun 07, 2015		U-233	M-61	Feb 23, 2010
	RE40000*PED	Dec 07, 2015			M-56	Aug 28, 2009
					PED	Aug 23, 2010
					PED	Feb 28, 2010
<u>CARVEDILOL - COREG</u>						
N020297 003	RE40000	Jun 07, 2015		U-233	M-61	Feb 23, 2010
	RE40000*PED	Dec 07, 2015			M-56	Aug 28, 2009
					PED	Aug 23, 2010
					PED	Feb 28, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARVEDILOL - COREG</u>						
N020297 004	RE40000	Jun 07, 2015		U-233	M-61	Feb 23, 2010
	RE40000*PED	Dec 07, 2015			M-56	Aug 28, 2009
					PED	Aug 23, 2010
					PED	Feb 28, 2010
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 001	5902821	Feb 07, 2016		U-313	M-56	Aug 28, 2009
	5902821	Feb 07, 2016		U-777	NDF	Oct 20, 2009
	5902821*PED	Aug 07, 2016			PED	Feb 28, 2010
	6022562	Oct 17, 2015		DP	PED	Apr 20, 2010
	6022562*PED	Apr 17, 2016				
	7268156	Jun 27, 2023	DS DP	U-313		
	7268156	Jun 27, 2023	DS DP	U-3		
	7268156*PED	Dec 27, 2023				
	RE40000	Jun 07, 2015		U-777		
	RE40000*PED	Dec 07, 2015				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 002	5902821	Feb 07, 2016		U-313	M-56	Aug 28, 2009
	5902821	Feb 07, 2016		U-777	NDF	Oct 20, 2009
	5902821*PED	Aug 07, 2016			PED	Feb 28, 2010
	6022562	Oct 17, 2015		DP	PED	Apr 20, 2010
	6022562*PED	Apr 17, 2016				
	7268156	Jun 27, 2023	DS DP	U-313		
	7268156	Jun 27, 2023	DS DP	U-3		
	7268156*PED	Dec 27, 2023				
	RE40000	Jun 07, 2015		U-777		
	RE40000*PED	Dec 07, 2015				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 003	5902821	Feb 07, 2016		U-777	M-56	Aug 28, 2009
	5902821	Feb 07, 2016		U-313	NDF	Oct 20, 2009
	5902821*PED	Aug 07, 2016			PED	Feb 28, 2010
	6022562	Oct 17, 2015		DP	PED	Apr 20, 2010
	6022562*PED	Apr 17, 2016				
	7268156	Jun 27, 2023	DS DP	U-313		
	7268156	Jun 27, 2023	DS DP	U-3		
	7268156*PED	Dec 27, 2023				
	RE40000	Jun 07, 2015		U-777		
	RE40000*PED	Dec 07, 2015				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 004	5902821	Feb 07, 2016		U-777	M-56	Aug 28, 2009
	5902821	Feb 07, 2016		U-313	NDF	Oct 20, 2009
	5902821*PED	Aug 07, 2016			PED	Feb 28, 2010
	6022562	Oct 17, 2015		DP	PED	Apr 20, 2010
	6022562*PED	Apr 17, 2016				
	7268156	Jun 27, 2023	DS DP	U-313		
	7268156	Jun 27, 2023	DS DP	U-3		
	7268156*PED	Dec 27, 2023				
	RE40000	Jun 07, 2015		U-777		
	RE40000*PED	Dec 07, 2015				
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N021227 001	5378804	Mar 16, 2013	DS			
	5378804*PED	Sep 16, 2013				
	5514650	Jan 26, 2015		DP	U-607	
	5514650*PED	Jul 26, 2015				
	5792746	Mar 16, 2013	DS DP	U-607		
	5792746*PED	Sep 16, 2013				
	5952300	Mar 28, 2017		DP		
	5952300*PED	Sep 28, 2017				
	6136783	Mar 28, 2017			U-607	
	6136783*PED	Sep 28, 2017				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N021227 002	5378804	Mar 16, 2013	DS			
	5378804*PED	Sep 16, 2013				
	5514650	Jan 26, 2015	DP	U-607		
	5514650*PED	Jul 26, 2015				
	5792746	Mar 16, 2013	DS	DP	U-607	
	5792746*PED	Sep 16, 2013				
	5952300	Mar 28, 2017	DP			
	5952300*PED	Sep 28, 2017				
	6136783	Mar 28, 2017		U-607		
	6136783*PED	Sep 28, 2017				
<u>CEFDINIR - OMNICEF</u>						
N050739 001	4935507	Dec 04, 2011	DS			
<u>CEFDINIR - OMNICEF</u>						
N050749 001	4935507	Dec 04, 2011	DS			
<u>CEFDINIR - OMNICEF</u>						
N050749 002	4935507	Dec 04, 2011	DS			
<u>CEFDITOREN PIVOXIL - SPECTRACEF</u>						
N021222 001	5958915	Oct 14, 2016				
<u>CEFDITOREN PIVOXIL - SPECTRACEF</u>						
N021222 002	5958915	Oct 14, 2016	DP			
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N050685 002	4634697	Oct 01, 2009	DS	DP	U-578	
	4634697	Oct 01, 2009	DS	DP	U-282	
	4812561	Dec 20, 2009	DS			
	5599557	Apr 30, 2013		DP		
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N050686 001	4634697	Oct 01, 2009	DS	DP	U-282	
	4634697	Oct 01, 2009	DS	DP	U-578	
	4812561	Dec 20, 2009	DS			
	5599557	Apr 30, 2013		DP	U-282	
	5599557	Apr 30, 2013		DP	U-578	
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N050686 002	4634697	Oct 01, 2009	DS	DP	U-282	
	4634697	Oct 01, 2009	DS	DP	U-578	
	4812561	Dec 20, 2009	DS			
	5599557	Apr 30, 2013		DP	U-578	
	5599557	Apr 30, 2013		DP	U-282	
<u>CELECOXIB - CELEBREX</u>						
N020998 001	5466823	Nov 30, 2013	DS		NPP	Dec 15, 2009
	5466823*PED	May 30, 2014			PED	Jun 15, 2010
	5563165	Nov 30, 2013	DP			
	5563165*PED	May 30, 2014				
	5760068	Jun 02, 2015			U-672	
	5760068	Jun 02, 2015			U-299	
	5760068*PED	Dec 02, 2015				
	5972986	Oct 14, 2017			U-299	
	5972986*PED	Apr 14, 2018				
<u>CELECOXIB - CELEBREX</u>						
N020998 002	5466823	Nov 30, 2013	DS		NPP	Dec 15, 2009
	5466823*PED	May 30, 2014			PED	Jun 15, 2010
	5563165	Nov 30, 2013	DP			
	5563165*PED	May 30, 2014				
	5760068	Jun 02, 2015			U-672	
	5760068	Jun 02, 2015			U-299	
	5760068*PED	Dec 02, 2015				
	5972986	Oct 14, 2017			U-299	
	5972986*PED	Apr 14, 2018				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELEBREX</u>						
N020998 003	5466823	Nov 30, 2013	DS		NPP	Dec 15, 2009
	5466823*PED	May 30, 2014			PED	Jun 15, 2010
	5563165	Nov 30, 2013	DP			
	5563165*PED	May 30, 2014				
	5760068	Jun 02, 2015		U-672		
	5760068	Jun 02, 2015		U-299		
	5760068*PED	Dec 02, 2015				
	5972986	Oct 14, 2017		U-299		
	5972986*PED	Apr 14, 2018				
<u>CELECOXIB - CELEBREX</u>						
N020998 004	5466823	Nov 30, 2013	DS		NPP	Dec 15, 2009
	5466823*PED	May 30, 2014			PED	Jun 15, 2010
	5563165	Nov 30, 2013	DP			
	5563165*PED	May 30, 2014				
	5760068	Jun 02, 2015		U-672		
	5760068*PED	Dec 02, 2015				
<u>CERIVASTATIN SODIUM - BAYCOL</u>						
N020740 001	5006530	Jun 26, 2011				
	5177080	Nov 26, 2011				
<u>CERIVASTATIN SODIUM - BAYCOL</u>						
N020740 002	5006530	Jun 26, 2011				
	5177080	Nov 26, 2011				
<u>CERIVASTATIN SODIUM - BAYCOL</u>						
N020740 003	5006530	Jun 26, 2011				
	5177080	Nov 26, 2011				
<u>CERIVASTATIN SODIUM - BAYCOL</u>						
N020740 004	5006530	Jun 26, 2011				
	5177080	Nov 26, 2011				
<u>CERIVASTATIN SODIUM - BAYCOL</u>						
N020740 005	5006530	Jun 26, 2011				
	5177080	Nov 26, 2011				
<u>CERIVASTATIN SODIUM - BAYCOL</u>						
N020740 006	5006530	Jun 26, 2011				
	5177080	Jan 26, 2011				
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N021621 003	6455533	Jul 02, 2018	DP	U-295		
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N021621 004	6455533	Jul 02, 2018	DP	U-295		
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N021621 005	6455533	Jul 02, 2018	DP	U-295		
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N021621 006	6455533	Jul 02, 2018	DP	U-295		
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR</u>						
N021150 002	6469009	Jul 13, 2019	DP	U-295		
	6489329	Apr 08, 2016	DP			
	7014867	Jun 10, 2022	DP			
	7226614	Jun 10, 2022		U-295		
<u>CETRORELIX - CETROTIDE</u>						
N021197 001	5198533	Oct 24, 2010	DS DP			
	6319192	Apr 23, 2018		U-426		
	6863891	Feb 22, 2014		U-426		
	7605121	Feb 22, 2014	DS DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CETRORELIX - CETROTIDE</u>						
N021197 002	5198533	Oct 24, 2010	DS DP			
	6319192	Apr 23, 2018		U-426		
	6863891	Feb 22, 2014		U-426		
	7605121	Feb 22, 2014	DS DP			
<u>CEVIMELINE HYDROCHLORIDE - EVOXAC</u>						
N020989 002	4855290	Aug 30, 2009				
	5340821	Jul 07, 2013		U-309		
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7066916	Feb 17, 2024		U-737		
	7427574	Apr 25, 2026	DP			
	7595021	May 12, 2023	DP	U-1022		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N020832 001	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N020832 004	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N020832 006	5690958	Sep 30, 2016	DP			
	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP FREPP</u>						
N020832 003	5538353	Aug 25, 2015	DP			
	5690958	Sep 30, 2016	DP			
	5752363	Apr 22, 2017	DP			
	5772346	Apr 22, 2017	DP			
	D386849	Nov 25, 2011	DP			
	D396911	Aug 11, 2012	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP SEPP</u>						
N021555 001	5690958	Sep 30, 2016	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 002	5690958	Sep 30, 2016	DP			
	6729786	Mar 14, 2023	DP			
	6991393	Mar 14, 2023	DP			
	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			
	7241065	Mar 14, 2023	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 005	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	6991393	Jan 31, 2024	DP			
	7241065	Mar 14, 2023	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 007	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	6991393	Mar 14, 2023	DP			
	7241065	Mar 14, 2023	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORASCUB MAXI SWABSTICK</u>						
N021524 003	D468424	Jan 07, 2017				
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N022224 001	7259186	Jan 07, 2025	DS		NP	Dec 15, 2011
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N022224 002	7259186	Jan 07, 2025	DS		NP	Dec 15, 2011

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N021149 001	5767251	Jun 16, 2015				
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N021149 002	5767251	Jun 16, 2015	DS			
	6706681	Mar 16, 2021		DP		
<u>CICLESONIDE - ALVESCO</u>						
N021658 002	5482934	Oct 24, 2017	DS DP	U-1002	NDF	Jan 10, 2011
	5605674	Feb 25, 2014		DP	NCE	Oct 20, 2011
	5683677	Nov 04, 2014		DP		
	5695743	Jul 06, 2010		DP	U-1001	
	5775321	Jul 07, 2015		DP		
	6006745	Dec 28, 2016		DP		
	6036942	Apr 30, 2013		DP		
	6120752	May 13, 2018		DP		
	6264923	May 13, 2013		DP		
<u>CICLESONIDE - ALVESCO</u>						
N021658 003	5482934	Oct 24, 2017	DS DP	U-1002	NDF	Jan 10, 2011
	5605674	Feb 25, 2014		DP	NCE	Oct 20, 2011
	5683677	Nov 04, 2014		DP		
	5695743	Jul 06, 2010		DP	U-1001	
	5775321	Jul 07, 2015		DP		
	6006745	Dec 28, 2016		DP		
	6036942	Apr 30, 2013		DP		
	6120752	May 13, 2018		DP		
	6264923	May 13, 2013		DP		
<u>CICLESONIDE - OMNARIS</u>						
N022004 001	5482934	Oct 24, 2017	DS DP	U-557	I-548	Nov 21, 2010
	6767901	Oct 21, 2020		DP	NCE	Oct 20, 2011
	6939559	Apr 21, 2019		DP		
	7235247	Apr 21, 2019		DP		
<u>CICLOPIROX - LOPROX</u>						
N020519 001	7018656	Sep 05, 2018		DP		
	7026337	Apr 02, 2018			U-714	
<u>CIDOFOVIR - VISTIDE</u>						
N020638 001	5142051	Jun 26, 2010				
<u>CILASTATIN SODIUM; IMPENEM - PRIMAXIN</u>						
N050587 001	5147868	Sep 15, 2009	DS DP	U-928		
<u>CILASTATIN SODIUM; IMPENEM - PRIMAXIN</u>						
N050587 002	5147868	Sep 15, 2009	DS DP	U-928		
<u>CILASTATIN SODIUM; IMPENEM - PRIMAXIN</u>						
N050630 001	5147868	Sep 15, 2009	DS DP	U-928		
<u>CILASTATIN SODIUM; IMPENEM - PRIMAXIN</u>						
N050630 002	5147868	Sep 15, 2009	DS DP	U-928		
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 001	6011068	Dec 14, 2016	DS DP		ODE	Mar 08, 2011
	6031003	Dec 14, 2016		U-559		
	6211244	Oct 23, 2015	DS DP	U-560		
	6313146	Dec 14, 2016	DS DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 002	6011068	Dec 14, 2016	DS DP		ODE	Mar 08, 2011
	6031003	Dec 14, 2016				
	6211244	Oct 23, 2015	DS DP	U-560		
	6313146	Dec 14, 2016	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 003	6011068	Dec 14, 2016	DS DP		ODE	Mar 08, 2011
	6031003	Dec 14, 2016		U-559		
	6211244	Oct 23, 2015	DS DP	U-560		
	6313146	Dec 14, 2016	DS DP			
<u>CIPROFLOXACIN - CIPRO</u>						
N020780 001	5695784	Dec 09, 2014				
	5695784*PED	Jun 09, 2015				
	6136347	Jan 06, 2013		U-362		
	6136347*PED	Jul 06, 2013				
<u>CIPROFLOXACIN - CIPRO</u>						
N020780 002	5695784	Dec 09, 2014				
	5695784*PED	Jun 09, 2015				
	6136347	Jan 06, 2013		U-362		
	6136347*PED	Jul 06, 2013				
<u>CIPROFLOXACIN HYDROCHLORIDE - CETRAXAL</u>						
N021918 001					NDF	May 01, 2012
<u>CIPROFLOXACIN HYDROCHLORIDE - CIPRO</u>						
N019537 001	5286754	Feb 15, 2011				
	5286754*PED	Aug 15, 2011				
<u>CIPROFLOXACIN HYDROCHLORIDE - CIPRO</u>						
N019537 002	5286754	Feb 15, 2011				
	5286754*PED	Aug 15, 2011				
<u>CIPROFLOXACIN HYDROCHLORIDE - CIPRO</u>						
N019537 003	5286754	Feb 15, 2011				
	5286754*PED	Aug 15, 2011				
<u>CIPROFLOXACIN HYDROCHLORIDE - CIPRO</u>						
N019537 004	5286754	Feb 15, 2011				
	5286754*PED	Aug 15, 2011				
<u>CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR</u>						
N021744 001	5972389	Sep 19, 2016	DP	U-663		
	6340475	Sep 19, 2016	DP	U-663		
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP	U-663		
<u>CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPRO HC</u>						
N020805 001	5843930	Jun 06, 2015		U-646		
	5965549	Jun 06, 2015	DP			
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N021537 001	6284804	Aug 10, 2020				
	6359016	Aug 10, 2020				
<u>CISAPRIDE MONOHYDRATE - PROPULSID QUICKSOLV</u>						
N020767 001	5648093	Jul 15, 2014				
<u>CISATRACURIUM BESYLATE - NIMBEX</u>						
N020551 001	5453510	Sep 26, 2012		U-127		
<u>CISATRACURIUM BESYLATE - NIMBEX PRESERVATIVE FREE</u>						
N020551 002	5453510	Sep 26, 2012		U-127		
<u>CISATRACURIUM BESYLATE - NIMBEX PRESERVATIVE FREE</u>						
N020551 003	5453510	Sep 26, 2012		U-127		
<u>CLARITHROMYCIN - BIAVIN XL</u>						
N050775 001	6010718	Apr 11, 2017	DP	U-924		
	6551616	Jul 15, 2017		U-924		
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 001	5739152	Apr 14, 2015	DP	U-893	NCE	Aug 01, 2013
	5856346	Jan 05, 2016	DS DP	U-893		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 002	5739152	Apr 14, 2015	DP U-893		NCE	Aug 01, 2013
	5856346	Jan 05, 2016	DS DP U-893			
<u>CLINDAMYCIN PHOSPHATE - CLEOCIN</u>						
N050767 001	6495157	Jul 20, 2020	DP			
<u>CLINDAMYCIN PHOSPHATE - CLINDAGEL</u>						
N050782 001	6387383	Aug 03, 2020	DP U-818			
<u>CLINDAMYCIN PHOSPHATE - CLINDESSE</u>						
N050793 001	5266329	Nov 30, 2010	DP			
	5993856	Nov 17, 2017	DP U-137			
	6899890	Apr 27, 2023	DP U-137			
<u>CLINDAMYCIN PHOSPHATE - EVOCLIN</u>						
N050801 001	7141237	Jan 23, 2024	DS DP			
	7374747	Aug 09, 2026	DS DP U-921			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA</u>						
N050802 001	5721275	Feb 24, 2015	DP			
	6387383	Aug 03, 2020	DP U-916			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N021535 001	6106848	Sep 22, 2017				
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N021644 001	7316810	Jun 17, 2019	DP			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N021835 001	5972920	Feb 12, 2018	DP			
	5990100	Mar 24, 2018	DP U-742			
<u>CLOBETASOL PROPIONATE - OLUX</u>						
N021142 001	6126920	Mar 01, 2016			U-484	
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N022013 001	6730288	Sep 08, 2019	DP		NP	Jan 12, 2010
	7029659	Sep 08, 2019	DP			
<u>CLOFARABINE - CLOLAR</u>						
N021673 001	5661136	Jan 14, 2018			U-626	
					NCE	Dec 28, 2009
					ODE	Dec 28, 2011
					PED	Jun 28, 2012
					PED	Jun 28, 2010
<u>CLONIDINE HYDROCHLORIDE - JENLOGA</u>						
N022331 001					NP	Sep 29, 2012
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 001	4847265	Nov 17, 2011	DS DP		I-502	Aug 17, 2009
	5576328	Jan 31, 2014		U-432	Y	
	6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 002	4847265	Nov 17, 2011	DS DP		I-502	Aug 17, 2009
	6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			
<u>CLOZAPINE - FAZACLO ODT</u>						
N021590 001	5178878	Jan 12, 2010	DP			
	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOZAPINE - FAZACLO ODT</u>						
N021590 002	5178878	Jan 12, 2010	DP			
	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N021590 003	5178878	Jan 12, 2010	DP			
	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N021590 004	5178878	Jan 12, 2010	DP			
	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7601758	Feb 10, 2029		U-1007	I-603	Jul 30, 2012
	7619004	Dec 03, 2028		U-1020	ODE	Jul 29, 2016
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N021141 001	5607669	Jun 10, 2014		U-323		
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014		U-323		
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014				
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014		U-323		
	5917007*PED	Oct 29, 2014				
	5919832	Jun 10, 2014				
	5919832*PED	Dec 10, 2014				
	6066678	Jun 10, 2014		U-323		
	6066678*PED	Dec 10, 2014				
	6433026	Jun 10, 2014				
	6433026*PED	Dec 10, 2014				
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N021176 001	5607669	Jun 10, 2014		U-323	I-608	Oct 02, 2012
	5607669*PED	Dec 10, 2014			I-553	Jan 18, 2011
	5679717	Apr 29, 2014		U-323	PED	Apr 02, 2013
	5679717*PED	Oct 29, 2014			PED	Jul 18, 2011
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS	U-323		
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS	U-323		
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP	U-757		
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022		U-851		
	7229613*PED	Oct 17, 2022				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N022362 001	5607669	Jun 10, 2014		U-757	I-608	Oct 02, 2012
	5679717	Apr 29, 2014		U-757	I-553	Jan 18, 2011
	5693675	Dec 02, 2014	DS		PED	Apr 02, 2013
	5917007	Apr 29, 2014	DS	U-757	PED	Jul 18, 2011
	5919832	Apr 29, 2014	DS			
	6066678	Apr 29, 2014	DS	U-757		
	6433026	Apr 29, 2014	DS			
	6784254	Apr 29, 2014	DS DP			
	7101960	Apr 29, 2014	DS DP	U-757		
	7229613	Apr 17, 2022		U-493		
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N022362 002	5607669	Jun 10, 2014		U-757	I-608	Oct 02, 2012
	5679717	Apr 29, 2014		U-757	I-553	Jan 18, 2011
	5693675	Dec 02, 2014	DS		PED	Apr 02, 2013
	5917007	Apr 29, 2014	DS	U-757	PED	Jul 18, 2011
	5919832	Apr 29, 2014	DS			
	6066678	Apr 29, 2014	DS	U-757		
	6433026	Apr 29, 2014	DS			
	6784254	Apr 29, 2014	DS DP			
	7101960	Apr 29, 2014	DS DP	U-757		
	7229613	Apr 17, 2022		U-493		
<u>COLESTIPOL HYDROCHLORIDE - COLESTID</u>						
N020222 001	5490987	Feb 13, 2013		DP		
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>						
N021697 001	5723606	Dec 15, 2019	DS DP	U-698	I-526	Feb 28, 2010
	5723606	Dec 15, 2019	DS DP	U-868	NCE	Dec 29, 2010
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER</u>						
N021697 002	5723606	Dec 15, 2019	DS DP	U-698	I-526	Feb 28, 2010
	5723606	Dec 15, 2019	DS DP	U-868	NCE	Dec 29, 2010
<u>CYANOCOBALAMIN - CALOMIST</u>						
N022102 001					NP	Jul 22, 2010
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N021642 001	7229636	Jun 11, 2024	DP	U-817		
	7404489	Mar 12, 2024	DP			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N021777 001	7387793	Feb 26, 2025	DP		NDF	Feb 01, 2010
	7544372	Nov 14, 2023		U-979		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N021777 002	7387793	Feb 26, 2025	DP		NDF	Feb 01, 2010
	7544372	Nov 14, 2023		U-979		
<u>CYCLOSPORINE - NEORAL</u>						
N050715 001	5342625	Aug 30, 2011	DP			
	5741512	Aug 30, 2011	DP	U-906		
	5866159	Sep 13, 2009	DP	U-906		
	5916589	Sep 13, 2009	DP	U-906		
	5962014	Sep 13, 2009	DP	U-906		
	5962017	Sep 13, 2009	DP	U-906		
	5985321	Sep 26, 2014	DP			
	6007840	Sep 13, 2009	DP	U-906		
	6024978	Sep 13, 2009	DP	U-906		
	6258808	Jun 25, 2012	DP			
	6262022	Jun 25, 2012	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - NEORAL</u>						
N050715 002	5342625	Aug 30, 2011	DP			
	5741512	Aug 30, 2011	DP	U-906		
	5866159	Sep 13, 2009	DP	U-906		
	5916589	Sep 13, 2009	DP	U-906		
	5962014	Sep 13, 2009	DP	U-906		
	5962017	Sep 13, 2009	DP	U-906		
	5985321	Sep 26, 2014	DP			
	6007840	Sep 13, 2009	DP	U-906		
	6024978	Sep 13, 2009	DP	U-906		
	6258808	Jun 25, 2012	DP			
	6262022	Jun 25, 2012	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N050715 003	5342625	Aug 30, 2011	DP			
	5741512	Aug 30, 2011	DP	U-906		
	5866159	Sep 13, 2009	DP	U-906		
	5916589	Sep 13, 2009	DP	U-906		
	5962014	Sep 13, 2009	DP	U-906		
	5962017	Sep 13, 2009	DP	U-906		
	5985321	Sep 26, 2014	DP			
	6007840	Sep 13, 2009	DP	U-906		
	6024978	Sep 13, 2009	DP	U-906		
	6258808	Jun 25, 2012	DP			
	6262022	Jun 25, 2012	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N050716 001	5342625	Aug 30, 2011	DP			
	5741512	Aug 30, 2011	DP	U-906		
	5866159	Sep 13, 2009	DP	U-906		
	5916589	Sep 13, 2009	DP	U-906		
	5962014	Sep 13, 2009	DP	U-906		
	5962017	Sep 13, 2009	DP	U-906		
	5985321	Sep 26, 2014	DP			
	6007840	Sep 13, 2009	DP	U-906		
	6024978	Sep 13, 2009	DP	U-906		
	6258808	Jun 25, 2012	DP			
	6262022	Jun 25, 2012	DP			
<u>CYCLOSPORINE - RESTASIS</u>						
N050790 001	4839342	Aug 02, 2009		U-927		
	5474979	May 17, 2014	DP			
<u>CYCLOSPORINE - SANDIMMUNE</u>						
N050625 001	7511014	Feb 16, 2010	DP			
<u>CYCLOSPORINE - SANDIMMUNE</u>						
N050625 002	7511014	Feb 16, 2010	DP			
<u>CYCLOSPORINE - SANDIMMUNE</u>						
N050625 003	7511014	Feb 16, 2010	DP			
<u>CYTARABINE - DEPOCYT</u>						
N021041 001	5455044	May 14, 2013		U-806		
	5723147	Mar 03, 2015	DP	U-806		
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N020287 001					I-534	May 01, 2010
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N020287 002					I-534	May 01, 2010
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N020287 003					I-534	May 01, 2010
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N020287 004					I-534	May 01, 2010
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N020287 005					I-534	May 01, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N020287	006				I-534	May 01, 2010
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N020287	007				I-534	May 01, 2010
<u>DANAPAROID SODIUM - ORGARAN</u>						
N020430	001	5164377	Oct 03, 2010			
<u>DAPSONE - ACZONE</u>						
N021794	001	5863560	Sep 11, 2016	DP	M-76	Mar 14, 2011
		6060085	Sep 11, 2016	U-124		
		6620435	Sep 11, 2016	DP		
<u>DAPTOMYCIN - CUBICIN</u>						
N021572	001	6468967	Sep 24, 2019	U-282		
		6852689	Sep 24, 2019	U-282		
<u>DAPTOMYCIN - CUBICIN</u>						
N021572	002	6468967	Sep 24, 2019	U-282		
		6852689	Sep 24, 2019	U-282		
		RE39071	Jun 15, 2016	DS DP U-728		
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N021513	001	5096890	Mar 13, 2015	DS DP U-631	NCE	Dec 22, 2009
		6106864	Aug 21, 2016	DP U-630		
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N021513	002	5096890	Mar 13, 2015	DS DP U-631	NCE	Dec 22, 2009
		6106864	Aug 21, 2016	DP U-630		
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976	001	5843946	Dec 01, 2015	DP U-903	D-119	Dec 18, 2011
		5843946	Dec 01, 2015	DP U-935	I-578	Oct 21, 2011
		5843946	Dec 01, 2015	DP U-744	NCE	Jun 23, 2011
		6248775	Aug 13, 2014	DS		
		6335460	Aug 25, 2012	DS DP U-903		
		6335460	Aug 25, 2012	DS DP U-935		
		6335460	Aug 25, 2012	DS DP U-744		
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976	002	5843946	Dec 01, 2015	DP U-935	D-119	Dec 18, 2011
		5843946	Dec 01, 2015	DP U-903	I-578	Oct 21, 2011
		5843946	Dec 01, 2015	DP U-744	NCE	Jun 23, 2011
		6248775	Aug 13, 2014	DS		
		6335460	Aug 25, 2012	DS DP U-935		
		6335460	Aug 25, 2012	DS DP U-903		
		6335460	Aug 25, 2012	DS DP U-744		
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976	003	5843946	Dec 01, 2015	DP U-744	D-119	Dec 18, 2011
		5843946	Dec 01, 2015	DP U-935	D-118	Oct 21, 2011
		5843946	Dec 01, 2015	DP U-903	I-578	Oct 21, 2011
		6248775	Aug 13, 2014	DS	NCE	Jun 23, 2011
		6335460	Aug 25, 2012	DS DP U-903		
		6335460	Aug 25, 2012	DS DP U-935		
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976	004	5843946	Dec 01, 2015	DP U-935	D-119	Dec 18, 2011
		6248775	Aug 13, 2014	DS	NS	Dec 18, 2011
		6335460	Aug 25, 2012	DS DP U-935		
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976	005	5843946	Dec 01, 2015	DP U-935	D-119	Dec 18, 2011
		6248775	Aug 13, 2014	DS	NS	Dec 18, 2011
		6335460	Aug 25, 2012	DS DP U-935		



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N021986 001	6596746	Jun 28, 2020	DS DP U-780		D-120	May 21, 2012
	6596746	Jun 28, 2020	DS DP U-748		D-109	Nov 06, 2010
	7125875	Apr 13, 2020	U-780		M-70	Nov 06, 2010
	7125875	Apr 13, 2020	U-779		NCE	Jun 28, 2011
	7153856	Apr 28, 2020	U-780		ODE	Jun 28, 2013
	7491725	Sep 05, 2025	DS DP		ODE	Jun 28, 2013
<u>DASATINIB - SPRYCEL</u>						
N021986 002	6596746	Jun 28, 2020	DS DP U-748		D-120	May 21, 2012
	6596746	Jun 28, 2020	DS DP U-780		D-109	Nov 06, 2010
	7125875	Apr 13, 2020	U-780		M-70	Nov 06, 2010
	7125875	Apr 13, 2020	U-779		NCE	Jun 28, 2011
	7153856	Apr 28, 2020	U-780		ODE	Jun 28, 2013
	7491725	Oct 13, 2025	DS DP		ODE	Jun 28, 2013
<u>DASATINIB - SPRYCEL</u>						
N021986 003	6596746	Jun 28, 2020	DS DP U-748		D-120	May 21, 2012
	6596746	Jun 28, 2020	DS DP U-780		D-109	Nov 06, 2010
	7125875	Apr 13, 2020	U-780		M-70	Nov 06, 2010
	7125875	Apr 13, 2020	U-779		NCE	Jun 28, 2011
	7153856	Apr 28, 2020	U-780		ODE	Jun 28, 2013
	7491725	Oct 13, 2025	DS DP		ODE	Jun 28, 2013
<u>DASATINIB - SPRYCEL</u>						
N021986 004	6596746	Jun 28, 2020	DS DP U-780		D-120	May 21, 2012
	6596746	Jun 28, 2020	DS DP U-748		D-109	Nov 06, 2010
	7125875	Apr 13, 2020	U-780		M-70	Nov 06, 2010
	7125875	Apr 13, 2020	U-779		NCE	Jun 28, 2011
	7153856	Apr 28, 2020	U-780		ODE	Jun 28, 2013
	7491725	Oct 13, 2025	DS DP		ODE	Jun 28, 2013
<u>DECITABINE - DACOGEN</u>						
N021790 001					NCE	May 02, 2011
					ODE	May 02, 2013
<u>DEFERASIROX - EXJADE</u>						
N021882 001	6465504	Apr 05, 2019	DS DP		NCE	Nov 02, 2010
	6596750	Jun 24, 2017	DS U-735		ODE	Nov 02, 2012
<u>DEFERASIROX - EXJADE</u>						
N021882 002	6465504	Apr 05, 2019	DS DP		NCE	Nov 02, 2010
	6596750	Jun 24, 2017	DS U-735		ODE	Nov 02, 2012
<u>DEFERASIROX - EXJADE</u>						
N021882 003	6465504	Apr 05, 2019	DS DP		NCE	Nov 02, 2010
	6596750	Jun 24, 2017	DS U-735		ODE	Nov 02, 2012
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	5925730	Apr 11, 2017	DS DP U-943		NCE	Dec 24, 2013
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	5925730	Apr 11, 2017	DS DP U-943		NCE	Dec 24, 2013
<u>DELAVIRDINE MESYLATE - RESCRIPTOR</u>						
N020705 001	5563142	Oct 08, 2013				
<u>DELAVIRDINE MESYLATE - RESCRIPTOR</u>						
N020705 002	5563142	Oct 08, 2013				
	6177101	Jun 07, 2019				
<u>DESFLURANE - SUPRANE</u>						
N020118 001	5617906	Apr 08, 2014	DP			
	5617906*PED	Oct 08, 2014				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESIRUDIN RECOMBINANT - IPRIVASK</u>						
N021271 001	4745177	May 17, 2010	DS DP			
	5733874	Mar 31, 2015				
<u>DES Loratadine - CLARINEX</u>						
N021165 001	6100274	Jul 07, 2019				
	6100274*PED	Jan 07, 2020				
	7211582	Dec 30, 2014		U-809		
	7211582*PED	Jun 30, 2015				
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014		U-138		
	7214684*PED	Jun 30, 2015				
	7405223	Jul 07, 2019		U-886		
	7405223*PED	Jan 07, 2020				
<u>DES Loratadine - CLARINEX</u>						
N021300 001	6514520	Jun 01, 2018	DP			
	6514520*PED	Dec 01, 2018				
	7211582	Dec 30, 2014		U-809		
	7211582*PED	Jun 30, 2015				
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014		U-138		
	7214684*PED	Jun 30, 2015				
<u>DES Loratadine - CLARINEX</u>						
N021312 001	5178878	Jan 12, 2010	DP			
	5178878*PED	Jul 12, 2010				
	5607697	Jun 07, 2015		DP		
	5607697*PED	Dec 07, 2015				
	6100274	Jul 07, 2019	DP			
	6100274*PED	Jan 07, 2020				
	7211582	Dec 30, 2014		U-809		
	7211582*PED	Jun 30, 2015				
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014		U-138		
	7214684*PED	Jun 30, 2015				
	7618649	Dec 19, 2020	DP	U-1017		
	7618649*PED	Jun 19, 2021				
<u>DES Loratadine - CLARINEX</u>						
N021312 002	5178878	Jan 12, 2010	DP			
	5178878*PED	Jul 12, 2010				
	5607697	Jun 07, 2015		DP		
	5607697*PED	Dec 07, 2015				
	6100274	Jul 07, 2019	DP			
	6100274*PED	Jan 07, 2020				
	7211582	Dec 30, 2014		U-809		
	7211582*PED	Jun 30, 2015				
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014		U-138		
	7214684*PED	Jun 30, 2015				
	7618649	Dec 19, 2020	DP	U-1017		
	7618649*PED	Jun 19, 2021				
<u>DES Loratadine; Pseudoephedrine Sulfate - CLARINEX D 24 HOUR</u>						
N021605 001	6100274	Jul 07, 2019	DP			
	6100274*PED	Jan 07, 2020				
	6979463	Mar 28, 2022	DP			
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014		U-138		
	7214684*PED	Jun 30, 2015				
	7618649	Dec 19, 2020	DP	U-1017		
	7618649*PED	Jun 19, 2021				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N021313 001	6100274	Jul 07, 2019	DP			
	6100274*PED	Jan 07, 2020				
	6709676	Feb 18, 2021	DP U-707			
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014		U-138		
	7214684*PED	Jun 30, 2015				
	7618649	Dec 19, 2020	DP U-1017			
	7618649*PED	Jun 19, 2021				
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N017922 001	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N017922 002	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N018938 001	5500413	Jun 29, 2013				
	5763407	Jun 29, 2013				
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N018938 002	5500413	Jun 29, 2013				
	5763407	Jun 29, 2013				
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N019955 001	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
	7022340	Apr 30, 2023	DP			
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N019955 002	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
	7022340	Apr 30, 2023	DP			
<u>DESMOPRESSIN ACETATE - DDAVP (NEEDS NO REFRIGERATION)</u>						
N017922 003	5482931	Jun 29, 2013				
	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
N021795 001	7022340	Apr 30, 2023	DP		NP	May 08, 2011
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
N021795 002	7022340	Apr 30, 2023	DP		NP	May 08, 2011
<u>DESONIDE - DESONATE</u>						
N021844 001	6387383	Aug 03, 2020	DS DP U-783		NDF	Oct 20, 2009
<u>DESONIDE - VERDES0</u>						
N021978 001	6730288	Sep 08, 2019	DP		NDF	Sep 19, 2009
	7029659	Sep 08, 2019	DP			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 001	6673838	Feb 11, 2022	DS DP U-860		NCE	Mar 01, 2013
	7291347	Feb 11, 2022	DP			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 002	6673838	Feb 11, 2022	DS DP U-860		NCE	Mar 01, 2013
	7291347	Feb 11, 2022	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXAMETHASONE - OZURDEX</u>						
N022315 001	6726918	Oct 20, 2020	DP	U-985	NDF	Jun 17, 2012
	6899717	Nov 01, 2023		U-985		
	7033605	Oct 20, 2020	DP			
	7625582	Nov 28, 2021		U-985		
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX</u>						
N050592 001	5149694	Sep 22, 2009		U-923		
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX</u>						
N050616 001	5149694	Sep 22, 2009		U-923		
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N050818 001	5149694	Sep 22, 2009		U-953		
<u>DEXLANSOPRAZOLE - KAPIDEX</u>						
N022287 001	6462058	Jun 15, 2020	DS DP	U-949	NP	Jan 30, 2012
	6462058	Jun 15, 2020	DS DP	U-951	PED	Jul 30, 2012
	6462058	Jun 15, 2020	DS DP	U-950		
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP	U-949		
	6664276	Jun 15, 2020	DS DP	U-951		
	6664276	Jun 15, 2020	DS DP	U-950		
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020		U-951		
	6939971	Jun 15, 2020		U-950		
	6939971	Jun 15, 2020		U-949		
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
<u>DEXLANSOPRAZOLE - KAPIDEX</u>						
N022287 002	6462058	Jun 15, 2020	DS DP	U-951	NP	Jan 30, 2012
	6462058	Jun 15, 2020	DS DP	U-950	PED	Jul 30, 2012
	6462058	Jun 15, 2020	DS DP	U-949		
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP	U-951		
	6664276	Jun 15, 2020	DS DP	U-950		
	6664276	Jun 15, 2020	DS DP	U-949		
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020		U-951		
	6939971	Jun 15, 2020		U-950		
	6939971	Jun 15, 2020		U-949		
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
<u>DEXMEDETOMIDINE - PRECEDEX</u>						
N021038 001	4910214	Jul 15, 2013	DS DP	U-421	I-577	Oct 17, 2011
	5344840	Sep 06, 2011		U-912		
	6716867	Mar 31, 2019		U-572		
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N021278 001	5908850	Dec 04, 2015		U-422		
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N021278 002	5908850	Dec 04, 2015		U-422		
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N021278 003	5908850	Dec 04, 2015		U-422		
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 001	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676	M-80	Oct 17, 2011
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 002	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676	M-80	Oct 17, 2011
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 003	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676	M-80	Oct 17, 2011
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 004	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676	M-80	Oct 17, 2011
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 005					D-121	Oct 23, 2012
					M-80	Oct 17, 2011
<u>DEXRAZOXANE HYDROCHLORIDE - TOTECT</u>						
N022025 001	6727253	Mar 13, 2020		U-829	NP	Sep 06, 2010
					ODE	Sep 06, 2014
<u>DEXRAZOXANE HYDROCHLORIDE - ZINECARD</u>						
N020212 001	5242901	Sep 07, 2010		U-339		
<u>DEXRAZOXANE HYDROCHLORIDE - ZINECARD</u>						
N020212 002	5242901	Sep 07, 2010		U-339		
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N021620 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP	U-685		
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N021620 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP	U-685		
<u>DEXTROMETHORPHAN POLISTIREX - DELSYM</u>						
N018658 001	5980882	Apr 16, 2017	DP			
<u>DIAZEPAM - DIASTAT</u>						
N020648 001	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>						
N020648 002	5462740	Sep 17, 2013	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIAZEPAM - DIASTAT</u>						
N020648 003	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>						
N020648 004	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>						
N020648 005	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT ACUDIAL</u>						
N020648 006	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT ACUDIAL</u>						
N020648 007	5462740	Sep 17, 2013	DP			
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N021234 001	5607690	Apr 13, 2014	DP		NE NDF	Jan 31, 2010 Jan 31, 2010
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	6974595	May 15, 2017	U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	6365180	Jul 16, 2019	DP U-980		NDF	Jun 16, 2012
<u>DICLOFENAC SODIUM - DICLOFENAC SODIUM</u>						
N020809 001	5603929	Nov 16, 2014	U-239			
	5653972	Nov 16, 2014	U-239			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N020947 001					NDF	Nov 04, 2012
<u>DICLOFENAC SODIUM - SOLARAZE</u>						
N021005 001	5639738	Jun 17, 2014	U-402			
	5792753	Aug 11, 2015				
	5852002	Jun 17, 2014	U-402			
	5914322	Aug 11, 2015				
	5929048	Jul 27, 2016	U-402			
	5985850	Nov 16, 2016				
<u>DICLOFENAC SODIUM - VOLTAREN</u>						
N022122 001					NP	Oct 17, 2010
<u>DICLOFENAC SODIUM; MISOPROSTOL - ARTHROTEC</u>						
N020607 001	5601843	Feb 11, 2014				
	5698225	May 03, 2010	U-392			
<u>DICLOFENAC SODIUM; MISOPROSTOL - ARTHROTEC</u>						
N020607 002	5601843	Feb 11, 2014				
	5698225	May 03, 2010	U-392			
<u>DIDANOSINE - VIDEX</u>						
N020154 002	5880106	Jul 22, 2011				
	5880106*PED	Jan 22, 2012				
<u>DIDANOSINE - VIDEX</u>						
N020154 003	5880106	Jul 22, 2011				
	5880106*PED	Jan 22, 2012				
<u>DIDANOSINE - VIDEX</u>						
N020154 004	5880106	Jul 22, 2011				
	5880106*PED	Jan 22, 2012				
<u>DIDANOSINE - VIDEX</u>						
N020154 005	5880106	Jul 22, 2011				
	5880106*PED	Jan 22, 2012				
<u>DIDANOSINE - VIDEX</u>						
N020154 006	5880106	Jul 22, 2011				
	5880106*PED	Jan 22, 2012				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212 001	6114319	May 12, 2018	DP		NCE	Jun 23, 2013
<u>DIHYDROERGOTAMINE MESYLATE - MIGRANAL</u>						
N020148 001	5169849	Dec 08, 2009	U-227			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 001	5286497	May 20, 2011				
	5364620	Nov 14, 2011	U-3			
	5439689	Aug 08, 2012	U-107			
	5470584	May 20, 2011				
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 002	5286497	May 20, 2011				
	5364620	Nov 14, 2011	U-3			
	5439689	Aug 08, 2012	U-107			
	5470584	May 20, 2011				
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 003	5286497	May 20, 2011				
	5364620	Nov 14, 2011	U-3			
	5439689	Aug 08, 2012	U-107			
	5470584	May 20, 2011				
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 004	5286497	May 20, 2011				
	5364620	Nov 14, 2011	U-3			
	5439689	Aug 08, 2012	U-107			
	5470584	May 20, 2011				
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 005	5286497	May 20, 2011	DP			
	5439689	Aug 08, 2012	DP	U-107		
	5470584	May 20, 2011	DP			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 001	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP	U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 002	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP	U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 003	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP	U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 004	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP	U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 005	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP	U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 006	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP	U-107		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DILTIAZEM HYDROCHLORIDE - DILACOR XR</u>						
N020092 001	5422123	Jun 06, 2012				
<u>DILTIAZEM HYDROCHLORIDE - DILACOR XR</u>						
N020092 002	5422123	Jun 06, 2012				
<u>DILTIAZEM HYDROCHLORIDE - DILACOR XR</u>						
N020092 003	5422123	Jun 06, 2012				
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
N020939 001	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
N020939 002	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
N020939 003	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
N020939 004	5288505	Jun 26, 2011				
	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 001	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 002	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 003	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 004	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 005	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 006	5529791	Jun 25, 2013				
<u>DIMYRISTOYL LECITHIN; PERFLEXANE - IMAGENT</u>						
N021191 001	5605673	Feb 25, 2014				
	5626833	May 16, 2014		U-458		
	5639443	Jun 17, 2014				
	5695741	Dec 09, 2014		U-458		
	5720938	Feb 24, 2015				
	5798091	Aug 25, 2015		U-458		
	6280704	Jul 30, 2013				
	6280705	Jul 30, 2013				
	6287539	Jul 30, 2013				
<u>DINOPROSTONE - CERVIDIL</u>						
N020411 001	5269321	Jul 14, 2012	DP	U-110		
<u>DIVALPROEX SODIUM - DEPAKOTE</u>						
N019680 001					M-34 PED	Mar 24, 2011 Sep 24, 2011



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N021168 001	6419953	Dec 18, 2018			M-34	Mar 24, 2011
	6419953*PED	Jun 18, 2019			PED	Sep 24, 2011
	6511678	Dec 18, 2018				
	6511678*PED	Jun 18, 2019				
	6528090	Dec 18, 2018	DP			
	6528090*PED	Jun 18, 2019				
	6528091	Dec 18, 2018		U-106		
	6528091*PED	Jun 18, 2019				
	6713086	Dec 18, 2018	DP	U-579		
	6713086*PED	Jun 18, 2019				
	6720004	Dec 18, 2018	DP			
	6720004*PED	Jun 18, 2019				
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N021168 002	6511678	Dec 18, 2018			M-34	Mar 24, 2011
	6511678*PED	Jun 18, 2019			PED	Sep 24, 2011
	6528090	Dec 18, 2018	DP			
	6528090*PED	Jun 18, 2019				
	6713086	Dec 18, 2018	DP	U-579		
	6713086*PED	Jun 18, 2019				
	6720004	Dec 18, 2018	DP			
	6720004*PED	Jun 18, 2019				
<u>DIVALPROEX SODIUM - DIVALPROEX SODIUM</u>						
A077567 002					PC	Aug 01, 2009
<u>DOCETAXEL - TAXOTERE</u>						
N020449 001	4814470	May 14, 2010	DS DP		I-543	Sep 28, 2010
	5438072	Nov 22, 2013			I-542	Sep 28, 2010
	5698582	Jul 03, 2012			I-519	Oct 17, 2009
	5714512	Jul 03, 2012				
	5750561	Jul 03, 2012	DP			
<u>DOCOSANOL - ABREVA</u>						
N020941 001	4874794	Apr 28, 2014		U-815		
	5534554	Dec 13, 2013	DP	U-815		
<u>DOFETILIDE - TIKOSYN</u>						
N020931 001	4959366	Sep 25, 2012	DS DP	U-652		
	6124363	Oct 09, 2018				
<u>DOFETILIDE - TIKOSYN</u>						
N020931 002	4959366	Sep 25, 2012	DS DP	U-652		
	6124363	Oct 09, 2018				
<u>DOFETILIDE - TIKOSYN</u>						
N020931 003	4959366	Sep 25, 2012	DS DP	U-652		
	6124363	Oct 09, 2018				
<u>DOLASETRON MESYLATE - ANZEMET</u>						
N020623 001	4906755	Jul 02, 2011				
<u>DOLASETRON MESYLATE - ANZEMET</u>						
N020623 002	4906755	Jul 02, 2011				
<u>DOLASETRON MESYLATE - ANZEMET</u>						
N020624 001	4906755	Jul 02, 2011				
<u>DOLASETRON MESYLATE - ANZEMET</u>						
N020624 002	4906755	Jul 02, 2011				
<u>DOLASETRON MESYLATE - ANZEMET</u>						
N020624 003	4906755	Jul 02, 2011				
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N020690 001	4895841	Nov 25, 2010			I-529	Oct 13, 2009
	5985864	Dec 30, 2016				
	6140321	Dec 30, 2016				
	6245911	Dec 01, 2018				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N020690 002	4895841	Nov 25, 2010			I-529	Oct 13, 2009
	5985864	Dec 30, 2016				
	6140321	Dec 30, 2016				
	6245911	Dec 01, 2018				
	6372760	Mar 31, 2019		Y		
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N021719 001					I-529	Oct 13, 2009
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N021720 001	4895841	Nov 25, 2010	DS DP U-713		I-529	Oct 13, 2009
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N021720 002	4895841	Nov 25, 2010	DS DP U-713		I-529	Oct 13, 2009
<u>DORIPENEM - DORIBAX</u>						
N022106 001	5317016	Aug 14, 2012	DS DP U-282		NCE	Oct 12, 2012
<u>DOXERCALCIFEROL - HECTOROL</u>						
N020862 001	5602116	Feb 11, 2014		U-278		
	5602116	Feb 11, 2014		U-987		
	6903083	Jul 18, 2021	DS DP		Y	
<u>DOXERCALCIFEROL - HECTOROL</u>						
N020862 002	5602116	Feb 11, 2014		U-278		
	5602116	Feb 11, 2014		U-987		
	6903083	Jul 18, 2021	DS DP		Y	
<u>DOXERCALCIFEROL - HECTOROL</u>						
N020862 003	5602116	Feb 11, 2014		U-987		
<u>DOXERCALCIFEROL - HECTOROL</u>						
N021027 001	5602116	Feb 11, 2014		U-321		
	5707980	Aug 17, 2010		U-321	Y	
	6903083	Jul 18, 2021	DS DP		Y	
	7148211	Sep 14, 2023	DP			
<u>DOXORUBICIN HYDROCHLORIDE - DOXIL</u>						
N050718 001	5013556	Oct 20, 2009	DP U-942		ODE	May 17, 2014
	5013556	Oct 20, 2009	DP U-941			
	5013556	Oct 20, 2009	DP U-940			
	5213804	Oct 20, 2009	DP U-940			
	5213804	Oct 20, 2009	DP U-941			
<u>DOXORUBICIN HYDROCHLORIDE - DOXIL</u>						
N050718 002	5013556	Oct 20, 2009	DP U-942		ODE	May 17, 2014
	5013556	Oct 20, 2009	DP U-941			
	5013556	Oct 20, 2009	DP U-940			
	5213804	Oct 20, 2009	DP U-941			
	5213804	Oct 20, 2009	DP U-940			
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	5789395	Aug 30, 2016		U-925		
	5919775	Aug 30, 2016		U-925		
	7211267	Apr 05, 2022		U-925		
	7232572	Apr 05, 2022		U-925		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N050795 001	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N050795 002	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N050795 003	6958161	Dec 15, 2022	DP U-918			
<u>DRONABINOL - MARINOL</u>						
N018651 001	6703418	Feb 26, 2011		U-563		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DRONABINOL - MARINOL</u>						
N018651 002	6703418	Feb 26, 2011	U-563			
<u>DRONABINOL - MARINOL</u>						
N018651 003	6703418	Feb 26, 2011	U-563			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	5223510	Jul 26, 2011	DS DP U-992		NCE	Jul 01, 2014
	7323493	Jun 19, 2018	DP			
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 002	6933395	Aug 11, 2017	DS			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN</u>						
N021098 001	5569652	Oct 29, 2013		U-1		
	6787531	Aug 31, 2020		DP		
	6933395	Aug 11, 2017	DS			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N021676 001	5569652	Oct 29, 2013		U-1	I-522	Jan 26, 2010
	5798338	Jul 10, 2015	DP		I-508	Oct 04, 2009
	6787531	Aug 31, 2020	DP			
	6933395	Aug 11, 2017	DP			
	6958326	Dec 20, 2021	DP			
	6987101	Dec 22, 2017		U-758		
	7163931	Dec 20, 2021		U-1		
	RE37564	Jun 30, 2014	DP			
	RE37838	Jun 30, 2014	DP			
	RE38253	Jun 30, 2014	DP			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001	5023269	Jun 11, 2013	DS DP U-605		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-795		I-566	Jun 13, 2011
	5023269	Jun 11, 2013	DS DP U-796		I-524	Feb 23, 2010
	5023269	Jun 11, 2013	DS DP U-797		M-71	Nov 28, 2010
	5023269	Jun 11, 2013	DS DP U-398		NCE	Aug 03, 2009
	5023269	Jun 11, 2013	DS DP U-839			
	5023269	Jun 11, 2013	DS DP U-799			
	5023269	Jun 11, 2013	DS DP U-882			
	5508276	Jul 18, 2014	DP			
	6596756	Sep 10, 2019		U-882		
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002	5023269	Jun 11, 2013	DS DP U-605		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-882		I-566	Jun 13, 2011
	5023269	Jun 11, 2013	DS DP U-799		I-524	Feb 23, 2010
	5023269	Jun 11, 2013	DS DP U-795		M-71	Nov 28, 2010
	5023269	Jun 11, 2013	DS DP U-796		NCE	Aug 03, 2009
	5023269	Jun 11, 2013	DS DP U-797			
	5023269	Jun 11, 2013	DS DP U-839			
	5023269	Jun 11, 2013	DS DP U-398			
	5508276	Jul 18, 2014	DP			
	6596756	Sep 10, 2019		U-882		
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 003					I-617	Nov 19, 2012
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-797		I-566	Jun 13, 2011
	5023269	Jun 11, 2013	DS DP U-796		I-524	Feb 23, 2010
	5023269	Jun 11, 2013	DS DP U-795		M-71	Nov 28, 2010
	5023269	Jun 11, 2013	DS DP U-398		NCE	Aug 03, 2009
	5023269	Jun 11, 2013	DS DP U-799			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-882			
	5508276	Jul 18, 2014	DP			
	6596756	Sep 10, 2019		U-882		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DUTASTERIDE - AVODART</u>						
N021319 001	5565467	Nov 20, 2015	DS DP		I-565	Jun 19, 2011
	5846976	Sep 17, 2013		U-476		
	5998427	Sep 17, 2013	DS DP	U-477		
<u>EFAVIRENZ - SUSTIVA</u>						
N020972 001	5519021	May 21, 2013	DS DP			
	5663169	Sep 02, 2014		U-257		
	5811423	Aug 07, 2012	DS DP	U-256		
	6238695	Apr 06, 2019		DP		
	6555133	Apr 06, 2019		U-248		
	6639071	Feb 14, 2018	DS			
	6939964	Jan 20, 2018	DS			
<u>EFAVIRENZ - SUSTIVA</u>						
N020972 002	5519021	May 21, 2013	DS DP			
	5663169	Sep 02, 2014		U-257		
	5811423	Aug 07, 2012	DS DP	U-256		
	6238695	Apr 06, 2019		DP		
	6555133	Apr 06, 2019		U-248		
	6639071	Feb 14, 2018	DS			
	6939964	Jan 20, 2018	DS			
<u>EFAVIRENZ - SUSTIVA</u>						
N020972 003	5519021	May 21, 2013	DS DP			
	5663169	Sep 02, 2014		U-257		
	5811423	Aug 07, 2012	DS DP	U-256		
	6238695	Apr 06, 2019		DP		
	6555133	Apr 06, 2019		U-248		
	6639071	Feb 14, 2018	DS			
	6939964	Jan 20, 2018	DS			
<u>EFAVIRENZ - SUSTIVA</u>						
N021360 001	5519021	May 21, 2013				
	5663169	Sep 02, 2014				
	5811423	Aug 07, 2012			U-256	
	6639071	Feb 14, 2018	DS			
	6939964	Jan 20, 2018	DS			
<u>EFAVIRENZ - SUSTIVA</u>						
N021360 002	5519021	May 21, 2013	DS DP			
	5663169	Sep 02, 2014		U-248		
	5811423	Aug 07, 2012		U-256		
	6639071	Feb 14, 2018	DS			
	6939964	Jan 20, 2018	DS			
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5210085	May 11, 2010			U-750	
	5210085*PED	Nov 11, 2010				
	5519021	May 21, 2013	DS DP			
	5663169	Sep 02, 2014			U-750	
	5811423	Aug 07, 2012			U-750	
	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	5922695	Jul 25, 2017	DS		U-750	
	5935946	Jul 25, 2017	DS DP		U-750	
	5977089	Jul 25, 2017	DS DP		U-750	
	6043230	Jul 25, 2017			U-750	
	6639071	Feb 14, 2018	DS			
	6642245	Nov 04, 2020			U-750	
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6939964	Jan 20, 2018	DS			
	7402588	Feb 01, 2010		DP	U-257	
	7402588*PED	Aug 01, 2010				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFLORNITHINE HYDROCHLORIDE - VANIQ</u>						
N021145 001	5648394	Jul 15, 2014	U-334			
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N021016 001	5545644	Dec 26, 2016	DS DP U-876			
	6110940	Aug 29, 2017				
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N021016 002	5545644	Dec 26, 2016	DS DP U-876			
	6110940	Aug 29, 2017				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	6280959	Oct 30, 2018	DS DP U-930		NCE	Nov 20, 2013
	7160870	Dec 08, 2021	DS DP U-930		ODE	Nov 20, 2015
	7332481	May 24, 2021	U-930			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7547719	Mar 04, 2024	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	6280959	Oct 30, 2018	DS DP U-930		NCE	Nov 20, 2013
	7160870	Dec 08, 2021	DS DP U-930		ODE	Nov 20, 2015
	7332481	May 24, 2021	U-930			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7547719	Mar 04, 2024	DS DP U-930			
<u>EMEDASTINE DIFUMARATE - EMADINE</u>						
N020706 001	5441958	Dec 08, 2013	U-404			
<u>EMTRICITABINE - EMTRIVA</u>						
N021500 001	5210085	May 11, 2010	U-257			
	5210085*PED	Nov 11, 2010				
	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245	Nov 04, 2020	U-541			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7402588	Feb 01, 2010	DP U-257			
	7402588*PED	Aug 01, 2010				
<u>EMTRICITABINE - EMTRIVA</u>						
N021896 001	5210085	May 11, 2010	U-257		NPP	Dec 22, 2009
	5210085*PED	Nov 11, 2010			PED	Jun 22, 2010
	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N021752 001	5210085	May 11, 2010				U-248
	5210085	May 11, 2010				U-541
	5210085*PED	Nov 11, 2010				
	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS DP			U-248
	5914331*PED	Jan 02, 2018	DS			
	5922695	Jul 25, 2017	DS			U-541
	5922695	Jul 25, 2017	DS			U-248
	5935946	Jul 25, 2017	DS DP			U-541
	5935946	Jul 25, 2017	DS DP			U-248
	5977089	Jul 25, 2017	DS DP			U-248
	5977089	Jul 25, 2017	DS DP			U-541
	6043230	Jul 25, 2017				DP U-541
	6043230	Jul 25, 2017				DP U-248
	6642245	Nov 04, 2020				U-248
	6642245	Nov 04, 2020				U-541
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7402588	Feb 01, 2010				DP U-257
	7402588*PED	Aug 01, 2010				
<u>ENFUVIRTIDE - FUZEON</u>						
N021481 001	5464933	Jun 07, 2013			M-59	Sep 29, 2009
	6133418	Nov 17, 2014	DS DP			
	6475491	Jun 07, 2015				U-248
<u>ENOXAPARIN SODIUM - LOVENOX</u>						
N020164 009	5389618	Feb 14, 2012	DS DP		I-533	May 16, 2010
	RE38743	Feb 14, 2012	DS DP			U-545
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 001	5389618	Feb 14, 2012	DS DP		I-533	May 16, 2010
	RE38743	Feb 14, 2012	DS DP			U-545
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 002	5389618	Feb 14, 2012	DS DP		I-533	May 16, 2010
	RE38743	Feb 14, 2012	DS DP			U-545
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 003	5389618	Feb 14, 2012	DS DP		I-533	May 16, 2010
	RE38743	Feb 14, 2012	DS DP			U-545
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 004	5389618	Feb 14, 2012	DS DP		I-533	May 16, 2010
	RE38743	Feb 14, 2012	DS DP			U-545
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 005	5389618	Feb 14, 2012	DS DP		I-533	May 16, 2010
	RE38743	Feb 14, 2012	DS DP			U-545
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 006	5389618	Feb 14, 2012	DS DP		I-533	May 16, 2010
	RE38743	Feb 14, 2012	DS DP			U-545
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 007	5389618	Feb 14, 2012	DS DP		I-533	May 16, 2010
	RE38743	Feb 14, 2012	DS DP			U-545
<u>ENOXAPARIN SODIUM - LOVENOX (PRESERVATIVE FREE)</u>						
N020164 008	5389618	Feb 14, 2012	DS DP		I-533	May 16, 2010
	RE38743	Feb 14, 2012	DS DP			U-545
<u>ENTACAPONE - COMTAN</u>						
N020796 001	5135950	Oct 31, 2010	DS DP			U-219
	5446194	Oct 19, 2013	DS			
	6599530	Sep 14, 2018				DP U-219

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ENTECAVIR - BARACLUDE</u>						
N021797 001	5206244	Feb 21, 2015	DS		NCE	Mar 29, 2010
<u>ENTECAVIR - BARACLUDE</u>						
N021797 002	5206244	Feb 21, 2015	DS		NCE	Mar 29, 2010
<u>ENTECAVIR - BARACLUDE</u>						
N021798 001	5206244	Feb 21, 2015	DS		NCE	Mar 29, 2010
<u>EPINASTINE HYDROCHLORIDE - ELESTAT</u>						
N021565 001	7429602	Nov 29, 2020		U-765	Y	
<u>EPINEPHRINE - EPIPEN</u>						
N019430 001	7449012	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N019430 002	7449012	Sep 11, 2025	DP			
<u>EPINEPHRINE - TWINJECT 0.15</u>						
N020800 002	7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
<u>EPINEPHRINE - TWINJECT 0.3</u>						
N020800 001	7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT</u>						
N021504 001	5246418	Sep 30, 2013	DS DP			
	5873850	Sep 30, 2013	DS DP			
	6377847	Sep 30, 2013	DS DP			
	6385488	Sep 30, 2013	DS DP			
	6629968	Jun 30, 2020	DS DP			
	6635045	Jun 29, 2021	DS DP			
	6862473	Sep 30, 2013	DP			
<u>EPLERENONE - INSPRA</u>						
N021437 001	6410054	Dec 08, 2019		U-3	M-72	Jan 31, 2011
	6410054	Dec 08, 2019		U-537	PED	Jul 31, 2011
	6410054*PED	Jun 08, 2020				
	6410524	Nov 05, 2019		U-467		
	6410524*PED	May 05, 2020				
	6495165	Dec 08, 2019		U-3		
	6495165	Dec 08, 2019		U-537		
	6495165*PED	Jun 08, 2020				
	6534093	Dec 08, 2019		U-3		
	6534093	Dec 08, 2019		U-537		
	6534093*PED	Jun 08, 2020				
	6558707	Dec 08, 2019	DP	U-537		
	6558707*PED	Jun 08, 2020				
	6747020	Nov 05, 2019		U-587		
	6747020*PED	May 05, 2020				
	6863902	Apr 10, 2020	DP	U-664		
	6863902*PED	Oct 10, 2020				
	7157101	Dec 08, 2019	DP	U-664		
	7157101*PED	Jun 08, 2020				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPLERENONE - INSPRA</u>						
N021437 002	6410054	Dec 08, 2019	U-3		M-72	Jan 31, 2011
	6410054	Dec 08, 2019	U-537		PED	Jul 31, 2011
	6410054*PED	Jun 08, 2020				
	6410524	Nov 05, 2019	U-467			
	6410524*PED	May 05, 2020				
	6495165	Dec 08, 2019	U-537			
	6495165	Dec 08, 2019	U-3			
	6495165*PED	Jun 08, 2020				
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6534093*PED	Jun 08, 2020				
	6558707	Dec 08, 2019	DP U-537			
	6558707*PED	Jun 08, 2020				
	6747020	Nov 05, 2019	U-587			
	6747020*PED	May 05, 2020				
	6863902	Apr 10, 2020	DP U-664			
	6863902*PED	Oct 10, 2020				
	7157101	Dec 08, 2019	DP U-664			
	7157101*PED	Jun 08, 2020				
<u>EPLERENONE - INSPRA</u>						
N021437 003	6410054	Dec 08, 2019	U-537			
	6410054	Dec 08, 2019	U-3			
	6410054*PED	Jun 08, 2020				
	6410524	Nov 05, 2019	U-467			
	6410524*PED	May 05, 2020				
	6495165	Dec 08, 2019	U-537			
	6495165	Dec 08, 2019	U-3			
	6495165*PED	Jun 08, 2020				
	6534093	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093*PED	Jun 08, 2020				
	6558707	Dec 08, 2019	DP U-537			
	6558707*PED	Jun 08, 2020				
	6747020	Nov 05, 2019	U-587			
	6747020*PED	May 05, 2020				
	6863902	Apr 10, 2020	DP U-664			
	6863902*PED	Oct 10, 2020				
	7157101	Dec 08, 2019	DP U-664			
	7157101*PED	Jun 08, 2020				
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N020738 004	5185351	Feb 09, 2010	U-3			
	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N020738 005	5185351	Feb 09, 2010	U-3			
	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N020738 006	5185351	Feb 09, 2010	U-3			
	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE - TEVETEN HCT</u>						
N021268 001	5185351	Feb 09, 2010	U-3			
	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE - TEVETEN HCT</u>						
N021268 002	5185351	Feb 09, 2010	U-3			
	5656650	Aug 12, 2014	U-3			
<u>EPTIFIBATIDE - INTEGRILIN</u>						
N020718 001	5686570	Nov 11, 2014				
	5747447	May 05, 2015				
	5756451	Nov 11, 2014				
	5807825	Sep 15, 2015	U-244			
	5968902	Jun 02, 2015	U-453			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPTIFIBATIDE - INTEGRILIN</u>						
N020718 002	5686570	Nov 11, 2014				
	5747447	May 05, 2015				
	5756451	Nov 11, 2014				
	5807825	Sep 15, 2015		U-244		
	5968902	Jun 02, 2015		U-453		
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 001	5747498	Nov 08, 2018	DS DP	U-659	M-79	Sep 19, 2011
	6900221	Nov 09, 2020	DS DP	U-875	NCE	Nov 18, 2009
	6900221	Nov 09, 2020	DS DP	U-659		
	7087613	Nov 09, 2020		U-659		
	RE41065	Nov 08, 2018	DS DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 002	5747498	Nov 08, 2018	DS DP	U-659	M-79	Sep 19, 2011
	6900221	Nov 09, 2020	DS DP	U-875	NCE	Nov 18, 2009
	6900221	Nov 09, 2020	DS DP	U-659		
	7087613	Nov 09, 2020		U-659		
	RE41065	Nov 08, 2018	DS DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 003	5747498	Nov 08, 2018	DS DP	U-659	M-79	Sep 19, 2011
	6900221	Nov 09, 2020	DS DP	U-659	NCE	Nov 18, 2009
	6900221	Nov 09, 2020	DS DP	U-875		
	7087613	Nov 09, 2020		U-659		
	RE41065	Nov 08, 2018	DS DP			
<u>ERTAPENEM SODIUM - INVANZ</u>						
N021337 001	5478820	Nov 21, 2015	DS DP	U-160	I-515	Aug 10, 2009
	5478820*PED	May 21, 2016				
	5652233	Feb 02, 2013	DS DP	U-160		
	5652233*PED	Aug 02, 2013				
	5952323	May 15, 2017		DP		
	5952323*PED	Nov 15, 2017				
	7342005	Feb 02, 2013		DP		
	7342005*PED	Aug 02, 2013				
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N021323 001	6916941	Aug 12, 2022	DS DP		NPP	Mar 19, 2012
	6916941*PED	Feb 12, 2023	DS DP			
	7420069	Aug 12, 2022		DP		
	7420069*PED	Feb 12, 2023				
	RE34712	Sep 14, 2011	DS DP			
	RE34712*PED	Mar 14, 2012				
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N021323 002	6916941	Aug 12, 2022	DS DP		NPP	Mar 19, 2012
	6916941*PED	Feb 12, 2023	DS DP			
	7420069	Aug 12, 2022		DP		
	7420069*PED	Feb 12, 2023				
	RE34712	Sep 14, 2011	DS DP			
	RE34712*PED	Mar 14, 2012				
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N021323 003	6916941	Aug 12, 2022	DS DP		NPP	Mar 19, 2012
	6916941*PED	Feb 12, 2023	DS DP			
	7420069	Aug 12, 2022		DP		
	7420069*PED	Feb 12, 2023				
	RE34712	Sep 14, 2011	DS DP			
	RE34712*PED	Mar 14, 2012				
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N021365 001	RE34712	Sep 14, 2011	DS DP		NPP	Mar 19, 2012
	RE34712*PED	Mar 14, 2012				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N019386 006	6310094	Jan 12, 2021				
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021				
	6528540*PED	Jul 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N019386 007	6310094	Jan 12, 2021				
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021				
	6528540*PED	Jul 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N019386 005	6310094	Jan 12, 2021				
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021				
	6528540*PED	Jul 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER</u>						
N019386 004	6310094	Jan 12, 2021				
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021				
	6528540*PED	Jul 12, 2021				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021153 001	5690960	Nov 25, 2014	DP U-729		I-504	Oct 11, 2009
	5690960	Nov 25, 2014	DP U-373		PED	Oct 28, 2009
	5690960	Nov 25, 2014	DP U-770			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-770			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-373			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	DP U-770			
	5877192	May 27, 2014	DP U-373			
	5877192	May 27, 2014	DP U-729			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-373			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-770			
	5900424*PED	Nov 04, 2016				
	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-770			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-770			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-469			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021153 002	5690960	Nov 25, 2014	DP U-770		I-504	Oct 11, 2009
	5690960	Nov 25, 2014	DP U-373		PED	Oct 28, 2009
	5690960	Nov 25, 2014	DP U-729			
	5690960*PED	May 25, 2015	U-373			
	5714504	Feb 03, 2015	DP U-373			
	5714504	Feb 03, 2015	DP U-770			
	5714504	Feb 03, 2015	DP U-729			
	5714504*PED	Aug 03, 2015	U-373			
	5877192	May 27, 2014	DP U-770			
	5877192	May 27, 2014	DP U-729			
	5877192	May 27, 2014	DP U-373			
	5877192*PED	Nov 27, 2014	U-373			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-770			
	5900424	May 04, 2016	DS U-373			
	5900424*PED	Nov 04, 2016	U-373			
	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				
	6369085	May 25, 2018	DS DP U-770			
	6369085	May 25, 2018	DS DP U-729			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-469			
	6428810	Nov 03, 2019	DP U-770			
	6428810	Nov 03, 2019	DP U-729			
	6428810*PED	May 03, 2020	U-469			
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001	5690960	Nov 25, 2014	DP U-729		I-504	Oct 11, 2009
	5690960	Nov 25, 2014	DP U-773		M-86	Jun 18, 2012
	5690960*PED	May 25, 2015			PED	Dec 18, 2012
	5714504	Feb 03, 2015	DP U-773		PED	Oct 28, 2009
	5714504	Feb 03, 2015	DP U-729			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-773			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-773			
	5900424	May 04, 2016	DS U-729			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-773			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-773			
	6428810	Nov 03, 2019	DP U-729			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002	5690960	Nov 25, 2014	DP U-729		I-504	Oct 11, 2009
	5690960	Nov 25, 2014	DP U-773		M-86	Jun 18, 2012
	5690960*PED	May 25, 2015			PED	Dec 18, 2012
	5714504	Feb 03, 2015	DP U-729		PED	Oct 28, 2009
	5714504	Feb 03, 2015	DP U-773			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014		U-773		
	5877192	May 27, 2014		U-729		
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS	U-729		
	5900424	May 04, 2016	DS	U-773		
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP	U-773		
	6369085	May 25, 2018	DS DP	U-729		
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP	U-773		
	6428810	Nov 03, 2019	DP	U-729		
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N022101 001	5690960	Nov 25, 2014	DP U-858		I-504	Oct 11, 2009
	5690960*PED	May 25, 2015			NPP	Feb 27, 2011
	5714504	Feb 03, 2015	DP U-858		PED	Aug 27, 2011
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014		U-858		
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS	U-858		
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP	U-858		
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP	U-858		
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N021689 001	5877192	May 27, 2014		U-643		
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2014	DP	U-643		
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N021689 002	5877192	May 27, 2014		U-643		
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2014	DP	U-643		
<u>ESTRADIOL - ALORA</u>						
N020655 001	5122383	May 17, 2011				
	5164190	Dec 11, 2010				
	5212199	May 17, 2011				
	5227169	May 17, 2011				
<u>ESTRADIOL - ALORA</u>						
N020655 002	5122383	May 17, 2011				
	5164190	Dec 11, 2010				
	5212199	May 17, 2011				
	5227169	May 17, 2011				
<u>ESTRADIOL - ALORA</u>						
N020655 003	5122383	May 17, 2011				
	5164190	Dec 11, 2010				
	5212199	May 17, 2011				
	5227169	May 17, 2011				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - ALORA</u>						
N020655 004	5122383	May 17, 2011				
	5164190	Dec 11, 2010				
	5212199	May 17, 2011				
	5227169	May 17, 2011				
<u>ESTRADIOL - CLIMARA</u>						
N020375 001	5223261	Jun 29, 2010				
<u>ESTRADIOL - CLIMARA</u>						
N020375 002	5223261	Jun 29, 2010				
<u>ESTRADIOL - CLIMARA</u>						
N020375 003	5223261	Jun 29, 2010				
<u>ESTRADIOL - CLIMARA</u>						
N020375 004	5223261	Jun 29, 2010				
<u>ESTRADIOL - CLIMARA</u>						
N020375 005	5223261	Jun 29, 2010				
<u>ESTRADIOL - CLIMARA</u>						
N020375 006	5223261	Jun 29, 2010				
<u>ESTRADIOL - DIVIGEL</u>						
N022038 003					NP	Jun 04, 2010
<u>ESTRADIOL - ELESTRIN</u>						
N021813 001	7198801	Jun 25, 2022	DP		NP	Dec 15, 2009
	7470433	Aug 03, 2021	DP			
<u>ESTRADIOL - EVAMIST</u>						
N022014 001	6299900	Feb 19, 2017	DP U-889		NDF	Jul 27, 2010
	6299900	Feb 19, 2017	DP U-888			
	6818226	Feb 19, 2017	DP U-888			
	6818226	Feb 19, 2017	DP U-889			
	6923983	Feb 19, 2017	DP U-889			
	6923983	Feb 19, 2017	DP U-888			
	6978945	Nov 30, 2021	DP			
<u>ESTRADIOL - MENOSTAR</u>						
N021674 001	5223261	Jun 29, 2010	DP U-594			
	5891868	Nov 21, 2017	DP U-594			
	6692763	Nov 21, 2017	DP U-594			
<u>ESTRADIOL - VAGIFEM</u>						
N020908 002	7018992	Sep 17, 2022	U-1023		D-122	Nov 25, 2012
<u>ESTRADIOL - VIVELLE</u>						
N020323 001	5300291	Apr 05, 2011				
<u>ESTRADIOL - VIVELLE</u>						
N020323 002	5300291	Apr 05, 2011				
<u>ESTRADIOL - VIVELLE</u>						
N020323 003	5300291	Apr 05, 2011				
<u>ESTRADIOL - VIVELLE</u>						
N020323 004	5300291	Apr 05, 2011				
<u>ESTRADIOL - VIVELLE</u>						
N020323 005	5300291	Apr 05, 2011				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538 005	5474783	Dec 12, 2012				
	5656286	Aug 12, 2014				
	5958446	Dec 12, 2012				
	6024976	Jan 07, 2014				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538 006	5474783	Dec 12, 2012				
	5656286	Aug 12, 2014				
	5958446	Dec 12, 2012				
	6024976	Jan 07, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538 007	5474783	Dec 12, 2012				
	5656286	Aug 12, 2014				
	5958446	Dec 12, 2012				
	6024976	Jan 07, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538 008	5474783	Dec 12, 2012				
	5656286	Aug 12, 2014				
	5958446	Dec 12, 2012				
	6024976	Jan 07, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538 009	5474783	Dec 12, 2012	DP			
	5656286	Aug 12, 2014	DP			
	5958446	Dec 12, 2012	DP			
	6024976	Jan 07, 2014	DP			
<u>ESTRADIOL ACETATE - FEMRING</u>						
N021367 001	5855906	Dec 19, 2015		U-508		
<u>ESTRADIOL ACETATE - FEMRING</u>						
N021367 002	5855906	Dec 19, 2015		U-508		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633 001	6962908	Dec 21, 2021	DP			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633 002	6962908	Dec 21, 2021	DP			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633 003	6962908	Dec 21, 2021	DP			
<u>ESTRADIOL HEMIHYDRATE - ESTRASORB</u>						
N021371 001	5629021	Jan 31, 2015	DP			
<u>ESTRADIOL; LEVONORGESTREL - CLIMARA PRO</u>						
N021258 001	5252334	Oct 12, 2010	DP			
	5393529	Feb 28, 2012	DP			
	5676968	Oct 14, 2014	DP			
	5770219	Oct 12, 2010	DP			
<u>ESTRADIOL; NORETHINDRONE ACETATE - ACTIVELLA</u>						
N020907 002					D-104	Dec 28, 2009
					I-525	Dec 29, 2009
					NS	Dec 28, 2009
<u>ESTRADIOL; NORETHINDRONE ACETATE - COMBIPATCH</u>						
N020870 001	5474783	Dec 12, 2012				
	5656286	Aug 12, 2014				
	5958446	Dec 12, 2012				
	6024976	Jan 07, 2014				
<u>ESTRADIOL; NORETHINDRONE ACETATE - COMBIPATCH</u>						
N020870 002	5474783	Dec 12, 2012				
	5656286	Aug 12, 2014				
	5958446	Dec 12, 2012				
	6024976	Jan 07, 2014				
<u>ESTRADIOL; NORGESTIMATE - PREFEST</u>						
N021040 001	5382573	Jan 17, 2012				
	6747019	Mar 20, 2020		U-311		
	7320970	Mar 30, 2020	DP	U-844		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTROGENS, CONJUGATED - PREMARIN</u>						
N020216	001				I-579	Nov 07, 2011
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992	001	5908638	Jul 26, 2015	DP		
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992	002	5908638	Jul 26, 2015			
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992	003	5908638	Jul 26, 2015			
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992	004	5908638	Jul 26, 2015			
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992	005	5908638	Jul 26, 2015			
<u>ESTROGENS, CONJUGATED SYNTHETIC A - SYNTHETIC CONJUGATED ESTROGENS A</u>						
N021788	001				NP	Nov 28, 2011
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N021443	001	6660726	Mar 08, 2021	DS DP U-905	I-528	Apr 23, 2010
		6660726	Mar 08, 2021	DS DP U-904		
		6855703	Feb 12, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-904		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N021443	002	6660726	Mar 08, 2021	DS DP U-905		
		6660726	Mar 08, 2021	DS DP U-904		
		6855703	Feb 12, 2021	DS DP U-904		
		6855703	Feb 12, 2021	DS DP U-905		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N021443	003	6660726	Mar 08, 2021	DS DP U-904		
		6660726	Mar 08, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-904		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N021443	004	6660726	Mar 08, 2021	DS DP U-904		
		6660726	Mar 08, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-904		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N021443	005	6660726	Mar 08, 2021	DS DP U-904		
		6660726	Mar 08, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-904		
		6855703	Feb 12, 2021	DS DP U-905		
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPHASE (PREMARIN;CYCRIN 14/14)</u>						
N020303	002	5210081	Feb 26, 2012			
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPHASE 14/14</u>						
N020527	002	5547948	Jan 17, 2015			
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N020527	001	5547948	Jan 17, 2015			
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N020527	003	5547948	Jan 17, 2015			
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N020527	004	5547948	Jan 17, 2015			
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N020527	005	5547948	Jan 17, 2015			
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO (PREMARIN;CYCRIN)</u>						
N020303	001					

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTROGENS, CONJUGATED; MEPROBAMATE - PMB 200</u>						
N010971 005	5210081	Feb 26, 2012				
<u>ESTROGENS, CONJUGATED; MEPROBAMATE - PMB 400</u>						
N010971 003	5210081	Feb 26, 2012				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001	6319926	Jan 16, 2012		U-620	NCE	Dec 15, 2009
	6444673	Jan 16, 2012	DS DP			
	6864257	Aug 30, 2012		U-629		
	7381724	Jan 16, 2012	DS DP	U-629		
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002	6319926	Jan 16, 2012		U-620	NCE	Dec 15, 2009
	6444673	Jan 16, 2012	DS DP			
	6864257	Aug 30, 2012		U-629		
	7381724	Jan 16, 2012	DS DP	U-629		
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003	6319926	Jan 16, 2012		U-620	NCE	Dec 15, 2009
	6444673	Jan 16, 2012	DS DP			
	6864257	Aug 30, 2012		U-629		
	7381724	Jan 16, 2012	DS DP	U-629		
<u>ETHINYL ESTRADIOL; ETONOGESTREL - NUVARING</u>						
N021187 001	5989581	Apr 08, 2018				
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N022262 001	7615545	Jun 15, 2023		U-1	NP	Oct 24, 2011
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LYBREL</u>						
N021864 001	6500814	Sep 03, 2018		U-1	NP	May 22, 2010
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT</u>						
N020946 001	6156742	Dec 05, 2020		U-374		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONALE</u>						
N021544 001	5898032	Jun 23, 2017		U-1		
	RE39861	Jun 23, 2017		U-828		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N021840 001	7320969	Jan 30, 2024		U-828		
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA</u>						
N021180 001	5876746	Nov 20, 2015	DP	U-514		
	5972377	Jun 07, 2015		U-514		
<u>ETHINYL ESTRADIOL; NORETHINDRONE - FEMCON FE</u>						
N021490 001	6667050	Apr 06, 2019	DP	U-1		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMHRT</u>						
N021065 001	5208225	May 04, 2010		U-283		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMHRT</u>						
N021065 002	5208225	May 04, 2010		U-283		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE</u>						
N021871 001	5552394	Jul 22, 2014		U-1		
<u>ETHINYL ESTRADIOL; NORGESTIMATE - ORTHO TRI-CYCLEN LO</u>						
N021241 001	6214815	Jun 09, 2019		U-112		
	6214815*PED	Dec 09, 2019				
<u>ETHINYL ESTRADIOL; NORGESTIMATE - TRI LO SPRINTEC</u>						
A076784 001					PC	Dec 29, 2009
<u>ETONOGESTREL - IMPLANON</u>						
N021529 001	5150718	Sep 29, 2009		U-749	NDF	Jul 17, 2009
<u>ETOPOSID PHOSPHATE - ETOPOPHOS PRESERVATIVE FREE</u>						
N020457 001						



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETOPOSID PHOSPHATE - ETOPOPHOS PRESERVATIVE FREE</u>						
N020906 001	RE35524	May 17, 2010				
<u>ETOPOSID PHOSPHATE - ETOPOPHOS PRESERVATIVE FREE</u>						
N020906 002	RE35524	May 17, 2010				
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	6878717	Nov 05, 2019		U-256	NCE	Jan 18, 2013
	6878717	Nov 05, 2019		U-1016		
	7037917	Nov 05, 2019	DS DP	U-1016		
	7037917	Nov 05, 2019	DS DP	U-256		
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	5665772	Sep 09, 2014	DS DP		NCE	Mar 30, 2014
	6004973	Jul 12, 2016				
	7297703	Dec 06, 2019				
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	5665772	Sep 09, 2014	DS DP		NCE	Mar 30, 2014
	6004973	Jul 12, 2016				
	7297703	Dec 06, 2019				
<u>EXEMESTANE - AROMASIN</u>						
N020753 001	4808616	Apr 01, 2011	DS DP	U-658		
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001	5424286	Dec 01, 2016		U-653	I-520	Dec 22, 2009
	6858576	Jan 06, 2017		U-656	NCE	Apr 28, 2010
	6872700	Jan 14, 2020		U-654		
	6902744	Jan 14, 2020		DP		
	6956026	Jan 07, 2018		U-687		
	7297761	Oct 15, 2017		DP		
	7521423	Oct 15, 2017		DP		
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002	5424286	May 24, 2013		U-653	I-520	Dec 22, 2009
	6858576	Jan 06, 2017		U-656	NCE	Apr 28, 2010
	6872700	Jan 14, 2020		U-654		
	6902744	Jan 14, 2020		DP		
	6956026	Jan 07, 2018		U-687		
	7297761	Oct 15, 2017		DP		
	7521423	Oct 15, 2017		DP		
<u>EZETIMIBE - ZETIA</u>						
N021445 001	5846966	Sep 21, 2013		U-474	M-54	Jun 05, 2011
	5846966	Sep 21, 2013		U-473		
	5846966*PED	Mar 21, 2014			PED	Dec 05, 2011
	7030106	Jan 25, 2022		DP	PED	Nov 23, 2009
	7030106*PED	Jul 25, 2022				
	RE37721	Oct 25, 2016	DS DP	U-473		
	RE37721*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001	5846966	Sep 21, 2013	DP	U-593	M-54	Jun 05, 2011
	5846966	Sep 21, 2013	DP	U-473	M-60	Oct 03, 2009
	5846966*PED	Mar 21, 2014			PED	Dec 05, 2011
	RE37721	Oct 25, 2016	DS DP	U-473	PED	Sep 16, 2009
	RE37721*PED	Apr 25, 2017			PED	Apr 03, 2010
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002	5846966	Sep 21, 2013	DP	U-473	M-54	Jun 05, 2011
	5846966	Sep 21, 2013	DP	U-593	M-60	Oct 03, 2009
	5846966*PED	Mar 21, 2014			PED	Dec 05, 2011
	RE37721	Oct 25, 2016	DS DP	U-473	PED	Sep 16, 2009
	RE37721*PED	Apr 25, 2017			PED	Apr 03, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003	5846966	Sep 21, 2013	DP U-473		M-54	Jun 05, 2011
	5846966	Sep 21, 2013	DP U-593		M-60	Oct 03, 2009
	5846966*PED	Mar 21, 2014			PED	Sep 16, 2009
	RE37721	Oct 25, 2016	DS DP U-473		PED	Apr 03, 2010
	RE37721*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 004	5846966	Sep 21, 2013	DP U-473		M-54	Jun 05, 2011
	5846966	Sep 21, 2013	DP U-593		M-60	Oct 03, 2009
	5846966*PED	Mar 21, 2014			PED	Dec 05, 2011
	RE37721	Oct 25, 2016	DS DP U-473		PED	Sep 16, 2009
	RE37721*PED	Apr 25, 2017			PED	Apr 03, 2010
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 001	5246937	Sep 21, 2010		U-96	D-103	Jul 28, 2009
	5246937*PED	Mar 21, 2011			I-501	Jul 28, 2009
	5840763	Sep 01, 2015		U-96	M-54	Dec 24, 2012
	5840763*PED	Mar 01, 2016			PED	Jun 24, 2013
	5866581	Oct 04, 2014		U-96	PED	Jan 28, 2010
	5866581*PED	Apr 04, 2015			PED	Jan 28, 2010
	5916893	Sep 01, 2015		U-96		
	5916893*PED	Mar 01, 2016				
	6124304	Oct 04, 2014		U-96		
	6124304*PED	Apr 04, 2015				
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002	5246937	Sep 21, 2010		U-96	D-103	Jul 28, 2009
	5246937*PED	Mar 21, 2011			I-501	Jul 28, 2009
	5840763	Sep 01, 2015		U-96	M-54	Dec 24, 2012
	5840763*PED	Mar 01, 2016			PED	Jun 24, 2013
	5866581	Oct 04, 2014		U-96	PED	Jan 28, 2010
	5866581*PED	Apr 04, 2015			PED	Jan 28, 2010
	5916893	Sep 01, 2015		U-96		
	5916893*PED	Mar 01, 2016				
	6124304	Oct 04, 2014		U-96		
	6124304*PED	Apr 04, 2015				
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003	5246937	Sep 21, 2010		U-96	D-103	Jul 28, 2009
	5246937*PED	Mar 21, 2011			I-501	Jul 28, 2009
	5840763	Sep 01, 2015		U-96	M-54	Dec 24, 2012
	5840763*PED	Mar 01, 2016			PED	Jun 24, 2013
	5866581	Oct 04, 2014		U-96	PED	Jan 28, 2010
	5866581*PED	Apr 04, 2015			PED	Jan 28, 2010
	5916893	Sep 01, 2015		U-96		
	5916893*PED	Mar 01, 2016				
	6124304	Oct 04, 2014		U-96		
	6124304*PED	Apr 04, 2015				
<u>FAMOTIDINE - FLUXID</u>						
N021712 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>FAMOTIDINE - FLUXID</u>						
N021712 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>FAMOTIDINE - PEPCID AC</u>						
N020325 001	5854267	Dec 29, 2015		U-267		
	5854267*PED	Jun 29, 2016		U-267		
<u>FAMOTIDINE - PEPCID AC</u>						
N020801 001	5075114	Oct 23, 2010				
	5075114*PED	Nov 23, 2010				
	5667794	May 02, 2015			Y	
	5667794*PED	Nov 02, 2015				
	5854267	Dec 29, 2015		U-267		
	5854267*PED	Jun 29, 2016				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FAMOTIDINE - PEPCID AC</u>						
N020801 002	5075114	May 23, 2010	DP			
	5075114*PED	Nov 23, 2010				
	6814978	Aug 26, 2021	DP			
	6814978*PED	Feb 26, 2022				
<u>FAMOTIDINE - PEPCID AC (GELTAB)</u>						
N020902 001	5854267	Dec 29, 2015		U-368		
	5854267*PED	Jun 29, 2016		U-368		
<u>FEBUXOSTAT - ULORIC</u>						
N021856 001	5614520	Mar 25, 2014	DS DP	U-954	NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
<u>FEBUXOSTAT - ULORIC</u>						
N021856 002	5614520	Mar 25, 2014	DS DP	U-954	NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
<u>FELBAMATE - FELBATOL</u>						
N020189 001	4978680	Sep 26, 2009		U-83		
	5082861	Sep 26, 2009		U-83		
<u>FELBAMATE - FELBATOL</u>						
N020189 002	4978680	Sep 26, 2009		U-83		
	5082861	Sep 26, 2009		U-83		
<u>FELBAMATE - FELBATOL</u>						
N020189 003	4978680	Sep 26, 2009		U-83		
	5082861	Sep 26, 2009		U-83		
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695 001	7101574	Aug 20, 2020	DS DP			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695 003	7101574	Aug 20, 2020	DS DP			
<u>FENOFIBRATE - LIPOFEN</u>						
N021612 001	5545628	Jan 10, 2015	DP	U-701		
<u>FENOFIBRATE - LIPOFEN</u>						
N021612 002	5545628	Jan 10, 2015	DP	U-701		
<u>FENOFIBRATE - LIPOFEN</u>						
N021612 003	5545628	Jan 10, 2015	DP	U-701		
<u>FENOFIBRATE - TRICOR</u>						
N021203 001	6074670	Jan 09, 2018				
	6277405	Jan 09, 2018				
	6589552	Jan 09, 2018				
	6652881	Jan 09, 2018	DP			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
<u>FENOFIBRATE - TRICOR</u>						
N021203 003	6074670	Jan 09, 2018				
	6277405	Jan 09, 2018				
	6589552	Jan 09, 2018				
	6652881	Jan 09, 2018	DP			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - TRICOR</u>						
N021656 001	5145684	Jan 25, 2011	DP U-615			
	6277405	Jan 09, 2018	DS			
	6375986	Sep 21, 2020	DP U-615			
	6652881	Jan 09, 2018	DS			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023			U-847	
<u>FENOFIBRATE - TRICOR</u>						
N021656 002	5145684	Jan 25, 2011	DP U-615			
	6277405	Jan 09, 2018	DS			
	6375986	Sep 21, 2020	DP U-615			
	6652881	Jan 09, 2018	DS			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023			U-847	
<u>FENOFIBRATE - TRIGLIDE</u>						
N021350 001	6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRATE - TRIGLIDE</u>						
N021350 002	6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 001	7569612	Aug 20, 2027			U-1000	
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 002	7569612	Aug 20, 2027			U-1000	
<u>FENTANYL CITRATE - ACTIQ</u>						
N020747 001					M-63	Feb 07, 2010
<u>FENTANYL CITRATE - ACTIQ</u>						
N020747 002					M-63	Feb 07, 2010
<u>FENTANYL CITRATE - ACTIQ</u>						
N020747 003					M-63	Feb 07, 2010
<u>FENTANYL CITRATE - ACTIQ</u>						
N020747 004					M-63	Feb 07, 2010
<u>FENTANYL CITRATE - ACTIQ</u>						
N020747 005					M-63	Feb 07, 2010
<u>FENTANYL CITRATE - ACTIQ</u>						
N020747 006					M-63	Feb 07, 2010
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	6200604	Mar 26, 2019	U-767		NDF	Sep 25, 2009
	6974590	Mar 26, 2019	U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	6200604	Mar 26, 2019	U-767		NDF	Sep 25, 2009
	6974590	Mar 26, 2019	U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	6200604	Mar 26, 2019	U-767		NDF	Sep 25, 2009
	6974590	Mar 26, 2019	U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	6200604	Mar 26, 2019	U-767		NDF	Sep 25, 2009
	6974590	Mar 26, 2019	U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	6200604	Mar 26, 2019	U-767		NDF	Sep 25, 2009
	6974590	Mar 26, 2019	U-767			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 006	6200604	Mar 26, 2019	U-767		NDF	Sep 25, 2009
	6974590	Mar 26, 2019	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 001	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 002	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 003	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 004	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 005	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N021338 001	5697896	Dec 16, 2014	DP			
	5843014	Dec 01, 2015	DP			
	6169920	Jan 02, 2018	DP			
	6171294	Jun 05, 2015		U-736		
	6181963	Nov 02, 2019	DP			
	6195582	Jan 28, 2019	DP	U-736		
	6216033	Jun 05, 2015	DP			
	6317629	Jun 02, 2012	DP			
	6425892	Jun 05, 2015		U-736		
	6842640	Jun 02, 2015	DP			
	6881208	Apr 19, 2022		U-736		
	6975902	Apr 01, 2024	DP			
	7018370	Jun 05, 2015		U-736		
	7027859	Sep 26, 2014	DP			
	7302293	Jun 05, 2015	DP			
<u>FERRIC HEXACYANOFERRATE(II) - RADIOGARDASE (PRUSSIAN BLUE)</u>						
N021626 001					ODE	Oct 02, 2010
<u>FERUMOXIDES - FERIDEX I.V.</u>						
N020416 001	5219554	Jun 15, 2010				
	5248492	Sep 28, 2010				
<u>FERUMOXASIL - GASTROMARK</u>						
N020410 001	5219554	Jun 15, 2010				
<u>FERUMOXYTOL - FERAHEME</u>						
N022180 001	6599498	Mar 08, 2020	DS DP		NP	Jun 30, 2012
	7553479	Mar 08, 2020	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	6858650	May 11, 2019	DS	U-913	NCE	Oct 31, 2013
	7384980	Oct 14, 2019	DS DP	U-913		
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	6858650	May 11, 2019	DS	U-913	NCE	Oct 31, 2013
	7384980	Oct 14, 2019	DS DP	U-913		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N020625 001	5578610	Nov 26, 2013				U-192
	5578610*PED	May 26, 2014				U-192
	5738872	Feb 28, 2015				
	5738872*PED	Aug 28, 2015				
	5855912	Feb 28, 2015				
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015				
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017				U-138
	6037353*PED	Sep 14, 2017				U-138
	6113942	Feb 28, 2015				
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012				U-138
	6187791*PED	Nov 11, 2012				U-138
	6399632	May 11, 2012				U-468
	6399632*PED	Nov 11, 2012				U-468
	7135571	May 18, 2014	DS			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N020872 001	5578610	Nov 26, 2013	DS DP			U-684
	5578610	Nov 26, 2013	DS DP			U-139
	5578610*PED	May 26, 2014				U-139
	5855912	Feb 28, 2015		DP		
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015		DP		
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017				U-138
	6037353	Mar 14, 2017				U-684
	6037353*PED	Sep 14, 2017				U-138
	6113942	Feb 28, 2015		DP		
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012				U-138
	6187791	May 11, 2012				U-684
	6187791*PED	Nov 11, 2012				U-138
	6399632	May 11, 2012				U-468
	6399632	May 11, 2012				U-684
	6399632*PED	Nov 11, 2012				U-468
	7135571	May 18, 2014	DS			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N020872 002	5578610	Nov 26, 2013	DS DP			U-139
	5578610	Nov 26, 2013	DS DP			U-684
	5578610*PED	May 26, 2014				U-139
	5855912	Feb 28, 2015		DP		
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015		DP		
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017				U-684
	6037353	Mar 14, 2017				U-138
	6037353*PED	Sep 14, 2017				U-138
	6113942	Feb 28, 2015		DP		
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012				U-138
	6187791	May 11, 2012				U-684
	6187791*PED	Nov 11, 2012				U-138
	6399632	May 11, 2012				U-468
	6399632	May 11, 2012				U-684
	6399632*PED	Nov 11, 2012				U-468
	7135571	May 18, 2014	DS			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N020872 004	5578610	Nov 26, 2013	DS DP		U-684	
	5578610	Nov 26, 2013	DS DP		U-139	
	5578610*PED	May 26, 2014			U-139	
	5855912	Feb 28, 2015		DP		
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015		DP		
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017			U-684	
	6037353	Mar 14, 2017			U-138	
	6037353*PED	Sep 14, 2017			U-138	
	6113942	Feb 28, 2015		DP		
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012			U-684	
	6187791	May 11, 2012			U-138	
	6187791*PED	Nov 11, 2012			U-138	
	6399632	May 11, 2012			U-468	
	6399632	May 11, 2012			U-684	
	6399632*PED	Nov 11, 2012			U-468	
	7135571	May 18, 2014	DS			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N021909 001	5178878	Jan 12, 2010		DP	U-823	
	5578610	Nov 26, 2013	DS DP		U-823	
	5738872	Feb 28, 2015		DP		
	6037353	Mar 14, 2017			U-823	
	6187791	May 11, 2012			U-823	
	6399632	May 11, 2012			U-823	
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N021963 001	5578610	Nov 26, 2013	DS DP		U-772	
	6037353	Mar 14, 2017			U-772	
	6187791	May 11, 2012			U-772	
	6399632	May 11, 2012			U-772	
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA D 24 HOUR</u>						
N021704 001	5578610	Nov 26, 2013	DS DP		U-612	
	5578610*PED	May 26, 2014				
	6004582	May 29, 2018		DP		
	6037353	Mar 17, 2017			U-612	
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012			U-612	
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012			U-612	
	6399632*PED	Nov 11, 2012				
	6613357	Dec 25, 2020		DP	U-612	
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
	RE39069	May 29, 2018		DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR</u>						
N020786 001	5578610	Nov 26, 2013				
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015				
	5855912*PED	Aug 28, 2015				
	6037353	Mar 14, 2017		U-138		
	6037353*PED	Sep 14, 2017		U-138		
	6039974	Jul 31, 2018				
	6113942	Feb 28, 2015				
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012		U-138		
	6187791*PED	Nov 11, 2012		U-138		
	6399632	May 11, 2012		U-468		
	6399632*PED	Nov 11, 2012		U-468		
	7135571	May 18, 2014	DS			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE</u>						
A076236 001					PC	May 02, 2010
<u>FINASTERIDE - PROPECIA</u>						
N020788 001	5547957	Oct 15, 2013		U-236		
	5571817	Nov 05, 2013		U-259		
	5886184	Nov 19, 2012				
<u>FINASTERIDE - PROSCAR</u>						
N020180 001	5886184	Nov 19, 2012	DS			
	5942519	Oct 23, 2018		U-280		
	6046183	Mar 20, 2011	DP	U-577		
<u>FLUDARABINE PHOSPHATE - OFORTA</u>						
N022273 001	7148207	Dec 20, 2022	DP	U-944	NDF	Dec 18, 2011
	7547776	Dec 10, 2018	DS		ODE	Dec 18, 2015
<u>FLUOCINOLONE ACETONIDE - DERMA-SMOOTHIE/FS</u>						
N019452 001					NPP	Dec 12, 2010
<u>FLUOCINOLONE ACETONIDE - RETISERT</u>						
N021737 001	6217895	Mar 22, 2019	DP	U-708	ODE	Apr 08, 2012
	6548078	Mar 22, 2019	DP	U-708		
<u>FLUOCINONIDE - VANOS</u>						
N021758 001	6765001	Dec 21, 2021	DP			
	7220424	Jan 07, 2023		U-861		
<u>FLUOROMETHOLONE ACETATE; TOBRAMYCIN - TOBRASONE</u>						
N050628 001	5149693	Sep 22, 2009		U-923		
<u>FLUOROURACIL - CARAC</u>						
N020985 001	6670335	Jun 02, 2021	DP	U-68		
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N018936 001	6960577	Nov 01, 2017		U-963	I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N018936 003	6960577	Nov 01, 2017		U-963	I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N018936 006	6960577	Nov 01, 2017		U-963	I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY</u>						
N021235 001	5910319	May 29, 2017		U-396		
	5985322	May 29, 2017		U-397		
	RE39030	May 29, 2017	DP	U-396		
	RE39030	May 29, 2017	DP	U-397		



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 001	5229382	Apr 23, 2011	DS DP		I-593	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	6960577	Nov 01, 2017		U-962		
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 002	5229382	Apr 23, 2011	DS DP		I-593	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	5945416	Mar 24, 2017	DS DP	Y		
	6960577	Nov 01, 2017		U-962		
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 003	5229382	Apr 23, 2011	DS DP		I-593	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	5945416	Mar 24, 2017	DS DP	Y		
	6960577	Nov 01, 2017		U-962		
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 004	5229382	Apr 23, 2011	DS DP		I-593	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	5945416	Mar 24, 2017	DS DP	Y		
	6960577	Nov 01, 2017		U-962		
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 005	5229382	Apr 23, 2011	DS DP		I-593	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	5945416	Mar 24, 2017	DS DP	Y		
	6960577	Nov 01, 2017		U-962		
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N022051 001	6858596	Aug 03, 2021	DP	U-808		
	7101866	Aug 03, 2021	DS DP	U-808		
	7541350	Aug 03, 2021	DP	U-988		
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N021152 001	7300669	Oct 20, 2019	DP	U-835		
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 100</u>						
N020833 002	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 250</u>						
N020833 003	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 50</u>						
N020833 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 001	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Jun 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-581		
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 002	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-581		
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 003	5658549	Aug 19, 2014	DP	U-710		
	5658549*PED	Feb 19, 2015		U-710		
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP	U-582		
	6253762*PED	Oct 14, 2015		U-582		
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP	U-583		
	6546928*PED	Oct 14, 2015		U-583		
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-581		
	6743413*PED	Dec 01, 2021		U-581		
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
N021077 001	5590645	Mar 01, 2011	DP		I-558	Apr 30, 2011
	5590645*PED	Sep 01, 2011			M-84	Mar 31, 2012
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
	RE40045	Sep 07, 2010	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
N021077 002	5590645	Mar 01, 2011	DP		I-558	Apr 30, 2011
	5590645*PED	Sep 01, 2011			M-84	Mar 31, 2012
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
	RE40045	Sep 07, 2010	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
N021077 003	5590645	Mar 01, 2011	DP		I-558	Apr 30, 2011
	5590645*PED	Sep 01, 2011			M-84	Mar 31, 2012
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
	RE40045	Sep 07, 2010	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 001	5658549	Aug 19, 2014	DP			U-738
	5658549*PED	Feb 19, 2015				U-738
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6143277	Apr 14, 2015	DP			U-738
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP			U-738
	6253762*PED	Oct 14, 2015				U-738
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017				
	6510969*PED	Jun 23, 2018				
	6524555	Apr 14, 2015	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021				U-841
	6743413*PED	Dec 01, 2021				U-841
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
	RE40045	Sep 07, 2010	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 002	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6143277	Apr 14, 2015	DP U-738			
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6524555	Apr 14, 2015	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-841		
	6743413*PED	Dec 01, 2021		U-841		
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
	RE40045	Sep 07, 2010	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 003	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6143277	Apr 14, 2015	DP U-738			
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6524555	Apr 14, 2015	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-841		
	6743413*PED	Dec 01, 2021		U-841		
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
	RE40045	Sep 07, 2010	DP			
<u>FLUVASTATIN SODIUM - LESCOL</u>						
N020261 001	5354772	Oct 11, 2011	U-109		PED	Oct 10, 2009
	5354772	Oct 11, 2011	U-413			
	5354772*PED	Apr 11, 2012				
	5356896	Dec 12, 2011				
	5356896*PED	Jun 12, 2012				
<u>FLUVASTATIN SODIUM - LESCOL</u>						
N020261 002	5354772	Oct 11, 2011	U-413		PED	Oct 10, 2009
	5354772	Oct 11, 2011	U-109			
	5354772*PED	Apr 11, 2012				
	5356896	Dec 12, 2011				
	5356896*PED	Jun 12, 2012				
<u>FLUVASTATIN SODIUM - LESCOL XL</u>						
N021192 001	5354772	Oct 11, 2011	U-109		PED	Oct 10, 2009
	5354772	Oct 11, 2011	U-413			
	5354772*PED	Apr 11, 2012				
	5356896	Dec 12, 2011				
	5356896*PED	Jun 12, 2012				
	6242003	Apr 13, 2020				
	6242003*PED	Oct 13, 2020				
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
N021519 001						

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
N021519	002				M-83	Apr 14, 2011
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
N021519	003				M-83	Apr 14, 2011
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N022033	001	7465462	May 10, 2020	DP U-929	NDF	Feb 28, 2011
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N022033	002	7465462	May 10, 2020	DP U-929	NDF	Feb 28, 2011
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM</u>						
N020582	001	5270057	Mar 20, 2011			
		5767251	Jun 16, 2015			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM</u>						
N020582	002	5270057	Mar 20, 2011			
		5767251	Jun 16, 2015			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211	001	5767251	Jun 16, 2015	DS		
		5929028	Jan 14, 2018	DP U-567		
		7563763	Aug 23, 2019	U-993		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211	002	5767251	Jun 16, 2015	DS		
		5929028	Jan 14, 2018	DP U-567		
		7563763	Aug 23, 2019	U-993		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211	003	7563763	Aug 23, 2019		U-993	
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211	004	7563763	Aug 23, 2019		U-993	
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378	001	5767251	Jun 16, 2015	DS		
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378	002	5767251	Jun 16, 2015	DS		
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378	003	5767251	Jun 16, 2015	DS		
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378	004	5767067	Jun 16, 2015	DS		
		5767251	Jun 16, 2015	DS		
		7563763	Aug 23, 2019	DP		
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378	005	5767067	Jun 16, 2015	DS		
		5767251	Jun 16, 2015	DS		
		7563763	Aug 23, 2019	DP		
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N021765	001	5767251	Jun 16, 2015	DS		
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N021765	003	5767251	Jun 16, 2015	DS		
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF</u>						
N021765	002	5767067	Jun 16, 2015	DS		
		5767251	Jun 16, 2015	DS		
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
N021684	001	5767067	Jun 16, 2015	DS		
		5767251	Jun 16, 2015	DS		
		7446090	Aug 23, 2019	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
N021684 002	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
N021684 003	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019	DP			
<u>FOMEPIZOLE - ANTIZOL</u>						
N020696 001	7553863	Jun 30, 2027	DS DP			
<u>FOMIVIRSEN SODIUM - VITRAVENE PRESERVATIVE FREE</u>						
N020961 001	5264423	Nov 23, 2010		U-522		
	5276019	Jan 04, 2011		U-522		
	5442049	Aug 15, 2012				
	5595978	Aug 15, 2012		U-522		
<u>FORMOTEROL FUMARATE - FORADIL</u>						
N020831 001	6488027	Mar 08, 2019				
	6887459	Nov 28, 2020		U-762		
<u>FORMOTEROL FUMARATE - FORADIL CERTIHALER</u>						
N021592 001	6182655	Dec 05, 2016	DP		NP	Dec 15, 2009
	6645466	Nov 10, 2019	DP			
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N022007 001	6667344	Jun 22, 2021	DP		NP	May 11, 2010
	6814953	Jun 22, 2021	DP	U-813		
	7348362	Jun 22, 2021	DP			
	7462645	Jun 22, 2021	DP	U-813		
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001	6436989	Dec 24, 2017	DS DP	U-257		
	6514953	Jul 15, 2019	DS DP	U-257		
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116 001	6436989	Dec 24, 2017	DS DP	U-257	NDF	Jun 14, 2010
<u>FOSAPREPIRANT DIMEGLUMINE - EMEND</u>						
N022023 001	5512570	Mar 04, 2014		U-850	NCE	Jan 25, 2013
	5538982	Jul 23, 2013		U-850		
	5691336	Mar 04, 2014	DS DP			
	5716942	Feb 10, 2015		U-850		
	7214692	Sep 18, 2012		U-850		
<u>FOSINOPRIL SODIUM - MONOPRIL</u>						
N019915 002	5006344	Jul 10, 2009				
	5006344*PED	Jan 10, 2010				
<u>FOSINOPRIL SODIUM - MONOPRIL</u>						
N019915 003	5006344	Jul 10, 2009				
	5006344*PED	Jan 10, 2010				
<u>FOSINOPRIL SODIUM - MONOPRIL</u>						
N019915 004	5006344	Jul 10, 2009				
	5006344*PED	Jan 10, 2010				
<u>FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE - MONOPRIL-HCT</u>						
N020286 001	5006344	Jul 10, 2009				
	5006344*PED	Jan 10, 2010				
<u>FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE - MONOPRIL-HCT</u>						
N020286 002	5006344	Jul 10, 2009				
	5006344*PED	Jan 10, 2010				
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	6204257	Jun 07, 2018	DS DP	U-945	NCE	Dec 12, 2013

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FROVATRIPTAN SUCCINATE - FROVA</u>						
N021006 001	5464864	Nov 07, 2015	U-436			
	5616603	Apr 01, 2014	U-436			
	5637611	Jun 10, 2014	U-436			
	5827871	Oct 27, 2015	U-436			
	5962501	Dec 16, 2013	U-436			
<u>FULVESTRANT - FASLODEX</u>						
N021344 001	6774122	Jan 09, 2021	U-596			
	7456160	Jan 09, 2021	U-596			
<u>GABAPENTIN - NEURONTIN</u>						
N020235 001	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N020235 002	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N020235 003	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N020882 001	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N020882 002	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N021129 001	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
	7256216	May 28, 2022	DP			
	7256216*PED	Nov 28, 2022				
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 001	4916246	Apr 10, 2012	DS		NCE	Nov 23, 2009
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 002	4916246	Apr 10, 2012	DS		NCE	Nov 23, 2009
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 003	4916246	Apr 10, 2012	DS		NCE	Nov 23, 2009
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 004	4916246	Apr 10, 2012	DS		NCE	Nov 23, 2009
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK</u>						
N021358 001	4916246	Apr 10, 2012	DS		NCE	Nov 23, 2009
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK</u>						
N021358 002	4916246	Apr 10, 2012	DS		NCE	Nov 23, 2009
<u>GADODIAMIDE - OMNISCAN</u>						
N020123 001	5362475	Nov 08, 2011	DS			
	5560903	Oct 01, 2013	DP			
<u>GADODIAMIDE - OMNISCAN</u>						
N022066 001	5560903	Oct 01, 2013	DP			
<u>GADODIAMIDE - OMNISCAN</u>						
N022066 002	5362475	Nov 08, 2011	DS			
	5560903	Oct 01, 2013	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001					NCE	Dec 22, 2013
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002						Dec 22, 2013

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOPENTETATE DIMEGLUMINE - MAGNEVIST</u>						
N019596 001	5362475	Nov 08, 2011				
	5560903	Oct 01, 2013				
<u>GADOPENTETATE DIMEGLUMINE - MAGNEVIST</u>						
N021037 001	5362475	Nov 08, 2011				
	5560903	Oct 01, 2013				
<u>GADOTERIDOL - PROHANCE</u>						
N020131 001	5474756	Dec 12, 2012		U-480		
	5846519	Dec 08, 2015				
	6143274	Dec 12, 2012		U-480		
<u>GADOTERIDOL - PROHANCE MULTIPACK</u>						
N021489 001	5474756	Dec 12, 2012		U-536		
	5846519	Dec 08, 2015				
	6143274	Dec 12, 2012		U-536		
<u>GADOVERSETAMIDE - OPTIMARK</u>						
N020937 001	5130120	Jul 14, 2009				
	5137711	Jul 14, 2009				
<u>GADOVERSETAMIDE - OPTIMARK</u>						
N020937 002	5130120	Jul 14, 2009				
	5137711	Jul 14, 2009				
<u>GADOVERSETAMIDE - OPTIMARK</u>						
N020937 003	5130120	Jul 14, 2009				
	5137711	Jul 14, 2009				
<u>GADOVERSETAMIDE - OPTIMARK</u>						
N020937 004	5130120	Jul 14, 2009				
	5137711	Jul 14, 2009				
<u>GADOVERSETAMIDE - OPTIMARK</u>						
N020975 001	5130120	Jul 14, 2009				
	5137711	Jul 14, 2009				
<u>GADOVERSETAMIDE - OPTIMARK IN PLASTIC CONTAINER</u>						
N020976 001	5130120	Jul 14, 2009				
	5137711	Jul 14, 2009				
<u>GADOXETATE DISODIUM - EOVIIST</u>						
N022090 001					NCE	Jul 03, 2013
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N021169 001	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP	U-322		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N021169 002	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP	U-322		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N021169 003	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP	U-322		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N021615 001	7160559	Dec 20, 2019		DP		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N021615 002	7160559	Dec 20, 2019		DP		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N021615 003	7160559	Dec 20, 2019		DP		
<u>GANCICLOVIR - VITRASERT</u>						
N020569 001	5378475	Jan 03, 2012				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GANCICLOVIR - ZIRGAN</u>						
N022211	001				NDF ODE	Sep 15, 2012 Sep 15, 2016
<u>GANIRELIX ACETATE - GANIRELIX ACETATE INJECTION</u>						
N021057	001	4801577	Feb 05, 2012	DS DP		
		5767082	Jun 16, 2015			
<u>GATIFLOXACIN - ZYMAR</u>						
N021493	001	4980470	Dec 15, 2009	DS DP		
		4980470*PED	Jun 15, 2010			
		5880283	Dec 05, 2015			
		5880283*PED	Jun 05, 2016			
		6333045	Aug 20, 2019	DP		
		6333045*PED	Feb 20, 2020			
<u>GEFITINIB - IRESSA</u>						
N021399	001	5457105	Jan 19, 2013			
		5616582	Jan 19, 2013			
		5770599	May 05, 2017	DS DP	U-881	
<u>GEMCITABINE HYDROCHLORIDE - GEMZAR</u>						
N020509	001	4808614	May 15, 2010	DS	I-499	Jul 14, 2009
		4808614*PED	Nov 15, 2010			
		5464826	Nov 07, 2012		U-146	
		5464826*PED	May 07, 2013			
<u>GEMCITABINE HYDROCHLORIDE - GEMZAR</u>						
N020509	002	4808614	May 15, 2010	DS	I-499	Jul 14, 2009
		4808614*PED	Nov 15, 2010			
		5464826	Nov 07, 2012		U-146	
		5464826*PED	May 07, 2013			
<u>GEMIFLOXACIN MESYLATE - FACTIVE</u>						
N021158	001	5633262	Jun 15, 2015		D-106	May 01, 2010
		5776944	Apr 04, 2017	DS DP		
		5962468	Jun 15, 2015		U-282	
		6262071	Sep 21, 2019		U-513	
		6331550	Sep 21, 2019		U-511	
		6340689	Sep 14, 2019		U-512	
		6455540	Sep 21, 2019		U-511	
		6723734	Mar 20, 2018	DS DP		
		6803376	Sep 21, 2019	DS DP	U-609	
		6803376	Sep 21, 2019	DS DP	U-608	
<u>GEMTUZUMAB OZOGAMICIN - MYLOTARG</u>						
N021174	001	5585089	Dec 17, 2013			
		5606040	Feb 25, 2014			
		5693762	Dec 02, 2014			
		5739116	Apr 14, 2015			
		5767285	Jun 16, 2015			
		5773001	Jun 30, 2015		U-320	
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N020622	001	5981589	May 24, 2014		I-594	Feb 27, 2012
		6054430	May 24, 2014			
		6342476	May 24, 2014		U-441	
		6362161	May 24, 2014		U-441	
		6620847	May 24, 2014	DS		
		6939539	May 24, 2014	DS		
		7199098	May 24, 2014	DS		
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N020622	002	5981589	May 24, 2014		I-594	Feb 27, 2012
		6054430	May 24, 2014			
		6342476	May 24, 2014		U-441	
		6362161	May 24, 2014		U-441	
		6620847	May 24, 2014	DS		
		6939539	May 24, 2014	DS		
		7199098	May 24, 2014	DS		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N021925 001	4687777	Jan 17, 2011	DS			
	6150383	Jun 19, 2016			U-753	
	6211205	Jun 19, 2016			U-753	
	6303640	Aug 09, 2016			U-753	
	6329404	Jun 19, 2016	DP		U-753	
	7538125	Jun 19, 2016	DP			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N021925 002	4687777	Jan 17, 2011	DS			
	6150383	Jun 19, 2016			U-753	
	6211205	Jun 19, 2016			U-753	
	6303640	Aug 09, 2016			U-753	
	6329404	Jun 19, 2016	DP		U-753	
	7538125	Jun 19, 2016	DP			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N021700 001	5002953	Sep 17, 2011	DS DP		U-690	
	5002953	Sep 17, 2011	DS DP		U-781	
	5002953*PED	Mar 17, 2012			U-781	
	5741803	Apr 21, 2015	DS DP		U-690	
	5741803	Apr 21, 2015	DS DP		U-781	
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N021700 002	5002953	Sep 17, 2011	DS DP		U-781	
	5002953	Sep 17, 2011	DS DP		U-690	
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP		U-781	
	5741803	Apr 21, 2015	DS DP		U-690	
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N021700 003	5002953	Sep 17, 2011	DS DP		U-690	
	5002953	Sep 17, 2011	DS DP		U-781	
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP		U-690	
	5741803	Apr 21, 2015	DS DP		U-781	
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N021700 004	5002953	Sep 17, 2011	DS DP		U-840	
	5002953*PED	Mar 17, 2012				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N021700 005	5002953	Sep 17, 2011	DS DP		U-840	
	5002953*PED	Mar 17, 2012				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N020329 001	5024843	Sep 05, 2009				
	5091190	Sep 05, 2009			U-111	
	5591454	Jan 07, 2014			U-150	
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N020329 002	5024843	Sep 05, 2009				
	5091190	Sep 05, 2009			U-111	
	5591454	Jan 07, 2014			U-150	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N020329 003	5024843	Sep 05, 2009				
	5091190	Sep 05, 2009	U-111			
	5591454	Jan 07, 2014	U-111			
<u>GLUTAMINE - NUTRESTORE</u>						
N021667 001	5288703	Oct 07, 2011	U-898		ODE	Jun 10, 2011
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N021178 001	6303146	Jul 14, 2019	U-412			
	6303146*PED	Jan 14, 2020	U-412			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N021178 002	6303146	Jul 14, 2019	U-412			
	6303146*PED	Jan 14, 2020	U-412			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N021178 003	6303146	Jul 14, 2019	U-412			
	6303146*PED	Jan 14, 2020	U-412			
<u>GLYCOPYRROLATE - ROBINUL</u>						
N012827 001	7091236	Apr 24, 2024	U-877			
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N012827 002	7091236	Apr 24, 2024	U-877			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N019726 001	7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
	7500964	Feb 26, 2021	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N020578 001	7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
	7500964	Feb 26, 2021	DP			
<u>GRANISETRON - SANCUSO</u>						
N022198 001	7608282	Oct 22, 2024	DP U-1011		NE	Sep 12, 2011
					NDF	Sep 12, 2011
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 001	5952340	Sep 14, 2016	U-519			
	6294548	May 04, 2019				
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 002	5952340	Sep 14, 2016	U-519			
	6294548	May 04, 2019				
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 004	5952340	Sep 14, 2016	U-519			
	6294548	May 04, 2019				
<u>GREPAFLOXACIN HYDROCHLORIDE - RAXAR</u>						
N020695 001	5563138	Oct 08, 2013				
<u>GUAIFENESIN - MUCINEX</u>						
N021282 001	6372252	Apr 28, 2020	U-489			
	6955821	Apr 28, 2020	DP U-489			
<u>GUAIFENESIN - MUCINEX</u>						
N021282 002	6372252	Apr 28, 2020	U-489			
	6955821	Apr 28, 2020	DP U-489			
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N021585 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-686			
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N021585 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-686			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 001	5854290	Sep 21, 2015		U-494	NP	Sep 02, 2012
	6287599	Dec 20, 2020	DP			
	6811794	Jul 04, 2022	DP	U-494		
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 002	5854290	Sep 21, 2015		U-494	NP	Sep 02, 2012
	6287599	Dec 20, 2020	DP			
	6811794	Jul 04, 2022	DP	U-494		
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 003	5854290	Sep 21, 2015		U-494	NP	Sep 02, 2012
	6287599	Dec 20, 2020	DP			
	6811794	Jul 04, 2022	DP	U-494		
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 004	5854290	Sep 21, 2015		U-494	NP	Sep 02, 2012
	6287599	Dec 20, 2020	DP			
	6811794	Jul 04, 2022	DP	U-494		
<u>HISTRELIN ACETATE - SUPPRELIN LA</u>						
N022058 001	5266325	Nov 30, 2010	DP		NP	May 03, 2010
	5292515	Mar 08, 2011	DP		ODE	May 03, 2014
<u>HISTRELIN ACETATE - VANTAS</u>						
N021732 001	5266325	Nov 30, 2010	DP			
	5292515	Mar 08, 2011	DP			
<u>HYALURONIDASE - AMPHADASE</u>						
N021665 001					NCE	Oct 26, 2009
<u>HYALURONIDASE - HYDASE</u>						
N021716 001					NCE	Oct 25, 2010
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>						
N021859 001					NCE	Dec 02, 2010
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL</u>						
N020727 001	6465463	Sep 08, 2020		U-71		
	6784177	Sep 08, 2020		U-71		
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N020758 001	5270317	Sep 30, 2011			I-549	Nov 16, 2010
	5270317*PED	Mar 30, 2012				
	5994348	Jun 07, 2015				
	5994348*PED	Dec 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N020758 002	5270317	Sep 30, 2011			I-549	Nov 16, 2010
	5270317*PED	Mar 30, 2012				
	5994348	Jun 07, 2015				
	5994348*PED	Dec 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N020758 003	5270317	Sep 30, 2011			I-549	Nov 16, 2010
	5270317*PED	Mar 30, 2012				
	5994348	Jun 07, 2015				
	5994348*PED	Dec 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N020758 004	5270317	Sep 30, 2011	DS DP		I-549	Nov 16, 2010
	5270317*PED	Mar 30, 2012				
	5994348	Jun 07, 2015	DP			
	5994348*PED	Dec 07, 2015				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR</u>						
N020387 001	5138069	Aug 11, 2009	DS			
	5138069*PED	Feb 11, 2010				
	5153197	Oct 06, 2009	DP U-3			
	5153197	Oct 06, 2009	DP U-538			
	5153197*PED	Apr 06, 2010	U-3			
	5153197*PED	Apr 06, 2010	U-538			
	5608075	Mar 04, 2014		Y		
	5608075*PED	Sep 04, 2014				
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR</u>						
N020387 002	5138069	Aug 11, 2009	DS			
	5138069*PED	Feb 11, 2010				
	5153197	Oct 06, 2009	DP U-3			
	5153197	Oct 06, 2009	DP U-538			
	5153197*PED	Apr 06, 2010	U-3			
	5153197*PED	Apr 06, 2010	U-538			
	5608075	Mar 04, 2014		Y		
	5608075*PED	Sep 04, 2014				
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR</u>						
N020387 003	5138069	Aug 11, 2009	DS			
	5138069*PED	Feb 11, 2010				
	5153197	Oct 08, 2009	DP U-538			
	5153197	Oct 08, 2009	DP U-3			
	5153197*PED	Apr 06, 2010				
<u>HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE - DUTOPROL</u>						
N021956 001					NC	Aug 28, 2009
<u>HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE - DUTOPROL</u>						
N021956 002					NC	Aug 28, 2009
<u>HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE - DUTOPROL</u>						
N021956 003					NC	Aug 28, 2009
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N021532 002	5616599	Apr 25, 2016	DS DP U-500			
	5616599*PED	Oct 25, 2016				
	6878703	Nov 19, 2021	U-3			
	6878703*PED	May 19, 2022				
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N021532 003	5616599	Apr 25, 2016	DS DP U-500			
	5616599*PED	Oct 25, 2016				
	6878703	Nov 19, 2021	U-3			
	6878703*PED	May 19, 2022				
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N021532 005	5616599	Apr 25, 2016	DS DP U-500			
	5616599*PED	Oct 25, 2016				
	6878703	Nov 19, 2021	U-3			
	6878703*PED	May 19, 2022				
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N021162 001	5591762	Jan 07, 2014	DS DP U-3			
	6358986	Jan 10, 2020				
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N021162 002	5591762	Jan 07, 2014	DS DP U-3			
	6358986	Jan 10, 2020				
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N021162 003	5591762	Jan 07, 2014	DS DP U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818 001	5399578	Mar 21, 2012	U-3		I-567	Jul 31, 2011
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	U-3			
	6294197*PED	Dec 18, 2017				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818 002	5399578	Mar 21, 2012	U-3		I-567	Jul 31, 2011
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	U-3			
	6294197*PED	Dec 18, 2017				
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818 003	5399578	Mar 21, 2012	U-3		I-567	Jul 31, 2011
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	U-3			
	6294197*PED	Dec 18, 2017				
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818 004	5399578	Mar 21, 2012	U-3		I-567	Jul 31, 2011
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	U-3			
	6294197*PED	Dec 18, 2017				
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818 005	5399578	Mar 21, 2012	U-3		I-567	Jul 31, 2011
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	U-3			
	6294197*PED	Dec 18, 2017				
<u>HYDROCODONE BITARTRATE; IBUPROFEN - VICOPROFEN</u>						
N020716 001	6348216	Jun 10, 2017				
	6599531	Jun 10, 2017				
<u>HYDROCORTISONE BUTYRATE - LOCOID</u>						
N022076 001	7378405	Dec 19, 2026	DP		NDF	May 18, 2010
<u>HYDROCORTISONE BUTYRATE - LOCOID LIPOCREAM</u>						
N020769 001	5635497	Jun 03, 2014			I-613	Oct 19, 2012
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019891 001	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019892 001	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019892 002	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019892 003	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N019034 001	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N019034 002	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N021044 001	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP	U-616		
	5968551	Dec 24, 2011	DP			
	6294195	Dec 24, 2011	DP			
	6335033	Nov 04, 2014	DP	U-616		
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP	U-616		
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N021044 002	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP	U-616		
	5968551	Dec 24, 2011	DP			
	6294195	Dec 24, 2011	DP			
	6335033	Nov 04, 2014	DP	U-616		
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP	U-616		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N021044 003	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP	U-616		
	5968551	Dec 24, 2011	DP			
	6294195	Dec 24, 2011	DP			
	6335033	Nov 04, 2014	DP	U-616		
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP	U-616		
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N021044 004	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP	U-616		
	5968551	Dec 24, 2011	DP			
	6294195	Dec 24, 2011	DP			
	6335033	Nov 04, 2014	DP	U-616		
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP	U-616		
	6743442	Nov 04, 2014	DP			
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N022041 002	5834448	Nov 14, 2016	DP	U-789	NP	Dec 15, 2009
					ODE	Dec 15, 2013
<u>IBANDRONATE SODIUM - BONIVA</u>						
N021455 001	4927814	Mar 17, 2012	DS DP	U-642		
	4927814	Mar 17, 2012	DS DP	U-700		
	6143326	Apr 21, 2017		U-642		
	6294196	Oct 07, 2019	DP			
<u>IBANDRONATE SODIUM - BONIVA</u>						
N021455 002	4927814	Mar 17, 2012	DS DP	U-700		
	4927814	Mar 17, 2012	DS DP	U-642		
	6294196	Oct 07, 2019	DP			
	7192938	May 06, 2023		U-798		
	7410957	May 06, 2023		U-887		
<u>IBANDRONATE SODIUM - BONIVA</u>						
N021858 001	4927814	Mar 17, 2012	DS DP	U-700		
	5662918	Sep 02, 2014	DP			
<u>IBUPROFEN - CALDOLOR</u>						
N022348 001	6727286	Nov 27, 2021	DP	U-981	NP	Jun 11, 2012
<u>IBUPROFEN - CALDOLOR</u>						
N022348 002	6727286	Nov 27, 2021	DP	U-981	NP	Jun 11, 2012
<u>IBUPROFEN - CHILDREN'S MOTRIN</u>						
N020516 001	5374659	Dec 20, 2011				
	5374659*PED	Jun 20, 2012				
<u>IBUPROFEN - CHILDREN'S MOTRIN</u>						
N020601 001	5215755	Jun 01, 2010				
	5215755*PED	Dec 01, 2010				
<u>IBUPROFEN - CHILDREN'S MOTRIN</u>						
N020603 001	5374659	Dec 20, 2011				
	5374659*PED	Jun 20, 2012				
<u>IBUPROFEN - JUNIOR STRENGTH MOTRIN</u>						
N020601 003	5215755	Jun 01, 2010				
	5215755*PED	Dec 01, 2010				
<u>IBUPROFEN - MIDOL LIQUID GELS</u>						
N021472 001	6251426	Jun 25, 2018				
<u>IBUPROFEN - MOTRIN</u>						
N019842 001	5374659	Dec 20, 2011				
	5374659*PED	Jun 20, 2012				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBUPROFEN - MOTRIN</u>						
N020135 001	5215755	Jun 01, 2010				
	5215755*PED	Dec 01, 2010				
	5320855	Jun 14, 2011				
	5320855*PED	Dec 14, 2011				
<u>IBUPROFEN - MOTRIN</u>						
N020135 002	5215755	Jun 01, 2010				
	5215755*PED	Dec 01, 2010				
	5320855	Jun 14, 2011				
	5320855*PED	Dec 14, 2011				
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N021903 001	6342530	Nov 14, 2020	DS DP U-794		ODE	Apr 13, 2013
	6344479	Mar 20, 2021	DS DP U-794			
<u>IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S MOTRIN COLD</u>						
N021128 001	6211246	Jun 10, 2019				
<u>IBUTILIDE FUMARATE - CORVERT</u>						
N020491 001	5155268	Dec 28, 2009				
<u>ICODEXTRIN - EXTRANEAL</u>						
N021321 001	4761237	Aug 09, 2009	U-495		ODE	Dec 20, 2009
	6077836	Jun 20, 2017	U-495			
	6248726	Jun 19, 2018	U-495			
<u>ILOPERIDONE - FANAPT</u>						
N022192 001	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 002	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 003	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 004	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 005	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 006	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 007	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPROST - VENTAVIS</u>						
N021779 001					NCE	Dec 29, 2009
					ODE	Dec 29, 2011
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021335 001	5521184	Jan 04, 2015	DS DP		PED	Aug 01, 2009
	5521184*PED	Jul 04, 2015				
	6894051	May 23, 2019	DS DP U-649			
	6894051*PED	Nov 23, 2019				
	6958335	Dec 19, 2021	U-791			
	6958335*PED	Jun 19, 2022				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021335 002	5521184	Jan 04, 2015	DS DP U-649		PED	Aug 01, 2009
	5521184*PED	Jul 04, 2015				
	6894051	May 23, 2019	DS DP U-649			
	6894051*PED	Nov 23, 2019				
	6958335	Dec 19, 2021	U-791			
	6958335*PED	Jun 19, 2022				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001	5521184	Jan 04, 2015	DS DP		I-583	Dec 19, 2011
	5521184*PED	Jul 04, 2015			I-510	Oct 19, 2009
	6894051	May 23, 2019	DS DP	U-649	I-511	Oct 19, 2009
	6894051*PED	Nov 23, 2019			I-513	Oct 19, 2009
	6958335	Dec 19, 2021		U-791	I-512	Oct 19, 2009
	6958335*PED	Jun 19, 2022			I-514	Oct 19, 2009
	7544799	Jan 16, 2019	DS DP		ODE	Oct 19, 2013
	7544799*PED	Jul 16, 2019			ODE	Oct 19, 2013
					ODE	Oct 19, 2013
					ODE	Oct 19, 2013
					ODE	Oct 19, 2013
					PED	Aug 01, 2009
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002	5521184	Jan 04, 2015			I-583	Dec 19, 2011
	5521184*PED	Jul 04, 2015			I-512	Oct 19, 2009
	6894051	May 23, 2019	DS DP	U-649	I-513	Oct 19, 2009
	6894051*PED	Nov 23, 2019			I-511	Oct 19, 2009
	6958335	Dec 19, 2021		U-791	I-510	Oct 19, 2009
	6958335*PED	Jun 19, 2022			I-514	Oct 19, 2009
	7544799	Jan 16, 2019	DS DP		ODE	Oct 19, 2013
	7544799*PED	Jul 16, 2019			ODE	Oct 19, 2013
					ODE	Oct 19, 2013
					ODE	Oct 19, 2013
					ODE	Oct 19, 2013
					PED	Aug 01, 2009
<u>IMIGLUCERASE - CEREZYME</u>						
N020367 001	5549892	Aug 27, 2013		U-252		
<u>IMIGLUCERASE - CEREZYME</u>						
N020367 002	5549892	Aug 27, 2013		U-252		
<u>IMIQUIMOD - ALDARA</u>						
N020723 001	4689338	Aug 25, 2009		U-172		
	4689338*PED	Feb 25, 2010				
	5238944	Aug 24, 2010				
	5238944*PED	Feb 24, 2011				
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N020685 001	5413999	May 09, 2012		U-132		
	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021		U-554		
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N020685 003	5413999	May 09, 2012		U-132		
	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021		U-554		
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N020685 005	5413999	May 09, 2012		U-132		
	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021		U-554		
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N020685 006	5413999	May 09, 2012		U-132		
	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021		U-554		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 50/50</u>						
N021810 001	5547930	Sep 28, 2013	DS DP			
	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5834422	Sep 28, 2013	DP	U-471		
	5840680	Sep 28, 2013	DS DP	U-471		
	5866538	Jun 20, 2017	DP			
	5866538*PED	Dec 20, 2017				
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N021172 001	5547930	Sep 28, 2013				
	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5834422	Sep 28, 2013		U-471		
	5840680	Sep 28, 2013		U-471		
	5866538	Jun 19, 2017	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG</u>						
N020986 001	5618913	Jun 07, 2014	DS DP		D-112	Mar 14, 2011
	5618913*PED	Dec 07, 2014				
	5866538	Jun 20, 2017				
	5866538*PED	Dec 20, 2017				
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N021536 001	5750497	May 16, 2019	DS DP	U-668	NCE	Jun 16, 2010
	5866538	Jun 20, 2017		DP		
	6011007	Feb 02, 2014	DS DP	U-668		
	6869930	Feb 02, 2014	DS DP	U-668		
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N021081 001	5656722	Aug 12, 2014	DS DP	U-948		
	5656722*PED	Feb 12, 2015				
	6100376	Nov 06, 2009	DS DP	U-771		
	6100376*PED	May 06, 2010				
	7476652	Jul 23, 2023		DP		
	7476652*PED	Jan 23, 2024				
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N021629 001	6221633	Jun 18, 2018	DS DP	U-471	NPP	Oct 24, 2011
	6960561	Jan 25, 2023		DP	U-471	
	7452860	Mar 22, 2022		DP		
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N021629 002	6221633	Jun 18, 2018	DS DP	U-471	NPP	Oct 24, 2011
	6960561	Jan 25, 2023		DP	U-471	
	7452860	Mar 22, 2022		DP		
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N021629 003					NPP	Oct 24, 2011
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50</u>						
N021018 001	5461031	Jun 26, 2014				
	5474978	Jun 16, 2014				
	5514646	May 07, 2013				
	5747642	Jun 16, 2014				
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25</u>						
N021017 001	5461031	Jun 16, 2014				
	5474978	Jun 16, 2014				
	5514646	May 07, 2013				
	5747642	Jun 16, 2014				
<u>INSULIN LISPRO RECOMBINANT - HUMALOG</u>						
N020563 001	5474978	Jun 16, 2014		U-534		
	5514646	May 07, 2013		U-534		
<u>INSULIN LISPRO RECOMBINANT - HUMALOG PEN</u>						
N020563 002	5474978	Jun 16, 2014		U-534		
	5514646	May 07, 2013		U-534		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N021868 001	5740794	Apr 21, 2015	DP			
	5997848	Mar 07, 2014		U-704		
	6051256	Mar 07, 2014	DP			
	6257233	May 14, 2019		U-704		
	6423344	Mar 07, 2014	DP			
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6592904	Mar 07, 2014	DP			
	6685967	Sep 11, 2018	DP			
	6737045	Mar 07, 2014		U-704		
	RE37872	Feb 12, 2010	DP			
	RE38385	Feb 12, 2010	DP			
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N021868 002	5740794	Apr 21, 2015	DP			
	5997848	Mar 07, 2014		U-704		
	6051256	Mar 07, 2014	DP			
	6257233	May 14, 2019		U-704		
	6423344	Mar 07, 2014	DP			
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6592904	Mar 07, 2014	DP			
	6685967	Sep 11, 2018	DP			
	6737045	Mar 07, 2014		U-704		
	RE37872	Feb 12, 2010	DP			
	RE38385	Feb 12, 2010	DP			
<u>IOBENGUANE SULFATE I 123 - ADREVIEW</u>						
N022290 001					NCE	Sep 19, 2013
					ODE	Sep 19, 2015
<u>IODINE POVACRYLEX; ISOPROPYL ALCOHOL - DURAPREP</u>						
N021586 001					NC	Sep 29, 2009
<u>IODINE POVACRYLEX; ISOPROPYL ALCOHOL - DURAPREP</u>						
N021586 002					NC	Sep 29, 2009
<u>IODIXANOL - VISIPAQUE 270</u>						
N020351 001	5349085	Sep 20, 2011				
	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 270</u>						
N020808 001	5349085	Sep 20, 2011				
	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
N020351 002	5349085	Sep 20, 2011				
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
N020808 002	5349085	Sep 20, 2011				
	RE36418	Jul 12, 2011	DP			
<u>IOPROMIDE - ULTRAVIST (PHARMACY BULK)</u>						
N021425 002					I-619	Dec 30, 2012
<u>IOPROMIDE - ULTRAVIST 370</u>						
N020220 001					I-619	Dec 30, 2012
<u>IOXILAN - OXILAN-300</u>						
N020316 001	4954348	Dec 21, 2009				
<u>IOXILAN - OXILAN-350</u>						
N020316 002	4954348	Dec 21, 2009				



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N021527 001	5676930	Oct 14, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5695743	Jul 06, 2010	DP	U-610		
	5766573	Nov 28, 2009		U-610		
	6739333	May 26, 2020	DP			
	6983743	May 26, 2020	DP			
<u>IRBESARTAN - AVAPRO</u>						
N020757 001	5270317	Sep 30, 2011				
	5270317*PED	Mar 30, 2012				
	6342247	Jun 07, 2015				
	6342247*PED	Dec 07, 2015				
<u>IRBESARTAN - AVAPRO</u>						
N020757 002	5270317	Sep 30, 2011				
	5270317*PED	Mar 30, 2012				
	6342247	Jun 07, 2015				
	6342247*PED	Dec 07, 2015				
<u>IRBESARTAN - AVAPRO</u>						
N020757 003	5270317	Sep 30, 2011				
	5270317*PED	Mar 30, 2012				
	6342247	Jun 07, 2015				
	6342247*PED	Dec 07, 2015				
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N020571 001	6403569	Apr 28, 2020		U-449		
	6403569*PED	Oct 28, 2020				
	6794370	May 01, 2020		U-606		
	6794370*PED	Nov 01, 2020				
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N020571 002	6403569	Apr 28, 2020		U-449		
	6403569*PED	Oct 28, 2020				
	6794370	May 01, 2020		U-606		
	6794370*PED	Nov 01, 2020				
<u>IRON DEXTRAN - DEXFERRUM</u>						
A040024 001	5624668	Sep 29, 2015				
<u>ITRACONAZOLE - SPORANOX</u>						
N020083 001	5633015	May 27, 2014				
<u>ITRACONAZOLE - SPORANOX</u>						
N020657 001	5707975	Jan 13, 2015				
	6407079	Jun 18, 2019				
<u>ITRACONAZOLE - SPORANOX</u>						
N020966 001	6407079	Jun 18, 2019				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	6605599	May 26, 2018	DS DP	U-961	NCE	Oct 16, 2012
	6670384	Jan 23, 2022		U-959		
	6670384	Jan 23, 2022		U-960		
	7022330	Jan 23, 2022		U-958		
	7125899	May 26, 2018	DS DP	U-957		
	7312237	Aug 21, 2024		U-965		
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	6605599	May 26, 2018	DS DP	U-961	NCE	Oct 16, 2012
	6670384	Jan 23, 2022		U-960		
	6670384	Jan 23, 2022		U-959		
	7022330	Jan 23, 2022		U-958		
	7125899	May 26, 2018	DS DP	U-957		
	7312237	Aug 21, 2024		U-965		
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	7553835	Oct 19, 2018	DP	U-245	NDF	Jun 12, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>KETOCONAZOLE - NIZORAL A-D</u>						
N020310 001	5456851	Apr 07, 2014				
<u>KETOCONAZOLE - XOLEGEL</u>						
N021946 001	7179475	Dec 04, 2018	DP U-792		NDF	Jul 28, 2009
<u>KETOROLAC TROMETHAMINE - ACULAR</u>						
N019700 001	5110493*PED	Nov 05, 2009	U-75			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	5110493*PED	Nov 05, 2009				
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N022427 001					NP	Jul 22, 2012
<u>LACOSAMIDE - VIMPAT</u>						
N022253 001	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2017	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 002	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2017	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 003	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2017	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 004	5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	RE38551	Mar 17, 2017	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022254 001	5654301	Aug 05, 2014	DS DP U-911		NCE	Oct 28, 2013
	RE38551	Mar 17, 2017	DS DP U-911			
<u>LAMIVUDINE - EPIVIR</u>						
N020564 001	5047407	Nov 17, 2009	DS DP U-257			
	5047407*PED	May 17, 2010				
	5905082	May 18, 2016	DS DP U-248			
	5905082*PED	Nov 18, 2016				
	7119202*PED	Aug 08, 2009				
<u>LAMIVUDINE - EPIVIR</u>						
N020564 003	5047407	Nov 17, 2009				
	5047407*PED	May 17, 2010				
	5905082	May 18, 2016				
	5905082*PED	Nov 18, 2016				
	7119202*PED	Aug 08, 2009				
<u>LAMIVUDINE - EPIVIR</u>						
N020596 001	5047407	Nov 17, 2009				
	5047407*PED	May 17, 2010				
	6004968	Mar 20, 2018				
	6004968*PED	Sep 20, 2018				
	7119202*PED	Aug 08, 2009				
<u>LAMIVUDINE - EPIVIR-HBV</u>						
N021003 001	5047407	Nov 17, 2009				
	5047407*PED	May 17, 2010				
	5905082	May 18, 2016				
	5905082*PED	Nov 18, 2016				
	7119202*PED	Aug 08, 2009				
	RE39155	Jul 02, 2013	U-250			
	RE39155*PED	Jan 02, 2014				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMIVUDINE - EPIVIR-HBV</u>						
N021004 001	5047407	Nov 17, 2009				
	5047407*PED	May 17, 2010				
	6004968	Mar 20, 2018				
	6004968*PED	Sep 20, 2018				
	7119202*PED	Aug 08, 2009				
	RE39155	Jul 02, 2013		U-250		
	RE39155*PED	Jan 02, 2014				
<u>LAMIVUDINE; ZIDOVUDINE - COMBIVIR</u>						
N020857 001	5047407	Nov 17, 2009	DS DP	U-248		
	5047407*PED	May 17, 2010				
	5859021	May 15, 2012	DS DP	U-248		
	5905082	May 18, 2016	DS DP	U-248		
	5905082*PED	Nov 18, 2016		U-248		
	7119202*PED	Aug 08, 2009				
<u>LAMOTRIGINE - LAMICTAL</u>						
N020241 001					I-516 PED	Sep 22, 2009 Mar 22, 2010
<u>LAMOTRIGINE - LAMICTAL</u>						
N020241 002					I-516 PED	Sep 22, 2009 Mar 22, 2010
<u>LAMOTRIGINE - LAMICTAL</u>						
N020241 003					I-516 PED	Sep 22, 2009 Mar 22, 2010
<u>LAMOTRIGINE - LAMICTAL</u>						
N020241 004					I-516 PED	Sep 22, 2009 Mar 22, 2010
<u>LAMOTRIGINE - LAMICTAL</u>						
N020241 005					I-516 PED	Sep 22, 2009 Mar 22, 2010
<u>LAMOTRIGINE - LAMICTAL</u>						
N020241 006					I-516 PED	Sep 22, 2009 Mar 22, 2010
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N020764 001	5698226	Jan 29, 2012			I-516	Sep 22, 2009
	5698226*PED	Jul 29, 2012			PED	Mar 22, 2010
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N020764 002	5698226	Jan 29, 2012			I-516	Sep 22, 2009
	5698226*PED	Jul 29, 2012			PED	Mar 22, 2010
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N020764 003	5698226	Jan 29, 2012			I-516	Sep 22, 2009
	5698226*PED	Jul 29, 2012			PED	Mar 22, 2010
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N020764 004	5698226	Jan 29, 2012			I-516	Sep 22, 2009
	5698226*PED	Jul 29, 2012			PED	Mar 22, 2010
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 001					NDF	May 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 002					NDF	May 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 003					NDF	May 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 004					NDF	May 29, 2012

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 001	5595760	Mar 08, 2015	DP U-831		NCE ODE	Aug 30, 2012 Aug 30, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 002	5595760	Mar 08, 2015	DP U-831		NCE ODE	Aug 30, 2012 Aug 30, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 003	5595760	Mar 08, 2015	DP U-831		NCE ODE	Aug 30, 2012 Aug 30, 2014
<u>LANSOPRAZOLE - PREVACID</u>						
N020406 001	4628098*PED 5013743 5013743*PED	Nov 10, 2009 Feb 12, 2010 Aug 12, 2010		U-452	M-85 PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
N020406 002	4628098*PED 5013743 5013743*PED	Nov 10, 2009 Feb 12, 2010 Aug 12, 2010		U-452	M-85 PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
N021281 001	4628098*PED 5013743 5013743*PED	Nov 10, 2009 Feb 12, 2010 Aug 12, 2010		U-452	M-85 PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
N021281 002	4628098*PED 5013743 5013743*PED	Nov 10, 2009 Feb 12, 2010 Aug 12, 2010		U-452	M-85 PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 001	4628098*PED 5013743 5013743*PED 5464632 5464632*PED 6328994 6328994*PED 7399485 7399485*PED 7431942 7431942*PED	Nov 10, 2009 Feb 12, 2010 Aug 12, 2010 Nov 07, 2012 May 07, 2013 May 17, 2019 Nov 17, 2019 May 26, 2018 Nov 26, 2018 May 17, 2019 Nov 17, 2019		U-452       DP  DP	M-85 PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 002	4628098*PED 5013743 5013743*PED 5464632 5464632*PED 6328994 6328994*PED 7399485 7399485*PED 7431942 7431942*PED	Nov 10, 2009 Feb 12, 2010 Aug 12, 2010 Nov 07, 2012 May 07, 2013 May 17, 2019 Nov 17, 2019 May 26, 2018 Nov 26, 2018 May 17, 2019 Nov 17, 2019		U-452       DP  DP	M-85 PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID 24 HR</u>						
N022327 001					NP	May 18, 2012
<u>LANSOPRAZOLE - PREVACID IV</u>						
N021566 001	4628098*PED 7396841 7396841*PED	Nov 10, 2009 Aug 17, 2021 Feb 17, 2022		DP U-947		
<u>LANSOPRAZOLE; NAPROXEN - PREVACID NAPRAPAC 500 (COPACKAGED)</u>						
N021507 004	4628098*PED	Nov 10, 2009				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N021468 001	5968976	Oct 26, 2018	DP U-613		NCE	Oct 26, 2009
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N021468 002	5968976	Oct 26, 2018	DP U-613		NCE	Oct 26, 2009
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N021468 003	5968976	Oct 26, 2018	DP U-613		NCE	Oct 26, 2009
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N021468 004	5968976	Oct 26, 2018	DP U-613		NCE	Oct 26, 2009
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N022059 001	6391874	Jul 11, 2017	DS DP U-800		NCE	Mar 13, 2012
	6713485	Jan 08, 2019	DS DP U-800			
	6727256	Jan 08, 2019	DS DP U-800			
	6828320	Jul 11, 2017	U-800			
	7157466	Nov 19, 2021	DS DP			
<u>LATANOPROST - XALATAN</u>						
N020597 001	5296504	Mar 22, 2011	DP U-778			
	5422368	Mar 22, 2011	DP U-778	Y		
	6429226	Sep 06, 2009	DP U-778			
	7163959	Jun 19, 2010	DS			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	5635517	Oct 04, 2019	DS U-866		NCE	Dec 27, 2010
	6045501	Aug 28, 2018	U-694		ODE	Jun 29, 2013
	6281230	Jul 24, 2016	U-769		ODE	Dec 27, 2012
	6315720	Oct 23, 2020	U-694			
	6555554	Jul 24, 2016	DP			
	6561976	Aug 28, 2018	U-694			
	6561977	Oct 23, 2020	U-694			
	6755784	Oct 23, 2020	U-694			
	6908432	Aug 28, 2018	U-694			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-769			
	7465800	Apr 22, 2026	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	5635517	Oct 04, 2019	DS U-866		NCE	Dec 27, 2010
	6045501	Aug 28, 2018	U-694		ODE	Jun 29, 2013
	6281230	Jul 24, 2016	U-769		ODE	Dec 27, 2012
	6315720	Oct 23, 2020	U-694			
	6555554	Jul 24, 2016	DP			
	6561976	Aug 28, 2018	U-694			
	6561977	Oct 23, 2020	U-694			
	6755784	Oct 23, 2020	U-694			
	6908432	Aug 28, 2018	U-694			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-769			
	7465800	Apr 22, 2026	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	5635517	Oct 04, 2019	DS	U-866	NCE	Dec 27, 2010
	6045501	Aug 28, 2018		U-694	ODE	Jun 29, 2013
	6281230	Jul 24, 2016		U-769		
	6315720	Oct 23, 2020		U-694		
	6555554	Jul 24, 2016	DP			
	6561976	Aug 28, 2018		U-694		
	6561977	Oct 23, 2020		U-694		
	6755784	Oct 23, 2020		U-694		
	6908432	Aug 28, 2018		U-694		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-769		
	7465800	Apr 22, 2026	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	5635517	Oct 04, 2019	DS	U-866	NCE	Dec 27, 2010
	6045501	Aug 28, 2018		U-694	ODE	Jun 29, 2013
	6281230	Jul 24, 2016		U-769		
	6315720	Oct 23, 2020		U-694		
	6555554	Jul 24, 2016	DP			
	6561976	Aug 28, 2018		U-694		
	6561977	Oct 23, 2020		U-694		
	6755784	Oct 23, 2020		U-694		
	6908432	Aug 28, 2018		U-694		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-769		
	7465800	Apr 22, 2026	DS DP			
<u>LEPIRUDIN RECOMBINANT - REFLUDAN</u>						
N020807 001	5180668	Jan 19, 2010				
<u>LETROZOLE - FEMARA</u>						
N020726 001	4978672	Jun 03, 2011		U-203		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N021343 001	5278201	Jan 11, 2011				
	5324519	Oct 20, 2011				
	5599552	Feb 04, 2014				
	6395293	Sep 28, 2013	DP	U-801		
	6565874	Oct 28, 2018	DP	U-801		
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP	U-801		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N021379 001	5278201	Jan 11, 2011				
	5324519	Oct 20, 2011				
	5599552	Feb 04, 2014				
	6395293	Sep 28, 2013	DP			
	6565874	Oct 28, 2018	DP	U-801		
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP	U-801		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N021488 001	5278201	Jan 11, 2011				
	5324519	Oct 20, 2011				
	5599552	Feb 04, 2014				
	6395293	Sep 28, 2013	DP			
	6565874	Oct 28, 2018	DP	U-801		
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP	U-801		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N021731 001	5278201	Jan 11, 2011		DP		
	5324519	Jun 28, 2011		DP		
	5599552	Feb 04, 2014		DP	U-621	
	6395293	Sep 28, 2013		DP		
	6565874	Oct 28, 2018		DP	U-621	
	6626870	Mar 27, 2020		DP		
	6773714	Oct 28, 2018		U-621		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N019732 001	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020011 001	5575987	Sep 02, 2013				
	5631021	May 20, 2014				
	5716640	Sep 02, 2013				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020517 001	5480656	Jan 02, 2013				
	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5643607	Jan 02, 2013				
	5716640	Sep 02, 2013				
	5814342	Feb 01, 2011				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-3</u>						
N020708 001	5480656	Jan 02, 2013				
	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5643607	Jan 02, 2013				
	5716640	Sep 02, 2013				
	5814342	Feb 01, 2011				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-4</u>						
N020517 002	5480656	Jan 02, 2013				
	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5643607	Jan 02, 2013				
	5716640	Sep 02, 2013				
	5814342	Feb 01, 2011				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 002	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 003	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2013				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 004	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2013				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 005	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 006	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - VIADUR</u>						
N021088 001	5728396	Jan 30, 2017	U-316			
	5932547	Jun 13, 2017				
	5985305	Jan 30, 2017				
	6113938	Jul 24, 2018				
	6124261	Jun 13, 2017				
	6132420	Jan 30, 2017				
	6156331	Jan 30, 2017				
	6235712	Jun 13, 2017				
	6375978	Dec 17, 2018				
	6395292	Jan 30, 2017				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N020837 001	5362755	Mar 25, 2013	U-332			
	5547994	Aug 20, 2013	U-332			
	5760090	Jan 05, 2010	U-332			
	5844002	Jan 05, 2010	U-332			
	6083993	Jan 05, 2010	U-332			
	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N020837 002	5362755	Mar 25, 2013	U-332			
	5547994	Aug 20, 2013	U-332			
	5760090	Jan 05, 2010	U-332			
	5844002	Jan 05, 2010	U-332			
	6083993	Jan 05, 2010	U-332			
	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N020837 003	5362755	Mar 25, 2013	U-332			
	5547994	Aug 20, 2013	U-332			
	5760090	Jan 05, 2010	U-332			
	5844002	Jan 05, 2010	U-332			
	6083993	Jan 05, 2010	U-332			
	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N020837 004	5362755	Mar 25, 2013	U-332			
	5547994	Aug 20, 2013	U-332			
	5760090	Jan 05, 2010	U-332			
	5844002	Jan 05, 2010	U-5			
	6083993	Jan 05, 2010	U-332			
	6451289	Mar 21, 2021	DP			
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N021730 001	5225183	Jul 06, 2010	DP			
	5362755	Mar 25, 2013	U-636			
	5439670	Jul 06, 2010	DP			
	5547994	Aug 20, 2013	U-636			
	5605674	Feb 25, 2014	DP			
	5695743	Jul 06, 2010	DP	U-636		
	5760090	Jan 05, 2010	U-636			
	5836299	Nov 17, 2017	DP			
	5844002	Jan 05, 2010	U-636			
	6083993	Jan 05, 2010	U-636			
	6352684	Nov 28, 2009	DP			
	7256310	Oct 08, 2024	DS DP	U-636		
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 001					I-527	Mar 19, 2010
					I-506	Aug 15, 2009
					PED	Feb 15, 2010
					PED	Sep 19, 2010
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 002					I-527	Mar 19, 2010
					I-506	Aug 15, 2009
					PED	Feb 15, 2010
					PED	Sep 19, 2010



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - KEPPRA</u>						
N021035	003				I-527 I-506 PED PED	Mar 19, 2010 Aug 15, 2009 Feb 15, 2010 Sep 19, 2010
<u>LEVETIRACETAM - KEPPRA</u>						
N021035	004				I-527 I-506 PED PED	Mar 19, 2010 Aug 15, 2009 Feb 15, 2010 Sep 19, 2010
<u>LEVETIRACETAM - KEPPRA</u>						
N021505	001				I-527 I-506 PED PED	Mar 19, 2010 Aug 15, 2009 Feb 15, 2010 Sep 19, 2010
<u>LEVETIRACETAM - KEPPRA</u>						
N021872	001				I-563 I-544 NDF PED PED	Mar 19, 2010 Aug 15, 2009 Jul 31, 2009 Feb 15, 2010 Jan 31, 2010
<u>LEVETIRACETAM - KEPPRA XR</u>						
N022285	001				NDF	Sep 12, 2011
<u>LEVETIRACETAM - KEPPRA XR</u>						
N022285	002				NDF	Sep 12, 2011
<u>LEVOBETAXOLOL HYDROCHLORIDE - BETAXON</u>						
N021114	001	5540918	Jul 30, 2013	DP	M-54	Sep 28, 2009
		5540918*PED	Jan 30, 2014		PED	Mar 28, 2010
<u>LEVOBUPIVACAINE HYDROCHLORIDE - CHIROCAINE</u>						
N020997	001	5708011	Oct 13, 2014	U-276		
<u>LEVOBUPIVACAINE HYDROCHLORIDE - CHIROCAINE</u>						
N020997	002	5708011	Oct 13, 2014	U-276		
<u>LEVOBUPIVACAINE HYDROCHLORIDE - CHIROCAINE</u>						
N020997	003	5708011	Oct 13, 2014	U-276		
<u>LEVOCARNITINE - CARNITOR</u>						
N020182	001	6335369	Jan 18, 2021	U-433		
		6429230	Jan 18, 2021	U-433		
		6696493	Jan 18, 2021	U-433		
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022064	001	5698558	Sep 24, 2012	U-812	NPP	Aug 21, 2012
		5698558*PED	Mar 24, 2013		NP	May 25, 2010
					PED	Nov 25, 2010
					PED	Feb 21, 2013
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022157	001	5698558	Sep 24, 2012	U-852	NPP	Aug 21, 2012
		5698558*PED	Mar 24, 2013		NP	May 25, 2010
					PED	Nov 25, 2010
					PED	Feb 21, 2013
<u>LEVOFLOXACIN - IQUIX</u>						
N021571	001	5053407	Dec 20, 2010	DS DP	U-600	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N020634 001	5053407	Dec 20, 2010			D-108	Sep 14, 2010
	5053407*PED	Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N020634 002	5053407	Dec 20, 2010			D-108	Sep 14, 2010
	5053407*PED	Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N020634 003	5053407	Dec 20, 2010			D-108	Sep 14, 2010
	5053407*PED	Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N020635 001	5053407	Dec 20, 2010			D-108	Sep 14, 2010
	5053407*PED	Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N020635 004	5053407	Dec 20, 2010			D-108	Sep 14, 2010
	5053407*PED	Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N021721 001	5053407	Dec 20, 2010	DS	U-36	D-108	Sep 14, 2010
	5053407*PED	Jun 20, 2011			M-61	Sep 10, 2010
	6806256	Feb 26, 2022		DP	PED	Mar 10, 2011
	6806256*PED	Aug 26, 2022				
<u>LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER</u>						
N020635 002	5053407	Dec 20, 2010			D-108	Sep 14, 2010
	5053407*PED	Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER</u>						
N020635 003	5053407	Dec 20, 2010			D-108	Sep 14, 2010
	5053407*PED	Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER</u>						
N020635 005	5053407	Dec 20, 2010			D-108	Sep 14, 2010
	5053407*PED	Jun 20, 2011			M-61	Sep 10, 2010
					PED	Mar 10, 2011
<u>LEVOFLOXACIN - QUIXIN</u>						
N021199 001	5053407	Dec 20, 2010				
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 001	6500829	Dec 31, 2019	DS DP		NP	Mar 07, 2011
					ODE	Mar 07, 2015
<u>LEVONORGESTREL - MIRENA</u>						
N021225 001	5785053	Dec 05, 2015	DP		I-610	Oct 01, 2012
<u>LEVONORGESTREL - PLAN B</u>						
N021045 002					NP	Aug 24, 2009
<u>LEVONORGESTREL - PLAN B ONE-STEP</u>						
N021998 001					NP	Jul 10, 2012
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 001	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 002	6399101	Mar 30, 2020				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 003	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 004	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 005	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 006	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 007	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 008	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 009	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 010	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 011	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 001	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Aug 14, 2022			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 002	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Aug 14, 2022			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 003	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Aug 14, 2022			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 004	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Aug 14, 2022			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 005	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Aug 14, 2022			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 006	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Aug 14, 2022			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 007	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Aug 14, 2022			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 008	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Aug 14, 2022			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 009	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 010	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Aug 14, 2022			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 011	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Aug 14, 2022			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N021301 012	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Aug 14, 2022			U-759	
<u>LIDOCAINE - DENTIPATCH</u>						
N020575 001	5234957	Feb 27, 2011				
	5332576	Jul 26, 2011				
	5446070	Feb 27, 2011				
<u>LIDOCAINE - DENTIPATCH</u>						
N020575 002	5234957	Feb 27, 2011				
	5332576	Jul 26, 2011				
	5446070	Feb 27, 2011				
<u>LIDOCAINE - LIDODERM</u>						
N020612 001	5411738	May 02, 2012				
	5601838	May 02, 2012			U-488	
	5827529	Oct 27, 2015			U-486	
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N022221 001					NDF	Oct 07, 2011
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N022114 001	5630796	May 20, 2014			NPP	Jan 08, 2012
	5899880	May 04, 2016	DP			
	6004286	Mar 17, 2017	DP			
	6881200	Jun 11, 2016	DP			
<u>LIDOCAINE; PRILOCAINE - ORAQIX</u>						
N021451 001	6031007	Apr 01, 2017	DP		U-553	
<u>LIDOCAINE; TETRACAINE - LIDOCAINE AND TETRACAINE</u>						
N021717 001	5919479	Jul 28, 2015	DP			
	6528086	Sep 28, 2019	DP			
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N021623 001	5658583	Jul 28, 2015	DP			
	5919479	Jul 28, 2015	DP			
	6306431	Jul 28, 2015	DP			
	6465006	Jul 28, 2015	DP			
	6546281	Jul 28, 2015	DP			
	6780426	Jul 28, 2015	DP			
<u>LINEZOLID - ZYVOX</u>						
N021130 001	5688792	Nov 18, 2014	DS		U-319	
	5688792*PED	May 18, 2015				
	6514529	Mar 15, 2021		DP		
	6514529*PED	Sep 15, 2021				
	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N021130 002	5688792	Nov 18, 2014	DS		U-319	
	5688792*PED	May 18, 2015				
	6514529	Mar 15, 2021		DP		
	6514529*PED	Sep 15, 2021				
	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINEZOLID - ZYVOX</u>						
N021131 001	5688792	Nov 18, 2014	U-319			
	5688792*PED	May 18, 2015				
	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N021132 001	5688792	Nov 18, 2014	DS	U-319		
	5688792*PED	May 18, 2015				
	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7105486	Jun 29, 2023	U-727		NPP	Apr 23, 2011
	7223735	Jun 29, 2023	DP		NCE	Feb 23, 2012
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7105486	Jun 29, 2023	U-727		NPP	Apr 23, 2011
	7223735	Jun 29, 2023	DP		NCE	Feb 23, 2012
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 003	7105486	Jun 29, 2023	U-727		NPP	Apr 23, 2011
	7223735	Jun 29, 2023	DP		NCE	Feb 23, 2012
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 004	7105486	Jun 29, 2023	U-842		NPP	Apr 23, 2011
	7223735	Jun 29, 2023	DP		NCE	Feb 23, 2012
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 005	7105486	Jun 29, 2023	U-842		NPP	Apr 23, 2011
	7223735	Jun 29, 2023	DP		NCE	Feb 23, 2012
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7105486	Jun 29, 2023	U-842		NPP	Apr 23, 2011
	7223735	Jun 29, 2023	DP		NCE	Feb 23, 2012
<u>LODOXAMIDE TROMETHAMINE - ALOMIDE</u>						
N020191 001	5457126	Oct 10, 2012	U-117			
<u>LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS</u>						
N020448 001	5489436	Feb 06, 2013	DP			
	6814978	Aug 26, 2021	DP			
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMPTOM RELIEF</u>						
N020606 001	5248505	Jul 28, 2010				Y
	5489436	Feb 06, 2013				Y
	5612054	Sep 28, 2010				Y
	5679376	Oct 21, 2014				Y
	5716641	May 21, 2012	U-226			Y
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMPTOM RELIEF</u>						
N021140 001	6103260	Jul 17, 2017	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021226 001	5541206	Jul 30, 2013				
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014				
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014				
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014				
	5674882*PED	Apr 07, 2015				
	5846987	Dec 29, 2012				
	5846987*PED	Jun 29, 2013				
	5886036	Nov 19, 2013	DS DP			
	5886036*PED	May 19, 2014				
	5914332	Dec 13, 2015				
	5914332*PED	Jun 13, 2016				
	5948436	Sep 13, 2013		DP		
	5948436*PED	Mar 13, 2014				
	6037157	Jun 26, 2016				
	6037157*PED	Dec 26, 2016				
	6232333	Nov 07, 2017				
	6232333*PED	May 07, 2018				
	6284767	Feb 15, 2016		DP		U-688
	6284767	Feb 15, 2016		DP		U-401
	6284767*PED	Aug 15, 2016				
	6458818	Nov 07, 2017				
	6458818*PED	May 07, 2018				
	6521651	Nov 07, 2017		DP		
	6521651*PED	May 07, 2018				
	6703403	Jun 26, 2016				
	6703403*PED	Dec 26, 2016				
	7141593	May 22, 2020		DP		
	7141593*PED	Nov 22, 2020				
	7432294	May 22, 2020		DP		
	7432294*PED	Nov 22, 2020				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021251 001	5484801	Jan 28, 2014		DP		
	5484801*PED	Jul 28, 2014				
	5541206	Jul 30, 2013				
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014				
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014				
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014				
	5674882*PED	Apr 07, 2015				
	5846987	Dec 29, 2012				
	5846987*PED	Jun 29, 2013				
	5886036	Nov 19, 2013	DS DP			
	5886036*PED	May 19, 2014				
	5914332	Dec 13, 2015				
	5914332*PED	Jun 13, 2016				
	5948436	Sep 13, 2013		DP		
	5948436*PED	Mar 13, 2014				
	6037157	Jun 26, 2016				
	6037157*PED	Dec 26, 2016				
	6284767	Feb 15, 2016		DP		U-401
	6284767	Feb 15, 2016		DP		U-895
	6284767*PED	Aug 15, 2016				
	6703403	Jun 26, 2016				
	6703403*PED	Dec 26, 2016				
	6911214	Nov 28, 2021		DP		
	6911214*PED	May 28, 2022				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 001	5541206	Jul 30, 2013	DS DP U-688			
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014			U-688	
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014	DS DP			
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014			U-688	
	5674882*PED	Apr 07, 2015				
	5886036	Nov 19, 2013	DS DP			
	5886036*PED	May 19, 2014				
	5914332	Dec 13, 2015	DS DP U-688			
	5914332*PED	Jun 13, 2016				
	6037157	Jun 26, 2016			U-688	
	6037157*PED	Dec 26, 2016				
	6284767	Feb 15, 2016	DP U-688			
	6284767*PED	Aug 15, 2016				
	6703403	Jun 26, 2016			U-688	
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP U-688			
	7364752*PED	May 10, 2021				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 002	5541206	Jul 30, 2013	DS DP U-688			
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014			U-688	
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014	DS DP			
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014			U-688	
	5674882*PED	Apr 07, 2015				
	5886036	Nov 19, 2013	DS DP			
	5886036*PED	May 19, 2014				
	5914332	Dec 13, 2015	DS DP U-688			
	5914332*PED	Jun 13, 2016				
	6037157	Jun 26, 2016			U-688	
	6037157*PED	Dec 26, 2016				
	6284767	Feb 15, 2016	DP U-688			
	6284767*PED	Aug 15, 2016				
	6703403	Jun 26, 2016			U-688	
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP U-688			
	7364752*PED	May 10, 2021				
<u>LORATADINE - CLARITIN</u>						
N020641 002	6132758	Jun 01, 2018				
<u>LORATADINE; PSEUDOEPHEDRINE SULFATE - CLARITIN-D 24 HOUR</u>						
N020470 002	5314697	Oct 23, 2012				
<u>LOSARTAN POTASSIUM - COZAAR</u>						
N020386 001	5138069	Aug 11, 2009				
	5138069*PED	Feb 11, 2010				
	5153197	Oct 06, 2009			U-3	
	5153197*PED	Apr 06, 2010			U-3	
	5210079	May 11, 2010			U-496	
	5210079*PED	Nov 11, 2010			U-496	
	5608075	Mar 04, 2014				Y
	5608075*PED	Sep 04, 2014				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOSARTAN POTASSIUM - COZAAR</u>						
N020386 002	5138069	Aug 11, 2009				
	5138069*PED	Feb 11, 2010				
	5153197	Oct 06, 2009	U-3			
	5153197*PED	Apr 06, 2010	U-3			
	5210079	May 11, 2010	U-496			
	5210079*PED	Nov 11, 2010	U-496			
	5608075	Mar 04, 2014		Y		
	5608075*PED	Sep 04, 2014				
<u>LOSARTAN POTASSIUM - COZAAR</u>						
N020386 003	5138069	Aug 11, 2009				
	5138069*PED	Feb 11, 2010				
	5153197	Oct 06, 2009	U-3			
	5153197*PED	Apr 06, 2010	U-3			
	5210079	May 11, 2010	U-496			
	5210079*PED	Nov 11, 2010	U-496			
	5608075	Mar 04, 2014		Y		
	5608075*PED	Sep 04, 2014				
<u>LOTEPREDNOL ETABONATE - ALREX</u>						
N020803 001	4996335	Mar 09, 2012				
	5540930	Oct 25, 2013				
	5747061	Oct 25, 2013	DP U-576			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N020583 001	4996335	Mar 09, 2012				
	5540930	Oct 25, 2013				
	5747061	Oct 25, 2013	DP U-575			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N020841 001	5540930	Oct 25, 2013				
<u>LOTEPREDNOL ETABONATE; TOBRAMYCIN - ZYLET</u>						
N050804 001	4996335	Mar 09, 2012	DS DP U-920			
	5540930	Oct 25, 2013	DP			
	5747061	Oct 25, 2013	DP U-920			
<u>LOVASTATIN - ALTOPREV</u>						
N021316 001	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N021316 002	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N021316 003	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N021316 004	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 001	6080428	May 27, 2017	U-447			
	6129930	Sep 20, 2013	U-448			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	U-586			
	6818229	Feb 15, 2014	DP			
	7011848	Sep 20, 2013	U-712			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 002	6080428	May 27, 2017		U-447		
	6129930	Sep 20, 2013		U-448		
	6406715	Sep 20, 2013	DP	U-450		
	6469035	Mar 15, 2018		U-768		
	6676967	Sep 20, 2013		U-548		
	6746691	Sep 20, 2013		U-586		
	6818229	Feb 15, 2014	DP			
	7011848	Sep 20, 2013		U-712		
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 003	6080428	May 27, 2017		U-447		
	6129930	Sep 20, 2013		U-448		
	6406715	Sep 20, 2013	DP	U-450		
	6469035	Mar 15, 2018		U-768		
	6676967	Sep 20, 2013		U-548		
	6746691	Sep 20, 2013		U-586		
	7011848	Sep 20, 2013		U-712		
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 004	6406715	Sep 20, 2013		DP		
	6469035	Mar 15, 2018		U-768		
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	5284858	Jul 14, 2014	DS DP		NCE	Jan 31, 2011
	5317032	May 31, 2011	DS DP	U-717		
	6414016	Sep 05, 2020	DS DP	U-717		
	6583174	Oct 16, 2020	DS DP			
	7064148	Aug 30, 2022	DS DP	U-739		
	7417067	Oct 16, 2020	DS DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	5284858	Jul 14, 2014	DS DP		I-557	Apr 28, 2011
	5317032	May 31, 2011	DS DP	U-874	NS	Apr 28, 2011
	6414016	Sep 05, 2020	DS DP	U-874	NCE	Jan 31, 2011
	6583174	Oct 16, 2020	DS DP			
	7064148	Aug 30, 2022	DS DP	U-873		
	7417067	Oct 16, 2020	DS DP			
<u>LUTROPIN ALFA - LUVERIS</u>						
N021322 001	5767251	Jun 16, 2015	DS		ODE	Oct 08, 2011
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25</u>						
N021910 001	5945449	Oct 31, 2017	DP	U-785	ODE	Jul 26, 2013
	7300674	Mar 04, 2023	DP	U-785		
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 35</u>						
N021910 002	5945449	Oct 31, 2017	DP	U-785	ODE	Jul 26, 2013
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N022456 001	6489346	Jul 16, 2016	DP	U-1021		
	6489346	Jul 16, 2016	DP	U-588		
	6645988	Jul 16, 2016	DP			
	6699885	Jul 16, 2016	DP	U-588		
	6699885	Jul 16, 2016	DP	U-1021		
	7399772	Jul 16, 2016	DP	U-1021		
	7399772	Jul 16, 2016	DP	U-588		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N022456 002	6489346	Jul 16, 2016	DP	U-588		
	6489346	Jul 16, 2016	DP	U-1021		
	6645988	Jul 16, 2016	DP			
	6699885	Jul 16, 2016	DP	U-1021		
	6699885	Jul 16, 2016	DP	U-588		
	7399772	Jul 16, 2016	DP	U-588		
	7399772	Jul 16, 2016	DP	U-1021		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021850 001	6489346	Jul 16, 2016	DS DP			U-588
	6645988	Jul 16, 2016	DS DP			U-588
	6699885	Jul 16, 2016				U-588
	7399772	Jul 16, 2016				U-588
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021850 002	6489346	Jul 16, 2016	DS DP			U-623
	6645988	Jul 16, 2016	DS DP			U-623
	6699885	Jul 16, 2016				U-623
	7399772	Jul 16, 2016				U-623
<u>MALATHION - OVIDE</u>						
N018613 001	7560445	Feb 01, 2027	DS DP			U-986
<u>MANGAFODIPIR TRISODIUM - TESLASCAN</u>						
N020652 001	4933456	Nov 27, 2011				
	5223243	Jun 29, 2010				U-237
<u>MARAVIROC - SELZENTRY</u>						
N022128 001	6586430	Dec 01, 2019	DS DP		NCE	Aug 06, 2012
	6667314	May 25, 2021	DS DP			U-824
	7368460	Nov 25, 2022				U-824
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N022128 002	6586430	Dec 01, 2019	DS DP		NCE	Aug 06, 2012
	6667314	May 25, 2021	DS DP			U-824
	7368460	Nov 25, 2022				U-824
	7576097	May 25, 2021	DS			
<u>MECASERMIN RECOMBINANT - INCRELEX</u>						
N021839 001	5681814	Sep 18, 2017		DP		
	5824642	Jul 08, 2014			NCE	Aug 30, 2010
	6207640	Apr 07, 2014			ODE	Aug 30, 2012
<u>MECASERMIN RINFABATE RECOMBINANT - IPLEX</u>						
N021884 001	5200509	Apr 06, 2010	DS			
	5681818	Oct 28, 2014			ODE	Dec 12, 2012
						U-697
<u>MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104</u>						
N021583 001	6495534	May 15, 2020		DP		
<u>MEGESTROL ACETATE - MEGACE</u>						
N020264 001	5338732	Aug 16, 2011				
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N021778 001	5145684	Jan 25, 2011		DP		U-673
	6592903	Sep 21, 2020		DP		
	7101576	Apr 22, 2024				U-755
<u>MELOXICAM - MOBIC</u>						
N020938 001					ODE	Aug 11, 2012
					PED	Feb 11, 2013
<u>MELOXICAM - MOBIC</u>						
N020938 002					ODE	Aug 11, 2012
					PED	Feb 11, 2013
<u>MELOXICAM - MOBIC</u>						
N021530 001	6184220	Mar 25, 2019		DP		ODE
	6184220*PED	Sep 25, 2019				PED
						Aug 11, 2012
						Feb 11, 2013
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N021487 001	5061703	Apr 11, 2015				U-539
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N021487 002	5061703	Apr 11, 2015				U-539

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N021627 001	5061703	Apr 11, 2015	U-539			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N022029 001					NDF NC	Feb 20, 2011 Feb 20, 2011
<u>MEQUINOL; TRETINOIN - SOLAGE</u>						
N020922 001	5194247	Dec 10, 2013	DP U-294			
	5470567	Mar 19, 2010	U-294			
	6353029	Aug 24, 2020				
<u>MEROPENEM - MERREM I.V.</u>						
N050706 001	4943569	Jun 21, 2010	DS DP U-282			
<u>MEROPENEM - MERREM I.V.</u>						
N050706 003	4943569	Jun 21, 2010	DS DP U-282			
<u>MESALAMINE - APRISO</u>						
N022301 001	6551620	Apr 20, 2018	DS DP U-907		NP	Oct 31, 2011
<u>MESALAMINE - ASACOL</u>						
N019651 001	5541170	Jul 30, 2013	U-141			
	5541171	Jul 30, 2013	U-141			
<u>MESALAMINE - ASACOL HD</u>						
N021830 001	5541170	Jul 30, 2013	DP U-141		NP	May 29, 2011
	5541171	Jul 30, 2013	DP U-141			
	6893662	Nov 15, 2021	DP U-141			
<u>MESALAMINE - LIALDA</u>						
N022000 001	6773720	Jun 08, 2020	DP		NP	Jan 16, 2010
<u>MESNA - MESNEX</u>						
N020855 001	5252341	Jul 16, 2011				
	5262169	Jul 16, 2011				
<u>METAXALONE - SKELAXIN</u>						
N013217 001	6407128	Dec 03, 2021	U-189			
	6683102	Dec 03, 2021	U-189			
<u>METAXALONE - SKELAXIN</u>						
N013217 003	6407128	Dec 03, 2021	U-189			
	6683102	Dec 03, 2021	U-189			
	7122566	Feb 06, 2026	U-915			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 001	6099859	Mar 20, 2018	DP			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-604			
	6866866	Mar 17, 2021	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 002	6099859	Mar 20, 2018	DP			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-604			
	6866866	Mar 17, 2021	DP			
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N021202 001	6475521	Mar 19, 2018				
	6660300	Mar 19, 2018	U-542			
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N021202 004	6475521	Mar 19, 2018				
	6660300	Mar 19, 2018	U-542			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N021748 001	6340475	Sep 19, 2016	DS DP	U-669		
	6488962	Jun 20, 2020	DS DP			
	6635280	Sep 19, 2016	DS DP			
	6723340	Oct 25, 2021	DS DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N021748 002	6488962	Jun 20, 2020	DS DP			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N021591 001	6890957	Sep 14, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 001	4687777	Jan 17, 2011	DS			
	5965584	Jun 19, 2016	DP	U-679		
	6166042	Jun 19, 2016		U-679		
	6166043	Jun 19, 2016		U-679		
	6172090	Jun 19, 2016		U-679		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 002	4687777	Jan 17, 2011	DS			
	5965584	Jun 19, 2016	DP	U-679		
	6166042	Jun 19, 2016		U-679		
	6166043	Jun 19, 2016		U-679		
	6172090	Jun 19, 2016		U-679		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 001	4687777	Jan 17, 2011	DS			
	5965584	Jun 19, 2016	DP	U-973		
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016		U-973		
	6166043	Jun 19, 2016		U-973		
	6172090	Jun 19, 2016		U-973		
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021		U-974		
	6866866	Mar 17, 2021	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 002	4687777	Jan 17, 2011	DS			
	5965584	Jun 19, 2016	DP	U-973		
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016		U-973		
	6166043	Jun 19, 2016		U-973		
	6172090	Jun 19, 2016		U-973		
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021		U-974		
	6866866	Mar 17, 2021	DP			
<u>METFORMIN HYDROCHLORIDE; REPAGLINIDE - PRANDIMET</u>						
N022386 001	6677358	Jun 12, 2018	DP	U-546		
<u>METFORMIN HYDROCHLORIDE; REPAGLINIDE - PRANDIMET</u>						
N022386 002	6677358	Jun 12, 2018	DP	U-546		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 001	5002953	Sep 17, 2011	DS DP	U-690	M-62	Jan 31, 2010
	5002953	Sep 17, 2011	DS DP	U-734		
	5002953	Sep 17, 2011	DS DP	U-691		
	5002953	Sep 17, 2011	DS DP	U-493		
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP	U-734	Y	
	5741803	Apr 21, 2015	DS DP	U-493	Y	
	5741803*PED	Oct 21, 2015				
	5965584	Jun 19, 2016		U-493	Y	
	6166042	Jun 19, 2016		U-493	Y	
	6288095	Feb 11, 2017		U-493	Y	
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 002	5002953	Sep 17, 2011	DS DP U-493		M-62	Jan 31, 2010
	5002953	Sep 17, 2011	DS DP U-691			
	5002953	Sep 17, 2011	DS DP U-690			
	5002953	Sep 17, 2011	DS DP U-734			
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803*PED	Oct 21, 2015				
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 003	5002953	Sep 17, 2011	DS DP U-690		M-62	Jan 31, 2010
	5002953	Sep 17, 2011	DS DP U-493			
	5002953	Sep 17, 2011	DS DP U-691			
	5002953	Sep 17, 2011	DS DP U-734			
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5741803*PED	Oct 21, 2015				
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 004	5002953	Sep 17, 2011	DS DP U-734		M-62	Jan 31, 2010
	5002953	Sep 17, 2011	DS DP U-493			
	5002953	Sep 17, 2011	DS DP U-691			
	5002953	Sep 17, 2011	DS DP U-690			
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 005	5002953	Sep 17, 2011	DS DP U-493		M-62	Jan 31, 2010
	5002953	Sep 17, 2011	DS DP U-690			
	5002953	Sep 17, 2011	DS DP U-734			
	5002953	Sep 17, 2011	DS DP U-691			
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N022044 001	6303661	Apr 24, 2017	U-802		M-69	Oct 12, 2010
	6699871	Jul 26, 2022	DS DP U-802		M-68	Oct 12, 2010
	6890898	Feb 02, 2019	U-803		NC	Mar 30, 2010
	7078381	Feb 02, 2019	U-803			
	7125873	Jul 26, 2022	DP U-803		NCE	Oct 16, 2011
	7326708	Apr 11, 2026	DS DP U-802			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N022044 002	6303661	Apr 24, 2017	U-802		M-69	Oct 12, 2010
	6699871	Jul 26, 2022	DS DP U-802		M-68	Oct 12, 2010
	6890898	Feb 02, 2019	U-803		NC	Mar 30, 2010
	7078381	Feb 02, 2019	U-803			
	7125873	Jul 26, 2022	DP U-803		NCE	Oct 16, 2011
	7326708	Apr 11, 2026	DS DP U-802			
<u>METHYL AMINOLEVULINATE HYDROCHLORIDE - METVIXIA</u>						
N021415 001	6034267	Mar 08, 2016	U-804		M-77	Jun 26, 2011
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 001					NCE	Apr 24, 2013
<u>METHYLPHENIDATE - DAYTRANA</u>						
N021514 001	5958446	Dec 12, 2012	DP			
	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N021514 002	5958446	Dec 12, 2012	DP			
	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N021514 003	5958446	Dec 12, 2012	DP			
	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N021514 004	5958446	Dec 12, 2012	DP			
	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 001	6919373	Jul 31, 2017	U-666		M-88	Nov 04, 2012
	6919373*PED	Jan 31, 2018			NPP	Jun 27, 2011
	6930129	Jul 31, 2017	U-666			
	6930129*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 002	6919373	Jul 31, 2017	U-666		M-88	Nov 04, 2012
	6919373*PED	Jan 31, 2018			NPP	Jun 27, 2011
	6930129	Jul 31, 2017	U-666			
	6930129*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 003	6919373	Jul 31, 2017	U-666		M-88	Nov 04, 2012
	6919373*PED	Jan 31, 2018			NPP	Jun 27, 2011
	6930129	Jul 31, 2017	U-666			
	6930129*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 004	6919373	Jul 31, 2017	U-666		M-88	Nov 04, 2012
	6919373*PED	Jan 31, 2018			NPP	Jun 27, 2011
	6930129	Jul 31, 2017	U-666			
	6930129*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N021259 001	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N021259 002	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N021259 003	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N021259 004	6344215	Oct 27, 2020	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N021284 001	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N021284 002	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N021284 003	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N021284 004	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP			
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N022246 001	6413549	Jul 11, 2017	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N022246 002	6413549	Jul 11, 2017	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N021793 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N021793 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>METOPROLOL SUCCINATE - TOPROL-XL</u>						
N019962 001					M-61 PED	Jul 18, 2010 Jan 18, 2011
<u>METOPROLOL SUCCINATE - TOPROL-XL</u>						
N019962 002					M-61 PED	Jul 18, 2010 Jan 18, 2011
<u>METOPROLOL SUCCINATE - TOPROL-XL</u>						
N019962 003					M-61 PED	Jul 18, 2010 Jan 18, 2011
<u>METOPROLOL SUCCINATE - TOPROL-XL</u>						
N019962 004					M-61 PED	Jul 18, 2010 Jan 18, 2011
<u>METRONIDAZOLE - FLAGYL ER</u>						
N020868 001	6103262	Aug 15, 2017	DP	U-137		
<u>METRONIDAZOLE - METROGEL</u>						
N021789 001	6881726	Feb 21, 2022	DP	U-743		
	7348317	Feb 21, 2022	DP	U-743		
<u>METRONIDAZOLE - METROGEL-VAGINAL</u>						
N020208 001	5536743	Jul 16, 2013		U-137		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N021506 002	5376634	Dec 27, 2011	DS DP		I-554	Jan 22, 2011
	6107458	Mar 16, 2019	DS DP U-650		NCE	Mar 16, 2010
	6107458	Mar 16, 2019	DS DP U-845			
	6265536	Sep 29, 2015	DS DP U-650			
	6265536	Sep 29, 2015	DS DP U-845			
	6774104	Jan 08, 2021	DP U-845			
	6774104	Jan 08, 2021	DP U-650			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N021506 003	5376634	Dec 27, 2011	DS DP		I-554	Jan 22, 2011
	6107458	Mar 16, 2019	DS DP U-650		NCE	Mar 16, 2010
	6107458	Mar 16, 2019	DS DP U-845			
	6265536	Sep 29, 2015	DS DP U-845			
	6265536	Sep 29, 2015	DS DP U-650			
	6774104	Jan 08, 2021	DP U-845			
	6774104	Jan 08, 2021	DP U-650			
<u>MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK</u>						
N021308 001	5514698	Mar 21, 2014		Y		
	6153635	Nov 28, 2020		Y		
<u>MIGLUSTAT - ZAVESCA</u>						
N021348 001	5472969	May 13, 2013			ODE	Jul 31, 2010
	5525616	Jun 11, 2013				
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	5908838	Feb 19, 2018	U-917			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	5908838	Feb 19, 2018	U-917			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	5908838	Feb 19, 2018	U-917			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	5908838	Feb 19, 2018	U-917			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	5908838	Feb 19, 2018	U-917			
<u>MINOXIDIL - MEN'S ROGAINE</u>						
N021812 001	6946120	Apr 20, 2019	DP U-702			
<u>MIRTAZAPINE - REMERON SOLTAB</u>						
N021208 001	5178878	Jan 12, 2010				
<u>MIRTAZAPINE - REMERON SOLTAB</u>						
N021208 002	5178878	Jan 12, 2010				
<u>MIRTAZAPINE - REMERON SOLTAB</u>						
N021208 003	5178878	Jan 12, 2010				



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MODAFINIL - PROVIGIL</u>						
N020717 001	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014		U-255		
	RE37516*PED	Apr 06, 2015				
<u>MODAFINIL - PROVIGIL</u>						
N020717 002	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014		U-255		
	RE37516*PED	Apr 06, 2015				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 001	5394868	Jun 25, 2012	DP		NPP	Feb 01, 2011
	5394868*PED	Dec 25, 2012				
	5687710	Nov 18, 2014	DP			
	5687710*PED	May 18, 2015				
	5829434	Nov 03, 2015	DP			
	5829434*PED	May 03, 2016				
	5889015	Jan 27, 2014		U-645		
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP	U-645		
	6057307*PED	Jul 27, 2014				
	6240918	Feb 20, 2017	DP			
	6240918*PED	Aug 20, 2017				
	6365581	Jan 27, 2014		U-645		
	6365581*PED	Jul 27, 2014				
	6503537	Mar 17, 2018	DP			
	6503537*PED	Sep 17, 2018				
	6677322	Jan 27, 2014		U-645		
	6677322*PED	Jul 27, 2014				
	6949532	Jan 27, 2014		U-645		
	6949532*PED	Jul 27, 2014				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 002	5394868	Jun 25, 2012	DP		NPP	Feb 01, 2011
	5394868*PED	Dec 25, 2012				
	5687710	Nov 18, 2014	DP			
	5687710*PED	May 18, 2015				
	5829434	Nov 03, 2015	DP			
	5829434*PED	May 03, 2016				
	5889015	Jan 27, 2014		U-645		
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP	U-645		
	6057307*PED	Jul 27, 2014				
	6240918	Feb 20, 2017	DP			
	6240918*PED	Aug 20, 2017				
	6365581	Jan 27, 2014		U-645		
	6365581*PED	Jul 27, 2014				
	6503537	Mar 17, 2018	DP			
	6503537*PED	Sep 17, 2018				
	6677322	Jan 27, 2014		U-645		
	6677322*PED	Jul 27, 2014				
	6949532	Jan 27, 2014		U-645		
	6949532*PED	Jul 27, 2014				
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N020762 001	5837699	Jan 27, 2014	DP	U-625		
	5837699*PED	Jul 27, 2014				
	6127353	Oct 03, 2017	DS	DP		
	6127353*PED	Apr 03, 2018				
	6723713	Jan 27, 2014		U-625		
	6723713*PED	Jul 27, 2014				
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002	5565473	Feb 03, 2012	DS	DP	U-228	I-530
	5565473	Feb 03, 2012	DS	DP	U-807	Apr 13, 2010
	5565473	Feb 03, 2012	DS	DP	U-675	
	5565473*PED	Aug 03, 2012			U-228	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 001	5565473	Feb 03, 2012	DS DP U-807		I-530	Apr 13, 2010
	5565473	Feb 03, 2012	DS DP U-228			
	5565473	Feb 03, 2012	DS DP U-675			
	5565473*PED	Aug 03, 2012	U-228			
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 002	5565473	Feb 03, 2012	DS DP U-807		I-530	Apr 13, 2010
	5565473	Feb 03, 2012	DS DP U-675			
	5565473	Feb 03, 2012	DS DP U-228			
	5565473*PED	Aug 03, 2012	U-228			
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409 001	5565473	Feb 03, 2012	DS DP U-675		I-530	Apr 13, 2010
	5565473	Feb 03, 2012	DS DP U-807			
	5565473*PED	Aug 03, 2012				
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 001	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 002	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 003	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 004	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 006	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N021671 001	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931089	Jul 14, 2015	U-584			
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N021671 002	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931089	Jul 14, 2015	U-584			
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N021671 003	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931089	Jul 14, 2015	U-584			
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - KADIAN</u>						
N020616 001	5202128	Apr 13, 2010				
	5378474	Mar 23, 2010				
<u>MORPHINE SULFATE - KADIAN</u>						
N020616 002	5202128	Apr 13, 2010				
	5378474	Mar 23, 2010				
<u>MORPHINE SULFATE - KADIAN</u>						
N020616 003	5202128	Apr 13, 2010				
	5378474	Mar 23, 2010				
<u>MORPHINE SULFATE - KADIAN</u>						
N020616 004	5202128	Apr 13, 2010				
	5378474	Mar 23, 2010				
<u>MORPHINE SULFATE - KADIAN</u>						
N020616 005	5202128	Apr 13, 2010				
	5378474	Mar 23, 2010				
<u>MORPHINE SULFATE - KADIAN</u>						
N020616 006	5202128	Apr 13, 2010	DP			
	5378474	Mar 23, 2010	DP			
<u>MORPHINE SULFATE - KADIAN</u>						
N020616 007	5202128	Apr 13, 2010	DP			
	5378474	Mar 23, 2010	DP			
<u>MORPHINE SULFATE - KADIAN</u>						
N020616 008	5202128	Apr 13, 2010				
	5378474	Mar 23, 2010			DP	
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 001	5202128	Apr 13, 2010	DP	U-43	NC	Aug 13, 2012
	5378474	Mar 23, 2010	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 002	5202128	Apr 13, 2010	DP	U-43	NC	Aug 13, 2012
	5378474	Mar 23, 2010	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 003	5202128	Apr 13, 2010	DP	U-43	NC	Aug 13, 2012
	5378474	Mar 23, 2010	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 004	5202128	Apr 13, 2010	DP	U-43	NC	Aug 13, 2012
	5378474	Mar 23, 2010	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 005	5202128	Apr 13, 2010	DP	U-43	NC	Aug 13, 2012
	5378474	Mar 23, 2010	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 006	5202128	Apr 13, 2010	DP	U-43	NC	Aug 13, 2012
	5378474	Mar 23, 2010	DP			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
N021085 001	4990517	Dec 08, 2011	DS DP	U-298		
	5607942	Mar 04, 2014		U-298		
	5849752	Dec 05, 2016		U-298		
	6610327	Oct 29, 2019	DP	U-298		
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N021277 001	4990517	Dec 08, 2011	DS DP	U-298		
	5607942	Mar 04, 2014		U-298		
	5849752	Dec 05, 2016		U-298		
	6548079	Jul 25, 2020	DP	U-298		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>						
N021598 001	4990517	Dec 08, 2011	DS DP U-709			
	4990517*PED	Jun 08, 2012				
	5607942	Mar 04, 2014	DS DP U-709			
	5607942*PED	Sep 04, 2014				
	6716830	Sep 29, 2019	DP			
	6716830*PED	Mar 29, 2020				
<u>MUPIROCIN - CENTANY</u>						
N050788 001	6013657	Jul 08, 2018	DP			
<u>MYCOPHENOLATE MOFETIL - CELLCEPT</u>						
N050759 001	5688529	Nov 18, 2014	DP			
<u>MYCOPHENOLATE MOFETIL HYDROCHLORIDE - CELLCEPT</u>						
N050758 001	5543408	Sep 15, 2013	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N050791 001	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Apr 10, 2017	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N050791 002	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Apr 10, 2017	DP			
<u>NALTREXONE - VIVITROL</u>						
N021897 001	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6110503	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6264987	May 19, 2020	DP			
	6331317	Nov 12, 2019	DP			
	6379703	Dec 30, 2018	DP			
	6379704	May 19, 2020	DP			
	6395304	Nov 12, 2019	DP			
	6403114	May 02, 2017	DP			
	6495164	May 25, 2020	DP			
	6495166	Nov 12, 2019	DP			
	6534092	May 19, 2020	DP			
	6537586	Nov 12, 2019	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
	6713090	Nov 12, 2019	DP			
	6939033	Nov 12, 2019	DP			
<u>NAPROXEN SODIUM - NAPRELAN</u>						
N020353 001	5637320	Jun 10, 2014				
<u>NAPROXEN SODIUM - NAPRELAN</u>						
N020353 002	5637320	Jun 10, 2014				
<u>NAPROXEN SODIUM - NAPRELAN</u>						
N020353 003	5637320	Jun 10, 2014				
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N021926 001	6060499	Aug 14, 2017	DP U-867		NC	Apr 15, 2011
	6586458	Aug 14, 2017	DP U-867			
	7332183	Oct 02, 2025	DP U-867			
<u>NARATRIPTAN HYDROCHLORIDE - AMERGE</u>						
N020763 001	4997841	Jul 07, 2010	U-232			
<u>NARATRIPTAN HYDROCHLORIDE - AMERGE</u>						
N020763 002	4997841	Jul 07, 2010	U-232			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NATEGLINIDE - STARLIX</u>						
N021204 001	5463116	Oct 21, 2012				
	5488150	Jan 30, 2013				
	6559188	Sep 15, 2020	DP	U-827		
	6641841	Nov 14, 2017	DP	U-214		
	6844008	Nov 14, 2017	DP	U-214		
	6878749	Sep 15, 2020	DP			
	RE34878	Sep 08, 2009				
<u>NATEGLINIDE - STARLIX</u>						
N021204 002	5463116	Oct 21, 2012				
	5488150	Jan 30, 2013				
	6559188	Sep 15, 2020	DP	U-827		
	6641841	Nov 14, 2017	DP	U-214		
	6844008	Nov 14, 2017	DP	U-214		
	6878749	Sep 15, 2020	DP			
	RE34878	Sep 08, 2009				
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 002	5759580	Jun 02, 2015	DP		NCE	Dec 17, 2012
	6545040	Apr 08, 2020	DP	U-3		
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 003	5759580	Jun 02, 2015	DP		NCE	Dec 17, 2012
	6545040	Apr 08, 2020	DP	U-3		
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 004	5759580	Jun 02, 2015	DP		NCE	Dec 17, 2012
	6545040	Apr 08, 2020	DP	U-3		
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 005					NCE	Dec 17, 2012
<u>NEDOCROMIL SODIUM - ALOCRIL</u>						
N021009 001	RE38628	Aug 22, 2012		U-304		
<u>NELARABINE - ARRANON</u>						
N021877 001	5424295	Jun 13, 2012	DS DP		NCE	Oct 28, 2010
	5492897	Feb 20, 2013		U-689	ODE	Oct 28, 2012
	5747472	Feb 20, 2013		U-696		
	5747472	Feb 20, 2013		U-689		
	5747472	Feb 20, 2013		U-695		
	5821236	Feb 20, 2013		U-695		
<u>NELFINAVIR MESYLATE - VIRACEPT</u>						
N020778 001	5484926	Oct 07, 2013				
	5484926*PED	Apr 07, 2014				
	5952343	Oct 07, 2013		U-257		
	5952343*PED	Apr 07, 2014		U-257		
	6162812	Oct 07, 2013		U-248		
	6162812*PED	Apr 07, 2014		U-248		
<u>NELFINAVIR MESYLATE - VIRACEPT</u>						
N020779 001	5484926	Oct 07, 2013				
	5484926*PED	Apr 07, 2014				
	5952343	Oct 07, 2013		U-257		
	5952343*PED	Apr 07, 2014		U-257		
	6162812	Oct 07, 2013		U-248		
	6162812*PED	Apr 07, 2014		U-248		
<u>NELFINAVIR MESYLATE - VIRACEPT</u>						
N021503 001	5484926	Oct 07, 2013				
	5484926*PED	Apr 07, 2014				
	5952343	Oct 07, 2013		U-257		
	5952343*PED	Apr 07, 2014		U-257		
	6162812	Oct 07, 2013		U-248		
	6162812*PED	Apr 07, 2014		U-248		
<u>NEPAFENAC - NEVANAC</u>						
N021862 001	5475034	Jun 06, 2014		U-100	NCE	Aug 19, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NESIRITIDE RECOMBINANT - NATRECOR</u>						
N020920 001	5114923	May 19, 2014	DS DP U-855			
<u>NEVIRAPINE - VIRAMUNE</u>						
N020636 001	5366972	Nov 22, 2011	U-167			
	5366972*PED	May 22, 2012				
<u>NEVIRAPINE - VIRAMUNE</u>						
N020933 001	5366972	Nov 22, 2011				
	5366972*PED	May 22, 2012				
<u>NIACIN - NIASPAN</u>						
N020381 001	6080428	May 27, 2017	U-331			
	6129930	Sep 20, 2013	U-354			
	6406715	Sep 20, 2013	U-450			
	6746691	Sep 20, 2013	U-586			
	6818229	Feb 15, 2014	DP			
	7011848	Sep 20, 2013	U-712			
<u>NIACIN - NIASPAN</u>						
N020381 002	6080428	May 27, 2017	U-331			
	6129930	Sep 20, 2013	U-354			
	6406715	Sep 20, 2013	U-450			
	6469035	Mar 15, 2018	U-768			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	U-586			
	6818229	Feb 15, 2014	DP			
	7011848	Sep 20, 2013	U-712			
<u>NIACIN - NIASPAN</u>						
N020381 003	6080428	May 27, 2017	U-331			
	6129930	Sep 20, 2013	U-354			
	6406715	Sep 20, 2013	U-450			
	6469035	Mar 15, 2018	U-768			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	U-586			
	6818229	Feb 15, 2014	DP			
	7011848	Sep 20, 2013	U-712			
<u>NIACIN - NIASPAN</u>						
N020381 004	6080428	May 27, 2017	U-331			
	6129930	Sep 20, 2013	U-354			
	6406715	Sep 20, 2013	U-450			
	6469035	Mar 15, 2018	U-768			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	U-586			
	6818229	Feb 15, 2014	DP			
	7011848	Sep 20, 2013	U-712			
<u>NIACIN - NIASPAN TITRATION STARTER PACK</u>						
N020381 005	6080428	May 27, 2017	U-331			
	6129930	Sep 20, 2013	U-354			
	6406715	Sep 20, 2013	U-450			
	6746691	Sep 20, 2013	U-586			
	7011848	Sep 20, 2013	U-712			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 001	6080428	May 27, 2017	U-862		NC	Feb 15, 2011
	6129930	Sep 20, 2013	DP U-862			
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018	U-863			
	6676967	Sep 20, 2013	U-862			
	6746691	Sep 20, 2013	DP			
	6818229	Feb 15, 2014	DP			
	7011848	Sep 20, 2013	U-862			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 002	6080428	May 27, 2017		U-862	NC	Feb 15, 2011
	6129930	Sep 20, 2013	DP	U-862		
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018		U-863		
	6676967	Sep 20, 2013		U-862		
	6746691	Sep 20, 2013	DP			
	6818229	Feb 15, 2014	DP			
	7011848	Sep 20, 2013		U-862		
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 003	6080428	May 27, 2017		U-862	NC	Feb 15, 2011
	6129930	Sep 20, 2013	DP	U-862		
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018		U-863		
	6676967	Sep 20, 2013		U-862		
	6746691	Sep 20, 2013	DP			
	6818229	Feb 15, 2014	DP			
	7011848	Sep 20, 2013		U-862		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE</u>						
N019734 001	5164405	Nov 17, 2009				
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N019734 004	7612102	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N019734 003	7612102	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N019734 002	7612102	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N019734 005	7612102	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE SR</u>						
N020005 001	5198226	Mar 30, 2010				
<u>NICARDIPINE HYDROCHLORIDE - CARDENE SR</u>						
N020005 002	5198226	Mar 30, 2010				
<u>NICARDIPINE HYDROCHLORIDE - CARDENE SR</u>						
N020005 003	5198226	Mar 30, 2010				
<u>NICOTINE - NICODERM CQ</u>						
N020165 004	5508038	Apr 16, 2013				
<u>NICOTINE - NICODERM CQ</u>						
N020165 005	5508038	Apr 16, 2013				
<u>NICOTINE - NICODERM CQ</u>						
N020165 006	5508038	Apr 16, 2013				
<u>NICOTINE - NICOTROL</u>						
N020385 001	5656255	Aug 12, 2014				
<u>NICOTINE - NICOTROL</u>						
N020536 001	5501236	Jun 08, 2010				
	6098632	Jun 08, 2010				
<u>NICOTINE - NICOTROL</u>						
N020714 001	5167242	Jun 08, 2010				
	5400808	Jun 08, 2010				
	5501236	Jun 08, 2010				
	6098632	Jun 08, 2010				
<u>NICOTINE POLACRILEX - COMMIT</u>						
N021330 001	5110605	Aug 21, 2010				
<u>NICOTINE POLACRILEX - COMMIT</u>						
N021330 001	5110605	Aug 21, 2010				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N022360 001	5110605	Aug 21, 2010	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N022360 002	5110605	Aug 21, 2010	DP			
<u>NIFEDIPINE - ADALAT CC</u>						
N020198 001	5264446	Nov 23, 2010				
<u>NIFEDIPINE - ADALAT CC</u>						
N020198 002	5264446	Nov 23, 2010				
<u>NIFEDIPINE - ADALAT CC</u>						
N020198 003	5264446	Nov 23, 2010				
<u>NIFEDIPINE - PROCARDIA XL</u>						
N019684 001	5264446	Nov 23, 2010				
<u>NIFEDIPINE - PROCARDIA XL</u>						
N019684 002	5264446	Nov 23, 2010				
<u>NIFEDIPINE - PROCARDIA XL</u>						
N019684 003	5264446	Nov 23, 2010				
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 001	7169791	Jul 04, 2023	DS DP U-836		NCE ODE	Oct 29, 2012 Oct 29, 2014
<u>NISOLDIPINE - SULAR</u>						
N020356 005	5422123 5626874	Jun 06, 2012 Nov 30, 2014	DP DP			
<u>NISOLDIPINE - SULAR</u>						
N020356 006	5422123 5626874	Jun 06, 2012 Nov 30, 2014	DP DP			
<u>NISOLDIPINE - SULAR</u>						
N020356 007	5422123 5626874	Jun 06, 2012 Nov 30, 2014	DP DP			
<u>NISOLDIPINE - SULAR</u>						
N020356 008	5422123 5626874	Jun 06, 2012 Nov 30, 2014	DP DP			
<u>NITAZOXANIDE - ALINIA</u>						
N021497 001	5387598 5578621 5968961 6020353	Feb 07, 2012 Nov 26, 2013 May 07, 2017 Sep 18, 2014	DP U-524 DP U-525 DP DS DP		ODE	Nov 22, 2009
<u>NITAZOXANIDE - ALINIA</u>						
N021498 001	5387598 5578621 5965590 5968961 6020353 6117894	Feb 07, 2012 Sep 08, 2014 Jul 03, 2017 May 07, 2017 Sep 08, 2014 May 07, 2017	U-524 U-525 U-523		ODE ODE	Nov 22, 2009 Nov 22, 2009
<u>NITISINONE - ORFADIN</u>						
N021232 001	5550165	Aug 27, 2013				
<u>NITISINONE - ORFADIN</u>						
N021232 002	5550165	Aug 27, 2013				
<u>NITISINONE - ORFADIN</u>						
N021232 003	5550165	Aug 27, 2013				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 002	5485827 5873359	Jan 23, 2013 Jan 23, 2013	U-297 U-297			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N020845 003	5485827	Jan 23, 2013	U-297			
	5873359	Jan 23, 2013	U-297			
<u>NITROGLYCERIN - NITRO-DUR</u>						
N020145 001	5186938	Feb 16, 2010				
<u>NITROGLYCERIN - NITRO-DUR</u>						
N020145 002	5186938	Feb 16, 2010				
<u>NITROGLYCERIN - NITRO-DUR</u>						
N020145 003	5186938	Feb 16, 2010				
<u>NITROGLYCERIN - NITRO-DUR</u>						
N020145 004	5186938	Feb 16, 2010				
<u>NITROGLYCERIN - NITRO-DUR</u>						
N020145 005	5186938	Feb 16, 2010				
<u>NITROGLYCERIN - NITRO-DUR</u>						
N020145 006	5186938	Feb 16, 2010				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705 002	5186925	Mar 06, 2011	DP			
<u>NITROGLYCERIN - NITROMIST</u>						
N021780 001	5869082	Apr 16, 2016	DP		NP	Nov 02, 2009
<u>NITROGLYCERIN - NITROSTAT</u>						
N021134 001	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N021134 002	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N021134 003	6500456	Sep 16, 2018				
<u>NIZATIDINE - AXID</u>						
N021494 001	6930119	Jul 17, 2022	DP			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N019667 001	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N019667 002	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N019667 003	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N019667 004	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N019667 005	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N021008 001	5538739	Jul 23, 2013	DP		M-73	Mar 03, 2011
	5538739*PED	Jan 23, 2014			PED	Nov 10, 2009
	5639480	Jun 17, 2014	DP			
	5639480*PED	Dec 17, 2014				
	5688530	Nov 18, 2014		U-268		
	5688530*PED	May 18, 2015				
	5922338	Jul 13, 2016	DP			
	5922338*PED	Jan 13, 2017				
	5922682	Jul 13, 2016	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N021008 002	5538739	Jul 23, 2013			M-73	Mar 03, 2011
	5538739*PED	Jan 23, 2014			PED	Nov 10, 2009
	5639480	Jun 17, 2014	DP			
	5639480*PED	Dec 17, 2014				
	5688530	Nov 18, 2014		U-268		
	5688530*PED	May 18, 2015				
	5922338	Jul 13, 2016	DP			
	5922338*PED	Jan 13, 2017				
	5922682	Jul 13, 2016	DP			
	5922682*PED	Jan 13, 2017				
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N021008 003	5538739	Jul 23, 2013			M-73	Mar 03, 2011
	5538739*PED	Jan 23, 2014			PED	Nov 25, 2009
	5639480	Jun 17, 2014	DP			
	5639480*PED	Dec 17, 2014				
	5688530	Nov 18, 2014		U-268		
	5688530*PED	May 18, 2015				
	5922338	Jul 13, 2016	DP			
	5922338*PED	Jan 13, 2017				
	5922682	Jul 13, 2016	DP			
	5922682*PED	Jan 13, 2017				
<u>OFLOXACIN - FLOXIN OTIC</u>						
N020799 001	5401741	Mar 27, 2012		U-407		
<u>OLANZAPINE - ZYPREXA</u>						
N020592 001	5229382	Apr 23, 2011	DS DP	U-149	I-591	Mar 19, 2012
	5229382	Apr 23, 2011	DS DP	U-547	NPP	Dec 04, 2012
	5229382*PED	Oct 23, 2011			NPP	Dec 04, 2012
	5605897	Feb 25, 2014		U-176	PED	Jun 04, 2013
	5605897*PED	Aug 25, 2014			PED	Jun 04, 2013
	5627178	Apr 23, 2011		U-364		
	5627178*PED	Oct 23, 2011				
	5736541	Mar 24, 2015		U-307		
	5736541*PED	Sep 24, 2015				
	5817655	Apr 23, 2011		U-364		
	5817655*PED	Oct 23, 2011				
	5817656	Apr 23, 2011		U-360		
	5817656*PED	Oct 23, 2011				
	5817657	Apr 23, 2011		U-363		
	5817657*PED	Oct 23, 2011				
	5919485	Mar 24, 2015		U-308		
	5919485*PED	Sep 24, 2015				
	6251895	Sep 23, 2017				
	6251895*PED	Mar 23, 2018				
	6960577	Nov 01, 2017		U-963		
<u>OLANZAPINE - ZYPREXA</u>						
N020592 002	5229382	Apr 23, 2011	DS DP	U-547	I-591	Mar 19, 2012
	5229382	Apr 23, 2011	DS DP	U-149	NPP	Dec 04, 2012
	5229382*PED	Oct 23, 2011			NPP	Dec 04, 2012
	5605897	Feb 25, 2014		U-176	PED	Jun 04, 2013
	5605897*PED	Aug 25, 2014			PED	Jun 04, 2013
	5627178	Apr 23, 2011		U-364		
	5627178*PED	Oct 23, 2011				
	5736541	Mar 24, 2015		U-307		
	5736541*PED	Sep 24, 2015				
	5817655	Apr 23, 2011		U-364		
	5817655*PED	Oct 23, 2011				
	5817656	Apr 23, 2011		U-360		
	5817656*PED	Oct 23, 2011				
	5817657	Apr 23, 2011		U-363		
	5817657*PED	Oct 23, 2011				
	5919485	Mar 24, 2015		U-308		
	5919485*PED	Sep 24, 2015				
	6251895	Sep 23, 2017				
	6251895*PED	Mar 23, 2018				
	6960577	Nov 01, 2017		U-963		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE - ZYPREXA</u>						
N020592 003	5229382	Apr 23, 2011	DS DP U-149		I-591	Mar 19, 2012
	5229382	Apr 23, 2011	DS DP U-547		NPP	Dec 04, 2012
	5229382*PED	Oct 23, 2011			NPP	Dec 04, 2012
	5605897	Feb 25, 2014	U-176		PED	Jun 04, 2013
	5605897*PED	Aug 25, 2014			PED	Jun 04, 2013
	5627178	Apr 23, 2011	U-364			
	5627178*PED	Oct 23, 2011				
	5736541	Mar 24, 2015	U-307			
	5736541*PED	Sep 24, 2015				
	5817655	Apr 23, 2011	U-364			
	5817655*PED	Oct 23, 2011				
	5817656	Apr 23, 2011	U-360			
	5817656*PED	Oct 23, 2011				
	5817657	Apr 23, 2011	U-363			
	5817657*PED	Oct 23, 2011				
	5919485	Mar 24, 2015	U-308			
	5919485*PED	Sep 24, 2015				
	6251895	Sep 23, 2017				
	6251895*PED	Mar 23, 2018				
	6960577	Nov 01, 2017	U-963			
<u>OLANZAPINE - ZYPREXA</u>						
N020592 004	5229382	Apr 23, 2011	DS DP U-547		I-591	Mar 19, 2012
	5229382	Apr 23, 2011	DS DP U-149		NPP	Dec 04, 2012
	5229382*PED	Oct 23, 2011			NPP	Dec 04, 2012
	5605897	Feb 25, 2014	U-176		PED	Jun 04, 2013
	5605897*PED	Aug 25, 2014			PED	Jun 04, 2013
	5627178	Apr 23, 2011	U-364			
	5627178*PED	Oct 23, 2011				
	5736541	Mar 24, 2015	U-307			
	5736541*PED	Sep 24, 2015				
	5817655	Apr 23, 2011	U-364			
	5817655*PED	Oct 23, 2011				
	5817656	Apr 23, 2011	U-360			
	5817656*PED	Oct 23, 2011				
	5817657	Apr 23, 2011	U-363			
	5817657*PED	Oct 23, 2011				
	5919485	Mar 24, 2015	U-308			
	5919485*PED	Sep 24, 2015				
	6251895	Sep 23, 2017				
	6251895*PED	Mar 23, 2018				
	6960577	Nov 01, 2017	U-963			
<u>OLANZAPINE - ZYPREXA</u>						
N020592 005	5229382	Apr 23, 2011	DS DP U-547		I-591	Mar 19, 2012
	5229382	Apr 23, 2011	DS DP U-149		NPP	Dec 04, 2012
	5229382*PED	Oct 23, 2011			NPP	Dec 04, 2012
	5605897	Feb 25, 2014	U-176		PED	Jun 04, 2013
	5605897*PED	Aug 25, 2014			PED	Jun 04, 2013
	5627178	Apr 23, 2011	U-364			
	5627178*PED	Oct 23, 2011				
	5736541	Mar 24, 2015	U-307			
	5736541*PED	Sep 24, 2015				
	5817655	Apr 23, 2011	U-364			
	5817655*PED	Oct 23, 2011				
	5817656	Apr 23, 2011	U-360			
	5817656*PED	Oct 23, 2011				
	5817657	Apr 23, 2011	U-363			
	5817657*PED	Oct 23, 2011				
	5919485	Mar 24, 2015	U-308			
	5919485*PED	Sep 24, 2015				
	6251895	Sep 23, 2017				
	6251895*PED	Mar 23, 2018				
	6960577	Nov 01, 2017	U-963			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE - ZYPREXA</u>						
N020592 006	5229382	Apr 23, 2011	DS DP U-149		I-591	Mar 19, 2012
	5229382	Apr 23, 2011	DS DP U-547		NPP	Dec 04, 2012
	5229382*PED	Oct 23, 2011			NPP	Dec 04, 2012
	5605897	Feb 25, 2014	U-176		PED	Jun 04, 2013
	5605897*PED	Aug 25, 2014			PED	Jun 04, 2013
	5627178	Apr 23, 2011	U-364			
	5627178*PED	Oct 23, 2011				
	5736541	Mar 24, 2015	U-307			
	5736541*PED	Sep 24, 2015				
	5817655	Apr 23, 2011	U-364			
	5817655*PED	Oct 23, 2011				
	5817656	Apr 23, 2011	U-360			
	5817656*PED	Oct 23, 2011				
	5817657	Apr 23, 2011	U-363			
	5817657*PED	Oct 23, 2011				
	5919485	Mar 24, 2015	U-308			
	5919485*PED	Sep 24, 2015				
	6251895	Sep 23, 2017				
	6251895*PED	Mar 23, 2018				
	6960577	Nov 01, 2017	U-963			
<u>OLANZAPINE - ZYPREXA</u>						
N021253 001	5229382	Apr 23, 2011	DS DP U-571			
	5229382*PED	Oct 23, 2011				
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 001	5229382	Apr 23, 2011	U-324		I-591	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	6960577	Nov 01, 2017	U-964			
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 002	5229382	Apr 23, 2011	U-324		I-591	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	6960577	Nov 01, 2017	U-964			
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 003	5229382	Apr 23, 2011	U-324		I-591	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	6960577	Nov 01, 2017	U-964			
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 004	5229382	Apr 23, 2011	U-324		I-591	Mar 19, 2012
	5229382*PED	Oct 23, 2011				
	6960577	Nov 01, 2017	U-964			
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N022173 001	5229382	Apr 23, 2011	DS DP U-1026		NP	Dec 11, 2012
	5229382	Apr 23, 2011	DS DP U-543			
	5229382*PED	Oct 23, 2011				
	6169084	Sep 30, 2018	DP U-1026			
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N022173 002	5229382	Apr 23, 2011	DS DP U-1026		NP	Dec 11, 2012
	5229382	Apr 23, 2011	DS DP U-543			
	5229382*PED	Oct 23, 2011				
	6169084	Sep 30, 2018	DP U-1026			
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N022173 003	5229382	Apr 23, 2011	DS DP U-543		NP	Dec 11, 2012
	5229382	Apr 23, 2011	DS DP U-1026			
	5229382*PED	Oct 23, 2011				
	6169084	Sep 30, 2018	DP U-1026			
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 001	5616599	Apr 25, 2016	DS DP U-500			
	5616599*PED	Oct 25, 2016				
	6878703	Nov 19, 2021	U-3	Y		
	6878703*PED	May 19, 2022				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 003	5616599	Apr 25, 2016	DS DP U-500			
	5616599*PED	Oct 25, 2016				
	6878703	Nov 19, 2021		U-3	Y	
	6878703*PED	May 19, 2022				
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 004	5616599	Apr 25, 2016	DS DP U-500			
	5616599*PED	Oct 25, 2016				
	6878703	Nov 19, 2021		U-3	Y	
	6878703*PED	May 19, 2022				
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N021545 001	5116863	Dec 18, 2010	DS DP			
	5116863*PED	Jun 18, 2011				
	5641805	Jun 06, 2015			U-765	
	5641805*PED	Dec 06, 2015				
	6995186	Nov 12, 2023		DP	U-765	
	6995186*PED	May 12, 2024				
	7402609	Jun 19, 2022		DP		
	7402609*PED	Dec 19, 2022				
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N021861 001	5116863	Dec 18, 2010	DS DP		NPP	Dec 01, 2012
	5116863*PED	Jun 18, 2011			NDF	Apr 15, 2011
					PED	Jun 01, 2013
					PED	Oct 15, 2011
<u>OLOPATADINE HYDROCHLORIDE - PATANOL</u>						
N020688 001	5116863	Dec 18, 2010				
	5116863*PED	Jun 18, 2011				
	5641805	Jun 06, 2015			U-184	
	5641805*PED	Dec 06, 2015				
<u>OMEGA-3-ACID ETHYL ESTERS - LOVAZA</u>						
N021654 001	5502077	Mar 26, 2013	DS		M-87	Sep 16, 2012
	5656667	Apr 10, 2017	DS DP		M-64	Jun 12, 2010
	5698594	Aug 04, 2009	DS		NCE	Nov 10, 2009
<u>OMEPRAZOLE - PRILOSEC</u>						
N019810 001	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6150380	Nov 10, 2018				
	6150380*PED	May 10, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				
<u>OMEPRAZOLE - PRILOSEC</u>						
N019810 002	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6150380	Nov 10, 2018				
	6150380*PED	May 10, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				
<u>OMEPRAZOLE - PRILOSEC</u>						
N019810 003	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6150380	Nov 10, 2018				
	6150380*PED	May 10, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE MAGNESIUM - OMEPRAZOLE MAGNESIUM</u>						
A078878	001				PC	Jun 07, 2010
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N022056	001	5690960	Nov 25, 2014	DP	U-864	NPP Mar 20, 2011
		5900424	May 04, 2016	DS	U-864	PED Sep 20, 2011
		6428810	Nov 03, 2019	DP	U-864	
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N022056	002	5690960	Nov 25, 2014	DP	U-864	NPP Mar 20, 2011
		5900424	May 04, 2016	DS	U-864	PED Sep 20, 2011
		6428810	Nov 03, 2019	DP	U-864	
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC OTC</u>						
N021229	001	5690960	Nov 25, 2014			
		5753265	Jun 07, 2015			
		5817338	Oct 06, 2015			
		5900424	May 04, 2016			
		6403616	Nov 15, 2019			
		6428810	Nov 03, 2019			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021636	001	5840737	Jul 16, 2016		U-588	
		6489346	Jul 16, 2016	DS DP	U-588	
		6645988	Jul 16, 2016	DS DP		
		6699885	Jul 16, 2016		U-588	
		6780882	Jul 16, 2016	DS DP		
		7399772	Jul 16, 2016		U-588	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021636	002	5840737	Jul 16, 2016		U-623	
		5840737	Jul 16, 2016		U-624	
		6489346	Jul 16, 2016	DS DP	U-624	
		6489346	Jul 16, 2016	DS DP	U-623	
		6645988	Jul 16, 2016	DS DP		
		6699885	Jul 16, 2016		U-623	
		6699885	Jul 16, 2016		U-624	
		6780882	Jul 16, 2016	DS DP		
		7399772	Jul 16, 2016		U-623	
		7399772	Jul 16, 2016		U-624	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021849	001	6489346	Jul 16, 2016	DS DP	U-588	
		6645988	Jul 16, 2016	DS DP		
		6699885	Jul 16, 2016		U-588	
		7399772	Jul 16, 2016		U-588	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021849	002	6489346	Jul 16, 2016	DS DP	U-623	
		6645988	Jul 16, 2016	DS DP		
		6699885	Jul 16, 2016		U-623	
		7399772	Jul 16, 2016		U-623	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N022281	001	6489346	Jul 15, 2016	DP	U-1025	
		6645988	Jul 15, 2016	DP		
		6699885	Jul 15, 2016	DP		
		7399772	Jul 15, 2016		U-1025	
<u>ONDANSETRON - ZOFRAN ODT</u>						
N020781	001	5955488	Nov 14, 2015			
		5955488*PED	May 14, 2016			
		6063802	Nov 14, 2015			
		6063802*PED	May 14, 2016			
<u>ONDANSETRON - ZOFRAN ODT</u>						
N020781	002	5955488	Nov 14, 2015			
		5955488*PED	May 14, 2016			
		6063802	Nov 14, 2015			
		6063802*PED	May 14, 2016			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ONDANSETRON HYDROCHLORIDE - ZOFRAN</u>						
N020103 001	5344658	Sep 06, 2011				
	5344658*PED	Mar 06, 2012				
<u>ONDANSETRON HYDROCHLORIDE - ZOFRAN</u>						
N020103 002	5344658	Sep 06, 2011				
	5344658*PED	Mar 06, 2012				
<u>ONDANSETRON HYDROCHLORIDE - ZOFRAN</u>						
N020103 003	5344658	Sep 06, 2011				
	5344658*PED	Mar 06, 2012				
<u>ONDANSETRON HYDROCHLORIDE - ZOFRAN</u>						
N020605 001	5854270	Nov 20, 2015	DP U-44			
	5854270*PED	May 20, 2016				
<u>ORLISTAT - ALLI</u>						
N021887 001	6004996	Jan 06, 2018	DP		NP	Feb 07, 2010
<u>ORLISTAT - XENICAL</u>						
N020766 001	4598089*PED	Dec 18, 2009				
	6004996	Jan 06, 2018				
	6004996*PED	Jul 06, 2018				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 001	5763483	Dec 27, 2016				
	5763483*PED	Jun 27, 2017				
	5866601	Feb 02, 2016				
	5866601*PED	Aug 02, 2016				
	5952375	Feb 02, 2016				
	5952375*PED	Aug 02, 2016				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 001	5763483	Dec 27, 2016	U-376			
	5763483*PED	Jun 27, 2017				
	5866601	Feb 02, 2016				
	5866601*PED	Aug 02, 2016				
	5952375	Feb 02, 2016				
	5952375*PED	Aug 02, 2016				
<u>OXALIPLATIN - ELOXATIN</u>						
N021492 001	5290961	Jan 12, 2013	DS		M-61	Jan 10, 2010
	5290961*PED	Jul 12, 2013			PED	Jul 10, 2010
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
<u>OXALIPLATIN - ELOXATIN</u>						
N021492 002	5290961	Jan 12, 2013	DS		M-61	Jan 10, 2010
	5290961*PED	Jul 12, 2013			PED	Jul 10, 2010
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
<u>OXALIPLATIN - ELOXATIN</u>						
N021759 001	5290961	Jan 12, 2013	DS			
	5290961*PED	Jul 12, 2013				
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
	5716988	Aug 07, 2015		DP		
	5716988*PED	Feb 07, 2016				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXALIPLATIN - ELOXATIN</u>						
N021759 002	5290961	Jan 12, 2013	DS			
	5290961*PED	Jul 12, 2013				
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
	5716988	Aug 07, 2015		DP		
	5716988*PED	Feb 07, 2016				
<u>OXALIPLATIN - ELOXATIN</u>						
N021759 003	5290961	Jan 12, 2013	DS			
	5290961*PED	Jul 12, 2013				
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
	5716988	Aug 07, 2015		DP		
	5716988*PED	Feb 07, 2016				
<u>OXANDROLONE - OXANDRIN</u>						
N013718 001	5872147	Dec 05, 2017		U-585		
	6090799	Jul 18, 2017		U-585		
	6576659	Dec 05, 2017		U-585		
	6670351	Oct 20, 2012		U-585		
	6828313	Dec 05, 2017		U-585		
<u>OXANDROLONE - OXANDRIN</u>						
N013718 002	5872147	Dec 05, 2017		U-585		
	6090799	Jul 18, 2017		U-585		
	6576659	Dec 05, 2017		U-585		
	6670351	Oct 20, 2012		U-585		
	6828313	Dec 05, 2017		U-585		
<u>OXAPROZIN POTASSIUM - DAYPRO ALTA</u>						
N020776 001	6030643	May 16, 2017		U-497		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021014 001	7037525	Feb 12, 2018		U-724		
	7037525*PED	Aug 12, 2018				
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021014 002	7037525	Feb 12, 2018		U-724		
	7037525*PED	Aug 12, 2018				
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021014 003	7037525	Feb 12, 2018		U-724		
	7037525*PED	Aug 12, 2018				
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285 001	7037525	Feb 12, 2018		U-724		
	7037525*PED	Aug 12, 2018				
<u>OXYBUTYNIN - OXYTROL</u>						
N021351 002	5164190	Dec 11, 2010				
	5601839	Apr 26, 2015				
	5834010	Apr 26, 2015				
	6743441	Apr 26, 2020	DP	U-318		
	7081249	Apr 26, 2020	DP	U-318		
	7081250	Apr 26, 2020	DP	U-318		
	7081251	Apr 26, 2020	DP	U-318		
	7081252	Apr 26, 2020	DP	U-318		
	7179483	Apr 26, 2020	DS DP	U-318		



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N020897 001	5674895	May 22, 2015				
	5674895*PED	Nov 22, 2015				
	5840754	May 22, 2015				
	5840754*PED	Nov 22, 2015				
	5912268	May 22, 2015				
	5912268*PED	Nov 22, 2015				
	6262115	May 22, 2015		U-393		
	6262115*PED	Nov 22, 2015		U-393		
	6919092	May 22, 2015	DP	U-667		
	6919092*PED	Nov 22, 2015				
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N020897 002	5674895	May 22, 2015				
	5674895*PED	Nov 22, 2015				
	5840754	May 22, 2015				
	5840754*PED	Nov 22, 2015				
	5912268	May 22, 2015				
	5912268*PED	Nov 22, 2015				
	6262115	May 22, 2015		U-393		
	6262115*PED	Nov 22, 2015		U-393		
	6919092	May 22, 2015	DP	U-667		
	6919092*PED	Nov 22, 2015				
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N020897 003	5674895	May 22, 2015				
	5674895*PED	Nov 22, 2015				
	5840754	May 22, 2015				
	5840754*PED	Nov 22, 2015				
	5912268	May 22, 2015				
	5912268*PED	Nov 22, 2015				
	6262115	May 22, 2015		U-393		
	6262115*PED	Nov 22, 2015		U-393		
	6919092	May 22, 2015	DP	U-667		
	6919092*PED	Nov 22, 2015				
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N022204 001	7029694	Apr 26, 2020	DP	U-318	NDF	Jan 27, 2012
	7179483	Apr 26, 2020		U-318		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 001	5508042	Apr 16, 2013		U-443		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 002	5508042	Apr 16, 2013		U-443		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 003	5508042	Apr 16, 2013		U-443		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 004	5508042	Apr 16, 2013		U-443		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 005	5508042	Apr 16, 2013		U-443		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 006	5508042	Apr 16, 2013		U-443		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 007	5508042	Apr 16, 2013		U-443		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 008	5508042	Apr 16, 2013		U-443		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 001	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Jul 03, 2022	DP	U-826		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 002	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Jul 03, 2022	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 003	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Jul 03, 2022	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 004	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Jul 03, 2022	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 005	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Jul 03, 2022	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 006	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Jul 03, 2022	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 007	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Jul 03, 2022	DP U-826			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	5439686	Feb 22, 2013	DP			
	5498421	Mar 12, 2013	DP U-634			
	6096331	Feb 22, 2013	DP U-633			
	6506405	Feb 22, 2013	DP U-633			
	6537579	Feb 22, 2013	DP U-632			
	6749868	Feb 22, 2013	DP			
	6753006	Feb 22, 2013	DP			
<u>PALIPERIDONE - INVEGA</u>						
N021999 001	5158952	Apr 09, 2012	DP U-90		I-605	Jul 31, 2012
					I-606	Jul 31, 2012
					I-531	Apr 27, 2010
					NCE	Dec 19, 2011
<u>PALIPERIDONE - INVEGA</u>						
N021999 002	5158952	Apr 09, 2012	DP U-90		I-605	Jul 31, 2012
					I-606	Jul 31, 2012
					I-531	Apr 27, 2010
					NCE	Dec 19, 2011
<u>PALIPERIDONE - INVEGA</u>						
N021999 003	5158952	Apr 09, 2012	DP U-90		I-605	Jul 31, 2012
					I-606	Jul 31, 2012
					I-531	Apr 27, 2010
					NCE	Dec 19, 2011
<u>PALIPERIDONE - INVEGA</u>						
N021999 004	5158952	Apr 09, 2012	DP U-90		I-531	Apr 27, 2010
					NCE	Dec 19, 2011
<u>PALIPERIDONE - INVEGA</u>						
N021999 006	5158952	Apr 09, 2012	DP U-90		I-605	Jul 31, 2012
					I-606	Jul 31, 2012
					I-531	Apr 27, 2010
					NCE	Dec 19, 2011

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 001	5254556	Oct 27, 2010	DS DP U-543		NDF	Jul 31, 2012
	5352459	Dec 16, 2012	DP		NCE	Dec 19, 2011
	6077843	May 12, 2017	DP U-543			
	6555544	Nov 10, 2018	DP U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 002	5254556	Oct 27, 2010	DS DP U-543		NDF	Jul 31, 2012
	5352459	Dec 16, 2012	DP		NCE	Dec 19, 2011
	6077843	May 12, 2017	DP U-543			
	6555544	Nov 10, 2018	DP U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 003	5254556	Oct 27, 2010	DS DP U-543		NDF	Jul 31, 2012
	5352459	Dec 16, 2012	DP		NCE	Dec 19, 2011
	6077843	May 12, 2017	DP U-543			
	6555544	Nov 10, 2018	DP U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 004	5254556	Oct 27, 2010	DS DP U-543		NDF	Jul 31, 2012
	5352459	Dec 16, 2012	DP		NCE	Dec 19, 2011
	6077843	May 12, 2017	DP U-543			
	6555544	Nov 10, 2018	DP U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 005	5254556	Oct 27, 2010	DS DP U-543		NDF	Jul 31, 2012
	5352459	Dec 16, 2012	DP		NCE	Dec 19, 2011
	6077843	May 12, 2017	DP U-543			
	6555544	Nov 10, 2018	DP U-543			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 001	5202333	Apr 13, 2015	DS DP U-528			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 002	5202333	Apr 13, 2015	DS DP U-901		I-556 NS	Mar 01, 2011 Mar 01, 2011
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N022233 001	5202333	Apr 13, 2015	DS DP U-528		NDF	Aug 22, 2011
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 001					NCE	Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 002					NCE	Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 003					NCE	Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 001					NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 002					NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 003					NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 004					NCE	Aug 27, 2014
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N020987 001	4758579	Jul 19, 2010			I-614	Nov 12, 2012
	4758579*PED	Jan 19, 2011			M-54	Nov 12, 2012
	5997903	Dec 07, 2016			PED	May 12, 2013
	5997903*PED	Jun 07, 2017			PED	May 12, 2013

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N020987 002	4758579	Jul 19, 2010			I-614	Nov 12, 2012
	4758579*PED	Jan 19, 2011			M-54	Nov 12, 2012
	5997903	Dec 07, 2016			PED	May 12, 2013
	5997903*PED	Jun 07, 2017			PED	May 12, 2013
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N022020 001	4758579	Jul 19, 2010	DS DP	U-859	I-614	Nov 12, 2012
	4758579*PED	Jan 19, 2011			M-54	Nov 12, 2012
	7544370	Feb 07, 2026	DP		PED	May 12, 2013
	7544370*PED	Aug 07, 2026			PED	May 12, 2013
	7550153	Sep 30, 2024		U-859		
	7550153*PED	Mar 30, 2025				
	7553498	Sep 30, 2024		U-859		
	7553498*PED	Mar 30, 2025				
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N020988 001	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	6780881	Nov 17, 2021		DP		
	6780881*PED	May 17, 2022				
	7351723	Nov 17, 2021		DP		
	7351723*PED	May 17, 2022				
<u>PARICALCITOL - ZEMPLAR</u>						
N020819 001	5246925	Apr 17, 2012		U-314		
	5246925*PED	Oct 17, 2012				
	5587497	Dec 24, 2013				
	5587497*PED	Jun 24, 2014				
	6136799	Apr 08, 2018				
	6136799*PED	Oct 08, 2018				
	6361758	Apr 08, 2018		DP		
	6361758*PED	Oct 08, 2018				
<u>PARICALCITOL - ZEMPLAR</u>						
N020819 002	5246925	Apr 17, 2012		U-314		
	5246925*PED	Oct 17, 2012				
	5587497	Dec 24, 2013				
	5587497*PED	Jun 24, 2014				
	6136799	Apr 08, 2018				
	6136799*PED	Oct 08, 2018				
	6361758	Apr 08, 2018		DP		
	6361758*PED	Oct 08, 2018				
<u>PARICALCITOL - ZEMPLAR</u>						
N021606 001	5246925	Apr 17, 2012		U-671	I-599	Jun 29, 2012
	5246925*PED	Oct 17, 2012				
	5587497	Dec 24, 2013	DS			
	5587497*PED	Jun 24, 2014				
<u>PARICALCITOL - ZEMPLAR</u>						
N021606 002	5246925	Apr 17, 2012		U-671	I-599	Jun 29, 2012
	5246925*PED	Oct 17, 2012				
	5587497	Dec 24, 2013	DS			
	5587497*PED	Jun 24, 2014				
<u>PARICALCITOL - ZEMPLAR</u>						
N021606 003	5246925	Apr 17, 2012		U-671	I-599	Jun 29, 2012
	5246925*PED	Oct 17, 2012				
	5587497	Dec 24, 2013	DS			
	5587497*PED	Jun 24, 2014				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020031 001	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6113944	Dec 14, 2014				
	6113944*PED	Jun 14, 2015				
	6121291	Mar 17, 2017		U-431		
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020031 002	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6113944	Dec 14, 2014				
	6113944*PED	Jun 14, 2015				
	6121291	Mar 17, 2017		U-431		
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020031 003	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6113944	Dec 14, 2014				
	6113944*PED	Jun 14, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020031 004	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6113944	Dec 14, 2014				
	6113944*PED	Jun 14, 2015				
	6121291	Mar 17, 2017		U-431		
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020031 005	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6113944	Dec 14, 2014				
	6113944*PED	Jun 14, 2015				
	6121291	Mar 17, 2017		U-431		
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020710 001	5811436	Sep 22, 2015				
	5811436*PED	Mar 22, 2016				
	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-431		
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020885 001	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6063927	Apr 23, 2019				
	6063927*PED	Oct 23, 2019				
	6080759	May 19, 2015				
	6080759*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-431		
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
	6172233	Jan 15, 2018				
	6172233*PED	Jul 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020885 002	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6063927	Apr 23, 2019				
	6063927*PED	Oct 23, 2019				
	6080759	May 19, 2015				
	6080759*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-431		
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
	6172233	Jan 15, 2018				
	6172233*PED	Jul 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020885 003	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6063927	Apr 23, 2019				
	6063927*PED	Oct 23, 2019				
	6080759	May 19, 2015				
	6080759*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-431		
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
	6172233	Jan 15, 2018				
	6172233*PED	Jul 15, 2018				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020885 004	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6062927	Apr 23, 2019				
	6063927*PED	Oct 23, 2019				
	6080759	May 19, 2015				
	6080759*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
	6172233	Jan 15, 2018				
	6172233*PED	Jul 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N020936 001	5422123	Jun 06, 2012				
	5422123*PED	Dec 06, 2012				
	5789449*PED	Jul 06, 2009				
	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6133289*PED	Nov 19, 2015		U-286		
	6548084	Jul 19, 2016				
	6548084*PED	Jan 19, 2017				
	7229640	Jul 19, 2016	DP	U-816		
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N020936 002	5422123	Jun 06, 2012				
	5422123*PED	Dec 06, 2012				
	5789449*PED	Jul 06, 2009				
	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6133289*PED	Nov 19, 2015		U-286		
	6548084	Jul 19, 2016				
	6548084*PED	Jan 19, 2017				
	7229640	Jul 19, 2016	DP	U-816		
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N020936 003	5422123	Jun 06, 2012				
	5422123*PED	Dec 06, 2012				
	5789449*PED	Jul 06, 2009				
	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6133289*PED	Nov 19, 2015		U-286		
	6548084	Jul 19, 2016				
	6548084*PED	Jan 19, 2017				
	7229640	Jul 19, 2016	DP	U-816		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N021299 001	5874447	Jun 10, 2017	U-46			
	5874447	Jun 10, 2017	U-518			
	5874447	Jun 10, 2017	U-286			
	6703408	Oct 21, 2022	DP			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N021299 002	5874447	Jun 10, 2017	U-286			
	5874447	Jun 10, 2017	U-46			
	5874447	Jun 10, 2017	U-518			
	6703408	Oct 21, 2022	DP			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N021299 003	5874447	Jun 10, 2017	U-286			
	5874447	Jun 10, 2017	U-46			
	5874447	Jun 10, 2017	U-518			
	6703408	Oct 21, 2022	DP			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N021299 004	5874447	Jun 10, 2017	U-286			
	5874447	Jun 10, 2017	U-46			
	5874447	Jun 10, 2017	U-518			
	6703408	Oct 21, 2022	DP			
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 001	7105530	Dec 19, 2021	DS DP		NCE	Oct 19, 2014
	7262203	Dec 19, 2021	DS DP			
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 002	7105530	Dec 19, 2021	DS DP		NCE	Oct 19, 2014
	7262203	Dec 19, 2021	DS DP			
<u>PEGAPTANIB SODIUM - MACUGEN</u>						
N021756 001	5919455	Oct 27, 2013	DS		NCE	Dec 17, 2009
	5932462	Aug 03, 2016	DS			
	6011020	Jan 04, 2017	DS			
	6051698	May 19, 2015	DS	U-622		
	6113906	Oct 27, 2013	DS			
	6147204	Jun 11, 2010	DS			
	6426335	Jun 11, 2010		U-622		
<u>PEGVISOMANT - SOMAVENT</u>						
N021106 001	5350836	Sep 27, 2011		U-507	ODE	Mar 25, 2010
	5681809	Sep 27, 2011		U-507		
	5849535	Mar 25, 2017	DS			
	5958879	Sep 27, 2011		U-507		
	6057292	Sep 21, 2015		U-507		
	6583115	Sep 27, 2011		U-507		
<u>PEGVISOMANT - SOMAVENT</u>						
N021106 002	5350836	Sep 27, 2011		U-507	ODE	Mar 25, 2010
	5681809	Sep 27, 2011		U-507		
	5849535	Mar 25, 2017	DS			
	5958879	Sep 27, 2011		U-507		
	6057292	Sep 21, 2015		U-507		
	6583115	Sep 27, 2011		U-507		
<u>PEGVISOMANT - SOMAVENT</u>						
N021106 003	5350836	Sep 27, 2011		U-507	ODE	Mar 25, 2010
	5681809	Sep 27, 2011		U-507		
	5849535	Mar 25, 2017	DS			
	5958879	Sep 27, 2011		U-507		
	6057292	Sep 21, 2015		U-507		
	6583115	Sep 27, 2011		U-507		
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 001	5217974	Mar 29, 2011		U-551	I-601	Jul 02, 2012
	5344932	Jul 24, 2016	DS DP		I-571	Sep 26, 2011
					ODE	Feb 04, 2011



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 002	5217974	Mar 29, 2011		U-551	I-601	Jul 02, 2012
	5344932	Jul 24, 2016	DS DP		I-571	Sep 26, 2011
					ODE	Feb 04, 2011
<u>PEMIROLAST POTASSIUM - ALAMAST</u>						
N021079 001	5034230	Jan 02, 2011	DP	U-184		
	5034230*PED	Jul 02, 2011		U-184		
<u>PENCICLOVIR SODIUM - DENAVIR</u>						
N020629 001	5075445	Sep 24, 2010				
	5840763	Sep 01, 2015		U-501		
	5866581	Sep 04, 2014		U-501		
	5916893	Sep 01, 2015		U-501		
	6124304	Sep 04, 2014		U-501		
	6469015	Oct 22, 2019		U-501		
	6573378	Sep 24, 2010				
	6579981	Jun 17, 2020		U-501		
<u>PENTETATE CALCIUM TRISODIUM - PENTETATE CALCIUM TRISODIUM</u>						
N021749 001					NCE	Aug 11, 2009
					ODE	Aug 11, 2011
<u>PENTETATE ZINC TRISODIUM - PENTETATE ZINC TRISODIUM</u>						
N021751 001					NCE	Aug 11, 2009
					ODE	Aug 11, 2011
<u>PENTOSAN POLYSULFATE SODIUM - ELMIRON</u>						
N020193 001	5180715	Jan 19, 2010		U-159		
<u>PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE - SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS</u>						
N021084 001	5607979	May 30, 2015				
<u>PERFLUTREN - DEFINITY</u>						
N021064 001	5547656	Apr 05, 2011				
	5769080	Jul 20, 2010				
	6033645	Jun 19, 2016		U-665		
	6146657	Dec 22, 2009	DS			
	6528039	Apr 05, 2011	DS			
	6773696	Apr 05, 2011	DS			
<u>PERGOLIDE MESYLATE - PERMAX</u>						
N019385 001	5114948	Oct 19, 2009				
<u>PERGOLIDE MESYLATE - PERMAX</u>						
N019385 002	5114948	Oct 19, 2009				
<u>PERGOLIDE MESYLATE - PERMAX</u>						
N019385 003	5114948	Oct 19, 2009				
<u>PERINDOPRIL ERBUMINE - ACEON</u>						
N020184 001	5162362	Nov 10, 2009	DS DP	U-531		
<u>PERINDOPRIL ERBUMINE - ACEON</u>						
N020184 002	5162362	Nov 10, 2009	DS DP	U-531		
<u>PERINDOPRIL ERBUMINE - ACEON</u>						
N020184 003	5162362	Nov 10, 2009	DS DP	U-531		
<u>PHEMTOLAMINE MESYLATE - ORAVERSE</u>						
N022159 001	6764678	May 11, 2021		U-967	NP	May 09, 2011
	6872390	May 11, 2021		DP		
	7229630	Jun 20, 2023		DP		
	7569230	Oct 17, 2023		U-967		
	7575757	Apr 21, 2025		DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMECROLIMUS - ELIDEL</u>						
N021302 001	5912238	Jun 15, 2016				
	5912238*PED	Dec 15, 2016				
	6352998	Oct 26, 2015				
	6352998*PED	Apr 26, 2016				
	6423722	Jun 26, 2018				
	6423722*PED	Dec 26, 2018				
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N021073 001	4687777	Jan 17, 2011				
	5965584	Jun 19, 2016	U-417			
	6150383	Jun 19, 2016	U-418			
	6150384	Jun 19, 2016	U-419			
	6166042	Jun 19, 2016	U-414			
	6166043	Jun 19, 2016	U-415			
	6172090	Jun 19, 2016	U-416			
	6211205	Jun 19, 2016	U-410			
	6271243	Jun 19, 2016	U-411			
	6303640	Aug 09, 2016	U-425			
	6329404	Jun 19, 2016	U-430			
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N021073 002	4687777	Jan 17, 2011				
	5965584	Jun 19, 2016	U-417			
	6150383	Jun 19, 2016	U-418			
	6150384	Jun 19, 2016	U-419			
	6166042	Jun 19, 2016	U-414			
	6166043	Jun 19, 2016	U-415			
	6172090	Jun 19, 2016	U-416			
	6211205	Jun 19, 2016	U-410			
	6271243	Jun 19, 2016	U-411			
	6303640	Aug 09, 2016	U-425			
	6329404	Jun 19, 2016	U-430			
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N021073 003	4687777	Jan 17, 2011				
	5965584	Jun 19, 2016	U-417			
	6150383	Jun 19, 2016	U-418			
	6150384	Jun 19, 2016	U-419			
	6166042	Jun 19, 2016	U-414			
	6166043	Jun 19, 2016	U-415			
	6172090	Jun 19, 2016	U-416			
	6211205	Jun 19, 2016	U-410			
	6271243	Jun 19, 2016	U-411			
	6303640	Aug 09, 2016	U-425			
	6329404	Jun 19, 2016	U-430			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - PIPERACILLIN AND TAZOBACTAM</u>						
A065386 001					PC	Mar 30, 2010
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - PIPERACILLIN AND TAZOBACTAM</u>						
A065386 002					PC	Mar 28, 2010
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - PIPERACILLIN AND TAZOBACTAM</u>						
A065386 003					PC	Mar 21, 2010
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - PIPERACILLIN AND TAZOBACTAM</u>						
A065446 001					PC	Apr 27, 2010
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	6900184	Apr 14, 2023	DS DP	U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	6900184	Apr 14, 2023	DS DP	U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	6900184	Apr 14, 2023	DS DP	U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	6900184	Apr 14, 2023	DS DP	U-282		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	6207661	Feb 22, 2019	DS DP			
	6900184	Apr 14, 2023	DS DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	6207661	Feb 22, 2019	DS DP			
	6900184	Apr 14, 2023	DS DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	6207661	Feb 22, 2019	DS DP			
	6900184	Apr 14, 2023	DS DP U-282			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363 001	5753675	May 19, 2015	DS DP U-998		NCE	Aug 03, 2014
	5854259	Dec 29, 2015	DP			
	5856336	Jan 05, 2016	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363 002	5753675	May 19, 2015	DS DP U-998		NCE	Aug 03, 2014
	5854259	Dec 29, 2015	DP			
	5856336	Jan 05, 2016	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363 003	5753675	May 19, 2015	DS DP U-998		NCE	Aug 03, 2014
	5854259	Dec 29, 2015	DP			
	5856336	Jan 05, 2016	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
<u>PLERIXAFOR - MOZOBIL</u>						
N022311 001	5583131	Dec 10, 2013	DP		NCE	Dec 15, 2013
	6987102	Jul 22, 2023	U-936		ODE	Dec 15, 2015
<u>POLYETHYLENE GLYCOL 3350 - MIRALAX</u>						
N022015 001					NP	Oct 06, 2009
<u>PORFIMER SODIUM - PHOTOFRIN</u>						
N020451 001	5145863	Dec 15, 2009	U-129		ODE	Aug 01, 2010
	5438071	Aug 01, 2012				
<u>POSACONAZOLE - NOXAFIL</u>						
N022003 001	5661151	Jul 19, 2019	DS DP U-760		NCE	Sep 15, 2011
	5703079	Aug 26, 2014	DS DP U-760			
	6958337	Oct 05, 2018	DS DP U-760			
<u>PRALATREXATE - FOLOTYN</u>						
N022468 001	6028071	Jul 16, 2017	DS DP U-1004		NCE	Sep 24, 2014
	7622470	May 31, 2025	U-1015		ODE	Sep 24, 2016
<u>PRALATREXATE - FOLOTYN</u>						
N022468 002	6028071	Jul 16, 2017	DS DP U-1004		NCE	Sep 24, 2014
	7622470	May 31, 2025	U-1015		ODE	Sep 24, 2016
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 001	4886812	Oct 08, 2010	DS DP		I-517	Nov 07, 2009
	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 002	4886812	Oct 08, 2010	DS DP		I-517	Nov 07, 2009
	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 003	4886812	Oct 08, 2010	DS DP		I-517	Nov 07, 2009
	6001861	Jan 16, 2018		U-784		
	6194445	Jan 16, 2018		U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 004	4886812	Oct 08, 2010	DS DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 005	4886812	Oct 08, 2010	DS DP		I-517	Nov 07, 2009
	6001861	Jan 16, 2018		U-784		
	6194445	Jan 16, 2018		U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 006	4886812	Oct 08, 2010	DS DP		I-517	Nov 07, 2009
	6001861	Jan 16, 2018		U-784		
	6194445	Jan 16, 2018		U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 007	4886812	Oct 08, 2010	DS DP		I-517	Nov 07, 2009
	6001861	Jan 16, 2018		U-784		
	6194445	Jan 16, 2018		U-784		
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N021332 001	5686411	Mar 16, 2019	DS DP	U-638	NCE	Mar 16, 2010
	5814600	Sep 29, 2015		U-639		
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017		U-640		
	6608029	Sep 07, 2013		U-641		
	6610824	Mar 08, 2011	DS			
	7271238	Mar 08, 2011	DS	U-637		
	7271238	Mar 08, 2011	DS	U-638		
	7407934	Mar 08, 2011		U-640		
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N021332 002	5686411	Mar 16, 2019	DS DP	U-638	NCE	Mar 16, 2010
	5814600	Sep 29, 2015		U-639		
	5814600	Sep 29, 2015		U-638		
	5814600	Sep 29, 2015		U-637		
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017		U-640		
	6114304	Sep 05, 2017		U-637		
	6608029	Sep 07, 2013		U-641		
	6608029	Sep 07, 2013		U-640		
	6608029	Sep 07, 2013		U-637		
	6610824	Mar 03, 2011	DS			
	7271238	Mar 08, 2011	DS	U-637		
	7271238	Mar 08, 2011	DS	U-638		
	7407934	Mar 08, 2011		U-640		
	7407934	Mar 08, 2011		U-637		
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N021332 003	5686411	Mar 16, 2019	DS DP	U-638	NCE	Mar 16, 2010
	5814600	Sep 29, 2015		U-639		
	5814600	Sep 29, 2015		U-638		
	5814600	Sep 29, 2015		U-637		
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017		U-640		
	6114304	Sep 05, 2017		U-637		
	6608029	Sep 07, 2013		U-641		
	6608029	Sep 07, 2013		U-640		
	6608029	Sep 07, 2013		U-637		
	6610824	Mar 03, 2011	DS			
	7271238	Mar 08, 2011	DS	U-638		
	7271238	Mar 08, 2011	DS	U-637		
	7407934	Mar 08, 2011		U-640		
	7407934	Mar 08, 2011		U-637		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 001	5288726	Sep 08, 2012	DS DP U-991		NCE	Jul 10, 2014
	6693115	Jul 03, 2021	DS DP U-991			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 002	5288726	Sep 08, 2012	DS DP U-991		NCE	Jul 10, 2014
	6693115	Jul 03, 2021	DS DP U-991			
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N019898 002	5622985	Apr 22, 2014		U-335		
	5622985*PED	Oct 22, 2014		U-335		
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N019898 003	5622985	Apr 22, 2014		U-335		
	5622985*PED	Oct 22, 2014		U-335		
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N019898 004	5622985	Apr 22, 2014		U-335		
	5622985*PED	Oct 22, 2014		U-335		
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N019898 008	5622985	Apr 22, 2014		U-335		
	5622985*PED	Oct 22, 2014		U-335		
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 001	5881926	Mar 16, 2016		DP		
	6071523	Jun 03, 2018		DP		
	6102254	Mar 11, 2013		DP		
	6399079	Jun 03, 2018		DP		
	6656482	Jun 03, 2018		DP		
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 002	5881926	Mar 16, 2016		DP		
	6071523	Jun 03, 2018		DP		
	6102254	Mar 11, 2013		DP		
	6399079	Jun 03, 2018		DP		
	6656482	Jun 03, 2018		DP		
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 001	5178878	Jan 12, 2010		DP		
	6024981	Apr 09, 2018		DP		
	6221392	Apr 09, 2018		DP		
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 002	5178878	Jan 12, 2010		DP		
	6024981	Apr 09, 2018		DP		
	6221392	Apr 09, 2018		DP		
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 003	5178878	Jan 12, 2010		DP		
	6024981	Apr 09, 2018		DP		
	6221392	Apr 09, 2018		DP		
<u>PREGABALIN - LYRICA</u>						
N021446 001	5563175	Oct 08, 2013		U-661	I-535	Jun 21, 2010
	6001876	Dec 30, 2018		U-55	NCE	Dec 30, 2009
	6001876	Dec 30, 2018		U-819		
	6197819	Dec 30, 2018	DS DP			
<u>PREGABALIN - LYRICA</u>						
N021446 002	5563175	Oct 08, 2013		U-661	I-535	Jun 21, 2010
	6001876	Dec 30, 2018		U-55	NCE	Dec 30, 2009
	6001876	Dec 30, 2018		U-819		
	6197819	Dec 30, 2018	DS DP			
<u>PREGABALIN - LYRICA</u>						
N021446 003	5563175	Oct 08, 2013		U-661	I-535	Jun 21, 2010
	6001876	Dec 30, 2018		U-55	NCE	Dec 30, 2009
	6001876	Dec 30, 2018		U-819		
	6197819	Dec 30, 2018	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N021446 004	5563175	Oct 08, 2013		U-661	I-535	Jun 21, 2010
	6001876	Dec 30, 2018		U-55	NCE	Dec 30, 2009
	6001876	Dec 30, 2018		U-819		
	6197819	Dec 30, 2018	DS DP			
<u>PREGABALIN - LYRICA</u>						
N021446 005	5563175	Oct 08, 2013		U-661	I-535	Jun 21, 2010
	6001876	Dec 30, 2018		U-819	NCE	Dec 30, 2009
	6001876	Dec 30, 2018		U-55		
	6197819	Dec 30, 2018	DS DP			
<u>PREGABALIN - LYRICA</u>						
N021446 006	5563175	Oct 08, 2013		U-661	I-535	Jun 21, 2010
	6001876	Dec 30, 2018		U-55	NCE	Dec 30, 2009
	6001876	Dec 30, 2018		U-819		
	6197819	Dec 30, 2018	DS DP			
<u>PREGABALIN - LYRICA</u>						
N021446 007	5563175	Oct 08, 2013		U-661	I-535	Jun 21, 2010
	6001876	Dec 30, 2018		U-55	NCE	Dec 30, 2009
	6001876	Dec 30, 2018		U-819		
	6197819	Dec 30, 2018	DS DP			
<u>PREGABALIN - LYRICA</u>						
N021446 008	5563175	Oct 08, 2013		U-661	I-535	Jun 21, 2010
	6001876	Dec 30, 2018		U-819	NCE	Dec 30, 2009
	6001876	Dec 30, 2018		U-55		
	6197819	Dec 30, 2018	DS DP			
<u>PROCAINAMIDE HYDROCHLORIDE - PROCANBID</u>						
N020545 001	5656296	Aug 12, 2014				
<u>PROCAINAMIDE HYDROCHLORIDE - PROCANBID</u>						
N020545 002	5656296	Aug 12, 2014				
<u>PROGESTERONE - CRINONE</u>						
N020701 001	5543150	Sep 15, 2013		U-209		
<u>PROGESTERONE - CRINONE</u>						
N020701 002	5543150	Sep 15, 2013		U-209		
<u>PROGESTERONE - ENDOMETRIN</u>						
N022057 001	7300664	Nov 17, 2019		U-856	NP	Jun 21, 2010
	7320800	Nov 17, 2019		U-856		
	7393543	Nov 17, 2019	DP	U-880		
<u>PROPAPENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N021416 001	5681588	Oct 28, 2014				
<u>PROPAPENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N021416 002	5681588	Oct 28, 2014				
<u>PROPAPENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N021416 003	5681588	Oct 28, 2014				
<u>PROPOFOL - DIPRIVAN</u>						
N019627 002	5714520	Mar 22, 2015				
	5714520*PED	Sep 22, 2015				
	5731355	Mar 22, 2015		U-217		
	5731355*PED	Sep 22, 2015		U-217		
	5731356	Mar 22, 2015		U-218		
	5731356*PED	Sep 22, 2015		U-218		
	5908869	Mar 22, 2015		U-270		
	5908869*PED	Sep 22, 2015		U-270		
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 001	6500454	Dec 31, 2022				
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 002	6500454	Dec 31, 2022				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>QUAZEPAM - DORAL</u>						
N018708 001	7608616	Jun 03, 2028	U-1012			
<u>QUAZEPAM - DORAL</u>						
N018708 003	7608616	Jun 03, 2028	U-1012			
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
N020639 001	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					NPP	Dec 02, 2012
					NPP	Dec 02, 2012
					PED	Jun 02, 2013
					PED	Jun 02, 2013
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
N020639 002	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					NPP	Dec 02, 2012
					NPP	Dec 02, 2012
					PED	Jun 02, 2013
					PED	Jun 02, 2013
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
N020639 003	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					NPP	Dec 02, 2012
					NPP	Dec 02, 2012
					PED	Jun 02, 2013
					PED	Jun 02, 2013
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
N020639 004	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					NPP	Dec 02, 2012
					NPP	Dec 02, 2012
					PED	Jun 02, 2013
					PED	Jun 02, 2013
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
N020639 005	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					NPP	Dec 02, 2012
					NPP	Dec 02, 2012
					PED	Jun 02, 2013
					PED	Jun 02, 2013
					PED	Nov 13, 2011
					PED	Apr 20, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE		
<u>QUETIAPINE FUMARATE - SEROQUEL</u>								
N020639 006	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011		
	4879288*PED	Mar 26, 2012				I-503	Oct 20, 2009	
						NPP	Dec 02, 2012	
						NPP	Dec 02, 2012	
						PED	Jun 02, 2013	
						PED	Jun 02, 2013	
						PED	Nov 13, 2011	
						PED	Apr 20, 2010	
<u>QUETIAPINE FUMARATE - SEROQUEL</u>								
N020639 007	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011		
	4879288*PED	Mar 26, 2012				I-503	Oct 20, 2009	
						NPP	Dec 02, 2012	
						NPP	Dec 02, 2012	
						PED	Jun 02, 2013	
						PED	Jun 02, 2013	
						PED	Nov 13, 2011	
						PED	Apr 20, 2010	
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>								
N022047 001	4879288	Sep 26, 2011	DS DP U-839		D-117	Oct 08, 2011		
	4879288	Sep 26, 2011				DS DP U-814	I-618	Dec 02, 2012
	4879288	Sep 26, 2011				DS DP U-601	I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012					I-575	Oct 08, 2011
	5948437	May 28, 2017				DP U-839	I-574	Oct 08, 2011
	5948437	May 28, 2017				DP U-814	NDF	May 17, 2010
	5948437	May 28, 2017				DP U-601	PED	Nov 17, 2010
	5948437*PED	Nov 28, 2017					PED	Apr 08, 2012
							PED	Apr 08, 2012
							PED	Apr 08, 2012
			PED	Apr 08, 2012				
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>								
N022047 002	4879288	Sep 26, 2011	DS DP U-839		D-117	Oct 08, 2011		
	4879288	Sep 26, 2011				DS DP U-814	I-618	Dec 02, 2012
	4879288	Sep 26, 2011				DS DP U-601	I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012					I-575	Oct 08, 2011
	5948437	May 28, 2017				DP U-814	I-574	Oct 08, 2011
	5948437	May 28, 2017				DP U-839	NDF	May 17, 2010
	5948437	May 28, 2017				DP U-601	PED	Nov 17, 2010
	5948437*PED	Nov 28, 2017					PED	Apr 08, 2012
							PED	Apr 08, 2012
							PED	Apr 08, 2012
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>								
N022047 003	4879288	Sep 26, 2011	DS DP U-601		D-117	Oct 08, 2011		
	4879288	Sep 26, 2011				DS DP U-814	I-618	Dec 02, 2012
	4879288	Sep 26, 2011				DS DP U-839	I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012					I-575	Oct 08, 2011
	5948437	May 28, 2017				DP U-839	I-574	Oct 08, 2011
	5948437	May 28, 2017				DP U-601	NDF	May 17, 2010
	5948437	May 28, 2017				DP U-814	PED	Nov 17, 2010
	5948437*PED	Nov 28, 2017					PED	Apr 08, 2012
							PED	Apr 08, 2012
							PED	Apr 08, 2012



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N022047 004	4879288	Sep 26, 2011	DS DP U-839		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-618	Dec 02, 2012
	4879288	Sep 26, 2011	DS DP U-814		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-839		NDF	May 17, 2010
	5948437	May 28, 2017	DP U-814		PED	Nov 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Apr 08, 2012
					PED	Apr 08, 2012
					PED	Apr 08, 2012
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N022047 005	4879288	Sep 26, 2011	DS DP U-839		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-618	Dec 02, 2012
	4879288	Sep 26, 2011	DS DP U-814		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-839		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437	May 28, 2017	DP U-814		PED	Nov 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Apr 08, 2012
					PED	Apr 08, 2012
					PED	Apr 08, 2012
					PED	Apr 08, 2012
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N019885 001	5684016	Nov 04, 2014		U-210		
	5684016*PED	May 04, 2015		U-210		
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N019885 002	5684016	Nov 04, 2014		U-210		
	5684016*PED	May 04, 2015		U-210		
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N019885 003	5684016	Nov 04, 2014		U-210		
	5684016*PED	May 04, 2015		U-210		
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N019885 004	5684016	Nov 04, 2014		U-210		
	5684016*PED	May 04, 2015		U-210		
<u>QUININE SULFATE - QUALAQUIN</u>						
N021799 001					ODE	Aug 12, 2012
<u>RABEPRAZOLE SODIUM - ACIPHEX</u>						
N020973 001	5045552	May 08, 2013		U-385		
<u>RABEPRAZOLE SODIUM - ACIPHEX</u>						
N020973 002	5045552	May 08, 2013		U-385	NPP	Jun 30, 2011

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>						
N020815 001	5393763	Jul 28, 2012		U-114		
	5457117	Jul 28, 2012		U-114	I-539	Sep 13, 2010
	5478847	Mar 02, 2014		U-114	ODE	Sep 13, 2014
	5811120	Mar 02, 2014				
	5972383	Mar 02, 2014		U-287		
	6458811	Mar 10, 2017	DS DP	U-825		
	6797719	Mar 10, 2017		DP		
	6894064	Mar 10, 2017		DP	U-657	
	6906086	Jul 28, 2012			U-657	
	6906086	Jul 28, 2012			U-662	
	RE38968	Jul 28, 2012			U-662	
	RE38968	Jul 28, 2012			U-657	
	RE39049	Jul 28, 2012			U-657	
	RE39049	Jul 28, 2012			U-662	
	RE39050	Mar 02, 2014			U-657	
	RE39050	Mar 02, 2014			U-662	
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001	7169780	Oct 09, 2023	DS DP		NCE	Oct 12, 2012
	7217713	Oct 21, 2022		U-257		
	7435734	Oct 21, 2022		U-900		
<u>RAMELTEON - ROZEREM</u>						
N021782 001	6034239	Mar 06, 2017	DS DP	U-674	M-82	Oct 27, 2011
					NCE	Jul 22, 2010
<u>RAMIPRIL - ALTACE</u>						
N019901 001	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N019901 002	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N019901 003	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N019901 004	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N022021 001	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N022021 002	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N022021 003	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N022021 004	5403856	Apr 04, 2012		U-71		
	7368469	Aug 30, 2020		U-871		
<u>RANITIDINE BISMUTH CITRATE - TRITEC</u>						
N020559 001	5008256	Jul 17, 2009				
	5256684	Oct 26, 2010		U-199		
	5403830	Apr 04, 2012		U-200		
	5407688	Apr 04, 2012		U-201		
	5456925	Oct 10, 2012				
	5601848	Feb 11, 2014		U-202		
	5629297	May 13, 2014		U-186		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RANITIDINE HYDROCHLORIDE - ZANTAC 150</u>						
N020095 001	5028432	Feb 22, 2010				
	5028432*PED	Aug 22, 2010				
<u>RANITIDINE HYDROCHLORIDE - ZANTAC 150</u>						
N020251 001	5102665*PED	Dec 23, 2009				
<u>RANITIDINE HYDROCHLORIDE - ZANTAC 150</u>						
N020251 002	5102665*PED	Dec 23, 2009				
<u>RANITIDINE HYDROCHLORIDE - ZANTAC 150</u>						
N021698 002	5098715	Dec 20, 2010	DP			
<u>RANITIDINE HYDROCHLORIDE - ZANTAC 300</u>						
N020095 002	5028432	Feb 22, 2010				
	5028432*PED	Aug 22, 2010				
<u>RANOLAZINE - RANEXA</u>						
N021526 001	6303607	May 27, 2019		U-705	NCE	Jan 27, 2011
	6369062	May 27, 2019	DP			
	6479496	May 27, 2019		U-705		
	6503911	May 27, 2019	DP			
	6525057	May 27, 2019		U-705		
	6562826	May 27, 2019		U-705		
	6617328	May 27, 2019	DP			
	6620814	May 27, 2019		U-705		
	6852724	May 27, 2019		U-705		
	6864258	May 27, 2019		U-705		
<u>RANOLAZINE - RANEXA</u>						
N021526 002	6303607	May 27, 2019		U-705	NCE	Jan 27, 2011
	6369062	May 27, 2019	DP			
	6479496	May 27, 2019		U-705		
	6503911	May 27, 2019	DP			
	6525057	May 27, 2019		U-705		
	6562826	May 27, 2019		U-705		
	6617328	May 27, 2019	DP			
	6620814	May 27, 2019		U-705		
	6852724	May 27, 2019		U-705		
	6864258	May 27, 2019		U-705		
<u>RAPACURONIUM BROMIDE - RAPLON</u>						
N020984 001	5418226	Apr 14, 2013				
<u>RAPACURONIUM BROMIDE - RAPLON</u>						
N020984 002	5418226	Apr 14, 2013				
<u>RASAGILINE MESYLATE - AZILECT</u>						
N021641 001	5387612	Feb 07, 2012		U-219	NCE	May 16, 2011
	5453446	Feb 07, 2017		U-219		
	5457133	Feb 07, 2012	DS DP			
	5532415	Jul 02, 2013	DS			
	5786390	Feb 07, 2012		DP		
	6126968	Sep 18, 2016		DP		
	7572834	Dec 05, 2026		DP		
<u>RASAGILINE MESYLATE - AZILECT</u>						
N021641 002	5387612	Feb 07, 2012		U-219	NCE	May 16, 2011
	5453446	Feb 07, 2017		U-219		
	5457133	Feb 07, 2012	DS DP			
	5532415	Jul 02, 2013	DS			
	5786390	Feb 07, 2012		DP		
	6126968	Sep 18, 2016		DP		
	7572834	Dec 05, 2026		DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	6403567	Jun 22, 2019	DS DP U-869		NCE	Apr 10, 2013
	6642210	Jun 22, 2019	DS DP U-869			
	7144872	Jun 22, 2019	DS DP U-869			
	7144872	Jun 22, 2019	DS DP U-870			
	7144872	Jun 22, 2019	DS DP U-116			
	7183264	Jun 22, 2019	DP U-116			
	7183264	Jun 22, 2019	DP U-870			
	7183264	Jun 22, 2019	DP U-869			
	7582617	Jun 22, 2019	U-1003			
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N020630 001	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
	5466700	Aug 30, 2013	U-156			
	5466700*PED	Mar 01, 2014	U-156			
	5866591	Sep 10, 2017	DP			
	5866591*PED	Mar 10, 2018				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N020630 002	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
	5466700	Aug 30, 2013	U-156			
	5466700*PED	Mar 01, 2014				
	5866591	Sep 10, 2017	DP			
	5866591*PED	Mar 10, 2018				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N020630 003	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
	5466700	Aug 30, 2013	U-156			
	5466700*PED	Mar 01, 2014	U-156			
	5866591	Sep 10, 2017	DP			
	5866591*PED	Mar 10, 2018				
<u>REPAGLINIDE - PRANDIN</u>						
N020741 001	6677358	Jun 12, 2018	DS DP U-968			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 002	6677358	Jun 12, 2018	DS DP U-968			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 003	6677358	Jun 12, 2018	DS DP U-968			
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	RE39128	Oct 27, 2018	DS DP U-805		NCE	Apr 12, 2012
<u>RIBAVIRIN - REBETOL</u>						
N020903 001	6172046	Sep 21, 2017	U-377		ODE	Jul 29, 2010
	6172046	Sep 21, 2017	U-1014		PED	Jan 29, 2011
	6172046*PED	Mar 21, 2018	U-377			
	6177074	Nov 01, 2016	U-1013			
	6177074	Nov 01, 2016	U-454			
	6177074*PED	May 01, 2017	U-454			
	6461605	Nov 01, 2016	U-1013			
	6461605	Nov 01, 2016	U-478			
	6461605*PED	May 01, 2017	U-478			
	6472373	Sep 21, 2017	U-1014			
	6472373	Sep 21, 2017	U-479			
	6472373*PED	Mar 21, 2018	U-479			
	6524570	Nov 01, 2016	U-499			
	6524570	Nov 01, 2016	U-1013			
	6524570*PED	May 01, 2017	U-499			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBAVIRIN - REBETOL</u>						
N020903 002	6172046	Sep 21, 2017	U-377		ODE	Jul 29, 2010
	6172046	Sep 21, 2017	U-1014		PED	Jan 29, 2011
	6172046*PED	Mar 21, 2018	U-377			
	6177074	Nov 01, 2016	U-1013			
	6177074	Nov 01, 2016	U-454			
	6177074*PED	May 01, 2017	U-454			
	6461605	Nov 01, 2016	U-478			
	6461605	Nov 01, 2016	U-1013			
	6461605*PED	May 01, 2017	U-478			
	6472373	Sep 21, 2017	U-479			
	6472373	Sep 21, 2017	U-1014			
	6472373*PED	Mar 21, 2018	U-479			
	6524570	Nov 01, 2016	U-499			
	6524570	Nov 01, 2016	U-1013			
	6524570*PED	May 01, 2017	U-499			
<u>RIBAVIRIN - REBETOL</u>						
N021546 001	6172046	Sep 21, 2017	U-1014		ODE	Jul 29, 2010
	6172046	Sep 21, 2017	U-521		PED	Jan 29, 2011
	6172046*PED	Mar 21, 2018	U-521			
	6177074	Nov 01, 2016	U-1013			
	6177074*PED	May 01, 2017				
	6461605	Nov 01, 2016	U-521			
	6461605	Nov 01, 2016	U-1013			
	6461605*PED	May 01, 2017	U-521			
	6472373	Sep 21, 2017	U-521			
	6472373*PED	Mar 21, 2018	U-521			
	6524570	Nov 01, 2016	U-1013			
	6524570*PED	May 01, 2017				
	6790837	Apr 05, 2023	DP			
	6790837*PED	Oct 05, 2023	U-1014			
<u>RIBAVIRIN - VIRAZOLE</u>						
N018859 001	6150337	Nov 21, 2017	U-400			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	7045620	Jun 19, 2024	DS DP			
	7612199	Jun 19, 2024	DS DP			
<u>RILUZOLE - RILUTEK</u>						
N020599 001	5527814	Jun 18, 2013				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 001	5583122	Dec 10, 2013	U-222		M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			PED	Jan 23, 2013
	6096342	Nov 22, 2011				
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018				
	6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 002	5583122	Dec 10, 2013	U-222		M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			PED	Jan 23, 2013
	6096342	Nov 22, 2011				
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018				
	6165513*PED	Dec 10, 2018				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 003	5583122	Dec 10, 2013	DS DP U-222		I-309	Aug 11, 2009
	5583122	Dec 10, 2013	DS DP U-756		M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			PED	Jan 23, 2013
	5994329	Jul 17, 2018		U-353	PED	Feb 11, 2010
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018		U-353		
	6015801*PED	Jan 17, 2019				
	6096342	Nov 22, 2011		DP		
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018		DP		
	6165513*PED	Dec 10, 2018				
	6432932	Jul 17, 2018		U-595		
	6432932*PED	Jan 17, 2019				
	6465443	Aug 14, 2018		DP		
	6465443*PED	Feb 14, 2019				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 004	5583122	Dec 10, 2013	DS DP U-353		D-105	Apr 16, 2010
	5583122*PED	Jun 10, 2014			M-61	Jul 23, 2012
	6096342	Nov 22, 2011		DP U-353	PED	Jan 23, 2013
	6096342*PED	May 22, 2012			PED	Oct 16, 2010
	6165513	Jun 10, 2018		DP		
	6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 005	5583122	Dec 10, 2013	DS DP U-353		M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			NS	Apr 22, 2011
	6165513	Jun 10, 2018		DP	PED	Jan 23, 2013
	6165513*PED	Dec 10, 2018			PED	Oct 22, 2011
	7192938	May 06, 2023		U-353		
	7192938*PED	Nov 06, 2023				
<u>RISPERIDONE - RISPERDAL</u>						
N020272 001					I-540	Aug 22, 2010
					I-541	Aug 22, 2010
					I-509	Oct 06, 2009
					PED	Feb 22, 2011
					PED	Feb 22, 2011
					PED	Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>						
N020272 002					I-540	Aug 22, 2010
					I-541	Aug 22, 2010
					I-509	Oct 06, 2009
					PED	Feb 22, 2011
					PED	Feb 22, 2011
					PED	Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>						
N020272 003					I-540	Aug 22, 2010
					I-541	Aug 22, 2010
					I-509	Oct 06, 2009
					PED	Feb 22, 2011
					PED	Feb 22, 2011
					PED	Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>						
N020272 004					I-540	Aug 22, 2010
					I-541	Aug 22, 2010
					I-509	Oct 06, 2009
					PED	Feb 22, 2011
					PED	Feb 22, 2011
					PED	Apr 06, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL</u>						
N020272	005				I-540	Aug 22, 2010
					I-541	Aug 22, 2010
					PED	Feb 22, 2011
					PED	Feb 22, 2011
<u>RISPERIDONE - RISPERDAL</u>						
N020272	007				I-540	Aug 22, 2010
					I-541	Aug 22, 2010
					I-509	Oct 06, 2009
					PED	Feb 22, 2011
					PED	Feb 22, 2011
					PED	Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>						
N020272	008				I-540	Aug 22, 2010
					I-541	Aug 22, 2010
					I-509	Oct 06, 2009
					PED	Feb 22, 2011
					PED	Feb 22, 2011
					PED	Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>						
N020588	001	5453425	Jul 11, 2014	DP	I-541	Aug 22, 2010
		5453425*PED	Jan 11, 2015		I-540	Aug 22, 2010
		5616587	Jul 11, 2014		Y	
		5616587*PED	Jan 11, 2015		I-509	Oct 06, 2009
		RE39181	Jul 11, 2014	DP	PED	Feb 22, 2011
		RE39181*PED	Jan 11, 2015		PED	Feb 22, 2011
					PED	Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>						
N021444	001	5648093	Jul 15, 2014	DP	I-541	Aug 22, 2010
		5648093*PED	Jan 15, 2015		I-540	Aug 22, 2010
		6224905	Jun 10, 2017	DP	I-509	Oct 06, 2009
		6224905*PED	Dec 10, 2017		PED	Feb 22, 2011
					PED	Feb 22, 2011
					PED	Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>						
N021444	002	5648093	Jul 15, 2014	DP	I-541	Aug 22, 2010
		5648093*PED	Jan 15, 2015		I-540	Aug 22, 2010
		6224905	Jun 10, 2017	DP	I-509	Oct 06, 2009
		6224905*PED	Dec 10, 2017		PED	Feb 22, 2011
					PED	Feb 22, 2011
					PED	Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>						
N021444	003	5648093	Jul 15, 2014	DP	I-541	Aug 22, 2010
		5648093*PED	Jan 15, 2015		I-540	Aug 22, 2010
		6224905	Jun 10, 2017	DP	I-509	Oct 06, 2009
		6224905*PED	Dec 10, 2017		PED	Feb 22, 2011
					PED	Feb 22, 2011
					PED	Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>						
N021444	004	5648093	Jul 15, 2014	DP	I-541	Aug 22, 2010
		5648093*PED	Jan 15, 2015		I-540	Aug 22, 2010
		6224905	Jun 10, 2017	DP	I-509	Oct 06, 2009
		6224905*PED	Dec 10, 2017		PED	Feb 22, 2011
					PED	Feb 22, 2011
					PED	Apr 06, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL</u>						
N021444 005	5648093	Jul 15, 2014	DP		I-541	Aug 22, 2010
	5648093*PED	Jan 15, 2015			I-540	Aug 22, 2010
	6224905	Jun 10, 2017	DP		I-509	Oct 06, 2009
	6224905*PED	Dec 10, 2017			PED	Feb 22, 2011
					PED	Feb 22, 2011
					PED	Apr 06, 2010
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N021346 001	5688801	Nov 18, 2014		U-543	I-597	May 15, 2012
	5688801	Nov 18, 2014		U-972	I-596	May 15, 2012
	5688801*PED	May 18, 2015				
	5792477	May 02, 2017	DP			
	5792477*PED	Nov 02, 2017				
	5916598	May 02, 2017	DP			
	5916598*PED	Nov 02, 2017				
	5965168	Nov 19, 2013	DP			
	5965168*PED	May 19, 2014				
	6110921	Nov 19, 2013		U-543		
	6110921*PED	May 19, 2014				
	6194006	Dec 30, 2018	DP			
	6194006*PED	Jun 30, 2019				
	6368632	Nov 19, 2013		U-543		
	6368632*PED	May 19, 2014				
	6379703	Dec 30, 2018	DP			
	6379703*PED	Jun 30, 2019				
	6403114	May 02, 2017	DP			
	6403114*PED	Nov 02, 2017				
	6596316	Dec 30, 2018	DP			
	6596316*PED	Jun 30, 2019				
	6667061	May 25, 2020	DP			
	6667061*PED	Nov 25, 2020				
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N021346 002	5688801	Nov 18, 2014		U-543	I-597	May 15, 2012
	5688801	Nov 18, 2014		U-972	I-596	May 15, 2012
	5688801*PED	May 18, 2015				
	5792477	May 02, 2017	DP			
	5792477*PED	Nov 02, 2017				
	5916598	May 02, 2017	DP			
	5916598*PED	Nov 02, 2017				
	5965168	Nov 19, 2013	DP			
	5965168*PED	May 19, 2014				
	6110921	Nov 19, 2013		U-543		
	6110921*PED	May 19, 2014				
	6194006	Dec 30, 2018	DP			
	6194006*PED	Jun 30, 2019				
	6368632	Nov 19, 2013		U-543		
	6368632*PED	May 19, 2014				
	6379703	Dec 30, 2018	DP			
	6379703*PED	Jun 30, 2019				
	6403114	May 02, 2017	DP			
	6403114*PED	Nov 02, 2017				
	6596316	Dec 30, 2018	DP			
	6596316*PED	Jun 30, 2019				
	6667061	May 25, 2020	DP			
	6667061*PED	Nov 25, 2020				
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N021346 003	5688801	Nov 18, 2014		U-543		
	5688801	Nov 18, 2014		U-972	I-597	May 15, 2012
	5688801*PED	May 18, 2015			I-596	May 15, 2012
	5792477	May 02, 2017	DP			
	5792477*PED	Nov 02, 2017				
	5916598	May 02, 2017	DP			
	5916598*PED	Nov 02, 2017				
	5965168	Nov 19, 2013	DP			
	5965168*PED	May 19, 2014				
	6110921	Nov 19, 2013		U-543		
	6110921*PED	May 19, 2014				
	6194006	Dec 30, 2018	DP			
	6194006*PED	Jun 30, 2019				
	6368632	Nov 19, 2013		U-543		
	6368632*PED	May 19, 2014				
	6379703	Dec 30, 2018	DP			
	6379703*PED	Jun 30, 2019				
	6403114	May 02, 2017	DP			
	6403114*PED	Nov 02, 2017				
	6596316	Dec 30, 2018	DP			
	6596316*PED	Jun 30, 2019				
	6667061	May 25, 2020	DP			
	6667061*PED	Nov 25, 2020				
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N021346 004	5688801	Nov 18, 2014		U-972		
	5688801	Nov 18, 2014		U-543	I-597	May 15, 2012
	5688801*PED	May 18, 2015			I-596	May 15, 2012
	5792477	May 02, 2017	DP			
	5792477*PED	Nov 02, 2017				
	5916598	May 02, 2017	DP			
	5916598*PED	Nov 02, 2017				
	5965168	Nov 19, 2013	DP			
	5965168*PED	May 19, 2014				
	6110503	May 02, 2017	DP			
	6110503*PED	Nov 02, 2017				
	6110921	Nov 19, 2013		U-543		
	6110921*PED	May 19, 2014				
	6194006	Dec 30, 2018	DP			
	6194006*PED	Jun 30, 2019				
	6368632	Nov 19, 2013		U-543		
	6368632*PED	May 19, 2014				
	6379703	Dec 30, 2018	DP			
	6379703*PED	Jun 30, 2019				
	6403114	May 02, 2017	DP			
	6403114*PED	Nov 02, 2017				
	6596316	Dec 30, 2018	DP			
	6596316*PED	Jun 30, 2019				
	6667061	May 25, 2020	DP			
	6667061*PED	Nov 25, 2020				
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				
<u>RISPERIDONE - RISPERIDONE</u>						
A076440 001					PC	Jul 29, 2009
<u>RISPERIDONE - RISPERIDONE</u>						
A077494 001					PC	Nov 28, 2009
<u>RISPERIDONE - RISPERIDONE</u>						
A077494 005					PC	Nov 28, 2009
<u>RISPERIDONE - RISPERIDONE</u>						
A077494 006					PC	Nov 28, 2009

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RITONAVIR - NORVIR</u>						
N020659 001	5484801	Jan 28, 2014				
	5484801*PED	Jul 28, 2014				
	5541206	Jul 30, 2013	U-140			
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014	U-190			
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014				
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014				
	5674882*PED	Apr 07, 2015				
	5846987	Dec 29, 2012	U-190			
	5846987*PED	Jun 29, 2013				
	5948436	Sep 13, 2013	DP			
	5948436*PED	Mar 13, 2014				
	6037157	Jun 26, 2016				
	6037157*PED	Dec 26, 2016				
	6703403	Jun 26, 2016	U-564			
	6703403*PED	Dec 26, 2016				
<u>RITONAVIR - NORVIR</u>						
N020680 001	5541206	Jul 30, 2013	U-140			
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014	U-190			
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014				
	5648497*PED	Jan 15, 2015				
	5846987	Dec 29, 2012	U-190			
	5846987*PED	Jun 29, 2013				
	5948436	Sep 13, 2013				
	5948436*PED	Mar 13, 2014				
<u>RITONAVIR - NORVIR</u>						
N020945 001	5541206	Jul 30, 2013	U-348			
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014	U-347			
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014				
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014	U-895			
	5674882*PED	Apr 07, 2015				
	5846987	Dec 29, 2012	U-347			
	5846987*PED	Jun 29, 2013				
	5948436	Sep 13, 2013	DP			
	5948436*PED	Mar 13, 2014				
	6037157	Jun 26, 2016	U-895			
	6037157*PED	Dec 26, 2016				
	6232333	Nov 07, 2017				
	6232333*PED	May 07, 2018				
	6703403	Jun 26, 2016	U-564			
	6703403*PED	Dec 26, 2016				
	7141593	May 22, 2020	DP			
	7141593*PED	Nov 22, 2020				
	7432294	May 22, 2020	DP			
	7432294*PED	Nov 22, 2020				
<u>RIVASTIGMINE - EXELON</u>						
N022083 001	4948807	Aug 14, 2012	DS	U-322	NDF	Jul 06, 2010
	5602176	Feb 11, 2014	DS	DP U-322		
	6316023	Jan 08, 2019		DP		
	6335031	Jan 08, 2019		DP		
<u>RIVASTIGMINE - EXELON</u>						
N022083 002	4948807	Aug 14, 2012	DS	U-322	NDF	Jul 06, 2010
	5602176	Feb 11, 2014	DS	DP U-322		
	6316023	Jan 08, 2019		DP		
	6335031	Jan 08, 2019		DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N020823 003	4948807	Aug 14, 2012	DS	U-322		
	5602176	Feb 11, 2014		U-322		
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N020823 004	4948807	Aug 14, 2012	DS	U-322		
	5602176	Feb 11, 2014		U-322		
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N020823 005	4948807	Aug 14, 2012	DS	U-322		
	5602176	Feb 11, 2014		U-322		
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N020823 006	4948807	Aug 14, 2012	DS	U-322		
	5602176	Feb 11, 2014		U-322		
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N021025 001	4948807	Aug 14, 2012	DS	U-322		
	5602176	Feb 11, 2014		U-322		
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5298520	Jun 29, 2012			U-240	
	5602162	Feb 11, 2014				
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5298520	Jun 29, 2012			U-240	
	5602162	Feb 11, 2014				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5298520	Jun 29, 2012			U-240	
	5457895	Oct 01, 2013				
	5602162	Feb 11, 2014			U-240	
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5298520	Jun 29, 2012			U-240	
	5457895	Oct 01, 2013				
	5602162	Feb 11, 2014			U-240	
<u>ROCURONIUM BROMIDE - ZEMURON</u>						
N020214 001					NPP	Aug 28, 2011
					PED	Feb 28, 2012
<u>ROCURONIUM BROMIDE - ZEMURON</u>						
N020214 002					NPP	Aug 28, 2011
					PED	Feb 28, 2012
<u>ROCURONIUM BROMIDE - ZEMURON</u>						
N020214 003					NPP	Aug 28, 2011
					PED	Feb 28, 2012
<u>ROFECOXIB - VIOXX</u>						
N021042 001	5474995	Jun 24, 2013	DS DP	U-602		
	5474995*PED	Dec 24, 2013				
	5691374	May 18, 2015				
	5691374*PED	Nov 18, 2015				
	6063811	May 06, 2017			U-602	
	6063811*PED	Nov 06, 2017				
	6239173	Jun 24, 2013	DS DP	U-602		
	6239173*PED	Dec 24, 2013				
<u>ROFECOXIB - VIOXX</u>						
N021042 002	5474995	Jun 24, 2013	DS DP	U-602		
	5474995*PED	Dec 24, 2013				
	5691374	May 18, 2015				
	5691374*PED	Nov 18, 2015				
	6063811	May 06, 2017			U-602	
	6063811*PED	Nov 06, 2017				
	6239173	Jun 24, 2013	DS DP	U-602		
	6239173*PED	Dec 24, 2013				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROFECOXIB - VIOXX</u>						
N021042 003	5474995	Jun 24, 2013	DS DP U-602			
	5474995*PED	Dec 24, 2013				
	5691374	May 18, 2015				
	5691374*PED	Nov 18, 2015				
	6063811	May 06, 2017			U-602	
	6063811*PED	Nov 06, 2017				
	6239173	Jun 24, 2013	DS DP U-602			
	6239173*PED	Dec 24, 2013				
<u>ROFECOXIB - VIOXX</u>						
N021052 001	5474995	Jun 24, 2013			U-266	
	5474995*PED	Dec 24, 2013				
	5691374	May 18, 2015				
	5691374*PED	Nov 18, 2015				
	6063811	May 06, 2017			U-266	
	6063811*PED	Nov 06, 2017				
	6239173	Jun 24, 2013				
	6239173*PED	Dec 24, 2013				
<u>ROFECOXIB - VIOXX</u>						
N021052 002	5474995	Jun 24, 2013			U-266	
	5474995*PED	Dec 24, 2013				
	5691374	May 18, 2015				
	5691374*PED	Nov 18, 2015				
	6063811	May 06, 2017			U-266	
	6063811*PED	Nov 06, 2017				
	6239173	Jun 24, 2013				
	6239173*PED	Dec 24, 2013				
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001	4977138	Jul 06, 2010	DS DP		NCE	Nov 05, 2014
	7608280	Aug 22, 2021	DS			
	7611724	Aug 22, 2021	DS			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 001	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 002	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 003	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 004	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 005	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 006	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011
<u>ROPIVACAINE HYDROCHLORIDE MONOHYDRATE - NAROPIN</u>						
N020533 001	4870086	Sep 24, 2010				
	5670524	May 26, 2014	DS DP U-833			
	5834489	May 26, 2014	DS DP U-838			
<u>ROPIVACAINE HYDROCHLORIDE MONOHYDRATE - NAROPIN</u>						
N020533 003	4870086	Sep 24, 2010				
	5670524	May 26, 2014	DS DP U-833			
	5834489	May 26, 2014	DS DP U-838			
<u>ROPIVACAINE HYDROCHLORIDE MONOHYDRATE - NAROPIN</u>						
N020533 004	4870086	Sep 24, 2010				
	5670524	May 26, 2014	DS DP U-833			
	5834489	May 26, 2014	DS DP U-838			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPIVACAINE HYDROCHLORIDE MONOHYDRATE - NAROPIN</u>						
N020533 005	4870086	Sep 24, 2010				
	5670524	May 26, 2014	DS DP	U-833		
	5834489	May 26, 2014	DS DP	U-838		
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N021071 002	5002953	Sep 17, 2011	DS DP	U-628		
	5002953	Sep 17, 2011	DS DP	U-840		
	5002953	Sep 17, 2011	DS DP	U-329		
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP	U-628	Y	
	5741803	Apr 21, 2015	DS DP	U-329	Y	
	5741803*PED	Oct 21, 2015				
	6288095	Feb 11, 2017		U-420	Y	
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N021071 003	5002953	Sep 17, 2011	DS DP	U-628		
	5002953	Sep 17, 2011	DS DP	U-840		
	5002953	Sep 17, 2011	DS DP	U-329		
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP	U-329	Y	
	5741803	Apr 21, 2015	DS DP	U-628	Y	
	5741803*PED	Oct 21, 2015				
	6288095	Feb 11, 2017		U-420	Y	
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N021071 004	5002953	Sep 17, 2011	DS DP	U-628		
	5002953	Sep 17, 2011	DS DP	U-329		
	5002953	Sep 17, 2011	DS DP	U-840		
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS DP	U-628	Y	
	5741803	Apr 21, 2015	DS DP	U-329	Y	
	5741803*PED	Oct 21, 2015				
	6288095	Feb 11, 2017		U-420	Y	
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 002	6316460	Aug 04, 2020	DP		I-611	Oct 16, 2012
	6316460*PED	Feb 04, 2021			I-573	Nov 06, 2011
	6858618	Dec 17, 2021		U-618	I-547	Nov 08, 2010
	6858618*PED	Jun 17, 2022			PED	Apr 16, 2013
	RE37314	Jan 08, 2016	DS		PED	May 08, 2011
	RE37314*PED	Jul 08, 2016			PED	May 06, 2012
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 003	6316460	Aug 04, 2020	DP		I-611	Oct 16, 2012
	6316460*PED	Feb 04, 2021			I-573	Nov 06, 2011
	6858618	Dec 17, 2021		U-618	I-547	Nov 08, 2010
	6858618*PED	Jun 17, 2022			PED	Apr 16, 2013
	RE37314	Jan 08, 2016	DS		PED	May 08, 2011
	RE37314*PED	Jul 08, 2016			PED	May 06, 2012
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 004	6316460	Aug 04, 2020	DP		I-611	Oct 16, 2012
	6316460*PED	Feb 04, 2021			I-573	Nov 06, 2011
	6858618	Dec 17, 2021		U-618	I-547	Nov 08, 2010
	6858618*PED	Jun 17, 2022			PED	Apr 16, 2013
	RE37314	Jan 08, 2016	DS		PED	May 08, 2011
	RE37314*PED	Jul 08, 2016			PED	May 06, 2012

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 005	6316460	Aug 04, 2020	DP		I-611	Oct 16, 2012
	6316460*PED	Feb 04, 2021			I-573	Nov 06, 2011
	6858618	Dec 17, 2021		U-618	I-547	Nov 08, 2010
	6858618*PED	Jun 17, 2022			PED	Apr 16, 2013
	RE37314	Jan 08, 2016	DS		PED	May 08, 2011
	RE37314*PED	Jul 08, 2016			PED	May 06, 2012
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001	6884434	Mar 18, 2019	DP		NCE	May 09, 2012
	7413747	Mar 18, 2019	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002	6884434	Mar 18, 2019	DP		NCE	May 09, 2012
	7413747	Mar 18, 2019	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003	6884434	Mar 18, 2019	DP		NCE	May 09, 2012
	7413747	Mar 18, 2019	DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 001					NCE	Nov 14, 2013
					ODE	Nov 14, 2015
<u>RUFINAMIDE - BANZEL</u>						
N021911 002					NCE	Nov 14, 2013
					ODE	Nov 14, 2015
<u>RUFINAMIDE - BANZEL</u>						
N021911 003					NCE	Nov 14, 2013
					ODE	Nov 14, 2015
<u>SALMETEROL XINAFOATE - SEREVENT</u>						
N020692 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N022181 001	7566462	Nov 16, 2025	DP		NCE	Dec 13, 2012
	7566714	Nov 17, 2024		U-989	ODE	Dec 13, 2014
	7612073	Nov 17, 2024		U-1010		
<u>SAQUINAVIR - FORTOVASE</u>						
N020828 001	5196438	Nov 19, 2010				
	6008228	Jun 06, 2015				
	6352717	Nov 16, 2019				
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N020628 001	5196438	Nov 19, 2010				
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N021785 001	5196438	Nov 19, 2010	DS DP	U-834		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 001	6395767	Feb 16, 2021	DS DP U-995		NCE	Jul 31, 2014
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 002	6395767	Feb 16, 2021	DS DP U-995		NCE	Jul 31, 2014
<u>SELEGILINE - EMSAM</u>						
N021336 001	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
<u>SELEGILINE - EMSAM</u>						
N021336 002	7150881	Jun 12, 2018	DS DP			
<u>SELEGILINE - EMSAM</u>						
N021336 003	7150881	Jun 12, 2018	DS DP			
<u>SELEGILINE HYDROCHLORIDE - ZELAPAR</u>						
N021479 001	5648093	Jul 15, 2014		DP		
	6423342	Mar 01, 2016		DP		
<u>SERTACONAZOLE NITRATE - ERTACZO</u>						
N021385 001	5135943	May 31, 2014	DS DP U-786			
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 001	4962128	Nov 02, 2009		U-152		
	4962128*PED	May 02, 2010		U-152		
	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 002	4962128	Nov 02, 2009		U-152		
	4962128*PED	May 02, 2010		U-152		
	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 003	4962128	Nov 02, 2009		U-152		
	4962128*PED	May 02, 2010		U-152		
	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 004	4962128	Nov 02, 2009		U-152		
	4962128*PED	May 02, 2010		U-152		
	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 005	4962128	Nov 02, 2009		U-152		
	4962128*PED	May 02, 2010		U-152		
	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N020990 001	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
	6727283	Oct 11, 2019	DP	U-580		
	6727283*PED	Apr 11, 2020				
	7067555	Nov 10, 2019	DP			
	7067555*PED	May 10, 2020				
<u>SEVELAMER CARBONATE - RENVELA</u>						
N022127 001	5496545	Aug 11, 2013	DP	U-246	NE	Oct 19, 2010
	5667775	Sep 16, 2014		U-246		
	6509013	Aug 11, 2013	DP			
	6858203	Aug 11, 2013	DP	U-246		
	7014846	Aug 11, 2013	DP	U-246		
	7459151	Aug 11, 2013		U-246		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SEVELAMER CARBONATE - RENVELA</u>						
N022318 001	5496545	Aug 11, 2013	DP U-246		NDF	Aug 12, 2012
	5667775	Sep 16, 2014	U-246		NE	Oct 19, 2010
	6509013	Aug 11, 2013	DP			
	6858203	Aug 11, 2013	DP U-246			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N022318 002	5496545	Aug 11, 2013	DP U-246		NDF	Aug 12, 2012
	5667775	Sep 16, 2014	U-246		NE	Oct 19, 2010
	6509013	Aug 11, 2013	DP			
	6858203	Aug 11, 2013	DP U-246			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N020926 001	5496545	Aug 11, 2013	U-246			
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013				
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N021179 001	5496545	Aug 11, 2013	U-246		M-67	Oct 19, 2010
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013				
	6733780	Oct 18, 2020	DP			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N021179 002	5496545	Aug 11, 2013	U-246		M-67	Oct 19, 2010
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 13, 2013				
	6733780	Oct 18, 2020	DP			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
<u>SEVOFLURANE - ULTANE</u>						
N020478 001	5990176	Jan 27, 2017				
	5990176*PED	Jul 27, 2017				
	6074668	Jan 09, 2018				
	6074668*PED	Jul 09, 2018				
	6288127	Jan 27, 2017				
	6288127*PED	Jul 27, 2017				
	6444859	Jan 27, 2017				
	6444859*PED	Jul 27, 2017				
<u>SIBUTRAMINE HYDROCHLORIDE - MERIDIA</u>						
N020632 001	5436272	Jul 25, 2012	U-439			
	5436272*PED	Jan 25, 2013				
<u>SIBUTRAMINE HYDROCHLORIDE - MERIDIA</u>						
N020632 002	5436272	Jul 25, 2012	U-439			
	5436272*PED	Jan 25, 2013				
<u>SIBUTRAMINE HYDROCHLORIDE - MERIDIA</u>						
N020632 003	5436272	Jul 25, 2012	U-439			
	5436272*PED	Jan 25, 2013				
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534	Mar 27, 2012	DS DP		NDF	Nov 20, 2012
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 001	5250534	Mar 27, 2012				
	6469012	Oct 22, 2019	U-155			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 002	5250534	Mar 27, 2012				
	6469012	Oct 22, 2019		U-155		
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 003	5250534	Mar 27, 2012				
	6469012	Oct 22, 2019		U-155		
<u>SILODOSIN - RAPAFLO</u>						
N022206 001	5387603	Dec 01, 2013	DS DP		NCE	Oct 08, 2013
	5403847	Nov 13, 2012		U-902		
	5780485	Nov 13, 2012		U-902		
	6015819	Nov 13, 2012		U-902		
<u>SILODOSIN - RAPAFLO</u>						
N022206 002	5387603	Dec 01, 2013	DS DP		NCE	Oct 08, 2013
	5403847	Nov 13, 2012		U-902		
	5780485	Nov 13, 2012		U-902		
	6015819	Nov 13, 2012		U-902		
<u>SINCALIDE - KINEVAC</u>						
N017697 001	6803046	Aug 16, 2022	DP			
<u>SINECATECHINS - VEREGEN</u>						
N021902 001	5795911	Oct 31, 2020		U-172	NP	Oct 31, 2009
	5968973	Apr 10, 2017		U-172		
<u>SIROLIMUS - RAPAMUNE</u>						
N021083 001	5100899	Jul 07, 2013		U-290	D-114	Jan 30, 2010
	5100899*PED	Jan 07, 2014				
	5212155	May 18, 2010		U-291		
	5212155*PED	Nov 18, 2010				
	5308847	May 03, 2011		U-292		
	5308847*PED	Nov 03, 2011				
	5403833	Apr 04, 2012		U-293		
	5403833*PED	Oct 04, 2012				
	5536729	Sep 30, 2013	DP			
	5536729*PED	Mar 30, 2014				
<u>SIROLIMUS - RAPAMUNE</u>						
N021110 001	5100899	Jul 07, 2013		U-290	D-114	Jan 30, 2010
	5100899*PED	Jan 07, 2014				
	5145684	Jan 25, 2011	DP	U-857		
	5145684*PED	Jul 25, 2011				
	5212155	May 18, 2010		U-291		
	5212155*PED	Nov 18, 2010				
	5308847	May 03, 2011		U-292		
	5308847*PED	Nov 03, 2011				
	5403833	Apr 04, 2012		U-293		
	5403833*PED	Oct 04, 2012				
	5989591	Mar 11, 2018	DP			
	5989591*PED	Sep 11, 2018				
<u>SIROLIMUS - RAPAMUNE</u>						
N021110 002	5100899	Jul 07, 2013		U-290	D-114	Jan 30, 2010
	5100899*PED	Jan 07, 2014				
	5145684	Jan 25, 2011	DP	U-857		
	5145684*PED	Jul 25, 2011				
	5212155	May 18, 2010		U-291		
	5212155*PED	Nov 18, 2010				
	5308847	May 03, 2011		U-292		
	5308847*PED	Nov 03, 2011				
	5403833	Apr 04, 2012		U-293		
	5403833*PED	Oct 04, 2012				
	5989591	Mar 11, 2018	DP			
	5989591*PED	Sep 11, 2018				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIROLIMUS - RAPAMUNE</u>						
N021110 003	5100899	Jul 07, 2013				
	5100899*PED	Jan 07, 2014				
	5145684	Jan 25, 2011	DP		U-857	
	5145684*PED	Jul 25, 2011				
	5212155	May 18, 2010			U-291	
	5212155*PED	Nov 18, 2010				
	5403833	Apr 04, 2012			U-293	
	5403833*PED	Oct 04, 2012				
	5989591	Mar 11, 2018		DP		
	5989591*PED	Sep 11, 2018				
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N021995 001	6303661	Apr 24, 2017			M-68	Oct 12, 2010
	6699871	Jul 26, 2022	DS DP		M-69	Oct 12, 2010
	6890898	Feb 02, 2019			NCE	Oct 16, 2011
	7078381	Feb 02, 2019				
	7125873	Jul 26, 2022			U-775	
	7326708	Apr 11, 2026	DS DP		U-802	
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N021995 002	6303661	Apr 24, 2017			M-68	Oct 12, 2010
	6699871	Jul 26, 2022	DS DP		M-69	Oct 12, 2010
	6890898	Feb 02, 2019			NCE	Oct 16, 2011
	7078381	Feb 02, 2019				
	7125873	Jul 26, 2022			U-775	
	7326708	Apr 11, 2026	DS DP		U-802	
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N021995 003	6303661	Apr 24, 2017			M-68	Oct 12, 2010
	6699871	Jul 26, 2022	DS DP		M-69	Oct 12, 2010
	6890898	Feb 02, 2019			NCE	Oct 16, 2011
	7078381	Feb 02, 2019				
	7125873	Jul 26, 2022			U-775	
	7326708	Apr 11, 2026	DS DP		U-802	
<u>SODIUM BENZOATE; SODIUM PHENYLACETATE - AMMONUL</u>						
N020645 001					ODE	Feb 17, 2012
<u>SODIUM FLUORIDE; TRICLOSAN - COLGATE TOTAL</u>						
N020231 001	5156835	Oct 20, 2009		DP		
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	6780889	Jul 04, 2020		DP	ODE	Nov 18, 2012
	7262219	Jul 04, 2020		DP	ODE	Jul 17, 2009
<u>SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>						
N021892 001	5616346	May 18, 2013		DP	U-715	
<u>SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - VISICOL</u>						
N021097 001	5616346	May 18, 2013			U-359	
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N021518 001	6017927	Nov 19, 2018	DS DP		NCE	Nov 19, 2009
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N021518 002	6017927	Nov 19, 2018	DS DP		NCE	Nov 19, 2009
<u>SOMATROPIN RECOMBINANT - ACCRETROPIN</u>						
N021538 001					NP	Jan 23, 2011
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 001	5435076	Apr 16, 2013		DP		
	5501673	Apr 16, 2013		DP		
	5716338	Feb 10, 2015		DP		
	6152897	Nov 20, 2018		DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 002	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 003	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 005	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 008	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 009	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 010	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 011	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 012	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 013	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640 001					I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640 004	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
					I-518	Nov 01, 2009
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640 005	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
					I-518	Nov 01, 2009
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640 006	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
					I-518	Nov 01, 2009
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640 007	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
					I-518	Nov 01, 2009

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N021148 001	5849700	Dec 15, 2015	U-340		I-572	Oct 31, 2011
	5849704	Dec 15, 2015			I-551	Sep 20, 2010
					I-536	May 31, 2010
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N021148 002	5849700	Dec 15, 2015	U-340		I-572	Oct 31, 2011
	5849704	Dec 15, 2015			I-551	Sep 20, 2010
					I-536	May 31, 2010
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N021148 003	5633352	May 27, 2014			I-572	Oct 31, 2011
	5849700	Dec 15, 2015	U-340		I-551	Sep 20, 2010
	5849704	Dec 15, 2015			I-536	May 31, 2010
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 004	5849700	Dec 15, 2015	U-340		I-572	Oct 31, 2011
	5849704	Dec 15, 2015	DP U-340		I-551	Sep 20, 2010
					I-536	May 31, 2010
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 005	5849700	Dec 15, 2015	U-340		I-572	Oct 31, 2011
	5849704	Dec 15, 2015	DP U-340		I-551	Sep 20, 2010
					I-536	May 31, 2010
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 006	5849700	Dec 15, 2015	U-340		I-572	Oct 31, 2011
	5849704	Dec 15, 2015	DP U-340		I-551	Sep 20, 2010
					I-536	May 31, 2010
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 007	5849700	Dec 15, 2015	U-340		I-551	Sep 20, 2010
	5849704	Dec 15, 2015	DP U-340		I-536	May 31, 2010
					I-572	Oct 31, 2011
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NUTROPIN AQ</u>						
N020522 001	5763394	Jun 09, 2015		DP		
<u>SOMATROPIN RECOMBINANT - NUTROPIN AQ PEN</u>						
N020522 002	5763394	Jun 09, 2015		DP		
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N021075 001	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
	5912015	Mar 12, 2012				
	6051259	Dec 02, 2012	U-340			
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N021075 002	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
	5912015	Mar 12, 2012				
	6051259	Dec 02, 2012	U-340			
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N021075 003	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
	5912015	Mar 12, 2012				
	6051259	Dec 02, 2012	U-340			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
N019764 002	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
N019764 003	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N020604 001	5898030	Apr 27, 2016	DP		M-65	Jul 13, 2010
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N020604 002	5898030	Apr 27, 2016	DP		M-65	Jul 13, 2010
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N020604 003	5898030	Apr 27, 2016	DP		M-65	Jul 13, 2010
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N020604 004	5898030	Apr 27, 2016	DP		M-65	Jul 13, 2010
<u>SOMATROPIN RECOMBINANT - SEROSTIM LQ</u>						
N020604 005					M-65	Jul 13, 2010
<u>SOMATROPIN RECOMBINANT - VALTROPIN</u>						
N021905 001					NP	Apr 19, 2010
<u>SOMATROPIN RECOMBINANT - ZORBTIVE</u>						
N021597 001					ODE	Dec 01, 2010
<u>SOMATROPIN RECOMBINANT - ZORBTIVE</u>						
N021597 002					ODE	Dec 01, 2010
<u>SOMATROPIN RECOMBINANT - ZORBTIVE</u>						
N021597 003					ODE	Dec 01, 2010
<u>SOMATROPIN RECOMBINANT - ZORBTIVE</u>						
N021597 004	5288703	Oct 07, 2011		U-898	ODE	Dec 01, 2010
	5898030	Apr 27, 2016	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N021923 001	7235576	Jan 12, 2020	DS DP		I-546	Nov 16, 2010
	7351834	Jan 12, 2020	DS		NCE	Dec 20, 2010
					ODE	Nov 16, 2014
					ODE	Dec 20, 2012
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N022306 001					ODE	Jul 02, 2016
<u>SPARFLOXACIN - ZAGAM</u>						
N020677 001	4795751	Feb 04, 2010		U-160		
<u>STAVUDINE - ZERIT XR</u>						
N021453 001	7135465	Feb 18, 2023	DP	U-167		
	7135465*PED	Aug 18, 2023				
<u>STAVUDINE - ZERIT XR</u>						
N021453 002	7135465	Feb 18, 2023	DP	U-167		
	7135465*PED	Aug 18, 2023				
<u>STAVUDINE - ZERIT XR</u>						
N021453 003	7135465	Feb 18, 2023	DP	U-167		
	7135465*PED	Aug 18, 2023				
<u>STAVUDINE - ZERIT XR</u>						
N021453 004	7135465	Feb 18, 2023	DP	U-167		
	7135465*PED	Aug 18, 2023				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN - IMITREX</u>						
N020626 001	5307953	Dec 02, 2012				
	5307953*PED	Jun 02, 2013				
	5554639	Sep 10, 2013		U-232		
	5554639*PED	Mar 10, 2014				
	5705520	Dec 10, 2011		U-232		
	5705520*PED	Jun 10, 2012				
<u>SUMATRIPTAN - IMITREX</u>						
N020626 002	5307953	Dec 02, 2012				
	5307953*PED	Jun 02, 2013				
	5554639	Sep 10, 2013		U-232		
	5554639*PED	Mar 10, 2014				
	5705520	Dec 10, 2011		U-232		
	5705520*PED	Jun 10, 2012				
<u>SUMATRIPTAN - IMITREX</u>						
N020626 003	5307953	Dec 02, 2012				
	5307953*PED	Jun 02, 2013				
	5554639	Sep 10, 2013		U-232		
	5554639*PED	Mar 10, 2014				
	5705520	Dec 10, 2011		U-232		
	5705520*PED	Jun 10, 2012				
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
A076572 001					PC	Aug 08, 2009
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
A076840 001					PC	Aug 08, 2009
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
A076840 002					PC	Aug 08, 2009
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
A076840 003					PC	Aug 08, 2009
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	5891086	Jul 27, 2014	DP			
	5957886	Mar 08, 2016	DP			
	6135979	Mar 21, 2017	DP			
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 001	6573293	Feb 15, 2021	DS DP	U-703	NCE	Jan 26, 2011
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020		U-883		
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 002	6573293	Feb 15, 2021	DS DP	U-703	NCE	Jan 26, 2011
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020		U-883		
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 003	6573293	Feb 15, 2021	DS DP	U-703	NCE	Jan 26, 2011
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020		U-883		
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 004	6573293	Feb 15, 2021	DS DP	U-703	NCE	Jan 26, 2011
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020		U-883		
<u>TACROLIMUS - PROGRAF</u>						
N050708 001					ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>						
N050708 002					ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>						
N050708 003					ODE	Mar 29, 2013

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - PROGRAF</u>						
N050709 001	5260301	Feb 28, 2011	DP		ODE	Mar 29, 2013
<u>TACROLIMUS - PROTOPIC</u>						
N050777 001	5385907	Jan 31, 2012	DP			
	5665727	Sep 09, 2014		U-919		
<u>TACROLIMUS - PROTOPIC</u>						
N050777 002	5385907	Jan 31, 2012	DP			
	5665727	Sep 09, 2014		U-919		
<u>TADALAFIL - ADCIRCA</u>						
N022332 001	5859006	Nov 21, 2017	DS DP	U-975	NP	May 22, 2012
	6821975	Nov 19, 2020	DS DP		ODE	May 22, 2016
	7182958	Apr 26, 2020	DP			
<u>TADALAFIL - CIALIS</u>						
N021368 001	5859006	Nov 21, 2017	DS DP		D-111	Jan 07, 2011
	6140329	Jul 11, 2016	DP	U-155		
	6821975	Nov 19, 2020	DS DP	U-533		
	6821975	Nov 19, 2020	DS DP	U-614		
	6943166	Apr 26, 2020		U-155		
	6943166	Apr 26, 2020		U-614		
	7182958	Apr 26, 2020	DP	U-155		
<u>TADALAFIL - CIALIS</u>						
N021368 002	5859006	Nov 21, 2017	DS DP			
	6140329	Jul 11, 2016	DP	U-155		
	6821975	Nov 19, 2020	DS DP	U-533		
	6821975	Nov 19, 2020	DS DP	U-614		
	6943166	Apr 26, 2020		U-614		
	6943166	Apr 26, 2020		U-155		
	7182958	Apr 26, 2020	DP	U-155		
<u>TADALAFIL - CIALIS</u>						
N021368 003	5859006	Nov 21, 2017	DS DP			
	6140329	Jul 11, 2016	DP	U-155		
	6821975	Nov 19, 2020	DS DP	U-614		
	6821975	Nov 19, 2020	DS DP	U-533		
	6943166	Apr 26, 2020		U-614		
	7182958	Apr 26, 2020	DP	U-155		
<u>TADALAFIL - CIALIS</u>						
N021368 004	5859006	Nov 21, 2017	DS DP		D-111	Jan 07, 2011
	6140329	Jul 11, 2016	DP	U-155		
	6821975	Nov 19, 2020	DS DP	U-614		
	6821975	Nov 19, 2020	DS DP	U-533		
	6943166	Apr 26, 2020		U-614		
	7182958	Apr 26, 2020	DP	U-155		
<u>TAMOXIFEN CITRATE - SOLTAMOX</u>						
N021807 001	6127425	Jun 26, 2018	DP			
<u>TAMSULOSIN HYDROCHLORIDE - FLOMAX</u>						
N020579 001	4703063	Oct 27, 2009			M-54	Dec 22, 2012
	4703063*PED	Apr 27, 2010			PED	Jun 22, 2013
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 001	6071970	Jun 06, 2017			NCE	Nov 20, 2013
	RE39593	Jun 18, 2018	DS DP	U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 002	6071970	Jun 06, 2017			NCE	Nov 20, 2013
	RE39593	Jun 18, 2018	DS DP	U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 003	6071970	Jun 06, 2017			NCE	Nov 20, 2013
	RE39593	Jun 18, 2018	DS DP	U-931		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZAROTENE - AVAGE</u>						
N021184 003	5089509	Jun 13, 2011	U-481			
<u>TAZAROTENE - TAZORAC</u>						
N020600 001	5089509	Jun 13, 2011	U-193			
	5089509	Jun 13, 2011	U-481			
	5914334	Jun 07, 2014	U-517			
	6258830	Jun 07, 2014	U-517			
<u>TAZAROTENE - TAZORAC</u>						
N020600 002	5089509	Jun 13, 2011	U-481			
	5089509	Jun 13, 2011	U-193			
	5914334	Jun 07, 2014	U-517			
	6258830	Jun 07, 2014	U-517			
<u>TAZAROTENE - TAZORAC</u>						
N021184 001	5089509	Jun 13, 2011	U-481			
<u>TAZAROTENE - TAZORAC</u>						
N021184 002	5089509	Jun 13, 2011	U-481			
<u>TECHNETIUM TC-99M APCITIDE - ACUTECT</u>						
N020887 001	5443815	Aug 22, 2012				
	5508020	Apr 16, 2013				
	5645815	Jul 08, 2014				
<u>TECHNETIUM TC-99M BICISATE KIT - NEUROLITE</u>						
N020256 001	5431900	Jul 11, 2012	U-336			
<u>TECHNETIUM TC-99M SESTAMIBI KIT - CARDIOLITE</u>						
N019785 001					M-54 PED	Apr 30, 2011 Oct 30, 2011
<u>TECHNETIUM TC-99M TEBOROXIME KIT - CARDIOTEC</u>						
N019928 001	6056941	Jul 28, 2019	DP			
<u>TECHNETIUM TC-99M TETROFOSMIN KIT - MYOVUE</u>						
N020372 001	5045302	Feb 09, 2010				
<u>TEGASEROD MALEATE - ZELNORM</u>						
N021200 001	5510353	Apr 26, 2013	U-466			
<u>TEGASEROD MALEATE - ZELNORM</u>						
N021200 002	5510353	Apr 26, 2013	U-466			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	6635618	Sep 22, 2021	DS DP U-728		NCE	Sep 11, 2014
	6858584	Aug 24, 2022	DP			
	6872701	Jun 05, 2021	DP			
	7008923	May 06, 2021	U-1005			
	7208471	May 01, 2021	DS DP			
	7351691	May 01, 2021	DS DP U-728			
	7531623	Nov 26, 2026	DS			
	7544364	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	6635618	Sep 22, 2021	DS DP U-728		NCE	Sep 11, 2014
	6858584	Aug 24, 2022	DP			
	6872701	Jun 05, 2021	DP			
	7008923	May 06, 2021	U-1005			
	7208471	May 01, 2021	DS DP			
	7351691	May 01, 2021	DS DP U-728			
	7531623	Nov 26, 2026	DS			
	7544364	May 01, 2021	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TELBIVUDINE - TYZEKA</u>						
N022011 001	6395716	Aug 10, 2019	U-782		NCE	Oct 25, 2011
	6444652	Aug 10, 2019	U-782			
	6566344	Aug 10, 2019	U-782			
	6569837	Oct 25, 2020	U-999			
	6569837	Oct 25, 2020	U-782			
	7589079	Sep 11, 2023	DS DP U-999			
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001	6395716	Aug 10, 2019	U-999		NCE	Oct 25, 2011
	6444652	Aug 10, 2019	U-999			
	6566344	Aug 10, 2019	U-999			
	6569837	Oct 25, 2020	U-999			
<u>TELITHROMYCIN - KETEK</u>						
N021144 001	5635485	Apr 01, 2018	DS DP U-578			
	D459798	Sep 24, 2015	DP			
<u>TELITHROMYCIN - KETEK</u>						
N021144 002	5635485	Apr 01, 2018	DS DP U-578			
	D459798	Sep 24, 2015	DP			
<u>TELMISARTAN - MICARDIS</u>						
N020850 001	5591762	Jan 07, 2014	U-3			
	6358986	Jan 10, 2020				
<u>TELMISARTAN - MICARDIS</u>						
N020850 002	5591762	Jan 07, 2014	DS DP U-3		I-612	Oct 16, 2012
	6358986	Jan 10, 2020				
<u>TELMISARTAN - MICARDIS</u>						
N020850 003	5591762	Jan 07, 2014	U-3			
	6358986	Jan 10, 2020				
<u>TEMAZEPAM - RESTORIL</u>						
N018163 003	5211954	May 18, 2010				
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 001	5260291	Aug 11, 2013	DS DP U-619		ODE	Mar 15, 2012
	5260291*PED	Feb 11, 2014				
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 002	5260291	Aug 11, 2013	DS DP U-619		ODE	Mar 15, 2012
	5260291*PED	Feb 11, 2014				
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 003	5260291	Aug 11, 2013	DS DP U-619		ODE	Mar 15, 2012
	5260291*PED	Feb 11, 2014				
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 004	5260291	Aug 11, 2013	DS DP U-619		ODE	Mar 15, 2012
	5260291*PED	Feb 11, 2014				
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 005	5260291	Aug 11, 2013	DS DP U-619		ODE	Mar 15, 2012
	5260291*PED	Feb 11, 2014				
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 006	5260291	Aug 11, 2013	DS DP U-619		ODE	Mar 15, 2012
	5260291*PED	Feb 11, 2014				
<u>TEMOZOLOMIDE - TEMODAR</u>						
N022277 001	5260291	Aug 11, 2013	DS DP U-619			
	5260291*PED	Feb 11, 2014				
	6987108	Sep 08, 2023	DP			
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	5362718	Apr 18, 2014	DS DP		NCE	May 30, 2012
					ODE	May 30, 2014

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001	5922695	Jul 25, 2017	DS	U-250	I-569	Aug 11, 2011
	5922695	Jul 25, 2017	DS	U-248		
	5922695	Jul 25, 2017	DS	U-999		
	5922695	Jul 25, 2017	DS	U-256		
	5935946	Jul 25, 2017	DS DP	U-999		
	5935946	Jul 25, 2017	DS DP	U-250		
	5935946	Jul 25, 2017	DS DP	U-248		
	5935946	Jul 25, 2017	DS DP	U-256		
	5977089	Jul 25, 2017	DS DP	U-248		
	5977089	Jul 25, 2017	DS DP	U-999		
	5977089	Jul 25, 2017	DS DP	U-256		
	5977089	Jul 25, 2017	DS DP	U-250		
	6043230	Jul 25, 2017		U-248		
	6043230	Jul 25, 2017		U-256		
	6043230	Jul 25, 2017		U-250		
	6043230	Jul 25, 2017		U-999		
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N019057 001	5212176	Jun 29, 2010				
	5294615	Apr 29, 2013		U-165		
	5294615	Apr 29, 2013		U-3		
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N019057 002	5212176	Jun 29, 2010				
	5294615	Apr 29, 2013		U-165		
	5294615	Apr 29, 2013		U-3		
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N019057 003	5212176	Jun 29, 2010				
	5294615	Apr 29, 2013		U-165		
	5294615	Apr 29, 2013		U-3		
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N019057 004	5212176	Jun 29, 2010				
	5294615	Apr 29, 2013		U-165		
	5294615	Apr 29, 2013		U-3		
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N020347 001	5212176	Jun 29, 2010				
	5294615	Apr 29, 2013		U-3		
	5294615	Apr 29, 2013		U-165		
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N020347 002	5212176	Jun 29, 2010				
	5294615	Apr 29, 2013		U-165		
	5294615	Apr 29, 2013		U-3		
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N020347 003	5212176	Jun 29, 2010				
	5294615	Apr 29, 2013		U-3		
	5294615	Apr 29, 2013		U-165		
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N020347 004	5212176	Jun 29, 2010				
	5294615	Apr 29, 2013		U-3		
	5294615	Apr 29, 2013		U-165		
	5412095	Apr 29, 2013				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TERBINAFFINE - LAMISIL</u>						
N020846 001	5681849	Oct 28, 2014	DP			
	5681849*PED	Apr 28, 2015				
	5856355	May 18, 2012	DP U-502			
	5856355	May 18, 2012	DP U-540			
	5856355	May 18, 2012	DP U-504			
	5856355*PED	Nov 18, 2012				
	6005001	May 18, 2012	DP U-502			
	6005001	May 18, 2012	DP U-540			
	6005001	May 18, 2012	DP U-504			
	6005001*PED	Nov 18, 2012				
	6121314	May 18, 2012	DP U-504			
	6121314	May 18, 2012	DP U-540			
	6121314	May 18, 2012	DP U-502			
	6121314*PED	Nov 18, 2012				
<u>TERBINAFFINE - LAMISIL AT</u>						
N021958 001	5681849	Oct 28, 2014	DP			
	5856355	May 18, 2012	DP U-504			
	5856355	May 18, 2012	DP U-540			
	6121314	May 18, 2012	U-540			
	6121314	May 18, 2012	U-504			
<u>TERBINAFFINE HYDROCHLORIDE - LAMISIL</u>						
N020749 001	6121314	May 18, 2012	U-502			
	6121314*PED	Nov 18, 2012				
<u>TERBINAFFINE HYDROCHLORIDE - LAMISIL AT</u>						
N021124 001	5681849	Oct 28, 2014				
	5681849*PED	Apr 28, 2015				
	6121314	May 18, 2012	U-504			
	6121314*PED	Nov 18, 2012				
<u>TERBINAFFINE HYDROCHLORIDE - LAMISIL AT</u>						
N021124 002	5681849	Oct 28, 2014				
	5681849*PED	Apr 28, 2015				
	6121314	May 18, 2012	U-504			
	6121314*PED	Nov 18, 2012				
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N021318 001	6770623	Dec 08, 2018	DP U-597		I-602	Jul 22, 2012
	6977077	Aug 19, 2019	U-597			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-790			
	7351414	Aug 19, 2019	U-865			
	7550434	Dec 08, 2018	DP U-982			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N021318 002	6770623	Dec 08, 2018	DP U-982		I-602	Jul 22, 2012
	6977077	Aug 19, 2019	U-994			
	6977077	Aug 19, 2019	U-982			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-983			
	7163684	Aug 19, 2019	U-994			
	7351414	Aug 19, 2019	U-994			
	7351414	Aug 19, 2019	U-984			
	7550434	Dec 08, 2018	DP U-982			
<u>TESTOSTERONE - ANDRODERM</u>						
N020489 001	5152997	Dec 11, 2010	U-490			
	5164190	Dec 11, 2010				
<u>TESTOSTERONE - ANDRODERM</u>						
N020489 002	5152997	Dec 11, 2010	U-490			
	5164190	Dec 11, 2010				
<u>TESTOSTERONE - ANDROGEL</u>						
N021015 001	6503894	Aug 30, 2020	U-490			
	6503894*PED	Mar 01, 2021				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N021015 002	6503894	Aug 30, 2020	U-490			
	6503894*PED	Mar 01, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N021015 003	6503894	Aug 30, 2020	U-490			
	6503894*PED	Mar 01, 2021				
<u>TESTOSTERONE - STRIANT</u>						
N021543 001	6248358	Aug 23, 2019	U-527			
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	7320968	Jan 18, 2025	U-843			
	7608605	Apr 21, 2023	U-1009			
	7608606	Apr 21, 2023	U-1009			
	7608607	Apr 21, 2023	U-1009			
	7608608	Apr 21, 2023	U-1009			
	7608609	Apr 21, 2023	U-1009			
	7608610	Apr 21, 2023	U-1009			
<u>TESTOSTERONE - TESTODERM</u>						
N019762 001	5840327	Aug 15, 2016				
<u>TESTOSTERONE - TESTODERM</u>						
N019762 002	5840327	Aug 15, 2016				
<u>TESTOSTERONE - TESTODERM TTS</u>						
N020791 001	6348210	Nov 10, 2019	U-440			
<u>TETRABENAZINE - XENAZINE</u>						
N021894 001					NCE	Aug 15, 2013
					ODE	Aug 15, 2015
<u>TETRABENAZINE - XENAZINE</u>						
N021894 002					NCE	Aug 15, 2013
					ODE	Aug 15, 2015
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	5629327	May 13, 2014	U-731		ODE	May 25, 2013
	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6235756	Mar 01, 2013	U-731			
	6315720	Oct 23, 2020	U-731			
	6315720	Oct 23, 2020	U-442			
	6561976	Aug 28, 2018	U-731			
	6561976	Aug 28, 2018	U-371			
	6561977	Oct 23, 2020	U-731			
	6561977	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-371			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	5629327	May 13, 2014	U-731		ODE	May 25, 2013
	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6235756	Mar 01, 2013	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-731			
	6561976	Aug 28, 2018	U-371			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-733			
	6869399	Oct 23, 2020	U-732			
	6908432	Aug 28, 2018	U-731			
	6908432	Aug 28, 2018	U-371			
	7141018	Oct 23, 2020	U-733			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-371			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	5629327	May 13, 2014	U-731		ODE	May 25, 2013
	6045501	Aug 28, 2018	U-731			
	6045501	Aug 28, 2018	U-371			
	6235756	Mar 01, 2013	U-731			
	6315720	Oct 23, 2020	U-731			
	6315720	Oct 23, 2020	U-442			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-731			
	6561977	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-733			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-371			
	6908432	Aug 28, 2018	U-731			
	6908432	Aug 28, 2018	U-371			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	5629327	May 13, 2014	U-731		ODE	May 23, 2013
	6045501	Aug 28, 2018	U-731			
	6235756	Mar 01, 2013	U-731			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-731			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-731			
	7435745	Nov 03, 2017	U-899			
<u>THYROTROPIN ALFA - THYROGEN</u>						
N020898 001	5840566	Nov 24, 2015			I-552	Dec 14, 2010
	6365127	Nov 24, 2015	DS DP U-556		ODE	Dec 14, 2014

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N020646 001	5010090	Sep 30, 2011				
	5354760	Mar 24, 2012				
	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N020646 002	5010090	Sep 30, 2011				
	5354760	Mar 24, 2012				
	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N020646 003	5010090	Sep 30, 2011				
	5354760	Mar 24, 2012				
	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N020646 004	5010090	Sep 30, 2011				
	5354760	Mar 24, 2012				
	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N020646 005	5010090	Sep 30, 2011				
	5354760	Mar 24, 2012				
	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIGECYCLINE - TYGACIL</u>						
N021821 001	RE40086	Jun 25, 2013		U-282	I-588	Mar 20, 2012
	RE40183	Apr 09, 2016	DS DP		I-587	Mar 20, 2012
					I-586	Mar 20, 2012
					NCE	Jun 15, 2010
<u>TILUDRONATE DISODIUM - SKELID</u>						
N020707 001	4876248	Jan 30, 2010				
<u>TIMOLOL - BETIMOL</u>						
N020439 001	5231095	Jul 27, 2010				
<u>TIMOLOL - BETIMOL</u>						
N020439 002	5231095	Jul 27, 2010				
<u>TIMOLOL MALEATE - ISTALOL</u>						
N021516 001	6335335	Nov 02, 2018	DP			
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N020963 001	6174524	Mar 26, 2019	DP		M-14	Jun 08, 2010
	6174524*PED	Sep 26, 2019			PED	Dec 08, 2010
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N020963 002	6174524	Mar 26, 2019	DP			
	6174524*PED	Sep 26, 2019				
<u>TINIDAZOLE - TINDAMAX</u>						
N021618 001					I-532	May 21, 2010
					ODE	May 17, 2011
					ODE	May 17, 2011
<u>TINIDAZOLE - TINDAMAX</u>						
N021618 002					I-532	May 21, 2010
					ODE	May 17, 2011
					ODE	May 17, 2011

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>						
N021395 001	5478578	Dec 26, 2012	DP		M-89	Dec 17, 2012
	6777423	Sep 24, 2021	DS DP			
	6908928	Nov 25, 2022	DS DP U-566			
	7070800	Jan 22, 2022	DP U-566			
	7309707	Mar 10, 2023	DS DP			
	RE38912	Oct 11, 2021	DP			
	RE39820	Jan 30, 2018	DS DP U-566			
<u>TIPRANAVIR - APTIVUS</u>						
N021814 001	5852195	Jun 22, 2019	DS		I-568	Jun 23, 2011
	5852195*PED	Dec 22, 2019			NCE	Jun 22, 2010
	6147095	Oct 29, 2019		U-670	PED	Dec 23, 2011
	6147095*PED	Apr 29, 2020			PED	Dec 22, 2010
	6169181	May 06, 2014	DS			
	6169181*PED	Nov 06, 2014				
	6231887	Jul 27, 2018	DP			
	6231887*PED	Jan 27, 2019				
<u>TIPRANAVIR - APTIVUS</u>						
N022292 001	5852195	Jun 22, 2019	DS		I-568	Jun 23, 2011
	5852195*PED	Dec 22, 2019			NCE	Jun 22, 2010
	6147095	Oct 29, 2019		U-670	PED	Dec 23, 2011
	6147095*PED	Apr 29, 2020			PED	Dec 22, 2010
	6169181	May 06, 2014	DS			
	6169181*PED	Nov 06, 2014				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N020912 001	5292756	May 14, 2012		U-230		
	5658929	Sep 27, 2010				
	5733919	Oct 23, 2016				
	5880136	Sep 27, 2010		U-254		
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N020913 001	5292756	May 14, 2012		U-230		
	5658929	Sep 27, 2010				
	5733919	Oct 23, 2016				
	5880136	Sep 27, 2010		U-254		
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N020913 002	5292756	May 14, 2012		U-230		
	5658929	Sep 27, 2010				
	5733919	Oct 23, 2016				
	5880136	Sep 27, 2010		U-254		
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N020913 003	5292756	May 14, 2012		U-230		
	5658929	Sep 27, 2010				
	5733919	Oct 23, 2016				
	5880136	Sep 27, 2010		U-254		
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 001	6455557	Nov 28, 2021				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 002	6455557	Nov 28, 2021				
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 003	6455557	Nov 28, 2021				
<u>TOBRAMYCIN - TOBI</u>						
N050753 001	5508269	Oct 19, 2014	DP U-909			
<u>TOLCAPONE - TASMAR</u>						
N020697 001	5236952	Jan 29, 2012				
	5476875	Dec 19, 2012		U-219		
<u>TOLCAPONE - TASMAR</u>						
N020697 002	5236952	Jan 29, 2012				
	5476875	Dec 19, 2012		U-219		
<u>TOLTERODINE TARTRATE - DETROL</u>						
N020771 001	5382600	Mar 25, 2012				
	5382600*PED	Sep 25, 2012				
<u>TOLTERODINE TARTRATE - DETROL</u>						
N020771 002	5382600	Mar 25, 2012				
	5382600*PED	Sep 25, 2012				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N021228 001	5382600	Mar 25, 2012				
	5382600*PED	Sep 25, 2012				
	6630162	Nov 11, 2019	DP U-544			
	6630162*PED	May 11, 2020				
	6770295	Aug 26, 2019	DP U-544			
	6770295*PED	Feb 26, 2020				
	6911217	Aug 26, 2019	DP U-544			
	6911217*PED	Feb 26, 2020	DP U-544			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N021228 002	5382600	Mar 25, 2012				
	5382600*PED	Sep 25, 2012				
	6630162	Nov 11, 2019	DP U-544			
	6630162*PED	May 11, 2020				
	6770295	Aug 26, 2019	DP U-544			
	6770295*PED	Feb 26, 2020				
	6911217	Aug 26, 2019	DP U-544			
	6911217*PED	Feb 26, 2020	DP U-544			
<u>TOLVAPTAN - SAMSCA</u>						
N022275 001	5258510	Nov 02, 2010	DS		NCE	May 19, 2014
	5753677	May 19, 2015		U-978		
<u>TOLVAPTAN - SAMSCA</u>						
N022275 002	5258510	Nov 02, 2010	DS		NCE	May 19, 2014
	5753677	May 19, 2015		U-978		
<u>TOLVAPTAN - SAMSCA</u>						
N022275 003	5258510	Nov 02, 2010	DS		NCE	May 19, 2014
	5753677	May 19, 2015		U-978		
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 001	5998380	Oct 13, 2015		U-598	M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015		U-598		
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015		U-723		
	7018983*PED	Apr 13, 2016				
	7498311	Oct 13, 2015		U-955		
	7498311*PED	Apr 13, 2016				



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 002	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 003	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 004	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 005	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 006	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7125560	Mar 01, 2019	U-766			
	7125560*PED	Sep 01, 2019				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7125560	Mar 01, 2019	U-766			
	7125560*PED	Sep 01, 2019				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
N020844 003	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7125560	Mar 01, 2019	U-766			
	7125560*PED	Sep 01, 2019				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPIRAMATE</u>						
A076448 001					PC	Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
A076448 002					PC	Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
A077868 001					PC	Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
A077868 002					PC	Oct 12, 2009
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020671 001	5004758	May 28, 2010	DS DP U-741			
	5004758*PED	Nov 28, 2010				
	5674872	Oct 07, 2014	U-910			
	5674872*PED	Apr 07, 2015				
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 001	5004758	May 28, 2010	DS DP U-830		NDF	Oct 11, 2010
	5004758*PED	Nov 28, 2010				
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 002	5004758	May 28, 2010	DS DP U-830		NDF	Oct 11, 2010
	5004758*PED	Nov 28, 2010				
<u>TOREMIFENE CITRATE - FARESTON</u>						
N020497 001	4696949	Sep 29, 2009	U-196			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 001	5591452	May 10, 2014	DP		NP	Dec 30, 2011
	6254887	May 10, 2014	DP			
	6607748	Jun 29, 2020	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 002	5591452	May 10, 2014	DP		NP	Dec 30, 2011
	6254887	May 10, 2014	DP			
	6607748	Jun 29, 2020	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 003	5591452	May 10, 2014	DP		NP	Dec 30, 2011
	6254887	May 10, 2014	DP			
	6607748	Jun 29, 2020	DP			
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
N021693 001	5464632	Mar 22, 2013	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N020281 001	6339105	Oct 12, 2019				
	6339105*PED	Apr 12, 2020		U-435		
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N020281 002	6339105	Oct 12, 2019				
	6339105*PED	Apr 12, 2020		U-435		
<u>TRAMADOL HYDROCHLORIDE - ULTRAM ER</u>						
N021692 001	6254887	May 10, 2014				
	7074430	May 10, 2014		DP		
<u>TRAMADOL HYDROCHLORIDE - ULTRAM ER</u>						
N021692 002	6254887	May 10, 2014				
	7074430	May 10, 2014		DP		
<u>TRAMADOL HYDROCHLORIDE - ULTRAM ER</u>						
N021692 003	6254887	May 10, 2014				
	7074430	May 10, 2014		DP		
<u>TRANDOLAPRIL - MAVIK</u>						
N020528 001	5744496	Apr 28, 2015				
<u>TRANDOLAPRIL - MAVIK</u>						
N020528 002	5744496	Apr 28, 2015				
<u>TRANDOLAPRIL - MAVIK</u>						
N020528 003	5744496	Apr 28, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N020591 001	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N020591 002	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N020591 003	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N020591 004	5721244	Feb 24, 2015				
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N022430 001					NDF	Nov 13, 2012
<u>TRAVOPROST - TRAVATAN</u>						
N021257 001	5510383	Aug 03, 2013				
	5631287	Dec 22, 2014		DP		U-383
	5849792	Dec 22, 2014		DP		U-382
	5889052	Dec 02, 2014		DP		U-383
	6011062	Dec 22, 2014		DP		U-383
<u>TRAVOPROST - TRAVATAN Z</u>						
N021994 001	5510383	Aug 03, 2013				
	5889052	Dec 02, 2014		DP		U-383
	6503497	May 06, 2012		DP		
	6849253	May 06, 2012		DP		
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 001	5153222	Oct 06, 2014				
	6765117	Oct 24, 2017		DS		U-455
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 002	5153222	Oct 06, 2014				
	6765117	Oct 24, 2017		DS		U-455
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 003	5153222	Oct 06, 2014				
	6765117	Oct 24, 2017		DS		U-455

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 004	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
<u>TREPROSTINIL SODIUM - TYVASO</u>						
N022387 001	5153222	Oct 16, 2014		U-1019	NDF	Jul 30, 2012
	6521212	Nov 13, 2018		U-1018		
	6756033	Nov 13, 2018		U-1018		
	6765117	Oct 24, 2017	DS			
<u>TRETINOIN - ATRALIN</u>						
N022070 001	5670547	Sep 23, 2014	DP		NP	Jul 26, 2010
<u>TRETINOIN - RENOVA</u>						
N021108 001	6531141	Mar 07, 2020				
<u>TRETINOIN - RETIN-A MICRO</u>						
N020475 001	5955109	Sep 21, 2016	DP	U-134		
<u>TRETINOIN - RETIN-A MICRO</u>						
N020475 002	5955109	Sep 21, 2016		U-134		
<u>TRIAMCINOLONE ACETONIDE - NASACORT AQ</u>						
N020468 001	5976573	Jul 03, 2016	DP	U-295	NPP	Sep 19, 2011
	5976573	Jul 03, 2016	DP	U-896		
	6143329	Jul 03, 2016	DP	U-896		
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N022048 001	6395294	Jan 13, 2020	DP	U-846	NP	Nov 29, 2010
<u>TRIMETHOPRIM HYDROCHLORIDE - PRIMISOL</u>						
A074973 001	5763449	Aug 07, 2016				
	5962461	Aug 07, 2016				
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N020326 001	6017922	May 18, 2018				
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N020326 002	6017922	May 18, 2018				
<u>TRIPTORELIN PAMOATE - TRELSTAR DEPOT</u>						
N020715 001	5225205	Jul 20, 2010				
	5776885	Jul 07, 2015				
<u>TRIPTORELIN PAMOATE - TRELSTAR LA</u>						
N021288 001	5225205	Jul 20, 2010				
<u>TROGLITAZONE - PRELAY</u>						
N020719 001	5602133	Sep 15, 2013		U-173		
	5859037	Nov 13, 2017		U-251		
	6011049	Nov 13, 2017		U-301		
	6046202	Sep 15, 2013		U-317		
<u>TROGLITAZONE - PRELAY</u>						
N020719 002	5602133	Sep 15, 2013		U-173		
	5859037	Nov 13, 2017		U-251		
	6011049	Nov 13, 2017		U-301		
	6046202	Sep 15, 2013		U-317		
<u>TROGLITAZONE - PRELAY</u>						
N020719 003	5602133	Sep 15, 2013		U-173		
	5859037	Nov 13, 2017		U-251		
	6011049	Nov 13, 2017		U-301		
	6046202	Sep 15, 2013		U-317		
<u>TROGLITAZONE - REZULIN</u>						
N020720 001	5602133	Sep 15, 2013		U-173		
	5859037	Nov 13, 2017		U-251		
	6011049	Nov 13, 2017		U-301		
	6046202	Sep 15, 2013		U-317		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TROGLITAZONE - REZULIN</u>						
N020720 002	5602133	Sep 15, 2013		U-173		
	5859037	Nov 13, 2017		U-251		
	6011049	Nov 13, 2017		U-301		
	6046202	Sep 15, 2013		U-317		
<u>TROGLITAZONE - REZULIN</u>						
N020720 003	5602133	Sep 15, 2013		U-173		
	5859037	Nov 13, 2017		U-251		
	6011049	Nov 13, 2017		U-301		
	6046202	Sep 15, 2013		U-317		
<u>TROSPIDIUM CHLORIDE - SANCTURA XR</u>						
N022103 001	7410978	Feb 01, 2025	DP		NDF	Aug 03, 2010
<u>TROVAFLOXACIN MESYLATE - TROVAN</u>						
N020759 001	5164402	Dec 18, 2011		U-282		
	5763454	Jun 15, 2015		U-282		
	6187341	Jan 20, 2019				
<u>TROVAFLOXACIN MESYLATE - TROVAN</u>						
N020759 002	5164402	Dec 18, 2011		U-282		
	5763454	Jun 15, 2015		U-282		
	6187341	Jan 20, 2019				
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N022278 001					NCE	Dec 16, 2009
					ODE	Dec 16, 2011
<u>TRYPAN BLUE - VISIONBLUE</u>						
N021670 001					NCE	Dec 16, 2009
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N021214 001	5166178	Nov 24, 2009		U-333		
	5208256	May 21, 2011	DP	U-333		
	5212200	May 18, 2010		U-333		
	5221763	Jul 15, 2012	DS			
	6458836	Jul 09, 2021		U-333		
<u>UREA, C-13 - BREATHTEK UBT FOR H-PYLORI</u>						
N020586 002	4830010	Oct 27, 2009		U-147		
	5140993	Aug 24, 2009		U-148		
<u>UREA, C-13 - MERETEK UBT KIT (W/ PRANACTIN)</u>						
N020586 001	4830010	Oct 27, 2009		U-147		
	5140993	Aug 24, 2009		U-148		
<u>UROFOLLITROPIN - FERTINEX</u>						
N019415 004	5767067	Jun 16, 2015				
<u>UROFOLLITROPIN - FERTINEX</u>						
N019415 005	5767067	Jun 16, 2015				
<u>VALACYCLOVIR HYDROCHLORIDE - VALACYCLOVIR HYDROCHLORIDE</u>						
A076588 001					PC	May 24, 2010
<u>VALACYCLOVIR HYDROCHLORIDE - VALACYCLOVIR HYDROCHLORIDE</u>						
A076588 002					PC	May 24, 2010
<u>VALACYCLOVIR HYDROCHLORIDE - VALTREX</u>						
N020487 001	4957924*PED	Dec 23, 2009			I-570	Sep 02, 2011
	5879706	Jan 19, 2016	DP	U-530	NPP	Sep 02, 2011
	5879706	Jan 19, 2016	DP	U-894	PED	Mar 02, 2012
	5879706*PED	Jul 19, 2016			PED	Mar 02, 2012
	6107302	Jan 19, 2016	DS	U-530		
	6107302	Jan 19, 2016	DS	U-894		
	6107302*PED	Jul 19, 2016				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VALACYCLOVIR HYDROCHLORIDE - VALTREX</u>						
N020487 002	4957924*PED	Dec 23, 2009			I-570	Sep 02, 2011
	5879706	Jan 19, 2016	DP	U-530	NPP	Sep 02, 2011
	5879706	Jan 19, 2016	DP	U-894	PED	Mar 02, 2012
	5879706*PED	Jul 19, 2016			PED	Mar 02, 2012
	6107302	Jan 19, 2016	DS	U-894		
	6107302	Jan 19, 2016	DS	U-530		
	6107302*PED	Jul 19, 2016				
<u>VALDECOXIB - BEXTRA</u>						
N021341 002	5633272	Feb 13, 2015		U-462		
	7135489	Aug 12, 2017	DS DP			
<u>VALDECOXIB - BEXTRA</u>						
N021341 003	5633272	Feb 13, 2015		U-462		
	7135489	Aug 12, 2017	DS DP			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N021304 001	6083953	Mar 29, 2015	DS DP	U-384	I-604	Aug 28, 2012
	6083953	Mar 29, 2015	DS DP	U-854	PED	Feb 28, 2013
	6083953*PED	Sep 29, 2015				
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N022257 001	6083953	Mar 29, 2015	DS DP	U-384	NDF	Aug 28, 2012
	6083953	Mar 29, 2015	DS DP	U-854	PED	Feb 28, 2013
<u>VALSARTAN - DIOVAN</u>						
N020665 001	5399578	Mar 21, 2012		U-3		
	5399578*PED	Sep 21, 2012				
<u>VALSARTAN - DIOVAN</u>						
N020665 002	5399578	Mar 21, 2012		U-3		
	5399578*PED	Sep 21, 2012				
<u>VALSARTAN - DIOVAN</u>						
N021283 001	5399578	Mar 21, 2012			I-550	Nov 29, 2010
	5399578*PED	Sep 21, 2012			PED	May 29, 2011
	5972990	Oct 26, 2016		U-692		
	5972990*PED	Apr 26, 2017				
	6294197	Jun 18, 2017		U-3		
	6294197*PED	Dec 18, 2017				
<u>VALSARTAN - DIOVAN</u>						
N021283 002	5399578	Mar 21, 2012			I-550	Nov 29, 2010
	5399578*PED	Sep 21, 2012			PED	May 29, 2011
	5972990	Oct 26, 2016		U-692		
	5972990*PED	Apr 26, 2017				
	6294197	Jun 18, 2017		U-3		
	6294197*PED	Dec 18, 2017				
<u>VALSARTAN - DIOVAN</u>						
N021283 003	5399578	Mar 21, 2012			I-550	Nov 29, 2010
	5399578*PED	Sep 21, 2012			PED	May 29, 2011
	5972990	Oct 26, 2016		U-692		
	5972990*PED	Apr 26, 2017				
	6294197	Jun 18, 2017		U-3		
	6294197*PED	Dec 18, 2017				
<u>VALSARTAN - DIOVAN</u>						
N021283 004	5399578	Mar 21, 2012			I-550	Nov 29, 2010
	5399578*PED	Sep 21, 2012			PED	May 29, 2011
	5972990	Oct 26, 2016		U-692		
	5972990*PED	Apr 26, 2017				
	6294197	Jun 18, 2017		U-3		
	6294197*PED	Dec 18, 2017				
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 001	6362178	Oct 31, 2018	DS DP	U-533		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 002	6362178	Oct 31, 2018	DS DP U-533			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 003	6362178	Oct 31, 2018	DS DP U-533			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 004	6362178	Oct 31, 2018	DS DP U-533			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 001	6410550	May 10, 2020	DS DP U-56		NCE	May 10, 2011
	6890927	May 06, 2022	DS DP U-56			
	7265119	Aug 19, 2022	DS DP U-56			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 002	6410550	May 10, 2020	DS DP U-56		NCE	May 10, 2011
	6890927	May 06, 2022	DS DP U-56			
	7265119	Aug 19, 2022	DS DP U-56			
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N020699 001	5916923	Jun 28, 2013		U-398	I-561	Dec 14, 2010
	5916923*PED	Dec 28, 2013		U-398		
	6274171	Mar 20, 2017				
	6274171*PED	Sep 20, 2017				
	6310101	Jun 28, 2013		U-46		
	6403120	Mar 20, 2017		U-451		
	6403120	Mar 20, 2017		U-535		
	6403120*PED	Sep 20, 2017		U-535		
	6403120*PED	Sep 20, 2017		U-451		
	6419958	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958*PED	Sep 20, 2017		U-535		
	6419958*PED	Sep 20, 2017		U-459		
	6444708	Jun 28, 2013		U-398		
	6444708*PED	Dec 28, 2013		U-398		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N020699 002	5916923	Jun 28, 2013		U-398	I-561	Dec 14, 2010
	5916923*PED	Dec 28, 2013		U-398		
	6274171	Mar 20, 2017				
	6274171*PED	Sep 20, 2017				
	6310101	Jun 28, 2013		U-46		
	6403120	Mar 20, 2017		U-451		
	6403120	Mar 20, 2017		U-535		
	6403120*PED	Sep 20, 2017		U-535		
	6403120*PED	Sep 20, 2017		U-451		
	6419958	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958*PED	Sep 20, 2017		U-535		
	6419958*PED	Sep 20, 2017		U-459		
	6444708	Jun 28, 2013		U-398		
	6444708*PED	Dec 28, 2013		U-398		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N020699 003	5916923	Jun 28, 2013		U-398	I-561	Dec 14, 2010
	5916923*PED	Dec 28, 2013		U-398		
	6274171	Mar 20, 2017				
	6274171*PED	Sep 20, 2017				
	6403120	Mar 20, 2017		U-535		
	6403120	Mar 20, 2017		U-451		
	6403120*PED	Sep 20, 2017		U-451		
	6403120*PED	Sep 20, 2017		U-535		
	6419958	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958*PED	Sep 20, 2017		U-459		
	6419958*PED	Sep 20, 2017		U-535		
	6444708	Jun 28, 2013		U-398		
	6444708*PED	Dec 28, 2013		U-398		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N020699 004	5916923	Jun 28, 2013	U-398		I-561	Dec 14, 2010
	5916923*PED	Dec 28, 2013	U-398			
	6274171	Mar 20, 2017				
	6274171*PED	Sep 20, 2017				
	6310101	Jun 28, 2013	U-46			
	6403120	Mar 20, 2017	U-451			
	6403120	Mar 20, 2017	U-535			
	6403120*PED	Sep 20, 2017	U-451			
	6403120*PED	Sep 20, 2017	U-535			
	6419958	Mar 20, 2017	U-459			
	6419958	Mar 20, 2017	U-535			
	6419958*PED	Sep 20, 2017	U-459			
	6419958*PED	Sep 20, 2017	U-535			
	6444708	Jun 28, 2013	U-398			
	6444708*PED	Dec 28, 2013	U-398			
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N022104 001	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N022104 002	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N022104 003	6403120	Mar 20, 2017	U-839			
	6403120	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N022104 004	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N020552 001	5160744	Jun 27, 2011				
	5232705	Aug 31, 2010				
	5252338	Jun 27, 2011				
	5785994	Oct 22, 2009	U-315			
	6096339	Apr 04, 2017	U-365			
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N020552 002	5160744	Jun 27, 2011				
	5232705	Aug 31, 2010				
	5252338	Jun 27, 2011				
	5785994	Oct 22, 2009	U-315			
	6096339	Apr 04, 2017	U-365			
<u>VERTEPORFIN - VISUDYNE</u>						
N021119 001	5095030	Sep 09, 2011	DS			
	5214036	May 25, 2010				
	5707608	Aug 02, 2015				
	5756541	Mar 11, 2016	U-357			
	5770619	Jan 06, 2015	U-357			
	5798349	Aug 25, 2015	U-357			
	6074666	Feb 05, 2012				
<u>VIGABATRIN - SABRIL</u>						
N020427 001					NCE	Aug 21, 2014
<u>VIGABATRIN - SABRIL</u>						
N022006 001					NCE	Aug 21, 2014
					ORF	Aug 21, 2016



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VORICONAZOLE - VFEND</u>						
N021266 001	5116844	Aug 11, 2009	DP U-540			
	5364938	Nov 15, 2011	DS			
	5567817	May 24, 2016	DS DP U-540			
	5773443	Jan 25, 2011	DS DP U-540			
<u>VORICONAZOLE - VFEND</u>						
N021266 002	5116844	Aug 11, 2009	DP U-540			
	5364938	Nov 15, 2011	DS			
	5567817	May 24, 2016	DS DP U-540			
	5773443	Jan 25, 2011	DS DP U-540			
<u>VORICONAZOLE - VFEND</u>						
N021267 001	5116844	Aug 11, 2009	DP U-540			
	5134127	Jan 23, 2010	DP			
	5364938	Nov 15, 2011	DS			
	5376645	Jan 23, 2010	DP			
	5567817	May 24, 2016	DS DP U-540			
	5773443	Jan 25, 2011	DS DP U-540			
	6632803	Jun 02, 2018	DP			
<u>VORICONAZOLE - VFEND</u>						
N021630 001	5116844	Aug 11, 2009	DP U-540			
	5364938	Nov 15, 2011	DS			
	5567817	May 24, 2016	DS DP U-540			
	5773443	Jan 25, 2011	DS DP U-540			
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	6087367	Oct 04, 2011		U-776	NCE	Oct 06, 2011
	7399787	Feb 09, 2025		U-892	ODE	Oct 06, 2013
	7456219	Nov 14, 2026	DS			
	RE38506	Nov 29, 2011	DS DP			
<u>ZAFIRLUKAST - ACCOLATE</u>						
N020547 001	4859692	Sep 26, 2010				
	5294636	Dec 11, 2011				
	5319097	Dec 11, 2011				
	5482963	Jan 09, 2013				
	5583152	Sep 26, 2010				
	5612367	Mar 18, 2014			U-189	
	6143775	Dec 11, 2011				
<u>ZAFIRLUKAST - ACCOLATE</u>						
N020547 003	4859692	Sep 26, 2010				
	5294636	Dec 11, 2011				
	5319097	Dec 11, 2011				
	5482963	Jan 09, 2013				
	5583152	Sep 26, 2010				
	5612367	Mar 18, 2014			U-189	
	6143775	Dec 11, 2011				
<u>ZANAMIVIR - RELENZA</u>						
N021036 001	5360817	Jul 26, 2013	DS DP			
	5648379	Jul 15, 2014			U-722	
	5648379	Jul 15, 2014			U-274	
	5648379	Jul 15, 2014			U-721	
	6294572	Dec 15, 2014	DS DP			
<u>ZICONOTIDE - PRIALT</u>						
N021060 001	5364842	Dec 30, 2016		U-55	NCE	Dec 28, 2009
	5364842	Dec 30, 2016		U-48		
	5795864	Jun 27, 2015	DP			
	5859186	Dec 30, 2011		U-48		
	5859186	Dec 30, 2011		U-55		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZICONOTIDE - PRIALT</u>						
N021060 002	5364842	Dec 30, 2016		U-48	NCE	Dec 28, 2009
	5364842	Dec 30, 2016		U-55		
	5795864	Jun 27, 2015	DP			
	5859186	Dec 30, 2011		U-48		
	5859186	Dec 30, 2011		U-55		
<u>ZICONOTIDE - PRIALT</u>						
N021060 003	5364842	Dec 30, 2016		U-48	NCE	Dec 28, 2009
	5364842	Dec 30, 2016		U-55		
	5795864	Jun 27, 2015	DP			
	5859186	Dec 30, 2011		U-48		
	5859186	Dec 30, 2011		U-55		
<u>ZICONOTIDE - PRIALT</u>						
N021060 004	5364842	Dec 30, 2016		U-55	NCE	Dec 28, 2009
	5364842	Dec 30, 2016		U-48		
	5795864	Jun 27, 2015	DP			
	5859186	Dec 30, 2011		U-48		
	5859186	Dec 30, 2011		U-55		
<u>ZILEUTON - ZYFLO</u>						
N020471 001	4873259	Dec 10, 2010		U-168		
<u>ZILEUTON - ZYFLO</u>						
N020471 003	4873259	Dec 10, 2010		U-168		
<u>ZILEUTON - ZYFLO CR</u>						
N022052 001	4873259	Dec 09, 2010	DS			
	5422123	Jun 06, 2012		DP		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N020825 001	4831031	Mar 02, 2012	DS DP	U-720	I-615	Nov 20, 2012
	5312925	Sep 01, 2012	DS DP			
	6150366	May 27, 2019		DP		
	6245766	Dec 18, 2018		U-601		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N020825 002	4831031	Mar 02, 2012	DS DP	U-720	I-615	Nov 20, 2012
	5312925	Sep 01, 2012	DS DP			
	6150366	May 27, 2019		DP		
	6245766	Dec 18, 2018		U-601		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N020825 003	4831031	Mar 02, 2012	DS DP	U-720	I-615	Nov 20, 2012
	5312925	Sep 01, 2012	DS DP			
	6150366	May 27, 2019		DP		
	6245766	Dec 18, 2018		U-601		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N020825 004	4831031	Mar 02, 2012	DS DP	U-720	I-615	Nov 20, 2012
	5312925	Sep 01, 2012	DS DP			
	6150366	May 27, 2019		DP		
	6245766	Dec 18, 2018		U-601		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N021483 001	4831031	Mar 02, 2012	DS DP	U-720		
	5312925	Sep 01, 2012	DS DP	U-720		
	6150366	May 27, 2019		DP	U-719	
	6245766	Dec 18, 2018		U-601		
	7175855	May 18, 2020		DP		
<u>ZIPRASIDONE MESYLATE - GEODON</u>						
N020919 001	4831031	Mar 02, 2012	DS DP	U-720		
	5134127	Jan 23, 2010		DP		
	5376645	Jan 23, 2010		DP		
	6110918	Mar 26, 2017				
	6232304	Apr 01, 2017				
	6399777	Apr 01, 2017				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLEDRONIC ACID - RECLAST</u>						
N021817 001	4939130	Sep 02, 2012	DS DP U-662		I-595	May 29, 2012
	4939130*PED	Mar 02, 2013			I-584	Mar 15, 2012
					I-581	Dec 19, 2011
					I-271	Aug 17, 2010
					NP	Apr 16, 2010
					PED	Feb 17, 2011
					PED	Oct 16, 2010
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N021223 001	4939130	Sep 02, 2012	DS DP U-53			
	4939130*PED	Mar 02, 2013				
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N021223 002	4939130	Sep 02, 2012	DS DP U-53		M-61	Mar 20, 2011
	4939130*PED	Mar 02, 2013			PED	Sep 20, 2011
<u>ZOLMITRIPTAN - ZOMIG</u>						
N020768 001	5466699	Nov 14, 2012				
	5466699*PED	May 14, 2013				
	5863935	Nov 14, 2012				
	5863935*PED	May 14, 2013				
<u>ZOLMITRIPTAN - ZOMIG</u>						
N020768 002	5466699	Nov 14, 2012				
	5466699*PED	May 14, 2013				
	5863935	Nov 14, 2012				
	5863935*PED	May 14, 2013				
<u>ZOLMITRIPTAN - ZOMIG</u>						
N021450 004	5466699	Nov 14, 2012		U-436		
	5466699*PED	May 14, 2013				
	6750237	Nov 28, 2020		DP		
	6750237*PED	May 28, 2021				
	7220767	Nov 28, 2020		DP		
	7220767*PED	May 28, 2021				
<u>ZOLMITRIPTAN - ZOMIG-ZMT</u>						
N021231 001	5466699	Nov 14, 2012				
	5466699*PED	May 14, 2013				
<u>ZOLMITRIPTAN - ZOMIG-ZMT</u>						
N021231 002	5466699	Nov 14, 2012				
	5466699*PED	May 14, 2013				
<u>ZOLPIDEM TARTRATE - AMBIEN</u>						
N019908 001					M-54	Mar 29, 2010
					PED	Sep 29, 2010
<u>ZOLPIDEM TARTRATE - AMBIEN</u>						
N019908 002					M-54	Mar 29, 2010
					PED	Sep 29, 2010
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N021774 001	6514531	Dec 01, 2019	DP			
	6514531*PED	Jun 01, 2020				
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N021774 002	6514531	Dec 01, 2019	DP			
	6514531*PED	Jun 01, 2020				
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N021997 001	6761910	Sep 24, 2018	DP U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N021997 002	6761910	Sep 24, 2018	DP U-674			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
-----------------	-----------	------------------------------	-----------------	-------------------------------	------------------------	-----------------------------------

## Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST****DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

APPL/PROD NO	PATENT NO	PATENT DATE EXPIRATION	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%; VOLUVEN</u>						
N070012 001					NP	Dec 10, 2010

**PATENT AND EXCLUSIVITY TERMS**

ADB 1 of 45

**PATENT & EXCLUSIVITY ABBREVIATIONS**

D NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)  
 I NEW INDICATION (SEE INDIVIDUAL REFERENCES)  
 M MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)  
 NC NEW COMBINATION  
 NCE NEW CHEMICAL ENTITY  
 NDF NEW DOSAGE FORM  
 NE NEW ESTER OR SALT OF AN ACTIVE INGREDIENT  
 NP NEW PRODUCT  
 NP\* NEW PRODUCT (MINT FLAVORED)  
 NPP NEW PATIENT POPULATION  
 NR NEW ROUTE  
 NS NEW STRENGTH  
 ODE ORPHAN DRUG EXCLUSIVITY  
 PC PATENT CHALLENGE  
 PED PEDIATRIC EXCLUSIVITY  
 RTO RX TO OTC SWITCH OR OTC USE  
 U PATENT USE CODE (SEE INDIVIDUAL REFERENCES)  
 W EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

**EXCLUSIVITY DOSING SCHEDULE**

D-1 ONCE A DAY APPLICATION  
 D-2 ONCE DAILY DOSING  
 D-3 SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE  
 D-4 SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE  
 D-5 TEN DAYS/ELEVEN DAYS DOSING SCHEDULE  
 D-6 SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE  
 D-7 BID DOSING  
 D-8 INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING  
 D-9 NARCOTIC OVERDOSE IN ADULTS  
 D-10 NARCOTIC OVERDOSE IN CHILDREN  
 D-11 POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN  
 D-12 BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER  
 D-13 INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION  
 D-14 BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER  
 D-15 SINGLE DAILY DOSE OF 25MG/37.5MG  
 D-16 CONTINUOUS INTRAVENOUS INFUSION  
 D-17 400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS  
 D-18 LOWER RECOMMENDED STARTING DOSE GUIDELINES  
 D-19 BOLUS DOSING GUIDELINES  
 D-20 SINGLE 32MG DOSE  
 D-21 ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL  
 D-22 REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE  
 D-23 INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN  
 D-24 FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS  
 D-25 ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN  
 D-26 ONCE WEEKLY APPLICATION  
 D-27 BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY  
 D-28 USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300  
 D-29 INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS  
 D-30 5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS  
 D-31 CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)  
 D-32 REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS  
 D-33 ONCE DAILY DOSING FOR PLAQUE PSORIASIS  
 D-34 EVERY FOUR MONTHS DOSAGE REGIMEN  
 D-35 FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS  
 D-36 FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY

## PATENT AND EXCLUSIVITY TERMS

ADB 2 of 45

## EXCLUSIVITY DOSING SCHEDULE

- D-37 DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
- D-38 CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
- D-39 CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "...1/2 TO 1 HOUR BEFORE EATING" TO "... RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
- D-40 ONCE-A-DAY DOSING REGIMEN
- D-41 DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
- D-42 TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- D-43 INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
- D-44 IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
- D-45 ONCE DAILY DOSING FOR MAINTENANCE ONLY
- D-46 NEW DOSING REGIMEN OF 80MG DAILY
- D-47 PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
- D-48 ADMINISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPIENTAL
- D-49 PEDIATRIC DOSING GUIDELINES
- D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
- D-51 OPTIONAL STARTING DOSE OF 40MG/DAY
- D-52 ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
- D-53 USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
- D-54 USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
- D-55 ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
- D-56 ADDITION OF POSTPRANDIAL DOSING
- D-57 3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
- D-58 CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
- D-59 REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
- D-60 ADDITION OF A POST-OPERATIVE DOSING REGIMEN
- D-61 ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-62 ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-63 TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
- D-64 INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
- D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
- D-66 DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
- D-67 SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
- D-68 CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
- D-69 SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
- D-70 80MG ONCE DAILY DOSING REGIMEN
- D-71 EIGHT WEEK DOSING REGIMEN
- D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPAACON
- D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
- D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
- D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
- D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
- D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE

## PATENT AND EXCLUSIVITY TERMS

ADB 3 of 45

## EXCLUSIVITY DOSING SCHEDULE

- D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
- D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-83 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
- D-84 ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
- D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
- D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
- D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
- D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
- D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
- D-91 ALTERNATE INTERMITTENT DOSING REGIMEN
- D-92 ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
- D-93 ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
- D-94 NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD)
- D-95 BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
- D-96 ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
- D-97 PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
- D-98 DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
- D-99 ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
- D-100 750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
- D-101 ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- D-102 NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERGIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
- D-103 NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
- D-104 0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
- D-105 USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-106 FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
- D-107 PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-108 TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
- D-109 PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE
- D-110 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
- D-111 PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
- D-112 PROVIDES FOR PEDIATRIC PUMP USE
- D-113 ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
- D-114 NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
- D-115 STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
- D-116 ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULFATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS



**PATENT AND EXCLUSIVITY TERMS**

ADB 4 of 45

**EXCLUSIVITY DOSING SCHEDULE**

D-117 50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER  
 D-118 TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR  
 D-119 DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE  
 D-120 DOSING REGIMEN ADJUSTMENTS  
 D-121 CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION  
 D-122 USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE

**EXCLUSIVITY INDICATION**

I-1 DYSMENORRHEA  
 I-2 CHOLANGIOPANCREATOGRAPHY  
 I-3 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY  
 I-4 PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)  
 I-5 HYSTEROSALPINGOGRAPHY  
 I-6 TREATMENT OF JUVENILE ARTHRITIS  
 I-7 BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN  
 I-8 ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY  
 I-9 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING  
 I-10 PREVENTION OF POSTOPERATIVE DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY  
 I-11 RELIEF OF MILD TO MODERATE PAIN  
 I-12 TREATMENT OF CUTANEOUS CANDIDIASIS  
 I-13 URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI  
 I-14 SEBORRHEIC DERMATITIS  
 I-15 PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT  
 I-16 STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM  
 I-17 MANAGEMENT OF CONGESTIVE HEART FAILURE  
 I-18 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY  
 I-19 HERNIOGRAPHY  
 I-20 KNEE ARTHROGRAPHY  
 I-21 HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR  
 I-22 RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA  
 I-23 SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER  
 I-24 TREATMENT OF RHEUMATOID ARTHRITIS  
 I-25 ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS  
 I-26 TREATMENT OF LIVER FLUKES  
 I-27 ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE  
 I-28 SELECTIVE ADULT VISCERAL ARTERIOGRAPHY  
 I-29 METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION  
 I-30 TREATMENT OF TINEA PEDIS  
 I-31 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES  
 I-32 PEDIATRIC MYELOGRAPHY  
 I-33 ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN  
 I-34 ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT  
 I-35 PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING  
 I-36 ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS  
 I-37 RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS  
 I-38 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)  
 I-39 TREATMENT OF ACUTE MYOCARDIAL INFARCTION  
 I-40 PRIMARY NOCTURNAL ENURESIS  
 I-41 MIGRAINE HEADACHE PROPHYLAXIS  
 I-42 HERPES ZOSTER  
 I-43 HERPES SIMPLEX ENCEPHALITIS

## PATENT AND EXCLUSIVITY TERMS

ADB 5 of 45

## EXCLUSIVITY INDICATION

I-44 MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY  
I-45 ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS  
I-46 USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING  
I-47 TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE  
I-48 PEDIATRIC ANGIOCARDIOGRAPHY  
I-49 TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI  
I-50 FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER  
I-51 TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS  
I-52 PEDIATRIC EXCRETORY UROGRAPHY  
I-53 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA  
I-54 RENAL CONCENTRATION CAPACITY TEST  
I-55 HYPERTENSION  
I-56 EROSIIVE GASTROESOPHAGEAL REFLUX DISEASE  
I-57 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER  
I-58 INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS  
I-59 ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE  
I-60 SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE  
I-61 FEMALE ANDROGENETIC ALOPECIA  
I-62 PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS  
I-63 ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION  
I-64 PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS  
I-65 PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS  
I-66 UNCOMPLICATED GONORRHEA  
I-67 TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER  
I-68 CENTRAL PRECOCIOUS PUBERTY  
I-69 SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY  
I-70 USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER  
I-71 VARICELLA INFECTIONS (CHICKENPOX)  
I-72 PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE  
I-73 INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES  
I-74 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY  
I-75 TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIIVE ESOPHAGITIS  
I-76 PREVENTION OF OSTEOPOROSIS  
I-77 DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM  
I-78 CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY  
I-79 MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM  
I-80 DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE  
I-81 PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS  
I-82 TREATMENT OF TRAVELERS' DIARRHEA  
I-83 ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN  
I-84 INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION  
I-85 TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS  
I-86 TREATMENT OF SECONDARY CARNITINE DEFICIENCY  
I-87 RENAL IMAGING AGENT FOR USE IN CHILDREN  
I-88 MANAGEMENT OF ENDOMETRIOSIS  
I-89 EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE  
I-90 INTENSIVE CARE UNIT SEDATION  
I-91 MONOTHERAPY USE FOR HYPERTENSION  
I-92 ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE  
I-93 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS

## PATENT AND EXCLUSIVITY TERMS

ADB 6 of 45

## EXCLUSIVITY INDICATION

- I-94 USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
- I-95 TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- I-96 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
- I-97 ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
- I-98 TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
- I-99 PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
- I-100 TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
- I-101 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
- I-102 TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
- I-103 PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
- I-104 TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
- I-105 TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
- I-106 TREATMENT OF ACROMEGALY
- I-107 VAGINAL CANDIDIASIS
- I-108 EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
- I-109 TYPHOID FEVER
- I-110 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
- I-111 TREATMENT OF PAGET'S DISEASE OF BONE
- I-112 MANAGEMENT OF MODERATE TO SEVERE PAIN
- I-113 TREATMENT OF PROSTATITIS
- I-114 USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
- I-115 USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
- I-116 MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
- I-117 TO SLOW THE PROGRESSION FO CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
- I-118 PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
- I-119 TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
- I-120 MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
- I-121 EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
- I-122 PSORIASIS OF THE SCALP
- I-123 RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
- I-124 LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
- I-125 EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
- I-126 ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
- I-127 TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
- I-128 IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
- I-129 TREATMENT OF ALCOHOL DEPENDENCE
- I-130 MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
- I-131 PERIPHERAL ARTERIOGRAPHY
- I-132 TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
- I-133 MANAGEMENT OF CHRONIC STABLE ANGINA
- I-134 HEART FAILURE POST MYOCARDIAL INFARCTION
- I-135 BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
- I-136 IDIOPATHIC CHRONIC URTICARIA
- I-137 PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
- I-138 TREATMENT OF ACUTE RECURRENT GENITAL HERPES
- I-139 PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
- I-140 PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
- I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL

## PATENT AND EXCLUSIVITY TERMS

ADB 7 of 45

## EXCLUSIVITY INDICATION

- I-142 LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
- I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
- I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
- I-145 0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
- I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
- I-147 PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
- I-148 TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO2) IS LESS THAN OR EQUAL TO 55 TORR
- I-149 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
- I-150 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
- I-151 PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
- I-152 SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
- I-153 MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN]
- I-154 PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
- I-155 TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
- I-156 ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
- I-157 TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
- I-158 TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
- I-159 FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
- I-160 TREATMENT OF BACTERIAL CORNEAL ULCERS
- I-161 TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY FOR USE IN PATIENTS 6-11 YEARS OF AGE
- I-162 TREATMENT OF PHOTOPHOBIA
- I-163 CHRONIC BACTERIAL PROSTATITIS
- I-164 MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
- I-165 TREATMENT OF BULIMIA
- I-166 COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
- I-167 MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
- I-169 USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
- I-170 PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
- I-171 RELIEF OF SYMPTOMS OF THE COMMON COLD
- I-172 TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
- I-173 PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
- I-174 PELVIC INFLAMMATORY DISEASE
- I-175 TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
- I-176 TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
- I-177 TX OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
- I-178 TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
- I-179 NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
- I-180 TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
- I-181 TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
- I-182 TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
- I-183 MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
- I-184 TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
- I-185 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

## PATENT AND EXCLUSIVITY TERMS

ADB 8 of 45

## EXCLUSIVITY INDICATION

- I-186 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
- I-187 PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- I-188 TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
- I-189 TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
- I-190 PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
- I-191 ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
- I-192 THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
- I-193 TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
- I-194 CONGESTIVE HEART FAILURE
- I-195 FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
- I-196 ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- I-197 MAINTENANCE OF HEALING OF DUODENAL ULCER
- I-198 FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
- I-199 MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES
- I-200 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
- I-201 EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
- I-202 SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
- I-203 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
- I-204 USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- I-205 INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
- I-206 TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
- I-207 FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
- I-208 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
- I-209 PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
- I-210 TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
- I-211 FOR USE IN PEDIATRIC POPULATION
- I-212 TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
- I-213 TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
- I-214 TREATMENT OF OSTEOPOROSIS
- I-215 PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
- I-216 FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-217 PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
- I-218 USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
- I-219 USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
- I-220 TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
- I-221 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
- I-222 PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
- I-223 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
- I-224 FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS

## PATENT AND EXCLUSIVITY TERMS

ADB 9 of 45

## EXCLUSIVITY INDICATION

- I-225 USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
- I-226 FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
- I-227 SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
- I-228 PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
- I-229 PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- I-230 IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
- I-231 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
- I-232 TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
- I-233 PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
- I-234 FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
- I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
- I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
- I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
- I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
- I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
- I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
- I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
- I-245 TREATMENT OF ACUTE SINUSITIS
- I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
- I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
- I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
- I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
- I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
- I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER
- I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
- I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
- I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
- I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
- I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
- I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION
- I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
- I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
- I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
- I-261 TREATMENT OF SOCIAL ANXIETY DISORDER

## PATENT AND EXCLUSIVITY TERMS

ADB 10 of 45

## EXCLUSIVITY INDICATION

- I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
- I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
- I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
- I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
- I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
- I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
- I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
- I-269 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
- I-270 ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
- I-271 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-272 TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
- I-273 ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
- I-274 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
- I-275 USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
- I-276 USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
- I-277 TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
- I-278 TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
- I-279 TREATMENT OF POST-TRAUMATIC STRESS DISORDER
- I-280 USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- I-281 INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
- I-282 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
- I-283 TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
- I-284 TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
- I-285 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
- I-286 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
- I-287 USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
- I-288 CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINAPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
- I-289 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
- I-290 PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
- I-291 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-292 TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- I-293 TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
- I-294 TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
- I-295 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
- I-296 LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
- I-297 SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-298 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
- I-299 USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM

## PATENT AND EXCLUSIVITY TERMS

ADB 11 of 45

## EXCLUSIVITY INDICATION

- I-300 PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
- I-301 TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
- I-302 TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
- I-303 INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
- I-304 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
- I-305 TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
- I-306 INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
- I-307 NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
- I-308 TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
- I-309 USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- I-310 REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
- I-311 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
- I-312 FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
- I-313 EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
- I-314 TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
- I-315 THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
- I-316 TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
- I-317 PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
- I-318 FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
- I-319 USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
- I-320 TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
- I-321 JUVENILE RHEUMATOID ARTHRITIS
- I-322 USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
- I-323 COLORECTAL CANCER
- I-324 REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
- I-325 PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
- I-326 GENERALIZED ANXIETY DISORDER
- I-327 SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
- I-328 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
- I-329 UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
- I-330 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTEMS IN PATIENTS WITH GERD
- I-331 TREATMENT OF MODERATE ACNE VULGARIS
- I-332 EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
- I-333 TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
- I-334 LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
- I-335 ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
- I-336 EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
- I-337 PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SYNDROME
- I-338 MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
- I-339 TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
- I-340 ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
- I-341 BREAST CANCER COMBINATION THERAPY



## PATENT AND EXCLUSIVITY TERMS

ADB 12 of 45

## EXCLUSIVITY INDICATION

- I-342 USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-343 USE OF COREG FOR SEVERE HEART FAILURE
- I-344 ACNE VULGARIS
- I-345 TREATMENT OF POSTTRAUMATIC STRESS DISORDER
- I-346 TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
- I-347 TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
- I-348 LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
- I-349 ACUTE CORONARY SYNDROME
- I-350 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
- I-351 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
- I-352 ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
- I-353 TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
- I-354 MANAGEMENT OF POST HERPETIC NEURALGIA
- I-355 PREMENSTRUAL DYSPHORIC DISORDER
- I-356 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-357 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
- I-358 TREATMENT OF PANIC DISORDER
- I-359 TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
- I-360 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
- I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTI-NEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
- I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
- I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
- I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
- I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-367 COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
- I-368 USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
- I-369 PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
- I-370 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
- I-371 HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- I-372 NOSOCOMIAL PNEUMONIA
- I-373 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-374 SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
- I-375 FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- I-376 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
- I-377 USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
- I-378 RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-379 USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
- I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR

## PATENT AND EXCLUSIVITY TERMS

ADB 13 of 45

## EXCLUSIVITY INDICATION

- I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
- I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
- I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
- I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN >= 2 MCG/ML TO STREPTOCOCCUS PNEUMONIAE
- I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
- I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE
- I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
- I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE . . . .
- I-391 ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
- I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
- I-393 CHRONIC BACTERIAL PROSTATITIS
- I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
- I-395 TO IMPROVE PHYSICAL FUNCTION
- I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
- I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
- I-398 IDIOPATHIC SHORT STATURE
- I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSSES, PERITONITIS AND PLEURAL SPACE INFECTIONS
- I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-401 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
- I-402 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
- I-403 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESSIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
- I-404 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
- I-405 TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
- I-406 PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
- I-407 IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION <= 40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
- I-408 STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPANILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
- I-409 ESOPHAGEAL CANDIDIASIS
- I-410 USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
- I-411 EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
- I-412 MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-413 ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-414 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
- I-415 SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY

## PATENT AND EXCLUSIVITY TERMS

ADB 14 of 45

## EXCLUSIVITY INDICATION

- I-416 THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- I-417 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
- I-418 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
- I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
- I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
- I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
- I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- I-424 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
- I-425 FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
- I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
- I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
- I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
- I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
- I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
- I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
- I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
- I-435 CHRONIC IDIOPATHIC CONSTIPATION
- I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
- I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
- I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-441 USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
- I-442 USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
- I-443 TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
- I-444 USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIIVE ESOPHAGITIS
- I-445 TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
- I-446 EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
- I-447 USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
- I-448 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
- I-449 TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
- I-450 TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
- I-451 MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN

## PATENT AND EXCLUSIVITY TERMS

ADB 15 of 45

## EXCLUSIVITY INDICATION

- I-452 EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
- I-453 USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
- I-454 MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
- I-455 MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%)
- I-456 TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
- I-457 TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
- I-458 USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
- I-459 NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
- I-460 TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
- I-461 USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
- I-462 LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
- I-463 TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
- I-464 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
- I-465 PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
- I-466 FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
- I-467 USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
- I-468 USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION
- I-469 RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
- I-470 DIABETIC PERIPHERAL NEUROPATHIC PAIN
- I-471 INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
- I-472 USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
- I-473 USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
- I-474 TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECEIVING AN ERYTHROPOIETIN
- I-475 PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
- I-476 TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
- I-477 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
- I-478 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
- I-479 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
- I-480 PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
- I-481 INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-482 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
- I-483 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-484 FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
- I-485 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
- I-486 ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
- I-487 INDICATED FOR THE RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER

## PATENT AND EXCLUSIVITY TERMS

ADB 16 of 45

## EXCLUSIVITY INDICATION

- I-488 MAINTENANCE THERAPY IN BIPOLAR I DISORDER
- I-489 FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
- I-490 FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
- I-491 INFLUENZA PROPHYLAXIS
- I-492 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
- I-493 ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
- I-494 CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
- I-495 ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
- I-496 LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
- I-497 PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
- I-498 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- I-499 USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY
- I-500 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
- I-502 FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
- I-503 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-504 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-505 TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES
- I-506 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-507 ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-508 PREMENSTRUAL DYSPHONIC DISORDER
- I-509 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- I-510 ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP)
- I-511 ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
- I-512 ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
- I-513 ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
- I-514 ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)
- I-515 PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
- I-516 PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-517 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
- I-518 TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
- I-519 USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
- I-520 USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL
- I-521 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY
- I-522 TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.

## PATENT AND EXCLUSIVITY TERMS

ADB 17 of 45

## EXCLUSIVITY INDICATION

- I-523 USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE
- I-524 GENERALIZED ANXIETY DISORDER (GAD)
- I-525 USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
- I-526 TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
- I-527 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
- I-528 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
- I-529 TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE
- I-530 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER
- I-531 MAINTENANCE TREATMENT OF SCHIZOPHRENIA
- I-532 TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES
- I-533 ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)
- I-534 EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER
- I-535 MANAGEMENT OF FIBROMYALGIA
- I-536 FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME
- I-537 LONG TERM TREATMENT OF PANIC DISORDER
- I-538 SHORT TERM TREATMENT OF PANIC DISORDER
- I-539 REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER
- I-540 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17
- I-541 TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17
- I-542 EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS
- I-543 USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
- I-544 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-545 ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- I-546 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
- I-547 ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS
- I-548 SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE
- I-549 USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-550 TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE
- I-551 TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME
- I-552 ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER
- I-553 FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- I-554 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESES
- I-555 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
- I-556 PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY
- I-557 USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD
- I-558 MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-559 ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
- I-560 MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX
- I-561 LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
- I-562 MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
- I-563 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
- I-564 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
- I-565 USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)

## PATENT AND EXCLUSIVITY TERMS

ADB 18 of 45

## EXCLUSIVITY INDICATION

- I-566 MANAGEMENT OF FIBROMYALGIA
- I-567 INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-568 USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
- I-569 TREATMENT OF CHRONIC HEPATITIS B
- I-570 TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
- I-571 NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQUAMOUS NON-SMALL CELL LUNG CANCER
- I-572 TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
- I-573 TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
- I-574 MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
- I-575 MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
- I-576 ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
- I-577 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCUDURES
- I-578 EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
- I-579 TREATMENT OF MODERATE TO SEVERE DYSpareunia, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
- I-580 INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
- I-581 TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- I-582 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- I-583 ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTROINTESTINAL STROMAL TUMORS (GIST)
- I-584 TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICIDS FOR AT LEAST 12 MONTHS
- I-585 TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
- I-586 COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
- I-587 ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
- I-588 ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
- I-589 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
- I-590 ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
- I-591 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
- I-592 ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)
- I-593 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
- I-594 INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
- I-595 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-596 USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- I-597 MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- I-598 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
- I-599 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
- I-600 FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-601 MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
- I-602 TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
- I-603 GOUT FLARES
- I-604 PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK
- I-605 ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
- I-606 TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
- I-607 INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS

**PATENT AND EXCLUSIVITY TERMS**

ADB 19 of 45

**EXCLUSIVITY INDICATION**

- I-608 REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
- I-610 TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
- I-611 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
- I-612 MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
- I-613 MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
- I-614 SHORT TERM TREATMENT OF EROSIIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
- I-615 MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
- I-616 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
- I-617 MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
- I-618 ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
- I-619 INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY

**EXCLUSIVITY MISCELLANEOUS**

- M-1 INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
- M-2 APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
- M-3 ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
- M-4 CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
- M-5 INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
- M-6 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
- M-7 CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
- M-8 ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
- M-9 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
- M-10 INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
- M-11 USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
- M-12 NEW LANGUAGE FOR PEDIATRIC USE
- M-13 INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
- M-14 ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
- M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
- M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
- M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
- M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
- M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
- M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
- M-21 COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
- M-22 CHANGE IN TIME TO ONSET OF ACTION
- M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
- M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
- M-25 ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT



## PATENT AND EXCLUSIVITY TERMS

ADB 20 of 45

## EXCLUSIVITY MISCELLANEOUS

- M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
- M-27 INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
- M-28 INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
- M-29 LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
- M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
- M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
- M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
- M-38 SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
- M-39 FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST
- M-40 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS
- M-41 REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"
- M-42 ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION
- M-43 INCLUSION OF RESULTS OF STUDY-"PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION
- M-44 CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18
- M-45 INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING - EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- M-46 PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY
- M-47 PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS
- M-48 CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
- M-49 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN
- M-50 NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION
- M-51 INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY
- M-52 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- M-53 FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT
- M-54 INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
- M-55 INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.
- M-56 INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL
- M-57 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS
- M-58 CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS

## PATENT AND EXCLUSIVITY TERMS

ADB 21 of 45

## EXCLUSIVITY MISCELLANEOUS

- M-59 RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS
- M-60 CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WITH HYPERCHOLESTEROLEMIA
- M-61 REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-62 CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES
- M-63 DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY
- M-64 CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS
- M-65 ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)
- M-66 USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
- M-67 INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS
- M-68 DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
- M-69 RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
- M-70 PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY
- M-71 REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- M-72 INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS
- M-73 NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS
- M-74 REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
- M-75 PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)
- M-76 REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
- M-77 USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
- M-78 CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
- M-79 LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE
- M-80 ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
- M-81 ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)
- M-82 LABELING REVISIONS RELATED TO CLINICAL STUDIES
- M-83 ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
- M-84 STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
- M-85 INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
- M-86 LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
- M-87 INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
- M-88 ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
- M-89 PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM

## PATENT USE

- U-1 PREVENTION OF PREGNANCY
- U-2 TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
- U-3 TREATMENT OF HYPERTENSION
- U-4 PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS

**PATENT AND EXCLUSIVITY TERMS**

ADB 22 of 45

**PATENT USE**

U-5 METHOD OF PRODUCING BRONCHODILATION  
U-6 METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS  
U-7 INCREASING CARDIAC CONTRACTILITY  
U-8 ACUTE MYOCARDIAL INFARCTION  
U-9 CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT  
U-10 DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS  
U-11 TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS  
U-12 METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION  
U-13 A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT  
U-14 ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES  
U-15 METHOD OF LOWERING INTRAOCULAR PRESSURE  
U-16 USE IN LUNG SCANNING PROCEDURES  
U-17 TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS  
U-18 METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS  
U-19 TREATMENT OF INFLAMMATION  
U-20 A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT  
U-21 TREATMENT OF HUMANS SUFFERING UNDESIRE UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS  
U-22 METHOD OF COMBATting PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS  
U-23 METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE  
U-24 METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST  
U-25 REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS  
U-26 REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF  
U-27 DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF  
U-28 CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY  
U-29 CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY  
U-30 CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY  
U-31 INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY  
U-32 PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN  
U-33 TREATING VIRAL INFECTIONS IN A MAMMAL  
U-34 TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL  
U-35 TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION  
U-36 METHODS OF TREATING BACTERIAL ILLNESSES  
U-37 METHOD OF TREATING GASTROINTESTINAL DISEASE  
U-38 TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA  
U-39 ANGINA PECTORIS  
U-40 METHOD OF TREATMENT OF BURNS  
U-41 METHOD OF TREATING CARDIAC ARRHYTHMIAS  
U-42 ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER  
U-43 MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA  
U-44 RELIEF OF NAUSEA AND VOMITING  
U-45 TREATMENT OF INFLAMMATION AND ANALGESIA  
U-46 TREATMENT OF PANIC DISORDER  
U-47 STIMULATION OF THE RELEASE OF GROWTH HORMONE  
U-48 ANALGESIA  
U-49 SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA  
U-50 USE IN TREATING INFLAMMATORY DERMATOSES  
U-51 BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING  
U-52 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION  
U-53 HYPERCALCEMIA OF MALIGNANCY  
U-54 REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS  
U-55 TREATMENT OF PAIN  
U-56 AID TO SMOKING CESSATION

## PATENT AND EXCLUSIVITY TERMS

ADB 23 of 45

## PATENT USE

U-57 OPHTHALMIC USE OF NORFLOXACIN

U-58 METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES

U-59 METHOD OF TREATING HYPERCHOLESTEROLEMIA

U-60 NASAL ADMINISTRATION OF BUTORPHANOL

U-61 CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD

U-62 CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY

U-63 ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE

U-64 TREATMENT OF VIRAL INFECTIONS

U-65 METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV

U-66 TRIPHASIC REGIMEN

U-67 METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL

U-68 TREATMENT OF ACTINIC KERATOSIS

U-69 TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS

U-70 TREATMENT OF TRANSIENT INSOMNIA

U-71 METHOD OF TREATMENT OF HEART FAILURE

U-72 TREATMENT OF MIGRAINE

U-73 METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES

U-74 METHOD OF PROVIDING HYPNOTIC EFFECT

U-75 RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS

U-76 USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM

U-77 TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

U-78 ULCERATIVE COLITIS

U-79 SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD

U-80 METHOD OF TREATING OCULAR BACTERIAL INFECTIONS

U-81 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS

U-82 TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE

U-83 TREATMENT OF SEIZURES

U-84 A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS

U-85 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-86 METHOD OF TREATING CERTAIN FORMS OF EPILEPSY

U-87 METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS

U-88 TREATMENT OF MODERATE PLAQUE PSORIASIS

U-89 TREATMENT OR PROPHYLAXIS OF EMESIS

U-90 TREATMENT OF PYSCHOTIC DISORDERS

U-91 ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS

U-92 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY

U-93 USE AS AN ANTIHISTAMINE/DECONGESTANT

U-94 TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED

U-95 SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS

U-96 METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS

U-97 A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT

U-98 A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL

U-99 METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM

U-100 METHOD OF TREATING OCULAR INFLAMMATION

U-101 ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED

U-102 METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN

U-103 TREATMENT OF OCULAR HYPERTENSION

U-104 TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE

U-105 EMESIS

U-106 TREATMENT OF EPILEPSY

U-107 TREATMENT OF HYPERTENSION AND ANGINA PECTORIS

U-108 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIIVE ESOPHAGITIS

## PATENT AND EXCLUSIVITY TERMS

ADB 24 of 45

## PATENT USE

- U-109 ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
- U-110 USE AS A RETRIEVABLE PERSSARY
- U-111 DIABETES
- U-112 CONTRACEPTION
- U-113 METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
- U-114 USE FOR INHIBITING BONE RESORPTION
- U-115 USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
- U-116 METHOD OF MYOCARDIAL IMAGING
- U-117 TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES
- U-118 METHOD OF LOWERING BLOOD SUGAR LEVEL
- U-119 TREATMENT OF NASAL HYPERSECRETION
- U-120 CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES
- U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
- U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
- U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
- U-124 TREATMENT OF ACNE
- U-125 TREATMENT NEUROGENERATIVE DISEASES
- U-126 TREATMENT OF GASTRITIS
- U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
- U-128 METHOD FOR TREATMENT OF TUMORS
- U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS
- U-130 MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
- U-131 PHOTODAMAGED SKIN
- U-132 INHIBITING HIV PROTEASE
- U-133 MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
- U-134 TREATMENT OF ACNE VULGARIS
- U-135 ANTITUMOR AGENT
- U-136 PROCESS FOR WASTE NITROGEN REMOVAL
- U-137 METHOD OF TREATING BACTERIAL VAGINOSIS
- U-138 TREATMENT OF ALLERGIC RHINITIS
- U-139 TREATMENT OF ALLERGIC REACTIONS
- U-140 USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
- U-141 TREATMENT OF ULCERATIVE COLITIS
- U-142 METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
- U-143 BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
- U-144 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
- U-145 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
- U-146 METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
- U-147 DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2
- U-148 DEVICE FOR COLLECTING A BREATH SAMPLE
- U-149 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
- U-150 METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
- U-151 RELIEF OF SYMPTOMS OF THE COMMON COLD
- U-152 METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
- U-153 TREATMENT OF INITIAL EPISODE GENITAL HERPES
- U-154 METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
- U-155 TREATMENT OF ERECTILE DYSFUNCTION
- U-156 METHOD OF PROVIDING ANESTHESIA
- U-157 TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY
- U-158 ANGINA
- U-159 TREATMENT OF INTERSTITIAL CYSTITIS
- U-160 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

## PATENT AND EXCLUSIVITY TERMS

ADB 25 of 45

## PATENT USE

- U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
- U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
- U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
- U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
- U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
- U-166 TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER
- U-167 METHOD FOR TREATING HIV-1 INFECTION
- U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
- U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
- U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
- U-171 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
- U-172 TREATMENT OF GENITAL WARTS
- U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
- U-174 USE AS AN ANTIHISTAMINE AGENT
- U-175 METHOD OF TREATING MALIGNANT TUMORS
- U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
- U-177 FUNGICIDE
- U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN
- U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
- U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION
- U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
- U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
- U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
- U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS
- U-185 METHOD OF TREATING HYPERTENSION
- U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
- U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
- U-188 TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER
- U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
- U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
- U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
- U-192 USE IN TREATING ALLERGIC REACTIONS
- U-193 PSORIASIS
- U-194 TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE
- U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
- U-196 TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
- U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
- U-198 TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA
- U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
- U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
- U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
- U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
- U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-205 METHOD FOR TREATING HEARTBURN

## PATENT AND EXCLUSIVITY TERMS

ADB 26 of 45

## PATENT USE

- U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION
- U-207 USE AS NASAL SPRAY
- U-208 VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
- U-209 VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
- U-210 METHOD OF TREATING CONGESTIVE HEART FAILURE
- U-211 USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
- U-212 METHOD OF TREATMENT OF PARKINSON'S DISEASE
- U-213 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
- U-214 USE AS A BLOOD GLUCOSE-LOWERING AGENT
- U-215 TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
- U-216 TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
- U-217 METHOD OF PRODUCING ANESTHESIA
- U-218 METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
- U-219 TREATMENT OF PARKINSON'S DISEASE
- U-220 METHOD OF DIAGNOSIS
- U-221 SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
- U-222 METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
- U-223 TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
- U-224 CONTROLLING INTRAOCULAR PRESSURE
- U-225 MEHTOD FOR DELIVERY
- U-226 METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
- U-227 NASAL ADMINISTRATION
- U-228 ASTHMA
- U-229 CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
- U-230 PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
- U-231 USE IN PARKINSON'S DISEASE
- U-232 METHOD OF TREATING MIGRAINE
- U-233 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
- U-234 METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
- U-235 METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
- U-236 TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
- U-237 METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
- U-238 IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED...
- U-239 TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
- U-240 TREATMENT OF ACUTE MIGRAINE ATTACKS
- U-241 FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
- U-242 USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
- U-243 TOPICAL ADMINISTRATION
- U-244 PLATELET AGGREGATION INHIBITORS
- U-245 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
- U-246 PHOSPHATE BINDING
- U-247 TREATMENT OF RHEUMATOID ARTHRITIS
- U-248 TREATMENT OF HIV
- U-249 METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
- U-250 TREATMENT OF HEPATITIS B INFECTION
- U-251 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
- U-252 METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
- U-253 ORAL TRANSMUCOSAL USE

## PATENT AND EXCLUSIVITY TERMS

ADB 27 of 45

## PATENT USE

- U-254 USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
- U-255 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
- U-256 TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
- U-257 TREATMENT OF HIV INFECTION
- U-258 TREATMENT OF NEURODEGENERATIVE DISEASES
- U-259 TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
- U-260 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
- U-261 TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
- U-262 TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
- U-263 METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
- U-264 METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
- U-265 USE AS LAXATIVE
- U-266 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS
- U-267 PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
- U-268 ACROMEGALY
- U-269 EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
- U-270 METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
- U-271 METHOD OF TREATING TUMORS
- U-272 METHOD OF TREATING CARCINOMA
- U-273 CUTANEOUS T-CELL LYMPHOMA
- U-274 ZANAMIVIR FOR INHALATION
- U-275 METHOD OF USE OF THE DRUG SUBSTANCE
- U-276 METHOD OF USE OF LEVOBUPIVACAINE
- U-277 NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
- U-278 METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
- U-279 METHOD OF USE OF THE APPROVED PRODUCT
- U-280 TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
- U-281 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
- U-282 METHOD OF TREATING BACTERIAL INFECTIONS
- U-283 METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
- U-284 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
- U-285 DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
- U-286 DEPRESSION
- U-287 TREATMENT OR PREVENTION OF OSTEOPOROSIS
- U-288 THERAPY OF INFLUENZA
- U-289 TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
- U-290 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
- U-291 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
- U-292 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
- U-293 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
- U-294 TREATMENT OF HYPERPIGMENTARY DISORDERS
- U-295 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-296 TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
- U-297 PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
- U-298 METHOD OF COMBATING BACTERIA IN A PATIENT



## PATENT AND EXCLUSIVITY TERMS

ADB 28 of 45

## PATENT USE

- U-299 TREATMENT OF ADENOMATOUS POLYPS
- U-300 INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
- U-301 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
- U-302 TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
- U-303 METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
- U-304 A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
- U-305 METHODS FOR USING THE DRUG PRODUCT
- U-306 TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
- U-307 CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
- U-308 CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
- U-309 TREATING SJOEGREN SYNDROME
- U-310 TREATMENT OF XEROSTOMIA
- U-311 HORMONE REPLACEMENT
- U-312 PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
- U-313 TREATMENT OF CONGESTIVE HEART FAILURE
- U-314 METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
- U-315 METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
- U-316 METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
- U-317 METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
- U-318 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
- U-319 TREATMENT OF MICROBIAL INFECTIONS
- U-320 INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
- U-321 REDUCTION OF ELEVATED IPPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
- U-322 TREATMENT OF ALZHEIMER'S DEMENTIA
- U-323 USE AS A BILE ACID SEQUESTRANT
- U-324 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
- U-325 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
- U-326 METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
- U-327 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE
- U-328 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
- U-329 USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-330 TREATMENT OF NAUSEA AND VOMITING
- U-331 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-332 TREATMENT OR PREVENTION OF BRONCHOSPASM
- U-333 METHOD OF TREATING OCULAR HYPERTENSION
- U-334 TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
- U-335 USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
- U-336 DIAGNOSTIC RADIOIMAGING
- U-337 USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
- U-338 METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
- U-339 PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
- U-340 THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
- U-341 METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
- U-342 METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
- U-343 REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
- U-344 METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR

## PATENT AND EXCLUSIVITY TERMS

ADB 29 of 45

## PATENT USE

- U-345 RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
- U-346 METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
- U-347 METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
- U-348 METHOD OF USE FOR INHIBITING HIV INFECTION
- U-349 METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
- U-350 PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
- U-351 INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR
- U-352 INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
- U-353 PREVENTION AND TREATMENT OF OSTEOPOROSIS
- U-354 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-355 METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA...PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
- U-356 DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
- U-357 USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
- U-358 DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
- U-359 METHOD OF USE OF VISICOL
- U-360 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
- U-361 MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
- U-362 USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
- U-363 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
- U-364 TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
- U-365 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
- U-366 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
- U-367 TREATMENT OF CARDIOVASCULAR DISORDERS
- U-368 HEARTBURN
- U-369 METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
- U-370 INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
- U-371 APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
- U-372 METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
- U-373 GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- U-374 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
- U-375 METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
- U-376 TREATMENT OF INFLUENZA
- U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
- U-378 METHOD FOR TREATING INCONTINENCE
- U-379 METHOD OF TREATING ONYCHROMYCOSIS
- U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
- U-381 TREATMENT OF HYPERPHOSPHATEMIA
- U-382 METHOD OF STABILIZING PROSTAGLANDIN
- U-383 METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION

## PATENT AND EXCLUSIVITY TERMS

ADB 30 of 45

## PATENT USE

- U-384 TREATMENT OF CMV RETINITIS
- U-385 TREATMENT OF PEPTIC ULCERS
- U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
- U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
- U-388 SMOKING CESSATION AID APPLIED TO THE SKIN
- U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
- U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
- U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
- U-392 TREATMENT OF PATIENTS FOR INFLAMMATION
- U-393 MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
- U-394 METHOD OF USE OF ALPHAGAN
- U-395 METHOD OF USE OF ALPHAGAN P
- U-396 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
- U-397 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
- U-398 TREATMENT OF GENERALIZED ANXIETY DISORDER
- U-399 IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
- U-400 USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
- U-401 USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
- U-402 TREATMENT OF ACTINIC KERATOSES
- U-403 ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
- U-404 TREATMENT OF ALLERGIC CONJUNCTIVITIS
- U-405 FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
- U-406 METHOD OF USE OF ATOVAQUONE AND PROGUANIL
- U-407 METHOD OF TREATING OTOPATHY
- U-408 FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
- U-409 METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
- U-410 METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
- U-412 TREATMENT OF TYPE 2 DIABETES
- U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
- U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
- U-415 A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-416 A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-417 COMBINATION USE OF AD-4833 WITH A BIGUANIDE
- U-418 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-419 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
- U-420 METHOD OF TREATMENT OF TYPE II DIABETES
- U-421 USE FOR SEDATION
- U-422 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
- U-423 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
- U-424 FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS

## PATENT AND EXCLUSIVITY TERMS

ADB 31 of 45

## PATENT USE

- U-425 METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-426 PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
- U-427 METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
- U-428 METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
- U-429 METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
- U-430 METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
- U-431 POSTTRAUMATIC STRESS DISORDER
- U-432 REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
- U-433 USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- U-434 CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
- U-435 A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
- U-436 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- U-437 METHOD OF USE EQUAL TO PROCESS OF PREPARATION
- U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
- U-439 TREATMENT OF OBESITY
- U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
- U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
- U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
- U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- U-444 TREATMENT OF MIGRAINE
- U-445 USE AS AN ANTIMYCOTIC AGENT
- U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
- U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
- U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
- U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-452 USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
- U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
- U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
- U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
- U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
- U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
- U-458 METHOD OF USE OF IMAGENT
- U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
- U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
- U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
- U-463 VENOGRAPHY
- U-464 PERIPHERAL ARTERIOGRAPHY
- U-465 CT IMAGING OF THE HEAD
- U-466 TREATMENT OF IRRITABLE BOWEL SYNDROME

## PATENT AND EXCLUSIVITY TERMS

ADB 32 of 45

## PATENT USE

- U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
- U-468 METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
- U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
- U-470 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
- U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
- U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
- U-473 TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
- U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
- U-475 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF. .CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
- U-477 METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
- U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
- U-479 METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
- U-480 CONTRAST AGENT FOR MRI
- U-481 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
- U-482 METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
- U-483 METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
- U-484 METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
- U-485 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-486 EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
- U-487 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-488 METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
- U-489 EXPECTORANT
- U-490 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
- U-491 METHOD OF DELIVERING A DRUG TO THE LUNG
- U-492 METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
- U-493 TREATMENT OF TYPE 2 DIABETES MELLITUS
- U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
- U-495 PERITONEAL DIALYSIS SOLUTION
- U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE
- U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
- U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
- U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
- U-500 USE AS AN ANTIHYPERTENSIVE AGENT
- U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
- U-502 PITYRIASIS VERSICOLOR
- U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
- U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
- U-505 ULTRASOUND CONTRAST AGENT
- U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..

## PATENT AND EXCLUSIVITY TERMS

ADB 33 of 45

## PATENT USE

- U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
- U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
- U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
- U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
- U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
- U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC MYCOPLASMA BACTERIA
- U-514 PREVENTION OF OVULATION IN A WOMAN
- U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
- U-516 METHOD OF TREATING A PSYCHOTIC DISEASE
- U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
- U-518 OBSESSIVE COMPULSIVE DISORDER
- U-519 POST OPERATIVE NAUSEA AND VOMITING
- U-520 PREMENOPAUSAL OSTEOPOROSIS
- U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
- U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
- U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
- U-524 METHOD OF TREATING DIARRHEA
- U-525 METHOD OF TREATING PARASITIC INFECTIONS
- U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
- U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
- U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
- U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
- U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
- U-531 TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
- U-532 TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
- U-533 ERECTILE DYSFUNCTION
- U-534 HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
- U-535 TREATMENT OF SOCIAL ANXIETY DISORDER
- U-536 CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING
- U-537 TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
- U-538 FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
- U-539 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
- U-540 TREATMENT OF FUNGAL INFECTIONS
- U-541 METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
- U-542 METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
- U-543 TREATMENT OF SCHIZOPHRENIA
- U-544 TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
- U-545 METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
- U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
- U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
- U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
- U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
- U-550 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
- U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID

## PATENT AND EXCLUSIVITY TERMS

ADB 34 of 45

## PATENT USE

- U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
- U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS
- U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
- U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
- U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
- U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION; METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL; METHOD OF TREATING HYPERPARATHYROIDISM
- U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
- U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
- U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY
- U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
- U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-567 METHOD OF TREATING INFERTILITY
- U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
- U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
- U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
- U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
- U-572 INTENSIVE CARE UNIT SEDATION
- U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-575 LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.
- U-576 ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
- U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
- U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
- U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
- U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
- U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
- U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
- U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS

## PATENT AND EXCLUSIVITY TERMS

ADB 35 of 45

## PATENT USE

- U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
- U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6532955
- U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
- U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
- U-598 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
- U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
- U-601 TREATMENT OF BIPOLAR DISORDER
- U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
- U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
- U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
- U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD); ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
- U-606 USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER
- U-607 CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
- U-608 USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-609 USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-610 ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.
- U-611 METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
- U-612 TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-613 REDUCTION OF SERUM PHOSPHATE
- U-614 TREATMENT OF SEXUAL DYSFUNCTION
- U-615 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
- U-616 MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
- U-617 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-618 USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
- U-619 TREATMENT OF MALIGNANT NEOPLASM
- U-620 TREATMENT OF INSOMNIA
- U-621 METHOD OF TREATING CANCER
- U-622 TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
- U-623 SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- U-624 REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
- U-625 ALLERGIC RHINITIS OR NASAL POLYPS
- U-626 CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS



## PATENT AND EXCLUSIVITY TERMS

ADB 36 of 45

## PATENT USE

- U-627 TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
- U-628 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-629 METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
- U-630 TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
- U-631 TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN
- U-632 METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING
- U-633 METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR
- U-634 METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL
- U-635 TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS
- U-636 TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
- U-637 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
- U-638 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
- U-639 TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE
- U-640 USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGLYCEMIA
- U-641 USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION
- U-642 TREATMENT AND PREVENTION OF OSTEOPOROSIS
- U-643 THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE
- U-644 TREATMENT OF SEASONAL ALLERGIC RHINITIS
- U-645 TREATMENT OF ASTHMA
- U-646 METHOD OF TREATING OTITIS
- U-647 TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- U-648 THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN
- U-649 A METHOD FOR TREATING A TUMOR DISEASE
- U-650 TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
- U-651 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
- U-652 TREATMENT OF CARDIAC ARRHYTHMIA
- U-653 STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE
- U-654 LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4
- U-655 TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS
- U-656 REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
- U-657 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-658 TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER
- U-659 TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
- U-660 TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE
- U-661 TREATMENT OF SEIZURE DISORDER
- U-662 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-663 THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
- U-664 TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION
- U-665 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
- U-666 METHOD OF TREATING ADHD
- U-667 MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE
- U-668 LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS
- U-669 INDICATION OF TYPE II DIABETES

## PATENT AND EXCLUSIVITY TERMS

ADB 37 of 45

## PATENT USE

- U-670 TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
- U-671 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4
- U-672 TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
- U-673 METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML
- U-674 METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET
- U-675 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
- U-676 METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION
- U-677 A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM
- U-678 METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER
- U-679 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
- U-680 A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
- U-681 TREATMENT OF PRIMARY IGF-1 DEFICIENCY
- U-682 NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
- U-683 PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE
- U-684 TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-685 EXPECTORANT AND COUGH SUPPRESSANT
- U-686 EXPECTORANT AND NASAL DECONGESTANT
- U-687 REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
- U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
- U-689 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
- U-690 TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-691 USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-692 USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- U-693 THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
- U-694 LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.
- U-695 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
- U-696 TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
- U-697 A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY
- U-698 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA
- U-699 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-700 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-701 TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA
- U-702 TOPICAL AEROSOL HAIR REGROWTH TREATMENT
- U-703 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB
- U-704 METHOD OF ADMINISTERING INSULIN VIA INHALATION
- U-705 TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
- U-706 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
- U-707 ALLERGIC RHINITIS
- U-708 TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
- U-709 METHOD OF COMBATING BACTERIA IN A PATIENT

## PATENT AND EXCLUSIVITY TERMS

ADB 38 of 45

## PATENT USE

- U-710 A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549
- U-711 ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- U-712 A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA
- U-713 TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
- U-714 TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM
- U-715 FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER
- U-716 THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- U-717 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
- U-718 TREATMENT OF FUNGAL INFECTIONS
- U-719 TREATMENT OF PSYCHOSIS
- U-720 TREATMENT OF NEUROLEPTIC DISEASES
- U-721 TREATMENT OF INFLUENZA
- U-722 PROPHYLAXIS OF INFLUENZA
- U-723 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-724 METHOD OF TREATING SEIZURES
- U-725 ALLERGIC RHINITIS AND URTICARIA
- U-726 ALLERGIC RHINITIS
- U-727 FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
- U-728 METHOD FOR TREATING BACTERIAL INFECTION
- U-729 TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- U-730 USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS
- U-731 USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
- U-732 ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
- U-733 MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
- U-734 FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS
- U-735 METHOD OF TREATING CHRONIC IRON OVERLOAD
- U-736 METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
- U-737 DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE
- U-738 INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER
- U-739 METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT
- U-740 FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
- U-741 COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER
- U-742 TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
- U-743 ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
- U-744 TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS
- U-745 TREATMENT OR PREVENTION OF EMESIS
- U-746 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
- U-747 PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
- U-748 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
- U-749 METHOD OF CONTRACEPTION
- U-750 TREATMENT OF HIV-1 INFECTION IN ADULTS
- U-751 ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA
- U-752 SUNSCREEN
- U-753 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
- U-754 USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA
- U-755 TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
- U-756 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- U-757 USE AS A BILE ACID SEQUESTANT FOR LOWERING CHOLESTEROL

## PATENT AND EXCLUSIVITY TERMS

ADB 39 of 45

## PATENT USE

- U-758 TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER
- U-759 METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
- U-760 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS
- U-761 TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA
- U-762 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- U-763 ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION
- U-764 TREATMENT OF SCHIZOPHRENIA
- U-765 METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
- U-766 TREATMENT OF SEIZURES
- U-767 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
- U-768 A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID
- U-769 REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- U-770 LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS
- U-771 METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELLITUS, IN A HUMAN PATIENT
- U-772 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
- U-773 PATHOLOGICAL HYPERSECRETORY CONDITIONS
- U-774 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
- U-775 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
- U-776 TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.
- U-777 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
- U-778 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-779 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
- U-780 A METHOD FOR THE TREATMENT OF CANCER
- U-781 FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
- U-782 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTENT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
- U-783 DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER
- U-784 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
- U-785 USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
- U-786 PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS
- U-787 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
- U-788 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE
- U-789 TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING
- U-790 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
- U-791 GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
- U-792 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
- U-793 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-794 CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
- U-795 METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE
- U-796 METHOD OF TREATING DEPRESSION

## PATENT AND EXCLUSIVITY TERMS

ADB 40 of 45

## PATENT USE

U-797 METHOD OF TREATING ANXIETY

U-798 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID

U-799 METHOD FOR INHIBITING SEROTONIN UPTAKE

U-800 TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB

U-801 METHOD OF TREATING CANCER

U-802 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

U-803 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN

U-804 TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY

U-805 TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES

U-806 INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS

U-807 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION

U-808 THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER

U-809 TREATMENT OF CHRONIC IDIOPATHIC URTICARIA

U-810 METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE

U-811 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA

U-812 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-813 MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-814 TREATMENT OF SCHIZOPHRENIA

U-815 TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING

U-816 DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER

U-817 NASAL ADMINISTRATION OF CYANOCOBALAMIN

U-818 TOPICAL TREATMENT OF ACNE VULGARIS

U-819 MANAGEMENT OF FIBROMYALGIA

U-820 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER

U-821 METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.

U-822 USE IN LIPID MANAGEMENT

U-823 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE

U-824 METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1

U-825 USE FOR PREVENTION OF BREAST CANCER

U-826 RELIEF OF MODERATE TO SEVERE PAIN

U-827 USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES

U-828 PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

U-829 TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY

U-830 TREATMENT OF RELAPSED SMALL CELL LUNG CANCER

U-831 METHOD OF ADMINISTERING LANREOTIDE ACETATE

U-832 ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.

U-833 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE

U-834 INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION

U-835 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER

U-836 A METHOD FOR THE TREATMENT OF LEUKEMIAS

U-837 GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS

U-838 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE

U-839 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

U-840 TREATMENT FOR TYPE 2 DIABETES MELLITUS

## PATENT AND EXCLUSIVITY TERMS

ADB 41 of 45

## PATENT USE

- U-841 INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER
- U-842 INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
- U-843 METHOD FOR ADMINISTRATION OF TESTOSTERONE
- U-844 PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS
- U-845 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
- U-846 USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE
- U-847 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
- U-848 ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
- U-849 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
- U-850 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
- U-851 TREATMENT OF TYPE 2 DIABETES MELLITUS
- U-852 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- U-853 TREATMENT OR PREVENTION OF EMESIS
- U-854 PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
- U-855 METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION
- U-856 SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
- U-857 INHIBITION OF TRANSPLANT REJECTION
- U-858 PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIIVE ESOPHAGITIS
- U-859 EROSIIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD
- U-860 FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
- U-861 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
- U-862 ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
- U-863 TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY
- U-864 PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIIVE ESOPHAGITIS
- U-865 TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
- U-866 THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES
- U-867 TREATMENT OF MIGRAINE
- U-868 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYONATREMIA
- U-869 METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
- U-870 METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
- U-871 METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
- U-872 TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
- U-873 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)
- U-874 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
- U-875 FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
- U-876 TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
- U-877 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
- U-878 A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
- U-879 A METHOD OF TREATING OR PREVENTING ILEUS
- U-880 ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
- U-881 TREATMENT OF NON-SMALL CELL LUNG CANCER
- U-882 MANAGEMENT OF FIBROMYALGIA (FM)

## PATENT AND EXCLUSIVITY TERMS

ADB 42 of 45

## PATENT USE

U-883 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB

U-884 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

U-885 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY

U-886 ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA

U-887 TREATMENT AND PREVENTION OF OSTEOPOROSIS

U-888 FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN

U-889 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)

U-890 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE

U-891 USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE

U-892 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)

U-893 CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE

U-894 TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER

U-895 TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-896 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER

U-897 METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT

U-898 USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME

U-899 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-900 INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION

U-901 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING

U-902 USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)

U-903 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS

U-904 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

U-905 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE

U-906 PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS

U-907 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER

U-908 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS

U-909 TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-910 TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY

U-911 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE

U-912 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES

U-913 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY

U-914 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER

U-915 TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-916 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER

U-917 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

U-918 TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET

U-919 FOR THE TREATMENT OF DERMATITIS

U-920 STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS

U-921 TREATMENT OF ACNE VULGARIS

U-922 FOR THE TREATMENT OF FUNGAL INFECTIONS

U-923 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

U-924 TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS

U-925 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

## PATENT AND EXCLUSIVITY TERMS

ADB 43 of 45

## PATENT USE

- U-926 MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
- U-927 METHOD FOR INCREASING TEAR PRODUCTION
- U-928 TREATMENT OF BACTERIAL INFECTIOUS DISEASE
- U-929 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI
- U-930 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
- U-931 RELIEF OF MODERATE TO SEVERE ACUTE PAIN
- U-932 PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI
- U-933 FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- U-934 IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA
- U-935 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER
- U-936 USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA
- U-937 TREATMENT OF PROSTATE CANCER
- U-938 TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-939 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-940 METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA
- U-941 METHOD TO TREAT OVARIAN CANCER
- U-942 METHOD TO TREAT MULTIPLE MYELOMA
- U-943 GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
- U-944 TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- U-945 SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION
- U-946 TREATMENT OF BREAST CANCER
- U-947 WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIIVE ESOPHAGITIS
- U-948 TREATMENT OF DIABETES MELLITUS
- U-949 HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
- U-950 MAINTAIN HEALING OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
- U-951 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
- U-952 USE AS AN ANALGESIC
- U-953 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
- U-954 CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
- U-955 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-956 TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE
- U-957 A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE
- U-958 METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT
- U-959 METHOD OF TREATING CANCER, IV ADMIN, LYOPHILIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
- U-960 METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
- U-961 METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
- U-962 SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-963 PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-964 ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS



## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

- U-965 USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
- U-966 TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
- U-967 A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
- U-968 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-969 TREATMENT OF MIGRAINE
- U-970 TOPICAL TREATMENT OF LICE INFESTATIONS
- U-971 INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
- U-972 MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- U-973 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
- U-974 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
- U-975 TREATMENT OF PULMONARY HYPERTENSION
- U-976 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
- U-977 TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE
- U-978 METHOD OF TREATING HYPONATREMIA
- U-979 RELIEF OF MUSCLE SPASM
- U-980 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
- U-981 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
- U-982 A METHOD OF TREATING OSTEOPOROSIS
- U-983 METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
- U-984 METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
- U-985 TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
- U-986 TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR
- U-987 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
- U-988 TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350
- U-989 FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
- U-990 TREATMENT OF PROTOZOAL INFECTION
- U-991 TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS
- U-992 REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION
- U-993 METHOD OF TREATING INFERTILITY
- U-994 METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
- U-995 METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN
- U-996 AN ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA
- U-997 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
- U-998 ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
- U-999 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
- U-1000 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS
- U-1001 METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION
- U-1002 METHOD OF TREATING INFLAMMATORY CONDITIONS
- U-1003 A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW
- U-1004 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
- U-1005 METHOD OF TREATING A STAPHYLOCOCCAL INFECTION
- U-1006 NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)
- U-1007 METHOD OF TREATING GOUT FLARES

**PATENT AND EXCLUSIVITY TERMS**

ADB 45 of 45

**PATENT USE**

- U-1008 APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION
- U-1009 METHOD FOR ADMINISTRATION OF TESTOSTERONE
- U-1010 TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION
- U-1011 USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
- U-1012 METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION
- U-1013 METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TRAT PATIENTS WITH CHRONIC HEPATITIS C
- U-1014 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON 2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
- U-1015 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
- U-1016 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS
- U-1017 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
- U-1018 TREATMENT OF PULMONARY HYPERTENSION BY INHALATION
- U-1019 TREATMENT OF PULMONARY HYPERTENSION
- U-1020 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
- U-1021 SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER
- U-1022 FOR THE PREPARATIO NOF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION
- U-1023 TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
- U-1024 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP
- U-1025 TREATING FREQUENT HEARTBURN
- U-1026 A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.